{"ab01448f29ab97d07372e379e9f1be3ecd0b1abe": [["IntroductionAn optimal arterial carbon dioxide concentration, measured by the partial pressure of carbon dioxide (PaCO 2 ), is critical during mechanical ventilation.", [["arterial", "ANATOMY", 23, 31], ["carbon dioxide", "CHEMICAL", 32, 46], ["carbon dioxide", "CHEMICAL", 98, 112], ["PaCO 2", "CHEMICAL", 114, 120], ["carbon dioxide", "CHEMICAL", 32, 46], ["carbon dioxide", "CHEMICAL", 98, 112], ["PaCO 2", "CHEMICAL", 114, 120], ["arterial", "MULTI-TISSUE_STRUCTURE", 23, 31], ["carbon dioxide", "SIMPLE_CHEMICAL", 32, 46], ["carbon dioxide", "SIMPLE_CHEMICAL", 98, 112], ["IntroductionAn optimal arterial carbon dioxide concentration", "TREATMENT", 0, 60], ["the partial pressure of carbon dioxide (PaCO", "TREATMENT", 74, 118], ["mechanical ventilation", "TREATMENT", 143, 165], ["carbon dioxide", "OBSERVATION", 98, 112], ["mechanical ventilation", "OBSERVATION", 143, 165]]], ["Both hypercapnia and hypocapnia can contribute to brain damage in immature infants.", [["brain", "ANATOMY", 50, 55], ["hypercapnia", "DISEASE", 5, 16], ["hypocapnia", "DISEASE", 21, 31], ["brain damage", "DISEASE", 50, 62], ["brain", "ORGAN", 50, 55], ["infants", "ORGANISM", 75, 82], ["infants", "SPECIES", 75, 82], ["Both hypercapnia", "PROBLEM", 0, 16], ["hypocapnia", "PROBLEM", 21, 31], ["brain damage in immature infants", "PROBLEM", 50, 82], ["hypercapnia", "OBSERVATION", 5, 16], ["hypocapnia", "OBSERVATION", 21, 31], ["brain", "ANATOMY", 50, 55], ["damage", "OBSERVATION", 56, 62], ["immature infants", "OBSERVATION", 66, 82]]], ["Tighter control of PaCO 2 may be achieved in mechanically ventilated infants by setting appropriate minute ventilation (V E ), defined by tidal volume (V T ) and the respiratory rate (RR) [1] .", [["respiratory", "ANATOMY", 166, 177], ["PaCO 2", "CHEMICAL", 19, 25], ["PaCO 2", "GENE_OR_GENE_PRODUCT", 19, 25], ["infants", "ORGANISM", 69, 76], ["PaCO 2", "PROTEIN", 19, 25], ["infants", "SPECIES", 69, 76], ["PaCO 2", "TREATMENT", 19, 25], ["tidal volume", "TEST", 138, 150], ["the respiratory rate", "TEST", 162, 182], ["RR", "TEST", 184, 186]]], ["However, even when V T or V E are maintained, hypercapnia can occur.", [["hypercapnia", "DISEASE", 46, 57], ["V T", "GENE_OR_GENE_PRODUCT", 19, 22], ["V E", "GENE_OR_GENE_PRODUCT", 26, 29], ["hypercapnia", "PROBLEM", 46, 57], ["hypercapnia", "OBSERVATION", 46, 57]]], ["V T comprises Fowler dead space ((V d,Fowler ) volume of air in instruments and airways), alveolar dead space ((V d,alv ) volume of ventilated alveoli that do not receive blood flow and thus no gas exchange), and alveolar ventilation ((V A ) volume of alveoli with gas exchange).", [["airways", "ANATOMY", 80, 87], ["alveolar", "ANATOMY", 90, 98], ["alveoli", "ANATOMY", 143, 150], ["blood", "ANATOMY", 171, 176], ["alveolar", "ANATOMY", 213, 221], ["alveoli", "ANATOMY", 252, 259], ["V T", "GENE_OR_GENE_PRODUCT", 0, 3], ["airways", "MULTI-TISSUE_STRUCTURE", 80, 87], ["alveoli", "MULTI-TISSUE_STRUCTURE", 143, 150], ["blood", "ORGANISM_SUBSTANCE", 171, 176], ["alveolar", "MULTI-TISSUE_STRUCTURE", 213, 221], ["alveoli", "MULTI-TISSUE_STRUCTURE", 252, 259], ["Fowler dead space", "TEST", 14, 31], ["V d,Fowler ) volume of air in instruments and airways", "TEST", 34, 87], ["alveolar dead space ((V d,alv ) volume of ventilated alveoli", "PROBLEM", 90, 150], ["blood flow", "TEST", 171, 181], ["gas exchange", "TEST", 194, 206], ["alveolar ventilation", "TEST", 213, 233], ["gas exchange", "TEST", 265, 277], ["air", "OBSERVATION", 57, 60], ["airways", "ANATOMY", 80, 87], ["alveolar", "ANATOMY_MODIFIER", 90, 98], ["alv", "ANATOMY", 116, 119], ["ventilated alveoli", "OBSERVATION", 132, 150], ["alveolar ventilation", "OBSERVATION", 213, 233], ["gas exchange", "OBSERVATION", 265, 277]]], ["Therefore, minute alveolar ventilation (V A ), which is calculated as V A \u00d7 RR, is the key contributor in maintaining appropriate PaCO 2 [2, 3] .", [["alveolar", "ANATOMY", 18, 26], ["PaCO 2", "CHEMICAL", 130, 136], ["alveolar", "MULTI-TISSUE_STRUCTURE", 18, 26], ["alveolar ventilation", "OBSERVATION", 18, 38]]], ["The physiological dead space (V d,phys ), which is the sum of V d,Fowler and V d,alv , is commonly calculated in ventilated patients using volumetric capnography (V cap ).", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["The physiological dead space (V d,phys )", "PROBLEM", 0, 40], ["volumetric capnography", "TEST", 139, 161], ["dead space", "OBSERVATION", 18, 28], ["alv", "ANATOMY", 81, 84]]], ["This method employs a plot of expiratory CO 2 (P E CO 2 ) versus expired tidal volume (V T,E ), and specialised equipment with effective apparatus dead space for newborns with low V T [4] .", [["CO 2", "CHEMICAL", 41, 45], ["CO 2", "CHEMICAL", 51, 55], ["expiratory CO", "TEST", 30, 43], ["P E CO", "TEST", 47, 53], ["expired tidal volume", "TEST", 65, 85], ["effective apparatus dead space", "PROBLEM", 127, 157]]], ["We have previously reported the analysis of V cap using ventilator graphics and capnograms with low dead-space cap-ONE (Nihon Kohden, Tokyo, Japan) mainstream capnometers [5] .IntroductionWe hypothesised decreased V A was caused by increased V d,phys in well-ventilated infants with hypercapnia.", [["hypercapnia", "DISEASE", 283, 294], ["V A", "GENE_OR_GENE_PRODUCT", 214, 217], ["infants", "ORGANISM", 270, 277], ["V cap", "DNA", 44, 49], ["infants", "SPECIES", 270, 277], ["V cap", "TREATMENT", 44, 49], ["ventilator graphics", "TREATMENT", 56, 75], ["capnograms", "TREATMENT", 80, 90], ["low dead-space cap", "TREATMENT", 96, 114], ["increased V d", "PROBLEM", 232, 245], ["hypercapnia", "PROBLEM", 283, 294], ["decreased", "OBSERVATION", 204, 213], ["hypercapnia", "OBSERVATION", 283, 294]]], ["The objective of this current study was to clarify the relationship between dead space and PaCO 2 , and to assess V A in intubated well-ventilated neonates with hypercapnia, using V cap based on ventilator graphics and capnograms.", [["hypercapnia", "DISEASE", 161, 172], ["PaCO 2", "CHEMICAL", 91, 97], ["V A", "GENE_OR_GENE_PRODUCT", 114, 117], ["neonates", "ORGANISM", 147, 155], ["this current study", "TEST", 17, 35], ["PaCO", "TEST", 91, 95], ["hypercapnia", "PROBLEM", 161, 172], ["V cap", "TREATMENT", 180, 185], ["ventilator graphics", "TREATMENT", 195, 214], ["capnograms", "TREATMENT", 219, 229], ["hypercapnia", "OBSERVATION", 161, 172]]], ["We present evidence here that hypercapnia is attributed to decreased V A due to increased V d,phys .Patient populationThis was a single-centre, prospective, non-randomised study with consecutive patient enrolment, approved by the clinical ethics committee of the National Hospital Organization Maizuru Medical Center in Kyoto, Japan.", [["hypercapnia", "DISEASE", 30, 41], ["V A", "GENE_OR_GENE_PRODUCT", 69, 72], ["V d", "GENE_OR_GENE_PRODUCT", 90, 93], ["patient", "ORGANISM", 195, 202], ["Patient", "SPECIES", 100, 107], ["patient", "SPECIES", 195, 202], ["hypercapnia", "PROBLEM", 30, 41], ["decreased V A", "PROBLEM", 59, 72], ["increased V d,phys", "PROBLEM", 80, 98], ["non-randomised study", "TEST", 157, 177], ["consecutive patient enrolment", "TREATMENT", 183, 212], ["hypercapnia", "OBSERVATION", 30, 41]]], ["Ventilated infants with arterial lines admitted to the NICU between December 2017 and December 2019 were enrolled.", [["arterial lines", "ANATOMY", 24, 38], ["infants", "ORGANISM", 11, 18], ["arterial lines", "CELL", 24, 38], ["infants", "SPECIES", 11, 18], ["arterial lines", "TREATMENT", 24, 38], ["arterial lines", "OBSERVATION", 24, 38]]], ["Infants with a greater than 10% air leak, or with extremely low birth weights, were excluded ( Fig. 1) .", [["air leak", "DISEASE", 32, 40], ["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["a greater than 10% air leak", "PROBLEM", 13, 40], ["extremely low birth weights", "PROBLEM", 50, 77], ["greater", "OBSERVATION_MODIFIER", 15, 22], ["air leak", "OBSERVATION", 32, 40]]], ["Infants received either volume-targeted or pressure-controlled time-cycled ventilation at the discretion of each neonatologist via a VN500 (Dr\u00e4ger Medical, L\u00fcbeck, Germany) in synchronous intermittent mandatory ventilation mode.", [["Infants", "SPECIES", 0, 7], ["either volume", "TREATMENT", 17, 30], ["pressure", "TREATMENT", 43, 51], ["cycled ventilation", "TREATMENT", 68, 86], ["synchronous intermittent mandatory ventilation mode", "TREATMENT", 176, 227]]], ["Infants who weighed < 2500 g were intubated using either 2.5-mm or 3.0-mm endotracheal tubes without cuffs (Portex: Smiths Medical Japan, Tokyo, Japan).", [["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["intubated", "TREATMENT", 34, 43], ["3.0-mm endotracheal tubes", "TREATMENT", 67, 92], ["endotracheal tubes", "OBSERVATION", 74, 92], ["without", "UNCERTAINTY", 93, 100], ["cuffs", "OBSERVATION_MODIFIER", 101, 106]]], ["Infants weighing 2500 g or more were ventilated with 3.0-mm endotracheal tubes with cuffs (MicrocuffPET: Halyard, GA, USA) to reduce air leakage.", [["air leakage", "DISEASE", 133, 144], ["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["3.0-mm endotracheal tubes", "TREATMENT", 53, 78], ["air leakage", "PROBLEM", 133, 144], ["endotracheal tubes", "OBSERVATION", 60, 78], ["air leakage", "OBSERVATION", 133, 144]]], ["We adjusted the positive endexpiratory pressure (PEEP) and fraction of inspired oxygen to maintain the saturation of percutaneous oxygen between 90 and 98%; we set the peak inspiratory pressure (PIP) to achieve a V T of approximately 5 mL/kg.", [["percutaneous", "ANATOMY", 117, 129], ["oxygen", "CHEMICAL", 80, 86], ["oxygen", "CHEMICAL", 130, 136], ["oxygen", "CHEMICAL", 80, 86], ["oxygen", "CHEMICAL", 130, 136], ["oxygen", "SIMPLE_CHEMICAL", 80, 86], ["oxygen", "SIMPLE_CHEMICAL", 130, 136], ["the positive endexpiratory pressure (PEEP", "TREATMENT", 12, 53], ["inspired oxygen", "TREATMENT", 71, 86], ["the saturation", "TEST", 99, 113], ["percutaneous oxygen", "TEST", 117, 136], ["the peak inspiratory pressure", "TEST", 164, 193], ["positive", "OBSERVATION_MODIFIER", 16, 24], ["endexpiratory", "OBSERVATION_MODIFIER", 25, 38], ["pressure", "OBSERVATION_MODIFIER", 39, 47], ["inspired oxygen", "OBSERVATION", 71, 86]]], ["We performed volumetric capnography when infants were well-ventilated (200 ml/kg/minute \u2264 V E , and 3.5 ml/kg \u2264 V T ).Patient populationMedical records were reviewed for information regarding the patients' characteristics, and clinical, prenatal, and perinatal data.", [["infants", "ORGANISM", 41, 48], ["patients", "ORGANISM", 196, 204], ["infants", "SPECIES", 41, 48], ["Patient", "SPECIES", 118, 125], ["patients", "SPECIES", 196, 204], ["volumetric capnography", "TEST", 13, 35]]], ["The diagnosis of respiratory distress syndrome (RDS) was defined as infants who had clinical manifestations (tachypnoea, nasal flaring, and or grunting), and radiologic signs such as air bronchogram or widespread granular opacities.", [["respiratory", "ANATOMY", 17, 28], ["nasal", "ANATOMY", 121, 126], ["granular opacities", "ANATOMY", 213, 231], ["respiratory distress syndrome", "DISEASE", 17, 46], ["RDS", "DISEASE", 48, 51], ["tachypnoea", "DISEASE", 109, 119], ["granular opacities", "DISEASE", 213, 231], ["infants", "ORGANISM", 68, 75], ["nasal", "ORGANISM_SUBDIVISION", 121, 126], ["granular opacities", "PATHOLOGICAL_FORMATION", 213, 231], ["infants", "SPECIES", 68, 75], ["respiratory distress syndrome", "PROBLEM", 17, 46], ["RDS", "PROBLEM", 48, 51], ["clinical manifestations", "PROBLEM", 84, 107], ["tachypnoea", "PROBLEM", 109, 119], ["nasal flaring", "PROBLEM", 121, 134], ["grunting", "PROBLEM", 143, 151], ["radiologic signs", "TEST", 158, 174], ["air bronchogram", "PROBLEM", 183, 198], ["widespread granular opacities", "PROBLEM", 202, 231], ["respiratory", "OBSERVATION", 17, 28], ["distress syndrome", "OBSERVATION", 29, 46], ["nasal", "ANATOMY", 121, 126], ["flaring", "OBSERVATION", 127, 134], ["air bronchogram", "OBSERVATION", 183, 198], ["widespread", "OBSERVATION_MODIFIER", 202, 212], ["granular opacities", "OBSERVATION", 213, 231]]], ["We administered surfactant to infants diagnosed with RDS who had severe clinical symptoms.", [["RDS", "DISEASE", 53, 56], ["infants", "ORGANISM", 30, 37], ["infants", "SPECIES", 30, 37], ["surfactant", "TREATMENT", 16, 26], ["RDS", "PROBLEM", 53, 56], ["severe clinical symptoms", "PROBLEM", 65, 89]]], ["The diagnosis of persistent pulmonary hypertension of the newborns (PPHN) was confirmed by echocardiography with evidence of increased pulmonary pressure with demonstrable right-to-left shunts across the ductus arteriosus or foramen ovale.", [["pulmonary", "ANATOMY", 28, 37], ["pulmonary", "ANATOMY", 135, 144], ["right", "ANATOMY", 172, 177], ["ductus arteriosus", "ANATOMY", 204, 221], ["pulmonary hypertension", "DISEASE", 28, 50], ["PPHN", "DISEASE", 68, 72], ["ductus arteriosus or foramen ovale", "DISEASE", 204, 238], ["pulmonary", "ORGAN", 28, 37], ["newborns", "ORGANISM", 58, 66], ["pulmonary", "ORGAN", 135, 144], ["ductus arteriosus", "MULTI-TISSUE_STRUCTURE", 204, 221], ["persistent pulmonary hypertension of the newborns (PPHN", "PROBLEM", 17, 72], ["echocardiography", "TEST", 91, 107], ["increased pulmonary pressure", "PROBLEM", 125, 153], ["foramen ovale", "PROBLEM", 225, 238], ["persistent", "OBSERVATION_MODIFIER", 17, 27], ["pulmonary", "ANATOMY", 28, 37], ["hypertension", "OBSERVATION", 38, 50], ["increased", "OBSERVATION_MODIFIER", 125, 134], ["pulmonary pressure", "OBSERVATION", 135, 153], ["right", "ANATOMY_MODIFIER", 172, 177], ["to-", "ANATOMY_MODIFIER", 178, 181], ["left", "ANATOMY_MODIFIER", 181, 185], ["shunts", "OBSERVATION", 186, 192], ["ductus arteriosus", "ANATOMY", 204, 221], ["foramen", "ANATOMY_MODIFIER", 225, 232], ["ovale", "OBSERVATION", 233, 238]]], ["Pneumothorax and meconium aspiration syndrome (MAS) were diagnosed according to medical history, clinical manifestations, and chest X-ray.Patient populationWaveform sampling and V cap based on waveforms P E CO 2 was continuously monitored using cap-ONE (sampling frequency, 40 Hz; dead space, 0.5 mL) placed between the endotracheal tube and flow sensor of the ventilator circuit.", [["endotracheal tube", "ANATOMY", 320, 337], ["Pneumothorax", "DISEASE", 0, 12], ["meconium aspiration syndrome", "DISEASE", 17, 45], ["MAS", "DISEASE", 47, 50], ["CO 2", "CHEMICAL", 207, 211], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 320, 337], ["Patient", "SPECIES", 138, 145], ["Pneumothorax", "PROBLEM", 0, 12], ["meconium aspiration syndrome", "PROBLEM", 17, 45], ["chest X-ray", "TEST", 126, 137], ["Patient populationWaveform sampling", "TEST", 138, 173], ["V cap", "TEST", 178, 183], ["waveforms", "TEST", 193, 202], ["E CO", "TEST", 205, 209], ["cap", "TEST", 245, 248], ["dead space", "PROBLEM", 281, 291], ["the endotracheal tube", "TREATMENT", 316, 337], ["the ventilator circuit", "TREATMENT", 357, 379], ["meconium", "OBSERVATION_MODIFIER", 17, 25], ["aspiration", "OBSERVATION", 26, 36], ["chest", "ANATOMY", 126, 131], ["endotracheal tube", "OBSERVATION", 320, 337], ["ventilator circuit", "OBSERVATION", 361, 379]]], ["While ventilated neonates received arterial blood sampling necessary for treatment, we simultaneously obtained the capnogram waveforms of cap-ONE and volume waveforms of the ventilator in the supine position, using a screen capture programme, with ventilator parameters.", [["arterial blood", "ANATOMY", 35, 49], ["neonates", "ORGANISM", 17, 25], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 35, 49], ["arterial blood sampling", "TREATMENT", 35, 58], ["treatment", "TREATMENT", 73, 82], ["the capnogram waveforms", "TEST", 111, 134], ["cap", "TEST", 138, 141], ["volume waveforms", "TEST", 150, 166], ["the ventilator", "TREATMENT", 170, 184], ["a screen capture programme", "TEST", 215, 241], ["ventilator parameters", "TEST", 248, 269], ["ventilator", "OBSERVATION", 174, 184]]], ["Our method of analysis has previously been described [5] .", [["Our method of analysis", "TEST", 0, 22]]], ["Briefly, we manually superimposed the capnogram waveforms and volume waveforms at the beginning of inspiration, and measured the P E CO 2 and V T,E values at the same time at 30-50 points from the start to the end of expiration using ImageJ software (http://rsb.info.nih.gov/ij/).", [["the capnogram waveforms", "TEST", 34, 57], ["volume waveforms", "TEST", 62, 78], ["the P E CO", "TEST", 125, 135], ["V T", "TEST", 142, 145], ["E values", "TEST", 146, 154], ["ImageJ software", "TEST", 234, 249], ["volume waveforms", "OBSERVATION", 62, 78]]], ["Subsequently, P E CO 2 was plotted against V T,E for a single breath.", [["CO 2", "CHEMICAL", 18, 22], ["P E CO", "TEST", 14, 20], ["a single breath", "PROBLEM", 53, 68]]], ["V d,Fowler , V d,alv , and V A were calculated from the resulting curve, as described by Fletcher [6] (Fig. 2) .", [["Fowler , V d,alv , and V A", "PROBLEM", 4, 30], ["alv", "ANATOMY", 17, 20]]], ["The mean of at least three consecutive breaths was normalised to body weight at measurement.", [["body", "ANATOMY", 65, 69], ["body", "ORGANISM_SUBDIVISION", 65, 69], ["body weight", "TEST", 65, 76], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["V d,phys was calculated as V d,Fowler + V d,alv .", [["alv", "ANATOMY", 44, 47]]], ["V E and V A were calculated as follows:Patient populationWe performed regression analysis to evaluate the correlation between PaCO 2 and V T /kg or dead space from the obtained samples.", [["samples", "ANATOMY", 177, 184], ["V E", "GENE_OR_GENE_PRODUCT", 0, 3], ["V A", "GENE_OR_GENE_PRODUCT", 8, 11], ["PaCO 2", "GENE_OR_GENE_PRODUCT", 126, 132], ["V T", "GENE_OR_GENE_PRODUCT", 137, 140], ["Patient", "SPECIES", 39, 46], ["regression analysis", "TEST", 70, 89], ["PaCO", "TEST", 126, 130], ["dead space", "PROBLEM", 148, 158]]], ["Next, hypocapnia measurements (PaCO 2 < 35 mmHg) were excluded due to the small sample number and the remaining data points were classified as either normocapnia (35 mmHg \u2264 PaCO 2 < 45 mmHg), or hypercapnia (45 mmHg \u2264 PaCO 2 ) to clarify the normative reference data.Statistical analysesThe data were tested for normality with the Kolmogorov-Smirnov test; data were non-normally distributed.", [["hypercapnia", "DISEASE", 195, 206], ["hypocapnia measurements", "TEST", 6, 29], ["PaCO", "TEST", 31, 35], ["normocapnia", "TEST", 150, 161], ["PaCO", "TEST", 173, 177], ["hypercapnia", "PROBLEM", 195, 206], ["PaCO", "TEST", 218, 222], ["Statistical analyses", "TEST", 267, 287], ["The data", "TEST", 287, 295], ["the Kolmogorov-Smirnov test", "TEST", 327, 354], ["hypocapnia", "OBSERVATION", 6, 16], ["small", "OBSERVATION_MODIFIER", 74, 79], ["hypercapnia", "OBSERVATION", 195, 206]]], ["We analysed the correlation between PaCO 2 and each dead space using Spearman's correlation coefficients, and compared normocapnia and hypercapnia using the Mann-Whitney U test with Excel Tokei 2019 (Social Survey Research Information, Tokyo, Japan).", [["hypercapnia", "DISEASE", 135, 146], ["PaCO 2", "DNA", 36, 42], ["PaCO", "TEST", 36, 40], ["Spearman's correlation coefficients", "TEST", 69, 104], ["hypercapnia", "PROBLEM", 135, 146], ["hypercapnia", "OBSERVATION", 135, 146]]], ["Statistical significance was set at p < 0.05.ResultsThe study population consisted of 33 ventilated infants with a mean gestational age of 35.0 \u00b1 3.3 weeks and a mean birth weight of 2257 \u00b1 641 g ( Table 1 ).", [["infants", "ORGANISM", 100, 107], ["infants", "SPECIES", 100, 107], ["The study population", "TEST", 52, 72], ["a mean birth weight", "TEST", 160, 179]]], ["The predominant reasons for mechanical ventilation were as follows: RDS (66%), PPHN (12%), asphyxia (12%), pneumothorax (6%), and MAS (3%).ResultsOne hundred fifty-four measurements obtained from 33 ventilated infants were used for the regression analysis of the relationship between PaCO 2 and V T /kg or each dead space.", [["RDS", "DISEASE", 68, 71], ["PPHN", "DISEASE", 79, 83], ["asphyxia", "DISEASE", 91, 99], ["pneumothorax", "DISEASE", 107, 119], ["MAS", "DISEASE", 130, 133], ["infants", "ORGANISM", 210, 217], ["V T", "GENE_OR_GENE_PRODUCT", 295, 298], ["infants", "SPECIES", 210, 217], ["mechanical ventilation", "TREATMENT", 28, 50], ["RDS", "PROBLEM", 68, 71], ["PPHN", "TEST", 79, 83], ["asphyxia", "PROBLEM", 91, 99], ["pneumothorax", "PROBLEM", 107, 119], ["MAS", "TEST", 130, 133], ["four measurements", "TEST", 164, 181], ["the regression analysis", "TEST", 232, 255], ["PaCO", "TEST", 284, 288], ["each dead space", "PROBLEM", 306, 321], ["mechanical ventilation", "OBSERVATION", 28, 50], ["PPHN", "OBSERVATION", 79, 83], ["asphyxia", "OBSERVATION", 91, 99], ["pneumothorax", "OBSERVATION", 107, 119]]], ["Figure 3 shows that PaCO 2 values were positively correlated with V d,alv /V T (r = 0.54, p < 0.001) and V d,phys /V T (r = 0.48, p < 0.001), but not with V T /kg (r = 0.09, p = 0.35) and V d,Fowler /V T (r = 0.14, p = 0.12).ResultsThere were 82 normocapnia and 57 hypercapnia measurements.", [["PaCO 2", "CHEMICAL", 20, 26], ["PaCO 2", "GENE_OR_GENE_PRODUCT", 20, 26], ["V T", "GENE_OR_GENE_PRODUCT", 115, 118], ["PaCO 2", "PROTEIN", 20, 26], ["PaCO 2 values", "TEST", 20, 33], ["p", "TEST", 90, 91], ["V d,phys /V T", "PROBLEM", 105, 118], ["p", "TEST", 130, 131], ["p", "TEST", 174, 175], ["V d", "TEST", 188, 191], ["Fowler /V T", "TEST", 192, 203], ["p", "TEST", 215, 216], ["normocapnia", "TEST", 246, 257], ["hypercapnia measurements", "TEST", 265, 289], ["hypercapnia", "OBSERVATION", 265, 276]]], ["Table 2 presents the ventilator parameters and measurement values for each group.", [["the ventilator parameters", "TEST", 17, 42], ["measurement values", "TEST", 47, 65]]], ["Higher respiratory settings such as PIP and MAP, but not PEEP, were needed in the hypercapnia group than in the normocapnia group.", [["respiratory", "ANATOMY", 7, 18], ["hypercapnia", "DISEASE", 82, 93], ["PIP", "GENE_OR_GENE_PRODUCT", 36, 39], ["Higher respiratory settings", "TREATMENT", 0, 27], ["PIP", "TEST", 36, 39], ["MAP", "TEST", 44, 47], ["PEEP", "TREATMENT", 57, 61], ["respiratory settings", "OBSERVATION", 7, 27], ["hypercapnia", "OBSERVATION", 82, 93]]], ["The difference in V d,alv , V d,phys , and V A was statistically significant between the normocapnia and hypercapnia groups, while V T and V d,Fowler showed no difference.", [["hypercapnia", "DISEASE", 105, 116], ["V d", "GENE_OR_GENE_PRODUCT", 28, 31], ["V A", "GENE_OR_GENE_PRODUCT", 43, 46], ["V T", "GENE_OR_GENE_PRODUCT", 131, 134], ["The difference in V d,alv , V d,phys , and V A", "PROBLEM", 0, 46], ["the normocapnia and hypercapnia groups", "PROBLEM", 85, 123], ["difference", "PROBLEM", 160, 170], ["V d", "OBSERVATION_MODIFIER", 18, 21], ["alv", "ANATOMY", 22, 25], ["normocapnia", "OBSERVATION", 89, 100], ["hypercapnia", "OBSERVATION", 105, 116], ["no", "UNCERTAINTY", 157, 159]]], ["V d,alv and V d,phys were higher The resulting curve comprises three phases: phase 1 represents carbon dioxide-free gas from the airways and apparatus dead space, phase 2 represents the volume of transition between the airway and alveolar gas, and phase 3 reflects the pure alveolar gas compartment and volume exhaled from the rest of the alveoli.", [["airways", "ANATOMY", 129, 136], ["airway", "ANATOMY", 219, 225], ["alveolar gas", "ANATOMY", 230, 242], ["alveolar gas compartment", "ANATOMY", 274, 298], ["alveoli", "ANATOMY", 339, 346], ["carbon dioxide", "CHEMICAL", 96, 110], ["carbon dioxide", "CHEMICAL", 96, 110], ["carbon dioxide", "SIMPLE_CHEMICAL", 96, 110], ["airways", "MULTI-TISSUE_STRUCTURE", 129, 136], ["airway", "MULTI-TISSUE_STRUCTURE", 219, 225], ["alveolar", "MULTI-TISSUE_STRUCTURE", 230, 238], ["alveoli", "MULTI-TISSUE_STRUCTURE", 339, 346], ["carbon dioxide", "TEST", 96, 110], ["free gas from the airways", "TEST", 111, 136], ["apparatus dead space", "TEST", 141, 161], ["the airway and alveolar gas", "TEST", 215, 242], ["the pure alveolar gas compartment", "PROBLEM", 265, 298], ["volume exhaled", "TEST", 303, 317], ["alv", "ANATOMY", 4, 7], ["curve", "OBSERVATION_MODIFIER", 47, 52], ["free gas", "OBSERVATION", 111, 119], ["airways", "ANATOMY", 129, 136], ["dead space", "OBSERVATION", 151, 161], ["airway", "ANATOMY", 219, 225], ["alveolar gas", "OBSERVATION", 230, 242], ["pure", "OBSERVATION_MODIFIER", 269, 273], ["alveolar", "ANATOMY_MODIFIER", 274, 282], ["gas compartment", "OBSERVATION", 283, 298], ["volume exhaled", "OBSERVATION", 303, 317], ["rest of", "ANATOMY_MODIFIER", 327, 334], ["alveoli", "ANATOMY", 339, 346]]], ["A tangential line was constructed at the alveolar plateau between 90 and 98% of V T , and a vertical line was inserted in the middle of phase 2, such that two equal triangles were created.", [["tangential line", "ANATOMY", 2, 17], ["alveolar", "ANATOMY", 41, 49], ["alveolar", "MULTI-TISSUE_STRUCTURE", 41, 49], ["A tangential line", "TREATMENT", 0, 17], ["the alveolar plateau", "TEST", 37, 57], ["a vertical line", "TREATMENT", 90, 105], ["tangential line", "OBSERVATION", 2, 17], ["alveolar", "ANATOMY_MODIFIER", 41, 49], ["plateau", "ANATOMY", 50, 57], ["vertical line", "OBSERVATION", 92, 105], ["middle", "ANATOMY_MODIFIER", 126, 132], ["equal triangles", "OBSERVATION", 159, 174]]], ["The area below the arterial carbon dioxide line can be divided into three parts: X, which represents V A ; Y, which represents V d,alv ; and Z, which represents V d,Fowler .", [["arterial", "ANATOMY", 19, 27], ["carbon dioxide", "CHEMICAL", 28, 42], ["carbon dioxide", "CHEMICAL", 28, 42], ["arterial", "MULTI-TISSUE_STRUCTURE", 19, 27], ["alv", "PROTEIN", 131, 134], ["Z", "PROTEIN", 141, 142], ["the arterial carbon dioxide line", "TREATMENT", 15, 47], ["V d,alv ; and Z", "PROBLEM", 127, 142], ["arterial", "ANATOMY", 19, 27], ["carbon", "OBSERVATION", 28, 34], ["dioxide line", "OBSERVATION", 35, 47], ["V", "OBSERVATION", 101, 102], ["V d", "OBSERVATION", 127, 130], ["alv", "ANATOMY", 131, 134], ["V d", "OBSERVATION", 161, 164]]], ["V d,Fowler , V d,alv , and V A were calculated from respective area ratios to V T .DiscussionThe present study demonstrated that PaCO 2 values and deadspace ratios were correlated, and that ventilated infants with hypercapnia had a higher V d,phys , which resulted in a decrease of V A in the absence of a difference in either V T or V E .", [["hypercapnia", "DISEASE", 214, 225], ["PaCO 2", "CHEMICAL", 129, 135], ["PaCO 2", "GENE_OR_GENE_PRODUCT", 129, 135], ["deadspace", "SIMPLE_CHEMICAL", 147, 156], ["infants", "ORGANISM", 201, 208], ["V T", "GENE_OR_GENE_PRODUCT", 327, 330], ["V E", "GENE_OR_GENE_PRODUCT", 334, 337], ["infants", "SPECIES", 201, 208], ["Fowler , V d,alv , and V A", "PROBLEM", 4, 30], ["The present study", "TEST", 93, 110], ["PaCO", "TEST", 129, 133], ["deadspace ratios", "TEST", 147, 163], ["hypercapnia", "PROBLEM", 214, 225], ["a decrease of V A", "PROBLEM", 268, 285], ["alv", "ANATOMY", 17, 20], ["decrease", "OBSERVATION_MODIFIER", 270, 278]]], ["V d,Fowler (r = 0.14, p = 0.12).", [["p", "TEST", 22, 23]]], ["PaCO 2 , pressure of carbon oxide; V d,Fowler , Fowler dead space; V d,alv , alveolar dead space; V T , tidal volume; V d,phys , physiological dead space A previous study of low-birth-weight infants ventilated for RDS showed that PaCO 2 correlates reasonably well with V E , and that setting appropriate V E may allow closer targeting of PaCO 2 [1] .", [["alveolar", "ANATOMY", 77, 85], ["carbon oxide", "CHEMICAL", 21, 33], ["RDS", "DISEASE", 214, 217], ["PaCO 2", "CHEMICAL", 0, 6], ["carbon oxide", "CHEMICAL", 21, 33], ["PaCO 2", "CHEMICAL", 230, 236], ["PaCO 2", "CHEMICAL", 338, 344], ["carbon oxide", "SIMPLE_CHEMICAL", 21, 33], ["infants", "ORGANISM", 191, 198], ["PaCO 2", "GENE_OR_GENE_PRODUCT", 230, 236], ["V E", "GENE_OR_GENE_PRODUCT", 269, 272], ["V E", "GENE_OR_GENE_PRODUCT", 304, 307], ["PaCO 2", "GENE_OR_GENE_PRODUCT", 338, 344], ["infants", "SPECIES", 191, 198], ["PaCO", "TEST", 0, 4], ["pressure of carbon oxide", "TREATMENT", 9, 33], ["Fowler dead space", "TEST", 48, 65], ["V d,alv , alveolar dead space", "PROBLEM", 67, 96], ["tidal volume", "TEST", 104, 116], ["physiological dead space", "PROBLEM", 129, 153], ["A previous study", "TEST", 154, 170], ["RDS", "PROBLEM", 214, 217], ["PaCO", "TEST", 230, 234], ["PaCO", "TEST", 338, 342], ["alv", "ANATOMY", 71, 74], ["alveolar", "ANATOMY", 77, 85]]], ["However, it is known that the dead-space ratio depends on birth weight or gestational weeks, the volume of devices such as endotracheal tubes, and various respiratory conditions [2, 3, [7] [8] [9] .", [["endotracheal tubes", "ANATOMY", 123, 141], ["the dead-space ratio", "PROBLEM", 26, 46], ["the volume of devices", "TREATMENT", 93, 114], ["endotracheal tubes", "TREATMENT", 123, 141], ["endotracheal tubes", "OBSERVATION", 123, 141], ["respiratory conditions", "OBSERVATION", 155, 177]]], ["In our study, the regression analysis revealed that PaCO 2 values were positively correlated with V d,phys and V d,alv , but not V d,Fowler .", [["PaCO 2", "GENE_OR_GENE_PRODUCT", 52, 58], ["our study", "TEST", 3, 12], ["the regression analysis", "TEST", 14, 37], ["PaCO 2 values", "TEST", 52, 65], ["V d,phys and V d,alv", "PROBLEM", 98, 118], ["alv", "ANATOMY", 115, 118]]], ["Generally, V d,alv increases with high PEEP and lung hypoperfusion [2] .", [["lung", "ANATOMY", 48, 52], ["lung hypoperfusion", "DISEASE", 48, 66], ["lung", "ORGAN", 48, 52], ["high PEEP", "TREATMENT", 34, 43], ["lung hypoperfusion", "PROBLEM", 48, 66], ["high PEEP", "OBSERVATION", 34, 43], ["lung", "ANATOMY", 48, 52], ["hypoperfusion", "OBSERVATION", 53, 66]]], ["Although PEEP remained unchanged between the two groups in our study, low pulmonary circulation in the hypercapnia group could be responsible for the observed increase in V d,alv .", [["pulmonary", "ANATOMY", 74, 83], ["hypercapnia", "DISEASE", 103, 114], ["pulmonary", "ORGAN", 74, 83], ["PEEP", "TEST", 9, 13], ["our study", "TEST", 59, 68], ["low pulmonary circulation", "PROBLEM", 70, 95], ["the observed increase in V d,alv", "PROBLEM", 146, 178], ["unchanged", "OBSERVATION_MODIFIER", 23, 32], ["low", "OBSERVATION_MODIFIER", 70, 73], ["pulmonary circulation", "ANATOMY", 74, 95], ["hypercapnia", "OBSERVATION", 103, 114], ["could be responsible for", "UNCERTAINTY", 121, 145], ["increase", "OBSERVATION_MODIFIER", 159, 167], ["V d", "OBSERVATION", 171, 174], ["alv", "ANATOMY", 175, 178]]], ["The pulmonary transition at birth relies on an immediate drop in pulmonary vascular resistance with a concomitant increase in pulmonary blood flow.", [["pulmonary", "ANATOMY", 4, 13], ["pulmonary vascular", "ANATOMY", 65, 83], ["pulmonary", "ANATOMY", 126, 135], ["blood", "ANATOMY", 136, 141], ["increase in pulmonary blood flow", "DISEASE", 114, 146], ["pulmonary", "ORGAN", 4, 13], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 65, 83], ["pulmonary", "MULTI-TISSUE_STRUCTURE", 126, 135], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["The pulmonary transition", "PROBLEM", 0, 24], ["an immediate drop in pulmonary vascular resistance", "PROBLEM", 44, 94], ["a concomitant increase in pulmonary blood flow", "PROBLEM", 100, 146], ["pulmonary", "ANATOMY", 4, 13], ["transition", "OBSERVATION", 14, 24], ["immediate", "OBSERVATION_MODIFIER", 47, 56], ["drop", "OBSERVATION", 57, 61], ["pulmonary vascular", "ANATOMY", 65, 83], ["resistance", "OBSERVATION", 84, 94], ["concomitant", "OBSERVATION_MODIFIER", 102, 113], ["increase", "OBSERVATION_MODIFIER", 114, 122], ["pulmonary blood flow", "OBSERVATION", 126, 146]]], ["The main reasons for ventilator management in the NICU (RDS, MAS, infection, and asphyxia) may increase pulmonary vascular resistance [10] .", [["pulmonary vascular", "ANATOMY", 104, 122], ["RDS", "DISEASE", 56, 59], ["MAS", "DISEASE", 61, 64], ["infection", "DISEASE", 66, 75], ["asphyxia", "DISEASE", 81, 89], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 104, 122], ["ventilator management", "TREATMENT", 21, 42], ["RDS", "PROBLEM", 56, 59], ["MAS", "PROBLEM", 61, 64], ["infection", "PROBLEM", 66, 75], ["asphyxia", "PROBLEM", 81, 89], ["increase pulmonary vascular resistance", "PROBLEM", 95, 133], ["main", "OBSERVATION_MODIFIER", 4, 8], ["ventilator management", "OBSERVATION", 21, 42], ["infection", "OBSERVATION", 66, 75], ["pulmonary vascular", "ANATOMY", 104, 122]]], ["Even in wellventilated infants, a reduction in effective ventilation volumes can lead to hypercapnia, due to higher V d,phys because of decreased pulmonary blood flow.DiscussionFew studies have reported neonate V d,alv values [7, 11] .", [["pulmonary", "ANATOMY", 146, 155], ["blood", "ANATOMY", 156, 161], ["hypercapnia", "DISEASE", 89, 100], ["decreased pulmonary blood flow", "DISEASE", 136, 166], ["infants", "ORGANISM", 23, 30], ["pulmonary", "ORGAN", 146, 155], ["blood", "ORGANISM_SUBSTANCE", 156, 161], ["infants", "SPECIES", 23, 30], ["a reduction in effective ventilation volumes", "TREATMENT", 32, 76], ["hypercapnia", "PROBLEM", 89, 100], ["higher V d,phys", "PROBLEM", 109, 124], ["decreased pulmonary blood flow", "PROBLEM", 136, 166], ["DiscussionFew studies", "TEST", 167, 188], ["reduction", "OBSERVATION_MODIFIER", 34, 43], ["hypercapnia", "OBSERVATION", 89, 100], ["decreased", "OBSERVATION", 136, 145], ["pulmonary blood", "ANATOMY", 146, 161], ["flow", "OBSERVATION", 162, 166]]], ["Dassios et al. reported a median V d,alv of 0.3 ml/kg in prematurely born infants with a median weight of 1.18 kg, and 0.1 ml/kg for infants with a median weight of 3.3 kg; we report a higher mean V d,alv 0.6-1.0 ml/kg [7] .", [["infants", "ORGANISM", 74, 81], ["infants", "ORGANISM", 133, 140], ["infants", "SPECIES", 74, 81], ["infants", "SPECIES", 133, 140], ["a median weight", "TEST", 146, 161]]], ["This discrepancy might be explained by the fact that the previous study investigated infants during a clinically stable state when they were ready for extubation, while the present study examined infants during respiratory failure.DiscussionSeveral clinical implications can be derived from our study.", [["respiratory", "ANATOMY", 211, 222], ["respiratory failure", "DISEASE", 211, 230], ["infants", "ORGANISM", 85, 92], ["infants", "ORGANISM", 196, 203], ["infants", "SPECIES", 85, 92], ["infants", "SPECIES", 196, 203], ["the previous study", "TEST", 53, 71], ["extubation", "TREATMENT", 151, 161], ["the present study", "TEST", 169, 186], ["respiratory failure", "PROBLEM", 211, 230], ["our study", "TEST", 291, 300], ["might be explained", "UNCERTAINTY", 17, 35], ["respiratory failure", "OBSERVATION", 211, 230]]], ["Cases with a higher dead space could be detected at bedside to determine suitable ventilator settings, including a moderate level of PEEP and higher respiratory rates to maintain appropriate V A .", [["respiratory", "ANATOMY", 149, 160], ["a higher dead space", "PROBLEM", 11, 30], ["a moderate level of PEEP", "TREATMENT", 113, 137], ["higher respiratory rates", "TREATMENT", 142, 166], ["moderate", "OBSERVATION_MODIFIER", 115, 123]]], ["In addition, measurements of V d,alv are useful for the diagnosis of PPHN with lung hypoperfusion, as these techniques could estimate the effectiveness of inhaled nitric oxide, which induces pulmonary vasodilation.DiscussionThe limitations of our study included the absence of an evaluation of pulmonary blood flow and calculations of the physiological dead space using the Enghoff approach, which estimates not only the true dead space but also intrapulmonary right to left shunting and low ventilationperfusion regions of the lung [12] [13] [14] .", [["lung", "ANATOMY", 79, 83], ["pulmonary", "ANATOMY", 191, 200], ["pulmonary", "ANATOMY", 294, 303], ["blood", "ANATOMY", 304, 309], ["intrapulmonary right", "ANATOMY", 446, 466], ["lung", "ANATOMY", 528, 532], ["PPHN", "DISEASE", 69, 73], ["lung hypoperfusion", "DISEASE", 79, 97], ["nitric oxide", "CHEMICAL", 163, 175], ["nitric oxide", "CHEMICAL", 163, 175], ["V d", "GENE_OR_GENE_PRODUCT", 29, 32], ["alv", "GENE_OR_GENE_PRODUCT", 33, 36], ["lung", "ORGAN", 79, 83], ["nitric oxide", "SIMPLE_CHEMICAL", 163, 175], ["pulmonary", "ORGAN", 191, 200], ["pulmonary", "MULTI-TISSUE_STRUCTURE", 294, 303], ["blood", "ORGANISM_SUBSTANCE", 304, 309], ["lung", "ORGAN", 528, 532], ["ventilationperfusion regions", "PROTEIN", 492, 520], ["PPHN", "PROBLEM", 69, 73], ["lung hypoperfusion", "PROBLEM", 79, 97], ["inhaled nitric oxide", "TREATMENT", 155, 175], ["pulmonary vasodilation", "PROBLEM", 191, 213], ["our study", "TEST", 243, 252], ["an evaluation", "TEST", 277, 290], ["pulmonary blood flow", "TEST", 294, 314], ["the physiological dead space", "PROBLEM", 335, 363], ["the Enghoff approach", "TREATMENT", 370, 390], ["the true dead space", "PROBLEM", 417, 436], ["intrapulmonary right to left shunting", "PROBLEM", 446, 483], ["low ventilationperfusion regions of the lung", "PROBLEM", 488, 532], ["alv", "ANATOMY", 33, 36], ["PPHN", "OBSERVATION", 69, 73], ["lung", "ANATOMY", 79, 83], ["hypoperfusion", "OBSERVATION", 84, 97], ["pulmonary", "ANATOMY", 191, 200], ["vasodilation", "OBSERVATION", 201, 213], ["pulmonary blood", "ANATOMY", 294, 309], ["dead space", "OBSERVATION", 353, 363], ["intrapulmonary", "ANATOMY", 446, 460], ["right", "ANATOMY_MODIFIER", 461, 466], ["left", "ANATOMY_MODIFIER", 470, 474], ["shunting", "OBSERVATION", 475, 483], ["low ventilationperfusion", "OBSERVATION", 488, 512], ["lung", "ANATOMY", 528, 532]]], ["Enghoff's V d,alv may be overestimated in infants with collapsed alveoli caused by surfactant deficiency.", [["alveoli", "ANATOMY", 65, 72], ["alv", "GENE_OR_GENE_PRODUCT", 14, 17], ["infants", "ORGANISM", 42, 49], ["alveoli", "MULTI-TISSUE_STRUCTURE", 65, 72], ["infants", "SPECIES", 42, 49], ["collapsed alveoli", "PROBLEM", 55, 72], ["surfactant deficiency", "PROBLEM", 83, 104], ["collapsed", "OBSERVATION", 55, 64], ["alveoli", "ANATOMY_MODIFIER", 65, 72], ["surfactant deficiency", "OBSERVATION", 83, 104]]], ["Furthermore, the term and preterm neonates included in this study were intubated for various reasons.", [["neonates", "ORGANISM", 34, 42], ["the term and preterm neonates", "PROBLEM", 13, 42], ["this study", "TEST", 55, 65], ["intubated", "TREATMENT", 71, 80]]], ["In future studies, it will be important to study more homogenised samples to clarify the pathophysiology of the infants' respiratory diseases.ConclusionWe discovered that volumetric capnography in ventilated neonates with hypercapnia presents with a reduction of minute alveolar ventilation volume, in the absence of a decrease in minute ventilation volume.", [["samples", "ANATOMY", 66, 73], ["respiratory", "ANATOMY", 121, 132], ["alveolar", "ANATOMY", 270, 278], ["respiratory diseases", "DISEASE", 121, 141], ["hypercapnia", "DISEASE", 222, 233], ["infants", "ORGANISM", 112, 119], ["neonates", "ORGANISM", 208, 216], ["alveolar", "MULTI-TISSUE_STRUCTURE", 270, 278], ["infants", "SPECIES", 112, 119], ["future studies", "TEST", 3, 17], ["the infants' respiratory diseases", "PROBLEM", 108, 141], ["volumetric capnography", "TEST", 171, 193], ["hypercapnia", "PROBLEM", 222, 233], ["a reduction of minute alveolar ventilation volume", "TREATMENT", 248, 297], ["a decrease in minute ventilation volume", "TREATMENT", 317, 356], ["respiratory diseases", "OBSERVATION", 121, 141], ["hypercapnia", "OBSERVATION", 222, 233], ["reduction", "OBSERVATION_MODIFIER", 250, 259], ["alveolar ventilation volume", "OBSERVATION", 270, 297], ["decrease", "OBSERVATION_MODIFIER", 319, 327], ["minute ventilation volume", "OBSERVATION", 331, 356]]], ["We believe that hypercapnia in newborns with otherwise good ventilation is attributable to an increase in physiological dead space.", [["hypercapnia", "DISEASE", 16, 27], ["newborns", "ORGANISM", 31, 39], ["hypercapnia", "PROBLEM", 16, 27], ["an increase in physiological dead space", "PROBLEM", 91, 130], ["hypercapnia", "OBSERVATION", 16, 27], ["good ventilation", "OBSERVATION", 55, 71], ["increase", "OBSERVATION_MODIFIER", 94, 102], ["physiological dead space", "OBSERVATION", 106, 130]]]], "PMC7376592": [["Coronavirus disease-2019 (COVID-19) is a new disease entity caused by novel severe acute respiratory syndrome coronavirus 2 (SARS\u2013CoV-2).", [["Coronavirus disease", "DISEASE", 0, 19], ["acute respiratory syndrome coronavirus", "DISEASE", 83, 121], ["COVID-19", "CELL", 26, 34], ["SARS\u2013CoV-2", "ORGANISM", 125, 135], ["Coronavirus disease-2019 (COVID-19", "SPECIES", 0, 34], ["severe acute respiratory syndrome coronavirus", "SPECIES", 76, 121], ["SARS\u2013CoV-2", "SPECIES", 125, 135], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 26, 31], ["a new disease entity", "PROBLEM", 39, 59], ["novel severe acute respiratory syndrome coronavirus", "PROBLEM", 70, 121], ["SARS\u2013CoV", "TEST", 125, 133], ["new", "OBSERVATION_MODIFIER", 41, 44], ["disease", "OBSERVATION", 45, 52], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["respiratory syndrome", "OBSERVATION", 89, 109]]], ["COVID-19 has been declared a pandemic by the World Health Organization (WHO).1,2 The disease started from Wuhan of Hubei province of China and then moved to Asia, Australia, Europe, and American continent, and Africa in a discrete manner.3 Bangladesh, a country of 170 million people first reported three cases of COVID-19 on 8 March, 2020, and the first COVID-19-related mortality was detected on 18 March, 2020.4 A nationwide enforcement of physical distancing was declared from March 26th, 2020, with closure of almost all functional avenues except the emergency entities.", [["COVID-19", "CHEMICAL", 0, 8], ["1,2", "CHEMICAL", 77, 80], ["people", "ORGANISM", 277, 283], ["people", "SPECIES", 277, 283], ["The disease", "PROBLEM", 81, 92], ["COVID", "TEST", 314, 319], ["the first COVID", "TEST", 345, 360], ["closure", "TREATMENT", 504, 511], ["disease", "OBSERVATION", 85, 92]]], ["This lockdown approach has changed the overall life style of the people of the country.", [["people", "ORGANISM", 65, 71], ["people", "SPECIES", 65, 71], ["This lockdown approach", "TREATMENT", 0, 22]]], ["The social and economic impacts are tremendous on a developing country like Bangladesh, and more evaluation and analysis would be required to assess the mid- and long-term effects; the magnitude of which may not be assumed at this point as the country is still fighting to get rid of this pandemic.", [["more evaluation", "TEST", 92, 107], ["analysis", "TEST", 112, 120], ["this pandemic", "PROBLEM", 284, 297], ["tremendous", "OBSERVATION_MODIFIER", 36, 46], ["long-term effects", "OBSERVATION_MODIFIER", 162, 179]]]], "PMC7385288": [["IntroductionWhile the protection and repair of brain function is the raison d'\u00eatre for the practicing neurologist, neurological expertise can also be applied to the transition from life to death.IntroductionThe most obvious arena where this expertise is needed concerns the determination of brain death in a potential organ donor (1).", [["brain", "ANATOMY", 47, 52], ["neurological", "ANATOMY", 115, 127], ["brain", "ANATOMY", 291, 296], ["organ", "ANATOMY", 318, 323], ["death", "DISEASE", 189, 194], ["brain death", "DISEASE", 291, 302], ["brain", "ORGAN", 47, 52], ["brain", "ORGAN", 291, 296], ["organ", "ORGAN", 318, 323], ["the protection", "TREATMENT", 18, 32], ["repair", "TREATMENT", 37, 43], ["brain death", "PROBLEM", 291, 302], ["brain", "ANATOMY", 47, 52]]], ["In addition, donation after circulatory death (DCD) is increasingly practiced when brain-injured patients are deemed unlikely to enter brain death before withdrawal of life-sustaining therapy (2).", [["circulatory", "ANATOMY", 28, 39], ["brain", "ANATOMY", 83, 88], ["brain", "ANATOMY", 135, 140], ["circulatory death", "DISEASE", 28, 45], ["DCD", "DISEASE", 47, 50], ["brain death", "DISEASE", 135, 146], ["brain", "ORGAN", 83, 88], ["patients", "ORGANISM", 97, 105], ["brain", "ORGAN", 135, 140], ["patients", "SPECIES", 97, 105], ["circulatory death", "PROBLEM", 28, 45], ["brain death", "PROBLEM", 135, 146], ["life-sustaining therapy", "TREATMENT", 168, 191]]], ["In these cases, neurologists are typically consulted to confirm that meaningful recovery of brain function is futile, which requires proficiency in neuro-prognostication (3, 4).IntroductionFurther, knowledge about the cellular processes in the brain taking place after circulatory arrest is important to determine how much time should pass between cardiac standstill and organ procurement (3, 5).", [["brain", "ANATOMY", 92, 97], ["cellular", "ANATOMY", 218, 226], ["brain", "ANATOMY", 244, 249], ["cardiac", "ANATOMY", 348, 355], ["organ", "ANATOMY", 371, 376], ["circulatory arrest", "DISEASE", 269, 287], ["brain", "ORGAN", 92, 97], ["cellular", "CELL", 218, 226], ["brain", "ORGAN", 244, 249], ["cardiac", "ORGAN", 348, 355], ["organ", "ORGAN", 371, 376], ["circulatory arrest", "PROBLEM", 269, 287], ["brain", "ANATOMY", 92, 97], ["brain", "ANATOMY", 244, 249], ["arrest", "OBSERVATION", 281, 287], ["cardiac", "ANATOMY", 348, 355], ["standstill", "OBSERVATION", 356, 366]]], ["This is an important ethical problem because the amount of time elapsed is positively correlated with the certainty of lost brain function but negatively with the tissue quality of organ transplants (3, 5\u20137).", [["brain", "ANATOMY", 124, 129], ["tissue", "ANATOMY", 163, 169], ["organ", "ANATOMY", 181, 186], ["brain", "ORGAN", 124, 129], ["tissue", "TISSUE", 163, 169], ["organ", "ORGAN", 181, 186], ["organ transplants", "TREATMENT", 181, 198], ["organ", "ANATOMY", 181, 186], ["transplants", "OBSERVATION", 187, 198]]], ["Recent attempts of brain resuscitation in an animal model add another layer of complexity (8).IntroductionIn addition, neurology may offer a window to understand near-death experiences (NDE) which are empirically testable despite their mystic flavor.", [["brain", "ANATOMY", 19, 24], ["death", "DISEASE", 167, 172], ["brain", "ORGAN", 19, 24], ["brain resuscitation", "TREATMENT", 19, 38], ["brain", "ANATOMY", 19, 24], ["resuscitation", "OBSERVATION", 25, 38]]], ["Proposed biological mechanisms underlying NDE include temporoparietal lesions (9), N-methyl-D-aspartate receptor (NMDAR) hypofunction (10), rapid eye movement (REM) sleep intrusion (11), and migraine aura (12), all of which are familiar to neurologists.IntroductionThis paper highlights salient aspects of death and the dying brain, aiming to provide busy neurologists with a rapidly accessible overview including graphic information.", [["temporoparietal lesions", "ANATOMY", 54, 77], ["eye", "ANATOMY", 146, 149], ["brain", "ANATOMY", 326, 331], ["temporoparietal lesions", "DISEASE", 54, 77], ["N-methyl-D-aspartate", "CHEMICAL", 83, 103], ["hypofunction", "DISEASE", 121, 133], ["rapid eye movement (REM) sleep intrusion", "DISEASE", 140, 180], ["migraine aura", "DISEASE", 191, 204], ["death", "DISEASE", 306, 311], ["N-methyl-D-aspartate", "CHEMICAL", 83, 103], ["NDE", "SIMPLE_CHEMICAL", 42, 45], ["temporoparietal lesions", "CANCER", 54, 77], ["N-methyl-D-aspartate receptor", "SIMPLE_CHEMICAL", 83, 112], ["NMDAR", "SIMPLE_CHEMICAL", 114, 119], ["eye", "ORGAN", 146, 149], ["brain", "ORGAN", 326, 331], ["NMDAR", "PROTEIN", 114, 119], ["temporoparietal lesions", "PROBLEM", 54, 77], ["N-methyl-D-aspartate receptor", "TREATMENT", 83, 112], ["hypofunction", "PROBLEM", 121, 133], ["rapid eye movement (REM) sleep intrusion", "PROBLEM", 140, 180], ["migraine aura", "PROBLEM", 191, 204], ["temporoparietal", "ANATOMY", 54, 69], ["lesions", "OBSERVATION", 70, 77], ["eye", "ANATOMY", 146, 149], ["brain", "ANATOMY", 326, 331]]], ["As such, its intention is to share the author's personal view in an entertaining manner rather than to provide an exhaustive and strictly balanced review of the literature.An Historical Overview of Organ Donation After Brain Death and Circulatory DeathThe notion that organs from deceased people can be used to serve the living is many centuries old, the most prominent example being Mary Shelley's Frankenstein or The Modern Prometheus from 1818 (Figure 1).", [["Brain", "ANATOMY", 219, 224], ["organs", "ANATOMY", 268, 274], ["Brain Death", "DISEASE", 219, 230], ["Circulatory Death", "DISEASE", 235, 252], ["organs", "ORGAN", 268, 274], ["people", "ORGANISM", 289, 295], ["people", "SPECIES", 289, 295], ["Brain Death", "PROBLEM", 219, 230], ["Circulatory Death", "PROBLEM", 235, 252], ["Circulatory Death", "OBSERVATION", 235, 252], ["most prominent", "OBSERVATION_MODIFIER", 355, 369]]], ["The mid-20th century saw the first successful organ transplantations.", [["organ", "ANATOMY", 46, 51], ["organ", "ORGAN", 46, 51], ["the first successful organ transplantations", "TREATMENT", 25, 68], ["transplantations", "OBSERVATION", 52, 68]]], ["In 1950, a kidney was transplanted at the Little Company of Mary Hospital in Evergreen Park, Illinois, USA; and 17 years later, at the Groote Schuur Hospital in Cape Town, South Africa, Christiaan Barnard performed the first heart transplantation in a man who recovered consciousness post-surgery (although the patient died 18 days later of pneumonia).", [["kidney", "ANATOMY", 11, 17], ["heart", "ANATOMY", 225, 230], ["pneumonia", "DISEASE", 341, 350], ["kidney", "ORGAN", 11, 17], ["heart", "ORGAN", 225, 230], ["man", "ORGANISM", 252, 255], ["patient", "ORGANISM", 311, 318], ["man", "SPECIES", 252, 255], ["patient", "SPECIES", 311, 318], ["the first heart transplantation", "TREATMENT", 215, 246], ["surgery", "TREATMENT", 289, 296], ["pneumonia", "PROBLEM", 341, 350], ["kidney", "ANATOMY", 11, 17], ["transplanted", "OBSERVATION", 22, 34], ["heart", "ANATOMY", 225, 230], ["transplantation", "OBSERVATION", 231, 246], ["pneumonia", "OBSERVATION", 341, 350]]], ["The rise of intensive care medicine around the same time was key to the concept of brain death.", [["brain", "ANATOMY", 83, 88], ["brain death", "DISEASE", 83, 94], ["brain", "ORGAN", 83, 88], ["intensive care medicine", "TREATMENT", 12, 35], ["brain death", "PROBLEM", 83, 94], ["rise", "OBSERVATION_MODIFIER", 4, 8], ["brain", "ANATOMY", 83, 88], ["death", "OBSERVATION", 89, 94]]], ["The Blegdams Hospital (now defunct) in Copenhagen is typically credited for having established the first intensive care unit in the world in response to the 1952 poliomyelitis outbreak in Denmark's capital (13).", [["poliomyelitis", "DISEASE", 162, 175]]], ["H.C.A. Lassen reported in The Lancet that artificial ventilation was able to reduce the mortality from polio by half (14).", [["polio", "DISEASE", 103, 108], ["artificial ventilation", "TREATMENT", 42, 64]]], ["Soon thereafter, it was recognized that the bodies of people, except their brains, could be kept functioning for a prolonged period given intensive care management.", [["brains", "ANATOMY", 75, 81], ["people", "ORGANISM", 54, 60], ["people", "SPECIES", 54, 60], ["intensive care management", "TREATMENT", 138, 163]]], ["In 1959, \u201cafter 4 years of thinking,\u201d Frenchmen Mollaret and Goulon termed this condition coma d\u00e9pass\u00e9 (literally, \u201ca state beyond coma\u201d) (15).", [["coma", "DISEASE", 90, 94], ["coma", "DISEASE", 131, 135]]], ["The Harvard brain death criteria were published barely a decade later (16).", [["brain", "ANATOMY", 12, 17], ["brain death", "DISEASE", 12, 23], ["brain", "ORGAN", 12, 17]]], ["Although the criteria have been revised several times since, they captured the essential features of brain death.", [["brain", "ANATOMY", 101, 106], ["brain death", "DISEASE", 101, 112], ["brain", "ORGAN", 101, 106], ["brain death", "PROBLEM", 101, 112], ["brain", "ANATOMY", 101, 106], ["death", "OBSERVATION", 107, 112]]], ["In contrast to present day standards, however, the absence of spinal reflexes was a prerequisite for the diagnosis (16).", [["spinal", "ANATOMY", 62, 68], ["spinal reflexes", "PROBLEM", 62, 77], ["spinal", "ANATOMY", 62, 68]]], ["Pathologists noted in the early 1970'ies that corpses which had been kept on prolonged intensive care support had brains that were \u201cswollen, mottled gray-red, and extremely soft, at times diffluent; at autopsy, very often the mass of cerebrum flattens, detaches, and pours away from the base of the skull,\u201d the so-called respirator brain death syndrome (17).An Historical Overview of Organ Donation After Brain Death and Circulatory DeathOver the subsequent years, organ donation after brain death became the standard.", [["brains", "ANATOMY", 114, 120], ["cerebrum", "ANATOMY", 234, 242], ["detaches", "ANATOMY", 253, 261], ["skull", "ANATOMY", 299, 304], ["brain", "ANATOMY", 332, 337], ["Brain", "ANATOMY", 405, 410], ["organ", "ANATOMY", 465, 470], ["brain", "ANATOMY", 486, 491], ["flattens", "DISEASE", 243, 251], ["detaches", "DISEASE", 253, 261], ["brain death", "DISEASE", 332, 343], ["Brain Death", "DISEASE", 405, 416], ["brain death", "DISEASE", 486, 497], ["cerebrum", "ORGAN", 234, 242], ["skull", "ORGAN", 299, 304], ["brain", "ORGAN", 332, 337], ["organ", "ORGAN", 465, 470], ["brain", "ORGAN", 486, 491], ["prolonged intensive care support", "TREATMENT", 77, 109], ["swollen", "PROBLEM", 132, 139], ["mottled gray", "PROBLEM", 141, 153], ["autopsy", "TEST", 202, 209], ["the mass of cerebrum flattens", "PROBLEM", 222, 251], ["detaches", "PROBLEM", 253, 261], ["the so-called respirator brain death syndrome", "PROBLEM", 307, 352], ["organ donation", "TREATMENT", 465, 479], ["brain death", "PROBLEM", 486, 497], ["swollen", "OBSERVATION", 132, 139], ["mottled", "OBSERVATION_MODIFIER", 141, 148], ["red", "OBSERVATION", 154, 157], ["mass", "OBSERVATION", 226, 230], ["cerebrum", "ANATOMY", 234, 242], ["base", "ANATOMY_MODIFIER", 287, 291], ["skull", "ANATOMY", 299, 304], ["respirator brain", "OBSERVATION", 321, 337], ["death syndrome", "OBSERVATION", 338, 352]]], ["Organs for transplantation were no longer obtained from non-heart beating donors (NHBD), but most organ donors were now recruited after traumatic brain injury, cardiac arrest, and subarachnoid hemorrhage.", [["Organs", "ANATOMY", 0, 6], ["organ", "ANATOMY", 98, 103], ["brain", "ANATOMY", 146, 151], ["cardiac", "ANATOMY", 160, 167], ["subarachnoid", "ANATOMY", 180, 192], ["traumatic brain injury", "DISEASE", 136, 158], ["cardiac arrest", "DISEASE", 160, 174], ["subarachnoid hemorrhage", "DISEASE", 180, 203], ["Organs", "ORGAN", 0, 6], ["donors", "ORGANISM", 74, 80], ["organ", "ORGAN", 98, 103], ["donors", "ORGANISM", 104, 110], ["brain", "ORGAN", 146, 151], ["transplantation", "TREATMENT", 11, 26], ["traumatic brain injury", "PROBLEM", 136, 158], ["cardiac arrest", "PROBLEM", 160, 174], ["subarachnoid hemorrhage", "PROBLEM", 180, 203], ["transplantation", "OBSERVATION", 11, 26], ["no longer", "UNCERTAINTY", 32, 41], ["brain", "ANATOMY", 146, 151], ["injury", "OBSERVATION", 152, 158], ["cardiac", "ANATOMY", 160, 167], ["arrest", "OBSERVATION", 168, 174], ["subarachnoid", "ANATOMY", 180, 192], ["hemorrhage", "OBSERVATION", 193, 203]]], ["Yet in the 1990ies it became clear that patients in need of organs progressively outnumbered donors and transplants1.", [["organs", "ANATOMY", 60, 66], ["patients", "ORGANISM", 40, 48], ["organs", "ORGAN", 60, 66], ["donors", "ORGANISM", 93, 99], ["patients", "SPECIES", 40, 48], ["transplants", "TREATMENT", 104, 115], ["clear", "OBSERVATION", 29, 34]]], ["Additional methods to increase the rate of organ donations were needed.", [["organ", "ANATOMY", 43, 48], ["organ", "ORGAN", 43, 48], ["Additional methods", "TREATMENT", 0, 18], ["organ donations", "TREATMENT", 43, 58]]], ["In 1995, donation after circulatory death (DCD) was therefore (re-) introduced during the First International Workshop on NHBD, organized in Maastricht, the Netherlands (18).", [["circulatory", "ANATOMY", 24, 35], ["circulatory death", "DISEASE", 24, 41], ["DCD", "DISEASE", 43, 46], ["circulatory death", "PROBLEM", 24, 41], ["NHBD", "TREATMENT", 122, 126], ["NHBD", "OBSERVATION", 122, 126]]], ["The idea was that DCD would help to reduce the shortage of organs by expanding the donor pool (19).", [["organs", "ANATOMY", 59, 65], ["DCD", "DISEASE", 18, 21], ["organs", "ORGAN", 59, 65], ["DCD", "TREATMENT", 18, 21]]], ["In Europe, DCD is practiced most often in the Netherlands and in the UK.", [["DCD", "DISEASE", 11, 14], ["UK", "GENE_OR_GENE_PRODUCT", 69, 71], ["DCD", "TREATMENT", 11, 14]]], ["In 2017, 619 DCD donors were counted in the UK, roughly 40% of all deceased organ donors that year2.", [["organ", "ANATOMY", 76, 81], ["donors", "ORGANISM", 17, 23], ["organ", "ORGAN", 76, 81], ["donors", "ORGANISM", 82, 88], ["year2", "GENE_OR_GENE_PRODUCT", 94, 99]]], ["Given that many other countries are expected to introduce DCD programs, e.g., Denmark in 2020, the impact of DCD is destined to increase in the future.Brain Death CriteriaThe determination of brain death follows a three-step approach, with the third step (confirmatory laboratory investigations) being either unnecessary, optional, or mandatory.", [["Brain", "ANATOMY", 151, 156], ["brain", "ANATOMY", 192, 197], ["DCD", "DISEASE", 58, 61], ["DCD", "DISEASE", 109, 112], ["brain death", "DISEASE", 192, 203], ["Brain", "ORGAN", 151, 156], ["brain", "ORGAN", 192, 197], ["DCD programs", "TREATMENT", 58, 70], ["DCD", "TREATMENT", 109, 112], ["confirmatory laboratory investigations", "TEST", 256, 294], ["brain", "ANATOMY", 192, 197]]], ["In analogy to a traffic light, these three steps can be thought of as the red, the amber and the green phases (Figure 2, showing an example of a brain death protocol).", [["brain", "ANATOMY", 145, 150], ["brain death", "DISEASE", 145, 156], ["brain", "ORGAN", 145, 150], ["a brain death protocol", "TREATMENT", 143, 165], ["amber", "OBSERVATION", 83, 88]]], ["The red phase implies to the clinician to pause and to confirm that the prerequisites for a brain death protocol are fulfilled.", [["brain", "ANATOMY", 92, 97], ["brain death", "DISEASE", 92, 103], ["brain", "ORGAN", 92, 97], ["a brain death protocol", "TEST", 90, 112], ["red phase", "OBSERVATION_MODIFIER", 4, 13]]], ["The first is the unconditioned certainty that the brain disorder faced is irreversible and fatal, which requires that the cause of brain injury is known and well-understood.", [["brain", "ANATOMY", 50, 55], ["brain", "ANATOMY", 131, 136], ["brain disorder", "DISEASE", 50, 64], ["brain injury", "DISEASE", 131, 143], ["brain", "ORGAN", 50, 55], ["brain", "ORGAN", 131, 136], ["the brain disorder", "PROBLEM", 46, 64], ["brain injury", "PROBLEM", 131, 143], ["brain", "ANATOMY", 50, 55], ["disorder", "OBSERVATION", 56, 64], ["irreversible", "OBSERVATION_MODIFIER", 74, 86], ["fatal", "OBSERVATION_MODIFIER", 91, 96], ["brain", "ANATOMY", 131, 136], ["injury", "OBSERVATION", 137, 143]]], ["Restated, people with an unknown cause of brain injury cannot be declared brain-dead.", [["brain", "ANATOMY", 42, 47], ["brain", "ANATOMY", 74, 79], ["brain injury", "DISEASE", 42, 54], ["people", "ORGANISM", 10, 16], ["brain", "ORGAN", 42, 47], ["brain", "ORGAN", 74, 79], ["people", "SPECIES", 10, 16], ["brain injury", "PROBLEM", 42, 54], ["brain", "ANATOMY", 42, 47], ["injury", "OBSERVATION", 48, 54]]], ["The second aspect is to ensure that the circumstances to assess brain death are optimal, i.e., that physiological parameters are within an acceptable range and that confounders such as sedation and muscle relaxants are ruled out.", [["brain", "ANATOMY", 64, 69], ["muscle", "ANATOMY", 198, 204], ["brain death", "DISEASE", 64, 75], ["brain", "ORGAN", 64, 69], ["muscle", "ORGAN", 198, 204], ["brain death", "PROBLEM", 64, 75], ["sedation", "TREATMENT", 185, 193], ["muscle relaxants", "TREATMENT", 198, 214]]], ["Hence, it is advisable to allow 5\u20137 times of any drug's elimination half-life to pass prior to the clinical examination and, if needed, to prove lack of neuromuscular blockade by revealing muscle twitches following electrical stimulation of the ulnar nerve (1).", [["neuromuscular", "ANATOMY", 153, 166], ["muscle", "ANATOMY", 189, 195], ["ulnar nerve", "ANATOMY", 245, 256], ["neuromuscular blockade", "DISEASE", 153, 175], ["muscle twitches", "DISEASE", 189, 204], ["muscle", "ORGAN", 189, 195], ["ulnar nerve", "MULTI-TISSUE_STRUCTURE", 245, 256], ["the clinical examination", "TEST", 95, 119], ["neuromuscular blockade", "TREATMENT", 153, 175], ["muscle twitches", "PROBLEM", 189, 204], ["muscle", "ANATOMY", 189, 195], ["ulnar nerve", "ANATOMY", 245, 256]]], ["In the amber phase, the clinician proceeds to the clinical examination, which has three goals.", [["the clinical examination", "TEST", 46, 70], ["amber phase", "OBSERVATION_MODIFIER", 7, 18]]], ["The first is to document absence of signal transmission between the brain and the spinal cord; i.e., noxious stimuli applied to the head must not evoke a response in the remainder of the body, and noxious stimuli applied to the body must not evoke a response above the level of the foramen magnum (for caveats related to this rule, see below).", [["brain", "ANATOMY", 68, 73], ["spinal cord", "ANATOMY", 82, 93], ["head", "ANATOMY", 132, 136], ["body", "ANATOMY", 187, 191], ["body", "ANATOMY", 228, 232], ["foramen magnum", "ANATOMY", 282, 296], ["brain", "ORGAN", 68, 73], ["spinal cord", "ORGAN", 82, 93], ["head", "ORGANISM_SUBDIVISION", 132, 136], ["body", "ORGANISM_SUBDIVISION", 187, 191], ["body", "ORGANISM_SUBDIVISION", 228, 232], ["foramen magnum", "MULTI-TISSUE_STRUCTURE", 282, 296], ["signal transmission between the brain and the spinal cord", "PROBLEM", 36, 93], ["noxious stimuli", "TEST", 101, 116], ["noxious stimuli", "TEST", 197, 212], ["this rule", "TEST", 321, 330], ["brain", "ANATOMY", 68, 73], ["spinal cord", "ANATOMY", 82, 93], ["head", "ANATOMY", 132, 136], ["body", "ANATOMY", 187, 191], ["foramen magnum", "ANATOMY", 282, 296]]], ["The second goal is to confirm lack of brainstem reflexes, and the third is to confirm failure of hypercapnia to trigger the respiratory brainstem centers (apnea test).", [["brainstem", "ANATOMY", 38, 47], ["respiratory brainstem", "ANATOMY", 124, 145], ["hypercapnia", "DISEASE", 97, 108], ["apnea", "DISEASE", 155, 160], ["brainstem", "ANATOMICAL_SYSTEM", 38, 47], ["lack of brainstem reflexes", "PROBLEM", 30, 56], ["failure of hypercapnia", "PROBLEM", 86, 108], ["the respiratory brainstem centers", "PROBLEM", 120, 153], ["apnea test", "TEST", 155, 165], ["hypercapnia", "OBSERVATION", 97, 108], ["respiratory brainstem", "ANATOMY", 124, 145]]], ["Depending on the clinical situation and the legislation, a variety of confirmatory tests may be used in the green phase to confirm the clinical examination.", [["confirmatory tests", "TEST", 70, 88], ["the clinical examination", "TEST", 131, 155]]], ["These tests are either based on the documentation of absent intracranial blood flow (e.g., digital subtraction angiography, computed tomography angiography, transcranial doppler, positron emission tomography, nuclear scintigraphy) or lack of electrical brain activity (e.g., EEG, evoked potentials).", [["intracranial blood", "ANATOMY", 60, 78], ["nuclear", "ANATOMY", 209, 216], ["brain", "ANATOMY", 253, 258], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["brain", "ORGAN", 253, 258], ["These tests", "TEST", 0, 11], ["absent intracranial blood flow", "PROBLEM", 53, 83], ["digital subtraction angiography", "TEST", 91, 122], ["computed tomography angiography", "TEST", 124, 155], ["transcranial doppler", "TEST", 157, 177], ["positron emission tomography", "TEST", 179, 207], ["nuclear scintigraphy", "TEST", 209, 229], ["EEG", "TEST", 275, 278], ["intracranial blood", "ANATOMY", 60, 78]]], ["Although legislations of most countries require ancillary investigations under certain circumstances, it has been argued that these investigations often lead to confusing results (see below) and should be reserved for situations in which an apnea test cannot be performed because of hemodynamic instability, poor oxygenation, or chronic carbon dioxide retention (e.g., in patients with chronic obstructive pulmonary disease) or in which facial injury renders full examination of brainstem reflexes impossible (20).", [["pulmonary", "ANATOMY", 406, 415], ["facial", "ANATOMY", 437, 443], ["brainstem", "ANATOMY", 479, 488], ["apnea", "DISEASE", 241, 246], ["carbon dioxide", "CHEMICAL", 337, 351], ["chronic obstructive pulmonary disease", "DISEASE", 386, 423], ["facial injury", "DISEASE", 437, 450], ["carbon dioxide", "CHEMICAL", 337, 351], ["carbon dioxide", "SIMPLE_CHEMICAL", 337, 351], ["patients", "ORGANISM", 372, 380], ["pulmonary", "ORGAN", 406, 415], ["facial", "ORGAN", 437, 443], ["brainstem", "ORGANISM_SUBDIVISION", 479, 488], ["patients", "SPECIES", 372, 380], ["ancillary investigations", "TEST", 48, 72], ["these investigations", "TEST", 126, 146], ["an apnea test", "TEST", 238, 251], ["hemodynamic instability", "PROBLEM", 283, 306], ["poor oxygenation", "PROBLEM", 308, 324], ["chronic carbon dioxide retention", "PROBLEM", 329, 361], ["chronic obstructive pulmonary disease)", "PROBLEM", 386, 424], ["facial injury", "PROBLEM", 437, 450], ["full examination of brainstem reflexes", "TEST", 459, 497], ["chronic", "OBSERVATION_MODIFIER", 329, 336], ["carbon dioxide retention", "OBSERVATION", 337, 361], ["chronic", "OBSERVATION_MODIFIER", 386, 393], ["obstructive", "OBSERVATION_MODIFIER", 394, 405], ["pulmonary", "ANATOMY", 406, 415], ["disease", "OBSERVATION", 416, 423], ["facial", "ANATOMY", 437, 443], ["injury", "OBSERVATION", 444, 450]]], ["Others, by contrast, have pointed out the value of ancillary investigations in primarily infratentorial brain lesions (21).", [["infratentorial brain lesions", "ANATOMY", 89, 117], ["infratentorial brain lesions", "DISEASE", 89, 117], ["infratentorial brain lesions", "CANCER", 89, 117], ["ancillary investigations", "TEST", 51, 75], ["primarily infratentorial brain lesions", "PROBLEM", 79, 117], ["infratentorial", "ANATOMY_MODIFIER", 89, 103], ["brain", "ANATOMY", 104, 109], ["lesions", "OBSERVATION", 110, 117]]], ["Illustrative case examples of developing brain death, one related to global anoxic-ischemic injury and the other to basilar artery stroke, are shown in Figure 3.Brain Death CriteriaBesides a thorough knowledge of the legislation and of the details of local brain death protocols, neurologists performing brain death examinations must be aware of potential pitfalls.", [["brain", "ANATOMY", 41, 46], ["basilar artery", "ANATOMY", 116, 130], ["Brain", "ANATOMY", 161, 166], ["brain", "ANATOMY", 257, 262], ["brain", "ANATOMY", 304, 309], ["brain death", "DISEASE", 41, 52], ["ischemic injury", "DISEASE", 83, 98], ["basilar artery stroke", "DISEASE", 116, 137], ["brain death", "DISEASE", 257, 268], ["brain death", "DISEASE", 304, 315], ["brain", "ORGAN", 41, 46], ["basilar artery", "MULTI-TISSUE_STRUCTURE", 116, 130], ["brain", "ORGAN", 257, 262], ["brain", "ORGAN", 304, 309], ["developing brain death", "PROBLEM", 30, 52], ["global anoxic-ischemic injury", "PROBLEM", 69, 98], ["basilar artery stroke", "PROBLEM", 116, 137], ["brain death examinations", "TEST", 304, 328], ["brain", "ANATOMY", 41, 46], ["death", "OBSERVATION", 47, 52], ["global", "OBSERVATION_MODIFIER", 69, 75], ["anoxic", "OBSERVATION_MODIFIER", 76, 82], ["ischemic", "OBSERVATION_MODIFIER", 83, 91], ["injury", "OBSERVATION", 92, 98], ["basilar artery", "ANATOMY", 116, 130], ["stroke", "OBSERVATION", 131, 137]]], ["These relate to failures to adhere to the brain death protocol, including premature assessment of patients, misinterpretation of certain clinical signs as signaling preserved brain function and a lack of knowledge about the pathophysiological processes during the dying process that can confound the interpretation of ancillary investigations.Brain Death CriteriaFirst, failure to adhere to brain death protocols may happen when clinicians deviate from the rule that the cause of irreversible brain damage has to be known or when they overlook confounders, which has occurred in a number of reports related to \u201cbrain death mimics\u201d associated with, for instance, intoxications [e.g., baclofen (22)] and neuromuscular disorders [e.g., Guillain Barre syndrome (22)].", [["brain", "ANATOMY", 42, 47], ["brain", "ANATOMY", 175, 180], ["Brain", "ANATOMY", 343, 348], ["brain", "ANATOMY", 391, 396], ["brain", "ANATOMY", 493, 498], ["brain", "ANATOMY", 611, 616], ["neuromuscular", "ANATOMY", 702, 715], ["death", "DISEASE", 48, 53], ["brain death", "DISEASE", 391, 402], ["brain damage", "DISEASE", 493, 505], ["brain death", "DISEASE", 611, 622], ["baclofen", "CHEMICAL", 683, 691], ["neuromuscular disorders", "DISEASE", 702, 725], ["Guillain Barre syndrome", "DISEASE", 733, 756], ["baclofen", "CHEMICAL", 683, 691], ["brain", "ORGAN", 42, 47], ["patients", "ORGANISM", 98, 106], ["brain", "ORGAN", 175, 180], ["brain", "ORGAN", 391, 396], ["brain", "ORGAN", 493, 498], ["brain", "ORGAN", 611, 616], ["baclofen", "SIMPLE_CHEMICAL", 683, 691], ["patients", "SPECIES", 98, 106], ["failures", "PROBLEM", 16, 24], ["the brain death protocol", "TEST", 38, 62], ["premature assessment", "TEST", 74, 94], ["the pathophysiological processes", "PROBLEM", 220, 252], ["ancillary investigations", "TEST", 318, 342], ["Brain Death", "PROBLEM", 343, 354], ["failure", "PROBLEM", 370, 377], ["brain death protocols", "TREATMENT", 391, 412], ["irreversible brain damage", "PROBLEM", 480, 505], ["baclofen", "TREATMENT", 683, 691], ["neuromuscular disorders", "PROBLEM", 702, 725], ["Guillain Barre syndrome", "PROBLEM", 733, 756], ["failures", "OBSERVATION", 16, 24], ["failure", "OBSERVATION", 370, 377], ["neuromuscular", "ANATOMY", 702, 715], ["Barre syndrome", "OBSERVATION", 742, 756]]], ["Hence, a brain death protocol should be stopped immediately when it is evident that repeated neuroimaging reveals lack of major cerebral injury (1).Brain Death CriteriaSecond, certain clinical signs may be misinterpreted as reflecting preserved brain function.", [["brain", "ANATOMY", 9, 14], ["cerebral", "ANATOMY", 128, 136], ["Brain", "ANATOMY", 148, 153], ["brain", "ANATOMY", 245, 250], ["brain death", "DISEASE", 9, 20], ["cerebral injury", "DISEASE", 128, 143], ["brain", "ORGAN", 9, 14], ["cerebral", "ORGAN", 128, 136], ["brain", "ORGAN", 245, 250], ["a brain death protocol", "TREATMENT", 7, 29], ["repeated neuroimaging", "TEST", 84, 105], ["major cerebral injury", "PROBLEM", 122, 143], ["major", "OBSERVATION_MODIFIER", 122, 127], ["cerebral", "ANATOMY", 128, 136], ["injury", "OBSERVATION", 137, 143], ["brain function", "OBSERVATION", 245, 259]]], ["For instance, both pupillary constriction and dilation may occur after brain death due to rudimentary contractility of the iris muscles.", [["brain", "ANATOMY", 71, 76], ["iris muscles", "ANATOMY", 123, 135], ["pupillary constriction", "DISEASE", 19, 41], ["brain death", "DISEASE", 71, 82], ["brain", "ORGAN", 71, 76], ["iris muscles", "TISSUE", 123, 135], ["both pupillary constriction", "PROBLEM", 14, 41], ["dilation", "PROBLEM", 46, 54], ["brain death", "PROBLEM", 71, 82], ["rudimentary contractility of the iris muscles", "PROBLEM", 90, 135], ["pupillary constriction", "OBSERVATION", 19, 41], ["dilation", "OBSERVATION", 46, 54], ["rudimentary contractility", "OBSERVATION", 90, 115], ["iris muscles", "ANATOMY", 123, 135]]], ["It is normal for pupils to dilate during the final stage of the dying process, when (or better: if) catecholamines are released into the blood stream, which over the ensuing hours will result in slight pupillary constriction when catecholamine molecules are metabolized.", [["blood stream", "ANATOMY", 137, 149], ["catecholamines", "CHEMICAL", 100, 114], ["catecholamine", "CHEMICAL", 230, 243], ["catecholamines", "CHEMICAL", 100, 114], ["catecholamine", "CHEMICAL", 230, 243], ["catecholamines", "SIMPLE_CHEMICAL", 100, 114], ["blood", "ORGANISM_SUBSTANCE", 137, 142], ["catecholamine molecules", "SIMPLE_CHEMICAL", 230, 253], ["catecholamines", "PROBLEM", 100, 114], ["the blood stream", "TEST", 133, 149], ["slight pupillary constriction", "PROBLEM", 195, 224], ["catecholamine molecules", "PROBLEM", 230, 253], ["normal", "OBSERVATION", 6, 12], ["slight", "OBSERVATION_MODIFIER", 195, 201], ["pupillary constriction", "OBSERVATION", 202, 224]]], ["Further, pupillary dilatation as a spinal sympathetic reflex may occur with skin incision and cross-clamping during organ procurement (23).", [["spinal", "ANATOMY", 35, 41], ["skin", "ANATOMY", 76, 80], ["organ", "ANATOMY", 116, 121], ["skin", "ORGAN", 76, 80], ["organ", "ORGAN", 116, 121], ["pupillary dilatation", "PROBLEM", 9, 29], ["a spinal sympathetic reflex", "PROBLEM", 33, 60], ["skin incision", "TREATMENT", 76, 89], ["cross-clamping", "TREATMENT", 94, 108], ["organ procurement", "TEST", 116, 133], ["pupillary", "OBSERVATION_MODIFIER", 9, 18], ["dilatation", "OBSERVATION", 19, 29], ["spinal", "ANATOMY", 35, 41], ["sympathetic reflex", "OBSERVATION", 42, 60], ["skin", "ANATOMY", 76, 80], ["incision", "OBSERVATION", 81, 89], ["cross-clamping", "OBSERVATION", 94, 108]]], ["A similar reflex mechanism has been suggested in a notable case of a confirmed brain death in which the corpse repeatedly showed slow left eye opening in response to noxious stimulation of the ipsilateral nipple (but no other area), most likely due to sympathetically mediated activity of the superior tarsal muscle (aka.", [["brain", "ANATOMY", 79, 84], ["left eye", "ANATOMY", 134, 142], ["ipsilateral nipple", "ANATOMY", 193, 211], ["area", "ANATOMY", 226, 230], ["superior tarsal muscle", "ANATOMY", 293, 315], ["brain death", "DISEASE", 79, 90], ["brain", "ORGAN", 79, 84], ["eye", "ORGAN", 139, 142], ["nipple", "ORGAN", 205, 211], ["superior tarsal muscle", "TISSUE", 293, 315], ["aka", "GENE_OR_GENE_PRODUCT", 317, 320], ["brain death", "PROBLEM", 79, 90], ["slow left eye opening", "PROBLEM", 129, 150], ["noxious stimulation", "TEST", 166, 185], ["sympathetically mediated activity of the superior tarsal muscle", "PROBLEM", 252, 315], ["brain", "ANATOMY", 79, 84], ["death", "OBSERVATION", 85, 90], ["slow", "OBSERVATION_MODIFIER", 129, 133], ["left", "ANATOMY_MODIFIER", 134, 138], ["eye", "ANATOMY", 139, 142], ["opening", "OBSERVATION", 143, 150], ["noxious stimulation", "OBSERVATION", 166, 185], ["ipsilateral", "ANATOMY_MODIFIER", 193, 204], ["nipple", "ANATOMY", 205, 211], ["most likely due to", "UNCERTAINTY", 233, 251], ["activity", "OBSERVATION", 277, 285], ["superior", "ANATOMY_MODIFIER", 293, 301], ["tarsal muscle", "ANATOMY", 302, 315], ["aka", "ANATOMY", 317, 320]]], ["Muller's muscle) (24).", [["muscle", "ANATOMY", 9, 15], ["muscle", "ORGAN", 9, 15], ["muscle", "ANATOMY", 9, 15]]], ["While these clinical signs only rarely will lead to diagnostic confusion, awareness of spinal motor reflexes is crucial because these may become very evident.", [["spinal", "ANATOMY", 87, 93], ["confusion", "DISEASE", 63, 72], ["diagnostic confusion", "PROBLEM", 52, 72], ["spinal motor reflexes", "TEST", 87, 108], ["spinal", "ANATOMY", 87, 93]]], ["It is important to note that spinal motor reflexes tend to occur a few hours after declaration of brain death, the reason being that brain death equals a high upper cervical transection, which will result in spinal shock and muscular atonia that may transform over the ensuing hours into increased spinal activity with loss of supranuclear inhibitory control.", [["spinal", "ANATOMY", 29, 35], ["brain", "ANATOMY", 98, 103], ["brain", "ANATOMY", 133, 138], ["cervical", "ANATOMY", 165, 173], ["spinal", "ANATOMY", 208, 214], ["muscular", "ANATOMY", 225, 233], ["spinal", "ANATOMY", 298, 304], ["supranuclear", "ANATOMY", 327, 339], ["brain death", "DISEASE", 98, 109], ["brain death", "DISEASE", 133, 144], ["shock", "DISEASE", 215, 220], ["muscular atonia", "DISEASE", 225, 240], ["brain", "ORGAN", 98, 103], ["brain", "ORGAN", 133, 138], ["upper cervical", "ORGANISM_SUBDIVISION", 159, 173], ["spinal", "ORGAN", 298, 304], ["spinal motor reflexes", "TEST", 29, 50], ["brain death", "PROBLEM", 98, 109], ["brain death", "PROBLEM", 133, 144], ["a high upper cervical transection", "PROBLEM", 152, 185], ["spinal shock", "PROBLEM", 208, 220], ["muscular atonia", "PROBLEM", 225, 240], ["increased spinal activity", "PROBLEM", 288, 313], ["supranuclear inhibitory control", "TREATMENT", 327, 358], ["spinal", "ANATOMY", 29, 35], ["brain", "ANATOMY", 98, 103], ["upper", "ANATOMY_MODIFIER", 159, 164], ["cervical", "ANATOMY", 165, 173], ["transection", "OBSERVATION", 174, 185], ["spinal", "ANATOMY", 208, 214], ["shock", "OBSERVATION", 215, 220], ["muscular atonia", "OBSERVATION", 225, 240], ["spinal", "ANATOMY", 298, 304], ["supranuclear inhibitory", "OBSERVATION", 327, 350]]], ["Spinally mediated movements may result in distinct motor patterns that may mimic decerebrate rigidity (although evidently, this motor pattern is only induced by noxious stimuli below the foramen magnum) or reflect primitive reflexes such as the grip reflex (25).", [["foramen magnum", "ANATOMY", 187, 201], ["rigidity", "DISEASE", 93, 101], ["decerebrate", "ORGANISM_SUBDIVISION", 81, 92], ["foramen magnum", "MULTI-TISSUE_STRUCTURE", 187, 201], ["Spinally mediated movements", "PROBLEM", 0, 27], ["decerebrate rigidity", "PROBLEM", 81, 101], ["noxious stimuli", "TEST", 161, 176], ["primitive reflexes", "PROBLEM", 214, 232], ["the grip reflex", "TEST", 241, 256], ["decerebrate rigidity", "OBSERVATION", 81, 101], ["foramen magnum", "ANATOMY", 187, 201], ["primitive reflexes", "OBSERVATION", 214, 232]]], ["Tonic neck reflexes may be preserved as well, the most dramatic example being the Lazarus' sign in which intricate sequences of movements may develop over many seconds, including flexion of both arms to the chest, adduction of shoulders, hands raising up to the neck, with fingers held in dystonic postures, followed by crossing of the hands that finally move down to the bed again (26).", [["neck", "ANATOMY", 6, 10], ["chest", "ANATOMY", 207, 212], ["shoulders", "ANATOMY", 227, 236], ["neck", "ANATOMY", 262, 266], ["fingers", "ANATOMY", 273, 280], ["dystonic", "DISEASE", 289, 297], ["chest", "ORGANISM_SUBDIVISION", 207, 212], ["shoulders", "ORGANISM_SUBDIVISION", 227, 236], ["hands", "ORGANISM_SUBDIVISION", 238, 243], ["neck", "ORGANISM_SUBDIVISION", 262, 266], ["fingers", "ORGANISM_SUBDIVISION", 273, 280], ["hands", "ORGANISM_SUBDIVISION", 336, 341], ["Tonic neck reflexes", "PROBLEM", 0, 19], ["flexion", "TEST", 179, 186], ["dystonic postures", "TEST", 289, 306], ["neck", "ANATOMY", 6, 10], ["may be", "UNCERTAINTY", 20, 26], ["preserved", "OBSERVATION", 27, 36], ["both", "ANATOMY_MODIFIER", 190, 194], ["arms", "ANATOMY", 195, 199], ["chest", "ANATOMY", 207, 212], ["shoulders", "ANATOMY", 227, 236], ["hands", "ANATOMY", 238, 243], ["neck", "ANATOMY", 262, 266], ["fingers", "ANATOMY", 273, 280], ["hands", "ANATOMY", 336, 341]]], ["The Lazarus' sign should not be confused with the Lazarus' phenomenon which refers to autoresuscitation and which is incompatible with brain death (27).Brain Death CriteriaThird, ignorance of the pathophysiological processes during the dying process may lead to erroneous interpretation of ancillary investigations.", [["brain", "ANATOMY", 135, 140], ["Brain", "ANATOMY", 152, 157], ["autoresuscitation", "DISEASE", 86, 103], ["brain death", "DISEASE", 135, 146], ["brain", "ORGAN", 135, 140], ["confused", "PROBLEM", 32, 40], ["the Lazarus' phenomenon", "PROBLEM", 46, 69], ["brain death", "PROBLEM", 135, 146], ["the pathophysiological processes", "PROBLEM", 192, 224], ["ancillary investigations", "TEST", 290, 314]]], ["Most flawed conclusions can be avoided when remembering that the transition from (rudimentarily preserved) cerebral activity to (a clinical diagnosis of) brain death is not sharply defined but occurs typically over several minutes or even hours.", [["cerebral", "ANATOMY", 107, 115], ["brain", "ANATOMY", 154, 159], ["brain death", "DISEASE", 154, 165], ["cerebral", "ORGAN", 107, 115], ["brain", "ORGAN", 154, 159], ["brain death", "PROBLEM", 154, 165], ["brain", "ANATOMY", 154, 159], ["death", "OBSERVATION", 160, 165]]], ["The clinical examination relies on the assessment of the brainstem, which explains why islands of electrically functioning cortical neurons may give rise to residual EEG activity (28) and why rudimentary intracranial perfusion may be revealed by digital subtraction angiography for a limited time after a correctly performed clinical brain death examination.", [["brainstem", "ANATOMY", 57, 66], ["cortical neurons", "ANATOMY", 123, 139], ["intracranial", "ANATOMY", 204, 216], ["brain", "ANATOMY", 334, 339], ["brain death", "DISEASE", 334, 345], ["brainstem", "ANATOMICAL_SYSTEM", 57, 66], ["cortical neurons", "CELL", 123, 139], ["intracranial", "MULTI-TISSUE_STRUCTURE", 204, 216], ["brain", "ORGAN", 334, 339], ["electrically functioning cortical neurons", "CELL_TYPE", 98, 139], ["The clinical examination", "TEST", 0, 24], ["the assessment", "TEST", 35, 49], ["electrically functioning cortical neurons", "PROBLEM", 98, 139], ["residual EEG activity", "PROBLEM", 157, 178], ["rudimentary intracranial perfusion", "TEST", 192, 226], ["digital subtraction angiography", "TEST", 246, 277], ["clinical brain death examination", "TEST", 325, 357], ["brainstem", "ANATOMY", 57, 66]]], ["The author knows of a case in which organ procurement was stopped because of doubts related to spinal reflexes occurring several hours (sic) after a correct clinical brain death protocol, followed by a digital subtraction angiography revealing very weak filling of the proximal intracranial vasculature.", [["organ", "ANATOMY", 36, 41], ["spinal", "ANATOMY", 95, 101], ["brain", "ANATOMY", 166, 171], ["intracranial vasculature", "ANATOMY", 278, 302], ["brain death", "DISEASE", 166, 177], ["organ", "ORGAN", 36, 41], ["brain", "ORGAN", 166, 171], ["intracranial vasculature", "MULTI-TISSUE_STRUCTURE", 278, 302], ["organ procurement", "TREATMENT", 36, 53], ["spinal reflexes", "PROBLEM", 95, 110], ["a digital subtraction angiography", "TEST", 200, 233], ["very weak filling of the proximal intracranial vasculature", "PROBLEM", 244, 302], ["spinal reflexes", "ANATOMY", 95, 110], ["very", "OBSERVATION_MODIFIER", 244, 248], ["weak", "OBSERVATION", 249, 253], ["proximal", "ANATOMY_MODIFIER", 269, 277], ["intracranial", "ANATOMY_MODIFIER", 278, 290], ["vasculature", "ANATOMY", 291, 302]]], ["In this regard, it is important to be aware that most brain death protocols, including that presented in Figure 2, do not require inotropic support of blood pressure as a prerequisite for brain death.", [["brain", "ANATOMY", 54, 59], ["blood", "ANATOMY", 151, 156], ["brain", "ANATOMY", 188, 193], ["brain death", "DISEASE", 54, 65], ["brain death", "DISEASE", 188, 199], ["brain", "ORGAN", 54, 59], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["brain", "ORGAN", 188, 193], ["brain death protocols", "TEST", 54, 75], ["inotropic support", "TREATMENT", 130, 147], ["blood pressure", "TREATMENT", 151, 165], ["brain death", "PROBLEM", 188, 199]]], ["Restated, it is occasionally possible to declare brain death although the corpse supports its own blood pressure and although blood pressure control is mediated via the caudal ventrolateral medulla which is part of the brainstem (29).", [["brain", "ANATOMY", 49, 54], ["blood", "ANATOMY", 98, 103], ["blood", "ANATOMY", 126, 131], ["caudal ventrolateral medulla", "ANATOMY", 169, 197], ["brainstem", "ANATOMY", 219, 228], ["brain death", "DISEASE", 49, 60], ["brain", "ORGAN", 49, 54], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["blood", "ORGANISM_SUBSTANCE", 126, 131], ["caudal ventrolateral medulla", "MULTI-TISSUE_STRUCTURE", 169, 197], ["brainstem", "ANATOMICAL_SYSTEM", 219, 228], ["brain death", "PROBLEM", 49, 60], ["blood pressure", "TEST", 98, 112], ["blood pressure control", "TREATMENT", 126, 148], ["occasionally possible", "UNCERTAINTY", 16, 37], ["caudal", "ANATOMY_MODIFIER", 169, 175], ["ventrolateral", "ANATOMY_MODIFIER", 176, 189], ["medulla", "ANATOMY", 190, 197], ["brainstem", "ANATOMY", 219, 228]]], ["In this situation, it should therefore come as no surprise that digital subtraction angiography may show rudimentary intracranial filling of proximal vessels.", [["intracranial", "ANATOMY", 117, 129], ["proximal vessels", "ANATOMY", 141, 157], ["proximal vessels", "MULTI-TISSUE_STRUCTURE", 141, 157], ["digital subtraction angiography", "TEST", 64, 95], ["rudimentary intracranial filling of proximal vessels", "PROBLEM", 105, 157], ["rudimentary", "OBSERVATION", 105, 116], ["intracranial", "ANATOMY_MODIFIER", 117, 129], ["filling", "OBSERVATION", 130, 137], ["proximal", "ANATOMY_MODIFIER", 141, 149], ["vessels", "ANATOMY", 150, 157]]], ["Thus, as a rule of thumb, whenever documentation of complete absence of intracranial blood flow is mandatory (e.g., in Denmark following anoxic, but not traumatic, brain injury, Figure 2), neurologists should refrain from starting a brain death protocol until inotropic blood pressure support has become necessary and the patient is polyuric (1).Brain Death CriteriaAlthough brain death protocols must be strictly adhered to, it is important to keep in mind that they vary widely in detail from country to country (30, 31) (Figure 4).", [["thumb", "ANATOMY", 19, 24], ["intracranial blood", "ANATOMY", 72, 90], ["brain", "ANATOMY", 164, 169], ["brain", "ANATOMY", 233, 238], ["blood", "ANATOMY", 270, 275], ["Brain", "ANATOMY", 346, 351], ["brain", "ANATOMY", 375, 380], ["traumatic", "DISEASE", 153, 162], ["brain injury", "DISEASE", 164, 176], ["brain death", "DISEASE", 233, 244], ["brain death", "DISEASE", 375, 386], ["thumb", "ORGANISM_SUBDIVISION", 19, 24], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["brain", "ORGAN", 164, 169], ["brain", "ORGAN", 233, 238], ["blood", "ORGANISM_SUBSTANCE", 270, 275], ["patient", "ORGANISM", 322, 329], ["Brain", "ORGAN", 346, 351], ["brain", "ORGAN", 375, 380], ["patient", "SPECIES", 322, 329], ["thumb", "PROBLEM", 19, 24], ["intracranial blood flow", "PROBLEM", 72, 95], ["traumatic", "PROBLEM", 153, 162], ["brain injury", "PROBLEM", 164, 176], ["a brain death protocol", "TREATMENT", 231, 253], ["inotropic blood pressure support", "TREATMENT", 260, 292], ["Brain Death", "PROBLEM", 346, 357], ["brain death protocols", "TREATMENT", 375, 396], ["thumb", "ANATOMY", 19, 24], ["brain", "ANATOMY", 164, 169]]], ["While these protocols almost universally follow the three-step approach as outlined earlier, a recent study (30) found as many different protocols as countries surveyed (n = 24).", [["a recent study", "TEST", 93, 107]]], ["For instance, whereas 1 h must pass between the two clinical brain death examinations in Brazil, the time interval in Luxembourg is 6 h and in Germany between 12 and 72 h.", [["brain", "ANATOMY", 61, 66], ["brain death", "DISEASE", 61, 72], ["brain", "ORGAN", 61, 66], ["clinical brain death examinations", "TEST", 52, 85]]], ["In Sweden and Canada, legislation requires only 1 physician to perform the clinical examination, but at least 4 physicians are needed in South Korea.", [["the clinical examination", "TEST", 71, 95]]], ["Digital subtraction angiography is needed in Denmark in certain situations, whereas in Italy and Japan EEG is mandatory (30).", [["Digital subtraction angiography", "TEST", 0, 31], ["Japan EEG", "TEST", 97, 106]]], ["Also, while in most countries a patient is declared brain dead when clinical examination and confirmatory tests (if required) indicate irreversible loss of activity of the entire brain (\u201cwhole brain death\u201d), the UK and India, by contrast, have implemented the concept of brainstem death, i.e., evidence of the irreversible loss of brainstem activity is sufficient (33, 34).Donation After Circulatory Death (DCD)According to the Maastricht criteria (18, 19), DCD is classified into uncontrolled DCD and controlled DCD (Figure 5).", [["brain", "ANATOMY", 52, 57], ["brain", "ANATOMY", 179, 184], ["brain", "ANATOMY", 193, 198], ["brainstem", "ANATOMY", 271, 280], ["brainstem", "ANATOMY", 331, 340], ["loss of activity of the entire brain", "DISEASE", 148, 184], ["death", "DISEASE", 199, 204], ["brainstem death", "DISEASE", 271, 286], ["loss of brainstem activity", "DISEASE", 323, 349], ["Circulatory Death", "DISEASE", 388, 405], ["DCD", "DISEASE", 407, 410], ["DCD", "DISEASE", 458, 461], ["DCD", "DISEASE", 494, 497], ["DCD", "DISEASE", 513, 516], ["patient", "ORGANISM", 32, 39], ["brain", "ORGAN", 52, 57], ["brain", "ORGAN", 179, 184], ["brain", "ORGAN", 193, 198], ["brainstem", "ANATOMICAL_SYSTEM", 271, 280], ["brainstem", "ORGAN", 331, 340], ["patient", "SPECIES", 32, 39], ["clinical examination", "TEST", 68, 88], ["confirmatory tests", "TEST", 93, 111], ["irreversible loss of activity of the entire brain", "PROBLEM", 135, 184], ["brainstem death", "PROBLEM", 271, 286], ["the irreversible loss of brainstem activity", "PROBLEM", 306, 349], ["Circulatory Death", "PROBLEM", 388, 405], ["the Maastricht criteria", "TEST", 424, 447], ["DCD", "TREATMENT", 458, 461], ["irreversible", "OBSERVATION_MODIFIER", 135, 147], ["loss", "OBSERVATION", 148, 152], ["brain", "ANATOMY", 179, 184], ["brainstem death", "OBSERVATION", 271, 286], ["irreversible", "OBSERVATION_MODIFIER", 310, 322], ["loss", "OBSERVATION", 323, 327], ["brainstem activity", "OBSERVATION", 331, 349]]], ["Uncontrolled DCD refers to organ retrieval following unexpected cardiac arrest from which the patient cannot or should not be resuscitated.", [["organ", "ANATOMY", 27, 32], ["cardiac", "ANATOMY", 64, 71], ["DCD", "DISEASE", 13, 16], ["cardiac arrest", "DISEASE", 64, 78], ["organ", "ORGAN", 27, 32], ["cardiac", "ORGAN", 64, 71], ["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["Uncontrolled DCD", "PROBLEM", 0, 16], ["organ retrieval", "TREATMENT", 27, 42], ["unexpected cardiac arrest", "PROBLEM", 53, 78], ["cardiac", "ANATOMY", 64, 71], ["arrest", "OBSERVATION", 72, 78]]], ["In contrast, controlled DCD takes place in a planned setting where the decision of withdrawal of life-sustaining treatment is thought to be in the best interest of the patient given the expected poor neurological outcome.", [["neurological", "ANATOMY", 200, 212], ["patient", "ORGANISM", 168, 175], ["patient", "SPECIES", 168, 175], ["withdrawal of life", "TREATMENT", 83, 101], ["treatment", "TREATMENT", 113, 122]]], ["Hence, resuscitation is only attempted in uncontrolled DCD patients, but both settings involve a non-intervention period (\u201chands-off period\u201d) to rule out autoresuscitation (35).", [["DCD", "DISEASE", 55, 58], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["resuscitation", "TREATMENT", 7, 20]]], ["Loss of cardio-pulmonary function is documented by e.g., echocardiography, electrocardiogram, and invasive monitoring of pulse and blood pressure (35).", [["pulmonary", "ANATOMY", 15, 24], ["blood", "ANATOMY", 131, 136], ["pulmonary", "ORGAN", 15, 24], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["Loss of cardio-pulmonary function", "PROBLEM", 0, 33], ["echocardiography", "TEST", 57, 73], ["electrocardiogram", "TEST", 75, 92], ["invasive monitoring", "TEST", 98, 117], ["pulse", "TEST", 121, 126], ["blood pressure", "TEST", 131, 145], ["cardio", "ANATOMY", 8, 14], ["pulmonary", "ANATOMY", 15, 24]]], ["The period of non-intervention is variable and extends from seconds to several minutes (35\u201337).", [["non-intervention", "OBSERVATION", 14, 30], ["variable", "OBSERVATION_MODIFIER", 34, 42]]], ["Circulation is then restored, involving cannulation and extracorporeal membrane oxygenation, and organs are explanted.", [["extracorporeal membrane", "ANATOMY", 56, 79], ["organs", "ANATOMY", 97, 103], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 56, 79], ["organs", "ORGAN", 97, 103], ["cannulation", "TREATMENT", 40, 51], ["extracorporeal membrane oxygenation", "TEST", 56, 91], ["cannulation", "OBSERVATION", 40, 51], ["extracorporeal", "OBSERVATION_MODIFIER", 56, 70], ["membrane oxygenation", "OBSERVATION", 71, 91], ["organs", "ANATOMY", 97, 103]]], ["Lungs and kidneys are more robust to the detrimental effects of prolonged warm ischemia time than the liver and the heart; but both the latter organs are increasingly transplanted as well (6, 7).Donation After Circulatory Death (DCD)The number of countries that practice DCD is rapidly increasing, although the share of DCD in terms of organs transplanted is still low compared to organs from brain-dead donors.", [["Lungs", "ANATOMY", 0, 5], ["kidneys", "ANATOMY", 10, 17], ["liver", "ANATOMY", 102, 107], ["heart", "ANATOMY", 116, 121], ["organs", "ANATOMY", 143, 149], ["organs", "ANATOMY", 336, 342], ["organs", "ANATOMY", 381, 387], ["brain", "ANATOMY", 393, 398], ["ischemia", "DISEASE", 79, 87], ["Circulatory Death", "DISEASE", 210, 227], ["DCD", "DISEASE", 229, 232], ["DCD", "DISEASE", 271, 274], ["DCD", "DISEASE", 320, 323], ["Lungs", "ORGAN", 0, 5], ["kidneys", "ORGAN", 10, 17], ["liver", "ORGAN", 102, 107], ["heart", "ORGAN", 116, 121], ["organs", "ORGAN", 143, 149], ["organs", "ORGAN", 336, 342], ["organs", "ORGAN", 381, 387], ["brain", "ORGAN", 393, 398], ["donors", "ORGANISM", 404, 410], ["prolonged warm ischemia", "PROBLEM", 64, 87], ["Circulatory Death", "PROBLEM", 210, 227], ["practice DCD", "TREATMENT", 262, 274], ["DCD", "TREATMENT", 320, 323], ["organs transplanted", "TREATMENT", 336, 355], ["kidneys", "ANATOMY", 10, 17], ["more", "OBSERVATION_MODIFIER", 22, 26], ["robust", "OBSERVATION", 27, 33], ["prolonged", "OBSERVATION_MODIFIER", 64, 73], ["warm", "OBSERVATION_MODIFIER", 74, 78], ["ischemia", "OBSERVATION", 79, 87], ["liver", "ANATOMY", 102, 107], ["heart", "ANATOMY", 116, 121], ["latter", "OBSERVATION", 136, 142], ["increasingly", "OBSERVATION_MODIFIER", 154, 166], ["transplanted", "OBSERVATION", 167, 179], ["rapidly", "OBSERVATION_MODIFIER", 278, 285], ["increasing", "OBSERVATION_MODIFIER", 286, 296], ["organs", "ANATOMY", 336, 342], ["transplanted", "OBSERVATION", 343, 355], ["dead donors", "OBSERVATION", 399, 410]]], ["In 2019, DCD represented the major source for organs only in the Netherlands (30).", [["organs", "ANATOMY", 46, 52], ["DCD", "DISEASE", 9, 12], ["organs", "ORGAN", 46, 52], ["DCD", "TREATMENT", 9, 12]]], ["Like brain death protocols, DCD protocols vary considerably from country to country.", [["brain", "ANATOMY", 5, 10], ["brain death", "DISEASE", 5, 16], ["brain", "ORGAN", 5, 10], ["brain death protocols", "TREATMENT", 5, 26], ["DCD protocols", "TREATMENT", 28, 41]]], ["Guidelines require documentation of the absence of circulation and spontaneous respiration either by electrical asystole on ECG and/or lack of arterial pulsations demonstrated by arterial pressure monitoring.", [["arterial", "ANATOMY", 143, 151], ["arterial", "ANATOMY", 179, 187], ["asystole", "DISEASE", 112, 120], ["arterial", "MULTI-TISSUE_STRUCTURE", 143, 151], ["arterial", "MULTI-TISSUE_STRUCTURE", 179, 187], ["spontaneous respiration", "PROBLEM", 67, 90], ["electrical asystole", "PROBLEM", 101, 120], ["ECG", "TEST", 124, 127], ["arterial pulsations", "TEST", 143, 162], ["arterial pressure monitoring", "TEST", 179, 207], ["arterial", "ANATOMY", 143, 151], ["arterial pressure", "OBSERVATION", 179, 196]]], ["Other criteria such as heart auscultation, absence of a palpable pulse, skin perfusion, immobility, unresponsiveness to verbal or tactile stimuli, and loss of brainstem reflexes, vary between countries.", [["heart", "ANATOMY", 23, 28], ["skin", "ANATOMY", 72, 76], ["brainstem", "ANATOMY", 159, 168], ["unresponsiveness to verbal or tactile stimuli", "DISEASE", 100, 145], ["loss of brainstem reflexes", "DISEASE", 151, 177], ["heart", "ORGAN", 23, 28], ["skin", "ORGAN", 72, 76], ["brainstem", "ORGANISM_SUBDIVISION", 159, 168], ["heart auscultation", "TEST", 23, 41], ["a palpable pulse", "PROBLEM", 54, 70], ["skin perfusion", "TEST", 72, 86], ["immobility", "PROBLEM", 88, 98], ["unresponsiveness", "PROBLEM", 100, 116], ["tactile stimuli", "TEST", 130, 145], ["loss of brainstem reflexes", "PROBLEM", 151, 177], ["heart", "ANATOMY", 23, 28], ["skin", "ANATOMY", 72, 76]]], ["As stated earlier, before the patient can be declared dead guidelines usually require a \u201chands-off period,\u201d during which physicians must not intervene, to rule out autoresuscitation.", [["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37], ["autoresuscitation", "PROBLEM", 164, 181]]], ["The length of this period varies from 2 min in the UK to 10 min in Spain or is unspecified (Australia, New Zealand) (30), but a recent survey showed that 10 out of 64 (16%) European centers immediately retrieve organs after a flatline ECG (38).Cellular Mechanisms In The Dying BrainNeurovascular coupling is fundamental to the physiology of the living and the dying brain.", [["organs", "ANATOMY", 211, 217], ["Cellular", "ANATOMY", 244, 252], ["brain", "ANATOMY", 366, 371], ["organs", "ORGAN", 211, 217], ["brain", "ORGAN", 366, 371], ["a recent survey", "TEST", 126, 141], ["a flatline ECG", "TEST", 224, 238], ["length", "OBSERVATION_MODIFIER", 4, 10], ["brain", "ANATOMY", 366, 371]]], ["The term refers to interactions within the \u201cneurovascular unit,\u201d which consists of neurons, astrocytes and vascular cells, including the blood-brain barrier (Figure 6).", [["neurovascular unit", "ANATOMY", 44, 62], ["neurons", "ANATOMY", 83, 90], ["astrocytes", "ANATOMY", 92, 102], ["vascular cells", "ANATOMY", 107, 121], ["blood-brain barrier", "ANATOMY", 137, 156], ["neurons", "CELL", 83, 90], ["astrocytes", "CELL", 92, 102], ["vascular cells", "CELL", 107, 121], ["blood", "ORGANISM_SUBSTANCE", 137, 142], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 143, 156], ["neurons", "CELL_TYPE", 83, 90], ["astrocytes", "CELL_TYPE", 92, 102], ["vascular cells", "CELL_TYPE", 107, 121], ["the blood-brain barrier", "TREATMENT", 133, 156], ["vascular cells", "ANATOMY", 107, 121], ["brain", "ANATOMY", 143, 148]]], ["Briefly, neuronal activation is accompanied by increased cerebral blood flow and modestly increased cerebral metabolic rate for oxygen, leading to functional hyperemia and energy supply (39).", [["neuronal", "ANATOMY", 9, 17], ["cerebral", "ANATOMY", 57, 65], ["blood", "ANATOMY", 66, 71], ["cerebral", "ANATOMY", 100, 108], ["oxygen", "CHEMICAL", 128, 134], ["hyperemia", "DISEASE", 158, 167], ["oxygen", "CHEMICAL", 128, 134], ["neuronal", "CELL", 9, 17], ["cerebral", "ORGANISM_SUBSTANCE", 57, 65], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["cerebral", "ORGAN", 100, 108], ["oxygen", "SIMPLE_CHEMICAL", 128, 134], ["increased cerebral blood flow", "PROBLEM", 47, 76], ["modestly increased cerebral metabolic rate", "PROBLEM", 81, 123], ["oxygen", "TREATMENT", 128, 134], ["functional hyperemia", "PROBLEM", 147, 167], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["cerebral", "ANATOMY", 57, 65], ["blood flow", "OBSERVATION", 66, 76], ["modestly", "OBSERVATION_MODIFIER", 81, 89], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["cerebral", "OBSERVATION_MODIFIER", 100, 108], ["metabolic rate", "OBSERVATION", 109, 123], ["hyperemia", "OBSERVATION", 158, 167]]], ["Neurovascular coupling thus reflects the close temporal and regional connection between neuronal activity and cerebral blood flow (39\u201342).", [["Neurovascular", "ANATOMY", 0, 13], ["neuronal", "ANATOMY", 88, 96], ["cerebral", "ANATOMY", 110, 118], ["blood", "ANATOMY", 119, 124], ["neuronal", "CELL", 88, 96], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 110, 124], ["Neurovascular coupling", "PROBLEM", 0, 22], ["cerebral blood flow", "TEST", 110, 129], ["temporal", "OBSERVATION_MODIFIER", 47, 55], ["regional", "ANATOMY_MODIFIER", 60, 68], ["connection", "OBSERVATION", 69, 79], ["neuronal activity", "OBSERVATION", 88, 105], ["cerebral blood", "ANATOMY", 110, 124]]], ["Impairment of neurovascular coupling is associated with the development of spreading depolarizations (SD), including terminal SDs and spreading ischemia which are the final cellular mechanisms in the dying cerebral cortex (43\u201345).Cellular Mechanisms In The Dying BrainAlthough terminal SDs without repolarization mark the transition from life to (cerebral) death, there are three accompanying events that occur always, albeit not automatically in the same sequence: loss of respiration, blood flow, and spontaneous electrocorticographic activity (44\u201346).", [["neurovascular", "ANATOMY", 14, 27], ["cellular", "ANATOMY", 173, 181], ["cerebral cortex", "ANATOMY", 206, 221], ["Cellular", "ANATOMY", 230, 238], ["cerebral", "ANATOMY", 347, 355], ["blood", "ANATOMY", 487, 492], ["SD", "DISEASE", 102, 104], ["ischemia", "DISEASE", 144, 152], ["cerebral) death", "DISEASE", 347, 362], ["neurovascular", "MULTI-TISSUE_STRUCTURE", 14, 27], ["cellular", "CELL", 173, 181], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 206, 221], ["cerebral", "ORGAN", 347, 355], ["blood", "ORGANISM_SUBSTANCE", 487, 492], ["Impairment of neurovascular coupling", "PROBLEM", 0, 36], ["spreading depolarizations (SD)", "PROBLEM", 75, 105], ["terminal SDs", "PROBLEM", 117, 129], ["spreading ischemia", "PROBLEM", 134, 152], ["terminal SDs", "PROBLEM", 277, 289], ["loss of respiration", "PROBLEM", 466, 485], ["blood flow", "TEST", 487, 497], ["spontaneous electrocorticographic activity", "TEST", 503, 545], ["neurovascular", "ANATOMY", 14, 27], ["spreading depolarizations", "OBSERVATION", 75, 100], ["spreading", "OBSERVATION_MODIFIER", 134, 143], ["ischemia", "OBSERVATION", 144, 152], ["final", "OBSERVATION_MODIFIER", 167, 172], ["cellular mechanisms", "OBSERVATION", 173, 192], ["cerebral cortex", "ANATOMY", 206, 221], ["without", "UNCERTAINTY", 290, 297], ["repolarization mark", "OBSERVATION", 298, 317]]], ["With circulatory death, the most common scenario, arrest of systemic circulation, respiration, and electrocorticographic activity occurs more or less at the same time, while terminal SDs follow the complete arrest of electrocorticographic activity after 13\u2013266 s (44, 45).Cellular Mechanisms In The Dying BrainThe sequence of events is different in brain death.", [["circulatory", "ANATOMY", 5, 16], ["Cellular", "ANATOMY", 272, 280], ["Brain", "ANATOMY", 305, 310], ["brain", "ANATOMY", 349, 354], ["circulatory death", "DISEASE", 5, 22], ["brain death", "DISEASE", 349, 360], ["brain", "ORGAN", 349, 354], ["circulatory death", "PROBLEM", 5, 22], ["arrest of systemic circulation", "PROBLEM", 50, 80], ["electrocorticographic activity", "TEST", 99, 129], ["terminal SDs", "PROBLEM", 174, 186], ["electrocorticographic activity", "TEST", 217, 247], ["Cellular Mechanisms", "PROBLEM", 272, 291], ["brain death", "PROBLEM", 349, 360], ["circulatory death", "OBSERVATION", 5, 22], ["systemic circulation", "OBSERVATION", 60, 80], ["Brain", "ANATOMY", 305, 310], ["different", "OBSERVATION_MODIFIER", 336, 345], ["brain", "ANATOMY", 349, 354], ["death", "OBSERVATION", 355, 360]]], ["At the neuronal level, toxic cellular changes include gradually increasing intracellular calcium and extracellular potassium concentrations, decreasing extracellular pH, exhaustion of adenosine triphosphate (ATP) stores and failure of ATP-dependent membrane pumps such as the Na,K-ATPase which becomes unable to replenish leaking ions (47\u201352).", [["neuronal", "ANATOMY", 7, 15], ["cellular", "ANATOMY", 29, 37], ["intracellular", "ANATOMY", 75, 88], ["extracellular", "ANATOMY", 101, 114], ["extracellular", "ANATOMY", 152, 165], ["membrane", "ANATOMY", 249, 257], ["calcium", "CHEMICAL", 89, 96], ["potassium", "CHEMICAL", 115, 124], ["adenosine triphosphate", "CHEMICAL", 184, 206], ["ATP", "CHEMICAL", 208, 211], ["ATP", "CHEMICAL", 235, 238], ["Na", "CHEMICAL", 276, 278], ["calcium", "CHEMICAL", 89, 96], ["potassium", "CHEMICAL", 115, 124], ["adenosine triphosphate", "CHEMICAL", 184, 206], ["ATP", "CHEMICAL", 208, 211], ["ATP", "CHEMICAL", 235, 238], ["Na", "CHEMICAL", 276, 278], ["K-", "CHEMICAL", 279, 281], ["neuronal", "CELL", 7, 15], ["cellular", "CELL", 29, 37], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 88], ["calcium", "SIMPLE_CHEMICAL", 89, 96], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 101, 114], ["potassium", "SIMPLE_CHEMICAL", 115, 124], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 152, 165], ["adenosine triphosphate", "SIMPLE_CHEMICAL", 184, 206], ["ATP", "SIMPLE_CHEMICAL", 208, 211], ["ATP", "SIMPLE_CHEMICAL", 235, 238], ["membrane", "CELLULAR_COMPONENT", 249, 257], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 276, 287], ["Na,K-ATPase", "PROTEIN", 276, 287], ["toxic cellular changes", "PROBLEM", 23, 45], ["gradually increasing intracellular calcium", "PROBLEM", 54, 96], ["extracellular potassium concentrations", "PROBLEM", 101, 139], ["decreasing extracellular pH", "PROBLEM", 141, 168], ["adenosine triphosphate (ATP) stores", "PROBLEM", 184, 219], ["failure of ATP", "PROBLEM", 224, 238], ["dependent membrane pumps", "TREATMENT", 239, 263], ["the Na", "TEST", 272, 278], ["K-ATPase", "PROBLEM", 279, 287], ["toxic", "OBSERVATION_MODIFIER", 23, 28], ["cellular changes", "OBSERVATION", 29, 45], ["gradually", "OBSERVATION_MODIFIER", 54, 63], ["increasing", "OBSERVATION_MODIFIER", 64, 74], ["intracellular calcium", "OBSERVATION", 75, 96], ["potassium concentrations", "OBSERVATION", 115, 139], ["decreasing", "OBSERVATION_MODIFIER", 141, 151], ["extracellular pH", "OBSERVATION", 152, 168]]], ["Vesicular release of various transmitters, including glutamate and \u03b3-aminobutyric acid, may lead to an incoherent, massive increase in miniature excitatory and inhibitory postsynaptic potentials, replacing normal postsynaptic potentials and disrupting regular neuronal interactions (53\u201355).", [["Vesicular", "ANATOMY", 0, 9], ["neuronal", "ANATOMY", 260, 268], ["glutamate", "CHEMICAL", 53, 62], ["\u03b3-aminobutyric acid", "CHEMICAL", 67, 86], ["glutamate", "CHEMICAL", 53, 62], ["\u03b3-aminobutyric acid", "CHEMICAL", 67, 86], ["Vesicular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 9], ["glutamate", "SIMPLE_CHEMICAL", 53, 62], ["\u03b3-aminobutyric acid", "SIMPLE_CHEMICAL", 67, 86], ["neuronal", "CELL", 260, 268], ["various transmitters", "TREATMENT", 21, 41], ["glutamate and \u03b3-aminobutyric acid", "TREATMENT", 53, 86], ["massive increase in miniature excitatory and inhibitory postsynaptic potentials", "PROBLEM", 115, 194], ["various transmitters", "OBSERVATION", 21, 41], ["massive", "OBSERVATION_MODIFIER", 115, 122], ["increase", "OBSERVATION_MODIFIER", 123, 131], ["postsynaptic potentials", "OBSERVATION", 213, 236], ["neuronal interactions", "OBSERVATION", 260, 281]]], ["Neuronal hyperpolarization turns into neuronal depolarization.", [["Neuronal", "ANATOMY", 0, 8], ["neuronal", "ANATOMY", 38, 46], ["Neuronal", "CELL", 0, 8], ["neuronal", "CELL", 38, 46], ["Neuronal hyperpolarization", "PROBLEM", 0, 26], ["hyperpolarization", "OBSERVATION", 9, 26], ["neuronal depolarization", "OBSERVATION", 38, 61]]], ["Clinically, following the onset of dilated pupils and loss of brainstem reflexes, indicating imminent brain death, electrocorticography may reveal terminal clusters of SDs (inset, Figure 6), propagating from one electrode to the next and indicating terminal depolarization.", [["brainstem", "ANATOMY", 62, 71], ["brain", "ANATOMY", 102, 107], ["loss of brainstem reflexes", "DISEASE", 54, 80], ["brain death", "DISEASE", 102, 113], ["brain", "ORGAN", 102, 107], ["dilated pupils", "PROBLEM", 35, 49], ["loss of brainstem reflexes", "PROBLEM", 54, 80], ["imminent brain death", "PROBLEM", 93, 113], ["electrocorticography", "TEST", 115, 135], ["terminal clusters of SDs", "PROBLEM", 147, 171], ["terminal depolarization", "PROBLEM", 249, 272], ["dilated", "OBSERVATION_MODIFIER", 35, 42], ["pupils", "OBSERVATION", 43, 49], ["brainstem reflexes", "ANATOMY", 62, 80], ["terminal", "OBSERVATION_MODIFIER", 147, 155], ["clusters", "OBSERVATION_MODIFIER", 156, 164], ["terminal depolarization", "OBSERVATION", 249, 272]]], ["Although the negative ultraslow potentials signal irreversible neuronal death, the arterial blood pressure remains stable (46).", [["neuronal", "ANATOMY", 63, 71], ["arterial blood", "ANATOMY", 83, 97], ["neuronal death", "DISEASE", 63, 77], ["neuronal", "CELL", 63, 71], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 83, 97], ["signal irreversible neuronal death", "PROBLEM", 43, 77], ["the arterial blood pressure", "TEST", 79, 106], ["irreversible", "OBSERVATION_MODIFIER", 50, 62], ["neuronal death", "OBSERVATION", 63, 77], ["arterial", "ANATOMY", 83, 91], ["stable", "OBSERVATION_MODIFIER", 115, 121]]], ["In the intensive care setting, loss of circulation and respiration, indicating cessation of cardiopulmonary activity, occurs typically first after terminal extubation.Cellular Mechanisms In The Dying BrainVirtually all animals with a central nervous system, including insects (56) and humans (44, 45), undergo terminal SD at the end of their life.", [["cardiopulmonary", "ANATOMY", 92, 107], ["Cellular", "ANATOMY", 167, 175], ["central nervous system", "ANATOMY", 234, 256], ["loss of circulation", "DISEASE", 31, 50], ["SD", "DISEASE", 319, 321], ["central nervous system", "ANATOMICAL_SYSTEM", 234, 256], ["humans", "ORGANISM", 285, 291], ["humans", "SPECIES", 285, 291], ["humans", "SPECIES", 285, 291], ["loss of circulation and respiration", "PROBLEM", 31, 66], ["cardiopulmonary activity", "PROBLEM", 92, 116], ["terminal extubation", "TREATMENT", 147, 166], ["terminal SD", "PROBLEM", 310, 321], ["cardiopulmonary activity", "OBSERVATION", 92, 116], ["central", "ANATOMY_MODIFIER", 234, 241], ["nervous system", "ANATOMY", 242, 256]]], ["Using phylogenetic bracketing (a method to infer the probability of unknown traits in organisms based on their location in a phylogenetic tree), we can conclude that terminal SDs must have occurred in the last universal common ancestor of insects and humans as well.", [["humans", "ORGANISM", 251, 257], ["humans", "SPECIES", 251, 257], ["humans", "SPECIES", 251, 257], ["phylogenetic bracketing", "TREATMENT", 6, 29], ["a method", "TREATMENT", 31, 39], ["unknown traits in organisms", "PROBLEM", 68, 95], ["terminal SDs", "PROBLEM", 166, 178]]], ["In other words, terminal SDs must have been the final neuronal pathway to death for probably as long as there has been life with a nervous system on Earth, i.e., at least since the \u201cCambrian explosion\u201d about 520 to 560 million years ago (57, 58).Near-Death Experience\u2014Phenomenology, Epidemiology, and Biological MechanismsNDE are conscious perceptual experiences, including self-related emotional, spiritual, and mystical experiences, occurring in close encounters with death or in non-life-threatening situations (59, 60).", [["neuronal", "ANATOMY", 54, 62], ["nervous system", "ANATOMY", 131, 145], ["death", "DISEASE", 74, 79], ["death", "DISEASE", 470, 475], ["neuronal", "CELL", 54, 62], ["nervous system", "ANATOMICAL_SYSTEM", 131, 145], ["terminal SDs", "PROBLEM", 16, 28]]], ["Typical elements comprise life reviews, out-of-body experiences, entering a tunnel of bright light, feeling peace and joy, becoming one with universe, meeting spirits and entering an unearthly realm (61\u201363).", [["body", "ANATOMY", 47, 51], ["body", "ORGANISM_SUBDIVISION", 47, 51]]], ["Accounts of NDE have been collected from all parts of the world, spanning many centuries and various cultural areas including religion, the visual arts, and fictious literature (Figure 7).Near-Death Experience\u2014Phenomenology, Epidemiology, and Biological MechanismsAlthough NDE may have an esoteric flavor, their stereotypy and universality make it likely that there is a biological basis (60).", [["NDE", "CANCER", 12, 15], ["NDE", "DNA", 12, 15], ["an esoteric flavor", "PROBLEM", 286, 304], ["various", "OBSERVATION_MODIFIER", 93, 100], ["cultural", "OBSERVATION_MODIFIER", 101, 109], ["areas", "OBSERVATION_MODIFIER", 110, 115]]], ["Like other entirely subjective neurological phenomena such as migraine aura or time-space synesthesia, once NDE are systematically described and classified, epidemiologically studies on prevalence and semiology and testing of biological hypotheses become possible (10\u201312, 64, 65) (Figure 8).", [["neurological", "ANATOMY", 31, 43], ["migraine aura", "DISEASE", 62, 75], ["subjective neurological phenomena", "PROBLEM", 20, 53], ["migraine aura", "PROBLEM", 62, 75], ["time-space synesthesia", "PROBLEM", 79, 101], ["semiology", "TEST", 201, 210], ["neurological phenomena", "OBSERVATION", 31, 53]]], ["Thus, the Greyson NDE scale (66), which consists of 16 questions with a maximum of 32 points and an (arbitrary) cut-off of 7 points for a validated NDE, allows conclusions that the phenomenology of NDE appears to be indistinguishable in life-threatening and non-life-threatening situations (11, 12, 63, 72, 73) and that the sequence of features is highly variable (63).", [["NDE", "CHEMICAL", 198, 201], ["NDE", "CANCER", 198, 201], ["the Greyson NDE scale", "TEST", 6, 27]]], ["NDE occur in around 9\u201313% of cardiac arrest survivors (67, 74), and the worldwide prevalence in the general public is around 8\u201310% (11, 12, 68\u201370).Near-Death Experience\u2014Phenomenology, Epidemiology, and Biological MechanismsAlthough there is no cerebral lesion associated with NDE, electrical stimulation of and structural lesions at the temporoparietal junction have been linked to out-of-body experiences (9).", [["cardiac", "ANATOMY", 29, 36], ["cerebral lesion", "ANATOMY", 244, 259], ["lesions", "ANATOMY", 322, 329], ["temporoparietal junction", "ANATOMY", 337, 361], ["body", "ANATOMY", 389, 393], ["NDE", "DISEASE", 0, 3], ["cardiac arrest", "DISEASE", 29, 43], ["cerebral lesion", "DISEASE", 244, 259], ["NDE", "DISEASE", 276, 279], ["cerebral lesion", "PATHOLOGICAL_FORMATION", 244, 259], ["lesions", "PATHOLOGICAL_FORMATION", 322, 329], ["temporoparietal junction", "MULTI-TISSUE_STRUCTURE", 337, 361], ["cardiac arrest survivors", "TREATMENT", 29, 53], ["cerebral lesion", "PROBLEM", 244, 259], ["structural lesions at the temporoparietal junction", "PROBLEM", 311, 361], ["cardiac", "ANATOMY", 29, 36], ["arrest", "OBSERVATION", 37, 43], ["no", "UNCERTAINTY", 241, 243], ["cerebral", "ANATOMY", 244, 252], ["lesion", "OBSERVATION", 253, 259], ["structural", "OBSERVATION_MODIFIER", 311, 321], ["lesions", "OBSERVATION", 322, 329], ["temporoparietal junction", "ANATOMY", 337, 361]]], ["This makes sense given that in this brain area tactile, proprioceptive, and vestibular inputs are integrated into the perception of personal space, so dysfunction of the temporoparietal junction is believed to lead to disintegration of personal (tactile, proprioceptive) and extra-personal (visual) space, which results in an out-of-body experience (9).Near-Death Experience\u2014Phenomenology, Epidemiology, and Biological MechanismsIn a remarkably creative attempt to assess the neurochemical underpinnings of NDE, Martial et al. used a text mining approach to search for semantic similarities in 15,000 written consumer reports on 165 psychoactive substances and 625 NDE narratives (10).", [["brain area", "ANATOMY", 36, 46], ["vestibular inputs", "ANATOMY", 76, 93], ["temporoparietal junction", "ANATOMY", 170, 194], ["body", "ANATOMY", 333, 337], ["NDE", "DISEASE", 507, 510], ["brain", "ORGAN", 36, 41], ["temporoparietal junction", "MULTI-TISSUE_STRUCTURE", 170, 194], ["dysfunction of the temporoparietal junction", "PROBLEM", 151, 194], ["disintegration of personal (tactile, proprioceptive) and extra-personal (visual) space", "PROBLEM", 218, 304], ["a text mining approach", "TREATMENT", 532, 554], ["temporoparietal junction", "ANATOMY", 170, 194]]], ["The substance standing out was ketamine, a NMDAR antagonist.", [["ketamine", "CHEMICAL", 31, 39], ["ketamine", "CHEMICAL", 31, 39], ["ketamine", "SIMPLE_CHEMICAL", 31, 39], ["NMDAR", "SIMPLE_CHEMICAL", 43, 48], ["ketamine", "TREATMENT", 31, 39], ["a NMDAR antagonist", "TREATMENT", 41, 59]]], ["Supporting the importance of NMDAR hypofunction, ketamine is associated with dissociative properties (75); these properties are a psychiatric feature of NMDAR encephalitis (76); and recreational use of ketamine may induce NDE (10, 12).Near-Death Experience\u2014Phenomenology, Epidemiology, and Biological MechanismsOther biological hypotheses that have been tested include REM sleep intrusion (11, 77) and migraine aura (12) (Figure 9).", [["ketamine", "CHEMICAL", 49, 57], ["psychiatric", "DISEASE", 130, 141], ["encephalitis", "DISEASE", 159, 171], ["ketamine", "CHEMICAL", 202, 210], ["NDE", "DISEASE", 222, 225], ["REM sleep intrusion", "DISEASE", 369, 388], ["migraine aura", "DISEASE", 402, 415], ["ketamine", "CHEMICAL", 49, 57], ["ketamine", "CHEMICAL", 202, 210], ["NDE", "CHEMICAL", 222, 225], ["NMDAR", "GENE_OR_GENE_PRODUCT", 29, 34], ["ketamine", "SIMPLE_CHEMICAL", 49, 57], ["ketamine", "SIMPLE_CHEMICAL", 202, 210], ["NMDAR hypofunction", "PROBLEM", 29, 47], ["ketamine", "TREATMENT", 49, 57], ["NMDAR encephalitis", "PROBLEM", 153, 171], ["ketamine", "TREATMENT", 202, 210], ["REM sleep intrusion", "PROBLEM", 369, 388], ["migraine aura", "PROBLEM", 402, 415], ["NMDAR hypofunction", "OBSERVATION", 29, 47]]], ["REM sleep is an attractive candidate mechanism for NDE because it is a natural phenomenon, occurs instantaneously, occurs several times each night in everyone, is associated with dissociative features including muscle atonia and hallucinations, and REM sleep intrusion into wakefulness is a feature of narcolepsy as well as of healthy people (78\u201380).", [["muscle", "ANATOMY", 211, 217], ["muscle atonia", "DISEASE", 211, 224], ["hallucinations", "DISEASE", 229, 243], ["REM sleep intrusion", "DISEASE", 249, 268], ["narcolepsy", "DISEASE", 302, 312], ["muscle", "ORGAN", 211, 217], ["people", "ORGANISM", 335, 341], ["people", "SPECIES", 335, 341], ["a natural phenomenon", "PROBLEM", 69, 89], ["dissociative features", "PROBLEM", 179, 200], ["muscle atonia", "PROBLEM", 211, 224], ["hallucinations", "PROBLEM", 229, 243], ["REM sleep intrusion into wakefulness", "PROBLEM", 249, 285], ["narcolepsy", "PROBLEM", 302, 312], ["muscle", "ANATOMY", 211, 217], ["atonia", "OBSERVATION", 218, 224], ["hallucinations", "OBSERVATION", 229, 243]]], ["So far, two studies have investigated the association of NDE with REM sleep (11, 77).", [["two studies", "TEST", 8, 19]]], ["In a case-control study, the prevalence of REM sleep intrusion was 23% in a sample of people with NDE and 0% in controls (77).", [["REM sleep intrusion", "DISEASE", 43, 62], ["NDE", "DISEASE", 98, 101], ["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92], ["control study", "TEST", 10, 23], ["REM sleep intrusion", "PROBLEM", 43, 62], ["NDE", "TEST", 98, 101]]], ["This study was criticized because of its selection bias: Although the groups matched for age and gender, the NDE sample was drawn from people who had taken the initiative to self-register their experience online, whereas the control group consisted of medical staff who most likely was more aware of the implications of the questions related to REM sleep intrusion (81).", [["REM sleep intrusion", "DISEASE", 345, 364], ["people", "ORGANISM", 135, 141], ["people", "SPECIES", 135, 141], ["This study", "TEST", 0, 10], ["the NDE sample", "TEST", 105, 119], ["REM sleep intrusion", "PROBLEM", 345, 364]]], ["A crowdsourcing study recruiting over 1,000 unprimed laypeople from 35 countries, however, confirmed an association: While age, gender, place of residence, employment status, and perceived threat did not seem to influence the prevalence of near-death experiences, people with REM intrusion were much more likely to exhibit NDE than those without (OR 2.85, p < 0.0001) (Figure 9A).", [["death", "DISEASE", 245, 250], ["REM intrusion", "DISEASE", 276, 289], ["NDE", "DISEASE", 323, 326], ["people", "ORGANISM", 264, 270], ["people", "SPECIES", 264, 270], ["A crowdsourcing study", "TEST", 0, 21], ["REM intrusion", "PROBLEM", 276, 289]]], ["Migraine aura is also an attractive candidate mechanism for NDE because a short-lasting variant of SD is considered the pathophysiological correlate of migraine aura, while terminal SD occurs in humans at the end of life as outlined earlier.", [["Migraine aura", "DISEASE", 0, 13], ["NDE", "DISEASE", 60, 63], ["SD", "DISEASE", 99, 101], ["migraine aura", "DISEASE", 152, 165], ["SD", "DISEASE", 182, 184], ["humans", "ORGANISM", 195, 201], ["humans", "SPECIES", 195, 201], ["humans", "SPECIES", 195, 201], ["Migraine aura", "PROBLEM", 0, 13], ["migraine aura", "PROBLEM", 152, 165], ["migraine", "OBSERVATION", 152, 160]]], ["Indeed, migraine aura was also a predictor of NDE in another crowdsourcing study of unprimed lay people adjusted for age and gender (OR 2.33, p < 0.001) (Figure 9B), but it has not been investigated in more traditional interview-based surveys yet.Near-Death Experience\u2014Phenomenology, Epidemiology, and Biological MechanismsAlthough REM sleep intrusion and migraine aura are strongly associated with NDE (the first perhaps even more so), neither of these two predictors, nor NMDAR hypofunction, and dysfunction of temporoparietal cortex, are sufficient or necessary to explain NDE.", [["temporoparietal cortex", "ANATOMY", 513, 535], ["migraine aura", "DISEASE", 8, 21], ["NDE", "DISEASE", 46, 49], ["sleep intrusion", "DISEASE", 336, 351], ["migraine aura", "DISEASE", 356, 369], ["NDE", "DISEASE", 399, 402], ["hypofunction", "DISEASE", 480, 492], ["dysfunction of temporoparietal cortex", "DISEASE", 498, 535], ["NDE", "DISEASE", 576, 579], ["people", "ORGANISM", 97, 103], ["temporoparietal cortex", "MULTI-TISSUE_STRUCTURE", 513, 535], ["people", "SPECIES", 97, 103], ["migraine aura", "PROBLEM", 8, 21], ["another crowdsourcing study", "TEST", 53, 80], ["Biological MechanismsAlthough REM sleep intrusion", "PROBLEM", 302, 351], ["migraine aura", "PROBLEM", 356, 369], ["NMDAR hypofunction", "PROBLEM", 474, 492], ["dysfunction of temporoparietal cortex", "PROBLEM", 498, 535], ["NMDAR hypofunction", "OBSERVATION", 474, 492], ["temporoparietal cortex", "ANATOMY", 513, 535]]], ["Figure 10 shows an attempt to construct a unifying model using the evidence discussed.Near-Death Experience\u2014Phenomenology, Epidemiology, and Biological MechanismsAccording to the hypothesis of Nelson and colleagues, danger (be it real or only perceived) stimulates neuronal pathways that generate REM-associated responses (77, 81).", [["neuronal", "ANATOMY", 265, 273], ["neuronal", "CELL", 265, 273]]], ["This can be interpreted as a \u201cdiathesis-stress model\u201d: An unusually sensitive arousal system (i.e., the diathesis), as evidenced by the experience of REM sleep intrusion, would predispose people to NDE in life-threatening situations and emotional stress (77, 81).", [["diathesis", "DISEASE", 30, 39], ["diathesis", "DISEASE", 104, 113], ["REM sleep intrusion", "DISEASE", 150, 169], ["NDE", "CHEMICAL", 198, 201], ["people", "ORGANISM", 188, 194], ["people", "SPECIES", 188, 194], ["a \u201cdiathesis", "PROBLEM", 27, 39], ["An unusually sensitive arousal system", "PROBLEM", 55, 92], ["the diathesis", "PROBLEM", 100, 113], ["REM sleep intrusion", "PROBLEM", 150, 169], ["diathesis", "OBSERVATION", 104, 113]]], ["Migraine aura, NMDAR antagonism and temporoparietal dysfunction could be understood as contributing factors.", [["temporoparietal", "ANATOMY", 36, 51], ["Migraine aura", "DISEASE", 0, 13], ["temporoparietal dysfunction", "DISEASE", 36, 63], ["NMDAR", "SIMPLE_CHEMICAL", 15, 20], ["temporoparietal", "MULTI-TISSUE_STRUCTURE", 36, 51], ["Migraine aura", "PROBLEM", 0, 13], ["NMDAR antagonism", "PROBLEM", 15, 31], ["temporoparietal dysfunction", "PROBLEM", 36, 63], ["temporoparietal", "ANATOMY", 36, 51], ["dysfunction", "OBSERVATION", 52, 63]]], ["This model seems consistent with the fact that the semiology of NDE appears to be identical in situations that are associated with real danger and the possibility for compromised brain physiology (e.g., during resuscitation after cardiac arrest), situations associated with real danger but without evidence of impaired brain physiology (e.g., a near miss traffic accident) and in those that may only just feel threatening but where true danger is absent (e.g., meditation).", [["brain", "ANATOMY", 179, 184], ["cardiac", "ANATOMY", 230, 237], ["brain", "ANATOMY", 319, 324], ["NDE", "DISEASE", 64, 67], ["cardiac arrest", "DISEASE", 230, 244], ["impaired brain physiology", "DISEASE", 310, 335], ["brain", "ORGAN", 179, 184], ["brain", "ORGAN", 319, 324], ["compromised brain physiology", "PROBLEM", 167, 195], ["resuscitation", "TREATMENT", 210, 223], ["cardiac arrest", "PROBLEM", 230, 244], ["impaired brain physiology", "PROBLEM", 310, 335], ["seems consistent with", "UNCERTAINTY", 11, 32], ["without evidence of", "UNCERTAINTY", 290, 309], ["impaired", "OBSERVATION", 310, 318]]], ["In any case, recall of NDE many years later requires that the subject has survived without any major brain damage.", [["brain", "ANATOMY", 101, 106], ["NDE", "DISEASE", 23, 26], ["brain damage", "DISEASE", 101, 113], ["NDE", "CANCER", 23, 26], ["brain", "ORGAN", 101, 106], ["any major brain damage", "PROBLEM", 91, 113], ["brain", "ANATOMY", 101, 106], ["damage", "OBSERVATION", 107, 113]]], ["We can conclude that it seems likely that some of us will experience features of NDE during the process of dying and just before loss of consciousness and immediate death, but we may never know how many of us, because for evident reasons no one will ever have the chance to provide this information after they have died.", [["NDE", "DISEASE", 81, 84], ["loss of consciousness", "DISEASE", 129, 150], ["death", "DISEASE", 165, 170], ["NDE", "CANCER", 81, 84], ["loss of consciousness", "PROBLEM", 129, 150], ["seems likely", "UNCERTAINTY", 24, 36]]], ["If terminal SD is compatible with the possibility for any conscious percept remains to be determined (12).Near-Death Experience\u2014Phenomenology, Epidemiology, and Biological MechanismsGiven that NDE is a universal phenomenon that has been preserved in humans for many centuries, the question arises if it serves a specific biological purpose.", [["SD", "DISEASE", 12, 14], ["NDE", "CHEMICAL", 193, 196], ["humans", "ORGANISM", 250, 256], ["humans", "SPECIES", 250, 256], ["humans", "SPECIES", 250, 256], ["terminal SD", "PROBLEM", 3, 14], ["any conscious percept", "PROBLEM", 54, 75], ["a universal phenomenon", "PROBLEM", 200, 222], ["compatible with the possibility", "UNCERTAINTY", 18, 49]]], ["Metaphysical explanations aside, the author hypothesizes that NDE may have an evolutionary benefit.", [["NDE", "CHEMICAL", 62, 65], ["NDE", "GENE_OR_GENE_PRODUCT", 62, 65]]], ["There are countless examples within the animal kingdom that playing dead saves lives (Figure 10).", [["animal", "OBSERVATION_MODIFIER", 40, 46], ["kingdom", "OBSERVATION_MODIFIER", 47, 54]]], ["Thanatosis or death-feigning occurs in invertebrates (82\u201385) and vertebrates (86, 87), including mammals (88, 89) and possibly humans (90), indicating that it is a phylogenetically highly preserved phenomenon.", [["Thanatosis", "DISEASE", 0, 10], ["death", "DISEASE", 14, 19], ["humans", "ORGANISM", 127, 133], ["humans", "SPECIES", 127, 133], ["humans", "SPECIES", 127, 133], ["Thanatosis", "PROBLEM", 0, 10], ["death", "PROBLEM", 14, 19], ["feigning", "PROBLEM", 20, 28], ["vertebrates", "TEST", 65, 76], ["a phylogenetically highly preserved phenomenon", "PROBLEM", 162, 208], ["preserved", "OBSERVATION_MODIFIER", 188, 197], ["phenomenon", "OBSERVATION", 198, 208]]], ["Thanatosis is an anti-predator strategy and the terminal defense response when all other options of fight or flight are futile (91\u201394).", [["Thanatosis", "DISEASE", 0, 10], ["an anti-predator strategy", "TREATMENT", 14, 39], ["terminal", "OBSERVATION_MODIFIER", 48, 56], ["defense response", "OBSERVATION", 57, 73]]], ["It is characterized by the sudden onset of immobility, with or without loss of tonic muscular activity, and unresponsiveness to external stimuli, while awareness of the environment is fully preserved (92).", [["muscular", "ANATOMY", 85, 93], ["muscular", "ORGAN", 85, 93], ["immobility", "PROBLEM", 43, 53], ["loss of tonic muscular activity", "PROBLEM", 71, 102], ["unresponsiveness", "PROBLEM", 108, 124], ["external stimuli", "TEST", 128, 144], ["immobility", "OBSERVATION", 43, 53]]], ["This is not unlike lucid dreaming and cataplexy which are features of REM sleep intrusion into wakefulness (80) that can occur in NDE (11).", [["cataplexy", "DISEASE", 38, 47], ["NDE", "CHEMICAL", 130, 133], ["cataplexy", "PROBLEM", 38, 47], ["REM sleep intrusion into wakefulness", "PROBLEM", 70, 106], ["not unlike", "UNCERTAINTY", 8, 18], ["lucid", "OBSERVATION", 19, 24]]], ["Thanatosis increases chances for escape from imminent danger and, being a heritable behavioral trait, it can evolve under natural selection for fitness of survival (95).", [["Thanatosis", "DISEASE", 0, 10], ["Thanatosis", "PROBLEM", 0, 10], ["a heritable behavioral trait", "PROBLEM", 72, 100]]], ["Although its association with NDE is still entirely speculative, it seems fair to say that panicking in situations of unescapable danger is never a good option for humans either.ConclusionsAs shown here, neurologists are well-equipped to address the science behind questions about the transition from life to death.", [["NDE", "DISEASE", 30, 33], ["panicking", "DISEASE", 91, 100], ["death", "DISEASE", 309, 314], ["humans", "ORGANISM", 164, 170], ["humans", "SPECIES", 164, 170], ["humans", "SPECIES", 164, 170]]], ["Key areas for future research and activities include aligning brain death guidelines across countries, increasing the rate of organ donation by implementing DCD, determining the length of the \u201chands-off period\u201d prior to organ procurement, improving methods to detect and prevent terminal SDs in intensive care patients with brain injury, and investigating if terminal SDs are compatible with NDE-like features and if thanatosis can be confirmed as the evolutionary origin of NDE.", [["brain", "ANATOMY", 62, 67], ["organ", "ANATOMY", 126, 131], ["organ", "ANATOMY", 220, 225], ["brain", "ANATOMY", 324, 329], ["brain death", "DISEASE", 62, 73], ["DCD", "DISEASE", 157, 160], ["brain injury", "DISEASE", 324, 336], ["thanatosis", "DISEASE", 417, 427], ["NDE", "DISEASE", 475, 478], ["brain", "ORGAN", 62, 67], ["organ", "ORGAN", 126, 131], ["organ", "ORGAN", 220, 225], ["patients", "ORGANISM", 310, 318], ["brain", "ORGAN", 324, 329], ["NDE", "CANCER", 475, 478], ["patients", "SPECIES", 310, 318], ["organ donation", "TREATMENT", 126, 140], ["DCD", "TREATMENT", 157, 160], ["organ procurement", "TREATMENT", 220, 237], ["terminal SDs", "PROBLEM", 279, 291], ["brain injury", "PROBLEM", 324, 336], ["terminal SDs", "PROBLEM", 359, 371], ["NDE-like features", "PROBLEM", 392, 409], ["thanatosis", "PROBLEM", 417, 427], ["brain", "ANATOMY", 324, 329], ["injury", "OBSERVATION", 330, 336], ["compatible with", "UNCERTAINTY", 376, 391]]], ["Moreover, in the perhaps not so distant future, neurologists will be consulted about their opinions on ethical considerations (96, 97) related to attempts of brain resuscitation (8).", [["brain", "ANATOMY", 158, 163], ["brain", "ORGAN", 158, 163], ["brain resuscitation", "TREATMENT", 158, 177]]], ["In a highly publicized experiment, Vrselja et al. recently showed they were able to preserve cytoarchitecture, to attenuate neuronal cell death, and to restore vasculature and glial cell responses as well as active cerebral metabolism and synaptic activity in the pig brain 4 h after death (8).", [["neuronal cell", "ANATOMY", 124, 137], ["vasculature", "ANATOMY", 160, 171], ["glial cell", "ANATOMY", 176, 186], ["cerebral", "ANATOMY", 215, 223], ["synaptic", "ANATOMY", 239, 247], ["brain", "ANATOMY", 268, 273], ["death", "DISEASE", 138, 143], ["death", "DISEASE", 284, 289], ["neuronal cell", "CELL", 124, 137], ["vasculature", "MULTI-TISSUE_STRUCTURE", 160, 171], ["glial cell", "CELL", 176, 186], ["cerebral", "ORGAN", 215, 223], ["pig", "ORGANISM", 264, 267], ["brain", "ORGAN", 268, 273], ["pig", "SPECIES", 264, 267], ["pig", "SPECIES", 264, 267], ["neuronal cell death", "PROBLEM", 124, 143], ["active cerebral metabolism", "PROBLEM", 208, 234], ["neuronal cell death", "OBSERVATION", 124, 143], ["vasculature", "ANATOMY", 160, 171], ["glial cell", "OBSERVATION", 176, 186], ["cerebral", "ANATOMY", 215, 223], ["metabolism", "OBSERVATION", 224, 234], ["synaptic activity", "OBSERVATION", 239, 256], ["pig brain", "ANATOMY", 264, 273]]], ["Although recovery of consciousness was ruled out by lack of global electrocorticographic activity, this shows that within the neurology of the dying brain, boundaries are being pushed just like in any other area of the clinical neurosciences.Author ContributionsThe author confirms being the sole contributor of this work and has approved it for publication.Conflict of InterestThe author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["brain", "ANATOMY", 149, 154], ["brain", "ORGAN", 149, 154], ["consciousness", "PROBLEM", 21, 34], ["global electrocorticographic activity", "PROBLEM", 60, 97], ["electrocorticographic activity", "OBSERVATION", 67, 97], ["brain", "ANATOMY", 149, 154]]]], "d6d57b6f325a9ee5bb1e1b4fdd5757c6165a1258": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported to cause respiratory illness in China in December 2019, with the disease designated as COronaVIrus Disease 2019 (COVID-19) 1 .", [["respiratory", "ANATOMY", 101, 112], ["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["respiratory illness", "DISEASE", 101, 120], ["COronaVIrus Disease", "DISEASE", 179, 198], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["SARS-CoV", "TEST", 61, 69], ["respiratory illness", "PROBLEM", 101, 120], ["the disease", "PROBLEM", 153, 164], ["COronaVIrus Disease", "PROBLEM", 179, 198], ["COVID", "TEST", 205, 210], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["respiratory", "ANATOMY", 101, 112], ["illness", "OBSERVATION", 113, 120], ["COronaVIrus Disease", "OBSERVATION", 179, 198]]], ["SARS-CoV-2 has caused significant morbidity and mortality globally; as of September 21, 2020, there have been 31,200,220 documented cases worldwide and 963,000 confirmed deaths with the highest national burden thus far in the United States 2 .IntroductionGiven this impact, there has been great interest in finding potential treatments for COVID-19 3 although early enthusiasm and adoption of possible candidate drugs, such as hydroxychloroquine, has been tempered upon rigorous study 4 .IntroductionCurrently, two drugs have shown benefit in randomized controlled trials.", [["SARS", "DISEASE", 0, 4], ["deaths", "DISEASE", 170, 176], ["hydroxychloroquine", "CHEMICAL", 427, 445], ["hydroxychloroquine", "CHEMICAL", 427, 445], ["SARS-CoV-2", "ORGANISM", 0, 10], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 427, 445], ["SARS-CoV", "SPECIES", 0, 8], ["significant morbidity", "PROBLEM", 22, 43], ["COVID", "TEST", 340, 345], ["drugs", "TREATMENT", 412, 417], ["hydroxychloroquine", "TREATMENT", 427, 445], ["rigorous study", "TEST", 470, 484], ["randomized controlled trials", "TREATMENT", 543, 571], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["morbidity", "OBSERVATION", 34, 43]]], ["First, remdesivir, a RNA polymerase inhibitor with broad antiviral activity and in vitro effect against SARS-CoV-2 3 , was shown to have benefit in a randomized controlled trial in the United States sponsored by the National Institute of Health 5 with a list price of $2340 US dollars per treatment course 6 .", [["remdesivir", "CHEMICAL", 7, 17], ["remdesivir", "CHEMICAL", 7, 17], ["remdesivir", "SIMPLE_CHEMICAL", 7, 17], ["SARS-CoV-2 3", "ORGANISM", 104, 116], ["SARS-CoV", "SPECIES", 104, 112], ["remdesivir", "TREATMENT", 7, 17], ["a RNA polymerase inhibitor", "TREATMENT", 19, 45], ["broad antiviral activity", "TREATMENT", 51, 75], ["SARS", "PROBLEM", 104, 108], ["CoV", "TEST", 109, 112]]], ["More recently, dexamethasone was shown to improve COVID-19 outcomes in a randomized controlled trial in the United Kingdom 7 with a list price of approximately $20 per treatment course 8 .IntroductionIncomplete 28-day mortality data suggests that the benefit of antiviral therapy with remdesivir is highest in patients needing supplemental oxygen with a 8.5% reduction in mortality and a reduced length of stay 5 , while the anti-inflammatory effect of dexamethasone appears somewhat beneficial in patients on oxygen, reducing mortality by 3.5%, and most beneficial in those requiring mechanical ventilation with a reduction of mortality by 11.7% 7 .", [["dexamethasone", "CHEMICAL", 15, 28], ["remdesivir", "CHEMICAL", 285, 295], ["oxygen", "CHEMICAL", 340, 346], ["dexamethasone", "CHEMICAL", 453, 466], ["oxygen", "CHEMICAL", 510, 516], ["dexamethasone", "CHEMICAL", 15, 28], ["remdesivir", "CHEMICAL", 285, 295], ["oxygen", "CHEMICAL", 340, 346], ["dexamethasone", "CHEMICAL", 453, 466], ["oxygen", "CHEMICAL", 510, 516], ["dexamethasone", "SIMPLE_CHEMICAL", 15, 28], ["remdesivir", "SIMPLE_CHEMICAL", 285, 295], ["patients", "ORGANISM", 310, 318], ["oxygen", "SIMPLE_CHEMICAL", 340, 346], ["dexamethasone", "SIMPLE_CHEMICAL", 453, 466], ["patients", "ORGANISM", 498, 506], ["oxygen", "SIMPLE_CHEMICAL", 510, 516], ["patients", "SPECIES", 310, 318], ["patients", "SPECIES", 498, 506], ["dexamethasone", "TREATMENT", 15, 28], ["COVID", "TEST", 50, 55], ["antiviral therapy", "TREATMENT", 262, 279], ["remdesivir", "TREATMENT", 285, 295], ["supplemental oxygen", "TREATMENT", 327, 346], ["a 8.5% reduction in mortality", "TREATMENT", 352, 381], ["dexamethasone", "TREATMENT", 453, 466], ["oxygen", "TREATMENT", 510, 516], ["mechanical ventilation", "TREATMENT", 585, 607], ["a reduction of mortality", "TREATMENT", 613, 637], ["antiviral therapy", "OBSERVATION", 262, 279]]], ["Given the economic implications of COVID-19 and these potential treatments, we developed a cost-effectiveness .", [["COVID", "TEST", 35, 40], ["these potential treatments", "TREATMENT", 48, 74]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintIntroductionThe copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.21.20199182 doi: medRxiv preprint analysis of these drugs in the United States context with additional global considerations assessed by willingness-to-pay thresholds.Introduction.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["these drugs", "TREATMENT", 373, 384], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint infections, remdesivir to moderate and dexamethasone to severe COVID-19 infections, and best supportive care to all patients.", [["CC", "CHEMICAL", 0, 2], ["infections", "DISEASE", 212, 222], ["remdesivir", "DISEASE", 224, 234], ["dexamethasone", "CHEMICAL", 251, 264], ["COVID", "DISEASE", 275, 280], ["infections", "DISEASE", 284, 294], ["dexamethasone", "CHEMICAL", 251, 264], ["dexamethasone", "SIMPLE_CHEMICAL", 251, 264], ["patients", "ORGANISM", 328, 336], ["patients", "SPECIES", 328, 336], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["preprint infections", "PROBLEM", 203, 222], ["remdesivir", "TREATMENT", 224, 234], ["dexamethasone", "TREATMENT", 251, 264], ["severe COVID-19 infections", "PROBLEM", 268, 294], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["infections", "OBSERVATION", 212, 222], ["infections", "OBSERVATION", 284, 294]]], ["Patients who did not receive either therapy were assumed to receive best supportive care.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["therapy", "TREATMENT", 36, 43], ["best supportive care", "TREATMENT", 68, 88]]], ["For patients receiving dexamethasone, they were assumed to receive 6 mg per day for 10 days 7 .", [["dexamethasone", "CHEMICAL", 23, 36], ["dexamethasone", "CHEMICAL", 23, 36], ["patients", "ORGANISM", 4, 12], ["dexamethasone", "SIMPLE_CHEMICAL", 23, 36], ["patients", "SPECIES", 4, 12], ["dexamethasone", "TREATMENT", 23, 36]]], ["For patients receiving remdesivir for severe COVID-19 infections, they were assumed to receive 200 mg on day 1 and then 100 mg daily for 9 additional days.", [["remdesivir", "CHEMICAL", 23, 33], ["COVID", "DISEASE", 45, 50], ["infections", "DISEASE", 54, 64], ["remdesivir", "CHEMICAL", 23, 33], ["patients", "ORGANISM", 4, 12], ["remdesivir", "SIMPLE_CHEMICAL", 23, 33], ["patients", "SPECIES", 4, 12], ["remdesivir", "TREATMENT", 23, 33], ["severe COVID-19 infections", "PROBLEM", 38, 64], ["infections", "OBSERVATION", 54, 64]]], ["For moderate COVID-19 infections, patients were assumed to receive a 5 day course of remdesivir; 200 mg on day 1 and then 100 mg daily for 4 additional days given data suggesting similar efficacy of 5 and 10 day courses in this population 9 .", [["infections", "DISEASE", 22, 32], ["remdesivir", "CHEMICAL", 85, 95], ["remdesivir", "CHEMICAL", 85, 95], ["patients", "ORGANISM", 34, 42], ["remdesivir", "SIMPLE_CHEMICAL", 85, 95], ["patients", "SPECIES", 34, 42], ["moderate COVID-19 infections", "PROBLEM", 4, 32], ["remdesivir", "TREATMENT", 85, 95], ["moderate", "OBSERVATION_MODIFIER", 4, 12], ["infections", "OBSERVATION", 22, 32]]], ["In this simple model, a patient would either recover from their infection and survive or die with no transition between ward and ICU.IntroductionTo account for clinical situations in which patients may be admitted to the ICU on high flow oxygen, a scenario analysis was performed where all patients were assumed to be admitted to the ICU with the expected increase in costs.", [["infection", "DISEASE", 64, 73], ["oxygen", "CHEMICAL", 238, 244], ["oxygen", "CHEMICAL", 238, 244], ["patient", "ORGANISM", 24, 31], ["patients", "ORGANISM", 189, 197], ["oxygen", "SIMPLE_CHEMICAL", 238, 244], ["patients", "ORGANISM", 290, 298], ["patient", "SPECIES", 24, 31], ["patients", "SPECIES", 189, 197], ["patients", "SPECIES", 290, 298], ["their infection", "PROBLEM", 58, 73], ["high flow oxygen", "TREATMENT", 228, 244], ["a scenario analysis", "TEST", 246, 265], ["infection", "OBSERVATION", 64, 73], ["increase", "OBSERVATION_MODIFIER", 356, 364]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["Medicare Part B database 8 for dexamethasone and the published price for remdesivir 6 .", [["dexamethasone", "CHEMICAL", 31, 44], ["dexamethasone", "CHEMICAL", 31, 44], ["remdesivir 6", "CHEMICAL", 73, 85], ["dexamethasone", "SIMPLE_CHEMICAL", 31, 44], ["dexamethasone", "TREATMENT", 31, 44], ["remdesivir", "TREATMENT", 73, 83]]], ["Utilities were based on previous experiences with H1N1 and influenza 11, 12 ; patients were assumed to have these utilities for 28 days and then return to the US average utility of 0.947 13 for the remainder of the year if they survived.", [["H1N1", "DISEASE", 50, 54], ["influenza", "DISEASE", 59, 68], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["H1N1", "PROBLEM", 50, 54], ["influenza", "PROBLEM", 59, 68]]], ["Univariate analysis and a multivariate probabilistic sensitivity analysis using 100,000 simulations were performed to assess the model.MethodologyThe model was internally validated and was determined to have good face validity.", [["Univariate analysis", "TEST", 0, 19], ["a multivariate probabilistic sensitivity analysis", "TEST", 24, 73]]], ["Ethics approval was not required as the data used in this study came from publicly available data.Methodology.", [["this study", "TEST", 53, 63]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintMethodologyThe copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.21.20199182 doi: medRxiv preprintRole of the funding sourceThis study was unfunded.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["This study", "TEST", 385, 395], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The corresponding author had full access to all the modelling data and output in the study and had final responsibility for the decision to submit for publication.Role of the funding source.", [["the study", "TEST", 81, 90]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintRole of the funding sourceThe copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.21.20199182 doi: medRxiv preprintResultsIn the base-case model ( Figure 1 , Table 2 ), supportive care for moderate-severe COVID-19 had a cost of $11,112.98 for 0.8256 quality adjusted life years (QALY).", [["CC", "CHEMICAL", 0, 2], ["COVID", "DISEASE", 464, 469], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["supportive care", "TREATMENT", 428, 443], ["moderate-severe COVID", "PROBLEM", 448, 469], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Using remdesivir for moderate and dexamethasone for severe infections had an incremental cost effectiveness ratio (ICER) of $19,764.56/QALY versus supportive care and was the most cost effective of the strategies evaluated.", [["remdesivir", "CHEMICAL", 6, 16], ["dexamethasone", "CHEMICAL", 34, 47], ["infections", "DISEASE", 59, 69], ["remdesivir", "CHEMICAL", 6, 16], ["dexamethasone", "CHEMICAL", 34, 47], ["remdesivir", "SIMPLE_CHEMICAL", 6, 16], ["dexamethasone", "SIMPLE_CHEMICAL", 34, 47], ["remdesivir", "TREATMENT", 6, 16], ["dexamethasone", "TREATMENT", 34, 47], ["severe infections", "PROBLEM", 52, 69], ["supportive care", "TREATMENT", 147, 162], ["moderate", "OBSERVATION_MODIFIER", 21, 29], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["infections", "OBSERVATION", 59, 69]]], ["Using remdesivir for all patients or remdesivir for severe infections only were both less effective and more costly than dexamethasone-based strategies and were considered dominated.", [["remdesivir", "CHEMICAL", 6, 16], ["remdesivir", "CHEMICAL", 37, 47], ["infections", "DISEASE", 59, 69], ["dexamethasone", "CHEMICAL", 121, 134], ["remdesivir", "CHEMICAL", 6, 16], ["dexamethasone", "CHEMICAL", 121, 134], ["remdesivir", "SIMPLE_CHEMICAL", 6, 16], ["patients", "ORGANISM", 25, 33], ["dexamethasone", "SIMPLE_CHEMICAL", 121, 134], ["patients", "SPECIES", 25, 33], ["remdesivir", "TREATMENT", 6, 16], ["remdesivir", "TREATMENT", 37, 47], ["severe infections", "PROBLEM", 52, 69], ["dexamethasone", "TREATMENT", 121, 134], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["infections", "OBSERVATION", 59, 69]]], ["Using remdesivir for moderate COVID-19 infection only was considered to be extendedly dominated, meaning that the incremental cost-effectiveness ratio was higher than a more effective strategy.ResultsIn the scenario analysis where all patients were assumed to be admitted to the ICU, supportive care now cost $33,247.15/0.8256 QALY.", [["remdesivir", "CHEMICAL", 6, 16], ["infection", "DISEASE", 39, 48], ["patients", "ORGANISM", 235, 243], ["patients", "SPECIES", 235, 243], ["remdesivir", "TREATMENT", 6, 16], ["moderate COVID-19 infection", "PROBLEM", 21, 48], ["the incremental cost-effectiveness ratio", "TEST", 110, 150], ["the scenario analysis", "TEST", 203, 224], ["moderate", "OBSERVATION_MODIFIER", 21, 29], ["infection", "OBSERVATION", 39, 48]]], ["The incremental cost-effectiveness ratios and rankings remained unchanged from the base case except that each strategy cost an additional $22,134.17 accounting for the additional costs of ICU admission as compared to admission to the ward.ResultsIn univariate sensitivity analysis, the preferred strategy of remdesivir for moderate and dexamethasone for severe COVID-19 infections remained unchanged with all variables.", [["remdesivir", "CHEMICAL", 308, 318], ["dexamethasone", "CHEMICAL", 336, 349], ["COVID", "DISEASE", 361, 366], ["infections", "DISEASE", 370, 380], ["remdesivir", "CHEMICAL", 308, 318], ["dexamethasone", "CHEMICAL", 336, 349], ["remdesivir", "SIMPLE_CHEMICAL", 308, 318], ["dexamethasone", "SIMPLE_CHEMICAL", 336, 349], ["The incremental cost-effectiveness ratios", "TEST", 0, 41], ["sensitivity analysis", "TEST", 260, 280], ["remdesivir", "TREATMENT", 308, 318], ["dexamethasone", "TREATMENT", 336, 349], ["severe COVID-19 infections", "PROBLEM", 354, 380], ["unchanged", "OBSERVATION_MODIFIER", 64, 73], ["infections", "OBSERVATION", 370, 380], ["unchanged", "OBSERVATION_MODIFIER", 390, 399]]], ["The ICER for the remdesivir for moderate strategy exceeded $100,000 if remdesivir cost >$4.08 per tablet, the probability of death of moderate COVID-19 was >0.055, the probability of death of severe COVID-19 was >0.386 and the risk reduction of remdesivir for moderate infections >0.41.", [["remdesivir", "CHEMICAL", 17, 27], ["death", "DISEASE", 125, 130], ["death", "DISEASE", 183, 188], ["remdesivir", "CHEMICAL", 245, 255], ["infections", "DISEASE", 269, 279], ["remdesivir", "CHEMICAL", 245, 255], ["The ICER", "TREATMENT", 0, 8], ["the remdesivir", "TREATMENT", 13, 27], ["moderate COVID", "TEST", 134, 148], ["severe COVID", "PROBLEM", 192, 204], ["remdesivir", "TREATMENT", 245, 255], ["moderate infections", "PROBLEM", 260, 279], ["moderate", "OBSERVATION_MODIFIER", 134, 142], ["severe", "OBSERVATION_MODIFIER", 192, 198], ["moderate", "OBSERVATION_MODIFIER", 260, 268], ["infections", "OBSERVATION", 269, 279]]], ["Remdesivir for moderate and severe COVID-19 infections was dominated in all cases (more expensive and less effective) unless the cost per tablet was less than $0.30.Results.", [["Remdesivir", "CHEMICAL", 0, 10], ["COVID", "DISEASE", 35, 40], ["infections", "DISEASE", 44, 54], ["Remdesivir", "TREATMENT", 0, 10], ["moderate and severe COVID-19 infections", "PROBLEM", 15, 54], ["moderate", "OBSERVATION_MODIFIER", 15, 23], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["infections", "OBSERVATION", 44, 54]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintResultsThe copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.21.20199182 doi: medRxiv preprint Probabilistic sensitivity analysis of all strategies based on a willingness to pay threshold of $100,000 showed that the use of remdesivir in moderate and dexamethasone in severe COVID-19 infections would be favoured in 88.58% of simulations while dexamethasone in moderatesevere COVID-19 infections would be the most cost-effective strategy in 11.38% of simulations.ResultsAll other strategies were extremely unlikely to be cost-effective with probabilities between 0.001-0.002%.ResultsThe cost effectiveness acceptability curve ( Figure 2) shows that as the willingness to pay threshold increases the remdesivir for moderate and dexamethasone for severe infection strategy continued to be more likely to be favoured.", [["CC", "CHEMICAL", 0, 2], ["remdesivir", "CHEMICAL", 484, 494], ["dexamethasone", "CHEMICAL", 511, 524], ["COVID", "DISEASE", 535, 540], ["infections", "DISEASE", 544, 554], ["dexamethasone", "CHEMICAL", 604, 617], ["COVID-19", "CHEMICAL", 636, 644], ["infections", "DISEASE", 645, 655], ["remdesivir", "CHEMICAL", 959, 969], ["dexamethasone", "CHEMICAL", 987, 1000], ["infection", "DISEASE", 1012, 1021], ["remdesivir", "CHEMICAL", 484, 494], ["dexamethasone", "CHEMICAL", 511, 524], ["dexamethasone", "CHEMICAL", 604, 617], ["dexamethasone", "CHEMICAL", 987, 1000], ["remdesivir", "SIMPLE_CHEMICAL", 484, 494], ["dexamethasone", "SIMPLE_CHEMICAL", 511, 524], ["dexamethasone", "SIMPLE_CHEMICAL", 604, 617], ["remdesivir", "SIMPLE_CHEMICAL", 959, 969], ["dexamethasone", "SIMPLE_CHEMICAL", 987, 1000], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 339, 346], ["remdesivir", "TREATMENT", 484, 494], ["dexamethasone", "TREATMENT", 511, 524], ["severe COVID-19 infections", "PROBLEM", 528, 554], ["dexamethasone", "TREATMENT", 604, 617], ["moderatesevere COVID", "TREATMENT", 621, 641], ["infections", "PROBLEM", 645, 655], ["probabilities", "TEST", 801, 814], ["the remdesivir", "TREATMENT", 955, 969], ["dexamethasone", "TREATMENT", 987, 1000], ["severe infection strategy", "PROBLEM", 1005, 1030], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["severe", "OBSERVATION_MODIFIER", 1005, 1011], ["infection", "OBSERVATION", 1012, 1021]]], ["Conversely, with willingness to pay thresholds lower than the typical US standard of $100,000, the use of dexamethasone for all hospitalized infections would be favoured with a willingness to pay between approximately $250-$37,500; supportive care would be favoured with a willingness to pay threshold of less than $250.Results.", [["dexamethasone", "CHEMICAL", 106, 119], ["infections", "DISEASE", 141, 151], ["dexamethasone", "CHEMICAL", 106, 119], ["dexamethasone", "SIMPLE_CHEMICAL", 106, 119], ["dexamethasone", "TREATMENT", 106, 119], ["all hospitalized infections", "PROBLEM", 124, 151], ["supportive care", "TREATMENT", 232, 247]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintResultsThe copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.21.20199182 doi: medRxiv preprintDiscussionIn our base-case analysis, we found that using remdesivir for moderate and dexamethasone for severe infections was the most cost-effective strategy to treat moderate-severe COVID-19Discussioninfections with a cost of $13,823/QALY.", [["CC", "CHEMICAL", 0, 2], ["remdesivir", "CHEMICAL", 412, 422], ["dexamethasone", "CHEMICAL", 440, 453], ["infections", "DISEASE", 465, 475], ["COVID", "DISEASE", 538, 543], ["remdesivir", "CHEMICAL", 412, 422], ["dexamethasone", "CHEMICAL", 440, 453], ["remdesivir", "SIMPLE_CHEMICAL", 412, 422], ["dexamethasone", "SIMPLE_CHEMICAL", 440, 453], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["remdesivir", "TREATMENT", 412, 422], ["dexamethasone", "TREATMENT", 440, 453], ["severe infections", "PROBLEM", 458, 475], ["moderate-severe COVID", "PROBLEM", 522, 543], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["severe", "OBSERVATION_MODIFIER", 458, 464], ["infections", "OBSERVATION", 465, 475], ["severe", "OBSERVATION_MODIFIER", 531, 537]]], ["No strategies using remdesivir monotherapy were favoured and in most cases were less effective and more costly than other strategies in the basecase.", [["remdesivir", "CHEMICAL", 20, 30], ["remdesivir", "CHEMICAL", 20, 30], ["remdesivir", "SIMPLE_CHEMICAL", 20, 30], ["remdesivir monotherapy", "TREATMENT", 20, 42]]], ["Multivariate analysis showed that remdesivir for moderate and dexamethasone for severe infections remained the preferred choice when willingness to pay thresholds are over $37,500 USD, which is a relevant threshold in countries such as Canada, Ireland, Australia, Spain and the United Kingdom 16 .DiscussionGiven the significant morbidity and mortality of moderate-severe COVID-19 infection, development of a vaccine will be critical.", [["remdesivir", "CHEMICAL", 34, 44], ["dexamethasone", "CHEMICAL", 62, 75], ["infections", "DISEASE", 87, 97], ["COVID", "DISEASE", 372, 377], ["infection", "DISEASE", 381, 390], ["remdesivir", "CHEMICAL", 34, 44], ["dexamethasone", "CHEMICAL", 62, 75], ["remdesivir", "SIMPLE_CHEMICAL", 34, 44], ["dexamethasone", "SIMPLE_CHEMICAL", 62, 75], ["Multivariate analysis", "TEST", 0, 21], ["remdesivir", "TREATMENT", 34, 44], ["dexamethasone", "TREATMENT", 62, 75], ["severe infections", "PROBLEM", 80, 97], ["the significant morbidity", "PROBLEM", 313, 338], ["moderate-severe COVID-19 infection", "PROBLEM", 356, 390], ["a vaccine", "TREATMENT", 407, 416], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["infections", "OBSERVATION", 87, 97], ["significant", "OBSERVATION_MODIFIER", 317, 328], ["morbidity", "OBSERVATION", 329, 338], ["moderate", "OBSERVATION_MODIFIER", 356, 364], ["severe", "OBSERVATION_MODIFIER", 365, 371], ["infection", "OBSERVATION", 381, 390]]], ["In the interim, any treatment that may improve outcomes is valuable but must be balanced with treatment affordability and health care sustainability given the opportunity cost associated with use of these drugs.", [["any treatment", "TREATMENT", 16, 29], ["treatment affordability", "TREATMENT", 94, 117], ["health care sustainability", "TREATMENT", 122, 148], ["these drugs", "TREATMENT", 199, 210]]], ["This model compares the two agents with current randomized controlled trial data showing potential mortality benefit in moderate-severe COVID-19 infections, with remdesivir showing a statistical trend to survival in the preliminary report with a larger effect in patients with moderate infections and dexamethasone demonstrating a statistically significant benefit in both moderate and severe infections.", [["COVID", "DISEASE", 136, 141], ["infections", "DISEASE", 145, 155], ["remdesivir", "CHEMICAL", 162, 172], ["infections", "DISEASE", 286, 296], ["dexamethasone", "CHEMICAL", 301, 314], ["infections", "DISEASE", 393, 403], ["dexamethasone", "CHEMICAL", 301, 314], ["remdesivir", "SIMPLE_CHEMICAL", 162, 172], ["patients", "ORGANISM", 263, 271], ["dexamethasone", "SIMPLE_CHEMICAL", 301, 314], ["patients", "SPECIES", 263, 271], ["moderate-severe COVID-19 infections", "PROBLEM", 120, 155], ["remdesivir", "TREATMENT", 162, 172], ["moderate infections", "PROBLEM", 277, 296], ["dexamethasone", "TREATMENT", 301, 314], ["both moderate and severe infections", "PROBLEM", 368, 403], ["moderate", "OBSERVATION_MODIFIER", 120, 128], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["larger", "OBSERVATION_MODIFIER", 246, 252], ["moderate", "OBSERVATION_MODIFIER", 277, 285], ["infections", "OBSERVATION", 286, 296], ["both moderate", "OBSERVATION_MODIFIER", 368, 381], ["severe", "OBSERVATION_MODIFIER", 386, 392], ["infections", "OBSERVATION", 393, 403]]], ["Combining remdesivir for moderate infections and dexamethasone for the most severe infections was found to be the most effective and economical strategy with willingness to pay thresholds over $37,500 USD.Discussion.", [["remdesivir", "CHEMICAL", 10, 20], ["infections", "DISEASE", 34, 44], ["dexamethasone", "CHEMICAL", 49, 62], ["infections", "DISEASE", 83, 93], ["dexamethasone", "CHEMICAL", 49, 62], ["remdesivir", "SIMPLE_CHEMICAL", 10, 20], ["dexamethasone", "SIMPLE_CHEMICAL", 49, 62], ["Combining remdesivir", "TREATMENT", 0, 20], ["moderate infections", "PROBLEM", 25, 44], ["dexamethasone", "TREATMENT", 49, 62], ["the most severe infections", "PROBLEM", 67, 93], ["moderate", "OBSERVATION_MODIFIER", 25, 33], ["infections", "OBSERVATION", 34, 44], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["infections", "OBSERVATION", 83, 93]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["The model design uses a fixed cost for admission with the DRG code and does not account for potential shorter stays in hospital.", [["the DRG code", "TREATMENT", 54, 66]]], ["In our base case scenario, we assumed that moderate COVID-19 infections would be admitted to the ward and severe infections admitted to the ICU.", [["infections", "DISEASE", 61, 71], ["infections", "DISEASE", 113, 123], ["moderate COVID-19 infections", "PROBLEM", 43, 71], ["severe infections", "PROBLEM", 106, 123], ["moderate", "OBSERVATION_MODIFIER", 43, 51], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["infections", "OBSERVATION", 113, 123]]], ["This practice is not consistent throughout the United States; some centers will admit patients on high flow oxygen to ICU.", [["oxygen", "CHEMICAL", 108, 114], ["oxygen", "CHEMICAL", 108, 114], ["patients", "ORGANISM", 86, 94], ["oxygen", "SIMPLE_CHEMICAL", 108, 114], ["patients", "SPECIES", 86, 94], ["high flow oxygen", "TREATMENT", 98, 114], ["not consistent", "UNCERTAINTY", 17, 31]]], ["In our analysis of this scenario, we found that the league table and ICER values between strategies remain unchanged, but all strategies would cost an additional $22,134.17.DiscussionThe economic and health impact of COVID-19 has been substantial globally 17 ; treatments that can reduce its burden are eagerly sought.", [["COVID-19", "CHEMICAL", 217, 225], ["COVID-19", "CHEMICAL", 217, 225], ["ICER", "PROTEIN", 69, 73], ["ICER values", "TEST", 69, 80], ["COVID", "TREATMENT", 217, 222], ["treatments", "TREATMENT", 261, 271], ["unchanged", "OBSERVATION_MODIFIER", 107, 116]]], ["Use of either dexamethasone or remdesivir for COVID-19 needs to be considered in the context of the local burden of COVID-19 disease as well as healthcare budgets and priorities.", [["dexamethasone", "CHEMICAL", 14, 27], ["remdesivir", "CHEMICAL", 31, 41], ["COVID-19", "CHEMICAL", 46, 54], ["COVID", "DISEASE", 116, 121], ["dexamethasone", "CHEMICAL", 14, 27], ["remdesivir", "CHEMICAL", 31, 41], ["COVID-19", "CHEMICAL", 46, 54], ["dexamethasone", "SIMPLE_CHEMICAL", 14, 27], ["remdesivir", "SIMPLE_CHEMICAL", 31, 41], ["dexamethasone", "TREATMENT", 14, 27], ["remdesivir", "TREATMENT", 31, 41], ["COVID", "TREATMENT", 46, 51], ["COVID-19 disease", "PROBLEM", 116, 132]]], ["Decisions of treatment and resource utilization need to be made rationally and with consideration of the values and priorities of the population.", [["treatment", "TREATMENT", 13, 22]]], ["Economic analysis with cost/QALY can help optimize resource utilization and to try to promote equity for accessing treatment of diseases 18 .", [["Economic analysis", "TEST", 0, 17], ["cost/QALY", "TREATMENT", 23, 32], ["resource utilization", "TREATMENT", 51, 71], ["accessing treatment of diseases", "TREATMENT", 105, 136]]], ["Although our representative analysis utilized a United States perspective, we feel that these results can be extrapolated to other jurisdictions world-wide, as the major cost for each strategy was hospitalization; with lower costs of hospitalization, the incremental cost-effectiveness ratios between choices will remain similar given all strategies would have the same reduction in total cost.", [["the incremental cost-effectiveness ratios", "TREATMENT", 251, 292]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.21.20199182 doi: medRxiv preprint Thresholds for cost-effectiveness worldwide vary; in the United States, the threshold is typically $100,000 while the threshold is generally considered to be around $50,000 CDN ($36,784 USD) 19 in Canada and between 20,000-30,000 pounds ($25,245-$37,868 USD) 20in the UnitedKingdom.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 331, 338], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["For lower income countries, the cost-effectiveness threshold is markedly lower ranging from $3-$8982 (2020 US dollars) 21 .", [["the cost-effectiveness threshold", "TEST", 28, 60], ["markedly lower", "PROBLEM", 64, 78]]], ["In our analyses, we show that for countries of low to middle income, with willingness to pay thresholds between $350-$37,500, dexamethasone for severe COVID-19 infections would likely be the most favoured strategy based on current data.in the UnitedFor very low-income countries, the price of dexamethasone may be unaffordable and so supportive care would be the preferred strategy.COVID-19 has had disproportionate impacts on patients in the United States based on ethnic background, location and socioeconomic status.", [["dexamethasone", "CHEMICAL", 126, 139], ["COVID-19", "CHEMICAL", 151, 159], ["infections", "DISEASE", 160, 170], ["dexamethasone", "CHEMICAL", 293, 306], ["COVID-19", "CHEMICAL", 382, 390], ["dexamethasone", "CHEMICAL", 126, 139], ["dexamethasone", "CHEMICAL", 293, 306], ["dexamethasone", "SIMPLE_CHEMICAL", 126, 139], ["dexamethasone", "SIMPLE_CHEMICAL", 293, 306], ["patients", "ORGANISM", 427, 435], ["patients", "SPECIES", 427, 435], ["dexamethasone", "TREATMENT", 126, 139], ["severe COVID-19 infections", "PROBLEM", 144, 170], ["dexamethasone", "TREATMENT", 293, 306], ["supportive care", "TREATMENT", 334, 349], ["disproportionate", "OBSERVATION_MODIFIER", 399, 415], ["impacts", "OBSERVATION_MODIFIER", 416, 423]]], ["Patients of colour including African Americans,Latinx and Native Americans, immigrants, patients in rural settings and patients with lower socioeconomic status in the United States have had increased morbidity and mortality due to COVID-19 [22] [23] [24] .", [["COVID-19", "CHEMICAL", 231, 239], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 88, 96], ["patients", "ORGANISM", 119, 127], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 119, 127], ["Latinx", "TREATMENT", 47, 53], ["increased morbidity", "PROBLEM", 190, 209], ["COVID", "TEST", 231, 236]]], ["Similar findings have been reported worldwide, especially in countries of lower socioeconomic status 25 .", [["worldwide", "OBSERVATION_MODIFIER", 36, 45]]], ["This situation is further complicated by the limited global supply of remdesivir and its considerable expense for some jurisdictions.", [["remdesivir", "CHEMICAL", 70, 80], ["remdesivir", "CHEMICAL", 70, 80], ["remdesivir", "SIMPLE_CHEMICAL", 70, 80], ["remdesivir", "TREATMENT", 70, 80]]], ["There is a significant risk that patients who could most benefit from remdesivir (moderate severity) may not have access to remdesivir, which will likely further negatively impact people of colour, rural patients or patients with lower socioeconomic status.", [["remdesivir", "CHEMICAL", 70, 80], ["remdesivir", "CHEMICAL", 124, 134], ["remdesivir", "CHEMICAL", 70, 80], ["remdesivir", "CHEMICAL", 124, 134], ["patients", "ORGANISM", 33, 41], ["remdesivir", "SIMPLE_CHEMICAL", 70, 80], ["remdesivir", "SIMPLE_CHEMICAL", 124, 134], ["people", "ORGANISM", 180, 186], ["patients", "ORGANISM", 204, 212], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 33, 41], ["people", "SPECIES", 180, 186], ["patients", "SPECIES", 204, 212], ["patients", "SPECIES", 216, 224], ["remdesivir", "TREATMENT", 70, 80], ["remdesivir", "TREATMENT", 124, 134], ["significant", "OBSERVATION_MODIFIER", 11, 22]]], ["In our model, the potential benefit loss without remdesivir is 0.002 QALY or 0.66 days; however, this possible benefit is enormous in aggregate.", [["remdesivir", "CHEMICAL", 49, 59], ["remdesivir", "CHEMICAL", 49, 59], ["remdesivir", "SIMPLE_CHEMICAL", 49, 59], ["remdesivir", "TREATMENT", 49, 59], ["enormous", "OBSERVATION_MODIFIER", 122, 130]]], ["Increased access to and lower cost of remdesivir will be critical to best treat these more marginalized patients.COVID-19 has had disproportionate impacts on patients in the United States based on ethnic background, location and socioeconomic status.", [["remdesivir", "CHEMICAL", 38, 48], ["COVID-19", "CHEMICAL", 113, 121], ["remdesivir", "CHEMICAL", 38, 48], ["remdesivir", "SIMPLE_CHEMICAL", 38, 48], ["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 158, 166], ["Increased access", "TREATMENT", 0, 16], ["lower cost of remdesivir", "TREATMENT", 24, 48], ["disproportionate", "OBSERVATION_MODIFIER", 130, 146], ["impacts", "OBSERVATION_MODIFIER", 147, 154]]], ["Patients of colour including African Americans,.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["There has been one published cost-effectiveness analysis of remdesivir looking at cost-effective threshold prices finding that a treatment course of remdesivir should be approximately $19,000 to be cost effective based on a willingness to pay of $100,000 and about $4700 based on a willingness to pay of $50,000, suggesting that a cost recovery price should be between $1000-1600 26 .", [["remdesivir", "CHEMICAL", 149, 159], ["remdesivir", "CHEMICAL", 149, 159], ["remdesivir", "SIMPLE_CHEMICAL", 60, 70], ["remdesivir", "SIMPLE_CHEMICAL", 149, 159], ["remdesivir", "TREATMENT", 60, 70], ["a treatment course of remdesivir", "TREATMENT", 127, 159]]], ["This model takes a lifetime perspective and uses remdesivir for all patients.", [["remdesivir", "CHEMICAL", 49, 59], ["remdesivir", "CHEMICAL", 49, 59], ["remdesivir", "SIMPLE_CHEMICAL", 49, 59], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["remdesivir", "TREATMENT", 49, 59]]], ["Our model has a few key differences.", [["few", "OBSERVATION_MODIFIER", 16, 19], ["key", "OBSERVATION_MODIFIER", 20, 23], ["differences", "OBSERVATION_MODIFIER", 24, 35]]], ["We have taken a 1-year time-horizon, used severity-stratified drug efficacy based on current clinical trials data to better reflect the differences between moderate and severe infections, and utilized Medicare rates which may underestimate costs in the United States.", [["infections", "DISEASE", 176, 186], ["moderate and severe infections", "PROBLEM", 156, 186], ["Medicare rates", "TREATMENT", 201, 215], ["moderate", "OBSERVATION_MODIFIER", 156, 164], ["severe", "OBSERVATION_MODIFIER", 169, 175], ["infections", "OBSERVATION", 176, 186]]], ["In our analysis, we directly compare remdesivir versus dexamethasone for all hospitalized patients, as well as remdesivir for moderate and dexamethasone for severe infections to reflect current pragmatic treatment approaches based on the two available trials; we do not combine dexamethasone and remdesivir as treatment as there is no data for this.", [["remdesivir", "CHEMICAL", 37, 47], ["dexamethasone", "CHEMICAL", 55, 68], ["remdesivir", "CHEMICAL", 111, 121], ["dexamethasone", "CHEMICAL", 139, 152], ["infections", "DISEASE", 164, 174], ["dexamethasone", "CHEMICAL", 278, 291], ["remdesivir", "CHEMICAL", 296, 306], ["remdesivir", "CHEMICAL", 37, 47], ["dexamethasone", "CHEMICAL", 55, 68], ["remdesivir", "CHEMICAL", 111, 121], ["dexamethasone", "CHEMICAL", 139, 152], ["dexamethasone", "CHEMICAL", 278, 291], ["remdesivir", "CHEMICAL", 296, 306], ["remdesivir", "SIMPLE_CHEMICAL", 37, 47], ["dexamethasone", "SIMPLE_CHEMICAL", 55, 68], ["patients", "ORGANISM", 90, 98], ["remdesivir", "SIMPLE_CHEMICAL", 111, 121], ["dexamethasone", "SIMPLE_CHEMICAL", 139, 152], ["dexamethasone", "SIMPLE_CHEMICAL", 278, 291], ["remdesivir", "SIMPLE_CHEMICAL", 296, 306], ["patients", "SPECIES", 90, 98], ["dexamethasone", "TREATMENT", 55, 68], ["remdesivir", "TREATMENT", 111, 121], ["dexamethasone", "TREATMENT", 139, 152], ["severe infections", "PROBLEM", 157, 174], ["current pragmatic treatment approaches", "TREATMENT", 186, 224], ["dexamethasone", "TREATMENT", 278, 291], ["remdesivir", "TREATMENT", 296, 306], ["treatment", "TREATMENT", 310, 319], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["infections", "OBSERVATION", 164, 174]]], ["When we compare only remdesivir for moderate and severe infections versus best supportive care, we find an incremental cost-effectiveness ratio of $32,792/QALY at the current list price of remdesivir similar to the other published model.COVID-19 has had disproportionate impacts on patients in the United States based on ethnic background, location and socioeconomic status.", [["remdesivir", "CHEMICAL", 21, 31], ["infections", "DISEASE", 56, 66], ["remdesivir", "CHEMICAL", 189, 199], ["COVID-19", "CHEMICAL", 237, 245], ["remdesivir", "CHEMICAL", 189, 199], ["patients", "ORGANISM", 282, 290], ["patients", "SPECIES", 282, 290], ["remdesivir", "TREATMENT", 21, 31], ["moderate and severe infections", "PROBLEM", 36, 66], ["remdesivir", "TREATMENT", 189, 199], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["infections", "OBSERVATION", 56, 66], ["disproportionate", "OBSERVATION_MODIFIER", 254, 270], ["impacts", "OBSERVATION_MODIFIER", 271, 278]]], ["Patients of colour including African Americans,There are several limitations to our model.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Given that COVID-19 is an emerging disease with rapidly evolving literature, the assumptions in the model are subject to change, especially as the remdesivir report does not contain full 28-day mortality data and the dexamethasone study is only a preliminary report.", [["dexamethasone", "CHEMICAL", 217, 230], ["dexamethasone", "CHEMICAL", 217, 230], ["dexamethasone", "SIMPLE_CHEMICAL", 217, 230], ["COVID", "TEST", 11, 16], ["an emerging disease", "PROBLEM", 23, 42], ["the dexamethasone study", "TEST", 213, 236], ["disease", "OBSERVATION", 35, 42], ["rapidly", "OBSERVATION_MODIFIER", 48, 55]]], ["Data regarding utility in COVID-19 does not yet exist and was extrapolated from similar experience with H1N1 and severe .", [["H1N1", "DISEASE", 104, 108], ["COVID", "TEST", 26, 31], ["H1N1", "PROBLEM", 104, 108], ["severe", "OBSERVATION_MODIFIER", 113, 119]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintCOVID-19 has had disproportionate impacts on patients in the United States based on ethnic background, location and socioeconomic status.", [["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 256, 264], ["patients", "SPECIES", 256, 264], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["disproportionate", "OBSERVATION_MODIFIER", 228, 244], ["impacts", "OBSERVATION_MODIFIER", 245, 252]]], ["Patients of colour including African Americans,The copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.21.20199182 doi: medRxiv preprint influenza.", [["influenza", "DISEASE", 185, 194], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["influenza", "PROBLEM", 185, 194], ["influenza", "OBSERVATION", 185, 194]]], ["Given COVID-19 was only first described in December 2019, 1-year data is not yet available about outcomes.", [["COVID-19", "DNA", 6, 14]]], ["Further, although there are some data regarding effects post infection 27 , the impact of COVID-19 after the initial infection is still to be determined.", [["infection", "DISEASE", 61, 70], ["COVID-19", "CHEMICAL", 90, 98], ["infection", "DISEASE", 117, 126], ["infection", "PROBLEM", 61, 70], ["COVID", "TREATMENT", 90, 95], ["the initial infection", "PROBLEM", 105, 126], ["infection", "OBSERVATION", 117, 126]]], ["To mitigate the uncertainty, we performed a probability sensitivity analysis where the estimates of costs, utilities and probabilities were varied simultaneously over their distributions and found that remdesivir for moderate and dexamethasone for severe COVID-19 infections remained favoured.", [["remdesivir", "CHEMICAL", 202, 212], ["dexamethasone", "CHEMICAL", 230, 243], ["COVID", "DISEASE", 255, 260], ["infections", "DISEASE", 264, 274], ["remdesivir", "CHEMICAL", 202, 212], ["dexamethasone", "CHEMICAL", 230, 243], ["remdesivir", "SIMPLE_CHEMICAL", 202, 212], ["dexamethasone", "SIMPLE_CHEMICAL", 230, 243], ["a probability sensitivity analysis", "TEST", 42, 76], ["remdesivir", "TREATMENT", 202, 212], ["dexamethasone", "TREATMENT", 230, 243], ["severe COVID-19 infections", "PROBLEM", 248, 274], ["infections", "OBSERVATION", 264, 274]]], ["This model does not combine use of dexamethasone and remdesivir in individual patients as there is no published data for this strategy.COVID-19 has had disproportionate impacts on patients in the United States based on ethnic background, location and socioeconomic status.", [["dexamethasone", "CHEMICAL", 35, 48], ["remdesivir", "CHEMICAL", 53, 63], ["COVID-19", "CHEMICAL", 135, 143], ["dexamethasone", "CHEMICAL", 35, 48], ["remdesivir", "CHEMICAL", 53, 63], ["dexamethasone", "SIMPLE_CHEMICAL", 35, 48], ["remdesivir", "SIMPLE_CHEMICAL", 53, 63], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 180, 188], ["dexamethasone", "TREATMENT", 35, 48], ["remdesivir", "TREATMENT", 53, 63], ["this strategy", "TREATMENT", 121, 134], ["disproportionate", "OBSERVATION_MODIFIER", 152, 168], ["impacts", "OBSERVATION_MODIFIER", 169, 176]]], ["Patients of colour including African Americans,In summary, use of remdesivir for moderate infections and dexamethasone for severe infections emerged as the most cost-effective management for moderate-severe COVID-19 infections, and dexamethasone for severe infections was favoured with lower willingness to pay thresholds, although further data may change this conclusion.", [["remdesivir", "CHEMICAL", 66, 76], ["infections", "DISEASE", 90, 100], ["dexamethasone", "CHEMICAL", 105, 118], ["infections", "DISEASE", 130, 140], ["COVID", "DISEASE", 207, 212], ["infections", "DISEASE", 216, 226], ["dexamethasone", "CHEMICAL", 232, 245], ["infections", "DISEASE", 257, 267], ["dexamethasone", "CHEMICAL", 105, 118], ["dexamethasone", "CHEMICAL", 232, 245], ["Patients", "ORGANISM", 0, 8], ["remdesivir", "SIMPLE_CHEMICAL", 66, 76], ["dexamethasone", "SIMPLE_CHEMICAL", 105, 118], ["dexamethasone", "SIMPLE_CHEMICAL", 232, 245], ["Patients", "SPECIES", 0, 8], ["remdesivir", "TREATMENT", 66, 76], ["moderate infections", "PROBLEM", 81, 100], ["dexamethasone", "TREATMENT", 105, 118], ["severe infections", "PROBLEM", 123, 140], ["moderate-severe COVID-19 infections", "PROBLEM", 191, 226], ["dexamethasone", "TREATMENT", 232, 245], ["severe infections", "PROBLEM", 250, 267], ["further data", "TEST", 332, 344], ["moderate", "OBSERVATION_MODIFIER", 81, 89], ["infections", "OBSERVATION", 90, 100], ["infections", "OBSERVATION", 130, 140], ["severe", "OBSERVATION_MODIFIER", 200, 206], ["infections", "OBSERVATION", 216, 226], ["severe", "OBSERVATION_MODIFIER", 250, 256], ["infections", "OBSERVATION", 257, 267]]], ["Additional information about the effect of remdesivir is required to better assess the cost-effectiveness of its use.Data Availability:Data inputs used for the model are available in Table 1 .Data Availability:.", [["remdesivir", "CHEMICAL", 43, 53], ["remdesivir", "CHEMICAL", 43, 53], ["remdesivir", "SIMPLE_CHEMICAL", 43, 53], ["remdesivir", "TREATMENT", 43, 53]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["Drs. Varughese, Brown, Clement and Saxinger report no potential conflicts of interest.Data Availability:This study was unfunded.Data Availability:.", [["This study", "TEST", 104, 114], ["Brown", "ANATOMY", 16, 21]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["Infections.", [["Infections", "DISEASE", 0, 10], ["Infections", "PROBLEM", 0, 10]]], ["Comparison of all strategies modelled for moderate-severe respiratory COVID-19Data Availability:infections.", [["infections", "DISEASE", 96, 106], ["all strategies", "TEST", 14, 28], ["moderate-severe respiratory COVID", "PROBLEM", 42, 75], ["infections", "PROBLEM", 96, 106], ["infections", "OBSERVATION", 96, 106]]], ["The remdesivir for all and remdesivir for severe infections strategies are dominated (less effective and more costly).", [["remdesivir", "CHEMICAL", 4, 14], ["remdesivir", "CHEMICAL", 27, 37], ["infections", "DISEASE", 49, 59], ["remdesivir", "SIMPLE_CHEMICAL", 4, 14], ["The remdesivir", "TREATMENT", 0, 14], ["remdesivir", "TREATMENT", 27, 37], ["severe infections strategies", "PROBLEM", 42, 70], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["infections", "OBSERVATION", 49, 59], ["less effective", "OBSERVATION_MODIFIER", 86, 100]]], ["Remdesivir for moderate infections is extendedly dominated meaning that the incremental cost-effectiveness ratio was higher than a more effective strategy. .", [["Remdesivir", "CHEMICAL", 0, 10], ["infections", "DISEASE", 24, 34], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["Remdesivir", "TREATMENT", 0, 10], ["moderate infections", "PROBLEM", 15, 34], ["the incremental cost-effectiveness ratio", "TEST", 72, 112], ["moderate", "OBSERVATION_MODIFIER", 15, 23], ["infections", "OBSERVATION", 24, 34]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintData Availability:The copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.21.20199182 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprint", "TREATMENT", 350, 366], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintData Availability:The copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.21.20199182 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 350, 357], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]]], "PMC7537442": [["Previous findings (pilot study) ::: IntroductionAGT-Reha-WK is part of the collaborative research project \u2018Health-enabling Technologies for Rehabilitation Training\u2019 (AGT-Reha).", [["IntroductionAGT", "TEST", 36, 51], ["Rehabilitation Training", "TREATMENT", 140, 163]]], ["The aim of the project is to investigate the use of HETs for home-based telerehabilitation in the outpatient postrehabilitation phase.", [["home-based telerehabilitation", "TREATMENT", 61, 90]]], ["The project is structured as follows: (1) prototypical implementation and evaluation of feasibility of telerehabilitation training using HET, (2) empirical testing at patients\u2019 home through a feasibility study (AGT-Reha-P2) and (3) analysis of the efficacy through a non-inferiority trial (AGT-Reha-WK).Previous findings (pilot study) ::: IntroductionThe prospective, single-arm, monocentric, explorative pilot study AGT-Reha-P2 showed the technical feasibility of AGT-Reha at patients\u2019 home.16 AGT-Reha enables patients to exercise independently at home, while the corresponding data on exercise quality and quantity are automatically forwarded via a web interface to physical therapists.", [["AGT-Reha", "CHEMICAL", 465, 473], ["patients", "ORGANISM", 167, 175], ["AGT-Reha-P2", "SIMPLE_CHEMICAL", 417, 428], ["AGT-Reha", "SIMPLE_CHEMICAL", 465, 473], ["patients", "ORGANISM", 477, 485], ["AGT", "GENE_OR_GENE_PRODUCT", 495, 498], ["patients", "ORGANISM", 512, 520], ["AGT", "PROTEIN", 290, 293], ["AGT-Reha-P2", "DNA", 417, 428], ["AGT", "PROTEIN", 465, 468], ["AGT", "PROTEIN", 495, 498], ["patients", "SPECIES", 167, 175], ["patients", "SPECIES", 477, 485], ["patients", "SPECIES", 512, 520], ["evaluation", "TEST", 74, 84], ["telerehabilitation training", "TREATMENT", 103, 130], ["empirical testing", "TEST", 146, 163], ["a feasibility study", "TEST", 190, 209], ["AGT", "TEST", 211, 214], ["a non-inferiority trial", "TREATMENT", 265, 288], ["AGT", "TEST", 290, 293], ["explorative pilot study", "TEST", 393, 416], ["AGT", "TEST", 417, 420], ["Reha", "TEST", 421, 425], ["AGT", "PROBLEM", 465, 468], ["arm", "ANATOMY", 375, 378]]], ["AGT-Reha-P2 also shows the general acceptance by treating physical therapists and patients.16 All the 12 participants would recommend the system, 10 would reuse it and 7 would continue to use it after 3 months of therapy.", [["AGT-Reha-P2", "GENE_OR_GENE_PRODUCT", 0, 11], ["patients", "ORGANISM", 82, 90], ["participants", "ORGANISM", 105, 117], ["AGT", "PROTEIN", 0, 3], ["P2", "DNA", 9, 11], ["patients", "SPECIES", 82, 90], ["participants", "SPECIES", 105, 117], ["therapy", "TREATMENT", 213, 220]]], ["Almost all participants perceive AGT-Reha as a motivational assistance for their home-based training.", [["AGT", "GENE_OR_GENE_PRODUCT", 33, 36], ["AGT", "PROTEIN", 33, 36], ["participants", "SPECIES", 11, 23]]], ["Secondary outcome of AGT-Reha-P2 was the medical rehabilitation success to estimate the expected effect size for aftercare with AGT-Reha in preparation of sample size calculation for AGT-Reha-WK.", [["AGT-Reha", "CHEMICAL", 128, 136], ["AGT", "GENE_OR_GENE_PRODUCT", 21, 24], ["AGT-Reha", "SIMPLE_CHEMICAL", 128, 136], ["AGT", "GENE_OR_GENE_PRODUCT", 183, 186], ["AGT", "PROTEIN", 21, 24], ["P2", "DNA", 30, 32], ["AGT", "PROTEIN", 128, 131], ["AGT", "PROTEIN", 183, 186], ["AGT", "TEST", 21, 24], ["the medical rehabilitation success", "TREATMENT", 37, 71], ["AGT", "TEST", 128, 131], ["sample size calculation", "TEST", 155, 178], ["AGT", "TEST", 183, 186]]], ["Therefore, the shoulder function (pain and disability) was assessed with the German version of the Shoulder Pain and Disability Index (SPADI) at discharge from rehabilitation centre and post-therapy.", [["shoulder", "ANATOMY", 15, 23], ["pain", "DISEASE", 34, 38], ["disability", "DISEASE", 43, 53], ["Pain", "DISEASE", 108, 112], ["shoulder", "ORGANISM_SUBDIVISION", 15, 23], ["the shoulder function (pain and disability)", "PROBLEM", 11, 54], ["the Shoulder Pain", "PROBLEM", 95, 112], ["Disability Index", "PROBLEM", 117, 133], ["therapy", "TREATMENT", 191, 198], ["shoulder", "ANATOMY", 15, 23], ["Shoulder", "ANATOMY", 99, 107]]], ["The difference in means (MD) in SPADI was \u221217 points with a SD of 15.53.Objectives ::: IntroductionThe primary objective of AGT-Reha-WK is to investigate whether home-based telerehabilitation with AGT-Reha is non-inferior to the standard aftercare, MET.", [["AGT-Reha", "CHEMICAL", 197, 205], ["AGT", "SIMPLE_CHEMICAL", 124, 127], ["AGT-Reha", "SIMPLE_CHEMICAL", 197, 205], ["AGT", "PROTEIN", 124, 127], ["AGT", "PROTEIN", 197, 200], ["a SD", "TEST", 58, 62], ["AGT", "TEST", 197, 200], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["Efficacy, as medical rehabilitation success, that is, shoulder function (primary outcome), is evaluated with respect to ability to work, return to work, as well as continuity and sustainability of training (secondary outcomes).", [["shoulder", "ANATOMY", 54, 62], ["shoulder", "ORGANISM_SUBDIVISION", 54, 62], ["medical rehabilitation success", "TREATMENT", 13, 43], ["shoulder", "ANATOMY", 54, 62]]], ["Since there are already established aftercare measures in the outpatient postrehabilitation phase, AGT-Reha-WK comparatively investigates economic aspects of AGT-Reha (secondary objective).Objectives ::: IntroductionThe findings of AGT-Reha-WK will serve to facilitate a decision on the deployment and establishment of AGT-Reha as an alternative or supplement to other forms of aftercare.Study design ::: Methods and analysisAGT-Reha-WK is a prospective, phase III, non-inferiority trial using a parallel arm design.", [["AGT-Reha", "CHEMICAL", 319, 327], ["AGT", "GENE_OR_GENE_PRODUCT", 99, 102], ["AGT-Reha", "SIMPLE_CHEMICAL", 158, 166], ["AGT", "GENE_OR_GENE_PRODUCT", 232, 235], ["AGT", "GENE_OR_GENE_PRODUCT", 319, 322], ["AGT", "PROTEIN", 99, 102], ["AGT", "PROTEIN", 158, 161], ["AGT", "PROTEIN", 232, 235], ["AGT", "PROTEIN", 319, 322], ["AGT", "TEST", 99, 102], ["AGT", "TEST", 158, 161], ["AGT", "TEST", 232, 235], ["the deployment", "TREATMENT", 283, 297], ["AGT", "TREATMENT", 319, 322], ["Reha", "TREATMENT", 323, 327], ["Methods", "TEST", 405, 412], ["analysisAGT", "TEST", 417, 428], ["a parallel arm design", "TREATMENT", 494, 515], ["arm", "ANATOMY", 505, 508]]], ["For logistical reasons, for example, delivery and pick-up of AGT-Reha systems, and the assessment procedures, randomisation and blinding are not possible (non-randomised, unblinded).", [["AGT", "GENE_OR_GENE_PRODUCT", 61, 64], ["AGT", "PROTEIN", 61, 64], ["delivery", "TREATMENT", 37, 45], ["AGT", "TEST", 61, 64], ["the assessment procedures", "TEST", 83, 108], ["randomisation", "TEST", 110, 123], ["blinding", "PROBLEM", 128, 136]]], ["Participation in the study is voluntary.", [["the study", "TEST", 17, 26]]], ["After 3 weeks of inpatient rehabilitation at the Rehabilitation Center Bad Pyrmont, subjects in the intervention group undergo physical training at home with AGT-Reha, while subjects in the control group receive their prescribed MET, each for 6 months.", [["AGT", "SIMPLE_CHEMICAL", 158, 161], ["AGT", "PROTEIN", 158, 161], ["inpatient rehabilitation", "TREATMENT", 17, 41], ["physical training", "TREATMENT", 127, 144]]], ["In consideration of available AGT-Reha systems, the estimated handover times of systems, and the number of recruitable shoulder patients available at the Rehabilitation Center Bad Pyrmont, the estimated total study duration is 2.5 years.Patient population and eligibility criteria ::: Methods and analysisAll subjects are working-age (18 to 65 years) patients of the participating rehabilitation centre currently undergoing inpatient rehabilitation for (chronic) shoulder pain as a result of shoulder complaints.", [["shoulder", "ANATOMY", 463, 471], ["shoulder", "ANATOMY", 492, 500], ["shoulder pain", "DISEASE", 463, 476], ["shoulder complaints", "DISEASE", 492, 511], ["AGT", "GENE_OR_GENE_PRODUCT", 30, 33], ["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 351, 359], ["shoulder", "ORGANISM_SUBDIVISION", 463, 471], ["shoulder", "ORGANISM_SUBDIVISION", 492, 500], ["AGT", "PROTEIN", 30, 33], ["patients", "SPECIES", 128, 136], ["Patient", "SPECIES", 237, 244], ["patients", "SPECIES", 351, 359], ["inpatient rehabilitation", "TREATMENT", 424, 448], ["chronic) shoulder pain", "PROBLEM", 454, 476], ["shoulder complaints", "PROBLEM", 492, 511], ["shoulder", "ANATOMY", 119, 127], ["shoulder", "ANATOMY", 463, 471], ["shoulder", "ANATOMY", 492, 500]]], ["This includes patients with 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) codes of the categories M19 \u2018other arthrosis\u2019, especially of the shoulder joint, and M75 \u2018shoulder lesions\u2019.", [["shoulder joint", "ANATOMY", 204, 218], ["M75 \u2018shoulder lesions", "ANATOMY", 224, 245], ["arthrosis\u2019", "DISEASE", 174, 184], ["patients", "ORGANISM", 14, 22], ["shoulder joint", "MULTI-TISSUE_STRUCTURE", 204, 218], ["shoulder lesions", "CANCER", 229, 245], ["patients", "SPECIES", 14, 22], ["10th revision", "TREATMENT", 28, 41], ["Diseases", "PROBLEM", 93, 101], ["the categories", "TEST", 148, 162], ["\u2018other arthrosis\u2019", "PROBLEM", 167, 184], ["shoulder lesions", "PROBLEM", 229, 245], ["Diseases", "OBSERVATION", 93, 101], ["shoulder joint", "ANATOMY", 204, 218], ["shoulder", "ANATOMY", 229, 237], ["lesions", "OBSERVATION", 238, 245]]], ["For treatment in both groups, it is particularly important that these patients can perform the selected exercises without risks of injuries.", [["injuries", "DISEASE", 131, 139], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["treatment", "TREATMENT", 4, 13], ["injuries", "PROBLEM", 131, 139]]], ["Therefore, patients are excluded who are not able to or should not perform these exercises.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["This also pertains in case of a new disease or an acute relapse during the study.", [["a new disease", "PROBLEM", 30, 43], ["an acute relapse", "PROBLEM", 47, 63], ["the study", "TEST", 71, 80], ["new", "OBSERVATION_MODIFIER", 32, 35], ["disease", "OBSERVATION", 36, 43], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["relapse", "OBSERVATION", 56, 63]]], ["A decision on this will be made by a treating physical therapist or physician based on a subjective appraisal of the patients\u2019 state of health and the individual therapeutic objectives.", [["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125]]], ["Furthermore, patients should not receive any other form of aftercare in parallel.Patient population and eligibility criteria ::: Methods and analysisThe AGT-Reha system has to be able to adequately capture and assess the patients\u2019 movements.", [["patients", "ORGANISM", 13, 21], ["AGT", "GENE_OR_GENE_PRODUCT", 153, 156], ["patients", "ORGANISM", 221, 229], ["AGT", "PROTEIN", 153, 156], ["patients", "SPECIES", 13, 21], ["Patient", "SPECIES", 81, 88], ["patients", "SPECIES", 221, 229], ["Methods", "TEST", 129, 136], ["analysis", "TEST", 141, 149], ["The AGT", "TEST", 149, 156]]], ["Therefore, a body mass index of over 35 kg/m2 is one exclusion criteria.", [["body", "ANATOMY", 13, 17], ["body", "ORGANISM_SUBDIVISION", 13, 17], ["a body mass index", "TEST", 11, 28], ["body", "ANATOMY_MODIFIER", 13, 17], ["mass", "OBSERVATION", 18, 22]]], ["To guarantee first-level support and personal examinations post-therapy at patients\u2019 home, subjects must reside in Lower Saxony and be pension insured with Deutsche Rentenversicherung Braunschweig-Hannover (DRV).", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["personal examinations", "TEST", 37, 58], ["therapy", "TREATMENT", 64, 71]]], ["All eligibility criteria are listed in box 1.Medical exercise therapy ::: Interventions ::: Methods and analysisMET is the quasi standard in Germany.", [["box 1", "DNA", 39, 44]]], ["As per guideline, training starts with a 10 to 15 min warm-up on two different training devices.", [["two different training devices", "TREATMENT", 65, 95]]], ["Afterwards patients carry out five different exercises with three sets of 20 repetitions.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["The exercise plan should include both exercises for muscle strengthening and mobility (80% of exercises) as well as cardiovascular training for overweight or obese patients.18 Patients are supervised by physical therapist.", [["muscle", "ANATOMY", 52, 58], ["cardiovascular", "ANATOMY", 116, 130], ["overweight or obese", "DISEASE", 144, 163], ["muscle", "ORGAN", 52, 58], ["patients", "ORGANISM", 164, 172], ["Patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 164, 172], ["Patients", "SPECIES", 176, 184], ["The exercise plan", "TREATMENT", 0, 17], ["both exercises", "TREATMENT", 33, 47], ["muscle strengthening", "TREATMENT", 52, 72], ["cardiovascular training", "TREATMENT", 116, 139], ["muscle", "ANATOMY", 52, 58]]], ["For each patient, an individual exercise plan (exercises, number of exercises, number of repetitions, difficulty levels) is compiled according to age, endurance and the patients\u2019 own assessment.Therapy with AGT-Reha ::: Interventions ::: Methods and analysisSubjects in the intervention group perform AGT-Reha enhanced physical training at home for 6 months.", [["patient", "ORGANISM", 9, 16], ["patients", "ORGANISM", 169, 177], ["AGT-Reha", "SIMPLE_CHEMICAL", 207, 215], ["AGT-Reha", "SIMPLE_CHEMICAL", 301, 309], ["AGT", "PROTEIN", 207, 210], ["AGT", "PROTEIN", 301, 304], ["patient", "SPECIES", 9, 16], ["patients", "SPECIES", 169, 177], ["own assessment", "TEST", 179, 193], ["Methods", "TREATMENT", 238, 245], ["AGT", "TEST", 301, 304]]], ["Exercise sessions last on average 30 min.Therapy with AGT-Reha ::: Interventions ::: Methods and analysisAGT-Reha consists of an all-in-one personal computer (PC) and the marker-less motion capture system (depth camera) \u2018Kinect for Windows\u2019 (see figure 1).", [["AGT-Reha", "SIMPLE_CHEMICAL", 54, 62], ["AGT", "PROTEIN", 54, 57], ["analysisAGT", "TEST", 97, 108], ["the marker", "TEST", 167, 177]]], ["The self-developed AGT-Reha client software guides patients through 10 physical exercises (see online supplemental additional file 1).", [["AGT", "SIMPLE_CHEMICAL", 19, 22], ["patients", "ORGANISM", 51, 59], ["AGT", "PROTEIN", 19, 22], ["patients", "SPECIES", 51, 59]]], ["These exercises have been specifically defined in cooperation with physical therapists of the Rehabilitation Center Bad Pyrmont for patients with (chronic) shoulder diseases.", [["shoulder", "ANATOMY", 156, 164], ["chronic) shoulder diseases", "DISEASE", 147, 173], ["patients", "ORGANISM", 132, 140], ["shoulder", "ORGANISM_SUBDIVISION", 156, 164], ["patients", "SPECIES", 132, 140], ["chronic) shoulder diseases", "PROBLEM", 147, 173], ["shoulder", "ANATOMY", 156, 164], ["diseases", "OBSERVATION", 165, 173]]], ["Treating physical therapists can individually adapt the training for each patient (exercises, number of repetitions, different difficulty levels for single exercises).", [["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["the training", "TREATMENT", 52, 64], ["different difficulty levels", "PROBLEM", 117, 144]]], ["For this purpose, they can access the training data (exercise quantity and quality) via web interface.Therapy with AGT-Reha ::: Interventions ::: Methods and analysisWhen the all-in-one PC is switched on, training with AGT-Reha starts automatically after a short calibration phase ensuring the correct positioning of patients in front of the depth camera.", [["AGT-Reha", "SIMPLE_CHEMICAL", 115, 123], ["AGT-Reha", "SIMPLE_CHEMICAL", 219, 227], ["patients", "ORGANISM", 317, 325], ["AGT", "PROTEIN", 115, 118], ["AGT", "PROTEIN", 219, 222], ["Reha", "DNA", 223, 227], ["patients", "SPECIES", 317, 325], ["the training data", "TEST", 34, 51], ["Methods", "TEST", 146, 153], ["AGT", "TEST", 219, 222], ["a short calibration phase", "TREATMENT", 255, 280]]], ["Following a short video explaining the upcoming exercise, AGT-Reha guides the patient through the first exercise.", [["AGT-Reha", "GENE_OR_GENE_PRODUCT", 58, 66], ["patient", "ORGANISM", 78, 85], ["AGT", "PROTEIN", 58, 61], ["patient", "SPECIES", 78, 85]]], ["The training scene shows a three-dimensional visualisation (trainer avatar), showing the intended exercise execution.", [["The training scene", "TEST", 0, 18]]], ["At the same time, the depth camera detects the patient\u2019s movements and mirrors the user on the screen.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["the depth camera", "TEST", 18, 34], ["the screen", "TEST", 91, 101]]], ["A coloured bar ranging from \u2018+\u2019 to \u2018\u2013\u2019 on the bottom of the screen provides a continuous evaluation of exercise execution.", [["A coloured bar", "TEST", 0, 14], ["a continuous evaluation", "TEST", 76, 99], ["coloured bar", "OBSERVATION", 2, 14]]], ["This way, patients can easily detect and correct wrong movements.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["During this time, a summary of execution quality\u2014this is, accuracy, balance and speed\u2014is displayed followed by the introduction of the next exercise.Risk analysis ::: Interventions ::: Methods and analysisFor patients of the AGT-Reha group, a comprehensive risk analysis was conducted in accordance with \u2018the basic rules of training\u2019 by Haber.19 The following aspects were examined in more detail to assess potential risks of injuries and overstress: quantification and appropriateness of training, selection of proper movement patterns, individualisation of training and information of patients.", [["injuries", "DISEASE", 426, 434], ["patients", "ORGANISM", 209, 217], ["AGT", "GENE_OR_GENE_PRODUCT", 225, 228], ["patients", "ORGANISM", 587, 595], ["AGT", "PROTEIN", 225, 228], ["patients", "SPECIES", 209, 217], ["patients", "SPECIES", 587, 595], ["analysis", "TEST", 197, 205], ["the AGT", "TEST", 221, 228], ["a comprehensive risk analysis", "TEST", 241, 270], ["injuries", "PROBLEM", 426, 434], ["training", "TREATMENT", 489, 497]]], ["Standard frequency and intensity of training with AGT-Reha (five times a week, 30 min) was specified together with physical therapists.", [["AGT-Reha", "GENE_OR_GENE_PRODUCT", 50, 58], ["AGT", "PROTEIN", 50, 53]]], ["Treating physical therapists are able to individually adjust the duration, intensity and frequency of the AGT-Reha training for their patients.", [["AGT", "GENE_OR_GENE_PRODUCT", 106, 109], ["patients", "ORGANISM", 134, 142], ["AGT", "PROTEIN", 106, 109], ["patients", "SPECIES", 134, 142], ["the AGT", "TREATMENT", 102, 109], ["Reha training", "TREATMENT", 110, 123]]], ["Every decision is made telephonically in consultation with the patient.", [["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70]]], ["If a patient indicates training is too easy or too hard, contact with the treating physical therapist at the Rehabilitation Center Bad Pyrmont will be established.Assessment of shoulder function ::: Outcome measures ::: Methods and analysisThe German version of the reliable and valid standardised questionnaire SPADI is used to assess the shoulder function.20 SPADI enables both recording of pain intensity by means of a Visual Analogue Scale and a questionnaire-based survey of shoulder mobility (range of motion, ROM).", [["shoulder", "ANATOMY", 177, 185], ["shoulder", "ANATOMY", 340, 348], ["shoulder", "ANATOMY", 480, 488], ["pain", "DISEASE", 393, 397], ["patient", "ORGANISM", 5, 12], ["shoulder", "ORGANISM_SUBDIVISION", 177, 185], ["shoulder", "ORGANISM_SUBDIVISION", 340, 348], ["shoulder", "ORGANISM_SUBDIVISION", 480, 488], ["SPADI", "DNA", 312, 317], ["patient", "SPECIES", 5, 12], ["pain intensity", "PROBLEM", 393, 407], ["a Visual Analogue Scale", "TREATMENT", 420, 443], ["shoulder mobility", "PROBLEM", 480, 497], ["shoulder", "ANATOMY", 177, 185], ["shoulder", "ANATOMY", 340, 348], ["shoulder", "ANATOMY", 480, 488]]], ["The questionnaire consists of 13 items, 5 in the dimension pain and 8 in the dimension disability.21 For evaluation, the SPADI total score is used.Assessment of costs ::: Outcome measures ::: Methods and analysisCosts for an AGT-Reha system include following elements: (A) staff costs for therapeutic care of patients in the postrehabilitation phase, (B) staff costs for technical support, (C) maintenance and repair costs, (D) delivery costs and (E) procurement and replacement costs.", [["pain", "DISEASE", 59, 63], ["disability", "DISEASE", 87, 97], ["patients", "ORGANISM", 309, 317], ["SPADI", "DNA", 121, 126], ["patients", "SPECIES", 309, 317], ["the dimension pain", "PROBLEM", 45, 63], ["evaluation", "TEST", 105, 115], ["the SPADI total score", "TEST", 117, 138], ["an AGT", "TEST", 222, 228], ["therapeutic care", "TREATMENT", 289, 305], ["technical support, (C) maintenance and repair costs, (D) delivery costs and (E) procurement", "TREATMENT", 371, 462], ["replacement costs", "TREATMENT", 467, 484], ["13 items", "OBSERVATION_MODIFIER", 30, 38]]], ["The time spent for calls with patients, use of the web interface, first-level support, as well as maintenance and repair has to be documented here continuously.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["first-level support", "TREATMENT", 66, 85], ["repair", "TREATMENT", 114, 120], ["repair", "OBSERVATION", 114, 120]]], ["Procurement and replacement costs (E) have to be estimated based on current prices for hardware and lifetime of all-in-one PCs, taking discounting into account.", [["Procurement and replacement costs (E)", "TREATMENT", 0, 37], ["hardware", "TREATMENT", 87, 95], ["replacement", "OBSERVATION_MODIFIER", 16, 27]]], ["All other costs (C, D) have to be documented continuously during the study.Assessment of costs ::: Outcome measures ::: Methods and analysisCosts for MET are assessed via DRVs\u2019 settlement data.", [["the study", "TEST", 65, 74], ["analysisCosts", "TEST", 132, 145]]], ["In addition to personal data, the period of aftercare, the first appointment and the number of treatments attended are stored.Assessment of shoulder mobility ::: Outcome measures ::: Methods and analysisIn addition to SPADI, ROM is measured using the Neutral-0-Method22 by the same medical student, both in the rehabilitation centre (t1) and at patients\u2019 home (t2).", [["shoulder", "ANATOMY", 140, 148], ["shoulder", "ORGANISM_SUBDIVISION", 140, 148], ["patients", "ORGANISM", 345, 353], ["patients", "SPECIES", 345, 353], ["SPADI", "TEST", 218, 223], ["ROM", "TEST", 225, 228], ["shoulder", "ANATOMY", 140, 148]]], ["The measurement is performed using a goniometer.23 The individual joint positions (relation to abduction/adduction, flexion/extension, external/internal rotation and external rotation/internal rotation at 90\u00b0 abduction) are directly documented in OpenClinica.24", [["joint", "ANATOMY", 66, 71], ["joint", "MULTI-TISSUE_STRUCTURE", 66, 71], ["The measurement", "TEST", 0, 15], ["abduction", "TEST", 95, 104], ["adduction", "TEST", 105, 114], ["flexion/extension", "TREATMENT", 116, 133], ["external/internal rotation", "TREATMENT", 135, 161], ["external rotation/internal rotation", "TREATMENT", 166, 201], ["joint", "ANATOMY", 66, 71], ["internal", "ANATOMY_MODIFIER", 144, 152]]]], "7bc896dd6d0eb18bb780d772c3ee53cc7c8dab8b": [["Reference(s)[ Primary immunodeficiency diseases are a heterogeneous group of disorders, caused by inherited defects in the immune system, and characterised by wide spectrum of clinical manifestations, particularly an increased susceptibility to infections and a predisposition to autoimmune diseases and malignancies.", [["immune system", "ANATOMY", 123, 136], ["malignancies", "ANATOMY", 304, 316], ["Primary immunodeficiency diseases", "DISEASE", 14, 47], ["defects in the immune system", "DISEASE", 108, 136], ["infections", "DISEASE", 245, 255], ["autoimmune diseases", "DISEASE", 280, 299], ["malignancies", "DISEASE", 304, 316], ["malignancies", "CANCER", 304, 316], ["Primary immunodeficiency diseases", "PROBLEM", 14, 47], ["a heterogeneous group of disorders", "PROBLEM", 52, 86], ["inherited defects in the immune system", "PROBLEM", 98, 136], ["clinical manifestations", "PROBLEM", 176, 199], ["an increased susceptibility to infections", "PROBLEM", 214, 255], ["autoimmune diseases", "PROBLEM", 280, 299], ["malignancies", "PROBLEM", 304, 316], ["immunodeficiency diseases", "OBSERVATION", 22, 47], ["heterogeneous", "OBSERVATION_MODIFIER", 54, 67], ["inherited", "OBSERVATION_MODIFIER", 98, 107], ["defects", "OBSERVATION", 108, 115], ["immune system", "ANATOMY", 123, 136], ["wide", "OBSERVATION_MODIFIER", 159, 163], ["increased", "OBSERVATION_MODIFIER", 217, 226], ["infections", "OBSERVATION", 245, 255], ["malignancies", "OBSERVATION", 304, 316]]], ["Recurrent infections or infection with unusual organisms are the most commonly presentation of primary immunodeficiency diseases.", [["infections", "DISEASE", 10, 20], ["infection", "DISEASE", 24, 33], ["primary immunodeficiency diseases", "DISEASE", 95, 128], ["Recurrent infections", "PROBLEM", 0, 20], ["infection", "PROBLEM", 24, 33], ["unusual organisms", "PROBLEM", 39, 56], ["primary immunodeficiency diseases", "PROBLEM", 95, 128], ["infections", "OBSERVATION", 10, 20], ["infection", "OBSERVATION", 24, 33], ["most commonly", "OBSERVATION_MODIFIER", 65, 78], ["primary immunodeficiency diseases", "OBSERVATION", 95, 128]]], ["Although recurrent respiratory tract infections and gastrointestinal manifestations are the most common features of these diseases, especially in predominantly antibody deficiencies and combined immunodeficiencies, other organs can be involved as well.", [["respiratory tract", "ANATOMY", 19, 36], ["gastrointestinal", "ANATOMY", 52, 68], ["organs", "ANATOMY", 221, 227], ["respiratory tract infections", "DISEASE", 19, 47], ["immunodeficiencies", "DISEASE", 195, 213], ["tract", "ORGANISM_SUBDIVISION", 31, 36], ["gastrointestinal", "ORGAN", 52, 68], ["organs", "ORGAN", 221, 227], ["recurrent respiratory tract infections", "PROBLEM", 9, 47], ["gastrointestinal manifestations", "PROBLEM", 52, 83], ["these diseases", "PROBLEM", 116, 130], ["predominantly antibody deficiencies", "PROBLEM", 146, 181], ["combined immunodeficiencies", "PROBLEM", 186, 213], ["recurrent", "OBSERVATION_MODIFIER", 9, 18], ["respiratory tract", "ANATOMY", 19, 36], ["infections", "OBSERVATION", 37, 47], ["gastrointestinal", "ANATOMY", 52, 68], ["most common", "OBSERVATION_MODIFIER", 92, 103], ["diseases", "OBSERVATION", 122, 130], ["predominantly", "OBSERVATION_MODIFIER", 146, 159], ["antibody deficiencies", "OBSERVATION", 160, 181]]], ["Recurrent cutaneous abscesses with unusual organisms or deep abscesses may represent infections with an association with immunodeficiencies, particularly in phagocytes defects.", [["cutaneous abscesses", "ANATOMY", 10, 29], ["abscesses", "ANATOMY", 61, 70], ["phagocytes", "ANATOMY", 157, 167], ["abscesses", "DISEASE", 20, 29], ["abscesses", "DISEASE", 61, 70], ["infections", "DISEASE", 85, 95], ["immunodeficiencies", "DISEASE", 121, 139], ["cutaneous abscesses", "PATHOLOGICAL_FORMATION", 10, 29], ["deep abscesses", "PATHOLOGICAL_FORMATION", 56, 70], ["phagocytes", "CELL", 157, 167], ["Recurrent cutaneous abscesses", "PROBLEM", 0, 29], ["unusual organisms", "PROBLEM", 35, 52], ["deep abscesses", "PROBLEM", 56, 70], ["infections", "PROBLEM", 85, 95], ["immunodeficiencies", "PROBLEM", 121, 139], ["phagocytes defects", "PROBLEM", 157, 175], ["cutaneous", "ANATOMY", 10, 19], ["abscesses", "OBSERVATION", 20, 29], ["deep", "OBSERVATION_MODIFIER", 56, 60], ["abscesses", "OBSERVATION", 61, 70], ["may represent", "UNCERTAINTY", 71, 84], ["infections", "OBSERVATION", 85, 95], ["immunodeficiencies", "OBSERVATION", 121, 139], ["phagocytes defects", "OBSERVATION", 157, 175]]], ["Meningococcal infections could have an association with complement deficiencies.", [["Meningococcal infections", "DISEASE", 0, 24], ["Meningococcal infections", "PROBLEM", 0, 24], ["complement deficiencies", "PROBLEM", 56, 79], ["infections", "OBSERVATION", 14, 24]]], ["Meanwhile other bacterial infections, mainly Streptococcus pneumoniae and Staphylococcus aureus, as well as infections with viruses, fungi and parasites are also common in several primary immunodeficiency diseases.", [["bacterial infections", "DISEASE", 16, 36], ["Streptococcus pneumoniae", "DISEASE", 45, 69], ["Staphylococcus aureus", "DISEASE", 74, 95], ["infections", "DISEASE", 108, 118], ["fungi and parasites", "DISEASE", 133, 152], ["primary immunodeficiency diseases", "DISEASE", 180, 213], ["Streptococcus pneumoniae", "ORGANISM", 45, 69], ["Staphylococcus aureus", "ORGANISM", 74, 95], ["Streptococcus pneumoniae", "SPECIES", 45, 69], ["Staphylococcus aureus", "SPECIES", 74, 95], ["Streptococcus pneumoniae", "SPECIES", 45, 69], ["Staphylococcus aureus", "SPECIES", 74, 95], ["other bacterial infections", "PROBLEM", 10, 36], ["Streptococcus pneumoniae", "PROBLEM", 45, 69], ["Staphylococcus aureus", "PROBLEM", 74, 95], ["infections", "PROBLEM", 108, 118], ["viruses", "PROBLEM", 124, 131], ["fungi", "PROBLEM", 133, 138], ["parasites", "PROBLEM", 143, 152], ["several primary immunodeficiency diseases", "PROBLEM", 172, 213], ["bacterial", "OBSERVATION_MODIFIER", 16, 25], ["infections", "OBSERVATION", 26, 36], ["Streptococcus pneumoniae", "OBSERVATION", 45, 69], ["Staphylococcus aureus", "OBSERVATION", 74, 95], ["viruses", "OBSERVATION", 124, 131], ["several", "OBSERVATION_MODIFIER", 172, 179], ["primary immunodeficiency", "OBSERVATION", 180, 204]]], ["Autoimmune diseases such as idiopathic thrombocytopenic purpura, autoimmune haemolytic anaemia, systemic lupus erythematosus, juvenile arthritis, sclerosing cholangitis, and vasculitis are common in primary immunodeficiency diseases.", [["Autoimmune diseases", "DISEASE", 0, 19], ["idiopathic thrombocytopenic purpura", "DISEASE", 28, 63], ["autoimmune haemolytic anaemia", "DISEASE", 65, 94], ["systemic lupus erythematosus", "DISEASE", 96, 124], ["juvenile arthritis", "DISEASE", 126, 144], ["sclerosing cholangitis", "DISEASE", 146, 168], ["vasculitis", "DISEASE", 174, 184], ["primary immunodeficiency diseases", "DISEASE", 199, 232], ["Autoimmune diseases", "PROBLEM", 0, 19], ["idiopathic thrombocytopenic purpura", "PROBLEM", 28, 63], ["autoimmune haemolytic anaemia", "PROBLEM", 65, 94], ["systemic lupus erythematosus", "PROBLEM", 96, 124], ["juvenile arthritis", "PROBLEM", 126, 144], ["sclerosing cholangitis", "PROBLEM", 146, 168], ["vasculitis", "PROBLEM", 174, 184], ["primary immunodeficiency diseases", "PROBLEM", 199, 232], ["idiopathic", "OBSERVATION_MODIFIER", 28, 38], ["thrombocytopenic purpura", "OBSERVATION", 39, 63], ["autoimmune", "OBSERVATION_MODIFIER", 65, 75], ["haemolytic anaemia", "OBSERVATION", 76, 94], ["systemic", "OBSERVATION_MODIFIER", 96, 104], ["lupus erythematosus", "OBSERVATION", 105, 124], ["juvenile", "OBSERVATION_MODIFIER", 126, 134], ["arthritis", "OBSERVATION", 135, 144], ["sclerosing", "OBSERVATION_MODIFIER", 146, 156], ["cholangitis", "OBSERVATION", 157, 168], ["vasculitis", "OBSERVATION", 174, 184], ["primary immunodeficiency", "OBSERVATION", 199, 223]]], ["Whilst some syndromic immunodeficiencies (e.g., Wiskott Aldrich syndrome, Di George syndrome) have a strong association with autoimmunity, there are a group of disorders (e.g., ALPS, APECED, IPEX) that the autoimmune manifestations are typically the first and most significant findings.", [["syndromic immunodeficiencies", "DISEASE", 12, 40], ["Wiskott Aldrich syndrome", "DISEASE", 48, 72], ["Di George syndrome", "DISEASE", 74, 92], ["autoimmunity", "DISEASE", 125, 137], ["ALPS", "DISEASE", 177, 181], ["some syndromic immunodeficiencies", "PROBLEM", 7, 40], ["Wiskott Aldrich syndrome", "PROBLEM", 48, 72], ["Di George syndrome", "PROBLEM", 74, 92], ["autoimmunity", "PROBLEM", 125, 137], ["a group of disorders", "PROBLEM", 149, 169], ["the autoimmune manifestations", "PROBLEM", 202, 231], ["syndromic immunodeficiencies", "OBSERVATION", 12, 40]]], ["Malignancies are also common in some primary immunodeficiency diseases (e.g., CVID, ALPS, XLP, and DNA repair defects).", [["primary immunodeficiency diseases", "DISEASE", 37, 70], ["CVID", "DISEASE", 78, 82], ["ALPS", "DISEASE", 84, 88], ["Malignancies", "CANCER", 0, 12], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["Malignancies", "PROBLEM", 0, 12], ["some primary immunodeficiency diseases", "PROBLEM", 32, 70], ["CVID", "PROBLEM", 78, 82], ["ALPS", "PROBLEM", 84, 88], ["XLP", "PROBLEM", 90, 93], ["DNA repair defects", "TREATMENT", 99, 117], ["primary immunodeficiency", "OBSERVATION", 37, 61], ["repair defects", "OBSERVATION", 103, 117]]], ["Other manifestations such as dysmorphic features, associated anomalies, skeletal dysplasia, and oculocutaneous hypopigmentation can be unique characteristics of some cases with primary immunodeficiency diseases.Reference(s)The clinical manifestations of these diseases are often helpful in guiding the appropriate evaluation of the patients.", [["skeletal dysplasia", "ANATOMY", 72, 90], ["oculocutaneous", "ANATOMY", 96, 110], ["skeletal dysplasia", "DISEASE", 72, 90], ["oculocutaneous hypopigmentation", "DISEASE", 96, 127], ["primary immunodeficiency diseases", "DISEASE", 177, 210], ["skeletal dysplasia", "PATHOLOGICAL_FORMATION", 72, 90], ["patients", "ORGANISM", 332, 340], ["patients", "SPECIES", 332, 340], ["Other manifestations", "PROBLEM", 0, 20], ["dysmorphic features", "PROBLEM", 29, 48], ["associated anomalies", "PROBLEM", 50, 70], ["skeletal dysplasia", "PROBLEM", 72, 90], ["oculocutaneous hypopigmentation", "PROBLEM", 96, 127], ["primary immunodeficiency diseases", "PROBLEM", 177, 210], ["these diseases", "PROBLEM", 254, 268], ["the appropriate evaluation", "TEST", 298, 324], ["anomalies", "OBSERVATION", 61, 70], ["skeletal", "ANATOMY", 72, 80], ["dysplasia", "OBSERVATION", 81, 90], ["oculocutaneous hypopigmentation", "OBSERVATION", 96, 127], ["primary immunodeficiency", "OBSERVATION", 177, 201]]], ["Prompt and precise diagnostic laboratory evaluation should be performed in the patients with such features, whereas early diagnosis and successful management of these patients prevent irreparable organ system damage and improve the prognosis.E. de Vries\u00b0('s-Hertogenbosch, NL)Immunodeficiency specialists from all over Europe have composed a multistage diagnostic protocol that is based on their expert opinion, in order to increase the awareness of PID among doctors working in different fields.", [["organ system", "ANATOMY", 196, 208], ["organ system damage", "DISEASE", 196, 215], ["PID", "DISEASE", 450, 453], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 167, 175], ["organ", "ORGAN", 196, 201], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 167, 175], ["precise diagnostic laboratory evaluation", "TEST", 11, 51], ["successful management", "TREATMENT", 136, 157], ["irreparable organ system damage", "PROBLEM", 184, 215], ["a multistage diagnostic protocol", "TREATMENT", 340, 372]]], ["The protocol starts from the clinical presentation of the patient; immunological skills are not needed for its use.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["The protocol", "TREATMENT", 0, 12]]], ["A list of relevant symptoms and signs from the history and physical examination that should alert any physician to potential PID is given.", [["PID", "DISEASE", 125, 128], ["relevant symptoms", "PROBLEM", 10, 27], ["physical examination", "TEST", 59, 79], ["PID", "PROBLEM", 125, 128]]], ["These are grouped together to form eight typical clinical presentations of PID: recurrent ENT and airway infections; failure to thrive from early infancy; recurrent pyogenic infections; unusual infections or unusually severe course of infections; recurrent infections with the same type of pathogen; autoimmune or chronic inflammatory disease, or lymphoproliferation; characteristic combinations of clinical features in eponymous syndromes; and angioneurotic edema.", [["airway", "ANATOMY", 98, 104], ["angioneurotic edema", "ANATOMY", 445, 464], ["PID", "DISEASE", 75, 78], ["airway infections", "DISEASE", 98, 115], ["infections", "DISEASE", 174, 184], ["infections", "DISEASE", 194, 204], ["infections", "DISEASE", 235, 245], ["infections", "DISEASE", 257, 267], ["chronic inflammatory disease", "DISEASE", 314, 342], ["lymphoproliferation", "DISEASE", 347, 366], ["angioneurotic edema", "DISEASE", 445, 464], ["airway", "MULTI-TISSUE_STRUCTURE", 98, 104], ["edema", "PATHOLOGICAL_FORMATION", 459, 464], ["PID", "PROBLEM", 75, 78], ["recurrent ENT and airway infections", "PROBLEM", 80, 115], ["failure to thrive", "PROBLEM", 117, 134], ["early infancy", "PROBLEM", 140, 153], ["recurrent pyogenic infections", "PROBLEM", 155, 184], ["unusual infections", "PROBLEM", 186, 204], ["infections", "PROBLEM", 235, 245], ["recurrent infections", "PROBLEM", 247, 267], ["pathogen", "PROBLEM", 290, 298], ["autoimmune", "PROBLEM", 300, 310], ["chronic inflammatory disease", "PROBLEM", 314, 342], ["lymphoproliferation", "PROBLEM", 347, 366], ["eponymous syndromes", "PROBLEM", 420, 439], ["angioneurotic edema", "PROBLEM", 445, 464], ["airway", "ANATOMY", 98, 104], ["infections", "OBSERVATION", 105, 115], ["recurrent", "OBSERVATION_MODIFIER", 155, 164], ["pyogenic", "OBSERVATION_MODIFIER", 165, 173], ["infections", "OBSERVATION", 174, 184], ["infections", "OBSERVATION", 194, 204], ["unusually", "OBSERVATION_MODIFIER", 208, 217], ["severe", "OBSERVATION_MODIFIER", 218, 224], ["infections", "OBSERVATION", 235, 245], ["recurrent", "OBSERVATION_MODIFIER", 247, 256], ["infections", "OBSERVATION", 257, 267], ["pathogen", "OBSERVATION", 290, 298], ["autoimmune", "OBSERVATION", 300, 310], ["chronic", "OBSERVATION_MODIFIER", 314, 321], ["inflammatory disease", "OBSERVATION", 322, 342], ["lymphoproliferation", "OBSERVATION", 347, 366], ["eponymous syndromes", "OBSERVATION", 420, 439], ["angioneurotic", "OBSERVATION_MODIFIER", 445, 458], ["edema", "OBSERVATION", 459, 464]]], ["These presentations lead the user towards different algorithms, which in fact represent the traditional division into antibody, complement, lymphocyte, and phagocyte deficiencies, respectively.", [["lymphocyte", "ANATOMY", 140, 150], ["phagocyte", "ANATOMY", 156, 165], ["lymphocyte", "CELL", 140, 150], ["phagocyte", "CELL", 156, 165], ["different algorithms", "TEST", 42, 62], ["lymphocyte", "TEST", 140, 150], ["phagocyte deficiencies", "PROBLEM", 156, 178], ["lymphocyte", "ANATOMY", 140, 150], ["phagocyte deficiencies", "OBSERVATION", 156, 178]]], ["This multistage design allows cost-effective screening for PID within the large pool of potential cases in all hospitals in the early phases, while more expensive tests are reserved for definitive classification in collaboration with an immunologist at a later stage.Update on HIV for the non-HIV expert S5 Male circumcision \u2212 only for Sub-Saharan Africa?G. Schmid\u00b0(Geneva, CH) In 1986, articles suggesting that male circumcision (MC) decreased the risk of HIV infection appeared.", [["HIV infection", "DISEASE", 457, 470], ["HIV", "ORGANISM", 277, 280], ["HIV", "ORGANISM", 457, 460], ["HIV", "SPECIES", 277, 280], ["HIV", "SPECIES", 457, 460], ["HIV", "SPECIES", 277, 280], ["HIV", "SPECIES", 457, 460], ["cost-effective screening", "TEST", 30, 54], ["PID", "PROBLEM", 59, 62], ["expensive tests", "TEST", 153, 168], ["HIV infection", "PROBLEM", 457, 470], ["HIV", "OBSERVATION_MODIFIER", 457, 460], ["infection", "OBSERVATION", 461, 470]]], ["Ecologic studies showed strong correlations between prevalences of MC and HIV, e.g., tribes with low prevalences of MC had high prevalences of HIV infection.", [["MC", "CHEMICAL", 116, 118], ["HIV infection", "DISEASE", 143, 156], ["HIV", "ORGANISM", 143, 146], ["HIV", "SPECIES", 74, 77], ["HIV", "SPECIES", 143, 146], ["HIV", "SPECIES", 74, 77], ["HIV", "SPECIES", 143, 146], ["Ecologic studies", "TEST", 0, 16], ["MC", "PROBLEM", 67, 69], ["HIV", "PROBLEM", 74, 77], ["low prevalences of MC", "PROBLEM", 97, 118], ["HIV infection", "PROBLEM", 143, 156], ["low prevalences", "OBSERVATION_MODIFIER", 97, 112], ["high prevalences", "OBSERVATION_MODIFIER", 123, 139], ["HIV infection", "OBSERVATION", 143, 156]]], ["Observational cross-sectional studies showed that uncircumcised men had higher rates of HIV than circumcised men.", [["men", "ORGANISM", 64, 67], ["HIV", "ORGANISM", 88, 91], ["men", "ORGANISM", 109, 112], ["men", "SPECIES", 64, 67], ["HIV", "SPECIES", 88, 91], ["men", "SPECIES", 109, 112], ["HIV", "SPECIES", 88, 91], ["Observational cross-sectional studies", "TEST", 0, 37], ["uncircumcised", "OBSERVATION", 50, 63]]], ["Observational cohort studies confirmed these weaker study design findings.", [["Observational cohort studies", "TEST", 0, 28]]], ["A systematic review of observational studies in 2000 found a relative risk (RR) of 0.42 (95% CI, 0.34\u22120.54), a 58% protective effect.Update on HIV for the non-HIV expert S5 Male circumcision \u2212 only for Sub-Saharan Africa?In 2005 and 2007, results from three randomised controlled trials, all from sub-Saharan Africa, were reported.", [["HIV", "ORGANISM", 143, 146], ["HIV", "SPECIES", 143, 146], ["HIV", "SPECIES", 143, 146], ["observational studies", "TEST", 23, 44], ["RR", "TEST", 76, 78], ["CI", "TEST", 93, 95]]], ["Results were consistent, and the pooled RR of 0.42 (95% CI, 0.31\u22120.57) was identical to that of the observational studies.", [["the pooled RR", "TEST", 29, 42], ["CI", "TEST", 56, 58], ["the observational studies", "TEST", 96, 121]]], ["The protective effect in the three trials, found at about 21\u221224 months' follow-up, has been extended in one trial to a protective effect of 64% at 42 months of follow-up.", [["protective", "OBSERVATION_MODIFIER", 4, 14], ["effect", "OBSERVATION_MODIFIER", 15, 21]]], ["WHO and UNAIDS have strongly endorsed MC as an effective HIV prevention strategy in generalised HIV epidemics where MC is uncommon.", [["MC", "CHEMICAL", 38, 40], ["HIV epidemics", "DISEASE", 96, 109], ["MC", "DISEASE", 116, 118], ["HIV", "SPECIES", 57, 60], ["HIV", "SPECIES", 96, 99], ["an effective HIV prevention strategy", "TREATMENT", 44, 80], ["generalised HIV epidemics", "PROBLEM", 84, 109]]], ["HIV incidence is low enough that MC for HIV prevention purposes is unlikely to have much impact.", [["MC", "CHEMICAL", 33, 35], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 40, 43], ["HIV incidence", "PROBLEM", 0, 13], ["HIV prevention purposes", "TREATMENT", 40, 63], ["low enough", "OBSERVATION_MODIFIER", 17, 27]]], ["No public health authority recommends routine neonatal circumcision.", [["routine neonatal circumcision", "TREATMENT", 38, 67]]], ["Increasingly, however, data are showing benefits of MC in addition to HIV prevention.", [["MC", "CHEMICAL", 52, 54], ["HIV", "ORGANISM", 70, 73], ["HIV", "SPECIES", 70, 73], ["MC", "TREATMENT", 52, 54], ["HIV prevention", "TREATMENT", 70, 84]]], ["Lessened risk of urinary tract infection in infants (RR 0.13, 95% CI 0.08\u22120.20) and lifetime avoidance of phimosis and associated conditions occur when MC is performed neonatally.", [["urinary tract", "ANATOMY", 17, 30], ["urinary tract infection", "DISEASE", 17, 40], ["phimosis", "DISEASE", 106, 114], ["MC", "CHEMICAL", 152, 154], ["urinary tract", "ORGANISM_SUBDIVISION", 17, 30], ["infants", "ORGANISM", 44, 51], ["infants", "SPECIES", 44, 51], ["urinary tract infection", "PROBLEM", 17, 40], ["RR", "TEST", 53, 55], ["CI", "TEST", 66, 68], ["phimosis", "PROBLEM", 106, 114], ["associated conditions", "PROBLEM", 119, 140], ["urinary tract", "ANATOMY", 17, 30], ["infection", "OBSERVATION", 31, 40], ["phimosis", "OBSERVATION", 106, 114]]], ["MC protects against acquiring sexually transmitted infections characterised by genital ulcers-syphilis, chancroid and herpes-and possibly trichomoniasis.", [["genital", "ANATOMY", 79, 86], ["MC", "CHEMICAL", 0, 2], ["sexually transmitted infections", "DISEASE", 30, 61], ["ulcers", "DISEASE", 87, 93], ["syphilis", "DISEASE", 94, 102], ["chancroid and herpes-and possibly trichomoniasis", "DISEASE", 104, 152], ["genital ulcers", "PATHOLOGICAL_FORMATION", 79, 93], ["herpes", "ORGANISM", 118, 124], ["MC protects", "TREATMENT", 0, 11], ["sexually transmitted infections", "PROBLEM", 30, 61], ["genital ulcers", "PROBLEM", 79, 93], ["syphilis", "PROBLEM", 94, 102], ["chancroid", "PROBLEM", 104, 113], ["herpes", "PROBLEM", 118, 124], ["trichomoniasis", "PROBLEM", 138, 152], ["infections", "OBSERVATION", 51, 61], ["genital", "ANATOMY", 79, 86], ["ulcers", "OBSERVATION", 87, 93], ["syphilis", "OBSERVATION", 94, 102], ["chancroid", "OBSERVATION_MODIFIER", 104, 113], ["herpes", "OBSERVATION", 118, 124], ["possibly", "UNCERTAINTY", 129, 137], ["trichomoniasis", "OBSERVATION", 138, 152]]], ["Circumcised men may be less likely to acquire HPV and are more likely to clear the infection.", [["infection", "DISEASE", 83, 92], ["men", "ORGANISM", 12, 15], ["HPV", "ORGANISM", 46, 49], ["men", "SPECIES", 12, 15], ["HPV", "SPECIES", 46, 49], ["HPV", "PROBLEM", 46, 49], ["the infection", "PROBLEM", 79, 92], ["infection", "OBSERVATION", 83, 92]]], ["Through the protective effect against HPV, MC halves risk of penile cancer (RR 0.52, 95% CI 0.33\u22120.82) and partners of circumcised men are at lessened risk of cervical cancer.", [["penile cancer", "ANATOMY", 61, 74], ["cervical cancer", "ANATOMY", 159, 174], ["penile cancer", "DISEASE", 61, 74], ["cervical cancer", "DISEASE", 159, 174], ["HPV", "ORGANISM", 38, 41], ["penile cancer", "CANCER", 61, 74], ["men", "ORGANISM", 131, 134], ["cervical cancer", "CANCER", 159, 174], ["men", "SPECIES", 131, 134], ["HPV", "SPECIES", 38, 41], ["HPV", "PROBLEM", 38, 41], ["penile cancer", "PROBLEM", 61, 74], ["RR", "TEST", 76, 78], ["CI", "TEST", 89, 91], ["cervical cancer", "PROBLEM", 159, 174], ["penile", "ANATOMY", 61, 67], ["cancer", "OBSERVATION", 68, 74], ["cervical", "ANATOMY", 159, 167], ["cancer", "OBSERVATION", 168, 174]]], ["Cultural objections may occur, but MC in the developing world is readily accepted in non-circumcising societies.", [["MC", "CHEMICAL", 35, 37]]], ["And, surgical risk and cost must be considered.", [["cost", "TREATMENT", 23, 27], ["surgical risk", "OBSERVATION", 5, 18]]], ["While many sub-Saharan African countries are scaling up MC services to prevent HIV infection, public health agencies in many industrialised countries are reconsidering MC policies-the outcomes of both efforts are being followed with interest.T. Heikkinen\u00b0(Turku, FI)Acute otitis media (AOM) is generally considered a bacterial infection that is treated with antibiotics.", [["HIV infection", "DISEASE", 79, 92], ["Acute otitis media", "DISEASE", 266, 284], ["AOM", "DISEASE", 286, 289], ["bacterial infection", "DISEASE", 317, 336], ["HIV", "SPECIES", 79, 82], ["HIV", "SPECIES", 79, 82], ["HIV infection", "PROBLEM", 79, 92], ["Acute otitis media", "PROBLEM", 266, 284], ["AOM", "PROBLEM", 286, 289], ["a bacterial infection", "PROBLEM", 315, 336], ["antibiotics", "TREATMENT", 358, 369], ["prevent", "UNCERTAINTY", 71, 78], ["HIV", "OBSERVATION_MODIFIER", 79, 82], ["infection", "OBSERVATION", 83, 92], ["Acute", "OBSERVATION_MODIFIER", 266, 271], ["otitis", "OBSERVATION", 272, 278], ["bacterial", "OBSERVATION_MODIFIER", 317, 326], ["infection", "OBSERVATION", 327, 336]]], ["However, despite extensive use of broadspectrum antibiotics for this condition, the clinical response to the treatment is often poor.", [["broadspectrum antibiotics", "TREATMENT", 34, 59], ["this condition", "PROBLEM", 64, 78], ["the treatment", "TREATMENT", 105, 118]]], ["This fact, together with vast clinical experience connecting AOM with viral respiratory infections, has prompted research into the role of viruses in AOM.", [["respiratory", "ANATOMY", 76, 87], ["AOM", "DISEASE", 61, 64], ["viral respiratory infections", "DISEASE", 70, 98], ["AOM", "DISEASE", 150, 153], ["AOM", "PATHOLOGICAL_FORMATION", 150, 153], ["AOM", "PROBLEM", 61, 64], ["viral respiratory infections", "PROBLEM", 70, 98], ["viral", "OBSERVATION_MODIFIER", 70, 75], ["respiratory infections", "OBSERVATION", 76, 98], ["viruses", "OBSERVATION", 139, 146], ["AOM", "OBSERVATION", 150, 153]]], ["To date, ample evidence from studies ranging from animal experiments to large clinical trials supports a crucial role for respiratory viruses in the aetiology and pathogenesis of AOM.", [["respiratory viruses", "DISEASE", 122, 141], ["AOM", "DISEASE", 179, 182], ["AOM", "PATHOLOGICAL_FORMATION", 179, 182], ["studies", "TEST", 29, 36], ["large clinical trials", "PROBLEM", 72, 93], ["respiratory viruses", "PROBLEM", 122, 141], ["AOM", "PROBLEM", 179, 182], ["viruses", "OBSERVATION", 134, 141], ["AOM", "OBSERVATION", 179, 182]]], ["In most cases, viral infection of the upper respiratory mucosa initiates the whole cascade of events that finally leads to the development of AOM as a complication.", [["upper respiratory mucosa", "ANATOMY", 38, 62], ["viral infection", "DISEASE", 15, 30], ["AOM", "DISEASE", 142, 145], ["upper respiratory mucosa", "MULTI-TISSUE_STRUCTURE", 38, 62], ["AOM", "PATHOLOGICAL_FORMATION", 142, 145], ["viral infection of the upper respiratory mucosa", "PROBLEM", 15, 62], ["AOM", "PROBLEM", 142, 145], ["a complication", "PROBLEM", 149, 163], ["viral", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 21, 30], ["upper", "ANATOMY_MODIFIER", 38, 43], ["respiratory mucosa", "ANATOMY", 44, 62], ["AOM", "OBSERVATION", 142, 145]]], ["The pathogenesis of AOM involves a complex interplay between viruses, bacteria, and the host's inflammatory response.T. Heikkinen\u00b0(Turku, FI)Recent studies indicate that with sensitive techniques viruses can be found in the middle-ear fluid in most children with AOM, either alone or together with bacteria.", [["middle-ear fluid", "ANATOMY", 224, 240], ["AOM", "DISEASE", 20, 23], ["AOM", "DISEASE", 263, 266], ["AOM", "PATHOLOGICAL_FORMATION", 20, 23], ["ear fluid", "TISSUE", 231, 240], ["children", "ORGANISM", 249, 257], ["children", "SPECIES", 249, 257], ["AOM", "PROBLEM", 20, 23], ["a complex interplay between viruses", "PROBLEM", 33, 68], ["bacteria", "PROBLEM", 70, 78], ["the host's inflammatory response", "PROBLEM", 84, 116], ["Recent studies", "TEST", 141, 155], ["sensitive techniques viruses", "PROBLEM", 175, 203], ["AOM", "PROBLEM", 263, 266], ["bacteria", "PROBLEM", 298, 306], ["AOM", "OBSERVATION", 20, 23], ["middle", "ANATOMY_MODIFIER", 224, 230], ["ear", "ANATOMY", 231, 234], ["fluid", "OBSERVATION", 235, 240]]], ["Viruses appear to enhance the inflammatory process in the middle ear, and they may profoundly impair the resolution of otitis media.", [["middle ear", "ANATOMY", 58, 68], ["otitis", "DISEASE", 119, 125], ["ear", "ORGAN", 65, 68], ["Viruses", "PROBLEM", 0, 7], ["the inflammatory process in the middle ear", "PROBLEM", 26, 68], ["otitis media", "PROBLEM", 119, 131], ["inflammatory", "OBSERVATION", 30, 42], ["middle ear", "ANATOMY", 58, 68], ["resolution", "OBSERVATION_MODIFIER", 105, 115], ["otitis", "OBSERVATION", 119, 125]]], ["It is important to understand, however, that our increasing knowledge of the importance of viruses in the etiopathogenesis of AOM does not diminish the central role of bacteria in AOM.", [["AOM", "DISEASE", 126, 129], ["AOM", "DISEASE", 180, 183], ["AOM", "SIMPLE_CHEMICAL", 180, 183], ["viruses", "PROBLEM", 91, 98], ["AOM", "PROBLEM", 126, 129], ["bacteria in AOM", "PROBLEM", 168, 183], ["central", "OBSERVATION_MODIFIER", 152, 159], ["bacteria", "OBSERVATION", 168, 176], ["AOM", "OBSERVATION", 180, 183]]], ["Therefore, while viruses may explain many of the problems encountered in treating AOM, the ultimate decision on whether or not to treat AOM with antibiotics cannot be based solely on the degree of viral involvement in AOM.D. Spiro\u00b0(Portland, US)The non-judicious use of antibiotics has lead to an epidemic in antimicrobial resistance.", [["AOM", "DISEASE", 82, 85], ["AOM", "DISEASE", 136, 139], ["AOM", "PROBLEM", 82, 85], ["AOM", "PROBLEM", 136, 139], ["antibiotics", "TREATMENT", 145, 156], ["antibiotics", "TREATMENT", 270, 281], ["an epidemic in antimicrobial resistance", "PROBLEM", 294, 333], ["viral", "OBSERVATION", 197, 202], ["antimicrobial resistance", "OBSERVATION", 309, 333]]], ["Acute otitis media (AOM) is the most common indication for use of antibiotics in children in the United States (US).", [["Acute otitis media", "DISEASE", 0, 18], ["AOM", "DISEASE", 20, 23], ["children", "ORGANISM", 81, 89], ["children", "SPECIES", 81, 89], ["Acute otitis media", "PROBLEM", 0, 18], ["antibiotics", "TREATMENT", 66, 77], ["otitis", "OBSERVATION", 6, 12]]], ["Despite available evidence that supports a wait and see approach, most US physicians immediately prescribe antibiotics for the treatment of AOM.D. Spiro\u00b0(Portland, US)The American Academy of Pediatrics published a guideline in 2004 that addressed the diagnosis and treatment of AOM.", [["AOM", "DISEASE", 278, 281], ["AOM", "PATHOLOGICAL_FORMATION", 278, 281], ["antibiotics", "TREATMENT", 107, 118], ["treatment", "TREATMENT", 265, 274], ["AOM", "PROBLEM", 278, 281], ["AOM", "OBSERVATION", 278, 281]]], ["This guideline recommends the use of observation as a potential strategy for the treatment of AOM.", [["AOM", "DISEASE", 94, 97], ["AOM", "PATHOLOGICAL_FORMATION", 94, 97], ["a potential strategy", "TREATMENT", 52, 72], ["the treatment", "TREATMENT", 77, 90], ["AOM", "PROBLEM", 94, 97], ["AOM", "OBSERVATION", 94, 97]]], ["The key components of this published guideline will be discussed, as well as the evidence and rationale that supports the use of observation as an initial strategy to treat AOM.R. Dagan\u00b0(Beer-Sheva, IL)Otitis media (OM) is the most common bacterial infection in children aged <5 years for which antibiotic treatment is prescribed worldwide.", [["AOM", "DISEASE", 173, 176], ["Otitis", "DISEASE", 202, 208], ["bacterial infection", "DISEASE", 239, 258], ["children", "ORGANISM", 262, 270], ["children", "SPECIES", 262, 270], ["an initial strategy", "TREATMENT", 144, 163], ["AOM", "PROBLEM", 173, 176], ["Otitis media", "PROBLEM", 202, 214], ["antibiotic treatment", "TREATMENT", 295, 315], ["most common", "OBSERVATION_MODIFIER", 227, 238], ["bacterial", "OBSERVATION_MODIFIER", 239, 248], ["infection", "OBSERVATION", 249, 258]]], ["Although most of the time this entity resolves spontaneously it is associated with morbidity, family dysfunction, antibiotic use and burden on the medical system.", [["morbidity", "PROBLEM", 83, 92], ["family dysfunction", "PROBLEM", 94, 112], ["antibiotic use", "TREATMENT", 114, 128], ["burden on the medical system", "PROBLEM", 133, 161]]], ["Efforts to reduce the burden of OM by vaccination have not been extremely rewarding, but some progress has been made.", [["OM", "DISEASE", 32, 34], ["the burden of OM", "PROBLEM", 18, 34]]], ["The first obvious step would be to reduce viral infections leading secondarily to OM.", [["infections", "DISEASE", 48, 58], ["OM", "DISEASE", 82, 84], ["viral infections", "PROBLEM", 42, 58], ["infections", "OBSERVATION", 48, 58]]], ["In the modern era, the only viral vaccine with proven effect on AOM is the influenza virus vaccine.", [["AOM", "DISEASE", 64, 67], ["AOM", "SIMPLE_CHEMICAL", 64, 67], ["influenza virus", "ORGANISM", 75, 90], ["influenza virus vaccine", "SPECIES", 75, 98], ["viral vaccine", "TREATMENT", 28, 41], ["AOM", "PROBLEM", 64, 67], ["the influenza virus vaccine", "TREATMENT", 71, 98]]], ["Both the inactivated and the live virus showed some effect, but since influenza virus has only a limited season yearly the effect on the overall OM rate is far from being remarkable.", [["influenza virus", "DISEASE", 70, 85], ["influenza virus", "ORGANISM", 70, 85], ["influenza virus", "SPECIES", 70, 85], ["the live virus", "PROBLEM", 25, 39], ["influenza virus", "PROBLEM", 70, 85]]], ["Haemophilus influenzae (Hi) b vaccine did not reduce OM since most Hi causing OM are nontypable (NTHi) and not Hib.", [["Haemophilus influenzae", "DISEASE", 0, 22], ["Haemophilus influenzae", "ORGANISM", 0, 22], ["Hi) b", "ORGANISM", 24, 29], ["Haemophilus influenzae", "SPECIES", 0, 22], ["Haemophilus influenzae", "SPECIES", 0, 22], ["Haemophilus influenzae", "PROBLEM", 0, 22], ["Hi) b vaccine", "TREATMENT", 24, 37], ["OM", "PROBLEM", 53, 55], ["nontypable", "PROBLEM", 85, 95], ["NTHi", "PROBLEM", 97, 101], ["Hib", "PROBLEM", 111, 114]]], ["The newly developed pneumococcal conjugate vaccines (PCVs) have all been shown to reduce >50% of the OM caused by the serotypes included in the vaccines, but some replacement with serotypes not included in the vaccines and non pneumococcal organisms was demonstrated to reduce the overall effect of pneumococcal vaccines.", [["OM", "DISEASE", 101, 103], ["pneumococcal", "SPECIES", 20, 32], ["pneumococcal", "SPECIES", 227, 239], ["pneumococcal", "SPECIES", 299, 311], ["pneumococcal conjugate vaccines", "TREATMENT", 20, 51], ["PCVs", "TREATMENT", 53, 57], ["the serotypes", "PROBLEM", 114, 127], ["the vaccines", "TREATMENT", 140, 152], ["some replacement", "TREATMENT", 158, 174], ["serotypes", "TREATMENT", 180, 189], ["the vaccines", "TREATMENT", 206, 218], ["non pneumococcal organisms", "PROBLEM", 223, 249], ["pneumococcal vaccines", "TREATMENT", 299, 320], ["pneumococcal", "OBSERVATION_MODIFIER", 20, 32], ["conjugate vaccines", "OBSERVATION", 33, 51], ["pneumococcal vaccines", "OBSERVATION", 299, 320]]], ["The effect of PCV on the reduction of recurrent OM, OM with effusion, the need for ventilation tubes and frequent visits for AOM has been suggested, and the real impact is still being studied.R. Dagan\u00b0(Beer-Sheva, IL)Aiming with PCV at those with established recurrent OM has proved disappointing.", [["OM", "DISEASE", 48, 50], ["OM", "DISEASE", 52, 54], ["effusion", "DISEASE", 60, 68], ["AOM", "DISEASE", 125, 128], ["OM", "DISEASE", 269, 271], ["PCV", "TREATMENT", 14, 17], ["recurrent OM", "PROBLEM", 38, 50], ["effusion", "PROBLEM", 60, 68], ["ventilation tubes", "TREATMENT", 83, 100], ["AOM", "PROBLEM", 125, 128], ["Sheva, IL)", "TREATMENT", 207, 217], ["PCV", "TREATMENT", 229, 232], ["effusion", "OBSERVATION", 60, 68], ["ventilation tubes", "OBSERVATION", 83, 100]]], ["PCVs can reduce OM caused by antibiotic-resistant S. pneumoniae but the continued overuse of antibiotics is responsible for the increase in antibiotic resistance in non-vaccine serotypes.", [["PCVs", "CHEMICAL", 0, 4], ["OM", "DISEASE", 16, 18], ["PCVs", "SIMPLE_CHEMICAL", 0, 4], ["S. pneumoniae", "ORGANISM", 50, 63], ["S. pneumoniae", "SPECIES", 50, 63], ["S. pneumoniae", "SPECIES", 50, 63], ["PCVs", "TREATMENT", 0, 4], ["OM", "PROBLEM", 16, 18], ["antibiotic", "TREATMENT", 29, 39], ["resistant S. pneumoniae", "PROBLEM", 40, 63], ["antibiotics", "TREATMENT", 93, 104], ["antibiotic resistance", "TREATMENT", 140, 161], ["non-vaccine serotypes", "PROBLEM", 165, 186], ["pneumoniae", "OBSERVATION", 53, 63], ["increase", "OBSERVATION_MODIFIER", 128, 136], ["antibiotic resistance", "OBSERVATION", 140, 161], ["non-vaccine serotypes", "OBSERVATION", 165, 186]]], ["A newly developed PCV with an outer membrane protein for Hi (PnPD) is suggested to reduce also OM caused by Hi, but confirmation studies are needed.", [["outer membrane", "ANATOMY", 30, 44], ["OM", "DISEASE", 95, 97], ["outer membrane", "CELLULAR_COMPONENT", 30, 44], ["outer membrane protein", "PROTEIN", 30, 52], ["A newly developed PCV", "PROBLEM", 0, 21], ["an outer membrane protein", "TREATMENT", 27, 52], ["Hi", "PROBLEM", 108, 110], ["confirmation studies", "TEST", 116, 136]]], ["The expansion of the 7 serotypes included in the current licensed PCV to 10 or more serotypes may add to the prevention of OM in the near future.R. Dagan\u00b0(Beer-Sheva, IL)In the next decade, OM will continue to be an important disease in children.", [["OM", "DISEASE", 123, 125], ["children", "ORGANISM", 237, 245], ["children", "SPECIES", 237, 245], ["the 7 serotypes", "TREATMENT", 17, 32], ["the current licensed PCV", "TREATMENT", 45, 69], ["expansion", "OBSERVATION_MODIFIER", 4, 13], ["7 serotypes", "OBSERVATION_MODIFIER", 21, 32]]], ["However, we can expect it to be modified in terms of bacteriologic aetiologies, antibiotic resistance and hopefully short and long term consequences.S14 EarthquakesV.", [["bacteriologic aetiologies", "TEST", 53, 78], ["antibiotic resistance", "TREATMENT", 80, 101], ["hopefully short and long term consequences", "PROBLEM", 106, 148]]], ["Korten\u00b0(Istanbul, TR) Infectious consequences of an earthquake mainly involve several types of communicable diseases and crush related infections.", [["earthquake", "DISEASE", 52, 62], ["communicable diseases", "DISEASE", 95, 116], ["crush", "DISEASE", 121, 126], ["infections", "DISEASE", 135, 145], ["an earthquake", "PROBLEM", 49, 62], ["communicable diseases", "PROBLEM", 95, 116], ["crush related infections", "PROBLEM", 121, 145], ["Infectious", "OBSERVATION_MODIFIER", 22, 32], ["several types", "OBSERVATION_MODIFIER", 78, 91], ["communicable diseases", "OBSERVATION", 95, 116], ["crush related", "OBSERVATION_MODIFIER", 121, 134], ["infections", "OBSERVATION", 135, 145]]], ["Water-borne and food-borne illnesses often result from the disruption of the public water and sewage systems and contamination of water supply.", [["water", "SIMPLE_CHEMICAL", 130, 135], ["borne illnesses", "PROBLEM", 21, 36], ["sewage systems", "TREATMENT", 94, 108], ["contamination of water supply", "TREATMENT", 113, 142]]], ["Overcrowding, poor hygiene and sanitation in temporary shelters also may be factors.", [["Overcrowding", "DISEASE", 0, 12], ["Overcrowding", "PROBLEM", 0, 12], ["sanitation in temporary shelters", "TREATMENT", 31, 63], ["poor", "OBSERVATION_MODIFIER", 14, 18], ["hygiene", "OBSERVATION", 19, 26]]], ["The type of infectious diseases are associated with the epidemiology of communicable diseases in the area where the earthquake occurred.", [["infectious diseases", "DISEASE", 12, 31], ["communicable diseases", "DISEASE", 72, 93], ["earthquake", "DISEASE", 116, 126], ["infectious diseases", "PROBLEM", 12, 31], ["communicable diseases", "PROBLEM", 72, 93], ["infectious", "OBSERVATION", 12, 22]]], ["The most common outbreaks associated with earthquakes are gastroenteritis, infectious hepatitis and pulmonary infections.", [["pulmonary", "ANATOMY", 100, 109], ["earthquakes", "DISEASE", 42, 53], ["gastroenteritis", "DISEASE", 58, 73], ["infectious hepatitis", "DISEASE", 75, 95], ["pulmonary infections", "DISEASE", 100, 120], ["pulmonary", "ORGAN", 100, 109], ["earthquakes", "PROBLEM", 42, 53], ["gastroenteritis", "PROBLEM", 58, 73], ["infectious hepatitis", "PROBLEM", 75, 95], ["pulmonary infections", "PROBLEM", 100, 120], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["gastroenteritis", "OBSERVATION", 58, 73], ["infectious", "OBSERVATION_MODIFIER", 75, 85], ["hepatitis", "OBSERVATION", 86, 95], ["pulmonary", "ANATOMY", 100, 109], ["infections", "OBSERVATION", 110, 120]]], ["In unvaccinated populations, there are reports of increased measles.", [["measles", "DISEASE", 60, 67], ["increased measles", "PROBLEM", 50, 67], ["unvaccinated", "OBSERVATION", 3, 15], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["measles", "OBSERVATION", 60, 67]]], ["Tetanus can be seen in populations where vaccination coverage levels are low.", [["Tetanus", "DISEASE", 0, 7], ["Tetanus", "TREATMENT", 0, 7], ["vaccination coverage levels", "TEST", 41, 68], ["low", "OBSERVATION_MODIFIER", 73, 76]]], ["The risk for diarrhoeal disease outbreaks following earthquakes is higher in developing countries than in industrialised countries.", [["diarrhoeal disease", "DISEASE", 13, 31], ["earthquakes", "DISEASE", 52, 63], ["diarrhoeal disease outbreaks", "PROBLEM", 13, 41], ["earthquakes", "PROBLEM", 52, 63], ["risk for", "UNCERTAINTY", 4, 12], ["diarrhoeal disease", "OBSERVATION", 13, 31], ["higher", "OBSERVATION_MODIFIER", 67, 73]]], ["An outbreak of acute watery diarrhoea involved >750 cases occurred in a camp after the 2005 earthquake in Pakistan.", [["watery diarrhoea", "DISEASE", 21, 37], ["acute watery diarrhoea", "PROBLEM", 15, 37], ["outbreak", "OBSERVATION_MODIFIER", 3, 11], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["watery", "OBSERVATION_MODIFIER", 21, 27], ["diarrhoea", "OBSERVATION", 28, 37]]], ["Acute respiratory infections, hepatitis E clusters and measles (>400 clinical cases in the 6 months) also occurred among the displaced victims after the same earthquake.", [["respiratory", "ANATOMY", 6, 17], ["Acute respiratory infections", "DISEASE", 0, 28], ["hepatitis", "DISEASE", 30, 39], ["measles", "DISEASE", 55, 62], ["earthquake", "DISEASE", 158, 168], ["Acute respiratory infections", "PROBLEM", 0, 28], ["hepatitis E clusters", "PROBLEM", 30, 50], ["measles", "PROBLEM", 55, 62], ["respiratory", "ANATOMY", 6, 17], ["infections", "OBSERVATION", 18, 28], ["hepatitis", "OBSERVATION", 30, 39], ["displaced", "OBSERVATION_MODIFIER", 125, 134]]], ["Contamination of drinking water led to an outbreak of rotavirus after the 2005 earthquake in Kashmir, India.", [["rotavirus", "DISEASE", 54, 63], ["rotavirus", "SPECIES", 54, 63], ["rotavirus", "TREATMENT", 54, 63]]], ["An unusual outbreak of coccidiomycosis associated with exposure to increased levels of airborne dust occurred after the 1994 Southern California earthquake.", [["coccidiomycosis", "DISEASE", 23, 38], ["coccidiomycosis", "CANCER", 23, 38], ["coccidiomycosis", "PROBLEM", 23, 38], ["increased levels of airborne dust", "PROBLEM", 67, 100], ["unusual", "OBSERVATION_MODIFIER", 3, 10], ["outbreak", "OBSERVATION_MODIFIER", 11, 19], ["coccidiomycosis", "OBSERVATION", 23, 38], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["levels", "OBSERVATION_MODIFIER", 77, 83], ["airborne dust", "OBSERVATION", 87, 100]]], ["Persons who have been trapped by rubble for several hours or days may develop compartment syndromes requiring fasciotomy or amputation.", [["compartment syndromes", "DISEASE", 78, 99], ["Persons", "ORGANISM", 0, 7], ["Persons", "SPECIES", 0, 7], ["compartment syndromes", "PROBLEM", 78, 99], ["fasciotomy", "TREATMENT", 110, 120], ["amputation", "TREATMENT", 124, 134], ["compartment syndromes", "OBSERVATION", 78, 99], ["fasciotomy", "OBSERVATION", 110, 120], ["amputation", "OBSERVATION", 124, 134]]], ["Infectious complications were common in renal victims of the1999 Marmara Earthquake in Turkey and were associated with increased mortality when complicated by sepsis.", [["renal", "ANATOMY", 40, 45], ["Earthquake", "DISEASE", 73, 83], ["sepsis", "DISEASE", 159, 165], ["renal", "ORGAN", 40, 45], ["Infectious complications", "PROBLEM", 0, 24], ["sepsis", "PROBLEM", 159, 165], ["renal", "ANATOMY", 40, 45], ["sepsis", "OBSERVATION", 159, 165]]], ["Of 639 renal victims, 223 (34.9%) had infectious complications, mainly sepsis and wound infections.", [["renal", "ANATOMY", 7, 12], ["wound", "ANATOMY", 82, 87], ["sepsis", "DISEASE", 71, 77], ["wound infections", "DISEASE", 82, 98], ["renal", "ORGAN", 7, 12], ["wound", "PATHOLOGICAL_FORMATION", 82, 87], ["renal victims", "TEST", 7, 20], ["infectious complications", "PROBLEM", 38, 62], ["sepsis", "PROBLEM", 71, 77], ["wound infections", "PROBLEM", 82, 98], ["renal", "ANATOMY", 7, 12], ["infectious", "OBSERVATION_MODIFIER", 38, 48], ["complications", "OBSERVATION", 49, 62], ["sepsis", "OBSERVATION", 71, 77], ["wound", "ANATOMY", 82, 87], ["infections", "OBSERVATION", 88, 98]]], ["Most of the infections were nosocomial in origin and caused by Gram-negative aerobic bacteria and Staphylococcus spp.", [["infections", "DISEASE", 12, 22], ["Gram-", "GENE_OR_GENE_PRODUCT", 63, 68], ["Staphylococcus spp", "ORGANISM", 98, 116], ["Staphylococcus spp", "SPECIES", 98, 116], ["Staphylococcus spp", "SPECIES", 98, 116], ["the infections", "PROBLEM", 8, 22], ["nosocomial", "PROBLEM", 28, 38], ["Gram-negative aerobic bacteria", "PROBLEM", 63, 93], ["Staphylococcus spp", "PROBLEM", 98, 116], ["infections", "OBSERVATION", 12, 22], ["aerobic bacteria", "OBSERVATION", 77, 93], ["Staphylococcus spp", "OBSERVATION", 98, 116]]], ["Multivariate analysis of the risk-factors for nosocomial infections revealed a significant association with fasciotomy and length of hospital stay in a back up university hospital.", [["nosocomial infections", "DISEASE", 46, 67], ["Multivariate analysis", "TEST", 0, 21], ["nosocomial infections", "PROBLEM", 46, 67], ["fasciotomy", "TREATMENT", 108, 118], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["fasciotomy", "OBSERVATION", 108, 118]]], ["The most frequent pathogens isolated from pus and/or wounds culture in 2008 Wenchuan earthquake survivors were S. aureus, E. coli, A. baumannii, E. cloacae, and P. aeruginosa.", [["pus", "ANATOMY", 42, 45], ["wounds", "ANATOMY", 53, 59], ["Wenchuan earthquake", "DISEASE", 76, 95], ["pus", "ORGANISM_SUBSTANCE", 42, 45], ["wounds", "PATHOLOGICAL_FORMATION", 53, 59], ["S. aureus", "ORGANISM", 111, 120], ["E. coli", "ORGANISM", 122, 129], ["A. baumannii", "ORGANISM", 131, 143], ["E. cloacae", "ORGANISM", 145, 155], ["P. aeruginosa", "ORGANISM", 161, 174], ["S. aureus", "SPECIES", 111, 120], ["E. coli", "SPECIES", 122, 129], ["A. baumannii", "SPECIES", 131, 143], ["E. cloacae", "SPECIES", 145, 155], ["P. aeruginosa", "SPECIES", 161, 174], ["S. aureus", "SPECIES", 111, 120], ["E. coli", "SPECIES", 122, 129], ["A. baumannii", "SPECIES", 131, 143], ["E. cloacae", "SPECIES", 145, 155], ["P. aeruginosa", "SPECIES", 161, 174], ["The most frequent pathogens", "PROBLEM", 0, 27], ["pus", "PROBLEM", 42, 45], ["wounds culture", "TEST", 53, 67], ["S. aureus", "PROBLEM", 111, 120], ["E. coli", "PROBLEM", 122, 129], ["A. baumannii", "PROBLEM", 131, 143], ["E. cloacae", "PROBLEM", 145, 155], ["P. aeruginosa", "PROBLEM", 161, 174], ["pus", "OBSERVATION", 42, 45], ["wounds", "ANATOMY", 53, 59], ["E. coli", "OBSERVATION", 122, 129]]], ["Disaster-preparedness plans, focused on trauma and mass casualty management and also on health needs of the surviving affected populations may decrease the health impact of earthquakes.", [["trauma", "DISEASE", 40, 46], ["earthquakes", "DISEASE", 173, 184], ["trauma", "PROBLEM", 40, 46], ["mass casualty management", "TREATMENT", 51, 75]]], ["S16 Infections in the disaster setting: famine.", [["Infections", "DISEASE", 4, 14], ["Infections", "OBSERVATION", 4, 14]]], ["Krcmery\u00b0(Bratislava, SK)Clinic malnutrition is a known risk factor for ID worldwide.", [["malnutrition", "DISEASE", 31, 43], ["ID", "DISEASE", 71, 73]]], ["Subsaharan Africa and India is at higher risk due to vegetarian habits on absolute absence of animal meat proteins, resulting to depletion of micronutritients (Zinc, Iron, Selenium), responsible for recovery of postmalarial anaemia.", [["meat", "ANATOMY", 101, 105], ["Zinc", "CHEMICAL", 160, 164], ["Iron", "CHEMICAL", 166, 170], ["Selenium", "CHEMICAL", 172, 180], ["anaemia", "DISEASE", 224, 231], ["Zinc", "CHEMICAL", 160, 164], ["Iron", "CHEMICAL", 166, 170], ["Selenium", "CHEMICAL", 172, 180], ["meat", "ORGANISM_SUBDIVISION", 101, 105], ["micronutritients", "SIMPLE_CHEMICAL", 142, 158], ["Zinc", "SIMPLE_CHEMICAL", 160, 164], ["Iron", "SIMPLE_CHEMICAL", 166, 170], ["Selenium", "SIMPLE_CHEMICAL", 172, 180], ["animal meat proteins", "PROTEIN", 94, 114], ["Subsaharan Africa", "PROBLEM", 0, 17], ["vegetarian habits", "PROBLEM", 53, 70], ["animal meat proteins", "PROBLEM", 94, 114], ["depletion of micronutritients", "PROBLEM", 129, 158], ["Zinc", "TREATMENT", 160, 164], ["postmalarial anaemia", "PROBLEM", 211, 231], ["postmalarial anaemia", "OBSERVATION", 211, 231]]], ["In addition, depletion of proteins results to immunoglobulinaemia and to delayed response to many bacterial pathogens causing ID in topics (pneumococci, Salmonella, etc.) .", [["immunoglobulinaemia", "DISEASE", 46, 65], ["ID", "DISEASE", 126, 128], ["depletion of proteins", "PROBLEM", 13, 34], ["immunoglobulinaemia", "PROBLEM", 46, 65], ["many bacterial pathogens", "PROBLEM", 93, 117], ["pneumococci", "PROBLEM", 140, 151], ["Salmonella", "PROBLEM", 153, 163], ["bacterial pathogens", "OBSERVATION", 98, 117]]], ["Third problem is absence of vitamins dissolved in oil and fat, resulting to delayed phagocytic activity.", [["oil", "ANATOMY", 50, 53], ["fat", "ANATOMY", 58, 61], ["vitamins", "CHEMICAL", 28, 36], ["vitamins", "CHEMICAL", 28, 36], ["vitamins", "SIMPLE_CHEMICAL", 28, 36], ["oil", "ORGANISM_SUBSTANCE", 50, 53], ["fat", "TISSUE", 58, 61], ["Third problem", "PROBLEM", 0, 13], ["vitamins", "TREATMENT", 28, 36], ["delayed phagocytic activity", "PROBLEM", 76, 103], ["vitamins dissolved", "OBSERVATION_MODIFIER", 28, 46], ["fat", "ANATOMY", 58, 61], ["phagocytic activity", "OBSERVATION", 84, 103]]], ["Therefore proteinocaloric malnutrition results to significant adverse outcome in HIV, TB (diarrhoea, pneumonia), the major killers of children under five.", [["proteinocaloric malnutrition", "DISEASE", 10, 38], ["HIV, TB", "DISEASE", 81, 88], ["diarrhoea", "DISEASE", 90, 99], ["pneumonia", "DISEASE", 101, 110], ["children", "ORGANISM", 134, 142], ["HIV", "SPECIES", 81, 84], ["children", "SPECIES", 134, 142], ["HIV", "SPECIES", 81, 84], ["proteinocaloric malnutrition", "PROBLEM", 10, 38], ["significant adverse outcome", "PROBLEM", 50, 77], ["HIV", "PROBLEM", 81, 84], ["TB", "PROBLEM", 86, 88], ["diarrhoea", "PROBLEM", 90, 99], ["pneumonia", "PROBLEM", 101, 110], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["adverse", "OBSERVATION_MODIFIER", 62, 69], ["pneumonia", "OBSERVATION", 101, 110]]], ["St. Elizabeth University Tropical programme runs 4 antimalnutrition centres: 1 in Sudan, Darfour and 2 in Kenya Amaong upcountry refugees from major conflict areas (Sudan \u2212 Turrana Border) and 1 in Uganda trying to rehabilitate malnourished children under 5 and helping them to combat disease, responsible for 12.5 million deaths in children mean 5 a year \u2212 malaria (1.2 mil), TB (1.1 mil), HIV (2.0 mil), pneumonia (7.5 mil) and diarrhoea (0.5 mil. children deaths approximately a year).Use and abuse of antimicrobials: are we getting what we deserve?", [["malnourished", "DISEASE", 228, 240], ["deaths", "DISEASE", 323, 329], ["malaria", "DISEASE", 358, 365], ["TB", "DISEASE", 377, 379], ["pneumonia", "DISEASE", 406, 415], ["diarrhoea", "DISEASE", 430, 439], ["deaths", "DISEASE", 459, 465], ["children", "ORGANISM", 241, 249], ["children", "ORGANISM", 333, 341], ["children", "ORGANISM", 450, 458], ["children", "SPECIES", 241, 249], ["children", "SPECIES", 333, 341], ["HIV", "SPECIES", 391, 394], ["children", "SPECIES", 450, 458], ["HIV", "SPECIES", 391, 394], ["malaria", "PROBLEM", 358, 365], ["TB", "PROBLEM", 377, 379], ["HIV", "PROBLEM", 391, 394], ["pneumonia", "PROBLEM", 406, 415], ["diarrhoea", "PROBLEM", 430, 439], ["pneumonia", "OBSERVATION", 406, 415]]], ["S17 The Greek experience with carbapenem resistance in EnterobacteriaceaeH.", [["carbapenem", "CHEMICAL", 30, 40], ["EnterobacteriaceaeH", "CHEMICAL", 55, 74], ["carbapenem", "CHEMICAL", 30, 40], ["carbapenem", "SIMPLE_CHEMICAL", 30, 40], ["EnterobacteriaceaeH", "SIMPLE_CHEMICAL", 55, 74], ["carbapenem resistance in EnterobacteriaceaeH", "PROBLEM", 30, 74], ["carbapenem resistance", "OBSERVATION", 30, 51]]], ["Giamarellou\u00b0(Athens, GR) For the last six years Greece has faced a large number of infections, mainly in the intensive care units (ICU), due to carbapenemsresistant Klebsiella pneumoniae.", [["infections", "DISEASE", 83, 93], ["carbapenemsresistant Klebsiella pneumoniae", "ORGANISM", 144, 186], ["GR", "PROTEIN", 21, 23], ["Klebsiella pneumoniae", "SPECIES", 165, 186], ["Klebsiella pneumoniae", "SPECIES", 165, 186], ["infections", "PROBLEM", 83, 93], ["carbapenemsresistant Klebsiella pneumoniae", "PROBLEM", 144, 186], ["large", "OBSERVATION_MODIFIER", 67, 72], ["number", "OBSERVATION_MODIFIER", 73, 79], ["infections", "OBSERVATION", 83, 93], ["Klebsiella pneumoniae", "OBSERVATION", 165, 186]]], ["The proportion of imipenem-resistant K. pneumoniae has increased from less than 1% in 2001, to 23% in isolates from hospital wards and to 53% in isolates from ICUs in 2008.", [["imipenem", "CHEMICAL", 18, 26], ["imipenem", "CHEMICAL", 18, 26], ["imipenem", "SIMPLE_CHEMICAL", 18, 26], ["K. pneumoniae", "ORGANISM", 37, 50], ["K. pneumoniae", "SPECIES", 37, 50], ["K. pneumoniae", "SPECIES", 37, 50], ["imipenem", "TREATMENT", 18, 26], ["resistant K. pneumoniae", "PROBLEM", 27, 50], ["imipenem", "OBSERVATION", 18, 26], ["pneumoniae", "OBSERVATION", 40, 50], ["increased", "OBSERVATION_MODIFIER", 55, 64]]], ["Until 2007 this situation was due to the spread of the blaVIM-1 cassette among the rapidly evolving multiresistant plasmids and multiresistant or even panresistant strains of mainly K. pneumoniae and also other enterobacterial species.", [["plasmids", "ANATOMY", 115, 123], ["blaVIM-1", "GENE_OR_GENE_PRODUCT", 55, 63], ["K. pneumoniae", "ORGANISM", 182, 195], ["blaVIM-1 cassette", "DNA", 55, 72], ["K. pneumoniae", "SPECIES", 182, 195], ["K. pneumoniae", "SPECIES", 182, 195], ["multiresistant plasmids", "TREATMENT", 100, 123], ["multiresistant", "PROBLEM", 128, 142], ["mainly K. pneumoniae", "PROBLEM", 175, 195], ["other enterobacterial species", "PROBLEM", 205, 234], ["multiresistant plasmids", "OBSERVATION", 100, 123], ["enterobacterial species", "OBSERVATION", 211, 234]]], ["However, the fact that most strains display MIC values below or near the CLSI resistance breakpoint create diagnostic and therapeutic problems, and possibly obstruct the assessment of the real incidence of these strains.", [["MIC values", "TEST", 44, 54], ["the CLSI resistance breakpoint", "PROBLEM", 69, 99], ["therapeutic problems", "PROBLEM", 122, 142], ["the assessment", "TEST", 166, 180], ["these strains", "PROBLEM", 206, 219]]], ["As of 2007, the emergence of KPC-producing K. pneumoniae has been noted in ICUs of some Greek hospitals and has now spread to most hospitals throughout the country creating a countywide outbreak in 2008.", [["KPC", "CHEMICAL", 29, 32], ["K. pneumoniae", "DISEASE", 43, 56], ["KPC", "GENE_OR_GENE_PRODUCT", 29, 32], ["K. pneumoniae", "ORGANISM", 43, 56], ["K. pneumoniae", "SPECIES", 43, 56], ["K. pneumoniae", "SPECIES", 43, 56], ["KPC", "TEST", 29, 32], ["K. pneumoniae", "PROBLEM", 43, 56], ["pneumoniae", "OBSERVATION", 46, 56]]], ["In Attikon University Hospital we recently described the ICU outbreak of KPC-producing K. pneumoniae.", [["KPC", "CHEMICAL", 73, 76], ["KPC", "CANCER", 73, 76], ["K. pneumoniae", "ORGANISM", 87, 100], ["K. pneumoniae", "SPECIES", 87, 100], ["K. pneumoniae", "SPECIES", 87, 100], ["KPC", "PROBLEM", 73, 76], ["K. pneumoniae", "PROBLEM", 87, 100], ["pneumoniae", "OBSERVATION", 90, 100]]], ["Twenty-nine patients (admitted from February to December 2008) were colonised mainly in GI tract.", [["GI tract", "ANATOMY", 88, 96], ["patients", "ORGANISM", 12, 20], ["GI tract", "ORGANISM_SUBDIVISION", 88, 96], ["patients", "SPECIES", 12, 20], ["GI tract", "ANATOMY", 88, 96]]], ["Fifteen patients were male (52%) and the median APACHE II was 19.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["the median APACHE II", "TEST", 37, 57]]], ["Patients had already long hospital stays preceding ICU admission with a median of 25 (17\u221240) days.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["In twenty-two of these patients (76%) KPC-producing K. pneumoniae colonisation was definitely ICUacquired while in 7 (24%) acquisition in other wards or other hospitals was hypothesized.", [["KPC", "CHEMICAL", 38, 41], ["patients", "ORGANISM", 23, 31], ["K. pneumoniae", "ORGANISM", 52, 65], ["patients", "SPECIES", 23, 31], ["K. pneumoniae", "SPECIES", 52, 65], ["K. pneumoniae", "SPECIES", 52, 65], ["KPC", "TEST", 38, 41], ["K. pneumoniae colonisation", "PROBLEM", 52, 78]]], ["Five of these patients are still hospitalised in the ICU and, of the remaining 24, 11 died (ICU mortality 46%).", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Ten of the 29 colonised patients were clinically infected.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["clinically infected", "PROBLEM", 38, 57], ["infected", "OBSERVATION", 49, 57]]], ["Fifteen infections were documented, mostly BSI (11/15), followed by VAP (2/15) and SSI (2/15).", [["infections", "DISEASE", 8, 18], ["BSI", "DISEASE", 43, 46], ["VAP", "DISEASE", 68, 71], ["Fifteen infections", "PROBLEM", 0, 18], ["VAP", "TEST", 68, 71], ["SSI", "TREATMENT", 83, 86], ["infections", "OBSERVATION", 8, 18]]], ["Only 1 patient died from this infection (1/15, 6.7%).", [["infection", "DISEASE", 30, 39], ["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["this infection", "PROBLEM", 25, 39], ["infection", "OBSERVATION", 30, 39]]], ["An evidence-based consensus on the therapeutic strategy for these infections has been reached by KEELPNO and the Greek Ministry of Health which proposed the use of high dose meropenem (6\u22128 g/day) combined with an active aminoglycoside or colistin for strains with an MIC 4 mg/ml whereas for strains with a higher MIC the use of carbapenems is contraindicated and active alternatives (monotherapy with tigecycline, colistin, or an aminoglycoside or aztreonam-based combinations) could be used.", [["infections", "DISEASE", 66, 76], ["meropenem", "CHEMICAL", 174, 183], ["aminoglycoside", "CHEMICAL", 220, 234], ["colistin", "CHEMICAL", 238, 246], ["MIC", "CHEMICAL", 313, 316], ["carbapenems", "CHEMICAL", 328, 339], ["tigecycline", "CHEMICAL", 401, 412], ["colistin", "CHEMICAL", 414, 422], ["aminoglycoside", "CHEMICAL", 430, 444], ["aztreonam", "CHEMICAL", 448, 457], ["meropenem", "CHEMICAL", 174, 183], ["aminoglycoside", "CHEMICAL", 220, 234], ["colistin", "CHEMICAL", 238, 246], ["carbapenems", "CHEMICAL", 328, 339], ["tigecycline", "CHEMICAL", 401, 412], ["colistin", "CHEMICAL", 414, 422], ["aminoglycoside", "CHEMICAL", 430, 444], ["aztreonam", "CHEMICAL", 448, 457], ["meropenem", "SIMPLE_CHEMICAL", 174, 183], ["aminoglycoside", "SIMPLE_CHEMICAL", 220, 234], ["colistin", "SIMPLE_CHEMICAL", 238, 246], ["carbapenems", "SIMPLE_CHEMICAL", 328, 339], ["tigecycline", "SIMPLE_CHEMICAL", 401, 412], ["colistin", "SIMPLE_CHEMICAL", 414, 422], ["aminoglycoside", "SIMPLE_CHEMICAL", 430, 444], ["aztreonam", "SIMPLE_CHEMICAL", 448, 457], ["these infections", "PROBLEM", 60, 76], ["high dose meropenem", "TREATMENT", 164, 183], ["an active aminoglycoside", "TREATMENT", 210, 234], ["colistin", "TREATMENT", 238, 246], ["strains", "PROBLEM", 251, 258], ["an MIC", "TREATMENT", 264, 270], ["strains", "PROBLEM", 291, 298], ["carbapenems", "TREATMENT", 328, 339], ["active alternatives", "TREATMENT", 363, 382], ["monotherapy", "TREATMENT", 384, 395], ["tigecycline", "TREATMENT", 401, 412], ["colistin", "TREATMENT", 414, 422], ["an aminoglycoside", "TREATMENT", 427, 444], ["aztreonam", "TREATMENT", 448, 457], ["infections", "OBSERVATION", 66, 76]]], ["Antibiotic stewardship is of great importance in such a dismal situation but stringent adherence to infection control measures is probably of even greater importance for the effective containment of these pandrugresistant strains.Use and abuse of antimicrobials: are we getting what we deserve?", [["infection", "DISEASE", 100, 109], ["Antibiotic stewardship", "TREATMENT", 0, 22], ["a dismal situation", "PROBLEM", 54, 72], ["infection control measures", "TREATMENT", 100, 126], ["these pandrugresistant strains", "TREATMENT", 199, 229], ["infection", "OBSERVATION", 100, 109]]], ["S17 The Greek experience with carbapenem resistance in EnterobacteriaceaeThe presentation of Clostridium difficile infection (CDI) varies from mild diarrhoea to a potentially fatal pseudomembranous colitis.", [["carbapenem", "CHEMICAL", 30, 40], ["Clostridium difficile infection", "DISEASE", 93, 124], ["CDI", "DISEASE", 126, 129], ["diarrhoea", "DISEASE", 148, 157], ["pseudomembranous colitis", "DISEASE", 181, 205], ["carbapenem", "CHEMICAL", 30, 40], ["carbapenem", "SIMPLE_CHEMICAL", 30, 40], ["Enterobacteriaceae", "CANCER", 55, 73], ["Clostridium difficile", "ORGANISM", 93, 114], ["pseudomembranous colitis", "PATHOLOGICAL_FORMATION", 181, 205], ["Clostridium difficile", "SPECIES", 93, 114], ["Clostridium difficile", "SPECIES", 93, 114], ["carbapenem resistance", "PROBLEM", 30, 51], ["Enterobacteriaceae", "PROBLEM", 55, 73], ["Clostridium difficile infection", "PROBLEM", 93, 124], ["mild diarrhoea", "PROBLEM", 143, 157], ["a potentially fatal pseudomembranous colitis", "PROBLEM", 161, 205], ["carbapenem resistance", "OBSERVATION", 30, 51], ["Enterobacteriaceae", "OBSERVATION_MODIFIER", 55, 73], ["Clostridium difficile", "OBSERVATION", 93, 114], ["mild", "OBSERVATION_MODIFIER", 143, 147], ["diarrhoea", "OBSERVATION", 148, 157], ["potentially", "UNCERTAINTY", 163, 174], ["fatal", "OBSERVATION_MODIFIER", 175, 180], ["pseudomembranous colitis", "OBSERVATION", 181, 205]]], ["The recent emergence of types 027 and 078 of C. difficile has been associated with increased virulence.", [["027 and 078", "CHEMICAL", 30, 41], ["C. difficile", "DISEASE", 45, 57], ["C. difficile", "ORGANISM", 45, 57], ["C. difficile", "SPECIES", 45, 57], ["C. difficile", "SPECIES", 45, 57], ["C. difficile", "PROBLEM", 45, 57], ["increased virulence", "PROBLEM", 83, 102], ["difficile", "OBSERVATION", 48, 57], ["associated with", "UNCERTAINTY", 67, 82], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["virulence", "OBSERVATION", 93, 102]]], ["C. difficile takes advantage of disruption of the normal intestinal flora as caused by antibiotic therapy.", [["intestinal flora", "ANATOMY", 57, 73], ["C. difficile", "DISEASE", 0, 12], ["C. difficile", "ORGANISM", 0, 12], ["intestinal flora", "ORGAN", 57, 73], ["C. difficile", "SPECIES", 0, 12], ["C. difficile", "SPECIES", 0, 12], ["C. difficile", "PROBLEM", 0, 12], ["the normal intestinal flora", "PROBLEM", 46, 73], ["antibiotic therapy", "TREATMENT", 87, 105], ["difficile", "OBSERVATION", 3, 12], ["normal intestinal flora", "OBSERVATION", 50, 73]]], ["The antibiotical class and the antimicrobial resistance pattern of C. difficile influence the development of disease.", [["C. difficile", "DISEASE", 67, 79], ["C. difficile", "ORGANISM", 67, 79], ["C. difficile", "SPECIES", 67, 79], ["C. difficile", "SPECIES", 67, 79], ["The antibiotical class", "TREATMENT", 0, 22], ["the antimicrobial resistance pattern", "TREATMENT", 27, 63], ["C. difficile", "PROBLEM", 67, 79], ["disease", "PROBLEM", 109, 116], ["antimicrobial resistance", "OBSERVATION", 31, 55], ["C. difficile", "OBSERVATION", 67, 79], ["disease", "OBSERVATION", 109, 116]]], ["In The Netherlands, significantly more patients with CDI due to Type 027 used fluoroquinolones (OR, 2.88; 95% CI, 1.01\u22128.20) compared with those who were infected with other PCR ribotypes.", [["CDI", "DISEASE", 53, 56], ["fluoroquinolones", "CHEMICAL", 78, 94], ["fluoroquinolones", "CHEMICAL", 78, 94], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["Type 027", "SPECIES", 64, 72], ["CDI", "PROBLEM", 53, 56], ["fluoroquinolones", "TREATMENT", 78, 94], ["other PCR ribotypes", "PROBLEM", 168, 187]]], ["Similar as Type 027 CDI, patients infected with Type 078 also more frequently received fluoroquinolones therapy (OR, 2.17; .", [["CDI", "DISEASE", 20, 23], ["fluoroquinolones", "CHEMICAL", 87, 103], ["fluoroquinolones", "CHEMICAL", 87, 103], ["patients", "ORGANISM", 25, 33], ["fluoroquinolones", "SIMPLE_CHEMICAL", 87, 103], ["patients", "SPECIES", 25, 33], ["Type 027", "SPECIES", 11, 19], ["fluoroquinolones therapy", "TREATMENT", 87, 111]]], ["The risk to develop CDI due to Type 027 was particularly high in persons receiving a combination of cephalosporin and fluoroquinolone (OR 57.5, ).", [["CDI", "DISEASE", 20, 23], ["cephalosporin", "CHEMICAL", 100, 113], ["fluoroquinolone", "CHEMICAL", 118, 133], ["cephalosporin", "CHEMICAL", 100, 113], ["fluoroquinolone", "CHEMICAL", 118, 133], ["persons", "ORGANISM", 65, 72], ["cephalosporin", "SIMPLE_CHEMICAL", 100, 113], ["fluoroquinolone", "SIMPLE_CHEMICAL", 118, 133], ["persons", "SPECIES", 65, 72], ["Type 027", "SPECIES", 31, 39], ["CDI", "PROBLEM", 20, 23], ["Type 027", "PROBLEM", 31, 39], ["cephalosporin", "TREATMENT", 100, 113], ["fluoroquinolone", "TREATMENT", 118, 133], ["CDI", "OBSERVATION", 20, 23]]], ["This association was also strongly dependent on the duration of therapy.", [["therapy", "TREATMENT", 64, 71]]], ["The use of clindamycin was found as a protective factor.", [["clindamycin", "CHEMICAL", 11, 22], ["clindamycin", "CHEMICAL", 11, 22], ["clindamycin", "SIMPLE_CHEMICAL", 11, 22], ["clindamycin", "TREATMENT", 11, 22]]], ["However, the recent detection of clindamycin-resistant C. difficile Type 027 strains in other European countries is an important and worrying development.", [["clindamycin", "CHEMICAL", 33, 44], ["C. difficile", "DISEASE", 55, 67], ["clindamycin", "CHEMICAL", 33, 44], ["clindamycin", "SIMPLE_CHEMICAL", 33, 44], ["C. difficile Type 027", "ORGANISM", 55, 76], ["strains", "ORGANISM", 77, 84], ["C. difficile", "SPECIES", 55, 67], ["C. difficile Type 027", "SPECIES", 55, 76], ["clindamycin", "TREATMENT", 33, 44], ["resistant C. difficile Type 027 strains", "PROBLEM", 45, 84], ["difficile", "OBSERVATION_MODIFIER", 58, 67]]], ["Since the association of CDI with fluoroquinolones has only been investigated at patient level, a study was performed to investigate the relationship between CDI incidence and the preceding use of different antibiotic classes at hospital level in The Netherlands.", [["CDI", "DISEASE", 25, 28], ["fluoroquinolones", "CHEMICAL", 34, 50], ["CDI", "DISEASE", 158, 161], ["fluoroquinolones", "CHEMICAL", 34, 50], ["fluoroquinolones", "SIMPLE_CHEMICAL", 34, 50], ["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["CDI", "PROBLEM", 25, 28], ["fluoroquinolones", "TREATMENT", 34, 50], ["a study", "TEST", 96, 103], ["CDI incidence", "PROBLEM", 158, 171], ["different antibiotic classes", "TREATMENT", 197, 225], ["CDI", "OBSERVATION", 25, 28], ["fluoroquinolones", "OBSERVATION", 34, 50]]], ["Comparisons were made between hospitals where type 027 caused an epidemic, hospitals where only isolated cases of type 027 were observed and hospitals where no outbreak of CDI or type 027 were encountered.", [["CDI", "DISEASE", 172, 175], ["type 027", "PROBLEM", 114, 122], ["CDI", "PROBLEM", 172, 175], ["type 027", "PROBLEM", 179, 187], ["epidemic", "OBSERVATION_MODIFIER", 65, 73], ["no", "UNCERTAINTY", 157, 159]]], ["In the pre-epidemic period, the total use antibiotics was comparable between affected and unaffected hospitals.", [["antibiotics", "TREATMENT", 42, 53]]], ["Higher use of secondgeneration cephalosporins, macrolides and all other studied antibiotics were independently associated with a small increase in CDI incidence, but the effect was too small to predict which hospitals might be more prone to 027-associated outbreaks.", [["secondgeneration cephalosporins", "CHEMICAL", 14, 45], ["macrolides", "CHEMICAL", 47, 57], ["CDI", "DISEASE", 147, 150], ["cephalosporins", "CHEMICAL", 31, 45], ["macrolides", "CHEMICAL", 47, 57], ["secondgeneration cephalosporins", "SIMPLE_CHEMICAL", 14, 45], ["macrolides", "SIMPLE_CHEMICAL", 47, 57], ["secondgeneration cephalosporins", "TREATMENT", 14, 45], ["macrolides", "TREATMENT", 47, 57], ["all other studied antibiotics", "TREATMENT", 62, 91], ["a small increase in CDI incidence", "PROBLEM", 127, 160], ["small", "OBSERVATION_MODIFIER", 129, 134], ["increase", "OBSERVATION_MODIFIER", 135, 143], ["CDI", "OBSERVATION", 147, 150]]], ["Despite the fact that The Netherlands is known by its restrictive and conservative use of antibiotics, outbreaks of CDI due to new emerging types have been recognized.", [["CDI", "DISEASE", 116, 119], ["antibiotics", "TREATMENT", 90, 101], ["CDI", "PROBLEM", 116, 119], ["restrictive", "OBSERVATION_MODIFIER", 54, 65]]], ["This is probably associated with the use of antibiotics at patient level and hospital department level rather than the use of antibiotics at the level of the healthcare institute.O24 Pharmacokinetics/-dynamics of piperacillin-tazobactam in plasma and alveolar epithelial lining fluid when administered as continuous infusion in severely ill patientsM.", [["plasma", "ANATOMY", 240, 246], ["alveolar epithelial lining fluid", "ANATOMY", 251, 283], ["piperacillin-tazobactam", "CHEMICAL", 213, 236], ["piperacillin-tazobactam", "CHEMICAL", 213, 236], ["patient", "ORGANISM", 59, 66], ["O24", "SIMPLE_CHEMICAL", 179, 182], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 213, 236], ["plasma", "ORGANISM_SUBSTANCE", 240, 246], ["alveolar epithelial lining", "TISSUE", 251, 277], ["fluid", "ORGANISM_SUBSTANCE", 278, 283], ["patient", "SPECIES", 59, 66], ["antibiotics", "TREATMENT", 44, 55], ["antibiotics", "TREATMENT", 126, 137], ["Pharmacokinetics", "TEST", 183, 199], ["piperacillin", "TREATMENT", 213, 225], ["tazobactam", "TREATMENT", 226, 236], ["plasma and alveolar epithelial lining fluid", "TREATMENT", 240, 283], ["continuous infusion", "TREATMENT", 305, 324], ["probably associated with", "UNCERTAINTY", 8, 32], ["alveolar epithelial", "ANATOMY", 251, 270], ["lining fluid", "OBSERVATION", 271, 283]]], ["Peiffer, J. Bulitta, H.A. Haeberle, M. Kinzig-Schippers, M. Rodamer, V. Jakob, B. Noh\u00e9, F. S\u00f6rgel, W.A. Krueger\u00b0(Trier, DE; Albany, US; Tubingen, Nuremberg, Constance, DE) Piperacillin-tazobactam (pip-tazo) is a broad spectrum antibiotic, used for treatment of severe infections such as ventilator-associated pneumonia (VAP).", [["Piperacillin-tazobactam", "CHEMICAL", 172, 195], ["pip-tazo", "CHEMICAL", 197, 205], ["infections", "DISEASE", 268, 278], ["ventilator-associated pneumonia", "DISEASE", 287, 318], ["VAP", "DISEASE", 320, 323], ["Piperacillin-tazobactam", "CHEMICAL", 172, 195], ["pip-tazo", "CHEMICAL", 197, 205], ["Piperacillin-tazobactam", "SIMPLE_CHEMICAL", 172, 195], ["pip-tazo", "SIMPLE_CHEMICAL", 197, 205], ["Piperacillin", "TREATMENT", 172, 184], ["tazobactam", "TREATMENT", 185, 195], ["pip-tazo", "TREATMENT", 197, 205], ["a broad spectrum antibiotic", "TREATMENT", 210, 237], ["severe infections", "PROBLEM", 261, 278], ["ventilator-associated pneumonia", "PROBLEM", 287, 318], ["VAP", "PROBLEM", 320, 323], ["severe", "OBSERVATION_MODIFIER", 261, 267], ["infections", "OBSERVATION", 268, 278], ["pneumonia", "OBSERVATION", 309, 318]]], ["The effectiveness of betalactams is best predicted by the duration of free drug concentrations above the minimal inhibitory concentration (t > MIC) of infecting pathogens [1] .", [["betalactams", "CHEMICAL", 21, 32], ["betalactams", "CHEMICAL", 21, 32], ["betalactams", "SIMPLE_CHEMICAL", 21, 32], ["betalactams", "TREATMENT", 21, 32], ["free drug concentrations", "TREATMENT", 70, 94], ["the minimal inhibitory concentration", "TREATMENT", 101, 137], ["infecting pathogens", "PROBLEM", 151, 170]]], ["Animal experiments suggest that more than 50% of t > MIC should be reached.", [["Animal experiments", "TEST", 0, 18], ["t > MIC", "TREATMENT", 49, 56]]], ["Continuous infusion (CI) of pip-tazo may enhance the therapeutic performance, but there is little data on pharmacokinetic/-dynamic (PK/PD) parameters, when CI is used in critically ill patients.O24 Pharmacokinetics/-dynamics of piperacillin-tazobactam in plasma and alveolar epithelial lining fluid when administered as continuous infusion in severely ill patientsObjectives: The aim of our study was to determine concentrations of pip-tazo in plasma and broncho-alveolar epithelial lining fluid (ELF) at steady state during CI.", [["plasma", "ANATOMY", 255, 261], ["alveolar epithelial lining fluid", "ANATOMY", 266, 298], ["plasma", "ANATOMY", 444, 450], ["broncho-alveolar epithelial lining fluid", "ANATOMY", 455, 495], ["ELF", "ANATOMY", 497, 500], ["pip-tazo", "CHEMICAL", 28, 36], ["critically ill", "DISEASE", 170, 184], ["piperacillin-tazobactam", "CHEMICAL", 228, 251], ["pip-tazo", "CHEMICAL", 432, 440], ["piperacillin-tazobactam", "CHEMICAL", 228, 251], ["pip-tazo", "SIMPLE_CHEMICAL", 28, 36], ["patients", "ORGANISM", 185, 193], ["O24", "SIMPLE_CHEMICAL", 194, 197], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 228, 251], ["plasma", "ORGANISM_SUBSTANCE", 255, 261], ["alveolar epithelial lining", "TISSUE", 266, 292], ["fluid", "ORGANISM_SUBSTANCE", 293, 298], ["patients", "ORGANISM", 356, 364], ["pip-tazo", "SIMPLE_CHEMICAL", 432, 440], ["plasma", "ORGANISM_SUBSTANCE", 444, 450], ["broncho-alveolar epithelial lining fluid", "TISSUE", 455, 495], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 356, 364], ["Continuous infusion (CI", "TREATMENT", 0, 23], ["pip-tazo", "TREATMENT", 28, 36], ["pharmacokinetic/-dynamic (PK/PD) parameters", "TREATMENT", 106, 149], ["CI", "TEST", 156, 158], ["Pharmacokinetics", "TEST", 198, 214], ["piperacillin", "TREATMENT", 228, 240], ["tazobactam", "TREATMENT", 241, 251], ["plasma and alveolar epithelial lining fluid", "TREATMENT", 255, 298], ["continuous infusion", "TREATMENT", 320, 339], ["our study", "TEST", 387, 396], ["pip-tazo", "TREATMENT", 432, 440], ["CI", "TEST", 525, 527], ["alveolar epithelial", "ANATOMY", 266, 285], ["lining fluid", "OBSERVATION", 286, 298], ["-alveolar epithelial", "ANATOMY", 462, 482], ["lining fluid", "OBSERVATION", 483, 495]]], ["Based on these results, the penetration ratio (plasma/ELF) and PK/PD parameters for pip-tazo are derived.", [["plasma", "ANATOMY", 47, 53], ["plasma", "ORGANISM_SUBSTANCE", 47, 53], ["PK", "GENE_OR_GENE_PRODUCT", 63, 65], ["pip-tazo", "SIMPLE_CHEMICAL", 84, 92], ["the penetration ratio", "TEST", 24, 45], ["plasma/ELF", "TEST", 47, 57], ["PK/PD parameters", "TEST", 63, 79], ["pip-tazo", "TREATMENT", 84, 92]]], ["Methods: After approval by the Ethics Committee, 16 mechanically ventilated critically ill patients were enrolled during treatment in 3 intensive care units.", [["critically ill", "DISEASE", 76, 90], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["treatment", "TREATMENT", 121, 130]]], ["Each patient received a loading dose of 4 g/0.5 g of pip-tazo, followed by CI of 12 g/1.5 g over 24 h.", [["pip-tazo", "CHEMICAL", 53, 61], ["patient", "ORGANISM", 5, 12], ["pip-tazo", "SIMPLE_CHEMICAL", 53, 61], ["patient", "SPECIES", 5, 12], ["a loading dose", "TREATMENT", 22, 36], ["pip-tazo", "TREATMENT", 53, 61]]], ["At steady state (67.8 + 39.5 h after loading dose), a total of 30 blood samples were drawn and bronchoalveolar lavage (BAL) was simultaneously performed in 8 cases (1 sample discarded for technical reasons).", [["blood samples", "ANATOMY", 66, 79], ["bronchoalveolar lavage", "ANATOMY", 95, 117], ["BAL", "ANATOMY", 119, 122], ["blood samples", "ORGANISM_SUBSTANCE", 66, 79], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 95, 117], ["BAL", "MULTI-TISSUE_STRUCTURE", 119, 122], ["blood samples", "TEST", 66, 79], ["bronchoalveolar lavage (BAL)", "TEST", 95, 123], ["bronchoalveolar lavage", "OBSERVATION", 95, 117]]], ["Samples were stored at \u221280\u00baC until analysis by liquid chromatography coupled with mass-spectrometry (LC-MS).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["analysis", "TEST", 35, 43], ["liquid chromatography", "TEST", 47, 68]]], ["ELF-concentrations were calculated from BAL-samples using the relation of ureaplasma:ureaBAL as dilution factor.", [["BAL-samples", "ANATOMY", 40, 51], ["ureaBAL", "CHEMICAL", 85, 92], ["ELF", "GENE_OR_GENE_PRODUCT", 0, 3], ["ureaplasma", "SIMPLE_CHEMICAL", 74, 84], ["ureaBAL", "SIMPLE_CHEMICAL", 85, 92], ["ELF", "PROTEIN", 0, 3], ["ureaplasma:ureaBAL as dilution factor", "PROTEIN", 74, 111], ["BAL", "TEST", 40, 43], ["ureaplasma", "PROBLEM", 74, 84]]], ["Results: Plasma concentrations of pip and tazo (n = 30 in 16 pts.) amounted to 15.38+8.89 mg/ml, and 1.31+0.95 mg/ml, respectively.", [["tazo", "CHEMICAL", 42, 46], ["Plasma", "ORGANISM_SUBSTANCE", 9, 15], ["pip", "SIMPLE_CHEMICAL", 34, 37], ["tazo", "SIMPLE_CHEMICAL", 42, 46], ["Plasma concentrations", "TEST", 9, 30], ["pip", "TEST", 34, 37], ["tazo", "TEST", 42, 46]]], ["ELFlevels (n = 7) were 56.63+27.24 mg/ml, and 5.95+3.74 mg/ml.", [["ELFlevels", "TEST", 0, 9]]], ["ELF-levels were 368+236%, and 587+584% of corresponding plasma levels (n = 7) for pip and tazo, respectively.", [["plasma", "ANATOMY", 56, 62], ["ELF", "GENE_OR_GENE_PRODUCT", 0, 3], ["plasma", "ORGANISM_SUBSTANCE", 56, 62], ["ELF", "PROTEIN", 0, 3], ["ELF-levels", "TEST", 0, 10], ["plasma levels", "TEST", 56, 69], ["pip", "TEST", 82, 85]]], ["The ratio pip:tazo was 11.74:1 in plasma, and 9.52:1 in ELF.", [["plasma", "ANATOMY", 34, 40], ["tazo", "SIMPLE_CHEMICAL", 14, 18], ["plasma", "ORGANISM_SUBSTANCE", 34, 40], ["The ratio pip", "TEST", 0, 13], ["tazo", "TEST", 14, 18], ["plasma", "TEST", 34, 40]]], ["Conclusions: Using advanced analytical techniques, ELF concentrations were higher compared to traditional bolus administration [2] .", [["ELF", "SIMPLE_CHEMICAL", 51, 54], ["advanced analytical techniques", "TREATMENT", 19, 49], ["ELF concentrations", "TEST", 51, 69], ["traditional bolus administration", "TREATMENT", 94, 126]]], ["CI yielded steady state plasma concentrations in excess of MICs of susceptible bacteria (<8 mg/ml, according to EUCAST) in 76.6% of measurements, respectively, but ELF levels exceeded 8 mg/ml in all cases.", [["plasma", "ANATOMY", 24, 30], ["MICs", "CHEMICAL", 59, 63], ["CI", "SIMPLE_CHEMICAL", 0, 2], ["plasma", "ORGANISM_SUBSTANCE", 24, 30], ["CI", "TEST", 0, 2], ["steady state plasma concentrations", "PROBLEM", 11, 45], ["susceptible bacteria", "PROBLEM", 67, 87], ["EUCAST", "TEST", 112, 118], ["ELF levels", "TEST", 164, 174]]], ["Taken together, our data provide further arguments for CI being the preferred mode of administration for pip-tazo in critically ill patients with suspected VAP.Reference(s)[ Objectives: Staphylococcus aureus is a potential pathogenic microorganism and a causative agent of~25% of infections in intensive care patients.", [["pip-tazo", "CHEMICAL", 105, 113], ["critically ill", "DISEASE", 117, 131], ["VAP", "DISEASE", 156, 159], ["Staphylococcus aureus", "DISEASE", 186, 207], ["infections", "DISEASE", 280, 290], ["CI", "SIMPLE_CHEMICAL", 55, 57], ["pip-tazo", "SIMPLE_CHEMICAL", 105, 113], ["patients", "ORGANISM", 132, 140], ["Staphylococcus aureus", "ORGANISM", 186, 207], ["patients", "ORGANISM", 309, 317], ["patients", "SPECIES", 132, 140], ["Staphylococcus aureus", "SPECIES", 186, 207], ["patients", "SPECIES", 309, 317], ["Staphylococcus aureus", "SPECIES", 186, 207], ["pip-tazo", "TREATMENT", 105, 113], ["VAP", "PROBLEM", 156, 159], ["Staphylococcus aureus", "PROBLEM", 186, 207], ["a potential pathogenic microorganism", "PROBLEM", 211, 247], ["infections", "PROBLEM", 280, 290], ["VAP", "OBSERVATION", 156, 159], ["Staphylococcus aureus", "OBSERVATION", 186, 207]]], ["An optimal empiric choice for the treatment of these infections will result in a reduction in morbidity and mortality.", [["infections", "DISEASE", 53, 63], ["An optimal empiric choice", "TREATMENT", 0, 25], ["the treatment", "TREATMENT", 30, 43], ["these infections", "PROBLEM", 47, 63], ["a reduction in morbidity", "PROBLEM", 79, 103], ["infections", "OBSERVATION", 53, 63], ["reduction", "OBSERVATION_MODIFIER", 81, 90], ["morbidity", "OBSERVATION", 94, 103]]], ["Therefore, it is essential to provide the clinician with resistance data of the bacterial population to be treated.", [["the bacterial population", "TREATMENT", 76, 100], ["bacterial population", "OBSERVATION", 80, 100]]], ["To optimise the empiric choice and to monitor the emergence of microbial resistance, a national surveillance program of the SWAB was started in the Netherlands in 1996.This study describes the results of the resistance development of S. aureus from ICU's of 14 hospitals all over the Netherlands over a ten year period.", [["S. aureus", "ORGANISM", 234, 243], ["S. aureus", "SPECIES", 234, 243], ["S. aureus", "SPECIES", 234, 243], ["the empiric choice", "TREATMENT", 12, 30], ["the SWAB", "TEST", 120, 128], ["This study", "TEST", 168, 178], ["S. aureus", "PROBLEM", 234, 243], ["aureus", "OBSERVATION", 237, 243]]], ["Methods: In the first 6 months of each year, the participating hospitals collected clinical isolates from among others blood and respiratory samples.", [["blood", "ANATOMY", 119, 124], ["respiratory samples", "ANATOMY", 129, 148], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["respiratory samples", "CANCER", 129, 148], ["blood and respiratory samples", "TEST", 119, 148]]], ["In total 943 isolates were collected: 250 from 3 hospitals in the north, 187 from 2 in the east, 229 from five in the west and 280 from four in the south.", [["isolates", "TEST", 13, 21]]], ["The antimicrobial susceptibility was determined as a micro broth dilution method according to the CLSI guidelines.", [["The antimicrobial susceptibility", "TEST", 0, 32], ["a micro broth dilution method", "TREATMENT", 51, 80], ["antimicrobial susceptibility", "OBSERVATION", 4, 32]]], ["Results: An increase in resistance to ciprofloxacin was observed from 4% until 2002 to 14% from in 2005, which dropped again to 7% in 2006.", [["ciprofloxacin", "CHEMICAL", 38, 51], ["ciprofloxacin", "CHEMICAL", 38, 51], ["ciprofloxacin", "SIMPLE_CHEMICAL", 38, 51], ["ciprofloxacin", "TREATMENT", 38, 51], ["increase", "OBSERVATION_MODIFIER", 12, 20]]], ["The resistance to moxifloxacin was rather constant over time, i.e. 2%, only in 2003 8% resistance was found.", [["moxifloxacin", "CHEMICAL", 18, 30], ["moxifloxacin", "CHEMICAL", 18, 30], ["moxifloxacin", "SIMPLE_CHEMICAL", 18, 30], ["moxifloxacin", "TREATMENT", 18, 30], ["resistance", "OBSERVATION_MODIFIER", 4, 14], ["moxifloxacin", "OBSERVATION", 18, 30]]], ["Resistance to clarithromycin increased to 10% in 2003, but decreased in 2006 to 6% the level before 2003.", [["clarithromycin", "CHEMICAL", 14, 28], ["clarithromycin", "CHEMICAL", 14, 28], ["clarithromycin", "SIMPLE_CHEMICAL", 14, 28], ["clarithromycin", "TREATMENT", 14, 28], ["clarithromycin", "OBSERVATION_MODIFIER", 14, 28], ["increased", "OBSERVATION_MODIFIER", 29, 38]]], ["Resistance to penicillin, clindamycin and tetracycline fluctuated over time at~75%, 4\u22128% and 2\u221210% respectively.", [["penicillin", "CHEMICAL", 14, 24], ["clindamycin", "CHEMICAL", 26, 37], ["tetracycline", "CHEMICAL", 42, 54], ["penicillin", "CHEMICAL", 14, 24], ["clindamycin", "CHEMICAL", 26, 37], ["tetracycline", "CHEMICAL", 42, 54], ["penicillin", "SIMPLE_CHEMICAL", 14, 24], ["clindamycin", "SIMPLE_CHEMICAL", 26, 37], ["tetracycline", "SIMPLE_CHEMICAL", 42, 54], ["penicillin", "TREATMENT", 14, 24], ["clindamycin", "TREATMENT", 26, 37], ["tetracycline", "TREATMENT", 42, 54]]], ["During the study period seven methicillin resistant S. aureus were isolated, no resistance to vancomycin, teicoplanin and linezolid was observed.", [["methicillin", "CHEMICAL", 30, 41], ["S. aureus", "DISEASE", 52, 61], ["vancomycin", "CHEMICAL", 94, 104], ["teicoplanin", "CHEMICAL", 106, 117], ["linezolid", "CHEMICAL", 122, 131], ["methicillin", "CHEMICAL", 30, 41], ["vancomycin", "CHEMICAL", 94, 104], ["teicoplanin", "CHEMICAL", 106, 117], ["linezolid", "CHEMICAL", 122, 131], ["S. aureus", "ORGANISM", 52, 61], ["vancomycin", "SIMPLE_CHEMICAL", 94, 104], ["teicoplanin", "SIMPLE_CHEMICAL", 106, 117], ["linezolid", "SIMPLE_CHEMICAL", 122, 131], ["S. aureus", "SPECIES", 52, 61], ["S. aureus", "SPECIES", 52, 61], ["the study", "TEST", 7, 16], ["methicillin resistant S. aureus", "PROBLEM", 30, 61], ["vancomycin", "TREATMENT", 94, 104], ["teicoplanin", "TREATMENT", 106, 117], ["linezolid", "TREATMENT", 122, 131], ["aureus", "OBSERVATION", 55, 61]]], ["Resistance to gentamicin and rifampicin was sporadicly found.", [["gentamicin", "CHEMICAL", 14, 24], ["rifampicin", "CHEMICAL", 29, 39], ["gentamicin", "CHEMICAL", 14, 24], ["rifampicin", "CHEMICAL", 29, 39], ["gentamicin", "SIMPLE_CHEMICAL", 14, 24], ["rifampicin", "SIMPLE_CHEMICAL", 29, 39], ["gentamicin", "TREATMENT", 14, 24], ["rifampicin", "TREATMENT", 29, 39], ["gentamicin", "OBSERVATION", 14, 24]]], ["Regional differences were observed for ciprofloxacin, being the highest in the western and southern part and tetracycline being the lowest in the northern part.Reference(s)Conclusion: During the 10 year study period only an increase in resistance to ciprofloxacin was observed.", [["ciprofloxacin", "CHEMICAL", 39, 52], ["tetracycline", "CHEMICAL", 109, 121], ["ciprofloxacin", "CHEMICAL", 250, 263], ["ciprofloxacin", "CHEMICAL", 39, 52], ["tetracycline", "CHEMICAL", 109, 121], ["ciprofloxacin", "CHEMICAL", 250, 263], ["ciprofloxacin", "SIMPLE_CHEMICAL", 39, 52], ["tetracycline", "SIMPLE_CHEMICAL", 109, 121], ["ciprofloxacin", "SIMPLE_CHEMICAL", 250, 263], ["ciprofloxacin", "TREATMENT", 39, 52], ["tetracycline", "TREATMENT", 109, 121], ["ciprofloxacin", "TREATMENT", 250, 263], ["increase", "OBSERVATION_MODIFIER", 224, 232]]], ["The data presented justify the empiric choice of flucloxacillin, (with rifampicin or gentamicin depending on the indication) in case of an infection in ICU patients probably caused by S. aureus.O38 Clonal dissemination of vancomycin-intermediate and methicillin-resistant Staphylococcus aureus in TaiwanJ.J. Lu\u00b0, P.R. Hsueh, S.Y. Lee (Taichung, Taipei, TW) Objectives: To investigate the prevalence of VISA in hospitalised patients with MRSA infections or colonisations at a teaching hospital in Taiwan and to evaluate the possible clonal spread of VISA in the hospital.", [["flucloxacillin", "CHEMICAL", 49, 63], ["rifampicin", "CHEMICAL", 71, 81], ["gentamicin", "CHEMICAL", 85, 95], ["infection", "DISEASE", 139, 148], ["vancomycin", "CHEMICAL", 222, 232], ["methicillin", "CHEMICAL", 250, 261], ["Staphylococcus aureus", "DISEASE", 272, 293], ["VISA", "DISEASE", 402, 406], ["MRSA infections", "DISEASE", 437, 452], ["colonisations", "DISEASE", 456, 469], ["flucloxacillin", "CHEMICAL", 49, 63], ["rifampicin", "CHEMICAL", 71, 81], ["gentamicin", "CHEMICAL", 85, 95], ["vancomycin", "CHEMICAL", 222, 232], ["methicillin", "CHEMICAL", 250, 261], ["flucloxacillin", "SIMPLE_CHEMICAL", 49, 63], ["rifampicin", "SIMPLE_CHEMICAL", 71, 81], ["gentamicin", "SIMPLE_CHEMICAL", 85, 95], ["patients", "ORGANISM", 156, 164], ["S. aureus", "ORGANISM", 184, 193], ["vancomycin-intermediate", "SIMPLE_CHEMICAL", 222, 245], ["methicillin-resistant", "SIMPLE_CHEMICAL", 250, 271], ["Staphylococcus aureus", "ORGANISM", 272, 293], ["patients", "ORGANISM", 423, 431], ["patients", "SPECIES", 156, 164], ["S. aureus", "SPECIES", 184, 193], ["Staphylococcus aureus", "SPECIES", 272, 293], ["patients", "SPECIES", 423, 431], ["MRSA", "SPECIES", 437, 441], ["S. aureus", "SPECIES", 184, 193], ["Staphylococcus aureus", "SPECIES", 272, 293], ["VISA", "SPECIES", 402, 406], ["MRSA", "SPECIES", 437, 441], ["VISA", "SPECIES", 549, 553], ["flucloxacillin", "TREATMENT", 49, 63], ["rifampicin", "TREATMENT", 71, 81], ["gentamicin", "TREATMENT", 85, 95], ["an infection", "PROBLEM", 136, 148], ["S. aureus", "PROBLEM", 184, 193], ["vancomycin", "TREATMENT", 222, 232], ["methicillin", "TEST", 250, 261], ["resistant Staphylococcus aureus", "PROBLEM", 262, 293], ["MRSA infections", "PROBLEM", 437, 452], ["colonisations", "PROBLEM", 456, 469], ["infection", "OBSERVATION", 139, 148], ["aureus", "OBSERVATION", 187, 193], ["Staphylococcus aureus", "OBSERVATION", 272, 293], ["VISA", "OBSERVATION", 549, 553]]], ["Methods: From September 2001 to August 2002, 1500 consecutive MRSA isolates were collected from various clinical specimens of 637 patients hospitalised at a teaching hospital in Taiwan.", [["specimens", "ANATOMY", 113, 122], ["patients", "ORGANISM", 130, 138], ["MRSA", "SPECIES", 62, 66], ["patients", "SPECIES", 130, 138], ["MRSA", "SPECIES", 62, 66], ["MRSA isolates", "TEST", 62, 75]]], ["Minimum inhibitory concentrations (MICs) of vancomycin for all MRSA isolates were determined by the broth microdilution method in accordance with CLSI guidelines.", [["vancomycin", "CHEMICAL", 44, 54], ["vancomycin", "CHEMICAL", 44, 54], ["vancomycin", "SIMPLE_CHEMICAL", 44, 54], ["MRSA", "SPECIES", 63, 67], ["MRSA", "SPECIES", 63, 67], ["Minimum inhibitory concentrations (MICs)", "TREATMENT", 0, 40], ["vancomycin", "TREATMENT", 44, 54], ["all MRSA isolates", "PROBLEM", 59, 76], ["the broth microdilution method", "TREATMENT", 96, 126]]], ["Molecular characteristics and antimicrobial susceptibilities of VISA isolates were investigated and Pulsed-field gel electrophoresis was used to evaluate the clonality of the isolates.", [["VISA", "ORGANISM", 64, 68], ["VISA", "SPECIES", 64, 68], ["antimicrobial susceptibilities of VISA isolates", "PROBLEM", 30, 77], ["Pulsed-field gel electrophoresis", "TEST", 100, 132], ["antimicrobial susceptibilities", "OBSERVATION", 30, 60]]], ["Results: Among the 1500 MRSA isolates, 43 (2.9%) were VISA.", [["MRSA", "SPECIES", 24, 28], ["MRSA", "SPECIES", 24, 28], ["VISA", "SPECIES", 54, 58], ["MRSA isolates", "TEST", 24, 37]]], ["Of the 43 VISA isolates, 35 had vancomycin MICs of 4 microgram/mL and 8 had vancomycin MICs of 8 microgram/mL.", [["vancomycin", "CHEMICAL", 32, 42], ["vancomycin", "CHEMICAL", 76, 86], ["vancomycin", "CHEMICAL", 32, 42], ["vancomycin", "CHEMICAL", 76, 86], ["vancomycin", "SIMPLE_CHEMICAL", 32, 42], ["vancomycin", "SIMPLE_CHEMICAL", 76, 86], ["vancomycin MICs", "TREATMENT", 32, 47], ["vancomycin MICs", "TREATMENT", 76, 91]]], ["All isolates were inhibited by tigecycline at 0.5 microgram/mL, linezolid at 1 microgram/mL, and ceftobiprole at 2 microgram/mL.", [["tigecycline", "CHEMICAL", 31, 42], ["linezolid", "CHEMICAL", 64, 73], ["ceftobiprole", "CHEMICAL", 97, 109], ["tigecycline", "CHEMICAL", 31, 42], ["linezolid", "CHEMICAL", 64, 73], ["ceftobiprole", "CHEMICAL", 97, 109], ["tigecycline", "SIMPLE_CHEMICAL", 31, 42], ["linezolid", "SIMPLE_CHEMICAL", 64, 73], ["ceftobiprole", "SIMPLE_CHEMICAL", 97, 109], ["All isolates", "TREATMENT", 0, 12], ["tigecycline", "TREATMENT", 31, 42], ["linezolid", "TREATMENT", 64, 73], ["ceftobiprole", "TREATMENT", 97, 109]]], ["Five (11.6%) isolates had reduced susceptibility to daptomycin (MICs of 1\u22122 microgram/mL).", [["daptomycin", "CHEMICAL", 52, 62], ["MICs", "CHEMICAL", 64, 68], ["daptomycin", "CHEMICAL", 52, 62], ["daptomycin", "SIMPLE_CHEMICAL", 52, 62], ["daptomycin", "TREATMENT", 52, 62]]], ["Six of the 43 VISA isolates had decreased susceptibility to autolysis in 0.05% Triton X-100.", [["Triton X-100", "CHEMICAL", 79, 91], ["Triton X-100", "CHEMICAL", 79, 91], ["Triton X-100", "SIMPLE_CHEMICAL", 79, 91], ["autolysis", "TEST", 60, 69]]], ["The 43 VISA isolates were recovered from 21 patients; 13 of these patients had received glycopeptide treatment prior to the isolation of VISA.", [["patients", "ORGANISM", 44, 52], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 66, 74], ["VISA", "SPECIES", 7, 11], ["VISA", "SPECIES", 137, 141], ["glycopeptide treatment", "TREATMENT", 88, 110], ["the isolation of VISA", "TREATMENT", 120, 141]]], ["Five (23.8%) patients died despite vancomycin therapy.", [["vancomycin", "CHEMICAL", 35, 45], ["vancomycin", "CHEMICAL", 35, 45], ["patients", "ORGANISM", 13, 21], ["vancomycin", "SIMPLE_CHEMICAL", 35, 45], ["patients", "SPECIES", 13, 21], ["vancomycin therapy", "TREATMENT", 35, 53], ["vancomycin therapy", "OBSERVATION", 35, 53]]], ["All 43 VISA isolates carried SCCmec type III and agr group I but were negative for PVL gene (lukS-lukF).", [["SCCmec type III", "GENE_OR_GENE_PRODUCT", 29, 44], ["agr group I", "GENE_OR_GENE_PRODUCT", 49, 60], ["PVL", "GENE_OR_GENE_PRODUCT", 83, 86], ["lukS-lukF", "GENE_OR_GENE_PRODUCT", 93, 102], ["agr group I", "DNA", 49, 60], ["PVL gene", "DNA", 83, 91], ["lukS", "DNA", 93, 97], ["lukF", "DNA", 98, 102], ["PVL gene", "PROBLEM", 83, 91]]], ["None of the enterococcal van genes were detected in the 43 VISA isolates.", [["enterococcal van genes", "DNA", 12, 34], ["VISA", "SPECIES", 59, 63], ["the enterococcal van genes", "TEST", 8, 34], ["enterococcal", "OBSERVATION_MODIFIER", 12, 24], ["van genes", "OBSERVATION", 25, 34]]], ["Results of PFGE analysis revealed that one major clone of VISA isolates (90.5%, clone A exhibiting SCCmec type III, agr group I, and absence of PVL gene) had disseminated in the hospital.O38 Clonal dissemination of vancomycin-intermediate and methicillin-resistant Staphylococcus aureus in TaiwanConclusion: This retrospective study demonstrated that clonal dissemination of VISA had occurred in the hospital.", [["vancomycin", "CHEMICAL", 215, 225], ["methicillin", "CHEMICAL", 243, 254], ["Staphylococcus aureus", "DISEASE", 265, 286], ["vancomycin", "CHEMICAL", 215, 225], ["methicillin", "CHEMICAL", 243, 254], ["clone", "CELL", 49, 54], ["VISA", "GENE_OR_GENE_PRODUCT", 58, 62], ["SCCmec type III", "GENE_OR_GENE_PRODUCT", 99, 114], ["agr group I", "GENE_OR_GENE_PRODUCT", 116, 127], ["PVL", "GENE_OR_GENE_PRODUCT", 144, 147], ["vancomycin", "SIMPLE_CHEMICAL", 215, 225], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 243, 286], ["VISA", "ORGANISM", 375, 379], ["PVL gene", "DNA", 144, 152], ["Staphylococcus aureus", "SPECIES", 265, 286], ["VISA", "SPECIES", 58, 62], ["Staphylococcus aureus", "SPECIES", 265, 286], ["VISA", "SPECIES", 375, 379], ["PFGE analysis", "TEST", 11, 24], ["VISA isolates", "TEST", 58, 71], ["vancomycin", "TREATMENT", 215, 225], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 243, 286], ["This retrospective study", "TEST", 308, 332], ["clonal dissemination of VISA", "PROBLEM", 351, 379], ["disseminated", "OBSERVATION", 158, 170], ["Staphylococcus aureus", "OBSERVATION", 265, 286], ["clonal dissemination", "OBSERVATION", 351, 371]]], ["Rapid and correct detection of VISA and proper use of antibiotics are the most effective approaches for preventing its emergence and spread.O39 No change in MRSA vancomycin MICs among isolates from paediatric infections (2000-2007)X. Zheng\u00b0, C. Qi, A. O'Leary, M. Arrieta, S. Shulman (Chicago, US) Objectives: Vancomycin remains one of the major options for treating methicillin-resistant S. aureus (MRSA) related infections.", [["vancomycin", "CHEMICAL", 162, 172], ["infections", "DISEASE", 209, 219], ["Vancomycin", "CHEMICAL", 310, 320], ["methicillin", "CHEMICAL", 367, 378], ["S. aureus", "DISEASE", 389, 398], ["MRSA", "DISEASE", 400, 404], ["infections", "DISEASE", 414, 424], ["vancomycin", "CHEMICAL", 162, 172], ["Vancomycin", "CHEMICAL", 310, 320], ["methicillin", "CHEMICAL", 367, 378], ["vancomycin", "SIMPLE_CHEMICAL", 162, 172], ["Vancomycin", "SIMPLE_CHEMICAL", 310, 320], ["methicillin-resistant S. aureus", "ORGANISM", 367, 398], ["MRSA", "CANCER", 400, 404], ["MRSA", "SPECIES", 157, 161], ["S. aureus", "SPECIES", 389, 398], ["MRSA", "SPECIES", 400, 404], ["VISA", "SPECIES", 31, 35], ["S. aureus", "SPECIES", 389, 398], ["MRSA", "SPECIES", 400, 404], ["VISA", "PROBLEM", 31, 35], ["antibiotics", "TREATMENT", 54, 65], ["MRSA vancomycin MICs", "TREATMENT", 157, 177], ["paediatric infections", "PROBLEM", 198, 219], ["Vancomycin", "TREATMENT", 310, 320], ["methicillin", "PROBLEM", 367, 378], ["resistant S. aureus (MRSA) related infections", "PROBLEM", 379, 424], ["VISA", "OBSERVATION", 31, 35], ["change", "OBSERVATION_MODIFIER", 147, 153], ["MRSA vancomycin", "OBSERVATION", 157, 172], ["aureus", "OBSERVATION", 392, 398], ["MRSA", "OBSERVATION", 400, 404]]], ["Some but not all studies have shown an increase in prevalence of MRSA isolates with elevated vancomycin MIC values among recent clinical isolates, so called \"MIC creep\".", [["vancomycin", "CHEMICAL", 93, 103], ["vancomycin", "CHEMICAL", 93, 103], ["vancomycin", "SIMPLE_CHEMICAL", 93, 103], ["MRSA", "SPECIES", 65, 69], ["MRSA", "SPECIES", 65, 69], ["all studies", "TEST", 13, 24], ["MRSA isolates", "PROBLEM", 65, 78], ["elevated vancomycin MIC values", "PROBLEM", 84, 114], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["MRSA", "OBSERVATION", 65, 69]]], ["Although still within the susceptible range, higher MICs may be associated with increased chance of treatment failure.", [["higher MICs", "PROBLEM", 45, 56], ["treatment failure", "PROBLEM", 100, 117], ["treatment failure", "OBSERVATION", 100, 117]]], ["Because of the conflicting reports and lack of published data from paediatric patients, we sought to assess possible MIC change over time and to compare results generated by using different methodologies including Etest, agar dilution, and broth microdilution (MicroScan) methods.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["MIC change", "PROBLEM", 117, 127], ["Etest", "TEST", 214, 219], ["agar dilution", "TEST", 221, 234]]], ["Methods: We studied 318 MRSA isolates predominantly community acquired including all blood and normally sterile site isolates collected in our large Children's hospital in 2000/2001, 2003, 2005, and 2007Molecular bacteriology and biology including diagnosticsMolecular bacteriology O41 Genome sequence of a virulent, methicillin-sensitive Staphylococcus aureus clinical isolate that encodes the Panton-Valentine leukocidin toxin L. Faraj, L.A.S. Snyder, N.J. Loman, D.P. Turner, M.J. Pallen, D. Ala'Aldeen, R. James\u00b0(Nottingham, Birmingham, UK) Objective: To determine the genome sequence of a virulent meticillinsensitive Staphylococcus aureus (MSSA) clinical isolate SANOT01.", [["blood", "ANATOMY", 85, 90], ["methicillin", "CHEMICAL", 317, 328], ["Staphylococcus aureus", "DISEASE", 339, 360], ["Staphylococcus aureus", "DISEASE", 623, 644], ["SANOT01", "CHEMICAL", 669, 676], ["methicillin", "CHEMICAL", 317, 328], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["Staphylococcus aureus", "ORGANISM", 339, 360], ["virulent", "ORGANISM", 594, 602], ["meticillinsensitive Staphylococcus aureus", "ORGANISM", 603, 644], ["MSSA", "CANCER", 646, 650], ["MRSA", "SPECIES", 24, 28], ["Children", "SPECIES", 149, 157], ["Staphylococcus aureus", "SPECIES", 339, 360], ["Staphylococcus aureus", "SPECIES", 623, 644], ["Staphylococcus aureus", "SPECIES", 339, 360], ["Panton-Valentine leukocidin toxin L. Faraj", "SPECIES", 395, 437], ["Staphylococcus aureus", "SPECIES", 623, 644], ["MSSA", "SPECIES", 646, 650], ["MRSA isolates", "TEST", 24, 37], ["all blood", "TEST", 81, 90], ["normally sterile site isolates", "TREATMENT", 95, 125], ["diagnostics", "TEST", 248, 259], ["Molecular bacteriology", "TEST", 259, 281], ["Genome sequence", "TEST", 286, 301], ["a virulent, methicillin-sensitive Staphylococcus aureus clinical isolate", "PROBLEM", 305, 377], ["a virulent meticillinsensitive Staphylococcus aureus", "PROBLEM", 592, 644], ["Staphylococcus aureus", "OBSERVATION", 623, 644]]], ["Methods: Roche 454 sequencing determined the genome sequence of the clinical isolate at 12 times coverage.", [["the clinical isolate", "TREATMENT", 64, 84]]], ["Newbler sequence assembly (Roche) generated 10 scaffolds that were annotated using GenDB and compared with other S. aureus genome sequences.", [["S. aureus", "ORGANISM", 113, 122], ["GenDB", "DNA", 83, 88], ["S. aureus genome sequences", "DNA", 113, 139], ["S. aureus", "SPECIES", 113, 122], ["S. aureus", "SPECIES", 113, 122], ["other S. aureus genome sequences", "PROBLEM", 107, 139], ["aureus", "OBSERVATION", 116, 122]]], ["Results: An 11-year-old Asian girl presented with fever and a 1-week history of knee pain following a trivial fall.", [["knee", "ANATOMY", 80, 84], ["fever", "DISEASE", 50, 55], ["pain", "DISEASE", 85, 89], ["girl", "ORGANISM", 30, 34], ["knee", "ORGANISM_SUBDIVISION", 80, 84], ["girl", "SPECIES", 30, 34], ["fever", "PROBLEM", 50, 55], ["knee pain", "PROBLEM", 80, 89], ["a trivial fall", "PROBLEM", 100, 114], ["fever", "OBSERVATION", 50, 55], ["knee", "ANATOMY", 80, 84], ["pain", "OBSERVATION", 85, 89], ["trivial", "OBSERVATION_MODIFIER", 102, 109], ["fall", "OBSERVATION", 110, 114]]], ["An MR scan revealed a large subperiosteal abscess around the upper tibia secondary to metaphyseal osteomyelitis.", [["subperiosteal abscess", "ANATOMY", 28, 49], ["tibia", "ANATOMY", 67, 72], ["abscess", "DISEASE", 42, 49], ["osteomyelitis", "DISEASE", 98, 111], ["upper", "ORGANISM_SUBDIVISION", 61, 66], ["tibia", "ORGAN", 67, 72], ["MR", "PROTEIN", 3, 5], ["An MR scan", "TEST", 0, 10], ["a large subperiosteal abscess around the upper tibia", "PROBLEM", 20, 72], ["metaphyseal osteomyelitis", "PROBLEM", 86, 111], ["large", "OBSERVATION_MODIFIER", 22, 27], ["subperiosteal", "ANATOMY", 28, 41], ["abscess", "OBSERVATION", 42, 49], ["upper", "ANATOMY_MODIFIER", 61, 66], ["tibia", "ANATOMY", 67, 72], ["metaphyseal", "ANATOMY", 86, 97], ["osteomyelitis", "OBSERVATION", 98, 111]]], ["A PVL-positive, MSSA was isolated from blood cultures and pus.", [["blood cultures", "ANATOMY", 39, 53], ["pus", "ANATOMY", 58, 61], ["MSSA", "CHEMICAL", 16, 20], ["PVL", "GENE_OR_GENE_PRODUCT", 2, 5], ["MSSA", "CANCER", 16, 20], ["blood cultures", "ORGANISM_SUBSTANCE", 39, 53], ["pus", "ORGANISM_SUBSTANCE", 58, 61], ["A PVL", "TEST", 0, 5], ["MSSA", "PROBLEM", 16, 20], ["blood cultures", "TEST", 39, 53], ["pus", "PROBLEM", 58, 61], ["PVL", "OBSERVATION", 2, 5], ["positive", "OBSERVATION", 6, 14], ["MSSA", "OBSERVATION", 16, 20], ["pus", "OBSERVATION", 58, 61]]], ["The child deteriorated, required repeated debridement and developed septic shock.", [["septic shock", "DISEASE", 68, 80], ["child", "ORGANISM", 4, 9], ["repeated debridement", "TREATMENT", 33, 53], ["septic shock", "PROBLEM", 68, 80], ["debridement", "OBSERVATION", 42, 53], ["septic shock", "OBSERVATION", 68, 80]]], ["Further investigation revealed aortic valve endocarditis with an aortic root abscess.", [["aortic valve", "ANATOMY", 31, 43], ["aortic root abscess", "ANATOMY", 65, 84], ["aortic valve endocarditis", "DISEASE", 31, 56], ["aortic root abscess", "DISEASE", 65, 84], ["aortic valve", "PATHOLOGICAL_FORMATION", 31, 43], ["aortic root", "MULTI-TISSUE_STRUCTURE", 65, 76], ["Further investigation", "TEST", 0, 21], ["aortic valve endocarditis", "PROBLEM", 31, 56], ["an aortic root abscess", "PROBLEM", 62, 84], ["aortic valve", "ANATOMY", 31, 43], ["endocarditis", "OBSERVATION", 44, 56], ["aortic", "ANATOMY", 65, 71], ["root", "ANATOMY_MODIFIER", 72, 76], ["abscess", "OBSERVATION", 77, 84]]], ["Whole genome sequencing revealed that SANOT01 is the first sequence of an ST30 S. aureus isolate to be determined.", [["SANOT01", "GENE_OR_GENE_PRODUCT", 38, 45], ["ST30 S. aureus", "ORGANISM", 74, 88], ["SANOT01", "DNA", 38, 45], ["S. aureus", "SPECIES", 79, 88], ["S. aureus", "SPECIES", 79, 88], ["Whole genome sequencing", "TEST", 0, 23], ["aureus isolate", "PROBLEM", 82, 96], ["aureus", "OBSERVATION", 82, 88]]], ["SANOT01 is agr type III and carries three coding regions that are not found in any other S. aureus genome sequences.", [["SANOT01", "GENE_OR_GENE_PRODUCT", 0, 7], ["agr type III", "GENE_OR_GENE_PRODUCT", 11, 23], ["S. aureus", "ORGANISM", 89, 98], ["SANOT01", "DNA", 0, 7], ["agr type III", "DNA", 11, 23], ["S. aureus genome sequences", "DNA", 89, 115], ["S. aureus", "SPECIES", 89, 98], ["S. aureus", "SPECIES", 89, 98], ["agr type III", "PROBLEM", 11, 23], ["any other S. aureus genome sequences", "PROBLEM", 79, 115], ["type III", "OBSERVATION_MODIFIER", 15, 23], ["aureus", "OBSERVATION", 92, 98]]], ["Amongst the unique genes present in these regions is a dihydrofolate reductase gene (dfrG) which is present in addition to the usual dfrB gene.", [["dihydrofolate reductase", "GENE_OR_GENE_PRODUCT", 55, 78], ["dfrG", "GENE_OR_GENE_PRODUCT", 85, 89], ["dfrB", "GENE_OR_GENE_PRODUCT", 133, 137], ["dihydrofolate reductase gene", "DNA", 55, 83], ["dfrG", "DNA", 85, 89], ["dfrB gene", "DNA", 133, 142], ["a dihydrofolate reductase gene (dfrG)", "PROBLEM", 53, 90]]], ["Downstream of the orfX gene, a 6.5 kb remnant of SCCmec type IVc was found.", [["orfX", "GENE_OR_GENE_PRODUCT", 18, 22], ["SCCmec type IVc", "GENE_OR_GENE_PRODUCT", 49, 64], ["orfX gene", "DNA", 18, 27], ["6.5 kb remnant", "DNA", 31, 45], ["SCCmec type IVc", "DNA", 49, 64], ["a 6.5 kb remnant of SCCmec type IVc", "TREATMENT", 29, 64], ["SCCmec", "OBSERVATION", 49, 55], ["IVc", "ANATOMY", 61, 64]]], ["This sequence has only previously been found in the MRSA252 genome sequence where it is located between the orfX and SCCmec type II sequences.", [["MRSA252", "GENE_OR_GENE_PRODUCT", 52, 59], ["orfX", "GENE_OR_GENE_PRODUCT", 108, 112], ["SCCmec type II", "GENE_OR_GENE_PRODUCT", 117, 131], ["MRSA252 genome sequence", "DNA", 52, 75], ["orfX and SCCmec type II sequences", "DNA", 108, 141], ["SCCmec", "OBSERVATION", 117, 123]]], ["MRSA252 is unique in sharing 14 genome regions with S. aureus strain RF122, a causative agent of contagious bovine mastitis.", [["MRSA252", "CHEMICAL", 0, 7], ["bovine mastitis", "DISEASE", 108, 123], ["MRSA252", "GENE_OR_GENE_PRODUCT", 0, 7], ["S. aureus strain RF122", "ORGANISM", 52, 74], ["bovine", "ORGANISM", 108, 114], ["MRSA252", "DNA", 0, 7], ["14 genome regions", "DNA", 29, 46], ["S. aureus", "SPECIES", 52, 61], ["bovine", "SPECIES", 108, 114], ["S. aureus", "SPECIES", 52, 61], ["bovine", "SPECIES", 108, 114], ["S. aureus strain RF122", "PROBLEM", 52, 74], ["contagious bovine mastitis", "PROBLEM", 97, 123], ["aureus", "OBSERVATION", 55, 61], ["contagious", "OBSERVATION_MODIFIER", 97, 107], ["bovine mastitis", "OBSERVATION", 108, 123]]], ["All but one of these 14 genome regions are also present in SANOT01.", [["SANOT01", "GENE_OR_GENE_PRODUCT", 59, 66], ["14 genome regions", "DNA", 21, 38], ["SANOT01", "DNA", 59, 66], ["one", "OBSERVATION_MODIFIER", 8, 11], ["genome", "OBSERVATION", 24, 30]]], ["Conclusions: Comparison of the genome sequence of SANOT01 and the closely related MRSA252 HA-MRSA (EMRSA-16) isolate reveals new insights in the evolution of both CA-MRSA and HA-MRSA isolates and the link to S. aureus RF122.", [["SANOT01", "GENE_OR_GENE_PRODUCT", 50, 57], ["MRSA252 HA-MRSA", "ORGANISM", 82, 97], ["EMRSA-16", "ORGANISM", 99, 107], ["CA-MRSA", "ORGANISM", 163, 170], ["HA-MRSA isolates", "ORGANISM", 175, 191], ["S. aureus RF122", "ORGANISM", 208, 223], ["MRSA", "SPECIES", 93, 97], ["MRSA", "SPECIES", 166, 170], ["MRSA", "SPECIES", 178, 182], ["S. aureus", "SPECIES", 208, 217], ["S. aureus", "SPECIES", 208, 217], ["SANOT01", "TEST", 50, 57], ["HA", "TEST", 90, 92], ["MRSA", "PROBLEM", 93, 97], ["EMRSA", "TEST", 99, 104], ["both CA", "PROBLEM", 158, 165], ["MRSA", "PROBLEM", 166, 170], ["HA", "PROBLEM", 175, 177], ["MRSA isolates", "PROBLEM", 178, 191], ["S. aureus RF122", "PROBLEM", 208, 223], ["MRSA", "OBSERVATION", 93, 97], ["new", "OBSERVATION_MODIFIER", 125, 128], ["both", "OBSERVATION_MODIFIER", 158, 162], ["CA", "OBSERVATION", 163, 165], ["MRSA", "OBSERVATION", 166, 170], ["aureus", "OBSERVATION", 211, 217]]], ["PVL-encoding MSSA strains can be significant pathogens but are not currently under mandatory surveillance in UK.", [["PVL", "GENE_OR_GENE_PRODUCT", 0, 3], ["UK", "GENE_OR_GENE_PRODUCT", 109, 111], ["PVL", "PROBLEM", 0, 3], ["encoding MSSA strains", "PROBLEM", 4, 25], ["significant pathogens", "PROBLEM", 33, 54], ["MSSA", "OBSERVATION", 13, 17], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["pathogens", "OBSERVATION", 45, 54]]], ["As the cost of whole genome sequencing falls further it will become feasible to use this technology to monitor the evolution of both MSSA and MRSA in healthcare settings and reveal clinically relevant information that will help to improve patient outcomes.", [["MSSA", "CHEMICAL", 133, 137], ["MRSA", "DISEASE", 142, 146], ["MSSA", "CANCER", 133, 137], ["MRSA", "CANCER", 142, 146], ["patient", "ORGANISM", 239, 246], ["MRSA", "SPECIES", 142, 146], ["patient", "SPECIES", 239, 246], ["MRSA", "SPECIES", 142, 146], ["whole genome sequencing falls", "PROBLEM", 15, 44], ["this technology", "TREATMENT", 84, 99], ["MSSA", "PROBLEM", 133, 137], ["MRSA", "PROBLEM", 142, 146], ["MSSA", "OBSERVATION", 133, 137], ["MRSA", "OBSERVATION", 142, 146]]], ["Objectives: CA-MRSA often produce Panton-Valentine leukocidin (PVL), a leukocidin encoded by two co-transcribed genes located on lysogenised phages.", [["Panton-Valentine leukocidin", "CHEMICAL", 34, 61], ["CA-MRSA", "GENE_OR_GENE_PRODUCT", 12, 19], ["Panton-Valentine leukocidin", "GENE_OR_GENE_PRODUCT", 34, 61], ["PVL", "GENE_OR_GENE_PRODUCT", 63, 66], ["leukocidin", "GENE_OR_GENE_PRODUCT", 71, 81], ["co-transcribed genes", "DNA", 97, 117], ["lysogenised phages", "DNA", 129, 147], ["MRSA", "SPECIES", 15, 19], ["Panton-Valentine leukocidin (PVL)", "SPECIES", 34, 67], ["CA", "TEST", 12, 14], ["MRSA", "PROBLEM", 15, 19], ["Valentine leukocidin", "TREATMENT", 41, 61], ["a leukocidin", "TREATMENT", 69, 81]]], ["Five PVL-encoding phages have been described in S. aureus: phiPVL, phi108PVL, phiSLT, phiSa2mw and phiSa2958.", [["PVL", "GENE_OR_GENE_PRODUCT", 5, 8], ["S. aureus", "ORGANISM", 48, 57], ["phiPVL", "GENE_OR_GENE_PRODUCT", 59, 65], ["phi108PVL", "GENE_OR_GENE_PRODUCT", 67, 76], ["phiSLT", "GENE_OR_GENE_PRODUCT", 78, 84], ["phiSa2mw", "GENE_OR_GENE_PRODUCT", 86, 94], ["PVL-encoding phages", "DNA", 5, 24], ["phiPVL, phi108PVL, phiSLT, phiSa2mw and phiSa2958", "DNA", 59, 108], ["S. aureus", "SPECIES", 48, 57], ["S. aureus", "SPECIES", 48, 57], ["Five PVL-encoding phages", "PROBLEM", 0, 24], ["phiPVL", "TEST", 59, 65], ["phi108PVL", "TEST", 67, 76], ["phiSa", "TEST", 99, 104], ["PVL", "OBSERVATION", 5, 8], ["aureus", "OBSERVATION", 51, 57], ["phiPVL", "ANATOMY", 59, 65]]], ["Single nucleotide polymorphisms (SNPs) in the PVL genes tend to vary with lineage and may have structural and functional implications.", [["PVL", "GENE_OR_GENE_PRODUCT", 46, 49], ["PVL genes", "DNA", 46, 55], ["Single nucleotide polymorphisms (SNPs)", "TREATMENT", 0, 38], ["structural and functional implications", "PROBLEM", 95, 133]]], ["We examined a selection of PVL-positive CA-MRSA reported in our hospital to determine whether sequence variation and the PVL-encoding phage vary with lineage.", [["PVL", "GENE_OR_GENE_PRODUCT", 27, 30], ["CA", "GENE_OR_GENE_PRODUCT", 40, 42], ["PVL", "GENE_OR_GENE_PRODUCT", 121, 124], ["PVL-encoding phage", "DNA", 121, 139], ["MRSA", "SPECIES", 43, 47], ["PVL", "TEST", 27, 30], ["positive CA", "PROBLEM", 31, 42], ["MRSA", "PROBLEM", 43, 47], ["sequence variation", "TEST", 94, 112], ["the PVL", "PROBLEM", 117, 124], ["PVL", "OBSERVATION", 27, 30], ["PVL", "OBSERVATION", 121, 124]]], ["Methods: Twenty-two PVL-positive isolates were chosen to reflect MLST clonal complexes identified in our hospital: CC1, 5, 8, 59, 80, 88 and 154 .", [["PVL", "ORGANISM", 20, 23], ["two PVL", "TEST", 16, 23], ["positive isolates", "PROBLEM", 24, 41]]], ["Isolates were characterised by antimicrobial resistance profile, SCCmec and spa type, pulsed-field gel electrophoresis (PFGE) profile and multilocus sequence typing (MLST); an oligonuleotide array (Clondiag ArrayTube) was used to detect a range of toxin and antimicrobial resistance genes.", [["oligonuleotide array", "DNA", 176, 196], ["Clondiag ArrayTube", "DNA", 198, 216], ["toxin and antimicrobial resistance genes", "DNA", 248, 288], ["Isolates", "TEST", 0, 8], ["antimicrobial resistance profile", "TEST", 31, 63], ["SCCmec", "PROBLEM", 65, 71], ["spa type", "TEST", 76, 84], ["pulsed-field gel electrophoresis", "TEST", 86, 118], ["PFGE) profile", "TEST", 120, 133], ["multilocus sequence typing", "TEST", 138, 164], ["an oligonuleotide array (Clondiag ArrayTube)", "TREATMENT", 173, 217], ["antimicrobial resistance genes", "TREATMENT", 258, 288], ["antimicrobial resistance", "OBSERVATION", 31, 55], ["antimicrobial resistance", "OBSERVATION", 258, 282]]], ["Primers were designed to amplify and sequence the lukSF-PV genes.", [["lukSF-PV", "GENE_OR_GENE_PRODUCT", 50, 58], ["lukSF-PV genes", "DNA", 50, 64], ["the lukSF", "TEST", 46, 55], ["PV genes", "OBSERVATION", 56, 64]]], ["The PVL-encoding phage was characterised using a recently described PCR-based assay (Ma et al. J Clin Microbiol 2008; 40:3246\u221258) .", [["PVL", "GENE_OR_GENE_PRODUCT", 4, 7], ["PVL-encoding phage", "DNA", 4, 22], ["The PVL", "TEST", 0, 7], ["a recently described PCR", "TEST", 47, 71], ["PVL", "OBSERVATION", 4, 7]]], ["Results: SNPs were identified at seven positions in the lukSF-PV genes and the SNP profile varied with lineage.", [["SNP", "CHEMICAL", 79, 82], ["lukSF-PV", "GENE_OR_GENE_PRODUCT", 56, 64], ["lukSF", "DNA", 56, 61], ["PV genes", "DNA", 62, 70], ["SNPs", "PROBLEM", 9, 13], ["the SNP profile", "TEST", 75, 90], ["PV genes", "ANATOMY", 62, 70]]], ["Three of the SNPs were coding mutations, which may have structural and functional implications.", [["the SNPs", "PROBLEM", 9, 17], ["coding mutations", "PROBLEM", 23, 39]]], ["CC1 and CC80 isolates were both found to carry phiSa2mw.", [["CC1", "GENE_OR_GENE_PRODUCT", 0, 3], ["CC80", "GENE_OR_GENE_PRODUCT", 8, 12], ["phiSa2mw", "GENE_OR_GENE_PRODUCT", 47, 55], ["CC1", "PROTEIN", 0, 3], ["phiSa2mw", "PROTEIN", 47, 55]]], ["The PVLencoding phage was not definitively identified in the other lineages, although the CC59 isolates carried a phiSa2958-like phage and the CC8, CC80 and CC154 isolates carried elongated head-type phages.", [["head", "ANATOMY", 190, 194], ["CC59 isolates", "ORGANISM", 90, 103], ["phiSa2958", "GENE_OR_GENE_PRODUCT", 114, 123], ["CC154 isolates", "ORGANISM", 157, 171], ["PVLencoding phage", "DNA", 4, 21], ["phiSa2958-like phage", "DNA", 114, 134], ["CC154", "SPECIES", 157, 162], ["The PVLencoding phage", "TREATMENT", 0, 21], ["the CC59 isolates", "TEST", 86, 103]]], ["One of the CC1 isolates had an unexpected SNP pattern compared with other CC1 isolates; this isolate also carried a novel or variant phage.", [["SNP", "CHEMICAL", 42, 45], ["CC1", "GENE_OR_GENE_PRODUCT", 11, 14], ["the CC1 isolates", "TEST", 7, 23], ["an unexpected SNP pattern", "PROBLEM", 28, 53], ["SNP pattern", "OBSERVATION", 42, 53]]], ["Conclusion: PVL gene sequence and the PVL-encoding phage vary with lineage in PVL-positive CA-MRSA isolates.", [["PVL", "GENE_OR_GENE_PRODUCT", 12, 15], ["PVL", "GENE_OR_GENE_PRODUCT", 38, 41], ["PVL", "GENE_OR_GENE_PRODUCT", 78, 81], ["CA", "GENE_OR_GENE_PRODUCT", 91, 93], ["PVL gene sequence", "DNA", 12, 29], ["PVL-encoding phage", "DNA", 38, 56], ["MRSA", "SPECIES", 94, 98], ["PVL gene sequence", "TEST", 12, 29], ["the PVL", "TEST", 34, 41], ["encoding phage", "TREATMENT", 42, 56], ["PVL", "TEST", 78, 81], ["positive CA", "PROBLEM", 82, 93], ["MRSA isolates", "PROBLEM", 94, 107], ["PVL", "OBSERVATION", 38, 41]]], ["This suggests that certain lineages are susceptible to infection or lysogeny with certain phage types.", [["infection", "DISEASE", 55, 64], ["infection", "PROBLEM", 55, 64], ["lysogeny with certain phage types", "PROBLEM", 68, 101], ["infection", "OBSERVATION", 55, 64], ["certain phage", "OBSERVATION_MODIFIER", 82, 95]]], ["Although CA-MRSA commonly carry PVL genes, some strains do not; it is possible that some PVL-negative types are resistant to infection with PVL-encoding phage, perhaps via restriction modification systems.", [["infection", "DISEASE", 125, 134], ["CA-MRSA", "GENE_OR_GENE_PRODUCT", 9, 16], ["PVL", "GENE_OR_GENE_PRODUCT", 32, 35], ["PVL", "GENE_OR_GENE_PRODUCT", 89, 92], ["PVL", "GENE_OR_GENE_PRODUCT", 140, 143], ["PVL genes", "DNA", 32, 41], ["MRSA", "SPECIES", 12, 16], ["CA", "TEST", 9, 11], ["MRSA", "PROBLEM", 12, 16], ["PVL genes", "PROBLEM", 32, 41], ["some strains", "PROBLEM", 43, 55], ["some PVL", "PROBLEM", 84, 92], ["infection", "PROBLEM", 125, 134], ["PVL", "PROBLEM", 140, 143], ["encoding phage", "TREATMENT", 144, 158], ["PVL", "OBSERVATION", 89, 92], ["infection", "OBSERVATION", 125, 134]]], ["Crucially, our findings suggest the PVL genes have co-evolved with their phage and are not freely transmitted between different phages.", [["PVL", "GENE_OR_GENE_PRODUCT", 36, 39], ["PVL genes", "DNA", 36, 45], ["the PVL genes", "PROBLEM", 32, 45], ["PVL", "OBSERVATION", 36, 39]]], ["Further work is required to characterise the PVL-encoding phage in other isolates and to investigate whether the PVL sequence variants result in biological differences.E. Boakes\u00b0, A.M. Kearns, M.J. Ellington (London, UK)Objectives: Community-associated MRSA (CA-MRSA) of many different MLST clonal complexes (CCs) can harbour lysogenised bacteriophage DNA (prophage) encoding Panton-Valentine Leukocidin (PVL).", [["clonal complexes", "ANATOMY", 291, 307], ["CCs", "ANATOMY", 309, 312], ["MRSA", "DISEASE", 253, 257], ["Panton-Valentine Leukocidin", "CHEMICAL", 376, 403], ["PVL", "GENE_OR_GENE_PRODUCT", 45, 48], ["PVL", "GENE_OR_GENE_PRODUCT", 113, 116], ["CA-MRSA", "ORGANISM", 259, 266], ["CCs", "CANCER", 309, 312], ["DNA", "CELLULAR_COMPONENT", 352, 355], ["Panton-Valentine Leukocidin", "GENE_OR_GENE_PRODUCT", 376, 403], ["PVL sequence variants", "DNA", 113, 134], ["lysogenised bacteriophage DNA", "DNA", 326, 355], ["prophage", "DNA", 357, 365], ["MRSA", "SPECIES", 253, 257], ["MRSA", "SPECIES", 262, 266], ["the PVL", "PROBLEM", 41, 48], ["encoding phage in other isolates", "PROBLEM", 49, 81], ["the PVL sequence variants", "TEST", 109, 134], ["MRSA (CA", "PROBLEM", 253, 261], ["MRSA", "PROBLEM", 262, 266], ["harbour lysogenised bacteriophage DNA (prophage", "TREATMENT", 318, 365], ["Valentine Leukocidin", "TREATMENT", 383, 403], ["PVL", "OBSERVATION", 45, 48], ["MRSA", "OBSERVATION", 253, 257]]], ["Five PVL phages (phiPVL, phiSLT, phiSa2mw, phi108PVL, and phiSa2958) have been reported to date.", [["PVL phages", "GENE_OR_GENE_PRODUCT", 5, 15], ["phiPVL", "GENE_OR_GENE_PRODUCT", 17, 23], ["phiSLT", "GENE_OR_GENE_PRODUCT", 25, 31], ["phiSa2mw", "GENE_OR_GENE_PRODUCT", 33, 41], ["phi108PVL", "GENE_OR_GENE_PRODUCT", 43, 52], ["PVL phages", "DNA", 5, 15], ["phiPVL", "DNA", 17, 23], ["phiSLT", "DNA", 25, 31], ["phiSa2mw", "DNA", 33, 41], ["phi108PVL", "DNA", 43, 52], ["phiSa2958", "DNA", 58, 67], ["Five PVL phages", "TEST", 0, 15], ["phiPVL", "TEST", 17, 23], ["phiSLT", "TEST", 25, 31], ["phi108PVL", "TEST", 43, 52]]], ["We sought to determine the distribution of chromosomally integrated copies of these lysogenised PVL-phages amongst dominant clones of PVL MRSA in England and Wales.", [["PVL MRSA", "DISEASE", 134, 142], ["PVL", "GENE_OR_GENE_PRODUCT", 96, 99], ["lysogenised PVL-phages", "DNA", 84, 106], ["MRSA", "SPECIES", 138, 142], ["PVL", "SPECIES", 134, 137], ["these lysogenised PVL", "TEST", 78, 99], ["PVL MRSA", "PROBLEM", 134, 142], ["PVL", "OBSERVATION_MODIFIER", 134, 137], ["MRSA", "OBSERVATION", 138, 142]]], ["Methods: Seventy isolates of previously characterised PVL-MRSA were analysed by PCRs developed by Ma et. al, (JCM, 2008) , to identify and discriminate between the five known PVL phages.", [["PVL-MRSA", "CANCER", 54, 62], ["MRSA", "SPECIES", 58, 62], ["MRSA", "PROBLEM", 58, 62], ["PVL", "OBSERVATION", 54, 57], ["MRSA", "OBSERVATION", 58, 62], ["PVL", "OBSERVATION", 175, 178]]], ["To maximise any underlying diversity, representatives of each CC were selected based upon their spa, staphylococcal cassette chromosome mec (SCCmec), toxin gene and Pulsed-field Gel Electrophoresis (PFGE) profiles.", [["CC", "CHEMICAL", 62, 64], ["CC", "CANCER", 62, 64], ["staphylococcal cassette chromosome mec", "GENE_OR_GENE_PRODUCT", 101, 139], ["SCCmec", "GENE_OR_GENE_PRODUCT", 141, 147], ["spa", "DNA", 96, 99], ["staphylococcal cassette chromosome mec", "DNA", 101, 139], ["SCCmec", "DNA", 141, 147], ["toxin gene", "DNA", 150, 160], ["staphylococcal cassette chromosome mec (SCCmec", "TREATMENT", 101, 147], ["toxin gene", "TEST", 150, 160], ["Pulsed-field Gel Electrophoresis", "TEST", 165, 197], ["diversity", "OBSERVATION", 27, 36]]], ["These included isolates of internationally disseminated PVL-MRSA lineages CCs 8, 30 and 80 which resemble the USA300, South West Pacific (SWP) and European clones, respectively.", [["MRSA", "SPECIES", 60, 64], ["internationally disseminated PVL", "PROBLEM", 27, 59], ["MRSA lineages CCs", "TEST", 60, 77], ["European clones", "TREATMENT", 147, 162], ["disseminated", "OBSERVATION_MODIFIER", 43, 55], ["PVL", "OBSERVATION", 56, 59]]], ["In addition we analysed PVL-MRSA from CCs 1, 5, 22, 59, 88 and ST93.", [["PVL-MRSA", "GENE_OR_GENE_PRODUCT", 24, 32], ["ST93", "GENE_OR_GENE_PRODUCT", 63, 67], ["MRSA", "SPECIES", 28, 32], ["PVL", "TEST", 24, 27], ["MRSA", "PROBLEM", 28, 32], ["CCs", "TEST", 38, 41], ["PVL", "OBSERVATION", 24, 27], ["MRSA", "OBSERVATION", 28, 32]]], ["Results: All seven CC80 isolates, which included representatives of the European clone, possessed an elongated-head-type phage and were positive by the PCR specific for the phiSa2MW phage.", [["clone", "CELL", 81, 86], ["elongated-head-type phage", "DNA", 101, 126], ["phiSa2MW phage", "PROTEIN", 173, 187], ["the European clone", "PROBLEM", 68, 86], ["an elongated-head-type phage", "PROBLEM", 98, 126], ["the PCR", "TEST", 148, 155], ["the phiSa2MW phage", "TREATMENT", 169, 187], ["elongated", "OBSERVATION_MODIFIER", 101, 110], ["head", "ANATOMY", 111, 115], ["type phage", "OBSERVATION_MODIFIER", 116, 126]]], ["One of the CC30 isolates possessed a phi108PVL phage, four SWP representatives had elongated head type phages, whilst the remaining four CC30 isolates harboured an icosahedral-head-type phage.", [["head type phages", "ANATOMY", 93, 109], ["CC30", "ORGANISM", 11, 15], ["phi108", "GENE_OR_GENE_PRODUCT", 37, 43], ["head type phages", "CELL", 93, 109], ["phi108PVL phage", "DNA", 37, 52], ["a phi108PVL phage", "TREATMENT", 35, 52], ["elongated head type phages", "PROBLEM", 83, 109], ["head", "ANATOMY", 176, 180]]], ["One CC30 was positive for both head shapes.", [["head", "ANATOMY", 31, 35], ["CC30", "GENE_OR_GENE_PRODUCT", 4, 8], ["head", "ORGANISM_SUBDIVISION", 31, 35], ["CC30", "DNA", 4, 8], ["positive", "OBSERVATION", 13, 21]]], ["The 12 CC8 (including representatives of USA300), eight CC1, six CC88 isolates and the ST93 isolate were all positive for elongated-head-type phage.", [["the ST93 isolate", "TEST", 83, 99], ["head", "ANATOMY", 132, 136], ["type phage", "OBSERVATION_MODIFIER", 137, 147]]], ["Nine CC5 isolates were non-typeable for phage head shape and specific phage PCRs.", [["head", "ANATOMY", 46, 50], ["head", "ORGANISM_SUBDIVISION", 46, 50], ["Nine CC5 isolates", "TEST", 0, 17], ["phage head shape", "TEST", 40, 56], ["specific phage PCRs", "TEST", 61, 80]]], ["Three of four CC59 isolates, harboured a phiSa2958-like phage of an unknown head type and the other CC59 isolate was non-typeable.", [["head type", "ANATOMY", 76, 85], ["phiSa2958", "GENE_OR_GENE_PRODUCT", 41, 50], ["head type", "CANCER", 76, 85], ["phiSa2958", "PROTEIN", 41, 50], ["four CC59 isolates", "TEST", 9, 27], ["a phiSa2958", "TEST", 39, 50], ["non-typeable", "PROBLEM", 117, 129], ["head type", "OBSERVATION_MODIFIER", 76, 85], ["non-typeable", "OBSERVATION", 117, 129]]], ["All 14 CC22 isolates possessed an icosahedral-head-type phage, 13 were positive for the phiPVL phage type and one possessed phi108PVL type.Conclusion:We have determined the PVL phages present in a diverse panel of distinct PVL-MRSA clones and found considerable inter-lineage variation in the PVL prophage present.", [["PVL-MRSA clones", "CELL", 223, 238], ["PVL-MRSA clones", "CELL_LINE", 223, 238], ["PVL prophage", "DNA", 293, 305], ["MRSA", "SPECIES", 227, 231], ["All 14 CC22 isolates", "TEST", 0, 20], ["an icosahedral-head-type phage", "TEST", 31, 61], ["the phiPVL phage type", "PROBLEM", 84, 105], ["the PVL phages", "PROBLEM", 169, 183], ["distinct PVL", "PROBLEM", 214, 226], ["MRSA clones", "PROBLEM", 227, 238], ["considerable inter-lineage variation in the PVL prophage", "PROBLEM", 249, 305], ["head", "ANATOMY", 46, 50], ["distinct", "OBSERVATION_MODIFIER", 214, 222], ["PVL", "OBSERVATION", 223, 226], ["MRSA clones", "OBSERVATION", 227, 238], ["considerable", "OBSERVATION_MODIFIER", 249, 261], ["inter-lineage variation", "OBSERVATION", 262, 285], ["PVL prophage", "OBSERVATION", 293, 305]]], ["There was also evidence of intra lineage variation in some major CCs such as CCs 22, 30 and 59.", [["CCs", "ANATOMY", 65, 68], ["CCs", "CANCER", 65, 68], ["intra lineage variation", "PROBLEM", 27, 50], ["CCs", "TEST", 77, 80], ["evidence of", "UNCERTAINTY", 15, 26], ["intra lineage variation", "OBSERVATION", 27, 50]]], ["Together with variation in MLST CC and SCCmec, these data suggest PVL-MRSA have evolved on multiple occasions, sometimes within the same lineage.Conclusion:O44 Transcriptional profiling of Klebsiella pneumoniae genes controlled by the transcription factor, ramAT.", [["PVL-MRSA", "GENE_OR_GENE_PRODUCT", 66, 74], ["O44", "GENE_OR_GENE_PRODUCT", 156, 159], ["Klebsiella pneumoniae", "ORGANISM", 189, 210], ["ramAT", "GENE_OR_GENE_PRODUCT", 257, 262], ["SCCmec", "DNA", 39, 45], ["transcription factor", "PROTEIN", 235, 255], ["ramAT", "PROTEIN", 257, 262], ["MRSA", "SPECIES", 70, 74], ["Klebsiella pneumoniae", "SPECIES", 189, 210], ["Klebsiella pneumoniae", "SPECIES", 189, 210], ["MLST CC", "TEST", 27, 34], ["SCCmec", "PROBLEM", 39, 45], ["these data", "TEST", 47, 57], ["PVL", "PROBLEM", 66, 69], ["MRSA", "PROBLEM", 70, 74], ["Klebsiella pneumoniae genes", "PROBLEM", 189, 216], ["variation", "OBSERVATION_MODIFIER", 14, 23], ["PVL", "OBSERVATION", 66, 69], ["MRSA", "OBSERVATION", 70, 74], ["Klebsiella pneumoniae", "OBSERVATION", 189, 210]]], ["Schneiders\u00b0, A. Ivens (Edinburgh, UK)Objectives: RamA is an AraC/XylS family transcriptional activator where over expression is associated with a multidrug resistance phenotype.", [["AraC", "CHEMICAL", 60, 64], ["RamA", "GENE_OR_GENE_PRODUCT", 49, 53], ["AraC", "GENE_OR_GENE_PRODUCT", 60, 64], ["XylS", "GENE_OR_GENE_PRODUCT", 65, 69], ["AraC/XylS family transcriptional activator", "PROTEIN", 60, 102], ["an AraC/XylS family transcriptional activator", "TREATMENT", 57, 102], ["a multidrug resistance phenotype", "PROBLEM", 144, 176], ["multidrug resistance", "OBSERVATION", 146, 166]]], ["In both multidrug resistant Klebsiella and Salmonella isolates, the ramA gene has been associated with increase in expression of the acrAB efflux pump.", [["Klebsiella", "CANCER", 28, 38], ["Salmonella isolates", "ORGANISM", 43, 62], ["ramA", "GENE_OR_GENE_PRODUCT", 68, 72], ["acrAB efflux pump", "GENE_OR_GENE_PRODUCT", 133, 150], ["ramA gene", "DNA", 68, 77], ["acrAB", "PROTEIN", 133, 138], ["Salmonella", "SPECIES", 43, 53], ["both multidrug resistant Klebsiella", "PROBLEM", 3, 38], ["Salmonella isolates", "PROBLEM", 43, 62], ["the acrAB efflux pump", "TREATMENT", 129, 150], ["multidrug resistant Klebsiella", "OBSERVATION", 8, 38], ["Salmonella isolates", "OBSERVATION", 43, 62], ["increase", "OBSERVATION_MODIFIER", 103, 111], ["efflux pump", "OBSERVATION", 139, 150]]], ["In Salmonella it has been shown that a deletion of the ramA locus prevents the emergence of multidrug resistant mutants.", [["ramA", "GENE_OR_GENE_PRODUCT", 55, 59], ["ramA locus", "DNA", 55, 65], ["a deletion of the ramA locus", "PROBLEM", 37, 65], ["multidrug resistant mutants", "PROBLEM", 92, 119], ["multidrug resistant mutants", "OBSERVATION", 92, 119]]], ["Therefore in order to understand the role of this key regulator in the emergence and development of antibiotic resistance, transcriptomic analyses of its regulon were undertaken in K. pneumoniae.", [["K. pneumoniae", "ORGANISM", 181, 194], ["K. pneumoniae", "SPECIES", 181, 194], ["K. pneumoniae", "SPECIES", 181, 194], ["antibiotic resistance", "TREATMENT", 100, 121], ["transcriptomic analyses", "TEST", 123, 146], ["pneumoniae", "PROBLEM", 184, 194], ["pneumoniae", "OBSERVATION", 184, 194]]], ["Methods: RNA was extracted from a combination of isogenic mutants and clinical isolates using the Qiagen or RiboPure Kits.", [["isogenic mutants", "PROBLEM", 49, 65], ["the Qiagen or RiboPure Kits", "TREATMENT", 94, 121]]], ["RNA integrity was assessed using nanodrop and Agilent Nanochip systems.", [["RNA integrity", "TEST", 0, 13], ["nanodrop and Agilent Nanochip systems", "TREATMENT", 33, 70]]], ["The RNA was transcribed into double stranded cDNA prior to labelling with Cy3.", [["Cy3", "SIMPLE_CHEMICAL", 74, 77], ["double stranded cDNA", "DNA", 29, 49], ["double stranded cDNA", "TREATMENT", 29, 49]]], ["The cDNA was hybridised to the Nimblegen expression array platform designed from the K. pneumoniae MGH 78578 genome.T. Schneiders\u00b0, A. Ivens (Edinburgh, UK)Results: Approximately 50 genes were found to be affected by ramA expression, of which twenty (involved in metabolism, physiology, transcription, drug efflux, protection responses and the cell envelope) were confirmed by RT-PCR.", [["cell", "ANATOMY", 344, 348], ["K. pneumoniae", "ORGANISM", 85, 98], ["ramA", "GENE_OR_GENE_PRODUCT", 217, 221], ["cell", "CELL", 344, 348], ["cDNA", "DNA", 4, 8], ["Nimblegen expression array platform", "DNA", 31, 66], ["K. pneumoniae MGH 78578 genome", "DNA", 85, 115], ["ramA", "PROTEIN", 217, 221], ["K. pneumoniae", "SPECIES", 85, 98], ["K. pneumoniae MGH 78578", "SPECIES", 85, 108], ["The cDNA", "PROBLEM", 0, 8], ["drug efflux", "TREATMENT", 302, 313], ["the cell envelope", "TEST", 340, 357]]], ["The RamA protein appears to affect drug efflux operons not previously shown to be associated with multidrug resistance and or affected by similar proteins such as MarA.", [["RamA", "GENE_OR_GENE_PRODUCT", 4, 8], ["MarA", "GENE_OR_GENE_PRODUCT", 163, 167], ["RamA protein", "PROTEIN", 4, 16], ["drug efflux operons", "DNA", 35, 54], ["MarA", "PROTEIN", 163, 167], ["drug efflux operons", "PROBLEM", 35, 54], ["multidrug resistance", "PROBLEM", 98, 118], ["multidrug resistance", "OBSERVATION", 98, 118]]], ["Comparative transcriptome analyses of different K. pneumoniae clinical isolates overexpressing ramA showed that variations exist in the levels of expression of the drug efflux genes.", [["K. pneumoniae", "ORGANISM", 48, 61], ["ramA", "ORGANISM", 95, 99], ["drug efflux genes", "DNA", 164, 181], ["K. pneumoniae", "SPECIES", 48, 61], ["K. pneumoniae", "SPECIES", 48, 61], ["the drug efflux genes", "PROBLEM", 160, 181], ["drug efflux genes", "OBSERVATION", 164, 181]]], ["Of note genes shown to be directly regulated by RamA have a marbox-like sequence within the promoter sequences.", [["RamA", "GENE_OR_GENE_PRODUCT", 48, 52], ["RamA", "PROTEIN", 48, 52], ["marbox-like sequence", "DNA", 60, 80], ["promoter sequences", "DNA", 92, 110]]], ["Conclusion: In this study, the transcriptome of the regulatory protein, RamA, was determined in the pathogen K. pneumoniae.", [["RamA", "GENE_OR_GENE_PRODUCT", 72, 76], ["K. pneumoniae", "ORGANISM", 109, 122], ["regulatory protein", "PROTEIN", 52, 70], ["RamA", "PROTEIN", 72, 76], ["K. pneumoniae", "SPECIES", 109, 122], ["K. pneumoniae", "SPECIES", 109, 122], ["this study", "TEST", 15, 25], ["pneumoniae", "PROBLEM", 112, 122], ["pneumoniae", "OBSERVATION", 112, 122]]], ["Drug efflux proteins not previously associated with ramA overexpression were found to be directly affected.", [["ramA", "GENE_OR_GENE_PRODUCT", 52, 56], ["Drug efflux proteins", "PROTEIN", 0, 20], ["ramA", "PROTEIN", 52, 56], ["Drug efflux proteins", "PROBLEM", 0, 20], ["ramA overexpression", "PROBLEM", 52, 71]]], ["The RamA regulon overlaps with the MarA and SoxS regulons in E. coli and Salmonella but is directly associated with regulating the expression of a subset of genes via a marbox sequence.", [["RamA", "GENE_OR_GENE_PRODUCT", 4, 8], ["MarA", "GENE_OR_GENE_PRODUCT", 35, 39], ["SoxS", "GENE_OR_GENE_PRODUCT", 44, 48], ["E. coli", "ORGANISM", 61, 68], ["RamA regulon", "DNA", 4, 16], ["MarA and SoxS regulons", "DNA", 35, 57], ["marbox sequence", "DNA", 169, 184], ["E. coli", "SPECIES", 61, 68], ["E. coli", "SPECIES", 61, 68], ["the MarA", "TREATMENT", 31, 39], ["E. coli", "PROBLEM", 61, 68], ["Salmonella", "PROBLEM", 73, 83], ["a marbox sequence", "TEST", 167, 184], ["E. coli", "OBSERVATION", 61, 68], ["Salmonella", "OBSERVATION", 73, 83]]], ["Interestingly, variations in the levels of the expression of the regulon genes were found in the different ramA overexpressing strains.O45 Rapid detection and identification of tick-borne pathogens directly from clinical samples using PCR and electrospray ionisation mass spectrometryM.", [["samples", "ANATOMY", 221, 228], ["ramA", "GENE_OR_GENE_PRODUCT", 107, 111], ["regulon genes", "DNA", 65, 78], ["ramA", "PROTEIN", 107, 111], ["Rapid detection", "TEST", 139, 154], ["tick-borne pathogens", "PROBLEM", 177, 197], ["clinical samples", "TEST", 212, 228], ["PCR", "TEST", 235, 238], ["electrospray ionisation mass spectrometryM.", "TREATMENT", 243, 286], ["regulon genes", "OBSERVATION", 65, 78]]], ["Eshoo\u00b0, C. Crowder, H. Li, H. Matthews, S. Meng, S. Sefers, R. Sampath, C. Stratton, D. Ecker, Y.W. Tang (Carlsbad, Nashville, US) Objectives: The potential for fatal outcome from tick-borne human infections such as ehrlichiosis emphasizes the need for rapid diagnosis.", [["infections", "DISEASE", 197, 207], ["ehrlichiosis", "DISEASE", 216, 228], ["human", "ORGANISM", 191, 196], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 191, 196], ["fatal outcome", "PROBLEM", 161, 174], ["tick-borne human infections", "PROBLEM", 180, 207], ["ehrlichiosis", "PROBLEM", 216, 228]]], ["We developed and validated an Ibis T5000 assay (Ibis Biosciences, Inc., Carlsbad, CA) that can detect and identify a wide range of tick-borne pathogens from clinical samples.", [["samples", "ANATOMY", 166, 173], ["samples", "CANCER", 166, 173], ["an Ibis", "TEST", 27, 34], ["tick-borne pathogens", "PROBLEM", 131, 151], ["clinical samples", "TEST", 157, 173]]], ["Methods: A multi-locus assay was used that employs 16 broadrange PCR primer pairs targeting all known bacterial tick-borne pathogen families.", [["broadrange PCR primer pairs", "DNA", 54, 81], ["A multi-locus assay", "TEST", 9, 28], ["PCR primer pairs", "TEST", 65, 81], ["bacterial tick", "OBSERVATION", 102, 116]]], ["Electrospray ionisation mass spectrometry of the PCR amplicons was used to determine their base composition.", [["PCR amplicons", "DNA", 49, 62], ["Electrospray ionisation mass spectrometry", "TEST", 0, 41], ["the PCR amplicons", "TREATMENT", 45, 62]]], ["These base composition signatures were subsequently used to identify the organisms found in the samples.", [["samples", "ANATOMY", 96, 103], ["These base composition signatures", "TEST", 0, 33]]], ["The assay was developed using field collected ticks and a wide range of clinical sample types and has been shown to be sensitive to the stochastic limits of PCR.", [["sample", "ANATOMY", 81, 87], ["The assay", "TEST", 0, 9], ["field collected ticks", "TREATMENT", 30, 51], ["PCR", "TEST", 157, 160]]], ["Results: Whole blood (198) , cerebrospinal fluid (20) and plasma (1) samples, which were originally submitted for Ehrlichia species detection by a colorimetric microtiter plate PCR (PCR-EIA), were collected consecutively from January 5 to August 1, 2008 at Vanderbilt University Hospital.", [["Whole blood", "ANATOMY", 9, 20], ["cerebrospinal fluid", "ANATOMY", 29, 48], ["plasma", "ANATOMY", 58, 64], ["samples", "ANATOMY", 69, 76], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 29, 48], ["plasma", "ORGANISM_SUBSTANCE", 58, 64], ["Ehrlichia", "ORGANISM", 114, 123], ["Whole blood", "TEST", 9, 20], ["cerebrospinal fluid", "TEST", 29, 48], ["plasma (1) samples", "TEST", 58, 76], ["Ehrlichia species detection", "TEST", 114, 141], ["a colorimetric microtiter plate PCR", "TEST", 145, 180], ["PCR", "TEST", 182, 185], ["EIA", "TEST", 186, 189], ["cerebrospinal", "ANATOMY", 29, 42], ["fluid", "OBSERVATION", 43, 48]]], ["Among the total 219 specimens, PCR-EIA detected 40 Ehrlichia species with a positive rate of 18.3%.", [["specimens", "ANATOMY", 20, 29], ["Ehrlichia", "ORGANISM", 51, 60], ["the total 219 specimens", "TEST", 6, 29], ["PCR", "TEST", 31, 34], ["EIA", "TEST", 35, 38], ["Ehrlichia species", "TEST", 51, 68], ["a positive rate", "TEST", 74, 89]]], ["The Ibis system detected Ehrlichia in 38 of the 40 PCR-EIA-positive samples and 1 in 179 of the PCR-EIA-negative specimens, giving sensitivity and specificity of 95.0% and 99.4%, respectively.", [["samples", "ANATOMY", 68, 75], ["specimens", "ANATOMY", 113, 122], ["Ehrlichia", "ORGANISM", 25, 34], ["The Ibis system", "TEST", 0, 15], ["Ehrlichia", "TEST", 25, 34], ["the 40 PCR", "TEST", 44, 54], ["EIA", "TEST", 55, 58], ["the PCR", "TEST", 92, 99], ["EIA", "TEST", 100, 103], ["sensitivity", "TEST", 131, 142], ["specificity", "TEST", 147, 158]]], ["The Ibis system further characterised the 38 Ehrlichia-dual positive specimens to the species level (E. cheffeensis, 35; E. ewingii, 3) with a 100% agreement to that identified by PCR-EIA using additional species-specific probes.", [["specimens", "ANATOMY", 69, 78], ["Ehrlichia", "ORGANISM", 45, 54], ["E. cheffeensis", "ORGANISM", 101, 115], ["E. ewingii", "ORGANISM", 121, 131], ["E. cheffeensis", "SPECIES", 101, 115], ["E. ewingii", "SPECIES", 121, 131], ["E. cheffeensis", "SPECIES", 101, 115], ["E. ewingii", "SPECIES", 121, 131], ["Ehrlichia", "TEST", 45, 54], ["the species level", "TEST", 82, 99], ["E. cheffeensis", "TEST", 101, 115], ["PCR", "TEST", 180, 183], ["EIA", "TEST", 184, 187]]], ["In addition we demonstrated the detection of Borrelia burgdorferi from the blood and skin of a patient with Lyme disease.", [["blood", "ANATOMY", 75, 80], ["skin", "ANATOMY", 85, 89], ["Borrelia burgdorferi", "DISEASE", 45, 65], ["Lyme disease", "DISEASE", 108, 120], ["Borrelia burgdorferi", "ORGANISM", 45, 65], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["skin", "ORGAN", 85, 89], ["patient", "ORGANISM", 95, 102], ["Borrelia burgdorferi", "SPECIES", 45, 65], ["patient", "SPECIES", 95, 102], ["Borrelia burgdorferi", "SPECIES", 45, 65], ["Borrelia burgdorferi", "PROBLEM", 45, 65], ["the blood", "TEST", 71, 80], ["Lyme disease", "PROBLEM", 108, 120], ["blood", "ANATOMY", 75, 80], ["skin", "ANATOMY", 85, 89], ["Lyme disease", "OBSERVATION", 108, 120]]], ["Conclusions: We demonstrate broad-range detection of tick-borne pathogens in a single assay using skin, whole blood, plasma, skin and CSF.", [["skin", "ANATOMY", 98, 102], ["whole blood", "ANATOMY", 104, 115], ["plasma", "ANATOMY", 117, 123], ["skin", "ANATOMY", 125, 129], ["skin", "ORGAN", 98, 102], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["plasma", "ORGANISM_SUBSTANCE", 117, 123], ["skin", "ORGAN", 125, 129], ["CSF", "ORGANISM_SUBSTANCE", 134, 137], ["tick-borne pathogens", "PROBLEM", 53, 73], ["whole blood, plasma, skin and CSF", "TEST", 104, 137], ["skin", "ANATOMY", 98, 102], ["skin", "ANATOMY", 125, 129], ["CSF", "ANATOMY", 134, 137]]], ["In addition to Ehrlichia, the Ibis system detected 4 Rickettsia rickettsii positive specimens, which were confirmed by serology and clinical findings.", [["specimens", "ANATOMY", 84, 93], ["Ehrlichia", "ORGANISM", 15, 24], ["Rickettsia rickettsii", "SPECIES", 53, 74], ["Rickettsia rickettsii", "SPECIES", 53, 74], ["Ehrlichia", "PROBLEM", 15, 24], ["the Ibis system", "TEST", 26, 41], ["4 Rickettsia rickettsii positive specimens", "PROBLEM", 51, 93], ["serology", "TEST", 119, 127], ["Ehrlichia", "OBSERVATION", 15, 24]]], ["The Ibis T5000 system, which can be completed within five hours from specimen processing to result reporting, provides rapid and accurate detection and identification of a broad range of pathogens causing tick-borne human infections.Molecular biology O46 Rapid detection and characterisation of pathogens causing healthcare-associated infections using PCR/ESI-MSR.", [["tick-borne human infections", "DISEASE", 205, 232], ["infections", "DISEASE", 335, 345], ["human", "ORGANISM", 216, 221], ["human", "SPECIES", 216, 221], ["human", "SPECIES", 216, 221], ["a broad range of pathogens", "PROBLEM", 170, 196], ["tick-borne human infections", "PROBLEM", 205, 232], ["Rapid detection", "TEST", 255, 270], ["pathogens", "PROBLEM", 295, 304], ["healthcare-associated infections", "PROBLEM", 313, 345], ["PCR", "TEST", 352, 355], ["borne human", "OBSERVATION_MODIFIER", 210, 221], ["infections", "OBSERVATION", 222, 232]]], ["Sampath\u00b0, L. Blyn, R. Ranken, C. Massire, T. Hall, M. Eshoo, R. Lovari, H. Matthews, D. Toleno, R. Housley, S. Hofstadler, D. Ecker (Carlsbad, US) Objective: To investigate the use of a novel platform-based approach for rapid characterisation of HAI organisms.", [["a novel platform-based approach", "TREATMENT", 184, 215], ["HAI organisms", "PROBLEM", 246, 259], ["L. Blyn", "ANATOMY", 10, 17], ["R.", "ANATOMY", 19, 21]]], ["Pathogens that cause healthcare-associated infections (HAIs) pose an ongoing and increasing challenge to hospitals, both in the clinical treatment and in the prevention of the cross-transmission of these problematic pathogens.", [["healthcare-associated infections", "DISEASE", 21, 53], ["HAIs", "DISEASE", 55, 59], ["healthcare-associated infections", "PROBLEM", 21, 53], ["the clinical treatment", "TREATMENT", 124, 146], ["these problematic pathogens", "PROBLEM", 198, 225], ["infections", "OBSERVATION", 43, 53]]], ["Here we describe the utility of a PCR Electrospray Ionization Mass Spectrometry (PCR/ESI-MS) detection platform as an innovative, rapid approach for detection and complete characterisation of important HAI pathogens.", [["a PCR Electrospray", "TREATMENT", 32, 50], ["Ionization Mass Spectrometry", "TEST", 51, 79], ["PCR", "TEST", 81, 84], ["important HAI pathogens", "PROBLEM", 192, 215]]], ["Methods: We have developed PCR/ESI-MS based methods to rapidly identify and characterise MRSA, VRE, C. difficile (NAP-1 strain), P. aeruginosa and A. baumannii.", [["C. difficile", "DISEASE", 100, 112], ["C. difficile", "ORGANISM", 100, 112], ["NAP-1 strain", "ORGANISM", 114, 126], ["P. aeruginosa", "ORGANISM", 129, 142], ["A. baumannii", "ORGANISM", 147, 159], ["MRSA", "SPECIES", 89, 93], ["C. difficile", "SPECIES", 100, 112], ["P. aeruginosa", "SPECIES", 129, 142], ["A. baumannii", "SPECIES", 147, 159], ["MRSA", "SPECIES", 89, 93], ["C. difficile", "SPECIES", 100, 112], ["NAP-1", "SPECIES", 114, 119], ["P. aeruginosa", "SPECIES", 129, 142], ["A. baumannii", "SPECIES", 147, 159], ["PCR", "TEST", 27, 30], ["ESI", "TEST", 31, 34], ["MRSA", "PROBLEM", 89, 93], ["VRE", "PROBLEM", 95, 98], ["C. difficile", "PROBLEM", 100, 112], ["NAP", "TEST", 114, 117], ["P. aeruginosa", "PROBLEM", 129, 142], ["A. baumannii", "PROBLEM", 147, 159], ["MRSA", "OBSERVATION", 89, 93], ["baumannii", "OBSERVATION", 150, 159]]], ["Each target organism can be analyzed using an independent 8-well assay that can be run on the same platform and can provide species and strain ID, virulence factors, antibiotic resistance and genotyping as appropriate.", [["virulence factors", "PROTEIN", 147, 164], ["Each target organism", "PROBLEM", 0, 20], ["virulence factors", "PROBLEM", 147, 164], ["antibiotic resistance", "TREATMENT", 166, 187]]], ["Validation studies were performed using 100-300 retrospective, well-characterised clinical isolates for each organism.", [["Validation studies", "TEST", 0, 18], ["each organism", "PROBLEM", 104, 117]]], ["This was followed by a prospective study for one of the 5 organisms, MRSA, that included screening of 557 clinical specimens (nares swab) from patients who were admitted to a medical unit with a high prevalence of MRSA clinical infections.", [["specimens", "ANATOMY", 115, 124], ["nares swab", "ANATOMY", 126, 136], ["MRSA", "DISEASE", 214, 218], ["infections", "DISEASE", 228, 238], ["nares swab", "ORGANISM_SUBDIVISION", 126, 136], ["patients", "ORGANISM", 143, 151], ["MRSA", "SPECIES", 69, 73], ["patients", "SPECIES", 143, 151], ["MRSA", "SPECIES", 214, 218], ["MRSA", "SPECIES", 214, 218], ["a prospective study", "TEST", 21, 40], ["the 5 organisms", "PROBLEM", 52, 67], ["MRSA", "PROBLEM", 69, 73], ["screening", "TEST", 89, 98], ["clinical specimens", "TEST", 106, 124], ["nares swab", "TEST", 126, 136], ["MRSA clinical infections", "PROBLEM", 214, 238], ["MRSA", "OBSERVATION", 214, 218], ["infections", "OBSERVATION", 228, 238]]], ["Results: For each of the five HAI organisms, PCR/ESI-MS species identifications were compared to Gold Standard testing results from the clinical microbiology laboratory and showed 100% concordance.", [["the five HAI organisms", "TEST", 21, 43], ["PCR", "TEST", 45, 48], ["ESI", "TEST", 49, 52], ["MS species identifications", "PROBLEM", 53, 79]]], ["For S. aureus, P. aeruginosa and A. baumannii, molecular genotyping by PCR/ESI-MS was compared to pulse field gel electrophoresis (PFGE) clusters and showed >95% concordance.", [["S. aureus", "ORGANISM", 4, 13], ["P. aeruginosa", "ORGANISM", 15, 28], ["A. baumannii", "ORGANISM", 33, 45], ["S. aureus", "SPECIES", 4, 13], ["P. aeruginosa", "SPECIES", 15, 28], ["A. baumannii", "SPECIES", 33, 45], ["S. aureus", "SPECIES", 4, 13], ["P. aeruginosa", "SPECIES", 15, 28], ["A. baumannii", "SPECIES", 33, 45], ["S. aureus", "PROBLEM", 4, 13], ["P. aeruginosa", "PROBLEM", 15, 28], ["A. baumannii", "PROBLEM", 33, 45], ["molecular genotyping", "TEST", 47, 67], ["PCR", "TEST", 71, 74], ["MS", "PROBLEM", 79, 81], ["pulse field gel electrophoresis", "TEST", 98, 129], ["aureus", "OBSERVATION", 7, 13]]], ["Characterisation of virulence and/or drug resistance was performed for MRSA, VRE and C. difficile and showed 90\u221295% correct detection compared to existing testing methods.", [["VRE and C. difficile", "DISEASE", 77, 97], ["C. difficile", "ORGANISM", 85, 97], ["MRSA", "SPECIES", 71, 75], ["C. difficile", "SPECIES", 85, 97], ["MRSA", "SPECIES", 71, 75], ["C. difficile", "SPECIES", 85, 97], ["virulence", "PROBLEM", 20, 29], ["drug resistance", "PROBLEM", 37, 52], ["MRSA", "PROBLEM", 71, 75], ["VRE", "PROBLEM", 77, 80], ["C. difficile", "PROBLEM", 85, 97], ["existing testing methods", "TEST", 146, 170], ["virulence", "OBSERVATION", 20, 29]]], ["Analysis of clinical specimens for MRSA showed that of the 557 swabs, 95 (15%) contained MRSA, either singly or as a dual infection with CoNS, 33 (5%) were MSSA and 358 (58%) contained mecA+ coagulase negative Staphylococcus (MR-CoNS).", [["specimens", "ANATOMY", 21, 30], ["swabs", "ANATOMY", 63, 68], ["MRSA", "DISEASE", 89, 93], ["infection", "DISEASE", 122, 131], ["CoNS", "DISEASE", 137, 141], ["MSSA", "CHEMICAL", 156, 160], ["MRSA", "CANCER", 35, 39], ["MRSA", "CANCER", 89, 93], ["MSSA", "CANCER", 156, 160], ["mecA", "GENE_OR_GENE_PRODUCT", 185, 189], ["mecA", "DNA", 185, 189], ["MR", "PROTEIN", 226, 228], ["MRSA", "SPECIES", 35, 39], ["MRSA", "SPECIES", 89, 93], ["MRSA", "SPECIES", 35, 39], ["MRSA", "SPECIES", 89, 93], ["clinical specimens", "TEST", 12, 30], ["MRSA", "PROBLEM", 35, 39], ["swabs", "TEST", 63, 68], ["MRSA", "PROBLEM", 89, 93], ["a dual infection", "PROBLEM", 115, 131], ["CoNS", "TEST", 137, 141], ["MSSA", "TEST", 156, 160], ["mecA", "TEST", 185, 189], ["coagulase negative Staphylococcus", "PROBLEM", 191, 224], ["MR", "TEST", 226, 228], ["MRSA", "OBSERVATION", 89, 93]]], ["Comparison to gold standard analysis showed 100% sensitivity for MRSA detection with 96.8% specificity, 84% PPV and 100%NPV.Conclusion:The PCR/ESI-MS technology is a high throughput assay system useful for infection control and for epidemiological studies.", [["infection", "DISEASE", 206, 215], ["MRSA", "SPECIES", 65, 69], ["MRSA", "SPECIES", 65, 69], ["gold standard analysis", "TEST", 14, 36], ["MRSA detection", "TEST", 65, 79], ["specificity", "TEST", 91, 102], ["PPV", "TEST", 108, 111], ["NPV", "TEST", 120, 123], ["The PCR", "TEST", 135, 142], ["MS technology", "TEST", 147, 160], ["infection control", "TREATMENT", 206, 223], ["epidemiological studies", "TEST", 232, 255]]], ["It is capable of simultaneous identification of HAI organisms while detecting presence of key phenotypic markers and genotypic strain characterisation.O48 Multiplex real-time assay for the detection of 7 viruses causing infections of the central nervous systemM.", [["central nervous systemM", "ANATOMY", 238, 261], ["infections of the central nervous systemM", "DISEASE", 220, 261], ["central nervous systemM", "ANATOMICAL_SYSTEM", 238, 261], ["HAI organisms", "PROBLEM", 48, 61], ["key phenotypic markers", "PROBLEM", 90, 112], ["genotypic strain characterisation", "PROBLEM", 117, 150], ["the detection", "TEST", 185, 198], ["7 viruses", "PROBLEM", 202, 211], ["infections of the central nervous systemM", "PROBLEM", 220, 261], ["infections", "OBSERVATION", 220, 230], ["central", "ANATOMY_MODIFIER", 238, 245], ["nervous systemM", "ANATOMY", 246, 261]]], ["Reijans\u00b0, J. Ossel, J. Keijdener, G. Simons (Maastricht, NL) Objective: Molecular diagnostics play an increasingly important role in the detection of infectious agents in cerebrospinal fluids.", [["cerebrospinal fluids", "ANATOMY", 171, 191], ["cerebrospinal fluids", "ORGANISM_SUBSTANCE", 171, 191], ["infectious agents", "TREATMENT", 150, 167], ["cerebrospinal fluids", "TREATMENT", 171, 191], ["infectious", "OBSERVATION", 150, 160]]], ["However, the growing list of targets and the relatively small sample volumes are challenges that demand an improved molecular diagnostic approach.", [["the relatively small sample volumes", "PROBLEM", 41, 76], ["growing", "OBSERVATION_MODIFIER", 13, 20], ["relatively", "OBSERVATION_MODIFIER", 45, 55], ["small", "OBSERVATION_MODIFIER", 56, 61], ["improved", "OBSERVATION_MODIFIER", 107, 115]]], ["The MeningoFinder is a MultiFinder assay allowing the simultaneous detection of 7 viruses and 1 internal control in 1 reaction.", [["the simultaneous detection", "TEST", 50, 76], ["7 viruses", "PROBLEM", 80, 89]]], ["Until now, the analysis of MultiFinder assays was based on size-fractionation, identifying each MultiFinder probe due to its specific length.", [["MultiFinder probe", "DNA", 96, 113], ["the analysis", "TEST", 11, 23], ["MultiFinder assays", "TEST", 27, 45]]], ["Here we present an alternative approach allowing realtime detection of eight MeningoFinder probes in a single tube.", [["tube", "TISSUE", 110, 114], ["realtime detection", "TEST", 49, 67], ["eight MeningoFinder probes", "TREATMENT", 71, 97], ["a single tube", "TREATMENT", 101, 114], ["tube", "OBSERVATION", 110, 114]]], ["The realtime detection enables a faster analysis, less handling and lowers the risk of contamination.", [["a faster analysis", "TEST", 31, 48], ["contamination", "PROBLEM", 87, 100], ["contamination", "OBSERVATION", 87, 100]]], ["Method: The MeningoFinder assay is a MultiFinder assay which detects herpes simplex virus 1 and 2 (HSV1\u22122), human parechovirus (HPeV), cytomegalovirus (CMV), Epstein-Barr Virus (EBV), enterovirus (EV) and varicella-zoster Virus (VZV) plus an internal control in a single reaction.", [["herpes simplex virus", "DISEASE", 69, 89], ["Epstein-Barr Virus (EBV), enterovirus (EV) and varicella-zoster Virus", "DISEASE", 158, 227], ["herpes simplex virus 1", "ORGANISM", 69, 91], ["2", "GENE_OR_GENE_PRODUCT", 96, 97], ["HSV1\u22122", "ORGANISM", 99, 105], ["human", "ORGANISM", 108, 113], ["parechovirus", "GENE_OR_GENE_PRODUCT", 114, 126], ["HPeV", "GENE_OR_GENE_PRODUCT", 128, 132], ["cytomegalovirus", "ORGANISM", 135, 150], ["CMV", "ORGANISM", 152, 155], ["Epstein-Barr Virus", "ORGANISM", 158, 176], ["EBV", "ORGANISM", 178, 181], ["enterovirus (EV)", "ORGANISM", 184, 200], ["varicella-zoster Virus", "ORGANISM", 205, 227], ["VZV", "ORGANISM", 229, 232], ["herpes simplex virus 1", "SPECIES", 69, 91], ["human", "SPECIES", 108, 113], ["Barr Virus", "SPECIES", 166, 176], ["varicella-zoster Virus", "SPECIES", 205, 227], ["herpes simplex virus 1", "SPECIES", 69, 91], ["HSV1", "SPECIES", 99, 103], ["human", "SPECIES", 108, 113], ["HPeV", "SPECIES", 128, 132], ["CMV", "SPECIES", 152, 155], ["Epstein-Barr Virus", "SPECIES", 158, 176], ["EBV", "SPECIES", 178, 181], ["EV", "SPECIES", 197, 199], ["varicella-zoster Virus", "SPECIES", 205, 227], ["VZV", "SPECIES", 229, 232], ["The MeningoFinder assay", "TEST", 8, 31], ["a MultiFinder assay", "TEST", 35, 54], ["herpes simplex virus", "TEST", 69, 89], ["HSV1", "TEST", 99, 103], ["human parechovirus (HPeV", "TEST", 108, 132], ["cytomegalovirus", "PROBLEM", 135, 150], ["CMV", "TEST", 152, 155], ["Epstein-Barr Virus (EBV", "PROBLEM", 158, 181], ["enterovirus", "PROBLEM", 184, 195], ["varicella-zoster Virus", "PROBLEM", 205, 227], ["VZV", "PROBLEM", 229, 232], ["an internal control", "TREATMENT", 239, 258], ["a single reaction", "PROBLEM", 262, 279], ["Barr Virus", "OBSERVATION", 166, 176], ["zoster Virus", "OBSERVATION", 215, 227]]], ["Each MeningoFinder probe can be distinguished based upon the specific length of each probe by size-fractionation using gel or capillary electrophoresis.", [["capillary", "TISSUE", 126, 135], ["MeningoFinder probe", "DNA", 5, 24], ["Each MeningoFinder probe", "TREATMENT", 0, 24], ["gel or capillary electrophoresis", "TREATMENT", 119, 151]]], ["We developed an alternative detection method using fluorescently labelled probes which allow specific identification of 8 MultiFinder probes in a realtime PCR machine.", [["MultiFinder probes", "DNA", 122, 140], ["fluorescently labelled probes", "TREATMENT", 51, 80], ["a realtime PCR machine", "TREATMENT", 144, 166]]], ["Results: A large number of QCMD samples (N = 44), several enterovirus types (N = 27) and characterised clinical samples (N = 66) were analyzed using the MeningoFinder.", [["QCMD samples", "ANATOMY", 27, 39], ["samples", "ANATOMY", 112, 119], ["QCMD samples", "CANCER", 27, 39], ["QCMD samples", "TEST", 27, 39], ["several enterovirus types", "TEST", 50, 75], ["characterised clinical samples", "TEST", 89, 119], ["the MeningoFinder", "TREATMENT", 149, 166], ["large", "OBSERVATION_MODIFIER", 11, 16]]], ["All MeningoFinder reactions were analyzed by capillary electrophoresis and by fluorescently labelled probes in a realtime PCR machine.", [["capillary", "TISSUE", 45, 54], ["All MeningoFinder reactions", "TREATMENT", 0, 27], ["capillary electrophoresis", "TEST", 45, 70], ["a realtime PCR machine", "TREATMENT", 111, 133]]], ["The results of the MeningoFinder showed a very good correlation with the expected results (>95%).", [["the MeningoFinder", "TEST", 15, 32]]], ["Furthermore, the results of both MeningoFinder analyses showed a high degree of correlation.", [["both MeningoFinder analyses", "TEST", 28, 55], ["high degree", "OBSERVATION_MODIFIER", 65, 76]]], ["The realtime detection of the MeningoFinder probes decreases the analysis time and post PCR handling dramatically.Conclusions:We developed a new assay for the realtime detection of 8 MeningoFinder probes.", [["MeningoFinder probes", "DNA", 30, 50], ["the MeningoFinder probes", "TREATMENT", 26, 50], ["the analysis", "TEST", 61, 73], ["a new assay", "TEST", 139, 150], ["the realtime detection", "TEST", 155, 177], ["8 MeningoFinder probes", "TREATMENT", 181, 203]]], ["The realtime analysis showed a very good correlation with the conventional capillary electrophoresis analysis.", [["capillary", "TISSUE", 75, 84], ["The realtime analysis", "TEST", 0, 21], ["the conventional capillary electrophoresis analysis", "TEST", 58, 109]]], ["In addition, the realtime detection reduced contamination risk and patient results became available more quickly.", [["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74], ["the realtime detection reduced contamination risk", "PROBLEM", 13, 62]]], ["The combination of MultiFinder technology combined with realtime detection shows great potential in fast and easy multiparameter screening of clinical samples for infectious pathogens.", [["samples", "ANATOMY", 151, 158], ["realtime detection", "TEST", 56, 74], ["easy multiparameter screening", "TEST", 109, 138], ["clinical samples", "TEST", 142, 158], ["infectious pathogens", "PROBLEM", 163, 183]]], ["In-house NAATs were applied to nucleic acid extracts obtained by own in-house methodology in each centre.", [["extracts", "ANATOMY", 44, 52], ["nucleic acid", "CHEMICAL", 31, 43], ["NAATs", "SIMPLE_CHEMICAL", 9, 14], ["nucleic acid extracts", "TEST", 31, 52]]], ["Results: Sensitivities for the detection of the respiratory viruses were 40% for commercial MX NAAT, 86% for in-house MW NAAT, and 90% for mono in-house NAAT.", [["respiratory viruses", "DISEASE", 48, 67], ["MX", "CHEMICAL", 92, 94], ["Sensitivities", "TEST", 9, 22], ["the detection", "TEST", 27, 40], ["the respiratory viruses", "PROBLEM", 44, 67], ["commercial MX NAAT", "TEST", 81, 99], ["respiratory viruses", "OBSERVATION", 48, 67]]], ["The viral load was low each time false-negative results were obtained.", [["The viral load", "TEST", 0, 14], ["viral load", "OBSERVATION", 4, 14]]], ["False positive results were obtained by all methods used, resulting in specificities ranging from 88%-97%.", [["specificities", "TEST", 71, 84]]], ["For the atypical bacteria, the 2 multiplex NAATs failed to detect low L. pneumophila positive samples and low M. pneumoniae positive sample resulting in sensitivities of 25% and 75% compared to 100% in the inhouse mono NAATs.", [["samples", "ANATOMY", 94, 101], ["sample", "ANATOMY", 133, 139], ["L. pneumophila", "ORGANISM", 70, 84], ["M. pneumoniae", "ORGANISM", 110, 123], ["L. pneumophila", "SPECIES", 70, 84], ["M. pneumoniae", "SPECIES", 110, 123], ["L. pneumophila", "SPECIES", 70, 84], ["M. pneumoniae", "SPECIES", 110, 123], ["the atypical bacteria", "PROBLEM", 4, 25], ["the 2 multiplex NAATs", "TEST", 27, 48], ["low L. pneumophila positive samples", "PROBLEM", 66, 101], ["low M. pneumoniae positive sample", "PROBLEM", 106, 139], ["sensitivities", "TEST", 153, 166], ["atypical", "OBSERVATION_MODIFIER", 8, 16], ["bacteria", "OBSERVATION", 17, 25], ["pneumophila positive samples", "OBSERVATION", 73, 101]]], ["The commercial MX NAAT also failed to detect strong positive samples.", [["samples", "ANATOMY", 61, 68], ["MX", "CHEMICAL", 15, 17], ["The commercial MX NAAT", "TEST", 0, 22], ["strong positive samples", "PROBLEM", 45, 68]]], ["No false positive results were obtained for the atypical bacteria.Conclusions:Revisiting phage therapy against problematic pathogens S61 How the past feeds the future: from d'Herelle to modern phagotherapyT.", [["S61", "CHEMICAL", 133, 136], ["S61", "CHEMICAL", 133, 136], ["T.", "SPECIES", 205, 207], ["false positive results", "PROBLEM", 3, 25], ["the atypical bacteria", "PROBLEM", 44, 65], ["Revisiting phage therapy", "TREATMENT", 78, 102], ["problematic pathogens", "PROBLEM", 111, 132], ["false", "OBSERVATION_MODIFIER", 3, 8], ["positive", "OBSERVATION", 9, 17], ["atypical", "OBSERVATION_MODIFIER", 48, 56], ["bacteria", "OBSERVATION", 57, 65]]], ["H\u00e4usler\u00b0(Basel, CH)The increasing antibiotic resistance problem boosts the interest in alternative treatments for infections.", [["infections", "DISEASE", 114, 124], ["H\u00e4usler\u00b0(Basel, CH", "TREATMENT", 0, 18], ["The increasing antibiotic resistance problem", "TREATMENT", 19, 63], ["alternative treatments", "TREATMENT", 87, 109], ["infections", "PROBLEM", 114, 124], ["increasing", "OBSERVATION_MODIFIER", 23, 33], ["antibiotic resistance", "OBSERVATION", 34, 55]]], ["A prominent example for this is the so-called phagotherapy.", [["the so-called phagotherapy", "TREATMENT", 32, 58]]], ["It makes use of bacterial viruses \u2212 bacteriophages \u2212 as drugs against bacterial agents.T. H\u00e4usler\u00b0(Basel, CH)These bacteriophages are isolated from nature, characterised and then tested against the bacterial strains that are targeted.", [["bacterial viruses \u2212 bacteriophages", "TREATMENT", 16, 50], ["drugs", "TREATMENT", 56, 61], ["bacterial agents", "TREATMENT", 70, 86], ["These bacteriophages", "PROBLEM", 109, 129], ["the bacterial strains", "PROBLEM", 194, 215], ["bacterial viruses", "OBSERVATION", 16, 33], ["bacteriophages", "OBSERVATION", 115, 129], ["bacterial strains", "OBSERVATION", 198, 215]]], ["For instance, bacteriophages infect, as a rule, their bacterial prey very specifically.", [["bacteriophages infect", "PROBLEM", 14, 35], ["bacteriophages infect", "OBSERVATION", 14, 35]]], ["Therefore, they do not harm the commensal bacteria of the patient.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65]]], ["Additionally, if a bacterial strain becomes resistant against a certain bacteriophage strain, evolution will provide for new and active bacteriophage strains.", [["a bacterial strain", "PROBLEM", 17, 35], ["a certain bacteriophage strain", "PROBLEM", 62, 92], ["new and active bacteriophage strains", "PROBLEM", 121, 157], ["active", "OBSERVATION_MODIFIER", 129, 135], ["bacteriophage strains", "OBSERVATION", 136, 157]]], ["In practice, phagotherapy has been used for a long time.", [["phagotherapy", "TREATMENT", 13, 25]]], ["Already one of the two discoverers of bacteriophages, F\u00e9lix d'Herelle, was an ardent advocate of this method.", [["bacteriophages", "TREATMENT", 38, 52], ["this method", "TREATMENT", 97, 108], ["bacteriophages", "OBSERVATION", 38, 52]]], ["In fact, he was the first to use bacteriophages against infections \u2212 1919 against bacterial diarrhoea (Shigella spp.).", [["infections", "DISEASE", 56, 66], ["\u2212 1919", "CHEMICAL", 67, 73], ["bacterial diarrhoea", "DISEASE", 82, 101], ["Shigella spp.", "ORGANISM", 103, 116], ["Shigella spp.", "SPECIES", 103, 116], ["Shigella spp.", "SPECIES", 103, 116], ["bacteriophages", "TREATMENT", 33, 47], ["infections", "PROBLEM", 56, 66], ["bacterial diarrhoea (Shigella spp.", "PROBLEM", 82, 116]]], ["After that, phagotherapy has been used to quite some extent in Europe, the US and other parts of the world until penicillin entered the market in the 1940 s.", [["penicillin", "CHEMICAL", 113, 123], ["penicillin", "CHEMICAL", 113, 123], ["penicillin", "SIMPLE_CHEMICAL", 113, 123], ["phagotherapy", "TREATMENT", 12, 24], ["the US", "TEST", 71, 77], ["penicillin", "TREATMENT", 113, 123]]], ["In some parts of the former Soviet Union and the Eastern Bloc, the method has been utilised until today.", [["the Eastern Bloc", "TREATMENT", 45, 61], ["the method", "TREATMENT", 63, 73]]], ["Now, several companies and university researchers are developing bacteriophages for therapeutical purposes again.", [["therapeutical purposes", "TREATMENT", 84, 106]]], ["Historical documents related to phagotherapy and oral history reveal a fascinating past.", [["oral", "ANATOMY", 49, 53], ["oral", "ORGANISM_SUBDIVISION", 49, 53], ["phagotherapy", "TREATMENT", 32, 44]]], ["Bacteriophages have been employed against a wide variety of bacterial diseases in a time in which there were virtually no other anti-infectives.", [["bacterial diseases", "DISEASE", 60, 78], ["Bacteriophages", "TREATMENT", 0, 14], ["bacterial diseases", "PROBLEM", 60, 78], ["bacterial diseases", "OBSERVATION", 60, 78]]], ["For example, in India, millions of cholera patients were treated with bacteriophages in the 1930 s.", [["cholera", "DISEASE", 35, 42], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["bacteriophages", "TREATMENT", 70, 84], ["millions", "OBSERVATION_MODIFIER", 23, 31]]], ["Anti-cholera phages were also poured into drinking wells as prophylactics.", [["Anti-cholera phages", "TREATMENT", 0, 19], ["prophylactics", "TREATMENT", 60, 73]]], ["Bacterial viruses have also been utilised by the German and Soviet armies in the Second World War.T. H\u00e4usler\u00b0(Basel, CH)The history of phagotherapy makes for more than an exciting story, however.", [["Bacterial viruses", "PROBLEM", 0, 17], ["phagotherapy", "TREATMENT", 135, 147], ["viruses", "OBSERVATION", 10, 17]]], ["Analysis of the old literature helps identify important factors for success and failure.", [["failure", "PROBLEM", 80, 87], ["failure", "OBSERVATION", 80, 87]]], ["Additionally, examination of the strategy used for phagotherapy in the Soviet Union and Poland also contributes to a better application of this method today.M. Kutateladze\u00b0(Tbilisi, GE)The discovery of bacteriophages, particularly their ability to replicate and lyse pathogenic bacteria may have been among the most important milestones in the history of biomedical sciences.", [["examination", "TEST", 14, 25], ["phagotherapy", "TREATMENT", 51, 63], ["this method", "TREATMENT", 139, 150], ["bacteriophages", "PROBLEM", 202, 216], ["lyse pathogenic bacteria", "PROBLEM", 262, 286], ["bacteriophages", "OBSERVATION", 202, 216]]], ["In the pre-antibiotic era of the early 20th century, phage therapy was becoming a powerful weapon against infectious diseases of bacterial aetiology.", [["infectious diseases of bacterial aetiology", "DISEASE", 106, 148], ["phage therapy", "TREATMENT", 53, 66], ["bacterial aetiology", "PROBLEM", 129, 148], ["bacterial aetiology", "OBSERVATION", 129, 148]]], ["Unfortunately, phage treatment and research was largely forgotten in the Western world as antibiotics became widely available.", [["phage treatment", "TREATMENT", 15, 30], ["antibiotics", "TREATMENT", 90, 101]]], ["Nowadays, the rapid propagation of multi-drug resistant bacterial strains is leading to renewed interest in phage therapy.M. Kutateladze\u00b0(Tbilisi, GE)In contrast to its decline in the West, phage therapy remained a standard part of the healthcare systems in Eastern Europe and the USSR during the second half of the 20th century.", [["multi-drug resistant bacterial strains", "PROBLEM", 35, 73], ["phage therapy", "TREATMENT", 108, 121], ["phage therapy", "TREATMENT", 190, 203], ["bacterial strains", "OBSERVATION", 56, 73]]], ["Phage preparations were used for diagnostic, therapeutic and prophylactic purposes to combat various bacterial infections.", [["bacterial infections", "DISEASE", 101, 121], ["Phage preparations", "TREATMENT", 0, 18], ["prophylactic purposes", "TREATMENT", 61, 82], ["various bacterial infections", "PROBLEM", 93, 121], ["bacterial", "OBSERVATION_MODIFIER", 101, 110], ["infections", "OBSERVATION", 111, 121]]], ["The Eliava Institute of Bacteriophages, Microbiology and Virology (Tbilisi, Georgia) is perhaps the most famous institution in the world focused on the study of bacteriophages, particularly the isolation and selection of phages active against various bacterial pathogens.", [["the study", "TEST", 148, 157], ["bacteriophages", "TREATMENT", 161, 175], ["the isolation", "TREATMENT", 190, 203], ["selection of phages", "TREATMENT", 208, 227], ["various bacterial pathogens", "PROBLEM", 243, 270], ["bacterial", "OBSERVATION_MODIFIER", 251, 260], ["pathogens", "OBSERVATION", 261, 270]]], ["Phages have been isolated against bacterial strains received from all over the former USSR and socialist East European countries; consequently, a huge collection of phages and pathogenic bacterial strains has been constructed at the Institute.", [["Phages", "TREATMENT", 0, 6], ["bacterial strains", "PROBLEM", 34, 51], ["a huge collection of phages", "TREATMENT", 144, 171], ["pathogenic bacterial strains", "PROBLEM", 176, 204], ["bacterial strains", "OBSERVATION", 187, 204]]], ["Thousands of people were treated with individual phages and phage mixtures during the Soviet era.", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["individual phages", "TREATMENT", 38, 55], ["phage mixtures", "TREATMENT", 60, 74]]], ["However, little of this information has ever been published and even when details are available, the trial reports do not meet internationally approved regulations and standards.M. Kutateladze\u00b0(Tbilisi, GE)Bacteriophages have a number of advantages in comparison to antibiotics.", [["Kutateladze\u00b0(Tbilisi, GE)Bacteriophages", "TREATMENT", 181, 220], ["antibiotics", "TREATMENT", 266, 277]]], ["Phage therapy as an alternative approach for treatment of infections has become an evident and promising remedy.", [["infections", "DISEASE", 58, 68], ["Phage therapy", "TREATMENT", 0, 13], ["an alternative approach", "TREATMENT", 17, 40], ["treatment", "TREATMENT", 45, 54], ["infections", "PROBLEM", 58, 68], ["infections", "OBSERVATION", 58, 68]]], ["Today, many people from various parts of the world express their willingness to take phage treatment against different infections, including those that are caused by antibiotic-resistant bacterial pathogens.", [["infections", "DISEASE", 119, 129], ["people", "ORGANISM", 12, 18], ["people", "SPECIES", 12, 18], ["phage treatment", "TREATMENT", 85, 100], ["different infections", "PROBLEM", 109, 129], ["antibiotic-resistant bacterial pathogens", "PROBLEM", 166, 206], ["bacterial pathogens", "OBSERVATION", 187, 206]]], ["The Eliava Institute has elaborated new, phage-based products and technological schemes for their production.", [["phage-based products", "TREATMENT", 41, 61], ["technological schemes", "TREATMENT", 66, 87], ["new", "OBSERVATION_MODIFIER", 36, 39]]], ["Strong collaboration with the medical community in the design of clinical trials according to international standards is absolutely critical to supporting the broader implementation of phage therapy.P. Charles\u00b0(Melbourne, AU)An Australian male aged 57 years died from an intracerebral haemorrhage ten days after he returned from a trip to rural Yugoslavia.", [["intracerebral", "ANATOMY", 271, 284], ["intracerebral haemorrhage", "DISEASE", 271, 296], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 271, 284], ["clinical trials", "TREATMENT", 65, 80], ["phage therapy", "TREATMENT", 185, 198], ["an intracerebral haemorrhage", "PROBLEM", 268, 296], ["intracerebral", "ANATOMY", 271, 284], ["haemorrhage", "OBSERVATION", 285, 296]]], ["His kidneys and liver were donated to three female recipients aged 44 years (kidney), 63 years (kidney), and 64 years (liver).", [["kidneys", "ANATOMY", 4, 11], ["liver", "ANATOMY", 16, 21], ["kidney", "ANATOMY", 77, 83], ["kidney", "ANATOMY", 96, 102], ["liver", "ANATOMY", 119, 124], ["kidneys", "ORGAN", 4, 11], ["liver", "ORGAN", 16, 21], ["recipients", "ORGANISM", 51, 61], ["kidney", "ORGAN", 77, 83], ["kidney", "ORGAN", 96, 102], ["liver", "ORGAN", 119, 124], ["kidneys", "ANATOMY", 4, 11], ["liver", "ANATOMY", 16, 21], ["kidney", "ANATOMY", 77, 83], ["kidney", "ANATOMY", 96, 102], ["liver", "ANATOMY", 119, 124]]], ["Four to five weeks after the organ donation, all three recipients died.", [["organ", "ANATOMY", 29, 34], ["organ", "ORGAN", 29, 34], ["recipients", "ORGANISM", 55, 65], ["the organ donation", "TREATMENT", 25, 43]]], ["All had febrile illnesses with altered mental status.", [["febrile illnesses", "DISEASE", 8, 25], ["febrile illnesses", "PROBLEM", 8, 25], ["altered mental status", "PROBLEM", 31, 52], ["febrile", "OBSERVATION_MODIFIER", 8, 15], ["illnesses", "OBSERVATION", 16, 25], ["altered", "OBSERVATION_MODIFIER", 31, 38], ["mental status", "OBSERVATION", 39, 52]]], ["Subsequent testing of post-mortem tissues from the recipients identified a novel arenavirus, which was related to lymphocyctic choriomeningitis virus (LCMV).", [["post-mortem tissues", "ANATOMY", 22, 41], ["arenavirus", "DISEASE", 81, 91], ["lymphocyctic choriomeningitis virus", "DISEASE", 114, 149], ["post-mortem tissues", "TISSUE", 22, 41], ["recipients", "ORGANISM", 51, 61], ["arenavirus", "ORGANISM", 81, 91], ["lymphocyctic choriomeningitis virus", "ORGANISM", 114, 149], ["LCMV", "ORGANISM", 151, 155], ["lymphocyctic choriomeningitis virus", "SPECIES", 114, 149], ["lymphocyctic choriomeningitis virus", "SPECIES", 114, 149], ["LCMV", "SPECIES", 151, 155], ["post-mortem tissues", "PROBLEM", 22, 41], ["a novel arenavirus", "PROBLEM", 73, 91], ["lymphocyctic choriomeningitis virus", "PROBLEM", 114, 149], ["arenavirus", "OBSERVATION", 81, 91], ["lymphocyctic", "OBSERVATION_MODIFIER", 114, 126], ["choriomeningitis", "OBSERVATION", 127, 143]]], ["This viral detection process involved the use of high-throughput sequencing techniques to identify novel microbial RNA sequences.", [["microbial RNA sequences", "DNA", 105, 128], ["This viral detection process", "PROBLEM", 0, 28], ["novel microbial RNA sequences", "TEST", 99, 128]]], ["Confirmatory testing was performed using the techniques of reverse transcriptasepolymerase chain reaction, immunohistochemical analysis for arenavirus antigens, and immunofluorescent testing for IgG and IgM antibodies.", [["arenavirus", "ORGANISM", 140, 150], ["IgG", "GENE_OR_GENE_PRODUCT", 195, 198], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 203, 217], ["arenavirus antigens", "PROTEIN", 140, 159], ["IgG", "PROTEIN", 195, 198], ["IgM antibodies", "PROTEIN", 203, 217], ["Confirmatory testing", "TEST", 0, 20], ["the techniques", "TEST", 41, 55], ["reverse transcriptasepolymerase chain reaction", "TREATMENT", 59, 105], ["immunohistochemical analysis", "TEST", 107, 135], ["arenavirus antigens", "TEST", 140, 159], ["immunofluorescent testing", "TEST", 165, 190], ["IgG", "TEST", 195, 198], ["IgM antibodies", "TEST", 203, 217]]], ["The clinical features in these four patients as well as other similar problems with transplant-related illness from classic LCMV will be discussed, as well as details of the laboratory identification of this new virus, and implications for organ transplantation protocols in future.M. Arendrup\u00b0(Copenhagen, DK)Successful management of invasive fungal infections depends on timely and correct treatment.", [["organ", "ANATOMY", 240, 245], ["fungal infections", "DISEASE", 344, 361], ["patients", "ORGANISM", 36, 44], ["LCMV", "ORGANISM", 124, 128], ["organ", "ORGAN", 240, 245], ["patients", "SPECIES", 36, 44], ["LCMV", "SPECIES", 124, 128], ["transplant", "TREATMENT", 84, 94], ["related illness", "PROBLEM", 95, 110], ["classic LCMV", "PROBLEM", 116, 128], ["this new virus", "PROBLEM", 203, 217], ["organ transplantation protocols", "TREATMENT", 240, 271], ["Successful management", "TREATMENT", 310, 331], ["invasive fungal infections", "PROBLEM", 335, 361], ["correct treatment", "TREATMENT", 384, 401], ["transplant", "OBSERVATION", 84, 94], ["LCMV", "OBSERVATION", 124, 128], ["invasive", "OBSERVATION_MODIFIER", 335, 343], ["fungal", "OBSERVATION_MODIFIER", 344, 350], ["infections", "OBSERVATION", 351, 361]]], ["Over the last decades a number of new tests have become available which have improved the diagnostic options.", [["new tests", "TEST", 34, 43]]], ["In contrast to the scenario for bacterial infections, acquired resistance in fungi is rare and thus species identification is a valuable tool guiding choice of treatment.", [["bacterial infections", "DISEASE", 32, 52], ["bacterial infections", "PROBLEM", 32, 52], ["acquired resistance in fungi", "PROBLEM", 54, 82], ["treatment", "TREATMENT", 160, 169], ["bacterial", "OBSERVATION_MODIFIER", 32, 41], ["infections", "OBSERVATION", 42, 52]]], ["Therefore, microscopy & culture is still a corner stone in diagnosis, but culture and identification are time consuming (app.", [["corner stone", "ANATOMY", 43, 55], ["microscopy & culture", "TEST", 11, 31], ["a corner stone", "PROBLEM", 41, 55], ["culture", "TEST", 74, 81], ["stone", "OBSERVATION", 50, 55]]], ["The sensitivity and speed of microscopy have been improved by the use of fluorescent brighteners such as calcofluor white or blankophor.", [["The sensitivity", "TEST", 0, 15], ["microscopy", "TEST", 29, 39], ["fluorescent brighteners", "TREATMENT", 73, 96]]], ["But only with the recent development of PNA probes specific for a number of the Candida spp. has species identification become possible directly from a positive blood culture before subculture on agar media.", [["blood", "ANATOMY", 161, 166], ["Candida spp", "ORGANISM", 80, 91], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["PNA probes", "PROBLEM", 40, 50], ["the Candida spp", "PROBLEM", 76, 91], ["species identification", "PROBLEM", 97, 119], ["a positive blood culture", "PROBLEM", 150, 174], ["agar media", "TREATMENT", 196, 206], ["PNA", "OBSERVATION", 40, 43], ["Candida spp", "OBSERVATION", 80, 91]]], ["Chromogenic agars allow a presumptive identification of several Candida spp. and facilitate the recognition of yeast isolates in samples containing several yeasts or yeast and bacteria in combination.", [["samples", "ANATOMY", 129, 136], ["Candida spp.", "ORGANISM", 64, 76], ["Candida spp.", "SPECIES", 64, 76], ["yeast", "SPECIES", 111, 116], ["yeast", "SPECIES", 166, 171], ["Candida spp.", "SPECIES", 64, 76], ["yeast", "SPECIES", 111, 116], ["yeast", "SPECIES", 166, 171], ["Chromogenic agars", "TEST", 0, 17], ["several Candida spp.", "PROBLEM", 56, 76], ["yeast isolates", "PROBLEM", 111, 125], ["several yeasts", "PROBLEM", 148, 162], ["yeast", "PROBLEM", 166, 171], ["bacteria", "PROBLEM", 176, 184], ["yeast isolates", "OBSERVATION", 111, 125], ["bacteria", "OBSERVATION_MODIFIER", 176, 184]]], ["The use of such plates has been shown to lead to a better identification of mixed cultures in a recent Nordic EQA scheme including more than 50 laboratories.", [["mixed cultures", "CELL_LINE", 76, 90], ["such plates", "TREATMENT", 11, 22], ["mixed cultures", "PROBLEM", 76, 90]]], ["Rapid species identification of the most important Candida spp. is possible in the routine laboratory using easy commercially available kits.", [["Candida spp", "ORGANISM", 51, 62], ["Rapid species", "PROBLEM", 0, 13], ["Candida spp", "OBSERVATION", 51, 62]]], ["Thus, a species identification of C. albicans, C. dubliniensis and C. krusei can be obtained within minutes using latex agglutination kits (BICHRO-DUBLI, KRUSEI-COLOR; Fumouze Diagnostics) and C. glabrata can be rapidly identified due to its high amounts of preformed intracellular trehalase enzyme (Glabrata RTT; Fumouze Diagnostics).", [["intracellular", "ANATOMY", 268, 281], ["C. albicans", "ORGANISM", 34, 45], ["C. dubliniensis", "ORGANISM", 47, 62], ["C. krusei", "ORGANISM", 67, 76], ["C. glabrata", "ORGANISM", 193, 204], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 268, 281], ["trehalase enzyme", "GENE_OR_GENE_PRODUCT", 282, 298], ["intracellular trehalase enzyme", "PROTEIN", 268, 298], ["C. albicans", "SPECIES", 34, 45], ["C. dubliniensis", "SPECIES", 47, 62], ["C. krusei", "SPECIES", 67, 76], ["C. glabrata", "SPECIES", 193, 204], ["C. albicans", "SPECIES", 34, 45], ["C. dubliniensis", "SPECIES", 47, 62], ["C. krusei", "SPECIES", 67, 76], ["C. glabrata", "SPECIES", 193, 204], ["a species identification", "TEST", 6, 30], ["C. albicans", "PROBLEM", 34, 45], ["C. dubliniensis", "PROBLEM", 47, 62], ["C. krusei", "PROBLEM", 67, 76], ["latex agglutination kits", "TEST", 114, 138], ["BICHRO", "TEST", 140, 146], ["KRUSEI", "TEST", 154, 160], ["C. glabrata", "PROBLEM", 193, 204], ["preformed intracellular trehalase enzyme", "TEST", 258, 298]]], ["Finally, PNA probes and fluorescence microscopy can also be used for a same day identification of a range of the clinically relevant Candida spp.", [["PNA", "SIMPLE_CHEMICAL", 9, 12], ["Candida spp", "ORGANISM", 133, 144], ["PNA probes", "PROBLEM", 9, 19], ["fluorescence microscopy", "TEST", 24, 47], ["PNA", "OBSERVATION", 9, 12], ["Candida spp", "OBSERVATION", 133, 144]]], ["Susceptibility testing is possible using Etest and the results are comparable with those obtained by reference methodologies in head to head comparisons.", [["head", "ANATOMY", 128, 132], ["head", "ANATOMY", 136, 140], ["head", "ORGANISM_SUBDIVISION", 128, 132], ["head", "ORGANISM_SUBDIVISION", 136, 140], ["Susceptibility testing", "TEST", 0, 22], ["Etest", "TEST", 41, 46], ["head to head comparisons", "TEST", 128, 152]]], ["However, recent data from EQA distributions suggest that detection of isolates with acquired resistance causes many laboratories difficulties.", [["isolates", "PROBLEM", 70, 78], ["acquired resistance", "PROBLEM", 84, 103], ["many laboratories difficulties", "PROBLEM", 111, 141]]], ["This illustrates that a critical number of isolates should be tested per technician per week and quality control strains should be included on a regular basis.M. Arendrup\u00b0(Copenhagen, DK)In conclusion, a number of new diagnostic tests have become available over the last decade and the diagnostic laboratories are encouraged to take advantage of these new options.S1619th ECCMID, Oral presentationsV.", [["quality control strains", "TREATMENT", 97, 120], ["new diagnostic tests", "TEST", 214, 234], ["these new options", "TREATMENT", 346, 363]]], ["Rickerts\u00b0(Seattle, US)Since the introduction of newer antifungals with different in vitro spectra, the aetiology of invasive fungal infections (IFI) has become a major diagnostic issue as a prerequisite for a guided antifungal therapy.", [["invasive fungal infections", "DISEASE", 116, 142], ["IFI", "DISEASE", 144, 147], ["antifungal", "CANCER", 216, 226], ["newer antifungals", "TREATMENT", 48, 65], ["different in vitro spectra", "TREATMENT", 71, 97], ["invasive fungal infections", "PROBLEM", 116, 142], ["a guided antifungal therapy", "TREATMENT", 207, 234], ["invasive", "OBSERVATION_MODIFIER", 116, 124], ["fungal", "OBSERVATION_MODIFIER", 125, 131], ["infections", "OBSERVATION", 132, 142]]], ["While molecular methods, such as PCR and Sequencing for the diagnosis of IFI have been evaluated from specimens such as blood and bronchoalveolar lavage fluid for some years, they have been less studied for biopsies.", [["specimens", "ANATOMY", 102, 111], ["blood", "ANATOMY", 120, 125], ["bronchoalveolar lavage fluid", "ANATOMY", 130, 158], ["IFI", "DISEASE", 73, 76], ["IFI", "CANCER", 73, 76], ["blood", "ORGANISM_SUBSTANCE", 120, 125], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 130, 158], ["biopsies", "TISSUE", 207, 215], ["PCR", "TEST", 33, 36], ["IFI", "PROBLEM", 73, 76], ["specimens", "TEST", 102, 111], ["blood and bronchoalveolar lavage fluid", "TEST", 120, 158], ["biopsies", "TEST", 207, 215], ["bronchoalveolar lavage", "OBSERVATION", 130, 152]]], ["Characteristics inherent to these molecular methods, e.g. sensitivity, specificity and short turnaround time makes them promising as adjuncts to conventional diagnostic tests, e.g. culture and histopathology from organ biopsies.", [["organ biopsies", "ANATOMY", 213, 227], ["organ biopsies", "MULTI-TISSUE_STRUCTURE", 213, 227], ["these molecular methods", "TEST", 28, 51], ["conventional diagnostic tests", "TEST", 145, 174], ["e.g. culture", "TEST", 176, 188], ["histopathology", "TEST", 193, 207], ["organ biopsies", "TEST", 213, 227], ["organ", "ANATOMY", 213, 218], ["biopsies", "OBSERVATION", 219, 227]]], ["Studies using tissue from animal models of mould infections suggest that PCR might be more sensitive than culture and allows for a better species identification than histopathology.", [["tissue", "ANATOMY", 14, 20], ["mould infections", "DISEASE", 43, 59], ["tissue", "TISSUE", 14, 20], ["mould infections", "PROBLEM", 43, 59], ["PCR", "TEST", 73, 76], ["culture", "TEST", 106, 113], ["histopathology", "TEST", 166, 180]]], ["However, most of these studies used assays detecting only a small range of agents or even single organisms.", [["these studies", "TEST", 17, 30], ["assays", "TEST", 36, 42], ["a small range of agents", "TREATMENT", 58, 81], ["small", "OBSERVATION_MODIFIER", 60, 65]]], ["While this may increase the sensitivity of the assays and reduces the likelihood of contaminations it limits the usefulness in the clinical setting, given the broad range of potential fungal pathogens.", [["the assays", "TEST", 43, 53], ["contaminations", "PROBLEM", 84, 98], ["potential fungal pathogens", "PROBLEM", 174, 200], ["contaminations", "OBSERVATION", 84, 98], ["fungal pathogens", "OBSERVATION", 184, 200]]], ["Studies using fresh clinical samples suggest that the detection and identification of a wide range of fungi is possible using broad range assays in combination with sequencing or by combining more specific PCR assays.", [["samples", "ANATOMY", 29, 36], ["fresh clinical samples", "TEST", 14, 36], ["the detection", "TEST", 50, 63], ["a wide range of fungi", "PROBLEM", 86, 107], ["broad range assays", "TREATMENT", 126, 144], ["combining more specific PCR assays", "PROBLEM", 182, 216]]], ["Further studies are needed to optimise DNA extraction, define the best molecular targets and the best method for amplicon detection.", [["DNA", "CELLULAR_COMPONENT", 39, 42], ["Further studies", "TEST", 0, 15], ["DNA extraction", "TREATMENT", 39, 53], ["amplicon detection", "TEST", 113, 131]]], ["The prevention of contaminations due to ubiquitous fungi and unspecific amplifications are a major problem, especially when using broad range assays.", [["contaminations", "PROBLEM", 18, 32], ["ubiquitous fungi", "PROBLEM", 40, 56], ["unspecific amplifications", "PROBLEM", 61, 86], ["broad range assays", "TEST", 130, 148], ["fungi", "OBSERVATION", 51, 56]]], ["In contrast, FISH probes may potentially be more specific than PCR due to the visualisation of fungal elements in tissue.", [["tissue", "ANATOMY", 114, 120], ["tissue", "TISSUE", 114, 120], ["FISH probes", "DNA", 13, 24], ["fungal elements", "DNA", 95, 110], ["PCR", "TEST", 63, 66], ["fungal elements in tissue", "PROBLEM", 95, 120], ["fungal elements", "OBSERVATION", 95, 110]]], ["In contrast to PCR, they appear to work well with formalin fixed specimens.", [["specimens", "ANATOMY", 65, 74], ["formalin", "CHEMICAL", 50, 58], ["PCR", "TEST", 15, 18], ["formalin fixed specimens", "TEST", 50, 74]]], ["Species identification might be more challenging than by PCR and sequencing.", [["Species identification", "TEST", 0, 22], ["PCR", "TEST", 57, 60]]], ["Direct comparisons between FISH and PCR are needed to characterise the pros and cons of each method in determining the aetiology of IFI.", [["IFI", "DISEASE", 132, 135], ["Direct comparisons between FISH and PCR", "TEST", 0, 39], ["IFI", "PROBLEM", 132, 135], ["IFI", "OBSERVATION", 132, 135]]], ["Molecular tissue diagnosis has the potential to evolve into a useful method to describe the aetiology of IFI even in culture negative samples.", [["tissue", "ANATOMY", 10, 16], ["samples", "ANATOMY", 134, 141], ["IFI", "DISEASE", 105, 108], ["tissue", "TISSUE", 10, 16], ["IFI", "CANCER", 105, 108], ["IFI", "PROBLEM", 105, 108], ["culture", "TEST", 117, 124], ["tissue", "OBSERVATION", 10, 16]]], ["Results might be obtained fast enough to guide the antifungal therapy in patients with IFI progressive to empiric antifungal therapy.", [["IFI", "DISEASE", 87, 90], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["the antifungal therapy", "TREATMENT", 47, 69], ["IFI", "TREATMENT", 87, 90], ["empiric antifungal therapy", "TREATMENT", 106, 132], ["antifungal therapy", "OBSERVATION", 114, 132]]], ["In these patients, the risk associated with invasive tissue sampling might be outweighed by potential benefits of a guided antifungal therapy.T. Walsh\u00b0(Cardiff, UK)The two groups of carbapenemases (serine carbapenemases and metallobeta-lactamases (MBLs)) can be encoded by genes that can be carried on plasmids.", [["tissue", "ANATOMY", 53, 59], ["plasmids", "ANATOMY", 302, 310], ["serine", "CHEMICAL", 198, 204], ["patients", "ORGANISM", 9, 17], ["tissue", "TISSUE", 53, 59], ["carbapenemases", "GENE_OR_GENE_PRODUCT", 182, 196], ["serine carbapenemases", "SIMPLE_CHEMICAL", 198, 219], ["metallobeta-lactamases", "GENE_OR_GENE_PRODUCT", 224, 246], ["MBLs", "GENE_OR_GENE_PRODUCT", 248, 252], ["carbapenemases", "PROTEIN", 182, 196], ["serine carbapenemases", "PROTEIN", 198, 219], ["metallobeta", "PROTEIN", 224, 235], ["MBLs", "PROTEIN", 248, 252], ["plasmids", "DNA", 302, 310], ["patients", "SPECIES", 9, 17], ["invasive tissue sampling", "TREATMENT", 44, 68], ["a guided antifungal therapy", "TREATMENT", 114, 141], ["carbapenemases", "PROBLEM", 182, 196], ["serine carbapenemases", "TREATMENT", 198, 219], ["metallobeta", "TEST", 224, 235], ["plasmids", "TREATMENT", 302, 310]]], ["The serine carbapenemases are distinctly either class A or OXA (class D); the latter being mainly associated with Acinetobacter spp.T. Walsh\u00b0(Cardiff, UK)The dominant MBL subgroups, VIM and IMP have genes that are reportedly carried on plasmids and chromosomes.", [["plasmids", "ANATOMY", 236, 244], ["chromosomes", "ANATOMY", 249, 260], ["OXA", "CHEMICAL", 59, 62], ["serine", "CHEMICAL", 4, 10], ["serine", "AMINO_ACID", 4, 10], ["OXA (class D", "GENE_OR_GENE_PRODUCT", 59, 71], ["UK", "GENE_OR_GENE_PRODUCT", 151, 153], ["MBL", "GENE_OR_GENE_PRODUCT", 167, 170], ["VIM", "GENE_OR_GENE_PRODUCT", 182, 185], ["IMP", "GENE_OR_GENE_PRODUCT", 190, 193], ["chromosomes", "CELLULAR_COMPONENT", 249, 260], ["VIM", "PROTEIN", 182, 185], ["IMP", "PROTEIN", 190, 193], ["plasmids", "DNA", 236, 244], ["chromosomes", "DNA", 249, 260], ["Acinetobacter spp.T. Walsh\u00b0", "SPECIES", 114, 141], ["The serine carbapenemases", "PROBLEM", 0, 25], ["Acinetobacter", "PROBLEM", 114, 127], ["The dominant MBL subgroups, VIM and IMP have genes", "PROBLEM", 154, 204], ["carbapenemases", "OBSERVATION", 11, 25], ["dominant", "OBSERVATION_MODIFIER", 158, 166], ["MBL", "OBSERVATION", 167, 170]]], ["Recent evidence has shown that the majority of blaVIM-2, even those initially reported, are indeed plasmid mediated and probably accounts for their rapid dissemination. blaVIM-1 genes have been recently shown to be carried on IncN and IncW plasmids.", [["blaVIM-2", "GENE_OR_GENE_PRODUCT", 47, 55], ["blaVIM-1", "GENE_OR_GENE_PRODUCT", 169, 177], ["IncN", "GENE_OR_GENE_PRODUCT", 226, 230], ["IncW", "GENE_OR_GENE_PRODUCT", 235, 239], ["blaVIM", "PROTEIN", 47, 53], ["blaVIM-1 genes", "DNA", 169, 183], ["IncN and IncW plasmids", "DNA", 226, 248], ["their rapid dissemination", "PROBLEM", 142, 167], ["probably accounts for", "UNCERTAINTY", 120, 141], ["rapid", "OBSERVATION_MODIFIER", 148, 153], ["dissemination", "OBSERVATION", 154, 167]]], ["The \"Brazilian\" MBL gene, blaSPM-1, is exclusively chromosomally encoded.", [["MBL", "GENE_OR_GENE_PRODUCT", 16, 19], ["blaSPM-1", "GENE_OR_GENE_PRODUCT", 26, 34], ["Brazilian\" MBL gene", "DNA", 5, 24], ["blaSPM-1", "DNA", 26, 34]]], ["The MBLs SIM-1 and AIM-1 are both chromosomally encoded whereas GIM-1 is encoded from a plasmid of approx.", [["MBLs SIM-1", "GENE_OR_GENE_PRODUCT", 4, 14], ["AIM-1", "GENE_OR_GENE_PRODUCT", 19, 24], ["GIM-1", "GENE_OR_GENE_PRODUCT", 64, 69], ["MBLs SIM-1 and AIM-1", "DNA", 4, 24], ["GIM-1", "DNA", 64, 69], ["plasmid", "DNA", 88, 95], ["The MBLs SIM", "TEST", 0, 12]]], ["The recently described blaKMH-1 gene is also carried on a plasmid (200 kb).", [["plasmid", "ANATOMY", 58, 65], ["blaKMH-1", "GENE_OR_GENE_PRODUCT", 23, 31], ["blaKMH-1 gene", "DNA", 23, 36], ["plasmid", "DNA", 58, 65], ["a plasmid", "TREATMENT", 56, 65]]], ["Hitherto, only two MBL-positive plasmid sequences are available thus far -those carrying blaIMP-8 and blaVIM-7.", [["MBL", "GENE_OR_GENE_PRODUCT", 19, 22], ["blaIMP-8", "GENE_OR_GENE_PRODUCT", 89, 97], ["blaVIM-7", "GENE_OR_GENE_PRODUCT", 102, 110], ["MBL-positive plasmid sequences", "DNA", 19, 49], ["blaIMP-8 and blaVIM-7", "DNA", 89, 110], ["two MBL", "TEST", 15, 22], ["positive plasmid sequences", "PROBLEM", 23, 49], ["blaIMP", "TEST", 89, 95], ["blaVIM", "TEST", 102, 108]]], ["The former carries other resistance genes and are approx.", [["resistance genes", "DNA", 25, 41], ["resistance genes", "OBSERVATION", 25, 41]]], ["302 kb (IncHI2), whereas the latter is a small plasmid (24 kb) and shows similarities with IncP plasmids.T. Walsh\u00b0(Cardiff, UK)OXA carbapenemase genes have been shown to be both plasmid and chromosomally mediated.", [["plasmid", "ANATOMY", 47, 54], ["OXA", "CHEMICAL", 127, 130], ["IncHI2", "GENE_OR_GENE_PRODUCT", 8, 14], ["IncP", "GENE_OR_GENE_PRODUCT", 91, 95], ["UK", "GENE_OR_GENE_PRODUCT", 124, 126], ["OXA carbapenemase", "GENE_OR_GENE_PRODUCT", 127, 144], ["IncHI2", "DNA", 8, 14], ["small plasmid", "DNA", 41, 54], ["IncP plasmids", "DNA", 91, 104], ["OXA carbapenemase genes", "DNA", 127, 150], ["plasmid", "DNA", 178, 185], ["a small plasmid", "PROBLEM", 39, 54], ["IncP plasmids", "TREATMENT", 91, 104], ["OXA carbapenemase genes", "TREATMENT", 127, 150], ["small", "OBSERVATION_MODIFIER", 41, 46], ["IncP plasmids", "OBSERVATION", 91, 104]]], ["Thus far, the blaOXA-23 and blaOXA-24/40 clusters can be both plasmid and chromosomal and have mainly been found in Acinetobacter spp.", [["plasmid", "ANATOMY", 62, 69], ["chromosomal", "ANATOMY", 74, 85], ["blaOXA-23", "GENE_OR_GENE_PRODUCT", 14, 23], ["blaOXA-24/40", "GENE_OR_GENE_PRODUCT", 28, 40], ["chromosomal", "CELLULAR_COMPONENT", 74, 85], ["Acinetobacter spp", "ORGANISM", 116, 133], ["blaOXA-23 and blaOXA-24/40 clusters", "DNA", 14, 49], ["plasmid", "DNA", 62, 69], ["the blaOXA", "TEST", 10, 20], ["blaOXA", "TEST", 28, 34], ["Acinetobacter spp", "PROBLEM", 116, 133], ["Acinetobacter spp", "OBSERVATION", 116, 133]]], ["The blaOXA-48 and blaOXA-58 clusters have been found in K. pneumoniae and Acinetobacter spp., respectively, and both are plasmid mediated. blaOXA-48 and blaOXA-58 have been shown to be carried on 70 kb and 28-100 kb plasmids, respectively.", [["plasmids", "ANATOMY", 216, 224], ["blaOXA-58", "CHEMICAL", 153, 162], ["blaOXA-48", "GENE_OR_GENE_PRODUCT", 4, 13], ["blaOXA-58", "GENE_OR_GENE_PRODUCT", 18, 27], ["K. pneumoniae", "ORGANISM", 56, 69], ["Acinetobacter spp.", "ORGANISM", 74, 92], ["blaOXA-48", "GENE_OR_GENE_PRODUCT", 139, 148], ["blaOXA-58", "GENE_OR_GENE_PRODUCT", 153, 162], ["blaOXA-48 and blaOXA-58 clusters", "DNA", 4, 36], ["blaOXA", "PROTEIN", 139, 145], ["blaOXA-58", "DNA", 153, 162], ["70 kb and 28-100 kb plasmids", "DNA", 196, 224], ["K. pneumoniae", "SPECIES", 56, 69], ["Acinetobacter spp.", "SPECIES", 74, 92], ["K. pneumoniae", "SPECIES", 56, 69], ["Acinetobacter spp.", "SPECIES", 74, 92], ["The blaOXA", "TEST", 0, 10], ["blaOXA", "TEST", 18, 24], ["K. pneumoniae", "PROBLEM", 56, 69], ["Acinetobacter spp.", "PROBLEM", 74, 92], ["blaOXA", "TEST", 139, 145], ["blaOXA", "TEST", 153, 159], ["pneumoniae", "OBSERVATION", 59, 69]]], ["A blaOXA-58 plasmid has been recently sequenced and shown to carry two different replicases.", [["blaOXA-58", "GENE_OR_GENE_PRODUCT", 2, 11], ["blaOXA-58 plasmid", "DNA", 2, 19], ["A blaOXA", "TEST", 0, 8]]], ["The class A carbapenemase genes, blaKPC, blaIMI-2 and blaGES are all carried on plasmids. blaKPC is found mainly in K. pneumoniae and carried on plasmids that vary in size 12\u221295 kb and mostly possessing the origin of replication IncN.", [["plasmids", "ANATOMY", 80, 88], ["plasmids", "ANATOMY", 145, 153], ["class A carbapenemase", "GENE_OR_GENE_PRODUCT", 4, 25], ["blaKPC", "GENE_OR_GENE_PRODUCT", 33, 39], ["blaIMI-2", "GENE_OR_GENE_PRODUCT", 41, 49], ["blaGES", "GENE_OR_GENE_PRODUCT", 54, 60], ["blaKPC", "GENE_OR_GENE_PRODUCT", 90, 96], ["K. pneumoniae", "ORGANISM", 116, 129], ["IncN", "GENE_OR_GENE_PRODUCT", 229, 233], ["class A carbapenemase genes", "DNA", 4, 31], ["blaKPC", "DNA", 33, 39], ["blaIMI", "DNA", 41, 47], ["blaGES", "DNA", 54, 60], ["plasmids", "DNA", 80, 88], ["blaKPC", "PROTEIN", 90, 96], ["plasmids", "DNA", 145, 153], ["replication IncN", "DNA", 217, 233], ["K. pneumoniae", "SPECIES", 116, 129], ["K. pneumoniae", "SPECIES", 116, 129], ["blaKPC", "TEST", 33, 39], ["blaIMI", "TEST", 41, 47], ["blaGES", "TREATMENT", 54, 60], ["plasmids", "TREATMENT", 80, 88], ["blaKPC", "TEST", 90, 96], ["pneumoniae", "PROBLEM", 119, 129], ["plasmids", "TREATMENT", 145, 153], ["pneumoniae", "OBSERVATION", 119, 129], ["size", "OBSERVATION_MODIFIER", 167, 171], ["replication", "OBSERVATION", 217, 228]]], ["However, KPC-2 has recently described in a Pseudomonas as being chromosomally mediated. blaIMI-2 is exclusive to the USA and carried on a 66 kb plasmid although blaIMI-1 is chromosomal.", [["plasmid", "ANATOMY", 144, 151], ["chromosomal", "ANATOMY", 173, 184], ["KPC-2", "GENE_OR_GENE_PRODUCT", 9, 14], ["blaIMI-2", "GENE_OR_GENE_PRODUCT", 88, 96], ["blaIMI-1", "GENE_OR_GENE_PRODUCT", 161, 169], ["chromosomal", "CELLULAR_COMPONENT", 173, 184], ["KPC", "PROTEIN", 9, 12], ["blaIMI", "PROTEIN", 88, 94], ["66 kb plasmid", "DNA", 138, 151], ["blaIMI-1", "DNA", 161, 169], ["KPC", "TEST", 9, 12], ["a Pseudomonas", "PROBLEM", 41, 54], ["blaIMI", "TEST", 161, 167], ["Pseudomonas", "OBSERVATION", 43, 54]]], ["The blaGES genes have been found in P. aeruginosa and Enterobacteriaceae of which GES-2, 4, 5 and 6 have been shown to be plasmid mediated although little else in known.", [["blaGES", "GENE_OR_GENE_PRODUCT", 4, 10], ["P. aeruginosa", "ORGANISM", 36, 49], ["GES-2", "GENE_OR_GENE_PRODUCT", 82, 87], ["4", "GENE_OR_GENE_PRODUCT", 89, 90], ["5", "GENE_OR_GENE_PRODUCT", 92, 93], ["6", "GENE_OR_GENE_PRODUCT", 98, 99], ["blaGES genes", "DNA", 4, 16], ["P. aeruginosa", "SPECIES", 36, 49], ["P. aeruginosa", "SPECIES", 36, 49], ["The blaGES genes", "PROBLEM", 0, 16], ["P. aeruginosa", "PROBLEM", 36, 49], ["Enterobacteriaceae", "PROBLEM", 54, 72], ["aeruginosa", "OBSERVATION", 39, 49], ["Enterobacteriaceae", "OBSERVATION", 54, 72]]], ["This lecture will provide a synopsis, discuss the evolution of resistance due to plasmids and briefly predict what we may face in the 21C with respect to carbapenemase resistance.Y. Arakawa\u00b0(Tokyo, JP)Nosocomial infections caused by multidrug-resistant pathogens, especially Gram-negative bacilli, have become a serious clinical concern in every healthcare setting worldwide.", [["Nosocomial infections", "DISEASE", 201, 222], ["plasmids", "DNA", 81, 89], ["resistance", "PROBLEM", 63, 73], ["plasmids", "TREATMENT", 81, 89], ["carbapenemase resistance", "TREATMENT", 154, 178], ["Nosocomial infections", "PROBLEM", 201, 222], ["multidrug-resistant pathogens", "PROBLEM", 233, 262], ["Gram-negative bacilli", "PROBLEM", 275, 296], ["JP", "ANATOMY", 198, 200], ["resistant", "OBSERVATION_MODIFIER", 243, 252], ["pathogens", "OBSERVATION", 253, 262], ["negative bacilli", "OBSERVATION", 280, 296]]], ["As well as carpapenemhydrolysing metallo-b-lactamases, CTX-M-type b-lactamases, and qunolone-resistance genetic determinants such as qnr, aac(6 )-Ib-cr, and qepA, plasmid-mediated novel molecular mechanisms such as RmtA, RmtB, RmtC, RmtD, ArmA, and NpmA responsible for pan-resistance to aminoglycosides have recently been identified in Pseudomonas aeruginosa, Acinetobacter spp., Serratia marcescens, Esherichia coli, Klebsiella pneumoniae, Proteus mirabilis etc. since 2003, and these enzymes have indeed methylation activity of 1405G or 1408A at the A-site of the bacterial 16S rRNA as found in aminoglycoside-producing actinomycetes.", [["metallo-b-lactamases", "CHEMICAL", 33, 53], ["CTX-M-type b-lactamases", "CHEMICAL", 55, 78], ["qunolone", "CHEMICAL", 84, 92], ["aminoglycosides", "CHEMICAL", 288, 303], ["aminoglycoside", "CHEMICAL", 598, 612], ["qunolone", "CHEMICAL", 84, 92], ["aminoglycosides", "CHEMICAL", 288, 303], ["aminoglycoside", "CHEMICAL", 598, 612], ["carpapenemhydrolysing metallo-b-lactamases", "SIMPLE_CHEMICAL", 11, 53], ["CTX-M-type b-lactamases", "SIMPLE_CHEMICAL", 55, 78], ["qunolone", "SIMPLE_CHEMICAL", 84, 92], ["qnr", "GENE_OR_GENE_PRODUCT", 133, 136], ["aac(6 )-Ib-cr", "GENE_OR_GENE_PRODUCT", 138, 151], ["qepA", "GENE_OR_GENE_PRODUCT", 157, 161], ["RmtA", "GENE_OR_GENE_PRODUCT", 215, 219], ["RmtB", "GENE_OR_GENE_PRODUCT", 221, 225], ["RmtC", "GENE_OR_GENE_PRODUCT", 227, 231], ["RmtD", "GENE_OR_GENE_PRODUCT", 233, 237], ["ArmA", "GENE_OR_GENE_PRODUCT", 239, 243], ["NpmA", "GENE_OR_GENE_PRODUCT", 249, 253], ["aminoglycosides", "SIMPLE_CHEMICAL", 288, 303], ["Pseudomonas aeruginosa", "ORGANISM", 337, 359], ["Acinetobacter spp.", "ORGANISM", 361, 379], ["Serratia marcescens", "ORGANISM", 381, 400], ["Esherichia coli", "ORGANISM", 402, 417], ["Klebsiella pneumoniae", "ORGANISM", 419, 440], ["Proteus mirabilis", "ORGANISM", 442, 459], ["etc", "ORGANISM", 460, 463], ["aminoglycoside", "SIMPLE_CHEMICAL", 598, 612], ["qnr", "PROTEIN", 133, 136], ["Ib", "PROTEIN", 146, 148], ["cr", "PROTEIN", 149, 151], ["qepA", "PROTEIN", 157, 161], ["plasmid", "DNA", 163, 170], ["RmtA", "PROTEIN", 215, 219], ["RmtB", "PROTEIN", 221, 225], ["RmtC", "PROTEIN", 227, 231], ["RmtD", "PROTEIN", 233, 237], ["ArmA", "PROTEIN", 239, 243], ["NpmA", "PROTEIN", 249, 253], ["A-site", "DNA", 553, 559], ["bacterial 16S rRNA", "DNA", 567, 585], ["Pseudomonas aeruginosa", "SPECIES", 337, 359], ["Acinetobacter spp.", "SPECIES", 361, 379], ["Serratia marcescens", "SPECIES", 381, 400], ["Esherichia coli", "SPECIES", 402, 417], ["Klebsiella pneumoniae", "SPECIES", 419, 440], ["Proteus mirabilis", "SPECIES", 442, 459], ["Pseudomonas aeruginosa", "SPECIES", 337, 359], ["Acinetobacter spp.", "SPECIES", 361, 379], ["Serratia marcescens", "SPECIES", 381, 400], ["Esherichia coli", "SPECIES", 402, 417], ["Klebsiella pneumoniae", "SPECIES", 419, 440], ["Proteus mirabilis", "SPECIES", 442, 459], ["carpapenemhydrolysing", "TEST", 11, 32], ["metallo", "TEST", 33, 40], ["CTX", "TEST", 55, 58], ["type b-lactamases", "PROBLEM", 61, 78], ["qunolone", "TREATMENT", 84, 92], ["resistance genetic determinants", "PROBLEM", 93, 124], ["aac", "TEST", 138, 141], ["cr", "TEST", 149, 151], ["qepA", "TREATMENT", 157, 161], ["plasmid", "TREATMENT", 163, 170], ["RmtA", "TEST", 215, 219], ["ArmA", "PROBLEM", 239, 243], ["pan-resistance", "PROBLEM", 270, 284], ["aminoglycosides", "TREATMENT", 288, 303], ["Pseudomonas aeruginosa", "PROBLEM", 337, 359], ["Acinetobacter spp.", "PROBLEM", 361, 379], ["Serratia marcescens", "PROBLEM", 381, 400], ["Esherichia coli", "PROBLEM", 402, 417], ["Klebsiella pneumoniae", "PROBLEM", 419, 440], ["Proteus mirabilis etc", "PROBLEM", 442, 463], ["these enzymes", "TEST", 481, 494], ["methylation activity", "PROBLEM", 507, 527], ["the bacterial 16S rRNA", "PROBLEM", 563, 585], ["aminoglycoside", "TREATMENT", 598, 612], ["actinomycetes", "PROBLEM", 623, 636], ["Serratia marcescens", "OBSERVATION", 381, 400], ["Klebsiella pneumoniae", "OBSERVATION", 419, 440], ["Proteus mirabilis", "OBSERVATION", 442, 459], ["bacterial", "OBSERVATION", 567, 576], ["16S rRNA", "OBSERVATION", 577, 585], ["actinomycetes", "OBSERVATION", 623, 636]]], ["These plasmid-mediated 16S rRNA methylases are speculated to be originated from some nonpathogenic environmental microbes that produce aminoglycosides or some similar compounds, so it is quite natural that several new enzymes would be further identified hereafter in both clinical and livestock farming environments.", [["aminoglycosides", "CHEMICAL", 135, 150], ["aminoglycosides", "CHEMICAL", 135, 150], ["aminoglycosides", "SIMPLE_CHEMICAL", 135, 150], ["plasmid", "DNA", 6, 13], ["16S rRNA methylases", "DNA", 23, 42], ["These plasmid-mediated 16S rRNA methylases", "TREATMENT", 0, 42], ["aminoglycosides", "TREATMENT", 135, 150], ["new enzymes", "TEST", 214, 225], ["nonpathogenic", "OBSERVATION_MODIFIER", 85, 98], ["environmental microbes", "OBSERVATION", 99, 121], ["aminoglycosides", "OBSERVATION_MODIFIER", 135, 150], ["similar", "OBSERVATION_MODIFIER", 159, 166], ["compounds", "OBSERVATION_MODIFIER", 167, 176]]], ["RmtB and ArmA have widely spread in Asia, Europe, America and Australia via various pathogenic Gram-negative bacilli, we should pay special attention to the further spread of such hazardous microbes.", [["ArmA", "CHEMICAL", 9, 13], ["RmtB", "GENE_OR_GENE_PRODUCT", 0, 4], ["ArmA", "GENE_OR_GENE_PRODUCT", 9, 13], ["Gram", "GENE_OR_GENE_PRODUCT", 95, 99], ["RmtB", "PROTEIN", 0, 4], ["ArmA", "PROTEIN", 9, 13], ["ArmA", "PROBLEM", 9, 13], ["various pathogenic Gram", "TEST", 76, 99], ["negative bacilli", "PROBLEM", 100, 116], ["ArmA", "ANATOMY_MODIFIER", 9, 13], ["widely", "OBSERVATION_MODIFIER", 19, 25], ["spread", "OBSERVATION_MODIFIER", 26, 32], ["Asia", "OBSERVATION_MODIFIER", 36, 40], ["negative bacilli", "OBSERVATION", 100, 116], ["hazardous microbes", "OBSERVATION", 180, 198]]], ["In my talk, I would like to give an outline of newly identified molecular mechanisms that confer pan-resistance to aminoglycosides in pathogenic microbes isolated from both human and veterinary environments.Reference(s)[ Acquired resistance to quinolones mainly results from chromosomal mutations responsible for modification(s) of DNA gyrase and topoisomerase IV, and for a decrease of drug accumulation into bacteria due to decreased permeability and/or overexpression of efflux systems.", [["chromosomal", "ANATOMY", 275, 286], ["aminoglycosides", "CHEMICAL", 115, 130], ["quinolones", "CHEMICAL", 244, 254], ["aminoglycosides", "CHEMICAL", 115, 130], ["quinolones", "CHEMICAL", 244, 254], ["aminoglycosides", "SIMPLE_CHEMICAL", 115, 130], ["human", "ORGANISM", 173, 178], ["quinolones", "SIMPLE_CHEMICAL", 244, 254], ["chromosomal", "CELLULAR_COMPONENT", 275, 286], ["DNA", "CELLULAR_COMPONENT", 332, 335], ["gyrase", "GENE_OR_GENE_PRODUCT", 336, 342], ["topoisomerase IV", "GENE_OR_GENE_PRODUCT", 347, 363], ["DNA gyrase", "PROTEIN", 332, 342], ["topoisomerase IV", "PROTEIN", 347, 363], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 173, 178], ["aminoglycosides", "TREATMENT", 115, 130], ["pathogenic microbes", "PROBLEM", 134, 153], ["quinolones", "TREATMENT", 244, 254], ["chromosomal mutations", "PROBLEM", 275, 296], ["DNA gyrase", "TREATMENT", 332, 342], ["topoisomerase IV", "TREATMENT", 347, 363], ["drug accumulation into bacteria", "PROBLEM", 387, 418], ["decreased permeability", "PROBLEM", 426, 448], ["overexpression of efflux systems", "PROBLEM", 456, 488], ["decreased permeability", "OBSERVATION", 426, 448]]], ["Plasmid-mediated quinolone resistance (PMQR) was first reported in 1998 from the USA, and two other mechanisms have been identified to date.", [["quinolone", "CHEMICAL", 17, 26], ["quinolone", "CHEMICAL", 17, 26], ["quinolone", "SIMPLE_CHEMICAL", 17, 26], ["Plasmid-mediated quinolone resistance", "TREATMENT", 0, 37], ["quinolone resistance", "OBSERVATION", 17, 37]]], ["The first PMQR determinants, Qnr proteins, belong to the family of pentapeptide repeat proteins.", [["PMQR", "GENE_OR_GENE_PRODUCT", 10, 14], ["Qnr proteins", "GENE_OR_GENE_PRODUCT", 29, 41], ["PMQR determinants", "PROTEIN", 10, 27], ["Qnr proteins", "PROTEIN", 29, 41], ["pentapeptide repeat proteins", "PROTEIN", 67, 95], ["Qnr proteins", "TEST", 29, 41], ["pentapeptide repeat proteins", "TREATMENT", 67, 95]]], ["Five determinants have been identified: QnrA, QnrB, QnrC, QnrD, and QnrS with 6, 20, 1, 1, and 3 different variants, respectively.", [["QnrA", "GENE_OR_GENE_PRODUCT", 40, 44], ["QnrB", "GENE_OR_GENE_PRODUCT", 46, 50], ["QnrC", "GENE_OR_GENE_PRODUCT", 52, 56], ["QnrD", "GENE_OR_GENE_PRODUCT", 58, 62], ["QnrS", "GENE_OR_GENE_PRODUCT", 68, 72], ["QnrA", "PROTEIN", 40, 44], ["QnrB", "PROTEIN", 46, 50], ["QnrC", "PROTEIN", 52, 56], ["QnrD", "PROTEIN", 58, 62], ["QnrS", "PROTEIN", 68, 72], ["QnrA", "TEST", 40, 44], ["QnrC", "TEST", 52, 56], ["QnrS", "TEST", 68, 72]]], ["They may act by binding directly to both DNA gyrase and topoisomerase IV leading to protect them from quinolone inhibition.", [["quinolone", "CHEMICAL", 102, 111], ["quinolone", "CHEMICAL", 102, 111], ["DNA", "CELLULAR_COMPONENT", 41, 44], ["gyrase", "GENE_OR_GENE_PRODUCT", 45, 51], ["topoisomerase IV", "GENE_OR_GENE_PRODUCT", 56, 72], ["quinolone", "SIMPLE_CHEMICAL", 102, 111], ["DNA gyrase", "PROTEIN", 41, 51], ["topoisomerase IV", "PROTEIN", 56, 72], ["DNA gyrase", "TREATMENT", 41, 51], ["topoisomerase IV", "TREATMENT", 56, 72], ["quinolone inhibition", "TREATMENT", 102, 122]]], ["They confer resistance to nalidixic acid and reduced susceptibility to fluoroquinolones (FQs), but may facilitate recovery of mutants with higher level of resistance.", [["nalidixic acid", "CHEMICAL", 26, 40], ["fluoroquinolones", "CHEMICAL", 71, 87], ["FQs", "CHEMICAL", 89, 92], ["nalidixic acid", "CHEMICAL", 26, 40], ["fluoroquinolones", "CHEMICAL", 71, 87], ["FQs", "CHEMICAL", 89, 92], ["nalidixic acid", "SIMPLE_CHEMICAL", 26, 40], ["fluoroquinolones", "SIMPLE_CHEMICAL", 71, 87], ["FQs", "SIMPLE_CHEMICAL", 89, 92], ["nalidixic acid", "TREATMENT", 26, 40], ["fluoroquinolones (FQs", "TREATMENT", 71, 92]]], ["The overall prevalence of QnrA, QnrB, and QnrS determinants generally ranges from 1 to 5%, and they have been identified worldwide mostly in ESBL-producing enterobacterial isolates.", [["QnrA", "GENE_OR_GENE_PRODUCT", 26, 30], ["QnrB", "GENE_OR_GENE_PRODUCT", 32, 36], ["QnrS", "GENE_OR_GENE_PRODUCT", 42, 46], ["enterobacterial isolates", "CELL", 156, 180], ["QnrA", "PROTEIN", 26, 30], ["QnrB", "PROTEIN", 32, 36], ["QnrS", "PROTEIN", 42, 46], ["QnrA", "TREATMENT", 26, 30], ["QnrB", "TREATMENT", 32, 36], ["QnrS determinants", "TEST", 42, 59], ["ESBL", "PROBLEM", 141, 145], ["enterobacterial isolates", "PROBLEM", 156, 180], ["enterobacterial isolates", "OBSERVATION", 156, 180]]], ["The origin of the qnrA and qnrS genes were identified as Shewanella algae and Vibrio splendidus, respectively.", [["qnrA", "GENE_OR_GENE_PRODUCT", 18, 22], ["qnrS", "GENE_OR_GENE_PRODUCT", 27, 31], ["Shewanella algae", "ORGANISM", 57, 73], ["Vibrio splendidus", "ORGANISM", 78, 95], ["qnrA and qnrS genes", "DNA", 18, 37], ["Vibrio splendidus", "SPECIES", 78, 95], ["Vibrio splendidus", "SPECIES", 78, 95], ["origin", "ANATOMY_MODIFIER", 4, 10], ["qnrS genes", "OBSERVATION", 27, 37], ["Vibrio splendidus", "ANATOMY", 78, 95]]], ["The second type of PMQR determinant, AAC(6 )-Ib-cr, is a variant of the aminoglycoside acetyltransferase AAC(6 )-Ib which confers resistance to kanamycin, tobramycin and amikacin.", [["aminoglycoside", "CHEMICAL", 72, 86], ["kanamycin", "CHEMICAL", 144, 153], ["tobramycin", "CHEMICAL", 155, 165], ["amikacin", "CHEMICAL", 170, 178], ["aminoglycoside", "CHEMICAL", 72, 86], ["kanamycin", "CHEMICAL", 144, 153], ["tobramycin", "CHEMICAL", 155, 165], ["amikacin", "CHEMICAL", 170, 178], ["AAC(6 )-Ib-cr", "GENE_OR_GENE_PRODUCT", 37, 50], ["aminoglycoside acetyltransferase AAC(6 )-Ib", "GENE_OR_GENE_PRODUCT", 72, 115], ["kanamycin", "SIMPLE_CHEMICAL", 144, 153], ["tobramycin", "SIMPLE_CHEMICAL", 155, 165], ["amikacin", "SIMPLE_CHEMICAL", 170, 178], ["PMQR determinant", "PROTEIN", 19, 35], ["Ib", "PROTEIN", 45, 47], ["cr", "PROTEIN", 48, 50], ["aminoglycoside acetyltransferase AAC(6 )-Ib", "PROTEIN", 72, 115], ["AAC", "TEST", 37, 40], ["the aminoglycoside acetyltransferase AAC", "TREATMENT", 68, 108], ["kanamycin", "TREATMENT", 144, 153], ["tobramycin", "TREATMENT", 155, 165], ["amikacin", "TREATMENT", 170, 178]]], ["This variant possesses two substitutions (Trp102Arg and Asp179Tyr) that are sufficient to acetylation of ciprofloxacin and norfloxacin with a 2-to-4-fold MIC increase.", [["ciprofloxacin", "CHEMICAL", 105, 118], ["norfloxacin", "CHEMICAL", 123, 134], ["Trp", "CHEMICAL", 42, 45], ["Asp", "CHEMICAL", 56, 59], ["ciprofloxacin", "CHEMICAL", 105, 118], ["norfloxacin", "CHEMICAL", 123, 134], ["Trp", "AMINO_ACID", 42, 45], ["Asp", "AMINO_ACID", 56, 59], ["179Tyr", "AMINO_ACID", 59, 65], ["ciprofloxacin", "SIMPLE_CHEMICAL", 105, 118], ["norfloxacin", "SIMPLE_CHEMICAL", 123, 134], ["Trp", "TEST", 42, 45], ["Asp", "TEST", 56, 59], ["ciprofloxacin", "TREATMENT", 105, 118], ["norfloxacin", "TREATMENT", 123, 134], ["two substitutions", "OBSERVATION", 23, 40]]], ["The overall prevalence of aac(6 )-Ib-cr may range from 0.4 to up to 34%, and it has been reported mainly in Escherichia coli and Klebsiella pneumoniae.", [["aac(6 )-Ib-cr", "CHEMICAL", 26, 39], ["aac(6 )-Ib-cr", "GENE_OR_GENE_PRODUCT", 26, 39], ["Escherichia coli", "ORGANISM", 108, 124], ["Klebsiella pneumoniae", "ORGANISM", 129, 150], ["Ib", "PROTEIN", 34, 36], ["cr", "PROTEIN", 37, 39], ["Escherichia coli", "SPECIES", 108, 124], ["Klebsiella pneumoniae", "SPECIES", 129, 150], ["Escherichia coli", "SPECIES", 108, 124], ["Klebsiella pneumoniae", "SPECIES", 129, 150], ["aac", "TEST", 26, 29], ["Ib-cr", "TEST", 34, 39], ["Escherichia coli", "PROBLEM", 108, 124], ["Klebsiella pneumoniae", "PROBLEM", 129, 150], ["aac", "OBSERVATION", 26, 29], ["Escherichia coli", "OBSERVATION", 108, 124], ["Klebsiella pneumoniae", "OBSERVATION", 129, 150]]], ["The third type of PMQR determinant, QepA, has been identified in two E. coli clinical isolates from Japan and Belgium.", [["QepA", "CHEMICAL", 36, 40], ["PMQR", "GENE_OR_GENE_PRODUCT", 18, 22], ["QepA", "GENE_OR_GENE_PRODUCT", 36, 40], ["E. coli", "ORGANISM", 69, 76], ["PMQR determinant", "PROTEIN", 18, 34], ["QepA", "PROTEIN", 36, 40], ["E. coli", "SPECIES", 69, 76], ["E. coli", "SPECIES", 69, 76], ["QepA", "TREATMENT", 36, 40], ["two E. coli clinical isolates", "PROBLEM", 65, 94]]], ["The qepA gene encodes a 14-transmembrane-segment putative efflux pump belonging to the major facilitator superfamily.", [["qepA", "GENE_OR_GENE_PRODUCT", 4, 8], ["qepA gene", "DNA", 4, 13], ["14-transmembrane-segment putative efflux pump", "PROTEIN", 24, 69], ["major facilitator superfamily", "PROTEIN", 87, 116], ["a 14-transmembrane-segment putative efflux pump", "TREATMENT", 22, 69], ["efflux pump", "OBSERVATION", 58, 69]]], ["This protein confers decreased susceptibility to hydrophilic FQs (e.g. norfloxacin, ciprofloxacin and enrofloxacin) with an 8-to-32-fold MIC increase.", [["hydrophilic FQs", "CHEMICAL", 49, 64], ["norfloxacin", "CHEMICAL", 71, 82], ["ciprofloxacin", "CHEMICAL", 84, 97], ["enrofloxacin", "CHEMICAL", 102, 114], ["FQs", "CHEMICAL", 61, 64], ["norfloxacin", "CHEMICAL", 71, 82], ["ciprofloxacin", "CHEMICAL", 84, 97], ["enrofloxacin", "CHEMICAL", 102, 114], ["FQs", "SIMPLE_CHEMICAL", 61, 64], ["norfloxacin", "SIMPLE_CHEMICAL", 71, 82], ["ciprofloxacin", "SIMPLE_CHEMICAL", 84, 97], ["enrofloxacin", "SIMPLE_CHEMICAL", 102, 114], ["decreased susceptibility to hydrophilic FQs", "PROBLEM", 21, 64], ["norfloxacin", "TREATMENT", 71, 82], ["ciprofloxacin", "TREATMENT", 84, 97], ["enrofloxacin", "TREATMENT", 102, 114], ["decreased", "OBSERVATION_MODIFIER", 21, 30], ["hydrophilic FQs", "OBSERVATION", 49, 64]]], ["The two epidemiological surveys for QepA may indicate its low prevalence (<1%).", [["QepA", "TREATMENT", 36, 40]]], ["The natural reservoir of qepA remains unknown but might be an actinomycetal species.", [["qepA", "CHEMICAL", 25, 29], ["qepA", "GENE_OR_GENE_PRODUCT", 25, 29], ["qepA", "PROTEIN", 25, 29], ["an actinomycetal species", "PROBLEM", 59, 83], ["natural", "OBSERVATION_MODIFIER", 4, 11], ["reservoir", "OBSERVATION_MODIFIER", 12, 21], ["might be", "UNCERTAINTY", 50, 58], ["actinomycetal species", "OBSERVATION", 62, 83]]], ["Discovering of three main mechanisms of PMQR within the last ten years is peculiar.", [["PMQR", "GENE_OR_GENE_PRODUCT", 40, 44], ["PMQR", "PROTEIN", 40, 44], ["three", "OBSERVATION_MODIFIER", 15, 20], ["main", "OBSERVATION_MODIFIER", 21, 25], ["PMQR", "OBSERVATION", 40, 44]]], ["It may reflect the emergence of novel mechanisms of resistance but also a deeper investigation of resistance mechanisms in clinical isolates.Reference(s)Emerging infections: can we cope with them?O77 Seroprevalence of tularaemia under foxes and raccoon dogs in GermanyA.", [["infections", "DISEASE", 162, 172], ["raccoon dogs", "ORGANISM", 245, 257], ["dogs", "SPECIES", 253, 257], ["resistance mechanisms in clinical isolates", "PROBLEM", 98, 140], ["tularaemia", "TREATMENT", 218, 228], ["raccoon dogs", "TREATMENT", 245, 257]]], ["K\u00fchn\u00b0, C. Schulze, H. Ranisch, P. Kutzer, H. Nattermann, R. Grunow (Berlin, Frankfurt-Oder, DE) Objective: Little is known about the prevalence of Francisella tularensis in humans and animals in Germany.", [["Francisella tularensis", "DISEASE", 147, 169], ["Francisella tularensis", "ORGANISM", 147, 169], ["humans", "ORGANISM", 173, 179], ["Francisella tularensis", "SPECIES", 147, 169], ["humans", "SPECIES", 173, 179], ["Francisella tularensis", "SPECIES", 147, 169], ["humans", "SPECIES", 173, 179], ["Francisella tularensis", "PROBLEM", 147, 169], ["tularensis", "OBSERVATION", 159, 169]]], ["Interestingly, the pathogen emerged recently when several marmosets (Callithrix jacchus) died from tularaemia and a group of hunters became infected in the areas of western Germany.", [["tularaemia", "DISEASE", 99, 109], ["marmosets", "ORGANISM", 58, 67], ["Callithrix jacchus", "ORGANISM", 69, 87], ["tularaemia", "CANCER", 99, 109], ["marmosets", "SPECIES", 58, 67], ["Callithrix jacchus", "SPECIES", 69, 87], ["Callithrix jacchus", "SPECIES", 69, 87], ["tularaemia", "PROBLEM", 99, 109], ["infected", "OBSERVATION", 140, 148]]], ["To find out more about the distribution of the pathogen also in eastern Germany we investigated the seroprevalence of tularaemia under foxes (Vulpes vulpes) and raccoon dogs (Nyctereutes procyonoides) in the area of Brandenburg (around Berlin).", [["tularaemia", "DISEASE", 118, 128], ["Vulpes vulpes", "ORGANISM", 142, 155], ["raccoon dogs", "ORGANISM", 161, 173], ["Nyctereutes procyonoides", "ORGANISM", 175, 199], ["Vulpes vulpes", "SPECIES", 142, 155], ["dogs", "SPECIES", 169, 173], ["Nyctereutes procyonoides", "SPECIES", 175, 199], ["Vulpes vulpes", "SPECIES", 142, 155], ["raccoon dogs", "SPECIES", 161, 173], ["Nyctereutes procyonoides", "SPECIES", 175, 199], ["the pathogen", "PROBLEM", 43, 55], ["tularaemia under foxes (Vulpes vulpes", "TREATMENT", 118, 155], ["raccoon dogs (Nyctereutes procyonoides", "TREATMENT", 161, 199], ["pathogen", "OBSERVATION", 47, 55]]], ["Methods: Sera of animals (n = 351 and n = 32, respectively) from the years 2007 and 2008 were tested for F. tularensis \u2212 LPS antibodies in an indirect ELISA and suspicious samples were confirmed by Western blot for LPS ladder recognition using Protein G \u2212 POD conjugate.", [["samples", "ANATOMY", 172, 179], ["LPS", "CHEMICAL", 121, 124], ["LPS", "CHEMICAL", 215, 218], ["Sera", "ORGANISM", 9, 13], ["animals", "ORGANISM", 17, 24], ["F. tularensis", "ORGANISM", 105, 118], ["samples", "CANCER", 172, 179], ["LPS", "SIMPLE_CHEMICAL", 215, 218], ["Protein G \u2212 POD conjugate", "SIMPLE_CHEMICAL", 244, 269], ["Protein G \u2212 POD conjugate", "PROTEIN", 244, 269], ["F. tularensis", "SPECIES", 105, 118], ["F. tularensis", "SPECIES", 105, 118], ["Sera of animals", "TEST", 9, 24], ["F. tularensis", "TEST", 105, 118], ["LPS antibodies", "TEST", 121, 135], ["an indirect ELISA", "TEST", 139, 156], ["suspicious samples", "TEST", 161, 179], ["LPS ladder recognition", "TEST", 215, 237], ["Protein G", "TREATMENT", 244, 253]]], ["Furthermore we investigated the serum samples by a competitive ELISA using a peroxidase-conjugated anti \u2212 LPS monoclonal antibody.", [["serum samples", "ANATOMY", 32, 45], ["LPS", "CHEMICAL", 106, 109], ["serum samples", "ORGANISM_SUBSTANCE", 32, 45], ["peroxidase", "SIMPLE_CHEMICAL", 77, 87], ["peroxidase", "PROTEIN", 77, 87], ["anti \u2212 LPS monoclonal antibody", "PROTEIN", 99, 129], ["the serum samples", "TEST", 28, 45], ["a competitive ELISA", "TEST", 49, 68], ["a peroxidase", "TEST", 75, 87], ["conjugated anti \u2212 LPS monoclonal antibody", "TREATMENT", 88, 129], ["monoclonal antibody", "OBSERVATION", 110, 129]]], ["Results: From the serum collection, we tested 31 (8.8%) foxes and 3 raccoon dogs (9.4%) positive for specific F. tularensis antibodies.", [["serum", "ANATOMY", 18, 23], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["foxes", "ORGANISM", 56, 61], ["dogs", "ORGANISM", 76, 80], ["F. tularensis", "ORGANISM", 110, 123], ["F. tularensis antibodies", "PROTEIN", 110, 134], ["dogs", "SPECIES", 76, 80], ["F. tularensis", "SPECIES", 110, 123], ["F. tularensis", "SPECIES", 110, 123], ["the serum collection", "TEST", 14, 34], ["foxes", "TEST", 56, 61], ["3 raccoon dogs", "TEST", 66, 80], ["specific F. tularensis antibodies", "TEST", 101, 134]]], ["The geographical distribution showed hot spots in the area of the investigated region.Conclusions:Our results indicate for a higher seroprevalence in wildlife for tularaemia in eastern regions of Germany than assumed.", [["tularaemia", "DISEASE", 163, 173], ["hot spots", "PROBLEM", 37, 46], ["tularaemia", "PROBLEM", 163, 173], ["geographical", "OBSERVATION_MODIFIER", 4, 16], ["distribution", "OBSERVATION_MODIFIER", 17, 29], ["hot spots", "OBSERVATION", 37, 46], ["area", "ANATOMY_MODIFIER", 54, 58]]], ["Since the reported human cases for the last decade seem to be underestimated, the real prevalence of the pathogen is unknown.", [["human", "ORGANISM", 19, 24], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["the pathogen", "PROBLEM", 101, 113], ["pathogen", "OBSERVATION", 105, 113]]], ["The high number of tularaemia antibody positive foxes and raccoon dogs indicates that this zoonose is present in wildlife in eastern Germany.", [["zoonose", "CHEMICAL", 91, 98], ["tularaemia antibody", "GENE_OR_GENE_PRODUCT", 19, 38], ["raccoon dogs", "ORGANISM", 58, 70], ["tularaemia antibody", "PROTEIN", 19, 38], ["dogs", "SPECIES", 66, 70], ["tularaemia antibody positive foxes", "PROBLEM", 19, 53], ["high", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15]]], ["However, the impact of transmission of zoonotic pathogens from wildlife to domestic animals and humans is not yet well studied.", [["zoonotic pathogens", "DISEASE", 39, 57], ["humans", "ORGANISM", 96, 102], ["humans", "SPECIES", 96, 102], ["humans", "SPECIES", 96, 102], ["zoonotic pathogens", "PROBLEM", 39, 57], ["zoonotic", "OBSERVATION_MODIFIER", 39, 47]]], ["In conclusion, the obtained data will contribute for creating of up-to-date strategy for more efficient control of the two rickettsial zoonoses.O78 Aetiological and epidemiological studies on Q fever andObjective: Helicobacter pylori is established as the primary cause of gastritis and peptic ulceration in humans.", [["peptic", "ANATOMY", 287, 293], ["rickettsial zoonoses", "DISEASE", 123, 143], ["Q fever", "DISEASE", 192, 199], ["Helicobacter pylori", "DISEASE", 214, 233], ["gastritis", "DISEASE", 273, 282], ["peptic ulceration", "DISEASE", 287, 304], ["Helicobacter pylori", "ORGANISM", 214, 233], ["gastritis", "PATHOLOGICAL_FORMATION", 273, 282], ["peptic ulceration", "PATHOLOGICAL_FORMATION", 287, 304], ["humans", "ORGANISM", 308, 314], ["Helicobacter pylori", "SPECIES", 214, 233], ["humans", "SPECIES", 308, 314], ["Helicobacter pylori", "SPECIES", 214, 233], ["humans", "SPECIES", 308, 314], ["epidemiological studies", "TEST", 165, 188], ["fever", "PROBLEM", 194, 199], ["Helicobacter pylori", "PROBLEM", 214, 233], ["gastritis", "PROBLEM", 273, 282], ["peptic ulceration in humans", "PROBLEM", 287, 314], ["Helicobacter pylori", "OBSERVATION", 214, 233], ["gastritis", "OBSERVATION", 273, 282], ["peptic", "OBSERVATION_MODIFIER", 287, 293], ["ulceration", "OBSERVATION", 294, 304]]], ["In a minority of patients with upper gastrointestinal symptoms long tightly coiled spiral bacteria, clearly distinct from H. pylori, and provisionally named as \"H. heilmannii\", can be observed in gastric biopsies.", [["gastrointestinal", "ANATOMY", 37, 53], ["gastric biopsies", "ANATOMY", 196, 212], ["patients", "ORGANISM", 17, 25], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 31, 53], ["H. pylori", "ORGANISM", 122, 131], ["H. heilmannii", "ORGANISM", 161, 174], ["gastric biopsies", "MULTI-TISSUE_STRUCTURE", 196, 212], ["patients", "SPECIES", 17, 25], ["H. pylori", "SPECIES", 122, 131], ["H. heilmannii", "SPECIES", 161, 174], ["H. pylori", "SPECIES", 122, 131], ["H. heilmannii", "SPECIES", 161, 174], ["upper gastrointestinal symptoms", "PROBLEM", 31, 62], ["long tightly coiled spiral bacteria", "PROBLEM", 63, 98], ["H. pylori", "PROBLEM", 122, 131], ["gastric biopsies", "TEST", 196, 212], ["upper", "ANATOMY_MODIFIER", 31, 36], ["gastrointestinal", "ANATOMY", 37, 53], ["spiral bacteria", "OBSERVATION_MODIFIER", 83, 98], ["H. pylori", "OBSERVATION", 122, 131], ["gastric", "ANATOMY", 196, 203], ["biopsies", "OBSERVATION", 204, 212]]], ["Our objective was to isolate and identify the spiral organism, resembling \"H. heilmannii\" from the gastric mucosa of a Finnish patient presenting with severe dyspeptic symptoms.", [["gastric mucosa", "ANATOMY", 99, 113], ["dyspeptic symptoms", "DISEASE", 158, 176], ["H. heilmannii", "ORGANISM", 75, 88], ["gastric mucosa", "MULTI-TISSUE_STRUCTURE", 99, 113], ["patient", "ORGANISM", 127, 134], ["H. heilmannii", "SPECIES", 75, 88], ["patient", "SPECIES", 127, 134], ["H. heilmannii", "SPECIES", 75, 88], ["the spiral organism", "PROBLEM", 42, 61], ["severe dyspeptic symptoms", "PROBLEM", 151, 176], ["spiral organism", "OBSERVATION", 46, 61], ["gastric mucosa", "ANATOMY", 99, 113], ["severe", "OBSERVATION_MODIFIER", 151, 157]]], ["Methods: We used two different selective media for the isolation of the bacteria from gastric biopsy samples before and after treatment of the patient with a 7-day course with lansoprazole, tetracycline and metronidazole.", [["gastric biopsy samples", "ANATOMY", 86, 108], ["lansoprazole", "CHEMICAL", 176, 188], ["tetracycline", "CHEMICAL", 190, 202], ["metronidazole", "CHEMICAL", 207, 220], ["lansoprazole", "CHEMICAL", 176, 188], ["tetracycline", "CHEMICAL", 190, 202], ["metronidazole", "CHEMICAL", 207, 220], ["gastric biopsy samples", "CANCER", 86, 108], ["patient", "ORGANISM", 143, 150], ["lansoprazole", "SIMPLE_CHEMICAL", 176, 188], ["tetracycline", "SIMPLE_CHEMICAL", 190, 202], ["metronidazole", "SIMPLE_CHEMICAL", 207, 220], ["patient", "SPECIES", 143, 150], ["two different selective media", "TREATMENT", 17, 46], ["the bacteria", "PROBLEM", 68, 80], ["gastric biopsy samples", "TEST", 86, 108], ["treatment", "TREATMENT", 126, 135], ["lansoprazole", "TREATMENT", 176, 188], ["tetracycline", "TREATMENT", 190, 202], ["metronidazole", "TREATMENT", 207, 220], ["gastric", "ANATOMY", 86, 93], ["biopsy", "OBSERVATION", 94, 100]]], ["The isolates were characterised by testing for urease and catalase activity, light and electron microscopy, and sequencing the partial 16S rRNA and ureAB genes.", [["urease", "GENE_OR_GENE_PRODUCT", 47, 53], ["catalase", "SIMPLE_CHEMICAL", 58, 66], ["16S", "GENE_OR_GENE_PRODUCT", 135, 138], ["rRNA", "CELLULAR_COMPONENT", 139, 143], ["ureAB", "GENE_OR_GENE_PRODUCT", 148, 153], ["urease", "PROTEIN", 47, 53], ["catalase", "PROTEIN", 58, 66], ["16S rRNA", "DNA", 135, 143], ["ureAB genes", "DNA", 148, 159], ["The isolates", "TEST", 0, 12], ["testing", "TEST", 35, 42], ["urease", "TEST", 47, 53], ["catalase activity", "TEST", 58, 75], ["light and electron microscopy", "TEST", 77, 106], ["the partial 16S rRNA", "TEST", 123, 143]]], ["Single enzyme AFLP was used to analyse the genetic diversity among the isolates.", [["Single enzyme AFLP", "TEST", 0, 18]]], ["Results: Growth of long spiral organisms was obtained from 7 out of 8 antrum and all 8 corpus biopsies before and all three antrum biopsies after treatment of the patient.", [["antrum", "ANATOMY", 70, 76], ["corpus biopsies", "ANATOMY", 87, 102], ["antrum biopsies", "ANATOMY", 124, 139], ["antrum", "MULTI-TISSUE_STRUCTURE", 70, 76], ["corpus biopsies", "MULTI-TISSUE_STRUCTURE", 87, 102], ["antrum biopsies", "MULTI-TISSUE_STRUCTURE", 124, 139], ["patient", "ORGANISM", 163, 170], ["patient", "SPECIES", 163, 170], ["long spiral organisms", "PROBLEM", 19, 40], ["all 8 corpus biopsies", "TEST", 81, 102], ["all three antrum biopsies", "TREATMENT", 114, 139], ["treatment", "TREATMENT", 146, 155]]], ["The partial 16S rRNA gene sequence showed high sequence similarities with other gastric Helicobacter species.", [["gastric Helicobacter species", "ORGANISM", 80, 108], ["16S rRNA gene sequence", "DNA", 12, 34], ["The partial 16S rRNA gene sequence", "TEST", 0, 34], ["high sequence similarities", "PROBLEM", 42, 68], ["other gastric Helicobacter species", "PROBLEM", 74, 108], ["gastric", "ANATOMY", 80, 87], ["Helicobacter species", "OBSERVATION", 88, 108]]], ["The partial ureAB gene showed high sequence similarity with H. bizzozeronii and was clearly distinct from other gastric Helicobacter species.", [["ureAB", "GENE_OR_GENE_PRODUCT", 12, 17], ["H. bizzozeronii", "ORGANISM", 60, 75], ["gastric Helicobacter species", "ORGANISM", 112, 140], ["ureAB gene", "DNA", 12, 22], ["H. bizzozeronii", "SPECIES", 60, 75], ["H. bizzozeronii", "SPECIES", 60, 75], ["The partial ureAB gene", "TEST", 0, 22], ["H. bizzozeronii", "TREATMENT", 60, 75], ["other gastric Helicobacter species", "PROBLEM", 106, 140], ["gastric", "ANATOMY", 112, 119], ["Helicobacter species", "OBSERVATION", 120, 140]]], ["AFLP indicated that the isolates belonged to the same clone however some minor genetic diversity was observed among the isolates.", [["clone", "CELL", 54, 59], ["AFLP", "TEST", 0, 4], ["the isolates", "PROBLEM", 20, 32], ["some minor genetic diversity", "PROBLEM", 68, 96]]], ["Results: B. pseudomallei was primarily found in close proximity to streams and in grass-rich areas but was also correlated with environmentally disturbed soil such as caused by the presence of animals, farming or irrigation.", [["B. pseudomallei", "ORGANISM", 9, 24], ["B. pseudomallei", "SPECIES", 9, 24], ["B. pseudomallei", "SPECIES", 9, 24], ["B. pseudomallei", "PROBLEM", 9, 24], ["irrigation", "TREATMENT", 213, 223], ["pseudomallei", "OBSERVATION", 12, 24]]], ["Prediction maps are currently being verified by sampling predicted B. pseudomallei \"hot-\" and \"cold-spots\".", [["B. pseudomallei", "ORGANISM", 67, 82], ["B. pseudomallei", "SPECIES", 67, 82], ["B. pseudomallei", "SPECIES", 67, 82], ["Prediction maps", "TEST", 0, 15]]], ["See in figure a prediction map for rural Darwin with red areas indicating high probability for presence of B. pseudomallei.Conclusions:This study contributes to the elucidation of the environmental distribution of B. pseudomallei in endemic tropical Australia and to the clarification of environmental factors influencing its occurrence.", [["B. pseudomallei", "DISEASE", 214, 229], ["B. pseudomallei", "ORGANISM", 107, 122], ["B. pseudomallei", "ORGANISM", 214, 229], ["B. pseudomallei", "SPECIES", 107, 122], ["B. pseudomallei", "SPECIES", 214, 229], ["B. pseudomallei", "SPECIES", 107, 122], ["B. pseudomallei", "SPECIES", 214, 229], ["red areas", "PROBLEM", 53, 62], ["B. pseudomallei", "PROBLEM", 107, 122], ["This study", "TEST", 135, 145], ["B. pseudomallei", "PROBLEM", 214, 229], ["high probability", "OBSERVATION_MODIFIER", 74, 90], ["pseudomallei", "OBSERVATION", 110, 122], ["pseudomallei", "OBSERVATION", 217, 229]]], ["It also raises concerns that B. pseudomallei are spreading due to changes in land management.Conclusions:O82 Concurrent multi-serotypic dengue infections in various body fluids W. Kulwichit\u00b0, S. Krajiw, D. Chansinghakul, G. Suwanpimolkul, O. Prommalikit, P. Suandork, J. Pupaibool, K. Arunyingmongkol, C. Pancharoen, U. Thisyakorn (Bangkok, TH) Objectives: Dengue virus infection is one of the rapidly-spreading emerging diseases worldwide.", [["body", "ANATOMY", 165, 169], ["dengue infections", "DISEASE", 136, 153], ["Dengue virus infection", "DISEASE", 357, 379], ["B. pseudomallei", "ORGANISM", 29, 44], ["body", "ORGANISM_SUBDIVISION", 165, 169], ["Dengue virus", "ORGANISM", 357, 369], ["B. pseudomallei", "SPECIES", 29, 44], ["Dengue virus", "SPECIES", 357, 369], ["B. pseudomallei", "SPECIES", 29, 44], ["Dengue virus", "SPECIES", 357, 369], ["B. pseudomallei", "PROBLEM", 29, 44], ["land management", "TREATMENT", 77, 92], ["Concurrent multi-serotypic dengue infections", "PROBLEM", 109, 153], ["Dengue virus infection", "PROBLEM", 357, 379], ["pseudomallei", "OBSERVATION", 32, 44], ["infections", "OBSERVATION", 143, 153], ["Dengue virus infection", "OBSERVATION", 357, 379]]], ["The virus is divided into 4 distinct serotypes with limited cross-protective immunity; therefore, one can be reinfected with different serotypes.", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["4 distinct", "OBSERVATION_MODIFIER", 26, 36], ["serotypes", "OBSERVATION_MODIFIER", 37, 46]]], ["While each episode is usually caused by a single serotype, an individual can occasionally be infected by concurrent multiple ones.", [["a single serotype", "PROBLEM", 40, 57], ["infected", "OBSERVATION", 93, 101]]], ["Our group has previously detected dengue virus from urine and oral specimens of some patients.", [["urine", "ANATOMY", 52, 57], ["oral specimens", "ANATOMY", 62, 76], ["dengue", "DISEASE", 34, 40], ["urine", "ORGANISM_SUBSTANCE", 52, 57], ["oral specimens", "CANCER", 62, 76], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["dengue virus", "SPECIES", 34, 46], ["dengue virus from urine", "PROBLEM", 34, 57], ["oral specimens", "TEST", 62, 76]]], ["In this study, we sought to determine the characteristics of multi-serotype infections when analysing beyond the patients' blood compartments.", [["blood compartments", "ANATOMY", 123, 141], ["infections", "DISEASE", 76, 86], ["patients", "ORGANISM", 113, 121], ["blood compartments", "MULTI-TISSUE_STRUCTURE", 123, 141], ["patients", "SPECIES", 113, 121], ["this study", "TEST", 3, 13], ["multi-serotype infections", "PROBLEM", 61, 86], ["infections", "OBSERVATION", 76, 86]]], ["Methods: During 2003 During -2007 and adult patients suspected of dengue infections were enrolled.", [["dengue infections", "DISEASE", 66, 83], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["dengue", "SPECIES", 66, 72], ["dengue infections", "PROBLEM", 66, 83], ["dengue", "OBSERVATION_MODIFIER", 66, 72], ["infections", "OBSERVATION", 73, 83]]], ["Plasma, peripheral blood mononuclear cells (PBMC), urine pellets, buccal brushes, and saliva were collected during and after the febrile episode.", [["Plasma", "ANATOMY", 0, 6], ["peripheral blood mononuclear cells", "ANATOMY", 8, 42], ["PBMC", "ANATOMY", 44, 48], ["urine pellets", "ANATOMY", 51, 64], ["buccal brushes", "ANATOMY", 66, 80], ["febrile", "DISEASE", 129, 136], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["peripheral blood mononuclear cells", "CELL", 8, 42], ["PBMC", "CELL", 44, 48], ["urine", "ORGANISM_SUBSTANCE", 51, 56], ["buccal brushes", "MULTI-TISSUE_STRUCTURE", 66, 80], ["saliva", "ORGANISM_SUBSTANCE", 86, 92], ["peripheral blood mononuclear cells", "CELL_TYPE", 8, 42], ["PBMC", "CELL_TYPE", 44, 48], ["Plasma", "TEST", 0, 6], ["peripheral blood mononuclear cells", "TEST", 8, 42], ["PBMC", "TEST", 44, 48], ["urine pellets", "TEST", 51, 64], ["buccal brushes", "TREATMENT", 66, 80], ["the febrile episode", "PROBLEM", 125, 144], ["peripheral", "ANATOMY_MODIFIER", 8, 18], ["blood", "ANATOMY", 19, 24], ["mononuclear cells", "OBSERVATION", 25, 42], ["buccal brushes", "ANATOMY", 66, 80]]], ["Only specimens from patients with both positive dengue serology and pan-dengue-specific RT-PCR were included.", [["specimens", "ANATOMY", 5, 14], ["dengue", "DISEASE", 48, 54], ["specimens", "CANCER", 5, 14], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["dengue", "SPECIES", 48, 54], ["specimens", "TEST", 5, 14], ["dengue serology", "TEST", 48, 63], ["pan-dengue", "TEST", 68, 78], ["specific RT-PCR", "TEST", 79, 94]]], ["Serotype-specific RT-PCR was then performed on the aforementioned various specimens of each patient.", [["specimens", "ANATOMY", 74, 83], ["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99], ["Serotype-specific RT-PCR", "TEST", 0, 24]]], ["Results: 95 patients met the above criteria.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["Serotyping was successful in 85 patients.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["Serotyping", "TEST", 0, 10]]], ["DEN-4 was the most common serotype, accounting for half of the cases.", [["DEN-4", "CHEMICAL", 0, 5], ["DEN-4", "CHEMICAL", 0, 5], ["DEN-4", "ORGANISM", 0, 5]]], ["20 of these 85 (23.5%) demonstrated multiserotypic infections when combining data from all specimen types in each individual.", [["specimen", "ANATOMY", 91, 99], ["infections", "DISEASE", 51, 61], ["multiserotypic infections", "PROBLEM", 36, 61], ["infections", "OBSERVATION", 51, 61]]], ["Serotyping using single, conventional serum/plasma specimens, however, would detect only half of the cases.", [["serum", "ANATOMY", 38, 43], ["plasma specimens", "ANATOMY", 44, 60], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["plasma", "ORGANISM_SUBSTANCE", 44, 50], ["Serotyping", "TEST", 0, 10], ["conventional serum/plasma specimens", "TEST", 25, 60]]], ["The phenomenon of concurrent multi-serotypic infections was present in all examined specimen types, including urine pellets, buccal brushes, and saliva.", [["specimen", "ANATOMY", 84, 92], ["urine", "ANATOMY", 110, 115], ["buccal brushes", "ANATOMY", 125, 139], ["infections", "DISEASE", 45, 55], ["urine", "ORGANISM_SUBSTANCE", 110, 115], ["buccal brushes", "MULTI-TISSUE_STRUCTURE", 125, 139], ["saliva", "ORGANISM_SUBSTANCE", 145, 151], ["concurrent multi-serotypic infections", "PROBLEM", 18, 55], ["urine pellets", "TEST", 110, 123], ["buccal brushes", "TREATMENT", 125, 139], ["saliva", "PROBLEM", 145, 151], ["multi-serotypic", "OBSERVATION_MODIFIER", 29, 44], ["infections", "OBSERVATION", 45, 55], ["urine pellets", "OBSERVATION", 110, 123], ["buccal brushes", "ANATOMY", 125, 139], ["saliva", "ANATOMY", 145, 151]]], ["The most frequent combinations were DEN-1 + DEN-4 and DEN-2 + DEN-4 (5 cases each).", [["DEN-1", "CHEMICAL", 36, 41], ["DEN-4", "CHEMICAL", 44, 49], ["DEN-2", "CHEMICAL", 54, 59], ["DEN-4", "CHEMICAL", 62, 67], ["DEN-1", "SIMPLE_CHEMICAL", 36, 41], ["DEN-4", "SIMPLE_CHEMICAL", 44, 49], ["DEN-2", "SIMPLE_CHEMICAL", 54, 59], ["DEN-4", "ORGANISM", 62, 67], ["DEN", "TEST", 36, 39], ["DEN", "TEST", 54, 57]]], ["Two patients were simultaneously infected by serotypes 1, 2, and 4 and one by serotypes 1, 3, and 4.", [["patients", "ORGANISM", 4, 12], ["3", "GENE_OR_GENE_PRODUCT", 91, 92], ["patients", "SPECIES", 4, 12], ["infected", "OBSERVATION", 33, 41]]], ["There was no demonstrable significant difference in clinical severity between single-and multi-serotypic infections.", [["infections", "DISEASE", 105, 115], ["clinical severity between single-and multi-serotypic infections", "PROBLEM", 52, 115], ["no demonstrable", "UNCERTAINTY", 10, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["difference", "OBSERVATION_MODIFIER", 38, 48], ["infections", "OBSERVATION", 105, 115]]], ["Conclusion: In a dengue-hyperendemic country with simultaneous circulation of all four serotypes, the phenomenon of concurrent multiserotypic infections are more common than previously demonstrated by traditional serotyping on single serum/plasma specimens.", [["serum", "ANATOMY", 234, 239], ["plasma specimens", "ANATOMY", 240, 256], ["dengue", "DISEASE", 17, 23], ["infections", "DISEASE", 142, 152], ["serum", "ORGANISM_SUBSTANCE", 234, 239], ["plasma specimens", "ORGANISM_SUBSTANCE", 240, 256], ["dengue", "SPECIES", 17, 23], ["all four serotypes", "PROBLEM", 78, 96], ["concurrent multiserotypic infections", "PROBLEM", 116, 152], ["traditional serotyping", "TEST", 201, 223], ["single serum/plasma specimens", "TEST", 227, 256], ["multiserotypic", "OBSERVATION_MODIFIER", 127, 141], ["infections", "OBSERVATION", 142, 152]]], ["This may be explained by the sensitivity limitation of the detection method or by biological behaviour of the virus.", [["the detection method", "TEST", 55, 75], ["the virus", "PROBLEM", 106, 115], ["may be explained", "UNCERTAINTY", 5, 21]]], ["Our findings have an implication for potentially more accurate epidemiologic studies in the future, and for further exploratory investigations regarding dengue virus in various secretions and excretions.Conclusions:O83 Emerging concepts about the evolutionary history of hantaviruses H.J. Kang, S.N. Bennett, L. Sumibcay, S. Arai, A.G. Hope, J.A. Cook, J.W. Song, R. Yanagihara\u00b0(Honolulu, Albuquerque, US; Tokyo, JP; Seoul, KR) Objective: Recent discovery of genetically distinct hantaviruses in shrews (family Soricidae), captured in widely separated geographic regions, challenges the conventional view that rodents are the principal and progenitor reservoir hosts of hantaviruses, and raises the possibility that other soricomorphs, notably moles (family Talpidae), harbour hantaviruses.", [["secretions", "ANATOMY", 177, 187], ["dengue", "DISEASE", 153, 159], ["hantaviruses", "DISEASE", 480, 492], ["hantaviruses", "DISEASE", 670, 682], ["hantaviruses", "DISEASE", 777, 789], ["dengue virus", "ORGANISM", 153, 165], ["hantaviruses", "ORGANISM", 480, 492], ["shrews", "ORGANISM_SUBDIVISION", 496, 502], ["Talpidae", "GENE_OR_GENE_PRODUCT", 758, 766], ["dengue virus", "SPECIES", 153, 165], ["accurate epidemiologic studies", "TEST", 54, 84], ["further exploratory investigations", "TEST", 108, 142], ["dengue virus in various secretions and excretions", "PROBLEM", 153, 202], ["hantaviruses", "PROBLEM", 271, 283], ["genetically distinct hantaviruses", "PROBLEM", 459, 492], ["hantaviruses", "PROBLEM", 670, 682], ["hantaviruses", "OBSERVATION", 271, 283], ["JP", "ANATOMY", 413, 415], ["distinct", "OBSERVATION_MODIFIER", 471, 479], ["hantaviruses", "OBSERVATION", 480, 492], ["hantaviruses", "OBSERVATION", 670, 682], ["raises the possibility", "UNCERTAINTY", 688, 710]]], ["Methods: Using oligonucleotide primers based on conserved genomic regions of rodent-and soricid-borne hantaviruses, RNA extracts from tissues of the Japanese shrew mole (Urotrichus talpoides), American shrew mole (Neurotrichus gibbsii) and European common mole (Talpa europaea) were analyzed for hantavirus sequences by RT-PCR.", [["extracts", "ANATOMY", 120, 128], ["tissues", "ANATOMY", 134, 141], ["hantaviruses", "ORGANISM", 102, 114], ["tissues", "TISSUE", 134, 141], ["shrew", "ORGANISM", 158, 163], ["Urotrichus talpoides", "ORGANISM", 170, 190], ["American", "ORGANISM", 193, 201], ["shrew mole", "ORGANISM", 202, 212], ["Neurotrichus gibbsii", "ORGANISM", 214, 234], ["Talpa europaea", "ORGANISM", 262, 276], ["conserved genomic regions", "DNA", 48, 73], ["hantavirus sequences", "DNA", 296, 316], ["rodent", "SPECIES", 77, 83], ["Japanese shrew", "SPECIES", 149, 163], ["Urotrichus talpoides", "SPECIES", 170, 190], ["American shrew", "SPECIES", 193, 207], ["Neurotrichus gibbsii", "SPECIES", 214, 234], ["Talpa europaea", "SPECIES", 262, 276], ["Japanese shrew", "SPECIES", 149, 163], ["Urotrichus talpoides", "SPECIES", 170, 190], ["American shrew", "SPECIES", 193, 207], ["Neurotrichus gibbsii", "SPECIES", 214, 234], ["Talpa europaea", "SPECIES", 262, 276], ["oligonucleotide primers", "TREATMENT", 15, 38], ["rodent", "TEST", 77, 83], ["RNA extracts", "TREATMENT", 116, 128], ["hantavirus sequences", "TEST", 296, 316], ["PCR", "TEST", 323, 326]]], ["Newfound S-, M-and L-segment sequences were aligned using Clustal W and were analyzed phylogenetically by the maximum-likelihood and Markov Chain Monte Carlo tree-sampling methods, with the GTR+I+G model of evolution.", [["Newfound S-, M-and L-segment sequences", "DNA", 0, 38], ["Clustal W", "DNA", 58, 67], ["Clustal W", "TREATMENT", 58, 67], ["the GTR", "TREATMENT", 186, 193], ["I+G model", "OBSERVATION_MODIFIER", 194, 203]]], ["Results: Novel hantavirus genomes, designated Asama virus (ASAV), Oxbow virus (OXBV) and Nova virus (NVAV), were detected in tissues of Urotrichus talpoides, Neurotrichus gibbsii and Talpa europaea, respectively.", [["tissues", "ANATOMY", 125, 132], ["hantavirus", "ORGANISM", 15, 25], ["Asama virus", "ORGANISM", 46, 57], ["ASAV", "GENE_OR_GENE_PRODUCT", 59, 63], ["Oxbow virus", "ORGANISM", 66, 77], ["OXBV)", "ORGANISM", 79, 84], ["Nova virus", "ORGANISM", 89, 99], ["NVAV", "GENE_OR_GENE_PRODUCT", 101, 105], ["tissues", "TISSUE", 125, 132], ["Urotrichus talpoides", "ORGANISM", 136, 156], ["Neurotrichus gibbsii", "ORGANISM", 158, 178], ["Talpa europaea", "ORGANISM", 183, 197], ["Asama virus", "SPECIES", 46, 57], ["Oxbow virus", "SPECIES", 66, 77], ["Nova virus", "SPECIES", 89, 99], ["Urotrichus talpoides", "SPECIES", 136, 156], ["Neurotrichus gibbsii", "SPECIES", 158, 178], ["Talpa europaea", "SPECIES", 183, 197], ["Asama virus", "SPECIES", 46, 57], ["ASAV", "SPECIES", 59, 63], ["Oxbow virus", "SPECIES", 66, 77], ["OXBV", "SPECIES", 79, 83], ["Nova virus", "SPECIES", 89, 99], ["NVAV", "SPECIES", 101, 105], ["Urotrichus talpoides", "SPECIES", 136, 156], ["Neurotrichus gibbsii", "SPECIES", 158, 178], ["Talpa europaea", "SPECIES", 183, 197], ["Novel hantavirus genomes", "PROBLEM", 9, 33], ["Asama virus", "PROBLEM", 46, 57], ["Oxbow virus", "PROBLEM", 66, 77], ["Nova virus (NVAV)", "PROBLEM", 89, 106], ["hantavirus genomes", "OBSERVATION", 15, 33]]], ["Sequence and phylogenetic analyses indicated that ASAV and OXBV were related to hantaviruses harboured by soricine shrews in Eurasia and North America, respectively.", [["hantaviruses", "DISEASE", 80, 92], ["ASAV", "GENE_OR_GENE_PRODUCT", 50, 54], ["OXBV", "GENE_OR_GENE_PRODUCT", 59, 63], ["soricine shrews", "ORGANISM", 106, 121], ["ASAV", "DNA", 50, 54], ["OXBV", "DNA", 59, 63], ["ASAV", "SPECIES", 50, 54], ["OXBV", "SPECIES", 59, 63], ["Sequence and phylogenetic analyses", "TEST", 0, 34], ["ASAV and OXBV", "PROBLEM", 50, 63], ["hantaviruses", "PROBLEM", 80, 92]]], ["By contrast, phylogenetic analyses of full-length S-and L-segment sequences showed that NVAV formed a unique clade, clearly distinct and evolutionarily distant from all other hantaviruses.", [["NVAV", "GENE_OR_GENE_PRODUCT", 88, 92], ["full-length S-and L-segment sequences", "DNA", 38, 75], ["NVAV", "DNA", 88, 92], ["phylogenetic analyses", "TEST", 13, 34], ["full-length S", "TEST", 38, 51], ["L-segment sequences", "TEST", 56, 75], ["distant", "OBSERVATION_MODIFIER", 152, 159], ["hantaviruses", "OBSERVATION", 175, 187]]], ["Despite the high degree of sequence divergence at the nucleotide and amino acid levels, the secondary structures of the nucleocapsid proteins, as well as the L-segment motifs, of the moleassociated hantaviruses were well conserved.", [["nucleotide", "CHEMICAL", 54, 64], ["amino acid", "CHEMICAL", 69, 79], ["nucleotide", "CHEMICAL", 54, 64], ["amino acid", "CHEMICAL", 69, 79], ["amino acid", "AMINO_ACID", 69, 79], ["nucleocapsid proteins", "PROTEIN", 120, 141], ["L-segment motifs", "PROTEIN", 158, 174], ["the high degree of sequence divergence", "PROBLEM", 8, 46], ["the nucleotide and amino acid levels", "TEST", 50, 86], ["the nucleocapsid proteins", "TEST", 116, 141], ["the moleassociated hantaviruses", "PROBLEM", 179, 210], ["high degree", "OBSERVATION_MODIFIER", 12, 23], ["nucleocapsid proteins", "OBSERVATION", 120, 141], ["hantaviruses", "OBSERVATION", 198, 210]]], ["Conclusions: While cross-species transmission has influenced the course of hantavirus evolution, such host-switching events alone do not satisfactorily explain the co-existence and distribution of genetically distinct hantaviruses among species in two taxonomic orders of small mammals spanning four continents.", [["hantavirus", "DISEASE", 75, 85], ["hantaviruses", "DISEASE", 218, 230], ["hantavirus", "SPECIES", 75, 85], ["hantavirus evolution", "PROBLEM", 75, 95], ["genetically distinct hantaviruses", "PROBLEM", 197, 230], ["small mammals", "PROBLEM", 272, 285], ["hantavirus", "OBSERVATION", 75, 85], ["distinct", "OBSERVATION_MODIFIER", 209, 217], ["hantaviruses", "OBSERVATION", 218, 230], ["small", "OBSERVATION_MODIFIER", 272, 277], ["mammals", "OBSERVATION_MODIFIER", 278, 285]]], ["When viewed within the context of molecular phylogeny and zoogeography, the close association between distinct hantavirus clades and specific subfamilies of rodents, shrews and moles is likely the result of alternating and variable periodic codivergence at certain taxonomic levels through evolutionary time.", [["distinct hantavirus clades", "PROBLEM", 102, 128], ["variable periodic codivergence", "PROBLEM", 223, 253], ["distinct", "OBSERVATION_MODIFIER", 102, 110], ["hantavirus", "OBSERVATION", 111, 121]]], ["Thus, the primeval hantavirus might have arisen from an insect-borne virus, with ancestral soricomorphs, rather than rodents, serving as the original mammalian hosts.O84 High transmission of hepatitis E virus among piglets in farmsfrom south-eastern France M. Kaba, B. Davoust, J.L. Mari\u00e9, M. Barthet, M. Henry, C. Tamalet, J.M. Rolain, D. Raoult, P. Colson\u00b0(Marseille, Toulon, FR) Objectives: Autochthonous hepatitis E is currently considered as an emerging disease in industrialised countries and several studies suggest that hepatitis E is a zoonosis, especially in pigs, boars and deer.", [["hantavirus", "DISEASE", 19, 29], ["hepatitis E", "DISEASE", 191, 202], ["Autochthonous hepatitis E", "DISEASE", 394, 419], ["hepatitis E", "DISEASE", 528, 539], ["zoonosis", "DISEASE", 545, 553], ["primeval hantavirus", "ORGANISM", 10, 29], ["insect-borne virus", "ORGANISM", 56, 74], ["hepatitis E virus", "ORGANISM", 191, 208], ["piglets", "ORGANISM", 215, 222], ["Autochthonous hepatitis E", "ORGANISM", 394, 419], ["hepatitis E", "ORGANISM", 528, 539], ["pigs", "ORGANISM", 569, 573], ["boars", "ORGANISM", 575, 580], ["deer", "ORGANISM", 585, 589], ["hepatitis E virus", "SPECIES", 191, 208], ["piglets", "SPECIES", 215, 222], ["pigs", "SPECIES", 569, 573], ["hepatitis E virus", "SPECIES", 191, 208], ["hepatitis E", "SPECIES", 528, 539], ["pigs", "SPECIES", 569, 573], ["the primeval hantavirus", "PROBLEM", 6, 29], ["an insect-borne virus", "PROBLEM", 53, 74], ["ancestral soricomorphs", "TREATMENT", 81, 103], ["hepatitis E virus", "PROBLEM", 191, 208], ["Autochthonous hepatitis E", "PROBLEM", 394, 419], ["an emerging disease", "PROBLEM", 447, 466], ["several studies", "TEST", 499, 514], ["hepatitis E", "PROBLEM", 528, 539], ["hantavirus", "OBSERVATION", 19, 29], ["hepatitis", "OBSERVATION", 191, 200], ["disease", "OBSERVATION", 459, 466], ["hepatitis", "OBSERVATION", 528, 537]]], ["We aimed to study whether hepatitis E virus (HEV) is commonly present in domestic pigs in southern France, and to determine the relationship between HEV sequences detected from pigs and those described in human hepatitis E cases.", [["hepatitis E", "DISEASE", 26, 37], ["hepatitis E", "DISEASE", 211, 222], ["hepatitis E virus", "ORGANISM", 26, 43], ["HEV", "ORGANISM", 45, 48], ["pigs", "ORGANISM", 82, 86], ["HEV", "ORGANISM", 149, 152], ["pigs", "ORGANISM", 177, 181], ["human", "ORGANISM", 205, 210], ["hepatitis E", "ORGANISM", 211, 222], ["HEV sequences", "DNA", 149, 162], ["hepatitis E virus", "SPECIES", 26, 43], ["pigs", "SPECIES", 82, 86], ["pigs", "SPECIES", 177, 181], ["human", "SPECIES", 205, 210], ["hepatitis E virus", "SPECIES", 26, 43], ["HEV", "SPECIES", 45, 48], ["pigs", "SPECIES", 82, 86], ["HEV", "SPECIES", 149, 152], ["pigs", "SPECIES", 177, 181], ["human", "SPECIES", 205, 210], ["hepatitis E virus", "PROBLEM", 26, 43], ["HEV sequences", "TEST", 149, 162]]], ["Methods: Serum and stools samples were collected from 207 three or six-month-old pigs from different regions of southern France.", [["Serum", "ANATOMY", 9, 14], ["stools samples", "ANATOMY", 19, 33], ["Serum", "ORGANISM_SUBSTANCE", 9, 14], ["stools samples", "ORGANISM_SUBSTANCE", 19, 33], ["pigs", "ORGANISM", 81, 85], ["pigs", "SPECIES", 81, 85], ["Serum and stools samples", "TEST", 9, 33], ["southern France", "OBSERVATION", 112, 127]]], ["107 sixmonth-old pigs were from a slaughterhouse, and 100 three-month-old pigs were from a pig farm.", [["pigs", "ORGANISM", 17, 21], ["pigs", "ORGANISM", 74, 78], ["pig", "ORGANISM", 91, 94], ["pigs", "SPECIES", 17, 21], ["pigs", "SPECIES", 74, 78], ["pig", "SPECIES", 91, 94], ["pigs", "SPECIES", 17, 21], ["pigs", "SPECIES", 74, 78], ["pig", "SPECIES", 91, 94], ["a pig farm", "TREATMENT", 89, 99]]], ["Swine IgG anti-HEV antibodies testing was performed using a commercial ELISA kit for clinical diagnosis with minor modifications.", [["Swine IgG anti-HEV antibodies", "PROTEIN", 0, 29], ["Swine", "SPECIES", 0, 5], ["Swine", "SPECIES", 0, 5], ["Swine IgG anti-HEV antibodies testing", "TEST", 0, 37]]], ["Swine HEV RNA detection was conducted by realtime PCR and amplification/sequencing assays using in house protocols targeting the 5 ORF2 region of the HEV genome.", [["Swine HEV", "ORGANISM", 0, 9], ["HEV", "ORGANISM", 150, 153], ["5 ORF2 region", "DNA", 129, 142], ["HEV genome", "DNA", 150, 160], ["Swine", "SPECIES", 0, 5], ["HEV", "SPECIES", 6, 9], ["HEV", "SPECIES", 150, 153], ["Swine HEV RNA detection", "TEST", 0, 23], ["realtime PCR", "TEST", 41, 53], ["amplification/sequencing assays", "TEST", 58, 89], ["HEV genome", "OBSERVATION", 150, 160]]], ["Results: 40% of pigs were seropositive, and 65% of three-monthold pigs were HEV RNA-positive, whereas none of the six-monthold pigs were HEV RNA-positive.", [["pigs", "ORGANISM", 16, 20], ["pigs", "ORGANISM", 66, 70], ["HEV", "ORGANISM", 76, 79], ["pigs", "ORGANISM", 127, 131], ["HEV", "ORGANISM", 137, 140], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 66, 70], ["pigs", "SPECIES", 127, 131], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 66, 70], ["HEV", "SPECIES", 76, 79], ["pigs", "SPECIES", 127, 131], ["HEV", "SPECIES", 137, 140], ["pigs", "TEST", 16, 20], ["seropositive", "TEST", 26, 38], ["HEV RNA", "TEST", 76, 83], ["the six-monthold pigs", "TEST", 110, 131], ["HEV RNA", "TEST", 137, 144]]], ["HEV RNA was significantly more frequently detected from stools than from serum (65% versus 22%; p < 0.001).", [["stools", "ANATOMY", 56, 62], ["serum", "ANATOMY", 73, 78], ["HEV", "ORGANISM", 0, 3], ["stools", "ORGANISM_SUBSTANCE", 56, 62], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["HEV RNA", "RNA", 0, 7], ["HEV", "SPECIES", 0, 3], ["HEV RNA", "TEST", 0, 7], ["serum", "TEST", 73, 78], ["p", "TEST", 96, 97], ["RNA", "OBSERVATION", 4, 7], ["significantly", "OBSERVATION_MODIFIER", 12, 25], ["more frequently", "OBSERVATION_MODIFIER", 26, 41], ["stools", "OBSERVATION", 56, 62]]], ["Phylogenetic analysis showed that swine HEV sequences belong to genotype 3f or 3e and formed two clusters within which sequences showed high nucleotide homology (>97%).", [["nucleotide", "CHEMICAL", 141, 151], ["nucleotide", "CHEMICAL", 141, 151], ["swine HEV", "ORGANISM", 34, 43], ["swine HEV sequences", "DNA", 34, 53], ["swine", "SPECIES", 34, 39], ["swine HEV", "SPECIES", 34, 43], ["Phylogenetic analysis", "TEST", 0, 21], ["swine HEV sequences", "TEST", 34, 53], ["high nucleotide homology", "PROBLEM", 136, 160]]], ["These clusters were correlated with the geographical origin of pigs as well as with their repartition into pens and buildings in the pig farm where samples were collected.", [["samples", "ANATOMY", 148, 155], ["pigs", "ORGANISM", 63, 67], ["pig", "ORGANISM", 133, 136], ["pigs", "SPECIES", 63, 67], ["pig", "SPECIES", 133, 136], ["pigs", "SPECIES", 63, 67], ["pig", "SPECIES", 133, 136], ["pig farm", "OBSERVATION", 133, 141]]], ["Swine HEV sequences from the present study were genetically close to HEV sequences found from humans or swine in Europe, although no strong phylogenetic link could be observed neither with these latter sequences nor with those from human hepatitis E cases diagnosed in the laboratory.", [["hepatitis E", "DISEASE", 238, 249], ["Swine HEV", "ORGANISM", 0, 9], ["HEV", "ORGANISM", 69, 72], ["humans", "ORGANISM", 94, 100], ["human", "ORGANISM", 232, 237], ["hepatitis E", "ORGANISM", 238, 249], ["HEV sequences", "DNA", 69, 82], ["Swine", "SPECIES", 0, 5], ["humans", "SPECIES", 94, 100], ["swine", "SPECIES", 104, 109], ["human", "SPECIES", 232, 237], ["Swine HEV", "SPECIES", 0, 9], ["HEV", "SPECIES", 69, 72], ["humans", "SPECIES", 94, 100], ["swine", "SPECIES", 104, 109], ["human hepatitis E", "SPECIES", 232, 249], ["Swine HEV sequences", "TEST", 0, 19], ["the present study", "TEST", 25, 42], ["HEV sequences", "TEST", 69, 82], ["human hepatitis E cases", "TEST", 232, 255]]], ["Conclusion: Our data indicate that three-month-old farm pigs from southern France might represent a potential source of contamination to humans, and they underscore the great potential of HEV to cause epizootic infections in populations of farm pigs.O84 High transmission of hepatitis E virus among piglets in farmsO85 Clostridium difficile: changing epidemiology trends, 2000 -2007 Objectives: Clostridium difficile Infection (CDI) has become a growing concern world-wide with an increased reported incidence and an increase in the associated financial burden.", [["infections", "DISEASE", 211, 221], ["hepatitis E", "DISEASE", 275, 286], ["Clostridium difficile", "DISEASE", 319, 340], ["Clostridium difficile Infection", "DISEASE", 395, 426], ["CDI", "DISEASE", 428, 431], ["pigs", "ORGANISM", 56, 60], ["humans", "ORGANISM", 137, 143], ["HEV", "ORGANISM", 188, 191], ["pigs", "ORGANISM", 245, 249], ["hepatitis E virus", "ORGANISM", 275, 292], ["piglets", "ORGANISM", 299, 306], ["O85 Clostridium difficile", "ORGANISM", 315, 340], ["Clostridium difficile", "ORGANISM", 395, 416], ["pigs", "SPECIES", 56, 60], ["humans", "SPECIES", 137, 143], ["pigs", "SPECIES", 245, 249], ["hepatitis E virus", "SPECIES", 275, 292], ["piglets", "SPECIES", 299, 306], ["Clostridium difficile", "SPECIES", 319, 340], ["Clostridium difficile", "SPECIES", 395, 416], ["pigs", "SPECIES", 56, 60], ["humans", "SPECIES", 137, 143], ["HEV", "SPECIES", 188, 191], ["hepatitis E virus", "SPECIES", 275, 292], ["Clostridium difficile", "SPECIES", 319, 340], ["Clostridium difficile", "SPECIES", 395, 416], ["Our data", "TEST", 12, 20], ["contamination", "PROBLEM", 120, 133], ["epizootic infections", "PROBLEM", 201, 221], ["hepatitis E virus", "PROBLEM", 275, 292], ["Clostridium difficile", "PROBLEM", 319, 340], ["Clostridium difficile Infection", "PROBLEM", 395, 426], ["the associated financial burden", "PROBLEM", 529, 560], ["contamination", "OBSERVATION", 120, 133], ["epizootic", "OBSERVATION_MODIFIER", 201, 210], ["infections", "OBSERVATION", 211, 221], ["farm pigs", "OBSERVATION", 240, 249], ["hepatitis", "OBSERVATION", 275, 284], ["Clostridium difficile", "OBSERVATION_MODIFIER", 395, 416], ["Infection", "OBSERVATION", 417, 426], ["increased", "OBSERVATION_MODIFIER", 481, 490], ["increase", "OBSERVATION_MODIFIER", 517, 525]]], ["Our aim therefore was to review trends in CDI occurring from 2000-2007 inclusive.", [["CDI", "DISEASE", 42, 45], ["CDI", "PROBLEM", 42, 45]]], ["Methods: All patients admitted to Lothian University Hospitals Division (LUHD) tested for C. difficile toxins A+B by EIA were included.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["C. difficile", "SPECIES", 90, 102], ["C. difficile", "SPECIES", 90, 102], ["C. difficile toxins", "PROBLEM", 90, 109], ["EIA", "TEST", 117, 120]]], ["Retrospective analysis of prospectively collected data was performed.", [["Retrospective analysis", "TEST", 0, 22], ["prospectively collected data", "TEST", 26, 54]]], ["The most recent published costs associated with CDI were used to estimate potential costs to Lothian NHS Trust.", [["CDI", "PROBLEM", 48, 51]]], ["Results: 50,590 faecal samples were tested for C. difficile toxins from 2000-2007 inclusive; of these 7301 samples were positive.", [["faecal samples", "ANATOMY", 16, 30], ["samples", "ANATOMY", 107, 114], ["faecal samples", "ORGANISM_SUBSTANCE", 16, 30], ["C. difficile", "ORGANISM", 47, 59], ["samples", "CANCER", 107, 114], ["C. difficile", "SPECIES", 47, 59], ["C. difficile", "SPECIES", 47, 59], ["faecal samples", "TEST", 16, 30], ["C. difficile toxins", "PROBLEM", 47, 66]]], ["Overall CDI was identified in 15.2 cases/10000 patient days and 5.8 cases/1000 inpatient hospital admissions.", [["CDI", "DISEASE", 8, 11], ["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["Overall CDI", "TEST", 0, 11], ["CDI", "OBSERVATION", 8, 11]]], ["The incidence of identified CDI rose from 3.6cases/10000 patient days in 2000 to 14.8cases/10000 patient days in 2007.", [["CDI", "DISEASE", 28, 31], ["patient", "ORGANISM", 57, 64], ["patient", "ORGANISM", 97, 104], ["patient", "SPECIES", 57, 64], ["patient", "SPECIES", 97, 104], ["CDI", "PROBLEM", 28, 31], ["CDI", "OBSERVATION", 28, 31]]], ["Incidence also increased with age from 3.3cases/10000 patient days in the 0\u221220 years age group to 18.1cases/10000 patient days in the 61\u221280 years age group.", [["patient", "ORGANISM", 54, 61], ["patient", "ORGANISM", 114, 121], ["patient", "SPECIES", 54, 61], ["patient", "SPECIES", 114, 121], ["increased", "OBSERVATION_MODIFIER", 15, 24]]], ["Renal Medicine and Intensive Care had the highest incidences of identified CDI with greater than 57cases/10000 patient days each followed by Infectious Diseases and Gastrointestinal Medicine whose rates were 47.5 and 42.6 cases/10000 patient days respectively.", [["Renal", "ANATOMY", 0, 5], ["CDI", "DISEASE", 75, 78], ["Infectious Diseases", "DISEASE", 141, 160], ["Renal", "ORGAN", 0, 5], ["patient", "ORGANISM", 111, 118], ["patient", "ORGANISM", 234, 241], ["patient", "SPECIES", 111, 118], ["patient", "SPECIES", 234, 241], ["Renal Medicine", "TREATMENT", 0, 14], ["CDI", "PROBLEM", 75, 78], ["CDI", "OBSERVATION", 75, 78], ["Infectious", "OBSERVATION", 141, 151], ["Gastrointestinal", "ANATOMY", 165, 181]]], ["Medicine of the Elderly in comparison had an incidence of 19.5cases/10000 patient days.", [["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81]]], ["Of note 10% of all patients were transferred through a minimum of two specialties during the period in which they remained positive for C. difficile toxins.", [["C. difficile toxins", "DISEASE", 136, 155], ["patients", "ORGANISM", 19, 27], ["C. difficile toxins", "SIMPLE_CHEMICAL", 136, 155], ["patients", "SPECIES", 19, 27], ["C. difficile", "SPECIES", 136, 148], ["C. difficile", "SPECIES", 136, 148], ["C. difficile toxins", "PROBLEM", 136, 155]]], ["Estimated costs over the study period for toxin testing alone were in the region of \u00a3126,500 and the minimal potential hospitalisation costs of patients with CDI was in the region of \u00a320,000,000.", [["CDI", "DISEASE", 158, 161], ["patients", "ORGANISM", 144, 152], ["toxin", "PROTEIN", 42, 47], ["patients", "SPECIES", 144, 152], ["the study", "TEST", 21, 30], ["toxin testing", "TEST", 42, 55], ["CDI", "PROBLEM", 158, 161], ["minimal", "OBSERVATION_MODIFIER", 101, 108], ["CDI", "OBSERVATION", 158, 161], ["region", "ANATOMY_MODIFIER", 173, 179]]], ["Conclusion: The incidence of patients identified with CDI has risen markedly and not surprisingly the incidence has also been noted to increase with age.", [["CDI", "DISEASE", 54, 57], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["CDI", "PROBLEM", 54, 57], ["CDI", "OBSERVATION", 54, 57], ["increase", "OBSERVATION_MODIFIER", 135, 143]]], ["Medicine of the Elderly however had a much lower incidence than several other specialties and therefore risk assessment of CDI development and containment should now also be targeted within other specialties.", [["CDI", "DISEASE", 123, 126], ["risk assessment", "TEST", 104, 119], ["CDI development", "PROBLEM", 123, 138]]], ["With 10% of identified CDI patients transferred through different specialties and the significant financial burden CDI imposes on healthcare institutions judicious application of infection control measures remains an important factor to prevent CDI spread.", [["CDI", "DISEASE", 23, 26], ["CDI", "DISEASE", 115, 118], ["infection", "DISEASE", 179, 188], ["CDI", "DISEASE", 245, 248], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["CDI", "PROBLEM", 23, 26], ["the significant financial burden CDI", "PROBLEM", 82, 118], ["healthcare institutions", "TREATMENT", 130, 153], ["infection control measures", "TREATMENT", 179, 205], ["CDI spread", "PROBLEM", 245, 255], ["CDI", "OBSERVATION", 23, 26], ["significant", "OBSERVATION_MODIFIER", 86, 97], ["infection", "OBSERVATION", 179, 188]]], ["Isolates of this strain were PVL negative, but positive for enterotoxin A (sea) and, in most cases, also for seb, sek and seq.", [["PVL", "GENE_OR_GENE_PRODUCT", 29, 32], ["enterotoxin A", "GENE_OR_GENE_PRODUCT", 60, 73], ["seb", "GENE_OR_GENE_PRODUCT", 109, 112], ["enterotoxin A", "PROTEIN", 60, 73], ["seb, sek and seq", "PROTEIN", 109, 125], ["this strain", "TEST", 12, 23], ["PVL", "TEST", 29, 32], ["enterotoxin", "PROBLEM", 60, 71]]], ["A fifth strain was the \"Taiwan Clone\", ST59/952-MRSA-V (WA MRSA-9 and -52) which also comprised two closely related sequence types.", [["MRSA", "SPECIES", 48, 52], ["MRSA", "SPECIES", 59, 63], ["ST59/952-MRSA-V", "SPECIES", 39, 54], ["A fifth strain", "PROBLEM", 0, 14], ["ST59", "TEST", 39, 43], ["MRSA", "PROBLEM", 48, 52], ["WA MRSA", "TEST", 56, 63]]], ["This strain carried a SCCmec element of type V(T) or VII as well as PVL and, usually, seb, sek and seq.", [["type V(T)", "GENE_OR_GENE_PRODUCT", 40, 49], ["VII", "GENE_OR_GENE_PRODUCT", 53, 56], ["PVL", "GENE_OR_GENE_PRODUCT", 68, 71], ["seb", "GENE_OR_GENE_PRODUCT", 86, 89], ["SCCmec element", "DNA", 22, 36], ["type V(T) or VII", "PROBLEM", 40, 56], ["PVL", "PROBLEM", 68, 71], ["PVL", "OBSERVATION", 68, 71]]], ["The sixth strain differed from the \"Taiwan Clone\" in the presence of a SCCmec type V element and in the absence of PVL.Conclusion:The differentiation of this clonal complex into various different strains indicates a rapid evolution and spread of SCCmec elements, and the diagnostic microarray technology allows one to distinguish beyond MLST level and hence to accurately trace outbreaks and spread of these strains.O92 Identification of a clinical methicillin-resistanta Sample taker 12 has daily contact with poultry and is excluded from analysis. b Sample taker 5 reported no contact with livestock elsewhere than in this study at that moment (spa-types of sample taker 5 and farm are not corresponding). c Sample taker 6 tested MRSA-negative in following tests. d Sample taker 9 was not tested again.Results:Complete data sets (samples taken before, directly after and 24 hours after a visit) were collected on 141 visits by 29 sample takers visiting 50 farms.", [["samples", "ANATOMY", 832, 839], ["PVL", "DISEASE", 115, 118], ["methicillin", "CHEMICAL", 449, 460], ["methicillin", "CHEMICAL", 449, 460], ["PVL", "GENE_OR_GENE_PRODUCT", 115, 118], ["SCCmec type V element", "DNA", 71, 92], ["SCCmec elements", "DNA", 246, 261], ["MRSA", "SPECIES", 732, 736], ["The sixth strain", "PROBLEM", 0, 16], ["a SCCmec type V element", "PROBLEM", 69, 92], ["PVL", "PROBLEM", 115, 118], ["this clonal complex into various different strains", "PROBLEM", 153, 203], ["SCCmec elements", "PROBLEM", 246, 261], ["the diagnostic microarray technology", "TEST", 267, 303], ["these strains", "PROBLEM", 402, 415], ["a clinical methicillin-resistanta Sample taker", "TREATMENT", 438, 484], ["Sample taker", "TEST", 552, 564], ["this study", "TEST", 620, 630], ["c Sample taker", "TEST", 708, 722], ["MRSA", "PROBLEM", 732, 736], ["d Sample taker", "TEST", 766, 780], ["SCCmec", "OBSERVATION", 71, 77], ["V element", "OBSERVATION", 83, 92], ["PVL", "OBSERVATION", 115, 118], ["rapid", "OBSERVATION_MODIFIER", 216, 221], ["SCCmec elements", "OBSERVATION", 246, 261]]], ["On 28 farms MRSA was collected from pigs or stabledust (56%).", [["pigs", "ORGANISM", 36, 40], ["MRSA", "SPECIES", 12, 16], ["pigs", "SPECIES", 36, 40], ["pigs", "SPECIES", 36, 40], ["MRSA", "PROBLEM", 12, 16], ["MRSA", "OBSERVATION", 12, 16]]], ["One sample taker (#12) was positive for MRSA before visiting a farm, he was removed from the following analysis.", [["sample", "ANATOMY", 4, 10], ["MRSA", "SPECIES", 40, 44], ["MRSA", "SPECIES", 40, 44], ["One sample taker", "TEST", 0, 16], ["MRSA", "PROBLEM", 40, 44], ["MRSA", "OBSERVATION", 40, 44]]], ["Fifteen of the 78 (19%) visits to MRSA-positive farms resulted in acquisition of MRSA and 11/23 (48%) sample takers acquired MRSA at least once after visiting a positive farm.", [["MRSA", "CHEMICAL", 34, 38], ["MRSA", "DISEASE", 81, 85], ["MRSA", "CHEMICAL", 125, 129], ["MRSA", "SPECIES", 34, 38], ["MRSA", "SPECIES", 81, 85], ["MRSA", "SPECIES", 125, 129], ["MRSA", "SPECIES", 81, 85], ["MRSA", "SPECIES", 125, 129], ["MRSA", "PROBLEM", 34, 38], ["positive farms", "PROBLEM", 39, 53], ["MRSA", "PROBLEM", 81, 85], ["acquired MRSA", "PROBLEM", 116, 129], ["MRSA", "OBSERVATION", 81, 85]]], ["Of these 11 positive sample takers 2 acquired MRSA twice and 1 sample taker acquired MRSA three times after separate visits.", [["MRSA", "DISEASE", 46, 50], ["MRSA", "SPECIES", 46, 50], ["MRSA", "SPECIES", 85, 89], ["MRSA", "PROBLEM", 46, 50], ["MRSA", "PROBLEM", 85, 89]]], ["Of the 15 acquisitions of MRSA, 13 were negative after 24 hours.", [["MRSA", "DISEASE", 26, 30], ["MRSA", "SPECIES", 26, 30], ["MRSA", "PROBLEM", 26, 30], ["MRSA", "OBSERVATION", 26, 30]]], ["The spa-types of MRSA isolates found on the farms and sample takers were grossly comparable.", [["MRSA", "SPECIES", 17, 21], ["MRSA", "SPECIES", 17, 21], ["MRSA isolates", "PROBLEM", 17, 30], ["sample takers", "TEST", 54, 67], ["MRSA isolates", "OBSERVATION", 17, 30], ["grossly", "OBSERVATION_MODIFIER", 73, 80], ["comparable", "OBSERVATION_MODIFIER", 81, 91]]], ["On the 32 negative farms, none of the 60 visits resulted in MRSA acquisition.", [["MRSA", "SPECIES", 60, 64], ["MRSA", "SPECIES", 60, 64], ["MRSA acquisition", "TEST", 60, 76]]], ["Discussion: MRSA-CC398 was acquired by 48% of the sample takers after occupational exposure in this study.", [["MRSA-CC398", "CELL", 12, 22], ["MRSA", "SPECIES", 12, 16], ["MRSA", "PROBLEM", 12, 16], ["this study", "TEST", 95, 105]]], ["However, in 11 of the 13 cases the strain was not recovered the next day, therefore acquisition was of short duration, posing a limited treat to human health.", [["human", "ORGANISM", 145, 150], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 145, 150]]], ["Some persons seemed to be more vulnerable to acquire MRSA during their work.", [["MRSA", "DISEASE", 53, 57], ["persons", "ORGANISM", 5, 12], ["persons", "SPECIES", 5, 12], ["MRSA", "SPECIES", 53, 57], ["MRSA", "SPECIES", 53, 57], ["MRSA", "PROBLEM", 53, 57]]], ["The sample size of this study was too small to draw final conclusions concerning this inter-personal variation.", [["this study", "TEST", 19, 29], ["this inter-personal variation", "PROBLEM", 81, 110], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["This requires a more extensive study.Reference(s)[ Objectives: Community-associated MRSA is an increasing problem and an association with food animal contact has been made in some regions.", [["MRSA", "DISEASE", 84, 88], ["MRSA", "SPECIES", 84, 88], ["a more extensive study", "TEST", 14, 36], ["MRSA", "PROBLEM", 84, 88], ["an increasing problem", "PROBLEM", 92, 113], ["MRSA", "OBSERVATION", 84, 88], ["increasing", "OBSERVATION_MODIFIER", 95, 105]]], ["This has led to concerns about the potential role of food in MRSA transmission.", [["MRSA", "SPECIES", 61, 65], ["MRSA", "SPECIES", 61, 65], ["MRSA", "OBSERVATION", 61, 65]]], ["The objective of this study was to evaluate the prevalence of MRSA colonisation of retail pork in Canada.", [["pork", "ORGANISM_SUBDIVISION", 90, 94], ["MRSA", "SPECIES", 62, 66], ["MRSA", "SPECIES", 62, 66], ["pork", "SPECIES", 90, 94], ["this study", "TEST", 17, 27], ["MRSA colonisation", "PROBLEM", 62, 79], ["MRSA", "OBSERVATION", 62, 66], ["retail pork", "OBSERVATION", 83, 94]]], ["Methods: Pork chops, ground pork and pork shoulders were purchased at retail outlets in four Canadian provinces in conjunction with the Canadian Integrated Program for Antimicrobial Resistance Surveillance.", [["shoulders", "ANATOMY", 42, 51], ["pork", "ORGANISM_SUBDIVISION", 28, 32], ["pork", "ORGANISM_SUBDIVISION", 37, 41], ["shoulders", "ORGANISM_SUBDIVISION", 42, 51], ["pork", "SPECIES", 37, 41], ["pork", "SPECIES", 28, 32], ["pork", "SPECIES", 37, 41], ["ground pork and pork shoulders", "TREATMENT", 21, 51], ["Antimicrobial Resistance Surveillance", "TREATMENT", 168, 205], ["shoulders", "ANATOMY", 42, 51]]], ["Both direct inoculation of meat into enrichment broth and rinsing of meat in broth were performed for pork chops and shoulders, followed by inoculation onto Chromogenic agar.", [["meat", "ANATOMY", 27, 31], ["meat", "ANATOMY", 69, 73], ["pork chops", "ANATOMY", 102, 112], ["shoulders", "ANATOMY", 117, 126], ["meat", "ORGANISM_SUBDIVISION", 27, 31], ["meat", "ORGANISM_SUBDIVISION", 69, 73], ["shoulders", "ORGANISM_SUBDIVISION", 117, 126], ["pork", "SPECIES", 102, 106], ["enrichment broth", "TREATMENT", 37, 53], ["rinsing of meat in broth", "TREATMENT", 58, 82], ["inoculation", "OBSERVATION_MODIFIER", 12, 23], ["shoulders", "ANATOMY", 117, 126]]], ["Ground pork was tested only using the direct method.", [["the direct method", "TEST", 34, 51]]], ["MRSA isolates were typed by PFGE and spa typing.", [["MRSA", "SPECIES", 0, 4], ["MRSA", "SPECIES", 0, 4], ["MRSA isolates", "PROBLEM", 0, 13], ["spa typing", "TEST", 37, 47]]], ["Real time PCR was used to detect Panton-Valentine leukocidin genes.", [["Panton-Valentine leukocidin", "GENE_OR_GENE_PRODUCT", 33, 60], ["Panton-Valentine leukocidin genes", "DNA", 33, 66], ["Real time PCR", "TEST", 0, 13], ["Panton", "TEST", 33, 39]]], ["Results: MRSA was isolated from 31/402 (7.7%, 95% CI 5.5\u221210.7%) of samples.", [["samples", "ANATOMY", 67, 74], ["samples", "CANCER", 67, 74], ["MRSA", "SPECIES", 9, 13], ["MRSA", "SPECIES", 9, 13], ["MRSA", "PROBLEM", 9, 13], ["CI", "TEST", 50, 52], ["samples", "TEST", 67, 74], ["MRSA", "OBSERVATION", 9, 13]]], ["There was a significant difference between provinces (P < 0.001) but no difference between different products, with MRSA isolated from 23/296 (7.7%) pork chops, 7/94 (7.4%) ground pork and 1/12 (8.3%) pork shoulders (P = 0.99).", [["pork chops", "ANATOMY", 149, 159], ["shoulders", "ANATOMY", 206, 215], ["pork chops", "DISEASE", 149, 159], ["pork", "ORGANISM_SUBDIVISION", 201, 205], ["shoulders", "ORGANISM_SUBDIVISION", 206, 215], ["MRSA", "SPECIES", 116, 120], ["MRSA", "SPECIES", 116, 120], ["pork", "SPECIES", 149, 153], ["pork", "SPECIES", 201, 205], ["difference between different products", "PROBLEM", 72, 109], ["MRSA", "PROBLEM", 116, 120], ["pork chops", "TEST", 149, 159], ["ground pork", "TEST", 173, 184], ["pork shoulders", "TEST", 201, 215], ["P", "TEST", 217, 218], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["difference", "OBSERVATION_MODIFIER", 24, 34], ["MRSA", "OBSERVATION", 116, 120], ["shoulders", "ANATOMY", 206, 215]]], ["21/403 (5.2%) samples were positive using direct culture while MRSA was isolated from 15/355 (4.2%) of samples testing using the rinse method.", [["samples", "ANATOMY", 14, 21], ["samples", "ANATOMY", 103, 110], ["samples", "CANCER", 14, 21], ["MRSA", "SPECIES", 63, 67], ["MRSA", "SPECIES", 63, 67], ["samples", "TEST", 14, 21], ["direct culture", "TEST", 42, 56], ["MRSA", "PROBLEM", 63, 67], ["samples testing", "TEST", 103, 118], ["the rinse method", "TREATMENT", 125, 141]]], ["Nine samples were positive on direct culture but negative using the rinse method, while 10 others were positive only with the rinse method and only 5 were positive with both methods.", [["samples", "ANATOMY", 5, 12], ["Nine samples", "TEST", 0, 12], ["direct culture", "TEST", 30, 44], ["the rinse method", "TEST", 64, 80], ["the rinse method", "TEST", 122, 138]]], ["Seven samples (ground pork) that were positive on direct culture were not tested using the rinse method.", [["samples", "ANATOMY", 6, 13], ["pork", "ORGANISM_SUBDIVISION", 22, 26], ["Seven samples (ground pork)", "TEST", 0, 27], ["direct culture", "TEST", 50, 64], ["the rinse method", "TREATMENT", 87, 103]]], ["3 main clones were present.", [["clones", "ANATOMY", 7, 13], ["clones", "CELL", 7, 13], ["main", "OBSERVATION_MODIFIER", 2, 6], ["clones", "OBSERVATION", 7, 13]]], ["The most common (40% of isolates) was a group of 3 related spa types (t064, t008 and new related type) were classified as Canadian epidemic MRSA-5 by PFGE, an ST8 human epidemic clone that has been associated with horses.", [["human", "ORGANISM", 163, 168], ["clone", "CELL", 178, 183], ["horses", "ORGANISM_SUBDIVISION", 214, 220], ["MRSA", "SPECIES", 140, 144], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["Canadian epidemic MRSA", "TEST", 122, 144], ["an ST8 human epidemic clone", "PROBLEM", 156, 183]]], ["PFGE-non-typable spa t034 were not surprisingly common, accounting for 30% of isolates.", [["spa t034", "GENE_OR_GENE_PRODUCT", 17, 25], ["typable spa t034", "DNA", 9, 25], ["PFGE", "TEST", 0, 4], ["typable spa", "TEST", 9, 20]]], ["The 3rd main group was 3 related spa types (t002, t045 and new type) that were CMRSA-2 (USA100), an ST5 clone that is common in humans in Canada, that also accounted for 30% of isolates.Discussion:The clinical relevance of MRSA contamination of pork is currently unclear.", [["CMRSA-2", "GENE_OR_GENE_PRODUCT", 79, 86], ["USA100", "ORGANISM", 88, 94], ["ST5 clone", "CELL", 100, 109], ["humans", "ORGANISM", 128, 134], ["MRSA", "ORGANISM", 223, 227], ["pork", "ORGANISM_SUBDIVISION", 245, 249], ["humans", "SPECIES", 128, 134], ["MRSA", "SPECIES", 223, 227], ["humans", "SPECIES", 128, 134], ["pork", "SPECIES", 245, 249], ["CMRSA", "TEST", 79, 84], ["an ST5 clone", "PROBLEM", 97, 109], ["MRSA contamination of pork", "PROBLEM", 223, 249], ["MRSA", "OBSERVATION", 223, 227]]], ["It is possible that contact with contaminated food could be a mode of MRSA transmission in the community, although further study of the prevalence of contamination, amount of MRSA in contaminated samples, sources of contamination and implications on human health are required.Discussion:O95 Prevalence of the novel trimethoprim resistance gene dfrK among German staphylococcal isolates of the Bft-GermVet monitoring study K. Kadlec\u00b0, S. Schwarz (Neustadt-Mariensee, DE) Objectives: Very recently a novel trimethoprim resistance gene, dfrK, was identified on a tet(L)-harbouring plasmid in a porcine MRSA isolate from the BfT-GermVet monitoring study.", [["samples", "ANATOMY", 196, 203], ["plasmid", "ANATOMY", 578, 585], ["MRSA", "CHEMICAL", 175, 179], ["trimethoprim", "CHEMICAL", 315, 327], ["trimethoprim", "CHEMICAL", 504, 516], ["trimethoprim", "CHEMICAL", 315, 327], ["trimethoprim", "CHEMICAL", 504, 516], ["human", "ORGANISM", 250, 255], ["trimethoprim", "SIMPLE_CHEMICAL", 315, 327], ["dfrK", "GENE_OR_GENE_PRODUCT", 344, 348], ["trimethoprim", "SIMPLE_CHEMICAL", 504, 516], ["dfrK", "GENE_OR_GENE_PRODUCT", 534, 538], ["tet(L)", "GENE_OR_GENE_PRODUCT", 560, 566], ["porcine", "ORGANISM", 591, 598], ["trimethoprim resistance gene dfrK", "DNA", 315, 348], ["trimethoprim resistance gene", "DNA", 504, 532], ["dfrK", "DNA", 534, 538], ["tet(L)-harbouring plasmid", "DNA", 560, 585], ["MRSA", "SPECIES", 70, 74], ["MRSA", "SPECIES", 175, 179], ["human", "SPECIES", 250, 255], ["porcine", "SPECIES", 591, 598], ["MRSA", "SPECIES", 599, 603], ["MRSA", "SPECIES", 70, 74], ["MRSA", "SPECIES", 175, 179], ["human", "SPECIES", 250, 255], ["MRSA transmission", "PROBLEM", 70, 87], ["further study", "TEST", 115, 128], ["contamination", "PROBLEM", 150, 163], ["MRSA", "PROBLEM", 175, 179], ["contaminated samples", "PROBLEM", 183, 203], ["contamination", "PROBLEM", 216, 229], ["the novel trimethoprim resistance gene", "TREATMENT", 305, 343], ["German staphylococcal isolates", "TREATMENT", 355, 385], ["a novel trimethoprim resistance gene", "TREATMENT", 496, 532], ["a tet(L)-harbouring plasmid", "TREATMENT", 558, 585], ["a porcine MRSA isolate", "TREATMENT", 589, 611], ["the BfT", "TEST", 617, 624], ["GermVet monitoring study", "TEST", 625, 649], ["MRSA", "OBSERVATION", 70, 74], ["MRSA", "OBSERVATION", 175, 179]]], ["This study included in total 248 independent coagulase-positive and coagulase-variable staphylococci collected between 2004 and 2006 all over Germany: 46 isolates from infections of the urinary-genital tract of pigs, 44 isolates from skin infections of pigs, 57 isolates from respiratory tract infections of dogs/cats, and 101 isolates from infections of skin/ear/mouth of dogs/cats.", [["urinary-genital tract", "ANATOMY", 186, 207], ["skin", "ANATOMY", 234, 238], ["respiratory tract", "ANATOMY", 276, 293], ["skin", "ANATOMY", 355, 359], ["ear", "ANATOMY", 360, 363], ["mouth", "ANATOMY", 364, 369], ["infections", "DISEASE", 168, 178], ["skin infections", "DISEASE", 234, 249], ["respiratory tract infections", "DISEASE", 276, 304], ["infections", "DISEASE", 341, 351], ["urinary-", "PATHOLOGICAL_FORMATION", 186, 194], ["genital tract", "ORGANISM_SUBDIVISION", 194, 207], ["pigs", "ORGANISM", 211, 215], ["skin", "ORGAN", 234, 238], ["pigs", "ORGANISM", 253, 257], ["respiratory tract", "ORGANISM_SUBDIVISION", 276, 293], ["dogs", "ORGANISM", 308, 312], ["cats", "ORGANISM", 313, 317], ["skin", "ORGAN", 355, 359], ["ear", "ORGAN", 360, 363], ["mouth", "ORGANISM_SUBDIVISION", 364, 369], ["dogs", "ORGANISM", 373, 377], ["cats", "ORGANISM", 378, 382], ["coagulase", "PROTEIN", 45, 54], ["pigs", "SPECIES", 211, 215], ["pigs", "SPECIES", 253, 257], ["dogs", "SPECIES", 308, 312], ["cats", "SPECIES", 313, 317], ["dogs", "SPECIES", 373, 377], ["cats", "SPECIES", 378, 382], ["pigs", "SPECIES", 211, 215], ["pigs", "SPECIES", 253, 257], ["This study", "TEST", 0, 10], ["independent coagulase", "TEST", 33, 54], ["coagulase", "TEST", 68, 77], ["variable staphylococci", "PROBLEM", 78, 100], ["infections", "PROBLEM", 168, 178], ["skin infections of pigs", "PROBLEM", 234, 257], ["respiratory tract infections of dogs/cats", "PROBLEM", 276, 317], ["infections of skin/ear", "PROBLEM", 341, 363], ["infections", "OBSERVATION", 168, 178], ["urinary", "ANATOMY", 186, 193], ["genital tract", "ANATOMY", 194, 207], ["skin", "ANATOMY", 234, 238], ["infections", "OBSERVATION", 239, 249], ["respiratory tract", "ANATOMY", 276, 293], ["skin", "ANATOMY", 355, 359], ["ear", "ANATOMY", 360, 363], ["mouth", "ANATOMY", 364, 369]]], ["In this study, we investigated the prevalence and the plasmid location of the dfrK gene among these isolates.", [["dfrK", "GENE_OR_GENE_PRODUCT", 78, 82], ["dfrK gene", "DNA", 78, 87], ["this study", "TEST", 3, 13]]], ["Methods: PCR primers were designed and a PCR with subsequent restriction analysis of the PCR product was established to detect dfrK.Discussion:Isolates with positive results were tested for a plasmid location of dfrK by transfer experiments and dfrK-carrying plasmids were further analysed.Results:The trimethoprim resistance gene dfrK was detected in another 10 isolates.", [["plasmid", "ANATOMY", 192, 199], ["trimethoprim", "CHEMICAL", 302, 314], ["trimethoprim", "CHEMICAL", 302, 314], ["dfrK", "GENE_OR_GENE_PRODUCT", 127, 131], ["dfrK", "GENE_OR_GENE_PRODUCT", 212, 216], ["dfrK", "GENE_OR_GENE_PRODUCT", 245, 249], ["trimethoprim", "SIMPLE_CHEMICAL", 302, 314], ["dfrK", "GENE_OR_GENE_PRODUCT", 331, 335], ["PCR primers", "DNA", 9, 20], ["dfrK", "PROTEIN", 127, 131], ["dfrK", "DNA", 212, 216], ["dfrK", "PROTEIN", 245, 249], ["trimethoprim resistance gene", "DNA", 302, 330], ["dfrK", "DNA", 331, 335], ["PCR primers", "TEST", 9, 20], ["a PCR", "TEST", 39, 44], ["subsequent restriction analysis", "TEST", 50, 81], ["the PCR product", "TEST", 85, 100], ["dfrK", "PROBLEM", 127, 131], ["dfrK-carrying plasmids", "TREATMENT", 245, 267], ["The trimethoprim resistance gene dfrK", "PROBLEM", 298, 335]]], ["All isolates were from pigs: 9 from skin infections and the remaining 1 from a urinary-genital tract infection.", [["skin", "ANATOMY", 36, 40], ["urinary", "ANATOMY", 79, 86], ["genital tract", "ANATOMY", 87, 100], ["skin infections", "DISEASE", 36, 51], ["urinary-genital tract infection", "DISEASE", 79, 110], ["pigs", "ORGANISM", 23, 27], ["skin", "ORGAN", 36, 40], ["urinary", "ORGANISM_SUBDIVISION", 79, 86], ["genital tract", "ORGANISM_SUBDIVISION", 87, 100], ["pigs", "SPECIES", 23, 27], ["All isolates", "TREATMENT", 0, 12], ["skin infections", "PROBLEM", 36, 51], ["a urinary-genital tract infection", "PROBLEM", 77, 110], ["skin", "ANATOMY", 36, 40], ["infections", "OBSERVATION", 41, 51], ["urinary", "ANATOMY", 79, 86], ["genital tract", "ANATOMY", 87, 100], ["infection", "OBSERVATION", 101, 110]]], ["Six Staphylococcus hyicus subsp. hyicus isolates, 3 S. aureus isolates (2 MRSA and 1 MSSA) and 1 S. pseudintermedius.", [["Staphylococcus hyicus", "ORGANISM", 4, 25], ["hyicus", "ORGANISM", 33, 39], ["S. aureus isolates", "ORGANISM", 52, 70], ["S. pseudintermedius", "ORGANISM", 97, 116], ["Staphylococcus hyicus subsp", "SPECIES", 4, 31], ["hyicus", "SPECIES", 33, 39], ["S. aureus", "SPECIES", 52, 61], ["MRSA", "SPECIES", 74, 78], ["S. pseudintermedius", "SPECIES", 97, 116], ["Staphylococcus hyicus subsp", "SPECIES", 4, 31], ["hyicus", "SPECIES", 33, 39], ["S. aureus", "SPECIES", 52, 61], ["S. pseudintermedius", "SPECIES", 97, 116], ["Six Staphylococcus hyicus subsp", "PROBLEM", 0, 31], ["hyicus isolates", "TEST", 33, 48], ["3 S. aureus isolates", "PROBLEM", 50, 70], ["MRSA", "PROBLEM", 74, 78], ["Staphylococcus", "OBSERVATION_MODIFIER", 4, 18], ["hyicus subsp", "OBSERVATION", 19, 31], ["aureus isolates", "OBSERVATION", 55, 70], ["pseudintermedius", "OBSERVATION", 100, 116]]], ["All these isolates harboured plasmids.", [["plasmids", "ANATOMY", 29, 37], ["plasmids", "DNA", 29, 37], ["All these isolates harboured plasmids", "TREATMENT", 0, 37], ["isolates", "OBSERVATION_MODIFIER", 10, 18], ["harboured plasmids", "OBSERVATION", 19, 37]]], ["In 7 isolates (4 S. hyicus, 2 MRSA and the single S. pseudintermedius), the plasmid location of dfrK was confirmed by protoplast transformation with subsequent susceptibility testing and PCR analysis of the transformants.", [["plasmid", "ANATOMY", 76, 83], ["protoplast", "ANATOMY", 118, 128], ["transformants", "ANATOMY", 207, 220], ["S. hyicus", "ORGANISM", 17, 26], ["S. pseudintermedius", "ORGANISM", 50, 69], ["dfrK", "GENE_OR_GENE_PRODUCT", 96, 100], ["transformants", "CELL", 207, 220], ["dfrK", "DNA", 96, 100], ["S. hyicus", "SPECIES", 17, 26], ["MRSA", "SPECIES", 30, 34], ["S. pseudintermedius", "SPECIES", 50, 69], ["S. hyicus", "SPECIES", 17, 26], ["S. pseudintermedius", "SPECIES", 50, 69], ["MRSA", "PROBLEM", 30, 34], ["protoplast transformation", "PROBLEM", 118, 143], ["subsequent susceptibility testing", "TEST", 149, 182], ["PCR analysis", "TEST", 187, 199], ["the transformants", "TREATMENT", 203, 220], ["pseudintermedius", "OBSERVATION", 53, 69], ["protoplast transformation", "OBSERVATION", 118, 143]]], ["In all 7 cases, the plasmids harbouring dfrK also carried a tet(L) tetracycline resistance gene.", [["plasmids", "ANATOMY", 20, 28], ["tetracycline", "CHEMICAL", 67, 79], ["tetracycline", "CHEMICAL", 67, 79], ["dfrK", "GENE_OR_GENE_PRODUCT", 40, 44], ["tet(L) tetracycline", "GENE_OR_GENE_PRODUCT", 60, 79], ["plasmids", "DNA", 20, 28], ["dfrK", "DNA", 40, 44], ["tet(L) tetracycline resistance gene", "DNA", 60, 95], ["a tet(L) tetracycline resistance gene", "TREATMENT", 58, 95]]], ["The results of a combined PCR assay with primers from tet(L) and dfrK confirmed that the dfrK gene was always located immediately downstream of the tet(L) gene.", [["tet(L)", "GENE_OR_GENE_PRODUCT", 54, 60], ["dfrK", "GENE_OR_GENE_PRODUCT", 65, 69], ["dfrK", "GENE_OR_GENE_PRODUCT", 89, 93], ["tet(L)", "GENE_OR_GENE_PRODUCT", 148, 154], ["tet(L)", "DNA", 54, 60], ["dfrK", "DNA", 65, 69], ["dfrK gene", "DNA", 89, 98], ["tet(L) gene", "DNA", 148, 159], ["a combined PCR assay", "TEST", 15, 35], ["primers", "TEST", 41, 48]]], ["Further analysis of these dfrK-and tet(L)-harbouring plasmids showed that they varied in size between 6 and 40 kb and that similar sized plasmids differed in their EcoRV and HindIII restriction patterns.Conclusion:The novel trimethoprim resistance gene dfrK occurred in 11 (12.2%) of the 90 porcine staphylococcal isolates from the BfT-GermVet study.", [["plasmids", "ANATOMY", 53, 61], ["plasmids", "ANATOMY", 137, 145], ["trimethoprim", "CHEMICAL", 224, 236], ["trimethoprim", "CHEMICAL", 224, 236], ["dfrK", "GENE_OR_GENE_PRODUCT", 26, 30], ["tet(L)", "GENE_OR_GENE_PRODUCT", 35, 41], ["EcoRV", "GENE_OR_GENE_PRODUCT", 164, 169], ["HindIII", "GENE_OR_GENE_PRODUCT", 174, 181], ["trimethoprim", "SIMPLE_CHEMICAL", 224, 236], ["dfrK", "GENE_OR_GENE_PRODUCT", 253, 257], ["porcine", "ORGANISM", 291, 298], ["dfrK-and tet(L)-harbouring plasmids", "DNA", 26, 61], ["plasmids", "DNA", 137, 145], ["dfrK", "DNA", 253, 257], ["Further analysis", "TEST", 0, 16], ["these dfrK", "TEST", 20, 30], ["tet(L)-harbouring plasmids", "TREATMENT", 35, 61], ["similar sized plasmids", "PROBLEM", 123, 145], ["their EcoRV and HindIII restriction patterns", "TREATMENT", 158, 202], ["The novel trimethoprim resistance gene dfrK", "TEST", 214, 257], ["the 90 porcine staphylococcal isolates", "TREATMENT", 284, 322], ["the BfT-GermVet study", "TEST", 328, 349], ["size", "OBSERVATION_MODIFIER", 89, 93], ["sized", "OBSERVATION_MODIFIER", 131, 136], ["plasmids", "OBSERVATION", 137, 145]]], ["In 8 (72.7%) of the 11 isolates, it was located on structurally diverse plasmids, however, always in close proximity to a tet(L) gene.", [["plasmids", "ANATOMY", 72, 80], ["tet(L)", "GENE_OR_GENE_PRODUCT", 122, 128], ["plasmids", "DNA", 72, 80], ["tet(L) gene", "DNA", 122, 133], ["a tet(L) gene", "TREATMENT", 120, 133], ["diverse", "OBSERVATION_MODIFIER", 64, 71], ["plasmids", "OBSERVATION", 72, 80]]], ["The linkage of the dfrK and tet(L) genes allows the maintenance and coselection of such plasmids under selective pressure by either tetracyclines or trimethoprim, both of which are widely used in veterinary medicine.", [["plasmids", "ANATOMY", 88, 96], ["tetracyclines", "CHEMICAL", 132, 145], ["trimethoprim", "CHEMICAL", 149, 161], ["tetracyclines", "CHEMICAL", 132, 145], ["trimethoprim", "CHEMICAL", 149, 161], ["dfrK", "GENE_OR_GENE_PRODUCT", 19, 23], ["tet(L)", "GENE_OR_GENE_PRODUCT", 28, 34], ["tetracyclines", "SIMPLE_CHEMICAL", 132, 145], ["trimethoprim", "SIMPLE_CHEMICAL", 149, 161], ["dfrK and tet(L) genes", "DNA", 19, 40], ["plasmids", "DNA", 88, 96], ["the dfrK and tet(L) genes", "TREATMENT", 15, 40], ["such plasmids", "TREATMENT", 83, 96], ["selective pressure", "TREATMENT", 103, 121], ["tetracyclines", "TREATMENT", 132, 145], ["trimethoprim", "TREATMENT", 149, 161]]], ["The isolates were resistant to ciprofloxacin, clindamycin, erythromycin, gentamicin but susceptible to vancomycin.", [["ciprofloxacin", "CHEMICAL", 31, 44], ["clindamycin", "CHEMICAL", 46, 57], ["erythromycin", "CHEMICAL", 59, 71], ["gentamicin", "CHEMICAL", 73, 83], ["vancomycin", "CHEMICAL", 103, 113], ["ciprofloxacin", "CHEMICAL", 31, 44], ["clindamycin", "CHEMICAL", 46, 57], ["erythromycin", "CHEMICAL", 59, 71], ["gentamicin", "CHEMICAL", 73, 83], ["vancomycin", "CHEMICAL", 103, 113], ["ciprofloxacin", "SIMPLE_CHEMICAL", 31, 44], ["clindamycin", "SIMPLE_CHEMICAL", 46, 57], ["erythromycin", "SIMPLE_CHEMICAL", 59, 71], ["gentamicin", "SIMPLE_CHEMICAL", 73, 83], ["vancomycin", "SIMPLE_CHEMICAL", 103, 113], ["The isolates", "PROBLEM", 0, 12], ["ciprofloxacin", "TREATMENT", 31, 44], ["clindamycin", "TREATMENT", 46, 57], ["erythromycin", "TREATMENT", 59, 71], ["gentamicin", "TREATMENT", 73, 83], ["vancomycin", "TREATMENT", 103, 113]]], ["Only one SE was methicillin-susceptible and two isolates were quinupristin/dalfopristin non-susceptible.", [["SE", "DISEASE", 9, 11], ["methicillin", "CHEMICAL", 16, 27], ["quinupristin", "CHEMICAL", 62, 74], ["dalfopristin", "CHEMICAL", 75, 87], ["methicillin", "CHEMICAL", 16, 27], ["quinupristin", "CHEMICAL", 62, 74], ["dalfopristin", "CHEMICAL", 75, 87], ["methicillin", "SIMPLE_CHEMICAL", 16, 27], ["quinupristin", "SIMPLE_CHEMICAL", 62, 74], ["dalfopristin", "SIMPLE_CHEMICAL", 75, 87], ["methicillin", "TREATMENT", 16, 27], ["two isolates", "TREATMENT", 44, 56], ["dalfopristin", "TREATMENT", 75, 87]]], ["All strains were clonally related and clustered into three subtypes (A, A1 and A2). cfr gene was detected in a linezolid non-susceptible strain (MIC, 64 mg/L), which was recovered from a 57 y/o male who underwent liver transplantation.", [["strain", "ANATOMY", 137, 143], ["liver", "ANATOMY", 213, 218], ["linezolid", "CHEMICAL", 111, 120], ["linezolid", "CHEMICAL", 111, 120], ["A2", "GENE_OR_GENE_PRODUCT", 79, 81], ["cfr", "GENE_OR_GENE_PRODUCT", 84, 87], ["linezolid", "SIMPLE_CHEMICAL", 111, 120], ["liver", "ORGAN", 213, 218], ["cfr gene", "DNA", 84, 92], ["All strains", "PROBLEM", 0, 11], ["a linezolid non-susceptible strain", "PROBLEM", 109, 143], ["liver transplantation", "TREATMENT", 213, 234], ["liver", "ANATOMY", 213, 218], ["transplantation", "OBSERVATION", 219, 234]]], ["Plasmid analysis identified six plasmid bands ranging from c.a.", [["plasmid bands", "DNA", 32, 45], ["Plasmid analysis", "TEST", 0, 16], ["six plasmid bands", "TEST", 28, 45], ["six", "OBSERVATION_MODIFIER", 28, 31], ["plasmid bands", "OBSERVATION", 32, 45]]], ["1.5-to 154-kb in the cfrcarrying strain.", [["the cfrcarrying strain", "PROBLEM", 17, 39]]], ["Hybridisation signals were observed from the 154-kb plasmid band as well as from a chromosomal band after I-CeuI digestion.O96 Acquisition of cfr gene by an epidemic cluster ofMutations at the 23S rRNA, L4 or L22 were not detected.Conclusion:The cfr increased the linezolid MIC value between 8-and 16-fold.", [["chromosomal", "ANATOMY", 83, 94], ["linezolid", "CHEMICAL", 264, 273], ["linezolid", "CHEMICAL", 264, 273], ["O96", "GENE_OR_GENE_PRODUCT", 123, 126], ["cfr", "GENE_OR_GENE_PRODUCT", 142, 145], ["23S", "GENE_OR_GENE_PRODUCT", 193, 196], ["rRNA", "CELLULAR_COMPONENT", 197, 201], ["L22", "GENE_OR_GENE_PRODUCT", 209, 212], ["cfr", "GENE_OR_GENE_PRODUCT", 246, 249], ["linezolid", "SIMPLE_CHEMICAL", 264, 273], ["154-kb plasmid band", "DNA", 45, 64], ["cfr gene", "DNA", 142, 150], ["23S rRNA", "DNA", 193, 201], ["L4", "DNA", 203, 205], ["L22", "DNA", 209, 212], ["Hybridisation signals", "TEST", 0, 21], ["kb plasmid band", "TREATMENT", 49, 64], ["a chromosomal band after I-CeuI digestion", "TREATMENT", 81, 122], ["an epidemic cluster ofMutations", "PROBLEM", 154, 185], ["The cfr", "TEST", 242, 249], ["the linezolid MIC value", "TEST", 260, 283], ["epidemic", "OBSERVATION_MODIFIER", 157, 165], ["L4", "ANATOMY", 203, 205], ["not detected", "UNCERTAINTY", 218, 230], ["linezolid", "OBSERVATION", 264, 273]]], ["This report highlights the ability of SE to acquire linezolid resistances.", [["SE", "DISEASE", 38, 40], ["linezolid", "CHEMICAL", 52, 61], ["linezolid", "CHEMICAL", 52, 61], ["linezolid", "SIMPLE_CHEMICAL", 52, 61], ["linezolid resistances", "TREATMENT", 52, 73], ["linezolid", "OBSERVATION", 52, 61]]], ["The potential mobility of cfr combined with the clonal tendency for dissemination among Staphylococcus spp., represent a serious threat to several potent Gram-positive-active agents, including oxazolidinones.", [["Staphylococcus spp.", "DISEASE", 88, 107], ["Gram-", "CHEMICAL", 154, 159], ["oxazolidinones", "CHEMICAL", 193, 207], ["oxazolidinones", "CHEMICAL", 193, 207], ["cfr", "GENE_OR_GENE_PRODUCT", 26, 29], ["Staphylococcus spp.", "ORGANISM", 88, 107], ["Gram-", "GENE_OR_GENE_PRODUCT", 154, 159], ["oxazolidinones", "SIMPLE_CHEMICAL", 193, 207], ["cfr", "PROTEIN", 26, 29], ["Staphylococcus spp.", "SPECIES", 88, 107], ["Staphylococcus spp.", "SPECIES", 88, 107], ["cfr", "PROBLEM", 26, 29], ["the clonal tendency", "PROBLEM", 44, 63], ["dissemination among Staphylococcus spp.", "PROBLEM", 68, 107], ["active agents", "TREATMENT", 168, 181], ["oxazolidinones", "TREATMENT", 193, 207], ["mobility", "OBSERVATION_MODIFIER", 14, 22], ["active agents", "OBSERVATION", 168, 181]]], ["Active surveillance combined with effective infection control and molecular studies seem prudent to minimise the spread of these resistance mechanisms.H. Peltola\u00b0(Helsinki, FI)The objective is to get a glimpse of the potential impact of infectious diseases on music, as regards to the composer's or performing musician's own disease, living conditions or other relevant elements which might have affected the end result, the music we enjoy today.", [["infection", "DISEASE", 44, 53], ["infectious diseases", "DISEASE", 237, 256], ["effective infection control", "TREATMENT", 34, 61], ["molecular studies", "TEST", 66, 83], ["these resistance mechanisms", "PROBLEM", 123, 150], ["infectious diseases", "PROBLEM", 237, 256], ["own disease", "PROBLEM", 321, 332], ["infectious", "OBSERVATION", 237, 247]]], ["As music is an art of senses, full of drama, despair, realities of life \u2212 or just the opposite, blissful ignorance of those realities, full of romance, beauty, and delicacy \u2212 various forms of music was researched paying special attention to infections which potentially have played a significant role in the birth of that particular piece or performance.", [["infections", "DISEASE", 241, 251], ["infections", "PROBLEM", 241, 251]]], ["Musical examples, served to the audience along with the essential background data, will show the extent to which infections have impacted music.", [["infections", "DISEASE", 113, 123], ["infections", "OBSERVATION", 113, 123]]], ["Regarding the aetiology of those infections, bacterial, viral and parasitic agents are well represented.", [["infections", "DISEASE", 33, 43], ["those infections", "PROBLEM", 27, 43], ["bacterial, viral and parasitic agents", "PROBLEM", 45, 82], ["infections", "OBSERVATION", 33, 43], ["viral", "OBSERVATION", 56, 61], ["parasitic agents", "OBSERVATION", 66, 82]]], ["In addition, many epochs in history have played their role.", [["many", "OBSERVATION_MODIFIER", 13, 17], ["epochs", "OBSERVATION", 18, 24]]], ["Sometimes, the connections are surprising, even dramatic.", [["dramatic", "OBSERVATION_MODIFIER", 48, 56]]], ["If listened to with a tender ear, music quite often turns out to be affected also by infectious diseases.", [["tender ear", "ANATOMY", 22, 32], ["infectious diseases", "DISEASE", 85, 104], ["ear", "ORGAN", 29, 32], ["a tender ear", "PROBLEM", 20, 32], ["ear", "ANATOMY", 29, 32], ["infectious", "OBSERVATION", 85, 95]]], ["As physicians we should realise the strength with which some people are driven by this demonic, divine \u2212 but altogether beautiful force: music.A. Kamarulzaman\u00b0(Kuala Lumpur, MY)The prevalence of antibiotic resistance has been increasing in Asian countries in recent years.", [["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["antibiotic resistance", "TREATMENT", 195, 216], ["antibiotic resistance", "OBSERVATION", 195, 216], ["increasing", "OBSERVATION_MODIFIER", 226, 236]]], ["This problem has most likely arisen due to a combination of inadequate infection control practices particularly in hospital settings and the widespread misuse of antibiotics in hospital and community settings.A. Kamarulzaman\u00b0(Kuala Lumpur, MY)Factors that lead to antibiotic misuse include inappropriate antibiotic prescription due to a lack of clinical, microbiological and/or imaging data in many clinical settings in the Asian region.", [["infection", "DISEASE", 71, 80], ["inadequate infection control practices", "PROBLEM", 60, 98], ["antibiotics", "TREATMENT", 162, 173], ["community settings", "TREATMENT", 190, 208], ["antibiotic misuse", "TREATMENT", 264, 281], ["inappropriate antibiotic prescription", "TREATMENT", 290, 327], ["imaging data", "TEST", 378, 390], ["most likely", "UNCERTAINTY", 17, 28], ["inadequate", "OBSERVATION_MODIFIER", 60, 70], ["infection", "OBSERVATION", 71, 80], ["widespread", "OBSERVATION_MODIFIER", 141, 151]]], ["A lack of separation of prescribing and dispensing by medical practitioners as practised in many countries in Asia as well as the easy availability of over the counter medications also contribute to antibiotic misuse.", [["the counter medications", "TREATMENT", 156, 179], ["antibiotic misuse", "PROBLEM", 199, 216]]], ["Optimal control of antibiotic use can only be achieved through a multipronged approach that includes better education of the public and medical practitioners on rational use of antibiotic, a review of the health system structure, as well as better control of over the counter sales of antibiotics.", [["antibiotic use", "TREATMENT", 19, 33], ["a multipronged approach", "TREATMENT", 63, 86], ["antibiotic", "TREATMENT", 177, 187], ["antibiotics", "TREATMENT", 285, 296]]], ["Upgrading of microbiology and other laboratories and radiological facilities that will enhance the accuracy of clinical diagnosis is also urgently needed in most developing countries to keep pace with the complexities of managing patients in this new era to minimise the widespread practise of inappropriate antibiotic use.C. \u00d8stergaard\u00b0(Herlev, DK)Examination of the CSF for microorganisms, WBC and differential counts, and concentrations of glucose and protein is the primary investigation to diagnose meningitis.", [["WBC", "ANATOMY", 392, 395], ["glucose", "CHEMICAL", 443, 450], ["meningitis", "DISEASE", 504, 514], ["glucose", "CHEMICAL", 443, 450], ["patients", "ORGANISM", 230, 238], ["CSF", "GENE_OR_GENE_PRODUCT", 368, 371], ["WBC", "CELL", 392, 395], ["glucose", "SIMPLE_CHEMICAL", 443, 450], ["patients", "SPECIES", 230, 238], ["other laboratories", "TEST", 30, 48], ["inappropriate antibiotic use", "TREATMENT", 294, 322], ["Examination of the CSF", "TEST", 349, 371], ["microorganisms", "PROBLEM", 376, 390], ["WBC", "TEST", 392, 395], ["differential counts", "TEST", 400, 419], ["glucose", "TEST", 443, 450], ["the primary investigation", "TEST", 466, 491], ["meningitis", "PROBLEM", 504, 514], ["meningitis", "OBSERVATION", 504, 514]]], ["However, this CSF examination may not always be conclusive, and it can be difficult to distinguish bacterial from viral meningitis.", [["viral meningitis", "DISEASE", 114, 130], ["CSF", "GENE_OR_GENE_PRODUCT", 14, 17], ["this CSF examination", "TEST", 9, 29], ["bacterial from viral meningitis", "PROBLEM", 99, 130], ["viral", "OBSERVATION_MODIFIER", 114, 119], ["meningitis", "OBSERVATION", 120, 130]]], ["Therefore, improvement in diagnostic sensitivity and specificity of bacterial meningitis and development of rapid test for a bacterial aetiology are still needed.", [["meningitis", "DISEASE", 78, 88], ["diagnostic sensitivity", "TEST", 26, 48], ["bacterial meningitis", "PROBLEM", 68, 88], ["rapid test", "TEST", 108, 118], ["a bacterial aetiology", "PROBLEM", 123, 144], ["improvement", "OBSERVATION_MODIFIER", 11, 22], ["bacterial", "OBSERVATION_MODIFIER", 68, 77], ["meningitis", "OBSERVATION", 78, 88]]], ["This presentation gives a review of the strength and weakness of several analyses and methods to reveal the microbiological agent (i.e. CSF microscopy and culture, antigen or antibody detection, molecular methods to detect DNA or RNA) and the use of several mediators of the host immune response for diagnostic and prognostic purposes.D. van de Beek\u00b0(Amsterdam, NL)Bacterial meningitis is a medical emergency that requires a multidisciplinary approach.", [["Bacterial meningitis", "DISEASE", 365, 385], ["DNA", "CELLULAR_COMPONENT", 223, 226], ["weakness", "PROBLEM", 53, 61], ["several analyses", "TEST", 65, 81], ["CSF microscopy", "TEST", 136, 150], ["culture", "TEST", 155, 162], ["antigen", "TEST", 164, 171], ["antibody detection", "TEST", 175, 193], ["DNA", "PROBLEM", 223, 226], ["prognostic purposes", "TEST", 315, 334], ["Bacterial meningitis", "PROBLEM", 365, 385], ["a multidisciplinary approach", "TREATMENT", 423, 451], ["Bacterial", "OBSERVATION_MODIFIER", 365, 374], ["meningitis", "OBSERVATION", 375, 385]]], ["A diagnosis of bacterial meningitis is often considered, but the disease can be difficult to recognize.", [["bacterial meningitis", "DISEASE", 15, 35], ["bacterial meningitis", "PROBLEM", 15, 35], ["the disease", "PROBLEM", 61, 72], ["bacterial", "OBSERVATION_MODIFIER", 15, 24], ["meningitis", "OBSERVATION", 25, 35], ["disease", "OBSERVATION", 65, 72]]], ["Recommendations for antimicrobial therapy are changing as a result of the emergence of antimicrobial resistance.", [["antimicrobial therapy", "TREATMENT", 20, 41], ["antimicrobial resistance", "TREATMENT", 87, 111], ["antimicrobial resistance", "OBSERVATION", 87, 111]]], ["In this lecture, current concepts of the initial approach to the treatment of adults with bacterial meningitis will be summarised.", [["bacterial meningitis", "DISEASE", 90, 110], ["adults", "ORGANISM", 78, 84], ["bacterial meningitis", "PROBLEM", 90, 110], ["meningitis", "OBSERVATION", 100, 110]]], ["The management of the critically ill patient with bacterial meningitis poses important dilemmas.", [["critically ill", "DISEASE", 22, 36], ["bacterial meningitis", "DISEASE", 50, 70], ["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["bacterial meningitis", "PROBLEM", 50, 70], ["bacterial", "OBSERVATION_MODIFIER", 50, 59], ["meningitis", "OBSERVATION", 60, 70]]], ["Controversial areas (i.e., prehospital admission antibiotics) will be reviewed and relevant literature will be discussed in the framework of current treatment guidelines, highlighting new developments in adjunctive dexamethasone therapy.U. Koedel\u00b0(Munich, DE)Acute bacterial meningitis (ABM), especifically when caused by infection with Streptococcus pneumoniae, still has an unacceptably poor prognosis with a mortality of 10\u221230%.", [["dexamethasone", "CHEMICAL", 215, 228], ["bacterial meningitis", "DISEASE", 265, 285], ["ABM", "DISEASE", 287, 290], ["infection", "DISEASE", 322, 331], ["Streptococcus pneumoniae", "DISEASE", 337, 361], ["dexamethasone", "CHEMICAL", 215, 228], ["dexamethasone", "SIMPLE_CHEMICAL", 215, 228], ["Streptococcus pneumoniae", "ORGANISM", 337, 361], ["Streptococcus pneumoniae", "SPECIES", 337, 361], ["Streptococcus pneumoniae", "SPECIES", 337, 361], ["Controversial areas", "PROBLEM", 0, 19], ["prehospital admission antibiotics", "TREATMENT", 27, 60], ["current treatment guidelines", "TREATMENT", 141, 169], ["adjunctive dexamethasone therapy", "TREATMENT", 204, 236], ["Acute bacterial meningitis", "PROBLEM", 259, 285], ["infection", "PROBLEM", 322, 331], ["Streptococcus pneumoniae", "PROBLEM", 337, 361], ["Acute", "OBSERVATION_MODIFIER", 259, 264], ["bacterial", "OBSERVATION_MODIFIER", 265, 274], ["meningitis", "OBSERVATION", 275, 285], ["infection", "OBSERVATION", 322, 331], ["Streptococcus pneumoniae", "OBSERVATION", 337, 361], ["unacceptably", "OBSERVATION_MODIFIER", 376, 388]]], ["Bacterial infection of the meninges causes one of the most powerful inflammatory reactions known in medicine.", [["meninges", "ANATOMY", 27, 35], ["infection of the meninges", "DISEASE", 10, 35], ["meninges", "ORGAN", 27, 35], ["Bacterial infection of the meninges", "PROBLEM", 0, 35], ["the most powerful inflammatory reactions", "PROBLEM", 50, 90], ["infection", "OBSERVATION", 10, 19], ["meninges", "ANATOMY", 27, 35], ["powerful", "OBSERVATION_MODIFIER", 59, 67], ["inflammatory", "OBSERVATION", 68, 80]]], ["Yet 50 years ago, this inflammatory reaction was suggested to contribute substantially to brain damage.", [["brain", "ANATOMY", 90, 95], ["brain damage", "DISEASE", 90, 102], ["brain", "ORGAN", 90, 95], ["this inflammatory reaction", "PROBLEM", 18, 44], ["brain damage", "PROBLEM", 90, 102], ["inflammatory", "OBSERVATION_MODIFIER", 23, 35], ["brain", "ANATOMY", 90, 95], ["damage", "OBSERVATION", 96, 102]]], ["This concept underlies the use of anti-inflammatory agents as adjunctive therapy in ABM.", [["anti-inflammatory agents", "TREATMENT", 34, 58], ["adjunctive therapy", "TREATMENT", 62, 80], ["ABM", "PROBLEM", 84, 87]]], ["Of all adjunctive treatments in ABM, only corticosteroids have been properly evaluated in clinical trials.", [["corticosteroids", "CHEMICAL", 42, 57], ["corticosteroids", "SIMPLE_CHEMICAL", 42, 57], ["all adjunctive treatments", "TREATMENT", 3, 28], ["ABM", "TREATMENT", 32, 35], ["corticosteroids", "TREATMENT", 42, 57], ["adjunctive", "OBSERVATION_MODIFIER", 7, 17]]], ["These trials recommend corticosteroids in patients with Haemophilus influenzae type B and pneumococcal meningitis (PM).", [["Haemophilus influenzae type B", "DISEASE", 56, 85], ["pneumococcal meningitis", "DISEASE", 90, 113], ["corticosteroids", "CHEMICAL", 23, 38], ["patients", "ORGANISM", 42, 50], ["Haemophilus influenzae type B", "ORGANISM", 56, 85], ["patients", "SPECIES", 42, 50], ["Haemophilus influenzae", "SPECIES", 56, 78], ["Haemophilus influenzae type B", "SPECIES", 56, 85], ["pneumococcal", "SPECIES", 90, 102], ["corticosteroids", "TREATMENT", 23, 38], ["Haemophilus influenzae type B", "PROBLEM", 56, 85], ["pneumococcal meningitis", "PROBLEM", 90, 113], ["pneumococcal", "OBSERVATION_MODIFIER", 90, 102], ["meningitis", "OBSERVATION", 103, 113]]], ["However, adjunctive corticosteroid therapy has several weaknesses such as a narrow treatment window and borderline effects on neurologic sequelae.", [["neurologic", "ANATOMY", 126, 136], ["neurologic sequelae", "DISEASE", 126, 145], ["adjunctive corticosteroid therapy", "TREATMENT", 9, 42], ["several weaknesses", "PROBLEM", 47, 65], ["a narrow treatment window", "TREATMENT", 74, 99], ["borderline effects on neurologic sequelae", "PROBLEM", 104, 145], ["corticosteroid therapy", "OBSERVATION", 20, 42], ["narrow", "OBSERVATION_MODIFIER", 76, 82]]], ["Thus, there is still the need for additional or alternate adjuvants in the therapy of ABM.", [["alternate adjuvants", "TREATMENT", 48, 67], ["the therapy of ABM", "TREATMENT", 71, 89]]], ["Experimental studies using animal models (predominantly of PM) have provided insight into the pathogenic mechanisms underlying brain injury in ABM.", [["brain", "ANATOMY", 127, 132], ["brain injury", "DISEASE", 127, 139], ["PM", "MULTI-TISSUE_STRUCTURE", 59, 61], ["brain", "ORGAN", 127, 132], ["Experimental studies", "TEST", 0, 20], ["animal models", "TEST", 27, 40], ["brain injury in ABM", "PROBLEM", 127, 146], ["brain", "ANATOMY", 127, 132], ["injury", "OBSERVATION", 133, 139]]], ["It is now clear that the autodestructive inflammatory reaction is initiated by the interaction of bacterial components with host pattern recognition receptors (PRR) like Toll-like receptors (TLR).", [["host pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 124, 158], ["PRR", "GENE_OR_GENE_PRODUCT", 160, 163], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 170, 189], ["TLR", "GENE_OR_GENE_PRODUCT", 191, 194], ["host pattern recognition receptors", "PROTEIN", 124, 158], ["PRR", "PROTEIN", 160, 163], ["Toll-like receptors", "PROTEIN", 170, 189], ["TLR", "PROTEIN", 191, 194], ["the autodestructive inflammatory reaction", "PROBLEM", 21, 62], ["bacterial components", "TREATMENT", 98, 118], ["clear", "OBSERVATION", 10, 15], ["autodestructive", "OBSERVATION_MODIFIER", 25, 40], ["inflammatory", "OBSERVATION_MODIFIER", 41, 53], ["reaction", "OBSERVATION", 54, 62]]], ["PRR signaling results in the activation of transcription factors like NF-kB which up-regulate the production of proinflammatory cytokines.", [["PRR", "GENE_OR_GENE_PRODUCT", 0, 3], ["NF-kB", "GENE_OR_GENE_PRODUCT", 70, 75], ["PRR", "PROTEIN", 0, 3], ["transcription factors", "PROTEIN", 43, 64], ["NF-kB", "PROTEIN", 70, 75], ["proinflammatory cytokines", "PROTEIN", 112, 137], ["transcription factors", "PROBLEM", 43, 64], ["proinflammatory cytokines", "PROBLEM", 112, 137], ["proinflammatory cytokines", "OBSERVATION", 112, 137]]], ["Cytokines like IL-1b are also potent triggers of NF-kB activation and therefore can exaggerate the inflammatory reaction (via positive feedback loops).", [["IL-1b", "GENE_OR_GENE_PRODUCT", 15, 20], ["NF-kB", "GENE_OR_GENE_PRODUCT", 49, 54], ["Cytokines", "PROTEIN", 0, 9], ["IL-1b", "PROTEIN", 15, 20], ["NF-kB", "PROTEIN", 49, 54], ["NF-kB activation", "TREATMENT", 49, 65], ["the inflammatory reaction", "PROBLEM", 95, 120], ["potent", "OBSERVATION_MODIFIER", 30, 36], ["inflammatory", "OBSERVATION_MODIFIER", 99, 111]]], ["As a consequence, great numbers of neutrophils are recruited to the meninges.", [["neutrophils", "ANATOMY", 35, 46], ["meninges", "ANATOMY", 68, 76], ["neutrophils", "CELL", 35, 46], ["meninges", "ORGAN", 68, 76], ["neutrophils", "CELL_TYPE", 35, 46], ["great", "OBSERVATION_MODIFIER", 18, 23], ["numbers", "OBSERVATION_MODIFIER", 24, 31], ["neutrophils", "OBSERVATION", 35, 46], ["meninges", "ANATOMY", 68, 76]]], ["Activated neutrophils release many potentially cytotoxic agents including oxidants and matrix metalloproteinases that can cause collateral damage to brain tissue.", [["neutrophils", "ANATOMY", 10, 21], ["collateral", "ANATOMY", 128, 138], ["brain tissue", "ANATOMY", 149, 161], ["collateral damage", "DISEASE", 128, 145], ["neutrophils", "CELL", 10, 21], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 87, 112], ["collateral", "TISSUE", 128, 138], ["brain tissue", "TISSUE", 149, 161], ["Activated neutrophils", "CELL_TYPE", 0, 21], ["matrix metalloproteinases", "PROTEIN", 87, 112], ["Activated neutrophils release", "TREATMENT", 0, 29], ["cytotoxic agents", "TREATMENT", 47, 63], ["oxidants and matrix metalloproteinases", "TREATMENT", 74, 112], ["collateral damage to brain tissue", "PROBLEM", 128, 161], ["collateral damage", "OBSERVATION", 128, 145], ["brain tissue", "OBSERVATION", 149, 161]]], ["Additionally to the inflammatory response, direct bacterial cytotoxicty has been identified as a contributor to tissue damage in ABM.", [["tissue", "ANATOMY", 112, 118], ["tissue", "TISSUE", 112, 118], ["the inflammatory response", "PROBLEM", 16, 41], ["direct bacterial cytotoxicty", "PROBLEM", 43, 71], ["tissue damage in ABM", "PROBLEM", 112, 132], ["inflammatory", "OBSERVATION_MODIFIER", 20, 32]]], ["Thus, experimental studies point at four different targets of adjunctive therapy, namely interference with (I) the induction of inflammation (e.g., TLR blockade), (II) the exaggeration of inflammation (e.g., IL-1 antagonism), and (III+IV) the generation of cytotoxic factors (either of host or bacterial origin, e.g., scavenging of oxidants).", [["inflammation", "DISEASE", 128, 140], ["inflammation", "DISEASE", 188, 200], ["TLR", "GENE_OR_GENE_PRODUCT", 148, 151], ["IL-1", "GENE_OR_GENE_PRODUCT", 208, 212], ["TLR", "PROTEIN", 148, 151], ["cytotoxic factors", "PROTEIN", 257, 274], ["experimental studies", "TEST", 6, 26], ["adjunctive therapy", "TREATMENT", 62, 80], ["inflammation", "PROBLEM", 128, 140], ["TLR blockade", "TREATMENT", 148, 160], ["inflammation", "PROBLEM", 188, 200], ["IL", "TEST", 208, 210], ["cytotoxic factors", "PROBLEM", 257, 274], ["bacterial origin", "PROBLEM", 294, 310], ["inflammation", "OBSERVATION", 128, 140], ["inflammation", "OBSERVATION", 188, 200], ["cytotoxic factors", "OBSERVATION", 257, 274], ["bacterial origin", "OBSERVATION_MODIFIER", 294, 310]]], ["This presentation will give an overview of the pathophysiology of ABM (with special emphasis on PM) and highlight promising targets for adjunctive therapy in ABM, as deduced from experimental studies.U. Koedel\u00b0(Munich, DE)A clinician's approach to managing difficult infections S120 Acute post-surgical prosthetic joint infectionJ.", [["joint", "ANATOMY", 314, 319], ["ABM", "DISEASE", 66, 69], ["infections", "DISEASE", 267, 277], ["post-surgical prosthetic joint infectionJ", "DISEASE", 289, 330], ["PM", "MULTI-TISSUE_STRUCTURE", 96, 98], ["ABM", "PROBLEM", 66, 69], ["adjunctive therapy", "TREATMENT", 136, 154], ["ABM", "PROBLEM", 158, 161], ["experimental studies", "TEST", 179, 199], ["difficult infections", "PROBLEM", 257, 277], ["Acute post-surgical prosthetic joint infectionJ", "PROBLEM", 283, 330], ["Acute", "OBSERVATION_MODIFIER", 283, 288], ["post-surgical", "OBSERVATION_MODIFIER", 289, 302], ["prosthetic joint infectionJ", "OBSERVATION", 303, 330]]], ["Cobo\u00b0(Madrid, ES)Optimal management of prosthetic joint infections (PJI) remains undefined.", [["joint", "ANATOMY", 50, 55], ["prosthetic joint infections", "DISEASE", 39, 66], ["PJI", "DISEASE", 68, 71], ["joint", "MULTI-TISSUE_STRUCTURE", 50, 55], ["Cobo\u00b0(Madrid, ES)", "TREATMENT", 0, 17], ["prosthetic joint infections", "PROBLEM", 39, 66], ["PJI", "PROBLEM", 68, 71], ["prosthetic joint infections", "OBSERVATION", 39, 66], ["PJI", "OBSERVATION", 68, 71]]], ["Important issues such us when the implant can be retained (conservative strategy), optimal duration of antimicrobial therapy (AT) or the role of rifampin are yet matter of controversy.", [["rifampin", "CHEMICAL", 145, 153], ["rifampin", "CHEMICAL", 145, 153], ["rifampin", "SIMPLE_CHEMICAL", 145, 153], ["the implant", "TREATMENT", 30, 41], ["conservative strategy)", "TREATMENT", 59, 81], ["antimicrobial therapy", "TREATMENT", 103, 124], ["rifampin", "TREATMENT", 145, 153]]], ["In spite of a number of reports, literature appears confusing.", [["confusing", "PROBLEM", 52, 61]]], ["Among the limitations of the literature we must emphasize: 1) Different criteria to classify PJI; 2) Different criteria to select for conservative strategy (CS); 3) No description of the initial population from which patients were selected for CS; 4) Very different AT (from 4 weeks to chronic suppressive therapy); 5) Low numbers of patients or short follow-up; 6) Absence of clinical trials.", [["PJI", "DISEASE", 93, 96], ["patients", "ORGANISM", 217, 225], ["patients", "ORGANISM", 334, 342], ["patients", "SPECIES", 217, 225], ["patients", "SPECIES", 334, 342], ["PJI", "PROBLEM", 93, 96], ["conservative strategy (CS)", "TREATMENT", 134, 160], ["chronic suppressive therapy", "TREATMENT", 286, 313]]], ["The most useful classification to approach PJI was proposed by Tsukayama (1996) .", [["PJI", "DISEASE", 43, 46], ["approach PJI", "TREATMENT", 34, 46], ["PJI", "OBSERVATION", 43, 46]]], ["In his series 25 out of 35 patients with early PJI managed by a CS (debridement, exchange of polyethylen and implant retention) were cured after 4 weeks of AT.", [["PJI", "DISEASE", 47, 50], ["polyethylen", "CHEMICAL", 93, 104], ["polyethylen", "CHEMICAL", 93, 104], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["early PJI", "PROBLEM", 41, 50], ["a CS (debridement", "TREATMENT", 62, 79], ["polyethylen and implant retention", "TREATMENT", 93, 126], ["PJI", "OBSERVATION", 47, 50]]], ["The Spanish group for the study of PJI was constituted in 2003 within the Spanish network for the study of infectious pathology (REIPI), a public funded initiative.", [["PJI", "DISEASE", 35, 38], ["REIPI", "DISEASE", 129, 134], ["the study", "TEST", 22, 31], ["PJI", "PROBLEM", 35, 38], ["the study", "TEST", 94, 103]]], ["Data from 139 consecutive cases of early PJI attended in 10 hospitals were recorded in an online database.", [["PJI", "DISEASE", 41, 44], ["PJI", "CANCER", 41, 44], ["early PJI", "PROBLEM", 35, 44], ["PJI", "OBSERVATION", 41, 44]]], ["117 cases managed with CS could be analysed (mean followup of 2 years).", [["CS", "TREATMENT", 23, 25]]], ["Sixty-seven patients (57.3%) were cured after a mean of 81 days of AT.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["In 35 (29.9%) the infection was not controlled (or relapsed) after a mean of 84 days of AT, and the implant had to be removed.", [["infection", "DISEASE", 18, 27], ["the infection", "PROBLEM", 14, 27], ["the implant", "TREATMENT", 96, 107], ["infection", "OBSERVATION", 18, 27]]], ["In other 15 patients (12.8%) the implant was not removed, but suppressive AT was given because of suspected ongoing infection.", [["infection", "DISEASE", 116, 125], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["the implant", "TREATMENT", 29, 40], ["ongoing infection", "PROBLEM", 108, 125], ["ongoing", "OBSERVATION_MODIFIER", 108, 115], ["infection", "OBSERVATION", 116, 125]]], ["No other factors resulted statistically significant, but there was a trend of worse results for MRSA produced infections (p = 0.06).", [["MRSA", "DISEASE", 96, 100], ["infections", "DISEASE", 110, 120], ["MRSA", "SPECIES", 96, 100], ["MRSA", "SPECIES", 96, 100], ["MRSA produced infections", "PROBLEM", 96, 120]]], ["Time from the symptoms appearance to debridement was shorter in successfully treated cases (median, 7 days) than in failures (median, 10 days); p = 0.08.", [["the symptoms", "PROBLEM", 10, 22], ["debridement", "TREATMENT", 37, 48], ["debridement", "OBSERVATION", 37, 48]]], ["Good functional results were obtained in patients with successfully CS.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49]]], ["In summary, a substantial proportion of early PJI can be managed with CS strategy and a definite (non suppressive) AT.", [["PJI", "DISEASE", 46, 49], ["PJI", "CANCER", 46, 49], ["early PJI", "PROBLEM", 40, 49], ["CS strategy", "TREATMENT", 70, 81], ["a definite (non suppressive) AT", "PROBLEM", 86, 117], ["early", "OBSERVATION_MODIFIER", 40, 45], ["PJI", "OBSERVATION", 46, 49]]], ["It is difficult to identify patients at higher risk for failure, although MRSA aetiology and longer time until debridement seem to predict failures.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["MRSA", "SPECIES", 74, 78], ["failure", "PROBLEM", 56, 63], ["MRSA aetiology", "PROBLEM", 74, 88], ["debridement", "TREATMENT", 111, 122], ["failures", "PROBLEM", 139, 147], ["failure", "OBSERVATION", 56, 63], ["MRSA", "OBSERVATION", 74, 78]]], ["Different outcomes in some centres suggest that surgical technique could be an important factor for failure.J.L. Mainardi\u00b0(Paris, FR)More than 3 million cardiac pacing systems are implanted worldwide and the estimated rate of infections after implantation of permanent endocardial leads is 1% to 2%, but varies between 0.1 to 20%.", [["cardiac", "ANATOMY", 153, 160], ["endocardial", "ANATOMY", 269, 280], ["infections", "DISEASE", 226, 236], ["endocardial", "MULTI-TISSUE_STRUCTURE", 269, 280], ["surgical technique", "TREATMENT", 48, 66], ["failure", "PROBLEM", 100, 107], ["Mainardi\u00b0(Paris, FR)", "TREATMENT", 113, 133], ["3 million cardiac pacing systems", "TREATMENT", 143, 175], ["the estimated rate of infections", "PROBLEM", 204, 236], ["implantation of permanent endocardial leads", "TREATMENT", 243, 286], ["surgical", "OBSERVATION", 48, 56], ["failure", "OBSERVATION", 100, 107], ["pacing", "OBSERVATION", 161, 167], ["infections", "OBSERVATION", 226, 236], ["permanent", "OBSERVATION_MODIFIER", 259, 268], ["endocardial leads", "OBSERVATION", 269, 286]]], ["Pacemaker infections correspond to different clinical situations including localised infection in the device pocket, pacemaker leads to systemic infection associated with bacteraemia and lead-associated endocarditis.", [["Pacemaker infections", "DISEASE", 0, 20], ["infection", "DISEASE", 85, 94], ["systemic infection", "DISEASE", 136, 154], ["bacteraemia", "DISEASE", 171, 182], ["endocarditis", "DISEASE", 203, 215], ["Pacemaker infections", "PROBLEM", 0, 20], ["different clinical situations", "PROBLEM", 35, 64], ["localised infection in the device pocket", "PROBLEM", 75, 115], ["pacemaker", "TREATMENT", 117, 126], ["systemic infection", "PROBLEM", 136, 154], ["bacteraemia", "PROBLEM", 171, 182], ["lead-associated endocarditis", "PROBLEM", 187, 215], ["infections", "OBSERVATION", 10, 20], ["different", "OBSERVATION_MODIFIER", 35, 44], ["localised", "OBSERVATION_MODIFIER", 75, 84], ["infection", "OBSERVATION", 85, 94], ["pocket", "OBSERVATION_MODIFIER", 109, 115], ["pacemaker", "OBSERVATION", 117, 126], ["systemic", "OBSERVATION_MODIFIER", 136, 144], ["infection", "OBSERVATION", 145, 154], ["bacteraemia", "OBSERVATION", 171, 182], ["endocarditis", "OBSERVATION", 203, 215]]], ["This latter represents 10 to 25% of all cases of pacemaker infections.", [["pacemaker infections", "DISEASE", 49, 69], ["pacemaker infections", "PROBLEM", 49, 69], ["10 to 25", "OBSERVATION_MODIFIER", 23, 31], ["pacemaker infections", "OBSERVATION", 49, 69]]], ["The severity of pacemaker related infective endocarditis is sustained by a mortality range between 10 to 20%.", [["infective endocarditis", "DISEASE", 34, 56], ["pacemaker", "TREATMENT", 16, 25], ["infective endocarditis", "PROBLEM", 34, 56], ["pacemaker", "OBSERVATION", 16, 25], ["infective", "OBSERVATION_MODIFIER", 34, 43], ["endocarditis", "OBSERVATION", 44, 56]]], ["Risk factors related to infections of implanted pacemakers are correlated with fever before 24 h before implantation, temporary pacing before implantation and early re-interventions (haematoma, lead dislodgment).", [["infections", "DISEASE", 24, 34], ["fever", "DISEASE", 79, 84], ["haematoma", "DISEASE", 183, 192], ["Risk factors", "PROBLEM", 0, 12], ["infections of implanted pacemakers", "TREATMENT", 24, 58], ["fever", "PROBLEM", 79, 84], ["implantation", "TREATMENT", 104, 116], ["temporary pacing", "TREATMENT", 118, 134], ["implantation", "TREATMENT", 142, 154], ["early re-interventions", "TREATMENT", 159, 181], ["haematoma", "PROBLEM", 183, 192], ["lead dislodgment", "PROBLEM", 194, 210], ["implanted pacemakers", "OBSERVATION", 38, 58], ["haematoma", "OBSERVATION", 183, 192]]], ["In contrast, an inverse correlation is observed between development of infection and antibiotic prophylaxis and implantation of a new system.", [["infection", "DISEASE", 71, 80], ["infection", "PROBLEM", 71, 80], ["antibiotic prophylaxis", "TREATMENT", 85, 107], ["implantation", "TREATMENT", 112, 124], ["a new system", "TREATMENT", 128, 140], ["infection", "OBSERVATION", 71, 80], ["antibiotic prophylaxis", "OBSERVATION", 85, 107], ["new", "OBSERVATION_MODIFIER", 130, 133]]], ["Data to guide therapy in patients with pacemaker infection are limited and the most appropriate management remains to be determined.", [["pacemaker infection", "DISEASE", 39, 58], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["therapy", "TREATMENT", 14, 21], ["pacemaker infection", "PROBLEM", 39, 58], ["infection", "OBSERVATION", 49, 58]]], ["According to different series, staphylococci accounted for 60 to >90% of the responsible organisms.", [["staphylococci", "DISEASE", 31, 44], ["staphylococci", "CANCER", 31, 44], ["staphylococci", "PROBLEM", 31, 44]]], ["Coagulase-negative staphylococci (CNS) are reported as predominant pathogens following by Staphylocococcus aureus.", [["CNS", "ANATOMY", 34, 37], ["Coagulase-negative staphylococci", "GENE_OR_GENE_PRODUCT", 0, 32], ["CNS", "ANATOMICAL_SYSTEM", 34, 37], ["Staphylocococcus aureus", "ORGANISM", 90, 113], ["Staphylocococcus aureus", "SPECIES", 90, 113], ["Staphylocococcus aureus", "SPECIES", 90, 113], ["Coagulase", "TEST", 0, 9], ["staphylococci", "PROBLEM", 19, 32], ["predominant pathogens", "PROBLEM", 55, 76], ["Staphylocococcus aureus", "PROBLEM", 90, 113], ["negative staphylococci", "OBSERVATION", 10, 32]]], ["The biofilm production, responsible for bacterial survival, and the emergence of methicillin-resistant in S. aureus and CNS have complicated the management of pacemaker infections.", [["biofilm", "ANATOMY", 4, 11], ["CNS", "ANATOMY", 120, 123], ["methicillin", "CHEMICAL", 81, 92], ["pacemaker infections", "DISEASE", 159, 179], ["methicillin", "CHEMICAL", 81, 92], ["methicillin", "SIMPLE_CHEMICAL", 81, 92], ["S. aureus", "ORGANISM", 106, 115], ["CNS", "ANATOMICAL_SYSTEM", 120, 123], ["S. aureus", "SPECIES", 106, 115], ["S. aureus", "SPECIES", 106, 115], ["The biofilm production", "PROBLEM", 0, 22], ["bacterial survival", "PROBLEM", 40, 58], ["methicillin", "TREATMENT", 81, 92], ["S. aureus", "PROBLEM", 106, 115], ["pacemaker infections", "PROBLEM", 159, 179], ["biofilm production", "OBSERVATION", 4, 22], ["aureus", "OBSERVATION", 109, 115], ["pacemaker infections", "OBSERVATION", 159, 179]]], ["This implies that empiric treatment of suspected pacemaker infection should coverage for staphylococci including methicillin-resistant strains.", [["pacemaker infection", "DISEASE", 49, 68], ["staphylococci", "DISEASE", 89, 102], ["methicillin", "CHEMICAL", 113, 124], ["methicillin", "CHEMICAL", 113, 124], ["methicillin", "SIMPLE_CHEMICAL", 113, 124], ["empiric treatment", "TREATMENT", 18, 35], ["suspected pacemaker infection", "PROBLEM", 39, 68], ["staphylococci", "PROBLEM", 89, 102], ["methicillin", "TREATMENT", 113, 124], ["resistant strains", "PROBLEM", 125, 142], ["pacemaker infection", "OBSERVATION", 49, 68]]], ["Streptococci, Corynebacterium spp, Propionibacterium acnes, Gram-negative bacilli and Candida spp can cause occasional infections.", [["Candida spp", "DISEASE", 86, 97], ["infections", "DISEASE", 119, 129], ["Corynebacterium spp", "ORGANISM", 14, 33], ["Propionibacterium acnes", "ORGANISM", 35, 58], ["Gram-", "GENE_OR_GENE_PRODUCT", 60, 65], ["Candida spp", "ORGANISM", 86, 97], ["Corynebacterium spp", "SPECIES", 14, 33], ["Propionibacterium acnes", "SPECIES", 35, 58], ["Corynebacterium spp", "SPECIES", 14, 33], ["Propionibacterium acnes", "SPECIES", 35, 58], ["Candida spp", "SPECIES", 86, 97], ["Streptococci", "TEST", 0, 12], ["Corynebacterium spp", "TEST", 14, 33], ["Propionibacterium acnes", "PROBLEM", 35, 58], ["Gram-negative bacilli", "PROBLEM", 60, 81], ["Candida spp", "PROBLEM", 86, 97], ["occasional infections", "PROBLEM", 108, 129], ["Corynebacterium spp", "OBSERVATION", 14, 33], ["infections", "OBSERVATION", 119, 129]]], ["The optimal therapy combines complete device extraction (percutaneous ablation or surgical removal during extracorporeal circulation) and prolonged course of antibiotics, in particular in case of multiresistant bacteria.", [["percutaneous", "ANATOMY", 57, 69], ["extracorporeal", "ANATOMY", 106, 120], ["The optimal therapy", "TREATMENT", 0, 19], ["complete device extraction", "TREATMENT", 29, 55], ["percutaneous ablation", "TREATMENT", 57, 78], ["surgical removal", "TREATMENT", 82, 98], ["extracorporeal circulation", "TREATMENT", 106, 132], ["antibiotics", "TREATMENT", 158, 169], ["multiresistant bacteria", "PROBLEM", 196, 219], ["multiresistant bacteria", "OBSERVATION", 196, 219]]], ["Leaving the device intact is associated with increased mortality and risk of relapsing or persistent infections.", [["infections", "DISEASE", 101, 111], ["the device", "TREATMENT", 8, 18], ["increased mortality", "PROBLEM", 45, 64], ["persistent infections", "PROBLEM", 90, 111], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["mortality", "OBSERVATION", 55, 64], ["relapsing", "OBSERVATION_MODIFIER", 77, 86], ["persistent", "OBSERVATION_MODIFIER", 90, 100], ["infections", "OBSERVATION", 101, 111]]], ["In absence of prospective studies, the duration of antibiotic treatment remains to be determined but 1 month has been shown not to be associated with an increased incidence of relapse.", [["prospective studies", "TEST", 14, 33], ["antibiotic treatment", "TREATMENT", 51, 71], ["an increased incidence of relapse", "PROBLEM", 150, 183], ["not to be associated with", "UNCERTAINTY", 124, 149], ["increased", "OBSERVATION_MODIFIER", 153, 162], ["relapse", "OBSERVATION", 176, 183]]], ["Shortest course of treatment (2 weeks) has been proposed in case of vegetations strictly localised to leads without affecting cardiac valves.", [["cardiac valves", "ANATOMY", 126, 140], ["vegetations", "PATHOLOGICAL_FORMATION", 68, 79], ["cardiac valves", "MULTI-TISSUE_STRUCTURE", 126, 140], ["treatment", "TREATMENT", 19, 28], ["vegetations", "PROBLEM", 68, 79], ["cardiac valves", "TREATMENT", 126, 140], ["vegetations", "OBSERVATION", 68, 79], ["cardiac valves", "ANATOMY", 126, 140]]], ["Antibiotic therapy working alone should be reserved for highly selected patients.S. Sacar\u00b0(Denizli, TR)Infection remains the most critical complication of ventriculoperitoneal shunt placement with an incidence of 2.2\u221239%.", [["ventriculoperitoneal", "ANATOMY", 155, 175], ["Infection", "DISEASE", 103, 112], ["patients", "ORGANISM", 72, 80], ["ventriculoperitoneal shunt", "PATHOLOGICAL_FORMATION", 155, 181], ["patients", "SPECIES", 72, 80], ["Antibiotic therapy", "TREATMENT", 0, 18], ["Sacar\u00b0(Denizli, TR)Infection", "PROBLEM", 84, 112], ["ventriculoperitoneal shunt placement", "TREATMENT", 155, 191], ["Infection", "OBSERVATION", 103, 112], ["ventriculoperitoneal shunt", "OBSERVATION", 155, 181]]], ["Factors as the age of patient, aetiology of hydrocephalus, the type of shunt implanted, and the surgeon's experience are determined to be associated with increased risk of infection.", [["hydrocephalus", "DISEASE", 44, 57], ["infection", "DISEASE", 172, 181], ["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["hydrocephalus", "PROBLEM", 44, 57], ["shunt implanted", "TREATMENT", 71, 86], ["infection", "PROBLEM", 172, 181], ["hydrocephalus", "OBSERVATION", 44, 57], ["shunt implanted", "OBSERVATION", 71, 86], ["infection", "OBSERVATION", 172, 181]]], ["Children are more likely than adults to acquire shunt infection.", [["shunt infection", "DISEASE", 48, 63], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["shunt infection", "PROBLEM", 48, 63], ["more likely", "UNCERTAINTY", 13, 24], ["infection", "OBSERVATION", 54, 63]]], ["The possible reasons are longer hospital stay, higher skin bacterial concentrations, immature immune systems, or more adherent strains of bacteria.", [["skin", "ANATOMY", 54, 58], ["skin", "ORGAN", 54, 58], ["higher skin bacterial concentrations", "PROBLEM", 47, 83], ["immature immune systems", "PROBLEM", 85, 108], ["more adherent strains of bacteria", "PROBLEM", 113, 146], ["possible", "UNCERTAINTY", 4, 12], ["skin", "ANATOMY", 54, 58], ["bacterial concentrations", "OBSERVATION", 59, 83], ["more adherent", "OBSERVATION_MODIFIER", 113, 126]]], ["Staphylococci, as skin commensals, are the main causative organisms.", [["skin", "ANATOMY", 18, 22], ["Staphylococci", "DISEASE", 0, 13], ["skin", "ORGAN", 18, 22], ["Staphylococci", "PROBLEM", 0, 13], ["skin", "ANATOMY", 18, 22], ["main", "OBSERVATION_MODIFIER", 43, 47], ["causative organisms", "OBSERVATION", 48, 67]]], ["Nevertheless, in recent years a change in the epidemiology of microorganisms was observed with an increase of Gram-negative bacteria.", [["Gram", "GENE_OR_GENE_PRODUCT", 110, 114], ["microorganisms", "PROBLEM", 62, 76], ["Gram-negative bacteria", "PROBLEM", 110, 132], ["negative bacteria", "OBSERVATION", 115, 132]]], ["Appropriate systemic antibiotics according to the antimicrobial susceptibility testing and surgical removal of the shunt with temporary external cerebrospinal fluid drainage and shunt replacement following the eradication of the infection are the cornerstone of the treatment of cerebrospinal fluid shunt infections.", [["cerebrospinal fluid", "ANATOMY", 145, 164], ["cerebrospinal fluid", "ANATOMY", 279, 298], ["infection", "DISEASE", 229, 238], ["cerebrospinal fluid shunt infections", "DISEASE", 279, 315], ["cerebrospinal fluid", "MULTI-TISSUE_STRUCTURE", 145, 164], ["cerebrospinal fluid", "MULTI-TISSUE_STRUCTURE", 279, 298], ["Appropriate systemic antibiotics", "TREATMENT", 0, 32], ["the antimicrobial susceptibility testing", "TEST", 46, 86], ["surgical removal", "TREATMENT", 91, 107], ["the shunt", "TREATMENT", 111, 120], ["temporary external cerebrospinal fluid drainage", "TREATMENT", 126, 173], ["shunt replacement", "TREATMENT", 178, 195], ["the infection", "PROBLEM", 225, 238], ["the treatment", "TREATMENT", 262, 275], ["cerebrospinal fluid shunt infections", "PROBLEM", 279, 315], ["shunt", "OBSERVATION", 115, 120], ["temporary", "OBSERVATION_MODIFIER", 126, 135], ["external", "OBSERVATION_MODIFIER", 136, 144], ["cerebrospinal", "OBSERVATION", 145, 158], ["fluid drainage", "OBSERVATION", 159, 173], ["shunt replacement", "OBSERVATION", 178, 195], ["infection", "OBSERVATION", 229, 238], ["cerebrospinal", "ANATOMY", 279, 292], ["fluid shunt", "OBSERVATION", 293, 304], ["infections", "OBSERVATION", 305, 315]]], ["Good compliance with infection control practices, inserion of the catheter under aseptic techniques and short-term perioperative antimicrobial prophylaxis in order to prevent the emergence of drug-resistant subpopulations are important steps in the prevention of shunt infections.", [["infection", "DISEASE", 21, 30], ["shunt infections", "DISEASE", 263, 279], ["infection control practices", "TREATMENT", 21, 48], ["the catheter", "TREATMENT", 62, 74], ["aseptic techniques", "TREATMENT", 81, 99], ["short-term perioperative antimicrobial prophylaxis", "TREATMENT", 104, 154], ["drug-resistant subpopulations", "TREATMENT", 192, 221], ["shunt infections", "PROBLEM", 263, 279], ["compliance", "OBSERVATION_MODIFIER", 5, 15], ["infection", "OBSERVATION", 21, 30], ["catheter", "OBSERVATION", 66, 74], ["shunt infections", "OBSERVATION", 263, 279]]], ["O125 Influenza in adults admitted to Canadian hospitals: data from two seasons A. McGeer, D. Gravel, G. Taylor\u00b0, C. Weir, C. Frenette, J. Vayalumkal, A. Wong, D. Moore, S. Michaud, B. Amihod (Toronto, Ottawa, Edmonton, Montreal, Saskatoon, Sherbrooke, CA) Objective: Seasonal influenza (flu) remains a cause of substantial morbidity and mortality.", [["Influenza", "DISEASE", 5, 14], ["influenza (flu", "DISEASE", 276, 290], ["Influenza", "SPECIES", 5, 14], ["Seasonal influenza (flu)", "PROBLEM", 267, 291], ["substantial morbidity", "PROBLEM", 311, 332], ["substantial", "OBSERVATION_MODIFIER", 311, 322], ["morbidity", "OBSERVATION", 323, 332]]], ["Antiviral treatment should be considered for all hospitalised patients with influenza.", [["influenza", "DISEASE", 76, 85], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["Antiviral treatment", "TREATMENT", 0, 19], ["influenza", "PROBLEM", 76, 85]]], ["To better understand the epidemiology and burden of illness within the hospital sector in Canada and the current use of antiviral therapy, we carried out a multihospital survey of virologically confirmed flu in hospitalised adults.", [["flu", "DISEASE", 204, 207], ["adults", "ORGANISM", 224, 230], ["antiviral therapy", "TREATMENT", 120, 137]]], ["Methods: CNISP is a network of largely teaching hospitals across Canada that collaborates to collect data on infections in hospitalised patients.", [["infections", "DISEASE", 109, 119], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144]]], ["During two consecutive years (2006/2007 and 2007/2008) hospitals within CNISP identified inpatients >16 years who had virologically confirmed flu.", [["flu", "PROBLEM", 142, 145], ["flu", "OBSERVATION", 142, 145]]], ["Case patient charts were reviewed to capture demographic and clinical data and to determine whether flu was community (CA) or hospital acquired (HA).", [["flu", "DISEASE", 100, 103], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["clinical data", "TEST", 61, 74], ["flu", "PROBLEM", 100, 103]]], ["Deaths at 30 days were reviewed to determine whether flu was a main or contributing cause.", [["flu", "DISEASE", 53, 56], ["flu", "PROBLEM", 53, 56]]], ["Results: Fifteen (06/07) and 11 (07/08) hospitals were recruited from the CNISP network.", [["CNISP network", "MULTI-TISSUE_STRUCTURE", 74, 87]]], ["532 virologically confirmed cases of flu were found, 182 in 06/07 (95% flu A) and 358 in 07/08 (56% flu A).", [["flu", "DISEASE", 37, 40], ["flu", "PROBLEM", 37, 40]]], ["Mean patient age was 67 years, 52% were male.", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12]]], ["There was documentation of patient vaccination that season in 29%.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["patient vaccination", "TREATMENT", 27, 46]]], ["Incidence of CA flu was 11/10,000 admissions in 06/07 (range by hospital 2 \u2212 23) and 27 in 07/08 (1 \u2212 47).", [["flu", "DISEASE", 16, 19], ["CA flu", "TEST", 13, 19], ["CA", "OBSERVATION", 13, 15]]], ["Admitting diagnoses in CA cases were: pneumonia or influenza 48%, exacerbation of COPD 20%, sepsis or fever not otherwise specified 9%, cardiac diagnoses 7%, other diagnoses 16%.", [["cardiac", "ANATOMY", 136, 143], ["pneumonia", "DISEASE", 38, 47], ["influenza", "DISEASE", 51, 60], ["COPD", "DISEASE", 82, 86], ["sepsis", "DISEASE", 92, 98], ["fever", "DISEASE", 102, 107], ["cardiac", "ORGAN", 136, 143], ["pneumonia", "PROBLEM", 38, 47], ["influenza", "PROBLEM", 51, 60], ["exacerbation", "PROBLEM", 66, 78], ["COPD", "PROBLEM", 82, 86], ["sepsis", "PROBLEM", 92, 98], ["fever", "PROBLEM", 102, 107], ["cardiac diagnoses", "TEST", 136, 153], ["pneumonia", "OBSERVATION", 38, 47], ["sepsis", "OBSERVATION", 92, 98]]], ["24% of cases were HA, range by hospital 3.9 \u2212 5.4/100,000 patient days.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["cases", "TEST", 7, 12], ["HA", "TEST", 18, 20]]], ["68% of patients were managed with droplet and contact isolation practices, an N-95 mask was used in 19%.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["droplet", "TREATMENT", 34, 41], ["contact isolation practices", "TREATMENT", 46, 73], ["an N-95 mask", "TREATMENT", 75, 87]]], ["29% of CA cases but 75% of HA cases received antiviral therapy p < 0.01, almost entirely oseltamivir.", [["oseltamivir", "CHEMICAL", 89, 100], ["oseltamivir", "CHEMICAL", 89, 100], ["CA", "GENE_OR_GENE_PRODUCT", 7, 9], ["oseltamivir", "SIMPLE_CHEMICAL", 89, 100], ["CA cases", "TEST", 7, 15], ["HA cases", "PROBLEM", 27, 35], ["antiviral therapy", "TREATMENT", 45, 62], ["oseltamivir", "TREATMENT", 89, 100]]], ["9% of cases were admitted to an ICU; 30-day mortality was 8% with 2.6% attributed to influenza.", [["influenza", "DISEASE", 85, 94], ["influenza", "PROBLEM", 85, 94], ["influenza", "OBSERVATION", 85, 94]]], ["Conclusion: There is considerable season-season and hospital-hospital variation in flu in patients in Canadian hospitals.", [["flu", "DISEASE", 83, 86], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["flu", "PROBLEM", 83, 86]]], ["Hospitalised patients CA flu present with a wide spectrum of clinical diagnoses; nearly a quarter of all cases were HA.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["Hospitalised patients CA flu", "PROBLEM", 0, 28], ["HA", "PROBLEM", 116, 118]]], ["Few CA cases but most HA cases were treated with antiviral drugs.", [["CA", "GENE_OR_GENE_PRODUCT", 4, 6], ["Few CA cases", "PROBLEM", 0, 12], ["most HA cases", "PROBLEM", 17, 30], ["antiviral drugs", "TREATMENT", 49, 64]]], ["Attributable 30 day mortality was 2.6%.O126 Influenza vaccination coverage among Greek adultsV.", [["Influenza vaccination coverage", "TREATMENT", 44, 74]]], ["Papastamopoulos, E. Kakalou\u00b0, T. Panagiotopoulos, J. Baraboutis, M. Samarkos, A. Skoutelis (Athens, GR) Objectives: Our study sought to describe influenza vaccination coverage among adults in Greece for the season 2007/08.", [["Papastamopoulos", "CHEMICAL", 0, 15], ["Papastamopoulos", "TREATMENT", 0, 15], ["Our study", "TEST", 116, 125], ["influenza vaccination coverage", "TREATMENT", 145, 175]]], ["Methods: We conducted a random-sampling, telephone based household survey among adult individuals in Greece.", [["individuals", "ORGANISM", 86, 97]]], ["Two target groups were determined for analysis: persons >65 years of age and persons with chronic conditions such as respiratory and heart conditions (other than hypertension), diabetes mellitus and other conditions.", [["respiratory", "ANATOMY", 117, 128], ["heart", "ANATOMY", 133, 138], ["respiratory and heart conditions", "DISEASE", 117, 149], ["hypertension", "DISEASE", 162, 174], ["diabetes mellitus", "DISEASE", 177, 194], ["persons", "ORGANISM", 48, 55], ["persons", "ORGANISM", 77, 84], ["heart", "ORGAN", 133, 138], ["persons", "SPECIES", 48, 55], ["persons", "SPECIES", 77, 84], ["chronic conditions", "PROBLEM", 90, 108], ["respiratory and heart conditions", "PROBLEM", 117, 149], ["hypertension", "PROBLEM", 162, 174], ["diabetes mellitus", "PROBLEM", 177, 194], ["other conditions", "PROBLEM", 199, 215], ["heart", "ANATOMY", 133, 138]]], ["Results: The influenza vaccination rate for the season 2007/08 among the adult population in Greece was: 16% for the overall adult population (19.5% for men, 12.7% for women), 48.1% for people >65 years of age, 31% for persons with chronic illness (32.5% for persons with respiratory illness, 50.2 for persons with heart conditions, 35% for persons with diabetes mellitus).", [["respiratory", "ANATOMY", 272, 283], ["heart", "ANATOMY", 315, 320], ["influenza", "DISEASE", 13, 22], ["chronic illness", "DISEASE", 232, 247], ["respiratory illness", "DISEASE", 272, 291], ["heart conditions", "DISEASE", 315, 331], ["diabetes mellitus", "DISEASE", 354, 371], ["men", "ORGANISM", 153, 156], ["women", "ORGANISM", 168, 173], ["people", "ORGANISM", 186, 192], ["persons", "ORGANISM", 219, 226], ["persons", "ORGANISM", 259, 266], ["heart", "ORGAN", 315, 320], ["men", "SPECIES", 153, 156], ["women", "SPECIES", 168, 173], ["people", "SPECIES", 186, 192], ["persons", "SPECIES", 219, 226], ["persons", "SPECIES", 259, 266], ["persons", "SPECIES", 302, 309], ["persons", "SPECIES", 341, 348], ["The influenza vaccination rate", "TEST", 9, 39], ["chronic illness", "PROBLEM", 232, 247], ["respiratory illness", "PROBLEM", 272, 291], ["heart conditions", "PROBLEM", 315, 331], ["diabetes mellitus", "PROBLEM", 354, 371], ["chronic", "OBSERVATION_MODIFIER", 232, 239], ["illness", "OBSERVATION", 240, 247], ["heart", "ANATOMY", 315, 320]]], ["A high rate of 81% of the overall population reaching 88% among persons with chronic conditions report having had any type of contact with the National Health System or a private physician within the last three years.", [["persons", "ORGANISM", 64, 71], ["persons", "SPECIES", 64, 71], ["A high rate", "TEST", 0, 11], ["the overall population", "PROBLEM", 22, 44], ["chronic conditions", "PROBLEM", 77, 95], ["high", "OBSERVATION_MODIFIER", 2, 6]]], ["Among the ones recommended any vaccination, 80.5% of persons with respiratory illness, 100% of persons with diabetes mellitus and 89.1% of persons with heart conditions had been recommended to get the influenza vaccine.", [["heart", "ANATOMY", 152, 157], ["respiratory illness", "DISEASE", 66, 85], ["diabetes mellitus", "DISEASE", 108, 125], ["persons", "ORGANISM", 53, 60], ["persons", "ORGANISM", 95, 102], ["persons", "ORGANISM", 139, 146], ["heart", "ORGAN", 152, 157], ["persons", "SPECIES", 53, 60], ["persons", "SPECIES", 95, 102], ["persons", "SPECIES", 139, 146], ["any vaccination", "TREATMENT", 27, 42], ["respiratory illness", "PROBLEM", 66, 85], ["diabetes mellitus", "PROBLEM", 108, 125], ["heart conditions", "PROBLEM", 152, 168], ["the influenza vaccine", "TREATMENT", 197, 218], ["heart", "ANATOMY", 152, 157]]], ["Conclusions: Available data show unacceptably low levels of influenza vaccination coverage among vulnerable groups such as the population over 65 years of age and people living with chronic illness.", [["chronic illness", "DISEASE", 182, 197], ["people", "ORGANISM", 163, 169], ["people", "SPECIES", 163, 169], ["Available data", "TEST", 13, 27], ["unacceptably low levels", "PROBLEM", 33, 56], ["influenza vaccination coverage", "TREATMENT", 60, 90], ["chronic illness", "PROBLEM", 182, 197], ["chronic", "OBSERVATION_MODIFIER", 182, 189], ["illness", "OBSERVATION", 190, 197]]], ["Influenza vaccination is the only preventive measure reducing influenza morbidity and mortality and its use has proven cost-effective among high risk groups.", [["Influenza", "DISEASE", 0, 9], ["Influenza vaccination", "TREATMENT", 0, 21], ["influenza morbidity", "PROBLEM", 62, 81]]], ["However the overall rate of physicians recommendation of vaccination is very low.", [["vaccination", "TREATMENT", 57, 68]]], ["Dynamic efforts are thus needed to design and implement strategies and policies that have demonstrated their rigorous effectiveness in enhancing influenza vaccination coverage rates.", [["enhancing influenza vaccination coverage rates", "TREATMENT", 135, 181]]], ["Conclusions: Nasopharyngeal sampling with flocked swabs is well tolerated and suitable to be used in an outpatient setting.", [["Nasopharyngeal", "ANATOMY", 13, 27], ["Nasopharyngeal", "ORGAN", 13, 27], ["Nasopharyngeal sampling with flocked swabs", "TREATMENT", 13, 55], ["Nasopharyngeal", "ANATOMY", 13, 27]]], ["Implementation of real-time mono and multiplex NAATs results in a significant improvement of the rate in diagnosing LRTI.", [["LRTI", "DISEASE", 116, 120], ["multiplex NAATs", "TEST", 37, 52], ["significant", "OBSERVATION_MODIFIER", 66, 77], ["improvement", "OBSERVATION_MODIFIER", 78, 89], ["LRTI", "OBSERVATION", 116, 120]]], ["HRV account for the majority of viral LRTI in primary care followed by influenza and coronaviruses but also RSV and hMPV are prevalent in an adult population.", [["LRTI", "DISEASE", 38, 42], ["influenza and coronaviruses", "DISEASE", 71, 98], ["hMPV", "DISEASE", 116, 120], ["coronaviruses", "ORGANISM", 85, 98], ["RSV", "ORGANISM", 108, 111], ["hMPV", "ORGANISM", 116, 120], ["RSV", "SPECIES", 108, 111], ["hMPV", "SPECIES", 116, 120], ["viral LRTI", "TREATMENT", 32, 42], ["primary care", "TREATMENT", 46, 58], ["influenza", "PROBLEM", 71, 80], ["coronaviruses", "PROBLEM", 85, 98], ["RSV", "PROBLEM", 108, 111], ["hMPV", "PROBLEM", 116, 120], ["hMPV", "OBSERVATION", 116, 120]]], ["In this study, 19 polyomaviruses were detected of which 10 were involved in a double infection.", [["infection", "DISEASE", 85, 94], ["polyomaviruses", "ORGANISM", 18, 32], ["this study", "TEST", 3, 13], ["19 polyomaviruses", "PROBLEM", 15, 32], ["a double infection", "PROBLEM", 76, 94], ["double", "OBSERVATION_MODIFIER", 78, 84], ["infection", "OBSERVATION", 85, 94]]], ["Methods: Observational analysis of a prospective cohort of 1041 nonseverely immunosuppressed adults with PP requiring hospitalisation (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) .", [["Observational analysis", "TEST", 9, 31]]], ["Of them, 556 were diagnosed by urinary antigen and/or 650 were diagnosed by culture.", [["urinary", "ANATOMY", 31, 38], ["urinary antigen", "GENE_OR_GENE_PRODUCT", 31, 46], ["urinary antigen", "TEST", 31, 46], ["culture", "TEST", 76, 83], ["urinary", "ANATOMY", 31, 38]]], ["Overall, 86% of pneumococcal strains were available for serotyping (Quellung) and 58% for PFGE (Smal) and or MLST.", [["pneumococcal", "ORGANISM", 16, 28], ["pneumococcal", "SPECIES", 16, 28], ["pneumococcal strains", "PROBLEM", 16, 36], ["serotyping", "TEST", 56, 66], ["PFGE", "TEST", 90, 94], ["MLST", "PROBLEM", 109, 113]]], ["The diagnosis of septic shock was based on a systolic blood pressure <90 mmHg and peripheral hypoperfusion with clinical or bacteriologic evidence of uncontrolled infection.", [["blood", "ANATOMY", 54, 59], ["septic shock", "DISEASE", 17, 29], ["peripheral hypoperfusion", "DISEASE", 82, 106], ["infection", "DISEASE", 163, 172], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["septic shock", "PROBLEM", 17, 29], ["a systolic blood pressure", "TEST", 43, 68], ["peripheral hypoperfusion", "PROBLEM", 82, 106], ["uncontrolled infection", "PROBLEM", 150, 172], ["septic shock", "OBSERVATION", 17, 29], ["hypoperfusion", "OBSERVATION", 93, 106], ["uncontrolled", "OBSERVATION_MODIFIER", 150, 162], ["infection", "OBSERVATION", 163, 172]]], ["Results: A total of 114 (11%) patients with PP had septic shock at presentation.", [["septic shock", "DISEASE", 51, 63], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["PP", "TEST", 44, 46], ["septic shock", "PROBLEM", 51, 63], ["septic shock", "OBSERVATION", 51, 63]]], ["Patients with shock were younger (61 vs 66 yrs; p = 0.003), were more frequently current smokers (45% vs 28%; p = 0.002), had received more commonly corticosteroid therapy (13% vs 6%; p = 0.015), and were more frequently classified into high-risk PSI classes (81% vs 60%; p < 0.001) than those who did not have this complication.", [["shock", "DISEASE", 14, 19], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["shock", "PROBLEM", 14, 19], ["p", "TEST", 110, 111], ["corticosteroid therapy", "TREATMENT", 149, 171], ["this complication", "PROBLEM", 311, 328], ["shock", "OBSERVATION", 14, 19]]], ["They were also less likely to have received prior influenza vaccine (31% vs 48%; p = 0.007) and had more frequently bacteraemia (41% vs 30%; p = 0.014).", [["influenza", "DISEASE", 50, 59], ["bacteraemia", "DISEASE", 116, 127], ["prior influenza vaccine", "TREATMENT", 44, 67], ["p", "TEST", 81, 82], ["more frequently bacteraemia", "PROBLEM", 100, 127], ["p", "TEST", 141, 142]]], ["No significant differences were found in rates of penicillin-(2% vs 2%) and erythromycin-resistance (16% vs 12%).", [["penicillin", "CHEMICAL", 50, 60], ["erythromycin", "CHEMICAL", 76, 88], ["penicillin", "CHEMICAL", 50, 60], ["erythromycin", "CHEMICAL", 76, 88], ["penicillin", "SIMPLE_CHEMICAL", 50, 60], ["erythromycin", "SIMPLE_CHEMICAL", 76, 88], ["significant differences", "PROBLEM", 3, 26], ["penicillin", "TREATMENT", 50, 60], ["erythromycin", "TREATMENT", 76, 88], ["significant", "OBSERVATION_MODIFIER", 3, 14]]], ["Serotype 3 was more commonly associated with shock (40% vs 24%; p = 0.007), whereas serotype 1 was rarely associated with this complication (2% vs 9%; p = 0.041).", [["shock", "DISEASE", 45, 50], ["Serotype 3", "GENE_OR_GENE_PRODUCT", 0, 10], ["shock", "PROBLEM", 45, 50], ["p", "TEST", 64, 65], ["this complication", "PROBLEM", 122, 139]]], ["No significant differences were found regarding genotypes: ST2603 (26% vs 16%), Netherlands-ser8-ST53 (10% vs 3%), Netherlands-ser3-ST180 (10% vs 8%), Spain-ser9V-ST156 (10% vs 12%).", [["Netherlands-ser8-ST53", "GENE_OR_GENE_PRODUCT", 80, 101], ["genotypes", "TEST", 48, 57], ["ST2603", "TEST", 59, 65], ["Netherlands", "TEST", 80, 91], ["ser8", "TEST", 92, 96], ["Netherlands", "TEST", 115, 126], ["ser3", "TEST", 127, 131], ["Spain", "TEST", 151, 156], ["ser9V", "TEST", 157, 162], ["significant", "OBSERVATION_MODIFIER", 3, 14]]], ["Patients with shock required more frequently mechanical ventilation (38% vs 4%; p < 0.001), and had longer LOS (19 vs 10 days; p < 0.001).", [["shock", "DISEASE", 14, 19], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["shock", "PROBLEM", 14, 19], ["frequently mechanical ventilation", "TREATMENT", 34, 67], ["shock", "OBSERVATION", 14, 19]]], ["Early (10% vs 1%; p < 0.001) and overall case-fatality rates (25% vs 5%; p < 0.001) were higher in patients with shock.", [["shock", "DISEASE", 113, 118], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["fatality rates", "TEST", 46, 60], ["shock", "PROBLEM", 113, 118], ["shock", "OBSERVATION", 113, 118]]], ["Conclusions: PP presenting with septic shock is still associated with a poor outcome.", [["septic shock", "DISEASE", 32, 44], ["septic shock", "PROBLEM", 32, 44], ["a poor outcome", "PROBLEM", 70, 84], ["septic shock", "OBSERVATION", 32, 44]]], ["It occurs mainly in current smokers, patients receiving corticosteroids, and in those infections caused by serotype 3.", [["infections", "DISEASE", 86, 96], ["corticosteroids", "CHEMICAL", 56, 71], ["patients", "ORGANISM", 37, 45], ["serotype 3", "ORGANISM", 107, 117], ["patients", "SPECIES", 37, 45], ["corticosteroids", "TREATMENT", 56, 71], ["mainly", "OBSERVATION_MODIFIER", 10, 16], ["infections", "OBSERVATION", 86, 96]]], ["Prior influenza vaccination and PP caused by serotype 1 are associated with a lower risk of shock.O128 PVL-SA as a cause of CAP inO131 High long-term mortality rate after initial recovery from severe community-acquired pneumoniaA.", [["influenza", "DISEASE", 6, 15], ["shock", "DISEASE", 92, 97], ["CAP", "DISEASE", 124, 127], ["pneumoniaA", "DISEASE", 219, 229], ["serotype 1", "SPECIES", 45, 55], ["Prior influenza vaccination", "TREATMENT", 0, 27], ["PP", "PROBLEM", 32, 34], ["serotype", "PROBLEM", 45, 53], ["shock", "PROBLEM", 92, 97], ["PVL", "PROBLEM", 103, 106], ["CAP", "PROBLEM", 124, 127], ["severe community-acquired pneumoniaA", "PROBLEM", 193, 229], ["shock", "OBSERVATION", 92, 97], ["CAP", "OBSERVATION_MODIFIER", 124, 127], ["severe", "OBSERVATION_MODIFIER", 193, 199]]], ["Bruns, J.J. Oosterheert\u00b0, M. Cucciolillo, A. Hoepelman on behalf of the SAT-P Study GroupBackground: Despite the presence of antibiotics and vaccination strategies against pneumocci, community-acquired pneumonia (CAP) is still a major cause for mortality in developed countries.", [["pneumonia", "DISEASE", 202, 211], ["CAP", "DISEASE", 213, 216], ["the SAT", "TEST", 68, 75], ["antibiotics", "TREATMENT", 125, 136], ["vaccination strategies", "TREATMENT", 141, 163], ["pneumocci", "PROBLEM", 172, 181], ["community-acquired pneumonia (CAP)", "PROBLEM", 183, 217], ["pneumonia", "OBSERVATION", 202, 211]]], ["However, it is unclear how an episode of CAP influences long-term survival after initial recovery.", [["CAP", "DISEASE", 41, 44], ["CAP influences", "PROBLEM", 41, 55], ["CAP", "OBSERVATION_MODIFIER", 41, 44]]], ["Therefore, we determined mortality up to 5 years after discharge in patients hospitalised because of an episode of severe CAP in a non-intensive care setting.", [["CAP", "DISEASE", 122, 125], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["severe CAP", "PROBLEM", 115, 125], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["CAP", "OBSERVATION", 122, 125]]], ["Methods: In 5 hospitals in the Netherlands, patients (pts) with severe CAP (PSI class IV and V without need for treatment in ICU) were prospectively followed for 28 days and mortality up to 5 years after discharge was determined using the Dutch Municipal Public Records Database.", [["CAP", "DISEASE", 71, 74], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["severe CAP", "PROBLEM", 64, 74], ["PSI class IV", "TREATMENT", 76, 88], ["treatment", "TREATMENT", 112, 121]]], ["We used Cox regression analysis to examine predictors for mortality.", [["Cox regression analysis", "TEST", 8, 31], ["mortality", "PROBLEM", 58, 67]]], ["Results: Compared to strategy 2, strategy 1 resulted in slightly higher costs (CHF 8,748 vs. 8,981) but fewer infections (.008 vs. 0.006) during patients' mean length-of-stay, producing an incremental costeffectiveness ratio (ICER) of CHF 83,303 per MRSA infection avoided.", [["CHF", "DISEASE", 79, 82], ["infections", "DISEASE", 110, 120], ["CHF", "DISEASE", 235, 238], ["infection", "DISEASE", 255, 264], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["MRSA", "SPECIES", 250, 254], ["MRSA", "SPECIES", 250, 254], ["strategy", "TEST", 21, 29], ["strategy", "TEST", 33, 41], ["slightly higher costs (CHF", "PROBLEM", 56, 82], ["fewer infections", "PROBLEM", 104, 120], ["an incremental costeffectiveness ratio", "PROBLEM", 186, 224], ["CHF", "PROBLEM", 235, 238], ["MRSA infection", "PROBLEM", 250, 264], ["slightly", "OBSERVATION_MODIFIER", 56, 64], ["higher", "OBSERVATION_MODIFIER", 65, 71], ["fewer", "OBSERVATION_MODIFIER", 104, 109], ["infections", "OBSERVATION", 110, 120], ["CHF", "OBSERVATION", 235, 238], ["MRSA", "OBSERVATION_MODIFIER", 250, 254], ["infection", "OBSERVATION", 255, 264]]], ["Sensitivity analyses suggest that prevalence of colonisation on admission is a stronger predictor of cost-effectiveness than the costs of infection or rapid screening, the probability of cross-transmission, or the incremental costs of isolation and contact precautions.", [["infection", "DISEASE", 138, 147], ["Sensitivity analyses", "TEST", 0, 20], ["colonisation", "PROBLEM", 48, 60], ["infection", "PROBLEM", 138, 147], ["rapid screening", "TEST", 151, 166], ["the incremental costs of isolation", "TREATMENT", 210, 244], ["contact precautions", "TREATMENT", 249, 268], ["colonisation", "OBSERVATION", 48, 60], ["infection", "OBSERVATION", 138, 147]]], ["Increasing the relatively low on-admission prevalence at our centre by 20% lowers the ICER to CHF 60,973 per infection avoided.", [["CHF", "DISEASE", 94, 97], ["infection", "DISEASE", 109, 118], ["CHF", "PROBLEM", 94, 97], ["infection", "PROBLEM", 109, 118], ["relatively", "OBSERVATION_MODIFIER", 15, 25], ["low", "OBSERVATION_MODIFIER", 26, 29], ["infection", "OBSERVATION", 109, 118]]], ["In contrast, increasing the cost of each infection, the cost of rapid screening, or the risk of cross-transmission by 20% only marginally affects the ICER.", [["infection", "DISEASE", 41, 50], ["cross-transmission", "DISEASE", 96, 114], ["ICER", "PROTEIN", 150, 154], ["each infection", "PROBLEM", 36, 50], ["rapid screening", "TEST", 64, 79], ["increasing", "OBSERVATION_MODIFIER", 13, 23], ["infection", "OBSERVATION", 41, 50]]], ["Conclusion: This analysis suggests that compared to risk factor identification and pre-emptive isolation, universal rapid screening upon surgical admission is not strongly cost-effective at our centre.", [["This analysis", "TEST", 12, 25], ["pre-emptive isolation", "TREATMENT", 83, 104], ["universal rapid screening", "TEST", 106, 131]]], ["In particular, settings with higher prevalence of colonisation on admission may find universal rapid screening more cost-effective.", [["universal rapid screening", "PROBLEM", 85, 110], ["colonisation", "OBSERVATION", 50, 62]]], ["Of note, no screening is undesirable, as costs and infections would be higher.", [["infections", "DISEASE", 51, 61], ["screening", "TEST", 12, 21], ["infections", "PROBLEM", 51, 61], ["infections", "OBSERVATION", 51, 61]]], ["Results: Admission and weekly screening coupled with patient isolation was found to dramatically reduce the number of MRSA acquisitions.", [["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["MRSA", "SPECIES", 118, 122], ["weekly screening", "TEST", 23, 39], ["patient isolation", "TREATMENT", 53, 70], ["MRSA acquisitions", "TEST", 118, 135], ["MRSA", "OBSERVATION", 118, 122]]], ["The largest reductions were obtained with PCR technology, followed by chromogenic agar.", [["PCR technology", "TEST", 42, 56], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["reductions", "OBSERVATION_MODIFIER", 12, 22]]], ["The differences, however, were surprisingly small, and all screening technologies achieved reductions in MRSA acquisition of close to 80% compared with the no-intervention scenario.", [["MRSA", "SPECIES", 105, 109], ["all screening technologies", "TEST", 55, 81], ["MRSA acquisition", "TEST", 105, 121], ["small", "OBSERVATION_MODIFIER", 44, 49], ["MRSA", "OBSERVATION", 105, 109]]], ["Nonetheless, chromogenic and PCR-based systems were able to decrease the number of unisolated MRSA-bed-days by approximately 15 and 35% respectively.O135 Model-based assessment of the effectiveness and costeffectiveness of methicillin-resistantConclusions: The small differences in the ability of the screening technologies to reduce MRSA acquisition reflect both a relatively low estimated isolation efficacy and the observed highly skewed distribution of ICU-stays, and may provide some important insights into the reasons for recent disappointing trial results.", [["methicillin", "CHEMICAL", 223, 234], ["MRSA", "DISEASE", 334, 338], ["methicillin", "CHEMICAL", 223, 234], ["methicillin", "SIMPLE_CHEMICAL", 223, 234], ["MRSA", "SPECIES", 94, 98], ["MRSA", "SPECIES", 334, 338], ["MRSA", "SPECIES", 334, 338], ["chromogenic", "TEST", 13, 24], ["PCR", "TEST", 29, 32], ["based assessment", "TEST", 160, 176], ["methicillin", "TREATMENT", 223, 234], ["The small differences", "PROBLEM", 257, 278], ["the screening technologies", "TEST", 297, 323], ["MRSA acquisition", "TEST", 334, 350], ["a relatively low estimated isolation efficacy", "PROBLEM", 364, 409], ["MRSA", "OBSERVATION", 94, 98], ["small", "OBSERVATION_MODIFIER", 261, 266], ["differences", "OBSERVATION_MODIFIER", 267, 278], ["highly", "OBSERVATION_MODIFIER", 427, 433], ["skewed", "OBSERVATION_MODIFIER", 434, 440], ["distribution", "OBSERVATION_MODIFIER", 441, 453]]], ["In particular, the skewed length of stay distribution means that most MRSA-bed days are accounted for by relatively long-stay patients for whom rapid detection will make the least difference.", [["patients", "ORGANISM", 126, 134], ["MRSA", "SPECIES", 70, 74], ["patients", "SPECIES", 126, 134], ["rapid detection", "TEST", 144, 159], ["skewed", "OBSERVATION_MODIFIER", 19, 25], ["length", "OBSERVATION_MODIFIER", 26, 32]]], ["Key sources of uncertainty were found to be isolation effectiveness and attributable mortality due to MRSA infections, both of which are difficult to accurately estimate with currently available data.O135 Model-based assessment of the effectiveness and costeffectiveness of methicillin-resistantThe model results allow us to quantify the expected value of reducing these key uncertainties, and help to provide a rational basis for setting future research priorities.", [["MRSA infections", "DISEASE", 102, 117], ["methicillin", "CHEMICAL", 274, 285], ["methicillin", "CHEMICAL", 274, 285], ["methicillin", "SIMPLE_CHEMICAL", 274, 285], ["MRSA", "SPECIES", 102, 106], ["MRSA", "SPECIES", 102, 106], ["MRSA infections", "PROBLEM", 102, 117], ["based assessment", "TEST", 211, 227], ["methicillin", "TREATMENT", 274, 285], ["MRSA", "OBSERVATION_MODIFIER", 102, 106], ["infections", "OBSERVATION", 107, 117]]], ["Objectives: We have shown that there is substantial colonisation of MRSA among nursing home residents and staff with our recently conducted point prevalence study in 45 nursing homes which revealed an overall prevalence rate of 24% in residents and 7.6% in staff.1 The aim of this study was, therefore, to test the effectiveness of an intervention in nursing homes which sought to improve standards of infection control as a means of reducing MRSA prevalence.", [["MRSA", "DISEASE", 68, 72], ["infection", "DISEASE", 402, 411], ["MRSA", "DISEASE", 443, 447], ["MRSA", "SPECIES", 68, 72], ["MRSA", "SPECIES", 443, 447], ["MRSA", "SPECIES", 68, 72], ["MRSA", "SPECIES", 443, 447], ["this study", "TEST", 276, 286], ["an intervention", "TREATMENT", 332, 347], ["infection control", "TREATMENT", 402, 419], ["reducing MRSA prevalence", "PROBLEM", 434, 458], ["substantial", "OBSERVATION_MODIFIER", 40, 51], ["colonisation", "OBSERVATION", 52, 64], ["MRSA", "OBSERVATION", 68, 72], ["infection", "OBSERVATION", 402, 411]]], ["Methods: A cluster randomised controlled trial (cRCT) involving 32 nursing homes, with each home representing the unit of analysis, was performed.", [["A cluster randomised controlled trial (cRCT)", "TREATMENT", 9, 53], ["analysis", "TEST", 122, 130]]], ["The study ran for 12 months with data collected at baseline, 3, 6 and 12 months.", [["The study", "TEST", 0, 9]]], ["Nasal swabs were taken at baseline from consenting residents and staff in all homes prior to randomisation with an audit of infection control procedures also undertaken.", [["Nasal swabs", "ANATOMY", 0, 11], ["infection", "DISEASE", 124, 133], ["Nasal swabs", "MULTI-TISSUE_STRUCTURE", 0, 11], ["Nasal swabs", "TEST", 0, 11], ["randomisation", "TREATMENT", 93, 106], ["infection control procedures", "TREATMENT", 124, 152], ["infection", "OBSERVATION", 124, 133]]], ["Following collection of these baseline data, nursing homes were allocated to the intervention or control arm (1:1).", [["nursing homes", "TREATMENT", 45, 58], ["arm", "ANATOMY", 105, 108]]], ["Intervention home staff were trained in infection control, specifically hand hygiene, catheter care, barrier approaches such as use of gloves, aprons and masks, and decontamination of equipment and the environment with usual practice continuing in control homes.", [["hand", "ANATOMY", 72, 76], ["infection", "DISEASE", 40, 49], ["hand", "ORGANISM_SUBDIVISION", 72, 76], ["infection control", "TREATMENT", 40, 57], ["catheter care", "TREATMENT", 86, 99], ["barrier approaches", "TREATMENT", 101, 119], ["gloves", "TREATMENT", 135, 141], ["aprons", "TREATMENT", 143, 149], ["masks", "TREATMENT", 154, 159], ["decontamination of equipment", "TREATMENT", 165, 193], ["usual practice", "TREATMENT", 219, 233], ["catheter", "OBSERVATION", 86, 94]]], ["After each data collection timepoint, feedback was given to the intervention homes in terms of their performance and further education and training provided as required.", [["further education and training", "TREATMENT", 117, 147]]], ["The primary outcome was the prevalence of MRSA in intervention homes compared to control sites.O136 Infection control practices associated with methicillinresistantResults: Preliminary analysis of the data has revealed no significant change in the prevalence of MRSA in the intervention and control homes, taking account of the clustering, over the one-year intervention period [risk ratio 0.83; 95% confidence intervals (CI) 0.53\u22121.29].", [["MRSA", "DISEASE", 42, 46], ["methicillinresistant", "CHEMICAL", 144, 164], ["MRSA", "DISEASE", 262, 266], ["methicillinresistant", "CHEMICAL", 144, 164], ["MRSA", "SPECIES", 42, 46], ["MRSA", "SPECIES", 262, 266], ["MRSA", "SPECIES", 42, 46], ["MRSA", "PROBLEM", 42, 46], ["intervention homes", "TREATMENT", 50, 68], ["Infection control practices", "TREATMENT", 100, 127], ["methicillinresistant", "TREATMENT", 144, 164], ["Preliminary analysis", "TEST", 173, 193], ["the data", "TEST", 197, 205], ["significant change", "PROBLEM", 222, 240], ["MRSA", "PROBLEM", 262, 266], ["the intervention", "TREATMENT", 270, 286], ["risk ratio", "TEST", 379, 389], ["CI", "TEST", 422, 424], ["MRSA", "OBSERVATION", 42, 46], ["no", "UNCERTAINTY", 219, 221], ["significant", "OBSERVATION_MODIFIER", 222, 233], ["change", "OBSERVATION", 234, 240], ["MRSA", "OBSERVATION", 262, 266]]], ["However, there was an improvement in infection control audit scores in the intervention homes, with a mean score in control homes at 12 months of 64.4% compared with 81.7% in the intervention sites; these scores were significantly different (paired t-test, p < 0.0001).Conclusions:The results suggest that infection control education and training as implemented in this study was not sufficient to affect MRSA prevalence.", [["infection", "DISEASE", 37, 46], ["infection", "DISEASE", 306, 315], ["MRSA", "DISEASE", 405, 409], ["MRSA", "CANCER", 405, 409], ["MRSA", "SPECIES", 405, 409], ["MRSA", "SPECIES", 405, 409], ["infection control audit scores", "PROBLEM", 37, 67], ["these scores", "TEST", 199, 211], ["paired t-test", "TEST", 242, 255], ["infection control education", "TREATMENT", 306, 333], ["this study", "TEST", 365, 375], ["MRSA prevalence", "PROBLEM", 405, 420], ["improvement", "OBSERVATION_MODIFIER", 22, 33], ["infection", "OBSERVATION", 37, 46], ["infection", "OBSERVATION", 306, 315]]], ["Therefore, a more detailed education and training package either alone or in combination with MRSA decolonisation of staff and residents, may be required to reduce MRSA prevalence within this unique environment.Reference(s)[M. Wassenberg\u00b0, D. Severs, M. Bonten (Utrecht, NL)Objectives: In a response to the rapid global increase in the nosocomial prevalence of multi-resistant micro-organisms, infection control measures, such as patient isolation, are increasingly used.", [["MRSA", "DISEASE", 164, 168], ["infection", "DISEASE", 394, 403], ["patient", "ORGANISM", 430, 437], ["MRSA", "SPECIES", 94, 98], ["MRSA", "SPECIES", 164, 168], ["patient", "SPECIES", 430, 437], ["MRSA", "SPECIES", 164, 168], ["training package", "TREATMENT", 41, 57], ["MRSA prevalence", "PROBLEM", 164, 179], ["the rapid global increase", "PROBLEM", 303, 328], ["multi-resistant micro-organisms", "PROBLEM", 361, 392], ["infection control measures", "TREATMENT", 394, 420], ["patient isolation", "TREATMENT", 430, 447], ["rapid", "OBSERVATION_MODIFIER", 307, 312], ["global", "OBSERVATION_MODIFIER", 313, 319], ["increase", "OBSERVATION_MODIFIER", 320, 328], ["multi-resistant micro-organisms", "OBSERVATION", 361, 392], ["infection", "OBSERVATION", 394, 403]]], ["It is unknown how these measures influence the quality of life (QOL) of patients during short-term isolation, and this was determined in a prospective matched cohort study.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["short-term isolation", "TREATMENT", 88, 108], ["a prospective matched cohort study", "TEST", 137, 171]]], ["Methods: All adult patients needing isolation in a single-patient room between 11/06 and 03/07 in the UMC Utrecht were eligible and included 24\u221248 hours after start of isolation (after giving informed consent and being able to fulfil study requirements).", [["patients", "ORGANISM", 19, 27], ["patient", "ORGANISM", 58, 65], ["patients", "SPECIES", 19, 27], ["patient", "SPECIES", 58, 65], ["isolation", "TREATMENT", 36, 45]]], ["For each index patient we identified two control patients, admitted to the same wards at the same time, yet not subjected to any isolation measure.", [["patient", "ORGANISM", 15, 22], ["patients", "ORGANISM", 49, 57], ["patient", "SPECIES", 15, 22], ["patients", "SPECIES", 49, 57]]], ["Anxiety and depression and QOL were assessed using the Hospital Anxiety and Depression Scale (HADS) and Visual Analogue Scale (EQ-5D-VAS) in all patients.", [["Anxiety", "DISEASE", 0, 7], ["depression", "DISEASE", 12, 22], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["Anxiety", "PROBLEM", 0, 7], ["depression", "PROBLEM", 12, 22], ["Depression Scale (HADS)", "PROBLEM", 76, 99], ["Visual Analogue Scale", "TEST", 104, 125]]], ["Opinions on and experiences with isolation were measured in isolated patients by means of a self-developed 'isolation evaluation questionnaire'.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["isolation", "TREATMENT", 33, 42], ["'isolation evaluation", "TEST", 107, 128]]], ["Results: 42 isolated patients and 84 controls were included, with comparable baseline characteristics (age, sex, nationality, level of education, length of hospital stay and severity of underlying disease and co-morbidity (using the Cumulative Illness Rating Scale)).", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["underlying disease", "PROBLEM", 186, 204], ["co-morbidity", "PROBLEM", 209, 221], ["disease", "OBSERVATION", 197, 204]]], ["Reasons for isolation were clostridium difficile-associated disease (n = 17, 40%), high risk for MRSA carriage (n = 12, 29%), or resistant Gram-negative bacteria (n = 7, 17%).", [["clostridium difficile-associated disease", "DISEASE", 27, 67], ["MRSA carriage", "DISEASE", 97, 110], ["clostridium difficile", "ORGANISM", 27, 48], ["clostridium difficile", "SPECIES", 27, 48], ["MRSA", "SPECIES", 97, 101], ["clostridium difficile", "SPECIES", 27, 48], ["MRSA", "SPECIES", 97, 101], ["isolation", "PROBLEM", 12, 21], ["clostridium difficile", "PROBLEM", 27, 48], ["associated disease", "PROBLEM", 49, 67], ["MRSA carriage", "PROBLEM", 97, 110], ["resistant Gram-negative bacteria", "PROBLEM", 129, 161], ["negative bacteria", "OBSERVATION", 144, 161]]], ["Mean scores of questionnaires are presented in table 1. isIn univariate analysis only duration of isolation of 48 hours (compared to 24 hours) was associated with a reduced quality of life (VAS 57.7 compared to 68.7, p 0.02).", [["Mean scores", "TEST", 0, 11], ["VAS", "TEST", 190, 193]]], ["On a visual analogue score of opposite terms isolation measures were rated with means of 87.5, 83.3 and 70.8 for safety, usefulness and quietness, respectively.", [["means", "TEST", 80, 85]]], ["Conclusion: Short-term isolation (up to 48 hours) is not associated with anxiousness or depression, but with positive feelings about safety, usefulness and quietness.HADS-A HADS-D HADS-total VASIndex patients (n = 42), mean (SD) 4.7 (3.5) 5.3 (3.5) 9.9 (6.0) 62.3 (15.5) Control patients (n = 84), mean (SD) 5.4 (3.7) 5.2 (3.6) 10.6 (6.", [["depression", "DISEASE", 88, 98], ["patients", "ORGANISM", 200, 208], ["patients", "ORGANISM", 279, 287], ["patients", "SPECIES", 200, 208], ["patients", "SPECIES", 279, 287], ["Short-term isolation", "TREATMENT", 12, 32], ["anxiousness", "PROBLEM", 73, 84], ["depression", "PROBLEM", 88, 98], ["quietness", "PROBLEM", 156, 165], ["mean (SD)", "TEST", 219, 228], ["mean (SD)", "TEST", 298, 307], ["Short-term", "OBSERVATION_MODIFIER", 12, 22], ["not associated with", "UNCERTAINTY", 53, 72]]], ["Objectives: There is a lack of data about the impact of Healthcare Associated Infection (HAI) on the experience of individual patients.", [["Infection", "DISEASE", 78, 87], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["Healthcare Associated Infection", "PROBLEM", 56, 87], ["Infection", "OBSERVATION", 78, 87]]], ["This information is essential to empower health organisations to understand, prioritise, develop and implement solutions that will minimise risks to patients.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157]]], ["This study explored comparable narratives from patients who had experienced a Staphylococcus aureus blood stream infection with patients who had not.Methods:We conducted qualitative semi-structured interviews with eighteen adults who had previously been an in-patient in an acute teaching hospital in Scotland.", [["blood", "ANATOMY", 100, 105], ["Staphylococcus aureus blood stream infection", "DISEASE", 78, 122], ["patients", "ORGANISM", 47, 55], ["Staphylococcus aureus", "ORGANISM", 78, 99], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["patients", "ORGANISM", 128, 136], ["adults", "ORGANISM", 223, 229], ["patient", "ORGANISM", 260, 267], ["patients", "SPECIES", 47, 55], ["Staphylococcus aureus", "SPECIES", 78, 99], ["patients", "SPECIES", 128, 136], ["patient", "SPECIES", 260, 267], ["Staphylococcus aureus", "SPECIES", 78, 99], ["This study", "TEST", 0, 10], ["a Staphylococcus aureus blood stream infection", "PROBLEM", 76, 122], ["Staphylococcus aureus", "OBSERVATION", 78, 99]]], ["Nine patients had had a laboratory diagnosed Staphylococcus aureus blood stream infection and nine had no blood stream infection.", [["blood", "ANATOMY", 67, 72], ["blood", "ANATOMY", 106, 111], ["Staphylococcus aureus blood stream infection", "DISEASE", 45, 89], ["blood stream infection", "DISEASE", 106, 128], ["patients", "ORGANISM", 5, 13], ["Staphylococcus aureus", "ORGANISM", 45, 66], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["blood", "ORGANISM_SUBSTANCE", 106, 111], ["patients", "SPECIES", 5, 13], ["Staphylococcus aureus", "SPECIES", 45, 66], ["Staphylococcus aureus", "SPECIES", 45, 66], ["a laboratory diagnosed Staphylococcus aureus blood stream infection", "PROBLEM", 22, 89], ["blood stream infection", "PROBLEM", 106, 128], ["Staphylococcus aureus", "OBSERVATION", 45, 66], ["stream", "OBSERVATION_MODIFIER", 112, 118], ["infection", "OBSERVATION", 119, 128]]], ["All patients were interviewed for 20\u221240 minutes.Methods:The interviewer asked patients about their thoughts around HAI, what concerns they had or still do, what measures they took to safeguard themselves from HAI and how their experience impacted on their confidence of the NHS.", [["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 78, 86]]], ["Preliminary analysis showed that all patients had positive and negative comments about infection prevention and control practice in the hospital.", [["infection", "DISEASE", 87, 96], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["Preliminary analysis", "TEST", 0, 20], ["infection prevention", "TREATMENT", 87, 107]]], ["Specific concerns included poor communication, poor cleanliness, awareness of patient boarding, lack of facilities, staff shortages and multi-tasking.", [["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85]]], ["Some patients who had experienced bacteraemia said they had not been informed about the infection.", [["bacteraemia", "DISEASE", 34, 45], ["infection", "DISEASE", 88, 97], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["bacteraemia", "PROBLEM", 34, 45], ["the infection", "PROBLEM", 84, 97], ["infection", "OBSERVATION", 88, 97]]], ["Those who had been informed were not given clear information about treatment or subsequent results.", [["treatment", "TREATMENT", 67, 76]]], ["Most patients were not specifically told what they or their family should do to safeguard them from infection and little or no written information about HAI was provided.", [["infection", "DISEASE", 100, 109], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["infection", "PROBLEM", 100, 109], ["infection", "OBSERVATION", 100, 109]]], ["Most patients are worried about HAI on future admissions.Conclusions:The concerns of patients were not fundamentally different if they did or did not experience blood stream infection.", [["blood", "ANATOMY", 161, 166], ["blood stream infection", "DISEASE", 161, 183], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 85, 93], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 85, 93], ["blood stream infection", "PROBLEM", 161, 183], ["infection", "OBSERVATION", 174, 183]]], ["The patient's reported experiences show that they have a broad awareness of systems issues that may increase risk of infection.", [["infection", "DISEASE", 117, 126], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["systems issues", "PROBLEM", 76, 90], ["infection", "PROBLEM", 117, 126], ["infection", "OBSERVATION", 117, 126]]], ["Consequently we need to involve patients in the design and evaluation of systems change and information that will improve patient experience.", [["patients", "ORGANISM", 32, 40], ["patient", "ORGANISM", 122, 129], ["patients", "SPECIES", 32, 40], ["patient", "SPECIES", 122, 129], ["evaluation of systems change", "TEST", 59, 87]]], ["Improving the safety and reliability of the system will have direct benefits for all patients in the hospital, not just the ones at risk of HAI.", [["HAI", "DISEASE", 140, 143], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["HAI", "PROBLEM", 140, 143]]], ["Analysis of surgical specialties separately revealed a significant reduction of mortality in cardiothoracic surgery who had been treated with MUP-CHX (2.3% (5/218) vs. 6.5% (11/170), p = 0.040, figure) .", [["MUP-CHX", "CHEMICAL", 142, 149], ["CHX", "CHEMICAL", 146, 149], ["MUP-CHX", "SIMPLE_CHEMICAL", 142, 149], ["cardiothoracic surgery", "TREATMENT", 93, 115], ["MUP-CHX", "TREATMENT", 142, 149], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["reduction", "OBSERVATION_MODIFIER", 67, 76], ["cardiothoracic", "ANATOMY", 93, 107], ["surgery", "OBSERVATION", 108, 115]]], ["In other surgical specialties no significant difference was found.", [["significant difference", "PROBLEM", 33, 55], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["difference", "OBSERVATION", 45, 55]]], ["Conclusion: Peri-operative application of MUP-CHX in nasal carriers of S. aureus undergoing cardiothoracic surgery results in a threefold reduction of mortality after one year.O140 The success and effectiveness of the world's first national cleanyourhands campaign in England andO142 A lot done, more to do \u2212 a survey of teaching about healthcare-associated infections in UK and Irish medical schools H. Humphreys\u00b0, D. O'Brien, J. Richards, K. Walton, G. Phillips (Dublin, IE; Norwich, Newcastle-upon-Tyne, Dundee, UK) Objectives: Patient safety and the prevention of healthcare-associated infections (HCAI) are increasingly important health issues.", [["nasal", "ANATOMY", 53, 58], ["MUP-CHX", "CHEMICAL", 42, 49], ["O140", "CHEMICAL", 176, 180], ["infections", "DISEASE", 358, 368], ["infections", "DISEASE", 590, 600], ["HCAI", "DISEASE", 602, 606], ["CHX", "CHEMICAL", 46, 49], ["MUP-CHX", "SIMPLE_CHEMICAL", 42, 49], ["nasal", "ORGAN", 53, 58], ["S. aureus", "ORGANISM", 71, 80], ["S. aureus", "SPECIES", 71, 80], ["Patient", "SPECIES", 531, 538], ["S. aureus", "SPECIES", 71, 80], ["MUP-CHX", "TREATMENT", 42, 49], ["S. aureus", "PROBLEM", 71, 80], ["cardiothoracic surgery", "TREATMENT", 92, 114], ["healthcare-associated infections", "PROBLEM", 568, 600], ["nasal", "ANATOMY", 53, 58], ["aureus", "OBSERVATION", 74, 80], ["infections", "OBSERVATION", 590, 600]]], ["Medical doctors have traditionally been poor in complying with preventative measures to minimise HCAI such as hand hygiene compliance.", [["hand", "ANATOMY", 110, 114], ["hand", "ORGANISM_SUBDIVISION", 110, 114], ["preventative measures", "TREATMENT", 63, 84], ["hand hygiene compliance", "TREATMENT", 110, 133]]], ["Methods: A questionnaire was drafted, piloted and then subsequently forwarded to the heads of medical schools as well as to known contact professionals with an interest in HCAI in 38 medical schools.", [["HCAI", "DISEASE", 172, 176]]], ["Results: Replies were received from 31 (82%) medical schools; two supplied data on their undergraduate and postgraduate courses.", [["postgraduate courses", "TREATMENT", 107, 127]]], ["Only 18 (60%) covered HCAI as a quality and safety issue but over 90% covered prevalence, recognised risk factors, transmission, and preventative measures.", [["HCAI", "DISEASE", 22, 26], ["preventative measures", "TREATMENT", 133, 154]]], ["24 (80%) medical schools assessed competence in undertaking aseptic techniques and the disposal of sharps and MCQs were the most common (87%) means of assessment.", [["aseptic techniques", "TREATMENT", 60, 78], ["assessment", "TEST", 151, 161]]], ["There is potential for agreeing a core curriculum on HCAI and for sharing teaching resources such as videos and e-learning material.Z. Sadique\u00b0, B. Cooper, J. Edmunds, B. Lopman (London, UK)Objectives: Noroviruses are most common cause of outbreaks of gastroenteritis in UK National Health Service hospitals, leading to ward closure costing as much as \u00a3115 million per annum.", [["gastroenteritis", "DISEASE", 252, 267], ["Noroviruses", "ORGANISM", 202, 213], ["Noroviruses", "PROBLEM", 202, 213], ["gastroenteritis", "PROBLEM", 252, 267], ["ward closure", "TREATMENT", 320, 332], ["Noroviruses", "OBSERVATION", 202, 213], ["gastroenteritis", "OBSERVATION", 252, 267], ["closure", "OBSERVATION", 325, 332]]], ["Using a detailed data set on norovirus outbreaks from three hospital systems in the South West of England, we estimated (1) the relative importance of introduction of norovirus from the community and within the hospital and (2) the cost effectiveness of ward closure at different time points during an outbreak.", [["norovirus outbreaks", "DISEASE", 29, 48], ["norovirus", "DISEASE", 167, 176], ["norovirus", "ORGANISM", 29, 38], ["norovirus", "ORGANISM", 167, 176], ["norovirus", "PROBLEM", 29, 38], ["norovirus", "PROBLEM", 167, 176], ["ward closure", "TREATMENT", 254, 266], ["norovirus", "OBSERVATION", 29, 38]]], ["Methods: Using regression models we examined the association between number of new outbreaks in a hospital and community levels of activity and number of outbreaks currently occurring in other wards within the hospital.", [["new", "OBSERVATION_MODIFIER", 79, 82], ["outbreaks", "OBSERVATION", 83, 92]]], ["We then undertook as analysis of cost (-effectiveness) of unit closure by developing a dynamic transmission model taking into account that ward closure may reduce norovirus transmission within and between wards.", [["norovirus", "DISEASE", 163, 172], ["norovirus", "SPECIES", 163, 172], ["unit closure", "TREATMENT", 58, 70], ["a dynamic transmission model", "TREATMENT", 85, 113], ["ward closure", "TREATMENT", 139, 151], ["norovirus transmission", "PROBLEM", 163, 185], ["norovirus", "OBSERVATION", 163, 172]]], ["The stochastic simulation model was based on the actual characteristics of an acute hospital and the norovirus transmission parameters quantified in the statistical analysis.", [["the norovirus transmission parameters", "TEST", 97, 134], ["the statistical analysis", "TEST", 149, 173], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["norovirus", "OBSERVATION", 101, 110]]], ["We measured the costs and benefits of closing affected wards at 1, 3 and 5 days after the onset of symptoms in the first case.", [["symptoms", "PROBLEM", 99, 107]]], ["Results: Community level of norovirus infection had a significant effect on the occurrence of new outbreaks as did outbreaks in admission and general medical units.", [["norovirus infection", "DISEASE", 28, 47], ["norovirus", "ORGANISM", 28, 37], ["norovirus", "SPECIES", 28, 37], ["norovirus infection", "PROBLEM", 28, 47], ["general medical units", "TREATMENT", 142, 163], ["norovirus", "OBSERVATION", 28, 37], ["new", "OBSERVATION_MODIFIER", 94, 97], ["outbreaks", "OBSERVATION", 98, 107]]], ["The cost of closing wards to new admissions varied between \u00a30.5 million to \u00a30.9 million depending on the assumed effectiveness of closure in curtailing transmission.", [["closure", "TREATMENT", 130, 137], ["closure", "OBSERVATION", 130, 137]]], ["Cost of bed day loss \u2212 compared with staff illness -accounted for around 90% of the total cost of closure.", [["illness", "DISEASE", 43, 50], ["closure", "TREATMENT", 98, 105], ["closure", "OBSERVATION", 98, 105]]], ["Although the total number of cases tends to fall with rapid ward closure (by around 50% compared with no closure), the actual cost of control is similar regardless of when the closure is performed.Conclusion:We have developed a modelling framework to assess the effectiveness and cost-effectiveness of strategies to control norovirus outbreaks in hospital settings.", [["norovirus", "DISEASE", 324, 333], ["norovirus", "ORGANISM", 324, 333], ["norovirus", "SPECIES", 324, 333], ["rapid ward closure", "TREATMENT", 54, 72], ["closure", "TREATMENT", 105, 112], ["the closure", "TREATMENT", 172, 183], ["cost-effectiveness of strategies", "TREATMENT", 280, 312], ["norovirus", "PROBLEM", 324, 333], ["closure", "OBSERVATION", 65, 72], ["closure", "OBSERVATION", 176, 183]]], ["Ward closure is effective at preventing cases but since closure itself is an expensive intervention, it may not always be cost-effective. .", [["Ward closure", "TREATMENT", 0, 12], ["closure", "TREATMENT", 56, 63], ["an expensive intervention", "TREATMENT", 74, 99], ["closure", "OBSERVATION", 5, 12]]], ["Other prevalent ribotypes were 001 (25%) and 106 (36%).", [["Other prevalent ribotypes", "TEST", 0, 25]]], ["The remaining 18 isolates of ribotype 027 originated from 11 hospitals across Scotland.", [["ribotype 027", "SPECIES", 29, 41], ["ribotype", "PROBLEM", 29, 37], ["18 isolates", "OBSERVATION_MODIFIER", 14, 25]]], ["In vitro 96% of 027 isolates were resistant to clindamycin with a MIC range of 8\u221224 mg/L, MIC50 of 12 mg/L and MIC90 of 16 mg/L. Furthermore 100% of the 027isolates were highly resistant to erythromycin (MIC50 256 mg/L, MIC90 256 mg/L), and to levofloxacin and moxifloxacin (MIC50 32 mg/L, MIC90 32 mg/L for both), while 65% of these isolates were resistant to cefotaxime (MIC50=64 mg/L, MIC90=96 mg/L).", [["clindamycin", "CHEMICAL", 47, 58], ["MIC50", "CHEMICAL", 90, 95], ["erythromycin", "CHEMICAL", 190, 202], ["MIC50", "CHEMICAL", 204, 209], ["levofloxacin", "CHEMICAL", 244, 256], ["moxifloxacin", "CHEMICAL", 261, 273], ["MIC50", "CHEMICAL", 275, 280], ["cefotaxime", "CHEMICAL", 361, 371], ["MIC50", "CHEMICAL", 373, 378], ["clindamycin", "CHEMICAL", 47, 58], ["erythromycin", "CHEMICAL", 190, 202], ["levofloxacin", "CHEMICAL", 244, 256], ["moxifloxacin", "CHEMICAL", 261, 273], ["cefotaxime", "CHEMICAL", 361, 371], ["clindamycin", "SIMPLE_CHEMICAL", 47, 58], ["erythromycin", "SIMPLE_CHEMICAL", 190, 202], ["levofloxacin", "SIMPLE_CHEMICAL", 244, 256], ["moxifloxacin", "SIMPLE_CHEMICAL", 261, 273], ["cefotaxime", "SIMPLE_CHEMICAL", 361, 371], ["clindamycin", "TREATMENT", 47, 58], ["MIC50", "TREATMENT", 90, 95], ["MIC90", "TREATMENT", 111, 116], ["erythromycin", "TREATMENT", 190, 202], ["MIC50", "TREATMENT", 204, 209], ["MIC90", "TREATMENT", 220, 225], ["levofloxacin", "TREATMENT", 244, 256], ["moxifloxacin", "TREATMENT", 261, 273], ["MIC50", "TREATMENT", 275, 280], ["MIC90", "TREATMENT", 290, 295], ["these isolates", "PROBLEM", 328, 342], ["cefotaxime", "TREATMENT", 361, 371], ["MIC50", "TREATMENT", 373, 378], ["MIC90", "TREATMENT", 388, 393]]], ["All 027isolates were susceptible to metronidazole, vancomycin, meropenem and piperacillin-tazobactam.", [["metronidazole", "CHEMICAL", 36, 49], ["vancomycin", "CHEMICAL", 51, 61], ["meropenem", "CHEMICAL", 63, 72], ["piperacillin-tazobactam", "CHEMICAL", 77, 100], ["metronidazole", "CHEMICAL", 36, 49], ["vancomycin", "CHEMICAL", 51, 61], ["meropenem", "CHEMICAL", 63, 72], ["piperacillin-tazobactam", "CHEMICAL", 77, 100], ["metronidazole", "SIMPLE_CHEMICAL", 36, 49], ["vancomycin", "SIMPLE_CHEMICAL", 51, 61], ["meropenem", "SIMPLE_CHEMICAL", 63, 72], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 77, 100], ["All 027isolates", "TREATMENT", 0, 15], ["metronidazole", "TREATMENT", 36, 49], ["vancomycin", "TREATMENT", 51, 61], ["meropenem", "TREATMENT", 63, 72], ["piperacillin", "TREATMENT", 77, 89], ["tazobactam", "TREATMENT", 90, 100]]], ["High frequencies of clindamycin, erythromycin, levofloxacin, moxifloxacin and cefotaxime resistance were also found among isolates of ribotype 001 (90\u221299%) and 106 (94-100%).", [["clindamycin", "CHEMICAL", 20, 31], ["erythromycin", "CHEMICAL", 33, 45], ["levofloxacin", "CHEMICAL", 47, 59], ["moxifloxacin", "CHEMICAL", 61, 73], ["cefotaxime", "CHEMICAL", 78, 88], ["clindamycin", "CHEMICAL", 20, 31], ["erythromycin", "CHEMICAL", 33, 45], ["levofloxacin", "CHEMICAL", 47, 59], ["moxifloxacin", "CHEMICAL", 61, 73], ["cefotaxime", "CHEMICAL", 78, 88], ["clindamycin", "SIMPLE_CHEMICAL", 20, 31], ["erythromycin", "SIMPLE_CHEMICAL", 33, 45], ["levofloxacin", "SIMPLE_CHEMICAL", 47, 59], ["moxifloxacin", "SIMPLE_CHEMICAL", 61, 73], ["cefotaxime", "SIMPLE_CHEMICAL", 78, 88], ["clindamycin", "TREATMENT", 20, 31], ["erythromycin", "TREATMENT", 33, 45], ["levofloxacin", "TREATMENT", 47, 59], ["moxifloxacin", "TREATMENT", 61, 73], ["cefotaxime resistance", "TREATMENT", 78, 99], ["ribotype", "TEST", 134, 142]]], ["Conclusion: Until 2008 C. difficile ribotype 027 was only reported infrequently in Scotland.", [["C. difficile ribotype 027", "ORGANISM", 23, 48], ["C. difficile", "SPECIES", 23, 35], ["C. difficile ribotype 027", "SPECIES", 23, 48], ["C. difficile ribotype", "PROBLEM", 23, 44]]], ["In 2008, reports of ribotype 027 became more frequent and clusters were detected in 5 hospitals.", [["ribotype 027", "SPECIES", 20, 32], ["ribotype", "PROBLEM", 20, 28]]], ["The majority (96%) of ribotype 027 isolates were resistant to clindamycin.", [["clindamycin", "CHEMICAL", 62, 73], ["clindamycin", "CHEMICAL", 62, 73], ["clindamycin", "SIMPLE_CHEMICAL", 62, 73], ["ribotype 027", "SPECIES", 22, 34], ["ribotype 027 isolates", "PROBLEM", 22, 43], ["clindamycin", "TREATMENT", 62, 73]]], ["Three other European countries have previously reported clindamycin resistance in PCR ribotype 027, albeit with a higher MIC90 of >256 mg/L.I. Guti\u00e9rrez\u00b0, M.L. Lambert, A. Kongs, D. Mazina, H. van Oyen (Brussels, BE)Objectives: To analyze trends in mortality due to Clostridium difficile enterocolitis and to describe the most affected groups in order to better understand current Clostridium difficile changing epidemiology.", [["clindamycin", "CHEMICAL", 56, 67], ["MIC90", "CHEMICAL", 121, 126], ["Clostridium difficile enterocolitis", "DISEASE", 266, 301], ["Clostridium difficile", "DISEASE", 381, 402], ["clindamycin", "CHEMICAL", 56, 67], ["clindamycin", "SIMPLE_CHEMICAL", 56, 67], ["Clostridium difficile", "ORGANISM", 266, 287], ["Clostridium difficile", "ORGANISM", 381, 402], ["Clostridium difficile", "SPECIES", 266, 287], ["Clostridium difficile", "SPECIES", 381, 402], ["ribotype 027", "SPECIES", 86, 98], ["Clostridium difficile", "SPECIES", 266, 287], ["Clostridium difficile", "SPECIES", 381, 402], ["clindamycin resistance", "TREATMENT", 56, 78], ["PCR ribotype", "TEST", 82, 94], ["a higher MIC90", "TREATMENT", 112, 126], ["Clostridium difficile enterocolitis", "PROBLEM", 266, 301], ["current Clostridium difficile changing epidemiology", "PROBLEM", 373, 424]]], ["We selected those records in which ICD-10 code A04.7 (enterocolitis due to Clostridium difficile) appeared as underlying cause of death within the death certificate.", [["enterocolitis", "DISEASE", 54, 67], ["Clostridium difficile", "DISEASE", 75, 96], ["death", "DISEASE", 130, 135], ["death", "DISEASE", 147, 152], ["Clostridium difficile", "SPECIES", 75, 96], ["Clostridium difficile", "SPECIES", 75, 96], ["ICD", "TREATMENT", 35, 38], ["enterocolitis", "PROBLEM", 54, 67], ["Clostridium difficile", "PROBLEM", 75, 96], ["death", "PROBLEM", 130, 135], ["enterocolitis", "OBSERVATION", 54, 67]]], ["Age-and sex-specific mortality rates were calculated for the period 1998-2006.", [["sex-specific mortality rates", "TEST", 8, 36]]], ["Direct standardisation was performed using the European standard population and 95% confidence intervals were calculated.", [["Direct standardisation", "TEST", 0, 22], ["the European standard population", "TREATMENT", 43, 75]]], ["Stata 10 \u00ae and Excel \u00ae were used as statistical software.", [["Excel \u00ae", "DNA", 15, 22]]], ["Objectives: Toxigenic Clostridium difficile is an enteric pathogen typical in the hospital environment but also community-acquired cases have been reported.", [["Clostridium difficile", "DISEASE", 22, 43], ["Toxigenic Clostridium difficile", "ORGANISM", 12, 43], ["Clostridium difficile", "SPECIES", 22, 43], ["Clostridium difficile", "SPECIES", 22, 43], ["Toxigenic Clostridium difficile", "PROBLEM", 12, 43], ["an enteric pathogen", "PROBLEM", 47, 66], ["enteric", "OBSERVATION_MODIFIER", 50, 57], ["pathogen", "OBSERVATION", 58, 66]]], ["However, relatively few attempts have been made to clarify the role of soil or water as a source of C. difficile infection.I. Guti\u00e9rrez\u00b0, M.L. Lambert, A. Kongs, D. Mazina, H. van Oyen (Brussels, BE)In November-December 2007, the drinking water distribution system in the town of Nokia, Finland was massively contaminated with treated sewage effluent resulting in a large gastroenteritis outbreak.", [["C. difficile infection", "DISEASE", 100, 122], ["gastroenteritis", "DISEASE", 372, 387], ["C. difficile", "ORGANISM", 100, 112], ["C. difficile", "SPECIES", 100, 112], ["C. difficile", "SPECIES", 100, 112], ["C. difficile infection", "PROBLEM", 100, 122], ["a large gastroenteritis outbreak", "PROBLEM", 364, 396], ["difficile", "OBSERVATION_MODIFIER", 103, 112], ["infection", "OBSERVATION", 113, 122], ["large", "OBSERVATION_MODIFIER", 366, 371], ["gastroenteritis", "OBSERVATION", 372, 387]]], ["The aim of the present study was to evaluate if contaminated water in this outbreak was also a potential source of C. difficile infection.Methods:A sample from the contaminated tap water and a treated sewage effluent sample were collected as soon as possible after the massive faecal contamination of the drinking water distribution system had occurred.", [["sample", "ANATOMY", 217, 223], ["faecal", "ANATOMY", 277, 283], ["C. difficile infection", "DISEASE", 115, 137], ["C. difficile", "ORGANISM", 115, 127], ["faecal", "ORGANISM_SUBSTANCE", 277, 283], ["C. difficile", "SPECIES", 115, 127], ["C. difficile", "SPECIES", 115, 127], ["the present study", "TEST", 11, 28], ["C. difficile infection", "PROBLEM", 115, 137], ["the contaminated tap water", "TREATMENT", 160, 186], ["a treated sewage effluent sample", "TREATMENT", 191, 223], ["the massive faecal contamination", "PROBLEM", 265, 297], ["difficile", "OBSERVATION_MODIFIER", 118, 127], ["infection", "OBSERVATION", 128, 137], ["massive", "OBSERVATION_MODIFIER", 269, 276], ["faecal contamination", "OBSERVATION", 277, 297]]], ["C. difficile was isolated from heat-treated water samples by filtrating of 100 ml, 10 ml and 1 ml volumes of water and placing the membranes on selective CCEY agar plates, which were anaerobically incubated for 3 d.", [["samples", "ANATOMY", 50, 57], ["membranes", "ANATOMY", 131, 140], ["C. difficile", "ORGANISM", 0, 12], ["membranes", "CELLULAR_COMPONENT", 131, 140], ["C. difficile", "SPECIES", 0, 12], ["C. difficile", "SPECIES", 0, 12], ["C. difficile", "PROBLEM", 0, 12], ["water samples", "TREATMENT", 44, 57], ["the membranes", "TREATMENT", 127, 140], ["selective CCEY agar plates", "TREATMENT", 144, 170], ["difficile", "OBSERVATION", 3, 12]]], ["Stool samples from the patients fallen ill during the epidemic were examined for enteric pathogens, including C. difficile.", [["Stool samples", "ANATOMY", 0, 13], ["enteric pathogens", "DISEASE", 81, 98], ["C. difficile", "DISEASE", 110, 122], ["Stool samples", "CANCER", 0, 13], ["patients", "ORGANISM", 23, 31], ["C. difficile", "ORGANISM", 110, 122], ["patients", "SPECIES", 23, 31], ["C. difficile", "SPECIES", 110, 122], ["C. difficile", "SPECIES", 110, 122], ["Stool samples", "TEST", 0, 13], ["the epidemic", "PROBLEM", 50, 62], ["enteric pathogens", "PROBLEM", 81, 98], ["C. difficile", "PROBLEM", 110, 122], ["difficile", "OBSERVATION", 113, 122]]], ["All potential C. difficile colonies were subcultured on CCFA agar plates and toxin-positive isolates were identified by PCR.", [["colonies", "ANATOMY", 27, 35], ["C. difficile", "ORGANISM", 14, 26], ["toxin", "GENE_OR_GENE_PRODUCT", 77, 82], ["C. difficile", "SPECIES", 14, 26], ["C. difficile", "SPECIES", 14, 26], ["All potential C. difficile colonies", "PROBLEM", 0, 35], ["CCFA agar plates", "TEST", 56, 72], ["toxin", "TEST", 77, 82], ["positive isolates", "PROBLEM", 83, 100], ["PCR", "TEST", 120, 123], ["difficile colonies", "OBSERVATION", 17, 35]]], ["PCR ribotyping was performed according to the protocol of the Anaerobe Reference Unit in Cardiff, UK, using the Cardiff-ECDC culture collection as a set of reference strains.", [["PCR ribotyping", "TEST", 0, 14]]], ["After gel electrophoresis, the band patterns were analyzed using the BioNumerics software.", [["gel electrophoresis", "TEST", 6, 25], ["the band patterns", "TEST", 27, 44]]], ["Results: Altogether 22 C. difficile isolates were found in water samples.", [["samples", "ANATOMY", 65, 72], ["C. difficile", "ORGANISM", 23, 35], ["C. difficile", "SPECIES", 23, 35], ["C. difficile", "SPECIES", 23, 35], ["C. difficile isolates", "TEST", 23, 44]]], ["Twelve isolates were toxin-positive; 5 isolates were from contaminated tap water and 7 isolates from treated sewage effluent, the latter being the contamination source.", [["Twelve isolates", "TEST", 0, 15], ["toxin", "TEST", 21, 26], ["contaminated tap water", "TREATMENT", 58, 80], ["sewage effluent", "OBSERVATION", 109, 124]]], ["Among the tap water and sewage effluent isolates, 4 and 5 distinct PCR ribotype profiles were identified, respectively.", [["the tap water", "TREATMENT", 6, 19], ["sewage effluent isolates", "TEST", 24, 48], ["distinct PCR ribotype profiles", "TEST", 58, 88]]], ["The 9 human faecal C. difficile isolates detected were divided into 4 distinct PCR ribotype profiles.", [["human", "ORGANISM", 6, 11], ["faecal C. difficile", "ORGANISM", 12, 31], ["human", "SPECIES", 6, 11], ["C. difficile", "SPECIES", 19, 31], ["human", "SPECIES", 6, 11], ["C. difficile", "SPECIES", 19, 31], ["The 9 human faecal C. difficile isolates", "TEST", 0, 40]]], ["None of the profiles were identical with that of the hypervirulent PCR ribotype 027.", [["ribotype 027", "SPECIES", 71, 83], ["the hypervirulent PCR ribotype", "PROBLEM", 49, 79]]], ["Two isolates, one from tap water and another from a patient, had an indistinguishable PCR ribotype profile.", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["an indistinguishable PCR ribotype profile", "PROBLEM", 65, 106], ["PCR ribotype", "OBSERVATION", 86, 98]]], ["Conclusion: Our observation implies that C. difficile contamination of a tap water distribution system had occurred.", [["C. difficile", "DISEASE", 41, 53], ["C. difficile", "ORGANISM", 41, 53], ["C. difficile", "SPECIES", 41, 53], ["C. difficile", "SPECIES", 41, 53], ["Our observation", "TEST", 12, 27], ["C. difficile contamination", "PROBLEM", 41, 67], ["a tap water distribution system", "TREATMENT", 71, 102]]], ["Waterborne transmission of toxigenic C. difficile and subsequent C. difficile infection seems possible.", [["toxigenic C. difficile", "DISEASE", 27, 49], ["C. difficile infection", "DISEASE", 65, 87], ["C. difficile", "ORGANISM", 37, 49], ["C. difficile", "ORGANISM", 65, 77], ["C. difficile", "SPECIES", 37, 49], ["C. difficile", "SPECIES", 65, 77], ["C. difficile", "SPECIES", 37, 49], ["C. difficile", "SPECIES", 65, 77], ["toxigenic C. difficile", "PROBLEM", 27, 49], ["subsequent C. difficile infection", "PROBLEM", 54, 87], ["difficile", "OBSERVATION", 40, 49], ["difficile", "OBSERVATION_MODIFIER", 68, 77], ["infection", "OBSERVATION", 78, 87]]], ["Objectives: An accurate and rapid method is needed for typing of toxigenic Clostridium difficile.", [["Clostridium difficile", "DISEASE", 75, 96], ["Clostridium difficile", "ORGANISM", 75, 96], ["Clostridium difficile", "SPECIES", 75, 96], ["Clostridium difficile", "SPECIES", 75, 96], ["toxigenic Clostridium difficile", "PROBLEM", 65, 96]]], ["A commercial automated repetitive PCR system (rep-PCR; DiversiLab \u00ae , Biom\u00e9rieux Inc., St Louis, USA) utilises amplification and subsequent automated electrophoretic separation of the repetitive extragenic palindromic sequences of C. difficile.", [["C. difficile", "ORGANISM", 231, 243], ["repetitive extragenic palindromic sequences", "DNA", 184, 227], ["C. difficile", "SPECIES", 231, 243], ["C. difficile", "SPECIES", 231, 243], ["A commercial automated repetitive PCR system", "TEST", 0, 44], ["PCR", "TEST", 50, 53], ["DiversiLab", "TEST", 55, 65], ["subsequent automated electrophoretic separation", "TREATMENT", 129, 176], ["the repetitive extragenic palindromic sequences", "PROBLEM", 180, 227], ["C. difficile", "PROBLEM", 231, 243], ["difficile", "OBSERVATION", 234, 243]]], ["Our aim was to evaluate the performance of this rep-PCR method for genotyping of C. difficile isolates and to compare it to PCR ribotyping.", [["C. difficile", "ORGANISM", 81, 93], ["C. difficile", "SPECIES", 81, 93], ["C. difficile", "SPECIES", 81, 93], ["this rep-PCR method", "TEST", 43, 62], ["C. difficile isolates", "PROBLEM", 81, 102], ["PCR ribotyping", "TEST", 124, 138]]], ["In addition, the correlation between the rep-PCR and the virulence gene profiles of C. difficile strains was studied.", [["C. difficile strains", "ORGANISM", 84, 104], ["rep-PCR", "DNA", 41, 48], ["C. difficile", "SPECIES", 84, 96], ["C. difficile", "SPECIES", 84, 96], ["the rep-PCR", "TEST", 37, 48], ["C. difficile strains", "PROBLEM", 84, 104]]], ["Methods: A total of 195 toxin-positive C. difficile isolates were studied.", [["toxin", "GENE_OR_GENE_PRODUCT", 24, 29], ["C. difficile", "ORGANISM", 39, 51], ["C. difficile", "SPECIES", 39, 51], ["C. difficile", "SPECIES", 39, 51], ["195 toxin", "TEST", 20, 29], ["positive C. difficile isolates", "PROBLEM", 30, 60]]], ["We included consecutive isolates from two laboratories in Finland, containing also strains of the hypervirulent C. difficile ribotype 027.", [["C. difficile", "DISEASE", 112, 124], ["C. difficile ribotype 027", "ORGANISM", 112, 137], ["C. difficile", "SPECIES", 112, 124], ["C. difficile ribotype 027", "SPECIES", 112, 137], ["the hypervirulent C. difficile ribotype", "PROBLEM", 94, 133], ["hypervirulent", "OBSERVATION_MODIFIER", 98, 111], ["difficile", "OBSERVATION_MODIFIER", 115, 124]]], ["In addition, selected C. difficile strains with >18 bp deletions in their tcdC genes were analyzed.", [["C. difficile strains", "ORGANISM", 22, 42], ["tcdC", "GENE_OR_GENE_PRODUCT", 74, 78], ["tcdC genes", "DNA", 74, 84], ["C. difficile", "SPECIES", 22, 34], ["C. difficile", "SPECIES", 22, 34], ["selected C. difficile strains", "PROBLEM", 13, 42], [">18 bp deletions", "TREATMENT", 48, 64]]], ["The DNA was extracted and the rep-PCR performed according to the manufacturer's instructions.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["rep-PCR", "DNA", 30, 37], ["the rep-PCR", "TEST", 26, 37]]], ["The amplification products of rep-PCR were detected and analyzed using the DiversiLab system.", [["rep", "DNA", 30, 33], ["rep-PCR", "TEST", 30, 37]]], ["Further analysis was performed with the web-based software accompanying the system.", [["Further analysis", "TEST", 0, 16]]], ["The usefulness of the library construction option of the DiversLab system for isolate comparison was tested.", [["the DiversLab system", "TREATMENT", 53, 73]]], ["The virulence genes (tcdA, tcdB, cdtA, cdtB and tcdC) were analyzed by conventional PCR and the whole gene sequencing of tcdC was performed from isolates with deletions >18 bp.", [["tcdA", "GENE_OR_GENE_PRODUCT", 21, 25], ["tcdB", "GENE_OR_GENE_PRODUCT", 27, 31], ["cdtA", "GENE_OR_GENE_PRODUCT", 33, 37], ["cdtB", "GENE_OR_GENE_PRODUCT", 39, 43], ["tcdC", "GENE_OR_GENE_PRODUCT", 48, 52], ["tcdC", "GENE_OR_GENE_PRODUCT", 121, 125], ["virulence genes", "DNA", 4, 19], ["tcdA", "DNA", 21, 25], ["tcdB", "DNA", 27, 31], ["cdtA", "DNA", 33, 37], ["cdtB", "DNA", 39, 43], ["tcdC", "DNA", 48, 52], ["tcdC", "DNA", 121, 125], ["tcdA", "TEST", 21, 25], ["tcdB", "TEST", 27, 31], ["conventional PCR", "TEST", 71, 87], ["tcdC", "PROBLEM", 121, 125], ["deletions", "TEST", 159, 168], ["bp", "TEST", 173, 175]]], ["PCR ribotyping was performed using the protocol of the Anaerobe Reference Unit in Cardiff, UK.Results:The correlation between the rep-PCR profile and the ribotype was excellent.", [["PCR ribotyping", "TEST", 0, 14], ["the rep-PCR profile", "TEST", 126, 145], ["the ribotype", "TEST", 150, 162]]], ["All major ribotype groups were clustered in their own rep-PCR groups.", [["rep", "DNA", 54, 57], ["All major ribotype groups", "PROBLEM", 0, 25]]], ["Interestingly, subgroups could be found with rep-PCR within two most prevalent ribotypes 001 and 027.", [["rep-PCR", "TEST", 45, 52]]], ["The automated rep-PCR proved to be reproducible; the results from separate DNA isolations and PCR-runs/microfluid electrophoresis as well as the results performed by different individuals of laboratory personnel were comparable.", [["DNA", "CELLULAR_COMPONENT", 75, 78], ["The automated rep-PCR", "TEST", 0, 21], ["separate DNA isolations", "TEST", 66, 89], ["PCR", "TEST", 94, 97], ["runs/microfluid electrophoresis", "TEST", 98, 129]]], ["The rep-PCR profiles and PCR ribotypes correlated also with the virulence gene profiles.Results:Conclusion: This automated rep-PCR represents an effective and reproducible method for the genetic characterisation of C. difficile strains in clinical laboratories with molecular biology facilities.", [["C. difficile", "DISEASE", 215, 227], ["C. difficile", "ORGANISM", 215, 227], ["PCR ribotypes", "DNA", 25, 38], ["C. difficile", "SPECIES", 215, 227], ["C. difficile", "SPECIES", 215, 227], ["The rep-PCR profiles", "TEST", 0, 20], ["PCR ribotypes", "TEST", 25, 38], ["This automated rep-PCR", "TEST", 108, 130], ["C. difficile strains", "PROBLEM", 215, 235]]], ["The constructed C. difficile library allows comparing the relatedness of C. difficile strains and their fingerprints over time.", [["C. difficile", "ORGANISM", 16, 28], ["C. difficile", "ORGANISM", 73, 85], ["C. difficile", "SPECIES", 16, 28], ["C. difficile", "SPECIES", 73, 85], ["C. difficile", "SPECIES", 16, 28], ["C. difficile", "SPECIES", 73, 85], ["The constructed C. difficile library", "PROBLEM", 0, 36], ["C. difficile strains", "PROBLEM", 73, 93], ["difficile", "OBSERVATION", 19, 28]]], ["Objectives: Clostridium difficile infection (CDI) is a serious diarrhoeal illness associated with high morbidity and mortality.", [["Clostridium difficile infection", "DISEASE", 12, 43], ["CDI", "DISEASE", 45, 48], ["diarrhoeal illness", "DISEASE", 63, 81], ["Clostridium difficile", "ORGANISM", 12, 33], ["Clostridium difficile", "SPECIES", 12, 33], ["Clostridium difficile", "SPECIES", 12, 33], ["Clostridium difficile infection", "PROBLEM", 12, 43], ["CDI", "PROBLEM", 45, 48], ["a serious diarrhoeal illness", "PROBLEM", 53, 81], ["high morbidity", "PROBLEM", 98, 112], ["Clostridium difficile", "OBSERVATION_MODIFIER", 12, 33], ["infection", "OBSERVATION", 34, 43]]], ["Currently available treatments (oral vancomycin or metronidazole) usually produce good resolution of diarrhoea but are associated with a 20% to 30% incidence of recurrence.", [["oral", "ANATOMY", 32, 36], ["vancomycin", "CHEMICAL", 37, 47], ["metronidazole", "CHEMICAL", 51, 64], ["diarrhoea", "DISEASE", 101, 110], ["vancomycin", "CHEMICAL", 37, 47], ["metronidazole", "CHEMICAL", 51, 64], ["oral", "ORGANISM_SUBDIVISION", 32, 36], ["vancomycin", "SIMPLE_CHEMICAL", 37, 47], ["metronidazole", "SIMPLE_CHEMICAL", 51, 64], ["treatments", "TREATMENT", 20, 30], ["oral vancomycin", "TREATMENT", 32, 47], ["metronidazole", "TREATMENT", 51, 64], ["diarrhoea", "PROBLEM", 101, 110], ["recurrence", "PROBLEM", 161, 171], ["good", "OBSERVATION_MODIFIER", 82, 86], ["resolution", "OBSERVATION_MODIFIER", 87, 97], ["diarrhoea", "OBSERVATION", 101, 110], ["recurrence", "OBSERVATION", 161, 171]]], ["OPT-80, the first in a new class of macrocyclic antibiotics, is bactericidal via unique inhibition of RNA polymerase.", [["OPT-80", "CHEMICAL", 0, 6], ["OPT-80", "CHEMICAL", 0, 6], ["OPT-80", "SIMPLE_CHEMICAL", 0, 6], ["RNA polymerase", "PROTEIN", 102, 116], ["OPT", "TEST", 0, 3], ["macrocyclic antibiotics", "TREATMENT", 36, 59], ["bactericidal", "PROBLEM", 64, 76], ["RNA polymerase", "PROBLEM", 102, 116], ["RNA polymerase", "OBSERVATION", 102, 116]]], ["This phase 3, non-inferiority clinical trial was conducted in more than 100 sites in North America and compared the efficacy and safety of OPT-80 and vancomycin in treating CDI.", [["OPT-80", "CHEMICAL", 139, 145], ["vancomycin", "CHEMICAL", 150, 160], ["CDI", "DISEASE", 173, 176], ["OPT-80", "CHEMICAL", 139, 145], ["vancomycin", "CHEMICAL", 150, 160], ["OPT-80", "SIMPLE_CHEMICAL", 139, 145], ["vancomycin", "SIMPLE_CHEMICAL", 150, 160], ["OPT", "TEST", 139, 142], ["vancomycin", "TREATMENT", 150, 160], ["CDI", "PROBLEM", 173, 176], ["CDI", "OBSERVATION", 173, 176]]], ["Methods: Eligible patients were adults with acute CDI symptoms and a positive stool toxin test.", [["patients", "ORGANISM", 18, 26], ["stool", "ORGANISM_SUBSTANCE", 78, 83], ["patients", "SPECIES", 18, 26], ["acute CDI symptoms", "PROBLEM", 44, 62], ["a positive stool toxin test", "TEST", 67, 94]]], ["Patients received oral OPT-80 (200 mg twice daily) or oral vancomycin (125 mg 4 times daily) for 10 days.", [["oral", "ANATOMY", 18, 22], ["oral", "ANATOMY", 54, 58], ["OPT-80", "CHEMICAL", 23, 29], ["vancomycin", "CHEMICAL", 59, 69], ["OPT-80", "CHEMICAL", 23, 29], ["vancomycin", "CHEMICAL", 59, 69], ["Patients", "ORGANISM", 0, 8], ["oral", "ORGANISM_SUBDIVISION", 18, 22], ["oral", "ORGANISM_SUBDIVISION", 54, 58], ["vancomycin", "SIMPLE_CHEMICAL", 59, 69], ["Patients", "SPECIES", 0, 8], ["oral OPT", "TREATMENT", 18, 26], ["oral vancomycin", "TREATMENT", 54, 69]]], ["Primary end point was clinical cure (resolution of symptoms and no further need for CDI therapy 2 days after stopping study drug).", [["CDI", "DISEASE", 84, 87], ["symptoms", "PROBLEM", 51, 59], ["CDI therapy", "TREATMENT", 84, 95]]], ["Secondary end point was CDI recurrence (diarrhoea and positive stool toxin test within 4 weeks after treatment).", [["CDI", "DISEASE", 24, 27], ["diarrhoea", "DISEASE", 40, 49], ["CDI recurrence", "PROBLEM", 24, 38], ["diarrhoea", "PROBLEM", 40, 49], ["positive stool toxin test", "TEST", 54, 79], ["treatment", "TREATMENT", 101, 110], ["CDI", "OBSERVATION_MODIFIER", 24, 27], ["recurrence", "OBSERVATION", 28, 38]]], ["Global cure was defined as a clinical cure with no recurrence.", [["Global cure", "PROBLEM", 0, 11], ["recurrence", "PROBLEM", 51, 61], ["cure", "OBSERVATION", 7, 11], ["no", "UNCERTAINTY", 48, 50], ["recurrence", "OBSERVATION", 51, 61]]], ["Results: 629 patients were enrolled and 87% were evaluable.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["In the per protocol (PP) population (n = 548), mean age was 61.3\u00b117.1 years and 44.0% of patients were male.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["mean age", "TEST", 47, 55]]], ["Equivalent rates of clinical cure were observed with OPT-80 (92%) and vancomycin (90%) in the PP analysis; similar outcomes were observed in a modified intent-to-treat (mITT) analysis.", [["OPT-80", "CHEMICAL", 53, 59], ["vancomycin", "CHEMICAL", 70, 80], ["OPT-80", "CHEMICAL", 53, 59], ["vancomycin", "CHEMICAL", 70, 80], ["OPT-80", "SIMPLE_CHEMICAL", 53, 59], ["vancomycin", "SIMPLE_CHEMICAL", 70, 80], ["OPT", "TEST", 53, 56], ["vancomycin", "TREATMENT", 70, 80], ["the PP analysis", "TEST", 90, 105]]], ["Significantly fewer patients treated with OPT-80 (13%) than vancomycin (24%) experienced recurrence in the PP analysis (P = 0.004) and in the mITT analysis (15% vs 25%; P = 0.005).", [["OPT-80", "CHEMICAL", 42, 48], ["vancomycin", "CHEMICAL", 60, 70], ["OPT-80", "CHEMICAL", 42, 48], ["vancomycin", "CHEMICAL", 60, 70], ["patients", "ORGANISM", 20, 28], ["vancomycin", "SIMPLE_CHEMICAL", 60, 70], ["patients", "SPECIES", 20, 28], ["OPT", "TEST", 42, 45], ["vancomycin", "TREATMENT", 60, 70], ["recurrence", "PROBLEM", 89, 99], ["the PP analysis", "TEST", 103, 118], ["P", "TEST", 120, 121], ["the mITT analysis", "TEST", 138, 155], ["P", "TEST", 169, 170]]], ["Significantly more OPT-80-treated patients achieved global cure (78%) than vancomycintreated patients in the PP analysis (67%; P = 0.006) and in the mITT analysis (75% vs 64%; P = 0.006).", [["OPT-80", "CHEMICAL", 19, 25], ["OPT-80", "CHEMICAL", 19, 25], ["OPT-80", "SIMPLE_CHEMICAL", 19, 25], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 93, 101], ["the PP analysis", "TEST", 105, 120], ["P", "TEST", 127, 128], ["the mITT analysis", "TEST", 145, 162], ["P", "TEST", 176, 177]]], ["OPT-80 was well tolerated with an adverse event profile similar to that of vancomycin.Conclusions:In this study -the largest comparative trial of a new antimicrobial agent versus vancomycin for the treatment of CDI -clinical cure rates after treatment with OPT-80 or vancomycin were equivalent.", [["OPT-80", "CHEMICAL", 0, 6], ["vancomycin", "CHEMICAL", 75, 85], ["vancomycin", "CHEMICAL", 179, 189], ["CDI", "DISEASE", 211, 214], ["OPT-80", "CHEMICAL", 257, 263], ["vancomycin", "CHEMICAL", 267, 277], ["OPT-80", "CHEMICAL", 0, 6], ["vancomycin", "CHEMICAL", 75, 85], ["vancomycin", "CHEMICAL", 179, 189], ["OPT-80", "CHEMICAL", 257, 263], ["vancomycin", "CHEMICAL", 267, 277], ["OPT-80", "SIMPLE_CHEMICAL", 0, 6], ["vancomycin", "SIMPLE_CHEMICAL", 75, 85], ["vancomycin", "SIMPLE_CHEMICAL", 179, 189], ["OPT-80", "SIMPLE_CHEMICAL", 257, 263], ["vancomycin", "SIMPLE_CHEMICAL", 267, 277], ["an adverse event profile", "PROBLEM", 31, 55], ["vancomycin", "TREATMENT", 75, 85], ["this study", "TEST", 101, 111], ["a new antimicrobial agent", "TREATMENT", 146, 171], ["vancomycin", "TREATMENT", 179, 189], ["CDI", "PROBLEM", 211, 214], ["treatment", "TREATMENT", 242, 251], ["OPT", "TREATMENT", 257, 260], ["vancomycin", "TREATMENT", 267, 277]]], ["However, OPT-80 was associated with a significantly lower recurrence rate and a higher global cure rate than vancomycin.", [["OPT-80", "CHEMICAL", 9, 15], ["vancomycin", "CHEMICAL", 109, 119], ["OPT-80", "CHEMICAL", 9, 15], ["vancomycin", "CHEMICAL", 109, 119], ["OPT-80", "GENE_OR_GENE_PRODUCT", 9, 15], ["vancomycin", "SIMPLE_CHEMICAL", 109, 119], ["OPT", "TEST", 9, 12], ["a significantly lower recurrence rate", "PROBLEM", 36, 73], ["vancomycin", "TREATMENT", 109, 119]]], ["OPT-80 is an oral, non-absorbed agent that has a convenient (twice daily) dosing schedule and low risk of adverse events.", [["oral", "ANATOMY", 13, 17], ["OPT-80", "CHEMICAL", 0, 6], ["OPT-80", "CHEMICAL", 0, 6], ["OPT-80", "SIMPLE_CHEMICAL", 0, 6], ["oral", "ORGANISM_SUBDIVISION", 13, 17], ["OPT", "TEST", 0, 3], ["adverse events", "PROBLEM", 106, 120]]], ["OPT-80 represents a potential new treatment option for CDI that is associated with a lower recurrence rate than currently available treatments.", [["OPT-80", "CHEMICAL", 0, 6], ["CDI", "DISEASE", 55, 58], ["OPT-80", "CHEMICAL", 0, 6], ["OPT-80", "GENE_OR_GENE_PRODUCT", 0, 6], ["new treatment option", "TREATMENT", 30, 50], ["CDI", "PROBLEM", 55, 58], ["a lower recurrence rate", "PROBLEM", 83, 106], ["lower", "OBSERVATION_MODIFIER", 85, 90], ["recurrence", "OBSERVATION", 91, 101]]], ["Results: Sequence analysis (SA) revealed that locus A is absent in Type 078 and that some mismatches are present in the primer annealing sites for loci B, C and G. Lowering the annealing temperature and increasing the magnesium chloride concentration for loci B, C and G resolved the low yield of PCR products.", [["magnesium chloride", "CHEMICAL", 218, 236], ["magnesium chloride", "CHEMICAL", 218, 236], ["magnesium chloride", "SIMPLE_CHEMICAL", 218, 236], ["C", "SIMPLE_CHEMICAL", 263, 264], ["locus A", "DNA", 46, 53], ["Type 078", "DNA", 67, 75], ["primer annealing sites", "DNA", 120, 142], ["loci B", "DNA", 147, 153], ["Type 078", "SPECIES", 67, 75], ["Sequence analysis", "TEST", 9, 26], ["some mismatches", "PROBLEM", 85, 100], ["loci B, C and G.", "PROBLEM", 147, 163], ["the annealing temperature", "PROBLEM", 173, 198], ["increasing the magnesium chloride concentration", "TREATMENT", 203, 250], ["loci B, C and G", "PROBLEM", 255, 270], ["PCR products", "TREATMENT", 297, 309], ["absent", "OBSERVATION_MODIFIER", 57, 63], ["some", "OBSERVATION_MODIFIER", 85, 89], ["mismatches", "OBSERVATION", 90, 100], ["low yield", "OBSERVATION_MODIFIER", 284, 293]]], ["Applying the MLVA on 54 type 078 strains revealed that 42 (80%) strains, encompassing isolates from human (n = 42) and porcine (n = 11) origin, are genetically related with a summed tandem repeat differences (STRD) 10).", [["human", "ORGANISM", 100, 105], ["human", "SPECIES", 100, 105], ["porcine", "SPECIES", 119, 126], ["human", "SPECIES", 100, 105], ["the MLVA", "TEST", 9, 17], ["strains", "PROBLEM", 64, 71], ["a summed tandem repeat differences", "PROBLEM", 173, 207]]], ["Three clonal complexes (CC, defined by STRD 2) were recognized; one CC contained both human (n = 4) and porcine (n = 3) strains.", [["clonal complexes", "ANATOMY", 6, 22], ["CC", "CHEMICAL", 68, 70], ["human", "ORGANISM", 86, 91], ["porcine", "ORGANISM", 104, 111], ["clonal complexes", "PROTEIN", 6, 22], ["CC", "PROTEIN", 24, 26], ["STRD 2", "PROTEIN", 39, 45], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["porcine (n", "TREATMENT", 104, 114], ["strains", "PROBLEM", 120, 127], ["clonal complexes", "OBSERVATION", 6, 22]]], ["The optimised MLVA identified 3 genetically related clusters and 6 CC among the 67 isolates from E and NI.", [["CC", "CHEMICAL", 67, 69]]], ["CCs contain isolates from more than one hospital and indeed for several clusters isolates from both E and NI.", [["CCs", "ANATOMY", 0, 3], ["isolates", "OBSERVATION_MODIFIER", 12, 20]]], ["2 isolates obtained from NI 8 years earlier were part of one large CC.Conclusions:The optimised MLVA can distinguish and/or group Type 078 strains from distinct settings.", [["CC", "CHEMICAL", 67, 69], ["CC", "CANCER", 67, 69], ["The optimised MLVA", "TEST", 82, 100]]], ["Type 078 strains from human and animal origin are genetically related.", [["human", "ORGANISM", 22, 27], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["Type 078 strains", "PROBLEM", 0, 16], ["animal origin", "OBSERVATION_MODIFIER", 32, 45]]], ["The clustering of some isolates from distinct settings is consistent with community sources for Type 078.", [["some", "OBSERVATION_MODIFIER", 18, 22], ["isolates", "OBSERVATION_MODIFIER", 23, 31], ["consistent with", "UNCERTAINTY", 58, 73]]], ["The last 2 observations suggest zoonotic transmission.", [["zoonotic transmission", "DISEASE", 32, 53], ["zoonotic transmission", "PROBLEM", 32, 53], ["zoonotic", "OBSERVATION_MODIFIER", 32, 40]]], ["Objectives: This paper updates our assessment of the contribution that community-associated Clostridium difficile infection (CDI), as reported to the English mandatory surveillance scheme since 2007, makes to both the acute and community sectors of the National Health Service (NHS) in England.", [["Clostridium difficile infection", "DISEASE", 92, 123], ["CDI", "DISEASE", 125, 128], ["Clostridium difficile", "ORGANISM", 92, 113], ["Clostridium difficile", "SPECIES", 92, 113], ["Clostridium difficile", "SPECIES", 92, 113], ["our assessment", "TEST", 31, 45], ["Clostridium difficile infection", "PROBLEM", 92, 123], ["Clostridium", "OBSERVATION_MODIFIER", 92, 103], ["difficile", "OBSERVATION_MODIFIER", 104, 113], ["infection", "OBSERVATION", 114, 123]]], ["Methods: NHS acute Trusts (hospital groups) in England are required to report all C. difficile toxin positive diarrhoeal specimens processed by their laboratories whether the patients were in hospital or the community at the time of onset of the illness or when the specimen was taken via a web enabled reporting system.", [["specimens", "ANATOMY", 121, 130], ["specimen", "ANATOMY", 266, 274], ["illness", "DISEASE", 246, 253], ["C. difficile", "ORGANISM", 82, 94], ["patients", "ORGANISM", 175, 183], ["C. difficile", "SPECIES", 82, 94], ["patients", "SPECIES", 175, 183], ["C. difficile", "SPECIES", 82, 94], ["all C. difficile toxin positive diarrhoeal specimens", "PROBLEM", 78, 130], ["the illness", "PROBLEM", 242, 253], ["the specimen", "TEST", 262, 274], ["acute", "OBSERVATION_MODIFIER", 13, 18]]], ["Positive specimens from the same patient within 28 days are not reported.", [["specimens", "ANATOMY", 9, 18], ["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["specimens", "OBSERVATION", 9, 18]]], ["Reported cases in patients under 2 years of age were omitted from this analysis.O151 Community-associatedEnhanced surveillance data (including information on date of admission, patient location prior to testing, sex, age and patient category) on CDI have been collected through a web-enabled reporting system since April 2007.", [["patients", "ORGANISM", 18, 26], ["patient", "ORGANISM", 177, 184], ["patient", "ORGANISM", 225, 232], ["patients", "SPECIES", 18, 26], ["patient", "SPECIES", 177, 184], ["patient", "SPECIES", 225, 232], ["this analysis", "TEST", 66, 79], ["testing", "TEST", 203, 210], ["CDI", "PROBLEM", 246, 249]]], ["Risk factor information is completed on a voluntary basis.O151 Community-associatedResults: More than 75,000 cases of CDI in patients aged >2 years were reported, 23% of these cases were taken in non-acute settings of which 74% were taken by a General Practitioner.", [["CDI", "DISEASE", 118, 121], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["CDI", "PROBLEM", 118, 121], ["CDI", "OBSERVATION", 118, 121]]], ["A further 17% of specimens were taken on presentation or <2 days of admission into an acute Trust.", [["specimens", "ANATOMY", 17, 26], ["specimens", "CANCER", 17, 26], ["specimens", "TEST", 17, 26], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["Trust", "OBSERVATION", 92, 97]]], ["The information reported suggests that only 3% of the community associated cases were from patients with continued infection or relapsed episodes of CDI, this is compared to 8% of the hospital acquired cases who had continued infection or relapsed episodes of CDI.", [["infection", "DISEASE", 115, 124], ["CDI", "DISEASE", 149, 152], ["infection", "DISEASE", 226, 235], ["CDI", "DISEASE", 260, 263], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["continued infection", "PROBLEM", 105, 124], ["CDI", "PROBLEM", 149, 152], ["continued infection", "PROBLEM", 216, 235], ["CDI", "PROBLEM", 260, 263], ["infection", "OBSERVATION", 115, 124], ["CDI", "OBSERVATION", 149, 152], ["infection", "OBSERVATION", 226, 235], ["CDI", "OBSERVATION", 260, 263]]], ["Conclusions: 23% of the C. difficile specimens reported by acute Trusts were diagnosed in a community setting.", [["specimens", "ANATOMY", 37, 46], ["C. difficile", "DISEASE", 24, 36], ["C. difficile specimens", "ORGANISM", 24, 46], ["C. difficile", "SPECIES", 24, 36], ["C. difficile", "SPECIES", 24, 36], ["the C. difficile specimens", "TEST", 20, 46], ["acute", "OBSERVATION_MODIFIER", 59, 64]]], ["Published studies suggest that 12\u221215% of these might be expected to have been acquired during a hospital stay within the previous month (i.e. were community onset hospital acquired cases).", [["Published studies", "TEST", 0, 17]]], ["Future work is required to investigate whether there are differences in the epidemiology, risk factors e.g. antibiotic exposure and outcome of patients with community onset disease.O151 Community-associatedO152 Clostridium difficile-associated disease: a newly notifiable disease in Ireland M. Skally, F. Roche, D. O'Flanagan, P. McKeown, F. Fitzpatrick\u00b0( Dublin, IE) New cases of Clostridium difficile-associated disease (CDAD) became notifiable in Ireland on 4th May 2008.", [["Clostridium difficile-associated disease", "DISEASE", 211, 251], ["Clostridium difficile-associated disease", "DISEASE", 381, 421], ["CDAD", "DISEASE", 423, 427], ["patients", "ORGANISM", 143, 151], ["O152 Clostridium difficile", "ORGANISM", 206, 232], ["Clostridium difficile", "ORGANISM", 381, 402], ["patients", "SPECIES", 143, 151], ["Clostridium difficile", "SPECIES", 211, 232], ["Clostridium difficile", "SPECIES", 381, 402], ["Clostridium difficile", "SPECIES", 211, 232], ["Clostridium difficile", "SPECIES", 381, 402], ["antibiotic exposure", "TREATMENT", 108, 127], ["community onset disease", "PROBLEM", 157, 180], ["Clostridium difficile", "PROBLEM", 211, 232], ["a newly notifiable disease", "PROBLEM", 253, 279], ["Clostridium difficile", "PROBLEM", 381, 402], ["associated disease (CDAD", "PROBLEM", 403, 427], ["Clostridium difficile", "OBSERVATION", 381, 402]]], ["The main objective of this new notification process was to provide a national overview of the epidemiology and burden of CDAD.", [["CDAD", "DISEASE", 121, 125], ["CDAD", "PROBLEM", 121, 125], ["main", "OBSERVATION_MODIFIER", 4, 8], ["CDAD", "OBSERVATION", 121, 125]]], ["Methods: The interim case definitions for new and recurrent CDAD cases proposed by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for C. difficile were employed.", [["CDAD", "DISEASE", 60, 64], ["Infectious Diseases", "DISEASE", 134, 153], ["C. difficile", "DISEASE", 179, 191], ["C. difficile", "SPECIES", 179, 191], ["C. difficile", "SPECIES", 179, 191], ["new and recurrent CDAD cases", "PROBLEM", 42, 70], ["Clinical Microbiology", "TEST", 108, 129], ["C. difficile", "PROBLEM", 179, 191]]], ["This report reviews the weekly events of CDAD extracted from the Computerised Infectious Disease Reporting (CIDR) system in January 2009.", [["CDAD", "DISEASE", 41, 45], ["Infectious Disease", "DISEASE", 78, 96], ["CDAD", "PROBLEM", 41, 45]]], ["Census of Population 2006 figures were used as denominator data in the calculation of incidence rates.", [["denominator data", "TEST", 47, 63]]], ["Results: There were 1581 new CDAD cases notified on CIDR between the 4th May 2008 and 27th December 2008, representing a crude incidence rate (CIR) of 37.3 cases/100000 population (estimated annual CIR is 57.0 cases/100,000).", [["CDAD", "DISEASE", 29, 33], ["CIDR", "TREATMENT", 52, 56], ["annual CIR", "TEST", 191, 201]]], ["There was a higher occurrence of cases in females.", [["higher", "OBSERVATION_MODIFIER", 12, 18]]], ["The male:female ratio for the period was 1:1.6.", [["female", "ORGANISM", 9, 15]]], ["71.4% of cases were in the greater than 65 years age category.", [["cases", "TEST", 9, 14]]], ["The preliminary data submitted on CIDR indicate that 63.0% of cases were hospital inpatients and 8.9% of cases were either GP patients or outpatients.", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["outpatients", "SPECIES", 138, 149], ["The preliminary data", "TEST", 0, 20], ["CIDR", "TREATMENT", 34, 38]]], ["The origin of 28.1% of samples is unknown.", [["samples", "ANATOMY", 23, 30], ["samples", "CANCER", 23, 30], ["samples", "TEST", 23, 30], ["origin", "ANATOMY_MODIFIER", 4, 10]]], ["There was large variation between the 8 public health regions (Table 1) .Conclusions:The incidence of CDAD in Ireland is prominent in older age groups and in healthcare settings.", [["CDAD", "DISEASE", 102, 106], ["large variation between the 8 public health regions", "PROBLEM", 10, 61], ["CDAD", "PROBLEM", 102, 106], ["large", "OBSERVATION_MODIFIER", 10, 15], ["variation", "OBSERVATION_MODIFIER", 16, 25], ["CDAD", "OBSERVATION", 102, 106], ["prominent", "OBSERVATION_MODIFIER", 121, 130]]], ["The seasonal trend is indistinguishable at present due to late and batch notifications from institutions.Conclusions:O153 Clostridium difficile-associated diarrhoea in immunosuppressed patients with cancerConclusions:Objective: To assess the epidemiology, clinical features and outcome of Clostridium difficile (CD) associated diarrhoea in immunosuppressed patients with cancer.Conclusions:Methods: Review of all episodes of CD associated diarrhoea documented in adults with cancer and haematopoietic stem cell recipients (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) .", [["cancer", "ANATOMY", 371, 377], ["cancer", "ANATOMY", 475, 481], ["haematopoietic stem cell", "ANATOMY", 486, 510], ["Clostridium difficile", "DISEASE", 122, 143], ["diarrhoea", "DISEASE", 155, 164], ["Clostridium difficile", "DISEASE", 289, 310], ["CD", "DISEASE", 312, 314], ["diarrhoea", "DISEASE", 327, 336], ["cancer", "DISEASE", 371, 377], ["CD", "DISEASE", 425, 427], ["diarrhoea", "DISEASE", 439, 448], ["cancer", "DISEASE", 475, 481], ["O153 Clostridium difficile", "ORGANISM", 117, 143], ["patients", "ORGANISM", 185, 193], ["Clostridium difficile", "ORGANISM", 289, 310], ["patients", "ORGANISM", 357, 365], ["cancer", "CANCER", 371, 377], ["cancer", "CANCER", 475, 481], ["haematopoietic stem cell", "CELL", 486, 510], ["Clostridium difficile", "SPECIES", 122, 143], ["patients", "SPECIES", 185, 193], ["Clostridium difficile", "SPECIES", 289, 310], ["patients", "SPECIES", 357, 365], ["Clostridium difficile", "SPECIES", 122, 143], ["Clostridium difficile", "SPECIES", 289, 310], ["Clostridium difficile", "PROBLEM", 122, 143], ["diarrhoea", "PROBLEM", 155, 164], ["Clostridium difficile (CD)", "PROBLEM", 289, 315], ["diarrhoea", "PROBLEM", 327, 336], ["cancer", "PROBLEM", 371, 377], ["CD associated diarrhoea", "PROBLEM", 425, 448], ["cancer", "PROBLEM", 475, 481], ["haematopoietic stem cell recipients", "TREATMENT", 486, 521], ["diarrhoea", "OBSERVATION", 155, 164], ["diarrhoea", "OBSERVATION", 327, 336], ["cancer", "OBSERVATION", 371, 377], ["diarrhoea", "OBSERVATION", 439, 448], ["cancer", "OBSERVATION", 475, 481], ["haematopoietic stem cell recipients", "OBSERVATION", 486, 521]]], ["Microbiologic diagnosis included CD isolation from stool samples, direct detection of CD toxin, and testing for cytotoxin production by the isolated strain.Results:We documented a significant increase of CD associated diarrhoea, from 0.34/1000 admissions in 2000 to 4.05/1000 admissions in 2008 (p < 0.01).", [["stool samples", "ANATOMY", 51, 64], ["CD", "DISEASE", 204, 206], ["diarrhoea", "DISEASE", 218, 227], ["CD toxin", "GENE_OR_GENE_PRODUCT", 86, 94], ["cytotoxin", "GENE_OR_GENE_PRODUCT", 112, 121], ["CD toxin", "PROTEIN", 86, 94], ["cytotoxin", "PROTEIN", 112, 121], ["CD isolation", "PROBLEM", 33, 45], ["stool samples", "TEST", 51, 64], ["direct detection", "TEST", 66, 82], ["CD toxin", "TEST", 86, 94], ["testing", "TEST", 100, 107], ["cytotoxin production", "PROBLEM", 112, 132], ["the isolated strain", "PROBLEM", 136, 155], ["CD associated diarrhoea", "PROBLEM", 204, 227], ["significant", "OBSERVATION_MODIFIER", 180, 191], ["increase", "OBSERVATION_MODIFIER", 192, 200], ["CD associated", "OBSERVATION_MODIFIER", 204, 217], ["diarrhoea", "OBSERVATION", 218, 227]]], ["There were 56 episodes in 54 patients.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37]]], ["Thirty-one patients were male (55%) with a mean age of 52 years (\u00b1 16).", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["Forty three (77%) patients had an haematological underlying disease and 13 had solid tumour; 41 (73%) had received previous chemotherapy, 14 (25%) were stem cell transplant recipients (3 presenting with GVHD) and 17 (30%) were neutropenic (<500).", [["solid tumour", "ANATOMY", 79, 91], ["stem cell", "ANATOMY", 152, 161], ["tumour", "DISEASE", 85, 91], ["GVHD", "DISEASE", 203, 207], ["neutropenic", "DISEASE", 227, 238], ["patients", "ORGANISM", 18, 26], ["solid tumour", "CANCER", 79, 91], ["stem cell", "CELL", 152, 161], ["patients", "SPECIES", 18, 26], ["an haematological underlying disease", "PROBLEM", 31, 67], ["solid tumour", "PROBLEM", 79, 91], ["previous chemotherapy", "TREATMENT", 115, 136], ["stem cell transplant recipients", "TREATMENT", 152, 183], ["GVHD", "PROBLEM", 203, 207], ["neutropenic", "PROBLEM", 227, 238], ["disease", "OBSERVATION", 60, 67], ["tumour", "OBSERVATION", 85, 91], ["stem cell transplant", "OBSERVATION", 152, 172]]], ["In the previous month 52 patients (93%) had received one or more antibiotics (cephalosporins 63.5%, glycopeptides 40%, carbapenems 38.5%, betalactam + betalactam inhibitors 29%, quinolones 19%).", [["cephalosporins", "CHEMICAL", 78, 92], ["carbapenems", "CHEMICAL", 119, 130], ["betalactam", "CHEMICAL", 138, 148], ["betalactam", "CHEMICAL", 151, 161], ["quinolones", "CHEMICAL", 178, 188], ["cephalosporins", "CHEMICAL", 78, 92], ["carbapenems", "CHEMICAL", 119, 130], ["betalactam", "CHEMICAL", 138, 148], ["quinolones", "CHEMICAL", 178, 188], ["patients", "ORGANISM", 25, 33], ["cephalosporins", "SIMPLE_CHEMICAL", 78, 92], ["carbapenems", "SIMPLE_CHEMICAL", 119, 130], ["betalactam + betalactam", "SIMPLE_CHEMICAL", 138, 161], ["patients", "SPECIES", 25, 33], ["antibiotics", "TREATMENT", 65, 76], ["cephalosporins", "TREATMENT", 78, 92], ["glycopeptides", "TREATMENT", 100, 113], ["carbapenems", "TREATMENT", 119, 130], ["betalactam + betalactam inhibitors", "TREATMENT", 138, 172], ["quinolones", "TREATMENT", 178, 188]]], ["Fever >38\u00baC (71%) and abdominal pain (44%) were the most frequent manifestations, and the diarrhoea was hemorrhagic in 8% of the cases.", [["abdominal", "ANATOMY", 22, 31], ["Fever", "DISEASE", 0, 5], ["38\u00baC", "DISEASE", 7, 11], ["abdominal pain", "DISEASE", 22, 36], ["diarrhoea", "DISEASE", 90, 99], ["hemorrhagic", "DISEASE", 104, 115], ["abdominal", "ORGANISM_SUBDIVISION", 22, 31], ["Fever", "PROBLEM", 0, 5], ["abdominal pain", "PROBLEM", 22, 36], ["the most frequent manifestations", "PROBLEM", 48, 80], ["the diarrhoea", "PROBLEM", 86, 99], ["hemorrhagic", "PROBLEM", 104, 115], ["abdominal", "ANATOMY", 22, 31], ["most frequent", "OBSERVATION_MODIFIER", 52, 65], ["hemorrhagic", "OBSERVATION_MODIFIER", 104, 115]]], ["Most patients (77%) were treated with metronidazole (median 11 days), and the antibiotic therapy was discontinued in 56%.", [["metronidazole", "CHEMICAL", 38, 51], ["metronidazole", "CHEMICAL", 38, 51], ["patients", "ORGANISM", 5, 13], ["metronidazole", "SIMPLE_CHEMICAL", 38, 51], ["patients", "SPECIES", 5, 13], ["metronidazole", "TREATMENT", 38, 51], ["the antibiotic therapy", "TREATMENT", 74, 96]]], ["In 5 patients who had recovered from neutropenia, the diarrhoea resolved just by discontinuing the antibiotic therapy.", [["neutropenia", "DISEASE", 37, 48], ["diarrhoea", "DISEASE", 54, 63], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["neutropenia", "PROBLEM", 37, 48], ["the diarrhoea", "PROBLEM", 50, 63], ["the antibiotic therapy", "TREATMENT", 95, 117], ["neutropenia", "OBSERVATION", 37, 48]]], ["No patient developed toxic megacolon or needed surgery.", [["toxic megacolon", "DISEASE", 21, 36], ["patient", "ORGANISM", 3, 10], ["patient", "SPECIES", 3, 10], ["toxic megacolon", "PROBLEM", 21, 36], ["surgery", "TREATMENT", 47, 54], ["toxic", "OBSERVATION_MODIFIER", 21, 26], ["megacolon", "OBSERVATION", 27, 36]]], ["Three patients (5.5%) had relapses.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["relapses", "PROBLEM", 26, 34]]], ["Overall mortality (<30 days) was 22% (12 patients).Conclusion:The incidence of CD associated diarrhoea in cancer patients has increased significantly in recent years.", [["cancer", "ANATOMY", 106, 112], ["CD", "DISEASE", 79, 81], ["diarrhoea", "DISEASE", 93, 102], ["cancer", "DISEASE", 106, 112], ["patients", "ORGANISM", 41, 49], ["cancer", "CANCER", 106, 112], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 113, 121], ["CD associated diarrhoea in cancer", "PROBLEM", 79, 112], ["diarrhoea", "OBSERVATION", 93, 102], ["cancer", "OBSERVATION", 106, 112], ["increased", "OBSERVATION_MODIFIER", 126, 135], ["significantly", "OBSERVATION_MODIFIER", 136, 149]]], ["It is related with important morbidity and mortality.", [["related with", "UNCERTAINTY", 6, 18]]], ["Better strategies to improve its prevention and treatment are needed.From lab to ward: optimising treatment strategies for invasive Candida infections (Symposium organised by Astellas)S154 Linking research to the clinic: how laboratory findings relate to management of invasive Candida infectionsF.", [["Candida infections", "DISEASE", 132, 150], ["Candida infectionsF", "DISEASE", 278, 297], ["treatment", "TREATMENT", 48, 57], ["treatment strategies", "TREATMENT", 98, 118], ["invasive Candida infections", "PROBLEM", 123, 150], ["invasive Candida infectionsF", "PROBLEM", 269, 297], ["invasive", "OBSERVATION_MODIFIER", 269, 277], ["Candida infectionsF", "OBSERVATION", 278, 297]]], ["Odds\u00b0(Aberdeen, UK)The role of the research laboratory in the management of invasive Candida infections goes beyond routinely available tests for identification of Candida species and susceptibility testing of antifungal agents.", [["Candida infections", "DISEASE", 85, 103], ["invasive Candida infections", "PROBLEM", 76, 103], ["tests", "TEST", 136, 141], ["Candida species", "PROBLEM", 164, 179], ["susceptibility testing", "TEST", 184, 206], ["antifungal agents", "TREATMENT", 210, 227], ["invasive", "OBSERVATION_MODIFIER", 76, 84], ["Candida infections", "OBSERVATION", 85, 103], ["Candida species", "OBSERVATION", 164, 179]]], ["Cutting-edge molecular epidemiology technologies have been used to type isolates of Candida species based on their DNA sequences.", [["Candida species", "ORGANISM", 84, 99], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["DNA sequences", "DNA", 115, 128], ["Candida species", "PROBLEM", 84, 99], ["their DNA sequences", "TEST", 109, 128], ["edge", "OBSERVATION_MODIFIER", 8, 12], ["Candida species", "OBSERVATION", 84, 99]]], ["Multilocus sequence typing schemes have been designed for C. albicans, C. dubliniensis, C. glabrata, C. krusei and C. tropicalis.F. Odds\u00b0(Aberdeen, UK)Multi-locus sequence typing can be used to investigate possible hospital outbreaks of infection (finding widely different strain types within a unit indicates no outbreak, although the converse is not true).", [["infection", "DISEASE", 237, 246], ["C. albicans", "ORGANISM", 58, 69], ["C. dubliniensis", "ORGANISM", 71, 86], ["C. glabrata", "ORGANISM", 88, 99], ["C. krusei", "ORGANISM", 101, 110], ["C. tropicalis", "ORGANISM", 115, 128], ["C. albicans", "SPECIES", 58, 69], ["C. dubliniensis", "SPECIES", 71, 86], ["C. glabrata", "SPECIES", 88, 99], ["C. krusei", "SPECIES", 101, 110], ["C. tropicalis", "SPECIES", 115, 128], ["C. albicans", "SPECIES", 58, 69], ["C. dubliniensis", "SPECIES", 71, 86], ["C. glabrata", "SPECIES", 88, 99], ["C. krusei", "SPECIES", 101, 110], ["C. tropicalis", "SPECIES", 115, 128], ["Multilocus sequence typing schemes", "TEST", 0, 34], ["C. albicans", "PROBLEM", 58, 69], ["C. dubliniensis", "PROBLEM", 71, 86], ["C. tropicalis", "PROBLEM", 115, 128], ["Multi-locus sequence typing", "TEST", 151, 178], ["infection", "PROBLEM", 237, 246], ["outbreak", "PROBLEM", 313, 321], ["infection", "OBSERVATION", 237, 246], ["no", "UNCERTAINTY", 310, 312]]], ["For C. albicans, typing multiple isolates from the same patient has shown that people tend to harbour as commensals a mixture of closely related but different strain types, which may provide for selection of the most appropriate type for invasion of a particular tissue or in response to antifungal treatment.", [["tissue", "ANATOMY", 263, 269], ["C. albicans", "ORGANISM", 4, 15], ["patient", "ORGANISM", 56, 63], ["people", "ORGANISM", 79, 85], ["tissue", "TISSUE", 263, 269], ["C. albicans", "SPECIES", 4, 15], ["patient", "SPECIES", 56, 63], ["people", "SPECIES", 79, 85], ["C. albicans", "SPECIES", 4, 15], ["C. albicans", "PROBLEM", 4, 15], ["different strain types", "PROBLEM", 149, 171], ["a particular tissue", "PROBLEM", 250, 269], ["antifungal treatment", "TREATMENT", 288, 308], ["antifungal treatment", "OBSERVATION", 288, 308]]], ["Strains in C. albicans clade 1, the largest group of related strain types, have a higher proportion of isolates resistant to flucytosine than other clades, and they all share a common resistance mechanism.", [["flucytosine", "CHEMICAL", 125, 136], ["flucytosine", "CHEMICAL", 125, 136], ["C. albicans clade 1", "ORGANISM", 11, 30], ["flucytosine", "SIMPLE_CHEMICAL", 125, 136], ["C. albicans", "SPECIES", 11, 22], ["C. albicans clade 1", "SPECIES", 11, 30], ["Strains in C. albicans clade", "PROBLEM", 0, 28], ["flucytosine", "TREATMENT", 125, 136], ["albicans clade", "OBSERVATION", 14, 28], ["largest", "OBSERVATION_MODIFIER", 36, 43], ["common resistance", "OBSERVATION", 177, 194]]], ["Research on mechanisms of resistance of Candida species to many types of antifungal has progressed to the point that some investigators are looking to design DNA chips that could be used both for identification and for susceptibility testing of a Candida isolate.", [["Candida species", "ORGANISM", 40, 55], ["antifungal", "CANCER", 73, 83], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["Candida species", "PROBLEM", 40, 55], ["antifungal", "TREATMENT", 73, 83], ["DNA chips", "TREATMENT", 158, 167], ["susceptibility testing", "TEST", 219, 241], ["a Candida isolate", "PROBLEM", 245, 262], ["resistance", "OBSERVATION_MODIFIER", 26, 36], ["Candida species", "OBSERVATION", 40, 55], ["antifungal", "OBSERVATION", 73, 83]]], ["Much research effort goes into detailed study of host-fungus crosstalk in experimental Candida infections.", [["Candida infections", "DISEASE", 87, 105], ["Candida infections", "ORGANISM", 87, 105], ["detailed study", "TEST", 31, 45], ["experimental Candida infections", "PROBLEM", 74, 105], ["fungus crosstalk", "OBSERVATION", 54, 70], ["Candida infections", "OBSERVATION", 87, 105]]], ["Animal models of infection have been greatly refined and the latest research shows how early release of chemokines that attract neutrophils into infected tissues contributes to the immunopathology of Candida infection.", [["neutrophils", "ANATOMY", 128, 139], ["tissues", "ANATOMY", 154, 161], ["infection", "DISEASE", 17, 26], ["Candida infection", "DISEASE", 200, 217], ["neutrophils", "CELL", 128, 139], ["tissues", "TISSUE", 154, 161], ["Candida infection", "ORGANISM", 200, 217], ["chemokines", "PROTEIN", 104, 114], ["neutrophils", "CELL_TYPE", 128, 139], ["infection", "PROBLEM", 17, 26], ["neutrophils into infected tissues", "PROBLEM", 128, 161], ["Candida infection", "PROBLEM", 200, 217], ["infection", "OBSERVATION", 17, 26], ["infected tissues", "OBSERVATION", 145, 161], ["Candida", "OBSERVATION_MODIFIER", 200, 207], ["infection", "OBSERVATION", 208, 217]]], ["This rapid, innate immune response also emphasizes the need for antifungal intervention at the earliest possible stage to provide the best chance for successful treatment of a disseminated Candida infection \u2212 a finding now supported by clinical data as well as experimental models.", [["Candida infection", "DISEASE", 189, 206], ["antifungal intervention", "TREATMENT", 64, 87], ["successful treatment", "TREATMENT", 150, 170], ["a disseminated Candida infection", "PROBLEM", 174, 206], ["disseminated", "OBSERVATION_MODIFIER", 176, 188], ["Candida infection", "OBSERVATION", 189, 206]]], ["Translation of the latest research advances into practical diagnostic tests and new therapeutic approaches for Candida infections always takes a long time \u2212 typically years \u2212 and not all research results find clinical applications.", [["Candida infections", "DISEASE", 111, 129], ["practical diagnostic tests", "TEST", 49, 75], ["Candida infections", "PROBLEM", 111, 129]]], ["However, the level of effort invested in basic Candida research ensures support for steady progress in diagnosis and management.W. Hope\u00b0(Manchester, UK)The echinocandins are semi-synthetic lipopeptides that are increasingly used for the prevention and treatment of invasive fungal infections.", [["echinocandins", "CHEMICAL", 156, 169], ["fungal infections", "DISEASE", 274, 291], ["echinocandins", "CHEMICAL", 156, 169], ["echinocandins", "SIMPLE_CHEMICAL", 156, 169], ["management", "TREATMENT", 117, 127], ["The echinocandins", "TREATMENT", 152, 169], ["semi-synthetic lipopeptides", "TREATMENT", 174, 201], ["the prevention", "TREATMENT", 233, 247], ["invasive fungal infections", "PROBLEM", 265, 291], ["invasive", "OBSERVATION_MODIFIER", 265, 273], ["fungal", "OBSERVATION_MODIFIER", 274, 280], ["infections", "OBSERVATION", 281, 291]]], ["Understanding the pharmacokinetic and pharmacodynamic (PK/PD) characteristics of these compounds is critical for their optimal clinical use.W. Hope\u00b0(Manchester, UK)The echinocandins have potent in vitro activity against Candida spp., although C. parapsilosis is less susceptible than other Candida species.", [["echinocandins", "CHEMICAL", 168, 181], ["Candida spp.", "DISEASE", 220, 232], ["echinocandins", "CHEMICAL", 168, 181], ["echinocandins", "SIMPLE_CHEMICAL", 168, 181], ["Candida spp.", "ORGANISM", 220, 232], ["C. parapsilosis", "ORGANISM", 243, 258], ["Candida species", "ORGANISM", 290, 305], ["Candida spp.", "SPECIES", 220, 232], ["C. parapsilosis", "SPECIES", 243, 258], ["Candida spp.", "SPECIES", 220, 232], ["C. parapsilosis", "SPECIES", 243, 258], ["pharmacodynamic (PK/PD)", "TREATMENT", 38, 61], ["The echinocandins", "TREATMENT", 164, 181], ["Candida spp.", "PROBLEM", 220, 232], ["C. parapsilosis", "PROBLEM", 243, 258], ["other Candida species", "PROBLEM", 284, 305], ["parapsilosis", "OBSERVATION", 246, 258], ["Candida species", "OBSERVATION", 290, 305]]], ["The molecular mechanisms of resistance in Candida species, which relate to amino acid substitutions in 'hot spots' within the FKS1 gene, are becoming well characterised.", [["amino acid", "CHEMICAL", 75, 85], ["amino acid", "CHEMICAL", 75, 85], ["Candida species", "ORGANISM", 42, 57], ["amino acid", "AMINO_ACID", 75, 85], ["FKS1", "GENE_OR_GENE_PRODUCT", 126, 130], ["FKS1 gene", "DNA", 126, 135], ["resistance in Candida species", "PROBLEM", 28, 57], ["amino acid substitutions", "PROBLEM", 75, 99], ["resistance", "OBSERVATION_MODIFIER", 28, 38], ["Candida species", "OBSERVATION", 42, 57], ["amino", "OBSERVATION", 75, 80], ["acid substitutions", "OBSERVATION", 81, 99], ["FKS1", "ANATOMY_MODIFIER", 126, 130], ["gene", "ANATOMY", 131, 135]]], ["Susceptibility breakpoints for all three clinically available compounds have been determined recently by the Clinical Laboratory Standards Institute, with a 'susceptible-only' breakpoint of >2 mg/l suggested.", [["Susceptibility breakpoints", "PROBLEM", 0, 26]]], ["The PK/PD of the echinocandins have been determined in experimental models of disseminated candidiasis, and of both disseminated and pulmonary invasive aspergillosis.", [["pulmonary invasive aspergillosis", "ANATOMY", 133, 165], ["echinocandins", "CHEMICAL", 17, 30], ["candidiasis", "DISEASE", 91, 102], ["pulmonary invasive aspergillosis", "DISEASE", 133, 165], ["echinocandins", "CHEMICAL", 17, 30], ["PK", "GENE_OR_GENE_PRODUCT", 4, 6], ["echinocandins", "CANCER", 17, 30], ["pulmonary invasive aspergillosis", "CANCER", 133, 165], ["The PK", "TEST", 0, 6], ["the echinocandins", "TREATMENT", 13, 30], ["disseminated candidiasis", "PROBLEM", 78, 102], ["both disseminated and pulmonary invasive aspergillosis", "PROBLEM", 111, 165], ["disseminated", "OBSERVATION_MODIFIER", 78, 90], ["candidiasis", "OBSERVATION", 91, 102], ["both", "OBSERVATION_MODIFIER", 111, 115], ["disseminated", "OBSERVATION_MODIFIER", 116, 128], ["pulmonary", "ANATOMY", 133, 142], ["invasive", "OBSERVATION_MODIFIER", 143, 151], ["aspergillosis", "OBSERVATION", 152, 165]]], ["These studies suggest that the echinocandins: (1) display concentration-dependent antifungal killing (or effect); (2) are extensively distributed into peripheral tissues, where they exhibit prolonged mean residence times at the site of infection;W. Hope\u00b0(Manchester, UK)(3) are fungicidal against Candida spp. and induce dose-dependent morphological changes in Aspergillus spp.; and (4) result in a diminished propensity for angioinvasion by Aspergillus spp.", [["peripheral tissues", "ANATOMY", 151, 169], ["echinocandins", "CHEMICAL", 31, 44], ["infection", "DISEASE", 236, 245], ["Candida spp", "DISEASE", 297, 308], ["angioinvasion", "DISEASE", 425, 438], ["Aspergillus spp", "DISEASE", 442, 457], ["echinocandins", "CHEMICAL", 31, 44], ["echinocandins", "SIMPLE_CHEMICAL", 31, 44], ["peripheral tissues", "TISSUE", 151, 169], ["Candida spp", "ORGANISM", 297, 308], ["Aspergillus spp.", "ORGANISM", 361, 377], ["Aspergillus spp", "ORGANISM", 442, 457], ["Aspergillus spp.", "SPECIES", 361, 377], ["Aspergillus spp.", "SPECIES", 361, 377], ["These studies", "TEST", 0, 13], ["concentration-dependent antifungal killing", "PROBLEM", 58, 100], ["infection", "PROBLEM", 236, 245], ["Candida spp", "PROBLEM", 297, 308], ["dependent morphological changes", "PROBLEM", 326, 357], ["Aspergillus spp.", "PROBLEM", 361, 377], ["a diminished propensity", "PROBLEM", 397, 420], ["angioinvasion", "PROBLEM", 425, 438], ["Aspergillus spp", "PROBLEM", 442, 457], ["antifungal killing", "OBSERVATION", 82, 100], ["peripheral tissues", "ANATOMY", 151, 169], ["prolonged", "OBSERVATION_MODIFIER", 190, 199], ["infection", "OBSERVATION", 236, 245], ["dependent morphological", "OBSERVATION_MODIFIER", 326, 349], ["Aspergillus spp.", "OBSERVATION", 361, 377], ["diminished", "OBSERVATION_MODIFIER", 399, 409], ["Aspergillus spp", "OBSERVATION", 442, 457]]], ["Recent evidence also suggests that the echinocandins have important immunomodulatory properties, which may contribute significantly to their observed antifungal effect.", [["echinocandins", "CHEMICAL", 39, 52], ["echinocandins", "CHEMICAL", 39, 52], ["echinocandins", "SIMPLE_CHEMICAL", 39, 52], ["the echinocandins", "TREATMENT", 35, 52]]], ["PK/PD modelling and laboratory animal-to-human bridging techniques have been used to identify safe and effective dosages for the echinocandins for relatively uncommon clinical syndromes such as neonatal haematogenous Candida meningoencephalitis.", [["echinocandins", "CHEMICAL", 129, 142], ["Candida meningoencephalitis", "DISEASE", 217, 244], ["PK", "GENE_OR_GENE_PRODUCT", 0, 2], ["human", "ORGANISM", 41, 46], ["echinocandins", "SIMPLE_CHEMICAL", 129, 142], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["PK/PD modelling", "TEST", 0, 15], ["laboratory animal", "TEST", 20, 37], ["human bridging techniques", "TREATMENT", 41, 66], ["the echinocandins", "TREATMENT", 125, 142], ["relatively uncommon clinical syndromes", "PROBLEM", 147, 185], ["neonatal haematogenous Candida meningoencephalitis", "PROBLEM", 194, 244], ["haematogenous Candida meningoencephalitis", "OBSERVATION", 203, 244]]], ["These techniques are an efficient method of identifying effective regimens for humans that can be expedited for study in clinical trials.W. Hope\u00b0(Manchester, UK)PK/PD modelling techniques can and should be used to address outstanding clinical queries in relation to these compounds, including optimal dosages, decision-support analysis for the setting of in vitro antifungal susceptibility breakpoints and the clinical relevance of inherent or acquired reduced antifungal susceptibility.", [["humans", "ORGANISM", 79, 85], ["humans", "SPECIES", 79, 85], ["humans", "SPECIES", 79, 85], ["effective regimens", "TREATMENT", 56, 74], ["PK/PD modelling techniques", "TREATMENT", 161, 187], ["support analysis", "TEST", 319, 335], ["vitro antifungal susceptibility breakpoints", "PROBLEM", 358, 401], ["acquired reduced antifungal susceptibility", "PROBLEM", 444, 486], ["antifungal susceptibility", "OBSERVATION", 461, 486]]], ["S156 Invasive candidiasis: which antifungal treatment for which patient?B. Dupont\u00b0(Paris, FR)Management of patients with invasive candidiasis represents a complex issue owing to the heterogeneity of patients in whom these infections occur.", [["invasive candidiasis", "ANATOMY", 121, 141], ["Invasive candidiasis", "DISEASE", 5, 25], ["invasive candidiasis", "DISEASE", 121, 141], ["infections", "DISEASE", 222, 232], ["patient", "ORGANISM", 64, 71], ["patients", "ORGANISM", 107, 115], ["candidiasis", "CANCER", 130, 141], ["patients", "ORGANISM", 199, 207], ["patient", "SPECIES", 64, 71], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 199, 207], ["Invasive candidiasis", "PROBLEM", 5, 25], ["antifungal treatment", "TREATMENT", 33, 53], ["invasive candidiasis", "PROBLEM", 121, 141], ["these infections", "PROBLEM", 216, 232], ["Invasive", "OBSERVATION_MODIFIER", 5, 13], ["candidiasis", "OBSERVATION", 14, 25], ["invasive", "OBSERVATION_MODIFIER", 121, 129], ["candidiasis", "OBSERVATION", 130, 141], ["infections", "OBSERVATION", 222, 232]]], ["Established risk factors for invasive candidiasis, which include total parenteral nutrition, multiple organ failure and Candida colonisation, are common to many types of patients that are treated within the critical care setting.", [["parenteral", "ANATOMY", 71, 81], ["organ", "ANATOMY", 102, 107], ["candidiasis", "DISEASE", 38, 49], ["organ failure", "DISEASE", 102, 115], ["Candida colonisation", "DISEASE", 120, 140], ["organ", "ORGAN", 102, 107], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["invasive candidiasis", "PROBLEM", 29, 49], ["total parenteral nutrition", "TREATMENT", 65, 91], ["multiple organ failure", "PROBLEM", 93, 115], ["Candida colonisation", "PROBLEM", 120, 140], ["invasive", "OBSERVATION_MODIFIER", 29, 37], ["candidiasis", "OBSERVATION", 38, 49], ["multiple", "OBSERVATION_MODIFIER", 93, 101], ["organ", "ANATOMY", 102, 107], ["failure", "OBSERVATION", 108, 115], ["Candida colonisation", "OBSERVATION", 120, 140]]], ["Furthermore, the severity of the underlying condition in these patients necessitates swift antifungal treatment to ensure optimal outcomes.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["the underlying condition", "PROBLEM", 29, 53], ["swift antifungal treatment", "TREATMENT", 85, 111]]], ["An additional factor for consideration when treating Candida infections is the changing epidemiology of Candida species; potentially fluconazole-resistant species such as C. glabrata and C. krusei are becoming more common, particularly in patients with prior fluconazole exposure.", [["Candida infections", "DISEASE", 53, 71], ["fluconazole", "CHEMICAL", 133, 144], ["C. glabrata", "DISEASE", 171, 182], ["C. krusei", "DISEASE", 187, 196], ["fluconazole", "CHEMICAL", 259, 270], ["fluconazole", "CHEMICAL", 133, 144], ["fluconazole", "CHEMICAL", 259, 270], ["Candida species", "ORGANISM", 104, 119], ["fluconazole", "SIMPLE_CHEMICAL", 133, 144], ["C. glabrata", "ORGANISM", 171, 182], ["C. krusei", "ORGANISM", 187, 196], ["patients", "ORGANISM", 239, 247], ["fluconazole", "SIMPLE_CHEMICAL", 259, 270], ["C. glabrata", "SPECIES", 171, 182], ["C. krusei", "SPECIES", 187, 196], ["patients", "SPECIES", 239, 247], ["C. glabrata", "SPECIES", 171, 182], ["C. krusei", "SPECIES", 187, 196], ["Candida infections", "PROBLEM", 53, 71], ["Candida species", "PROBLEM", 104, 119], ["fluconazole", "TREATMENT", 133, 144], ["resistant species", "PROBLEM", 145, 162], ["C. glabrata", "PROBLEM", 171, 182], ["C. krusei", "PROBLEM", 187, 196], ["prior fluconazole exposure", "TREATMENT", 253, 279], ["Candida species", "OBSERVATION", 104, 119], ["more common", "OBSERVATION_MODIFIER", 210, 221], ["fluconazole exposure", "OBSERVATION", 259, 279]]], ["A range of antifungal agents is available with in vitro activity against Candida species.", [["Candida species", "ORGANISM", 73, 88], ["antifungal agents", "TREATMENT", 11, 28], ["Candida species", "PROBLEM", 73, 88]]], ["However, not all of these agents are suitable options for the clinical management of invasive candidiasis because of the overall complexity of both infection and underlying condition.", [["invasive candidiasis", "ANATOMY", 85, 105], ["candidiasis", "DISEASE", 94, 105], ["infection", "DISEASE", 148, 157], ["candidiasis", "CANCER", 94, 105], ["these agents", "TREATMENT", 20, 32], ["the clinical management", "TREATMENT", 58, 81], ["invasive candidiasis", "PROBLEM", 85, 105], ["both infection", "PROBLEM", 143, 157], ["underlying condition", "PROBLEM", 162, 182], ["invasive", "OBSERVATION_MODIFIER", 85, 93], ["candidiasis", "OBSERVATION", 94, 105], ["both", "OBSERVATION_MODIFIER", 143, 147], ["infection", "OBSERVATION", 148, 157]]], ["For example, the position of the polyenes, particularly amphotericin B deoxycholate, is becoming less tenable as the risk of renal complications is increasingly regarded as unacceptable in patients that are likely to have or be at risk of multiple organ failure.", [["renal", "ANATOMY", 125, 130], ["organ", "ANATOMY", 248, 253], ["amphotericin B deoxycholate", "CHEMICAL", 56, 83], ["renal complications", "DISEASE", 125, 144], ["organ failure", "DISEASE", 248, 261], ["polyenes", "CHEMICAL", 33, 41], ["amphotericin B deoxycholate", "CHEMICAL", 56, 83], ["polyenes", "SIMPLE_CHEMICAL", 33, 41], ["amphotericin B deoxycholate", "SIMPLE_CHEMICAL", 56, 83], ["renal", "ORGAN", 125, 130], ["patients", "ORGANISM", 189, 197], ["organ", "ORGAN", 248, 253], ["patients", "SPECIES", 189, 197], ["the polyenes", "TREATMENT", 29, 41], ["amphotericin B deoxycholate", "TREATMENT", 56, 83], ["renal complications", "PROBLEM", 125, 144], ["multiple organ failure", "PROBLEM", 239, 261], ["renal", "ANATOMY", 125, 130], ["complications", "OBSERVATION", 131, 144], ["multiple", "OBSERVATION_MODIFIER", 239, 247], ["organ", "ANATOMY", 248, 253], ["failure", "OBSERVATION", 254, 261]]], ["Furthermore, because of the increasing prevalence of fluconazole-resistant species, recent guidelines no longer recommend the use of azoles as first-line treatment for invasive candidiasis except in special cases, focusing instead on the echinocandin agents.B. Dupont\u00b0(Paris, FR)There is now a wealth of clinical data available for the echinocandins.", [["invasive candidiasis", "ANATOMY", 168, 188], ["fluconazole", "CHEMICAL", 53, 64], ["azoles", "CHEMICAL", 133, 139], ["candidiasis", "DISEASE", 177, 188], ["echinocandin", "CHEMICAL", 238, 250], ["echinocandins", "CHEMICAL", 336, 349], ["fluconazole", "CHEMICAL", 53, 64], ["azoles", "CHEMICAL", 133, 139], ["echinocandins", "CHEMICAL", 336, 349], ["fluconazole", "SIMPLE_CHEMICAL", 53, 64], ["azoles", "SIMPLE_CHEMICAL", 133, 139], ["echinocandin agents", "SIMPLE_CHEMICAL", 238, 257], ["echinocandins", "SIMPLE_CHEMICAL", 336, 349], ["fluconazole", "TREATMENT", 53, 64], ["resistant species", "PROBLEM", 65, 82], ["azoles", "TREATMENT", 133, 139], ["first-line treatment", "TREATMENT", 143, 163], ["invasive candidiasis", "PROBLEM", 168, 188], ["the echinocandin agents", "TREATMENT", 234, 257], ["clinical data", "TEST", 304, 317], ["the echinocandins", "TREATMENT", 332, 349], ["invasive", "OBSERVATION_MODIFIER", 168, 176], ["candidiasis", "OBSERVATION", 177, 188]]], ["Micafungin, for example, has been assessed in invasive candidiasis in clinical trials that included a wide variety of underlying conditions and patterns of infection, including neutropenic patients and those with deep infections such as peritonitis.", [["Micafungin", "CHEMICAL", 0, 10], ["candidiasis", "DISEASE", 55, 66], ["infection", "DISEASE", 156, 165], ["neutropenic", "DISEASE", 177, 188], ["infections", "DISEASE", 218, 228], ["peritonitis", "DISEASE", 237, 248], ["Micafungin", "CHEMICAL", 0, 10], ["Micafungin", "SIMPLE_CHEMICAL", 0, 10], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["Micafungin", "TREATMENT", 0, 10], ["invasive candidiasis", "PROBLEM", 46, 66], ["underlying conditions", "PROBLEM", 118, 139], ["infection", "PROBLEM", 156, 165], ["neutropenic patients", "PROBLEM", 177, 197], ["deep infections", "PROBLEM", 213, 228], ["peritonitis", "PROBLEM", 237, 248], ["invasive", "OBSERVATION_MODIFIER", 46, 54], ["candidiasis", "OBSERVATION", 55, 66], ["infection", "OBSERVATION", 156, 165], ["deep", "ANATOMY_MODIFIER", 213, 217], ["infections", "OBSERVATION", 218, 228], ["peritonitis", "OBSERVATION", 237, 248]]], ["Furthermore, micafungin is the most extensively evaluated of the echinocandins in paediatric patients, having been tested both in children up to the age of 16 years and in premature infants and neonates.", [["micafungin", "CHEMICAL", 13, 23], ["echinocandins", "CHEMICAL", 65, 78], ["micafungin", "CHEMICAL", 13, 23], ["echinocandins", "CHEMICAL", 65, 78], ["micafungin", "SIMPLE_CHEMICAL", 13, 23], ["echinocandins", "SIMPLE_CHEMICAL", 65, 78], ["patients", "ORGANISM", 93, 101], ["children", "ORGANISM", 130, 138], ["infants", "ORGANISM", 182, 189], ["neonates", "ORGANISM", 194, 202], ["patients", "SPECIES", 93, 101], ["children", "SPECIES", 130, 138], ["infants", "SPECIES", 182, 189], ["micafungin", "TREATMENT", 13, 23], ["micafungin", "OBSERVATION", 13, 23]]], ["Optimal management of patients with invasive candidiasis depends on a strategy that takes into account the complex nature of the disease.B. Dupont\u00b0(Paris, FR)Judicious selection of antifungal treatment should be accompanied by consideration of non-drug-related factors that improve survival, such as careful assessment of intravenous catheters and their potential involvement in Candida infections.J. Perfect\u00b0(Durham, US)Patients with invasive candidiasis often have underlying conditions that are severe illnesses in themselves.", [["intravenous", "ANATOMY", 322, 333], ["invasive candidiasis", "ANATOMY", 435, 455], ["candidiasis", "DISEASE", 45, 56], ["Candida infections", "DISEASE", 379, 397], ["invasive candidiasis", "DISEASE", 435, 455], ["patients", "ORGANISM", 22, 30], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 322, 333], ["Candida infections", "ORGANISM", 379, 397], ["Patients", "ORGANISM", 421, 429], ["patients", "SPECIES", 22, 30], ["Patients", "SPECIES", 421, 429], ["Optimal management", "TREATMENT", 0, 18], ["invasive candidiasis", "PROBLEM", 36, 56], ["a strategy", "TREATMENT", 68, 78], ["the disease", "PROBLEM", 125, 136], ["antifungal treatment", "TREATMENT", 181, 201], ["careful assessment", "TEST", 300, 318], ["intravenous catheters", "TREATMENT", 322, 343], ["Candida infections", "PROBLEM", 379, 397], ["invasive candidiasis", "PROBLEM", 435, 455], ["underlying conditions", "PROBLEM", 467, 488], ["severe illnesses in themselves", "PROBLEM", 498, 528], ["invasive", "OBSERVATION_MODIFIER", 36, 44], ["candidiasis", "OBSERVATION", 45, 56], ["disease", "OBSERVATION", 129, 136], ["antifungal treatment", "OBSERVATION", 181, 201], ["Candida infections", "OBSERVATION", 379, 397], ["invasive", "OBSERVATION_MODIFIER", 435, 443], ["candidiasis", "OBSERVATION", 444, 455], ["severe", "OBSERVATION_MODIFIER", 498, 504]]], ["These range from neutropenia during cancer chemotherapy to the multi-organ failure of intensive care unit patients.", [["cancer", "ANATOMY", 36, 42], ["multi-organ", "ANATOMY", 63, 74], ["neutropenia", "DISEASE", 17, 28], ["cancer", "DISEASE", 36, 42], ["multi-organ failure", "DISEASE", 63, 82], ["cancer", "CANCER", 36, 42], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["neutropenia", "PROBLEM", 17, 28], ["cancer chemotherapy", "TREATMENT", 36, 55], ["neutropenia", "OBSERVATION", 17, 28], ["multi-organ", "ANATOMY", 63, 74], ["failure", "OBSERVATION", 75, 82]]], ["Against this background of severe underlying illness, it can be difficult to appreciate the success or otherwise of treatment strategies for Candida infections.J. Perfect\u00b0(Durham, US)In the last decade, major advances have been made in antifungal therapy with the introduction of 1. echinocandins; 2. extended-spectrum azoles; and 3. lipid formulations of amphotericin B.J. Perfect\u00b0(Durham, US)Robust clinical studies for their successful use in candidaemia have been published.", [["Candida infections", "DISEASE", 141, 159], ["echinocandins", "CHEMICAL", 283, 296], ["azoles", "CHEMICAL", 319, 325], ["amphotericin", "CHEMICAL", 356, 368], ["candidaemia", "DISEASE", 446, 457], ["echinocandins", "CHEMICAL", 283, 296], ["azoles", "CHEMICAL", 319, 325], ["amphotericin", "CHEMICAL", 356, 368], ["Candida infections", "ORGANISM", 141, 159], ["extended-spectrum azoles", "SIMPLE_CHEMICAL", 301, 325], ["lipid", "SIMPLE_CHEMICAL", 334, 339], ["amphotericin", "SIMPLE_CHEMICAL", 356, 368], ["candidaemia", "CANCER", 446, 457], ["severe underlying illness", "PROBLEM", 27, 52], ["treatment strategies", "TREATMENT", 116, 136], ["Candida infections", "PROBLEM", 141, 159], ["antifungal therapy", "TREATMENT", 236, 254], ["echinocandins", "TREATMENT", 283, 296], ["extended-spectrum azoles", "TREATMENT", 301, 325], ["lipid formulations", "TREATMENT", 334, 352], ["amphotericin", "TREATMENT", 356, 368], ["Robust clinical studies", "TEST", 394, 417], ["candidaemia", "PROBLEM", 446, 457], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["illness", "OBSERVATION", 45, 52], ["spectrum azoles", "OBSERVATION", 310, 325]]], ["However, it is important to translate these studies into practical strategies for the care of individual patients.", [["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["these studies", "TEST", 38, 51], ["practical strategies", "TREATMENT", 57, 77]]], ["In this presentation, individual cases will be used to provide insights into the successes and failures of these antifungal classes for the management of invasive candidiasis.", [["invasive candidiasis", "ANATOMY", 154, 174], ["candidiasis", "DISEASE", 163, 174], ["candidiasis", "CANCER", 163, 174], ["these antifungal classes", "TREATMENT", 107, 131], ["the management", "TREATMENT", 136, 150], ["invasive candidiasis", "PROBLEM", 154, 174], ["invasive", "OBSERVATION_MODIFIER", 154, 162], ["candidiasis", "OBSERVATION", 163, 174]]], ["Specific interest will be focused on the use of fluconazole versus the echinocandins.", [["fluconazole", "CHEMICAL", 48, 59], ["echinocandins", "CHEMICAL", 71, 84], ["fluconazole", "CHEMICAL", 48, 59], ["echinocandins", "CHEMICAL", 71, 84], ["fluconazole", "SIMPLE_CHEMICAL", 48, 59], ["echinocandins", "SIMPLE_CHEMICAL", 71, 84], ["fluconazole", "TREATMENT", 48, 59], ["the echinocandins", "TREATMENT", 67, 84]]], ["These micafungin-based cases will be supported by insights from the evidence-based literature combined with practical experiences at the bedside.", [["micafungin", "CHEMICAL", 6, 16], ["micafungin", "CHEMICAL", 6, 16], ["micafungin", "SIMPLE_CHEMICAL", 6, 16], ["These micafungin", "TREATMENT", 0, 16]]], ["The factors to be considered are: 1. spectrum of activity; 2. drug toxicity; 3. drug interactions; 4. drug resistance; 5. pharmacology; 6. diagnosis; 7. site of infection; 8. use of biomarkers/cultures in treatment strategies; and 9. costs.", [["toxicity", "DISEASE", 67, 75], ["infection", "DISEASE", 161, 170], ["drug toxicity", "PROBLEM", 62, 75], ["drug resistance", "PROBLEM", 102, 117], ["infection", "PROBLEM", 161, 170], ["biomarkers/cultures", "TEST", 182, 201], ["treatment strategies", "TREATMENT", 205, 225], ["activity", "OBSERVATION_MODIFIER", 49, 57], ["infection", "OBSERVATION", 161, 170]]], ["It is important to realise that large clinical trials exclude many patients with invasive candidiasis.", [["candidiasis", "DISEASE", 90, 101], ["patients", "ORGANISM", 67, 75], ["candidiasis", "CANCER", 90, 101], ["patients", "SPECIES", 67, 75], ["invasive candidiasis", "PROBLEM", 81, 101], ["invasive", "OBSERVATION_MODIFIER", 81, 89], ["candidiasis", "OBSERVATION", 90, 101]]], ["Therefore, with the use of individual cases, it is possible to provide further insights into the clinical use of these outstanding antifungal agents.J. Perfect\u00b0(Durham, US)Patient management: the era of rapid diagnostic results (Symposium organised by Cepheid) S161 Will community MRSA and Clostridium difficile change infection control in hospitals?F.C. Turnover\u00b0(Sunnyvale, US)Infections caused by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci, and Clostridium difficile are inter-related in healthcare institutions.", [["MRSA", "CHEMICAL", 281, 285], ["Clostridium difficile", "DISEASE", 290, 311], ["infection", "DISEASE", 319, 328], ["Infections", "DISEASE", 379, 389], ["methicillin", "CHEMICAL", 400, 411], ["Staphylococcus aureus", "DISEASE", 422, 443], ["MRSA", "CHEMICAL", 445, 449], ["vancomycin", "CHEMICAL", 452, 462], ["Clostridium difficile", "DISEASE", 490, 511], ["methicillin", "CHEMICAL", 400, 411], ["vancomycin", "CHEMICAL", 452, 462], ["Clostridium difficile", "ORGANISM", 290, 311], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 400, 443], ["MRSA", "CANCER", 445, 449], ["vancomycin", "SIMPLE_CHEMICAL", 452, 462], ["Clostridium difficile", "ORGANISM", 490, 511], ["MRSA", "SPECIES", 281, 285], ["Clostridium difficile", "SPECIES", 290, 311], ["Staphylococcus aureus", "SPECIES", 422, 443], ["MRSA", "SPECIES", 445, 449], ["Clostridium difficile", "SPECIES", 490, 511], ["Clostridium difficile", "SPECIES", 290, 311], ["Staphylococcus aureus", "SPECIES", 422, 443], ["MRSA", "SPECIES", 445, 449], ["Clostridium difficile", "SPECIES", 490, 511], ["these outstanding antifungal agents", "TREATMENT", 113, 148], ["MRSA", "PROBLEM", 281, 285], ["Clostridium difficile change infection control", "PROBLEM", 290, 336], ["Infections", "PROBLEM", 379, 389], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 400, 443], ["MRSA", "PROBLEM", 445, 449], ["vancomycin", "TREATMENT", 452, 462], ["resistant enterococci", "PROBLEM", 463, 484], ["Clostridium difficile", "PROBLEM", 490, 511], ["MRSA", "OBSERVATION", 281, 285], ["Clostridium difficile", "OBSERVATION", 290, 311], ["Staphylococcus aureus", "OBSERVATION", 422, 443], ["resistant enterococci", "OBSERVATION", 463, 484], ["Clostridium difficile", "OBSERVATION", 490, 511]]], ["The emergence of epidemic MRSA and C. difficile strains has placed a greater burden on infection control systems in healthcare facilities, which often must increase surveillance and change disinfection strategies to halt the transmission of these pathogens in hospitals.", [["MRSA", "DISEASE", 26, 30], ["C. difficile", "DISEASE", 35, 47], ["infection", "DISEASE", 87, 96], ["C. difficile", "ORGANISM", 35, 47], ["MRSA", "SPECIES", 26, 30], ["C. difficile", "SPECIES", 35, 47], ["MRSA", "SPECIES", 26, 30], ["C. difficile", "SPECIES", 35, 47], ["epidemic MRSA", "PROBLEM", 17, 30], ["C. difficile strains", "PROBLEM", 35, 55], ["infection control systems", "TREATMENT", 87, 112], ["disinfection strategies", "TREATMENT", 189, 212], ["epidemic", "OBSERVATION_MODIFIER", 17, 25], ["MRSA", "OBSERVATION", 26, 30], ["greater", "OBSERVATION_MODIFIER", 69, 76], ["burden", "OBSERVATION_MODIFIER", 77, 83], ["infection", "OBSERVATION", 87, 96]]], ["Ironically, the USA300 MRSA strain arose in the community but now is being transmitted frequently in healthcare settings, while the epidemic NAP1/BI/027 C. difficile strain was originally a healthcare-associated pathogen, which now is causing considerable morbidity in community settings.", [["USA300", "CHEMICAL", 16, 22], ["C. difficile", "DISEASE", 153, 165], ["USA300 MRSA strain", "ORGANISM", 16, 34], ["NAP1/BI/027", "ORGANISM", 141, 152], ["C. difficile", "ORGANISM", 153, 165], ["strain", "ORGANISM", 166, 172], ["MRSA", "SPECIES", 23, 27], ["C. difficile", "SPECIES", 153, 165], ["C. difficile", "SPECIES", 153, 165], ["the USA300 MRSA strain", "PROBLEM", 12, 34], ["the epidemic NAP1", "TEST", 128, 145], ["C. difficile strain", "PROBLEM", 153, 172], ["pathogen", "PROBLEM", 212, 220], ["considerable", "OBSERVATION_MODIFIER", 243, 255], ["morbidity", "OBSERVATION", 256, 265]]], ["To successfully slow the spread of these pathogens, infection control must work closely with both the laboratory and pharmacy services to ensure that these organisms are detected rapidly and that the selective pressure to maintain the organisms in the institution are reduced.", [["infection", "DISEASE", 52, 61], ["these pathogens", "PROBLEM", 35, 50], ["infection control", "TREATMENT", 52, 69], ["these organisms", "PROBLEM", 150, 165], ["the selective pressure", "TEST", 196, 218], ["pathogens", "OBSERVATION", 41, 50], ["infection", "OBSERVATION", 52, 61], ["reduced", "OBSERVATION_MODIFIER", 268, 275]]], ["Clearly, bundles of interventions, rather than single approaches, are necessary to contain the spread of these organisms in hospitals.", [["interventions", "TREATMENT", 20, 33], ["bundles", "OBSERVATION_MODIFIER", 9, 16]]], ["The continued influx of patients with communityacquired MRSA and C. difficile infections into healthcare institutions is a challenge for infection control practitioners that will clearly increase in the future.P. Cossart\u00b0(Paris, FR)The food borne pathogen L. monocytogenes discovered by Murray in 1926 is responsible for a severe infection with various clinical features (gastroenteritis, meningitis, meningoencephalitis and materno foetal infections) and a high mortality rate (30%).", [["foetal", "ANATOMY", 433, 439], ["MRSA", "DISEASE", 56, 60], ["C. difficile infections", "DISEASE", 65, 88], ["infection", "DISEASE", 137, 146], ["L. monocytogenes", "DISEASE", 256, 272], ["infection", "DISEASE", 330, 339], ["gastroenteritis", "DISEASE", 372, 387], ["meningitis", "DISEASE", 389, 399], ["meningoencephalitis", "DISEASE", 401, 420], ["materno foetal infections", "DISEASE", 425, 450], ["patients", "ORGANISM", 24, 32], ["C. difficile", "ORGANISM", 65, 77], ["L. monocytogenes", "ORGANISM", 256, 272], ["patients", "SPECIES", 24, 32], ["MRSA", "SPECIES", 56, 60], ["C. difficile", "SPECIES", 65, 77], ["L. monocytogenes", "SPECIES", 256, 272], ["C. difficile", "SPECIES", 65, 77], ["L. monocytogenes", "SPECIES", 256, 272], ["communityacquired MRSA", "PROBLEM", 38, 60], ["C. difficile infections", "PROBLEM", 65, 88], ["infection control practitioners", "TREATMENT", 137, 168], ["a severe infection", "PROBLEM", 321, 339], ["various clinical features", "PROBLEM", 345, 370], ["gastroenteritis", "PROBLEM", 372, 387], ["meningitis", "PROBLEM", 389, 399], ["meningoencephalitis", "PROBLEM", 401, 420], ["materno foetal infections", "PROBLEM", 425, 450], ["a high mortality rate", "PROBLEM", 456, 477], ["influx", "OBSERVATION_MODIFIER", 14, 20], ["MRSA", "OBSERVATION", 56, 60], ["difficile", "OBSERVATION_MODIFIER", 68, 77], ["severe", "OBSERVATION_MODIFIER", 323, 329], ["infection", "OBSERVATION", 330, 339], ["gastroenteritis", "OBSERVATION", 372, 387], ["meningitis", "OBSERVATION", 389, 399], ["meningoencephalitis", "OBSERVATION", 401, 420]]], ["The disease is due to the ability of Listeria to cross three host barriers during infection: the intestinal barrier, the placental barrier and the blood brain barrier.", [["intestinal barrier", "ANATOMY", 97, 115], ["placental barrier", "ANATOMY", 121, 138], ["blood brain barrier", "ANATOMY", 147, 166], ["infection", "DISEASE", 82, 91], ["intestinal barrier", "MULTI-TISSUE_STRUCTURE", 97, 115], ["placental barrier", "TISSUE", 121, 138], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 147, 166], ["The disease", "PROBLEM", 0, 11], ["Listeria", "PROBLEM", 37, 45], ["infection", "PROBLEM", 82, 91], ["the intestinal barrier", "TREATMENT", 93, 115], ["the placental barrier", "TREATMENT", 117, 138], ["the blood brain barrier", "TREATMENT", 143, 166], ["disease", "OBSERVATION", 4, 11], ["infection", "OBSERVATION", 82, 91], ["intestinal", "ANATOMY", 97, 107]]], ["It is also due to Listeria capacity to survive in macrophages and to enter into non phagocytic cells, such epithelial cells.", [["macrophages", "ANATOMY", 50, 61], ["non phagocytic cells", "ANATOMY", 80, 100], ["epithelial cells", "ANATOMY", 107, 123], ["macrophages", "CELL", 50, 61], ["phagocytic cells", "CELL", 84, 100], ["epithelial cells", "CELL", 107, 123], ["macrophages", "CELL_TYPE", 50, 61], ["phagocytic cells", "CELL_TYPE", 84, 100], ["epithelial cells", "CELL_TYPE", 107, 123], ["Listeria capacity", "PROBLEM", 18, 35], ["macrophages", "PROBLEM", 50, 61], ["such epithelial cells", "PROBLEM", 102, 123], ["also due to", "UNCERTAINTY", 6, 17], ["Listeria capacity", "OBSERVATION", 18, 35], ["phagocytic cells", "OBSERVATION", 84, 100], ["epithelial cells", "OBSERVATION", 107, 123]]], ["Recovery from infection and protection against reinfection are due to a T-cell response, explaining why Listeria has since many years has become a model in immunology.P. Cossart\u00b0(Paris, FR)Nearly three decades of molecular biology and cell biology approaches coupled to genetic and post-genomic studies have promoted Listeria among the best models in infection biology.", [["T-cell", "ANATOMY", 72, 78], ["cell", "ANATOMY", 235, 239], ["infection", "DISEASE", 14, 23], ["reinfection", "DISEASE", 47, 58], ["infection", "DISEASE", 351, 360], ["T-cell", "CELL", 72, 78], ["cell", "CELL", 235, 239], ["infection", "PROBLEM", 14, 23], ["protection", "TREATMENT", 28, 38], ["reinfection", "PROBLEM", 47, 58], ["a T-cell response", "PROBLEM", 70, 87], ["Listeria", "PROBLEM", 104, 112], ["post-genomic studies", "TEST", 282, 302], ["Listeria", "PROBLEM", 317, 325], ["infection", "OBSERVATION", 14, 23], ["infection", "OBSERVATION", 351, 360]]], ["In depth studies of the mechanism of entry into cells has help unraveling how Listeria crosses the intestinal and placental barrier.", [["cells", "ANATOMY", 48, 53], ["intestinal", "ANATOMY", 99, 109], ["placental barrier", "ANATOMY", 114, 131], ["cells", "CELL", 48, 53], ["intestinal", "ORGAN", 99, 109], ["placental barrier", "TISSUE", 114, 131], ["depth studies", "TEST", 3, 16], ["intestinal", "ANATOMY", 99, 109], ["placental", "ANATOMY", 114, 123]]], ["Unsuspected concepts in cell biology were discovered.", [["cell", "ANATOMY", 24, 28], ["cell", "CELL", 24, 28]]], ["Post-genomic studies have recently allowed to unveil the Listeria transcriptional landscape during switch from saprophytism to virulence.", [["saprophytism", "DISEASE", 111, 123], ["genomic studies", "TEST", 5, 20], ["virulence", "PROBLEM", 127, 136]]], ["The talk will give an overview highlighting recent results in the frame work of well established data.F. Odds\u00b0(Aberdeen, UK)The last several decades of research in medical mycology have offered great insights into fungal cell biology, epidemiology, phylogenetics and the cells and molecules involved in the pathogenesis of fungal disease.", [["cell", "ANATOMY", 221, 225], ["cells", "ANATOMY", 271, 276], ["fungal disease", "DISEASE", 323, 337], ["fungal cell", "CELL", 214, 225], ["cells", "CELL", 271, 276], ["fungal disease", "PROBLEM", 323, 337], ["fungal cell", "OBSERVATION", 214, 225], ["fungal disease", "OBSERVATION", 323, 337]]], ["A legitimate question is to ask to what extent our extensive advances in comprehension of the biology of fungal pathogens have contributed to improvements in diagnosis and treatment.", [["fungal pathogens", "DISEASE", 105, 121], ["fungal pathogens", "PROBLEM", 105, 121], ["treatment", "TREATMENT", 172, 181]]], ["To what extent do patients benefit from translation of basic research into tools for clinical management?", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["clinical management", "TREATMENT", 85, 104]]], ["And the equally valid question: to what extent does biological science benefit from study of fungi that are opportunistic pathogens?F. Odds\u00b0(Aberdeen, UK)The speaker will examine some of these questions from the perspective of long experience in the field and the curmudgeonly attitude that develops with age.J. Kalmusova, M. Musilek, P. Kriz\u00b0(Prague, CZ)Objectives: The incidence of invasive meningococcal disease (IMD) has been reported in the Czech Republic since 1943.", [["invasive meningococcal disease", "DISEASE", 384, 414], ["IMD", "DISEASE", 416, 419], ["fungi", "PROBLEM", 93, 98], ["opportunistic pathogens", "PROBLEM", 108, 131], ["invasive meningococcal disease", "PROBLEM", 384, 414], ["invasive", "OBSERVATION_MODIFIER", 384, 392], ["meningococcal disease", "OBSERVATION", 393, 414]]], ["In response to the emergence of a new hypervirulent clonal complex, cc11, nationwide enhanced surveillance of invasive meningococcal disease was implemented by the National Reference Laboratory for Meningococcal Infections (NRL) in 1993.Methods:The case definition is consistent with the ECDC guidelines.", [["meningococcal disease", "DISEASE", 119, 140], ["Meningococcal Infections", "DISEASE", 198, 222], ["meningococcal", "SPECIES", 119, 132], ["a new hypervirulent clonal complex", "PROBLEM", 32, 66], ["invasive meningococcal disease", "PROBLEM", 110, 140], ["Meningococcal Infections", "PROBLEM", 198, 222], ["new", "OBSERVATION_MODIFIER", 34, 37], ["hypervirulent", "OBSERVATION_MODIFIER", 38, 51], ["clonal complex", "OBSERVATION", 52, 66], ["invasive", "OBSERVATION_MODIFIER", 110, 118], ["meningococcal disease", "OBSERVATION", 119, 140], ["Infections", "OBSERVATION", 212, 222], ["consistent with", "UNCERTAINTY", 268, 283]]], ["Culture and PCR are used for confirmation of cases.", [["Culture", "TEST", 0, 7], ["PCR", "TEST", 12, 15], ["confirmation of cases", "TEST", 29, 50]]], ["Strains of Neisseria meningitidis isolated from IMD cases are referred by the field laboratories to the NRL to be characterised by serogrouping, PorA and FetA sequencing (http://neisseria.org/nm/typing/) and multilocus sequence typing (MLST) (http://pubmlst.org/neisseria/).", [["Neisseria meningitidis", "DISEASE", 11, 33], ["Neisseria meningitidis", "ORGANISM", 11, 33], ["NRL", "GENE_OR_GENE_PRODUCT", 104, 107], ["NRL", "PROTEIN", 104, 107], ["PorA", "DNA", 145, 149], ["Neisseria meningitidis", "SPECIES", 11, 33], ["Neisseria meningitidis", "SPECIES", 11, 33], ["Neisseria meningitidis", "PROBLEM", 11, 33], ["FetA sequencing", "TEST", 154, 169], ["multilocus sequence typing", "TEST", 208, 234], ["Neisseria meningitidis", "OBSERVATION", 11, 33]]], ["In the NRL, the epidemiological database is matched against that of strains to avoid duplicate reporting in the final enhanced surveillance database.", [["NRL", "GENE_OR_GENE_PRODUCT", 7, 10], ["NRL", "PROTEIN", 7, 10], ["strains", "PROBLEM", 68, 75]]], ["Results: Despite the stable trend in IMD incidence (0.8/100 000) since 2005, the case fatality rate was high (11.8%) in 2007.", [["IMD", "DISEASE", 37, 40], ["the case fatality rate", "TEST", 77, 99], ["stable", "OBSERVATION_MODIFIER", 21, 27]]], ["The disease was caused mainly by serogroup B meningococci (67.4%) in 2007, followed by serogroups C (20.9%) and Y (9.3%).", [["serogroup B meningococci", "ORGANISM", 33, 57], ["The disease", "PROBLEM", 0, 11], ["serogroup B meningococci", "TEST", 33, 57], ["serogroups C", "TEST", 87, 99], ["Y", "TEST", 112, 113], ["disease", "OBSERVATION", 4, 11]]], ["The most frequent clonal complexes were cc18, cc41/44 and cc32 (typical for serogroup B) and cc11 (typical for serogroup C).", [["clonal complexes", "ANATOMY", 18, 34], ["cc18", "GENE_OR_GENE_PRODUCT", 40, 44], ["cc41/44", "GENE_OR_GENE_PRODUCT", 46, 53], ["cc32", "GENE_OR_GENE_PRODUCT", 58, 62], ["serogroup B", "GENE_OR_GENE_PRODUCT", 76, 87], ["cc11", "GENE_OR_GENE_PRODUCT", 93, 97], ["cc18", "PROTEIN", 40, 44], ["cc41/44", "PROTEIN", 46, 53], ["cc32", "PROTEIN", 58, 62], ["serogroup B", "PROTEIN", 76, 87], ["cc11", "PROTEIN", 93, 97], ["cc32", "TEST", 58, 62], ["cc11", "TEST", 93, 97], ["clonal complexes", "OBSERVATION", 18, 34]]], ["The highest age-specific morbidity rates were observed in the lowest age groups, i.e. 0\u221211 months and 1\u22124 years (11.4/100 000 and 4.5/100 000, respectively), and were associated with high prevalence of serogroup B. The case fatality rate was the highest in infants under 1 year of age (38.5%).", [["infants", "ORGANISM", 257, 264], ["infants", "SPECIES", 257, 264], ["serogroup B.", "SPECIES", 202, 214], ["serogroup B.", "PROBLEM", 202, 214], ["highest", "OBSERVATION_MODIFIER", 4, 11]]], ["The incidence of IMD caused by serogroup C is currently low and there is no indication for mass vaccination with MenC conjugate vaccine.", [["IMD", "DISEASE", 17, 20], ["MenC conjugate", "CHEMICAL", 113, 127], ["serogroup C", "ORGANISM", 31, 42], ["MenC conjugate", "SIMPLE_CHEMICAL", 113, 127], ["IMD", "PROBLEM", 17, 20], ["serogroup C", "PROBLEM", 31, 42], ["mass vaccination", "TREATMENT", 91, 107], ["MenC conjugate vaccine", "TREATMENT", 113, 135], ["no indication for", "UNCERTAINTY", 73, 90]]], ["MenB vaccine is needed for infants, but the sero/subtype coverage by the currently developed porin-based vaccines is low for Czech meningococcal isolates (maximum 56.8% for nine-valent meningococcal PorA vaccine).", [["MenB", "CHEMICAL", 0, 4], ["PorA", "CHEMICAL", 199, 203], ["infants", "ORGANISM", 27, 34], ["porin", "GENE_OR_GENE_PRODUCT", 93, 98], ["PorA", "ORGANISM", 199, 203], ["porin", "PROTEIN", 93, 98], ["infants", "SPECIES", 27, 34], ["Czech meningococcal", "SPECIES", 125, 144], ["MenB vaccine", "TREATMENT", 0, 12], ["the sero/subtype coverage", "TREATMENT", 40, 65], ["porin-based vaccines", "TREATMENT", 93, 113], ["Czech meningococcal isolates", "PROBLEM", 125, 153], ["nine-valent meningococcal PorA vaccine", "TREATMENT", 173, 211]]], ["Additional interventions to improve vaccine uptake and outcome have included use of SMS texting to announce availability of influenza annually and improve adherence to completion of hepatitis B vaccination, educational programmes changes in guidelines e.g. varicella vaccination and creation of a vaccine passport.", [["influenza", "DISEASE", 124, 133], ["hepatitis B", "DISEASE", 182, 193], ["varicella", "DISEASE", 257, 266], ["hepatitis B", "ORGANISM", 182, 193], ["hepatitis B", "SPECIES", 182, 193], ["Additional interventions", "TREATMENT", 0, 24], ["vaccine uptake", "PROBLEM", 36, 50], ["SMS texting", "TREATMENT", 84, 95], ["influenza", "PROBLEM", 124, 133], ["hepatitis B vaccination", "TREATMENT", 182, 205], ["educational programmes changes", "TREATMENT", 207, 237], ["varicella vaccination", "TREATMENT", 257, 278], ["a vaccine passport", "TREATMENT", 295, 313]]], ["We reviewed vaccination clinic activity in the cohort of 1,700 HIV positive patients since introduction of a dedicated vaccine service.Methods:Results:There has been a large increase in the uptake of vaccinations since introduction of this service.", [["HIV positive", "DISEASE", 63, 75], ["HIV", "ORGANISM", 63, 66], ["patients", "ORGANISM", 76, 84], ["HIV", "SPECIES", 63, 66], ["patients", "SPECIES", 76, 84], ["HIV", "SPECIES", 63, 66], ["a dedicated vaccine service", "TREATMENT", 107, 134], ["a large increase", "PROBLEM", 166, 182], ["this service", "TREATMENT", 235, 247], ["large", "OBSERVATION_MODIFIER", 168, 173], ["increase", "OBSERVATION_MODIFIER", 174, 182]]], ["The varicella vaccination uptake increased from 8 (2007) to 43 (2008) due to targeted vaccine programme.(see graphic, legend reads left to right)Methods:Conclusion: Strategies implemented increased the uptake of recommended vaccinations in our HIV population.", [["varicella", "DISEASE", 4, 13], ["HIV", "SPECIES", 244, 247], ["HIV", "SPECIES", 244, 247], ["The varicella vaccination uptake", "TEST", 0, 32], ["targeted vaccine programme", "TREATMENT", 77, 103], ["vaccinations", "TREATMENT", 224, 236], ["varicella", "OBSERVATION", 4, 13], ["right", "ANATOMY_MODIFIER", 139, 144]]], ["These included appointment of a dedicated health professional team, use of IT supports, education of staff and patients and development of a vaccine passport.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["a vaccine passport", "TREATMENT", 139, 157]]], ["We developed the vaccine passport to help with patient education and awareness and it will serve as a record of vaccine administration for physicians off site.Methods:In the latter year, post guideline change, we have targeted our varicella non immune population.", [["varicella", "DISEASE", 231, 240], ["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["the vaccine passport", "TREATMENT", 13, 33], ["vaccine administration", "TREATMENT", 112, 134], ["our varicella non immune population", "TREATMENT", 227, 262]]], ["The next intervention planned is to assess all late entrants to our healthcare system to determine need for catch up vaccines, including MMR.", [["catch up vaccines", "TREATMENT", 108, 125]]], ["Results: Column purified recombinant protein SspB1 was found to be a good antigen for both groups of animals used for immunisation.O175 An umbilical cord blood model of dendritic cell vaccination demonstrates the ex vivo generation of de novo strain-specific T-lymphocyte responsesAntibodies against the recombinant SspB1 tested by opsonophagocytosis were found to enhance phagocytosis of 4 GBS strains belonging to different serotypes at the average 5.5 times relatively to control.", [["umbilical cord blood", "ANATOMY", 139, 159], ["dendritic cell", "ANATOMY", 169, 183], ["strain", "ANATOMY", 243, 249], ["T-lymphocyte", "ANATOMY", 259, 271], ["SspB1", "GENE_OR_GENE_PRODUCT", 45, 50], ["cord blood", "ORGANISM_SUBSTANCE", 149, 159], ["dendritic cell", "CELL", 169, 183], ["T-lymphocyte", "CELL", 259, 271], ["SspB1", "GENE_OR_GENE_PRODUCT", 316, 321], ["Column purified recombinant protein", "PROTEIN", 9, 44], ["SspB1", "PROTEIN", 45, 50], ["recombinant SspB1", "PROTEIN", 304, 321], ["Column purified recombinant protein SspB1", "TEST", 9, 50], ["immunisation", "TREATMENT", 118, 130], ["dendritic cell vaccination", "TREATMENT", 169, 195], ["de novo strain", "PROBLEM", 235, 249], ["Antibodies", "TEST", 281, 291], ["the recombinant SspB1", "TEST", 300, 321], ["opsonophagocytosis", "PROBLEM", 332, 350], ["phagocytosis", "TEST", 373, 385], ["GBS strains", "PROBLEM", 391, 402], ["different serotypes", "TREATMENT", 416, 435], ["umbilical cord", "ANATOMY", 139, 153], ["dendritic cell vaccination", "OBSERVATION", 169, 195]]], ["Affect against GAS strains was less pronounced (2.5 times) but still statistically significant.", [["GAS strains", "PROBLEM", 15, 26], ["GAS strains", "OBSERVATION", 15, 26], ["significant", "OBSERVATION_MODIFIER", 83, 94]]], ["Antibodies were also capable to interfere with adherence of GBS strains carrying SspB1 relatively to the strain without the protein.O175 An umbilical cord blood model of dendritic cell vaccination demonstrates the ex vivo generation of de novo strain-specific T-lymphocyte responsesAdherence of the strain with SspB1 towards different cell lines was dramatically higher which proves the function of the protein as adhesin.O175 An umbilical cord blood model of dendritic cell vaccination demonstrates the ex vivo generation of de novo strain-specific T-lymphocyte responsesIn passive protection test carried out with mice challenged with virulent GBS or GAS strains introduced intranasaly were eliminated from the lungs of the animals 20 times faster in case of the usage of anti SspB1 serum relatively the control.", [["umbilical cord blood", "ANATOMY", 140, 160], ["dendritic cell", "ANATOMY", 170, 184], ["strain", "ANATOMY", 244, 250], ["T-lymphocyte", "ANATOMY", 260, 272], ["cell lines", "ANATOMY", 335, 345], ["umbilical cord blood", "ANATOMY", 430, 450], ["dendritic cell", "ANATOMY", 460, 474], ["strain", "ANATOMY", 534, 540], ["T-lymphocyte", "ANATOMY", 550, 562], ["lungs", "ANATOMY", 713, 718], ["serum", "ANATOMY", 785, 790], ["SspB1", "CHEMICAL", 311, 316], ["GBS", "DISEASE", 646, 649], ["SspB1", "GENE_OR_GENE_PRODUCT", 81, 86], ["cord", "ORGANISM_SUBSTANCE", 150, 154], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["dendritic cell", "CELL", 170, 184], ["T-lymphocyte", "CELL", 260, 272], ["SspB1", "GENE_OR_GENE_PRODUCT", 311, 316], ["cell lines", "CELL", 335, 345], ["cord", "ORGANISM_SUBSTANCE", 440, 444], ["blood", "ORGANISM_SUBSTANCE", 445, 450], ["dendritic cell", "CELL", 460, 474], ["T-lymphocyte", "CELL", 550, 562], ["mice", "ORGANISM", 616, 620], ["GAS strains", "ORGANISM", 653, 664], ["lungs", "ORGAN", 713, 718], ["SspB1", "GENE_OR_GENE_PRODUCT", 779, 784], ["serum", "ORGANISM_SUBSTANCE", 785, 790], ["SspB1", "PROTEIN", 81, 86], ["SspB1", "PROTEIN", 311, 316], ["cell lines", "CELL_LINE", 335, 345], ["adhesin", "PROTEIN", 414, 421], ["anti SspB1", "PROTEIN", 774, 784], ["mice", "SPECIES", 616, 620], ["mice", "SPECIES", 616, 620], ["GBS strains", "PROBLEM", 60, 71], ["dendritic cell vaccination", "TREATMENT", 170, 196], ["de novo strain", "PROBLEM", 236, 250], ["the strain", "PROBLEM", 295, 305], ["SspB1", "TREATMENT", 311, 316], ["different cell lines", "TREATMENT", 325, 345], ["dendritic cell vaccination", "TREATMENT", 460, 486], ["de novo strain", "PROBLEM", 526, 540], ["passive protection test", "TEST", 575, 598], ["virulent GBS", "PROBLEM", 637, 649], ["GAS strains", "PROBLEM", 653, 664], ["anti SspB1 serum", "TREATMENT", 774, 790], ["umbilical cord", "ANATOMY", 140, 154], ["dendritic cell", "OBSERVATION", 170, 184], ["cell lines", "OBSERVATION", 335, 345], ["dramatically", "OBSERVATION_MODIFIER", 350, 362], ["higher", "OBSERVATION_MODIFIER", 363, 369], ["umbilical cord", "ANATOMY", 430, 444], ["dendritic cell", "OBSERVATION", 460, 474], ["lungs", "ANATOMY", 713, 718]]], ["In the experiments with active protection SspB1 immunised animals were found be significantly better protected against GBS and GAS infection.", [["GBS", "DISEASE", 119, 122], ["infection", "DISEASE", 131, 140], ["SspB1", "GENE_OR_GENE_PRODUCT", 42, 47], ["animals", "ORGANISM", 58, 65], ["active protection SspB1", "TREATMENT", 24, 47], ["GBS", "PROBLEM", 119, 122], ["GAS infection", "PROBLEM", 127, 140], ["active", "OBSERVATION_MODIFIER", 24, 30], ["GAS infection", "OBSERVATION", 127, 140]]], ["Conclusion: These data suggest that outcomes of both community-onset and nosocomial bloodstream infections due to S. aureus may be improved by an expert consultation service.", [["bloodstream", "ANATOMY", 84, 95], ["nosocomial bloodstream infections", "DISEASE", 73, 106], ["S. aureus", "ORGANISM", 114, 123], ["S. aureus", "SPECIES", 114, 123], ["S. aureus", "SPECIES", 114, 123], ["nosocomial bloodstream infections", "PROBLEM", 73, 106], ["S. aureus", "PROBLEM", 114, 123], ["aureus", "OBSERVATION", 117, 123]]], ["Objective: Worldwide, the present tuberculosis epidemic is characterised by an alarming emergence in drug resistance.", [["tuberculosis", "DISEASE", 34, 46], ["the present tuberculosis epidemic", "PROBLEM", 22, 55], ["tuberculosis", "OBSERVATION", 34, 46], ["drug resistance", "OBSERVATION", 101, 116]]], ["Given the limited therapeutic options in MDR (and especially XDR) tuberculosis, there is a need to define the resistance levels and mechanisms present in clinical isolates categorised as drug resistant on the basis of critical concentration testing, so as to facilitate rapid therapeutic decisions.", [["MDR (and especially XDR) tuberculosis", "DISEASE", 41, 78], ["MDR", "PROBLEM", 41, 44], ["tuberculosis", "PROBLEM", 66, 78], ["the resistance levels", "PROBLEM", 106, 127], ["critical concentration testing", "TEST", 218, 248], ["tuberculosis", "OBSERVATION", 66, 78]]], ["Methods: We determined quantitative resistance levels of drug resistant isolates of Mycobacterium tuberculosis sampled in Switzerland over the past 3 years.", [["Mycobacterium tuberculosis", "DISEASE", 84, 110], ["Mycobacterium tuberculosis", "ORGANISM", 84, 110], ["Mycobacterium tuberculosis", "SPECIES", 84, 110], ["Mycobacterium tuberculosis", "SPECIES", 84, 110], ["drug resistant isolates", "TREATMENT", 57, 80], ["Mycobacterium tuberculosis", "PROBLEM", 84, 110], ["Mycobacterium tuberculosis", "OBSERVATION", 84, 110]]], ["Resistance-conferring genetic alterations were identified by probe assays and PCR-mediated gene sequencing.", [["genetic alterations", "PROBLEM", 22, 41], ["probe assays", "TEST", 61, 73], ["PCR", "TEST", 78, 81]]], ["Results: Rifampicin resistant isolates unanimously showed a high-level resistant phenotype (>50 mg/L) associated with mutations in rpoB.", [["Rifampicin", "CHEMICAL", 9, 19], ["Rifampicin", "CHEMICAL", 9, 19], ["Rifampicin", "SIMPLE_CHEMICAL", 9, 19], ["Rifampicin resistant isolates", "TEST", 9, 38], ["a high-level resistant phenotype", "PROBLEM", 58, 90], ["mutations", "PROBLEM", 118, 127]]], ["In contrast, a significant fraction of clinical TB isolates categorised as isoniazid resistant on the basis of critical concentration testing showed a low-level resistant phenotype (mostly mutations in inhA); heterogeneous phenotypic resistance levels were associated with mutations in katG.", [["TB", "DISEASE", 48, 50], ["isoniazid", "CHEMICAL", 75, 84], ["isoniazid", "CHEMICAL", 75, 84], ["isoniazid", "SIMPLE_CHEMICAL", 75, 84], ["inhA", "GENE_OR_GENE_PRODUCT", 202, 206], ["katG", "GENE_OR_GENE_PRODUCT", 286, 290], ["katG", "DNA", 286, 290], ["clinical TB isolates", "PROBLEM", 39, 59], ["isoniazid", "TREATMENT", 75, 84], ["critical concentration testing", "TEST", 111, 141], ["a low-level resistant phenotype", "PROBLEM", 149, 180], ["mutations in inhA", "PROBLEM", 189, 206], ["heterogeneous phenotypic resistance levels", "PROBLEM", 209, 251], ["mutations in katG", "PROBLEM", 273, 290], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["fraction", "OBSERVATION_MODIFIER", 27, 35], ["low-level resistant", "OBSERVATION_MODIFIER", 151, 170], ["heterogeneous", "OBSERVATION_MODIFIER", 209, 222], ["phenotypic resistance", "OBSERVATION", 223, 244]]], ["One third of streptomycin resistant clinical isolates had a low-level resistance phenotype (<10 mg/L).", [["streptomycin", "CHEMICAL", 13, 25], ["streptomycin", "CHEMICAL", 13, 25], ["streptomycin", "SIMPLE_CHEMICAL", 13, 25], ["streptomycin resistant clinical isolates", "PROBLEM", 13, 53], ["a low-level resistance phenotype", "PROBLEM", 58, 90]]], ["Ethambutol resistance occurred mostly in MDR strains and was linked to alterations in embB, but resistance never exceeded 25 mg/L.Conclusions:Our data indicate that some first line agents may be considered as therapeutic treatment option despite in vitro resistance at the critical concentration.", [["Ethambutol", "CHEMICAL", 0, 10], ["Ethambutol", "CHEMICAL", 0, 10], ["Ethambutol", "SIMPLE_CHEMICAL", 0, 10], ["MDR strains", "CELL", 41, 52], ["embB", "GENE_OR_GENE_PRODUCT", 86, 90], ["embB", "DNA", 86, 90], ["Ethambutol resistance", "TREATMENT", 0, 21], ["MDR strains", "PROBLEM", 41, 52], ["Our data", "TEST", 142, 150], ["some first line agents", "TREATMENT", 165, 187], ["therapeutic treatment option", "TREATMENT", 209, 237], ["MDR strains", "OBSERVATION", 41, 52]]], ["Diagnostic mycobacteriology would benefit from standardised measures of quantitative drug susceptibility testing in particular for those drugs were significant variations in phenotypic resistance levels are found in clinical isolates, e.g. isoniazid, ethambutol and streptomycin.", [["isoniazid", "CHEMICAL", 240, 249], ["ethambutol", "CHEMICAL", 251, 261], ["streptomycin", "CHEMICAL", 266, 278], ["isoniazid", "CHEMICAL", 240, 249], ["ethambutol", "CHEMICAL", 251, 261], ["streptomycin", "CHEMICAL", 266, 278], ["isoniazid", "SIMPLE_CHEMICAL", 240, 249], ["ethambutol", "SIMPLE_CHEMICAL", 251, 261], ["streptomycin", "SIMPLE_CHEMICAL", 266, 278], ["Diagnostic mycobacteriology", "TEST", 0, 27], ["standardised measures", "TEST", 47, 68], ["quantitative drug susceptibility testing", "TEST", 72, 112], ["those drugs", "TREATMENT", 131, 142], ["significant variations in phenotypic resistance levels", "PROBLEM", 148, 202], ["clinical isolates", "TEST", 216, 233], ["isoniazid", "TREATMENT", 240, 249], ["ethambutol", "TREATMENT", 251, 261], ["streptomycin", "TREATMENT", 266, 278], ["phenotypic resistance", "OBSERVATION", 174, 195]]], ["Bergstr\u00f6m\u00b0(Gothenburg, SE)Recent advances in the diagnostics of varicella zoster virus (VZV) infections have changed the perception of this virus as a CNS pathogen.", [["CNS", "ANATOMY", 151, 154], ["varicella zoster virus (VZV) infections", "DISEASE", 64, 103], ["varicella zoster virus", "ORGANISM", 64, 86], ["VZV", "ORGANISM", 88, 91], ["varicella zoster virus", "SPECIES", 64, 86], ["varicella zoster virus", "SPECIES", 64, 86], ["VZV", "SPECIES", 88, 91], ["varicella zoster virus", "PROBLEM", 64, 86], ["VZV) infections", "PROBLEM", 88, 103], ["this virus", "PROBLEM", 135, 145], ["a CNS pathogen", "PROBLEM", 149, 163], ["varicella zoster", "OBSERVATION", 64, 80]]], ["A real-time PCR method amplifying a 70 nt segment of the VZV gB region gave 0.5 log improved sensitivity over conventional PCR and was employed for routine diagnosis of VZV DNA in samples of cerebrospinal fluid (CSF).", [["samples", "ANATOMY", 180, 187], ["cerebrospinal fluid", "ANATOMY", 191, 210], ["VZV", "ORGANISM", 57, 60], ["VZV", "ORGANISM", 169, 172], ["DNA", "CELLULAR_COMPONENT", 173, 176], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 191, 210], ["CSF", "ORGANISM_SUBSTANCE", 212, 215], ["70 nt segment", "DNA", 36, 49], ["VZV gB region", "DNA", 57, 70], ["VZV DNA", "DNA", 169, 176], ["VZV gB", "SPECIES", 57, 63], ["VZV", "SPECIES", 169, 172], ["the VZV gB region", "PROBLEM", 53, 70], ["conventional PCR", "TEST", 110, 126], ["VZV DNA", "PROBLEM", 169, 176], ["cerebrospinal fluid", "TEST", 191, 210], ["VZV", "OBSERVATION", 57, 60], ["gB", "ANATOMY", 61, 63], ["VZV DNA", "OBSERVATION", 169, 176], ["cerebrospinal", "ANATOMY", 191, 204], ["fluid", "OBSERVATION", 205, 210]]], ["In addition, a new ELISA method for detection of antibodies in the CSF to glycoprotein E was developed, using a mammalian cell expression system for optimal glycosylation of the antigen.", [["cell", "ANATOMY", 122, 126], ["CSF", "GENE_OR_GENE_PRODUCT", 67, 70], ["glycoprotein E", "GENE_OR_GENE_PRODUCT", 74, 88], ["mammalian cell", "CELL", 112, 126], ["antibodies", "PROTEIN", 49, 59], ["CSF", "PROTEIN", 67, 70], ["glycoprotein E", "PROTEIN", 74, 88], ["a new ELISA method", "TEST", 13, 31], ["antibodies in the CSF to glycoprotein E", "PROBLEM", 49, 88], ["a mammalian cell expression system", "TREATMENT", 110, 144]]], ["These methods were utilised for studies of VZV-induced CNS infections.", [["CNS", "ANATOMY", 55, 58], ["CNS infections", "DISEASE", 55, 69], ["VZV", "ORGANISM", 43, 46], ["CNS", "ANATOMICAL_SYSTEM", 55, 58], ["VZV", "SPECIES", 43, 46], ["studies", "TEST", 32, 39], ["VZV", "PROBLEM", 43, 46], ["CNS infections", "PROBLEM", 55, 69], ["CNS", "ANATOMY", 55, 58], ["infections", "OBSERVATION", 59, 69]]], ["In a retrospective study, almost all patients had a reactivated VZV infection, but only 60% showed skin lesions.", [["skin lesions", "ANATOMY", 99, 111], ["VZV infection", "DISEASE", 64, 77], ["patients", "ORGANISM", 37, 45], ["VZV", "ORGANISM", 64, 67], ["skin lesions", "CANCER", 99, 111], ["patients", "SPECIES", 37, 45], ["VZV", "SPECIES", 64, 67], ["a retrospective study", "TEST", 3, 24], ["a reactivated VZV infection", "PROBLEM", 50, 77], ["skin lesions", "PROBLEM", 99, 111], ["VZV", "OBSERVATION_MODIFIER", 64, 67], ["infection", "OBSERVATION", 68, 77], ["skin", "ANATOMY", 99, 103], ["lesions", "OBSERVATION", 104, 111]]], ["The following diagnoses were made: acute aseptic meningitis (AAM), n = 34; encephalitis, n= 22; meningoencephalitis, n = 6; cranial nerve affections, n = 20; encephalopathy, n = 5; and cerebrovascular disease, n = 6.", [["cranial nerve", "ANATOMY", 124, 137], ["cerebrovascular", "ANATOMY", 185, 200], ["acute aseptic meningitis", "DISEASE", 35, 59], ["AAM", "DISEASE", 61, 64], ["encephalitis", "DISEASE", 75, 87], ["meningoencephalitis", "DISEASE", 96, 115], ["cranial nerve affections", "DISEASE", 124, 148], ["encephalopathy", "DISEASE", 158, 172], ["cerebrovascular disease", "DISEASE", 185, 208], ["cranial nerve", "MULTI-TISSUE_STRUCTURE", 124, 137], ["cerebrovascular", "ORGAN", 185, 200], ["acute aseptic meningitis", "PROBLEM", 35, 59], ["encephalitis", "PROBLEM", 75, 87], ["meningoencephalitis", "PROBLEM", 96, 115], ["cranial nerve affections", "PROBLEM", 124, 148], ["encephalopathy", "PROBLEM", 158, 172], ["cerebrovascular disease", "PROBLEM", 185, 208], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["aseptic", "OBSERVATION_MODIFIER", 41, 48], ["meningitis", "OBSERVATION", 49, 59], ["meningoencephalitis", "OBSERVATION", 96, 115], ["cranial nerve", "ANATOMY", 124, 137], ["encephalopathy", "OBSERVATION", 158, 172], ["cerebrovascular", "ANATOMY", 185, 200], ["disease", "OBSERVATION", 201, 208]]], ["In 66 patients in whom VZV DNA levels were determined, significantly higher viral loads were found in those with AAM and encephalitis compared to patients with cranial nerve affection (including Ramsay Hunt syndrome).T. Bergstr\u00f6m\u00b0(Gothenburg, SE)Of the 50% (n = 50) who had a follow-up, 50% (n = 25) had neurological complications after 3 months.", [["cranial nerve", "ANATOMY", 160, 173], ["neurological", "ANATOMY", 304, 316], ["encephalitis", "DISEASE", 121, 133], ["cranial nerve affection", "DISEASE", 160, 183], ["Ramsay Hunt syndrome", "DISEASE", 195, 215], ["neurological complications", "DISEASE", 304, 330], ["patients", "ORGANISM", 6, 14], ["VZV", "ORGANISM", 23, 26], ["DNA", "CELLULAR_COMPONENT", 27, 30], ["patients", "ORGANISM", 146, 154], ["cranial nerve", "MULTI-TISSUE_STRUCTURE", 160, 173], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 146, 154], ["VZV", "SPECIES", 23, 26], ["VZV DNA levels", "TEST", 23, 37], ["significantly higher viral loads", "PROBLEM", 55, 87], ["AAM", "PROBLEM", 113, 116], ["encephalitis", "PROBLEM", 121, 133], ["cranial nerve affection", "PROBLEM", 160, 183], ["Ramsay Hunt syndrome", "PROBLEM", 195, 215], ["neurological complications", "PROBLEM", 304, 330], ["viral loads", "OBSERVATION", 76, 87], ["encephalitis", "OBSERVATION", 121, 133], ["cranial nerve", "ANATOMY", 160, 173], ["affection", "OBSERVATION", 174, 183]]], ["Sixty-two percent had a CT/MRI scan of the brain performed and 46% of these had pathological findings.", [["brain", "ANATOMY", 43, 48], ["brain", "ORGAN", 43, 48], ["a CT/MRI scan of the brain", "TEST", 22, 48], ["brain", "ANATOMY", 43, 48]]], ["VZV encephalitis showed a more broad disease spectrum as compared with herpes simplex encephalitis (HSE), as will be presented.", [["VZV encephalitis", "DISEASE", 0, 16], ["herpes simplex encephalitis", "DISEASE", 71, 98], ["HSE", "DISEASE", 100, 103], ["VZV", "ORGANISM", 0, 3], ["herpes simplex encephalitis", "ORGANISM", 71, 98], ["herpes simplex encephalitis", "SPECIES", 71, 98], ["VZV", "SPECIES", 0, 3], ["VZV encephalitis", "PROBLEM", 0, 16], ["a more broad disease spectrum", "PROBLEM", 24, 53], ["herpes simplex encephalitis", "PROBLEM", 71, 98], ["encephalitis", "OBSERVATION", 4, 16], ["more broad", "OBSERVATION_MODIFIER", 26, 36], ["disease", "OBSERVATION", 37, 44]]], ["Detection of intrathecal synthesis of VZV gE antibodies was positive in the VZV encephalitis patients, as well as in some of the HSE patients, arguing for a previous suggested role for VZV as a co-pathogen at least in some cases of the latter disease.", [["VZV encephalitis", "DISEASE", 76, 92], ["HSE", "DISEASE", 129, 132], ["VZV", "ORGANISM", 38, 41], ["VZV encephalitis", "ORGANISM", 76, 92], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 133, 141], ["VZV", "ORGANISM", 185, 188], ["VZV gE antibodies", "PROTEIN", 38, 55], ["VZV encephalitis", "SPECIES", 76, 92], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 133, 141], ["VZV gE", "SPECIES", 38, 44], ["VZV encephalitis", "SPECIES", 76, 92], ["VZV", "SPECIES", 185, 188], ["intrathecal synthesis of VZV gE antibodies", "TEST", 13, 55], ["the VZV encephalitis", "PROBLEM", 72, 92], ["VZV", "PROBLEM", 185, 188], ["the latter disease", "PROBLEM", 232, 250], ["VZV encephalitis", "OBSERVATION", 76, 92]]], ["VZV vasculitis was a more common finding (6% of all cases) than expected from the literature of case reports.", [["VZV vasculitis", "DISEASE", 0, 14], ["VZV", "ORGANISM", 0, 3], ["VZV", "SPECIES", 0, 3], ["VZV vasculitis", "PROBLEM", 0, 14], ["vasculitis", "OBSERVATION", 4, 14]]], ["MR findings showed that middle and posterior cerebral arteries were targeted.", [["posterior cerebral arteries", "ANATOMY", 35, 62], ["posterior cerebral arteries", "MULTI-TISSUE_STRUCTURE", 35, 62], ["MR", "PROTEIN", 0, 2], ["MR findings", "TEST", 0, 11], ["middle", "ANATOMY_MODIFIER", 24, 30], ["posterior cerebral arteries", "ANATOMY", 35, 62]]], ["Surprisingly, despite substantial VZV DNA loads in the CSF of these patients, investigated serum samples were PCR negative.", [["serum samples", "ANATOMY", 91, 104], ["VZV", "ORGANISM", 34, 37], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["CSF", "GENE_OR_GENE_PRODUCT", 55, 58], ["patients", "ORGANISM", 68, 76], ["serum samples", "ORGANISM_SUBSTANCE", 91, 104], ["patients", "SPECIES", 68, 76], ["VZV", "SPECIES", 34, 37], ["substantial VZV DNA loads", "PROBLEM", 22, 47], ["serum samples", "TEST", 91, 104], ["PCR", "TEST", 110, 113], ["substantial", "OBSERVATION_MODIFIER", 22, 33], ["VZV DNA", "OBSERVATION", 34, 41]]], ["Thus, VZV might be suggested to be neuronally transported to the arterial walls rather than haematogenously spread.T. Bergstr\u00f6m\u00b0(Gothenburg, SE)Conclusions: VZV is a serious and underestimated cause of CNS infection.", [["arterial walls", "ANATOMY", 65, 79], ["CNS", "ANATOMY", 202, 205], ["VZV", "DISEASE", 157, 160], ["infection", "DISEASE", 206, 215], ["VZV", "ORGANISM", 6, 9], ["arterial walls", "MULTI-TISSUE_STRUCTURE", 65, 79], ["VZV", "ORGANISM", 157, 160], ["CNS", "ANATOMICAL_SYSTEM", 202, 205], ["VZV", "SPECIES", 6, 9], ["VZV", "SPECIES", 157, 160], ["VZV", "PROBLEM", 6, 9], ["haematogenously spread", "PROBLEM", 92, 114], ["VZV", "PROBLEM", 157, 160], ["CNS infection", "PROBLEM", 202, 215], ["arterial", "ANATOMY", 65, 73], ["walls", "ANATOMY_MODIFIER", 74, 79], ["VZV", "OBSERVATION", 157, 160], ["CNS", "ANATOMY", 202, 205], ["infection", "OBSERVATION", 206, 215]]], ["A substantial number of the patients presented with serious neurological symptoms and sequela, and pathological findings on CT/MRI of the brain were abundant, especially in patients with encephalitis and vasculitis.T. Bergstr\u00f6m\u00b0(Gothenburg, SE)PK/PD controversies for the clinician S190 PK/PD and azolesW.", [["neurological", "ANATOMY", 60, 72], ["brain", "ANATOMY", 138, 143], ["encephalitis", "DISEASE", 187, 199], ["vasculitis", "DISEASE", 204, 214], ["PD", "DISEASE", 247, 249], ["PD", "DISEASE", 290, 292], ["azolesW", "CHEMICAL", 297, 304], ["patients", "ORGANISM", 28, 36], ["brain", "ORGAN", 138, 143], ["patients", "ORGANISM", 173, 181], ["azolesW", "SIMPLE_CHEMICAL", 297, 304], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 173, 181], ["serious neurological symptoms", "PROBLEM", 52, 81], ["sequela", "PROBLEM", 86, 93], ["pathological findings", "PROBLEM", 99, 120], ["CT/MRI of the brain", "TEST", 124, 143], ["encephalitis", "PROBLEM", 187, 199], ["vasculitis", "PROBLEM", 204, 214], ["PD", "TREATMENT", 290, 292], ["azolesW", "TREATMENT", 297, 304], ["substantial", "OBSERVATION_MODIFIER", 2, 13], ["number", "OBSERVATION_MODIFIER", 14, 20], ["brain", "ANATOMY", 138, 143], ["encephalitis", "OBSERVATION", 187, 199], ["vasculitis", "OBSERVATION", 204, 214]]], ["Hope\u00b0(Manchester, UK)The triazoles have revolutionised the treatment of invasive and allergic fungal diseases.", [["triazoles", "CHEMICAL", 25, 34], ["allergic fungal diseases", "DISEASE", 85, 109], ["triazoles", "CHEMICAL", 25, 34], ["triazoles", "SIMPLE_CHEMICAL", 25, 34], ["The triazoles", "TREATMENT", 21, 34], ["invasive and allergic fungal diseases", "PROBLEM", 72, 109], ["invasive", "OBSERVATION_MODIFIER", 72, 80], ["allergic fungal diseases", "OBSERVATION", 85, 109]]], ["Fluconazole, itraconazole, voriconazole and posaconazole are available for clinical use.", [["Fluconazole", "CHEMICAL", 0, 11], ["itraconazole", "CHEMICAL", 13, 25], ["voriconazole", "CHEMICAL", 27, 39], ["posaconazole", "CHEMICAL", 44, 56], ["Fluconazole", "CHEMICAL", 0, 11], ["itraconazole", "CHEMICAL", 13, 25], ["voriconazole", "CHEMICAL", 27, 39], ["posaconazole", "CHEMICAL", 44, 56], ["Fluconazole", "SIMPLE_CHEMICAL", 0, 11], ["itraconazole", "SIMPLE_CHEMICAL", 13, 25], ["voriconazole", "SIMPLE_CHEMICAL", 27, 39], ["posaconazole", "SIMPLE_CHEMICAL", 44, 56], ["Fluconazole", "TREATMENT", 0, 11], ["itraconazole", "TREATMENT", 13, 25], ["voriconazole", "TREATMENT", 27, 39], ["posaconazole", "TREATMENT", 44, 56]]], ["Isavuconazole and ravuconazole are in development.", [["Isavuconazole", "CHEMICAL", 0, 13], ["ravuconazole", "CHEMICAL", 18, 30], ["Isavuconazole", "CHEMICAL", 0, 13], ["ravuconazole", "CHEMICAL", 18, 30], ["Isavuconazole", "SIMPLE_CHEMICAL", 0, 13], ["ravuconazole", "SIMPLE_CHEMICAL", 18, 30], ["Isavuconazole", "TREATMENT", 0, 13], ["ravuconazole", "TREATMENT", 18, 30]]], ["The triazoles have broad spectrum antifungal activity.", [["triazoles", "CHEMICAL", 4, 13], ["triazoles", "CHEMICAL", 4, 13], ["triazoles", "SIMPLE_CHEMICAL", 4, 13], ["The triazoles", "TREATMENT", 0, 13], ["broad spectrum antifungal activity", "TREATMENT", 19, 53], ["antifungal activity", "OBSERVATION", 34, 53]]], ["The pharmacokinetics and pharmacodynamics (PK-PD) of the triazoles have been extensively investigated in murine models of disseminated candidiasis.", [["triazoles", "CHEMICAL", 57, 66], ["candidiasis", "DISEASE", 135, 146], ["triazoles", "CHEMICAL", 57, 66], ["triazoles", "SIMPLE_CHEMICAL", 57, 66], ["murine", "ORGANISM", 105, 111], ["candidiasis", "PATHOLOGICAL_FORMATION", 135, 146], ["murine", "SPECIES", 105, 111], ["The pharmacokinetics", "TREATMENT", 0, 20], ["pharmacodynamics (PK-PD)", "TREATMENT", 25, 49], ["the triazoles", "TREATMENT", 53, 66], ["disseminated candidiasis", "PROBLEM", 122, 146], ["disseminated", "OBSERVATION_MODIFIER", 122, 134], ["candidiasis", "OBSERVATION", 135, 146]]], ["The PD parameter that optimally links drug exposure with the observed antifungal effect is the ratio of the area under the concentration-time curve (AUC) to MIC (AUC:MIC).", [["The PD parameter", "TREATMENT", 0, 16], ["the observed antifungal effect", "TREATMENT", 57, 87], ["antifungal effect", "OBSERVATION", 70, 87]]], ["There is increasing information on the magnitude of the AUC:MIC that is required for optimal antifungal effect.", [["optimal antifungal effect", "TREATMENT", 85, 110], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["antifungal effect", "OBSERVATION", 93, 110]]], ["PK-PD principles have been used to define in vitro susceptibility breakpoints.", [["PK", "GENE_OR_GENE_PRODUCT", 0, 2], ["PK", "TEST", 0, 2], ["PD principles", "TREATMENT", 3, 16], ["vitro susceptibility breakpoints", "PROBLEM", 45, 77], ["susceptibility breakpoints", "OBSERVATION", 51, 77]]], ["The triazoles are fungistatic against Candida spp.", [["triazoles", "CHEMICAL", 4, 13], ["Candida spp", "DISEASE", 38, 49], ["triazoles", "CHEMICAL", 4, 13], ["triazoles", "SIMPLE_CHEMICAL", 4, 13], ["Candida spp", "ORGANISM", 38, 49], ["The triazoles", "TREATMENT", 0, 13], ["Candida spp", "PROBLEM", 38, 49]]], ["Their mode of action against Aspergillus spp. is less well defined, although they clearly exhibit dose-dependant decrement in fungal burden in laboratory animal models of invasive pulmonary aspergillosis.", [["invasive pulmonary aspergillosis", "ANATOMY", 171, 203], ["Aspergillus spp", "DISEASE", 29, 44], ["invasive pulmonary aspergillosis", "DISEASE", 171, 203], ["Aspergillus spp", "ORGANISM", 29, 44], ["pulmonary aspergillosis", "PATHOLOGICAL_FORMATION", 180, 203], ["Aspergillus spp", "PROBLEM", 29, 44], ["dependant decrement", "PROBLEM", 103, 122], ["fungal burden", "PROBLEM", 126, 139], ["invasive pulmonary aspergillosis", "PROBLEM", 171, 203], ["less well defined", "OBSERVATION_MODIFIER", 49, 66], ["fungal burden", "OBSERVATION", 126, 139], ["invasive", "OBSERVATION_MODIFIER", 171, 179], ["pulmonary", "ANATOMY", 180, 189], ["aspergillosis", "OBSERVATION", 190, 203]]], ["The triazoles accumulate in tissues and this is important for an understanding of their antifungal effect.", [["tissues", "ANATOMY", 28, 35], ["triazoles", "CHEMICAL", 4, 13], ["triazoles", "CHEMICAL", 4, 13], ["triazoles", "SIMPLE_CHEMICAL", 4, 13], ["tissues", "TISSUE", 28, 35], ["The triazoles", "TREATMENT", 0, 13]]], ["In humans, the triazoles are characterised by complicated pharmacokinetic properties.", [["triazoles", "CHEMICAL", 15, 24], ["triazoles", "CHEMICAL", 15, 24], ["humans", "ORGANISM", 3, 9], ["triazoles", "SIMPLE_CHEMICAL", 15, 24], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["the triazoles", "TREATMENT", 11, 24], ["complicated", "OBSERVATION_MODIFIER", 46, 57], ["pharmacokinetic properties", "OBSERVATION", 58, 84]]], ["Both itraconazole and voriconazole exhibit nonlinear pharmacokinetics.", [["itraconazole", "CHEMICAL", 5, 17], ["voriconazole", "CHEMICAL", 22, 34], ["itraconazole", "CHEMICAL", 5, 17], ["voriconazole", "CHEMICAL", 22, 34], ["itraconazole", "SIMPLE_CHEMICAL", 5, 17], ["voriconazole", "SIMPLE_CHEMICAL", 22, 34], ["Both itraconazole", "TREATMENT", 0, 17], ["voriconazole", "TREATMENT", 22, 34], ["itraconazole", "OBSERVATION", 5, 17]]], ["The triazoles all exhibit clinically relevant exposureresponse relationships.", [["triazoles", "CHEMICAL", 4, 13], ["triazoles", "CHEMICAL", 4, 13], ["triazoles", "SIMPLE_CHEMICAL", 4, 13], ["The triazoles", "TREATMENT", 0, 13]]], ["Recent work from our laboratory suggests that itraconazole exhibits clinically relevant concentration-toxicity relationships.", [["itraconazole", "CHEMICAL", 46, 58], ["toxicity", "DISEASE", 102, 110], ["itraconazole", "CHEMICAL", 46, 58], ["itraconazole", "SIMPLE_CHEMICAL", 46, 58], ["itraconazole", "TREATMENT", 46, 58]]], ["Higher concentrations of voriconazole are associated with a progressively higher probability of hepatotoxicity, photopsia and central nervous system toxicity.W. Hope\u00b0(Manchester, UK)Because of the significant pharmacokinetic variability and clinically relevant drug exposure-response relationships, therapeutic drug monitoring (TDM) is frequently used.", [["central nervous system", "ANATOMY", 126, 148], ["voriconazole", "CHEMICAL", 25, 37], ["hepatotoxicity", "DISEASE", 96, 110], ["photopsia", "DISEASE", 112, 121], ["central nervous system toxicity", "DISEASE", 126, 157], ["voriconazole", "CHEMICAL", 25, 37], ["voriconazole", "SIMPLE_CHEMICAL", 25, 37], ["nervous system", "ANATOMICAL_SYSTEM", 134, 148], ["voriconazole", "TREATMENT", 25, 37], ["hepatotoxicity", "PROBLEM", 96, 110], ["photopsia", "PROBLEM", 112, 121], ["central nervous system toxicity", "PROBLEM", 126, 157], ["the significant pharmacokinetic variability", "PROBLEM", 193, 236], ["therapeutic drug monitoring", "TREATMENT", 299, 326], ["voriconazole", "OBSERVATION", 25, 37], ["hepatotoxicity", "OBSERVATION", 96, 110], ["central", "ANATOMY_MODIFIER", 126, 133], ["nervous system toxicity", "OBSERVATION", 134, 157], ["significant", "OBSERVATION_MODIFIER", 197, 208], ["pharmacokinetic variability", "OBSERVATION", 209, 236]]], ["A strong argument can be made for the routine monitoring of itraconazole and voriconazole.", [["itraconazole", "CHEMICAL", 60, 72], ["voriconazole", "CHEMICAL", 77, 89], ["itraconazole", "CHEMICAL", 60, 72], ["voriconazole", "CHEMICAL", 77, 89], ["itraconazole", "SIMPLE_CHEMICAL", 60, 72], ["voriconazole", "SIMPLE_CHEMICAL", 77, 89], ["the routine monitoring", "TEST", 34, 56], ["itraconazole", "TREATMENT", 60, 72], ["voriconazole", "TREATMENT", 77, 89]]], ["There may also be grounds to consider monitoring posaconazole levels.", [["posaconazole", "CHEMICAL", 49, 61], ["posaconazole", "CHEMICAL", 49, 61], ["posaconazole", "SIMPLE_CHEMICAL", 49, 61], ["monitoring posaconazole levels", "TEST", 38, 68]]], ["TDM should be considered for all patients receiving triazoles who have refractory disease.", [["triazoles", "CHEMICAL", 52, 61], ["triazoles", "CHEMICAL", 52, 61], ["patients", "ORGANISM", 33, 41], ["triazoles", "SIMPLE_CHEMICAL", 52, 61], ["patients", "SPECIES", 33, 41], ["TDM", "TREATMENT", 0, 3], ["triazoles", "TREATMENT", 52, 61], ["refractory disease", "PROBLEM", 71, 89]]], ["Furthermore, TDM should be considered when compliance, drug interactions and variable pharmacokinetics result in uncertainty about resultant drug exposures.", [["TDM", "TREATMENT", 13, 16], ["drug interactions", "PROBLEM", 55, 72], ["resultant drug exposures", "PROBLEM", 131, 155]]], ["An understanding of the PK-PD relationships of the triazoles has been instrumental in optimising their clinical efficacy.W. Hope\u00b0(Manchester, UK)Innate immunity S192 The inflammasomes: danger sensing complexes triggering innate immunityJ.", [["triazoles", "CHEMICAL", 51, 60], ["S192", "CHEMICAL", 161, 165], ["triazoles", "CHEMICAL", 51, 60], ["PK", "GENE_OR_GENE_PRODUCT", 24, 26], ["triazoles", "SIMPLE_CHEMICAL", 51, 60], ["inflammasomes", "PROTEIN", 170, 183], ["danger sensing complexes", "PROTEIN", 185, 209], ["the triazoles", "TREATMENT", 47, 60], ["innate immunityJ", "TREATMENT", 221, 237], ["inflammasomes", "OBSERVATION", 170, 183]]], ["Tschopp\u00b0(Lausanne, CH)The NOD-like receptors (NLR) are a family of intracellular sensors of microbial motifs and 'danger signals' that have emerged as being crucial components of the innate immune responses and inflammation.", [["intracellular", "ANATOMY", 67, 80], ["inflammation", "DISEASE", 211, 223], ["Tschopp\u00b0", "SIMPLE_CHEMICAL", 0, 8], ["NOD-like receptors", "GENE_OR_GENE_PRODUCT", 26, 44], ["NLR", "GENE_OR_GENE_PRODUCT", 46, 49], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 67, 80], ["NOD-like receptors", "PROTEIN", 26, 44], ["NLR", "PROTEIN", 46, 49], ["inflammation", "PROBLEM", 211, 223], ["inflammation", "OBSERVATION", 211, 223]]], ["Several NLRs (NALPs and IPAF) form a caspase-1-activating multiprotein complex, termed inflammasome, that processes proinflammatory cytokines including IL-1beta.", [["NLRs", "GENE_OR_GENE_PRODUCT", 8, 12], ["NALPs", "GENE_OR_GENE_PRODUCT", 14, 19], ["IPAF", "GENE_OR_GENE_PRODUCT", 24, 28], ["caspase-1", "GENE_OR_GENE_PRODUCT", 37, 46], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 152, 160], ["NLRs", "PROTEIN", 8, 12], ["NALPs", "PROTEIN", 14, 19], ["IPAF", "PROTEIN", 24, 28], ["caspase-1-activating multiprotein complex", "PROTEIN", 37, 78], ["proinflammatory cytokines", "PROTEIN", 116, 141], ["IL-1beta", "PROTEIN", 152, 160], ["Several NLRs (NALPs and IPAF)", "TREATMENT", 0, 29], ["a caspase", "TEST", 35, 44], ["activating multiprotein complex", "PROBLEM", 47, 78], ["termed inflammasome", "PROBLEM", 80, 99], ["proinflammatory cytokines", "TREATMENT", 116, 141], ["IL-1beta", "TREATMENT", 152, 160], ["inflammasome", "OBSERVATION", 87, 99], ["proinflammatory", "OBSERVATION_MODIFIER", 116, 131]]], ["Amongst the various inflammasomes, the NALP3 inflammasome is particularly qualified to sense a plethora of diverse molecules, ranging from bacterial muramyldipeptide to monosodium urate crystals.", [["muramyldipeptide", "CHEMICAL", 149, 165], ["monosodium urate", "CHEMICAL", 169, 185], ["muramyldipeptide", "CHEMICAL", 149, 165], ["monosodium urate", "CHEMICAL", 169, 185], ["NALP3", "GENE_OR_GENE_PRODUCT", 39, 44], ["muramyldipeptide", "SIMPLE_CHEMICAL", 149, 165], ["monosodium urate crystals", "SIMPLE_CHEMICAL", 169, 194], ["inflammasomes", "PROTEIN", 20, 33], ["NALP3 inflammasome", "PROTEIN", 39, 57], ["the NALP3 inflammasome", "PROBLEM", 35, 57], ["diverse molecules", "PROBLEM", 107, 124], ["bacterial muramyldipeptide to monosodium urate crystals", "TREATMENT", 139, 194], ["various", "OBSERVATION_MODIFIER", 12, 19], ["inflammasomes", "OBSERVATION", 20, 33], ["NALP3 inflammasome", "OBSERVATION", 39, 57]]], ["The important role of the NALP3 inflammasome is emphasized by the identification of mutations in the NALP3 gene that are associated with a susceptibility to inflammatory disorders.", [["inflammatory disorders", "DISEASE", 157, 179], ["NALP3", "GENE_OR_GENE_PRODUCT", 26, 31], ["NALP3", "GENE_OR_GENE_PRODUCT", 101, 106], ["NALP3 inflammasome", "PROTEIN", 26, 44], ["NALP3 gene", "DNA", 101, 111], ["the NALP3 inflammasome", "TREATMENT", 22, 44], ["mutations in the NALP3 gene", "PROBLEM", 84, 111], ["a susceptibility to inflammatory disorders", "PROBLEM", 137, 179], ["NALP3 inflammasome", "OBSERVATION", 26, 44], ["inflammatory", "OBSERVATION_MODIFIER", 157, 169]]], ["These and other issues related to the inflammasome will be presented.N. Gay\u00b0(Cambridge, UK)It is now 20 years since Charles Janeway hypothesized the existence of clonally derived pattern recognition receptors and pointed to the importance of these in initial responses to bacterial and viral infections.", [["bacterial and viral infections", "DISEASE", 272, 302], ["pattern recognition receptors", "PROTEIN", 179, 208], ["the inflammasome", "PROBLEM", 34, 50], ["bacterial and viral infections", "PROBLEM", 272, 302], ["viral infections", "OBSERVATION", 286, 302]]], ["Janeway's hypothesis has been validated by the discovery of three groups of PRRs.", [["PRRs", "GENE_OR_GENE_PRODUCT", 76, 80], ["PRRs", "PROTEIN", 76, 80]]], ["First, are the Toll-like receptors which detect microbial lipids and non-self nucleic acids at the cell surface an in intracellular compartments.", [["cell surface", "ANATOMY", 99, 111], ["intracellular compartments", "ANATOMY", 118, 144], ["nucleic acids", "CHEMICAL", 78, 91], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 15, 34], ["nucleic acids", "AMINO_ACID", 78, 91], ["cell surface", "CELLULAR_COMPONENT", 99, 111], ["intracellular compartments", "CELLULAR_COMPONENT", 118, 144], ["Toll-like receptors", "PROTEIN", 15, 34], ["microbial lipids", "TEST", 48, 64], ["non-self nucleic acids", "TEST", 69, 91], ["intracellular compartments", "OBSERVATION", 118, 144]]], ["In addition cytoplasmic sensors of bacteria (NODs) and of viral nucleic acids (RIGs) have also been characterised.", [["cytoplasmic", "ANATOMY", 12, 23], ["nucleic acids", "CHEMICAL", 64, 77], ["cytoplasmic", "ORGANISM_SUBSTANCE", 12, 23], ["NODs", "GENE_OR_GENE_PRODUCT", 45, 49], ["RIGs", "GENE_OR_GENE_PRODUCT", 79, 83], ["NODs", "PROTEIN", 45, 49], ["viral nucleic acids", "PROTEIN", 58, 77], ["RIGs", "PROTEIN", 79, 83], ["bacteria", "PROBLEM", 35, 43], ["viral nucleic acids", "PROBLEM", 58, 77], ["cytoplasmic sensors", "OBSERVATION", 12, 31], ["nucleic acids", "OBSERVATION", 64, 77]]], ["As well as being critical for responses to infections, these PRRs also underlie a large burden of autoimmune and inflammatory disease in the human population and are thus important targets for therapy.", [["infections", "DISEASE", 43, 53], ["autoimmune and inflammatory disease", "DISEASE", 98, 133], ["PRRs", "GENE_OR_GENE_PRODUCT", 61, 65], ["human", "ORGANISM", 141, 146], ["PRRs", "PROTEIN", 61, 65], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 141, 146], ["infections", "PROBLEM", 43, 53], ["autoimmune and inflammatory disease in the human population", "PROBLEM", 98, 157], ["therapy", "TREATMENT", 193, 200], ["large", "OBSERVATION_MODIFIER", 82, 87], ["burden", "OBSERVATION_MODIFIER", 88, 94], ["autoimmune", "OBSERVATION", 98, 108], ["inflammatory", "OBSERVATION_MODIFIER", 113, 125]]], ["In my talk I will describe the molecular mechanisms by which these conserved pathogen associated moecules are recognized by the TLRs with particular reference to lipo polysaccharide and single stranded viral RNAs.", [["TLRs", "GENE_OR_GENE_PRODUCT", 128, 132], ["lipo polysaccharide", "GENE_OR_GENE_PRODUCT", 162, 181], ["TLRs", "PROTEIN", 128, 132], ["lipo polysaccharide and single stranded viral RNAs", "RNA", 162, 212], ["lipo polysaccharide", "TREATMENT", 162, 181], ["single stranded viral RNAs", "PROBLEM", 186, 212], ["viral RNAs", "OBSERVATION", 202, 212]]], ["I will also present new results which show how receptor activation is coupled to downstream signal transduction and in particular the role played by oligomeric signaling platforms assembled form adaptors and other signaling molecules involved in the pathway.", [["signaling molecules", "PROTEIN", 214, 233]]], ["I will discuss the potential for structural analysis to be used in the rational design of new drugs.M. Struelens\u00b0(Brussels, BE), D. Pittet\u00b0(Geneva, CH)This session proposes a critical review of the most salient recently published papers in the field with a special focus on control of multi drug-resistant organisms, prevention of infections in the intensive care unit, surgery etc. and highlights the need for validity/scope assessment.", [["infections", "DISEASE", 331, 341], ["structural analysis", "TEST", 33, 52], ["new drugs", "TREATMENT", 90, 99], ["multi drug-resistant organisms", "PROBLEM", 285, 315], ["infections", "PROBLEM", 331, 341], ["surgery", "TREATMENT", 370, 377], ["validity/scope assessment", "TEST", 411, 436], ["infections", "OBSERVATION", 331, 341]]], ["It emphasizes also the importance to prioritise information published in the abundant literature available so as to be able to summarise and understand the potential changes in clinical practice, and identify unresolved issues and areas of possible future clinical research.R. Isturiz\u00b0(Caracas, VE)Tourism is Europe's face to the world.", [["unresolved issues", "PROBLEM", 209, 226]]], ["It is also a major source of revenue, employment and productivity.", [["revenue", "OBSERVATION", 29, 36]]], ["Returning travelers are even more numerous and more often associated with disease transmission into Europe.R. Isturiz\u00b0(Caracas, VE)Within countries of the European continent, imported cases of environmental and zoonotic illnesses such as cholera, dengue, malaria, viral haemorrhagic fevers and West Nile virus infections are a rare but established fact.", [["zoonotic illnesses", "DISEASE", 211, 229], ["cholera", "DISEASE", 238, 245], ["dengue", "DISEASE", 247, 253], ["malaria", "DISEASE", 255, 262], ["viral haemorrhagic fevers", "DISEASE", 264, 289], ["West Nile virus infections", "DISEASE", 294, 320], ["West Nile virus", "ORGANISM", 294, 309], ["viral haemorrhagic fevers", "SPECIES", 264, 289], ["West Nile virus", "SPECIES", 294, 309], ["West Nile virus", "SPECIES", 294, 309], ["zoonotic illnesses", "PROBLEM", 211, 229], ["cholera", "PROBLEM", 238, 245], ["dengue", "PROBLEM", 247, 253], ["malaria", "PROBLEM", 255, 262], ["viral haemorrhagic fevers", "PROBLEM", 264, 289], ["West Nile virus infections", "PROBLEM", 294, 320]]], ["Diseases imported from Latin America with the potential for autochthonous transmission (chikungunya, malaria, yellow fever) and or high infectivity (viral haemorrhagic fevers) will be described in detail and the possibility of European outbreaks from Latin American countries will be discussed.", [["chikungunya", "DISEASE", 88, 99], ["malaria", "DISEASE", 101, 108], ["yellow fever", "DISEASE", 110, 122], ["viral haemorrhagic fevers", "DISEASE", 149, 174], ["Diseases", "PROBLEM", 0, 8], ["autochthonous transmission", "PROBLEM", 60, 86], ["chikungunya", "PROBLEM", 88, 99], ["malaria", "PROBLEM", 101, 108], ["yellow fever", "PROBLEM", 110, 122], ["high infectivity (viral haemorrhagic fevers", "PROBLEM", 131, 174], ["high infectivity", "OBSERVATION_MODIFIER", 131, 147]]], ["Cutaneous Leishmaniasis (CL) is a worldwide disease, endemic in 88 countries, that has shown an increasing incidence over the last two decades.", [["CL", "ANATOMY", 25, 27], ["Cutaneous Leishmaniasis", "DISEASE", 0, 23], ["CL", "DISEASE", 25, 27], ["CL", "MULTI-TISSUE_STRUCTURE", 25, 27], ["Cutaneous Leishmaniasis", "PROBLEM", 0, 23], ["a worldwide disease", "PROBLEM", 32, 51], ["Leishmaniasis", "OBSERVATION", 10, 23], ["worldwide", "OBSERVATION_MODIFIER", 34, 43], ["disease", "OBSERVATION", 44, 51], ["endemic", "OBSERVATION_MODIFIER", 53, 60], ["increasing", "OBSERVATION_MODIFIER", 96, 106], ["incidence", "OBSERVATION_MODIFIER", 107, 116]]], ["So far, pentavalent antimony compounds have been considered the treatment of choice, with rates of curing close to 85%.", [["antimony", "CHEMICAL", 20, 28], ["antimony", "CHEMICAL", 20, 28], ["pentavalent antimony compounds", "SIMPLE_CHEMICAL", 8, 38], ["pentavalent antimony compounds", "TREATMENT", 8, 38]]], ["However, the high efficacy of these drugs is counteracted by their adverse events.", [["these drugs", "TREATMENT", 30, 41], ["their adverse events", "PROBLEM", 61, 81], ["high", "OBSERVATION_MODIFIER", 13, 17], ["efficacy", "OBSERVATION_MODIFIER", 18, 26]]], ["Recently, in vitro and in vivo studies have shown that NO plays a key role in the eradication of the leishmania parasite Objective: To determine whether a NO donor patch (developed by electrospinning technique) is as effective as meglumine antimoniate in the treatment of CL while causing less adverse events Methods: A double-blind, randomised, placebo-controlled clinical trial was conducted with 178 patients diagnosed with CL in Santander, Colombia, South-America.", [["CL", "ANATOMY", 272, 274], ["NO", "CHEMICAL", 55, 57], ["NO", "CHEMICAL", 155, 157], ["meglumine", "CHEMICAL", 230, 239], ["CL", "DISEASE", 272, 274], ["NO", "CHEMICAL", 55, 57], ["NO", "CHEMICAL", 155, 157], ["meglumine", "CHEMICAL", 230, 239], ["NO", "SIMPLE_CHEMICAL", 55, 57], ["NO", "SIMPLE_CHEMICAL", 155, 157], ["meglumine", "SIMPLE_CHEMICAL", 230, 239], ["CL", "MULTI-TISSUE_STRUCTURE", 272, 274], ["patients", "ORGANISM", 403, 411], ["patients", "SPECIES", 403, 411], ["vivo studies", "TEST", 26, 38], ["a NO donor patch", "TREATMENT", 153, 169], ["meglumine antimoniate", "TREATMENT", 230, 251], ["A double-blind", "TREATMENT", 318, 332], ["placebo", "TREATMENT", 346, 353]]], ["The patients were randomly assigned to two groups.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["During 20 days Group 1 received simultaneously meglumine antimoniate and placebo of nitric oxide patches while Group 2 received active nitric oxide patches and placebo of meglumine antimoniate.", [["meglumine antimoniate", "CHEMICAL", 47, 68], ["nitric oxide", "CHEMICAL", 84, 96], ["nitric oxide", "CHEMICAL", 135, 147], ["meglumine", "CHEMICAL", 171, 180], ["meglumine antimoniate", "CHEMICAL", 47, 68], ["nitric oxide", "CHEMICAL", 84, 96], ["nitric oxide", "CHEMICAL", 135, 147], ["meglumine", "CHEMICAL", 171, 180], ["meglumine antimoniate", "SIMPLE_CHEMICAL", 47, 68], ["nitric oxide", "SIMPLE_CHEMICAL", 84, 96], ["nitric oxide patches", "SIMPLE_CHEMICAL", 135, 155], ["meglumine antimoniate", "SIMPLE_CHEMICAL", 171, 192], ["simultaneously meglumine antimoniate", "TREATMENT", 32, 68], ["placebo of nitric oxide patches", "TREATMENT", 73, 104], ["active nitric oxide patches", "TREATMENT", 128, 155], ["placebo of meglumine antimoniate", "TREATMENT", 160, 192]]], ["Biochemical determinations (aspartate aminotransferase, alanine aminotransferase, creatinine and pancreatic amilase) were measured at he beginning and at the end of the treatment.", [["pancreatic", "ANATOMY", 97, 107], ["aspartate", "CHEMICAL", 28, 37], ["alanine", "CHEMICAL", 56, 63], ["creatinine", "CHEMICAL", 82, 92], ["aspartate", "CHEMICAL", 28, 37], ["alanine", "CHEMICAL", 56, 63], ["creatinine", "CHEMICAL", 82, 92], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 28, 54], ["alanine", "AMINO_ACID", 56, 63], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 64, 80], ["creatinine", "SIMPLE_CHEMICAL", 82, 92], ["pancreatic", "ORGAN", 97, 107], ["amilase", "GENE_OR_GENE_PRODUCT", 108, 115], ["aspartate aminotransferase", "PROTEIN", 28, 54], ["alanine aminotransferase", "PROTEIN", 56, 80], ["Biochemical determinations", "TEST", 0, 26], ["aspartate aminotransferase", "TEST", 28, 54], ["alanine aminotransferase", "TEST", 56, 80], ["creatinine", "TEST", 82, 92], ["pancreatic amilase", "TEST", 97, 115], ["the treatment", "TREATMENT", 165, 178], ["pancreatic", "ANATOMY", 97, 107]]], ["A follow up was realised 21, 45 and 90 days after the beginning of the treatment Results: The study included 69 (38.77%) women and 109 (61.23%) men.", [["women", "ORGANISM", 121, 126], ["men", "ORGANISM", 144, 147], ["women", "SPECIES", 121, 126], ["men", "SPECIES", 144, 147], ["The study", "TEST", 90, 99]]], ["Clinical and demographic data were similar in the two groups.", [["Clinical and demographic data", "TEST", 0, 29]]], ["Treatment with NO patches generated both, a lower frequency of non-serious adverse events (fever, anorexia, myalgia, arthralgia, headache), and a reduced variation in biochemistry determinations (ASAT 26 The treatment with NO patches resulted in a lower percentage of complete clinical response compared with meglumine antimoniate.", [["NO", "CHEMICAL", 15, 17], ["fever", "DISEASE", 91, 96], ["anorexia", "DISEASE", 98, 106], ["myalgia", "DISEASE", 108, 115], ["arthralgia", "DISEASE", 117, 127], ["headache", "DISEASE", 129, 137], ["NO", "CHEMICAL", 223, 225], ["meglumine", "CHEMICAL", 309, 318], ["NO", "CHEMICAL", 15, 17], ["NO", "CHEMICAL", 223, 225], ["meglumine", "CHEMICAL", 309, 318], ["NO", "SIMPLE_CHEMICAL", 15, 17], ["NO", "SIMPLE_CHEMICAL", 223, 225], ["meglumine antimoniate", "SIMPLE_CHEMICAL", 309, 330], ["Treatment", "TREATMENT", 0, 9], ["patches", "TREATMENT", 18, 25], ["non-serious adverse events", "PROBLEM", 63, 89], ["fever", "PROBLEM", 91, 96], ["anorexia", "PROBLEM", 98, 106], ["myalgia", "PROBLEM", 108, 115], ["arthralgia", "PROBLEM", 117, 127], ["headache", "PROBLEM", 129, 137], ["a reduced variation", "PROBLEM", 144, 163], ["biochemistry determinations", "TEST", 167, 194], ["ASAT", "TEST", 196, 200], ["The treatment", "TREATMENT", 204, 217], ["patches", "TREATMENT", 226, 233], ["meglumine antimoniate", "TREATMENT", 309, 330]]], ["Despite its inferior effectiveness, the safety, the lower frequency of adverse events, the facility of administration (topical) and the low cost of the patches justifies its evaluation in further poblational studies, especially in populations as the Colombian ones, where the serious adverse events due to glucantime have increased dramatically.", [["glucantime", "CHEMICAL", 306, 316], ["glucantime", "CHEMICAL", 306, 316], ["glucantime", "SIMPLE_CHEMICAL", 306, 316], ["adverse events", "PROBLEM", 71, 85], ["administration (topical)", "TREATMENT", 103, 127], ["the patches", "TREATMENT", 148, 159], ["its evaluation", "TEST", 170, 184], ["further poblational studies", "TEST", 188, 215], ["the serious adverse events", "PROBLEM", 272, 298], ["glucantime", "TREATMENT", 306, 316], ["inferior", "OBSERVATION_MODIFIER", 12, 20], ["effectiveness", "OBSERVATION", 21, 34], ["increased", "OBSERVATION_MODIFIER", 322, 331]]], ["Objectives: Trichinellosis is a zoonotic disease which has never been reported in Taiwan and is rarely linked to consumption of reptiles.", [["Trichinellosis", "DISEASE", 12, 26], ["zoonotic disease", "DISEASE", 32, 48], ["Trichinellosis", "PROBLEM", 12, 26], ["a zoonotic disease", "PROBLEM", 30, 48], ["Trichinellosis", "OBSERVATION", 12, 26], ["zoonotic", "OBSERVATION_MODIFIER", 32, 40]]], ["We investigated the first documented outbreak of trichinellosis in Taiwan consisting of 8 patients who became acutely ill after eating at the same restaurant in May 2008.Methods:We conducted a retrospective cohort study by interviewing the patients and persons who ate together with them.", [["trichinellosis", "DISEASE", 49, 63], ["acutely ill", "DISEASE", 110, 121], ["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 240, 248], ["persons", "ORGANISM", 253, 260], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 240, 248], ["persons", "SPECIES", 253, 260], ["trichinellosis", "PROBLEM", 49, 63], ["acutely ill", "PROBLEM", 110, 121], ["a retrospective cohort study", "TEST", 191, 219], ["outbreak", "OBSERVATION_MODIFIER", 37, 45], ["trichinellosis", "OBSERVATION", 49, 63]]], ["A case was defined as illness in an attendee who had fever (>38.0\u00baC) or myalgia 4 weeks after the festivals and was seropositive to Trichinella antigen using an enzymelinked immunoassay and immunohistochemical staining.", [["illness", "DISEASE", 22, 29], ["fever", "DISEASE", 53, 58], ["myalgia", "DISEASE", 72, 79], ["Trichinella", "ORGANISM", 132, 143], ["fever", "PROBLEM", 53, 58], ["myalgia", "PROBLEM", 72, 79], ["seropositive to Trichinella antigen", "PROBLEM", 116, 151], ["an enzymelinked immunoassay", "TEST", 158, 185], ["immunohistochemical staining", "TEST", 190, 218]]], ["Environmental study of the soft-shelled turtle farm was performed.", [["turtle", "ORGANISM", 40, 46], ["Environmental study", "TEST", 0, 19]]], ["Results: Of the 23 attendees, 8 persons met the case definition (attack rate = 35%).", [["persons", "ORGANISM", 32, 39], ["persons", "SPECIES", 32, 39], ["attack rate", "TEST", 65, 76]]], ["The most common presenting symptoms were myalgia (88%), fever (88%), and periorbital swelling (38%).", [["periorbital", "ANATOMY", 73, 84], ["myalgia", "DISEASE", 41, 48], ["fever", "DISEASE", 56, 61], ["periorbital swelling", "DISEASE", 73, 93], ["The most common presenting symptoms", "PROBLEM", 0, 35], ["myalgia", "PROBLEM", 41, 48], ["fever", "PROBLEM", 56, 61], ["periorbital swelling", "PROBLEM", 73, 93], ["periorbital", "ANATOMY", 73, 84], ["swelling", "OBSERVATION", 85, 93]]], ["All 8 patients sought medical care; five were hospitalised.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["Of the 7 patients who underwent blood test, all had moderate eosinophilia.", [["blood", "ANATOMY", 32, 37], ["eosinophilia", "DISEASE", 61, 73], ["patients", "ORGANISM", 9, 17], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["patients", "SPECIES", 9, 17], ["blood test", "TEST", 32, 42], ["moderate eosinophilia", "PROBLEM", 52, 73], ["moderate", "OBSERVATION_MODIFIER", 52, 60], ["eosinophilia", "OBSERVATION", 61, 73]]], ["All 8 patients' serum samples were strongly reactive to Trichinella excretory-secretory antigen.", [["serum samples", "ANATOMY", 16, 29], ["patients", "ORGANISM", 6, 14], ["serum samples", "ORGANISM_SUBSTANCE", 16, 29], ["excretory-secretory antigen", "GENE_OR_GENE_PRODUCT", 68, 95], ["Trichinella excretory-secretory antigen", "PROTEIN", 56, 95], ["patients", "SPECIES", 6, 14], ["All 8 patients' serum samples", "TEST", 0, 29], ["Trichinella excretory", "TEST", 56, 77], ["reactive", "OBSERVATION_MODIFIER", 44, 52]]], ["The only food item significantly associated with illness was the raw softshelled turtle meat (relative risk undefined; p = 0.005).", [["meat", "ANATOMY", 88, 92], ["illness", "DISEASE", 49, 56], ["turtle", "ORGANISM", 81, 87], ["meat", "ORGANISM_SUBDIVISION", 88, 92], ["illness", "PROBLEM", 49, 56]]], ["Traced back to the farm, histological examination of soft-shelled turtles was negative for Trichinella species.Conclusion:The most likely cause of this outbreak was consumption of raw soft-shelled turtle served in the festivals.", [["turtles", "ORGANISM", 66, 73], ["Trichinella species", "ORGANISM", 91, 110], ["histological examination of soft-shelled turtles", "TEST", 25, 73], ["Trichinella species", "PROBLEM", 91, 110], ["this outbreak", "PROBLEM", 147, 160], ["soft", "ANATOMY", 53, 57], ["negative for", "UNCERTAINTY", 78, 90], ["Trichinella species", "OBSERVATION", 91, 110], ["most likely", "UNCERTAINTY", 126, 137], ["shelled turtle", "OBSERVATION", 189, 203]]], ["This investigation indicates Taiwan is not free of trichinellosis.", [["trichinellosis", "DISEASE", 51, 65], ["This investigation", "TEST", 0, 18], ["trichinellosis", "PROBLEM", 51, 65], ["trichinellosis", "OBSERVATION", 51, 65]]], ["Prevention and control programs of trichinellosis should be established.", [["trichinellosis", "DISEASE", 35, 49], ["trichinellosis", "PROBLEM", 35, 49], ["trichinellosis", "OBSERVATION", 35, 49]]], ["The public should be aware of the risk of acquiring trichinellosis from consumption of raw soft-shelled turtle.M. Jager\u00b0, R. Pique, C. Vandenbroucke-Grauls, T. Hekker (Amsterdam, NL)Objective: To develop and evaluate a modified, rapid Giemsa staining procedure for detection of malaria parasites in blood smears.", [["blood", "ANATOMY", 299, 304], ["trichinellosis", "DISEASE", 52, 66], ["malaria parasites", "DISEASE", 278, 295], ["blood smears", "ORGANISM_SUBSTANCE", 299, 311], ["acquiring trichinellosis", "PROBLEM", 42, 66], ["rapid Giemsa staining procedure", "TREATMENT", 229, 260], ["malaria parasites in blood smears", "PROBLEM", 278, 311], ["trichinellosis", "OBSERVATION", 52, 66], ["shelled turtle", "OBSERVATION", 96, 110], ["malaria", "OBSERVATION", 278, 285]]], ["For this reason, many laboratories use the Giemsa stain.", [["the Giemsa stain", "TEST", 39, 55]]], ["Shorter Giemsa staining times have been reported previously, however, to our knowledge, the effect of 5 and 10 minute staining in different Giemsa dilutions have not been evaluated.Methods:The stock solution of Giemsa stain (Merck, Darmstadt, Germany) was used in different dilutions (1:10 and 1:5) and incubated for different lengths of time (10 min and 5 min).", [["Giemsa", "SIMPLE_CHEMICAL", 8, 14], ["Giemsa stain", "SIMPLE_CHEMICAL", 211, 223], ["Shorter Giemsa staining", "TEST", 0, 23], ["Giemsa dilutions", "TEST", 140, 156], ["Giemsa stain", "TEST", 211, 223]]], ["The staining effect was compared to our standard Giemsa stain (1:40, 45 min).", [["The staining effect", "PROBLEM", 0, 19]]], ["Sensitivity was determined by examining smears of P. falciparum from fresh and EDTA blood.", [["blood", "ANATOMY", 84, 89], ["P. falciparum", "DISEASE", 50, 63], ["EDTA", "CHEMICAL", 79, 83], ["P. falciparum", "ORGANISM", 50, 63], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["P. falciparum", "SPECIES", 50, 63], ["P. falciparum", "SPECIES", 50, 63], ["Sensitivity", "TEST", 0, 11], ["smears", "TEST", 40, 46], ["P. falciparum", "PROBLEM", 50, 63], ["EDTA blood", "TEST", 79, 89]]], ["The level of parasitaemia was followed in two patients admitted to our hospital with P. falciparum parasitaemia's of 21.5% and 28.8% (see table; patient A and B) by examination of blood smears taken at different time points after initiation of therapy.", [["blood", "ANATOMY", 180, 185], ["parasitaemia", "DISEASE", 13, 25], ["P. falciparum parasitaemia", "DISEASE", 85, 111], ["patients", "ORGANISM", 46, 54], ["P. falciparum", "ORGANISM", 85, 98], ["patient", "ORGANISM", 145, 152], ["B", "CANCER", 159, 160], ["blood", "ORGANISM_SUBSTANCE", 180, 185], ["patients", "SPECIES", 46, 54], ["P. falciparum", "SPECIES", 85, 98], ["patient", "SPECIES", 145, 152], ["P. falciparum", "SPECIES", 85, 98], ["parasitaemia", "PROBLEM", 13, 25], ["P. falciparum parasitaemia's", "TEST", 85, 113], ["examination of blood smears", "TEST", 165, 192], ["therapy", "TREATMENT", 244, 251], ["parasitaemia", "OBSERVATION", 13, 25]]], ["These samples were used to evaluate the different Giemsa dilutions and staining times.", [["samples", "ANATOMY", 6, 13], ["These samples", "TEST", 0, 13]]], ["Smears were read by three independent observers (a clinical microbiologist, a laboratory technician specialised in parasitology, and a resident in clinical microbiology).Results:In the table results of the three staining methods on blood from two patients from Ghana with high parasitaemia's on admission and during follow-up are shown.", [["Smears", "ANATOMY", 0, 6], ["blood", "ANATOMY", 232, 237], ["parasitaemia", "DISEASE", 277, 289], ["Smears", "ORGANISM_SUBSTANCE", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 232, 237], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 247, 255], ["Smears", "TEST", 0, 6], ["high parasitaemia's", "PROBLEM", 272, 291]]], ["All smears were equally easy to read and yielded parasite counts within internationally accepted ranges of variation (see United Kingdom National External Quality Assessment Service).", [["All smears", "TEST", 0, 10], ["parasite counts", "TEST", 49, 64]]], ["Conclusion: Staining blood smears for detection of Plasmodium falciparum parasites with a 1:5 dilution of Giemsa stain for five minutes provides easy to read slides and results comparable to those obtained with the standard Giemsa staining.", [["blood", "ANATOMY", 21, 26], ["Plasmodium falciparum", "DISEASE", 51, 72], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["Plasmodium falciparum", "ORGANISM", 51, 72], ["Plasmodium falciparum", "SPECIES", 51, 72], ["Plasmodium falciparum", "SPECIES", 51, 72], ["Staining blood smears", "TEST", 12, 33], ["Plasmodium falciparum parasites", "PROBLEM", 51, 82], ["Giemsa stain", "TEST", 106, 118]]], ["Advantage of the rapid method is the shorter turnaround time, disadvantage is the larger amount of stain used.O204 Innovation in diagnosis of gastrointestinal protozoan parasitesObjectives: Diarrhoeal diseases are common in developed and developing countries and are major causes of morbidity and mortality worldwide.", [["gastrointestinal protozoan parasites", "DISEASE", 142, 178], ["Diarrhoeal diseases", "DISEASE", 190, 209], ["the rapid method", "TREATMENT", 13, 29], ["gastrointestinal protozoan parasites", "PROBLEM", 142, 178], ["Diarrhoeal diseases", "PROBLEM", 190, 209], ["morbidity", "PROBLEM", 283, 292], ["gastrointestinal", "ANATOMY", 142, 158], ["protozoan parasites", "OBSERVATION", 159, 178], ["Diarrhoeal diseases", "OBSERVATION", 190, 209]]], ["The need to differentially diagnose protozoan parasites versus other gastrointestinal (GI) aetiologies is well recognized.", [["gastrointestinal", "ANATOMY", 69, 85], ["GI", "ANATOMY", 87, 89], ["protozoan parasites", "DISEASE", 36, 55], ["gastrointestinal (GI) aetiologies", "DISEASE", 69, 102], ["gastrointestinal", "ORGANISM_SUBDIVISION", 69, 85], ["GI", "ANATOMICAL_SYSTEM", 87, 89], ["protozoan parasites", "PROBLEM", 36, 55], ["other gastrointestinal (GI) aetiologies", "PROBLEM", 63, 102], ["protozoan", "OBSERVATION_MODIFIER", 36, 45], ["parasites", "OBSERVATION", 46, 55], ["gastrointestinal", "ANATOMY", 69, 85]]], ["The most common GI protozoan parasites infecting humans worldwide are considered to be Entamoeba histolytica, Giardia lamblia, Blastocystis hominis, Dientamoeba fragilis and Cryptosporidium spp.", [["protozoan parasites", "DISEASE", 19, 38], ["Entamoeba histolytica", "DISEASE", 87, 108], ["Giardia lamblia", "DISEASE", 110, 125], ["Blastocystis hominis", "DISEASE", 127, 147], ["Cryptosporidium spp", "DISEASE", 174, 193], ["GI protozoan parasites", "ORGANISM", 16, 38], ["humans", "ORGANISM", 49, 55], ["Entamoeba histolytica", "ORGANISM", 87, 108], ["Giardia lamblia", "ORGANISM", 110, 125], ["Blastocystis hominis", "ORGANISM", 127, 147], ["Dientamoeba fragilis", "ORGANISM", 149, 169], ["Cryptosporidium spp", "ORGANISM", 174, 193], ["humans", "SPECIES", 49, 55], ["Entamoeba histolytica", "SPECIES", 87, 108], ["Giardia lamblia", "SPECIES", 110, 125], ["Blastocystis hominis", "SPECIES", 127, 147], ["Dientamoeba fragilis", "SPECIES", 149, 169], ["Cryptosporidium spp", "SPECIES", 174, 193], ["humans", "SPECIES", 49, 55], ["Entamoeba histolytica", "SPECIES", 87, 108], ["Giardia lamblia", "SPECIES", 110, 125], ["Blastocystis hominis", "SPECIES", 127, 147], ["Dientamoeba fragilis", "SPECIES", 149, 169], ["The most common GI protozoan parasites", "PROBLEM", 0, 38], ["Entamoeba histolytica", "PROBLEM", 87, 108], ["Giardia lamblia", "PROBLEM", 110, 125], ["Blastocystis hominis", "PROBLEM", 127, 147], ["Dientamoeba fragilis", "PROBLEM", 149, 169], ["Cryptosporidium spp", "PROBLEM", 174, 193], ["protozoan parasites", "OBSERVATION", 19, 38], ["Giardia lamblia", "OBSERVATION", 110, 125], ["Blastocystis hominis", "OBSERVATION", 127, 147], ["Cryptosporidium spp", "OBSERVATION", 174, 193]]], ["Laboratory detection of these parasites is relying on microscopic analysis of stool samples and water concentrates, as well as enzyme immunoassay (EIA) tests.", [["stool samples", "ANATOMY", 78, 91], ["stool samples", "ORGANISM_SUBSTANCE", 78, 91], ["Laboratory detection", "TEST", 0, 20], ["these parasites", "PROBLEM", 24, 39], ["microscopic analysis", "TEST", 54, 74], ["stool samples", "TEST", 78, 91], ["water concentrates", "TREATMENT", 96, 114], ["enzyme immunoassay (EIA) tests", "TEST", 127, 157], ["parasites", "OBSERVATION", 30, 39]]], ["Utilising the microscopic examination usually results in underdetection of GI parasites, while usage of EIA is often not cost-effective.", [["GI parasites", "DISEASE", 75, 87], ["GI parasites", "CELL", 75, 87], ["the microscopic examination", "TEST", 10, 37], ["GI parasites", "PROBLEM", 75, 87], ["EIA", "TEST", 104, 107], ["GI", "ANATOMY", 75, 77], ["parasites", "OBSERVATION", 78, 87]]], ["This approach includes 3 major aspects: (1) the ability to detect a panel of all the above 5 organisms in one test kit, (2) the possibility to perform the diagnosis in two steps \u2212 first, simultaneous detection of these organisms without distinguishing between the different species for screening of large number of specimens, and second, distinctive detection of the specific aetiology in the positively-found specimens, and (3) the ability to apply EIA diagnosis in formalin-preserved specimens for all the mentioned parasites.", [["specimens", "ANATOMY", 315, 324], ["specimens", "ANATOMY", 410, 419], ["specimens", "ANATOMY", 486, 495], ["formalin", "CHEMICAL", 467, 475], ["a panel", "TEST", 66, 73], ["these organisms", "PROBLEM", 213, 228], ["screening", "TEST", 286, 295], ["specimens", "TEST", 315, 324], ["EIA diagnosis in formalin", "TEST", 450, 475], ["large", "OBSERVATION_MODIFIER", 299, 304]]], ["Results: Polyclonal antibodies were produced in-house based on native antigen extracts, recombinant antigens and synthetic peptides.", [["extracts", "ANATOMY", 78, 86], ["extracts", "ORGANISM_SUBSTANCE", 78, 86], ["Polyclonal antibodies", "PROTEIN", 9, 30], ["recombinant antigens", "PROTEIN", 88, 108], ["Polyclonal antibodies", "TEST", 9, 30], ["native antigen extracts", "TREATMENT", 63, 86], ["synthetic peptides", "TREATMENT", 113, 131]]], ["The resulted inventory of antibodies enabled finding the optimal combination that provided the desired performance parameters for separate detection of each of the parasites in fresh, frozen or formalin preserved faeces specimens.", [["specimens", "ANATOMY", 220, 229], ["formalin", "CHEMICAL", 194, 202], ["faeces", "ORGANISM", 213, 219], ["antibodies", "PROTEIN", 26, 36], ["antibodies", "PROBLEM", 26, 36], ["separate detection", "TEST", 130, 148], ["the parasites", "PROBLEM", 160, 173], ["parasites", "OBSERVATION", 164, 173]]], ["The analytical limit of detection and the performance in characterised clinical specimens were comparable to microscopy or to reference EIA, when available.", [["specimens", "ANATOMY", 80, 89], ["specimens", "CANCER", 80, 89], ["microscopy", "TEST", 109, 119], ["EIA", "TEST", 136, 139]]], ["The results show unique detection of E. histolytica in formalin-preserved specimens, which is comparable to detection in fresh specimens.", [["specimens", "ANATOMY", 74, 83], ["specimens", "ANATOMY", 127, 136], ["formalin", "CHEMICAL", 55, 63], ["E. histolytica", "ORGANISM", 37, 51], ["formalin", "SIMPLE_CHEMICAL", 55, 63], ["E. histolytica", "SPECIES", 37, 51], ["E. histolytica", "SPECIES", 37, 51], ["E. histolytica in formalin", "TEST", 37, 63], ["fresh specimens", "TEST", 121, 136], ["histolytica", "OBSERVATION_MODIFIER", 40, 51]]], ["Furthermore, we demonstrate simultaneous detection of the parasites without compromising performance characteristics in fresh or preserved specimens.Conclusions:The presented work is a paradigm of an innovative approach, expected to advance the diagnosis of protozoan parasites in GI patients, thus, enabling appropriate and cost-effective diagnosis and treatment.", [["specimens", "ANATOMY", 139, 148], ["protozoan parasites", "DISEASE", 258, 277], ["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 284, 292], ["the parasites", "PROBLEM", 54, 67], ["an innovative approach", "TREATMENT", 197, 219], ["protozoan parasites", "PROBLEM", 258, 277], ["treatment", "TREATMENT", 354, 363], ["parasites", "OBSERVATION", 58, 67], ["protozoan", "OBSERVATION_MODIFIER", 258, 267], ["parasites", "OBSERVATION", 268, 277]]], ["Objectives: Systemic administration of certain facultative anaerob bacteria to mice bearing solid tumours leads to accumulation in tumours compared to normal target organs, like spleen and liver, and to retardation of tumour growth.", [["solid tumours", "ANATOMY", 92, 105], ["tumours", "ANATOMY", 131, 138], ["organs", "ANATOMY", 165, 171], ["spleen", "ANATOMY", 178, 184], ["liver", "ANATOMY", 189, 194], ["tumour", "ANATOMY", 218, 224], ["solid tumours", "DISEASE", 92, 105], ["tumour", "DISEASE", 218, 224], ["mice", "ORGANISM", 79, 83], ["solid tumours", "CANCER", 92, 105], ["tumours", "CANCER", 131, 138], ["organs", "ORGAN", 165, 171], ["spleen", "ORGAN", 178, 184], ["liver", "ORGAN", 189, 194], ["tumour", "CANCER", 218, 224], ["mice", "SPECIES", 79, 83], ["mice", "SPECIES", 79, 83], ["Systemic administration", "TREATMENT", 12, 35], ["certain facultative anaerob bacteria", "TREATMENT", 39, 75], ["mice bearing solid tumours", "PROBLEM", 79, 105], ["accumulation in tumours", "PROBLEM", 115, 138], ["tumour growth", "PROBLEM", 218, 231], ["tumours", "OBSERVATION", 131, 138], ["spleen", "ANATOMY", 178, 184], ["liver", "ANATOMY", 189, 194], ["tumour", "OBSERVATION", 218, 224], ["growth", "OBSERVATION_MODIFIER", 225, 231]]], ["Salmonella enterica serovar Typhimurium (S. typhimurium) as well as Escherichia coli 1917 Nissle (EcN) are such bacteria.", [["Salmonella enterica serovar Typhimurium", "ORGANISM", 0, 39], ["S. typhimurium", "ORGANISM", 41, 55], ["Escherichia coli", "ORGANISM", 68, 84], ["Nissle", "GENE_OR_GENE_PRODUCT", 90, 96], ["EcN", "GENE_OR_GENE_PRODUCT", 98, 101], ["Salmonella", "SPECIES", 0, 10], ["enterica serovar Typhimurium", "SPECIES", 11, 39], ["S. typhimurium", "SPECIES", 41, 55], ["Escherichia coli", "SPECIES", 68, 84], ["Salmonella enterica serovar Typhimurium", "SPECIES", 0, 39], ["S. typhimurium", "SPECIES", 41, 55], ["Escherichia coli", "SPECIES", 68, 84], ["Salmonella enterica serovar Typhimurium", "PROBLEM", 0, 39], ["Escherichia coli", "PROBLEM", 68, 84], ["such bacteria", "PROBLEM", 107, 120], ["Escherichia coli", "OBSERVATION", 68, 84]]], ["Preliminary experiments showed that such bacteria that exhibit the ability to form biofilms in vitro might also do so in tumours.", [["tumours", "ANATOMY", 121, 128], ["tumours", "CANCER", 121, 128], ["Preliminary experiments", "TEST", 0, 23], ["such bacteria", "PROBLEM", 36, 49]]], ["In the present study this was systematically investigated.", [["the present study", "TEST", 3, 20]]], ["Methods: Biofilm formation of bacteria were detected on low-salt biofilm plates.", [["Biofilm", "ANATOMY", 9, 16], ["bacteria", "PROBLEM", 30, 38], ["low-salt biofilm plates", "TREATMENT", 56, 79], ["bacteria", "OBSERVATION_MODIFIER", 30, 38], ["biofilm plates", "OBSERVATION", 65, 79]]], ["Additionally, Salmonella-or E. coli-infected CT26tumours of BALB/c mice that were left untreated or were treated with anti-Gr1 to deplete neutrophilic granulocytes were removed two days post infection, fixed and prepared for electron microscope analysis.", [["neutrophilic granulocytes", "ANATOMY", 138, 163], ["infection", "DISEASE", 191, 200], ["Salmonella", "ORGANISM", 14, 24], ["E. coli-infected CT26tumours", "ORGANISM", 28, 56], ["BALB/c mice", "ORGANISM", 60, 71], ["Gr1", "GENE_OR_GENE_PRODUCT", 123, 126], ["neutrophilic granulocytes", "CELL", 138, 163], ["Gr1", "PROTEIN", 123, 126], ["neutrophilic granulocytes", "CELL_TYPE", 138, 163], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 67, 71], ["Salmonella", "PROBLEM", 14, 24], ["E.", "PROBLEM", 28, 30], ["BALB/c mice", "TREATMENT", 60, 71], ["anti-Gr1", "TREATMENT", 118, 126], ["neutrophilic granulocytes", "PROBLEM", 138, 163], ["infection", "PROBLEM", 191, 200], ["electron microscope analysis", "TEST", 225, 253], ["left", "ANATOMY_MODIFIER", 82, 86], ["neutrophilic granulocytes", "OBSERVATION", 138, 163], ["infection", "OBSERVATION", 191, 200]]], ["The expression of different genes which are probably involved in the biofilm formation were tested via Real-time PCR.", [["biofilm", "ANATOMY", 69, 76], ["the biofilm formation", "PROBLEM", 65, 86], ["different genes", "OBSERVATION", 18, 33], ["probably involved", "UNCERTAINTY", 44, 61]]], ["Results: When examined after colonising tumours S. typhimurium SL7207 and SL1344 as well as EcN are almost exclusively found extracellular although they are able to invade the CT26 cells in vitro.", [["tumours", "ANATOMY", 40, 47], ["extracellular", "ANATOMY", 125, 138], ["CT26 cells", "ANATOMY", 176, 186], ["tumours", "CANCER", 40, 47], ["S. typhimurium", "ORGANISM", 48, 62], ["SL7207", "ORGANISM", 63, 69], ["SL1344", "ORGANISM", 74, 80], ["EcN", "GENE_OR_GENE_PRODUCT", 92, 95], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 125, 138], ["CT26 cells", "CELL", 176, 186], ["EcN", "PROTEIN", 92, 95], ["CT26 cells", "CELL_LINE", 176, 186], ["S. typhimurium", "SPECIES", 48, 62], ["SL1344", "SPECIES", 74, 80], ["S. typhimurium", "SPECIES", 48, 62], ["SL1344", "SPECIES", 74, 80], ["colonising tumours S. typhimurium SL7207", "TEST", 29, 69], ["CT26 cells", "OBSERVATION", 176, 186]]], ["Interestingly, like in vitro all three bacteria form biofilms to various extend when residing in the tumours.", [["tumours", "ANATOMY", 101, 108], ["tumours", "CANCER", 101, 108], ["tumours", "OBSERVATION", 101, 108]]], ["This was followed in more detail for S. typhimurium SL7207.", [["S. typhimurium", "ORGANISM", 37, 51], ["SL7207", "ORGANISM", 52, 58], ["S. typhimurium", "SPECIES", 37, 51], ["S. typhimurium", "SPECIES", 37, 51]]], ["Biofilms were not formed by SL7207 when neutrophils had been removed by antibodies.", [["neutrophils", "ANATOMY", 40, 51], ["SL7207", "CHEMICAL", 28, 34], ["SL7207", "CHEMICAL", 28, 34], ["SL7207", "SIMPLE_CHEMICAL", 28, 34], ["neutrophils", "CELL", 40, 51], ["neutrophils", "CELL_TYPE", 40, 51], ["antibodies", "PROTEIN", 72, 82], ["Biofilms", "TEST", 0, 8], ["neutrophils", "TEST", 40, 51]]], ["In addition, when ardA a central switch for biofilm formation in the Salmonellla had been deleted no biofilms could be found.", [["biofilm", "ANATOMY", 44, 51], ["a central switch", "TREATMENT", 23, 39], ["biofilm formation", "TREATMENT", 44, 61], ["biofilms", "PROBLEM", 101, 109]]], ["Importantly, now bacteria could be found intracellularly most likely in neutrophilic granulocytes.", [["neutrophilic granulocytes", "ANATOMY", 72, 97], ["neutrophilic granulocytes", "CELL", 72, 97], ["neutrophilic granulocytes", "CELL_TYPE", 72, 97], ["bacteria", "PROBLEM", 17, 25], ["neutrophilic granulocytes", "PROBLEM", 72, 97], ["bacteria", "OBSERVATION", 17, 25], ["most likely", "UNCERTAINTY", 57, 68], ["neutrophilic granulocytes", "OBSERVATION", 72, 97]]], ["Conclusion: The formation of biofilms by facultative anaerobic bacteria when residing in solid tumours is a novel and surprising finding.", [["solid tumours", "ANATOMY", 89, 102], ["solid tumours", "CANCER", 89, 102], ["biofilms", "PROBLEM", 29, 37], ["facultative anaerobic bacteria", "PROBLEM", 41, 71], ["solid tumours", "PROBLEM", 89, 102], ["solid tumours", "OBSERVATION", 89, 102]]], ["When neutrophils were removed, no biofilms are formed, while uptake into neutrophils is allowed when the ability of the bacteria to form biofilms was blocked.", [["neutrophils", "ANATOMY", 5, 16], ["biofilms", "ANATOMY", 34, 42], ["neutrophils", "ANATOMY", 73, 84], ["neutrophils", "CELL", 5, 16], ["neutrophils", "CELL", 73, 84], ["neutrophils", "CELL_TYPE", 5, 16], ["neutrophils", "CELL_TYPE", 73, 84], ["neutrophils", "TEST", 5, 16], ["biofilms", "PROBLEM", 34, 42], ["neutrophils", "TEST", 73, 84], ["the bacteria", "PROBLEM", 116, 128], ["biofilms", "PROBLEM", 137, 145]]], ["Hence, it appears that the bacteria use biofilm formation as a defence system against the immune system of the host.J. Findlay, T. Schneiders\u00b0(Edinburgh, UK)Objectives: RamA is an AraC/XylS family transcriptional activator found in Klebsiella pneumoniae, Salmonella spp. and Enterobacter spp., the overexpression of which is associated with an MDR phenotype.J. Findlay, T. Schneiders\u00b0(Edinburgh, UK)Recently a tetR-like gene that lies upstream of ramA, known as ramR, has been identified as a repressor of ramA.", [["biofilm", "ANATOMY", 40, 47], ["immune system", "ANATOMY", 90, 103], ["AraC", "CHEMICAL", 180, 184], ["immune system", "ANATOMICAL_SYSTEM", 90, 103], ["RamA", "GENE_OR_GENE_PRODUCT", 169, 173], ["AraC", "GENE_OR_GENE_PRODUCT", 180, 184], ["XylS", "GENE_OR_GENE_PRODUCT", 185, 189], ["Klebsiella pneumoniae", "ORGANISM", 232, 253], ["Salmonella spp.", "ORGANISM", 255, 270], ["Enterobacter spp.", "ORGANISM", 275, 292], ["tetR", "GENE_OR_GENE_PRODUCT", 410, 414], ["ramA", "GENE_OR_GENE_PRODUCT", 447, 451], ["ramR", "GENE_OR_GENE_PRODUCT", 462, 466], ["ramA", "GENE_OR_GENE_PRODUCT", 506, 510], ["AraC/XylS family transcriptional activator", "PROTEIN", 180, 222], ["tetR-like gene", "DNA", 410, 424], ["ramA", "DNA", 447, 451], ["ramR", "DNA", 462, 466], ["ramA", "PROTEIN", 506, 510], ["Klebsiella pneumoniae", "SPECIES", 232, 253], ["Salmonella spp.", "SPECIES", 255, 270], ["Enterobacter spp.", "SPECIES", 275, 292], ["Klebsiella pneumoniae", "SPECIES", 232, 253], ["Salmonella spp.", "SPECIES", 255, 270], ["Enterobacter spp.", "SPECIES", 275, 292], ["the bacteria", "PROBLEM", 23, 35], ["biofilm formation", "TREATMENT", 40, 57], ["an AraC/XylS family transcriptional activator", "TREATMENT", 177, 222], ["Klebsiella pneumoniae", "PROBLEM", 232, 253], ["Salmonella spp.", "PROBLEM", 255, 270], ["Enterobacter spp.", "PROBLEM", 275, 292], ["an MDR phenotype", "PROBLEM", 341, 357], ["bacteria", "OBSERVATION", 27, 35], ["Klebsiella pneumoniae", "OBSERVATION", 232, 253], ["MDR phenotype", "OBSERVATION", 344, 357]]], ["K. pneumoniae Kp342 is a diazotrophic endophyte strain which has been reported to exhibit notable resistance to antibiotics.", [["K", "CHEMICAL", 0, 1], ["Kp342", "CHEMICAL", 14, 19], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["pneumoniae", "ORGANISM", 3, 13], ["Kp342", "GENE_OR_GENE_PRODUCT", 14, 19], ["pneumoniae", "SPECIES", 3, 13], ["pneumoniae", "SPECIES", 3, 13], ["K", "TEST", 0, 1], ["pneumoniae", "PROBLEM", 3, 13], ["a diazotrophic endophyte strain", "PROBLEM", 23, 54], ["antibiotics", "TREATMENT", 112, 123], ["diazotrophic", "OBSERVATION_MODIFIER", 25, 37], ["endophyte strain", "OBSERVATION", 38, 54], ["notable", "OBSERVATION_MODIFIER", 90, 97], ["resistance", "OBSERVATION", 98, 108]]], ["Despite its MDR phenotype Kp342 has been shown to exhibit attenuated pathogenicity in mouse models in comparison to clinical K. pneumoniae strains.", [["Kp342", "CHEMICAL", 26, 31], ["Kp342", "GENE_OR_GENE_PRODUCT", 26, 31], ["mouse", "ORGANISM", 86, 91], ["K. pneumoniae", "ORGANISM", 125, 138], ["strains", "ORGANISM", 139, 146], ["Kp342", "PROTEIN", 26, 31], ["mouse", "SPECIES", 86, 91], ["K. pneumoniae", "SPECIES", 125, 138], ["mouse", "SPECIES", 86, 91], ["K. pneumoniae", "SPECIES", 125, 138], ["attenuated pathogenicity in mouse models", "PROBLEM", 58, 98], ["clinical K. pneumoniae strains", "PROBLEM", 116, 146], ["attenuated", "OBSERVATION_MODIFIER", 58, 68], ["pathogenicity", "OBSERVATION", 69, 82], ["mouse models", "OBSERVATION", 86, 98]]], ["The aims of this study were to: determine the levels of ramA expression and establish its role in Kp342's MDR phenotype; determine the effect of ramR complementation on ramA expression and antibiotic susceptibility.", [["ramA", "GENE_OR_GENE_PRODUCT", 56, 60], ["ramR", "GENE_OR_GENE_PRODUCT", 145, 149], ["ramA", "GENE_OR_GENE_PRODUCT", 169, 173], ["ramA", "PROTEIN", 56, 60], ["ramR", "PROTEIN", 145, 149], ["ramA", "PROTEIN", 169, 173], ["this study", "TEST", 12, 22], ["MDR phenotype", "PROBLEM", 106, 119], ["ramR complementation", "PROBLEM", 145, 165], ["antibiotic susceptibility", "PROBLEM", 189, 214]]], ["Methods: Genome and sequence analysis performed in K. pneumoniae strain Kp342 demonstrated a 96 bp deletion within the ramR gene.", [["K. pneumoniae", "ORGANISM", 51, 64], ["strain", "ORGANISM", 65, 71], ["Kp342", "ORGANISM", 72, 77], ["ramR", "GENE_OR_GENE_PRODUCT", 119, 123], ["96 bp deletion", "DNA", 93, 107], ["ramR gene", "DNA", 119, 128], ["K. pneumoniae", "SPECIES", 51, 64], ["K. pneumoniae", "SPECIES", 51, 64], ["Genome and sequence analysis", "TEST", 9, 37], ["K. pneumoniae strain", "TEST", 51, 71], ["a 96 bp deletion", "PROBLEM", 91, 107]]], ["Cloning and complementation with full size wild type ramR was performed in Kp342 (hereby known as Kp342/ramR).", [["ramR", "GENE_OR_GENE_PRODUCT", 53, 57], ["Kp342", "GENE_OR_GENE_PRODUCT", 75, 80], ["Kp342", "GENE_OR_GENE_PRODUCT", 98, 103], ["ramR", "GENE_OR_GENE_PRODUCT", 104, 108], ["ramR", "PROTEIN", 53, 57], ["Kp342", "PROTEIN", 75, 80], ["Kp342", "PROTEIN", 98, 103], ["ramR", "PROTEIN", 104, 108]]], ["RT-PCR was used to assess levels of gene expression which were subsequently quantified using Bio-Rad Quantity One software.", [["RT-PCR", "TEST", 0, 6], ["gene expression", "PROBLEM", 36, 51]]], ["MIC testing was performed against chloramphenicol (Cm), norfloxacin (Nor) and tetracycline (Tet) according to BSAC guidelines.", [["MIC", "CHEMICAL", 0, 3], ["chloramphenicol", "CHEMICAL", 34, 49], ["Cm", "CHEMICAL", 51, 53], ["norfloxacin", "CHEMICAL", 56, 67], ["Nor", "CHEMICAL", 69, 72], ["tetracycline", "CHEMICAL", 78, 90], ["Tet", "CHEMICAL", 92, 95], ["chloramphenicol", "CHEMICAL", 34, 49], ["Cm", "CHEMICAL", 51, 53], ["norfloxacin", "CHEMICAL", 56, 67], ["Nor", "CHEMICAL", 69, 72], ["tetracycline", "CHEMICAL", 78, 90], ["Tet", "CHEMICAL", 92, 95], ["chloramphenicol", "SIMPLE_CHEMICAL", 34, 49], ["Cm", "SIMPLE_CHEMICAL", 51, 53], ["norfloxacin", "SIMPLE_CHEMICAL", 56, 67], ["Nor", "SIMPLE_CHEMICAL", 69, 72], ["tetracycline", "SIMPLE_CHEMICAL", 78, 90], ["Tet", "SIMPLE_CHEMICAL", 92, 95], ["MIC testing", "TEST", 0, 11], ["chloramphenicol", "TREATMENT", 34, 49], ["norfloxacin", "TREATMENT", 56, 67], ["tetracycline", "TREATMENT", 78, 90]]], ["Biofilm formation was measured using a modified protocol of O'Toole and Kolter.", [["Biofilm", "ANATOMY", 0, 7], ["O'Toole", "SIMPLE_CHEMICAL", 60, 67], ["Biofilm formation", "TREATMENT", 0, 17], ["a modified protocol of O'Toole", "TREATMENT", 37, 67], ["Kolter", "TREATMENT", 72, 78]]], ["Results: Kp342 containing the mutated ramR gene (96 bp deletion) was shown to overexpress ramA and the putative outer membrane protein romA.", [["outer membrane", "ANATOMY", 112, 126], ["Kp342", "GENE_OR_GENE_PRODUCT", 9, 14], ["ramR", "GENE_OR_GENE_PRODUCT", 38, 42], ["ramA", "GENE_OR_GENE_PRODUCT", 90, 94], ["outer membrane", "CELLULAR_COMPONENT", 112, 126], ["romA", "GENE_OR_GENE_PRODUCT", 135, 139], ["Kp342", "DNA", 9, 14], ["mutated ramR gene", "DNA", 30, 47], ["96 bp deletion", "DNA", 49, 63], ["ramA", "PROTEIN", 90, 94], ["putative outer membrane protein", "PROTEIN", 103, 134], ["romA", "PROTEIN", 135, 139], ["the mutated ramR gene", "TREATMENT", 26, 47], ["bp deletion", "TEST", 52, 63], ["protein romA", "OBSERVATION", 127, 139]]], ["Complementation of the ramR gene resulted in the repression of both ramA and romA transcription by 3\u22124 fold.", [["ramR", "GENE_OR_GENE_PRODUCT", 23, 27], ["ramA", "GENE_OR_GENE_PRODUCT", 68, 72], ["romA", "GENE_OR_GENE_PRODUCT", 77, 81], ["ramR gene", "DNA", 23, 32], ["ramA", "PROTEIN", 68, 72], ["romA", "DNA", 77, 81]]], ["Interestingly, the ramR complemented strain demonstrated increased biofilm formation (up to 9-fold increase) over a 72 hour period in both LB and M9 medium after static growth at 37\u00baC.", [["biofilm", "ANATOMY", 67, 74], ["ramR", "GENE_OR_GENE_PRODUCT", 19, 23], ["ramR", "PROTEIN", 19, 23], ["the ramR complemented strain", "TEST", 15, 43], ["increased biofilm formation", "PROBLEM", 57, 84], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["biofilm formation", "OBSERVATION", 67, 84], ["both", "ANATOMY_MODIFIER", 134, 138], ["LB", "ANATOMY", 139, 141]]], ["MICs of the tested antibiotics were reduced up to 16-fold in Kp342/ramR compared to the ramR mutated Kp342.J. Findlay, T. Schneiders\u00b0(Edinburgh, UK)Conclusions: This result demonstrates that ramR acts as a repressor of both ramA and putative outer membrane protein romA thereby increasing its susceptibility to antibiotics.", [["outer membrane", "ANATOMY", 242, 256], ["Kp342", "CHEMICAL", 101, 106], ["Kp342", "GENE_OR_GENE_PRODUCT", 61, 66], ["ramR", "GENE_OR_GENE_PRODUCT", 67, 71], ["ramR", "GENE_OR_GENE_PRODUCT", 191, 195], ["ramA", "GENE_OR_GENE_PRODUCT", 224, 228], ["outer membrane", "CELLULAR_COMPONENT", 242, 256], ["romA", "GENE_OR_GENE_PRODUCT", 265, 269], ["Kp342", "PROTEIN", 61, 66], ["ramR", "PROTEIN", 67, 71], ["ramR", "PROTEIN", 88, 92], ["ramR", "PROTEIN", 191, 195], ["ramA", "PROTEIN", 224, 228], ["putative outer membrane protein", "PROTEIN", 233, 264], ["romA", "PROTEIN", 265, 269], ["the tested antibiotics", "TREATMENT", 8, 30], ["putative outer membrane protein romA", "TREATMENT", 233, 269], ["antibiotics", "TREATMENT", 311, 322], ["outer membrane", "OBSERVATION", 242, 256], ["protein romA", "OBSERVATION", 257, 269]]], ["However the restoration of a functional ramR in Kp342 also increases biofilm formation significantly, suggesting that ramR plays a role in the regulation of biofilm formation genes and possibly bacterial virulence.", [["biofilm", "ANATOMY", 69, 76], ["biofilm", "ANATOMY", 157, 164], ["Kp342", "CHEMICAL", 48, 53], ["ramR", "CHEMICAL", 118, 122], ["ramR", "GENE_OR_GENE_PRODUCT", 40, 44], ["Kp342", "GENE_OR_GENE_PRODUCT", 48, 53], ["biofilm", "PATHOLOGICAL_FORMATION", 69, 76], ["ramR", "GENE_OR_GENE_PRODUCT", 118, 122], ["ramR", "PROTEIN", 40, 44], ["Kp342", "PROTEIN", 48, 53], ["ramR", "PROTEIN", 118, 122], ["biofilm formation genes", "DNA", 157, 180], ["a functional ramR in Kp342", "PROBLEM", 27, 53], ["biofilm formation", "PROBLEM", 69, 86], ["biofilm formation genes", "PROBLEM", 157, 180], ["bacterial virulence", "PROBLEM", 194, 213], ["functional ramR", "OBSERVATION", 29, 44], ["increases", "OBSERVATION_MODIFIER", 59, 68], ["biofilm", "OBSERVATION_MODIFIER", 69, 76], ["biofilm formation", "OBSERVATION", 157, 174], ["possibly", "UNCERTAINTY", 185, 193], ["bacterial virulence", "OBSERVATION", 194, 213]]], ["Rifampicin showed the highest activity on biofilm matrix and bacteria in Sa and Pa biofilms.", [["biofilm matrix", "ANATOMY", 42, 56], ["Rifampicin", "CHEMICAL", 0, 10], ["Rifampicin", "CHEMICAL", 0, 10], ["Rifampicin", "SIMPLE_CHEMICAL", 0, 10], ["biofilm matrix", "CELLULAR_COMPONENT", 42, 56], ["Rifampicin", "TREATMENT", 0, 10], ["biofilm matrix", "TREATMENT", 42, 56], ["bacteria in Sa and Pa biofilms", "PROBLEM", 61, 91], ["highest activity", "OBSERVATION", 22, 38], ["bacteria", "OBSERVATION", 61, 69], ["Sa", "ANATOMY", 73, 75]]], ["Results also indicated that biofilm viable mass was more susceptible to treatment than the biofilm matrix, which is mainly responsible for biofilm persistence.", [["biofilm", "ANATOMY", 28, 35], ["biofilm matrix", "ANATOMY", 91, 105], ["biofilm", "ANATOMY", 139, 146], ["biofilm matrix", "CELLULAR_COMPONENT", 91, 105], ["biofilm viable mass", "PROBLEM", 28, 47], ["the biofilm matrix", "TREATMENT", 87, 105], ["biofilm persistence", "PROBLEM", 139, 158], ["biofilm", "OBSERVATION_MODIFIER", 28, 35], ["mass", "OBSERVATION", 43, 47], ["biofilm matrix", "OBSERVATION", 91, 105], ["mainly responsible for", "UNCERTAINTY", 116, 138], ["biofilm persistence", "OBSERVATION", 139, 158]]], ["Further research should specifically focus on compounds destroying matrix and which can be used as an adjunct to antibiotic therapy.Reference(s)[ Objectives: Staphylococcus epidermidis is a common cause of foreignbody infections (FBI) because of its ability to form biofilms.", [["matrix", "ANATOMY", 67, 73], ["foreignbody", "ANATOMY", 206, 217], ["Staphylococcus epidermidis", "DISEASE", 158, 184], ["foreignbody infections", "DISEASE", 206, 228], ["matrix", "CELLULAR_COMPONENT", 67, 73], ["Staphylococcus epidermidis", "ORGANISM", 158, 184], ["Staphylococcus epidermidis", "SPECIES", 158, 184], ["Staphylococcus epidermidis", "SPECIES", 158, 184], ["compounds destroying matrix", "TREATMENT", 46, 73], ["antibiotic therapy", "TREATMENT", 113, 131], ["Staphylococcus epidermidis", "PROBLEM", 158, 184], ["foreignbody infections", "PROBLEM", 206, 228], ["Staphylococcus epidermidis", "OBSERVATION", 158, 184], ["infections", "OBSERVATION", 218, 228]]], ["Biofilms are very resistant to antibiotics.", [["Biofilms", "PROBLEM", 0, 8], ["antibiotics", "TREATMENT", 31, 42], ["resistant", "OBSERVATION", 18, 27]]], ["Active and passive immunisation against biofilm-associated bacterial antigens may be an alternative.", [["biofilm", "ANATOMY", 40, 47], ["passive immunisation", "TREATMENT", 11, 31], ["biofilm", "PROBLEM", 40, 47], ["bacterial antigens", "PROBLEM", 59, 77]]], ["We studied the effect of immunisation against the LPXTG protein SesC in S. epidermidis biofilms in vitro and in vivo.", [["biofilms", "ANATOMY", 87, 95], ["LPXTG", "GENE_OR_GENE_PRODUCT", 50, 55], ["SesC", "GENE_OR_GENE_PRODUCT", 64, 68], ["S. epidermidis", "ORGANISM", 72, 86], ["LPXTG protein", "PROTEIN", 50, 63], ["SesC", "PROTEIN", 64, 68], ["S. epidermidis", "SPECIES", 72, 86], ["S. epidermidis", "SPECIES", 72, 86], ["immunisation", "TREATMENT", 25, 37], ["the LPXTG protein SesC", "TREATMENT", 46, 68], ["epidermidis biofilms", "TREATMENT", 75, 95], ["epidermidis biofilms", "OBSERVATION", 75, 95]]], ["We previously reported that SesC is present in all S. epidermidis strains tested.", [["SesC", "CHEMICAL", 28, 32], ["SesC", "GENE_OR_GENE_PRODUCT", 28, 32], ["S. epidermidis strains", "ORGANISM", 51, 73], ["SesC", "PROTEIN", 28, 32], ["S. epidermidis", "SPECIES", 51, 65], ["S. epidermidis", "SPECIES", 51, 65], ["epidermidis strains", "PROBLEM", 54, 73], ["epidermidis strains", "OBSERVATION", 54, 73]]], ["SesC is mainly expressed during the early and late FBI and at a higher level in sessile cells than in planktonic cells.", [["cells", "ANATOMY", 88, 93], ["cells", "ANATOMY", 113, 118], ["SesC", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 88, 93], ["planktonic cells", "CELL", 102, 118], ["SesC", "PROTEIN", 0, 4], ["sessile cells", "CELL_TYPE", 80, 93], ["planktonic cells", "CELL_TYPE", 102, 118], ["sessile cells", "OBSERVATION", 80, 93], ["planktonic cells", "OBSERVATION", 102, 118]]], ["Methods: We used rabbit polyclonal anti-SesC-IgGs (4 mg/ml) to study biofilm inhibition in vitro and in vivo in our rat model (50 mg IgG per rat) on 1-day old biofilms.", [["biofilm", "ANATOMY", 69, 76], ["biofilms", "ANATOMY", 159, 167], ["rabbit", "ORGANISM", 17, 23], ["rat", "ORGANISM", 116, 119], ["rat", "ORGANISM", 141, 144], ["anti-SesC", "PROTEIN", 35, 44], ["IgGs", "PROTEIN", 45, 49], ["rabbit", "SPECIES", 17, 23], ["rat", "SPECIES", 116, 119], ["rat", "SPECIES", 141, 144], ["rabbit", "SPECIES", 17, 23], ["rat", "SPECIES", 116, 119], ["rabbit polyclonal anti-SesC-IgGs", "TREATMENT", 17, 49], ["our rat model", "TREATMENT", 112, 125]]], ["We also vaccinated rats twice with SesC according to standard protocols.", [["rats", "ORGANISM", 19, 23], ["rats", "SPECIES", 19, 23]]], ["Serum samples taken at day 0 and 2 weeks after the 1st and 2nd immunisation were tested by ELISA and showed an increase in anti-SesC antibody levels.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["SesC", "GENE_OR_GENE_PRODUCT", 128, 132], ["SesC antibody", "PROTEIN", 128, 141], ["Serum samples", "TEST", 0, 13], ["2nd immunisation", "TEST", 59, 75], ["ELISA", "TEST", 91, 96], ["an increase in anti-SesC antibody levels", "PROBLEM", 108, 148], ["increase", "OBSERVATION_MODIFIER", 111, 119]]], ["S. epidermidis strains 10b and 1457 are biofilm forming strains and have been described before.", [["S. epidermidis strains 10b", "ORGANISM", 0, 26], ["S. epidermidis", "SPECIES", 0, 14], ["S. epidermidis", "SPECIES", 0, 14], ["S. epidermidis strains 10b", "PROBLEM", 0, 26], ["biofilm forming strains", "PROBLEM", 40, 63], ["epidermidis", "OBSERVATION", 3, 14]]], ["For in vitro experiments, S. epidermidis 10b or 1457 were mixed with anti-SesC-IgGs and incubated for 2 hours at 4\u00baC.", [["S. epidermidis 10b", "ORGANISM", 26, 44], ["anti-SesC-IgGs", "GENE_OR_GENE_PRODUCT", 69, 83], ["anti-SesC", "PROTEIN", 69, 78], ["IgGs", "PROTEIN", 79, 83], ["S. epidermidis", "SPECIES", 26, 40], ["S. epidermidis", "SPECIES", 26, 40], ["S. epidermidis 10b", "TREATMENT", 26, 44], ["anti-SesC-IgGs", "TREATMENT", 69, 83]]], ["Subsequently 10 6 cells were added to each well.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23]]], ["After 24 h at 37\u00baC biofilms were washed and stained with crystal violet and OD595 was measured.", [["OD595", "CHEMICAL", 76, 81], ["OD595", "SIMPLE_CHEMICAL", 76, 81], ["C biofilms", "PROBLEM", 17, 27], ["crystal violet", "TEST", 57, 71]]], ["For in vivo experiments, catheter fragments were pre-incubated with S. epidermidis 10b and implanted subcutaneously in each rat.", [["catheter fragments", "ANATOMY", 25, 43], ["subcutaneously", "ANATOMY", 101, 115], ["S. epidermidis 10b", "ORGANISM", 68, 86], ["rat", "ORGANISM", 124, 127], ["S. epidermidis", "SPECIES", 68, 82], ["rat", "SPECIES", 124, 127], ["S. epidermidis", "SPECIES", 68, 82], ["rat", "SPECIES", 124, 127], ["catheter fragments", "TREATMENT", 25, 43], ["S. epidermidis 10b", "TREATMENT", 68, 86], ["catheter fragments", "OBSERVATION", 25, 43], ["epidermidis", "OBSERVATION", 71, 82]]], ["Results: Our data show that rabbit anti-SesC-IgGs inhibit in vitro biofilm formation by S. epidermidis strains 10b and 1457 by 74% and 65%, respectively (n = 9).", [["biofilm", "ANATOMY", 67, 74], ["rabbit", "ORGANISM", 28, 34], ["anti-SesC-IgGs", "GENE_OR_GENE_PRODUCT", 35, 49], ["S. epidermidis strains 10b", "ORGANISM", 88, 114], ["anti-SesC", "PROTEIN", 35, 44], ["IgGs", "PROTEIN", 45, 49], ["rabbit", "SPECIES", 28, 34], ["S. epidermidis", "SPECIES", 88, 102], ["rabbit", "SPECIES", 28, 34], ["S. epidermidis", "SPECIES", 88, 102], ["Our data", "TEST", 9, 17], ["rabbit anti-SesC", "TREATMENT", 28, 44], ["IgGs", "TREATMENT", 45, 49], ["vitro biofilm formation", "TREATMENT", 61, 84], ["S. epidermidis strains", "TEST", 88, 110]]], ["In the in vivo rat model, rabbit anti-SesC-IgGs reduced the bacteria in a 1-day old biofilm 60-fold (n = 18).", [["rat", "ORGANISM", 15, 18], ["rabbit", "ORGANISM", 26, 32], ["anti-SesC-IgGs", "GENE_OR_GENE_PRODUCT", 33, 47], ["anti-SesC", "PROTEIN", 33, 42], ["IgGs", "PROTEIN", 43, 47], ["rat", "SPECIES", 15, 18], ["rabbit", "SPECIES", 26, 32], ["rat", "SPECIES", 15, 18], ["rabbit", "SPECIES", 26, 32], ["rabbit anti-SesC", "TEST", 26, 42], ["the bacteria", "PROBLEM", 56, 68], ["bacteria", "OBSERVATION_MODIFIER", 60, 68]]], ["Active immunisation with recombinant SesC led to a 10-fold reduction of CFU compared to control rats in 1 day-old biofilms (n = 10).", [["SesC", "CHEMICAL", 37, 41], ["SesC", "GENE_OR_GENE_PRODUCT", 37, 41], ["rats", "ORGANISM", 96, 100], ["recombinant SesC", "PROTEIN", 25, 41], ["rats", "SPECIES", 96, 100], ["a 10-fold reduction of CFU", "TREATMENT", 49, 75], ["old biofilms", "PROBLEM", 110, 122]]], ["After 3 days, the reduction in biofilm-associated bacteria in the immunised rats was 15-fold (n = 10) (Fig 1.) .", [["biofilm", "ANATOMY", 31, 38], ["rats", "ORGANISM", 76, 80], ["rats", "SPECIES", 76, 80], ["the reduction in biofilm-associated bacteria", "PROBLEM", 14, 58], ["the immunised rats", "TEST", 62, 80], ["reduction", "OBSERVATION_MODIFIER", 18, 27], ["bacteria", "OBSERVATION", 50, 58]]], ["Conclusion: SesC represents a promising target for prevention of S. epidermidis biofilm formation.", [["biofilm", "ANATOMY", 80, 87], ["SesC", "GENE_OR_GENE_PRODUCT", 12, 16], ["S. epidermidis", "ORGANISM", 65, 79], ["biofilm", "PATHOLOGICAL_FORMATION", 80, 87], ["SesC", "PROTEIN", 12, 16], ["S. epidermidis", "SPECIES", 65, 79], ["S. epidermidis", "SPECIES", 65, 79], ["S. epidermidis biofilm formation", "PROBLEM", 65, 97], ["epidermidis biofilm", "OBSERVATION", 68, 87]]], ["The higher effect of passive immunisation compared with active immunisation is probably due to the subcutaneous injection of anti-SesC-IgGs at the place of catheter insertion.", [["subcutaneous", "ANATOMY", 99, 111], ["catheter", "ANATOMY", 156, 164], ["anti-SesC-IgGs", "GENE_OR_GENE_PRODUCT", 125, 139], ["catheter", "IMMATERIAL_ANATOMICAL_ENTITY", 156, 164], ["anti-SesC", "PROTEIN", 125, 134], ["IgGs", "PROTEIN", 135, 139], ["passive immunisation", "TREATMENT", 21, 41], ["active immunisation", "TREATMENT", 56, 75], ["the subcutaneous injection of anti-SesC-IgGs", "TREATMENT", 95, 139], ["catheter insertion", "TREATMENT", 156, 174], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["effect", "OBSERVATION_MODIFIER", 11, 17], ["passive", "OBSERVATION_MODIFIER", 21, 28], ["immunisation", "OBSERVATION", 29, 41], ["probably due to", "UNCERTAINTY", 79, 94], ["catheter", "OBSERVATION", 156, 164]]], ["Objectives: Staphylococcus epidermidis has emerged as a pathogen associated with infections of implanted medical devices impeding their long-term use.", [["Staphylococcus epidermidis", "DISEASE", 12, 38], ["infections", "DISEASE", 81, 91], ["Staphylococcus epidermidis", "ORGANISM", 12, 38], ["Staphylococcus epidermidis", "SPECIES", 12, 38], ["Staphylococcus epidermidis", "SPECIES", 12, 38], ["Staphylococcus epidermidis", "PROBLEM", 12, 38], ["a pathogen", "PROBLEM", 54, 64], ["implanted medical devices", "TREATMENT", 95, 120], ["Staphylococcus epidermidis", "OBSERVATION", 12, 38]]], ["Characteristics of S. epidermidis that allow persistence of infection are the ability of bacteria to adhere to surfaces in multilayered cell clusters, followed by the production of a mucoid substance more commonly known as slime, encoded by the ica operon.", [["cell", "ANATOMY", 136, 140], ["infection", "DISEASE", 60, 69], ["S. epidermidis", "ORGANISM", 19, 33], ["cell clusters", "CELL", 136, 149], ["ica", "GENE_OR_GENE_PRODUCT", 245, 248], ["ica operon", "DNA", 245, 255], ["S. epidermidis", "SPECIES", 19, 33], ["S. epidermidis", "SPECIES", 19, 33], ["S. epidermidis", "PROBLEM", 19, 33], ["infection", "PROBLEM", 60, 69], ["bacteria", "PROBLEM", 89, 97], ["a mucoid substance", "PROBLEM", 181, 199], ["the ica operon", "TREATMENT", 241, 255], ["epidermidis", "OBSERVATION", 22, 33], ["infection", "OBSERVATION", 60, 69], ["multilayered cell clusters", "OBSERVATION", 123, 149]]], ["The adherent bacteria and slime are collectively known as biofilm.", [["slime", "ANATOMY", 26, 31], ["biofilm", "ANATOMY", 58, 65], ["The adherent bacteria", "PROBLEM", 0, 21], ["adherent", "OBSERVATION_MODIFIER", 4, 12], ["bacteria", "OBSERVATION", 13, 21]]], ["The coupled effects of specific chemical terminal surface groups and flow conditions on slime production and biofilm formation by S. epidermidis were investigated in correlation to the expression of two genes of the ica operon.", [["surface", "ANATOMY", 50, 57], ["biofilm", "ANATOMY", 109, 116], ["S. epidermidis", "ORGANISM", 130, 144], ["ica", "GENE_OR_GENE_PRODUCT", 216, 219], ["ica operon", "DNA", 216, 226], ["S. epidermidis", "SPECIES", 130, 144], ["S. epidermidis", "SPECIES", 130, 144], ["specific chemical terminal surface groups", "TREATMENT", 23, 64], ["flow conditions", "PROBLEM", 69, 84], ["slime production", "TEST", 88, 104], ["biofilm formation", "PROBLEM", 109, 126], ["S. epidermidis", "PROBLEM", 130, 144], ["the ica operon", "TREATMENT", 212, 226], ["chemical", "OBSERVATION_MODIFIER", 32, 40], ["terminal", "OBSERVATION_MODIFIER", 41, 49], ["surface", "OBSERVATION_MODIFIER", 50, 57], ["flow conditions", "OBSERVATION", 69, 84], ["epidermidis", "OBSERVATION", 133, 144]]], ["Methods: Reference control strains (ATCC35984, slime-positive and ATCC12228, slime-negative), and two clinical strains isolated from different hospitalised patients, (one ica-positive/slime-positive and one ica-positive/slime-negative) were tested.", [["ATCC35984", "ORGANISM", 36, 45], ["ATCC12228", "ORGANISM", 66, 75], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["Reference control strains", "TEST", 9, 34], ["slime", "TEST", 47, 52], ["ATCC12228", "TEST", 66, 75], ["slime", "TEST", 77, 82], ["two clinical strains", "PROBLEM", 98, 118], ["slime", "TEST", 184, 189], ["slime", "TEST", 220, 225]]], ["Bacteria grown in BHI medium were suspended in physiological saline at a concentration of~3\u00d710 9 cells/ml.", [["cells", "ANATOMY", 97, 102], ["Bacteria", "CELL", 0, 8], ["saline", "SIMPLE_CHEMICAL", 61, 67], ["Bacteria grown in BHI medium", "PROBLEM", 0, 28], ["physiological saline", "TREATMENT", 47, 67], ["BHI medium", "OBSERVATION_MODIFIER", 18, 28]]], ["Hydroxyl (OH)-terminated (hydrophilic) and methyl (CH3)terminated (hydrophobic) glass surfaces were used as substrates in a parallel plate flow chamber.", [["Hydroxyl", "CHEMICAL", 0, 8], ["OH", "CHEMICAL", 10, 12], ["methyl", "CHEMICAL", 43, 49], ["Hydroxyl", "CHEMICAL", 0, 8], ["OH", "CHEMICAL", 10, 12], ["methyl", "CHEMICAL", 43, 49], ["CH3", "CHEMICAL", 51, 54], ["Hydroxyl", "SIMPLE_CHEMICAL", 0, 8], ["OH", "SIMPLE_CHEMICAL", 10, 12], ["methyl (CH3)", "SIMPLE_CHEMICAL", 43, 55], ["Hydroxyl (OH)-terminated (hydrophilic) and methyl (CH3)terminated (hydrophobic) glass surfaces", "TREATMENT", 0, 94], ["a parallel plate flow chamber", "TREATMENT", 122, 151], ["flow chamber", "OBSERVATION", 139, 151]]], ["Bacterial adhesion was examined under two flow rates: 2 ml/min and 20 ml/min for two and four hours.", [["Bacterial", "ANATOMY", 0, 9], ["Bacterial adhesion", "PROBLEM", 0, 18], ["adhesion", "OBSERVATION", 10, 18]]], ["Total RNA from both planktonic (p) and adherent (a) bacteria, after detachment with trypsin, was isolated by the Trizol method.", [["trypsin", "GENE_OR_GENE_PRODUCT", 84, 91], ["trypsin", "PROTEIN", 84, 91], ["Total RNA", "PROBLEM", 0, 9], ["adherent (a) bacteria", "PROBLEM", 39, 60], ["detachment", "PROBLEM", 68, 78], ["trypsin", "TREATMENT", 84, 91], ["the Trizol method", "TREATMENT", 109, 126], ["both", "OBSERVATION_MODIFIER", 15, 19], ["planktonic", "OBSERVATION_MODIFIER", 20, 30]]], ["Reverse transcription followed by relative Real-Time PCR (rRT-PCR) towards a 207 bp part of 23S rRNA gene, allowed the detection of expression levels of icaA and icaD.", [["23S", "GENE_OR_GENE_PRODUCT", 92, 95], ["rRNA", "CELLULAR_COMPONENT", 96, 100], ["icaA", "GENE_OR_GENE_PRODUCT", 153, 157], ["icaD", "GENE_OR_GENE_PRODUCT", 162, 166], ["23S rRNA gene", "DNA", 92, 105], ["icaA", "PROTEIN", 153, 157], ["icaD", "PROTEIN", 162, 166], ["Time PCR", "TEST", 48, 56], ["rRT", "TEST", 58, 61], ["expression levels of icaA", "PROBLEM", 132, 157], ["icaD", "PROBLEM", 162, 166], ["icaD", "OBSERVATION", 162, 166]]], ["Adherent bacteria were investigated with Scanning Electron and Confocal Laser microscopes.", [["Adherent bacteria", "PROBLEM", 0, 17], ["Scanning Electron", "TEST", 41, 58], ["Confocal Laser microscopes", "TEST", 63, 89], ["bacteria", "OBSERVATION", 9, 17]]], ["Results: Higher expression levels of both icaA and icaD genes onto glass and especially methyl-terminated glass surfaces were calculated by rRT-PCR, under higher flow rate in two hours by the reference and the clinical slime-positive strains.", [["methyl", "CHEMICAL", 88, 94], ["methyl", "CHEMICAL", 88, 94], ["icaA", "GENE_OR_GENE_PRODUCT", 42, 46], ["icaD", "GENE_OR_GENE_PRODUCT", 51, 55], ["methyl", "SIMPLE_CHEMICAL", 88, 94], ["icaA and icaD genes", "DNA", 42, 61], ["Higher expression levels of both icaA and icaD genes onto glass", "PROBLEM", 9, 72], ["methyl-terminated glass surfaces", "TREATMENT", 88, 120], ["PCR", "TEST", 144, 147], ["the clinical slime", "TEST", 206, 224], ["positive strains", "PROBLEM", 225, 241], ["both", "ANATOMY_MODIFIER", 37, 41], ["icaA", "ANATOMY", 42, 46], ["icaD", "OBSERVATION", 51, 55]]], ["These results correlate well with adherent bacterial cell counts and images taken by both microscopes.", [["cell", "ANATOMY", 53, 57], ["bacterial cell", "CELL", 43, 57], ["adherent bacterial cell counts", "TEST", 34, 64], ["images", "TEST", 69, 75], ["bacterial cell counts", "OBSERVATION", 43, 64]]], ["The icapositive slime-negative clinical strain showed lower expression levels of ica genes, less adherent ability and PIA production on glass surfaces, as observed by microscopes.Conclusions:Higher flow rate enhances the expression level of both ica genes, with a peak in two hours.", [["ica", "GENE_OR_GENE_PRODUCT", 81, 84], ["PIA", "SIMPLE_CHEMICAL", 118, 121], ["ica", "GENE_OR_GENE_PRODUCT", 246, 249], ["ica genes", "DNA", 81, 90], ["ica genes", "DNA", 246, 255], ["The icapositive slime", "TEST", 0, 21], ["clinical strain", "TEST", 31, 46], ["lower expression levels of ica genes", "PROBLEM", 54, 90], ["Higher flow rate", "TEST", 191, 207], ["ica", "ANATOMY", 81, 84], ["less", "OBSERVATION_MODIFIER", 92, 96], ["adherent", "OBSERVATION_MODIFIER", 97, 105], ["Higher", "OBSERVATION_MODIFIER", 191, 197], ["flow", "OBSERVATION", 198, 202], ["both", "ANATOMY_MODIFIER", 241, 245], ["ica genes", "ANATOMY", 246, 255], ["peak", "OBSERVATION_MODIFIER", 264, 268]]], ["Hydrophobic biomaterial surfaces seem to play a crucial role to initial adherence, increasing ica gene expression and PIA synthesis.", [["ica", "GENE_OR_GENE_PRODUCT", 94, 97], ["PIA", "SIMPLE_CHEMICAL", 118, 121], ["ica gene", "DNA", 94, 102], ["Hydrophobic biomaterial surfaces", "TREATMENT", 0, 32], ["increasing ica gene expression", "PROBLEM", 83, 113], ["PIA synthesis", "PROBLEM", 118, 131], ["biomaterial surfaces", "OBSERVATION", 12, 32]]], ["Consenting men and women with DFI (predefined by clinical signs and symptoms) caused by MRSA were potentially eligible including those associated with bacteraemia.", [["MRSA", "DISEASE", 88, 92], ["bacteraemia", "DISEASE", 151, 162], ["men", "ORGANISM", 11, 14], ["women", "ORGANISM", 19, 24], ["men", "SPECIES", 11, 14], ["women", "SPECIES", 19, 24], ["MRSA", "SPECIES", 88, 92], ["MRSA", "SPECIES", 88, 92], ["DFI", "PROBLEM", 30, 33], ["symptoms", "PROBLEM", 68, 76], ["MRSA", "PROBLEM", 88, 92], ["bacteraemia", "PROBLEM", 151, 162], ["MRSA", "OBSERVATION", 88, 92], ["bacteraemia", "OBSERVATION", 151, 162]]], ["Patients with initial osteomyelitis were excluded.", [["osteomyelitis", "DISEASE", 22, 35], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["initial osteomyelitis", "PROBLEM", 14, 35], ["osteomyelitis", "OBSERVATION", 22, 35]]], ["Patients could receive L 600 mg bid either iv or po.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["L", "TREATMENT", 23, 24]]], ["Primary end point were cure or improvement rates (C+I) and microbiologic eradication (ME) at 60 days after the beginning of L. Secondary end points were C+I on days 5 and 30 after the beginning of treatment and hospital discharge day, need of amputation, duration of therapy and mortality rates.", [["microbiologic eradication", "TEST", 59, 84], ["treatment", "TREATMENT", 197, 206], ["amputation", "TREATMENT", 243, 253], ["therapy", "TREATMENT", 267, 274], ["mortality rates", "TEST", 279, 294], ["amputation", "OBSERVATION", 243, 253]]], ["All the adverse events were collected.", [["All the adverse events", "PROBLEM", 0, 22]]], ["Results: 70 patients were enrolled.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["Relation men:women was 2.1.The age of patients was 63.2\u00b113 years and the average period from the diagnosis of diabetes was 16.5\u00b19.7 years.", [["diabetes", "DISEASE", 110, 118], ["men", "ORGANISM", 9, 12], ["women", "ORGANISM", 13, 18], ["patients", "ORGANISM", 38, 46], ["men", "SPECIES", 9, 12], ["women", "SPECIES", 13, 18], ["patients", "SPECIES", 38, 46], ["diabetes", "PROBLEM", 110, 118]]], ["Associated bacteraemia was present in 27.1% of patients included.", [["bacteraemia", "DISEASE", 11, 22], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["Associated bacteraemia", "PROBLEM", 0, 22], ["bacteraemia", "OBSERVATION", 11, 22]]], ["Primary end points: C+I 60 days after the beginning of L was achieved in 91.4% of patients and ME was obtained in 84.3% of patients.", [["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 123, 131]]], ["Secondary end points: C+I on day 5, hospital discharge day and day 30 after the beginning of treatment and were; 70%; 84.3% and 88.6% respectively.", [["treatment", "TREATMENT", 93, 102]]], ["Only 8 patients needed a minor amputation.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["a minor amputation", "TREATMENT", 23, 41], ["amputation", "OBSERVATION", 31, 41]]], ["The primary and secondary end points in the subgroup of bacteraemic episodes were not statistically different of those previously described.", [["bacteraemic episodes", "PROBLEM", 56, 76], ["secondary", "OBSERVATION_MODIFIER", 16, 25], ["end", "OBSERVATION_MODIFIER", 26, 29], ["subgroup", "OBSERVATION_MODIFIER", 44, 52], ["bacteraemic episodes", "OBSERVATION", 56, 76], ["statistically different", "OBSERVATION_MODIFIER", 86, 109]]], ["The mean duration of therapy was 29.5\u00b118.4 days.", [["therapy", "TREATMENT", 21, 28], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Global mortality was 4.3%.", [["Global mortality", "TEST", 0, 16]]], ["Only one episode of polineuropathy was reported.", [["polineuropathy", "DISEASE", 20, 34], ["polineuropathy", "PROBLEM", 20, 34], ["polineuropathy", "OBSERVATION", 20, 34]]], ["Neither thrombocytopenia nor lactic acidosis was found.Conclusions:Conclusions: L achieved excellent C+I even at first evaluation visit in documented DFI caused by MRSA.", [["thrombocytopenia", "DISEASE", 8, 24], ["lactic acidosis", "DISEASE", 29, 44], ["MRSA", "DISEASE", 164, 168], ["C+I", "GENE_OR_GENE_PRODUCT", 101, 104], ["MRSA", "SPECIES", 164, 168], ["thrombocytopenia", "PROBLEM", 8, 24], ["lactic acidosis", "PROBLEM", 29, 44], ["first evaluation", "TEST", 113, 129], ["MRSA", "PROBLEM", 164, 168], ["thrombocytopenia", "OBSERVATION", 8, 24], ["lactic acidosis", "OBSERVATION", 29, 44], ["MRSA", "OBSERVATION", 164, 168]]], ["L also showed high ME rates.", [["high ME rates", "PROBLEM", 14, 27], ["high ME", "OBSERVATION", 14, 21]]], ["Although patients received prolonged periods of treatment, L was a safe drug.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["treatment", "TREATMENT", 48, 57], ["a safe drug", "TREATMENT", 65, 76]]], ["Objectives: Azithromycin microspheres formulation (AZM) was developed to enable a higher dosage of 2 g to be administered as a single oral dose without decreasing the safety profile.", [["oral", "ANATOMY", 134, 138], ["Azithromycin", "CHEMICAL", 12, 24], ["AZM", "CHEMICAL", 51, 54], ["Azithromycin", "CHEMICAL", 12, 24], ["Azithromycin", "SIMPLE_CHEMICAL", 12, 24], ["AZM", "SIMPLE_CHEMICAL", 51, 54], ["oral", "ORGANISM_SUBDIVISION", 134, 138], ["Azithromycin microspheres formulation (AZM", "TREATMENT", 12, 54], ["a single oral dose", "TREATMENT", 125, 143]]], ["This study compared AZM with moxifloxacin (MOX) aimed at confirming the efficacy and safety of AZM in acute exacerbations of chronic bronchitis (AECB).", [["AZM", "CHEMICAL", 20, 23], ["moxifloxacin", "CHEMICAL", 29, 41], ["MOX", "CHEMICAL", 43, 46], ["AZM", "CHEMICAL", 95, 98], ["chronic bronchitis", "DISEASE", 125, 143], ["AECB", "DISEASE", 145, 149], ["AZM", "CHEMICAL", 20, 23], ["moxifloxacin", "CHEMICAL", 29, 41], ["MOX", "CHEMICAL", 43, 46], ["AZM", "CHEMICAL", 95, 98], ["AZM", "SIMPLE_CHEMICAL", 20, 23], ["moxifloxacin", "SIMPLE_CHEMICAL", 29, 41], ["MOX", "SIMPLE_CHEMICAL", 43, 46], ["AZM", "SIMPLE_CHEMICAL", 95, 98], ["This study", "TEST", 0, 10], ["moxifloxacin (MOX)", "TREATMENT", 29, 47], ["AZM", "PROBLEM", 95, 98], ["acute exacerbations", "PROBLEM", 102, 121], ["chronic bronchitis", "PROBLEM", 125, 143], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["exacerbations", "OBSERVATION", 108, 121], ["chronic", "OBSERVATION_MODIFIER", 125, 132], ["bronchitis", "OBSERVATION", 133, 143]]], ["Methods: This prospective, multicentre, randomised, double-blind, double dummy study compared AZM 2 g single dose with MOX 400 mg once daily for 5 days, enrolled AECB patients 50 years old and above, with Anthonisen Type 1 exacerbations, and with at least 2 exacerbations of AECB in the past 12 months.", [["AZM", "CHEMICAL", 94, 97], ["MOX", "CHEMICAL", 119, 122], ["AECB", "DISEASE", 275, 279], ["AZM", "CHEMICAL", 94, 97], ["MOX", "CHEMICAL", 119, 122], ["MOX", "SIMPLE_CHEMICAL", 119, 122], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["Anthonisen Type 1", "SPECIES", 205, 222], ["double-blind", "TREATMENT", 52, 64], ["double dummy study", "TREATMENT", 66, 84], ["AZM", "TREATMENT", 94, 97], ["MOX", "TREATMENT", 119, 122], ["Anthonisen Type 1 exacerbations", "PROBLEM", 205, 236], ["AECB", "TREATMENT", 275, 279], ["AECB", "OBSERVATION", 275, 279]]], ["Subjects were to have a history of smoking of at least 20 pack-years and documented forced expiratory volume in 1 second (FEV1) less than 80% of predicted.", [["smoking", "CHEMICAL", 35, 42], ["Subjects", "ORGANISM", 0, 8], ["forced expiratory volume", "TEST", 84, 108], ["FEV1", "TEST", 122, 126], ["expiratory volume", "OBSERVATION", 91, 108]]], ["Results: A total of 396 patients were treated (198 in each of the treatment groups) The distribution of the age, and mean FEV1 were similar for the 2 treatment groups.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["the treatment groups", "TREATMENT", 62, 82], ["mean FEV1", "TEST", 117, 126], ["the 2 treatment groups", "TREATMENT", 144, 166], ["distribution", "OBSERVATION_MODIFIER", 88, 100]]], ["Pathogens were isolated from 62.9% of the patients (61.1% of patients on AZM and 62.9% of patients on MOX).", [["AZM", "CHEMICAL", 73, 76], ["MOX", "CHEMICAL", 102, 105], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 90, 98], ["Pathogens", "PROBLEM", 0, 9], ["AZM", "TEST", 73, 76]]], ["The clinical success (signs and symptoms related to the acute infection had returned to the subject's normal baseline level, or clinical improvement was such that no additional antibiotics were deemed necessary) rate for the Per Protocol Population at Test of Cure (TOC) at Day 12\u221219 was 93.0% for AZM and 94.2% for MOX group (95% CI \u22125.8, 3.9).", [["infection", "DISEASE", 62, 71], ["AZM", "CHEMICAL", 298, 301], ["MOX", "CHEMICAL", 316, 319], ["The clinical success (signs and symptoms", "PROBLEM", 0, 40], ["the acute infection", "PROBLEM", 52, 71], ["additional antibiotics", "TREATMENT", 166, 188], ["AZM", "TEST", 298, 301], ["CI", "TEST", 331, 333], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["infection", "OBSERVATION", 62, 71]]], ["Bacterial eradication rate (Bacteriologic Pre Protocol population) at TOC was 96.0% for AZM group and 96.7% for MOX group (95% CI \u22124.5, 3.3).", [["TOC", "CHEMICAL", 70, 73], ["AZM", "CHEMICAL", 88, 91], ["MOX", "CHEMICAL", 112, 115], ["AZM", "SIMPLE_CHEMICAL", 88, 91], ["Bacterial eradication rate", "TEST", 0, 26], ["Bacteriologic Pre Protocol population", "TREATMENT", 28, 65], ["TOC", "TEST", 70, 73], ["AZM group", "TEST", 88, 97], ["MOX group", "TEST", 112, 121], ["CI", "TEST", 127, 129], ["eradication", "OBSERVATION", 10, 21]]], ["Although the study population had history of at least 2 exacerbation in the past 12 months, less than half of the subjects experienced a recurrence during the follow-up, and there was no statistically significant treatment difference in time taken to first occurrence of AECB.", [["AECB", "DISEASE", 271, 275], ["AECB", "CANCER", 271, 275], ["the study", "TEST", 9, 18], ["2 exacerbation", "PROBLEM", 54, 68], ["a recurrence", "PROBLEM", 135, 147], ["AECB", "TREATMENT", 271, 275], ["at least", "OBSERVATION_MODIFIER", 45, 53], ["exacerbation", "OBSERVATION", 56, 68], ["recurrence", "OBSERVATION", 137, 147], ["no", "UNCERTAINTY", 184, 186], ["significant", "OBSERVATION_MODIFIER", 201, 212], ["treatment", "OBSERVATION", 213, 222]]], ["The incidence of treatment related adverse events was low, being reported by 17% of subjects receiving AZM and 12% of subjects receiving MOX.", [["AZM", "CHEMICAL", 103, 106], ["MOX", "CHEMICAL", 137, 140], ["AZM", "CHEMICAL", 103, 106], ["MOX", "CHEMICAL", 137, 140], ["AZM", "SIMPLE_CHEMICAL", 103, 106], ["MOX", "SIMPLE_CHEMICAL", 137, 140], ["adverse events", "PROBLEM", 35, 49], ["AZM", "TREATMENT", 103, 106], ["MOX", "TREATMENT", 137, 140]]], ["Most AEs were mild or moderate in severity.", [["mild or moderate in severity", "PROBLEM", 14, 42], ["mild", "OBSERVATION_MODIFIER", 14, 18], ["moderate", "OBSERVATION_MODIFIER", 22, 30], ["severity", "OBSERVATION_MODIFIER", 34, 42]]], ["The most common AEs were gastrointestinal disorders, being reported by 14% of subjects receiving AZM and 8% of subjects receiving MOX.", [["gastrointestinal", "ANATOMY", 25, 41], ["gastrointestinal disorders", "DISEASE", 25, 51], ["AZM", "CHEMICAL", 97, 100], ["MOX", "CHEMICAL", 130, 133], ["AZM", "CHEMICAL", 97, 100], ["MOX", "CHEMICAL", 130, 133], ["gastrointestinal", "ORGAN", 25, 41], ["MOX", "SIMPLE_CHEMICAL", 130, 133], ["gastrointestinal disorders", "PROBLEM", 25, 51], ["AZM", "TREATMENT", 97, 100], ["MOX", "TREATMENT", 130, 133], ["gastrointestinal", "ANATOMY", 25, 41], ["disorders", "OBSERVATION", 42, 51]]], ["Conclusions: A single oral dose of AZM was as effective as a 5-day course of MOX in the treatment of AECB and was well tolerated.", [["oral", "ANATOMY", 22, 26], ["AZM", "CHEMICAL", 35, 38], ["MOX", "CHEMICAL", 77, 80], ["AECB", "DISEASE", 101, 105], ["AZM", "CHEMICAL", 35, 38], ["MOX", "CHEMICAL", 77, 80], ["oral", "ORGANISM_SUBDIVISION", 22, 26], ["AZM", "SIMPLE_CHEMICAL", 35, 38], ["MOX", "SIMPLE_CHEMICAL", 77, 80], ["AECB", "CANCER", 101, 105], ["A single oral dose of AZM", "TREATMENT", 13, 38], ["MOX", "TREATMENT", 77, 80], ["AECB", "TREATMENT", 101, 105]]], ["Objectives: Optimal duration of gentamicin containing regimen for therapy of human brucellosis is not clearly determined.O212 Single-dose azithromycin microspheres versus 5-dayMethods: This randomised clinical study was conducted to compare the efficacy of gentamicin 5 mg/day for 5 days plus doxycycline 100 mg twice daily for eight weeks (GD group) versus streptomycin 1gr IM for 2 weeks plus the same dose of doxycycline for 45 days (SD group).", [["gentamicin", "CHEMICAL", 32, 42], ["brucellosis", "DISEASE", 83, 94], ["azithromycin", "CHEMICAL", 138, 150], ["gentamicin", "CHEMICAL", 257, 267], ["doxycycline", "CHEMICAL", 293, 304], ["streptomycin", "CHEMICAL", 358, 370], ["doxycycline", "CHEMICAL", 412, 423], ["gentamicin", "CHEMICAL", 32, 42], ["azithromycin", "CHEMICAL", 138, 150], ["gentamicin", "CHEMICAL", 257, 267], ["doxycycline", "CHEMICAL", 293, 304], ["doxycycline", "CHEMICAL", 412, 423], ["gentamicin", "SIMPLE_CHEMICAL", 32, 42], ["human", "ORGANISM", 77, 82], ["O212", "SIMPLE_CHEMICAL", 121, 125], ["azithromycin", "SIMPLE_CHEMICAL", 138, 150], ["5-dayMethods", "SIMPLE_CHEMICAL", 171, 183], ["gentamicin", "SIMPLE_CHEMICAL", 257, 267], ["doxycycline", "SIMPLE_CHEMICAL", 293, 304], ["streptomycin 1gr IM", "SIMPLE_CHEMICAL", 358, 377], ["doxycycline", "SIMPLE_CHEMICAL", 412, 423], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["gentamicin containing regimen", "TREATMENT", 32, 61], ["therapy", "TREATMENT", 66, 73], ["human brucellosis", "PROBLEM", 77, 94], ["Single-dose azithromycin microspheres", "TREATMENT", 126, 163], ["This randomised clinical study", "TEST", 185, 215], ["gentamicin", "TREATMENT", 257, 267], ["doxycycline", "TREATMENT", 293, 304], ["GD group)", "TREATMENT", 341, 350], ["streptomycin", "TREATMENT", 358, 370], ["doxycycline", "TREATMENT", 412, 423], ["brucellosis", "OBSERVATION", 83, 94]]], ["All cases were followed for one year after cessation of therapy.", [["therapy", "TREATMENT", 56, 63]]], ["Efficacy of both regimens (failure of therapy or relapse) were compared.", [["both regimens", "TREATMENT", 12, 25], ["failure of therapy", "TREATMENT", 27, 45], ["relapse", "PROBLEM", 49, 56]]], ["Results: Seventy-nine patients with the mean age of 35\u00b114.5 years and 75 cases with the mean age of 36.7\u00b113.9 years were treated with regimen of GD or SD, respectively.", [["SD", "DISEASE", 151, 153], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["regimen", "TREATMENT", 134, 141]]], ["The clinical manifestations in these two treated groups were similar.", [["The clinical manifestations", "PROBLEM", 0, 27]]], ["Failure of therapy was seen in one patient in GD group and in 2 cases in SD group ( Objectives: To study the efficacy of telavancin (TLV), an investigational bactericidal lipoglycopeptide, for the treatment of complicated skin and soft tissue infections (cSSTI) caused by presumed or confirmed Grampositive organisms.", [["skin", "ANATOMY", 222, 226], ["soft tissue", "ANATOMY", 231, 242], ["GD", "DISEASE", 46, 48], ["SD", "DISEASE", 73, 75], ["telavancin", "CHEMICAL", 121, 131], ["TLV", "CHEMICAL", 133, 136], ["lipoglycopeptide", "CHEMICAL", 171, 187], ["skin and soft tissue infections", "DISEASE", 222, 253], ["cSSTI", "DISEASE", 255, 260], ["telavancin", "CHEMICAL", 121, 131], ["TLV", "CHEMICAL", 133, 136], ["patient", "ORGANISM", 35, 42], ["telavancin", "SIMPLE_CHEMICAL", 121, 131], ["TLV", "SIMPLE_CHEMICAL", 133, 136], ["lipoglycopeptide", "SIMPLE_CHEMICAL", 171, 187], ["skin", "ORGAN", 222, 226], ["soft tissue", "TISSUE", 231, 242], ["patient", "SPECIES", 35, 42], ["therapy", "TREATMENT", 11, 18], ["telavancin (TLV", "TREATMENT", 121, 136], ["an investigational bactericidal lipoglycopeptide", "TREATMENT", 139, 187], ["the treatment", "TREATMENT", 193, 206], ["complicated skin and soft tissue infections", "PROBLEM", 210, 253], ["Grampositive organisms", "PROBLEM", 294, 316], ["therapy", "OBSERVATION", 11, 18], ["complicated", "OBSERVATION_MODIFIER", 210, 221], ["skin", "ANATOMY", 222, 226], ["soft tissue", "ANATOMY", 231, 242], ["infections", "OBSERVATION", 243, 253]]], ["Methods: ATLAS 1 and ATLAS 2 were methodologically identical, double-blind, randomised, multinational, Phase 3 studies.", [["multinational, Phase 3 studies", "TEST", 88, 118]]], ["Adult men and women presenting with cSSTI including major abscess were randomised 1:1 to TLV 10 mg/kg intravenous (IV) q24 h or vancomycin (VAN) 1 g IV q12 h for 7 to 14 days.", [["abscess", "ANATOMY", 58, 65], ["cSSTI", "DISEASE", 36, 41], ["major abscess", "DISEASE", 52, 65], ["vancomycin", "CHEMICAL", 128, 138], ["VAN", "CHEMICAL", 140, 143], ["vancomycin", "CHEMICAL", 128, 138], ["VAN", "CHEMICAL", 140, 143], ["men", "ORGANISM", 6, 9], ["women", "ORGANISM", 14, 19], ["vancomycin", "SIMPLE_CHEMICAL", 128, 138], ["VAN", "SIMPLE_CHEMICAL", 140, 143], ["men", "SPECIES", 6, 9], ["women", "SPECIES", 14, 19], ["cSSTI", "PROBLEM", 36, 41], ["major abscess", "PROBLEM", 52, 65], ["TLV", "TREATMENT", 89, 92], ["vancomycin (VAN)", "TREATMENT", 128, 144], ["abscess", "OBSERVATION", 58, 65]]], ["Test-of-cure (TOC) visit was conducted 7 to 14 days after end of study treatment.", [["Test", "TEST", 0, 4], ["study treatment", "TREATMENT", 65, 80]]], ["The all-treated population (AT) included patients with confirmed diagnosis of cSSTI who received 1 dose of study medication.", [["cSSTI", "DISEASE", 78, 83], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["cSSTI", "PROBLEM", 78, 83], ["study medication", "TREATMENT", 107, 123]]], ["This analysis examined the baseline characteristics and cure rates at TOC for patients with major abscess in the combined ATLAS AT population.", [["abscess", "ANATOMY", 98, 105], ["TOC", "CHEMICAL", 70, 73], ["abscess", "DISEASE", 98, 105], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["This analysis", "TEST", 0, 13], ["major abscess", "PROBLEM", 92, 105], ["abscess", "OBSERVATION", 98, 105]]], ["Results: In the pooled AT population of ATLAS, 772 patients presented with major abscess.", [["abscess", "ANATOMY", 81, 88], ["ATLAS", "DISEASE", 40, 45], ["abscess", "DISEASE", 81, 88], ["ATLAS", "CANCER", 40, 45], ["patients", "ORGANISM", 51, 59], ["abscess", "PATHOLOGICAL_FORMATION", 81, 88], ["patients", "SPECIES", 51, 59], ["major abscess", "PROBLEM", 75, 88], ["major", "OBSERVATION_MODIFIER", 75, 80], ["abscess", "OBSERVATION", 81, 88]]], ["More than 60% of these patients required hospitalisation.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31]]], ["The baseline lesion surface area exceeded 5 cm 2 in 98% of the cases, while 65% of the patients presented with lesions exceeding 50 cm 2 (Table 1) .", [["lesion surface area", "ANATOMY", 13, 32], ["lesions", "ANATOMY", 111, 118], ["patients", "ORGANISM", 87, 95], ["lesions", "PATHOLOGICAL_FORMATION", 111, 118], ["patients", "SPECIES", 87, 95], ["The baseline lesion surface area", "PROBLEM", 0, 32], ["lesions", "PROBLEM", 111, 118], ["baseline", "OBSERVATION_MODIFIER", 4, 12], ["lesion", "OBSERVATION", 13, 19], ["surface", "OBSERVATION_MODIFIER", 20, 27], ["area", "OBSERVATION_MODIFIER", 28, 32], ["exceeded", "OBSERVATION_MODIFIER", 33, 41], ["5 cm", "OBSERVATION_MODIFIER", 42, 46], ["lesions", "OBSERVATION", 111, 118], ["50 cm", "OBSERVATION_MODIFIER", 129, 134]]], ["Elevated white blood cell counts were found in more than 40% of the cases (Table 1) .", [["white blood cell", "ANATOMY", 9, 25], ["blood cell", "CELL", 15, 25], ["Elevated white blood cell counts", "PROBLEM", 0, 32]]], ["Nearly all patients required surgical drainage, with approximately 2/3 performed prior to the first dose of study medication.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["surgical drainage", "TREATMENT", 29, 46], ["study medication", "TREATMENT", 108, 124], ["surgical drainage", "OBSERVATION", 29, 46]]], ["Very few patients required a surgical procedure more than 4 days after the start of study medication.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["a surgical procedure", "TREATMENT", 27, 47], ["study medication", "TREATMENT", 84, 100], ["few", "OBSERVATION_MODIFIER", 5, 8]]], ["Clinical cure rates at TOC are presented in Table 1 .", [["Clinical cure rates", "PROBLEM", 0, 19]]], ["Overall, adverse events in the AT population were similar between the treatment groups with regard to type and severity.", [["adverse events", "PROBLEM", 9, 23], ["the treatment groups", "TREATMENT", 66, 86], ["type and severity", "PROBLEM", 102, 119], ["adverse", "OBSERVATION_MODIFIER", 9, 16]]], ["Conclusion: Telavancin administered once daily was non-inferior to vancomycin for the treatment of major abscess.", [["abscess", "ANATOMY", 105, 112], ["Telavancin", "CHEMICAL", 12, 22], ["vancomycin", "CHEMICAL", 67, 77], ["abscess", "DISEASE", 105, 112], ["Telavancin", "CHEMICAL", 12, 22], ["vancomycin", "CHEMICAL", 67, 77], ["Telavancin", "SIMPLE_CHEMICAL", 12, 22], ["vancomycin", "SIMPLE_CHEMICAL", 67, 77], ["abscess", "PATHOLOGICAL_FORMATION", 105, 112], ["Telavancin", "TREATMENT", 12, 22], ["vancomycin", "TREATMENT", 67, 77], ["the treatment", "TREATMENT", 82, 95], ["major abscess", "PROBLEM", 99, 112], ["major", "OBSERVATION_MODIFIER", 99, 104], ["abscess", "OBSERVATION", 105, 112]]], ["Objectives: B. fragilis and related species, members of the normal bowel flora, are the most widely isolated anaerobic bacteria from different infections.", [["bowel flora", "ANATOMY", 67, 78], ["infections", "DISEASE", 143, 153], ["B. fragilis", "ORGANISM", 12, 23], ["bowel flora", "MULTI-TISSUE_STRUCTURE", 67, 78], ["B. fragilis", "SPECIES", 12, 23], ["B. fragilis", "SPECIES", 12, 23], ["B. fragilis", "PROBLEM", 12, 23], ["related species", "PROBLEM", 28, 43], ["isolated anaerobic bacteria", "PROBLEM", 100, 127], ["different infections", "PROBLEM", 133, 153], ["fragilis", "OBSERVATION", 15, 23], ["bowel flora", "ANATOMY", 67, 78], ["anaerobic bacteria", "OBSERVATION", 109, 127], ["different", "OBSERVATION_MODIFIER", 133, 142], ["infections", "OBSERVATION", 143, 153]]], ["To follow the development and spread of the resistance among these strains is difficult, as antibiotic susceptibility testing of clinically relevant anaerobes in different routine laboratories in Europe is less and less frequently carried out due to the fact, that clinicians treat many presumed anaerobic infections empirically.", [["infections", "DISEASE", 306, 316], ["the resistance among these strains", "PROBLEM", 40, 74], ["antibiotic susceptibility testing", "TEST", 92, 125], ["clinically relevant anaerobes", "PROBLEM", 129, 158], ["different routine laboratories", "TEST", 162, 192], ["anaerobic infections", "PROBLEM", 296, 316], ["anaerobic infections", "OBSERVATION", 296, 316]]], ["To follow the changes in the antibiotic resistance of Bacteroides strains three Europe-wide studies were organised during the past twenty years.", [["Bacteroides strains", "ORGANISM", 54, 73], ["the antibiotic resistance", "TREATMENT", 25, 50], ["Bacteroides strains", "PROBLEM", 54, 73], ["wide studies", "TEST", 87, 99]]], ["The evaluation of the results of these studies may show changes in the resistance to different antianaerobic drugs.Methods:Only clinical isolates and no normal flora members of Bacteroides strains belonging to different species were collected from different countries throughout Europe during these studies.", [["Bacteroides strains", "ORGANISM", 177, 196], ["The evaluation", "TEST", 0, 14], ["these studies", "TEST", 33, 46], ["different antianaerobic drugs", "TREATMENT", 85, 114], ["clinical isolates", "TEST", 128, 145], ["Bacteroides strains", "PROBLEM", 177, 196], ["different species", "PROBLEM", 210, 227], ["these studies", "TEST", 293, 306]]], ["Agar dilution method was used for the antibiotic susceptibility determination.", [["Agar dilution method", "TREATMENT", 0, 20], ["the antibiotic susceptibility determination", "TEST", 34, 77]]], ["Actual breakpoints accepted by NCCLS (CLSI) and EUCAST were used.", [["Actual breakpoints", "PROBLEM", 0, 18], ["EUCAST", "TREATMENT", 48, 54]]], ["Molecular genetic investigations were carried out to detect resistance mechanisms.Results and Conclusions:Since the first study the chromosomally mediated beta-lactamase production and tetracyclin resistance is the most prevalent among Bacteroides strains in Europe.", [["tetracyclin", "CHEMICAL", 185, 196], ["beta-lactamase", "GENE_OR_GENE_PRODUCT", 155, 169], ["tetracyclin", "GENE_OR_GENE_PRODUCT", 185, 196], ["Bacteroides strains", "ORGANISM", 236, 255], ["Molecular genetic investigations", "TEST", 0, 32], ["resistance mechanisms", "PROBLEM", 60, 81], ["the first study", "TEST", 112, 127], ["the chromosomally mediated beta-lactamase production", "PROBLEM", 128, 180], ["tetracyclin resistance", "PROBLEM", 185, 207], ["Bacteroides strains", "PROBLEM", 236, 255], ["beta-lactamase", "OBSERVATION", 155, 169], ["tetracyclin resistance", "OBSERVATION", 185, 207], ["most prevalent", "OBSERVATION_MODIFIER", 215, 229]]], ["Clindamycin resistance in Bacteroides is mediated by a macrolide-lincomycin-streptogramin (MLS) mechanism and its frequency differs in different countries in Europe.", [["Clindamycin", "CHEMICAL", 0, 11], ["Bacteroides", "CHEMICAL", 26, 37], ["macrolide", "CHEMICAL", 55, 64], ["lincomycin", "CHEMICAL", 65, 75], ["streptogramin", "CHEMICAL", 76, 89], ["Clindamycin", "CHEMICAL", 0, 11], ["macrolide", "CHEMICAL", 55, 64], ["lincomycin", "CHEMICAL", 65, 75], ["streptogramin", "CHEMICAL", 76, 89], ["Clindamycin", "SIMPLE_CHEMICAL", 0, 11], ["Bacteroides", "SIMPLE_CHEMICAL", 26, 37], ["macrolide", "SIMPLE_CHEMICAL", 55, 64], ["lincomycin", "SIMPLE_CHEMICAL", 65, 75], ["streptogramin", "SIMPLE_CHEMICAL", 76, 89], ["MLS", "SIMPLE_CHEMICAL", 91, 94], ["Clindamycin resistance in Bacteroides", "TREATMENT", 0, 37], ["a macrolide-lincomycin", "TREATMENT", 53, 75], ["streptogramin (MLS) mechanism", "TREATMENT", 76, 105]]], ["Resistance to beta-lactam-beta-lactamase inhibitor combinations was studied using amoxicillin-clavulanic acid and/or piperacillintazobactam.", [["beta-lactam-beta-lactamase", "CHEMICAL", 14, 40], ["amoxicillin-clavulanic acid", "CHEMICAL", 82, 109], ["piperacillintazobactam", "CHEMICAL", 117, 139], ["beta-lactam", "CHEMICAL", 14, 25], ["amoxicillin-clavulanic acid", "CHEMICAL", 82, 109], ["piperacillintazobactam", "CHEMICAL", 117, 139], ["beta-lactam-beta-lactamase", "SIMPLE_CHEMICAL", 14, 40], ["amoxicillin-clavulanic acid", "SIMPLE_CHEMICAL", 82, 109], ["piperacillintazobactam", "SIMPLE_CHEMICAL", 117, 139], ["Resistance", "TEST", 0, 10], ["beta-lactam", "TREATMENT", 14, 25], ["beta-lactamase inhibitor combinations", "TREATMENT", 26, 63], ["amoxicillin", "TREATMENT", 82, 93], ["clavulanic acid", "TREATMENT", 94, 109], ["piperacillintazobactam", "TREATMENT", 117, 139]]], ["Increase in resistance was observed to both combinations throughout the years.", [["Increase in resistance", "PROBLEM", 0, 22], ["resistance", "OBSERVATION", 12, 22]]], ["The same is true for cefoxitine and in the third study several hetero-resistant isolates were found.", [["cefoxitine", "CHEMICAL", 21, 31], ["cefoxitine", "CHEMICAL", 21, 31], ["cefoxitine", "SIMPLE_CHEMICAL", 21, 31], ["cefoxitine", "TREATMENT", 21, 31], ["the third study", "TEST", 39, 54]]], ["The occurrence and spread of resistance to imipenem and metronidazole among Bacteroides strains merit special clinical importance.", [["imipenem", "CHEMICAL", 43, 51], ["metronidazole", "CHEMICAL", 56, 69], ["imipenem", "CHEMICAL", 43, 51], ["metronidazole", "CHEMICAL", 56, 69], ["imipenem", "SIMPLE_CHEMICAL", 43, 51], ["metronidazole", "SIMPLE_CHEMICAL", 56, 69], ["Bacteroides strains", "ORGANISM", 76, 95], ["imipenem", "TREATMENT", 43, 51], ["metronidazole", "TREATMENT", 56, 69], ["Bacteroides strains", "TREATMENT", 76, 95]]], ["The presence of the cfiA gene is much more prevalent than the expression of the imipenem resistance; however the spread of the cfiA gene among species other than B. fragilis is still very rare.", [["imipenem", "CHEMICAL", 80, 88], ["imipenem", "CHEMICAL", 80, 88], ["cfiA", "GENE_OR_GENE_PRODUCT", 20, 24], ["imipenem", "SIMPLE_CHEMICAL", 80, 88], ["cfiA", "GENE_OR_GENE_PRODUCT", 127, 131], ["B. fragilis", "ORGANISM", 162, 173], ["cfiA gene", "DNA", 20, 29], ["cfiA gene", "DNA", 127, 136], ["B. fragilis", "SPECIES", 162, 173], ["B. fragilis", "SPECIES", 162, 173], ["the cfiA gene", "PROBLEM", 16, 29], ["the imipenem resistance", "TREATMENT", 76, 99], ["the cfiA gene among species", "PROBLEM", 123, 150], ["B. fragilis", "PROBLEM", 162, 173], ["much more prevalent", "OBSERVATION_MODIFIER", 33, 52], ["imipenem resistance", "OBSERVATION", 80, 99], ["fragilis", "OBSERVATION", 165, 173]]], ["The molecular genetic methods looking for the resistance genes among strains with elevated MICs against these antibiotics prove that resistance breakpoints should be reconsidered.", [["MICs", "CHEMICAL", 91, 95], ["resistance genes", "DNA", 46, 62], ["the resistance genes among strains", "PROBLEM", 42, 76], ["elevated MICs", "TREATMENT", 82, 95], ["these antibiotics", "TREATMENT", 104, 121], ["resistance breakpoints", "PROBLEM", 133, 155]]], ["The resistance to moxifloxacin shows great differences in different countries.", [["moxifloxacin", "CHEMICAL", 18, 30], ["moxifloxacin", "CHEMICAL", 18, 30], ["moxifloxacin", "SIMPLE_CHEMICAL", 18, 30], ["moxifloxacin", "TREATMENT", 18, 30], ["great", "OBSERVATION_MODIFIER", 37, 42], ["differences", "OBSERVATION_MODIFIER", 43, 54]]], ["The lowest resistance rate was observed in the case of tigecyclin.L. Dubreuil\u00b0(Lille, FR)Many factors may affect the response to treatment such as site of infection, surgical procedures, severity of the illness, patient status, presence of other pathogens (mixed infection), Pk/Pd parameters of the antibacterial drugs.", [["tigecyclin", "CHEMICAL", 55, 65], ["infection", "DISEASE", 155, 164], ["illness", "DISEASE", 203, 210], ["infection", "DISEASE", 263, 272], ["tigecyclin", "CHEMICAL", 55, 65], ["Pd", "CHEMICAL", 278, 280], ["tigecyclin", "SIMPLE_CHEMICAL", 55, 65], ["patient", "ORGANISM", 212, 219], ["patient", "SPECIES", 212, 219], ["The lowest resistance rate", "TEST", 0, 26], ["tigecyclin", "TREATMENT", 55, 65], ["treatment", "TREATMENT", 129, 138], ["infection", "PROBLEM", 155, 164], ["surgical procedures", "TREATMENT", 166, 185], ["the illness", "PROBLEM", 199, 210], ["other pathogens", "PROBLEM", 240, 255], ["mixed infection)", "PROBLEM", 257, 273], ["Pk/Pd parameters", "TEST", 275, 291], ["the antibacterial drugs", "TREATMENT", 295, 318], ["lowest", "OBSERVATION_MODIFIER", 4, 10], ["resistance", "OBSERVATION", 11, 21], ["infection", "OBSERVATION", 155, 164], ["antibacterial drugs", "OBSERVATION", 299, 318]]], ["Thus, correlation between treatment failure and antibiotic resistance among anaerobes remains difficult to assess.", [["treatment failure", "PROBLEM", 26, 43], ["antibiotic resistance among anaerobes", "TREATMENT", 48, 85], ["antibiotic resistance", "OBSERVATION", 48, 69]]], ["The main discrepancies came from intra-abdominal infections and a worrisome disjunction between surgeon and microbiologist opinions emerged in the 1990's.", [["intra-abdominal", "ANATOMY", 33, 48], ["intra-abdominal infections", "DISEASE", 33, 59], ["The main discrepancies", "PROBLEM", 0, 22], ["intra-abdominal infections", "PROBLEM", 33, 59], ["main", "OBSERVATION_MODIFIER", 4, 8], ["discrepancies", "OBSERVATION", 9, 22], ["intra-abdominal", "ANATOMY", 33, 48], ["infections", "OBSERVATION", 49, 59], ["worrisome", "OBSERVATION_MODIFIER", 66, 75]]], ["But, patients in whom primary therapy failed had more resistant strains compared with patients in whom therapy succeeded.", [["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 86, 94], ["more resistant strains", "PROBLEM", 49, 71], ["therapy", "TREATMENT", 103, 110]]], ["In contrast many failures may be due to the lack of isolation of anaerobes from clinical samples!", [["samples", "ANATOMY", 89, 96], ["anaerobes", "PROBLEM", 65, 74], ["clinical samples", "TEST", 80, 96], ["failures", "OBSERVATION", 17, 25], ["may be due to", "UNCERTAINTY", 26, 39], ["anaerobes", "OBSERVATION", 65, 74]]], ["During anaerobic bacteraemia, Salonen et al. demonstrated that mortality increased dramatically from 17% for initially effective treatment to 55% when an ineffective treatment was started.", [["bacteraemia", "DISEASE", 17, 28], ["anaerobic bacteraemia", "PROBLEM", 7, 28], ["Salonen et al", "TREATMENT", 30, 43], ["an ineffective treatment", "TREATMENT", 151, 175], ["bacteraemia", "OBSERVATION", 17, 28]]], ["Facing new mechanisms of resistance and global increase resistance to many antibiotics among anaerobes may lead nowadays to a different answer.", [["resistance", "PROBLEM", 25, 35], ["global increase resistance", "PROBLEM", 40, 66], ["many antibiotics", "TREATMENT", 70, 86], ["anaerobes", "TREATMENT", 93, 102], ["resistance", "OBSERVATION_MODIFIER", 25, 35], ["global", "OBSERVATION_MODIFIER", 40, 46], ["increase resistance", "OBSERVATION", 47, 66]]], ["Clindamycin vs. penicillin studies for the treatment of lung infections pointed out the failure due to b-lactamase production among Gram-negative anaerobes.", [["lung", "ANATOMY", 56, 60], ["Clindamycin", "CHEMICAL", 0, 11], ["penicillin", "CHEMICAL", 16, 26], ["lung infections", "DISEASE", 56, 71], ["Clindamycin", "CHEMICAL", 0, 11], ["penicillin", "CHEMICAL", 16, 26], ["Clindamycin", "SIMPLE_CHEMICAL", 0, 11], ["penicillin", "SIMPLE_CHEMICAL", 16, 26], ["lung", "ORGAN", 56, 60], ["b-lactamase", "SIMPLE_CHEMICAL", 103, 114], ["Gram", "GENE_OR_GENE_PRODUCT", 132, 136], ["Clindamycin", "TREATMENT", 0, 11], ["penicillin studies", "TREATMENT", 16, 34], ["lung infections", "PROBLEM", 56, 71], ["the failure", "PROBLEM", 84, 95], ["b-lactamase production", "PROBLEM", 103, 125], ["Gram", "TEST", 132, 136], ["negative anaerobes", "PROBLEM", 137, 155], ["lung", "ANATOMY", 56, 60], ["infections", "OBSERVATION", 61, 71], ["failure", "OBSERVATION", 88, 95], ["negative anaerobes", "OBSERVATION", 137, 155]]], ["We found many reports of failure after clindamycin treatment in osteomyelitis, septic arthritis, brain abscess in presence of clindamycin-resistant anaerobes (Bacteroides fragilis group and Prevotella), probably because when resistance occurs, clindamycin MIC's are high.", [["brain abscess", "ANATOMY", 97, 110], ["clindamycin", "CHEMICAL", 39, 50], ["osteomyelitis", "DISEASE", 64, 77], ["septic arthritis", "DISEASE", 79, 95], ["brain abscess", "DISEASE", 97, 110], ["clindamycin", "CHEMICAL", 126, 137], ["clindamycin", "CHEMICAL", 244, 255], ["clindamycin", "CHEMICAL", 39, 50], ["clindamycin", "CHEMICAL", 126, 137], ["clindamycin", "CHEMICAL", 244, 255], ["clindamycin", "SIMPLE_CHEMICAL", 39, 50], ["brain", "ORGAN", 97, 102], ["clindamycin", "SIMPLE_CHEMICAL", 126, 137], ["Bacteroides fragilis", "ORGANISM", 159, 179], ["clindamycin", "SIMPLE_CHEMICAL", 244, 255], ["Bacteroides fragilis group", "SPECIES", 159, 185], ["Bacteroides fragilis", "SPECIES", 159, 179], ["failure", "PROBLEM", 25, 32], ["clindamycin treatment", "TREATMENT", 39, 60], ["osteomyelitis", "PROBLEM", 64, 77], ["septic arthritis", "PROBLEM", 79, 95], ["brain abscess", "PROBLEM", 97, 110], ["clindamycin", "TREATMENT", 126, 137], ["resistant anaerobes", "PROBLEM", 138, 157], ["Bacteroides fragilis", "PROBLEM", 159, 179], ["Prevotella", "PROBLEM", 190, 200], ["resistance", "PROBLEM", 225, 235], ["clindamycin MIC's", "TREATMENT", 244, 261], ["failure", "OBSERVATION", 25, 32], ["osteomyelitis", "OBSERVATION", 64, 77], ["septic", "OBSERVATION_MODIFIER", 79, 85], ["arthritis", "OBSERVATION", 86, 95], ["brain", "ANATOMY", 97, 102], ["abscess", "OBSERVATION", 103, 110], ["resistant", "OBSERVATION_MODIFIER", 138, 147], ["anaerobes", "OBSERVATION", 148, 157]]], ["Similarly, the lack of coverage of an undetected resistant anaerobe allows the selection of an anaerobic strain resistant to the treatment chosen against the associated aerobes such as imipenemresistant Eghertella lenta or metronidazole-resistant strains of Prevotella or Bacteroides fragilis.", [["imipenemresistant Eghertella lenta", "CHEMICAL", 185, 219], ["metronidazole", "CHEMICAL", 223, 236], ["metronidazole", "CHEMICAL", 223, 236], ["imipenemresistant", "SIMPLE_CHEMICAL", 185, 202], ["Eghertella lenta", "ORGANISM", 203, 219], ["metronidazole", "SIMPLE_CHEMICAL", 223, 236], ["Prevotella", "SIMPLE_CHEMICAL", 258, 268], ["Bacteroides fragilis", "ORGANISM", 272, 292], ["Eghertella lenta", "SPECIES", 203, 219], ["Bacteroides fragilis", "SPECIES", 272, 292], ["Eghertella lenta", "SPECIES", 203, 219], ["Bacteroides fragilis", "SPECIES", 272, 292], ["an undetected resistant anaerobe", "PROBLEM", 35, 67], ["an anaerobic strain", "PROBLEM", 92, 111], ["the treatment", "TREATMENT", 125, 138], ["the associated aerobes", "PROBLEM", 154, 176], ["imipenemresistant Eghertella lenta", "TREATMENT", 185, 219], ["metronidazole", "TREATMENT", 223, 236], ["resistant strains", "PROBLEM", 237, 254], ["Prevotella", "PROBLEM", 258, 268], ["Bacteroides fragilis", "PROBLEM", 272, 292], ["anaerobic strain", "OBSERVATION", 95, 111], ["aerobes", "OBSERVATION", 169, 176]]], ["The later failures may give opportunity to set up a new metronidazole breakpoint for resistance (MIC > 4 mg/L).", [["metronidazole", "CHEMICAL", 56, 69], ["metronidazole", "CHEMICAL", 56, 69], ["metronidazole", "SIMPLE_CHEMICAL", 56, 69], ["a new metronidazole breakpoint", "TREATMENT", 50, 80], ["resistance (MIC", "TREATMENT", 85, 100]]], ["The main problem is related to the difficulty to detect some heterogeneous resistant strains, that needs prolonged incubation period on agar medium.", [["strains", "ANATOMY", 85, 92], ["some heterogeneous resistant strains", "PROBLEM", 56, 92], ["agar medium", "TREATMENT", 136, 147], ["main", "OBSERVATION_MODIFIER", 4, 8], ["heterogeneous", "OBSERVATION_MODIFIER", 61, 74], ["resistant strains", "OBSERVATION", 75, 92]]], ["This kind of situation is probably the most suitable to correlate the bacterial antibiotic resistance with the failure of the antibiotic treatment.S. Kaplan\u00b0(Houston, US)Methicillin-resistant S. aureus isolates causing community-acquired infections (CA-MRSA) in children is a major problem in several areas around the world.", [["Methicillin", "CHEMICAL", 170, 181], ["S. aureus", "DISEASE", 192, 201], ["community-acquired infections (CA-MRSA", "DISEASE", 219, 257], ["Methicillin", "CHEMICAL", 170, 181], ["Methicillin-resistant", "ORGANISM", 170, 191], ["S. aureus isolates", "ORGANISM", 192, 210], ["children", "ORGANISM", 262, 270], ["S. aureus", "SPECIES", 192, 201], ["MRSA", "SPECIES", 253, 257], ["children", "SPECIES", 262, 270], ["S. aureus", "SPECIES", 192, 201], ["the bacterial antibiotic resistance", "TREATMENT", 66, 101], ["the antibiotic treatment", "TREATMENT", 122, 146], ["US", "TEST", 167, 169], ["Methicillin", "TEST", 170, 181], ["resistant S. aureus isolates", "PROBLEM", 182, 210], ["community-acquired infections", "PROBLEM", 219, 248], ["MRSA", "PROBLEM", 253, 257], ["bacterial antibiotic resistance", "OBSERVATION", 70, 101], ["major", "OBSERVATION_MODIFIER", 276, 281], ["problem", "OBSERVATION", 282, 289]]], ["CA-MRSA are associated with both skin and soft tissue infections and invasive infections.", [["skin", "ANATOMY", 33, 37], ["soft tissue", "ANATOMY", 42, 53], ["skin and soft tissue infections", "DISEASE", 33, 64], ["infections", "DISEASE", 78, 88], ["CA-MRSA", "GENE_OR_GENE_PRODUCT", 0, 7], ["skin", "ORGAN", 33, 37], ["soft tissue", "TISSUE", 42, 53], ["MRSA", "SPECIES", 3, 7], ["CA", "PROBLEM", 0, 2], ["MRSA", "PROBLEM", 3, 7], ["both skin and soft tissue infections", "PROBLEM", 28, 64], ["invasive infections", "PROBLEM", 69, 88], ["MRSA", "OBSERVATION", 3, 7], ["associated with", "UNCERTAINTY", 12, 27], ["both", "ANATOMY_MODIFIER", 28, 32], ["skin", "ANATOMY", 33, 37], ["soft tissue", "ANATOMY", 42, 53], ["infections", "OBSERVATION", 54, 64], ["invasive", "OBSERVATION_MODIFIER", 69, 77], ["infections", "OBSERVATION", 78, 88]]], ["Recurrent soft tissue infections and infections within the family caused by CA-MRSA isolates are common.", [["soft tissue", "ANATOMY", 10, 21], ["soft tissue infections", "DISEASE", 10, 32], ["infections", "DISEASE", 37, 47], ["soft tissue", "TISSUE", 10, 21], ["CA-MRSA", "ORGANISM", 76, 83], ["MRSA", "SPECIES", 79, 83], ["Recurrent soft tissue infections", "PROBLEM", 0, 32], ["infections", "PROBLEM", 37, 47], ["CA-MRSA isolates", "PROBLEM", 76, 92], ["soft tissue", "OBSERVATION_MODIFIER", 10, 21], ["infections", "OBSERVATION", 22, 32], ["infections", "OBSERVATION", 37, 47]]], ["CA-MRSA S. aureus isolates containing gene coding for PVL have been associated with serious staphylococcal pneumonia as well as osteomyelitis complicated by subperiosteal abscesses or venous thromboses.", [["subperiosteal abscesses", "ANATOMY", 157, 180], ["venous", "ANATOMY", 184, 190], ["staphylococcal pneumonia", "DISEASE", 92, 116], ["osteomyelitis", "DISEASE", 128, 141], ["subperiosteal abscesses", "DISEASE", 157, 180], ["venous thromboses", "DISEASE", 184, 201], ["CA-MRSA S. aureus isolates", "ORGANISM", 0, 26], ["PVL", "GENE_OR_GENE_PRODUCT", 54, 57], ["subperiosteal abscesses", "PATHOLOGICAL_FORMATION", 157, 180], ["venous thromboses", "PATHOLOGICAL_FORMATION", 184, 201], ["MRSA", "SPECIES", 3, 7], ["S. aureus", "SPECIES", 8, 17], ["S. aureus", "SPECIES", 8, 17], ["CA", "TEST", 0, 2], ["MRSA S. aureus isolates", "PROBLEM", 3, 26], ["PVL", "PROBLEM", 54, 57], ["serious staphylococcal pneumonia", "PROBLEM", 84, 116], ["osteomyelitis", "PROBLEM", 128, 141], ["subperiosteal abscesses", "PROBLEM", 157, 180], ["venous thromboses", "PROBLEM", 184, 201], ["aureus isolates", "OBSERVATION", 11, 26], ["associated with", "UNCERTAINTY", 68, 83], ["serious", "OBSERVATION_MODIFIER", 84, 91], ["staphylococcal", "OBSERVATION_MODIFIER", 92, 106], ["pneumonia", "OBSERVATION", 107, 116], ["osteomyelitis", "OBSERVATION", 128, 141], ["subperiosteal", "ANATOMY", 157, 170], ["abscesses", "OBSERVATION", 171, 180], ["venous", "ANATOMY", 184, 190], ["thromboses", "OBSERVATION", 191, 201]]], ["In addition to vancomycin, CA-MRSA generally are susceptible to clindamycin and trimethoprimsulfamethoxazole.", [["vancomycin", "CHEMICAL", 15, 25], ["clindamycin", "CHEMICAL", 64, 75], ["trimethoprimsulfamethoxazole", "CHEMICAL", 80, 108], ["vancomycin", "CHEMICAL", 15, 25], ["clindamycin", "CHEMICAL", 64, 75], ["trimethoprimsulfamethoxazole", "CHEMICAL", 80, 108], ["vancomycin", "SIMPLE_CHEMICAL", 15, 25], ["CA-MRSA", "SIMPLE_CHEMICAL", 27, 34], ["clindamycin", "SIMPLE_CHEMICAL", 64, 75], ["trimethoprimsulfamethoxazole", "SIMPLE_CHEMICAL", 80, 108], ["MRSA", "SPECIES", 30, 34], ["vancomycin", "TREATMENT", 15, 25], ["CA", "PROBLEM", 27, 29], ["MRSA", "PROBLEM", 30, 34], ["clindamycin", "TREATMENT", 64, 75], ["trimethoprimsulfamethoxazole", "TREATMENT", 80, 108], ["vancomycin", "OBSERVATION", 15, 25]]], ["Treatment of superficial skin and soft tissue infections involves surgical drainage of abscesses followed by an oral agent such as TMP-SMX or clindamycin.", [["skin", "ANATOMY", 25, 29], ["soft tissue", "ANATOMY", 34, 45], ["abscesses", "ANATOMY", 87, 96], ["oral", "ANATOMY", 112, 116], ["infections", "DISEASE", 46, 56], ["abscesses", "DISEASE", 87, 96], ["TMP-SMX", "CHEMICAL", 131, 138], ["clindamycin", "CHEMICAL", 142, 153], ["TMP-SMX", "CHEMICAL", 131, 138], ["clindamycin", "CHEMICAL", 142, 153], ["skin", "ORGAN", 25, 29], ["soft tissue", "TISSUE", 34, 45], ["abscesses", "PATHOLOGICAL_FORMATION", 87, 96], ["oral", "ORGANISM_SUBDIVISION", 112, 116], ["TMP-SMX", "SIMPLE_CHEMICAL", 131, 138], ["clindamycin", "SIMPLE_CHEMICAL", 142, 153], ["superficial skin and soft tissue infections", "PROBLEM", 13, 56], ["surgical drainage", "TREATMENT", 66, 83], ["abscesses", "PROBLEM", 87, 96], ["an oral agent", "TREATMENT", 109, 122], ["TMP-SMX", "TREATMENT", 131, 138], ["clindamycin", "TREATMENT", 142, 153], ["superficial", "ANATOMY_MODIFIER", 13, 24], ["skin", "ANATOMY", 25, 29], ["soft tissue", "OBSERVATION_MODIFIER", 34, 45], ["infections", "OBSERVATION", 46, 56], ["surgical", "OBSERVATION_MODIFIER", 66, 74], ["drainage", "OBSERVATION_MODIFIER", 75, 83], ["abscesses", "OBSERVATION", 87, 96]]], ["Minocycline or doxycycline is a consideration for children >8 years old.", [["Minocycline", "CHEMICAL", 0, 11], ["doxycycline", "CHEMICAL", 15, 26], ["Minocycline", "CHEMICAL", 0, 11], ["doxycycline", "CHEMICAL", 15, 26], ["Minocycline", "SIMPLE_CHEMICAL", 0, 11], ["doxycycline", "SIMPLE_CHEMICAL", 15, 26], ["children", "ORGANISM", 50, 58], ["children", "SPECIES", 50, 58], ["Minocycline", "TREATMENT", 0, 11], ["doxycycline", "TREATMENT", 15, 26]]], ["Empiric vancomycin is typically administered for more serious and invasive infections such as osteomyelitis, septic arthritis, serious head and neck infections or suspected Staphylococcal pneumonia.", [["head", "ANATOMY", 135, 139], ["neck", "ANATOMY", 144, 148], ["vancomycin", "CHEMICAL", 8, 18], ["infections", "DISEASE", 75, 85], ["osteomyelitis", "DISEASE", 94, 107], ["septic arthritis", "DISEASE", 109, 125], ["head and neck infections", "DISEASE", 135, 159], ["Staphylococcal pneumonia", "DISEASE", 173, 197], ["vancomycin", "CHEMICAL", 8, 18], ["vancomycin", "SIMPLE_CHEMICAL", 8, 18], ["head", "ORGANISM_SUBDIVISION", 135, 139], ["neck", "ORGANISM_SUBDIVISION", 144, 148], ["Empiric vancomycin", "TREATMENT", 0, 18], ["invasive infections", "PROBLEM", 66, 85], ["osteomyelitis", "PROBLEM", 94, 107], ["septic arthritis", "PROBLEM", 109, 125], ["serious head and neck infections", "PROBLEM", 127, 159], ["Staphylococcal pneumonia", "PROBLEM", 173, 197], ["invasive", "OBSERVATION_MODIFIER", 66, 74], ["infections", "OBSERVATION", 75, 85], ["osteomyelitis", "OBSERVATION", 94, 107], ["septic", "OBSERVATION_MODIFIER", 109, 115], ["arthritis", "OBSERVATION", 116, 125], ["neck", "ANATOMY", 144, 148], ["infections", "OBSERVATION", 149, 159], ["suspected", "UNCERTAINTY", 163, 172], ["Staphylococcal", "OBSERVATION_MODIFIER", 173, 187], ["pneumonia", "OBSERVATION", 188, 197]]], ["Clindamycin is efficacious in treating invasive CA-MRSA infections caused by susceptible organisms.", [["Clindamycin", "CHEMICAL", 0, 11], ["invasive CA-MRSA infections", "DISEASE", 39, 66], ["Clindamycin", "CHEMICAL", 0, 11], ["Clindamycin", "SIMPLE_CHEMICAL", 0, 11], ["CA-MRSA", "ORGANISM", 48, 55], ["MRSA", "SPECIES", 51, 55], ["Clindamycin", "TREATMENT", 0, 11], ["invasive CA", "PROBLEM", 39, 50], ["MRSA infections", "PROBLEM", 51, 66], ["susceptible organisms", "PROBLEM", 77, 98], ["MRSA", "OBSERVATION", 51, 55]]], ["Linezolid or daptomycin is another option in selected circumstances.", [["Linezolid", "CHEMICAL", 0, 9], ["daptomycin", "CHEMICAL", 13, 23], ["Linezolid", "CHEMICAL", 0, 9], ["daptomycin", "CHEMICAL", 13, 23], ["Linezolid", "SIMPLE_CHEMICAL", 0, 9], ["daptomycin", "SIMPLE_CHEMICAL", 13, 23], ["Linezolid", "TREATMENT", 0, 9], ["daptomycin", "TREATMENT", 13, 23]]], ["MRI is the optimal imaging modality for assessing children with CA-MRSA osteomyelitis.", [["osteomyelitis", "DISEASE", 72, 85], ["children", "ORGANISM", 50, 58], ["children", "SPECIES", 50, 58], ["MRSA", "SPECIES", 67, 71], ["MRI", "TEST", 0, 3], ["the optimal imaging modality", "TEST", 7, 35], ["CA", "PROBLEM", 64, 66], ["MRSA osteomyelitis", "PROBLEM", 67, 85], ["osteomyelitis", "OBSERVATION", 72, 85]]], ["Aggressive surgical drainage of subperiosteal abscesses or sites of pyomyositis is recommended.", [["subperiosteal abscesses", "ANATOMY", 32, 55], ["sites", "ANATOMY", 59, 64], ["abscesses", "DISEASE", 46, 55], ["pyomyositis", "DISEASE", 68, 79], ["subperiosteal abscesses", "PATHOLOGICAL_FORMATION", 32, 55], ["Aggressive surgical drainage", "TREATMENT", 0, 28], ["subperiosteal abscesses", "PROBLEM", 32, 55], ["pyomyositis", "PROBLEM", 68, 79], ["drainage", "OBSERVATION_MODIFIER", 20, 28], ["subperiosteal", "ANATOMY", 32, 45], ["abscesses", "OBSERVATION", 46, 55], ["pyomyositis", "OBSERVATION", 68, 79]]], ["Venous thombosis is increasingly recognized as a complication of CA-MRSA osteomyelitis.", [["Venous", "ANATOMY", 0, 6], ["Venous thombosis", "DISEASE", 0, 16], ["osteomyelitis", "DISEASE", 73, 86], ["Venous", "ORGANISM_SUBSTANCE", 0, 6], ["CA", "GENE_OR_GENE_PRODUCT", 65, 67], ["MRSA", "SPECIES", 68, 72], ["Venous thombosis", "PROBLEM", 0, 16], ["CA", "PROBLEM", 65, 67], ["MRSA osteomyelitis", "PROBLEM", 68, 86], ["thombosis", "OBSERVATION", 7, 16], ["MRSA", "OBSERVATION_MODIFIER", 68, 72], ["osteomyelitis", "OBSERVATION", 73, 86]]], ["Anti-coagulation until the thrombus has resolved is recommended.", [["thrombus", "ANATOMY", 27, 35], ["thrombus", "DISEASE", 27, 35], ["thrombus", "PATHOLOGICAL_FORMATION", 27, 35], ["Anti-coagulation", "TREATMENT", 0, 16], ["the thrombus", "PROBLEM", 23, 35], ["thrombus", "OBSERVATION", 27, 35]]], ["The optimal approach to prevention of recurrent CA-MRSA infections is unclear but a strategy that includes emphasizing personal hygiene, plus/minus antimicrobial soaps, mupirocin to the nose or \"bleach baths\" is frequently suggested.Invasive group A streptococcal diseaseS226 Understanding the pathogenesis of group A streptococcal disease: the bedside-to-bench approachS.", [["nose", "ANATOMY", 186, 190], ["infections", "DISEASE", 56, 66], ["mupirocin", "CHEMICAL", 169, 178], ["streptococcal disease", "DISEASE", 250, 271], ["streptococcal disease", "DISEASE", 318, 339], ["mupirocin", "CHEMICAL", 169, 178], ["CA-MRSA", "ORGANISM", 48, 55], ["mupirocin", "SIMPLE_CHEMICAL", 169, 178], ["nose", "ORGANISM_SUBDIVISION", 186, 190], ["MRSA", "SPECIES", 51, 55], ["recurrent CA", "PROBLEM", 38, 50], ["MRSA infections", "PROBLEM", 51, 66], ["personal hygiene", "TREATMENT", 119, 135], ["plus/minus antimicrobial soaps", "TREATMENT", 137, 167], ["mupirocin", "TREATMENT", 169, 178], ["\"bleach baths", "TREATMENT", 194, 207], ["Invasive group A streptococcal disease", "PROBLEM", 233, 271], ["A streptococcal disease", "PROBLEM", 316, 339], ["recurrent", "OBSERVATION_MODIFIER", 38, 47], ["CA", "OBSERVATION", 48, 50], ["MRSA", "OBSERVATION_MODIFIER", 51, 55], ["infections", "OBSERVATION", 56, 66], ["nose", "ANATOMY", 186, 190], ["streptococcal disease", "OBSERVATION", 250, 271], ["streptococcal disease", "OBSERVATION", 318, 339]]], ["Sriskandan\u00b0(London, UK)Invasive group A streptococcal (GAS) infection presents itself in a range of guises, most notoriously necrotising fasciitis and the streptococcal toxic shock syndrome.", [["Invasive group A streptococcal", "DISEASE", 23, 53], ["GAS) infection", "DISEASE", 55, 69], ["necrotising fasciitis", "DISEASE", 125, 146], ["streptococcal toxic shock syndrome", "DISEASE", 155, 189], ["group A streptococcal", "ORGANISM", 32, 53], ["Invasive group A streptococcal (GAS) infection", "PROBLEM", 23, 69], ["notoriously necrotising fasciitis", "PROBLEM", 113, 146], ["the streptococcal toxic shock syndrome", "PROBLEM", 151, 189], ["notoriously", "OBSERVATION_MODIFIER", 113, 124], ["necrotising", "OBSERVATION_MODIFIER", 125, 136], ["fasciitis", "OBSERVATION", 137, 146], ["streptococcal", "OBSERVATION_MODIFIER", 155, 168], ["toxic shock syndrome", "OBSERVATION", 169, 189]]], ["As a human pathogen, GAS pathogenesis research should ideally be shaped by clinical questions arising from either epidemiological or case-based investigation of human disease.", [["human", "ORGANISM", 5, 10], ["human", "ORGANISM", 161, 166], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 161, 166], ["a human pathogen", "PROBLEM", 3, 19], ["human disease", "PROBLEM", 161, 174]]], ["In the mid 1990 s, large epidemiological studies pointed to a central role for specific T cell-stimulating superantigens in the aetiology of streptococcal toxic shock.", [["T cell", "ANATOMY", 88, 94], ["streptococcal toxic shock", "DISEASE", 141, 166], ["T cell", "CELL", 88, 94], ["T cell-stimulating superantigens", "PROTEIN", 88, 120], ["large epidemiological studies", "TEST", 19, 48], ["specific T cell", "PROBLEM", 79, 94], ["streptococcal toxic shock", "PROBLEM", 141, 166], ["streptococcal", "OBSERVATION_MODIFIER", 141, 154], ["toxic shock", "OBSERVATION", 155, 166]]], ["This sparked a series of clinical and laboratory investigations that demonstrated production of superantigens during infection which were indeed capable of triggering massive T cell activation in patients but were unlikely, alone, to account for all the features observed in toxic shock.", [["T cell", "ANATOMY", 175, 181], ["infection", "DISEASE", 117, 126], ["toxic shock", "DISEASE", 275, 286], ["T cell", "CELL", 175, 181], ["patients", "ORGANISM", 196, 204], ["superantigens", "PROTEIN", 96, 109], ["patients", "SPECIES", 196, 204], ["laboratory investigations", "TEST", 38, 63], ["superantigens during infection", "PROBLEM", 96, 126], ["massive T cell activation", "PROBLEM", 167, 192], ["toxic shock", "PROBLEM", 275, 286], ["infection", "OBSERVATION", 117, 126], ["cell activation", "OBSERVATION", 177, 192], ["toxic shock", "OBSERVATION", 275, 286]]], ["Genomic, clinical and laboratory-based investigations have identified novel and highly potent superantigens that appear to directly contribute to sepsis pathogenesis and, together, may constitute targets for adjunctive treatments in invasive disease.", [["sepsis", "DISEASE", 146, 152], ["superantigens", "PROTEIN", 94, 107], ["sepsis pathogenesis", "PROBLEM", 146, 165], ["adjunctive treatments", "TREATMENT", 208, 229], ["invasive disease", "PROBLEM", 233, 249], ["sepsis", "OBSERVATION", 146, 152], ["invasive disease", "OBSERVATION", 233, 249]]], ["Epidemiological, clinical, and laboratory studies have highlighted a role for blunt trauma in the aetiology of at least a quarter of cases of GAS necrotising fasciitis.", [["blunt trauma", "DISEASE", 78, 90], ["necrotising fasciitis", "DISEASE", 146, 167], ["laboratory studies", "TEST", 31, 49], ["blunt trauma", "PROBLEM", 78, 90], ["GAS necrotising fasciitis", "PROBLEM", 142, 167], ["GAS", "OBSERVATION_MODIFIER", 142, 145], ["necrotising", "OBSERVATION_MODIFIER", 146, 157], ["fasciitis", "OBSERVATION", 158, 167]]], ["One of the most striking findings on examination of tissues from patients suffering with necrotising fasciitis is the failure of neutrophils to migrate to the focus of infection.", [["tissues", "ANATOMY", 52, 59], ["neutrophils", "ANATOMY", 129, 140], ["necrotising fasciitis", "DISEASE", 89, 110], ["infection", "DISEASE", 168, 177], ["tissues", "TISSUE", 52, 59], ["patients", "ORGANISM", 65, 73], ["neutrophils", "CELL", 129, 140], ["neutrophils", "CELL_TYPE", 129, 140], ["patients", "SPECIES", 65, 73], ["examination", "TEST", 37, 48], ["necrotising fasciitis", "PROBLEM", 89, 110], ["the failure of neutrophils", "PROBLEM", 114, 140], ["infection", "PROBLEM", 168, 177], ["most striking", "OBSERVATION_MODIFIER", 11, 24], ["findings", "OBSERVATION", 25, 33], ["necrotising", "OBSERVATION_MODIFIER", 89, 100], ["fasciitis", "OBSERVATION", 101, 110], ["infection", "OBSERVATION", 168, 177]]], ["Investigation of patients with invasive GAS infection led to the discovery that GAS produces an enzyme that can cleave and inactivate human chemokines and study of patients with bacteraemia has highlighted a likely role for the causal enzyme SpyCEP in disease pathogenesis; this bacterial surface enzyme has also shown promise as a potential vaccine antigen.", [["surface", "ANATOMY", 289, 296], ["GAS infection", "DISEASE", 40, 53], ["bacteraemia", "DISEASE", 178, 189], ["SpyCEP", "CHEMICAL", 242, 248], ["patients", "ORGANISM", 17, 25], ["GAS", "ORGANISM", 80, 83], ["human", "ORGANISM", 134, 139], ["patients", "ORGANISM", 164, 172], ["SpyCEP", "GENE_OR_GENE_PRODUCT", 242, 248], ["GAS", "DNA", 80, 83], ["human chemokines", "PROTEIN", 134, 150], ["SpyCEP", "PROTEIN", 242, 248], ["bacterial surface enzyme", "PROTEIN", 279, 303], ["patients", "SPECIES", 17, 25], ["human", "SPECIES", 134, 139], ["patients", "SPECIES", 164, 172], ["human", "SPECIES", 134, 139], ["invasive GAS infection", "PROBLEM", 31, 53], ["an enzyme", "TEST", 93, 102], ["human chemokines", "TEST", 134, 150], ["study", "TEST", 155, 160], ["bacteraemia", "PROBLEM", 178, 189], ["the causal enzyme SpyCEP in disease pathogenesis", "PROBLEM", 224, 272], ["this bacterial surface enzyme", "TEST", 274, 303], ["a potential vaccine antigen", "PROBLEM", 330, 357], ["invasive", "OBSERVATION_MODIFIER", 31, 39], ["infection", "OBSERVATION", 44, 53]]], ["Notwithstanding a potential role for individual virulence factors in disease causation, clinical studies have demonstrated that GAS bacteria may persist at the site of infection despite high concentrations of bactericidal antibiotics, and this has been borne out by experimental studies; the reasons behind such persistence are unclear but may include internalisation of GAS by immune cells, formation of biofilm, and antibiotic penetration of necrotic tissues.", [["immune cells", "ANATOMY", 378, 390], ["biofilm", "ANATOMY", 405, 412], ["necrotic tissues", "ANATOMY", 444, 460], ["infection", "DISEASE", 168, 177], ["necrotic", "DISEASE", 444, 452], ["GAS bacteria", "ORGANISM", 128, 140], ["GAS", "GENE_OR_GENE_PRODUCT", 371, 374], ["immune cells", "CELL", 378, 390], ["necrotic tissues", "TISSUE", 444, 460], ["virulence factors", "PROTEIN", 48, 65], ["immune cells", "CELL_TYPE", 378, 390], ["individual virulence factors", "PROBLEM", 37, 65], ["clinical studies", "TEST", 88, 104], ["GAS bacteria", "PROBLEM", 128, 140], ["infection", "PROBLEM", 168, 177], ["bactericidal antibiotics", "TREATMENT", 209, 233], ["experimental studies", "TEST", 266, 286], ["internalisation of GAS", "PROBLEM", 352, 374], ["immune cells", "PROBLEM", 378, 390], ["biofilm", "PROBLEM", 405, 412], ["antibiotic penetration", "TREATMENT", 418, 440], ["necrotic tissues", "PROBLEM", 444, 460], ["infection", "OBSERVATION", 168, 177], ["immune cells", "OBSERVATION", 378, 390], ["biofilm", "OBSERVATION_MODIFIER", 405, 412], ["necrotic tissues", "OBSERVATION", 444, 460]]], ["The persistence of viable bacteria in such cases is not widely recognized and deserves focused consideration in the research laboratory.J.M. Musser\u00b0(Houston, US)Genome-wide analysis of microbial pathogens and molecular pathogenesis processes has become an area of considerable activity in the last 10 years.", [["viable bacteria", "PROBLEM", 19, 34], ["microbial pathogens", "PROBLEM", 185, 204], ["molecular pathogenesis processes", "PROBLEM", 209, 241], ["persistence", "OBSERVATION_MODIFIER", 4, 15], ["viable", "OBSERVATION_MODIFIER", 19, 25], ["bacteria", "OBSERVATION", 26, 34], ["area", "OBSERVATION_MODIFIER", 256, 260], ["considerable", "OBSERVATION_MODIFIER", 264, 276], ["activity", "OBSERVATION_MODIFIER", 277, 285]]], ["These studies have been made possible by several advances, including completion of the human genome sequence, publication of genome sequences for many human pathogens, development of microarray technology and high-throughput proteomics, and maturation of bioinformatics.", [["human", "ORGANISM", 87, 92], ["human", "ORGANISM", 151, 156], ["human genome sequence", "DNA", 87, 108], ["genome sequences", "DNA", 125, 141], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 151, 156], ["These studies", "TEST", 0, 13], ["the human genome sequence", "TEST", 83, 108], ["genome sequences", "TEST", 125, 141], ["many human pathogens", "PROBLEM", 146, 166], ["microarray technology", "TEST", 183, 204]]], ["Despite these advances, relatively little effort has been expended in the bacterial pathogenesis arena to develop and use integrated research platforms in a systems biology approach to enhance our understanding of disease processes.", [["disease processes", "PROBLEM", 214, 231], ["disease", "OBSERVATION", 214, 221]]], ["We have exploited an integrated genome-wide research platform to gain new knowledge about how the human bacterial pathogen group A Streptococcus causes disease.J.M. Musser\u00b0(Houston, US)Results of these studies have provided many new avenues for basic pathogenesis research and translational research focused on development of an efficacious human vaccine and novel therapeutics.", [["human", "ORGANISM", 98, 103], ["bacterial pathogen group A Streptococcus", "ORGANISM", 104, 144], ["human", "ORGANISM", 341, 346], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 341, 346], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 341, 346], ["the human bacterial pathogen", "PROBLEM", 94, 122], ["disease", "PROBLEM", 152, 159], ["these studies", "TEST", 196, 209], ["an efficacious human vaccine", "TREATMENT", 326, 354], ["novel therapeutics", "TREATMENT", 359, 377]]], ["New data stemming from use of a systems biology approach to provide new data about group A Streptococcus pathogenesis will be presented.A. Norrby-Teglund\u00b0(Stockholm, SE)Streptococcal toxic shock syndrome and necrotising fasciitis caused by group A streptococcus are rapidly progressive invasive diseases that are associated with significant morbidity and mortality, ranging from 30\u221280% despite prompt antibiotic therapy and surgical debridement.", [["SE", "DISEASE", 166, 168], ["Streptococcal toxic shock syndrome", "DISEASE", 169, 203], ["necrotising fasciitis", "DISEASE", 208, 229], ["group A streptococcus", "DISEASE", 240, 261], ["A Streptococcus", "ORGANISM", 89, 104], ["group A streptococcus", "SPECIES", 240, 261], ["a systems biology approach", "TREATMENT", 30, 56], ["group A Streptococcus pathogenesis", "PROBLEM", 83, 117], ["Streptococcal toxic shock syndrome", "PROBLEM", 169, 203], ["necrotising fasciitis", "PROBLEM", 208, 229], ["group A streptococcus", "PROBLEM", 240, 261], ["rapidly progressive invasive diseases", "PROBLEM", 266, 303], ["significant morbidity", "PROBLEM", 329, 350], ["prompt antibiotic therapy", "TREATMENT", 394, 419], ["surgical debridement", "TREATMENT", 424, 444], ["Streptococcal", "OBSERVATION_MODIFIER", 169, 182], ["toxic shock syndrome", "OBSERVATION", 183, 203], ["necrotising", "OBSERVATION_MODIFIER", 208, 219], ["fasciitis", "OBSERVATION", 220, 229], ["rapidly", "OBSERVATION_MODIFIER", 266, 273], ["progressive", "OBSERVATION_MODIFIER", 274, 285], ["invasive", "OBSERVATION_MODIFIER", 286, 294], ["associated with", "UNCERTAINTY", 313, 328], ["significant", "OBSERVATION_MODIFIER", 329, 340], ["morbidity", "OBSERVATION", 341, 350], ["surgical debridement", "OBSERVATION", 424, 444]]], ["S. pyogenes is known to primarily cause disease by activating and modulating host immune responses.", [["S. pyogenes", "ORGANISM", 0, 11], ["S. pyogenes", "SPECIES", 0, 11], ["S. pyogenes", "SPECIES", 0, 11], ["S. pyogenes", "PROBLEM", 0, 11], ["disease", "PROBLEM", 40, 47], ["pyogenes", "OBSERVATION", 3, 11]]], ["The exotoxins with superantigenic activities have been demonstrated to be crucial triggers of excessive inflammatory responses and consequently systemic toxicity, organ dysfunction, tissue necrosis and shock.", [["organ", "ANATOMY", 163, 168], ["tissue", "ANATOMY", 182, 188], ["toxicity", "DISEASE", 153, 161], ["organ dysfunction", "DISEASE", 163, 180], ["necrosis", "DISEASE", 189, 197], ["shock", "DISEASE", 202, 207], ["organ", "ORGAN", 163, 168], ["tissue", "TISSUE", 182, 188], ["superantigenic activities", "TREATMENT", 19, 44], ["excessive inflammatory responses", "PROBLEM", 94, 126], ["systemic toxicity", "PROBLEM", 144, 161], ["organ dysfunction", "PROBLEM", 163, 180], ["tissue necrosis", "PROBLEM", 182, 197], ["shock", "PROBLEM", 202, 207], ["excessive", "OBSERVATION_MODIFIER", 94, 103], ["inflammatory", "OBSERVATION", 104, 116], ["tissue", "OBSERVATION_MODIFIER", 182, 188], ["necrosis", "OBSERVATION", 189, 197], ["shock", "OBSERVATION", 202, 207]]], ["Another important virulence determinant is the M-protein, which is classically known for its antiphagocytic properties, and lately, was shown to trigger pro-inflammatory responses as well as induction of vascular leakage and shock.", [["vascular", "ANATOMY", 204, 212], ["vascular leakage", "DISEASE", 204, 220], ["shock", "DISEASE", 225, 230], ["M-protein", "GENE_OR_GENE_PRODUCT", 47, 56], ["vascular", "MULTI-TISSUE_STRUCTURE", 204, 212], ["M-protein", "PROTEIN", 47, 56], ["the M-protein", "PROBLEM", 43, 56], ["vascular leakage", "PROBLEM", 204, 220], ["shock", "PROBLEM", 225, 230], ["M-protein", "OBSERVATION", 47, 56], ["vascular", "ANATOMY", 204, 212], ["leakage", "OBSERVATION", 213, 220], ["shock", "OBSERVATION", 225, 230]]], ["This likely represents important mechanisms contributing to the rapid development of shock and systemic toxicity in patients with severe invasive group A streptococcal infections.", [["shock", "DISEASE", 85, 90], ["toxicity", "DISEASE", 104, 112], ["streptococcal infections", "DISEASE", 154, 178], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["shock", "PROBLEM", 85, 90], ["systemic toxicity", "PROBLEM", 95, 112], ["severe invasive group A streptococcal infections", "PROBLEM", 130, 178], ["likely represents", "UNCERTAINTY", 5, 22], ["rapid", "OBSERVATION_MODIFIER", 64, 69], ["shock", "OBSERVATION", 85, 90], ["systemic", "OBSERVATION_MODIFIER", 95, 103], ["toxicity", "OBSERVATION", 104, 112], ["severe", "OBSERVATION_MODIFIER", 130, 136], ["invasive", "OBSERVATION_MODIFIER", 137, 145], ["streptococcal", "OBSERVATION_MODIFIER", 154, 167], ["infections", "OBSERVATION", 168, 178]]], ["The understanding of these infections as hyperinflammatory diseases highlighted the potential of immunotherapy to improve outcome.", [["infections", "DISEASE", 27, 37], ["hyperinflammatory diseases", "DISEASE", 41, 67], ["these infections", "PROBLEM", 21, 37], ["hyperinflammatory diseases", "PROBLEM", 41, 67], ["immunotherapy", "TREATMENT", 97, 110], ["infections", "OBSERVATION", 27, 37]]], ["One such strategy includes the administration of intravenous polyspecific immunoglobulin (IVIG) as adjunctive therapy.", [["intravenous", "ANATOMY", 49, 60], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 49, 60], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 74, 88], ["IVIG", "SIMPLE_CHEMICAL", 90, 94], ["polyspecific immunoglobulin", "PROTEIN", 61, 88], ["IVIG", "PROTEIN", 90, 94], ["intravenous polyspecific immunoglobulin (IVIG)", "TREATMENT", 49, 95], ["adjunctive therapy", "TREATMENT", 99, 117]]], ["The mechanistic actions of IVIG in this setting are believed to include opsonisation of the bacteria, neutralisation of the superantigens and suppression of the pro-inflammatory responses.", [["IVIG", "CHEMICAL", 27, 31], ["IVIG", "SIMPLE_CHEMICAL", 27, 31], ["superantigens", "PROTEIN", 124, 137], ["IVIG", "TREATMENT", 27, 31], ["the bacteria", "PROBLEM", 88, 100], ["the superantigens", "PROBLEM", 120, 137], ["bacteria", "OBSERVATION", 92, 100]]], ["There is growing evidence to support the use of IVIG in patients with streptococcal toxic shock syndrome.", [["streptococcal toxic shock syndrome", "DISEASE", 70, 104], ["IVIG", "SIMPLE_CHEMICAL", 48, 52], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["IVIG", "TREATMENT", 48, 52], ["streptococcal toxic shock syndrome", "PROBLEM", 70, 104], ["toxic shock syndrome", "OBSERVATION", 84, 104]]], ["These studies include one observational cohort study based on Canadian patients identified through active surveillance of invasive group A streptococcal infections, and one European multicentre placebo-controlled trial.", [["streptococcal infections", "DISEASE", 139, 163], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["These studies", "TEST", 0, 13], ["one observational cohort study", "TEST", 22, 52], ["invasive group A streptococcal infections", "PROBLEM", 122, 163], ["invasive", "OBSERVATION_MODIFIER", 122, 130], ["streptococcal", "OBSERVATION_MODIFIER", 139, 152], ["infections", "OBSERVATION", 153, 163]]], ["However, the question remains whether IVIG is efficacious also for the severe streptococcal deep tissue infections.", [["tissue", "ANATOMY", 97, 103], ["streptococcal deep tissue infections", "DISEASE", 78, 114], ["IVIG", "SIMPLE_CHEMICAL", 38, 42], ["tissue", "TISSUE", 97, 103], ["IVIG", "TREATMENT", 38, 42], ["the severe streptococcal deep tissue infections", "PROBLEM", 67, 114], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["streptococcal", "OBSERVATION_MODIFIER", 78, 91], ["deep tissue infections", "OBSERVATION", 92, 114]]], ["An observational study of seven patients with severe streptococcal deep tissue infections suggested that the use of high-dose IVIG in patients with severe GAS soft tissue infections may allow an initial non-operative or minimally invasive approach, which can limit the need to perform immediate wide debridements and amputations in unstable patients.", [["tissue", "ANATOMY", 72, 78], ["soft tissue", "ANATOMY", 159, 170], ["streptococcal deep tissue infections", "DISEASE", 53, 89], ["infections", "DISEASE", 171, 181], ["amputations", "DISEASE", 317, 328], ["patients", "ORGANISM", 32, 40], ["tissue", "TISSUE", 72, 78], ["IVIG", "SIMPLE_CHEMICAL", 126, 130], ["patients", "ORGANISM", 134, 142], ["tissue", "TISSUE", 164, 170], ["patients", "ORGANISM", 341, 349], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 134, 142], ["patients", "SPECIES", 341, 349], ["An observational study", "TEST", 0, 22], ["severe streptococcal deep tissue infections", "PROBLEM", 46, 89], ["high-dose IVIG", "TREATMENT", 116, 130], ["severe GAS soft tissue infections", "PROBLEM", 148, 181], ["an initial non-operative", "TREATMENT", 192, 216], ["minimally invasive approach", "TREATMENT", 220, 247], ["immediate wide debridements", "TREATMENT", 285, 312], ["amputations", "TREATMENT", 317, 328], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["streptococcal", "OBSERVATION_MODIFIER", 53, 66], ["deep tissue", "OBSERVATION_MODIFIER", 67, 78], ["infections", "OBSERVATION", 79, 89], ["severe", "OBSERVATION_MODIFIER", 148, 154], ["GAS", "OBSERVATION", 155, 158], ["soft tissue", "OBSERVATION_MODIFIER", 159, 170], ["infections", "OBSERVATION", 171, 181], ["minimally", "OBSERVATION_MODIFIER", 220, 229], ["invasive", "OBSERVATION", 230, 238], ["debridements", "OBSERVATION", 300, 312], ["amputations", "OBSERVATION", 317, 328], ["unstable", "OBSERVATION_MODIFIER", 332, 340]]], ["The fact that seven patients with severe group A streptococcal infections survived with this approach definitely warrants further studies to be conducted on the use of IVIG in these severe infections.Blood-borne viral diseasesHepatitis O229 Prevalence and outcome of pregnancy in chronic hepatitis C virus infection I. Julkunen\u00b0, A. Sariola, M. Sillanp\u00e4\u00e4, K. Melen, P. Koskela, P. Finne, A.L. J\u00e4rvenp\u00e4\u00e4, S. Riikonen, H.M. Surcel (Helsinki, Oulu, FI) Objectives: In the Western countries the incidence of hepatitis C virus (HCV) infection has steadily been increasing especially among young adults.", [["Blood", "ANATOMY", 200, 205], ["streptococcal infections", "DISEASE", 49, 73], ["infections", "DISEASE", 189, 199], ["viral diseases", "DISEASE", 212, 226], ["Hepatitis", "DISEASE", 226, 235], ["chronic hepatitis C virus infection", "DISEASE", 280, 315], ["hepatitis C virus (HCV) infection", "DISEASE", 504, 537], ["patients", "ORGANISM", 20, 28], ["IVIG", "SIMPLE_CHEMICAL", 168, 172], ["Blood", "ORGANISM_SUBSTANCE", 200, 205], ["Hepatitis O229", "ORGANISM", 226, 240], ["hepatitis C virus", "ORGANISM", 288, 305], ["hepatitis C virus", "ORGANISM", 504, 521], ["HCV", "ORGANISM", 523, 526], ["patients", "SPECIES", 20, 28], ["hepatitis C virus", "SPECIES", 288, 305], ["hepatitis C virus", "SPECIES", 504, 521], ["hepatitis C virus", "SPECIES", 288, 305], ["hepatitis C virus", "SPECIES", 504, 521], ["HCV", "SPECIES", 523, 526], ["severe group A streptococcal infections", "PROBLEM", 34, 73], ["this approach", "TREATMENT", 88, 101], ["further studies", "TEST", 122, 137], ["IVIG", "TREATMENT", 168, 172], ["these severe infections", "PROBLEM", 176, 199], ["Blood-borne viral diseases", "PROBLEM", 200, 226], ["Hepatitis", "PROBLEM", 226, 235], ["pregnancy", "PROBLEM", 267, 276], ["chronic hepatitis C virus infection", "PROBLEM", 280, 315], ["hepatitis C virus (HCV) infection", "PROBLEM", 504, 537], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["streptococcal", "OBSERVATION_MODIFIER", 49, 62], ["infections", "OBSERVATION", 63, 73], ["severe", "OBSERVATION_MODIFIER", 182, 188], ["infections", "OBSERVATION", 189, 199], ["viral diseases", "OBSERVATION", 212, 226], ["chronic", "OBSERVATION_MODIFIER", 280, 287], ["hepatitis", "OBSERVATION", 288, 297], ["hepatitis", "OBSERVATION", 504, 513]]], ["It is thus likely that an increasing prevalence of HCV infection is also found in pregnant women.", [["HCV infection", "DISEASE", 51, 64], ["HCV", "ORGANISM", 51, 54], ["women", "ORGANISM", 91, 96], ["women", "SPECIES", 91, 96], ["HCV", "SPECIES", 51, 54], ["HCV infection", "PROBLEM", 51, 64], ["thus likely", "UNCERTAINTY", 6, 17], ["increasing", "OBSERVATION_MODIFIER", 26, 36], ["HCV", "OBSERVATION_MODIFIER", 51, 54], ["infection", "OBSERVATION", 55, 64]]], ["Methods: To assess the frequency of HCV infection in the metropolitan area of Helsinki selected anti-HCV antibody testing was carried out for pregnant women during the years 1991-1999.", [["HCV infection", "DISEASE", 36, 49], ["HCV", "ORGANISM", 36, 39], ["women", "ORGANISM", 151, 156], ["women", "SPECIES", 151, 156], ["HCV", "SPECIES", 36, 39], ["HCV infection", "PROBLEM", 36, 49], ["Helsinki selected anti-HCV antibody testing", "TEST", 78, 121], ["HCV", "OBSERVATION_MODIFIER", 36, 39], ["infection", "OBSERVATION", 40, 49]]], ["In addition, HCV prevalence was analysed in serum specimens collected from pregnant maters during the years of 1985-2005.", [["serum specimens", "ANATOMY", 44, 59], ["HCV", "ORGANISM", 13, 16], ["serum specimens", "ORGANISM_SUBSTANCE", 44, 59], ["HCV", "SPECIES", 13, 16], ["HCV prevalence", "TEST", 13, 27], ["serum specimens", "TEST", 44, 59]]], ["Results: Altogether 145 mothers were identified among 44680 mothers.", [["mothers", "ORGANISM", 24, 31]]], ["The frequency of anti-HCV positivity rose from 0.13% in 1991 to 0.43\u22120.53 in 1997-1999.", [["anti-HCV positivity", "TEST", 17, 36], ["anti-HCV", "OBSERVATION", 17, 25]]], ["In early 90's only 20% of mothers knew about their seropositivity, whereas by the end of the follow-up period almost 70% of mothers knew about their HCV infection already before the pregnancy.", [["HCV infection", "DISEASE", 149, 162], ["mothers", "ORGANISM", 26, 33], ["mothers", "ORGANISM", 124, 131], ["HCV", "ORGANISM", 149, 152], ["HCV", "SPECIES", 149, 152], ["their HCV infection", "PROBLEM", 143, 162], ["the pregnancy", "PROBLEM", 178, 191], ["infection", "OBSERVATION", 153, 162]]], ["Intravenous drug abuse was the major risk factor (71% of cases) for contracting the disease.", [["drug abuse", "DISEASE", 12, 22], ["the disease", "PROBLEM", 80, 91], ["disease", "OBSERVATION", 84, 91]]], ["In 90% of the mothers chronic HCV infection was well under control and in this population the mean serum alanine aminotransferase (ALT) values decreased towards the end of the pregnancy.", [["serum", "ANATOMY", 99, 104], ["HCV infection", "DISEASE", 30, 43], ["alanine", "CHEMICAL", 105, 112], ["alanine", "CHEMICAL", 105, 112], ["mothers", "ORGANISM", 14, 21], ["HCV", "ORGANISM", 30, 33], ["serum", "ORGANISM_SUBSTANCE", 99, 104], ["alanine", "AMINO_ACID", 105, 112], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 113, 129], ["ALT", "SIMPLE_CHEMICAL", 131, 134], ["serum alanine aminotransferase", "PROTEIN", 99, 129], ["ALT", "PROTEIN", 131, 134], ["HCV", "SPECIES", 30, 33], ["the mothers chronic HCV infection", "PROBLEM", 10, 43], ["the mean serum alanine aminotransferase", "TEST", 90, 129], ["ALT", "TEST", 131, 134], ["HCV", "OBSERVATION_MODIFIER", 30, 33], ["infection", "OBSERVATION", 34, 43]]], ["However, 10% of anti-HCV Ab positive mothers developed intrahepatic cholestasis (odds ratio 16.4) as characterised by itching and elevated serum bile acid levels.", [["intrahepatic cholestasis", "ANATOMY", 55, 79], ["serum", "ANATOMY", 139, 144], ["intrahepatic cholestasis", "DISEASE", 55, 79], ["itching", "DISEASE", 118, 125], ["bile acid", "CHEMICAL", 145, 154], ["bile acid", "CHEMICAL", 145, 154], ["anti-HCV Ab", "ORGANISM", 16, 27], ["mothers", "ORGANISM", 37, 44], ["intrahepatic cholestasis", "PATHOLOGICAL_FORMATION", 55, 79], ["serum", "ORGANISM_SUBSTANCE", 139, 144], ["bile acid", "SIMPLE_CHEMICAL", 145, 154], ["anti-HCV Ab", "PROTEIN", 16, 27], ["anti-HCV Ab positive", "TEST", 16, 36], ["intrahepatic cholestasis", "PROBLEM", 55, 79], ["odds ratio", "TEST", 81, 91], ["itching", "PROBLEM", 118, 125], ["elevated serum bile acid levels", "PROBLEM", 130, 161], ["intrahepatic", "ANATOMY", 55, 67], ["cholestasis", "OBSERVATION", 68, 79], ["itching", "OBSERVATION", 118, 125], ["elevated", "OBSERVATION", 130, 138]]], ["The correspondig value in the control pregnancies was only 0.7%.", [["The correspondig value", "TEST", 0, 22]]], ["Anti-HCV Ab positive mothers were younger, delivered earlier and gave birth to babies with smaller birth weight as compared to control deliveries.", [["Ab", "GENE_OR_GENE_PRODUCT", 9, 11], ["babies", "ORGANISM", 79, 85], ["Anti-HCV", "TREATMENT", 0, 8], ["smaller birth weight", "PROBLEM", 91, 111], ["positive", "OBSERVATION", 12, 20]]], ["To have a more comprehensive view of the problem of HCV infection during pregnancy randomly selected serum specimens from the Finnish maternity cohort were tested.", [["serum specimens", "ANATOMY", 101, 116], ["HCV infection", "DISEASE", 52, 65], ["HCV", "ORGANISM", 52, 55], ["serum specimens", "ORGANISM_SUBSTANCE", 101, 116], ["HCV", "SPECIES", 52, 55], ["HCV infection", "PROBLEM", 52, 65], ["serum specimens", "TEST", 101, 116], ["HCV", "OBSERVATION_MODIFIER", 52, 55], ["infection", "OBSERVATION", 56, 65]]], ["2000-5000 serum specimens were tested in selected cohorts (1985, 1990, 1995, 2000 and 2005) .", [["serum specimens", "ANATOMY", 10, 25], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["specimens", "ORGANISM_SUBSTANCE", 16, 25], ["serum specimens", "TEST", 10, 25]]], ["In the metropolitan area of Helsinki the prevalence was higher being 0.68% and 0.70 in 1997 and 2002, respectively.", [["metropolitan", "ANATOMY_MODIFIER", 7, 19], ["higher", "OBSERVATION_MODIFIER", 56, 62]]], ["Conclusion: Our study indicates that there is an increasing problem of HCV infection in pregnant women in Finland.", [["HCV infection", "DISEASE", 71, 84], ["HCV", "ORGANISM", 71, 74], ["women", "ORGANISM", 97, 102], ["women", "SPECIES", 97, 102], ["HCV", "SPECIES", 71, 74], ["Our study", "TEST", 12, 21], ["HCV infection", "PROBLEM", 71, 84], ["increasing", "OBSERVATION_MODIFIER", 49, 59], ["HCV", "OBSERVATION_MODIFIER", 71, 74], ["infection", "OBSERVATION", 75, 84]]], ["Although most women cope well with their disease during pregnancy there is a subpopulation of mothers who develop cholestasis and their liver status should thus be followed-up carefully.", [["liver", "ANATOMY", 136, 141], ["cholestasis", "DISEASE", 114, 125], ["women", "ORGANISM", 14, 19], ["mothers", "ORGANISM", 94, 101], ["liver", "ORGAN", 136, 141], ["women", "SPECIES", 14, 19], ["their disease during pregnancy", "PROBLEM", 35, 65], ["cholestasis", "PROBLEM", 114, 125], ["cholestasis", "OBSERVATION", 114, 125], ["liver", "ANATOMY", 136, 141]]], ["Testing of all mothers for serum anti-HCV antibodies is recommended.", [["serum", "ANATOMY", 27, 32], ["mothers", "ORGANISM", 15, 22], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["serum anti-HCV antibodies", "PROTEIN", 27, 52], ["serum anti-HCV antibodies", "TEST", 27, 52]]], ["Objectives: The viral genome of hepatitis C virus constitutes a 9.6kb single-stranded positive-sense RNA which encodes altogether 11 viral proteins.", [["hepatitis C", "DISEASE", 32, 43], ["hepatitis C virus", "ORGANISM", 32, 49], ["viral genome", "DNA", 16, 28], ["9.6kb single-stranded positive-sense RNA", "RNA", 64, 104], ["viral proteins", "PROTEIN", 133, 147], ["hepatitis C virus", "SPECIES", 32, 49], ["hepatitis C virus", "SPECIES", 32, 49], ["hepatitis C virus", "PROBLEM", 32, 49], ["stranded positive-sense RNA", "PROBLEM", 77, 104], ["viral proteins", "TEST", 133, 147]]], ["In order to study the humoral immune responses against different HCV proteins in patients suffering from chronic HCV infection, we produced three structural (C, E1 and E2) and six nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) in Sf9 insect cells by using the baculovirus expression system.Methods:The recombinant HCV proteins were purified and used in Western blot analysis to determine antibody responses against individual HCV protein in 68 HCV RNA and antibody positive human sera that were obtained from patients suffering from genotype 1, 2, 3 or 4 infection.", [["cells", "ANATOMY", 255, 260], ["sera", "ANATOMY", 494, 498], ["HCV infection", "DISEASE", 113, 126], ["infection", "DISEASE", 569, 578], ["HCV", "ORGANISM", 65, 68], ["patients", "ORGANISM", 81, 89], ["E2", "GENE_OR_GENE_PRODUCT", 168, 170], ["NS2", "GENE_OR_GENE_PRODUCT", 204, 207], ["NS3", "GENE_OR_GENE_PRODUCT", 209, 212], ["NS4A", "GENE_OR_GENE_PRODUCT", 214, 218], ["NS4B", "GENE_OR_GENE_PRODUCT", 220, 224], ["NS5A", "GENE_OR_GENE_PRODUCT", 226, 230], ["NS5B", "GENE_OR_GENE_PRODUCT", 235, 239], ["Sf9 insect cells", "CELL", 244, 260], ["baculovirus", "ORGANISM", 274, 285], ["HCV", "ORGANISM", 328, 331], ["HCV", "ORGANISM", 440, 443], ["HCV", "ORGANISM", 458, 461], ["human", "ORGANISM", 488, 493], ["sera", "ORGANISM_SUBSTANCE", 494, 498], ["patients", "ORGANISM", 523, 531], ["HCV proteins", "PROTEIN", 65, 77], ["E1", "PROTEIN", 161, 163], ["E2", "PROTEIN", 168, 170], ["nonstructural proteins", "PROTEIN", 180, 202], ["NS2", "PROTEIN", 204, 207], ["NS3", "PROTEIN", 209, 212], ["NS4A", "PROTEIN", 214, 218], ["NS4B", "PROTEIN", 220, 224], ["NS5A", "PROTEIN", 226, 230], ["NS5B", "PROTEIN", 235, 239], ["Sf9 insect cells", "CELL_LINE", 244, 260], ["recombinant HCV proteins", "PROTEIN", 316, 340], ["HCV protein", "PROTEIN", 440, 451], ["patients", "SPECIES", 81, 89], ["human", "SPECIES", 488, 493], ["patients", "SPECIES", 523, 531], ["HCV", "SPECIES", 65, 68], ["HCV", "SPECIES", 113, 116], ["Sf9", "SPECIES", 244, 247], ["baculovirus", "SPECIES", 274, 285], ["HCV", "SPECIES", 328, 331], ["HCV", "SPECIES", 440, 443], ["HCV", "SPECIES", 458, 461], ["human", "SPECIES", 488, 493], ["different HCV proteins", "PROBLEM", 55, 77], ["chronic HCV infection", "PROBLEM", 105, 126], ["E1 and E2", "TREATMENT", 161, 170], ["six nonstructural proteins", "TEST", 176, 202], ["NS2", "TEST", 204, 207], ["NS3", "TREATMENT", 209, 212], ["NS4A", "TREATMENT", 214, 218], ["NS4B", "TREATMENT", 220, 224], ["NS5A", "TREATMENT", 226, 230], ["NS5B", "TREATMENT", 235, 239], ["Sf9 insect cells", "TREATMENT", 244, 260], ["the baculovirus expression system", "TREATMENT", 270, 303], ["The recombinant HCV proteins", "TREATMENT", 312, 340], ["Western blot analysis", "TEST", 367, 388], ["antibody responses", "TEST", 402, 420], ["individual HCV protein", "TEST", 429, 451], ["HCV RNA", "TEST", 458, 465], ["antibody positive human sera", "PROBLEM", 470, 498], ["4 infection", "PROBLEM", 567, 578], ["chronic", "OBSERVATION_MODIFIER", 105, 112], ["HCV", "OBSERVATION_MODIFIER", 113, 116], ["infection", "OBSERVATION", 117, 126], ["NS5A", "ANATOMY", 226, 230], ["infection", "OBSERVATION", 569, 578]]], ["Results: These sera were also analysed with INNO-LIA Score test for HCV antibodies against core, NS3, NS4AB and NS5A, and the results were similar to our Western blot method.", [["sera", "ANATOMY", 15, 19], ["sera", "ORGANISM_SUBSTANCE", 15, 19], ["HCV", "ORGANISM", 68, 71], ["NS3", "GENE_OR_GENE_PRODUCT", 97, 100], ["NS4AB", "GENE_OR_GENE_PRODUCT", 102, 107], ["NS5A", "GENE_OR_GENE_PRODUCT", 112, 116], ["HCV antibodies", "PROTEIN", 68, 82], ["NS3", "PROTEIN", 97, 100], ["NS4AB", "PROTEIN", 102, 107], ["NS5A", "PROTEIN", 112, 116], ["HCV", "SPECIES", 68, 71], ["These sera", "TEST", 9, 19], ["LIA Score test", "TEST", 49, 63], ["HCV antibodies", "TEST", 68, 82], ["NS3", "TREATMENT", 97, 100], ["NS4AB", "TREATMENT", 102, 107], ["NS5A", "TREATMENT", 112, 116]]], ["Based on our Western blot analyses we found that the major viral antigens were the core, NS4B, NS3 and NS5A proteins and they were recognized in 97%, 86%, 68% and 53% of patient sera, respectively.", [["sera", "ANATOMY", 178, 182], ["NS4B", "GENE_OR_GENE_PRODUCT", 89, 93], ["NS3", "GENE_OR_GENE_PRODUCT", 95, 98], ["NS5A", "GENE_OR_GENE_PRODUCT", 103, 107], ["patient", "ORGANISM", 170, 177], ["sera", "ORGANISM_SUBSTANCE", 178, 182], ["major viral antigens", "PROTEIN", 53, 73], ["NS4B", "PROTEIN", 89, 93], ["NS3", "PROTEIN", 95, 98], ["NS5A proteins", "PROTEIN", 103, 116], ["patient", "SPECIES", 170, 177], ["our Western blot analyses", "TEST", 9, 34], ["the major viral antigens", "TEST", 49, 73], ["NS4B", "TEST", 89, 93], ["NS3", "TEST", 95, 98], ["NS5A proteins", "TEST", 103, 116], ["patient sera", "TEST", 170, 182]]], ["There were no major genotype specific differences in antibody responses to individual HCV proteins.", [["HCV", "ORGANISM", 86, 89], ["HCV proteins", "PROTEIN", 86, 98], ["HCV", "SPECIES", 86, 89], ["major genotype specific differences in antibody responses", "PROBLEM", 14, 71], ["individual HCV proteins", "PROBLEM", 75, 98], ["no", "UNCERTAINTY", 11, 13], ["major", "OBSERVATION_MODIFIER", 14, 19]]], ["A common feature within the studied sera was that all except two sera recognized the core protein in high titers, whereas none of the sera recognized NS2 protein and only three sera (from genotype 3) recognised NS5B.Conclusion:The data shows significant variation in the specificity in humoral immunity in chronic HCV patients.", [["sera", "ANATOMY", 36, 40], ["sera", "ANATOMY", 65, 69], ["sera", "ANATOMY", 134, 138], ["sera", "ANATOMY", 177, 181], ["HCV", "DISEASE", 314, 317], ["sera", "ORGANISM_SUBSTANCE", 36, 40], ["sera", "ORGANISM_SUBSTANCE", 65, 69], ["sera", "ORGANISM_SUBSTANCE", 134, 138], ["NS2", "GENE_OR_GENE_PRODUCT", 150, 153], ["sera", "ORGANISM_SUBSTANCE", 177, 181], ["NS5B", "GENE_OR_GENE_PRODUCT", 211, 215], ["HCV", "ORGANISM", 314, 317], ["patients", "ORGANISM", 318, 326], ["core protein", "PROTEIN", 85, 97], ["NS2 protein", "PROTEIN", 150, 161], ["NS5B", "PROTEIN", 211, 215], ["patients", "SPECIES", 318, 326], ["HCV", "SPECIES", 314, 317], ["the core protein", "TEST", 81, 97], ["the sera", "TEST", 130, 138], ["NS2 protein", "TEST", 150, 161], ["three sera", "TEST", 171, 181], ["genotype", "TEST", 188, 196], ["NS5B", "PROBLEM", 211, 215], ["The data", "TEST", 227, 235], ["significant variation", "PROBLEM", 242, 263], ["chronic HCV patients", "PROBLEM", 306, 326], ["high titers", "OBSERVATION", 101, 112], ["NS5B", "OBSERVATION", 211, 215], ["significant", "OBSERVATION_MODIFIER", 242, 253], ["variation", "OBSERVATION", 254, 263], ["humoral immunity", "OBSERVATION", 286, 302], ["chronic", "OBSERVATION_MODIFIER", 306, 313], ["HCV", "OBSERVATION", 314, 317]]], ["Anti-HCV antibody pattern also remains very stable within one individual.", [["Anti-HCV antibody", "PROTEIN", 0, 17], ["Anti-HCV antibody pattern", "TEST", 0, 25], ["very", "OBSERVATION_MODIFIER", 39, 43], ["stable", "OBSERVATION", 44, 50]]], ["ALT and AST levels were tested in all subjects.", [["ALT", "SIMPLE_CHEMICAL", 0, 3], ["AST", "SIMPLE_CHEMICAL", 8, 11], ["ALT", "PROTEIN", 0, 3], ["AST", "PROTEIN", 8, 11], ["ALT", "TEST", 0, 3], ["AST levels", "TEST", 8, 18]]], ["The presence of HBV-DNA was determined quantitatively in plasma samples of HD patients with anti-HBc alone (HBsAg negative, anti-HBs negative and anti-HBc positive) by real-time PCR using the artus HBV RG PCR kit on the Rotor-Gene 3000 real-time thermal cycler.", [["plasma samples", "ANATOMY", 57, 71], ["HBsAg", "CHEMICAL", 108, 113], ["HBV", "ORGANISM", 16, 19], ["DNA", "CELLULAR_COMPONENT", 20, 23], ["plasma samples", "ORGANISM_SUBSTANCE", 57, 71], ["patients", "ORGANISM", 78, 86], ["HBsAg", "GENE_OR_GENE_PRODUCT", 108, 113], ["HBV-DNA", "DNA", 16, 23], ["HBsAg", "PROTEIN", 108, 113], ["anti-HBs", "PROTEIN", 124, 132], ["patients", "SPECIES", 78, 86], ["HBV", "SPECIES", 16, 19], ["HBV", "SPECIES", 198, 201], ["HBV-DNA", "PROBLEM", 16, 23], ["HD patients", "TREATMENT", 75, 86], ["anti-HBc", "TEST", 92, 100], ["HBsAg", "TEST", 108, 113], ["anti-HBs", "TEST", 124, 132], ["anti-HBc", "TEST", 146, 154], ["PCR", "TEST", 178, 181], ["the artus", "TEST", 188, 197], ["the Rotor", "TREATMENT", 216, 225], ["thermal cycler", "TREATMENT", 246, 260], ["HBV", "OBSERVATION", 16, 19]]], ["Results: Of 289 patients enrolled in this study, 18 subjects (6.2%, 95% CI, 3.5%-8.9%) had anti-HBc alone.", [["patients", "ORGANISM", 16, 24], ["HBc", "GENE_OR_GENE_PRODUCT", 96, 99], ["HBc", "PROTEIN", 96, 99], ["patients", "SPECIES", 16, 24], ["this study", "TEST", 37, 47], ["CI", "TEST", 72, 74], ["anti-HBc", "TREATMENT", 91, 99]]], ["HBV-DNA was detectable in 9 of 18 HD patients (50%, 95% CI, 27%-73%) with anti-HBc alone.", [["HBV", "ORGANISM", 0, 3], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["patients", "ORGANISM", 37, 45], ["HBc", "GENE_OR_GENE_PRODUCT", 79, 82], ["HBV-DNA", "DNA", 0, 7], ["HBc", "PROTEIN", 79, 82], ["patients", "SPECIES", 37, 45], ["HBV", "SPECIES", 0, 3], ["HBV", "TEST", 0, 3], ["DNA", "PROBLEM", 4, 7], ["CI", "TEST", 56, 58], ["anti-HBc", "TEST", 74, 82]]], ["Plasma HBV-DNA load was less than 50 IU/ml in all of these patients.Conclusion:Our study showed that detection of anti-HBc alone could reflect unrecognized occult HBV infection in HD patients.", [["HBV infection", "DISEASE", 163, 176], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["HBV", "ORGANISM", 7, 10], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["patients", "ORGANISM", 59, 67], ["anti-HBc", "ORGANISM", 114, 122], ["HBV", "ORGANISM", 163, 166], ["patients", "ORGANISM", 183, 191], ["anti-HBc", "PROTEIN", 114, 122], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 183, 191], ["HBV", "SPECIES", 7, 10], ["HBV", "SPECIES", 163, 166], ["Plasma HBV", "TEST", 0, 10], ["DNA load", "TEST", 11, 19], ["Our study", "TEST", 79, 88], ["anti-HBc", "PROBLEM", 114, 122], ["unrecognized occult HBV infection", "PROBLEM", 143, 176], ["HD patients", "TREATMENT", 180, 191], ["occult", "OBSERVATION_MODIFIER", 156, 162], ["HBV", "OBSERVATION_MODIFIER", 163, 166], ["infection", "OBSERVATION", 167, 176]]], ["The majority of these infections are associated with low viral loads. were included in the study.", [["infections", "DISEASE", 22, 32], ["these infections", "PROBLEM", 16, 32], ["low viral loads", "PROBLEM", 53, 68], ["the study", "TEST", 87, 96], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["infections", "OBSERVATION", 22, 32], ["low", "OBSERVATION_MODIFIER", 53, 56], ["viral loads", "OBSERVATION", 57, 68]]], ["All the subjects had never been exposed to antiretroviral therapy.", [["antiretroviral therapy", "TREATMENT", 43, 65]]], ["Genotypic resistance testing was performed at the time of diagnosis with a sequence-based assay (TRUGENE HIV-1 genotyping test) targeted at the protease region (codons 1 to 99) and RT region (codon 40 to 247) of the HIV-l genome.", [["protease region", "DNA", 144, 159], ["codons 1 to 99", "DNA", 161, 175], ["RT region", "DNA", 181, 190], ["codon 40 to 247", "DNA", 192, 207], ["HIV-l genome", "DNA", 216, 228], ["HIV", "SPECIES", 216, 219], ["HIV-1", "SPECIES", 105, 110], ["HIV-l", "SPECIES", 216, 221], ["Genotypic resistance testing", "TEST", 0, 28], ["a sequence", "TEST", 73, 83], ["based assay", "TEST", 84, 95], ["TRUGENE HIV", "TEST", 97, 108], ["genotyping test", "TEST", 111, 126], ["codons", "TEST", 161, 167], ["RT", "ANATOMY", 181, 183], ["region", "ANATOMY_MODIFIER", 184, 190]]], ["Results: 21 of 218 patients (9.63%) harboured a virus with at least one mutation associated with phenotypic resistance; 1/218 with mutations associated with resistance to nucleoside reverse-transcriptase inhibitors (NRTIs), 17/218 to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) and 3/218 to protease inhibitors (PI).", [["nucleoside", "CHEMICAL", 171, 181], ["NRTIs", "CHEMICAL", 216, 221], ["nucleoside", "CHEMICAL", 171, 181], ["patients", "ORGANISM", 19, 27], ["nucleoside reverse-transcriptase", "GENE_OR_GENE_PRODUCT", 171, 203], ["non-nucleoside reverse-transcriptase", "GENE_OR_GENE_PRODUCT", 234, 270], ["protease inhibitors", "SIMPLE_CHEMICAL", 304, 323], ["PI", "SIMPLE_CHEMICAL", 325, 327], ["nucleoside reverse-transcriptase", "PROTEIN", 171, 203], ["non-nucleoside reverse-transcriptase", "PROTEIN", 234, 270], ["patients", "SPECIES", 19, 27], ["a virus", "PROBLEM", 46, 53], ["phenotypic resistance", "PROBLEM", 97, 118], ["mutations", "PROBLEM", 131, 140], ["nucleoside reverse-transcriptase inhibitors", "TREATMENT", 171, 214], ["NRTIs", "TREATMENT", 216, 221], ["non-nucleoside reverse-transcriptase inhibitors", "TREATMENT", 234, 281], ["NNRTIs", "TREATMENT", 283, 289], ["protease inhibitors", "TREATMENT", 304, 323], ["phenotypic resistance", "OBSERVATION", 97, 118]]], ["Resistance to NRTIs was associated with the key mutation M184V, while resistance to NNRTIs was associated with Y181C and K103N mutations.", [["NRTIs", "CHEMICAL", 14, 19], ["NRTIs", "CHEMICAL", 14, 19], ["Resistance to NRTIs", "PROBLEM", 0, 19], ["the key mutation M184V", "PROBLEM", 40, 62], ["NNRTIs", "TREATMENT", 84, 90], ["Y181C", "PROBLEM", 111, 116], ["K103N mutations", "PROBLEM", 121, 136], ["NRTIs", "OBSERVATION", 14, 19]]], ["Among mutations to PI, major resistance mutations L90M and D30N were found in three patients, whereas there was a high prevalence of accessory PI resistance mutations at positions 10, 20, 36 and 63.", [["patients", "ORGANISM", 84, 92], ["PI", "GENE_OR_GENE_PRODUCT", 143, 145], ["D30N", "DNA", 59, 63], ["positions 10, 20, 36 and 63", "DNA", 170, 197], ["patients", "SPECIES", 84, 92], ["accessory PI resistance mutations", "PROBLEM", 133, 166], ["accessory PI resistance", "OBSERVATION", 133, 156]]], ["Conclusion: Our data estimate the prevalence of primary resistance and mutations patterns among naive HIV patients, underlining the importance of genotypic resistance testing in HIV patients before starting treatment, especially when NNRTIs would be included in the initial antiretroviral therapy.S. Wiboonchutikul, S. Sungkanuparph\u00b0, C. Sukasem, W. Chantratita (Bangkok, TH)Objectives: Few data are available on the genetic mechanisms of protease inhibitor (PI) resistance in non-B HIV-1, and PI resistanceassociated mutations (RAMs) are commonly observed in PI-naive patients with subtype A/E infection.", [["PI", "CHEMICAL", 459, 461], ["infection", "DISEASE", 595, 604], ["HIV", "ORGANISM", 102, 105], ["patients", "ORGANISM", 106, 114], ["HIV", "ORGANISM", 178, 181], ["patients", "ORGANISM", 182, 190], ["protease inhibitor", "GENE_OR_GENE_PRODUCT", 439, 457], ["PI", "SIMPLE_CHEMICAL", 459, 461], ["non-B HIV-1", "ORGANISM", 477, 488], ["PI resistanceassociated", "SIMPLE_CHEMICAL", 494, 517], ["RAMs", "PATHOLOGICAL_FORMATION", 529, 533], ["PI", "SIMPLE_CHEMICAL", 560, 562], ["patients", "ORGANISM", 569, 577], ["subtype A/E", "ORGANISM", 583, 594], ["HIV", "SPECIES", 102, 105], ["patients", "SPECIES", 106, 114], ["HIV", "SPECIES", 178, 181], ["patients", "SPECIES", 182, 190], ["HIV-1", "SPECIES", 483, 488], ["patients", "SPECIES", 569, 577], ["HIV", "SPECIES", 102, 105], ["HIV", "SPECIES", 178, 181], ["non-B HIV-1", "SPECIES", 477, 488], ["Our data", "TEST", 12, 20], ["primary resistance", "PROBLEM", 48, 66], ["mutations patterns", "PROBLEM", 71, 89], ["genotypic resistance testing", "TEST", 146, 174], ["treatment", "TREATMENT", 207, 216], ["NNRTIs", "TREATMENT", 234, 240], ["the initial antiretroviral therapy", "TREATMENT", 262, 296], ["protease inhibitor", "TREATMENT", 439, 457], ["non-B HIV", "PROBLEM", 477, 486], ["PI resistanceassociated mutations", "PROBLEM", 494, 527], ["subtype A/E infection", "PROBLEM", 583, 604], ["primary resistance", "OBSERVATION", 48, 66], ["infection", "OBSERVATION", 595, 604]]], ["This study aimed to compare PI-RAMs between PI-naive and -experienced patients.", [["PI", "CHEMICAL", 44, 46], ["PI", "SIMPLE_CHEMICAL", 44, 46], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["This study", "TEST", 0, 10], ["PI", "TEST", 28, 30]]], ["Methods: Genotypic resistance testing was conducted among a cohort of HIV-1 infected patients who had virologic failure.", [["HIV-1 infected", "DISEASE", 70, 84], ["virologic failure", "DISEASE", 102, 119], ["HIV-1", "ORGANISM", 70, 75], ["patients", "ORGANISM", 85, 93], ["HIV-1", "SPECIES", 70, 75], ["patients", "SPECIES", 85, 93], ["HIV-1", "SPECIES", 70, 75], ["Genotypic resistance testing", "TEST", 9, 37], ["virologic failure", "PROBLEM", 102, 119], ["virologic failure", "OBSERVATION", 102, 119]]], ["Patients were categorised into 2 groups: PI-naive and PI-experienced.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Results: We studied 137 patients (mean age, 41.8 years; 64% male).", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["Median CD4 cell count and HIV-1 RNA at virologic failure were 169 cells/cu.mm. and 14100 copies/mL, respectively.", [["CD4 cell", "ANATOMY", 7, 15], ["cells", "ANATOMY", 66, 71], ["CD4 cell", "CELL", 7, 15], ["HIV-1", "ORGANISM", 26, 31], ["CD4", "PROTEIN", 7, 10], ["HIV-1", "SPECIES", 26, 31], ["HIV-1", "SPECIES", 26, 31], ["Median CD4 cell count", "TEST", 0, 21], ["HIV", "TEST", 26, 29], ["RNA at virologic failure", "PROBLEM", 32, 56]]], ["85% of patients were infected with subtype A/E; the others had subtype B (12%), AB (2%), and C (1%).", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["subtype B", "TEST", 63, 72], ["AB", "TEST", 80, 82], ["C", "TEST", 93, 94], ["infected", "OBSERVATION", 21, 29]]], ["There were 75 patients in PI-naive group and 62 patients in PI-experienced group.", [["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 48, 56]]], ["The clinical characteristics between 2 groups were similar (p > 0.05) except for the duration of antiretroviral therapy which was shorter in PI-naive group (31.5 vs. 46.8 months, p = 0.028).", [["antiretroviral therapy", "TREATMENT", 97, 119], ["antiretroviral therapy", "OBSERVATION", 97, 119]]], ["Percentage of patients who had primary PI-RAMs was 1% in PInaive and 19% in PI-experienced groups (p = 0.001).", [["PInaive", "DISEASE", 57, 64], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["primary PI-RAMs", "PROBLEM", 31, 46], ["PInaive", "TEST", 57, 64], ["PI", "TEST", 76, 78]]], ["The most common primary PI-RAMs in the latter group were V82A (10%) and I54V (7%).", [["PI-RAMs", "CANCER", 24, 31], ["V82A", "TEST", 57, 61], ["I54V", "TEST", 72, 76]]], ["Percentage of patients with secondary PI-RAMs in the corresponding groups was 99% and 98%, respectively (p = 1.000).", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["secondary PI-RAMs", "PROBLEM", 28, 45]]], ["Median number of secondary PI-RAMs was also similar between 2 groups (p = 0.244).", [["secondary PI-RAMs", "PROBLEM", 17, 34], ["secondary PI", "OBSERVATION", 17, 29]]], ["The most common secondary PI-RAMs in both groups were M36I (91%), H69K (34%), L89M (30%), I13V (26%), L63P (25%), L10I We also defined a \"silent score\" (SS) and a \"resistance score\" (RS) as the number of synonymous mutations and of resistance mutations (in the second sequence in comparison with the first one) divided by number of days between the two tests, respectively.", [["H69K", "TEST", 66, 70], ["L89M", "TEST", 78, 82], ["I13V", "TEST", 90, 94], ["L63P", "TEST", 102, 106], ["a \"resistance score\"", "PROBLEM", 161, 181], ["synonymous mutations", "PROBLEM", 204, 224], ["resistance mutations", "PROBLEM", 232, 252], ["the two tests", "TEST", 345, 358], ["synonymous mutations", "OBSERVATION", 204, 224]]], ["(12); pts with DRMs in Non-B-ST (%) were 7 (23.3), 6 (14), 5 (7) and 3 (4.2).", [["DRMs", "TEST", 15, 19], ["Non-B-ST", "TEST", 23, 31]]], ["A significant increase of non-B-ST (p = 0.021) and a significant decrease in DRMs (p < 0.001) were observed.", [["a significant decrease in DRMs", "PROBLEM", 51, 81], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["non-B", "OBSERVATION_MODIFIER", 26, 31], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["decrease", "OBSERVATION_MODIFIER", 65, 73], ["DRMs", "OBSERVATION_MODIFIER", 77, 81]]], ["CRF02_AG was the prevalent non-B ST (44%).", [["non-B ST", "CANCER", 27, 35]]], ["35.3% of non-B ST pts were italians.", [["non-B ST pts", "CANCER", 9, 21]]], ["Among B-ST, DRMs predicted a reduced susceptibility to one drug class in 23, 17, 15 and 14 cases in the different periods; to two drug classes in 4, 6, 5 and 8; to three classes in 3, 2, 0 and 0.", [["B-ST", "CELL", 6, 10], ["DRMs", "CELLULAR_COMPONENT", 12, 16], ["DRMs", "PROBLEM", 12, 16]]], ["In non-B-ST, a reduced susceptibility to one drug class was found in 6, 6, 4 and 0 cases; to two drug classes in 1, 0, 0 and 2; to three drug classes in 0, 0, 1 and 1, respectively.", [["non-B-ST", "CELL", 3, 11], ["a reduced susceptibility", "PROBLEM", 13, 37]]], ["Among pts with one or two classes of resistance, a decrease of percentage of Protease Inhibitors related DRMs, and a persistence of Non Nucleoside RT Inhibitors involving DRMs, mainly 103N and 190A, were observed.", [["Nucleoside", "CHEMICAL", 136, 146], ["Nucleoside", "CHEMICAL", 136, 146], ["Protease", "GENE_OR_GENE_PRODUCT", 77, 85], ["DRMs", "CELLULAR_COMPONENT", 171, 175], ["Protease Inhibitors", "TREATMENT", 77, 96], ["DRMs", "PROBLEM", 105, 109], ["Non Nucleoside RT Inhibitors", "TREATMENT", 132, 160], ["DRMs", "PROBLEM", 171, 175], ["resistance", "OBSERVATION", 37, 47], ["decrease", "OBSERVATION_MODIFIER", 51, 59]]], ["Methods: From HIV+ persons with a history of, or an acute episode of OPC, oral fungal burden was evaluated bi-weekly and buccal mucosa tissue was collected bimonthly for a period of one year.", [["oral", "ANATOMY", 74, 78], ["buccal mucosa tissue", "ANATOMY", 121, 141], ["OPC", "DISEASE", 69, 72], ["HIV", "ORGANISM", 14, 17], ["persons", "ORGANISM", 19, 26], ["oral", "ORGANISM_SUBDIVISION", 74, 78], ["buccal mucosa tissue", "TISSUE", 121, 141], ["HIV", "SPECIES", 14, 17], ["persons", "SPECIES", 19, 26], ["HIV", "SPECIES", 14, 17], ["OPC", "PROBLEM", 69, 72], ["oral fungal burden", "PROBLEM", 74, 92], ["buccal mucosa tissue", "PROBLEM", 121, 141], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["oral", "ANATOMY", 74, 78], ["fungal", "OBSERVATION", 79, 85], ["buccal mucosa", "ANATOMY", 121, 134]]], ["Tissue was evaluated for the presence of CD8+ T cells and E-cadherin by immunohistochemistry or flow cytometry.", [["Tissue", "ANATOMY", 0, 6], ["CD8+ T cells", "ANATOMY", 41, 53], ["Tissue", "TISSUE", 0, 6], ["CD8", "GENE_OR_GENE_PRODUCT", 41, 44], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 58, 68], ["CD8", "PROTEIN", 41, 44], ["T cells", "CELL_TYPE", 46, 53], ["E-cadherin", "PROTEIN", 58, 68], ["CD8+ T cells", "PROBLEM", 41, 53], ["flow cytometry", "TEST", 96, 110], ["flow cytometry", "OBSERVATION", 96, 110]]], ["Objectives: To define the secular trends in the epidemiology of candidaemia in Queensland, Australia (population, 4.1 million) over a 10-year period.", [["candidaemia", "DISEASE", 64, 75], ["candidaemia", "PROBLEM", 64, 75], ["candidaemia", "OBSERVATION", 64, 75]]], ["Methods: All episodes of candidaemia within Queensland public hospitals from 1999-2008 were identified from laboratory information systems.", [["candidaemia", "DISEASE", 25, 36], ["candidaemia", "PROBLEM", 25, 36], ["candidaemia", "OBSERVATION", 25, 36]]], ["Data on species identification, antifungal susceptibility, demographics, and hospital ward of diagnosis, and denominator data (hospital admissions, accrued patient-days (pt-days) and fluconazole usage) were collected.", [["fluconazole", "CHEMICAL", 183, 194], ["fluconazole", "CHEMICAL", 183, 194], ["patient", "ORGANISM", 156, 163], ["fluconazole", "SIMPLE_CHEMICAL", 183, 194], ["patient", "SPECIES", 156, 163], ["species identification", "TEST", 8, 30], ["fluconazole usage", "TREATMENT", 183, 200]]], ["The median patient age was 56.4 years.", [["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18]]], ["The overall incidence-density was 0.45/10000 ptdays, highest in paediatric (1.28/10000 pt-days) and tertiary hospitals (0.62/10000 pt-days).", [["density", "OBSERVATION", 22, 29]]], ["Over the 10 years, the incidence-density increased 3.2-fold in tertiary hospitals and 6.6-fold in secondary hospitals (both p < 0.0001 for trend), but not in paediatric or smaller hospitals.", [["density", "OBSERVATION", 33, 40], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["3.2-fold", "OBSERVATION_MODIFIER", 51, 59]]], ["The incidence-density in ICUs (5.2/10000 pt-days) was 10-fold higher than in non-ICU wards, but did not significantly increase over the study period.", [["density", "OBSERVATION", 14, 21]]], ["The relative proportion of episodes occurring in adult general medical/surgical (ie non-oncology/non-ICU) wards significantly increased (p < 0.001), accounting for 62% of episodes at the end of the 10-year period, whereas that occurring in paediatric and adult oncology wards decreased (p < 0.001 and p = 0.07 respectively).", [["episodes", "PROBLEM", 27, 35], ["episodes", "PROBLEM", 171, 179], ["proportion", "OBSERVATION_MODIFIER", 13, 23]]], ["Overall, C. albicans accounted for 44%, C. parapsilosis 27% and C. glabrata 13%.", [["C. glabrata", "DISEASE", 64, 75], ["C. albicans", "ORGANISM", 9, 20], ["C. glabrata", "ORGANISM", 64, 75], ["C. albicans", "SPECIES", 9, 20], ["C. parapsilosis", "SPECIES", 40, 55], ["C. glabrata", "SPECIES", 64, 75], ["C. albicans", "SPECIES", 9, 20], ["C. parapsilosis", "SPECIES", 40, 55], ["C. glabrata", "SPECIES", 64, 75], ["C. albicans", "TEST", 9, 20], ["C. parapsilosis", "TEST", 40, 55], ["C. glabrata", "TEST", 64, 75], ["parapsilosis", "OBSERVATION", 43, 55]]], ["Although the incidence-density of all species increased over the study period, the relative proportion caused by C. albicans decreased (p = 0.007) and C. parapsilosis increased (p = 0.01).", [["C. albicans", "ORGANISM", 113, 124], ["C. albicans", "SPECIES", 113, 124], ["C. parapsilosis", "SPECIES", 151, 166], ["C. albicans", "SPECIES", 113, 124], ["C. parapsilosis", "SPECIES", 151, 166], ["all species", "PROBLEM", 34, 45], ["the study", "TEST", 61, 70], ["C. albicans", "PROBLEM", 113, 124], ["C. parapsilosis", "PROBLEM", 151, 166], ["density", "OBSERVATION", 23, 30], ["all", "OBSERVATION_MODIFIER", 34, 37], ["species", "OBSERVATION_MODIFIER", 38, 45], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["parapsilosis", "OBSERVATION_MODIFIER", 154, 166], ["increased", "OBSERVATION_MODIFIER", 167, 176]]], ["Despite significantly increased fluconazole usage (from 19.7 to 30.6 DDD/1000 pt-days, p < 0.0001), the relative proportion caused by C. glabrata/C. krusei did not change (p = 0.5).Conclusions:The overall incidence of candidaemia has increased almost 400% in Queensland public hospitals over the last 10 years.", [["fluconazole", "CHEMICAL", 32, 43], ["candidaemia", "DISEASE", 218, 229], ["fluconazole", "CHEMICAL", 32, 43], ["fluconazole", "SIMPLE_CHEMICAL", 32, 43], ["C. glabrata", "ORGANISM", 134, 145], ["C. krusei", "ORGANISM", 146, 155], ["C. glabrata", "SPECIES", 134, 145], ["C. krusei", "SPECIES", 146, 155], ["C. glabrata", "SPECIES", 134, 145], ["C. krusei", "SPECIES", 146, 155], ["significantly increased fluconazole usage", "TREATMENT", 8, 49], ["C. krusei", "PROBLEM", 146, 155], ["candidaemia", "PROBLEM", 218, 229], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["fluconazole", "OBSERVATION", 32, 43], ["candidaemia", "OBSERVATION", 218, 229], ["increased", "OBSERVATION_MODIFIER", 234, 243], ["almost", "OBSERVATION_MODIFIER", 244, 250], ["400%", "OBSERVATION_MODIFIER", 251, 255]]], ["The relative proportion of episodes occurring among general medical/surgical patients and caused by C. parapsilosis has increased.", [["C. parapsilosis", "DISEASE", 100, 115], ["patients", "ORGANISM", 77, 85], ["C. parapsilosis", "ORGANISM", 100, 115], ["patients", "SPECIES", 77, 85], ["C. parapsilosis", "SPECIES", 100, 115], ["C. parapsilosis", "SPECIES", 100, 115], ["episodes", "PROBLEM", 27, 35], ["C. parapsilosis", "PROBLEM", 100, 115], ["parapsilosis", "OBSERVATION", 103, 115], ["increased", "OBSERVATION_MODIFIER", 120, 129]]], ["Candidaemia is an increasing problem the epidemiology of which continues to evolve.", [["Candidaemia", "DISEASE", 0, 11], ["Candidaemia", "PROBLEM", 0, 11], ["increasing", "OBSERVATION_MODIFIER", 18, 28], ["problem", "OBSERVATION", 29, 36]]], ["It is increasingly affecting patients outside traditional risk groups.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37]]], ["Conclusions: This surveillance study and pharmaco-economic modelling has proved immensely beneficial in setting up inhouse processing, improved TAT, reduced costs of outsourcing and subsequent use of expensive antifungals.", [["TAT", "PROTEIN", 144, 147], ["This surveillance study", "TEST", 13, 36], ["pharmaco-economic modelling", "TREATMENT", 41, 68], ["expensive antifungals", "TREATMENT", 200, 221]]], ["Reduction in mortality has been noted but is not statistically significant.", [["Reduction in mortality", "PROBLEM", 0, 22], ["mortality", "OBSERVATION", 13, 22], ["not statistically", "UNCERTAINTY", 45, 62], ["significant", "OBSERVATION_MODIFIER", 63, 74]]], ["C. albicans was the commonest isolate; fluconazole resistance is minimal and associated mortality is lower than reported from Europe.", [["fluconazole", "CHEMICAL", 39, 50], ["fluconazole", "CHEMICAL", 39, 50], ["C. albicans", "ORGANISM", 0, 11], ["fluconazole", "SIMPLE_CHEMICAL", 39, 50], ["C. albicans", "SPECIES", 0, 11], ["C. albicans", "SPECIES", 0, 11], ["C. albicans", "PROBLEM", 0, 11], ["fluconazole resistance", "TREATMENT", 39, 61], ["minimal", "OBSERVATION_MODIFIER", 65, 72], ["lower", "OBSERVATION_MODIFIER", 101, 106]]], ["Many pts received systemic prophylaxis (72%); itraconazole and fluconazole were used in 68 and 33 pts respectively.", [["itraconazole", "CHEMICAL", 46, 58], ["fluconazole", "CHEMICAL", 63, 74], ["itraconazole", "CHEMICAL", 46, 58], ["fluconazole", "CHEMICAL", 63, 74], ["itraconazole", "SIMPLE_CHEMICAL", 46, 58], ["fluconazole", "SIMPLE_CHEMICAL", 63, 74], ["systemic prophylaxis", "TREATMENT", 18, 38], ["itraconazole", "TREATMENT", 46, 58], ["fluconazole", "TREATMENT", 63, 74]]], ["No differences emerged between empirical vs pre-emptive therapy and none of the drugs resulted to significantly influence outcome.", [["empirical vs pre-emptive therapy", "TREATMENT", 31, 63], ["the drugs", "TREATMENT", 76, 85]]], ["In 66% of pts initial empirical/pre-emptive drug remained unchanged after IA diagnosis, while in 16% clinicians shifted to a combined treatment.O241 Invasive aspergillosis in acute myeloid leukaemia: report ofConclusion: This study allows as to analyzed multiple factors as potentially influencing outcome.", [["acute myeloid leukaemia", "ANATOMY", 175, 198], ["aspergillosis", "DISEASE", 158, 171], ["acute myeloid leukaemia", "DISEASE", 175, 198], ["acute myeloid leukaemia", "CANCER", 175, 198], ["pre-emptive drug", "TREATMENT", 32, 48], ["a combined treatment", "TREATMENT", 123, 143], ["Invasive aspergillosis in acute myeloid leukaemia", "PROBLEM", 149, 198], ["This study", "TEST", 221, 231], ["unchanged", "OBSERVATION_MODIFIER", 58, 67], ["Invasive", "OBSERVATION_MODIFIER", 149, 157], ["aspergillosis", "OBSERVATION", 158, 171], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["myeloid leukaemia", "OBSERVATION", 181, 198]]], ["We confirmed that AML phase and neutropenia influence IA outcome.", [["AML", "ANATOMY", 18, 21], ["AML", "DISEASE", 18, 21], ["neutropenia", "DISEASE", 32, 43], ["AML", "CANCER", 18, 21], ["AML phase", "PROBLEM", 18, 27], ["neutropenia influence IA outcome", "PROBLEM", 32, 64], ["AML phase", "OBSERVATION", 18, 27], ["neutropenia", "OBSERVATION", 32, 43]]], ["Present data confirm the perception that during last years the application of a correct and timely diagnostic work-up and the availability of more efficacious and less toxic drugs (i.e.O241 Invasive aspergillosis in acute myeloid leukaemia: report ofvoriconazole, liposomal amphotericin B, caspofungin) have modified the course of IA.", [["acute myeloid leukaemia", "ANATOMY", 216, 239], ["aspergillosis", "DISEASE", 199, 212], ["acute myeloid leukaemia", "DISEASE", 216, 239], ["ofvoriconazole", "CHEMICAL", 248, 262], ["liposomal", "CHEMICAL", 264, 273], ["amphotericin B", "CHEMICAL", 274, 288], ["caspofungin", "CHEMICAL", 290, 301], ["ofvoriconazole", "CHEMICAL", 248, 262], ["amphotericin B", "CHEMICAL", 274, 288], ["caspofungin", "CHEMICAL", 290, 301], ["acute myeloid leukaemia", "CANCER", 216, 239], ["ofvoriconazole", "SIMPLE_CHEMICAL", 248, 262], ["liposomal amphotericin B", "SIMPLE_CHEMICAL", 264, 288], ["caspofungin", "SIMPLE_CHEMICAL", 290, 301], ["less toxic drugs", "TREATMENT", 163, 179], ["Invasive aspergillosis", "PROBLEM", 190, 212], ["acute myeloid leukaemia", "PROBLEM", 216, 239], ["ofvoriconazole", "TREATMENT", 248, 262], ["liposomal amphotericin B", "TREATMENT", 264, 288], ["caspofungin", "TREATMENT", 290, 301], ["acute", "OBSERVATION_MODIFIER", 216, 221], ["myeloid leukaemia", "OBSERVATION", 222, 239]]], ["However none of the new drugs emerged as the most efficacious in our series.", [["the new drugs", "TREATMENT", 16, 29], ["new", "OBSERVATION_MODIFIER", 20, 23], ["drugs", "OBSERVATION", 24, 29]]], ["Even combined treatment did not confer any advantage in survival analysis. (<3% each).", [["survival analysis", "TEST", 56, 73]]], ["The first line therapy was monotherapy with voriconazole (49%), caspofungin (14%), lipid formulations of AMB (9%) or used antifungal drugs combination (20%).", [["antifungal", "ANATOMY", 122, 132], ["voriconazole", "CHEMICAL", 44, 56], ["caspofungin", "CHEMICAL", 64, 75], ["AMB", "CHEMICAL", 105, 108], ["voriconazole", "CHEMICAL", 44, 56], ["caspofungin", "CHEMICAL", 64, 75], ["AMB", "CHEMICAL", 105, 108], ["voriconazole", "SIMPLE_CHEMICAL", 44, 56], ["caspofungin", "SIMPLE_CHEMICAL", 64, 75], ["lipid", "SIMPLE_CHEMICAL", 83, 88], ["AMB", "SIMPLE_CHEMICAL", 105, 108], ["The first line therapy", "TREATMENT", 0, 22], ["monotherapy", "TREATMENT", 27, 38], ["voriconazole", "TREATMENT", 44, 56], ["caspofungin", "TREATMENT", 64, 75], ["lipid formulations of AMB", "TREATMENT", 83, 108], ["antifungal drugs", "TREATMENT", 122, 138]]], ["The mortality rate at day 90 was 41% when first line therapy included voriconazole compared to 60% when it did not (p < 0.001).", [["voriconazole", "CHEMICAL", 70, 82], ["voriconazole", "CHEMICAL", 70, 82], ["voriconazole", "SIMPLE_CHEMICAL", 70, 82], ["The mortality rate", "TEST", 0, 18], ["first line therapy", "TREATMENT", 42, 60], ["voriconazole", "TREATMENT", 70, 82]]], ["Conclusion: Comprehensive collections of cases based on systematic reporting and description of cases using a dedicated network of hospitals in selected regions and stringent definition criteria applied by trained clinicians and microbiologists are useful to describe IA, to assess its burden and secular trends, and to identify potential changes in diagnostic and therapeutic procedures.", [["therapeutic procedures", "TREATMENT", 365, 387]]], ["This network will expand to other regions in the near future, and data will help assessing the impact of new management strategies such as prophylaxis with posaconazole, the impact of modification of new diagnostic criteria as recently proposed (Clin Infect Dis, 2008), and identifying new populations at risk for IA.C. Lass-Fl\u00f6rl\u00b0, S. Eschertzhuber, J. Auberger, C. Geltner, D. Nachbaur (Innsbruck, AT)Nosocomial aspergillosis represents a serious threat for severely immunocompromised patients and outbreaks have been attributed to airborne sources.", [["posaconazole", "CHEMICAL", 156, 168], ["Nosocomial aspergillosis", "DISEASE", 403, 427], ["posaconazole", "CHEMICAL", 156, 168], ["posaconazole", "SIMPLE_CHEMICAL", 156, 168], ["patients", "ORGANISM", 487, 495], ["patients", "SPECIES", 487, 495], ["new management strategies", "TREATMENT", 105, 130], ["prophylaxis", "TREATMENT", 139, 150], ["posaconazole", "TREATMENT", 156, 168], ["Nosocomial aspergillosis", "PROBLEM", 403, 427], ["severely immunocompromised", "PROBLEM", 460, 486], ["new", "OBSERVATION_MODIFIER", 286, 289], ["aspergillosis", "OBSERVATION", 414, 427], ["immunocompromised", "OBSERVATION", 469, 486]]], ["We investigated the relationship between fungal exposure prior hospitalisation and the ensuing onset of invasive mould infections (IMI) in patients at risk.", [["invasive mould infections", "DISEASE", 104, 129], ["IMI", "DISEASE", 131, 134], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["invasive mould infections", "PROBLEM", 104, 129], ["invasive", "OBSERVATION_MODIFIER", 104, 112], ["mould", "OBSERVATION_MODIFIER", 113, 118], ["infections", "OBSERVATION", 119, 129]]], ["Patients admitted to the Department of Haematology and Oncology or to the Department of Transplant Surgery of the Innsbruck Medical University received a structured questionnaire regarding their fungal exposure prior hospitalisation.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["their fungal exposure", "PROBLEM", 189, 210]]], ["Questions inquired heavy fungal exposures up to five days prior hospitalisation.C. Lass-Fl\u00f6rl\u00b0, S. Eschertzhuber, J. Auberger, C. Geltner, D. Nachbaur (Innsbruck, AT)234 patients were enrolled in this study and 19% were smokers, 22% suffered from an airborne allergy, 62% lived in old buildings, 73% were ruralists, 82% and 92% were exposed to any outdoor or indoor fungus sources.", [["airborne allergy", "DISEASE", 250, 266], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["C. Lass-Fl\u00f6rl\u00b0, S. Eschertzhuber", "SPECIES", 80, 112], ["this study", "TEST", 196, 206], ["an airborne allergy", "PROBLEM", 247, 266], ["ruralists", "TEST", 305, 314]]], ["Poor housing conditions and other fungus exposures were associated with the onset of community-acquired IMI only in patients with acute myelogenous leukaemia (P < 0.01).", [["acute myelogenous leukaemia", "ANATOMY", 130, 157], ["IMI", "DISEASE", 104, 107], ["acute myelogenous leukaemia", "DISEASE", 130, 157], ["patients", "ORGANISM", 116, 124], ["acute myelogenous leukaemia", "CANCER", 130, 157], ["patients", "SPECIES", 116, 124], ["Poor housing conditions", "PROBLEM", 0, 23], ["other fungus exposures", "PROBLEM", 28, 50], ["community-acquired IMI", "PROBLEM", 85, 107], ["acute myelogenous leukaemia", "PROBLEM", 130, 157], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["myelogenous leukaemia", "OBSERVATION", 136, 157]]], ["AML patients being more at risk for IMI when smoking cigarettes (P < 0.05), living on the country site (P < 0.05), having two or more fungus exposures (P < 0.05) and suffering from allergy to dust, pollen and/or moulds (P < 0.05).", [["AML", "ANATOMY", 0, 3], ["pollen", "ANATOMY", 198, 204], ["AML", "DISEASE", 0, 3], ["IMI", "DISEASE", 36, 39], ["smoking", "CHEMICAL", 45, 52], ["allergy", "DISEASE", 181, 188], ["AML", "CANCER", 0, 3], ["patients", "ORGANISM", 4, 12], ["pollen", "ORGANISM_SUBDIVISION", 198, 204], ["patients", "SPECIES", 4, 12], ["AML", "PROBLEM", 0, 3], ["IMI", "PROBLEM", 36, 39], ["more fungus exposures", "PROBLEM", 129, 150], ["allergy", "PROBLEM", 181, 188]]], ["A similar trend was for lung transplant recipients receiving extensive immunosuppressive agents to treat allograft rejection.", [["lung", "ANATOMY", 24, 28], ["allograft", "ANATOMY", 105, 114], ["lung", "ORGAN", 24, 28], ["allograft", "TISSUE", 105, 114], ["lung transplant recipients", "TREATMENT", 24, 50], ["extensive immunosuppressive agents", "TREATMENT", 61, 95], ["allograft rejection", "PROBLEM", 105, 124], ["lung", "ANATOMY", 24, 28], ["transplant", "OBSERVATION", 29, 39], ["allograft rejection", "OBSERVATION", 105, 124]]], ["Overall, 88% of IMI were community-acquired cases.", [["IMI", "DISEASE", 16, 19], ["IMI", "TEST", 16, 19]]], ["Hospital-independent fungal sources highlight risk-factors for IMI in severe immunocompromised patients and the rate of communityacquired IMI does increase.", [["IMI", "DISEASE", 63, 66], ["IMI", "DISEASE", 138, 141], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["IMI", "PROBLEM", 63, 66], ["severe immunocompromised patients", "PROBLEM", 70, 103], ["communityacquired IMI", "PROBLEM", 120, 141], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["immunocompromised", "OBSERVATION", 77, 94]]], ["An analysis of an individual patient's risk factors for fungal infection and the type of fungus to which they are most susceptible, indicates the preventative strategies that are likely to be successful. to the ICU-MHS with Aspergillus spp detected in significant amounts in clinical samples.", [["samples", "ANATOMY", 284, 291], ["fungal infection", "DISEASE", 56, 72], ["Aspergillus spp", "DISEASE", 224, 239], ["patient", "ORGANISM", 29, 36], ["Aspergillus spp", "ORGANISM", 224, 239], ["patient", "SPECIES", 29, 36], ["An analysis", "TEST", 0, 11], ["an individual patient's risk factors", "PROBLEM", 15, 51], ["fungal infection", "PROBLEM", 56, 72], ["fungus", "PROBLEM", 89, 95], ["Aspergillus spp", "PROBLEM", 224, 239], ["fungal", "OBSERVATION_MODIFIER", 56, 62], ["infection", "OBSERVATION", 63, 72], ["likely to be", "UNCERTAINTY", 179, 191], ["Aspergillus spp", "OBSERVATION", 224, 239], ["significant", "OBSERVATION_MODIFIER", 252, 263], ["amounts", "OBSERVATION_MODIFIER", 264, 271]]], ["The underlying conditions of the patients were heart transplantation (n = 5), major heart surgery (n = 4), and other (n = 2).", [["heart", "ANATOMY", 47, 52], ["heart", "ANATOMY", 84, 89], ["patients", "ORGANISM", 33, 41], ["heart", "ORGAN", 47, 52], ["heart", "ORGAN", 84, 89], ["patients", "SPECIES", 33, 41], ["heart transplantation", "TREATMENT", 47, 68], ["major heart surgery", "TREATMENT", 78, 97], ["heart", "ANATOMY", 47, 52], ["transplantation", "OBSERVATION", 53, 68], ["heart", "ANATOMY", 84, 89], ["surgery", "OBSERVATION", 90, 97]]], ["Eight (72.7%) patients developed proven/probable IA (4 with lung infection, 2 with mediastinitis, 1 with disseminated IA, and 1 with prostate involvement).", [["lung", "ANATOMY", 60, 64], ["prostate", "ANATOMY", 133, 141], ["IA", "DISEASE", 49, 51], ["lung infection", "DISEASE", 60, 74], ["mediastinitis", "DISEASE", 83, 96], ["IA", "DISEASE", 118, 120], ["prostate involvement", "DISEASE", 133, 153], ["patients", "ORGANISM", 14, 22], ["lung", "ORGAN", 60, 64], ["prostate", "CANCER", 133, 141], ["patients", "SPECIES", 14, 22], ["IA", "PROBLEM", 49, 51], ["lung infection", "PROBLEM", 60, 74], ["mediastinitis", "PROBLEM", 83, 96], ["disseminated IA", "PROBLEM", 105, 120], ["prostate involvement", "PROBLEM", 133, 153], ["probable", "UNCERTAINTY", 40, 48], ["lung", "ANATOMY", 60, 64], ["infection", "OBSERVATION", 65, 74], ["mediastinitis", "OBSERVATION", 83, 96], ["prostate", "ANATOMY", 133, 141]]], ["The mortality of patients with IA was 87.5%.", [["IA", "DISEASE", 31, 33], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["The ICU-MHS is divided into 3 areas, one of which is equipped with HEPA filters.", [["HEPA filters", "TREATMENT", 67, 79], ["HEPA filters", "OBSERVATION", 67, 79]]], ["Only 1 case of IA occurred in the protected area.", [["IA", "DISEASE", 15, 17], ["IA", "CANCER", 15, 17]]], ["We measured the fungal conidia levels in the air of each of the 3 areas (508 samples analyzed) monthly.", [["conidia", "ANATOMY", 23, 30], ["samples", "ANATOMY", 77, 84], ["the fungal conidia levels", "TEST", 12, 37], ["fungal", "OBSERVATION_MODIFIER", 16, 22], ["conidia levels", "OBSERVATION", 23, 37], ["air", "OBSERVATION_MODIFIER", 45, 48]]], ["A total of 172 strains of A. fumigatus (110 clinical strains from 10 patients and 62 environmental strains) were genotyped using microsatellites (de Valk et al, JCM 2005) .Results:The mean airborne conidia levels (6 months) before and after the outbreak were, respectively, 5.6 (0\u221215) CFU/m3 and 1.8 (0\u221210) CFU/m3.", [["A. fumigatus", "ORGANISM", 26, 38], ["patients", "ORGANISM", 69, 77], ["A. fumigatus", "SPECIES", 26, 38], ["patients", "SPECIES", 69, 77], ["A. fumigatus", "SPECIES", 26, 38], ["A. fumigatus", "PROBLEM", 26, 38], ["clinical strains", "TEST", 44, 60], ["The mean airborne conidia levels", "TEST", 180, 212], ["CFU", "TEST", 285, 288]]], ["No cases of IA occurred during these periods.", [["IA", "DISEASE", 12, 14], ["cases of IA", "PROBLEM", 3, 14]]], ["However, all cases of IA were linked to 4 peaks of abnormally high airborne conidia levels (65, 70, 200 and 500 CFU/m3).", [["conidia", "ANATOMY", 76, 83], ["IA", "DISEASE", 22, 24], ["abnormally high airborne conidia levels", "PROBLEM", 51, 90], ["abnormally", "OBSERVATION_MODIFIER", 51, 61], ["high", "OBSERVATION_MODIFIER", 62, 66], ["airborne conidia", "OBSERVATION", 67, 83]]], ["A. fumigatus was involved in 7 cases of IA; 1 patient was infected by non-fumigatus Aspergillus (not further genotyped).", [["IA", "DISEASE", 40, 42], ["A. fumigatus", "ORGANISM", 0, 12], ["IA", "CANCER", 40, 42], ["patient", "ORGANISM", 46, 53], ["non-fumigatus Aspergillus", "ORGANISM", 70, 95], ["A. fumigatus", "SPECIES", 0, 12], ["patient", "SPECIES", 46, 53], ["A. fumigatus", "SPECIES", 0, 12], ["non-fumigatus Aspergillus", "PROBLEM", 70, 95], ["fumigatus", "OBSERVATION", 3, 12]]], ["In 4 patients (1 mediastinitis, 2 pulmonary IA and 1 colonisation), we demonstrated similar genotypes in the air and in clinical samples.", [["pulmonary", "ANATOMY", 34, 43], ["samples", "ANATOMY", 129, 136], ["mediastinitis", "DISEASE", 17, 30], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["1 mediastinitis", "PROBLEM", 15, 30], ["similar genotypes in the air", "PROBLEM", 84, 112], ["mediastinitis", "OBSERVATION", 17, 30], ["pulmonary", "ANATOMY", 34, 43], ["similar", "OBSERVATION_MODIFIER", 84, 91], ["genotypes", "OBSERVATION", 92, 101], ["air", "OBSERVATION", 109, 112]]], ["Patient 1 was located in the protected area and had a unique genotype.", [["area", "ANATOMY", 39, 43], ["area", "CANCER", 39, 43], ["Patient", "SPECIES", 0, 7]]], ["Patient 2 had two different clusters of genotypes: one cluster was similar to that of patient 3 and the other was also found in patient 4 and in the air.", [["patient", "ORGANISM", 86, 93], ["patient", "ORGANISM", 128, 135], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 86, 93], ["patient", "SPECIES", 128, 135], ["air", "OBSERVATION", 149, 152]]], ["The genotype present in patients 2 and 4 was also detected in the air during a 6-month period.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["air", "ANATOMY", 66, 69]]], ["Conclusions: Epidemiologic and molecular typing suggests that there is a causal relationship between Aspergillus causing IA and those present in the air.", [["IA", "CHEMICAL", 121, 123], ["Epidemiologic and molecular typing", "TEST", 13, 47], ["Aspergillus", "PROBLEM", 101, 112], ["air", "OBSERVATION", 149, 152]]], ["Our finding also supports the need for HEPA filtration in ICU-MHS.", [["HEPA filtration", "TREATMENT", 39, 54]]], ["J. Guinea is contracted by FIS (CM05/00171).", [["J. Guinea", "ORGANISM", 0, 9], ["contracted", "OBSERVATION", 13, 23]]], ["Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated in reference to proven and probable cases of IA.", [["IA", "DISEASE", 155, 157], ["Sensitivity", "TEST", 0, 11], ["PPV", "TEST", 53, 56], ["NPV", "TEST", 89, 92]]], ["Reasons for performing bronchoscopy on patients were also recorded.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["performing bronchoscopy", "TEST", 12, 35]]], ["Results: From the 117 samples studied, 5 (4.3%) were classified as proven, 6 (5.1%) as probable, and 35 (29.9%) as possible cases of aspergillosis.", [["samples", "ANATOMY", 22, 29], ["aspergillosis", "DISEASE", 133, 146], ["aspergillosis", "CANCER", 133, 146], ["aspergillosis", "PROBLEM", 133, 146], ["aspergillosis", "OBSERVATION", 133, 146]]], ["Twelve samples (10.3%) represented colonisation, and 59 BAL samples were obtained during routine surveillance.", [["samples", "ANATOMY", 7, 14], ["BAL samples", "ANATOMY", 56, 67], ["BAL samples", "CANCER", 56, 67], ["Twelve samples", "TEST", 0, 14], ["colonisation", "TEST", 35, 47], ["BAL samples", "TEST", 56, 67], ["routine surveillance", "TEST", 89, 109]]], ["Pulmonary aspergillosis was the main clinical presentation of IA (63.6%).", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary aspergillosis", "DISEASE", 0, 23], ["IA", "DISEASE", 62, 64], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary aspergillosis", "PROBLEM", 0, 23], ["aspergillosis", "OBSERVATION", 10, 23], ["main", "OBSERVATION_MODIFIER", 32, 36]]], ["Using ROC analysis, the best cut-off for galactomannan testing in BAL was defined as 1.5 (sensitivity 90.9%, specificity 90.6%, PPV 48% and NPV 99.1%).", [["BAL", "ANATOMY", 66, 69], ["ROC analysis", "TEST", 6, 18], ["galactomannan testing", "TEST", 41, 62], ["BAL", "TEST", 66, 69], ["sensitivity", "TEST", 90, 101], ["specificity", "TEST", 109, 120], ["PPV", "TEST", 128, 131], ["NPV", "TEST", 140, 143]]], ["Median BAL GM index for the group of patients with proven/probable aspergillosis and for 'negative cases' were 3.3 and 0.5, respectively (p < 0.001).", [["BAL", "ANATOMY", 7, 10], ["GM", "CHEMICAL", 11, 13], ["aspergillosis", "DISEASE", 67, 80], ["patients", "ORGANISM", 37, 45], ["aspergillosis", "CANCER", 67, 80], ["patients", "SPECIES", 37, 45], ["Median BAL GM index", "TEST", 0, 19], ["aspergillosis", "PROBLEM", 67, 80], ["GM index", "OBSERVATION_MODIFIER", 11, 19], ["probable", "UNCERTAINTY", 58, 66], ["aspergillosis", "OBSERVATION", 67, 80]]], ["Overall mortality was 20% (n = 12).", [["Overall mortality", "TEST", 0, 17]]], ["The odds for death for patients diagnosed with IA were 11.8, in comparison to patients who did not have this infection (95% CI 2.9\u221248.4).", [["death", "DISEASE", 13, 18], ["infection", "DISEASE", 109, 118], ["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 78, 86], ["death", "PROBLEM", 13, 18], ["IA", "TEST", 47, 49], ["this infection", "PROBLEM", 104, 118], ["CI", "TEST", 124, 126], ["infection", "OBSERVATION", 109, 118]]], ["Conclusion: GM testing in the BAL added to the diagnosis of IA in lung transplant recipients.", [["BAL", "ANATOMY", 30, 33], ["lung", "ANATOMY", 66, 70], ["GM", "CHEMICAL", 12, 14], ["IA", "DISEASE", 60, 62], ["lung", "ORGAN", 66, 70], ["GM testing", "TEST", 12, 22], ["the BAL", "TEST", 26, 33], ["lung transplant recipients", "TREATMENT", 66, 92], ["lung", "ANATOMY", 66, 70], ["transplant", "OBSERVATION", 71, 81]]], ["In order to avoid false-positive results, a higher test cut-off should be applied to BAL samples, in comparison to sera.", [["BAL samples", "ANATOMY", 85, 96], ["sera", "ANATOMY", 115, 119], ["BAL samples", "CANCER", 85, 96], ["sera", "ORGANISM_SUBSTANCE", 115, 119], ["false-positive results", "PROBLEM", 18, 40], ["a higher test cut", "TREATMENT", 42, 59], ["BAL samples", "TEST", 85, 96], ["sera", "TEST", 115, 119]]], ["Increasing the cut-off to 1.5 resulted in a very high NPV, with an associated sensitivity of >90%.", [["a very high NPV", "PROBLEM", 42, 57]]], ["Objectives: 1) Determine the performance characteristics of the Galactomannan (GM) assay in broncho-alveolar lavage (BAL) in haematology-oncology patients; 2) Evaluate the prognostic value of the GM assay in this particular population.", [["broncho-alveolar lavage", "ANATOMY", 92, 115], ["BAL", "ANATOMY", 117, 120], ["Galactomannan", "CHEMICAL", 64, 77], ["GM", "CHEMICAL", 79, 81], ["GM", "CHEMICAL", 196, 198], ["Galactomannan", "SIMPLE_CHEMICAL", 64, 77], ["alveolar", "TISSUE", 100, 108], ["lavage", "ORGANISM_SUBSTANCE", 109, 115], ["BAL", "MULTI-TISSUE_STRUCTURE", 117, 120], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["the Galactomannan (GM) assay", "TEST", 60, 88], ["broncho-alveolar lavage", "TEST", 92, 115], ["the GM assay", "TEST", 192, 204], ["alveolar", "ANATOMY", 100, 108], ["lavage", "OBSERVATION", 109, 115]]], ["Methods: The Platelia GM EIA assay (Bio-Rad) was performed on all BAL specimens obtained from haematology-oncology patients at our institution between March 2005 and April 2008, in addition to routine laboratory stains and cultures.", [["BAL specimens", "ANATOMY", 66, 79], ["GM", "CHEMICAL", 22, 24], ["BAL specimens", "CANCER", 66, 79], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["The Platelia GM EIA assay", "TEST", 9, 34], ["all BAL specimens", "TEST", 62, 79], ["routine laboratory stains", "TEST", 193, 218], ["cultures", "TEST", 223, 231]]], ["We conducted chart reviews to classify cases as proven, probable, possible or without invasive pulmonary aspergillosis (IPA) according to the Revised Definitions of Invasive Fungal Disease from the EORTC/MSG Consensus Group.", [["invasive pulmonary aspergillosis", "ANATOMY", 86, 118], ["invasive pulmonary aspergillosis", "DISEASE", 86, 118], ["IPA", "DISEASE", 120, 123], ["Invasive Fungal Disease", "DISEASE", 165, 188], ["pulmonary", "ORGAN", 95, 104], ["aspergillosis", "PATHOLOGICAL_FORMATION", 105, 118], ["invasive pulmonary aspergillosis", "PROBLEM", 86, 118], ["Invasive Fungal Disease", "PROBLEM", 165, 188], ["probable, possible", "UNCERTAINTY", 56, 74], ["without", "UNCERTAINTY", 78, 85], ["invasive", "OBSERVATION_MODIFIER", 86, 94], ["pulmonary", "ANATOMY", 95, 104], ["aspergillosis", "OBSERVATION", 105, 118], ["Invasive", "OBSERVATION_MODIFIER", 165, 173], ["Fungal Disease", "OBSERVATION", 174, 188]]], ["For performance characteristics, proven and probable cases were considered as IPA; possible cases were considered as without IPA.", [["IPA", "CHEMICAL", 125, 128]]], ["The result of BAL GM was not considered as a criterium to classify cases in order to avoid incorporation bias.", [["GM", "CHEMICAL", 18, 20], ["BAL GM", "TEST", 14, 20], ["incorporation bias", "PROBLEM", 91, 109]]], ["In patients with >1 positive (GM index >0.5) specimen, only the first one was considered for the analysis.", [["specimen", "ANATOMY", 45, 53], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["GM index", "TEST", 30, 38], ["the analysis", "TEST", 93, 105]]], ["Mortality was calculated at 60 days following the first BAL procurement.", [["BAL", "ANATOMY", 56, 59], ["the first BAL procurement", "TREATMENT", 46, 71]]], ["Data were analyzed with Stata 8.0.", [["Stata", "TEST", 24, 29]]], ["Results: There were 173 BAL samples from 145 patients, including 101 haematopoietic stem cell transplant (HSCT) recipients.", [["BAL samples", "ANATOMY", 24, 35], ["haematopoietic stem cell", "ANATOMY", 69, 93], ["HSCT", "ANATOMY", 106, 110], ["BAL samples", "CANCER", 24, 35], ["patients", "ORGANISM", 45, 53], ["haematopoietic stem cell", "CELL", 69, 93], ["recipients", "ORGANISM", 112, 122], ["patients", "SPECIES", 45, 53], ["BAL samples", "TEST", 24, 35], ["101 haematopoietic stem cell transplant", "TREATMENT", 65, 104], ["haematopoietic stem cell transplant", "OBSERVATION", 69, 104]]], ["We found 5 proven, 7 probable and 35 possible cases of IPA (total of 12 IPA cases; 6.9%).", [["IPA", "DISEASE", 55, 58], ["IPA", "TEST", 55, 58], ["IPA cases", "TEST", 72, 81], ["5 proven", "OBSERVATION_MODIFIER", 9, 17]]], ["GM on BAL was positive in 47 (27.2%) specimens.", [["BAL", "ANATOMY", 6, 9], ["specimens", "ANATOMY", 37, 46], ["GM", "CHEMICAL", 0, 2], ["BAL", "ORGANISM_SUBSTANCE", 6, 9], ["GM on BAL", "TEST", 0, 9], ["specimens", "TEST", 37, 46]]], ["The sensitivity and specificity of the GM assay in BAL were 100% and 78.3% respectively.", [["BAL", "ANATOMY", 51, 54], ["GM", "CHEMICAL", 39, 41], ["BAL", "ORGANISM_SUBSTANCE", 51, 54], ["The sensitivity", "TEST", 0, 15], ["the GM assay", "TEST", 35, 47], ["BAL", "TEST", 51, 54]]], ["False-positive results were found in 21 patients without IPA and in 14 with possible IPA.", [["IPA", "DISEASE", 57, 60], ["IPA", "CHEMICAL", 85, 88], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["False", "TEST", 0, 5], ["IPA", "TEST", 57, 60], ["IPA", "PROBLEM", 85, 88]]], ["An index value 0.5 was significantly associated with a 60-day mortality risk (12/39 patients with a positive GM died within 60 days after BAL compared to 13/106 with a negative GM (OR = 3.2, 95%CI 1.3\u22127.8; p = 0.01).", [["GM", "CHEMICAL", 109, 111], ["GM", "CHEMICAL", 177, 179], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["An index value", "TEST", 0, 14], ["a positive GM", "PROBLEM", 98, 111], ["BAL", "TEST", 138, 141], ["CI", "TEST", 194, 196], ["p", "TEST", 206, 207]]], ["This association was even stronger when restricted to HSC recipients (OR =4.6, 95%CI 1.5\u221213.6; p = 0.006).Conclusions:The clinical utility of GM assay in BAL mainly lies in its negative predictive value, identifying patients at low risk of IPA.", [["HSC", "ANATOMY", 54, 57], ["BAL", "ANATOMY", 154, 157], ["GM", "CHEMICAL", 142, 144], ["IPA", "DISEASE", 240, 243], ["HSC", "CELL", 54, 57], ["BAL", "MULTI-TISSUE_STRUCTURE", 154, 157], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["CI", "TEST", 82, 84], ["p", "TEST", 95, 96], ["GM assay in BAL", "TEST", 142, 157]]], ["This test also carries a prognostic value in predicting patients at higher risk of mortality. (see table below) .", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["This test", "TEST", 0, 9]]], ["Not significant differences have been found among Pneumocystis colonisation and COPD status evaluated by FEV-1%.", [["Pneumocystis colonisation", "DISEASE", 50, 75], ["COPD", "DISEASE", 80, 84], ["Pneumocystis", "ORGANISM", 50, 62], ["Pneumocystis colonisation", "PROBLEM", 50, 75], ["COPD status", "PROBLEM", 80, 91], ["FEV", "TEST", 105, 108], ["Pneumocystis", "OBSERVATION", 50, 62], ["COPD", "OBSERVATION", 80, 84]]], ["As well as no significant differences respect to age, sex or lymphocytes and leucocytes blood count were found.", [["lymphocytes", "ANATOMY", 61, 72], ["leucocytes blood", "ANATOMY", 77, 93], ["lymphocytes", "CELL", 61, 72], ["leucocytes", "ORGANISM_SUBSTANCE", 77, 87], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["lymphocytes", "CELL_TYPE", 61, 72], ["leucocytes", "CELL_TYPE", 77, 87], ["lymphocytes", "TEST", 61, 72], ["leucocytes blood count", "TEST", 77, 99], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["lymphocytes", "ANATOMY", 61, 72]]], ["Background: Infliximab, a monoclonal antibody targeting tumour necrosis factor alpha (TNF-a), is indicated for the treatment of rheumatoid arthritis (RA) and other autoimmune diseases.", [["Infliximab", "CHEMICAL", 12, 22], ["tumour necrosis", "DISEASE", 56, 71], ["rheumatoid arthritis", "DISEASE", 128, 148], ["RA", "DISEASE", 150, 152], ["autoimmune diseases", "DISEASE", 164, 183], ["Infliximab", "SIMPLE_CHEMICAL", 12, 22], ["tumour necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 56, 84], ["TNF-a", "GENE_OR_GENE_PRODUCT", 86, 91], ["monoclonal antibody", "PROTEIN", 26, 45], ["tumour necrosis factor alpha", "PROTEIN", 56, 84], ["TNF", "PROTEIN", 86, 89], ["Infliximab", "TREATMENT", 12, 22], ["a monoclonal antibody targeting tumour necrosis factor alpha", "PROBLEM", 24, 84], ["TNF", "TEST", 86, 89], ["rheumatoid arthritis", "PROBLEM", 128, 148], ["other autoimmune diseases", "PROBLEM", 158, 183], ["Infliximab", "OBSERVATION", 12, 22], ["tumour", "OBSERVATION_MODIFIER", 56, 62], ["necrosis", "OBSERVATION", 63, 71], ["rheumatoid", "OBSERVATION_MODIFIER", 128, 138], ["arthritis", "OBSERVATION", 139, 148], ["RA", "ANATOMY", 150, 152], ["autoimmune diseases", "OBSERVATION", 164, 183]]], ["However, its use has been associated with opportunistic infections, including Pneumocystis jirovecii pneumonia (PcP).", [["opportunistic infections", "DISEASE", 42, 66], ["Pneumocystis jirovecii pneumonia", "DISEASE", 78, 110], ["PcP", "DISEASE", 112, 115], ["Pneumocystis jirovecii", "ORGANISM", 78, 100], ["Pneumocystis jirovecii", "SPECIES", 78, 100], ["Pneumocystis jirovecii", "SPECIES", 78, 100], ["opportunistic infections", "PROBLEM", 42, 66], ["Pneumocystis jirovecii pneumonia", "PROBLEM", 78, 110], ["associated with", "UNCERTAINTY", 26, 41], ["opportunistic", "OBSERVATION_MODIFIER", 42, 55], ["infections", "OBSERVATION", 56, 66], ["Pneumocystis", "OBSERVATION_MODIFIER", 78, 90], ["jirovecii", "OBSERVATION", 91, 100]]], ["Moreover, P. jirovecii has been observed colonising to humans with several disorders.", [["P. jirovecii", "DISEASE", 10, 22], ["P. jirovecii", "ORGANISM", 10, 22], ["humans", "ORGANISM", 55, 61], ["P. jirovecii", "SPECIES", 10, 22], ["humans", "SPECIES", 55, 61], ["P. jirovecii", "SPECIES", 10, 22], ["humans", "SPECIES", 55, 61], ["P. jirovecii", "PROBLEM", 10, 22], ["several disorders", "PROBLEM", 67, 84], ["jirovecii", "OBSERVATION", 13, 22]]], ["Objectives: To obtain information about P. jirovecii colonisation among patients with rheumatologic disease treated with infliximab.", [["P. jirovecii colonisation", "DISEASE", 40, 65], ["rheumatologic disease", "DISEASE", 86, 107], ["infliximab", "CHEMICAL", 121, 131], ["P. jirovecii", "ORGANISM", 40, 52], ["patients", "ORGANISM", 72, 80], ["infliximab", "SIMPLE_CHEMICAL", 121, 131], ["P. jirovecii", "SPECIES", 40, 52], ["patients", "SPECIES", 72, 80], ["P. jirovecii", "SPECIES", 40, 52], ["P. jirovecii colonisation", "PROBLEM", 40, 65], ["rheumatologic disease", "PROBLEM", 86, 107], ["infliximab", "TREATMENT", 121, 131]]], ["This information could be useful for assessing new strategies in the prevention of PcP in patients at risk.", [["PcP", "DISEASE", 83, 86], ["PcP", "SIMPLE_CHEMICAL", 83, 86], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98]]], ["Methods: 62 consecutive patients treated with infliximab for rheumatic disorders were included in the study.", [["infliximab", "CHEMICAL", 46, 56], ["rheumatic disorders", "DISEASE", 61, 80], ["patients", "ORGANISM", 24, 32], ["infliximab", "SIMPLE_CHEMICAL", 46, 56], ["patients", "SPECIES", 24, 32], ["infliximab", "TREATMENT", 46, 56], ["rheumatic disorders", "PROBLEM", 61, 80], ["the study", "TEST", 98, 107]]], ["Oropharyngeal washes (OW) samples were collected for P. jirovecii detection.", [["Oropharyngeal", "ANATOMY", 0, 13], ["samples", "ANATOMY", 26, 33], ["P. jirovecii", "DISEASE", 53, 65], ["P. jirovecii", "ORGANISM", 53, 65], ["P. jirovecii", "SPECIES", 53, 65], ["P. jirovecii", "SPECIES", 53, 65], ["Oropharyngeal washes", "TREATMENT", 0, 20], ["P. jirovecii detection", "TEST", 53, 75], ["jirovecii", "OBSERVATION", 56, 65]]], ["Clinical and demographic data were collected (sex, age, rheumatologic diagnosis, duration of infliximab use, concomitant use of other drugs for rheumatologic treatment, use of any other anti-TNF-a agent, use of anti-Pc drugs in the last six months, smoking, and diagnosis of chronic pulmonary respiratory disease).", [["pulmonary", "ANATOMY", 283, 292], ["infliximab", "CHEMICAL", 93, 103], ["chronic pulmonary respiratory disease", "DISEASE", 275, 312], ["TNF", "GENE_OR_GENE_PRODUCT", 191, 194], ["pulmonary", "ORGAN", 283, 292], ["TNF", "PROTEIN", 191, 194], ["Clinical and demographic data", "TEST", 0, 29], ["infliximab use", "TREATMENT", 93, 107], ["other drugs", "TREATMENT", 128, 139], ["rheumatologic treatment", "TREATMENT", 144, 167], ["anti-TNF", "TREATMENT", 186, 194], ["a agent", "TREATMENT", 195, 202], ["anti-Pc drugs", "TREATMENT", 211, 224], ["chronic pulmonary respiratory disease", "PROBLEM", 275, 312], ["chronic", "OBSERVATION_MODIFIER", 275, 282], ["pulmonary", "ANATOMY", 283, 292], ["respiratory disease", "OBSERVATION", 293, 312]]], ["P. jirovecii colonisation was identify in OW samples by PCR at mtLSU-rRNA gene, with primers pAZ102-X and pAZ102-Y.", [["samples", "ANATOMY", 45, 52], ["P. jirovecii", "DISEASE", 0, 12], ["P. jirovecii", "ORGANISM", 0, 12], ["pAZ102-X", "GENE_OR_GENE_PRODUCT", 93, 101], ["mtLSU-rRNA gene", "DNA", 63, 78], ["pAZ102", "DNA", 93, 99], ["X", "DNA", 100, 101], ["pAZ102", "DNA", 106, 112], ["P. jirovecii", "SPECIES", 0, 12], ["P. jirovecii", "SPECIES", 0, 12], ["P. jirovecii colonisation", "PROBLEM", 0, 25], ["PCR", "TEST", 56, 59], ["primers pAZ102", "TEST", 85, 99], ["jirovecii", "OBSERVATION", 3, 12]]], ["We adapted a method previously described to a real-time PCR setting, using a LightCycler 1.5 (Roche, Germany).", [["a LightCycler", "TEST", 75, 88]]], ["Individuals in whom the presence of P. jirovecii was detected at two independent assay in the absence of respiratory symptoms or radiological findings suggestive of PcP were considered to be colonised.", [["respiratory", "ANATOMY", 105, 116], ["P. jirovecii", "DISEASE", 36, 48], ["respiratory symptoms", "DISEASE", 105, 125], ["P. jirovecii", "ORGANISM", 36, 48], ["P. jirovecii", "SPECIES", 36, 48], ["P. jirovecii", "SPECIES", 36, 48], ["P. jirovecii", "PROBLEM", 36, 48], ["respiratory symptoms", "PROBLEM", 105, 125], ["radiological findings", "TEST", 129, 150], ["PcP", "PROBLEM", 165, 168], ["jirovecii", "OBSERVATION", 39, 48]]], ["Results: Clinical and demographic data for 62 patients treated with infliximab are presented in Table 1 Objectives: Most research with human bocavirus, a recently found respiratory pathogen, has been done by molecular biology (polymerase chain reaction, PCR).", [["infliximab", "CHEMICAL", 68, 78], ["respiratory pathogen", "DISEASE", 169, 189], ["patients", "ORGANISM", 46, 54], ["infliximab", "SIMPLE_CHEMICAL", 68, 78], ["human", "ORGANISM", 135, 140], ["bocavirus", "ORGANISM", 141, 150], ["patients", "SPECIES", 46, 54], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 135, 140], ["infliximab", "TREATMENT", 68, 78], ["human bocavirus", "PROBLEM", 135, 150], ["respiratory pathogen", "PROBLEM", 169, 189], ["polymerase chain reaction", "PROBLEM", 227, 252], ["PCR", "TEST", 254, 257], ["respiratory", "ANATOMY", 169, 180], ["pathogen", "OBSERVATION", 181, 189]]], ["The results have been ambiguous because the virus has often been found in co-infection with other viruses, and also in clinically healthy subjects.", [["the virus", "PROBLEM", 40, 49], ["co-infection", "PROBLEM", 74, 86], ["other viruses", "PROBLEM", 92, 105], ["co-infection", "OBSERVATION", 74, 86], ["viruses", "OBSERVATION", 98, 105]]], ["It has been proposed that, for bocavirus, antigen detection could better indicate the aetiology than qualitative nucleic acid detection.", [["nucleic acid", "CHEMICAL", 113, 125], ["bocavirus", "PROBLEM", 31, 40], ["antigen detection", "TEST", 42, 59], ["qualitative nucleic acid detection", "TEST", 101, 135]]], ["We have developed a rapid antigen detection test for the virus.Methods:The one-step test for bocavirus VP2 antigen is based on a separation-free two-photon excitation fluorometry (ArcDia TPX assay technique).", [["bocavirus", "ORGANISM", 93, 102], ["VP2 antigen", "GENE_OR_GENE_PRODUCT", 103, 114], ["bocavirus VP2 antigen", "PROTEIN", 93, 114], ["bocavirus", "SPECIES", 93, 102], ["a rapid antigen detection test", "TEST", 18, 48], ["the virus", "PROBLEM", 53, 62], ["step test", "TEST", 79, 88], ["bocavirus VP2 antigen", "TEST", 93, 114], ["a separation", "TREATMENT", 127, 139], ["free two-photon excitation fluorometry (ArcDia TPX assay technique", "TREATMENT", 140, 206]]], ["The assay protocol is simple; the swab sample is dissolved in sample buffer, and the solution is dispensed (20 ml) onto a 384-well microtitre plate (containing the reagents in dry form) for incubation and automated quantitative measurement.", [["swab sample", "ANATOMY", 34, 45], ["The assay protocol", "TEST", 0, 18], ["the swab sample", "TEST", 30, 45], ["the solution", "TREATMENT", 81, 93], ["a 384-well microtitre plate", "TREATMENT", 120, 147], ["the reagents", "TREATMENT", 160, 172], ["automated quantitative measurement", "TEST", 205, 239]]], ["The immunoassay applies microspheres as solid-phase carriers of purified bocavirus-specific polyclonal antibodies.", [["bocavirus", "SIMPLE_CHEMICAL", 73, 82], ["purified bocavirus-specific polyclonal antibodies", "PROTEIN", 64, 113], ["The immunoassay applies microspheres", "TREATMENT", 0, 36], ["purified bocavirus", "PROBLEM", 64, 82], ["polyclonal antibodies", "OBSERVATION", 92, 113]]], ["The virus antigens concentrate onto the solid-phase which is probed in real-time with fluorescently labelled antibody reagents.", [["virus antigens", "PROTEIN", 4, 18], ["The virus antigens", "PROBLEM", 0, 18], ["fluorescently labelled antibody reagents", "TREATMENT", 86, 126], ["virus", "OBSERVATION", 4, 9], ["solid-phase", "OBSERVATION_MODIFIER", 40, 51]]], ["Strong positive samples are reportable in 15 minutes, while low positive and negative samples are reported in 2 hours.", [["samples", "ANATOMY", 16, 23], ["samples", "ANATOMY", 86, 93], ["low positive and negative samples", "PROBLEM", 60, 93]]], ["The performance of the method was studied with recombinant human bocavirus-like particles (VP2), and purified respiratory pathogens (Group A streptococci, Streptococcus pneumoniae, and influenza A and B, respiratory syncytial, metapneumo, adeno, and parainfluenza 1\u22123 viruses).", [["respiratory pathogens", "DISEASE", 110, 131], ["Streptococcus pneumoniae", "DISEASE", 155, 179], ["respiratory syncytial, metapneumo, adeno, and parainfluenza 1\u22123 viruses", "DISEASE", 204, 275], ["human", "ORGANISM", 59, 64], ["bocavirus-like particles", "ORGANISM", 65, 89], ["VP2", "ORGANISM", 91, 94], ["Group A streptococci", "ORGANISM", 133, 153], ["Streptococcus pneumoniae", "ORGANISM", 155, 179], ["influenza A", "ORGANISM", 185, 196], ["B", "GENE_OR_GENE_PRODUCT", 201, 202], ["respiratory syncytial", "ORGANISM", 204, 225], ["parainfluenza 1\u22123 viruses", "ORGANISM", 250, 275], ["VP2", "PROTEIN", 91, 94], ["human", "SPECIES", 59, 64], ["Streptococcus pneumoniae", "SPECIES", 155, 179], ["parainfluenza", "SPECIES", 250, 263], ["human", "SPECIES", 59, 64], ["Group A streptococci", "SPECIES", 133, 153], ["Streptococcus pneumoniae", "SPECIES", 155, 179], ["recombinant human bocavirus", "PROBLEM", 47, 74], ["VP2", "TEST", 91, 94], ["purified respiratory pathogens", "PROBLEM", 101, 131], ["Group A streptococci", "TEST", 133, 153], ["Streptococcus pneumoniae", "PROBLEM", 155, 179], ["influenza", "PROBLEM", 185, 194], ["respiratory syncytial, metapneumo", "PROBLEM", 204, 237], ["adeno", "PROBLEM", 239, 244], ["parainfluenza", "PROBLEM", 250, 263], ["respiratory", "ANATOMY", 110, 121], ["respiratory syncytial", "ANATOMY", 204, 225]]], ["Results: Analytical detection sensitivity of the method (lowest limit of detection, 0-control + 3SDs) was 3 ng/ml, dynamic concentration range was three orders of magnitude, and intra-assay imprecision was 5\u221210%.Methods:Cross-reactions with the other respiratory pathogens were not found.Conclusion:The new method enables rapid detection of bocavirus antigens.", [["bocavirus antigens", "GENE_OR_GENE_PRODUCT", 341, 359], ["bocavirus antigens", "PROTEIN", 341, 359], ["the method", "TEST", 45, 55], ["detection", "TEST", 73, 82], ["intra-assay imprecision", "TEST", 178, 201], ["the other respiratory pathogens", "PROBLEM", 241, 272], ["bocavirus antigens", "PROBLEM", 341, 359]]], ["The new test is very easy to perform in comparison to standard ELISAs.", [["The new test", "TEST", 0, 12]]], ["The analytical sensitivity of the method is expected to allow analysis of clinical samples.", [["samples", "ANATOMY", 83, 90], ["clinical samples", "TEST", 74, 90]]], ["The sensitivity of the antigen detection test could be significantly increased by the use of monoclonal antibodies (10-100 fold).", [["monoclonal antibodies", "PROTEIN", 93, 114], ["the antigen detection test", "TEST", 19, 45], ["monoclonal antibodies", "TEST", 93, 114]]], ["Our future objectives include increasing the detection sensitivity, and analysis of clinical samples in order to study the correlation of antigen detection and the clinical aetiology. life-year for patients who survived.", [["samples", "ANATOMY", 93, 100], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["the detection sensitivity", "TEST", 41, 66], ["clinical samples", "TEST", 84, 100], ["antigen detection", "TEST", 138, 155]]], ["All analyses were performed using TreeAge Software (2008).", [["All analyses", "TEST", 0, 12]]], ["Results: The overall mortality rates for empiric vancomycin (V) and semi-synthetic-penicillin (SSP) was 30% and 35%, respectively, as apposed to 24% for those receiving the rapid MRSA PCR testing.", [["vancomycin", "CHEMICAL", 49, 59], ["penicillin", "CHEMICAL", 83, 93], ["vancomycin", "CHEMICAL", 49, 59], ["penicillin", "CHEMICAL", 83, 93], ["vancomycin", "SIMPLE_CHEMICAL", 49, 59], ["semi-synthetic-penicillin", "SIMPLE_CHEMICAL", 68, 93], ["MRSA", "SPECIES", 179, 183], ["MRSA", "SPECIES", 179, 183], ["empiric vancomycin (V)", "TREATMENT", 41, 63], ["semi-synthetic-penicillin (SSP)", "TREATMENT", 68, 99], ["the rapid MRSA PCR testing", "TEST", 169, 195]]], ["These mortality rates were similar in both the EU and US subsets.", [["These mortality rates", "TEST", 0, 21]]], ["Furthermore, the number needed to test in order to save one life was 20 and 11 for empiric V and SSP, respectively.", [["empiric V and SSP", "TREATMENT", 83, 100]]], ["Using sensitivity analysis the prevalence of MRSA was varied from 5% to 80% and yielded an absolute mortality difference favouring the PCR testing group of 10% and 2%, respectively as compared to empiric V and 1% and 18% compared to empiric SSP.O250 Mortality and cost-effectiveness of rapid MRSA PCR testing in hospitalised patients with bacteraemia: a decision modelIn EU the C/E for empiric V and SSP treated patients was \u20ac873 and \u20ac949, respectively as compared to \u20ac807 for rapid PCR testing.", [["MRSA", "DISEASE", 45, 49], ["bacteraemia", "DISEASE", 339, 350], ["patients", "ORGANISM", 325, 333], ["patients", "ORGANISM", 412, 420], ["MRSA", "SPECIES", 45, 49], ["MRSA", "SPECIES", 292, 296], ["patients", "SPECIES", 325, 333], ["patients", "SPECIES", 412, 420], ["MRSA", "SPECIES", 45, 49], ["MRSA", "SPECIES", 292, 296], ["sensitivity analysis", "TEST", 6, 26], ["MRSA", "PROBLEM", 45, 49], ["an absolute mortality difference", "PROBLEM", 88, 120], ["the PCR testing group", "TEST", 131, 152], ["empiric V", "TEST", 196, 205], ["empiric SSP", "TEST", 233, 244], ["rapid MRSA PCR testing", "TEST", 286, 308], ["bacteraemia", "PROBLEM", 339, 350], ["empiric V", "TREATMENT", 386, 395], ["rapid PCR testing", "TEST", 477, 494], ["MRSA", "OBSERVATION", 45, 49]]], ["In the US the C/E for empiric V was $1,049 as compared to $971 for rapid PCR testing.", [["empiric V", "TREATMENT", 22, 31], ["rapid PCR testing", "TEST", 67, 84]]], ["Using sensitivity analysis the prevalence of MRSA was varied from 5% to 80% and yielded favourable C/E in both the EU and US for rapid PCR testing regardless of the empiric treatment regimen.", [["MRSA", "DISEASE", 45, 49], ["MRSA", "SPECIES", 45, 49], ["MRSA", "SPECIES", 45, 49], ["sensitivity analysis", "TEST", 6, 26], ["MRSA", "PROBLEM", 45, 49], ["favourable C/E", "PROBLEM", 88, 102], ["rapid PCR testing", "TEST", 129, 146], ["the empiric treatment regimen", "TREATMENT", 161, 190]]], ["Conclusion: Rapid MRSA PCR testing using the Xpert MRSA/SA Blood Culture PCR assay appears to improve mortality rates and is cost effective in the EU and US across a wide range of MRSA prevalence rates.S. Malhotra-Kumar\u00b0, J. Corti\u00f1as Abrahantes, C. Lammens, G. Molenberghs, M. Aerts, H. Goossens on behalf of the MOSAR WP2 study groupBackground: Rapid detection of gastro-intestinal carriage of glycopeptide-resistant enterococci (GRE) from screening cultures is crucial for an efficient control of their spread.", [["intestinal", "ANATOMY", 372, 382], ["MRSA", "DISEASE", 180, 184], ["intestinal", "ORGAN", 372, 382], ["glycopeptide-resistant enterococci", "SIMPLE_CHEMICAL", 395, 429], ["MRSA", "SPECIES", 18, 22], ["MRSA", "SPECIES", 51, 55], ["MRSA", "SPECIES", 180, 184], ["MRSA", "SPECIES", 18, 22], ["Rapid MRSA PCR testing", "TEST", 12, 34], ["the Xpert MRSA", "TEST", 41, 55], ["SA Blood Culture PCR assay", "TEST", 56, 82], ["mortality rates", "TEST", 102, 117], ["MRSA prevalence rates", "TREATMENT", 180, 201], ["gastro-intestinal carriage of glycopeptide", "PROBLEM", 365, 407], ["resistant enterococci", "PROBLEM", 408, 429], ["screening cultures", "TEST", 441, 459], ["gastro", "ANATOMY", 365, 371], ["intestinal", "ANATOMY", 372, 382]]], ["We assessed 4 media \u2212 2 chromogenic, ChromID, (bioM\u00e9rieux), and CHROMagar (CHROMagar Microbiology), and 2 selective, VRE Selective (Oxoid) and ECCV (BD) \u2212 for their ability to detect GRE using well-characterised isolates and stool samples from hospitalised patients at high risk of GRE colonisation.", [["stool samples", "ANATOMY", 225, 238], ["ECCV", "SIMPLE_CHEMICAL", 143, 147], ["stool samples", "ORGANISM_SUBSTANCE", 225, 238], ["patients", "ORGANISM", 257, 265], ["GRE", "DNA", 183, 186], ["patients", "SPECIES", 257, 265], ["CHROMagar", "TEST", 64, 73], ["VRE", "PROBLEM", 117, 120], ["GRE", "TEST", 183, 186], ["stool samples", "TEST", 225, 238], ["GRE colonisation", "PROBLEM", 282, 298], ["colonisation", "OBSERVATION", 286, 298]]], ["Methods: Twenty-five isolates consisting of 13 GRE. faecalis/faecium carrying various van genes and 12 non-VRE at concentrations of 10 6 -10 1 CFU/ml and 10 6 CFU/ml, respectively, and 37 stool samples were randomised and spiral plated on all media and scored by 5 blinded investigators for characteristic colonies after 24 hrs incubation.", [["stool samples", "ANATOMY", 188, 201], ["colonies", "ANATOMY", 306, 314], ["VRE", "CHEMICAL", 107, 110], ["faecalis/faecium", "ORGANISM", 52, 68], ["GRE", "DNA", 47, 50], ["faecalis", "SPECIES", 52, 60], ["faecalis/faecium", "SPECIES", 52, 68], ["faecalis", "PROBLEM", 52, 60], ["stool samples", "TEST", 188, 201], ["spiral plated on all media", "TREATMENT", 222, 248], ["characteristic colonies", "PROBLEM", 291, 314], ["faecium", "OBSERVATION", 61, 68]]], ["Standard confirmatory tests were done on 1 putative GRE colony or on 1 characteristically coloured colony each for E. faecalis/faecium from the selective and chromogenic media, respectively.", [["colony", "ANATOMY", 56, 62], ["colony", "ANATOMY", 99, 105], ["E. faecalis/faecium", "ORGANISM", 115, 134], ["GRE colony", "DNA", 52, 62], ["E. faecalis", "SPECIES", 115, 126], ["E. faecalis/faecium", "SPECIES", 115, 134], ["Standard confirmatory tests", "TEST", 0, 27], ["E. faecalis/faecium", "PROBLEM", 115, 134]]], ["Detection of van genes, and ddl or sodA based speciation was done on PCR-sequencing.", [["ddl", "GENE_OR_GENE_PRODUCT", 28, 31], ["van genes", "DNA", 13, 22], ["ddl", "DNA", 28, 31], ["van genes", "PROBLEM", 13, 22], ["PCR", "TEST", 69, 72]]], ["Mean sensitivity (SEN) and specificity (SPEC), and confidence intervals (CIs) were estimated for each medium by a logistic regression model using a penalised likelihood approach based on the reader response for the stool samples and isolates, and additionally on confirmation test results for the stool samples, both at the aggregated (GRE detected) and penalised level (correct species-colony colour correlation).", [["stool samples", "ANATOMY", 215, 228], ["stool samples", "ANATOMY", 297, 310], ["colony", "ANATOMY", 387, 393], ["GRE", "DNA", 336, 339], ["Mean sensitivity", "TEST", 0, 16], ["specificity", "TEST", 27, 38], ["SPEC", "TEST", 40, 44], ["CIs", "TEST", 73, 76], ["a penalised likelihood approach", "TREATMENT", 146, 177], ["the stool samples", "TEST", 211, 228], ["confirmation test", "TEST", 263, 280], ["the stool samples", "TEST", 293, 310]]], ["Results: CHROMagar showed the highest SEN based on reader response at the aggregated and penalised level for both stool samples and isolates (Table) .", [["stool samples", "ANATOMY", 114, 127], ["CHROMagar", "TEST", 9, 18], ["both stool samples", "TEST", 109, 127]]], ["Using confirmation test results at the aggregated level, SEN for ECCV was highest while the two chromogenic media showed a decrease in SEN by at least 11% in comparison to the values obtained based on reader response.", [["ECCV", "SPECIES", 65, 69], ["confirmation test", "TEST", 6, 23], ["ECCV", "TEST", 65, 69], ["the two chromogenic media", "TEST", 88, 113], ["a decrease in SEN", "PROBLEM", 121, 138], ["decrease", "OBSERVATION_MODIFIER", 123, 131]]], ["SENs for the 2 chromogenic media were even lower (<70%) based on confirmation test results at the penalised level.", [["the 2 chromogenic media", "TEST", 9, 32], ["confirmation test", "TEST", 65, 82]]], ["ECCV and ChromID showed the highest SPECs with both reader response (stool samples) and confirmation test results at the aggregated level, and ChromID also at the penalised level, with narrow CIs indicating a high precision of this parameter estimate.", [["SPECs", "ANATOMY", 36, 41], ["stool samples", "ANATOMY", 69, 82], ["ChromID", "SIMPLE_CHEMICAL", 9, 16], ["SPECs", "CANCER", 36, 41], ["ECCV", "TEST", 0, 4], ["ChromID", "TEST", 9, 16], ["the highest SPECs", "PROBLEM", 24, 41], ["stool samples", "TEST", 69, 82], ["confirmation test", "TEST", 88, 105], ["ChromID", "TEST", 143, 150], ["narrow CIs", "PROBLEM", 185, 195], ["high precision", "OBSERVATION_MODIFIER", 209, 223]]], ["For isolates, SPECs were highest for CHROMagar at both levels.S. Malhotra-Kumar\u00b0, J. Corti\u00f1as Abrahantes, C. Lammens, G. Molenberghs, M. Aerts, H. Goossens on behalf of the MOSAR WP2 study groupConclusions: CHROMagar showed the best overall performance considering both SEN and SPEC estimates.", [["SPECs", "ANATOMY", 14, 19], ["SPECs", "CELL", 14, 19], ["CHROMagar", "SIMPLE_CHEMICAL", 37, 46], ["isolates", "TEST", 4, 12], ["SPECs", "TEST", 14, 19], ["CHROMagar", "TEST", 37, 46], ["CHROMagar", "TEST", 207, 216]]], ["ECCV performed well as a selective medium for GRE detection from stool samples.O252 Evaluation of a new E-test to detect metallo-beta-lactamases in Enterobacteriaceae L. Bylund\u00b0, P. Ho, T. Walsh, G. Zambardi, A. Engelhardt (Solna, SE; Cardiff, UK; La Balme, FR)Objectives: Metallo-beta-lactamases (MBLs) expressed from Pseudomonas are able to confer resistance to all beta-lactams with the exception of aztreonam.", [["stool samples", "ANATOMY", 65, 78], ["metallo-beta-lactamases", "CHEMICAL", 121, 144], ["Metallo-beta-lactamases", "CHEMICAL", 273, 296], ["aztreonam", "CHEMICAL", 403, 412], ["aztreonam", "CHEMICAL", 403, 412], ["stool samples", "ORGANISM_SUBSTANCE", 65, 78], ["metallo-beta-lactamases", "SIMPLE_CHEMICAL", 121, 144], ["Metallo-beta-lactamases", "GENE_OR_GENE_PRODUCT", 273, 296], ["MBLs", "GENE_OR_GENE_PRODUCT", 298, 302], ["Pseudomonas", "ORGANISM", 319, 330], ["beta-lactams", "GENE_OR_GENE_PRODUCT", 368, 380], ["aztreonam", "SIMPLE_CHEMICAL", 403, 412], ["GRE", "DNA", 46, 49], ["Metallo-beta-lactamases", "PROTEIN", 273, 296], ["MBLs", "PROTEIN", 298, 302], ["ECCV", "TEST", 0, 4], ["GRE detection", "TEST", 46, 59], ["stool samples", "TEST", 65, 78], ["Evaluation", "TEST", 84, 94], ["a new E-test", "TEST", 98, 110], ["metallo", "TEST", 121, 128], ["beta-lactamases (MBLs)", "TREATMENT", 281, 303], ["Pseudomonas", "PROBLEM", 319, 330], ["all beta-lactams", "TREATMENT", 364, 380], ["aztreonam", "TREATMENT", 403, 412]]], ["However, Enterobacteriaceae possessing MBLs exhibit moderate cephalosporin and low carbapenem MICs and thus are often underestimated.", [["cephalosporin", "CHEMICAL", 61, 74], ["carbapenem", "CHEMICAL", 83, 93], ["cephalosporin", "CHEMICAL", 61, 74], ["carbapenem", "CHEMICAL", 83, 93], ["MBLs", "SIMPLE_CHEMICAL", 39, 43], ["cephalosporin", "SIMPLE_CHEMICAL", 61, 74], ["Enterobacteriaceae possessing MBLs", "PROBLEM", 9, 43], ["moderate cephalosporin", "TREATMENT", 52, 74], ["low carbapenem MICs", "TREATMENT", 79, 98], ["moderate", "OBSERVATION_MODIFIER", 52, 60], ["cephalosporin", "OBSERVATION", 61, 74], ["low carbapenem MICs", "OBSERVATION", 79, 98]]], ["Herein, we describe data from new Etest prototypes specifically designed to detect this problematic resistance mechanism.", [["new Etest prototypes", "TEST", 30, 50], ["this problematic resistance mechanism", "PROBLEM", 83, 120]]], ["Methods: 82 MBL-positive (VIM or IMP derivatives) Enterobacteriaceae clinical isolates from 8 countries and 27 randomly selected Enterobacteriaceae negative controls (including the ATCC type strains) were tested against the 4 different Etest MBL prototypes.", [["MBL", "GENE_OR_GENE_PRODUCT", 12, 15], ["VIM", "GENE_OR_GENE_PRODUCT", 26, 29], ["IMP derivatives", "SIMPLE_CHEMICAL", 33, 48], ["MBL", "GENE_OR_GENE_PRODUCT", 242, 245], ["MBL", "PROTEIN", 12, 15], ["VIM", "PROTEIN", 26, 29], ["MBL", "PROTEIN", 242, 245], ["ATCC type strains", "SPECIES", 181, 198], ["Methods", "TEST", 0, 7], ["MBL", "TEST", 12, 15], ["VIM or IMP derivatives", "TREATMENT", 26, 48], ["Enterobacteriaceae clinical isolates", "TEST", 50, 86], ["the ATCC type strains", "TREATMENT", 177, 198]]], ["Beta-lactam substrates used were imipenem (IP), meropenem (MP), ceftazidime (TZ) and cefotaxime (CT) with or without the inhibitors dipicolinic acid (DPA) and EDTA.", [["Beta-lactam", "CHEMICAL", 0, 11], ["imipenem", "CHEMICAL", 33, 41], ["IP", "CHEMICAL", 43, 45], ["meropenem", "CHEMICAL", 48, 57], ["MP", "CHEMICAL", 59, 61], ["ceftazidime", "CHEMICAL", 64, 75], ["TZ", "CHEMICAL", 77, 79], ["cefotaxime", "CHEMICAL", 85, 95], ["CT", "CHEMICAL", 97, 99], ["dipicolinic acid", "CHEMICAL", 132, 148], ["DPA", "CHEMICAL", 150, 153], ["EDTA", "CHEMICAL", 159, 163], ["Beta-lactam", "CHEMICAL", 0, 11], ["imipenem", "CHEMICAL", 33, 41], ["meropenem", "CHEMICAL", 48, 57], ["ceftazidime", "CHEMICAL", 64, 75], ["TZ", "CHEMICAL", 77, 79], ["cefotaxime", "CHEMICAL", 85, 95], ["dipicolinic acid", "CHEMICAL", 132, 148], ["DPA", "CHEMICAL", 150, 153], ["EDTA", "CHEMICAL", 159, 163], ["Beta-lactam", "SIMPLE_CHEMICAL", 0, 11], ["imipenem", "SIMPLE_CHEMICAL", 33, 41], ["IP", "SIMPLE_CHEMICAL", 43, 45], ["meropenem", "SIMPLE_CHEMICAL", 48, 57], ["MP", "SIMPLE_CHEMICAL", 59, 61], ["ceftazidime", "SIMPLE_CHEMICAL", 64, 75], ["TZ", "SIMPLE_CHEMICAL", 77, 79], ["cefotaxime", "SIMPLE_CHEMICAL", 85, 95], ["CT", "SIMPLE_CHEMICAL", 97, 99], ["dipicolinic acid", "SIMPLE_CHEMICAL", 132, 148], ["DPA", "SIMPLE_CHEMICAL", 150, 153], ["EDTA", "SIMPLE_CHEMICAL", 159, 163], ["Beta-lactam substrates", "TREATMENT", 0, 22], ["imipenem", "TREATMENT", 33, 41], ["meropenem (MP)", "TREATMENT", 48, 62], ["ceftazidime (TZ)", "TREATMENT", 64, 80], ["cefotaxime", "TREATMENT", 85, 95], ["CT", "TEST", 97, 99]]], ["The Etest standard procedure for Gram negative aerobes was used and a reduction of beta-lactam MIC by equal to or greater than 3 dilutions by EDTA or DPA was interpreted as positive for MBL.", [["beta-lactam", "CHEMICAL", 83, 94], ["EDTA", "CHEMICAL", 142, 146], ["DPA", "CHEMICAL", 150, 153], ["beta-lactam", "CHEMICAL", 83, 94], ["EDTA", "CHEMICAL", 142, 146], ["DPA", "CHEMICAL", 150, 153], ["beta-lactam MIC", "SIMPLE_CHEMICAL", 83, 98], ["EDTA", "SIMPLE_CHEMICAL", 142, 146], ["DPA", "SIMPLE_CHEMICAL", 150, 153], ["MBL", "GENE_OR_GENE_PRODUCT", 186, 189], ["MBL", "PROTEIN", 186, 189], ["The Etest standard procedure", "TREATMENT", 0, 28], ["Gram negative aerobes", "PROBLEM", 33, 54], ["a reduction of beta-lactam MIC", "TREATMENT", 68, 98], ["EDTA or DPA", "TEST", 142, 153], ["MBL", "PROBLEM", 186, 189]]], ["Presence of ESBLs was tested using the Etest CT/CTL, TZ/TZL and cefepime (PM)/PML strips.", [["TZ", "CHEMICAL", 53, 55], ["TZL", "CHEMICAL", 56, 59], ["cefepime", "CHEMICAL", 64, 72], ["cefepime", "CHEMICAL", 64, 72], ["ESBLs", "GENE_OR_GENE_PRODUCT", 12, 17], ["TZ", "SIMPLE_CHEMICAL", 53, 55], ["TZL", "SIMPLE_CHEMICAL", 56, 59], ["cefepime", "SIMPLE_CHEMICAL", 64, 72], ["PM", "SIMPLE_CHEMICAL", 74, 76], ["ESBLs", "PROBLEM", 12, 17], ["the Etest CT", "TEST", 35, 47], ["TZ/TZL", "TREATMENT", 53, 59], ["cefepime", "TREATMENT", 64, 72], ["PML strips", "TREATMENT", 78, 88], ["ESBLs", "OBSERVATION", 12, 17]]], ["AmpC production was detected using the Etest cefoxitin (FX)/FXI and cefotetan (CN)/CNI strips.", [["cefoxitin", "CHEMICAL", 45, 54], ["cefotetan", "CHEMICAL", 68, 77], ["cefoxitin", "CHEMICAL", 45, 54], ["cefotetan", "CHEMICAL", 68, 77], ["AmpC", "GENE_OR_GENE_PRODUCT", 0, 4], ["cefoxitin", "SIMPLE_CHEMICAL", 45, 54], ["FX", "SIMPLE_CHEMICAL", 56, 58], ["FXI", "GENE_OR_GENE_PRODUCT", 60, 63], ["cefotetan", "SIMPLE_CHEMICAL", 68, 77], ["CN", "SIMPLE_CHEMICAL", 79, 81], ["CNI", "SIMPLE_CHEMICAL", 83, 86], ["AmpC", "PROTEIN", 0, 4], ["FXI", "PROTEIN", 60, 63], ["AmpC production", "TREATMENT", 0, 15], ["the Etest cefoxitin", "TREATMENT", 35, 54], ["FXI", "TREATMENT", 60, 63], ["cefotetan", "TREATMENT", 68, 77], ["CNI strips", "TREATMENT", 83, 93]]], ["Of the 784 Select specimens that were negative for GBS, 345 grew turquoise-blue colonies, but the majority that required further work to rule out GBS grew after 48 hours.", [["specimens", "ANATOMY", 18, 27], ["colonies", "ANATOMY", 80, 88], ["GBS", "DISEASE", 51, 54], ["GBS", "DISEASE", 146, 149], ["specimens", "CANCER", 18, 27], ["Select specimens", "TEST", 11, 27], ["GBS", "TEST", 51, 54], ["GBS", "PROBLEM", 146, 149], ["blue colonies", "OBSERVATION", 75, 88]]], ["Two strains of GBS that were missed grew as white colonies on Select, and even at 48 h, did not exhibit the characteristic turquoise-blue colour.", [["colonies", "ANATOMY", 50, 58], ["GBS", "DISEASE", 15, 18], ["GBS", "PROBLEM", 15, 18], ["white colonies", "PROBLEM", 44, 58], ["GBS", "OBSERVATION", 15, 18], ["blue colour", "OBSERVATION", 133, 144]]], ["Conclusion: SSB enrichment followed by Select subculture was extremely sensitive (99.2%) and superior to CNA/SSB for detection of GBS from genital specimens.", [["genital specimens", "ANATOMY", 139, 156], ["GBS", "DISEASE", 130, 133], ["SSB", "CELLULAR_COMPONENT", 12, 15], ["genital specimens", "CANCER", 139, 156], ["SSB", "PROTEIN", 12, 15], ["CNA", "DNA", 105, 108], ["SSB", "PROTEIN", 109, 112], ["SSB enrichment", "PROBLEM", 12, 26], ["Select subculture", "TEST", 39, 56], ["GBS", "PROBLEM", 130, 133], ["genital specimens", "TEST", 139, 156], ["GBS", "OBSERVATION", 130, 133], ["genital", "ANATOMY", 139, 146]]], ["However, non-GBS organisms can produce turquoise-blue colonies on Select and further work must be performed to rule out the presence of GBS.D. Baud, L. Regan, G. Greub\u00b0(Lausanne, CH; London, UK)Objectives: Screening for Chlamydia trachomatis (CT) specific antibodies is valuable in investigating recurrent cause of miscarriage, pelvic inflammatory disease and tubal damage following repeated episodes of pelvic inflammatory disease.", [["pelvic", "ANATOMY", 328, 334], ["tubal", "ANATOMY", 360, 365], ["pelvic", "ANATOMY", 404, 410], ["GBS", "DISEASE", 136, 139], ["Chlamydia trachomatis", "DISEASE", 220, 241], ["miscarriage", "DISEASE", 315, 326], ["pelvic inflammatory disease", "DISEASE", 328, 355], ["tubal damage", "DISEASE", 360, 372], ["pelvic inflammatory disease", "DISEASE", 404, 431], ["Chlamydia trachomatis", "ORGANISM", 220, 241], ["tubal", "MULTI-TISSUE_STRUCTURE", 360, 365], ["turquoise-blue colonies", "CELL_LINE", 39, 62], ["Chlamydia trachomatis (CT) specific antibodies", "PROTEIN", 220, 266], ["Chlamydia trachomatis", "SPECIES", 220, 241], ["Chlamydia trachomatis", "SPECIES", 220, 241], ["non-GBS organisms", "PROBLEM", 9, 26], ["turquoise-blue colonies", "PROBLEM", 39, 62], ["GBS", "PROBLEM", 136, 139], ["Chlamydia trachomatis", "PROBLEM", 220, 241], ["CT) specific antibodies", "TEST", 243, 266], ["miscarriage", "PROBLEM", 315, 326], ["pelvic inflammatory disease", "PROBLEM", 328, 355], ["tubal damage", "PROBLEM", 360, 372], ["pelvic inflammatory disease", "PROBLEM", 404, 431], ["blue colonies", "OBSERVATION", 49, 62], ["GBS", "OBSERVATION", 136, 139], ["miscarriage", "OBSERVATION", 315, 326], ["pelvic", "ANATOMY", 328, 334], ["inflammatory", "OBSERVATION", 335, 347], ["tubal", "ANATOMY", 360, 365], ["damage", "OBSERVATION", 366, 372], ["pelvic", "ANATOMY", 404, 410], ["inflammatory", "OBSERVATION", 411, 423]]], ["Immunofluorescence (IF) is considered the gold standard for detection of CT antibodies.", [["CT antibodies", "GENE_OR_GENE_PRODUCT", 73, 86], ["CT antibodies", "PROTEIN", 73, 86], ["Immunofluorescence", "TEST", 0, 18], ["CT antibodies", "TEST", 73, 86]]], ["The present study aims to compare the performance of 4 other commercial tests for the detection of serum IgG antibodies specific for CT: two CT IgG pELISA both using major outer membrane protein (MOMP; [\"MOMP-Medac\", CT-IgG-pELISA; Medac, Wedel, Germany and \"MOMP-Ruwag\", CT pELISA; Ruwag, Bettlach, Switzerland), one CT HSP-60 IgG pELISA (\"HSP60-Medac\", cHSP60-IgG-pELISA; Medac, Wedel, Germany), and a new automated epifluorescence immunoassay (\"Inodiag\", \"MuST Chlamydiae; Inodiag, Signes, France).", [["serum", "ANATOMY", 99, 104], ["outer membrane", "ANATOMY", 172, 186], ["serum", "ORGANISM_SUBSTANCE", 99, 104], ["IgG", "ORGANISM_SUBSTANCE", 105, 108], ["outer membrane", "CELLULAR_COMPONENT", 172, 186], ["MOMP", "CELLULAR_COMPONENT", 196, 200], ["HSP60", "GENE_OR_GENE_PRODUCT", 341, 346], ["serum IgG antibodies", "PROTEIN", 99, 119], ["CT", "PROTEIN", 133, 135], ["CT IgG pELISA", "PROTEIN", 141, 154], ["major outer membrane protein", "PROTEIN", 166, 194], ["MOMP", "PROTEIN", 196, 200], ["MOMP", "PROTEIN", 204, 208], ["Medac", "PROTEIN", 209, 214], ["CT", "PROTEIN", 217, 219], ["IgG", "PROTEIN", 220, 223], ["pELISA", "PROTEIN", 224, 230], ["MOMP", "PROTEIN", 259, 263], ["CT HSP-60 IgG pELISA", "PROTEIN", 318, 338], ["HSP60", "PROTEIN", 341, 346], ["Medac", "PROTEIN", 347, 352], ["cHSP60", "PROTEIN", 355, 361], ["IgG", "PROTEIN", 362, 365], ["pELISA", "PROTEIN", 366, 372], ["The present study", "TEST", 0, 17], ["commercial tests", "TEST", 61, 77], ["the detection", "TEST", 82, 95], ["serum IgG antibodies", "TEST", 99, 119], ["CT", "TEST", 133, 135], ["two CT IgG pELISA", "TEST", 137, 154], ["MOMP", "TEST", 204, 208], ["CT", "TEST", 217, 219], ["MOMP", "TEST", 259, 263], ["one CT HSP", "TEST", 314, 324], ["HSP60", "TEST", 341, 346], ["cHSP60", "TEST", 355, 361], ["a new automated epifluorescence immunoassay", "TEST", 402, 445]]], ["Methods: A total of 405 patients with (n = 251) and without (n = 154) miscarriages were tested by all 5 serological tests described above.", [["miscarriages", "DISEASE", 70, 82], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["miscarriages", "PROBLEM", 70, 82], ["all 5 serological tests", "TEST", 98, 121]]], ["Sensitivity and specificity were calculated using IF as gold standard.D. Baud, L. Regan, G. Greub\u00b0(Lausanne, CH; London, UK)A second standard, defining true positive or negative samples as sera respectively positive and negative in all 4 others tests, was also used (see table) .R. Rautemaa-Richardson\u00b0, A. Smith, D. Lockhart for the COMB Network -Clinical Oral Microbiology NetworkObjectives: Participation in diagnostic microbiology internal and external quality control (QC) processes is good laboratory practice, an essential component of a quality management system and compulsory in some European countries.", [["samples", "ANATOMY", 178, 185], ["sera", "ANATOMY", 189, 193], ["sera", "ORGANISM_SUBSTANCE", 189, 193], ["Sensitivity", "TEST", 0, 11], ["specificity", "TEST", 16, 27], ["sera", "TEST", 189, 193]]], ["Currently, there is no QC scheme for diagnostic oral microbiology.", [["oral", "ANATOMY", 48, 52], ["oral", "ORGANISM_SUBDIVISION", 48, 52], ["diagnostic oral microbiology", "TEST", 37, 65], ["no", "UNCERTAINTY", 20, 22]]], ["The aim of this study was to collate information on current QC needs, and processes undertaken in diagnostic oral microbiology laboratories.", [["oral", "ANATOMY", 109, 113], ["oral", "ORGANISM_SUBDIVISION", 109, 113], ["this study", "TEST", 11, 21]]], ["Method: An on-line questionnaire was devised to ascertain interest in participating in an oral microbiology QC scheme and sent to oral microbiology diagnostic laboratories.", [["oral", "ANATOMY", 90, 94], ["oral", "ANATOMY", 130, 134], ["oral", "ORGANISM_SUBDIVISION", 90, 94], ["oral", "ORGANISM_SUBDIVISION", 130, 134], ["an oral microbiology QC scheme", "TEST", 87, 117]]], ["The laboratories were identified from participants attending the European Oral Microbiology Workshop in Helsinki, 2008.", [["participants", "SPECIES", 38, 50]]], ["Following this, a pilot round of QC samples was distributed to all interested laboratories.", [["QC samples", "CANCER", 33, 43], ["QC samples", "TEST", 33, 43]]], ["Results: We identified 12 individuals that worked in diagnostic oral microbiology laboratories and received 7 (58%) positive responses.", [["oral", "ANATOMY", 64, 68], ["oral", "ORGANISM_SUBDIVISION", 64, 68]]], ["Of these 7 laboratories (representing 6 European countries) 71% did not participate in either internal or external QC.", [["European countries", "TEST", 40, 58]]], ["86% of participants were in favour of a European-wide oral microbiology QC scheme.", [["oral", "ANATOMY", 54, 58], ["participants", "ORGANISM", 7, 19], ["oral", "ORGANISM_SUBDIVISION", 54, 58], ["participants", "SPECIES", 7, 19]]], ["The preferred frequency for receiving external QC specimen was once in 3\u22124 months.", [["QC specimen", "ANATOMY", 47, 58], ["external QC specimen", "TREATMENT", 38, 58]]], ["The most preferred specimen types were periodontal pocket and oral pus specimens (both 29%), followed by oral mucosal swabs and caries activity tests.", [["specimen", "ANATOMY", 19, 27], ["periodontal pocket", "ANATOMY", 39, 57], ["oral pus specimens", "ANATOMY", 62, 80], ["oral mucosal", "ANATOMY", 105, 117], ["caries", "DISEASE", 128, 134], ["periodontal pocket", "MULTI-TISSUE_STRUCTURE", 39, 57], ["oral pus specimens", "ORGANISM_SUBSTANCE", 62, 80], ["oral", "ORGANISM_SUBDIVISION", 105, 109], ["mucosal swabs", "TISSUE", 110, 123], ["periodontal pocket", "PROBLEM", 39, 57], ["oral pus specimens", "TEST", 62, 80], ["oral mucosal swabs", "TEST", 105, 123], ["caries activity tests", "TEST", 128, 149], ["periodontal pocket", "OBSERVATION", 39, 57]]], ["All participating laboratories were willing to share and harmonise their specimen processing and interpretation standard operating procedures.", [["specimen", "ANATOMY", 73, 81]]], ["The pilot round specimen was a periodontal pocket sample.", [["round specimen", "ANATOMY", 10, 24], ["periodontal pocket sample", "ANATOMY", 31, 56], ["a periodontal pocket sample", "TEST", 29, 56], ["pilot", "OBSERVATION_MODIFIER", 4, 9], ["round", "OBSERVATION_MODIFIER", 10, 15], ["specimen", "OBSERVATION", 16, 24]]], ["Six laboratories reported their findings in the specified time.R. Rautemaa-Richardson\u00b0, A. Smith, D. Lockhart for the COMB Network -Clinical Oral Microbiology NetworkThe predominant pathogens (Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis) were identified by 5 of 6 laboratories.", [["Aggregatibacter actinomycetemcomitans", "ORGANISM", 193, 230], ["Porphyromonas gingivalis", "ORGANISM", 232, 256], ["Aggregatibacter actinomycetemcomitans", "SPECIES", 193, 230], ["Porphyromonas gingivalis", "SPECIES", 232, 256], ["Aggregatibacter actinomycetemcomitans", "SPECIES", 193, 230], ["Porphyromonas gingivalis", "SPECIES", 232, 256], ["Six laboratories", "TEST", 0, 16], ["Clinical Oral Microbiology", "TEST", 132, 158], ["The predominant pathogens (Aggregatibacter actinomycetemcomitans", "PROBLEM", 166, 230], ["Porphyromonas gingivalis", "PROBLEM", 232, 256]]], ["In addition to conventional culture, one laboratory used PCR.", [["conventional culture", "TEST", 15, 35], ["PCR", "TEST", 57, 60]]], ["5 laboratories performed antibacterial sensitivity testing primarily by disc diffusion.", [["disc", "ANATOMY", 72, 76], ["antibacterial sensitivity testing", "TEST", 25, 58], ["disc diffusion", "TEST", 72, 86], ["disc", "ANATOMY", 72, 76]]], ["Conclusions: This is the first attempt to a standardised Europeanwide approach to diagnostic oral microbiology.", [["oral", "ANATOMY", 93, 97], ["oral", "ORGANISM_SUBDIVISION", 93, 97], ["a standardised Europeanwide approach", "TREATMENT", 42, 78], ["diagnostic oral microbiology", "TEST", 82, 110]]], ["The findings from this feasibility study have indicated that a QC scheme for oral microbiology is of interest and have raised a number a pointers for subsequent rounds of specimens.", [["oral", "ANATOMY", 77, 81], ["specimens", "ANATOMY", 171, 180], ["oral", "ORGANISM_SUBDIVISION", 77, 81], ["this feasibility study", "TEST", 18, 40], ["oral microbiology", "TEST", 77, 94], ["specimens", "TEST", 171, 180]]], ["Further work to improve the quality, to standardise the methodology and the interpretation of diagnostic oral microbiology at the European level is on-going.", [["oral", "ANATOMY", 105, 109], ["oral", "ORGANISM_SUBDIVISION", 105, 109], ["diagnostic oral microbiology", "TEST", 94, 122]]], ["Objectives: Since severe sepsis with acute organ dysfunction can be fatal within hours, it is customary to start empirical broad-spectrum antimicrobial therapy in all patients hospitalised for a suspicion of systemic inflammatory response syndrome.", [["organ", "ANATOMY", 43, 48], ["sepsis", "DISEASE", 25, 31], ["acute organ dysfunction", "DISEASE", 37, 60], ["systemic inflammatory response syndrome", "DISEASE", 208, 247], ["organ", "ORGAN", 43, 48], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["severe sepsis", "PROBLEM", 18, 31], ["acute organ dysfunction", "PROBLEM", 37, 60], ["empirical broad-spectrum antimicrobial therapy", "TREATMENT", 113, 159], ["systemic inflammatory response syndrome", "PROBLEM", 208, 247], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["sepsis", "OBSERVATION", 25, 31], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["organ", "ANATOMY", 43, 48], ["dysfunction", "OBSERVATION", 49, 60], ["suspicion of", "UNCERTAINTY", 195, 207], ["systemic", "OBSERVATION_MODIFIER", 208, 216], ["inflammatory response syndrome", "OBSERVATION", 217, 247]]], ["However, increased use of broad-spectrum antimicrobials over the years has contributed to the emergence of drug resistant strains of bacteria.", [["broad-spectrum antimicrobials", "TREATMENT", 26, 55], ["drug resistant strains of bacteria", "PROBLEM", 107, 141], ["increased", "OBSERVATION_MODIFIER", 9, 18]]], ["Especially, drug resistance among Gram-positive bacteria, the leading cause of sepsis, is now a serious problem.", [["sepsis", "DISEASE", 79, 85], ["Gram", "GENE_OR_GENE_PRODUCT", 34, 38], ["drug resistance", "TEST", 12, 27], ["Gram", "TEST", 34, 38], ["positive bacteria", "PROBLEM", 39, 56], ["sepsis", "PROBLEM", 79, 85], ["a serious problem", "PROBLEM", 94, 111], ["positive bacteria", "OBSERVATION_MODIFIER", 39, 56], ["sepsis", "OBSERVATION", 79, 85], ["serious", "OBSERVATION_MODIFIER", 96, 103]]], ["The objective of this preliminary study was to develop a method for distinguishing between Gram\u2212 and Gram+ bacterial infection.", [["bacterial infection", "DISEASE", 107, 126], ["Gram\u2212", "GENE_OR_GENE_PRODUCT", 91, 96], ["this preliminary study", "TEST", 17, 39], ["a method", "TEST", 55, 63], ["Gram\u2212", "TEST", 91, 96], ["Gram", "TEST", 101, 105], ["bacterial infection", "PROBLEM", 107, 126], ["bacterial", "OBSERVATION_MODIFIER", 107, 116], ["infection", "OBSERVATION", 117, 126]]], ["Methods: In this prospective study, leukocyte and neutrophil counts, CRP, ESR, and quantitative flow cytometric analysis of neutrophil complement receptors 1 (CR1/CD35) and 3 (CR3/CD11b), were obtained from 289 hospitalised febrile patients, of which 89 had bacterial and 38 viral infection.", [["leukocyte", "ANATOMY", 36, 45], ["neutrophil", "ANATOMY", 50, 60], ["febrile", "DISEASE", 224, 231], ["viral infection", "DISEASE", 275, 290], ["leukocyte", "CELL", 36, 45], ["neutrophil", "CELL", 50, 60], ["CRP", "GENE_OR_GENE_PRODUCT", 69, 72], ["neutrophil complement receptors 1", "GENE_OR_GENE_PRODUCT", 124, 157], ["CR1", "GENE_OR_GENE_PRODUCT", 159, 162], ["CD35", "GENE_OR_GENE_PRODUCT", 163, 167], ["3", "GENE_OR_GENE_PRODUCT", 173, 174], ["CR3", "GENE_OR_GENE_PRODUCT", 176, 179], ["CD11b", "GENE_OR_GENE_PRODUCT", 180, 185], ["patients", "ORGANISM", 232, 240], ["CRP", "PROTEIN", 69, 72], ["ESR", "PROTEIN", 74, 77], ["neutrophil complement receptors 1", "PROTEIN", 124, 157], ["CR1", "PROTEIN", 159, 162], ["CD35", "PROTEIN", 163, 167], ["CR3", "PROTEIN", 176, 179], ["CD11b", "PROTEIN", 180, 185], ["patients", "SPECIES", 232, 240], ["this prospective study", "TEST", 12, 34], ["leukocyte", "TEST", 36, 45], ["neutrophil counts", "TEST", 50, 67], ["CRP", "TEST", 69, 72], ["ESR", "TEST", 74, 77], ["quantitative flow cytometric analysis", "TEST", 83, 120], ["neutrophil complement receptors", "TEST", 124, 155], ["CR1", "TEST", 159, 162], ["CD35", "TEST", 163, 167], ["CR3/CD11b", "TEST", 176, 185], ["bacterial and 38 viral infection", "PROBLEM", 258, 290], ["viral infection", "OBSERVATION", 275, 290]]], ["The patient data were compared to 60 healthy controls.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["The patient data", "TEST", 0, 16]]], ["Results: It was noticed that in Gram\u2212 infection (n = 21) the average amount of CD11b on neutrophils was significantly higher than in Gram+ infection (n = 22).", [["neutrophils", "ANATOMY", 88, 99], ["Gram\u2212 infection", "DISEASE", 32, 47], ["infection", "DISEASE", 139, 148], ["CD11b", "GENE_OR_GENE_PRODUCT", 79, 84], ["neutrophils", "CELL", 88, 99], ["CD11b", "PROTEIN", 79, 84], ["neutrophils", "CELL_TYPE", 88, 99], ["Gram\u2212 infection", "PROBLEM", 32, 47], ["CD11b on neutrophils", "TEST", 79, 99], ["Gram+ infection", "PROBLEM", 133, 148], ["infection", "OBSERVATION", 38, 47], ["average", "OBSERVATION_MODIFIER", 61, 68], ["amount", "OBSERVATION_MODIFIER", 69, 75], ["CD11b", "OBSERVATION", 79, 84], ["higher", "OBSERVATION_MODIFIER", 118, 124], ["infection", "OBSERVATION", 139, 148]]], ["On the contrary, serum CRP level was significantly higher in Gram+ than in Gram\u2212 infection.", [["serum", "ANATOMY", 17, 22], ["infection", "DISEASE", 81, 90], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["CRP", "GENE_OR_GENE_PRODUCT", 23, 26], ["Gram+", "GENE_OR_GENE_PRODUCT", 61, 66], ["Gram\u2212", "GENE_OR_GENE_PRODUCT", 75, 80], ["CRP", "PROTEIN", 23, 26], ["serum CRP level", "TEST", 17, 32], ["Gram", "TEST", 61, 65], ["Gram\u2212 infection", "PROBLEM", 75, 90], ["Gram\u2212", "ANATOMY", 75, 80], ["infection", "OBSERVATION", 81, 90]]], ["Other measured parameters did not differ significantly between Gram+ and Gram\u2212 infections.", [["infections", "DISEASE", 79, 89], ["Gram", "TEST", 63, 67], ["Gram\u2212 infections", "PROBLEM", 73, 89], ["infections", "OBSERVATION", 79, 89]]], ["We derived a CRP/CD11b RATIO dividing the serum CRP value by amount of CD11b on neutrophils.", [["serum", "ANATOMY", 42, 47], ["neutrophils", "ANATOMY", 80, 91], ["CRP", "GENE_OR_GENE_PRODUCT", 13, 16], ["CD11", "GENE_OR_GENE_PRODUCT", 17, 21], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["CRP", "GENE_OR_GENE_PRODUCT", 48, 51], ["CD11b", "GENE_OR_GENE_PRODUCT", 71, 76], ["neutrophils", "CELL", 80, 91], ["CRP", "PROTEIN", 13, 16], ["CD11b RATIO", "PROTEIN", 17, 28], ["CRP", "PROTEIN", 48, 51], ["CD11b", "PROTEIN", 71, 76], ["neutrophils", "CELL_TYPE", 80, 91], ["a CRP", "TEST", 11, 16], ["the serum CRP value", "TEST", 38, 57], ["neutrophils", "TEST", 80, 91]]], ["In thirteen (76%) out of 17 patients with GRAM+ sepsis had CRP/CD11b RATIO cutoff value of 3.1 (Figure 1 ).", [["sepsis", "DISEASE", 48, 54], ["patients", "ORGANISM", 28, 36], ["CRP", "GENE_OR_GENE_PRODUCT", 59, 62], ["CRP", "PROTEIN", 59, 62], ["CD11", "PROTEIN", 63, 67], ["patients", "SPECIES", 28, 36], ["GRAM", "TEST", 42, 46], ["sepsis", "PROBLEM", 48, 54], ["CRP", "TEST", 59, 62], ["CD11", "TEST", 63, 67], ["b RATIO cutoff value", "TEST", 67, 87], ["sepsis", "OBSERVATION", 48, 54]]], ["Of these 13 patients, 9 (70%) were diagnosed with Streptococcus pneumoniae, 2 with Staphylococcus aureus, 1 with Enterococcus faecalis, and 1 with both Streptococcus intermedius and Streptococcus oralis.", [["Streptococcus pneumoniae", "DISEASE", 50, 74], ["Staphylococcus aureus", "DISEASE", 83, 104], ["Enterococcus faecalis", "DISEASE", 113, 134], ["Streptococcus intermedius", "DISEASE", 152, 177], ["patients", "ORGANISM", 12, 20], ["Streptococcus pneumoniae", "ORGANISM", 50, 74], ["Staphylococcus aureus", "ORGANISM", 83, 104], ["Enterococcus faecalis", "ORGANISM", 113, 134], ["Streptococcus intermedius", "ORGANISM", 152, 177], ["Streptococcus oralis", "ORGANISM", 182, 202], ["patients", "SPECIES", 12, 20], ["Streptococcus pneumoniae", "SPECIES", 50, 74], ["Staphylococcus aureus", "SPECIES", 83, 104], ["Enterococcus faecalis", "SPECIES", 113, 134], ["Streptococcus intermedius", "SPECIES", 152, 177], ["Streptococcus oralis", "SPECIES", 182, 202], ["Streptococcus pneumoniae", "SPECIES", 50, 74], ["Staphylococcus aureus", "SPECIES", 83, 104], ["Enterococcus faecalis", "SPECIES", 113, 134], ["Streptococcus intermedius", "SPECIES", 152, 177], ["Streptococcus oralis", "SPECIES", 182, 202], ["Streptococcus pneumoniae", "PROBLEM", 50, 74], ["Staphylococcus aureus", "PROBLEM", 83, 104], ["Enterococcus faecalis", "PROBLEM", 113, 134], ["both Streptococcus intermedius", "PROBLEM", 147, 177], ["Streptococcus oralis", "PROBLEM", 182, 202], ["Streptococcus pneumoniae", "OBSERVATION", 50, 74], ["Staphylococcus aureus", "OBSERVATION", 83, 104], ["Enterococcus faecalis", "OBSERVATION", 113, 134], ["Streptococcus intermedius", "ANATOMY", 152, 177], ["Streptococcus oralis", "OBSERVATION", 182, 202]]], ["Corresponding percentages in patients with local Gram+ infection, Gram\u2212 infection, clinical pneumonia, other clinical infection, and viral infection were 20%, 14%, 30%, 15%, and 0%, respectively.", [["Gram+ infection", "DISEASE", 49, 64], ["Gram\u2212 infection", "DISEASE", 66, 81], ["pneumonia", "DISEASE", 92, 101], ["infection", "DISEASE", 118, 127], ["viral infection", "DISEASE", 133, 148], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["local Gram", "TEST", 43, 53], ["infection", "PROBLEM", 55, 64], ["Gram\u2212 infection", "PROBLEM", 66, 81], ["clinical pneumonia", "PROBLEM", 83, 101], ["other clinical infection", "PROBLEM", 103, 127], ["viral infection", "PROBLEM", 133, 148], ["percentages", "OBSERVATION_MODIFIER", 14, 25], ["infection", "OBSERVATION", 55, 64], ["infection", "OBSERVATION", 72, 81], ["pneumonia", "OBSERVATION", 92, 101], ["infection", "OBSERVATION", 118, 127], ["viral", "OBSERVATION_MODIFIER", 133, 138], ["infection", "OBSERVATION", 139, 148]]], ["Conclusion: The detection of Gram+ sepsis is possible after combination of neutrophil CD11b data and serum CRP level.", [["neutrophil", "ANATOMY", 75, 85], ["serum", "ANATOMY", 101, 106], ["sepsis", "DISEASE", 35, 41], ["Gram", "GENE_OR_GENE_PRODUCT", 29, 33], ["neutrophil", "CELL", 75, 85], ["CD11b", "GENE_OR_GENE_PRODUCT", 86, 91], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["CRP", "GENE_OR_GENE_PRODUCT", 107, 110], ["CD11b", "PROTEIN", 86, 91], ["CRP", "PROTEIN", 107, 110], ["Gram", "TEST", 29, 33], ["sepsis", "PROBLEM", 35, 41], ["neutrophil CD11b data", "TEST", 75, 96], ["serum CRP level", "TEST", 101, 116], ["sepsis", "OBSERVATION", 35, 41]]], ["CRP/CD11b RATIO Viral infections of the central nervous system S61 displayed 76% sensitivity and 80% specificity for detection of Gram+ sepsis.", [["central nervous system", "ANATOMY", 40, 62], ["Viral infections", "DISEASE", 16, 32], ["sepsis", "DISEASE", 136, 142], ["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD11", "GENE_OR_GENE_PRODUCT", 4, 8], ["central nervous system", "ANATOMICAL_SYSTEM", 40, 62], ["CRP", "PROTEIN", 0, 3], ["CRP", "TEST", 0, 3], ["CD11", "TEST", 4, 8], ["Viral infections of the central nervous system", "PROBLEM", 16, 62], ["sensitivity", "TEST", 81, 92], ["Gram", "TEST", 130, 134], ["sepsis", "PROBLEM", 136, 142], ["Viral infections", "OBSERVATION", 16, 32], ["central", "ANATOMY_MODIFIER", 40, 47], ["nervous system", "ANATOMY", 48, 62], ["sepsis", "OBSERVATION", 136, 142]]], ["The proposed CRP/CD11b RATIO test could, for its part, assist physicians to decide appropriate antibiotic treatment in patients with severe bacterial infection.N. H\u00f8iby\u00b0(Copenhagen, DK)A bacterial biofilm is a structured consortium of bacteria cells surrounded by a self-produced polymer matrix.", [["biofilm", "ANATOMY", 197, 204], ["cells", "ANATOMY", 244, 249], ["bacterial infection", "DISEASE", 140, 159], ["CRP", "GENE_OR_GENE_PRODUCT", 13, 16], ["patients", "ORGANISM", 119, 127], ["bacteria cells", "CELL", 235, 249], ["matrix", "CELLULAR_COMPONENT", 288, 294], ["CRP", "PROTEIN", 13, 16], ["CD11", "PROTEIN", 17, 21], ["bacteria cells", "CELL_TYPE", 235, 249], ["patients", "SPECIES", 119, 127], ["The proposed CRP/CD11b RATIO test", "TEST", 0, 33], ["appropriate antibiotic treatment", "TREATMENT", 83, 115], ["severe bacterial infection", "PROBLEM", 133, 159], ["A bacterial biofilm", "PROBLEM", 185, 204], ["bacteria cells", "PROBLEM", 235, 249], ["a self-produced polymer matrix", "TREATMENT", 264, 294], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["bacterial", "OBSERVATION_MODIFIER", 140, 149], ["infection", "OBSERVATION", 150, 159], ["bacterial biofilm", "OBSERVATION", 187, 204], ["bacteria cells", "OBSERVATION", 235, 249], ["polymer matrix", "OBSERVATION", 280, 294]]], ["Biofilms may be monospecies or polyspecies biofilms.", [["monospecies", "ANATOMY", 16, 27], ["Biofilms", "PROBLEM", 0, 8], ["polyspecies biofilms", "PROBLEM", 31, 51], ["may be", "UNCERTAINTY", 9, 15]]], ["Biofilm growing bacteria give rise to chronic infections, which persist in spite of therapy and in spite of the host's immune-and inflammatory responses.", [["infections", "DISEASE", 46, 56], ["Biofilm growing bacteria", "PROBLEM", 0, 24], ["chronic infections", "PROBLEM", 38, 56], ["therapy", "TREATMENT", 84, 91], ["inflammatory responses", "PROBLEM", 130, 152], ["bacteria", "OBSERVATION", 16, 24], ["chronic", "OBSERVATION_MODIFIER", 38, 45], ["infections", "OBSERVATION", 46, 56], ["inflammatory", "OBSERVATION", 130, 142]]], ["Biofilm infections are characterised by persisting pathology and immune response (in contrast to colonisation).", [["Biofilm", "ANATOMY", 0, 7], ["Biofilm infections", "DISEASE", 0, 18], ["Biofilm infections", "PROBLEM", 0, 18], ["persisting pathology", "PROBLEM", 40, 60], ["immune response", "PROBLEM", 65, 80], ["infections", "OBSERVATION", 8, 18], ["persisting", "OBSERVATION_MODIFIER", 40, 50], ["pathology", "OBSERVATION", 51, 60]]], ["Bacterial biofilms use both biofilm specific (B) and conventional (planktonic) resistance mechanisms (P) when they are exposed to antibiotics.", [["biofilms", "ANATOMY", 10, 18], ["biofilm", "ANATOMY", 28, 35], ["Bacterial biofilms", "TREATMENT", 0, 18], ["conventional (planktonic) resistance mechanisms", "TREATMENT", 53, 100], ["antibiotics", "TREATMENT", 130, 141], ["biofilms", "OBSERVATION", 10, 18]]], ["Stationary phase physiology (B), low oxygen tension (B) and slow growth (B) especially inside biofilms whereas the surface of biofilms is more similar to planktonic growth.", [["surface", "ANATOMY", 115, 122], ["oxygen", "CHEMICAL", 37, 43], ["oxygen", "CHEMICAL", 37, 43], ["oxygen", "SIMPLE_CHEMICAL", 37, 43], ["surface", "CELLULAR_COMPONENT", 115, 122], ["Stationary phase physiology", "TEST", 0, 27], ["low oxygen tension (B)", "PROBLEM", 33, 55], ["slow growth (B)", "PROBLEM", 60, 75], ["planktonic growth", "PROBLEM", 154, 171], ["low", "OBSERVATION_MODIFIER", 33, 36], ["oxygen tension", "OBSERVATION", 37, 51]]], ["Penetration barriers (B), binding to the polymer matrix (B).", [["Penetration barriers", "PROBLEM", 0, 20]]], ["Mutations, hypermutators (B, P).", [["Mutations", "PROBLEM", 0, 9]]], ["Chromosomal betalactamase is upregulated (B, P).", [["Chromosomal", "ANATOMY", 0, 11], ["Chromosomal", "CELLULAR_COMPONENT", 0, 11], ["betalactamase", "PROTEIN", 12, 25], ["Chromosomal betalactamase", "TEST", 0, 25]]], ["Antibiotic tolerance/adaptive resistance (B).", [["Antibiotic tolerance", "TREATMENT", 0, 20], ["adaptive resistance", "OBSERVATION", 21, 40]]], ["Efflux pumps (B, P).", [["Efflux pumps", "TREATMENT", 0, 12]]], ["Alginate production (B).", [["Alginate", "SIMPLE_CHEMICAL", 0, 8]]], ["High cell density and quorum sensing (B, P).", [["cell", "ANATOMY", 5, 9], ["cell", "CELL", 5, 9], ["High cell density", "PROBLEM", 0, 17], ["cell density", "OBSERVATION", 5, 17], ["quorum sensing", "OBSERVATION", 22, 36]]], ["PBP 3 \u2212 SOS response ?", [["PBP 3", "GENE_OR_GENE_PRODUCT", 0, 5], ["PBP", "TEST", 0, 3]]], ["The knowledge of these resistance mechanisms can, however, be used to design new therapeutica approaches especially as regards quorum sensing inhibitors.", [["new therapeutica approaches", "TREATMENT", 77, 104], ["quorum sensing inhibitors", "TREATMENT", 127, 152]]], ["We consider two factors that contribute to treatment failure in the absence of inherited resistance, the density of the population being treated and the physiological state of the bacteria.", [["treatment failure", "PROBLEM", 43, 60], ["inherited resistance", "PROBLEM", 79, 99], ["the bacteria", "PROBLEM", 176, 188], ["inherited", "OBSERVATION_MODIFIER", 79, 88], ["resistance", "OBSERVATION", 89, 99], ["density", "OBSERVATION_MODIFIER", 105, 112], ["population", "OBSERVATION_MODIFIER", 120, 130]]], ["We also explore how these factors might contribute to the evolution of inherited resistance during the course of treatment.", [["inherited resistance", "PROBLEM", 71, 91], ["treatment", "TREATMENT", 113, 122], ["inherited resistance", "OBSERVATION", 71, 91]]], ["We conclude with a computer-and chemostat-assisted consideration of the potential clinical implication of these density and physiology effects and make suggestions for treatment protocols to deal with them.", [["chemostat", "TREATMENT", 32, 41], ["treatment protocols", "TREATMENT", 168, 187], ["density", "OBSERVATION", 112, 119]]], ["Using in vitro cultures of Staphylococcus aureus ATCC25923 or the clinical isolate ps80 and antibiotics of six different classes we determined the functional relationship between the inoculum density and the efficacy of the antibiotics.", [["Staphylococcus aureus ATCC25923", "ORGANISM", 27, 58], ["ps80", "CELL", 83, 87], ["Staphylococcus aureus", "SPECIES", 27, 48], ["Staphylococcus aureus", "SPECIES", 27, 48], ["Staphylococcus aureus", "PROBLEM", 27, 48], ["antibiotics", "TREATMENT", 92, 103], ["the inoculum density", "TREATMENT", 179, 199], ["the antibiotics", "TREATMENT", 220, 235], ["Staphylococcus aureus", "OBSERVATION", 27, 48], ["inoculum density", "OBSERVATION", 183, 199]]], ["As measured by the rates and extent of kill and/or the minimum inhibitory concentration (MIC), the efficacy of all of these antibiotics declined with increases in the density of bacteria, albeit to different extents.", [["these antibiotics", "TREATMENT", 118, 135], ["bacteria", "PROBLEM", 178, 186], ["increases", "OBSERVATION_MODIFIER", 150, 159], ["density", "OBSERVATION_MODIFIER", 167, 174], ["bacteria", "OBSERVATION", 178, 186], ["different extents", "OBSERVATION_MODIFIER", 198, 215]]], ["For daptomycin and vancomycin, much of this density effect can be attributed to bacteria-associated declines in the effective concentration of the antibiotic in the medium.", [["daptomycin", "CHEMICAL", 4, 14], ["vancomycin", "CHEMICAL", 19, 29], ["daptomycin", "CHEMICAL", 4, 14], ["vancomycin", "CHEMICAL", 19, 29], ["daptomycin", "SIMPLE_CHEMICAL", 4, 14], ["vancomycin", "SIMPLE_CHEMICAL", 19, 29], ["daptomycin", "TREATMENT", 4, 14], ["vancomycin", "TREATMENT", 19, 29], ["bacteria", "PROBLEM", 80, 88], ["the antibiotic in the medium", "TREATMENT", 143, 171], ["bacteria", "OBSERVATION", 80, 88], ["declines", "OBSERVATION_MODIFIER", 100, 108]]], ["For gentamicin, vancomycin, ciprofloxacin and oxacillin, our bioassays failed to reveal significant reductions in their effective concentration in the medium.", [["gentamicin", "CHEMICAL", 4, 14], ["vancomycin", "CHEMICAL", 16, 26], ["ciprofloxacin", "CHEMICAL", 28, 41], ["oxacillin", "CHEMICAL", 46, 55], ["gentamicin", "CHEMICAL", 4, 14], ["vancomycin", "CHEMICAL", 16, 26], ["ciprofloxacin", "CHEMICAL", 28, 41], ["oxacillin", "CHEMICAL", 46, 55], ["gentamicin", "SIMPLE_CHEMICAL", 4, 14], ["vancomycin", "SIMPLE_CHEMICAL", 16, 26], ["ciprofloxacin", "SIMPLE_CHEMICAL", 28, 41], ["oxacillin", "SIMPLE_CHEMICAL", 46, 55], ["gentamicin", "TREATMENT", 4, 14], ["vancomycin", "TREATMENT", 16, 26], ["ciprofloxacin", "TREATMENT", 28, 41], ["oxacillin", "TREATMENT", 46, 55], ["our bioassays", "TEST", 57, 70], ["significant reductions", "PROBLEM", 88, 110], ["significant", "OBSERVATION_MODIFIER", 88, 99], ["reductions", "OBSERVATION_MODIFIER", 100, 110], ["effective", "OBSERVATION_MODIFIER", 120, 129], ["concentration", "OBSERVATION_MODIFIER", 130, 143]]], ["The effects of the physiological state of S. aureus on the efficacy of these antibiotics were examined for bacteria from cultures in \"stationary phase\" for different times and from chemostats run at different generation times.", [["S. aureus", "ORGANISM", 42, 51], ["S. aureus", "SPECIES", 42, 51], ["S. aureus", "SPECIES", 42, 51], ["S. aureus", "PROBLEM", 42, 51], ["these antibiotics", "TREATMENT", 71, 88], ["bacteria", "PROBLEM", 107, 115], ["cultures", "TEST", 121, 129], ["chemostats", "TREATMENT", 181, 191], ["aureus", "OBSERVATION", 45, 51]]], ["It is, however, clear that the efficacy of all of these antibiotics declines with the time in stationary phase (its \"age\").", [["these antibiotics", "TREATMENT", 50, 67]]], ["And, even slowly dividing cultures from chemostats are more susceptible to antibiotic-mediated killing that early stationary phase batch cultures.", [["cultures", "ANATOMY", 26, 34], ["chemostats", "TREATMENT", 40, 50], ["antibiotic-mediated killing", "TREATMENT", 75, 102], ["early stationary phase batch cultures", "TEST", 108, 145]]], ["The efficacy in killing non-growing bacteria varies among the bactericidal antibiotics examined.Reference(s)To ascertain the potential clinical implications of these density and physiological effects, we use both computer and in vitro simulations of antibiotic treatment.", [["killing non-growing bacteria", "PROBLEM", 16, 44], ["the bactericidal antibiotics", "TREATMENT", 58, 86], ["these density", "PROBLEM", 160, 173], ["antibiotic treatment", "TREATMENT", 250, 270], ["efficacy", "OBSERVATION_MODIFIER", 4, 12], ["bactericidal antibiotics", "OBSERVATION", 62, 86], ["density", "OBSERVATION", 166, 173]]], ["The results of these simulations provide compelling support for the proposition that antibiotic treatment regimes, including those designed to prevent the ascent of resistance, should take into account the anticipated density and physiological state of the target population of susceptible bacteria.H.G.M. Niesters\u00b0(Groningen, NL)There have been an increasing number of neurotrophic viral infections playing an important role in the World over the last decade.", [["viral infections", "DISEASE", 383, 399], ["these simulations", "TEST", 15, 32], ["compelling support", "TREATMENT", 41, 59], ["antibiotic treatment regimes", "TREATMENT", 85, 113], ["resistance", "PROBLEM", 165, 175], ["the anticipated density", "PROBLEM", 202, 225], ["susceptible bacteria", "PROBLEM", 278, 298], ["neurotrophic viral infections", "PROBLEM", 370, 399], ["density", "OBSERVATION", 218, 225], ["increasing", "OBSERVATION_MODIFIER", 349, 359], ["number", "OBSERVATION_MODIFIER", 360, 366], ["neurotrophic viral infections", "OBSERVATION", 370, 399]]], ["The list includes West Nile Virus, Nipah and Hendra virus (both paramyxoviruses), as well as Chikungunya virus which suddenly emerged.", [["Nipah and Hendra virus", "DISEASE", 35, 57], ["Chikungunya virus", "DISEASE", 93, 110], ["West Nile Virus", "ORGANISM", 18, 33], ["Nipah", "ORGANISM", 35, 40], ["Hendra virus", "ORGANISM", 45, 57], ["Chikungunya virus", "ORGANISM", 93, 110], ["Nile Virus", "SPECIES", 23, 33], ["Nipah", "SPECIES", 35, 40], ["Hendra virus", "SPECIES", 45, 57], ["Chikungunya virus", "SPECIES", 93, 110], ["West Nile Virus", "SPECIES", 18, 33], ["Hendra virus", "SPECIES", 45, 57], ["Chikungunya virus", "SPECIES", 93, 110], ["West Nile Virus", "PROBLEM", 18, 33], ["Nipah", "PROBLEM", 35, 40], ["Hendra virus (both paramyxoviruses", "TREATMENT", 45, 79], ["Chikungunya virus", "PROBLEM", 93, 110]]], ["Furthermore, the relation between JC virus in Progressive Multifocal Leukoencephalopathy (PML) in patients with multiple sclerosis treated with a new immunosuppressive drug, has triggered our attention.", [["PML", "ANATOMY", 90, 93], ["Multifocal Leukoencephalopathy", "DISEASE", 58, 88], ["PML", "DISEASE", 90, 93], ["multiple sclerosis", "DISEASE", 112, 130], ["JC virus", "ORGANISM", 34, 42], ["PML", "CANCER", 90, 93], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["JC virus", "SPECIES", 34, 42], ["JC virus", "PROBLEM", 34, 42], ["Progressive Multifocal Leukoencephalopathy (PML", "PROBLEM", 46, 93], ["multiple sclerosis", "PROBLEM", 112, 130], ["a new immunosuppressive drug", "TREATMENT", 144, 172], ["JC virus", "OBSERVATION", 34, 42], ["Progressive", "OBSERVATION_MODIFIER", 46, 57], ["Multifocal", "OBSERVATION_MODIFIER", 58, 68], ["Leukoencephalopathy", "OBSERVATION", 69, 88], ["PML", "OBSERVATION_MODIFIER", 90, 93], ["multiple", "OBSERVATION_MODIFIER", 112, 120], ["sclerosis", "OBSERVATION", 121, 130]]], ["The development and implementation of molecular based amplification method has assisted us to detect these viruses more efficiently.", [["these viruses", "PROBLEM", 101, 114]]], ["These technologies have been used now routinely in a large number of laboratories to enable the detection of more commonly known neurotrophic viruses, like HSV, VZV and the neurotrophic picornaviruses like enterovirus and parechovirus.", [["HSV", "ORGANISM", 156, 159], ["VZV", "ORGANISM", 161, 164], ["neurotrophic picornaviruses", "ORGANISM", 173, 200], ["enterovirus", "ORGANISM", 206, 217], ["HSV", "SPECIES", 156, 159], ["VZV", "SPECIES", 161, 164], ["the detection", "TEST", 92, 105], ["neurotrophic viruses", "PROBLEM", 129, 149], ["HSV", "PROBLEM", 156, 159], ["VZV", "PROBLEM", 161, 164], ["the neurotrophic picornaviruses", "PROBLEM", 169, 200], ["enterovirus", "PROBLEM", 206, 217], ["parechovirus", "PROBLEM", 222, 234], ["neurotrophic viruses", "OBSERVATION", 129, 149], ["neurotrophic picornaviruses", "OBSERVATION", 173, 200]]], ["The pitfalls of these molecular methods have been generally solved by implementing regular quality control testing schemes, like organised by QCMD (quality control of molecular diagnostics) and the introduction of internal controls during the whole diagnostic process.", [["these molecular methods", "TREATMENT", 16, 39], ["internal controls", "TREATMENT", 214, 231]]], ["Finally, with the ability to quantify the amount of nucleic acid present in CSF, more information on the pathogenesis of these viral infections, as well as significant tool to monitor the antiviral effect of treatment options for these viruses, has become available. to as a rare disease in Europe restricted to some endemic foci.", [["foci", "ANATOMY", 325, 329], ["nucleic acid", "CHEMICAL", 52, 64], ["viral infections", "DISEASE", 127, 143], ["CSF", "GENE_OR_GENE_PRODUCT", 76, 79], ["foci", "CELL", 325, 329], ["nucleic acid present in CSF", "PROBLEM", 52, 79], ["these viral infections", "PROBLEM", 121, 143], ["treatment options", "TREATMENT", 208, 225], ["these viruses", "PROBLEM", 230, 243], ["a rare disease", "PROBLEM", 273, 287], ["some endemic foci", "PROBLEM", 312, 329], ["viral", "OBSERVATION_MODIFIER", 127, 132], ["infections", "OBSERVATION", 133, 143], ["rare", "OBSERVATION_MODIFIER", 275, 279], ["disease", "OBSERVATION", 280, 287], ["some", "OBSERVATION_MODIFIER", 312, 316], ["endemic", "OBSERVATION_MODIFIER", 317, 324], ["foci", "OBSERVATION", 325, 329]]], ["However, current data suggest that the incidence of AE has significantly increased, and the disease is spreading to the North, West, and East.", [["AE", "PROBLEM", 52, 54], ["the disease", "PROBLEM", 88, 99], ["AE", "OBSERVATION", 52, 54], ["significantly", "OBSERVATION_MODIFIER", 59, 72], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["disease", "OBSERVATION", 92, 99]]], ["AE has become an emerging disease in the Baltic countries.", [["an emerging disease", "PROBLEM", 14, 33], ["emerging", "OBSERVATION_MODIFIER", 17, 25], ["disease", "OBSERVATION", 26, 33]]], ["Thus, human infections with E. multilocularis have arrived in the \"centre\" of Europe.", [["infections", "DISEASE", 12, 22], ["E. multilocularis", "DISEASE", 28, 45], ["human", "ORGANISM", 6, 11], ["E. multilocularis", "ORGANISM", 28, 45], ["human", "SPECIES", 6, 11], ["E. multilocularis", "SPECIES", 28, 45], ["human", "SPECIES", 6, 11], ["E. multilocularis", "SPECIES", 28, 45], ["human infections with E. multilocularis", "PROBLEM", 6, 45], ["infections", "OBSERVATION", 12, 22]]], ["AE is a lifethreatening disease, and is characterised by a tumour-like lesion in the liver.", [["tumour", "ANATOMY", 59, 65], ["lesion", "ANATOMY", 71, 77], ["liver", "ANATOMY", 85, 90], ["tumour", "DISEASE", 59, 65], ["tumour", "CANCER", 59, 65], ["liver", "ORGAN", 85, 90], ["a lifethreatening disease", "PROBLEM", 6, 31], ["a tumour-like lesion in the liver", "PROBLEM", 57, 90], ["lifethreatening", "OBSERVATION_MODIFIER", 8, 23], ["disease", "OBSERVATION", 24, 31], ["tumour", "OBSERVATION", 59, 65], ["lesion", "OBSERVATION", 71, 77], ["liver", "ANATOMY", 85, 90]]], ["The larva can infiltrate the surrounding tissues and metastasize to distant organs.", [["larva", "ANATOMY", 4, 9], ["tissues", "ANATOMY", 41, 48], ["organs", "ANATOMY", 76, 82], ["tissues", "TISSUE", 41, 48], ["organs", "ORGAN", 76, 82], ["larva", "ANATOMY", 4, 9], ["infiltrate", "OBSERVATION", 14, 24], ["surrounding tissues", "ANATOMY", 29, 48]]], ["In an attempt to classify the large variety of anatomical findings in AE, the PNM-classification system was developed and serves as a benchmark for standardised evaluation of diagnostic and therapeutic measures.", [["standardised evaluation", "TEST", 148, 171], ["therapeutic measures", "TREATMENT", 190, 210], ["large", "OBSERVATION_MODIFIER", 30, 35], ["variety", "OBSERVATION_MODIFIER", 36, 43]]], ["Modern imaging techniques, such as ultrasound, CT or MRI and PET/CT contributed not only to a much better description of the lesions, but also to a judgment upon the activity of the metacestode.", [["lesions", "ANATOMY", 125, 132], ["lesions", "PATHOLOGICAL_FORMATION", 125, 132], ["Modern imaging techniques", "TEST", 0, 25], ["ultrasound", "TEST", 35, 45], ["CT", "TEST", 47, 49], ["MRI", "TEST", 53, 56], ["PET/CT", "TEST", 61, 67], ["the lesions", "PROBLEM", 121, 132], ["lesions", "OBSERVATION", 125, 132], ["metacestode", "OBSERVATION", 182, 193]]], ["The differential diagnosis of AE varies from haemangioma-like lesion of the liver or cancer.", [["haemangioma-like lesion", "ANATOMY", 45, 68], ["liver", "ANATOMY", 76, 81], ["cancer", "ANATOMY", 85, 91], ["AE", "DISEASE", 30, 32], ["haemangioma", "DISEASE", 45, 56], ["lesion of the liver or cancer", "DISEASE", 62, 91], ["AE", "CANCER", 30, 32], ["haemangioma-like lesion", "CANCER", 45, 68], ["liver", "ORGAN", 76, 81], ["cancer", "CANCER", 85, 91], ["AE varies", "PROBLEM", 30, 39], ["haemangioma", "PROBLEM", 45, 56], ["lesion of the liver", "PROBLEM", 62, 81], ["cancer", "PROBLEM", 85, 91], ["AE varies", "OBSERVATION_MODIFIER", 30, 39], ["haemangioma", "OBSERVATION", 45, 56], ["lesion", "OBSERVATION", 62, 68], ["liver", "ANATOMY", 76, 81], ["cancer", "OBSERVATION", 85, 91]]], ["The diagnostic skills are limited, and are the reason for frequent misdiagnosis in geographic areas where AE is rather unknown.", [["frequent misdiagnosis in geographic areas", "PROBLEM", 58, 99]]], ["Continuous treatment with benzimidazoles is the backbone of a lifelong management of AE.", [["benzimidazoles", "CHEMICAL", 26, 40], ["benzimidazoles", "CHEMICAL", 26, 40], ["benzimidazoles", "SIMPLE_CHEMICAL", 26, 40], ["benzimidazoles", "TREATMENT", 26, 40], ["a lifelong management", "TREATMENT", 60, 81]]], ["However, radical resection is the procedure of choice and should always be strived for.", [["radical resection", "TREATMENT", 9, 26], ["the procedure of choice", "TREATMENT", 30, 53], ["radical", "OBSERVATION_MODIFIER", 9, 16], ["resection", "OBSERVATION", 17, 26]]], ["AE is still a rare disease in Europe, but where it occurs, it is often diagnosed too late.", [["a rare disease", "PROBLEM", 12, 26], ["rare", "OBSERVATION_MODIFIER", 14, 18], ["disease", "OBSERVATION", 19, 26]]], ["Patients are misdiagnosed for months and years, before receiving the correct treatment.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the correct treatment", "TREATMENT", 65, 86]]], ["At that late stage the disease has progressed, and radical cure of the liver lesion(s) is not anymore possible.", [["liver lesion", "ANATOMY", 71, 83], ["liver lesion", "DISEASE", 71, 83], ["liver", "ORGAN", 71, 76], ["the disease", "PROBLEM", 19, 30], ["radical cure of the liver lesion", "PROBLEM", 51, 83], ["late stage", "OBSERVATION_MODIFIER", 8, 18], ["disease", "OBSERVATION", 23, 30], ["progressed", "OBSERVATION_MODIFIER", 35, 45], ["radical", "OBSERVATION_MODIFIER", 51, 58], ["liver", "ANATOMY", 71, 76], ["lesion", "OBSERVATION", 77, 83], ["not anymore possible", "UNCERTAINTY", 90, 110]]], ["Recent reports provided hints for an accelerated larval growth of Echinococcus spp. in the immunodeficient host.", [["Echinococcus spp", "DISEASE", 66, 82], ["Echinococcus spp", "ORGANISM", 66, 82], ["Echinococcus spp", "SPECIES", 66, 82], ["an accelerated larval growth of Echinococcus spp", "PROBLEM", 34, 82], ["Echinococcus spp", "OBSERVATION", 66, 82], ["immunodeficient host", "OBSERVATION", 91, 111]]], ["A careful monitoring of patients receiving immune-modifying drugs is warranted.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["A careful monitoring", "TEST", 0, 20], ["immune-modifying drugs", "TREATMENT", 43, 65]]], ["The modern clinical management and long-term parasitostatic treatment with benzimidazoles are highly effective.", [["benzimidazoles", "CHEMICAL", 75, 89], ["benzimidazoles", "CHEMICAL", 75, 89], ["benzimidazoles", "SIMPLE_CHEMICAL", 75, 89], ["The modern clinical management", "TREATMENT", 0, 30], ["long-term parasitostatic treatment", "TREATMENT", 35, 69], ["benzimidazoles", "TREATMENT", 75, 89]]], ["Thus, a higher alertness for the \"tumours from the centre\" would increase the prognosis of this hepatic disease resembling liver cancer.O. Akhan\u00b0(Ankara, TR)The percutaneous treatment of liver hydatid cysts were considered to be contraindicated due to two main potential risks: anaphylactic shock and abdominal dissemination of the disease.", [["tumours", "ANATOMY", 34, 41], ["hepatic", "ANATOMY", 96, 103], ["liver cancer", "ANATOMY", 123, 135], ["percutaneous", "ANATOMY", 161, 173], ["liver hydatid cysts", "ANATOMY", 187, 206], ["abdominal", "ANATOMY", 301, 310], ["hepatic disease", "DISEASE", 96, 111], ["liver cancer", "DISEASE", 123, 135], ["liver hydatid cysts", "DISEASE", 187, 206], ["anaphylactic shock", "DISEASE", 278, 296], ["abdominal dissemination of the disease", "DISEASE", 301, 339], ["tumours", "CANCER", 34, 41], ["hepatic", "ORGAN", 96, 103], ["liver cancer", "CANCER", 123, 135], ["liver", "ORGAN", 187, 192], ["hydatid cysts", "PATHOLOGICAL_FORMATION", 193, 206], ["abdominal", "ORGANISM_SUBDIVISION", 301, 310], ["a higher alertness", "PROBLEM", 6, 24], ["the \"tumours", "PROBLEM", 29, 41], ["this hepatic disease", "PROBLEM", 91, 111], ["liver cancer", "PROBLEM", 123, 135], ["The percutaneous treatment", "TREATMENT", 157, 183], ["liver hydatid cysts", "PROBLEM", 187, 206], ["anaphylactic shock", "PROBLEM", 278, 296], ["abdominal dissemination of the disease", "PROBLEM", 301, 339], ["hepatic", "ANATOMY", 96, 103], ["disease", "OBSERVATION", 104, 111], ["liver", "ANATOMY", 123, 128], ["cancer", "OBSERVATION", 129, 135], ["liver", "ANATOMY", 187, 192], ["hydatid", "OBSERVATION", 193, 200], ["anaphylactic shock", "OBSERVATION", 278, 296], ["abdominal", "ANATOMY", 301, 310], ["dissemination", "OBSERVATION", 311, 324], ["disease", "OBSERVATION", 332, 339]]], ["Since the first case percutaneously treated was published, several series of successful percutaneous treatment of the liver and the other abdominal organs, peritoneum, thorax, soft tissue and orbital cavity hydatid cysts have appeared in the literature.", [["percutaneous", "ANATOMY", 88, 100], ["liver", "ANATOMY", 118, 123], ["abdominal organs", "ANATOMY", 138, 154], ["peritoneum", "ANATOMY", 156, 166], ["thorax", "ANATOMY", 168, 174], ["soft tissue", "ANATOMY", 176, 187], ["orbital cavity hydatid cysts", "ANATOMY", 192, 220], ["hydatid cysts", "DISEASE", 207, 220], ["liver", "ORGAN", 118, 123], ["abdominal organs", "MULTI-TISSUE_STRUCTURE", 138, 154], ["peritoneum", "MULTI-TISSUE_STRUCTURE", 156, 166], ["thorax", "ORGAN", 168, 174], ["soft tissue", "TISSUE", 176, 187], ["orbital cavity hydatid cysts", "PATHOLOGICAL_FORMATION", 192, 220], ["successful percutaneous treatment", "TREATMENT", 77, 110], ["soft tissue and orbital cavity hydatid cysts", "PROBLEM", 176, 220], ["percutaneous", "OBSERVATION", 88, 100], ["liver", "ANATOMY", 118, 123], ["abdominal", "ANATOMY_MODIFIER", 138, 147], ["organs", "ANATOMY", 148, 154], ["peritoneum", "ANATOMY", 156, 166], ["thorax", "ANATOMY", 168, 174], ["soft tissue", "ANATOMY", 176, 187], ["orbital cavity", "ANATOMY", 192, 206], ["cysts", "OBSERVATION", 215, 220]]], ["Percutaneous treatment of hydatid liver disease is an effective and safe procedure with its unique advantages (e.g., shorter hospital stay, low complication rate).", [["hydatid liver", "ANATOMY", 26, 39], ["hydatid liver disease", "DISEASE", 26, 47], ["liver", "ORGAN", 34, 39], ["Percutaneous treatment", "TREATMENT", 0, 22], ["hydatid liver disease", "PROBLEM", 26, 47], ["safe procedure", "TREATMENT", 68, 82], ["hydatid", "OBSERVATION", 26, 33], ["liver", "ANATOMY", 34, 39], ["disease", "OBSERVATION", 40, 47], ["effective", "OBSERVATION_MODIFIER", 54, 63]]], ["Today, the percutaneous approach has an important role in treatment of hydatid cysts not only in the liver but also in the other organs and tissue.", [["percutaneous", "ANATOMY", 11, 23], ["hydatid cysts", "ANATOMY", 71, 84], ["liver", "ANATOMY", 101, 106], ["organs", "ANATOMY", 129, 135], ["tissue", "ANATOMY", 140, 146], ["hydatid cysts", "DISEASE", 71, 84], ["hydatid cysts", "PATHOLOGICAL_FORMATION", 71, 84], ["liver", "ORGAN", 101, 106], ["organs", "ORGAN", 129, 135], ["tissue", "TISSUE", 140, 146], ["the percutaneous approach", "TREATMENT", 7, 32], ["hydatid cysts", "PROBLEM", 71, 84], ["percutaneous", "OBSERVATION", 11, 23], ["hydatid", "OBSERVATION_MODIFIER", 71, 78], ["cysts", "OBSERVATION", 79, 84], ["liver", "ANATOMY", 101, 106], ["organs", "ANATOMY", 129, 135], ["tissue", "OBSERVATION", 140, 146]]], ["Therefore it must be first treatment option whenever it is indicated.P. Marty\u00b0(Nice, FR)In Europe, Dirofilaria immitis and Dirofilaria repens are responsible of autochthonous filariases in dogs.", [["Dirofilaria immitis", "DISEASE", 99, 118], ["Dirofilaria repens", "DISEASE", 123, 141], ["filariases", "DISEASE", 175, 185], ["Dirofilaria immitis", "ORGANISM", 99, 118], ["Dirofilaria repens", "ORGANISM", 123, 141], ["filariases", "CANCER", 175, 185], ["dogs", "ORGANISM", 189, 193], ["Dirofilaria immitis", "SPECIES", 99, 118], ["Dirofilaria repens", "SPECIES", 123, 141], ["dogs", "SPECIES", 189, 193], ["Dirofilaria immitis", "SPECIES", 99, 118], ["Dirofilaria repens", "SPECIES", 123, 141], ["treatment option", "TREATMENT", 27, 43], ["Dirofilaria immitis", "TREATMENT", 99, 118], ["Dirofilaria repens", "TREATMENT", 123, 141], ["autochthonous filariases in dogs", "PROBLEM", 161, 193], ["Dirofilaria immitis", "OBSERVATION", 99, 118], ["Dirofilaria repens", "OBSERVATION", 123, 141], ["autochthonous filariases", "OBSERVATION", 161, 185]]], ["Adults of D. immitis kills the dogs with an heart location and D. repens is often found in subcutaneous nodules in dogs and cats.", [["heart", "ANATOMY", 44, 49], ["subcutaneous nodules", "ANATOMY", 91, 111], ["D. immitis", "DISEASE", 10, 20], ["Adults", "ORGANISM", 0, 6], ["D. immitis", "ORGANISM", 10, 20], ["dogs", "ORGANISM", 31, 35], ["heart", "ORGAN", 44, 49], ["D. repens", "ORGANISM", 63, 72], ["subcutaneous nodules", "PATHOLOGICAL_FORMATION", 91, 111], ["dogs", "ORGANISM", 115, 119], ["cats", "ORGANISM", 124, 128], ["Adults", "SPECIES", 0, 6], ["D. immitis", "SPECIES", 10, 20], ["dogs", "SPECIES", 31, 35], ["D. repens", "SPECIES", 63, 72], ["dogs", "SPECIES", 115, 119], ["cats", "SPECIES", 124, 128], ["D. immitis", "SPECIES", 10, 20], ["D. repens", "SPECIES", 63, 72], ["subcutaneous nodules in dogs and cats", "PROBLEM", 91, 128], ["immitis kills", "OBSERVATION", 13, 26], ["heart", "ANATOMY", 44, 49], ["subcutaneous", "ANATOMY", 91, 103], ["nodules", "OBSERVATION", 104, 111]]], ["The microfilariae are present in the blood of these animals.", [["microfilariae", "ANATOMY", 4, 17], ["blood", "ANATOMY", 37, 42], ["microfilariae", "ORGANISM", 4, 17], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["The microfilariae", "TREATMENT", 0, 17], ["microfilariae", "OBSERVATION", 4, 17]]], ["Dirofilariasis is due to the transmission of microfilariae by some mosquito bites (Aedes, Culex, Anopheles, Mansonia, Psorophora and Taeniorhynchus).", [["Dirofilariasis", "DISEASE", 0, 14], ["mosquito bites", "DISEASE", 67, 81], ["microfilariae", "ORGANISM", 45, 58], ["Aedes, Culex", "ORGANISM", 83, 95], ["Anopheles, Mansonia", "ORGANISM", 97, 116], ["Psorophora", "GENE_OR_GENE_PRODUCT", 118, 128], ["Taeniorhynchus", "GENE_OR_GENE_PRODUCT", 133, 147], ["Dirofilariasis", "PROBLEM", 0, 14], ["microfilariae", "PROBLEM", 45, 58], ["some mosquito bites", "PROBLEM", 62, 81], ["microfilariae", "OBSERVATION", 45, 58]]], ["Usually non pathogenic to humans, these parasites are particularly present around the Mediterranean basin.", [["humans", "ORGANISM", 26, 32], ["humans", "SPECIES", 26, 32], ["humans", "SPECIES", 26, 32], ["these parasites", "PROBLEM", 34, 49], ["non pathogenic", "OBSERVATION_MODIFIER", 8, 22], ["parasites", "OBSERVATION", 40, 49]]], ["D. immitis is very rare in humans in Europe, sometimes found in a pulmonary nodule and the heart location is not described.", [["pulmonary nodule", "ANATOMY", 66, 82], ["heart", "ANATOMY", 91, 96], ["D. immitis", "DISEASE", 0, 10], ["D. immitis", "ORGANISM", 0, 10], ["humans", "ORGANISM", 27, 33], ["pulmonary nodule", "CANCER", 66, 82], ["heart", "ORGAN", 91, 96], ["D. immitis", "SPECIES", 0, 10], ["humans", "SPECIES", 27, 33], ["D. immitis", "SPECIES", 0, 10], ["humans", "SPECIES", 27, 33], ["D. immitis", "PROBLEM", 0, 10], ["a pulmonary nodule", "PROBLEM", 64, 82], ["immitis", "OBSERVATION", 3, 10], ["very", "OBSERVATION_MODIFIER", 14, 18], ["rare", "OBSERVATION_MODIFIER", 19, 23], ["pulmonary", "ANATOMY", 66, 75], ["nodule", "OBSERVATION", 76, 82], ["heart", "ANATOMY", 91, 96]]], ["D. repens is more frequent and emerging in humans.", [["D. repens", "ORGANISM", 0, 9], ["humans", "ORGANISM", 43, 49], ["D. repens", "SPECIES", 0, 9], ["humans", "SPECIES", 43, 49], ["D. repens", "SPECIES", 0, 9], ["humans", "SPECIES", 43, 49], ["repens", "OBSERVATION", 3, 9], ["more frequent", "OBSERVATION_MODIFIER", 13, 26]]], ["Usually, only one larva develops, producing an immature adult worm inside a subcutaneous nodule.", [["larva", "ANATOMY", 18, 23], ["worm", "ANATOMY", 62, 66], ["subcutaneous nodule", "ANATOMY", 76, 95], ["larva", "ORGAN", 18, 23], ["subcutaneous nodule", "CANCER", 76, 95], ["a subcutaneous nodule", "PROBLEM", 74, 95], ["one larva", "OBSERVATION_MODIFIER", 14, 23], ["immature", "OBSERVATION_MODIFIER", 47, 55], ["adult", "OBSERVATION_MODIFIER", 56, 61], ["worm", "OBSERVATION_MODIFIER", 62, 66], ["subcutaneous", "ANATOMY", 76, 88], ["nodule", "OBSERVATION", 89, 95]]], ["Ultrasound examination may suggest the parasitic origin of the lesion before an extraction and a parasitological diagnosis of the worm.", [["lesion", "ANATOMY", 63, 69], ["worm", "ANATOMY", 130, 134], ["worm", "ORGANISM_SUBDIVISION", 130, 134], ["Ultrasound examination", "TEST", 0, 22], ["the lesion", "PROBLEM", 59, 69], ["an extraction", "TREATMENT", 77, 90], ["a parasitological diagnosis", "TEST", 95, 122], ["the worm", "PROBLEM", 126, 134], ["parasitic", "OBSERVATION_MODIFIER", 39, 48], ["lesion", "OBSERVATION", 63, 69]]], ["More often, a fortuitous diagnosis is made on histological examination.", [["histological examination", "TEST", 46, 70]]], ["Very rarely, an adult worm may mature and produce systemic diffusion of microfilariae.", [["worm", "ANATOMY", 22, 26], ["worm", "ORGANISM", 22, 26], ["microfilariae", "ORGANISM", 72, 85], ["systemic diffusion of microfilariae", "PROBLEM", 50, 85], ["systemic", "OBSERVATION_MODIFIER", 50, 58], ["microfilariae", "OBSERVATION", 72, 85]]], ["Dirofilariasis due to D. repens can present problems in diagnosis and treatment.", [["Dirofilariasis", "DISEASE", 0, 14], ["D. repens", "ORGANISM", 22, 31], ["D. repens", "SPECIES", 22, 31], ["D. repens", "SPECIES", 22, 31], ["Dirofilariasis", "PROBLEM", 0, 14], ["D. repens", "PROBLEM", 22, 31], ["treatment", "TREATMENT", 70, 79]]], ["An ocular and subconjunctival location of the worm and a subcutaneous nodule enclosing an immature adult are the commonest clinical forms.", [["ocular", "ANATOMY", 3, 9], ["subconjunctival", "ANATOMY", 14, 29], ["worm", "ANATOMY", 46, 50], ["subcutaneous nodule", "ANATOMY", 57, 76], ["ocular", "ORGAN", 3, 9], ["worm", "ORGAN", 46, 50], ["subcutaneous nodule", "CANCER", 57, 76], ["An ocular and subconjunctival location of the worm", "PROBLEM", 0, 50], ["a subcutaneous nodule", "PROBLEM", 55, 76], ["ocular", "ANATOMY", 3, 9], ["subconjunctival", "OBSERVATION", 14, 29], ["worm", "OBSERVATION", 46, 50], ["subcutaneous", "ANATOMY", 57, 69], ["nodule", "OBSERVATION", 70, 76], ["immature", "OBSERVATION_MODIFIER", 90, 98], ["adult", "OBSERVATION_MODIFIER", 99, 104]]], ["Exceptional pulmonary locations are described.", [["pulmonary", "ANATOMY", 12, 21], ["pulmonary", "ORGAN", 12, 21], ["pulmonary", "ANATOMY", 12, 21]]], ["The subcutaneous locations described are: skull, cheek, breast, inguinal area, buttocks, arms and legs.", [["subcutaneous", "ANATOMY", 4, 16], ["skull", "ANATOMY", 42, 47], ["cheek", "ANATOMY", 49, 54], ["breast", "ANATOMY", 56, 62], ["inguinal area", "ANATOMY", 64, 77], ["buttocks", "ANATOMY", 79, 87], ["arms", "ANATOMY", 89, 93], ["legs", "ANATOMY", 98, 102], ["skull", "MULTI-TISSUE_STRUCTURE", 42, 47], ["cheek", "ORGANISM_SUBDIVISION", 49, 54], ["breast", "ORGANISM_SUBDIVISION", 56, 62], ["inguinal area", "MULTI-TISSUE_STRUCTURE", 64, 77], ["buttocks", "ORGANISM_SUBDIVISION", 79, 87], ["legs", "ORGANISM_SUBDIVISION", 98, 102], ["skull, cheek, breast, inguinal area, buttocks, arms and legs", "PROBLEM", 42, 102], ["subcutaneous", "ANATOMY", 4, 16], ["skull", "ANATOMY", 42, 47], ["cheek", "ANATOMY", 49, 54], ["breast", "ANATOMY", 56, 62], ["inguinal", "ANATOMY", 64, 72], ["area", "ANATOMY_MODIFIER", 73, 77], ["buttocks", "ANATOMY", 79, 87], ["arms", "ANATOMY", 89, 93], ["legs", "ANATOMY", 98, 102]]], ["Cases of testicular location with painful symptoms have been observed.", [["testicular", "ANATOMY", 9, 19], ["testicular", "ORGAN", 9, 19], ["painful symptoms", "PROBLEM", 34, 50], ["testicular", "ANATOMY", 9, 19]]], ["Blood hypereosinophilia was exceptionally observed in human.", [["Blood", "ANATOMY", 0, 5], ["hypereosinophilia", "DISEASE", 6, 23], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["human", "ORGANISM", 54, 59], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["Blood hypereosinophilia", "PROBLEM", 0, 23], ["hypereosinophilia", "OBSERVATION", 6, 23]]], ["It is treated surgically, by excision, without chemotherapy.T. Naas\u00b0(Paris, FR)While the majority of ESBLs, isolated in clinically-relevant Gram negative bacteria (GNB) (mostly Enterobacteriaceae, P. aeruginosa, A. baumannii) are TEM-, SHV-or CTX-M-types, a few others have been reported (SFO, BES, BEL, TLA, GES, BEL, PER, VEB-types, and some OXA-ESBLs).", [["CTX", "CHEMICAL", 243, 246], ["OXA", "CHEMICAL", 344, 347], ["ESBLs", "GENE_OR_GENE_PRODUCT", 101, 106], ["Gram", "GENE_OR_GENE_PRODUCT", 140, 144], ["GNB", "CANCER", 164, 167], ["P. aeruginosa", "ORGANISM", 197, 210], ["A. baumannii", "ORGANISM", 212, 224], ["SHV", "GENE_OR_GENE_PRODUCT", 236, 239], ["CTX", "SIMPLE_CHEMICAL", 243, 246], ["SFO", "SIMPLE_CHEMICAL", 289, 292], ["OXA-ESBLs", "GENE_OR_GENE_PRODUCT", 344, 353], ["ESBLs", "PROTEIN", 348, 353], ["P. aeruginosa", "SPECIES", 197, 210], ["A. baumannii", "SPECIES", 212, 224], ["P. aeruginosa", "SPECIES", 197, 210], ["A. baumannii", "SPECIES", 212, 224], ["excision", "TREATMENT", 29, 37], ["chemotherapy", "TREATMENT", 47, 59], ["ESBLs", "PROBLEM", 101, 106], ["Gram negative bacteria (GNB)", "PROBLEM", 140, 168], ["Enterobacteriaceae", "PROBLEM", 177, 195], ["P. aeruginosa", "PROBLEM", 197, 210], ["A. baumannii", "PROBLEM", 212, 224], ["TEM", "TEST", 230, 233], ["SHV", "TEST", 236, 239], ["CTX", "TEST", 243, 246], ["BEL", "TEST", 299, 302], ["TLA", "TEST", 304, 307], ["BEL", "TEST", 314, 317], ["VEB", "TEST", 324, 327], ["some OXA", "PROBLEM", 339, 347], ["ESBLs", "PROBLEM", 348, 353], ["excision", "OBSERVATION", 29, 37], ["without", "UNCERTAINTY", 39, 46], ["ESBLs", "OBSERVATION", 101, 106], ["negative bacteria", "OBSERVATION_MODIFIER", 145, 162]]], ["Laboratory detection of ESBL-producers is important to avoid clinical failure due to inappropriate antimicrobial therapy and to prevent nosocomial outbreaks.", [["ESBL", "PROTEIN", 24, 28], ["Laboratory detection", "TEST", 0, 20], ["ESBL", "TEST", 24, 28], ["clinical failure", "PROBLEM", 61, 77], ["inappropriate antimicrobial therapy", "TREATMENT", 85, 120], ["nosocomial outbreaks", "PROBLEM", 136, 156], ["antimicrobial therapy", "OBSERVATION", 99, 120], ["nosocomial", "OBSERVATION_MODIFIER", 136, 146], ["outbreaks", "OBSERVATION", 147, 156]]], ["Selective culture media (MacConkey and Drigalski agar supplemented with cefotaxime and/or ceftazidime) have been proposed for detection of GNB resistant to expanded-spectrum cephalosporins (ESC).", [["cefotaxime", "CHEMICAL", 72, 82], ["ceftazidime", "CHEMICAL", 90, 101], ["GNB", "CHEMICAL", 139, 142], ["cephalosporins", "CHEMICAL", 174, 188], ["cefotaxime", "CHEMICAL", 72, 82], ["ceftazidime", "CHEMICAL", 90, 101], ["cephalosporins", "CHEMICAL", 174, 188], ["cefotaxime", "SIMPLE_CHEMICAL", 72, 82], ["ceftazidime", "SIMPLE_CHEMICAL", 90, 101], ["expanded-spectrum cephalosporins", "SIMPLE_CHEMICAL", 156, 188], ["ESC", "CELL", 190, 193], ["Selective culture media", "TEST", 0, 23], ["Drigalski agar", "TREATMENT", 39, 53], ["cefotaxime", "TREATMENT", 72, 82], ["ceftazidime", "TREATMENT", 90, 101], ["GNB", "PROBLEM", 139, 142], ["expanded-spectrum cephalosporins", "TREATMENT", 156, 188]]], ["Media using chromogenic based substrates and selective antibiotics have been developed recently for the detection and presumptive identification of ESBL-producing Enterobacteriaceae directly from clinical specimens.T. Naas\u00b0(Paris, FR)Detection of ESBLs based only on susceptibility testing is not easy due to the variety of b-lactamases and their variable expression of blactam resistance.", [["specimens", "ANATOMY", 205, 214], ["blactam", "CHEMICAL", 370, 377], ["ESBL-producing Enterobacteriaceae", "GENE_OR_GENE_PRODUCT", 148, 181], ["specimens", "CANCER", 205, 214], ["b-lactamases", "GENE_OR_GENE_PRODUCT", 324, 336], ["blactam", "GENE_OR_GENE_PRODUCT", 370, 377], ["ESBL", "PROTEIN", 148, 152], ["chromogenic based substrates", "TREATMENT", 12, 40], ["selective antibiotics", "TREATMENT", 45, 66], ["the detection", "TEST", 100, 113], ["ESBL", "PROBLEM", 148, 152], ["Enterobacteriaceae", "PROBLEM", 163, 181], ["clinical specimens", "TEST", 196, 214], ["ESBLs", "PROBLEM", 247, 252], ["susceptibility testing", "TEST", 267, 289], ["the variety of b-lactamases", "PROBLEM", 309, 336], ["blactam resistance", "PROBLEM", 370, 388], ["ESBL", "OBSERVATION", 148, 152], ["blactam resistance", "OBSERVATION", 370, 388]]], ["Commercially available ESBL detection methods yield at most 90% accurate ESBL identification, since some ESBL-producers may appear susceptible to some ESCs.", [["ESCs", "ANATOMY", 151, 155], ["ESBL", "GENE_OR_GENE_PRODUCT", 105, 109], ["ESCs", "CELL", 151, 155], ["ESBL", "PROTEIN", 105, 109], ["ESCs", "CELL_TYPE", 151, 155], ["ESBL detection methods", "TEST", 23, 45], ["ESBL identification", "TEST", 73, 92], ["some ESBL-producers", "PROBLEM", 100, 119], ["some ESCs", "PROBLEM", 146, 155]]], ["Therefore, any organism showing reduced susceptibility to ESC should be investigated using ESBL confirmatory tests.", [["ESC", "ANATOMY", 58, 61], ["ESC", "CELL", 58, 61], ["ESC", "CELL_TYPE", 58, 61], ["ESBL", "PROTEIN", 91, 95], ["any organism", "PROBLEM", 11, 23], ["reduced susceptibility to ESC", "PROBLEM", 32, 61], ["ESBL confirmatory tests", "TEST", 91, 114]]], ["These tests should be able to discriminate between ESBL-producers and those with other mechanisms conferring ESC resistance.", [["ESC", "ANATOMY", 109, 112], ["ESC", "CELL", 109, 112], ["ESBL", "PROTEIN", 51, 55], ["These tests", "TEST", 0, 11], ["ESBL", "TEST", 51, 55], ["ESC resistance", "OBSERVATION", 109, 123]]], ["These phenotypic tests (double-disk synergy test, ESBL Etest, and the combination disk method) are based on clavulanate inhibition and ESC susceptibility testing.", [["ESC", "ANATOMY", 135, 138], ["clavulanate", "CHEMICAL", 108, 119], ["clavulanate", "CHEMICAL", 108, 119], ["clavulanate", "SIMPLE_CHEMICAL", 108, 119], ["ESC", "CELL", 135, 138], ["These phenotypic tests", "TEST", 0, 22], ["double-disk synergy test", "TEST", 24, 48], ["ESBL Etest", "TEST", 50, 60], ["the combination disk method", "TEST", 66, 93], ["clavulanate inhibition", "TREATMENT", 108, 130], ["ESC susceptibility testing", "TEST", 135, 161]]], ["They often need slight changes by either reducing the distance between the disks of ESC and clavulanate, the use of cefepime (not hydrolysed by AmpCs), the use of cloxacillincontaining plates (that inhibits AmpC), or by double inhibition by EDTA and clavulanate (masking metallo-enzymes).", [["clavulanate", "CHEMICAL", 92, 103], ["cefepime", "CHEMICAL", 116, 124], ["AmpCs", "CHEMICAL", 144, 149], ["cloxacillincontaining", "CHEMICAL", 163, 184], ["EDTA", "CHEMICAL", 241, 245], ["clavulanate", "CHEMICAL", 250, 261], ["clavulanate", "CHEMICAL", 92, 103], ["cefepime", "CHEMICAL", 116, 124], ["cloxacillincontaining", "CHEMICAL", 163, 184], ["EDTA", "CHEMICAL", 241, 245], ["clavulanate", "CHEMICAL", 250, 261], ["ESC", "CELL", 84, 87], ["clavulanate", "SIMPLE_CHEMICAL", 92, 103], ["cefepime", "SIMPLE_CHEMICAL", 116, 124], ["AmpCs", "SIMPLE_CHEMICAL", 144, 149], ["AmpC", "GENE_OR_GENE_PRODUCT", 207, 211], ["EDTA", "SIMPLE_CHEMICAL", 241, 245], ["clavulanate", "SIMPLE_CHEMICAL", 250, 261], ["metallo-enzymes", "GENE_OR_GENE_PRODUCT", 271, 286], ["AmpC", "PROTEIN", 207, 211], ["slight changes", "PROBLEM", 16, 30], ["ESC", "TREATMENT", 84, 87], ["clavulanate", "TREATMENT", 92, 103], ["cefepime", "TREATMENT", 116, 124], ["cloxacillincontaining plates", "TREATMENT", 163, 191], ["AmpC)", "TREATMENT", 207, 212], ["clavulanate", "TREATMENT", 250, 261], ["slight", "OBSERVATION_MODIFIER", 16, 22], ["changes", "OBSERVATION", 23, 30]]], ["Enzymatic tests have also been proposed for identification of ESBL-producers.", [["ESBL", "GENE_OR_GENE_PRODUCT", 62, 66], ["ESBL", "PROTEIN", 62, 66], ["Enzymatic tests", "TEST", 0, 15], ["ESBL", "PROBLEM", 62, 66], ["ESBL", "OBSERVATION", 62, 66]]], ["Several PCR-based techniques (end-point or real time) have been developed on clinical samples or on colonies.", [["samples", "ANATOMY", 86, 93], ["colonies", "ANATOMY", 100, 108], ["Several PCR", "TEST", 0, 11]]], ["Several ESBL genes have been detected using PCR coupled to either pyrosequencing, inverse hybridisation, to dHPLC, or to fluorescent probes.", [["ESBL", "GENE_OR_GENE_PRODUCT", 8, 12], ["ESBL genes", "DNA", 8, 18], ["Several ESBL genes", "PROBLEM", 0, 18], ["PCR", "TEST", 44, 47], ["inverse hybridisation", "PROBLEM", 82, 103], ["dHPLC", "TEST", 108, 113], ["fluorescent probes", "TEST", 121, 139], ["ESBL genes", "OBSERVATION", 8, 18]]], ["Detection of ESBL-producer remains a challenge for the microbiology laboratory and one shall be aware that ESBL screening media are now available.F. Tenover\u00b0(Sunnyvale, US)Resistance to antimicrobial agents has become common in many bacterial species, particularly those that cause human infections.", [["infections", "DISEASE", 288, 298], ["ESBL", "GENE_OR_GENE_PRODUCT", 13, 17], ["human", "ORGANISM", 282, 287], ["ESBL", "PROTEIN", 13, 17], ["human", "SPECIES", 282, 287], ["human", "SPECIES", 282, 287], ["ESBL", "PROBLEM", 13, 17], ["the microbiology laboratory", "TEST", 51, 78], ["ESBL screening media", "TEST", 107, 127], ["antimicrobial agents", "TREATMENT", 186, 206], ["many bacterial species", "PROBLEM", 228, 250], ["human infections", "PROBLEM", 282, 298], ["ESBL", "OBSERVATION", 13, 17], ["bacterial species", "OBSERVATION", 233, 250], ["infections", "OBSERVATION", 288, 298]]], ["The rapid detection of resistant organisms directly in clinical samples by real-time PCR coupled with molecular beacons, or of potentially resistant bacteria and yeast in blood culture bottles by peptide nucleic acid-fluorescence in situ hybridisation (PNA-FISH) is already having a positive impact on antimicrobial therapy.", [["samples", "ANATOMY", 64, 71], ["blood", "ANATOMY", 171, 176], ["nucleic acid-", "CHEMICAL", 204, 217], ["blood", "ORGANISM_SUBSTANCE", 171, 176], ["yeast", "SPECIES", 162, 167], ["yeast", "SPECIES", 162, 167], ["resistant organisms", "PROBLEM", 23, 42], ["clinical samples", "TEST", 55, 71], ["real-time PCR", "TEST", 75, 88], ["molecular beacons", "PROBLEM", 102, 119], ["potentially resistant bacteria", "PROBLEM", 127, 157], ["yeast", "PROBLEM", 162, 167], ["blood culture bottles", "TEST", 171, 192], ["peptide nucleic acid-fluorescence", "TEST", 196, 229], ["antimicrobial therapy", "TREATMENT", 302, 323], ["resistant organisms", "OBSERVATION", 23, 42], ["resistant", "OBSERVATION_MODIFIER", 139, 148], ["bacteria", "OBSERVATION", 149, 157], ["antimicrobial therapy", "OBSERVATION", 302, 323]]], ["The direct detection of Mycobacterium tuberculosis in sputum in approximately 2 hours with concomitant detection of mutations in rpoB indicating rifampin resistance (as a surrogate for multidrug resistance) in the near future will likely improve the outcomes for tuberculosis patients in many developing and developed countries.", [["sputum", "ANATOMY", 54, 60], ["Mycobacterium tuberculosis", "DISEASE", 24, 50], ["rifampin", "CHEMICAL", 145, 153], ["tuberculosis", "DISEASE", 263, 275], ["rifampin", "CHEMICAL", 145, 153], ["Mycobacterium tuberculosis", "ORGANISM", 24, 50], ["sputum", "ORGANISM_SUBSTANCE", 54, 60], ["rpoB", "GENE_OR_GENE_PRODUCT", 129, 133], ["rifampin", "SIMPLE_CHEMICAL", 145, 153], ["patients", "ORGANISM", 276, 284], ["rpoB", "DNA", 129, 133], ["Mycobacterium tuberculosis", "SPECIES", 24, 50], ["patients", "SPECIES", 276, 284], ["Mycobacterium tuberculosis", "SPECIES", 24, 50], ["The direct detection", "TEST", 0, 20], ["Mycobacterium tuberculosis in sputum", "PROBLEM", 24, 60], ["mutations in rpoB", "PROBLEM", 116, 133], ["rifampin resistance", "TREATMENT", 145, 164], ["multidrug resistance", "TREATMENT", 185, 205], ["tuberculosis", "PROBLEM", 263, 275], ["Mycobacterium tuberculosis", "OBSERVATION", 24, 50], ["rifampin resistance", "OBSERVATION", 145, 164], ["tuberculosis", "OBSERVATION", 263, 275]]], ["Several molecular technologies, including microarrays, bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP), and ultra deep sequencing, have not yet transitioned to clinical laboratories but will likely provide even greater information about antimicrobial resistance not in just a single species, but in a whole community of microorganisms.", [["Several molecular technologies", "TEST", 0, 30], ["microarrays", "TEST", 42, 53], ["bacterial tag encoded FLX amplicon pyrosequencing", "TREATMENT", 55, 104], ["ultra deep sequencing", "TEST", 119, 140], ["clinical laboratories", "TEST", 171, 192], ["antimicrobial resistance", "TREATMENT", 248, 272], ["a single species", "PROBLEM", 285, 301]]], ["Complex wounds, like diabetic foot ulcers, containing multiple resistance genotypes are amenable to analysis by bTEFAP.", [["wounds", "ANATOMY", 8, 14], ["foot ulcers", "ANATOMY", 30, 41], ["diabetic foot ulcers", "DISEASE", 21, 41], ["wounds", "PATHOLOGICAL_FORMATION", 8, 14], ["foot", "ORGANISM_SUBDIVISION", 30, 34], ["ulcers", "PATHOLOGICAL_FORMATION", 35, 41], ["bTEFAP", "SIMPLE_CHEMICAL", 112, 118], ["bTEFAP", "PROTEIN", 112, 118], ["Complex wounds", "PROBLEM", 0, 14], ["diabetic foot ulcers", "PROBLEM", 21, 41], ["multiple resistance genotypes", "PROBLEM", 54, 83], ["analysis", "TEST", 100, 108], ["wounds", "OBSERVATION", 8, 14], ["diabetic", "OBSERVATION_MODIFIER", 21, 29], ["foot", "ANATOMY", 30, 34], ["ulcers", "OBSERVATION", 35, 41], ["multiple", "OBSERVATION_MODIFIER", 54, 62], ["resistance genotypes", "OBSERVATION", 63, 83]]], ["The implementation of these technologies in the clinical laboratory will be expensive but the potential to dramatically improve therapeutic outcomes especially for life-threatening diseases is unprecedented.", [["life-threatening diseases", "PROBLEM", 164, 189]]], ["Objective: To determine the appropriateness of antimicrobial therapy (AMT) in 11 Dutch hospitals.", [["antimicrobial therapy", "TREATMENT", 47, 68]]], ["Method: Data were obtained from a prevalence survey performed within the Dutch surveillance network for nosocomial infections (PREZIES).", [["nosocomial infections", "DISEASE", 104, 125], ["PREZIES", "DISEASE", 127, 134], ["a prevalence survey", "TEST", 32, 51], ["nosocomial infections", "PROBLEM", 104, 125]]], ["AMT administrated on the day of the survey was registered.", [["AMT", "CHEMICAL", 0, 3]]], ["Antiviral and antifungal drugs, tuberculostatics, cements containing AMT and prophylaxis administrated in the operation-theatre were excluded.", [["AMT", "CHEMICAL", 69, 72], ["AMT", "CHEMICAL", 69, 72], ["tuberculostatics", "SIMPLE_CHEMICAL", 32, 48], ["AMT", "SIMPLE_CHEMICAL", 69, 72], ["Antiviral", "TREATMENT", 0, 9], ["antifungal drugs", "TREATMENT", 14, 30], ["tuberculostatics", "TREATMENT", 32, 48], ["cements", "TREATMENT", 50, 57], ["AMT", "TREATMENT", 69, 72], ["prophylaxis", "TREATMENT", 77, 88], ["antifungal drugs", "OBSERVATION", 14, 30]]], ["The appropriateness of AMT was assessed according to a standardised algorithm based on the local antimicrobial prescription guidelines.", [["a standardised algorithm", "TEST", 53, 77], ["the local antimicrobial prescription guidelines", "TREATMENT", 87, 134]]], ["Per patient a classification in appropriate use, inappropriate use and insufficient information was made.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Figure: Relative risk of IA use of AMT against largest hospital (hospital C).Antibiotic use in hospitalsResults: A total of 3,546 patients were included of which 1,075 (30%, range per centre (RPC): 23\u221237%) received AMT.", [["AMT", "CHEMICAL", 35, 38], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["Antibiotic use", "TREATMENT", 77, 91], ["RPC", "TEST", 192, 195], ["AMT", "TEST", 215, 218]]], ["In the latter group, AMT was considered appropriate in 70% (RPC: 57\u221284%), inappropriate in 17% (RPC: 3\u221232%) and was not judged because of insufficient information in 13% (RPC: 1\u221230%).", [["AMT", "CHEMICAL", 21, 24], ["AMT", "TEST", 21, 24], ["RPC", "TEST", 60, 63], ["RPC", "TEST", 96, 99], ["RPC", "TEST", 171, 174]]], ["There was considerable variation in inappropriate use among the participating centres (figure).", [["considerable variation", "PROBLEM", 10, 32], ["considerable", "OBSERVATION_MODIFIER", 10, 22], ["variation", "OBSERVATION_MODIFIER", 23, 32], ["inappropriate", "OBSERVATION_MODIFIER", 36, 49]]], ["In univariate analysis older age, the use of quinolones, being on the urology ward and presence of a suprapubical catheter were associated significantly with inappropriate use.", [["suprapubical", "ANATOMY", 101, 113], ["quinolones", "CHEMICAL", 45, 55], ["quinolones", "CHEMICAL", 45, 55], ["quinolones", "SIMPLE_CHEMICAL", 45, 55], ["quinolones", "TREATMENT", 45, 55], ["a suprapubical catheter", "TREATMENT", 99, 122], ["catheter", "OBSERVATION", 114, 122]]], ["Admission on the ICU and presence of an intravascular catheter were associated significantly with appropriate use.Antibiotic use in hospitalsIn a multivariate analyses the presence of suprapubical catheter, being on the urology ward and the use of quinolones were determinants for inappropriate use.Conclusion:This study showed large differences in overall use and appropriateness of use of AMT between hospitals.", [["intravascular", "ANATOMY", 40, 53], ["quinolones", "CHEMICAL", 248, 258], ["AMT", "CHEMICAL", 391, 394], ["quinolones", "CHEMICAL", 248, 258], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 53], ["quinolones", "SIMPLE_CHEMICAL", 248, 258], ["an intravascular catheter", "TREATMENT", 37, 62], ["Antibiotic use", "TREATMENT", 114, 128], ["suprapubical catheter", "TREATMENT", 184, 205], ["quinolones", "TREATMENT", 248, 258], ["This study", "TEST", 310, 320], ["large differences", "PROBLEM", 328, 345], ["intravascular catheter", "OBSERVATION", 40, 62], ["suprapubical", "OBSERVATION_MODIFIER", 184, 196], ["catheter", "OBSERVATION", 197, 205], ["large", "OBSERVATION_MODIFIER", 328, 333], ["differences", "OBSERVATION_MODIFIER", 334, 345]]], ["Based on these results it is possible to define targets for intervention to improve the prudent use of AMT.", [["AMT", "CHEMICAL", 103, 106], ["AMT", "SIMPLE_CHEMICAL", 103, 106], ["intervention", "TREATMENT", 60, 72]]], ["The high fraction of patients with insufficient information in several centres may have influenced the analyses and should be addressed in future studies.O296 Validation of quality indicators for hospital antibiotic use by the ABS International \u2212 Quality Indicators (QI) ProjectM.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["future studies", "TEST", 139, 153], ["hospital antibiotic use", "TREATMENT", 196, 219], ["high", "OBSERVATION_MODIFIER", 4, 8], ["fraction", "OBSERVATION_MODIFIER", 9, 17]]], ["Struelens\u00b0, S. Metz-Gercek, R. Mechtler, F. Buyle, A. Lechner, H. Mittermayer, F. Allerberger, W. Kernand the ABS QI Team & Feasibility Study ParticipantsObjectives: The EU-Project Antibiotic Strategy International (ABS) QI team developed process QIs for auditing the performance of key treatment and prophylactic practices.", [["Participants", "SPECIES", 142, 154], ["process QIs", "TREATMENT", 239, 250], ["key treatment", "TREATMENT", 283, 296], ["prophylactic practices", "TREATMENT", 301, 323]]], ["An international network of pilot hospitals tested these tools for feasibility, reliability and sensitivity to improvement.", [["pilot hospitals", "TREATMENT", 28, 43]]], ["Methods: QIs included: 1. surgical prophylaxis (indication, drug choice, timing and duration of administration); 2. management of community-acquired pneumonia (CAP) (blood culture and Legionella antigen tests and drug choice for empirical treatment); 3. management of S. aureus bacteraemia (echocardiography, IV catheter removal and duration of therapy); and 4. iv-po switch for bio-available antibiotics.", [["blood", "ANATOMY", 166, 171], ["pneumonia", "DISEASE", 149, 158], ["CAP", "DISEASE", 160, 163], ["S. aureus bacteraemia", "DISEASE", 268, 289], ["blood", "ORGANISM_SUBSTANCE", 166, 171], ["Legionella antigen", "GENE_OR_GENE_PRODUCT", 184, 202], ["S. aureus", "ORGANISM", 268, 277], ["S. aureus", "SPECIES", 268, 277], ["S. aureus", "SPECIES", 268, 277], ["surgical prophylaxis", "TREATMENT", 26, 46], ["management", "TREATMENT", 116, 126], ["community-acquired pneumonia (CAP)", "PROBLEM", 130, 164], ["blood culture", "TEST", 166, 179], ["Legionella antigen tests", "TEST", 184, 208], ["empirical treatment", "TREATMENT", 229, 248], ["S. aureus bacteraemia", "PROBLEM", 268, 289], ["echocardiography", "TEST", 291, 307], ["IV catheter removal", "TREATMENT", 309, 328], ["therapy", "TREATMENT", 345, 352], ["iv", "TREATMENT", 362, 364], ["bio-available antibiotics", "TREATMENT", 379, 404], ["pneumonia", "OBSERVATION", 149, 158], ["aureus", "OBSERVATION_MODIFIER", 271, 277], ["bacteraemia", "OBSERVATION", 278, 289]]], ["A minimum of 40 consecutive cases per centre and QI were retrospectively reviewed from clinical, laboratory and administrative records and assessed for data availability, inter-observer reliability, data collection workload and performance score.", [["inter-observer reliability", "TEST", 171, 197], ["data collection workload", "TEST", 199, 223], ["performance score", "TEST", 228, 245]]], ["Results: A total of 1240 patients were evaluated in 11 acute care hospitals from 5 countries, with a range of 80 to 500 cases and 2 to 9 centres per indicator.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["Seven centres had already implemented antibiotic quality improvement and audit programmes.", [["audit programmes", "TREATMENT", 73, 89]]], ["Availability of data was >85% of cases and ranged between 87% (catheter removal in S. aureus bacteraemia) and 100% (diagnostic tests for CAP).", [["S. aureus bacteraemia", "DISEASE", 83, 104], ["CAP", "DISEASE", 137, 140], ["S. aureus", "ORGANISM", 83, 92], ["S. aureus", "SPECIES", 83, 92], ["S. aureus", "SPECIES", 83, 92], ["Availability of data", "TEST", 0, 20], ["cases", "TEST", 33, 38], ["catheter removal", "TREATMENT", 63, 79], ["S. aureus bacteraemia", "PROBLEM", 83, 104], ["diagnostic tests", "TEST", 116, 132], ["CAP", "TEST", 137, 140], ["aureus", "OBSERVATION_MODIFIER", 86, 92], ["bacteraemia", "OBSERVATION", 93, 104]]], ["13/14 indicators were found to be reliable with kappa 0.60 (good to excellent agreement).", [["kappa", "TEST", 48, 53]]], ["The intention to treat QI scores showed high levels of adherence to the surgical prophylaxis QI bundle, with median values of 81 to 97% for hip prosthesis and 65 to 92% for colo-rectal surgery.", [["hip", "ANATOMY", 140, 143], ["hip", "ORGANISM_SUBDIVISION", 140, 143], ["QI scores", "TEST", 23, 32], ["the surgical prophylaxis", "TREATMENT", 68, 92], ["median values", "TEST", 109, 122], ["hip prosthesis", "TREATMENT", 140, 154], ["colo-rectal surgery", "TREATMENT", 173, 192], ["hip", "ANATOMY", 140, 143], ["prosthesis", "OBSERVATION", 144, 154]]], ["For CAP management, diagnostic testing appeared sub-optimal (<56% compliance with IDSA guidelines).", [["CAP management", "TREATMENT", 4, 18], ["diagnostic testing", "TEST", 20, 38], ["IDSA guidelines", "TREATMENT", 82, 97]]], ["For S. aureus bacteraemia management, indicator results ranged from 60 to 65%.", [["S. aureus bacteraemia", "DISEASE", 4, 25], ["S. aureus", "ORGANISM", 4, 13], ["S. aureus", "SPECIES", 4, 13], ["S. aureus", "SPECIES", 4, 13], ["S. aureus bacteraemia management", "PROBLEM", 4, 36], ["aureus", "OBSERVATION_MODIFIER", 7, 13], ["bacteraemia", "OBSERVATION", 14, 25]]], ["For use of bio available antibiotics, a median of 45% iv administrations were avoidable.", [["bio available antibiotics", "TREATMENT", 11, 36], ["a median of 45% iv administrations", "TREATMENT", 38, 72]]], ["There were marked differences of scores between centres for all QIs.", [["marked", "OBSERVATION_MODIFIER", 11, 17], ["differences", "OBSERVATION_MODIFIER", 18, 29]]], ["Conclusions: The ABS QIs are reliable and broadly applicable tools for auditing antibiotic treatment and prophylactic practices.", [["The ABS QIs", "TEST", 13, 24], ["auditing antibiotic treatment", "TREATMENT", 71, 100], ["prophylactic practices", "TREATMENT", 105, 127]]], ["Inter-hospital variation in adherence to recommended practice indicates substantial potential for improvement with different local priorities.", [["different local priorities", "TREATMENT", 115, 141]]], ["These QIs can be recommended for assessing the effect of quality of care interventions at either local or multi-centre level.O297 Does a laminated hand-held card describing antibiotic policy influence the junior doctor prescribing in a geriatric medicine department?", [["hand", "ANATOMY", 147, 151], ["hand", "ORGANISM_SUBDIVISION", 147, 151], ["care interventions", "TREATMENT", 68, 86]]], ["A controlled interrupted time-seriesD.J. Noimark\u00b0, E. Charani, S. Smith, B. Cooper, I. Balakrishnan, S.P. Stone (London, UK) Introduction: Reduction of Clostridium difficile infection (CDI), which often follows use of third generation cephalosporins, is a national priority.", [["Clostridium difficile infection", "DISEASE", 152, 183], ["CDI", "DISEASE", 185, 188], ["cephalosporins", "CHEMICAL", 235, 249], ["cephalosporins", "CHEMICAL", 235, 249], ["Clostridium difficile", "ORGANISM", 152, 173], ["cephalosporins", "SIMPLE_CHEMICAL", 235, 249], ["Clostridium difficile", "SPECIES", 152, 173], ["Clostridium difficile", "SPECIES", 152, 173], ["Clostridium difficile infection", "PROBLEM", 152, 183], ["CDI", "PROBLEM", 185, 188], ["third generation cephalosporins", "TREATMENT", 218, 249], ["Stone", "OBSERVATION", 106, 111], ["Clostridium difficile", "OBSERVATION", 152, 173]]], ["Over a three year period, antibiotic policies were reviewed and changed in an elderly medicine department according to local sensitivities of common pathogens and levels of CDI.", [["CDI", "DISEASE", 173, 176], ["antibiotic policies", "TREATMENT", 26, 45], ["common pathogens", "PROBLEM", 142, 158], ["CDI", "PROBLEM", 173, 176], ["CDI", "OBSERVATION", 173, 176]]], ["A laminated pocket-sized card describing antibiotic policies was given to all doctors in the department on induction with instructions not to depart from these without microbiologists' approval.", [["A laminated pocket-sized card describing antibiotic policies", "TREATMENT", 0, 60], ["laminated", "OBSERVATION_MODIFIER", 2, 11], ["pocket", "OBSERVATION_MODIFIER", 12, 18], ["sized", "OBSERVATION_MODIFIER", 19, 24]]], ["This prospective controlled interrupted time series examines whether this intervention increased compliance with antibiotic policy and decreased CDI incidence.", [["CDI", "DISEASE", 145, 148], ["this intervention", "TREATMENT", 69, 86], ["antibiotic policy", "TREATMENT", 113, 130], ["decreased CDI incidence", "PROBLEM", 135, 158]]], ["Methods: The department's \"narrow-spectrum, no cephalosporin\" antibiotic policy was changed on 1st August 2006 to replace Trimethoprim with Cephradine (1st generation cephalopsporin) as empiric treatment for urinary tract infection, reflecting local Escheriscia Coli sensitivities.O297 Does a laminated hand-held card describing antibiotic policy influence the junior doctor prescribing in a geriatric medicine department?", [["urinary tract", "ANATOMY", 208, 221], ["hand", "ANATOMY", 303, 307], ["cephalosporin", "CHEMICAL", 47, 60], ["Trimethoprim", "CHEMICAL", 122, 134], ["Cephradine", "CHEMICAL", 140, 150], ["cephalopsporin", "CHEMICAL", 167, 181], ["urinary tract infection", "DISEASE", 208, 231], ["cephalosporin", "CHEMICAL", 47, 60], ["Trimethoprim", "CHEMICAL", 122, 134], ["Cephradine", "CHEMICAL", 140, 150], ["cephalopsporin", "CHEMICAL", 167, 181], ["cephalosporin", "SIMPLE_CHEMICAL", 47, 60], ["Trimethoprim", "SIMPLE_CHEMICAL", 122, 134], ["Cephradine", "SIMPLE_CHEMICAL", 140, 150], ["cephalopsporin", "SIMPLE_CHEMICAL", 167, 181], ["urinary tract", "ORGANISM_SUBDIVISION", 208, 221], ["hand", "ORGANISM_SUBDIVISION", 303, 307], ["Escheriscia Coli", "SPECIES", 250, 266], ["cephalosporin\" antibiotic policy", "TREATMENT", 47, 79], ["Trimethoprim", "TREATMENT", 122, 134], ["Cephradine", "TREATMENT", 140, 150], ["1st generation cephalopsporin)", "TREATMENT", 152, 182], ["empiric treatment", "TREATMENT", 186, 203], ["urinary tract infection", "PROBLEM", 208, 231], ["local Escheriscia Coli sensitivities", "PROBLEM", 244, 280], ["urinary tract", "ANATOMY", 208, 221], ["infection", "OBSERVATION", 222, 231], ["Escheriscia Coli sensitivities", "OBSERVATION", 250, 280]]], ["A controlled interrupted time-seriesIn October 2007, all cephalosporins and quinolones were removed from the policy as CDI levels had increased.", [["cephalosporins", "CHEMICAL", 57, 71], ["quinolones", "CHEMICAL", 76, 86], ["cephalosporins", "CHEMICAL", 57, 71], ["quinolones", "CHEMICAL", 76, 86], ["cephalosporins", "SIMPLE_CHEMICAL", 57, 71], ["quinolones", "SIMPLE_CHEMICAL", 76, 86], ["all cephalosporins", "TREATMENT", 53, 71], ["quinolones", "TREATMENT", 76, 86], ["CDI levels", "TEST", 119, 129], ["increased", "OBSERVATION_MODIFIER", 134, 143]]], ["Notional 7 day antibiotic usage was calculated from prospective pharmacy generated data with aspirin, calcium, bisphosphonate & laxative prescription use as a non-antibiotic control, and analysed by segmented regression with a robust variance estimator.", [["aspirin", "CHEMICAL", 93, 100], ["calcium", "CHEMICAL", 102, 109], ["bisphosphonate", "CHEMICAL", 111, 125], ["aspirin", "CHEMICAL", 93, 100], ["calcium", "CHEMICAL", 102, 109], ["bisphosphonate", "CHEMICAL", 111, 125], ["aspirin", "SIMPLE_CHEMICAL", 93, 100], ["calcium", "SIMPLE_CHEMICAL", 102, 109], ["bisphosphonate", "SIMPLE_CHEMICAL", 111, 125], ["Notional 7 day antibiotic usage", "TREATMENT", 0, 31], ["aspirin", "TREATMENT", 93, 100], ["calcium", "TREATMENT", 102, 109], ["bisphosphonate", "TREATMENT", 111, 125], ["laxative prescription", "TREATMENT", 128, 149], ["a non-antibiotic control", "TREATMENT", 157, 181], ["a robust variance estimator", "TREATMENT", 225, 252]]], ["CDI rates were prospectively collected separately & analysed by a Poisson regression model.", [["CDI rates", "TEST", 0, 9]]], ["Results: An immediate response to change in antibiotic guidelines was observed (Figure) .", [["antibiotic guidelines", "TREATMENT", 44, 65]]], ["From August 06-Sep 07 there was a highly significant increase in cephalosporins (85-100% of which was Cephradine alone) (p < 0.001), a significant fall in trimethoprim (p < 0.004) and a significant increasing trend in CDI ( No tools existed to assess the readiness of public hospitals to receive this technology, and therefore guide resource allocation to facilitate implementation.", [["cephalosporins", "CHEMICAL", 65, 79], ["Cephradine", "CHEMICAL", 102, 112], ["trimethoprim", "CHEMICAL", 155, 167], ["cephalosporins", "CHEMICAL", 65, 79], ["Cephradine", "CHEMICAL", 102, 112], ["trimethoprim", "CHEMICAL", 155, 167], ["cephalosporins", "SIMPLE_CHEMICAL", 65, 79], ["Cephradine", "SIMPLE_CHEMICAL", 102, 112], ["trimethoprim", "SIMPLE_CHEMICAL", 155, 167], ["cephalosporins", "TREATMENT", 65, 79], ["Cephradine", "TREATMENT", 102, 112], ["a significant fall", "PROBLEM", 133, 151], ["trimethoprim", "TREATMENT", 155, 167], ["a significant increasing trend in CDI", "PROBLEM", 184, 221], ["this technology", "TREATMENT", 296, 311], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["increase", "OBSERVATION_MODIFIER", 53, 61], ["significant", "OBSERVATION_MODIFIER", 135, 146], ["fall", "OBSERVATION", 147, 151], ["significant", "OBSERVATION_MODIFIER", 186, 197], ["increasing", "OBSERVATION_MODIFIER", 198, 208], ["trend", "OBSERVATION_MODIFIER", 209, 214], ["CDI", "OBSERVATION", 218, 221]]], ["Aim: To assess the readiness of Victorian public hospitals to introduce electronic antimicrobial stewardship.", [["electronic antimicrobial stewardship", "TREATMENT", 72, 108]]], ["Method: Literature on readiness for change, organisational culture and information technology acceptance were reviewed.", [["organisational culture", "TEST", 44, 66]]], ["Assessments at several hospitals highlighted a variety of issues at different sites and allowed early efforts to address these.Conclusion:A formative readiness assessment can be used to identify systematic problems that might facilitate or hinder uptake of electronic antimicrobial stewardship and to inform the adopters of potential resources required.Reference(s)[1] Buising, K, Thursky, K, Robertson, M, Black, J, Street, A, Richards, M & Brown, G (2008) .", [["Assessments", "TEST", 0, 11], ["A formative readiness assessment", "TEST", 138, 170], ["systematic problems", "PROBLEM", 195, 214], ["electronic antimicrobial stewardship", "TREATMENT", 257, 293], ["potential resources", "TREATMENT", 324, 343]]], ["Electronic antibiotic stewardship-reduced consumption of broad-spectrum antibiotics using a computerised antimicrobial approval system in a hospital setting.", [["Electronic antibiotic stewardship", "TREATMENT", 0, 33], ["broad-spectrum antibiotics", "TREATMENT", 57, 83], ["a computerised antimicrobial approval system", "TREATMENT", 90, 134]]], ["J Antimicrob Chemother.O299 Fluoroquinolone prophylaxis in haematology-oncology patients \u2212 is it still useful?W.V. Kern\u00b0, M. Steib-Bauert, A. Pritzkow, G. Peyerl-Hoffmann, H. von Baum, U. Frank, M. Dettenkofer, C. Schneider, K. de With, H. Bertz (Freiburg, Ulm, DE) Objectives: Fluoroquinolone prophylaxis (FQPx) may reduce morbidity and mortality in cancer patients (pts) with neutropenia, but the development of fluoroquinolone resistance (FQR) in Escherichia coli and other target organisms limits its usefulness.", [["cancer", "ANATOMY", 351, 357], ["O299", "CHEMICAL", 23, 27], ["Fluoroquinolone", "CHEMICAL", 28, 43], ["Fluoroquinolone", "CHEMICAL", 278, 293], ["FQPx", "CHEMICAL", 307, 311], ["cancer", "DISEASE", 351, 357], ["neutropenia", "DISEASE", 378, 389], ["fluoroquinolone", "CHEMICAL", 414, 429], ["Fluoroquinolone", "CHEMICAL", 28, 43], ["Fluoroquinolone", "CHEMICAL", 278, 293], ["fluoroquinolone", "CHEMICAL", 414, 429], ["O299", "SIMPLE_CHEMICAL", 23, 27], ["Fluoroquinolone", "SIMPLE_CHEMICAL", 28, 43], ["patients", "ORGANISM", 80, 88], ["Fluoroquinolone", "SIMPLE_CHEMICAL", 278, 293], ["cancer", "CANCER", 351, 357], ["patients", "ORGANISM", 358, 366], ["fluoroquinolone", "SIMPLE_CHEMICAL", 414, 429], ["Escherichia coli", "ORGANISM", 450, 466], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 358, 366], ["Escherichia coli", "SPECIES", 450, 466], ["Escherichia coli", "SPECIES", 450, 466], ["Fluoroquinolone prophylaxis", "TREATMENT", 28, 55], ["Fluoroquinolone prophylaxis (FQPx)", "TREATMENT", 278, 312], ["morbidity", "PROBLEM", 324, 333], ["neutropenia", "PROBLEM", 378, 389], ["fluoroquinolone resistance (FQR)", "PROBLEM", 414, 446], ["Escherichia coli", "PROBLEM", 450, 466], ["other target organisms", "PROBLEM", 471, 493], ["Hoffmann", "ANATOMY", 162, 170], ["cancer", "OBSERVATION", 351, 357], ["fluoroquinolone resistance", "OBSERVATION", 414, 440], ["Escherichia coli", "OBSERVATION", 450, 466]]], ["We evaluated changes in the incidence density of Gram-negative bloodstream infection (GNB) and in the in vitro FQR rates after the introduction of FQPx (with levofloxacin) as a standard of care for pts with high risk neutropenia in a university hospital.", [["bloodstream", "ANATOMY", 63, 74], ["bloodstream infection", "DISEASE", 63, 84], ["GNB", "DISEASE", 86, 89], ["FQPx", "CHEMICAL", 147, 151], ["levofloxacin", "CHEMICAL", 158, 170], ["neutropenia", "DISEASE", 217, 228], ["FQPx", "CHEMICAL", 147, 151], ["levofloxacin", "CHEMICAL", 158, 170], ["Gram", "GENE_OR_GENE_PRODUCT", 49, 53], ["FQPx", "SIMPLE_CHEMICAL", 147, 151], ["levofloxacin", "SIMPLE_CHEMICAL", 158, 170], ["Gram-negative bloodstream infection", "PROBLEM", 49, 84], ["GNB", "PROBLEM", 86, 89], ["FQPx", "TREATMENT", 147, 151], ["levofloxacin", "TREATMENT", 158, 170], ["high risk neutropenia", "PROBLEM", 207, 228], ["Gram", "OBSERVATION_MODIFIER", 49, 53], ["negative", "OBSERVATION_MODIFIER", 54, 62], ["bloodstream infection", "OBSERVATION", 63, 84]]], ["Methods: We collected individual data for 357 pts admitted during baseline and during the first months following the intervention to assess clinical outcomes.", [["the intervention", "TREATMENT", 113, 129]]], ["Individual pt data were compared with aggregate data (3-month periods).", [["Individual pt data", "TEST", 0, 18], ["aggregate data", "TEST", 38, 52]]], ["Aggregate data analysis (unit-wide antibiotic consumption, GNB and numbers of in vitro FQR bloodstream isolates) was continued for a total of eight 3-month periods for both the haematology-oncology service and for general internal medicine.Results:The new policy was introduced in the second half of the year 2005 when unit-wide baseline FQR of E. coli and of coagulase-negative staphylococcal (CoNS) bloodstream isolates had been 15% and 80% in the haematology-oncology unit, and 8% and 60% in general internal medicine, respectively.", [["E. coli", "ORGANISM", 345, 352], ["coagulase-negative staphylococcal", "GENE_OR_GENE_PRODUCT", 360, 393], ["E. coli", "SPECIES", 345, 352], ["E. coli", "SPECIES", 345, 352], ["Aggregate data analysis", "TEST", 0, 23], ["wide antibiotic consumption", "TREATMENT", 30, 57], ["GNB", "PROBLEM", 59, 62], ["vitro FQR bloodstream isolates", "TREATMENT", 81, 111], ["general internal medicine", "TREATMENT", 214, 239], ["E. coli", "PROBLEM", 345, 352], ["coagulase", "TEST", 360, 369], ["bloodstream isolates", "TEST", 401, 421], ["negative staphylococcal", "OBSERVATION_MODIFIER", 370, 393]]], ["The individual pt data analysis revealed that pts not given FQPx had a much higher incidence of GNB than those given FQPx ( -2007) .", [["GNB", "DISEASE", 96, 99], ["The individual pt data analysis", "TEST", 0, 31], ["FQPx", "TREATMENT", 60, 64], ["GNB", "PROBLEM", 96, 99]]], ["The monthly use of iv and oral QUIN was calculated based on data from the pharmacy department.", [["oral", "ANATOMY", 26, 30], ["QUIN", "CHEMICAL", 31, 35], ["QUIN", "CHEMICAL", 31, 35], ["oral", "ORGANISM_SUBDIVISION", 26, 30], ["QUIN", "SIMPLE_CHEMICAL", 31, 35], ["iv and oral QUIN", "TREATMENT", 19, 35]]], ["Statistical analyses were performed using segmented linear regression analysis.", [["Statistical analyses", "TEST", 0, 20], ["segmented linear regression analysis", "TEST", 42, 78]]], ["Bayesian Model Averaging was used to account for model uncertainty.Results:Results: Before the interventions the use of QUIN (both iv and total) was stable.", [["QUIN", "CHEMICAL", 120, 124], ["QUIN", "CHEMICAL", 120, 124], ["QUIN", "SIMPLE_CHEMICAL", 120, 124], ["QUIN (both iv", "TREATMENT", 120, 133], ["stable", "OBSERVATION_MODIFIER", 149, 155]]], ["The best fitting models indicated that the first intervention was associated with a stepwise reduction in IV use of 71 prescribed daily doses (PDD) (95% CI: 47, 95 (p < 0.001)).", [["a stepwise reduction", "TREATMENT", 82, 102], ["CI", "TEST", 153, 155]]], ["There was also an indication of smaller reduction in IV use associated with intervention 4, but only the intervention 1 effect was robust to model uncertainty.", [["smaller reduction", "PROBLEM", 32, 49], ["IV use", "TREATMENT", 53, 59], ["intervention", "TREATMENT", 76, 88], ["indication of", "UNCERTAINTY", 18, 31], ["smaller", "OBSERVATION_MODIFIER", 32, 39], ["reduction", "OBSERVATION_MODIFIER", 40, 49], ["IV use", "OBSERVATION_MODIFIER", 53, 59]]], ["The overall use of QUIN was also significantly reduced (figure) with a large stepwise reduction of 107 PDD (95% CI: 58, 156) associated with intervention 2.Conclusions:This study showed that the hospital-wide use of QUIN can be significantly improved (and decreased) by an active policy consisting of multiple interventions.", [["QUIN", "CHEMICAL", 19, 23], ["PDD", "DISEASE", 103, 106], ["QUIN", "CHEMICAL", 216, 220], ["QUIN", "CHEMICAL", 19, 23], ["QUIN", "CHEMICAL", 216, 220], ["QUIN", "SIMPLE_CHEMICAL", 19, 23], ["QUIN", "SIMPLE_CHEMICAL", 216, 220], ["QUIN", "TREATMENT", 19, 23], ["a large stepwise reduction", "TREATMENT", 69, 95], ["CI", "TEST", 112, 114], ["intervention", "TREATMENT", 141, 153], ["This study", "TEST", 168, 178], ["QUIN", "TREATMENT", 216, 220], ["multiple interventions", "TREATMENT", 301, 323], ["large", "OBSERVATION_MODIFIER", 71, 76], ["significantly", "OBSERVATION_MODIFIER", 228, 241], ["improved", "OBSERVATION_MODIFIER", 242, 250], ["active", "OBSERVATION_MODIFIER", 273, 279], ["multiple", "OBSERVATION_MODIFIER", 301, 309]]], ["Marwick\u00b0, J. Broomhall, C. McCowan, S. Gonzalez-McQuire, K. Akhras, S. Merchant, P. Davey (Dundee, High Wycombe, UK; Raritan, US) Aim and Objectives: to describe the antibiotic treatment and outcomes stratified by severity in a representative sample of adult patients aged 18 or older who were treated in hospital for skin and soft tissue infections. inadequate.", [["skin", "ANATOMY", 318, 322], ["soft tissue", "ANATOMY", 327, 338], ["skin and soft tissue infections", "DISEASE", 318, 349], ["patients", "ORGANISM", 259, 267], ["skin", "ORGAN", 318, 322], ["soft tissue", "TISSUE", 327, 338], ["patients", "SPECIES", 259, 267], ["the antibiotic treatment", "TREATMENT", 162, 186], ["skin and soft tissue infections", "PROBLEM", 318, 349], ["skin", "ANATOMY", 318, 322], ["soft tissue", "ANATOMY", 327, 338], ["infections", "OBSERVATION", 339, 349]]], ["We also judged that 43% of patients received unnecessarily broad spectrum therapy.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["unnecessarily broad spectrum therapy", "TREATMENT", 45, 81]]], ["Conclusions: SSTI is common and is associated with significant mortality.", [["SSTI", "DISEASE", 13, 17], ["SSTI", "PROBLEM", 13, 17], ["SSTI", "OBSERVATION", 13, 17], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["mortality", "OBSERVATION", 63, 72]]], ["However, choice of empirical therapy is not evidence based, with significant under treatment of high risk patients.", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["empirical therapy", "TREATMENT", 19, 36]]], ["AB were mostly (16/17) prescribed by GPs and delivered by public (n = 14) or hospital pharmacies (n = 3).", [["AB", "TEST", 0, 2]]], ["Surveillance of AB use in NHs was organised in only 4 MS. In 3 countries a NH specific pharmaceutical formulary was available.", [["NH", "CHEMICAL", 75, 77]]], ["Other quality improvement initiatives in NHs such as regular training of prescribers, promoting microbiological sampling, collection of antimicrobial resistance profiles or pharmacist advice on AB prescription were scarce.", [["regular training of prescribers", "TREATMENT", 53, 84], ["microbiological sampling", "TEST", 96, 120], ["antimicrobial resistance profiles", "TREATMENT", 136, 169], ["AB prescription", "TREATMENT", 194, 209], ["antimicrobial resistance", "OBSERVATION", 136, 160]]], ["Guidelines for AB treatment of most frequent infections were available in many countries but were focussing on ambulatory care and did not consider the specific NH situation.", [["infections", "DISEASE", 45, 55], ["NH", "CHEMICAL", 161, 163], ["AB treatment", "TREATMENT", 15, 27], ["most frequent infections", "PROBLEM", 31, 55], ["ambulatory care", "TREATMENT", 111, 126]]], ["Only in 1 country the presence of an infection control practitioner was compulsory and partnership with hospital infection control teams was legally imposed in 3 MS. Conclusion: Important structural, functional and regulatory NH differences exist between EU countries.", [["infection", "DISEASE", 37, 46], ["infection", "DISEASE", 113, 122], ["an infection control practitioner", "PROBLEM", 34, 67], ["hospital infection control teams", "TREATMENT", 104, 136], ["infection", "OBSERVATION", 37, 46]]], ["Specific tools to improve infection prevention and AB therapy in NHs should take into account these differences.", [["infection", "DISEASE", 26, 35], ["infection prevention", "TREATMENT", 26, 46], ["AB therapy", "TREATMENT", 51, 61], ["infection", "OBSERVATION", 26, 35]]], ["A European NH network was created in the framework of the ESAC NH subproject, which will organise point prevalence surveys on AB use in 2009.O301 Cohort study of adult patients with complicated skin and soft-tissue infectionsC.CTX-Ms for ever O304 Emergence of CTX-M type ESBLs among urinary tractEscherichia coli in south-western Finland J. Jalava\u00b0, O. Meurman, H. Marttila, A. Hakanen, M. Lindgren, K. Rantakokko-Jalava (Turku, FI) Objectives: Extended-spectrum betalactamases (ESBLs), especially enzymes of the CTX-M group, are spreading rapidly in Europe.", [["skin", "ANATOMY", 194, 198], ["soft-tissue", "ANATOMY", 203, 214], ["urinary tract", "ANATOMY", 284, 297], ["skin and soft-tissue infectionsC", "DISEASE", 194, 226], ["CTX", "CHEMICAL", 227, 230], ["CTX", "CHEMICAL", 261, 264], ["urinary tract", "DISEASE", 284, 297], ["CTX", "CHEMICAL", 514, 517], ["patients", "ORGANISM", 168, 176], ["skin", "ORGAN", 194, 198], ["soft-", "CANCER", 203, 208], ["tissue", "TISSUE", 208, 214], ["CTX-M type ESBLs", "GENE_OR_GENE_PRODUCT", 261, 277], ["urinary tract", "ORGANISM_SUBDIVISION", 284, 297], ["Escherichia coli", "ORGANISM", 297, 313], ["spectrum betalactamases", "SIMPLE_CHEMICAL", 455, 478], ["ESBLs", "GENE_OR_GENE_PRODUCT", 480, 485], ["CTX-M", "GENE_OR_GENE_PRODUCT", 514, 519], ["ESBLs", "PROTEIN", 480, 485], ["patients", "SPECIES", 168, 176], ["Escherichia coli", "SPECIES", 297, 313], ["M group", "SPECIES", 518, 525], ["Escherichia coli", "SPECIES", 297, 313], ["A European NH network", "TREATMENT", 0, 21], ["Cohort study", "TEST", 146, 158], ["complicated skin and soft-tissue infectionsC", "PROBLEM", 182, 226], ["CTX", "TEST", 227, 230], ["CTX", "TEST", 261, 264], ["type ESBLs among urinary tract", "PROBLEM", 267, 297], ["Escherichia coli", "PROBLEM", 297, 313], ["ESBLs", "PROBLEM", 480, 485], ["enzymes", "TEST", 499, 506], ["the CTX", "TEST", 510, 517], ["skin", "ANATOMY", 194, 198], ["soft-tissue", "OBSERVATION_MODIFIER", 203, 214], ["infectionsC", "OBSERVATION", 215, 226], ["urinary tract", "ANATOMY", 284, 297], ["coli", "OBSERVATION", 309, 313], ["spreading", "OBSERVATION_MODIFIER", 531, 540], ["rapidly", "OBSERVATION_MODIFIER", 541, 548]]], ["Enterobacteriaceae with reduced susceptibility to third generation cephalosporins and a positive ESBL confirmatory test are also increasing in Southwest Finland.", [["cephalosporins", "CHEMICAL", 67, 81], ["cephalosporins", "CHEMICAL", 67, 81], ["ESBL", "PROTEIN", 97, 101], ["Enterobacteriaceae", "PROBLEM", 0, 18], ["reduced susceptibility", "PROBLEM", 24, 46], ["third generation cephalosporins", "TREATMENT", 50, 81], ["a positive ESBL confirmatory test", "TEST", 86, 119], ["reduced", "OBSERVATION_MODIFIER", 24, 31]]], ["The purpose of this work was to study the resistance genetics of these ESBL-positive Enterobacteriaceae.", [["ESBL", "GENE_OR_GENE_PRODUCT", 71, 75], ["these ESBL", "TEST", 65, 75], ["positive Enterobacteriaceae", "PROBLEM", 76, 103], ["ESBL", "OBSERVATION", 71, 75], ["positive Enterobacteriaceae", "OBSERVATION", 76, 103]]], ["Methods: The study comprises a total of 271 clinical Enterobacteriaceae strains isolated from both inpatient and outpatient specimens.", [["specimens", "ANATOMY", 124, 133], ["The study", "TEST", 9, 18], ["clinical Enterobacteriaceae strains", "PROBLEM", 44, 79], ["outpatient specimens", "TEST", 113, 133]]], ["All Enterobacteriaceae strains that were ESBL confirmatory test positive between January 2004 and December 2008 were included in this study (263 Escherichia coli, 8 Klebsiella pneumoniae, one isolate per patient).", [["Klebsiella pneumoniae", "DISEASE", 165, 186], ["Escherichia coli", "ORGANISM", 145, 161], ["Klebsiella pneumoniae", "ORGANISM", 165, 186], ["patient", "ORGANISM", 204, 211], ["Escherichia coli", "SPECIES", 145, 161], ["Klebsiella pneumoniae", "SPECIES", 165, 186], ["patient", "SPECIES", 204, 211], ["Escherichia coli", "SPECIES", 145, 161], ["Klebsiella pneumoniae", "SPECIES", 165, 186], ["All Enterobacteriaceae strains", "PROBLEM", 0, 30], ["ESBL confirmatory test", "TEST", 41, 63], ["this study", "TEST", 129, 139], ["Escherichia coli", "TEST", 145, 161], ["8 Klebsiella pneumoniae", "PROBLEM", 163, 186], ["Enterobacteriaceae strains", "OBSERVATION", 4, 30]]], ["Of these strains, 225 (83%) were urine isolates.", [["urine", "ANATOMY", 33, 38], ["urine", "ORGANISM_SUBSTANCE", 33, 38], ["these strains", "TEST", 3, 16], ["urine isolates", "TEST", 33, 47], ["strains", "OBSERVATION_MODIFIER", 9, 16]]], ["Resistance determinations were done using disk diffusion method (CLSI) or Vitek 2 and ESBL confirmations by the double disk method using cefotaxime and ceftatzidime with and without clavulanate.", [["cefotaxime", "CHEMICAL", 137, 147], ["ceftatzidime", "CHEMICAL", 152, 164], ["clavulanate", "CHEMICAL", 182, 193], ["cefotaxime", "CHEMICAL", 137, 147], ["ceftatzidime", "CHEMICAL", 152, 164], ["clavulanate", "CHEMICAL", 182, 193], ["cefotaxime", "SIMPLE_CHEMICAL", 137, 147], ["ceftatzidime", "SIMPLE_CHEMICAL", 152, 164], ["clavulanate", "SIMPLE_CHEMICAL", 182, 193], ["Resistance determinations", "TEST", 0, 25], ["disk diffusion method", "TEST", 42, 63], ["Vitek", "TEST", 74, 79], ["ESBL confirmations", "TEST", 86, 104], ["the double disk method", "TREATMENT", 108, 130], ["cefotaxime", "TREATMENT", 137, 147], ["ceftatzidime", "TREATMENT", 152, 164], ["clavulanate", "TREATMENT", 182, 193]]], ["Thus far, 219 strains (those collected by end of June 2008) have been analysed for the presence of the most important ESBL genes (TEM, SHV and CTX-M) using PCR and pyrosequencing as described before (Haanpera et al. AAC, 52:2632; 2008) .", [["ESBL", "GENE_OR_GENE_PRODUCT", 118, 122], ["CTX-M", "GENE_OR_GENE_PRODUCT", 143, 148], ["ESBL genes", "DNA", 118, 128], ["TEM", "DNA", 130, 133], ["SHV", "DNA", 135, 138], ["CTX", "DNA", 143, 146], ["CTX", "TEST", 143, 146], ["PCR and pyrosequencing", "TREATMENT", 156, 178]]], ["Results: In 2004 only 10 ESBL-positive strains were found.", [["ESBL", "GENE_OR_GENE_PRODUCT", 25, 29], ["ESBL", "TEST", 25, 29], ["positive strains", "PROBLEM", 30, 46]]], ["All of them harboured a CTX-M type ESBL gene.", [["CTX", "CHEMICAL", 24, 27], ["CTX-M type ESBL", "GENE_OR_GENE_PRODUCT", 24, 39], ["CTX-M type ESBL gene", "DNA", 24, 44], ["a CTX", "TEST", 22, 27], ["ESBL gene", "OBSERVATION", 35, 44]]], ["Since then, the number ESBLproducing Enterobacteriaceae strains has increased significantly being tenfold in 2008 compared to year 2004 (Figure) .", [["Enterobacteriaceae strains", "PROBLEM", 37, 63], ["Enterobacteriaceae strains", "OBSERVATION", 37, 63], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["significantly", "OBSERVATION_MODIFIER", 78, 91]]], ["A high majority, 197 (90%) of the 219 strains analysed thus far had a CTX-M-type ESBL gene.", [["CTX", "CHEMICAL", 70, 73], ["CTX-M-type ESBL", "GENE_OR_GENE_PRODUCT", 70, 85], ["CTX-M-type ESBL gene", "DNA", 70, 90], ["the 219 strains", "TEST", 30, 45], ["a CTX", "TEST", 68, 73], ["high", "OBSERVATION_MODIFIER", 2, 6], ["ESBL gene", "OBSERVATION", 81, 90]]], ["Most of those (79%) belonged to the CTX-M-1 group according to the pyrosequencing results.", [["CTX-M-1", "CHEMICAL", 36, 43], ["CTX-M-1", "GENE_OR_GENE_PRODUCT", 36, 43], ["the CTX", "TEST", 32, 39]]], ["CTX-M-9 group was the next common, with 20% of the CTX-M genes belonging to this group.", [["CTX-M-9", "CHEMICAL", 0, 7], ["CTX-M-9", "GENE_OR_GENE_PRODUCT", 0, 7], ["CTX-M", "GENE_OR_GENE_PRODUCT", 51, 56], ["CTX-M genes", "DNA", 51, 62], ["CTX", "TEST", 0, 3], ["the CTX", "TREATMENT", 47, 54]]], ["Only two strains with CTX-M group 2 enzyme were found.", [["CTX", "CHEMICAL", 22, 25], ["CTX-M group 2", "GENE_OR_GENE_PRODUCT", 22, 35], ["CTX", "TEST", 22, 25], ["M group 2 enzyme", "TEST", 26, 42], ["two", "OBSERVATION_MODIFIER", 5, 8], ["strains", "OBSERVATION_MODIFIER", 9, 16]]], ["Conclusions: Enterobacteriaceae strains which produce ESBL are increasing rapidly in Southwest Finland.", [["Enterobacteriaceae strains", "ORGANISM", 13, 39], ["ESBL", "GENE_OR_GENE_PRODUCT", 54, 58], ["Enterobacteriaceae strains", "PROBLEM", 13, 39], ["ESBL", "PROBLEM", 54, 58], ["Enterobacteriaceae strains", "OBSERVATION", 13, 39], ["ESBL", "OBSERVATION", 54, 58], ["increasing", "OBSERVATION_MODIFIER", 63, 73], ["rapidly", "OBSERVATION_MODIFIER", 74, 81], ["Southwest", "OBSERVATION_MODIFIER", 85, 94]]], ["This is especially true with E. coli strains isolated from urine.", [["urine", "ANATOMY", 59, 64], ["E. coli", "ORGANISM", 29, 36], ["urine", "ORGANISM_SUBSTANCE", 59, 64], ["E. coli", "SPECIES", 29, 36], ["E. coli", "SPECIES", 29, 36], ["E. coli strains isolated from urine", "PROBLEM", 29, 64], ["coli strains", "OBSERVATION", 32, 44]]], ["Towards the end of the study period, the ESBL enzymes were almost exclusively CTX-M, CTX-M-1 group being the most common.", [["ESBL enzymes", "GENE_OR_GENE_PRODUCT", 41, 53], ["CTX-M-1", "GENE_OR_GENE_PRODUCT", 85, 92], ["ESBL enzymes", "PROTEIN", 41, 53], ["the study", "TEST", 19, 28], ["the ESBL enzymes", "TEST", 37, 53], ["CTX", "TEST", 78, 81], ["CTX", "TEST", 85, 88], ["most common", "OBSERVATION_MODIFIER", 109, 120]]], ["Further research is needed to characterise genetic elements that carry these ESBL genes.CTX-Ms for ever O304 Emergence of CTX-M type ESBLs among urinary tractESBL strains and the proportion of CTX-M genes in 2004-2008.", [["urinary tractESBL strains", "ANATOMY", 145, 170], ["CTX", "CHEMICAL", 88, 91], ["CTX", "CHEMICAL", 122, 125], ["ESBL", "GENE_OR_GENE_PRODUCT", 77, 81], ["CTX-M type ESBLs", "GENE_OR_GENE_PRODUCT", 122, 138], ["CTX-M", "GENE_OR_GENE_PRODUCT", 193, 198], ["ESBL genes", "DNA", 77, 87], ["CTX-M genes", "DNA", 193, 204], ["these ESBL genes", "PROBLEM", 71, 87], ["CTX", "TEST", 88, 91], ["CTX", "TEST", 122, 125], ["type ESBLs", "PROBLEM", 128, 138], ["urinary tractESBL strains", "PROBLEM", 145, 170], ["CTX", "TEST", 193, 196], ["ESBL genes", "OBSERVATION", 77, 87], ["urinary tractESBL", "ANATOMY", 145, 162]]], ["(2000) (2001) (2002) (2003) (2004) (2005) (2006) in France (n = 6), Spain (n = 4), Portugal (n = 6), UK (n = 11), Kuwait (n = 2), Canada (n = 13) and China (n = 10), including Hong Kong (n = 3) were studied.", [["Portugal (n", "TEST", 83, 94], ["UK (n", "TEST", 101, 106], ["Kuwait (n", "TEST", 114, 123], ["Canada (n", "TEST", 130, 139], ["China (n", "TEST", 150, 158]]], ["Clonality was established by PFGE and phylogenetic groups of EC and KP were determined as reported.", [["EC", "ANATOMY", 61, 63], ["EC", "CELL", 61, 63], ["KP", "SIMPLE_CHEMICAL", 68, 70], ["EC", "CELL_TYPE", 61, 63], ["Clonality", "TEST", 0, 9], ["EC", "TEST", 61, 63]]], ["Susceptibility testing (CLSI), blaCTX-M-14 transferability and location (I-Ceu-I/S1 nuclease) were investigated.", [["Ceu-I", "GENE_OR_GENE_PRODUCT", 75, 80], ["Ceu", "DNA", 75, 78], ["Susceptibility testing", "TEST", 0, 22], ["CLSI", "TEST", 24, 28], ["blaCTX", "TEST", 31, 37], ["Ceu-I/S1 nuclease", "TREATMENT", 75, 92]]], ["Plasmid analysis included determination of Inc group (PCR-replicon typing, hybridisation, sequencing) and comparison of RFLP patterns.", [["Inc", "GENE_OR_GENE_PRODUCT", 43, 46], ["Inc group", "DNA", 43, 52], ["RFLP", "DNA", 120, 124], ["Plasmid analysis", "TEST", 0, 16], ["Inc group (PCR", "TREATMENT", 43, 57], ["replicon typing", "TREATMENT", 58, 73], ["RFLP patterns", "TEST", 120, 133]]], ["Association of blaCTX-M-14 with ISEcp1, ISEcp1-IS10 or ISCR1 was established by PCR and sequencing.Results:We identified 42 PFGE types among 52 isolates: 38/47 EC, 3/4 KP and 1/1 CF.", [["EC", "ANATOMY", 160, 162], ["blaCTX-M-14", "GENE_OR_GENE_PRODUCT", 15, 26], ["ISEcp1", "GENE_OR_GENE_PRODUCT", 32, 38], ["ISEcp1-IS10", "GENE_OR_GENE_PRODUCT", 40, 51], ["ISCR1", "GENE_OR_GENE_PRODUCT", 55, 60], ["EC", "CELL", 160, 162], ["blaCTX-M-14", "DNA", 15, 26], ["ISEcp1", "DNA", 32, 38], ["ISEcp1", "DNA", 40, 46], ["IS10", "DNA", 47, 51], ["ISCR1", "DNA", 55, 60], ["blaCTX", "TEST", 15, 21], ["ISEcp1", "TEST", 32, 38], ["ISEcp1", "TEST", 40, 46], ["ISCR1", "PROBLEM", 55, 60], ["PCR", "TEST", 80, 83], ["PFGE types", "TEST", 124, 134], ["isolates", "TEST", 144, 152], ["EC", "TEST", 160, 162], ["KP", "TEST", 168, 170]]], ["Distribution among phylogroups were as follows: i) EC: A (n = 7), B1 (n = 3), B2 (n = 5) and D (n = 23), and ii) KP: KpI (n = 2) and KpII (n = 1).", [["EC", "ANATOMY", 51, 53], ["EC", "CELL", 51, 53], ["B1", "PROTEIN", 66, 68], ["B2", "PROTEIN", 78, 80], ["B1", "TEST", 66, 68], ["B2", "TEST", 78, 80], ["D (n", "TEST", 93, 97], ["KpI", "TEST", 117, 120], ["KpII", "TEST", 133, 137]]], ["Resistance to tetracycline (76%), nalidixic (74%), streptomycin (67%), sulfonamides (67%), ciprofloxacin (60%) and trimetroprim (43%) was common. were spreading horizontally in our hospitals and, here, we characterised the plasmids responsible in the major K. pneumoniae strains identified during the survey.", [["plasmids", "ANATOMY", 223, 231], ["tetracycline", "CHEMICAL", 14, 26], ["nalidixic", "CHEMICAL", 34, 43], ["streptomycin", "CHEMICAL", 51, 63], ["sulfonamides", "CHEMICAL", 71, 83], ["ciprofloxacin", "CHEMICAL", 91, 104], ["trimetroprim", "CHEMICAL", 115, 127], ["tetracycline", "CHEMICAL", 14, 26], ["nalidixic", "CHEMICAL", 34, 43], ["streptomycin", "CHEMICAL", 51, 63], ["sulfonamides", "CHEMICAL", 71, 83], ["ciprofloxacin", "CHEMICAL", 91, 104], ["trimetroprim", "CHEMICAL", 115, 127], ["tetracycline", "SIMPLE_CHEMICAL", 14, 26], ["nalidixic", "SIMPLE_CHEMICAL", 34, 43], ["streptomycin", "SIMPLE_CHEMICAL", 51, 63], ["sulfonamides", "SIMPLE_CHEMICAL", 71, 83], ["ciprofloxacin", "SIMPLE_CHEMICAL", 91, 104], ["trimetroprim", "SIMPLE_CHEMICAL", 115, 127], ["K. pneumoniae", "ORGANISM", 257, 270], ["plasmids", "DNA", 223, 231], ["K. pneumoniae", "SPECIES", 257, 270], ["K. pneumoniae", "SPECIES", 257, 270], ["tetracycline", "TREATMENT", 14, 26], ["nalidixic", "TREATMENT", 34, 43], ["streptomycin", "TREATMENT", 51, 63], ["sulfonamides", "TREATMENT", 71, 83], ["ciprofloxacin", "TREATMENT", 91, 104], ["trimetroprim", "TREATMENT", 115, 127], ["the plasmids", "PROBLEM", 219, 231], ["pneumoniae strains", "PROBLEM", 260, 278], ["horizontally", "OBSERVATION_MODIFIER", 161, 173], ["pneumoniae", "OBSERVATION", 260, 270]]], ["Methods: Plasmids from representative K. pneumoniae strains with CTX-M-15 enzyme were extracted by alkaline lysis and compared by ApaI, PstI and EcoRI restriction analysis.", [["CTX", "CHEMICAL", 65, 68], ["K. pneumoniae", "ORGANISM", 38, 51], ["CTX-M-15", "GENE_OR_GENE_PRODUCT", 65, 73], ["ApaI", "GENE_OR_GENE_PRODUCT", 130, 134], ["PstI", "GENE_OR_GENE_PRODUCT", 136, 140], ["EcoRI", "GENE_OR_GENE_PRODUCT", 145, 150], ["CTX-M-15 enzyme", "PROTEIN", 65, 80], ["K. pneumoniae", "SPECIES", 38, 51], ["K. pneumoniae", "SPECIES", 38, 51], ["pneumoniae strains", "PROBLEM", 41, 59], ["CTX", "TEST", 65, 68], ["enzyme", "TEST", 74, 80], ["alkaline lysis", "TREATMENT", 99, 113], ["ApaI", "TEST", 130, 134], ["PstI", "TEST", 136, 140], ["EcoRI restriction analysis", "TEST", 145, 171], ["alkaline lysis", "OBSERVATION", 99, 113]]], ["They were transferred into E. coli DH5a by electroporation.", [["E. coli", "ORGANISM", 27, 34], ["DH5a", "ORGANISM", 35, 39], ["E. coli", "SPECIES", 27, 34], ["E. coli", "SPECIES", 27, 34], ["coli DH5a", "OBSERVATION", 30, 39]]], ["Transformants were selected on cefotaxime-containing agar and were screened by PCR for beta-lactamase genes, the aminoglycoside resistance genes aac(6 )-Ib and aac3-IIb, and the plasmid-mediated quinolone resistance genes qnrA/B/S. Results: Twelve isolates were characterised, representing 5 major strains (A-D, and F) found in the most-affected hospitals.", [["Transformants", "ANATOMY", 0, 13], ["cefotaxime", "CHEMICAL", 31, 41], ["aminoglycoside", "CHEMICAL", 113, 127], ["quinolone", "CHEMICAL", 195, 204], ["cefotaxime", "CHEMICAL", 31, 41], ["aminoglycoside", "CHEMICAL", 113, 127], ["quinolone", "CHEMICAL", 195, 204], ["Transformants", "CELL", 0, 13], ["cefotaxime", "SIMPLE_CHEMICAL", 31, 41], ["beta-lactamase", "GENE_OR_GENE_PRODUCT", 87, 101], ["aminoglycoside", "SIMPLE_CHEMICAL", 113, 127], ["aac(6 )-Ib", "GENE_OR_GENE_PRODUCT", 145, 155], ["aac3-IIb", "GENE_OR_GENE_PRODUCT", 160, 168], ["quinolone", "SIMPLE_CHEMICAL", 195, 204], ["A-D", "CELL", 307, 310], ["beta-lactamase genes", "DNA", 87, 107], ["aminoglycoside resistance genes aac(6 )-Ib", "DNA", 113, 155], ["aac3", "DNA", 160, 164], ["IIb", "DNA", 165, 168], ["plasmid", "DNA", 178, 185], ["quinolone resistance genes", "DNA", 195, 221], ["qnrA", "DNA", 222, 226], ["B", "DNA", 227, 228], ["cefotaxime", "TREATMENT", 31, 41], ["agar", "TREATMENT", 53, 57], ["PCR", "TEST", 79, 82], ["beta-lactamase genes", "TEST", 87, 107], ["the aminoglycoside resistance genes", "TEST", 109, 144], ["aac", "TEST", 145, 148], ["Ib", "TEST", 153, 155], ["aac3", "TEST", 160, 164], ["the plasmid-mediated quinolone resistance genes", "TREATMENT", 174, 221], ["Twelve isolates", "TEST", 241, 256], ["IIb", "ANATOMY", 165, 168]]], ["Restriction analysis divided their plasmids into several groups.", [["plasmids", "ANATOMY", 35, 43], ["plasmids", "DNA", 35, 43], ["Restriction analysis", "TEST", 0, 20]]], ["Representatives of strain A (n = 4) had essentially the same plasmid (group 1), as did the two representatives of strain D (group 2a).", [["plasmid", "DNA", 61, 68]]], ["One strain F isolate had a plasmid (group 2b) very similar to plasmid 2a from strain D, indicating possible horizontal transfer.", [["plasmid", "ANATOMY", 27, 34], ["plasmid", "DNA", 27, 34], ["plasmid 2a", "DNA", 62, 72], ["a plasmid (group 2b", "TREATMENT", 25, 44], ["possible", "UNCERTAINTY", 99, 107]]], ["Plasmids of group 3 were retrieved from representatives of strains B and C, again indicating probable transfer.", [["B", "CELL", 67, 68], ["C", "CELL", 73, 74], ["strains B and C", "PROBLEM", 59, 74]]], ["Plasmids from three other strains differed substantially from each other and from plasmids 1, 2a, 2b and 3.", [["3", "GENE_OR_GENE_PRODUCT", 105, 106], ["plasmids 1, 2a, 2b and 3", "DNA", 82, 106], ["Plasmids", "TREATMENT", 0, 8]]], ["Nevertheless, on all plasmids, blaCTX-M genes were linked to an upstream ISEcp1 element, known to be involved in their mobilisation.", [["plasmids", "ANATOMY", 21, 29], ["blaCTX-M", "GENE_OR_GENE_PRODUCT", 31, 39], ["ISEcp1", "GENE_OR_GENE_PRODUCT", 73, 79], ["plasmids", "DNA", 21, 29], ["blaCTX-M genes", "DNA", 31, 45], ["upstream ISEcp1 element", "DNA", 64, 87], ["all plasmids", "TREATMENT", 17, 29]]], ["All encoded multi-resistance: all but one group 1 and one ungrouped plasmid carried aac(6 )-Ib; blaOXA-1 and aac(3)-IIa were detected on all except group 1 plasmids; blaTEM was found on group 1, 2b, one group 3 and two ungrouped plasmids. blaSHV and qnrA/B/S genes were not detected.Conclusion:The considerable diversity of plasmids encoding CTX-M-15 enzyme in major Slovenian K. pneumoniae strains suggested only limited transfer, even when multiple strains were present in the same hospital.", [["plasmid", "ANATOMY", 68, 75], ["plasmids", "ANATOMY", 156, 164], ["plasmids", "ANATOMY", 229, 237], ["plasmids", "ANATOMY", 324, 332], ["CTX-M-15", "CHEMICAL", 342, 350], ["aac(6 )-Ib", "GENE_OR_GENE_PRODUCT", 84, 94], ["blaOXA-1", "GENE_OR_GENE_PRODUCT", 96, 104], ["aac(3)-IIa", "GENE_OR_GENE_PRODUCT", 109, 119], ["blaTEM", "GENE_OR_GENE_PRODUCT", 166, 172], ["blaSHV", "GENE_OR_GENE_PRODUCT", 239, 245], ["qnrA", "GENE_OR_GENE_PRODUCT", 250, 254], ["B", "GENE_OR_GENE_PRODUCT", 255, 256], ["S", "GENE_OR_GENE_PRODUCT", 257, 258], ["CTX-M-15", "GENE_OR_GENE_PRODUCT", 342, 350], ["K. pneumoniae", "ORGANISM", 377, 390], ["ungrouped plasmid", "DNA", 58, 75], ["aac(6 )-Ib", "DNA", 84, 94], ["blaOXA-1", "DNA", 96, 104], ["aac(3)-IIa", "DNA", 109, 119], ["group 1 plasmids", "DNA", 148, 164], ["blaTEM", "DNA", 166, 172], ["ungrouped plasmids", "DNA", 219, 237], ["blaSHV and qnrA/B/S genes", "DNA", 239, 264], ["plasmids", "DNA", 324, 332], ["CTX-M-15 enzyme", "PROTEIN", 342, 357], ["K. pneumoniae", "SPECIES", 377, 390], ["blaSHV", "SPECIES", 239, 245], ["K. pneumoniae", "SPECIES", 377, 390], ["blaOXA", "TEST", 96, 102], ["aac", "TEST", 109, 112], ["IIa", "PROBLEM", 116, 119], ["blaTEM", "PROBLEM", 166, 172], ["two ungrouped plasmids", "TREATMENT", 215, 237], ["blaSHV", "TEST", 239, 245], ["qnrA/B/S genes", "TEST", 250, 264], ["CTX", "TEST", 342, 345], ["pneumoniae strains", "PROBLEM", 380, 398], ["multiple strains", "PROBLEM", 442, 458], ["multi-resistance", "OBSERVATION", 12, 28], ["IIa", "ANATOMY", 116, 119]]], ["Evidence of plasmid transfer was between strains B and C, and possibly between strains D and F, although these plasmids were not strictly identical.", [["plasmid", "ANATOMY", 12, 19], ["plasmids", "ANATOMY", 111, 119], ["B", "GENE_OR_GENE_PRODUCT", 49, 50], ["C", "CELL", 55, 56], ["plasmids", "DNA", 111, 119], ["plasmid transfer", "PROBLEM", 12, 28], ["strains B and C", "PROBLEM", 41, 56], ["strains D and F", "PROBLEM", 79, 94], ["these plasmids", "TREATMENT", 105, 119], ["plasmid", "OBSERVATION", 12, 19]]], ["Analysis of resistance genes encoded by the plasmids revealed diversity, with groupings coinciding largely with those based on restriction profiles.O307 Regional study of the genetic context of class 1 integron harbouring blaCTX-M-2 linked to ISCR1 in nosocomial Klebsiella pneumoniae isolates from Uruguay, Argentina and ChileA.", [["plasmids", "ANATOMY", 44, 52], ["nosocomial Klebsiella pneumoniae", "DISEASE", 252, 284], ["blaCTX-M-2", "GENE_OR_GENE_PRODUCT", 222, 232], ["ISCR1", "GENE_OR_GENE_PRODUCT", 243, 248], ["nosocomial Klebsiella pneumoniae", "ORGANISM", 252, 284], ["resistance genes", "DNA", 12, 28], ["plasmids", "DNA", 44, 52], ["class 1 integron", "DNA", 194, 210], ["blaCTX-M-2", "DNA", 222, 232], ["ISCR1", "DNA", 243, 248], ["Klebsiella pneumoniae", "SPECIES", 263, 284], ["class 1", "SPECIES", 194, 201], ["Klebsiella pneumoniae", "SPECIES", 263, 284], ["resistance genes", "PROBLEM", 12, 28], ["the plasmids", "TREATMENT", 40, 52], ["diversity", "PROBLEM", 62, 71], ["Regional study", "TEST", 153, 167], ["blaCTX", "TEST", 222, 228], ["ISCR1", "TEST", 243, 248], ["nosocomial Klebsiella pneumoniae isolates", "PROBLEM", 252, 293], ["resistance genes", "OBSERVATION", 12, 28], ["nosocomial", "OBSERVATION", 252, 262], ["Klebsiella pneumoniae", "OBSERVATION", 263, 284], ["ChileA", "ANATOMY", 322, 328]]], ["Ingold, G. Borthagaray, A.K. Merkier, D. Centr\u00f3n, H. Bello, C.M. M\u00e1rquez\u00b0(Montevideo, UY; Buenos Aires, AR; Concepci\u00f3n, CL) Objectives: To examine the genetic context of class 1 integron harbouring blaCTX-M-2 in fifteen nosocomial K. pneumoniae isolates from South America in order to enhance the understanding of the antibiotic resistance spread among the region.", [["blaCTX-M-2", "GENE_OR_GENE_PRODUCT", 198, 208], ["K. pneumoniae", "ORGANISM", 231, 244], ["K. pneumoniae", "SPECIES", 231, 244], ["class 1", "SPECIES", 170, 177], ["K. pneumoniae", "SPECIES", 231, 244], ["AR", "PROBLEM", 104, 106], ["pneumoniae isolates", "PROBLEM", 234, 253], ["the antibiotic resistance spread", "TREATMENT", 314, 346], ["antibiotic resistance", "OBSERVATION", 318, 339]]], ["Methods: DNA was extracted with the use of AxyPrepTM Bacterial Genomic DNA Miniprep Kit.", [["DNA", "CELLULAR_COMPONENT", 9, 12], ["AxyPrepTM", "TREATMENT", 43, 52]]], ["The analysis of the cassette array was carried out with the use of primers HS458/HS459 targeting adjacent conserved regions.", [["HS459", "GENE_OR_GENE_PRODUCT", 81, 86], ["primers HS458", "DNA", 67, 80], ["HS459", "DNA", 81, 86], ["adjacent conserved regions", "DNA", 97, 123], ["The analysis", "TEST", 0, 12], ["the cassette array", "TEST", 16, 34], ["primers HS458", "TEST", 67, 80]]], ["The examination of the surroundings were performed using two PCR primer pairs, HS817/HS818 and HS825/HS826, to amplify the initial(IRi) and the terminal(IRt), inverted repeat boundary, respectively.", [["PCR primer pairs", "DNA", 61, 77], ["HS818", "DNA", 85, 90], ["HS825", "DNA", 95, 100], ["HS826", "DNA", 101, 106], ["IRi", "DNA", 131, 134], ["IRt", "DNA", 153, 156], ["inverted repeat boundary", "DNA", 159, 183], ["The examination", "TEST", 0, 15], ["two PCR primer pairs", "TEST", 57, 77], ["HS825", "TEST", 95, 100], ["inverted repeat boundary", "TREATMENT", 159, 183], ["terminal", "OBSERVATION_MODIFIER", 144, 152]]], ["The primer pair HS825/HS911 was used whenever a negative result was obtained with HS825/HS826.", [["HS825", "CHEMICAL", 16, 21], ["HS911", "CHEMICAL", 22, 27], ["HS825", "CHEMICAL", 82, 87], ["HS825", "CHEMICAL", 82, 87], ["HS826", "CHEMICAL", 88, 93], ["HS911", "DNA", 22, 27], ["The primer pair HS825/HS911", "TEST", 0, 27]]], ["All PCR products were purified and sequenced and the data was analyzed with NCBI Blast Tool.Results:The sequence obtained with primers HS817/HS818 revealed the presence of three different transposons backbones at the IRi end.", [["PCR products", "DNA", 4, 16], ["HS817", "DNA", 135, 140], ["HS818", "DNA", 141, 146], ["IRi end", "DNA", 217, 224], ["All PCR products", "TREATMENT", 0, 16], ["the data", "TEST", 49, 57], ["The sequence", "TEST", 100, 112], ["primers HS817", "TEST", 127, 140], ["transposons backbones", "OBSERVATION", 188, 209]]], ["The Tn5036-like module and the Tn21-like module were present in 4 isolates, the Tn1696-like module was present in 7 isolates.", [["Tn5036", "GENE_OR_GENE_PRODUCT", 4, 10], ["Tn21", "GENE_OR_GENE_PRODUCT", 31, 35], ["Tn1696", "GENE_OR_GENE_PRODUCT", 80, 86], ["Tn5036-like module", "DNA", 4, 22], ["Tn21-like module", "DNA", 31, 47], ["Tn1696-like module", "DNA", 80, 98], ["The Tn5036", "TEST", 0, 10], ["the Tn21-like module", "PROBLEM", 27, 47]]], ["No amplicons were obtained with the use of primers HS825/HS826 that amplify a Tn21-like insertion.", [["HS826", "GENE_OR_GENE_PRODUCT", 57, 62], ["Tn21", "GENE_OR_GENE_PRODUCT", 78, 82], ["primers HS825", "DNA", 43, 56], ["HS826", "DNA", 57, 62], ["Tn21-like insertion", "DNA", 78, 97], ["amplicons", "PROBLEM", 3, 12], ["primers HS825", "TREATMENT", 43, 56], ["a Tn21-like insertion", "TREATMENT", 76, 97]]], ["Two Uruguayan isolates with a Tn5036 boundary at the IRi end were tested with HS825/HS911 that target a Tn5036-like backbone and one generated a product consistent with a Tn5036-like mer region.", [["HS825", "CHEMICAL", 78, 83], ["HS911", "CHEMICAL", 84, 89], ["Tn5036", "GENE_OR_GENE_PRODUCT", 104, 110], ["Tn5036 boundary", "DNA", 30, 45], ["IRi end", "DNA", 53, 60], ["HS911", "DNA", 84, 89], ["Tn5036-like backbone", "DNA", 104, 124], ["Tn5036-like mer region", "DNA", 171, 193]]], ["Uruguayan isolates carried a single aadA1 cassette (4/5) and the other one contained a dfrA17-aadA5 array, while the four Argentinian isolates carried the combination aacA4-aadA1-orfD.", [["aadA1", "GENE_OR_GENE_PRODUCT", 36, 41], ["dfrA17", "GENE_OR_GENE_PRODUCT", 87, 93], ["aadA5", "GENE_OR_GENE_PRODUCT", 94, 99], ["aacA4", "GENE_OR_GENE_PRODUCT", 167, 172], ["aadA1-orfD", "GENE_OR_GENE_PRODUCT", 173, 183], ["aadA1 cassette", "DNA", 36, 50], ["dfrA17-aadA5 array", "DNA", 87, 105], ["aacA4", "PROTEIN", 167, 172], ["aadA1", "DNA", 173, 178], ["orfD", "DNA", 179, 183], ["Uruguayan isolates", "TEST", 0, 18], ["a single aadA1 cassette", "TREATMENT", 27, 50], ["a dfrA17-aadA5 array", "TREATMENT", 85, 105]]], ["Chilean isolates arrays are in process.", [["Chilean isolates arrays", "TREATMENT", 0, 23]]], ["Conclusions: Among the extended-spectrum beta-lactamases, the cefotaximases constitute a rapidly growing cluster of enzymes that have disseminated geographically.", [["cefotaximases", "CHEMICAL", 62, 75], ["cefotaximases", "SIMPLE_CHEMICAL", 62, 75], ["enzymes", "PROTEIN", 116, 123], ["the extended-spectrum beta-lactamases", "PROBLEM", 19, 56], ["the cefotaximases", "TREATMENT", 58, 75], ["a rapidly growing cluster of enzymes", "PROBLEM", 87, 123], ["disseminated", "OBSERVATION_MODIFIER", 134, 146], ["geographically", "OBSERVATION_MODIFIER", 147, 161]]], ["There is a high frequency of isolation of CTX-M-2 producing K. pneumoniae associated with a class 1 integron in the region.", [["CTX-M-2", "CHEMICAL", 42, 49], ["CTX-M-2", "GENE_OR_GENE_PRODUCT", 42, 49], ["K. pneumoniae", "ORGANISM", 60, 73], ["class 1 integron", "DNA", 92, 108], ["K. pneumoniae", "SPECIES", 60, 73], ["K. pneumoniae", "SPECIES", 60, 73], ["CTX", "TEST", 42, 45], ["K. pneumoniae", "PROBLEM", 60, 73], ["high frequency", "OBSERVATION_MODIFIER", 11, 25], ["pneumoniae", "OBSERVATION", 63, 73], ["region", "ANATOMY_MODIFIER", 116, 122]]], ["Despite being common the presence of ISCR1 linked to blaCTX-M-2 in K. pneumoniae isolates, this study provides new and relevant information in the sequence context at the IRi.", [["ISCR1", "GENE_OR_GENE_PRODUCT", 37, 42], ["blaCTX-M-2", "GENE_OR_GENE_PRODUCT", 53, 63], ["K. pneumoniae", "ORGANISM", 67, 80], ["ISCR1", "PROTEIN", 37, 42], ["IRi", "DNA", 171, 174], ["K. pneumoniae", "SPECIES", 67, 80], ["K. pneumoniae", "SPECIES", 67, 80], ["ISCR1", "PROBLEM", 37, 42], ["blaCTX", "TEST", 53, 59], ["pneumoniae isolates", "PROBLEM", 70, 89], ["this study", "TEST", 91, 101]]], ["Here we report about the cassette array diversity and the diversity of elements in which the class 1 integron are embedded.", [["class 1 integron", "DNA", 93, 109], ["the cassette array diversity", "TREATMENT", 21, 49]]], ["Different integron/transposons carrying the blaCTX-M-2 gene seem to be circulating and different regional patterns could be emerging, this study highlights the ability of different genetic elements to act cooperatively to spread and rearrange antibiotic resistance.", [["blaCTX-M-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["integron", "DNA", 10, 18], ["transposons", "DNA", 19, 30], ["blaCTX-M-2 gene", "DNA", 44, 59], ["Different integron/transposons", "TREATMENT", 0, 30], ["this study", "TEST", 134, 144], ["antibiotic resistance", "TREATMENT", 243, 264]]], ["L. Vinu\u00e9, A. Garc\u00eda-Fern\u00e1ndez, D. Fortini, P. Poeta, M.A. Moreno, C. Torres, A. Carattoli\u00b0(Logro\u00f1o, ES; Rome, IT; Vila Real, PT; Madrid, ES) Objectives: CTX-M enzymes are frequently detected in Europe.", [["CTX-M enzymes", "GENE_OR_GENE_PRODUCT", 153, 166], ["CTX-M enzymes", "TEST", 153, 166]]], ["In particular, CTX-M-1 and CTX-M-32-producing strains have been recovered from both humans and farm animals in Spain, Italy, Greece, and Portugal, suggesting the existence of community reservoirs for these enzymes.", [["CTX-M-1", "CHEMICAL", 15, 22], ["CTX-M-32", "CHEMICAL", 27, 35], ["CTX-M-1", "GENE_OR_GENE_PRODUCT", 15, 22], ["CTX-M-32", "SIMPLE_CHEMICAL", 27, 35], ["humans", "ORGANISM", 84, 90], ["enzymes", "PROTEIN", 206, 213], ["humans", "SPECIES", 84, 90], ["humans", "SPECIES", 84, 90], ["CTX", "TEST", 15, 18], ["CTX", "TEST", 27, 30], ["strains", "PROBLEM", 46, 53], ["these enzymes", "TEST", 200, 213]]], ["The aim of this study was to compare Escherichia coli strains and plasmids harbouring blaCTX-M-1 and blaCTX-M-32 genes isolated from human and animals.", [["plasmids", "ANATOMY", 66, 74], ["Escherichia coli", "ORGANISM", 37, 53], ["blaCTX-M-1", "GENE_OR_GENE_PRODUCT", 86, 96], ["blaCTX-M-32", "GENE_OR_GENE_PRODUCT", 101, 112], ["human", "ORGANISM", 133, 138], ["plasmids", "DNA", 66, 74], ["blaCTX-M-1 and blaCTX-M-32 genes", "DNA", 86, 118], ["Escherichia coli", "SPECIES", 37, 53], ["human", "SPECIES", 133, 138], ["Escherichia coli", "SPECIES", 37, 53], ["human", "SPECIES", 133, 138], ["this study", "TEST", 11, 21], ["Escherichia coli strains", "PROBLEM", 37, 61], ["plasmids", "TEST", 66, 74], ["blaCTX", "TEST", 86, 92], ["blaCTX", "TEST", 101, 107]]], ["Methods: Four E. coli CTX-M-1 and eight CTX-M-32 epidemiologically unrelated producers from sick or healthy animals (pig, dog, cow and chickens) and from humans (urine, blood and faecal samples) were analysed by XbaI-PFGE, plasmid transferability, PCR-based replicon typing, plasmid restriction analysis and Southern blot hybridisation.", [["urine", "ANATOMY", 162, 167], ["blood", "ANATOMY", 169, 174], ["faecal samples", "ANATOMY", 179, 193], ["CTX", "CHEMICAL", 40, 43], ["E. coli", "ORGANISM", 14, 21], ["CTX-M-1", "GENE_OR_GENE_PRODUCT", 22, 29], ["pig", "ORGANISM", 117, 120], ["dog", "ORGANISM", 122, 125], ["cow", "ORGANISM", 127, 130], ["chickens", "ORGANISM", 135, 143], ["humans", "ORGANISM", 154, 160], ["urine", "ORGANISM_SUBSTANCE", 162, 167], ["blood", "ORGANISM_SUBSTANCE", 169, 174], ["faecal samples", "ORGANISM_SUBSTANCE", 179, 193], ["XbaI", "GENE_OR_GENE_PRODUCT", 212, 216], ["XbaI", "DNA", 212, 216], ["E. coli", "SPECIES", 14, 21], ["pig", "SPECIES", 117, 120], ["dog", "SPECIES", 122, 125], ["cow", "SPECIES", 127, 130], ["chickens", "SPECIES", 135, 143], ["humans", "SPECIES", 154, 160], ["E. coli", "SPECIES", 14, 21], ["pig", "SPECIES", 117, 120], ["dog", "SPECIES", 122, 125], ["cow", "SPECIES", 127, 130], ["chickens", "SPECIES", 135, 143], ["humans", "SPECIES", 154, 160], ["Four E. coli CTX", "TEST", 9, 25], ["CTX", "TEST", 40, 43], ["urine", "TEST", 162, 167], ["blood and faecal samples", "TEST", 169, 193], ["XbaI", "TEST", 212, 216], ["plasmid transferability", "TEST", 223, 246], ["PCR", "TEST", 248, 251], ["replicon typing", "TREATMENT", 258, 273], ["plasmid restriction analysis", "TREATMENT", 275, 303], ["Southern blot hybridisation", "PROBLEM", 308, 335]]], ["All isolates were from Spain but the dog isolate was from Portugal.", [["dog", "ORGANISM", 37, 40], ["dog", "SPECIES", 37, 40], ["All isolates", "PROBLEM", 0, 12]]], ["The genetic context of the blaCTX-M genes was previously investigated for all the strains.O308 Escherichia coli clones and plasmid-mediated later transfer disseminate CTX-M-1 and CTX-M-32 among animals and humansResults: three CTX-M-32 strains (one from healthy chicken and two from hospitalised patients) showed the same PFGE pattern.", [["clones", "ANATOMY", 112, 118], ["plasmid", "ANATOMY", 123, 130], ["CTX-M-1", "CHEMICAL", 167, 174], ["CTX-M-32", "CHEMICAL", 179, 187], ["CTX", "CHEMICAL", 227, 230], ["blaCTX-M", "GENE_OR_GENE_PRODUCT", 27, 35], ["O308 Escherichia coli clones", "CELL", 90, 118], ["CTX-M-1", "GENE_OR_GENE_PRODUCT", 167, 174], ["CTX-M-32", "SIMPLE_CHEMICAL", 179, 187], ["animals", "ORGANISM", 194, 201], ["CTX-M-32 strains", "ORGANISM", 227, 243], ["chicken", "ORGANISM", 262, 269], ["patients", "ORGANISM", 296, 304], ["blaCTX-M genes", "DNA", 27, 41], ["Escherichia coli", "SPECIES", 95, 111], ["chicken", "SPECIES", 262, 269], ["patients", "SPECIES", 296, 304], ["Escherichia coli", "SPECIES", 95, 111], ["chicken", "SPECIES", 262, 269], ["Escherichia coli clones", "PROBLEM", 95, 118], ["plasmid", "TEST", 123, 130], ["CTX", "TEST", 167, 170], ["CTX", "TEST", 179, 182], ["humansResults", "TEST", 206, 219], ["CTX", "TEST", 227, 230], ["coli clones", "OBSERVATION", 107, 118]]], ["A chromosomal localisation of the blaCTX-M-32 gene was suspected in these strains.", [["chromosomal", "ANATOMY", 2, 13], ["chromosomal", "CELLULAR_COMPONENT", 2, 13], ["blaCTX-M-32", "GENE_OR_GENE_PRODUCT", 34, 45], ["blaCTX-M-32 gene", "DNA", 34, 50], ["A chromosomal localisation", "TEST", 0, 26], ["chromosomal localisation", "OBSERVATION", 2, 26]]], ["The five remaining CTX-M-32 producers showed the blaCTX-M-32 gene on plasmids belonging to the IncN (4 strains) or untypable groups (1 strain).", [["plasmids", "ANATOMY", 69, 77], ["CTX-M-32", "CHEMICAL", 19, 27], ["CTX-M-32", "GENE_OR_GENE_PRODUCT", 19, 27], ["blaCTX-M-32", "GENE_OR_GENE_PRODUCT", 49, 60], ["blaCTX-M-32 gene", "DNA", 49, 65], ["plasmids", "DNA", 69, 77], ["The five remaining CTX", "TEST", 0, 22], ["the blaCTX", "TEST", 45, 55], ["plasmids", "TREATMENT", 69, 77], ["untypable groups (1 strain)", "PROBLEM", 115, 142]]], ["Two IncN plasmids showed identical PvuIIrestriction patterns: one was identified in a strain from a healthy chicken and one was from a hospitalised human patient; these two strains were isolated in 2002 and 2004, respectively and showed different PFGE patterns.", [["plasmids", "ANATOMY", 9, 17], ["IncN", "GENE_OR_GENE_PRODUCT", 4, 8], ["chicken", "ORGANISM", 108, 115], ["human", "ORGANISM", 148, 153], ["patient", "ORGANISM", 154, 161], ["IncN plasmids", "DNA", 4, 17], ["PvuIIrestriction patterns", "DNA", 35, 60], ["chicken", "SPECIES", 108, 115], ["human", "SPECIES", 148, 153], ["patient", "SPECIES", 154, 161], ["chicken", "SPECIES", 108, 115], ["human", "SPECIES", 148, 153], ["Two IncN plasmids", "TEST", 0, 17], ["PvuIIrestriction patterns", "OBSERVATION", 35, 60]]], ["CTX-M-1 producers (three from animal strains and one a healthy human) did not show clonality by PFGE and the blaCTX-M-1 gene was always located on plasmids, three belonging to the IncN and one to the IncI1 groups.", [["plasmids", "ANATOMY", 147, 155], ["CTX-M-1", "CHEMICAL", 0, 7], ["CTX-M-1", "GENE_OR_GENE_PRODUCT", 0, 7], ["human", "ORGANISM", 63, 68], ["blaCTX-M-1", "GENE_OR_GENE_PRODUCT", 109, 119], ["IncI1", "GENE_OR_GENE_PRODUCT", 200, 205], ["blaCTX-M-1 gene", "DNA", 109, 124], ["plasmids", "DNA", 147, 155], ["IncN", "DNA", 180, 184], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["CTX", "TEST", 0, 3], ["animal strains", "TEST", 30, 44], ["PFGE", "TEST", 96, 100], ["the blaCTX", "TEST", 105, 115]]], ["Two of the IncN plasmids carrying the blaCTX-M-1 gene showed highly related restriction patterns: one was from a healthy dog and one from a healthy human.", [["IncN", "GENE_OR_GENE_PRODUCT", 11, 15], ["blaCTX-M-1", "GENE_OR_GENE_PRODUCT", 38, 48], ["dog", "ORGANISM", 121, 124], ["human", "ORGANISM", 148, 153], ["IncN plasmids", "DNA", 11, 24], ["blaCTX-M-1 gene", "DNA", 38, 53], ["dog", "SPECIES", 121, 124], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["the IncN plasmids", "TREATMENT", 7, 24], ["the blaCTX", "TEST", 34, 44]]], ["Conclusion: This study demonstrated the presence of clonal E. coli CTX-M-32 producers in animal and human sources and also detected epidemic IncN plasmids disseminating among unrelated isolates from humans and animals, clearly suggesting a potential animal reservoir for the blaCTX-M-1/32 genes.Wide spectrum beta-lactamases in PseudomonasO309 Characterisation of blaDIM-1, a novel integron-located metallo-beta-lactamase gene from a Pseudomonas stutzeri clinical isolate in the Netherlands L. Poirel\u00b0, J. Rodriguez-Martinez, N. Al Naiemi, Y. Debets-Ossenkopp, P. Nordmann (K.-Bicetre, FR; Amsterdam, NL) Objectives: Characterisation of the mechanism involved in the uncommon resistance to carbapenems observed from a Pseudomonas stutzeri isolate recovered from a patient hospitalised in the Netherlands with a chronic tibia osteomyelitis.", [["plasmids", "ANATOMY", 146, 154], ["tibia", "ANATOMY", 819, 824], ["CTX-M-32", "CHEMICAL", 67, 75], ["carbapenems", "CHEMICAL", 690, 701], ["osteomyelitis", "DISEASE", 825, 838], ["carbapenems", "CHEMICAL", 690, 701], ["E. coli", "ORGANISM", 59, 66], ["CTX-M-32", "GENE_OR_GENE_PRODUCT", 67, 75], ["human", "ORGANISM", 100, 105], ["IncN plasmids", "CELL", 141, 154], ["humans", "ORGANISM", 199, 205], ["blaCTX-M-1/32", "GENE_OR_GENE_PRODUCT", 275, 288], ["blaDIM-1", "GENE_OR_GENE_PRODUCT", 364, 372], ["metallo-beta-lactamase", "GENE_OR_GENE_PRODUCT", 399, 421], ["Pseudomonas stutzeri", "ORGANISM", 434, 454], ["carbapenems", "SIMPLE_CHEMICAL", 690, 701], ["Pseudomonas stutzeri", "ORGANISM", 718, 738], ["patient", "ORGANISM", 764, 771], ["tibia", "ORGAN", 819, 824], ["epidemic IncN plasmids", "DNA", 132, 154], ["blaCTX-M-1/32 genes", "DNA", 275, 294], ["blaDIM-1", "DNA", 364, 372], ["metallo-beta-lactamase gene", "DNA", 399, 426], ["E. coli", "SPECIES", 59, 66], ["human", "SPECIES", 100, 105], ["humans", "SPECIES", 199, 205], ["Pseudomonas stutzeri", "SPECIES", 434, 454], ["Pseudomonas stutzeri", "SPECIES", 718, 738], ["patient", "SPECIES", 764, 771], ["E. coli", "SPECIES", 59, 66], ["human", "SPECIES", 100, 105], ["humans", "SPECIES", 199, 205], ["PseudomonasO309", "SPECIES", 328, 343], ["Pseudomonas stutzeri", "SPECIES", 434, 454], ["Pseudomonas stutzeri", "SPECIES", 718, 738], ["This study", "TEST", 12, 22], ["clonal E. coli CTX", "PROBLEM", 52, 70], ["epidemic IncN plasmids", "TREATMENT", 132, 154], ["the blaCTX", "TEST", 271, 281], ["Wide spectrum beta-lactamases", "TEST", 295, 324], ["Pseudomonas", "TEST", 328, 339], ["blaDIM", "TEST", 364, 370], ["a novel integron", "TEST", 374, 390], ["metallo", "TEST", 399, 406], ["a Pseudomonas stutzeri clinical isolate", "PROBLEM", 432, 471], ["the mechanism", "PROBLEM", 637, 650], ["carbapenems", "TREATMENT", 690, 701], ["a Pseudomonas stutzeri isolate", "PROBLEM", 716, 746], ["a chronic tibia osteomyelitis", "PROBLEM", 809, 838], ["coli CTX", "OBSERVATION", 62, 70], ["beta-lactamases", "OBSERVATION", 309, 324], ["Pseudomonas", "OBSERVATION", 328, 339], ["chronic", "OBSERVATION_MODIFIER", 811, 818], ["tibia", "ANATOMY", 819, 824], ["osteomyelitis", "OBSERVATION", 825, 838]]], ["That strain was resistant to ticarcillin, piperacillin-tazobactam, imipenem and meropenem, of intermediate susceptibility to ceftazidime and cefepime, and susceptible to aztreonam.", [["ticarcillin", "CHEMICAL", 29, 40], ["piperacillin-tazobactam", "CHEMICAL", 42, 65], ["imipenem", "CHEMICAL", 67, 75], ["meropenem", "CHEMICAL", 80, 89], ["ceftazidime", "CHEMICAL", 125, 136], ["cefepime", "CHEMICAL", 141, 149], ["aztreonam", "CHEMICAL", 170, 179], ["ticarcillin", "CHEMICAL", 29, 40], ["piperacillin-tazobactam", "CHEMICAL", 42, 65], ["imipenem", "CHEMICAL", 67, 75], ["meropenem", "CHEMICAL", 80, 89], ["ceftazidime", "CHEMICAL", 125, 136], ["cefepime", "CHEMICAL", 141, 149], ["aztreonam", "CHEMICAL", 170, 179], ["ticarcillin", "SIMPLE_CHEMICAL", 29, 40], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 42, 65], ["imipenem", "SIMPLE_CHEMICAL", 67, 75], ["meropenem", "SIMPLE_CHEMICAL", 80, 89], ["ceftazidime", "SIMPLE_CHEMICAL", 125, 136], ["cefepime", "SIMPLE_CHEMICAL", 141, 149], ["aztreonam", "SIMPLE_CHEMICAL", 170, 179], ["ticarcillin", "TREATMENT", 29, 40], ["piperacillin", "TREATMENT", 42, 54], ["tazobactam", "TREATMENT", 55, 65], ["imipenem", "TREATMENT", 67, 75], ["meropenem", "TREATMENT", 80, 89], ["ceftazidime", "TREATMENT", 125, 136], ["cefepime", "TREATMENT", 141, 149], ["aztreonam", "TREATMENT", 170, 179]]], ["Methods: Screening for metallo-beta-lactamase (MBL) production was performed using the E-test method with a strip combining imipenem and EDTA.", [["metallo-beta-lactamase", "CHEMICAL", 23, 45], ["imipenem", "CHEMICAL", 124, 132], ["EDTA", "CHEMICAL", 137, 141], ["imipenem", "CHEMICAL", 124, 132], ["EDTA", "CHEMICAL", 137, 141], ["metallo-beta-lactamase", "GENE_OR_GENE_PRODUCT", 23, 45], ["MBL", "GENE_OR_GENE_PRODUCT", 47, 50], ["imipenem", "SIMPLE_CHEMICAL", 124, 132], ["EDTA", "SIMPLE_CHEMICAL", 137, 141], ["MBL", "PROTEIN", 47, 50], ["Screening", "TEST", 9, 18], ["metallo", "TEST", 23, 30], ["a strip combining imipenem", "TREATMENT", 106, 132], ["EDTA", "TREATMENT", 137, 141]]], ["Shotgun cloning was performed with XbaI-digested DNA of P. stutzeri and pBK-CMV cloning vector.", [["XbaI", "GENE_OR_GENE_PRODUCT", 35, 39], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["P. stutzeri", "ORGANISM", 56, 67], ["pBK", "GENE_OR_GENE_PRODUCT", 72, 75], ["CMV", "ORGANISM", 76, 79], ["XbaI-digested DNA", "DNA", 35, 52], ["pBK-CMV cloning vector", "DNA", 72, 94], ["P. stutzeri", "SPECIES", 56, 67], ["P. stutzeri", "SPECIES", 56, 67], ["Shotgun cloning", "TREATMENT", 0, 15], ["P. stutzeri", "TREATMENT", 56, 67], ["CMV cloning vector", "TREATMENT", 76, 94]]], ["Selection was performed on amoxicillin and kanamycin-containing plates.", [["amoxicillin", "CHEMICAL", 27, 38], ["kanamycin", "CHEMICAL", 43, 52], ["amoxicillin", "CHEMICAL", 27, 38], ["kanamycin", "CHEMICAL", 43, 52], ["amoxicillin", "SIMPLE_CHEMICAL", 27, 38], ["kanamycin", "SIMPLE_CHEMICAL", 43, 52], ["amoxicillin", "TREATMENT", 27, 38], ["kanamycin-containing plates", "TREATMENT", 43, 70]]], ["Results: E. coli TOP10 (pDIM-1) recombinant strains were obtained, displaying resistance to penicillins and ceftazidime, reduced susceptibility to cefepime, imipenem and meropenem, and full susceptibility to aztreonam.", [["penicillins", "CHEMICAL", 92, 103], ["ceftazidime", "CHEMICAL", 108, 119], ["cefepime", "CHEMICAL", 147, 155], ["imipenem", "CHEMICAL", 157, 165], ["meropenem", "CHEMICAL", 170, 179], ["aztreonam", "CHEMICAL", 208, 217], ["penicillins", "CHEMICAL", 92, 103], ["ceftazidime", "CHEMICAL", 108, 119], ["cefepime", "CHEMICAL", 147, 155], ["imipenem", "CHEMICAL", 157, 165], ["meropenem", "CHEMICAL", 170, 179], ["aztreonam", "CHEMICAL", 208, 217], ["E. coli", "ORGANISM", 9, 16], ["TOP10", "ORGANISM", 17, 22], ["pDIM-1", "GENE_OR_GENE_PRODUCT", 24, 30], ["penicillins", "SIMPLE_CHEMICAL", 92, 103], ["ceftazidime", "SIMPLE_CHEMICAL", 108, 119], ["cefepime", "SIMPLE_CHEMICAL", 147, 155], ["imipenem", "SIMPLE_CHEMICAL", 157, 165], ["meropenem", "SIMPLE_CHEMICAL", 170, 179], ["aztreonam", "SIMPLE_CHEMICAL", 208, 217], ["E. coli", "SPECIES", 9, 16], ["E. coli", "SPECIES", 9, 16], ["E. coli TOP10", "TEST", 9, 22], ["pDIM", "TEST", 24, 28], ["recombinant strains", "PROBLEM", 32, 51], ["penicillins", "TREATMENT", 92, 103], ["ceftazidime", "TREATMENT", 108, 119], ["cefepime", "TREATMENT", 147, 155], ["imipenem", "TREATMENT", 157, 165], ["meropenem", "TREATMENT", 170, 179], ["aztreonam", "TREATMENT", 208, 217], ["E. coli", "OBSERVATION_MODIFIER", 9, 16]]], ["Sequence analysis identified a novel Ambler class B betalactamase DIM-1 for \"Dutch IMipenemase\" (pI 6.1) weakly related to all other MBLs.", [["DIM-1", "GENE_OR_GENE_PRODUCT", 66, 71], ["MBLs", "PATHOLOGICAL_FORMATION", 133, 137], ["Ambler class B betalactamase DIM-1", "DNA", 37, 71], ["MBLs", "DNA", 133, 137], ["Sequence analysis", "TEST", 0, 17]]], ["DIM-1 shared 52% amino acid identity with the most closely related MBL GIM-1, and 45 and 30% identity with the IMP and VIM subgroups, respectively.", [["DIM", "CHEMICAL", 0, 3], ["amino acid", "CHEMICAL", 17, 27], ["amino acid", "CHEMICAL", 17, 27], ["DIM-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["amino acid", "AMINO_ACID", 17, 27], ["MBL GIM-1", "GENE_OR_GENE_PRODUCT", 67, 76], ["IMP", "SIMPLE_CHEMICAL", 111, 114], ["VIM", "GENE_OR_GENE_PRODUCT", 119, 122], ["MBL", "PROTEIN", 67, 70], ["GIM", "PROTEIN", 71, 74], ["VIM", "PROTEIN", 119, 122], ["DIM", "TEST", 0, 3], ["amino acid identity", "TEST", 17, 36], ["MBL GIM", "TEST", 67, 74]]], ["DIM-1 hydrolyzes very efficiently imipenem and meropenem, expanded-spectrum cephalosporins, but spares aztreonam.", [["DIM-1", "CHEMICAL", 0, 5], ["imipenem", "CHEMICAL", 34, 42], ["meropenem", "CHEMICAL", 47, 56], ["cephalosporins", "CHEMICAL", 76, 90], ["aztreonam", "CHEMICAL", 103, 112], ["DIM-1", "CHEMICAL", 0, 5], ["imipenem", "CHEMICAL", 34, 42], ["meropenem", "CHEMICAL", 47, 56], ["cephalosporins", "CHEMICAL", 76, 90], ["aztreonam", "CHEMICAL", 103, 112], ["DIM-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["imipenem", "SIMPLE_CHEMICAL", 34, 42], ["meropenem", "SIMPLE_CHEMICAL", 47, 56], ["expanded-spectrum cephalosporins", "SIMPLE_CHEMICAL", 58, 90], ["aztreonam", "SIMPLE_CHEMICAL", 103, 112], ["imipenem", "TREATMENT", 34, 42], ["meropenem", "TREATMENT", 47, 56], ["expanded-spectrum cephalosporins", "TREATMENT", 58, 90], ["aztreonam", "TREATMENT", 103, 112]]], ["The blaDIM-1 gene was as a form of a gene cassette located at the first position in a class 1 integron, but the 59be of that gene cassette was truncated giving rise to a fusion with an aadB gene cassette encoding an aminoglycoside adenylyltransferase.", [["aminoglycoside", "CHEMICAL", 216, 230], ["aminoglycoside", "CHEMICAL", 216, 230], ["blaDIM-1", "GENE_OR_GENE_PRODUCT", 4, 12], ["aadB", "GENE_OR_GENE_PRODUCT", 185, 189], ["aminoglycoside", "SIMPLE_CHEMICAL", 216, 230], ["blaDIM-1 gene", "DNA", 4, 17], ["class 1 integron", "DNA", 86, 102], ["59be of that gene cassette", "DNA", 112, 138], ["aadB gene cassette", "DNA", 185, 203], ["aminoglycoside adenylyltransferase", "PROTEIN", 216, 250], ["The blaDIM", "TEST", 0, 10], ["a gene cassette", "TREATMENT", 35, 50], ["a fusion", "TREATMENT", 168, 176], ["an aadB gene cassette", "TREATMENT", 182, 203], ["an aminoglycoside adenylyltransferase", "TREATMENT", 213, 250]]], ["The third and last gene cassette corresponded to the qacH cassette encoding resistance to disinfectants.", [["qacH", "GENE_OR_GENE_PRODUCT", 53, 57], ["third and last gene cassette", "DNA", 4, 32], ["qacH cassette", "DNA", 53, 66], ["the qacH cassette", "TREATMENT", 49, 66]]], ["Conclusion: A novel MBL gene was identified in P. stutzeri further underlining (i) the diversity of acquired MBL genes, especially among non-fermenters, (ii) that Pseudomonas sp. may be a reservoir of these genes and (iii) the possibility of spread of important resistance determinants in Northern part of Europe.O310 Metallo-beta-lactamases in Pseudomonas aeruginosa clinicalisolates in Greece P. Giakkoupi, O. Pappa, M. Polemis, A. Bakosi, A. Vatopoulos\u00b0( Athens, GR) Objectives: Metallo-beta-lactamases of the VIM family are the main mechanism of carbapenem resistance in P. aeruginosa in Greece.", [["O310 Metallo-beta-lactamases", "CHEMICAL", 313, 341], ["carbapenem", "CHEMICAL", 550, 560], ["carbapenem", "CHEMICAL", 550, 560], ["MBL", "GENE_OR_GENE_PRODUCT", 20, 23], ["P. stutzeri", "ORGANISM", 47, 58], ["MBL", "GENE_OR_GENE_PRODUCT", 109, 112], ["Pseudomonas sp", "ORGANISM", 163, 177], ["Metallo-beta-lactamases", "GENE_OR_GENE_PRODUCT", 318, 341], ["Pseudomonas aeruginosa clinicalisolates", "ORGANISM", 345, 384], ["Metallo-beta-lactamases", "GENE_OR_GENE_PRODUCT", 482, 505], ["VIM", "GENE_OR_GENE_PRODUCT", 513, 516], ["carbapenem", "SIMPLE_CHEMICAL", 550, 560], ["P. aeruginosa", "ORGANISM", 575, 588], ["MBL gene", "DNA", 20, 28], ["MBL genes", "DNA", 109, 118], ["Metallo-beta-lactamases", "PROTEIN", 482, 505], ["VIM family", "PROTEIN", 513, 523], ["P. stutzeri", "SPECIES", 47, 58], ["Pseudomonas aeruginosa clinicalisolates", "SPECIES", 345, 384], ["P. aeruginosa", "SPECIES", 575, 588], ["P. stutzeri", "SPECIES", 47, 58], ["Pseudomonas aeruginosa", "SPECIES", 345, 367], ["P. aeruginosa", "SPECIES", 575, 588], ["A novel MBL gene", "PROBLEM", 12, 28], ["acquired MBL genes", "PROBLEM", 100, 118], ["Pseudomonas sp", "PROBLEM", 163, 177], ["Metallo", "TEST", 318, 325], ["Pseudomonas aeruginosa", "PROBLEM", 345, 367], ["Metallo", "TEST", 482, 489], ["carbapenem resistance", "PROBLEM", 550, 571], ["P. aeruginosa", "PROBLEM", 575, 588], ["MBL genes", "OBSERVATION", 109, 118], ["Pseudomonas", "OBSERVATION", 163, 174], ["resistance", "OBSERVATION", 262, 272], ["carbapenem resistance", "OBSERVATION", 550, 571]]], ["In this preliminary report we attempted to survey the subtypes of VIM betalactamase currently prevailing in P. aeruginosa clinical isolates in Greek hospitals, the genetic relatedness of the respective isolates, as well as the genetic environment of the blaVIM gene.", [["VIM", "GENE_OR_GENE_PRODUCT", 66, 69], ["P. aeruginosa", "ORGANISM", 108, 121], ["blaVIM", "GENE_OR_GENE_PRODUCT", 254, 260], ["VIM betalactamase", "PROTEIN", 66, 83], ["blaVIM gene", "DNA", 254, 265], ["P. aeruginosa", "SPECIES", 108, 121], ["P. aeruginosa", "SPECIES", 108, 121], ["VIM betalactamase", "PROBLEM", 66, 83]]], ["Methods: Fifteen MBL producing and epidemiologically unrelated P. aeruginosa clinical isolates were collected in September 2006 from fifteen different hospitals around Greece.", [["MBL", "GENE_OR_GENE_PRODUCT", 17, 20], ["P. aeruginosa", "ORGANISM", 63, 76], ["MBL", "PROTEIN", 17, 20], ["P. aeruginosa", "SPECIES", 63, 76], ["P. aeruginosa", "SPECIES", 63, 76], ["P. aeruginosa clinical isolates", "PROBLEM", 63, 94]]], ["MBL production was initially identified by an EDTA synergy test.", [["EDTA", "CHEMICAL", 46, 50], ["MBL", "GENE_OR_GENE_PRODUCT", 0, 3], ["EDTA", "SIMPLE_CHEMICAL", 46, 50], ["MBL", "PROTEIN", 0, 3], ["MBL production", "PROBLEM", 0, 14], ["an EDTA synergy test", "TEST", 43, 63]]], ["Identification of blaVIM gene, as well as mapping of the blaVIM cassette carrying integrons were performed by PCR and sequencing of the products.", [["blaVIM", "GENE_OR_GENE_PRODUCT", 18, 24], ["blaVIM", "GENE_OR_GENE_PRODUCT", 57, 63], ["blaVIM gene", "DNA", 18, 29], ["blaVIM cassette", "DNA", 57, 72], ["integrons", "DNA", 82, 91], ["blaVIM gene", "TREATMENT", 18, 29], ["PCR", "TEST", 110, 113]]], ["The O serotypes of the isolates were determined by a slide agglutination test using P. aeruginosa antisera (Biorad).", [["P. aeruginosa", "ORGANISM", 84, 97], ["P. aeruginosa", "SPECIES", 84, 97], ["P. aeruginosa", "SPECIES", 84, 97], ["the isolates", "TEST", 19, 31], ["a slide agglutination test", "TEST", 51, 77], ["P. aeruginosa antisera", "TREATMENT", 84, 106]]], ["Molecular typing was performed by pulse-field gel electrophoresis of SpeI-restricted genomic DNA.", [["DNA", "CELLULAR_COMPONENT", 93, 96], ["SpeI-restricted genomic DNA", "DNA", 69, 96], ["Molecular typing", "TEST", 0, 16], ["pulse-field gel electrophoresis", "TEST", 34, 65], ["SpeI-restricted genomic DNA", "PROBLEM", 69, 96], ["genomic DNA", "OBSERVATION", 85, 96]]], ["Results: blaVIM-2 gene was detected in nine isolates, blaVIM-4 in five and blaVIM-1 in only one isolate.", [["blaVIM-2", "GENE_OR_GENE_PRODUCT", 9, 17], ["blaVIM-4", "CELL", 54, 62], ["blaVIM-1", "GENE_OR_GENE_PRODUCT", 75, 83], ["blaVIM-2 gene", "DNA", 9, 22], ["blaVIM-4", "DNA", 54, 62], ["blaVIM-1", "DNA", 75, 83], ["blaVIM", "TEST", 9, 15], ["blaVIM", "TEST", 54, 60], ["blaVIM", "TEST", 75, 81]]], ["The blaVIM-2 cassette of all nine isolates was located on the 1600 bp variable region of a class I integron, preceded by aacA29 gene cassette. blaVIM-4 cassette of all five isolates was the first cassette of the 3200 bp variable region of a class I integron, followed by the aacA4 and blaPSE-1 gene cassettes. blaVIM-1 was the unique cassette of a class I integron.", [["blaVIM-2", "GENE_OR_GENE_PRODUCT", 4, 12], ["aacA29", "GENE_OR_GENE_PRODUCT", 121, 127], ["blaVIM-4", "GENE_OR_GENE_PRODUCT", 143, 151], ["aacA4", "GENE_OR_GENE_PRODUCT", 275, 280], ["blaPSE-1", "GENE_OR_GENE_PRODUCT", 285, 293], ["blaVIM-1", "GENE_OR_GENE_PRODUCT", 310, 318], ["blaVIM-2 cassette", "DNA", 4, 21], ["1600 bp variable region", "DNA", 62, 85], ["class I integron", "DNA", 91, 107], ["aacA29 gene cassette", "DNA", 121, 141], ["blaVIM-4 cassette", "DNA", 143, 160], ["3200 bp variable region", "DNA", 212, 235], ["class I integron", "DNA", 241, 257], ["aacA4 and blaPSE-1 gene cassettes", "DNA", 275, 308], ["blaVIM", "PROTEIN", 310, 316], ["class I integron", "DNA", 348, 364], ["The blaVIM", "TREATMENT", 0, 10], ["a class I integron", "TREATMENT", 89, 107], ["a class I integron", "TREATMENT", 239, 257], ["a class I integron", "TREATMENT", 346, 364]]], ["VIM-2 producers belonged to O8, O11 and O12 serotypes, whereas four isolates were non-typeable.", [["VIM-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["O8", "GENE_OR_GENE_PRODUCT", 28, 30], ["O11", "GENE_OR_GENE_PRODUCT", 32, 35], ["O12", "ORGANISM", 40, 43], ["VIM", "PROTEIN", 0, 3], ["VIM", "TEST", 0, 3], ["O12 serotypes", "TREATMENT", 40, 53]]], ["VIM-4 producers belonged to the same three serotypes, whereas only one was non-typeable.", [["VIM-4", "GENE_OR_GENE_PRODUCT", 0, 5], ["VIM", "PROTEIN", 0, 3], ["non-typeable", "PROBLEM", 75, 87]]], ["The VIM-1 producer belonged to O12 serotype.", [["VIM-1", "GENE_OR_GENE_PRODUCT", 4, 9], ["O12 serotype", "ORGANISM", 31, 43], ["VIM", "PROTEIN", 4, 7]]], ["The nine VIM-2 producing P. aeruginosa isolates revealed a great degree of variability in PFGE molecular typing, belonging to seven types.", [["VIM-2", "GENE_OR_GENE_PRODUCT", 9, 14], ["P. aeruginosa", "ORGANISM", 25, 38], ["VIM", "PROTEIN", 9, 12], ["P. aeruginosa", "SPECIES", 25, 38], ["P. aeruginosa", "SPECIES", 25, 38], ["The nine VIM", "TEST", 0, 12], ["P. aeruginosa isolates", "TEST", 25, 47], ["variability in PFGE molecular typing", "PROBLEM", 75, 111], ["great degree", "OBSERVATION_MODIFIER", 59, 71], ["variability", "OBSERVATION_MODIFIER", 75, 86]]], ["Contrary, the five VIM-4 producing P. aeruginosa isolates displayed higher genetic similarity and fell into one major type with 85% homology, which also included the VIM-1 producing isolate.", [["VIM-4", "GENE_OR_GENE_PRODUCT", 19, 24], ["P. aeruginosa isolates", "ORGANISM", 35, 57], ["VIM-1", "GENE_OR_GENE_PRODUCT", 166, 171], ["VIM", "PROTEIN", 19, 22], ["VIM", "PROTEIN", 166, 169], ["P. aeruginosa", "SPECIES", 35, 48], ["P. aeruginosa", "SPECIES", 35, 48], ["P. aeruginosa isolates", "PROBLEM", 35, 57], ["the VIM", "TEST", 162, 169]]], ["There was no correlation between the results of serotyping and molecular typing.", [["serotyping", "TEST", 48, 58], ["molecular typing", "TEST", 63, 79]]], ["Conclusions: MBL production in P. aeruginosa in Greece seems to be mainly due to specific class I integrons harbouring either blaVIM-2 or blaVIM-4 genes.", [["MBL", "GENE_OR_GENE_PRODUCT", 13, 16], ["P. aeruginosa", "ORGANISM", 31, 44], ["blaVIM-2", "GENE_OR_GENE_PRODUCT", 126, 134], ["blaVIM-4", "GENE_OR_GENE_PRODUCT", 138, 146], ["MBL", "PROTEIN", 13, 16], ["class I integrons", "DNA", 90, 107], ["blaVIM-2 or blaVIM-4 genes", "DNA", 126, 152], ["P. aeruginosa", "SPECIES", 31, 44], ["P. aeruginosa", "SPECIES", 31, 44], ["MBL production", "PROBLEM", 13, 27], ["P. aeruginosa", "PROBLEM", 31, 44], ["blaVIM", "TEST", 126, 132]]], ["Genetic variability was higher among bacteria carrying VIM-2 beta-lactamase, a fact indicating wider intraclonar spread of the respective integron.O311 Extended-spectrum cephalosporinases hydrolysing carbapenems in Pseudomonas aeruginosaJ.M. Rodriguez-Martinez, L. Poirel\u00b0, P. Nordmann (K.-Bicetre, FR) Objectives: Extended-spectrum beta-lactamases of AmpC-type (ESACs) contributing to reduced susceptibility to imipenem have been recently reported from Enterobacteriaceae.", [["carbapenems", "CHEMICAL", 200, 211], ["imipenem", "CHEMICAL", 412, 420], ["cephalosporinases", "CHEMICAL", 170, 187], ["carbapenems", "CHEMICAL", 200, 211], ["imipenem", "CHEMICAL", 412, 420], ["VIM-2", "GENE_OR_GENE_PRODUCT", 55, 60], ["beta-lactamase", "GENE_OR_GENE_PRODUCT", 61, 75], ["carbapenems", "SIMPLE_CHEMICAL", 200, 211], ["AmpC-type", "GENE_OR_GENE_PRODUCT", 352, 361], ["ESACs", "CANCER", 363, 368], ["imipenem", "SIMPLE_CHEMICAL", 412, 420], ["VIM", "PROTEIN", 55, 58], ["beta", "PROTEIN", 61, 65], ["integron", "DNA", 138, 146], ["Pseudomonas aeruginosaJ.M. Rodriguez-Martinez, L. Poirel\u00b0", "SPECIES", 215, 272], ["Genetic variability", "TEST", 0, 19], ["the respective integron", "TREATMENT", 123, 146], ["Extended-spectrum cephalosporinases hydrolysing carbapenems", "TREATMENT", 152, 211], ["Pseudomonas", "PROBLEM", 215, 226], ["Rodriguez", "TEST", 242, 251], ["Martinez", "TREATMENT", 252, 260], ["Extended-spectrum beta-lactamases", "TREATMENT", 315, 348], ["AmpC-type (ESACs", "TREATMENT", 352, 368], ["reduced susceptibility", "PROBLEM", 386, 408], ["imipenem", "TREATMENT", 412, 420], ["Enterobacteriaceae", "PROBLEM", 454, 472], ["wider", "OBSERVATION_MODIFIER", 95, 100], ["intraclonar spread", "OBSERVATION", 101, 119], ["respective integron", "OBSERVATION", 127, 146]]], ["The aim of the study was to evaluate the putative role of natural AmpC-type beta-lactamases of P. aeruginosa in a similar resistance profile.", [["P. aeruginosa", "ORGANISM", 95, 108], ["P. aeruginosa", "SPECIES", 95, 108], ["P. aeruginosa", "SPECIES", 95, 108], ["the study", "TEST", 11, 20], ["natural AmpC-type beta-lactamases", "TREATMENT", 58, 91], ["P. aeruginosa", "PROBLEM", 95, 108], ["natural AmpC", "OBSERVATION", 58, 70]]], ["Methods: Thirty-two non-repetitive P. aeruginosa clinical isolates recovered in our hospital in 2007 were included.", [["P. aeruginosa", "ORGANISM", 35, 48], ["P. aeruginosa", "SPECIES", 35, 48], ["P. aeruginosa", "SPECIES", 35, 48]]], ["They were selected on the basis of criteria of intermediate susceptibility or resistance to ceftazidime and intermediate susceptibility or resistance to imipenem.", [["ceftazidime", "CHEMICAL", 92, 103], ["imipenem", "CHEMICAL", 153, 161], ["ceftazidime", "CHEMICAL", 92, 103], ["imipenem", "CHEMICAL", 153, 161], ["ceftazidime", "SIMPLE_CHEMICAL", 92, 103], ["imipenem", "SIMPLE_CHEMICAL", 153, 161], ["intermediate susceptibility", "PROBLEM", 47, 74], ["ceftazidime", "TREATMENT", 92, 103], ["intermediate susceptibility", "PROBLEM", 108, 135], ["imipenem", "TREATMENT", 153, 161], ["intermediate susceptibility", "OBSERVATION", 47, 74]]], ["MICs were determined by agar dilution and E-test techniques.", [["MICs", "TREATMENT", 0, 4], ["E-test techniques", "TEST", 42, 59]]], ["The level of expression of the AmpC beta-lactamases was evaluated by measuring specific activities.", [["AmpC beta", "GENE_OR_GENE_PRODUCT", 31, 40], ["AmpC beta-lactamases", "PROTEIN", 31, 51], ["the AmpC beta-lactamases", "TEST", 27, 51]]], ["PCR, sequencing, and cloning allowed to characterise the different bla(ampC) genes.", [["bla", "GENE_OR_GENE_PRODUCT", 67, 70], ["ampC", "GENE_OR_GENE_PRODUCT", 71, 75], ["bla(ampC) genes", "DNA", 67, 82], ["PCR", "TEST", 0, 3], ["sequencing", "TEST", 5, 15]]], ["Identified ESACs were purified and their Km and kcat values for beta-lactams determined by spectrophotometry.O311 Extended-spectrum cephalosporinases hydrolysing carbapenems in Pseudomonas aeruginosaResults: Using cloxacillin-containing (an AmpC beta-lactamase inhibitor) plates, the susceptibility to ceftazidime was restored for 25 out of 32 isolates, suggesting overproduction of the AmpC.", [["carbapenems", "CHEMICAL", 162, 173], ["cloxacillin", "CHEMICAL", 214, 225], ["ceftazidime", "CHEMICAL", 302, 313], ["cephalosporinases", "CHEMICAL", 132, 149], ["carbapenems", "CHEMICAL", 162, 173], ["cloxacillin", "CHEMICAL", 214, 225], ["ceftazidime", "CHEMICAL", 302, 313], ["ESACs", "GENE_OR_GENE_PRODUCT", 11, 16], ["beta-lactams", "GENE_OR_GENE_PRODUCT", 64, 76], ["carbapenems", "SIMPLE_CHEMICAL", 162, 173], ["cloxacillin", "SIMPLE_CHEMICAL", 214, 225], ["AmpC beta-lactamase", "GENE_OR_GENE_PRODUCT", 241, 260], ["ceftazidime", "SIMPLE_CHEMICAL", 302, 313], ["AmpC", "GENE_OR_GENE_PRODUCT", 387, 391], ["ESACs", "PROTEIN", 11, 16], ["AmpC", "PROTEIN", 387, 391], ["kcat values", "TEST", 48, 59], ["beta-lactams", "TEST", 64, 76], ["Extended-spectrum cephalosporinases hydrolysing carbapenems", "TREATMENT", 114, 173], ["Pseudomonas aeruginosaResults", "PROBLEM", 177, 206], ["cloxacillin", "TREATMENT", 214, 225], ["an AmpC beta-lactamase inhibitor) plates", "TREATMENT", 238, 278], ["ceftazidime", "TREATMENT", 302, 313], ["the AmpC", "TREATMENT", 383, 391]]], ["In addition, in presence of cloxacillin, reduced MIC values were also observed with ceftazidime, cefepime and imipenem for 21 out of those 25 isolates.", [["cloxacillin", "CHEMICAL", 28, 39], ["ceftazidime", "CHEMICAL", 84, 95], ["cefepime", "CHEMICAL", 97, 105], ["imipenem", "CHEMICAL", 110, 118], ["cloxacillin", "CHEMICAL", 28, 39], ["ceftazidime", "CHEMICAL", 84, 95], ["cefepime", "CHEMICAL", 97, 105], ["imipenem", "CHEMICAL", 110, 118], ["cloxacillin", "SIMPLE_CHEMICAL", 28, 39], ["MIC", "SIMPLE_CHEMICAL", 49, 52], ["ceftazidime", "SIMPLE_CHEMICAL", 84, 95], ["cefepime", "SIMPLE_CHEMICAL", 97, 105], ["imipenem", "SIMPLE_CHEMICAL", 110, 118], ["cloxacillin", "TREATMENT", 28, 39], ["reduced MIC values", "PROBLEM", 41, 59], ["ceftazidime", "TREATMENT", 84, 95], ["cefepime", "TREATMENT", 97, 105], ["imipenem", "TREATMENT", 110, 118]]], ["Cloning and sequencing identified 10 distinct AmpC b-lactamase variants among the 32 isolates.", [["AmpC b-lactamase", "GENE_OR_GENE_PRODUCT", 46, 62], ["AmpC b-lactamase variants", "DNA", 46, 71], ["10 distinct AmpC b-lactamase variants", "PROBLEM", 34, 71]]], ["Recombinant plasmids expressing the AmpCs were transformed into reference P. aeruginosa strain and reduced susceptibility to cefepime and imipenem was observed only with recombinant P. aeruginosa strains expressing AmpC beta-lactamases that had an arginine residue at position 105.", [["plasmids", "ANATOMY", 12, 20], ["cefepime", "CHEMICAL", 125, 133], ["imipenem", "CHEMICAL", 138, 146], ["arginine", "CHEMICAL", 248, 256], ["cefepime", "CHEMICAL", 125, 133], ["imipenem", "CHEMICAL", 138, 146], ["arginine", "CHEMICAL", 248, 256], ["AmpCs", "GENE_OR_GENE_PRODUCT", 36, 41], ["P. aeruginosa", "ORGANISM", 74, 87], ["strain", "ORGANISM", 88, 94], ["cefepime", "SIMPLE_CHEMICAL", 125, 133], ["imipenem", "SIMPLE_CHEMICAL", 138, 146], ["P. aeruginosa strains", "ORGANISM", 182, 203], ["AmpC beta-lactamases", "GENE_OR_GENE_PRODUCT", 215, 235], ["Recombinant plasmids", "DNA", 0, 20], ["AmpCs", "DNA", 36, 41], ["AmpC beta-lactamases", "PROTEIN", 215, 235], ["P. aeruginosa", "SPECIES", 74, 87], ["P. aeruginosa", "SPECIES", 182, 195], ["P. aeruginosa", "SPECIES", 74, 87], ["P. aeruginosa", "SPECIES", 182, 195], ["Recombinant plasmids", "TREATMENT", 0, 20], ["the AmpCs", "TREATMENT", 32, 41], ["P. aeruginosa strain", "PROBLEM", 74, 94], ["cefepime", "TREATMENT", 125, 133], ["imipenem", "TREATMENT", 138, 146], ["recombinant P. aeruginosa strains", "PROBLEM", 170, 203], ["AmpC beta-lactamases", "PROBLEM", 215, 235], ["an arginine residue at position", "PROBLEM", 245, 276], ["arginine residue", "OBSERVATION", 248, 264]]], ["The catalytic efficiencies (kcat/Km) of the AmpC variants possessing this arginine residue were increased against oxyiminocephalosporins and imipenem.", [["arginine", "CHEMICAL", 74, 82], ["oxyiminocephalosporins", "CHEMICAL", 114, 136], ["imipenem", "CHEMICAL", 141, 149], ["arginine", "CHEMICAL", 74, 82], ["oxyiminocephalosporins", "CHEMICAL", 114, 136], ["imipenem", "CHEMICAL", 141, 149], ["AmpC", "GENE_OR_GENE_PRODUCT", 44, 48], ["arginine", "AMINO_ACID", 74, 82], ["oxyiminocephalosporins", "SIMPLE_CHEMICAL", 114, 136], ["imipenem", "SIMPLE_CHEMICAL", 141, 149], ["The catalytic efficiencies", "PROBLEM", 0, 26], ["kcat/Km)", "TREATMENT", 28, 36], ["the AmpC variants", "TREATMENT", 40, 57], ["this arginine residue", "PROBLEM", 69, 90], ["oxyiminocephalosporins", "TREATMENT", 114, 136], ["imipenem", "TREATMENT", 141, 149], ["catalytic efficiencies", "OBSERVATION", 4, 26], ["arginine residue", "OBSERVATION", 74, 90]]], ["In addition, in-vitro assays demonstrated that those AmpC variants constituted a favourable background for selection of additional degree of carbapenem resistance.O311 Extended-spectrum cephalosporinases hydrolysing carbapenems in Pseudomonas aeruginosaConclusions: Some AmpCs of P. aeruginosa possessing extended activity torward carbapenems may contribute to carbapenem resistance.", [["carbapenem", "CHEMICAL", 141, 151], ["carbapenems", "CHEMICAL", 216, 227], ["carbapenems", "CHEMICAL", 331, 342], ["carbapenem", "CHEMICAL", 361, 371], ["carbapenem", "CHEMICAL", 141, 151], ["cephalosporinases", "CHEMICAL", 186, 203], ["carbapenems", "CHEMICAL", 216, 227], ["carbapenem", "CHEMICAL", 361, 371], ["AmpC", "GENE_OR_GENE_PRODUCT", 53, 57], ["carbapenem", "SIMPLE_CHEMICAL", 141, 151], ["carbapenems", "SIMPLE_CHEMICAL", 216, 227], ["Pseudomonas aeruginosaConclusions", "ORGANISM", 231, 264], ["P. aeruginosa", "ORGANISM", 280, 293], ["carbapenems", "SIMPLE_CHEMICAL", 331, 342], ["carbapenem", "SIMPLE_CHEMICAL", 361, 371], ["P. aeruginosa", "SPECIES", 280, 293], ["Pseudomonas aeruginosaConclusions", "SPECIES", 231, 264], ["P. aeruginosa", "SPECIES", 280, 293], ["vitro assays", "TEST", 16, 28], ["those AmpC variants", "PROBLEM", 47, 66], ["carbapenem resistance", "PROBLEM", 141, 162], ["Extended-spectrum cephalosporinases hydrolysing carbapenems", "TREATMENT", 168, 227], ["Pseudomonas aeruginosaConclusions", "PROBLEM", 231, 264], ["P. aeruginosa", "TREATMENT", 280, 293], ["extended activity torward carbapenems", "TREATMENT", 305, 342], ["carbapenem resistance", "PROBLEM", 361, 382], ["carbapenem resistance", "OBSERVATION", 141, 162], ["carbapenem resistance", "OBSERVATION", 361, 382]]], ["Background: Most OXA-type ESBLs are OXA-10, OXA-2 or OXA-1 derivatives.", [["OXA", "CHEMICAL", 17, 20], ["OXA-10, OXA-2 or OXA-1 derivatives", "CHEMICAL", 36, 70], ["OXA-10", "CHEMICAL", 36, 42], ["OXA-2", "CHEMICAL", 44, 49], ["OXA-1", "CHEMICAL", 53, 58], ["OXA", "GENE_OR_GENE_PRODUCT", 17, 20], ["OXA-10", "GENE_OR_GENE_PRODUCT", 36, 42], ["OXA-2", "GENE_OR_GENE_PRODUCT", 44, 49], ["OXA-1 derivatives", "SIMPLE_CHEMICAL", 53, 70], ["Most OXA", "TEST", 12, 20], ["type ESBLs", "TEST", 21, 31], ["OXA", "TEST", 36, 39], ["OXA", "TEST", 44, 47], ["OXA", "PROBLEM", 53, 56]]], ["OXA-type ESBLs are divided into five groups according to the different homology by Frederic Bert, etc. Group 1 includes OXA-5, OXA-7, OXA-10 and its derivants;Group 2 includes OXA-2, OXA-3, OXA-15 and OXA-20;Group 3 includes OXA-1, OXA-4, OXA-30 and OXA-31; Group 4 is named after OXA-9; Group 5 only includes a single enzyme called LCR-1.", [["OXA", "CHEMICAL", 0, 3], ["OXA-5", "CHEMICAL", 120, 125], ["OXA-7, OXA-10", "CHEMICAL", 127, 140], ["OXA-2, OXA-3, OXA-15 and OXA-20", "CHEMICAL", 176, 207], ["OXA-1, OXA-4, OXA-30 and OXA-31", "CHEMICAL", 225, 256], ["OXA-9", "CHEMICAL", 281, 286], ["OXA-5", "CHEMICAL", 120, 125], ["OXA-7", "CHEMICAL", 127, 132], ["OXA-10", "CHEMICAL", 134, 140], ["OXA-2", "CHEMICAL", 176, 181], ["OXA-3", "CHEMICAL", 183, 188], ["OXA-15", "CHEMICAL", 190, 196], ["OXA-20", "CHEMICAL", 201, 207], ["OXA-1", "CHEMICAL", 225, 230], ["OXA-4", "CHEMICAL", 232, 237], ["OXA-30", "CHEMICAL", 239, 245], ["OXA-31", "CHEMICAL", 250, 256], ["OXA-9", "CHEMICAL", 281, 286], ["OXA-type ESBLs", "GENE_OR_GENE_PRODUCT", 0, 14], ["OXA-5", "SIMPLE_CHEMICAL", 120, 125], ["OXA-7", "SIMPLE_CHEMICAL", 127, 132], ["OXA-10", "SIMPLE_CHEMICAL", 134, 140], ["OXA-2", "SIMPLE_CHEMICAL", 176, 181], ["OXA-3", "SIMPLE_CHEMICAL", 183, 188], ["OXA-15", "SIMPLE_CHEMICAL", 190, 196], ["OXA-20", "SIMPLE_CHEMICAL", 201, 207], ["OXA-1", "SIMPLE_CHEMICAL", 225, 230], ["OXA-4", "SIMPLE_CHEMICAL", 232, 237], ["OXA-30", "SIMPLE_CHEMICAL", 239, 245], ["OXA-31", "SIMPLE_CHEMICAL", 250, 256], ["OXA-9", "SIMPLE_CHEMICAL", 281, 286], ["LCR-1", "GENE_OR_GENE_PRODUCT", 333, 338], ["LCR-1", "DNA", 333, 338], ["OXA", "PROBLEM", 0, 3], ["type ESBLs", "PROBLEM", 4, 14], ["OXA", "TEST", 120, 123], ["OXA", "TEST", 127, 130], ["OXA", "TEST", 134, 137], ["OXA", "TEST", 176, 179], ["OXA", "TEST", 183, 186], ["OXA", "TEST", 190, 193], ["OXA", "TEST", 201, 204], ["OXA", "TEST", 225, 228], ["OXA", "TEST", 232, 235]]], ["OXA-type ESBLs has been reported widespread in the world since the first report in 1987, such as Turkey, France, England and so on.", [["OXA-type ESBLs", "CHEMICAL", 0, 14], ["OXA-type ESBLs", "GENE_OR_GENE_PRODUCT", 0, 14], ["OXA", "PROBLEM", 0, 3], ["type ESBLs", "PROBLEM", 4, 14], ["widespread", "OBSERVATION_MODIFIER", 33, 43]]], ["But there is few report about it in China.", [["few", "OBSERVATION_MODIFIER", 13, 16]]], ["Objective: To investigate the prevalence and genotype distribution of OXA-type extended-spectrum beta-lactamases (ESBLs) in clinical Pseudomonas aeruginosa strains isolated from Xiangya Hospital of Central South University in Changsha city, Hunan Province, China.", [["OXA", "CHEMICAL", 70, 73], ["OXA", "SIMPLE_CHEMICAL", 70, 73], ["extended-spectrum beta-lactamases", "GENE_OR_GENE_PRODUCT", 79, 112], ["Pseudomonas aeruginosa", "ORGANISM", 133, 155], ["ESBLs", "PROTEIN", 114, 119], ["Pseudomonas aeruginosa", "SPECIES", 133, 155], ["Pseudomonas aeruginosa", "SPECIES", 133, 155], ["genotype distribution of OXA", "PROBLEM", 45, 73], ["type extended-spectrum beta-lactamases", "PROBLEM", 74, 112], ["ESBLs", "PROBLEM", 114, 119], ["clinical Pseudomonas aeruginosa strains", "PROBLEM", 124, 163]]], ["Methods: Ninety-seven non-repetitive clinical isolates of P. aeruginosa were collected between October 2006 and January 2007 from the hospital.", [["P. aeruginosa", "ORGANISM", 58, 71], ["P. aeruginosa", "SPECIES", 58, 71], ["P. aeruginosa", "SPECIES", 58, 71], ["P. aeruginosa", "PROBLEM", 58, 71]]], ["They were screened for OXA-type ESBLS production by polymerase chain reaction PCR with five pairs of primes specific for blaOXA genes, respectively.", [["OXA", "CHEMICAL", 23, 26], ["OXA", "SIMPLE_CHEMICAL", 23, 26], ["blaOXA", "GENE_OR_GENE_PRODUCT", 121, 127], ["blaOXA genes", "DNA", 121, 133], ["OXA", "PROBLEM", 23, 26], ["type ESBLS production", "PROBLEM", 27, 48], ["polymerase chain reaction PCR", "TEST", 52, 81]]], ["Then amplification of OXA-type ESBLS production was performed by PCR with specific primers.", [["OXA", "CHEMICAL", 22, 25], ["OXA", "GENE_OR_GENE_PRODUCT", 22, 25], ["ESBLS", "GENE_OR_GENE_PRODUCT", 31, 36], ["OXA", "PROBLEM", 22, 25], ["type ESBLS production", "PROBLEM", 26, 47]]], ["The purified and amplified products were sequenced to confirm the genotype of the OXA-type ESBLS.", [["OXA", "CHEMICAL", 82, 85], ["OXA", "GENE_OR_GENE_PRODUCT", 82, 85], ["OXA-type ESBLS", "PROTEIN", 82, 96], ["amplified products", "TREATMENT", 17, 35], ["the OXA", "TEST", 78, 85], ["type ESBLS", "PROBLEM", 86, 96]]], ["Results: The sequences of the three OXA-type ESBLS PCR products were then compared in GenBank database and there were no the completely same ribonucleotide and amino acid sequence with them.", [["OXA", "CHEMICAL", 36, 39], ["amino acid", "CHEMICAL", 160, 170], ["ribonucleotide", "CHEMICAL", 141, 155], ["amino acid", "CHEMICAL", 160, 170], ["OXA", "GENE_OR_GENE_PRODUCT", 36, 39], ["ribonucleotide", "SIMPLE_CHEMICAL", 141, 155], ["amino acid", "AMINO_ACID", 160, 170], ["OXA-type ESBLS PCR products", "DNA", 36, 63], ["the three OXA", "TEST", 26, 39], ["type ESBLS PCR products", "PROBLEM", 40, 63], ["GenBank database", "TEST", 86, 102], ["amino acid sequence", "TEST", 160, 179]]], ["They were two novel OXA-type ESBLS, named as blaOXA-128 and blaOXA-129, which have been registered in GenBank database under accession numbers EU573214 and EU573215, respectively.", [["OXA", "CHEMICAL", 20, 23], ["blaOXA-129", "CHEMICAL", 60, 70], ["OXA", "GENE_OR_GENE_PRODUCT", 20, 23], ["blaOXA-128", "GENE_OR_GENE_PRODUCT", 45, 55], ["blaOXA-129", "GENE_OR_GENE_PRODUCT", 60, 70], ["OXA-type ESBLS", "DNA", 20, 34], ["blaOXA-128", "DNA", 45, 55], ["blaOXA-129", "DNA", 60, 70], ["novel OXA", "TEST", 14, 23], ["type ESBLS", "TEST", 24, 34], ["blaOXA", "TEST", 45, 51], ["blaOXA", "TEST", 60, 66]]], ["Conclusions: There have occurred infections caused by P. aeruginosa producing OXA-type ESBLs in Xiangya Hospital of Central South University.", [["infections", "DISEASE", 33, 43], ["OXA", "CHEMICAL", 78, 81], ["P. aeruginosa", "ORGANISM", 54, 67], ["P. aeruginosa", "SPECIES", 54, 67], ["P. aeruginosa", "SPECIES", 54, 67], ["infections", "PROBLEM", 33, 43], ["P. aeruginosa", "PROBLEM", 54, 67], ["OXA", "PROBLEM", 78, 81], ["type ESBLs", "PROBLEM", 82, 92], ["infections", "OBSERVATION", 33, 43]]], ["Two novel OXA-type ESBLS in P. aeruginosa strains have been discovered in our study, which are named blaOXA-128 and blaOXA-129, respectively.", [["OXA", "CHEMICAL", 10, 13], ["ESBLS", "CHEMICAL", 19, 24], ["blaOXA-129", "CHEMICAL", 116, 126], ["OXA", "GENE_OR_GENE_PRODUCT", 10, 13], ["P. aeruginosa strains", "ORGANISM", 28, 49], ["blaOXA-128", "GENE_OR_GENE_PRODUCT", 101, 111], ["blaOXA-129", "GENE_OR_GENE_PRODUCT", 116, 126], ["P. aeruginosa", "SPECIES", 28, 41], ["P. aeruginosa", "SPECIES", 28, 41], ["Two novel OXA", "TEST", 0, 13], ["type ESBLS in P. aeruginosa strains", "PROBLEM", 14, 49], ["our study", "TEST", 74, 83], ["blaOXA", "TEST", 116, 122]]], ["Pneumonia is one of the most common nosocomial infections and is associated with high mortality.", [["Pneumonia", "DISEASE", 0, 9], ["nosocomial infections", "DISEASE", 36, 57], ["Pneumonia", "PROBLEM", 0, 9], ["the most common nosocomial infections", "PROBLEM", 20, 57], ["high mortality", "PROBLEM", 81, 95], ["most common", "OBSERVATION_MODIFIER", 24, 35], ["nosocomial", "OBSERVATION_MODIFIER", 36, 46], ["infections", "OBSERVATION", 47, 57], ["high", "OBSERVATION_MODIFIER", 81, 85], ["mortality", "OBSERVATION", 86, 95]]], ["In the last 15 years, Gram-positive bacterial pathogens have risen in prevalence as a cause of hospitalacquired pneumonia (HAP), including that occurring during mechanical ventilation (ventilator-associated pneumonia; VAP).", [["pneumonia", "DISEASE", 112, 121], ["HAP", "DISEASE", 123, 126], ["pneumonia", "DISEASE", 207, 216], ["VAP", "DISEASE", 218, 221], ["Gram-", "GENE_OR_GENE_PRODUCT", 22, 27], ["Gram-positive bacterial pathogens", "PROBLEM", 22, 55], ["hospitalacquired pneumonia", "PROBLEM", 95, 121], ["HAP", "PROBLEM", 123, 126], ["mechanical ventilation", "TREATMENT", 161, 183], ["pneumonia", "PROBLEM", 207, 216], ["VAP", "PROBLEM", 218, 221], ["bacterial pathogens", "OBSERVATION", 36, 55], ["pneumonia", "OBSERVATION", 112, 121], ["mechanical ventilation", "OBSERVATION", 161, 183], ["pneumonia", "OBSERVATION", 207, 216]]], ["In particular, Staphylococcus aureus is a major cause of HAP, including VAP.", [["Staphylococcus aureus", "DISEASE", 15, 36], ["HAP", "DISEASE", 57, 60], ["VAP", "DISEASE", 72, 75], ["Staphylococcus aureus", "ORGANISM", 15, 36], ["HAP", "CANCER", 57, 60], ["Staphylococcus aureus", "SPECIES", 15, 36], ["Staphylococcus aureus", "SPECIES", 15, 36], ["Staphylococcus aureus", "PROBLEM", 15, 36], ["HAP", "PROBLEM", 57, 60], ["VAP", "PROBLEM", 72, 75], ["Staphylococcus aureus", "OBSERVATION", 15, 36], ["HAP", "OBSERVATION", 57, 60], ["VAP", "OBSERVATION", 72, 75]]], ["The rise of multidrug-resistant infections is a source of concern, with methicillinresistant S. aureus (MRSA) accounting for >40% of S. aureus isolates in some European hospitals.", [["infections", "DISEASE", 32, 42], ["methicillinresistant S. aureus", "DISEASE", 72, 102], ["MRSA", "DISEASE", 104, 108], ["methicillinresistant S. aureus", "ORGANISM", 72, 102], ["MRSA", "CANCER", 104, 108], ["S. aureus", "ORGANISM", 133, 142], ["S. aureus", "SPECIES", 93, 102], ["MRSA", "SPECIES", 104, 108], ["S. aureus", "SPECIES", 133, 142], ["S. aureus", "SPECIES", 93, 102], ["MRSA", "SPECIES", 104, 108], ["S. aureus", "SPECIES", 133, 142], ["multidrug-resistant infections", "PROBLEM", 12, 42], ["methicillinresistant S. aureus", "PROBLEM", 72, 102], ["MRSA", "PROBLEM", 104, 108], ["S. aureus isolates", "PROBLEM", 133, 151], ["rise", "OBSERVATION_MODIFIER", 4, 8], ["multidrug", "OBSERVATION_MODIFIER", 12, 21], ["resistant", "OBSERVATION_MODIFIER", 22, 31], ["infections", "OBSERVATION", 32, 42], ["aureus", "OBSERVATION", 96, 102], ["MRSA", "OBSERVATION", 104, 108], ["aureus", "OBSERVATION", 136, 142]]], ["This symposium will take the format of a question-and-answer roundtable session in which experts will answer questions and initiate discussion surrounding emerging concerns and appropriate therapeutic strategies in nosocomial pneumonia, including that caused by multidrug-resistant Gram-positive pathogens.O311 Extended-spectrum cephalosporinases hydrolysing carbapenems in Pseudomonas aeruginosaRecently, shifts in the susceptibility of S. aureus to established therapeutic agents for nosocomial pneumonia have added to the challenge of selecting appropriate empiric therapy.", [["pneumonia", "DISEASE", 226, 235], ["carbapenems", "CHEMICAL", 359, 370], ["pneumonia", "DISEASE", 497, 506], ["cephalosporinases", "CHEMICAL", 329, 346], ["carbapenems", "CHEMICAL", 359, 370], ["Gram", "GENE_OR_GENE_PRODUCT", 282, 286], ["carbapenems", "SIMPLE_CHEMICAL", 359, 370], ["Pseudomonas aeruginosaRecently", "ORGANISM", 374, 404], ["S. aureus", "ORGANISM", 438, 447], ["S. aureus", "SPECIES", 438, 447], ["S. aureus", "SPECIES", 438, 447], ["nosocomial pneumonia", "PROBLEM", 215, 235], ["multidrug-resistant Gram-positive pathogens", "PROBLEM", 262, 305], ["Extended-spectrum cephalosporinases hydrolysing carbapenems", "TREATMENT", 311, 370], ["Pseudomonas aeruginosaRecently", "PROBLEM", 374, 404], ["S. aureus", "PROBLEM", 438, 447], ["therapeutic agents", "TREATMENT", 463, 481], ["nosocomial pneumonia", "PROBLEM", 486, 506], ["selecting appropriate empiric therapy", "TREATMENT", 538, 575], ["pneumonia", "OBSERVATION", 226, 235], ["positive pathogens", "OBSERVATION", 287, 305], ["hydrolysing carbapenems", "OBSERVATION", 347, 370], ["pneumonia", "OBSERVATION", 497, 506]]], ["In patients with suspected multidrug-resistant infections or those who are mechanically ventilated, prompt initiation of therapy, often before the pathogen has been confirmed, is critical.", [["multidrug-resistant infections", "DISEASE", 27, 57], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["multidrug-resistant infections", "PROBLEM", 27, 57], ["mechanically ventilated", "PROBLEM", 75, 98], ["therapy", "TREATMENT", 121, 128], ["resistant", "OBSERVATION_MODIFIER", 37, 46], ["infections", "OBSERVATION", 47, 57], ["mechanically", "OBSERVATION_MODIFIER", 75, 87], ["ventilated", "OBSERVATION", 88, 98]]], ["Vancomycin is the gold-standard treatment for multidrug-resistant infections and resistance has been remarkably slow to emerge.", [["Vancomycin", "CHEMICAL", 0, 10], ["infections", "DISEASE", 66, 76], ["Vancomycin", "CHEMICAL", 0, 10], ["Vancomycin", "SIMPLE_CHEMICAL", 0, 10], ["Vancomycin", "TREATMENT", 0, 10], ["the gold-standard treatment", "TREATMENT", 14, 41], ["multidrug-resistant infections", "PROBLEM", 46, 76], ["resistance", "PROBLEM", 81, 91], ["resistant", "OBSERVATION_MODIFIER", 56, 65], ["infections", "OBSERVATION", 66, 76]]], ["However, clinical reports in Europe of 'MIC creep' and the emergence of vancomycin-intermediate S. aureus (VISA), hVISA and linezolid-resistant MRSA have presented new clinical dilemmas.", [["vancomycin", "CHEMICAL", 72, 82], ["hVISA", "CHEMICAL", 114, 119], ["linezolid", "CHEMICAL", 124, 133], ["MRSA", "DISEASE", 144, 148], ["vancomycin", "CHEMICAL", 72, 82], ["linezolid", "CHEMICAL", 124, 133], ["vancomycin-intermediate", "ORGANISM", 72, 95], ["S. aureus", "ORGANISM", 96, 105], ["VISA", "ORGANISM", 107, 111], ["hVISA", "SIMPLE_CHEMICAL", 114, 119], ["linezolid", "SIMPLE_CHEMICAL", 124, 133], ["S. aureus", "SPECIES", 96, 105], ["MRSA", "SPECIES", 144, 148], ["S. aureus", "SPECIES", 96, 105], ["VISA", "SPECIES", 107, 111], ["'MIC creep'", "TREATMENT", 39, 50], ["vancomycin", "TREATMENT", 72, 82], ["intermediate S. aureus", "PROBLEM", 83, 105], ["hVISA", "PROBLEM", 114, 119], ["linezolid", "TREATMENT", 124, 133], ["resistant MRSA", "PROBLEM", 134, 148], ["new clinical dilemmas", "PROBLEM", 164, 185], ["aureus", "OBSERVATION", 99, 105], ["new", "OBSERVATION_MODIFIER", 164, 167]]], ["Elevated vancomycin MICs are linked to treatment failure and increased mortality.", [["vancomycin", "CHEMICAL", 9, 19], ["vancomycin", "CHEMICAL", 9, 19], ["vancomycin MICs", "SIMPLE_CHEMICAL", 9, 24], ["Elevated vancomycin MICs", "TREATMENT", 0, 24], ["treatment failure", "PROBLEM", 39, 56], ["increased mortality", "PROBLEM", 61, 80], ["vancomycin MICs", "OBSERVATION", 9, 24], ["treatment", "OBSERVATION_MODIFIER", 39, 48], ["failure", "OBSERVATION", 49, 56], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["mortality", "OBSERVATION_MODIFIER", 71, 80]]], ["Hence, while vancomycin remains a useful therapeutic tool, treatment decisions present an increasing challenge, especially in groups of patients in whom rapid eradication of infection with appropriate agents is critical.", [["vancomycin", "CHEMICAL", 13, 23], ["infection", "DISEASE", 174, 183], ["vancomycin", "CHEMICAL", 13, 23], ["vancomycin", "SIMPLE_CHEMICAL", 13, 23], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["vancomycin", "TREATMENT", 13, 23], ["an increasing challenge", "TREATMENT", 87, 110], ["infection", "PROBLEM", 174, 183], ["infection", "OBSERVATION", 174, 183]]], ["Telavancin is a novel lipoglycopeptide under investigation for treatment of nosocomial pneumonia.", [["Telavancin", "CHEMICAL", 0, 10], ["pneumonia", "DISEASE", 87, 96], ["Telavancin", "CHEMICAL", 0, 10], ["Telavancin", "SIMPLE_CHEMICAL", 0, 10], ["lipoglycopeptide", "SIMPLE_CHEMICAL", 22, 38], ["Telavancin", "TREATMENT", 0, 10], ["a novel lipoglycopeptide", "TREATMENT", 14, 38], ["nosocomial pneumonia", "PROBLEM", 76, 96], ["nosocomial", "OBSERVATION_MODIFIER", 76, 86], ["pneumonia", "OBSERVATION", 87, 96]]], ["A number of key features suggest telavancin as a potentially attractive option for nosocomial pneumonia.", [["telavancin", "CHEMICAL", 33, 43], ["pneumonia", "DISEASE", 94, 103], ["telavancin", "CHEMICAL", 33, 43], ["telavancin", "SIMPLE_CHEMICAL", 33, 43], ["telavancin", "TREATMENT", 33, 43], ["nosocomial pneumonia", "PROBLEM", 83, 103], ["pneumonia", "OBSERVATION", 94, 103]]], ["Telavancin has a unique dual mechanism of action that disrupts both bacterial cell wall biosynthesis and cell membrane integrity.", [["cell wall", "ANATOMY", 78, 87], ["cell membrane", "ANATOMY", 105, 118], ["Telavancin", "CHEMICAL", 0, 10], ["Telavancin", "CHEMICAL", 0, 10], ["Telavancin", "SIMPLE_CHEMICAL", 0, 10], ["cell wall", "CELLULAR_COMPONENT", 78, 87], ["cell membrane", "CELLULAR_COMPONENT", 105, 118], ["Telavancin", "TREATMENT", 0, 10], ["both bacterial cell wall biosynthesis", "PROBLEM", 63, 100], ["cell membrane integrity", "PROBLEM", 105, 128], ["bacterial cell", "OBSERVATION", 68, 82], ["wall biosynthesis", "OBSERVATION", 83, 100], ["cell membrane integrity", "OBSERVATION", 105, 128]]], ["The agent is rapidly bactericidal against a broad range of clinically relevant Grampositive bacteria, including MRSA.", [["MRSA", "DISEASE", 112, 116], ["MRSA", "SPECIES", 112, 116], ["MRSA", "SPECIES", 112, 116], ["rapidly bactericidal", "PROBLEM", 13, 33], ["Grampositive bacteria", "PROBLEM", 79, 100], ["MRSA", "PROBLEM", 112, 116], ["Grampositive bacteria", "OBSERVATION", 79, 100], ["MRSA", "OBSERVATION", 112, 116]]], ["Two pivotal Phase III studies have demonstrated telavancin efficacy equivalent to vancomycin in HAP, including VAP, including in seriously ill patient subgroups and in that caused by MRSA.A. Vaheri\u00b0(Helsinki, FI)Hantaviruses are enveloped RNA viruses, each carried primarily by rodents or insectivores of specific host species.", [["telavancin", "CHEMICAL", 48, 58], ["vancomycin", "CHEMICAL", 82, 92], ["HAP", "DISEASE", 96, 99], ["VAP", "DISEASE", 111, 114], ["Vaheri\u00b0", "CHEMICAL", 191, 198], ["telavancin", "CHEMICAL", 48, 58], ["vancomycin", "CHEMICAL", 82, 92], ["telavancin", "SIMPLE_CHEMICAL", 48, 58], ["vancomycin", "SIMPLE_CHEMICAL", 82, 92], ["patient", "ORGANISM", 143, 150], ["patient", "SPECIES", 143, 150], ["MRSA.A.", "SPECIES", 183, 190], ["Two pivotal Phase III studies", "TEST", 0, 29], ["telavancin efficacy", "TREATMENT", 48, 67], ["vancomycin", "TREATMENT", 82, 92], ["HAP", "PROBLEM", 96, 99], ["VAP", "PROBLEM", 111, 114], ["Vaheri\u00b0(Helsinki, FI)Hantaviruses", "TREATMENT", 191, 224], ["RNA viruses", "PROBLEM", 239, 250], ["RNA viruses", "OBSERVATION", 239, 250], ["host species", "OBSERVATION", 314, 326]]], ["They have coevolved with the hosts in which they cause almost asymptomatic and persistent infections.", [["infections", "DISEASE", 90, 100], ["persistent infections", "PROBLEM", 79, 100], ["persistent", "OBSERVATION_MODIFIER", 79, 89], ["infections", "OBSERVATION", 90, 100]]], ["In humans some hantaviruses cause disease: haemorrhagic fever with renal syndrome (HFRS) in Eurasia.", [["renal", "ANATOMY", 67, 72], ["hantaviruses", "DISEASE", 15, 27], ["haemorrhagic fever", "DISEASE", 43, 61], ["renal syndrome", "DISEASE", 67, 81], ["HFRS", "DISEASE", 83, 87], ["humans", "ORGANISM", 3, 9], ["renal", "ORGAN", 67, 72], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["disease", "PROBLEM", 34, 41], ["haemorrhagic fever", "PROBLEM", 43, 61], ["renal syndrome", "PROBLEM", 67, 81], ["hantaviruses", "OBSERVATION", 15, 27], ["haemorrhagic", "OBSERVATION_MODIFIER", 43, 55], ["fever", "OBSERVATION", 56, 61], ["renal", "ANATOMY", 67, 72], ["syndrome", "OBSERVATION", 73, 81], ["Eurasia", "OBSERVATION_MODIFIER", 92, 99]]], ["In Europe Puumala (PUUV) from bank voles and Saaremaa (SAAV) from field mice cause mild HFRS and Dobrava (DOBV) from yellow-necked mice severe HFRS.", [["HFRS", "DISEASE", 88, 92], ["HFRS", "DISEASE", 143, 147], ["Europe Puumala", "ORGANISM", 3, 17], ["PUUV", "ORGANISM", 19, 23], ["bank voles", "ORGANISM", 30, 40], ["Saaremaa (SAAV", "ORGANISM", 45, 59], ["mice", "ORGANISM", 72, 76], ["mice", "ORGANISM", 131, 135], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 131, 135], ["bank voles", "SPECIES", 30, 40], ["mice", "SPECIES", 72, 76], ["DOBV", "SPECIES", 106, 110], ["Saaremaa (SAAV)", "PROBLEM", 45, 60], ["mild HFRS", "PROBLEM", 83, 92], ["Dobrava (DOBV", "TREATMENT", 97, 110], ["yellow-necked mice severe HFRS", "PROBLEM", 117, 147], ["Puumala", "OBSERVATION", 10, 17], ["mild", "OBSERVATION_MODIFIER", 83, 87], ["HFRS", "OBSERVATION", 88, 92], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["HFRS", "OBSERVATION", 143, 147]]], ["In Asia HFRS is caused mainly by Hantaan and Seoul viruses.", [["HFRS", "DISEASE", 8, 12], ["Seoul viruses", "ORGANISM", 45, 58]]], ["In Americas some viruses cause hantavirus cardiopulmonary syndrome: Sin Nombre, Andes and other viruses carried by sigmodontine rodents, not found in Eurasia.", [["hantavirus cardiopulmonary syndrome", "DISEASE", 31, 66], ["Sin Nombre", "ORGANISM", 68, 78], ["sigmodontine rodents", "ORGANISM", 115, 135], ["hantavirus cardiopulmonary syndrome", "PROBLEM", 31, 66], ["viruses", "OBSERVATION", 17, 24], ["hantavirus cardiopulmonary syndrome", "OBSERVATION", 31, 66], ["viruses", "OBSERVATION", 96, 103]]], ["In addition, in Europe the common vole carries Tula and rats Seoul virus.", [["vole", "ORGANISM", 34, 38], ["rats Seoul virus", "ORGANISM", 56, 72], ["rats", "SPECIES", 56, 60], ["Seoul virus", "SPECIES", 61, 72], ["common vole", "ANATOMY", 27, 38]]], ["However, they have not been definitely associated with disease in Europe, although both can infect humans.", [["humans", "ORGANISM", 99, 105], ["humans", "SPECIES", 99, 105], ["humans", "SPECIES", 99, 105], ["disease", "PROBLEM", 55, 62], ["not been definitely associated with", "UNCERTAINTY", 19, 54], ["disease", "OBSERVATION", 55, 62]]], ["We discuss the epidemiology, molecular genetics, detection of infection in carrier hosts and humans (including RT-PCR and 5-min serological tests), functions of hantaviral proteins, risk factors for humans to catch hantavirus infection (including smoking) and disease (including risk and protective HLA haplotypes), role and mapping of epitopes of cytotoxic T-cells, mechanisms of hantavirus-induced apoptosis, newly discovered clinical features (including hypophyseal haemorrhages in PUUV infection), and long-term consequences and pathogenesis of HFRS (endothelial permeability, thrombocytopenia, TNF-alpha and IL-6).", [["cytotoxic T-cells", "ANATOMY", 348, 365], ["hypophyseal", "ANATOMY", 457, 468], ["endothelial", "ANATOMY", 555, 566], ["infection", "DISEASE", 62, 71], ["hantavirus infection", "DISEASE", 215, 235], ["smoking", "CHEMICAL", 247, 254], ["hantavirus", "DISEASE", 381, 391], ["hypophyseal haemorrhages", "DISEASE", 457, 481], ["PUUV infection", "DISEASE", 485, 499], ["HFRS", "DISEASE", 549, 553], ["thrombocytopenia", "DISEASE", 581, 597], ["humans", "ORGANISM", 93, 99], ["humans", "ORGANISM", 199, 205], ["cytotoxic T-cells", "CELL", 348, 365], ["hantavirus", "ORGANISM", 381, 391], ["hypophyseal", "ORGANISM_SUBDIVISION", 457, 468], ["endothelial", "TISSUE", 555, 566], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 599, 608], ["IL-6", "GENE_OR_GENE_PRODUCT", 613, 617], ["hantaviral proteins", "PROTEIN", 161, 180], ["risk factors", "PROTEIN", 182, 194], ["epitopes", "PROTEIN", 336, 344], ["cytotoxic T-cells", "CELL_TYPE", 348, 365], ["TNF", "PROTEIN", 599, 602], ["IL-6", "PROTEIN", 613, 617], ["humans", "SPECIES", 93, 99], ["humans", "SPECIES", 199, 205], ["humans", "SPECIES", 93, 99], ["humans", "SPECIES", 199, 205], ["PUUV", "SPECIES", 485, 489], ["infection in carrier hosts", "PROBLEM", 62, 88], ["RT-PCR", "TEST", 111, 117], ["serological tests", "TEST", 128, 145], ["hantaviral proteins", "PROBLEM", 161, 180], ["risk factors", "PROBLEM", 182, 194], ["catch hantavirus infection", "PROBLEM", 209, 235], ["disease", "PROBLEM", 260, 267], ["protective HLA haplotypes", "TREATMENT", 288, 313], ["cytotoxic T-cells", "PROBLEM", 348, 365], ["hantavirus", "PROBLEM", 381, 391], ["apoptosis", "PROBLEM", 400, 409], ["hypophyseal haemorrhages", "PROBLEM", 457, 481], ["PUUV infection", "PROBLEM", 485, 499], ["long-term consequences", "PROBLEM", 506, 528], ["HFRS", "PROBLEM", 549, 553], ["endothelial permeability", "TEST", 555, 579], ["thrombocytopenia", "PROBLEM", 581, 597], ["TNF", "TEST", 599, 602], ["alpha and IL", "TREATMENT", 603, 615], ["infection", "OBSERVATION", 62, 71], ["hantavirus", "OBSERVATION", 381, 391], ["PUUV infection", "OBSERVATION", 485, 499], ["long-term consequences", "OBSERVATION_MODIFIER", 506, 528], ["HFRS", "OBSERVATION", 549, 553], ["endothelial", "ANATOMY", 555, 566], ["thrombocytopenia", "OBSERVATION", 581, 597]]], ["PUUV occurs widely in Europe except in the far north and Mediterranean regions, SAAV in northern, eastern and central Europe and DOBV mainly in the Balkans.", [["PUUV", "DISEASE", 0, 4], ["PUUV", "ORGANISM", 0, 4], ["PUUV", "PROBLEM", 0, 4], ["central Europe", "TREATMENT", 110, 124], ["DOBV", "TREATMENT", 129, 133], ["widely", "OBSERVATION_MODIFIER", 12, 18], ["Mediterranean regions", "ANATOMY", 57, 78], ["Balkans", "ANATOMY", 148, 155]]], ["The epidemiological patterns differ: in western and central Europe HFRS epidemics follow mast years with increased oak and beech seed production promoting rodent breeding.", [["HFRS", "DISEASE", 67, 71], ["oak", "ORGANISM_SUBDIVISION", 115, 118], ["seed", "ORGANISM_SUBDIVISION", 129, 133], ["rodent", "SPECIES", 155, 161], ["increased oak", "PROBLEM", 105, 118], ["beech seed production", "TREATMENT", 123, 144]]], ["In the north, hantavirus infections and HFRS epidemics occur in 3\u22124 year cycles, driven by prey-predator interactions.", [["hantavirus infections", "DISEASE", 14, 35], ["HFRS", "DISEASE", 40, 44], ["hantavirus", "ORGANISM", 14, 24], ["hantavirus infections", "PROBLEM", 14, 35], ["HFRS epidemics", "PROBLEM", 40, 54], ["hantavirus infections", "OBSERVATION", 14, 35]]], ["The infections and HFRS are on the increase in Europe, partly because of better diagnostics and partly perhaps due to environmental changes.", [["infections", "DISEASE", 4, 14], ["HFRS", "DISEASE", 19, 23], ["The infections", "PROBLEM", 0, 14], ["HFRS", "PROBLEM", 19, 23], ["environmental changes", "PROBLEM", 118, 139], ["infections", "OBSERVATION", 4, 14], ["HFRS", "OBSERVATION", 19, 23], ["increase", "OBSERVATION_MODIFIER", 35, 43]]], ["In several European countries hantavirus infections are notifiable and in some countries (e.g. Belgium, Finland, France, Germany, Scandinavian countries, Slovenia) their epidemiology is relatively well studied.", [["hantavirus infections", "DISEASE", 30, 51], ["hantavirus", "ORGANISM", 30, 40], ["hantavirus infections", "PROBLEM", 30, 51]]], ["In large areas of Europe, however, hantavirus infections and HFRS have not been studied systematically and they are still heavily under-diagnosed.A. Vaheri\u00b0(Helsinki, FI)MRSA screening \u2212 will we ever agree?", [["hantavirus infections", "DISEASE", 35, 56], ["HFRS", "DISEASE", 61, 65], ["hantavirus", "ORGANISM", 35, 45], ["MRSA", "SPECIES", 170, 174], ["hantavirus infections", "PROBLEM", 35, 56], ["HFRS", "PROBLEM", 61, 65], ["MRSA screening", "TEST", 170, 184], ["large", "OBSERVATION_MODIFIER", 3, 8], ["areas", "OBSERVATION_MODIFIER", 9, 14], ["Europe", "OBSERVATION", 18, 24], ["hantavirus", "OBSERVATION_MODIFIER", 35, 45], ["infections", "OBSERVATION", 46, 56]]], ["S330 MRSA: universal screening!L. Peterson\u00b0, A. Robicsek (Evanston, US)The successful control of any outbreak or epidemic relies on detection of those harbouring the pathogen (infected and colonised persons) combined with eliminating spread to new individuals.", [["S330", "CHEMICAL", 0, 4], ["persons", "ORGANISM", 199, 206], ["MRSA", "SPECIES", 5, 9], ["persons", "SPECIES", 199, 206], ["universal screening", "TEST", 11, 30], ["the pathogen", "PROBLEM", 162, 174], ["MRSA", "OBSERVATION", 5, 9]]], ["The approach to containment and reduction of the global MRSA pandemic is now being discussed.", [["MRSA", "DISEASE", 56, 60], ["MRSA", "SPECIES", 56, 60], ["The approach to containment", "TREATMENT", 0, 27], ["the global MRSA pandemic", "PROBLEM", 45, 69], ["containment", "OBSERVATION_MODIFIER", 16, 27], ["reduction", "OBSERVATION_MODIFIER", 32, 41], ["global", "OBSERVATION_MODIFIER", 49, 55], ["MRSA", "OBSERVATION", 56, 60]]], ["A challenge for this infection is that most persons harbouring MRSA do not exhibit signs of disease and thus in order to detect all potential spreaders of this organism some surveillance must be done.", [["infection", "DISEASE", 21, 30], ["MRSA", "DISEASE", 63, 67], ["persons", "ORGANISM", 44, 51], ["persons", "SPECIES", 44, 51], ["MRSA", "SPECIES", 63, 67], ["MRSA", "SPECIES", 63, 67], ["A challenge", "TREATMENT", 0, 11], ["this infection", "PROBLEM", 16, 30], ["MRSA", "PROBLEM", 63, 67], ["disease", "PROBLEM", 92, 99], ["this organism", "PROBLEM", 155, 168], ["infection", "OBSERVATION", 21, 30], ["disease", "OBSERVATION", 92, 99]]], ["The required level of detection (surveillance through screening) is not known and likely varies with the prevalence of colonisation and disease.", [["surveillance through screening", "TEST", 33, 63], ["colonisation", "PROBLEM", 119, 131], ["disease", "PROBLEM", 136, 143], ["colonisation", "OBSERVATION", 119, 131]]], ["For a given MRSA prevalence, the factor that seems most crucial in reducing spread is the percentage of potential isolation days captured.", [["MRSA", "SPECIES", 12, 16], ["MRSA prevalence", "PROBLEM", 12, 27]]], ["The operational processes that highly influence this are 1) the sensitivity of screening detection (including sites tested and laboratory methods used), 2) the speed at which results of newly detected positive patients are reported from the laboratory (assuming pre-emptive isolation is not employed), and 3) the selection of patient populations who are to undergo screening.", [["patients", "ORGANISM", 210, 218], ["patient", "ORGANISM", 326, 333], ["patients", "SPECIES", 210, 218], ["patient", "SPECIES", 326, 333], ["screening detection", "TEST", 79, 98], ["laboratory methods", "TEST", 127, 145], ["pre-emptive isolation", "TREATMENT", 262, 283], ["screening", "TEST", 365, 374]]], ["Laboratory testing has a major impact on detecting MRSA colonised patients with real-time PCR having a sensitivity of 98% and a possible 2 hour reporting time compared to direct chromogenic agar cultures with a sensitivity of 80% and >24 hour reporting and enriched chromogenic agar testing with a sensitivity of 90% and >48 hour reporting (Am J Clin Pathol, 2009); both reduced sensitivity and prolonged reporting time negatively impacting the success of MRSA timely isolation.", [["patients", "ORGANISM", 66, 74], ["MRSA", "SPECIES", 51, 55], ["patients", "SPECIES", 66, 74], ["MRSA", "SPECIES", 456, 460], ["MRSA", "SPECIES", 51, 55], ["MRSA", "SPECIES", 456, 460], ["Laboratory testing", "TEST", 0, 18], ["MRSA", "PROBLEM", 51, 55], ["a sensitivity", "TEST", 101, 114], ["direct chromogenic agar cultures", "TEST", 171, 203], ["a sensitivity", "TEST", 209, 222], ["chromogenic agar testing", "TEST", 266, 290], ["a sensitivity", "TEST", 296, 309], ["both reduced sensitivity", "PROBLEM", 366, 390], ["MRSA timely isolation", "TREATMENT", 456, 477], ["MRSA", "OBSERVATION", 456, 460]]], ["We have shown that capturing 33% of MRSA isolation days in a modest MRSA prevalence setting (9 infections/10,000 patient days) with a high sensitivity test having a >24 hour result reporting time did not reduce hospital-wide MRSA disease (Ann Int Med 148:209, 2008) .", [["infections", "DISEASE", 95, 105], ["MRSA disease", "DISEASE", 225, 237], ["patient", "ORGANISM", 113, 120], ["MRSA", "SPECIES", 36, 40], ["MRSA", "SPECIES", 68, 72], ["patient", "SPECIES", 113, 120], ["MRSA", "SPECIES", 225, 229], ["MRSA isolation", "PROBLEM", 36, 50], ["a high sensitivity test", "PROBLEM", 132, 155], ["wide MRSA disease", "PROBLEM", 220, 237], ["MRSA", "OBSERVATION", 225, 229], ["Med", "ANATOMY", 247, 250]]], ["Others have demonstrated that surveillance in an ICU with similar MRSA prevalence, again with a high sensitivity test having 1 day result reporting, did not reduce ICU disease until preemptive isolation was initiated (Crit Care 10: R25, 2006) .", [["MRSA", "DISEASE", 66, 70], ["MRSA", "SPECIES", 66, 70], ["MRSA", "SPECIES", 66, 70], ["a high sensitivity test", "PROBLEM", 94, 117], ["ICU disease", "PROBLEM", 164, 175], ["preemptive isolation", "TREATMENT", 182, 202]]], ["Finally, we demonstrated that universal admission surveillance and decolonisation capturing 85% of possible MRSA isolation days had a dramatic impact by reducing 70% of all in-hospital infections from MRSA.", [["MRSA", "DISEASE", 108, 112], ["infections", "DISEASE", 185, 195], ["MRSA", "DISEASE", 201, 205], ["MRSA", "SPECIES", 108, 112], ["MRSA", "SPECIES", 201, 205], ["universal admission surveillance", "TEST", 30, 62], ["decolonisation", "TEST", 67, 81], ["MRSA isolation days", "PROBLEM", 108, 127], ["all in-hospital infections", "PROBLEM", 169, 195], ["MRSA", "PROBLEM", 201, 205], ["infections", "OBSERVATION", 185, 195], ["MRSA", "OBSERVATION", 201, 205]]], ["Future research in this area should focus on better defining those patients that benefit from MRSA screening and the role of decolonisation in these programs.M. Rupnik\u00b0(Maribor, SI)Clostridium difficile infection (CDI) is a toxin-mediated intestinal disease and extraintestinal manifestations are exceptional.", [["intestinal", "ANATOMY", 239, 249], ["Clostridium difficile infection", "DISEASE", 181, 212], ["CDI", "DISEASE", 214, 217], ["intestinal disease", "DISEASE", 239, 257], ["patients", "ORGANISM", 67, 75], ["Maribor, SI)Clostridium difficile", "ORGANISM", 169, 202], ["intestinal", "ORGAN", 239, 249], ["patients", "SPECIES", 67, 75], ["MRSA", "SPECIES", 94, 98], ["Clostridium difficile", "SPECIES", 181, 202], ["Clostridium difficile", "SPECIES", 181, 202], ["MRSA screening", "TEST", 94, 108], ["decolonisation in these programs", "TREATMENT", 125, 157], ["Clostridium difficile infection (CDI", "PROBLEM", 181, 217], ["a toxin-mediated intestinal disease", "PROBLEM", 222, 257], ["extraintestinal manifestations", "PROBLEM", 262, 292], ["intestinal", "ANATOMY", 239, 249], ["disease", "OBSERVATION", 250, 257], ["extraintestinal manifestations", "OBSERVATION", 262, 292]]], ["Clinical outcomes can range from asymptomatic colonisation to mild diarrhoea and more severe disease characterised by inflammatory lesions and pseudomembranes in the colon, toxic megacolon or bowel perforation, sepsis, shock, and death.", [["lesions", "ANATOMY", 131, 138], ["pseudomembranes", "ANATOMY", 143, 158], ["colon", "ANATOMY", 166, 171], ["bowel", "ANATOMY", 192, 197], ["diarrhoea", "DISEASE", 67, 76], ["pseudomembranes", "DISEASE", 143, 158], ["megacolon", "DISEASE", 179, 188], ["bowel perforation", "DISEASE", 192, 209], ["sepsis", "DISEASE", 211, 217], ["shock", "DISEASE", 219, 224], ["death", "DISEASE", 230, 235], ["inflammatory lesions", "PATHOLOGICAL_FORMATION", 118, 138], ["colon", "ORGAN", 166, 171], ["bowel", "ORGAN", 192, 197], ["asymptomatic colonisation", "PROBLEM", 33, 58], ["mild diarrhoea", "PROBLEM", 62, 76], ["more severe disease", "PROBLEM", 81, 100], ["inflammatory lesions", "PROBLEM", 118, 138], ["pseudomembranes in the colon", "PROBLEM", 143, 171], ["toxic megacolon", "PROBLEM", 173, 188], ["bowel perforation", "PROBLEM", 192, 209], ["sepsis", "PROBLEM", 211, 217], ["shock", "PROBLEM", 219, 224], ["death", "PROBLEM", 230, 235], ["mild", "OBSERVATION_MODIFIER", 62, 66], ["diarrhoea", "OBSERVATION", 67, 76], ["more severe", "OBSERVATION_MODIFIER", 81, 92], ["disease", "OBSERVATION", 93, 100], ["inflammatory", "OBSERVATION_MODIFIER", 118, 130], ["lesions", "OBSERVATION", 131, 138], ["colon", "ANATOMY", 166, 171], ["toxic", "OBSERVATION_MODIFIER", 173, 178], ["megacolon", "OBSERVATION", 179, 188], ["bowel", "ANATOMY", 192, 197], ["perforation", "OBSERVATION", 198, 209], ["sepsis", "OBSERVATION", 211, 217], ["shock", "OBSERVATION", 219, 224]]], ["The main clinical symptoms, secretory diarrhoea and inflammation of colonic mucosa, can be in great part explained by the actions of two large protein toxins, toxin A (TcdA) and toxin B (TcdB).", [["colonic mucosa", "ANATOMY", 68, 82], ["diarrhoea", "DISEASE", 38, 47], ["inflammation", "DISEASE", 52, 64], ["colonic mucosa", "MULTI-TISSUE_STRUCTURE", 68, 82], ["toxin A", "GENE_OR_GENE_PRODUCT", 159, 166], ["TcdA", "GENE_OR_GENE_PRODUCT", 168, 172], ["toxin B", "GENE_OR_GENE_PRODUCT", 178, 185], ["TcdB", "GENE_OR_GENE_PRODUCT", 187, 191], ["protein toxins", "PROTEIN", 143, 157], ["toxin A", "PROTEIN", 159, 166], ["TcdA", "PROTEIN", 168, 172], ["toxin B", "PROTEIN", 178, 185], ["TcdB", "PROTEIN", 187, 191], ["The main clinical symptoms", "PROBLEM", 0, 26], ["secretory diarrhoea", "PROBLEM", 28, 47], ["inflammation of colonic mucosa", "PROBLEM", 52, 82], ["two large protein toxins", "PROBLEM", 133, 157], ["toxin A (TcdA)", "TEST", 159, 173], ["toxin B (TcdB)", "TEST", 178, 192], ["main", "OBSERVATION_MODIFIER", 4, 8], ["secretory diarrhoea", "OBSERVATION", 28, 47], ["inflammation", "OBSERVATION", 52, 64], ["colonic mucosa", "ANATOMY", 68, 82]]], ["Both toxins are cytotoxic, destroy the intestinal epithelium and decrease colonic barrier function by disruption of the actin cytoskeleton and tight junctions resulting in a decreased transepithelial resistance allowing fluid accumulation.", [["intestinal epithelium", "ANATOMY", 39, 60], ["colonic barrier", "ANATOMY", 74, 89], ["cytoskeleton", "ANATOMY", 126, 138], ["tight junctions", "ANATOMY", 143, 158], ["transepithelial", "ANATOMY", 184, 199], ["fluid", "ANATOMY", 220, 225], ["intestinal epithelium", "TISSUE", 39, 60], ["colonic barrier", "TISSUE", 74, 89], ["actin", "GENE_OR_GENE_PRODUCT", 120, 125], ["cytoskeleton", "CELLULAR_COMPONENT", 126, 138], ["tight junctions", "CELLULAR_COMPONENT", 143, 158], ["transepithelial", "IMMATERIAL_ANATOMICAL_ENTITY", 184, 199], ["fluid", "ORGANISM_SUBSTANCE", 220, 225], ["actin", "PROTEIN", 120, 125], ["cytotoxic", "PROBLEM", 16, 25], ["the intestinal epithelium", "PROBLEM", 35, 60], ["a decreased transepithelial resistance allowing fluid accumulation", "PROBLEM", 172, 238], ["cytotoxic", "OBSERVATION_MODIFIER", 16, 25], ["intestinal", "ANATOMY", 39, 49], ["epithelium", "ANATOMY_MODIFIER", 50, 60], ["decrease", "OBSERVATION_MODIFIER", 65, 73], ["colonic", "ANATOMY", 74, 81], ["barrier function", "OBSERVATION", 82, 98], ["actin cytoskeleton", "OBSERVATION", 120, 138], ["tight junctions", "OBSERVATION", 143, 158], ["decreased", "OBSERVATION_MODIFIER", 174, 183], ["transepithelial resistance", "OBSERVATION", 184, 210], ["fluid accumulation", "OBSERVATION", 220, 238]]], ["In addition, C. difficile toxins also cause release of various inflammatory mediators which affect enteric nerves, sensory neurons and promote inflammatory cells, adding to the fluid secretion, inflammation and transmigration of neutrophils.", [["enteric nerves", "ANATOMY", 99, 113], ["sensory neurons", "ANATOMY", 115, 130], ["inflammatory cells", "ANATOMY", 143, 161], ["fluid", "ANATOMY", 177, 182], ["neutrophils", "ANATOMY", 229, 240], ["inflammation", "DISEASE", 194, 206], ["C. difficile toxins", "ORGANISM", 13, 32], ["enteric nerves", "MULTI-TISSUE_STRUCTURE", 99, 113], ["sensory neurons", "CELL", 115, 130], ["inflammatory cells", "CELL", 143, 161], ["fluid", "ORGANISM_SUBSTANCE", 177, 182], ["neutrophils", "CELL", 229, 240], ["inflammatory mediators", "PROTEIN", 63, 85], ["sensory neurons", "CELL_TYPE", 115, 130], ["inflammatory cells", "CELL_TYPE", 143, 161], ["neutrophils", "CELL_TYPE", 229, 240], ["C. difficile", "SPECIES", 13, 25], ["C. difficile", "SPECIES", 13, 25], ["C. difficile toxins", "PROBLEM", 13, 32], ["various inflammatory mediators", "PROBLEM", 55, 85], ["sensory neurons", "PROBLEM", 115, 130], ["inflammatory cells", "PROBLEM", 143, 161], ["the fluid secretion", "TEST", 173, 192], ["inflammation", "PROBLEM", 194, 206], ["transmigration of neutrophils", "PROBLEM", 211, 240], ["difficile", "OBSERVATION", 16, 25], ["inflammatory", "OBSERVATION", 63, 75], ["enteric nerves", "ANATOMY", 99, 113], ["sensory neurons", "ANATOMY", 115, 130], ["inflammatory cells", "OBSERVATION", 143, 161], ["fluid secretion", "OBSERVATION", 177, 192], ["inflammation", "OBSERVATION", 194, 206], ["transmigration", "OBSERVATION_MODIFIER", 211, 225]]], ["Some experimental evidence points also to possible extraintestinal action of C. difficile toxin B. In zebrafish embryos TcdB caused damage and edema in cardiac tissue and in hamsters the same toxin caused lung damage.M. Rupnik\u00b0(Maribor, SI)Only recently efficient systems have been developed to genetically manipulate C. difficile.", [["embryos", "ANATOMY", 112, 119], ["edema", "ANATOMY", 143, 148], ["cardiac tissue", "ANATOMY", 152, 166], ["lung", "ANATOMY", 205, 209], ["TcdB", "CHEMICAL", 120, 124], ["edema", "DISEASE", 143, 148], ["lung damage", "DISEASE", 205, 216], ["C. difficile", "DISEASE", 318, 330], ["C. difficile toxin B.", "ORGANISM", 77, 98], ["zebrafish", "ORGANISM", 102, 111], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 112, 119], ["TcdB", "GENE_OR_GENE_PRODUCT", 120, 124], ["edema", "PATHOLOGICAL_FORMATION", 143, 148], ["cardiac tissue", "TISSUE", 152, 166], ["hamsters", "ORGANISM", 174, 182], ["lung", "ORGAN", 205, 209], ["C. difficile", "ORGANISM", 318, 330], ["C. difficile", "SPECIES", 77, 89], ["zebrafish", "SPECIES", 102, 111], ["C. difficile", "SPECIES", 318, 330], ["C. difficile", "SPECIES", 77, 89], ["zebrafish", "SPECIES", 102, 111], ["hamsters", "SPECIES", 174, 182], ["C. difficile", "SPECIES", 318, 330], ["extraintestinal action", "PROBLEM", 51, 73], ["C. difficile toxin B.", "PROBLEM", 77, 98], ["damage", "PROBLEM", 132, 138], ["edema in cardiac tissue", "PROBLEM", 143, 166], ["lung damage", "PROBLEM", 205, 216], ["C. difficile", "PROBLEM", 318, 330], ["edema", "OBSERVATION", 143, 148], ["cardiac tissue", "ANATOMY", 152, 166], ["lung", "ANATOMY", 205, 209], ["damage", "OBSERVATION", 210, 216], ["difficile", "OBSERVATION", 321, 330]]], ["Comparison of knock-out mutants producing only one of both toxins have shown that TcdB-positive-only mutants retain the ability to kill hamsters, whereas TcdA-positive-only mutants were not virulent for hamsters.", [["TcdA", "CHEMICAL", 154, 158], ["TcdB", "GENE_OR_GENE_PRODUCT", 82, 86], ["hamsters", "ORGANISM", 136, 144], ["TcdA", "GENE_OR_GENE_PRODUCT", 154, 158], ["hamsters", "ORGANISM", 203, 211], ["TcdB", "PROTEIN", 82, 86], ["TcdA", "PROTEIN", 154, 158], ["hamsters", "SPECIES", 203, 211], ["hamsters", "SPECIES", 136, 144], ["hamsters", "SPECIES", 203, 211], ["knock-out mutants", "PROBLEM", 14, 31], ["TcdB", "TEST", 82, 86], ["TcdA", "TEST", 154, 158]]], ["These results are in concordance with epidemiological findings that naturally occurring A-B+ strains still cause the entire spectrum of CDI, but are not in concordance with effects observed after intragastric challenge of hamsters with purified toxins TcdA and TcdB.", [["CDI", "DISEASE", 136, 139], ["A-B+ strains", "ORGANISM", 88, 100], ["intragastric", "IMMATERIAL_ANATOMICAL_ENTITY", 196, 208], ["hamsters", "ORGANISM", 222, 230], ["TcdA", "GENE_OR_GENE_PRODUCT", 252, 256], ["TcdB", "GENE_OR_GENE_PRODUCT", 261, 265], ["TcdA", "PROTEIN", 252, 256], ["TcdB", "PROTEIN", 261, 265], ["hamsters", "SPECIES", 222, 230], ["strains", "PROBLEM", 93, 100], ["CDI", "PROBLEM", 136, 139], ["intragastric challenge of hamsters", "TREATMENT", 196, 230], ["CDI", "OBSERVATION", 136, 139]]], ["The role of the third toxin produced by C. difficile, binary toxin CDT in the development of human disease is not well understood.", [["human disease", "DISEASE", 93, 106], ["C. difficile", "ORGANISM", 40, 52], ["binary toxin CDT", "GENE_OR_GENE_PRODUCT", 54, 70], ["human", "ORGANISM", 93, 98], ["third toxin", "PROTEIN", 16, 27], ["binary toxin CDT", "PROTEIN", 54, 70], ["C. difficile", "SPECIES", 40, 52], ["human", "SPECIES", 93, 98], ["C. difficile", "SPECIES", 40, 52], ["human", "SPECIES", 93, 98], ["the third toxin", "TEST", 12, 27], ["C. difficile", "PROBLEM", 40, 52], ["binary toxin CDT", "PROBLEM", 54, 70], ["human disease", "PROBLEM", 93, 106], ["human disease", "OBSERVATION", 93, 106]]], ["CDT was shown to have enterotoxic effect in rabbit ileal loop assay, but natural strains producing CDT but neither TcdA nor TcdB colonised animals but were not lethal in hamsters.M. Rupnik\u00b0(Maribor, SI)Comparative genomic analysis will most likely reveal additional factors involved in pathogenesis and in increased virulence (including cell surface layer proteins, sporulation characteristics and antibiotic resistance).", [["ileal loop", "ANATOMY", 51, 61], ["cell surface layer", "ANATOMY", 337, 355], ["TcdA", "CHEMICAL", 115, 119], ["rabbit", "ORGANISM", 44, 50], ["ileal", "ORGANISM_SUBDIVISION", 51, 56], ["CDT", "GENE_OR_GENE_PRODUCT", 99, 102], ["TcdA", "GENE_OR_GENE_PRODUCT", 115, 119], ["TcdB", "GENE_OR_GENE_PRODUCT", 124, 128], ["animals", "ORGANISM", 139, 146], ["hamsters", "ORGANISM", 170, 178], ["cell", "CELL", 337, 341], ["CDT", "PROTEIN", 99, 102], ["cell surface layer proteins", "PROTEIN", 337, 364], ["rabbit", "SPECIES", 44, 50], ["hamsters", "SPECIES", 170, 178], ["rabbit", "SPECIES", 44, 50], ["hamsters", "SPECIES", 170, 178], ["CDT", "TEST", 0, 3], ["enterotoxic effect in rabbit ileal loop assay", "PROBLEM", 22, 67], ["natural strains producing CDT", "PROBLEM", 73, 102], ["Comparative genomic analysis", "TEST", 202, 230], ["pathogenesis", "PROBLEM", 286, 298], ["increased virulence", "PROBLEM", 306, 325], ["cell surface layer proteins", "TREATMENT", 337, 364], ["antibiotic resistance", "TREATMENT", 398, 419], ["enterotoxic effect", "OBSERVATION", 22, 40], ["ileal loop", "ANATOMY", 51, 61], ["increased", "OBSERVATION_MODIFIER", 306, 315], ["virulence", "OBSERVATION", 316, 325], ["antibiotic resistance", "OBSERVATION", 398, 419]]], ["Additionally, the role of the host immune response in CDI has just started to be better understood.T. Riley\u00b0(Perth, AU)Since 2002, there has been an escalation in rates of Clostridium difficile infection (CDI) with epidemic C. difficile (PCR ribotype 027/North American pulsed-field type 1 [NAP1]) responsible for outbreaks of severe infection in North America and Europe.", [["CDI", "DISEASE", 54, 57], ["Clostridium difficile infection", "DISEASE", 172, 203], ["CDI", "DISEASE", 205, 208], ["C. difficile", "DISEASE", 224, 236], ["infection", "DISEASE", 334, 343], ["Clostridium difficile", "ORGANISM", 172, 193], ["C. difficile", "ORGANISM", 224, 236], ["pulsed-field type 1", "GENE_OR_GENE_PRODUCT", 270, 289], ["Clostridium difficile", "SPECIES", 172, 193], ["C. difficile", "SPECIES", 224, 236], ["Clostridium difficile", "SPECIES", 172, 193], ["C. difficile", "SPECIES", 224, 236], ["CDI", "PROBLEM", 54, 57], ["Clostridium difficile infection", "PROBLEM", 172, 203], ["epidemic C. difficile (PCR ribotype", "PROBLEM", 215, 250], ["severe infection", "PROBLEM", 327, 343], ["escalation", "OBSERVATION_MODIFIER", 149, 159], ["Clostridium", "OBSERVATION_MODIFIER", 172, 183], ["difficile", "OBSERVATION_MODIFIER", 184, 193], ["infection", "OBSERVATION", 194, 203], ["difficile", "OBSERVATION_MODIFIER", 227, 236], ["severe", "OBSERVATION_MODIFIER", 327, 333], ["infection", "OBSERVATION", 334, 343]]], ["While fluoroqinolone resistance and over-use are thought to be driving the epidemic, the ageing population and improved case ascertainment are contributing to the dramatic increase in cases.", [["fluoroqinolone", "CHEMICAL", 6, 20], ["fluoroqinolone", "CHEMICAL", 6, 20], ["fluoroqinolone", "SIMPLE_CHEMICAL", 6, 20], ["the dramatic increase in cases", "PROBLEM", 159, 189], ["dramatic", "OBSERVATION_MODIFIER", 163, 171], ["increase", "OBSERVATION_MODIFIER", 172, 180]]], ["Other factors may also be important, such as the increase in prescription of proton pump inhibitors.", [["proton pump inhibitors", "TREATMENT", 77, 99], ["may also be", "UNCERTAINTY", 14, 25]]], ["In The Netherlands, since 2005, there has been an increase in prevalence of human CDI with ribotype 078 strains usually found in animals.", [["CDI", "DISEASE", 82, 85], ["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["human CDI", "PROBLEM", 76, 85], ["ribotype 078 strains", "PROBLEM", 91, 111], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["human CDI", "OBSERVATION", 76, 85]]], ["These infections were in a younger population and more frequently community acquired.", [["infections", "DISEASE", 6, 16], ["These infections", "PROBLEM", 0, 16], ["infections", "OBSERVATION", 6, 16]]], ["There was alarm when it was reported that 20% of retail beef samples in Canada contained C. difficile.", [["samples", "ANATOMY", 61, 68], ["C. difficile", "DISEASE", 89, 101], ["C. difficile", "ORGANISM", 89, 101], ["C. difficile", "SPECIES", 89, 101], ["beef", "SPECIES", 56, 60], ["C. difficile", "SPECIES", 89, 101], ["retail beef samples", "TEST", 49, 68], ["C. difficile", "PROBLEM", 89, 101], ["C. difficile", "OBSERVATION", 89, 101]]], ["The figure is higher in the USA where more than 40% of packaged meats (beef, pork and turkey) from 3 Arizona stores contained C. difficile.", [["meats", "ANATOMY", 64, 69], ["pork", "ANATOMY", 77, 81], ["C. difficile", "DISEASE", 126, 138], ["meats", "ORGANISM_SUBDIVISION", 64, 69], ["beef", "ORGANISM_SUBDIVISION", 71, 75], ["pork", "ORGANISM_SUBDIVISION", 77, 81], ["turkey", "ORGANISM_SUBDIVISION", 86, 92], ["C. difficile", "ORGANISM", 126, 138], ["beef", "SPECIES", 71, 75], ["pork", "SPECIES", 77, 81], ["turkey", "SPECIES", 86, 92], ["C. difficile", "SPECIES", 126, 138], ["beef", "SPECIES", 71, 75], ["pork", "SPECIES", 77, 81], ["turkey", "SPECIES", 86, 92], ["C. difficile", "SPECIES", 126, 138], ["C. difficile", "PROBLEM", 126, 138], ["higher", "OBSERVATION_MODIFIER", 14, 20], ["difficile", "OBSERVATION", 129, 138]]], ["Most animal isolates of C. difficile produce binary toxin, and both pigs and cattle harbour PCR ribotype 078 a strain that, like ribotype 027, also produces more toxins A and B, and binary toxin.", [["C. difficile", "DISEASE", 24, 36], ["C. difficile", "ORGANISM", 24, 36], ["pigs", "ORGANISM", 68, 72], ["cattle", "ORGANISM", 77, 83], ["B", "GENE_OR_GENE_PRODUCT", 175, 176], ["binary toxin", "SIMPLE_CHEMICAL", 182, 194], ["B", "PROTEIN", 175, 176], ["C. difficile", "SPECIES", 24, 36], ["pigs", "SPECIES", 68, 72], ["cattle", "SPECIES", 77, 83], ["C. difficile", "SPECIES", 24, 36], ["pigs", "SPECIES", 68, 72], ["cattle", "SPECIES", 77, 83], ["ribotype 027", "SPECIES", 129, 141], ["C. difficile produce binary toxin", "PROBLEM", 24, 57], ["cattle harbour PCR ribotype", "TEST", 77, 104], ["a strain", "PROBLEM", 109, 117], ["C. difficile", "OBSERVATION", 24, 36]]], ["In the eastern part of The Netherlands where >90% of pig farms are located, >20% of human isolates are now ribotype 078, and human and pig strains of C. difficile are highly genetically related.", [["ribotype 078", "CHEMICAL", 107, 119], ["C. difficile", "DISEASE", 150, 162], ["pig", "ORGANISM", 53, 56], ["human", "ORGANISM", 84, 89], ["ribotype 078", "CELL", 107, 119], ["human", "ORGANISM", 125, 130], ["pig strains", "ORGANISM", 135, 146], ["C. difficile", "ORGANISM", 150, 162], ["pig", "SPECIES", 53, 56], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 125, 130], ["pig", "SPECIES", 135, 138], ["C. difficile", "SPECIES", 150, 162], ["pig", "SPECIES", 53, 56], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 125, 130], ["pig", "SPECIES", 135, 138], ["C. difficile", "SPECIES", 150, 162], ["pig farms", "TREATMENT", 53, 62], ["human isolates", "TEST", 84, 98], ["ribotype", "PROBLEM", 107, 115], ["C. difficile", "PROBLEM", 150, 162], ["C. difficile", "OBSERVATION", 150, 162]]], ["It has been suggested that the overlap between the location of pig farms in The Netherlands and the occurrence of human ribotype 078 infections involves a common source.", [["infections", "DISEASE", 133, 143], ["pig", "ORGANISM", 63, 66], ["human", "ORGANISM", 114, 119], ["ribotype 078", "ORGANISM", 120, 132], ["human", "SPECIES", 114, 119], ["pig", "SPECIES", 63, 66], ["human ribotype 078", "SPECIES", 114, 132], ["pig farms", "TREATMENT", 63, 72], ["human ribotype 078 infections", "PROBLEM", 114, 143], ["pig farms", "OBSERVATION", 63, 72]]], ["That source is likely to be the environment.", [["is likely to be", "UNCERTAINTY", 12, 27]]], ["The upsurge in CDI has prompted diagnostic companies to try to either improve current tests or develop new ones.", [["CDI", "DISEASE", 15, 18], ["CDI", "PROBLEM", 15, 18], ["current tests", "TEST", 78, 91], ["CDI", "OBSERVATION", 15, 18]]], ["Laboratory diagnostic methods can be divided into 3 groups; traditional faecal cytotoxin detection (with or without culture), enzyme immunoassays (EIAs) and molecular methods.", [["faecal", "ORGANISM_SUBSTANCE", 72, 78], ["Laboratory diagnostic methods", "TEST", 0, 29], ["traditional faecal cytotoxin detection", "TEST", 60, 98], ["culture", "TEST", 116, 123], ["enzyme immunoassays", "TEST", 126, 145], ["EIAs", "TEST", 147, 151]]], ["Faecal cytotoxin detection is specific but lacks sensitivity, culture is sensitive but lacks specificity.", [["Faecal", "ORGANISM_SUBSTANCE", 0, 6], ["cytotoxin", "PROTEIN", 7, 16], ["Faecal cytotoxin detection", "TEST", 0, 26], ["culture", "TEST", 62, 69]]], ["New EIAs should find a niche in medium sized laboratories.", [["New EIAs", "PROBLEM", 0, 8]]], ["New commerciallyavailable platforms will make this methodology more accessible to smaller laboratories.", [["New commerciallyavailable platforms", "PROBLEM", 0, 35]]], ["Whatever method is chosen, it is necessary for the laboratory to have as fast a turn-around-time as possible, particularly in an outbreak situation.HPV vaccine S336 Why did France introduce the anti-HPV vaccine?D. L\u00e9vy-Bruhl\u00b0(Saint-Maurice, FR) In 2005, the Advisory Board on Immunisation (ABI) has been asked to make recommendations to the Ministry of Health regarding the inclusion or not in the French immunisation schedule of the soon to be licensed first HPV vaccine.", [["S336", "CHEMICAL", 160, 164], ["HPV", "ORGANISM", 148, 151], ["anti-HPV", "CANCER", 194, 202], ["HPV", "ORGANISM", 460, 463], ["HPV", "SPECIES", 460, 463], ["HPV vaccine", "TREATMENT", 148, 159], ["the anti-HPV vaccine", "TREATMENT", 190, 210]]], ["The main elements considered in the establishment of the benefit-risk balance of routine HPV vaccination were: On the benefit side: -the very significant potentially preventable burden of diseases; -the very high efficacy of the vaccine against persistent HPV 16/18 infections in naive subjects; -the expected additional impact on other HPV16/18 related lesions and cancers; -the fact that vaccination, by preventing the pre-cancerous lesions, has the advantage over screening to reduce the cost and anxiety related to their detection and management; -the available data in favour of a satisfactory safety profile; -the benefit of vaccination for the women not covered by the opportunistic screening program.", [["lesions", "ANATOMY", 354, 361], ["cancers", "ANATOMY", 366, 373], ["pre-cancerous lesions", "ANATOMY", 421, 442], ["HPV 16/18 infections", "DISEASE", 256, 276], ["cancers", "DISEASE", 366, 373], ["anxiety", "DISEASE", 500, 507], ["HPV", "ORGANISM", 89, 92], ["HPV 16/18", "ORGANISM", 256, 265], ["lesions", "PATHOLOGICAL_FORMATION", 354, 361], ["cancers", "CANCER", 366, 373], ["pre-cancerous lesions", "PATHOLOGICAL_FORMATION", 421, 442], ["women", "ORGANISM", 651, 656], ["women", "SPECIES", 651, 656], ["HPV", "SPECIES", 89, 92], ["HPV 16/18", "SPECIES", 256, 265], ["routine HPV vaccination", "TREATMENT", 81, 104], ["diseases", "PROBLEM", 188, 196], ["the vaccine", "TREATMENT", 225, 236], ["persistent HPV 16/18 infections in naive subjects", "PROBLEM", 245, 294], ["other HPV16/18 related lesions", "PROBLEM", 331, 361], ["cancers", "PROBLEM", 366, 373], ["vaccination", "TREATMENT", 390, 401], ["the pre-cancerous lesions", "PROBLEM", 417, 442], ["screening", "TEST", 467, 476], ["the cost", "PROBLEM", 487, 495], ["anxiety", "PROBLEM", 500, 507], ["their detection", "TEST", 519, 534], ["management", "TREATMENT", 539, 549], ["vaccination", "TREATMENT", 631, 642], ["main", "OBSERVATION_MODIFIER", 4, 8], ["diseases", "OBSERVATION", 188, 196], ["lesions", "OBSERVATION", 354, 361], ["cancers", "OBSERVATION", 366, 373], ["pre-cancerous", "OBSERVATION_MODIFIER", 421, 434], ["lesions", "OBSERVATION", 435, 442]]], ["On the \"risk\" side: -the high cost of vaccination; -the unknown duration of protection; -the need for continuation of screening, even for vaccinated women; -the fact that the majority of residual cervical cancers could be prevented by the organisation of the screening program; -the risk of a decrease in compliance to screening for vaccinated women; -the low benefit if vaccinated and screened women were the same.", [["cervical cancers", "ANATOMY", 196, 212], ["cervical cancers", "DISEASE", 196, 212], ["women", "ORGANISM", 149, 154], ["cervical cancers", "CANCER", 196, 212], ["women", "ORGANISM", 344, 349], ["women", "ORGANISM", 395, 400], ["women", "SPECIES", 149, 154], ["women", "SPECIES", 344, 349], ["women", "SPECIES", 395, 400], ["vaccination", "TREATMENT", 38, 49], ["screening", "TEST", 118, 127], ["residual cervical cancers", "PROBLEM", 187, 212], ["the screening program", "TEST", 255, 276], ["screening", "TEST", 319, 328], ["cervical", "ANATOMY", 196, 204], ["cancers", "OBSERVATION", 205, 212]]], ["A cost effectiveness analysis, carried out on a multi cohort Markov model, showed that, over a 70 years period, the impact of vaccinating 80% of 14 years old girls or of organising the screening were comparable (reduction of cancer deaths close to 20%).", [["cancer", "ANATOMY", 225, 231], ["cancer", "DISEASE", 225, 231], ["deaths", "DISEASE", 232, 238], ["cancer", "CANCER", 225, 231], ["girls", "SPECIES", 158, 163], ["A cost effectiveness analysis", "TEST", 0, 29], ["the screening", "TEST", 181, 194], ["cancer deaths", "PROBLEM", 225, 238]]], ["However, the cost-effectiveness ratio of the vaccination was higher than that of the screening organisation, resp.", [["the vaccination", "TREATMENT", 41, 56], ["the screening organisation", "TEST", 81, 107]]], ["On the basis of the economical analysis, the screening organisation was therefore the first priority.", [["the economical analysis", "TEST", 16, 39], ["the screening organisation", "TEST", 41, 67]]], ["However, if both interventions were implemented, the overall reduction in cervical cancer deaths was estimated at 32%.", [["cervical cancer", "ANATOMY", 74, 89], ["cervical cancer deaths", "DISEASE", 74, 96], ["cervical cancer", "CANCER", 74, 89], ["cervical cancer deaths", "PROBLEM", 74, 96], ["reduction", "OBSERVATION_MODIFIER", 61, 70], ["cervical", "ANATOMY", 74, 82], ["cancer", "OBSERVATION", 83, 89]]], ["The cost-effectiveness of the addition of vaccination on the top of the organisation of the screening appeared acceptable (55,000 \u20ac per life year saved).", [["vaccination", "TREATMENT", 42, 53], ["the screening", "TEST", 88, 101]]], ["Based on those results, the ABI issued in March 2007 a recommendation to include the HPV vaccination in the immunisation schedule for 14 years old girls, together with a catch up for 15 to 23 years old women not having started their sexual life more than one year ago.", [["HPV", "ORGANISM", 85, 88], ["women", "ORGANISM", 202, 207], ["girls", "SPECIES", 147, 152], ["women", "SPECIES", 202, 207], ["the ABI", "TEST", 24, 31], ["the HPV vaccination", "TREATMENT", 81, 100], ["the immunisation schedule", "TREATMENT", 104, 129]]], ["The vaccine cost has been reimbursed since July 2007.HPV vaccine S336 Why did France introduce the anti-HPV vaccine?Clinical microbiology \u2212 is outsourcing the way to go?", [["S336", "CHEMICAL", 65, 69], ["HPV", "ORGANISM", 53, 56], ["anti-HPV", "CANCER", 99, 107], ["The vaccine cost", "TREATMENT", 0, 16], ["HPV vaccine", "TREATMENT", 53, 64], ["the anti-HPV vaccine", "TREATMENT", 95, 115]]], ["S338 The (r)evolution of clinical microbiology in Europe \u2212 is it good or bad?G. Kahlmeter\u00b0(V\u00e4xj\u00f6, SE)Laboratory medicine in general and clinical microbiology in particular is presently subject to rapid (r)evolution.", [["S338", "CHEMICAL", 0, 4], ["S338", "CHEMICAL", 0, 4], ["S338", "PROTEIN", 0, 4], ["clinical microbiology", "TEST", 25, 46], ["clinical microbiology", "TEST", 136, 157], ["rapid (r)evolution", "PROBLEM", 196, 214]]], ["Is it good, bad or just plain necessary?", [["good", "OBSERVATION_MODIFIER", 6, 10]]], ["It is not one evolutionary process -it is several parallel processes with varying emphasis in different areas.", [["several parallel processes", "PROBLEM", 42, 68], ["not", "UNCERTAINTY", 6, 9], ["one", "OBSERVATION_MODIFIER", 10, 13], ["evolutionary", "OBSERVATION_MODIFIER", 14, 26], ["process", "OBSERVATION", 27, 34], ["several", "OBSERVATION_MODIFIER", 42, 49], ["parallel", "OBSERVATION_MODIFIER", 50, 58], ["processes", "OBSERVATION", 59, 68], ["varying", "OBSERVATION_MODIFIER", 74, 81], ["emphasis", "OBSERVATION_MODIFIER", 82, 90], ["different", "OBSERVATION_MODIFIER", 94, 103], ["areas", "OBSERVATION_MODIFIER", 104, 109]]], ["There are at least four distinctive major trends over the last 15 years; the gradual formation of bigger and bigger units (concentration), the amalgamation of many different laboratory services into one (Laboratory medicine), accreditation and an explosion of professional proficiencies and backgrounds of staff in microbiological laboratories.", [["professional proficiencies", "TREATMENT", 260, 286], ["at least", "OBSERVATION_MODIFIER", 10, 18], ["four", "OBSERVATION_MODIFIER", 19, 23], ["distinctive", "OBSERVATION_MODIFIER", 24, 35], ["major", "OBSERVATION_MODIFIER", 36, 41], ["trends", "OBSERVATION_MODIFIER", 42, 48], ["bigger", "OBSERVATION_MODIFIER", 98, 104], ["bigger units", "OBSERVATION_MODIFIER", 109, 121]]], ["A recent 5th trend, outsourcing microbiology services to large private consortiums, is splitting clinical microbiology into a purely analytical high-throughput money-saving activity, often leaving the consultative, clinical part of microbiology and health care infection control adrift.", [["infection", "DISEASE", 261, 270], ["health care infection control adrift", "TREATMENT", 249, 285]]], ["Not only cost-saving but also our inability to recruit medically trained microbiologists, the need to broaden the knowledge base of microbiology laboratories, automation, the development of new techniques and apparatus common to many laboratory disciplines, computerised medicine, political trendiness, power struggles, and much more.G. Kahlmeter\u00b0(V\u00e4xj\u00f6, SE)There is much to be gained by both concentration and amalgamation but much to be lost as well and many consider the heart and soul of clinical microbiology at risk.", [["heart", "ANATOMY", 474, 479], ["heart", "ORGAN", 474, 479], ["microbiology laboratories", "TEST", 132, 157], ["computerised medicine", "TREATMENT", 258, 279], ["heart", "ANATOMY", 474, 479]]], ["That may be fine for the production of negative HIV-antibody/antigen analysis as for the screening of blood-donors but certainly not for the bacteriological cultures taken in conjunction with a hip replacement.", [["blood", "ANATOMY", 102, 107], ["hip", "ANATOMY", 194, 197], ["HIV", "ORGANISM", 48, 51], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["donors", "ORGANISM", 108, 114], ["hip", "ORGANISM_SUBDIVISION", 194, 197], ["HIV", "SPECIES", 48, 51], ["antigen analysis", "TEST", 61, 77], ["the screening", "TEST", 85, 98], ["blood-donors", "PROBLEM", 102, 114], ["the bacteriological cultures", "TEST", 137, 165], ["a hip replacement", "TREATMENT", 192, 209], ["hip", "ANATOMY", 194, 197], ["replacement", "OBSERVATION", 198, 209]]], ["Or when it comes to understand and advise on the intricacies of antimicrobial resistance development.", [["antimicrobial resistance development", "TREATMENT", 64, 100], ["antimicrobial resistance", "OBSERVATION", 64, 88]]], ["In other cases \"outsourcing\" and/or \"amalgamation\" mean that blood cultures are sent to X-town, CMV-antibodies to Y-town and everything else to Z-ville.", [["blood cultures", "ANATOMY", 61, 75], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["CMV", "ORGANISM", 96, 99], ["CMV-antibodies", "PROTEIN", 96, 110], ["blood cultures", "TEST", 61, 75], ["CMV", "TEST", 96, 99]]], ["When that happens clinical microbiology is lost.G. Kahlmeter\u00b0(V\u00e4xj\u00f6, SE)There are several instances where concentration, amalgamation and/or outsourcing of clinical microbiological services, alone or with other services, have meant that the tie between clinical microbiology and infection control has been severed and that many, both small and large hospitals have lost the personalised service so necessary to control outbreaks of multi-resistant bacteria and other health care related infections.", [["SE", "DISEASE", 69, 71], ["infection", "DISEASE", 279, 288], ["infections", "DISEASE", 487, 497], ["clinical microbiology", "TEST", 253, 274], ["infection control", "TREATMENT", 279, 296], ["multi-resistant bacteria", "PROBLEM", 432, 456], ["other health care related infections", "PROBLEM", 461, 497], ["infection", "OBSERVATION", 279, 288], ["small", "OBSERVATION_MODIFIER", 334, 339], ["large", "OBSERVATION_MODIFIER", 344, 349], ["multi-resistant bacteria", "OBSERVATION", 432, 456]]], ["A service which encompasses too many branches of laboratory medicine cannot be expected to champion each and every one with equal strength and fervour.", [["laboratory medicine", "TREATMENT", 49, 68], ["branches", "OBSERVATION_MODIFIER", 37, 45]]], ["And when outsourced to \"big companies\", there is no \"clinical\", only \"microbiology\".", [["no", "UNCERTAINTY", 49, 51]]], ["It will have many facets, much strength, some weakness, great opportunities, but many threats.", [["some weakness", "PROBLEM", 41, 54], ["weakness", "OBSERVATION", 46, 54]]], ["ESCMID certainly intends to help shape microbiology in Europe.M. Drancourt\u00b0(Marseille, FR)The optimal organisation of microbiology laboratories in European metropolis is an evolutionary task, driven by the evolution in laboratory tasks, laboratory technologies, communication technologies, regulations and financial issues.", [["microbiology laboratories", "TEST", 118, 143], ["laboratory tasks", "TEST", 219, 235], ["laboratory technologies", "TEST", 237, 260], ["communication technologies", "TREATMENT", 262, 288]]], ["In the past five-ten years, medical and societal query for a more rapid and refined detection and identification of pathogens and antimicrobial resistance determinants coincided with the expansion of internet-based and remote tools for communication, an unprecedented revolution in laboratory technologies and new financial constraints.", [["pathogens", "PROBLEM", 116, 125], ["antimicrobial resistance determinants", "PROBLEM", 130, 167], ["laboratory technologies", "TEST", 282, 305], ["antimicrobial resistance", "OBSERVATION", 130, 154]]], ["The concentration of laboratory workforces into one unique laboratory is one way to address these apparently contradictory issues.", [["contradictory issues", "PROBLEM", 109, 129]]], ["The tertiary medical school hospital system in Marseille, a 2-million metropolitan area in France, comprises four hospitals for a total of 3,500 beds.", [["tertiary", "OBSERVATION_MODIFIER", 4, 12]]], ["The system had once four microbiology laboratories which have been progressively embedded into a unique, 600,000 acts per year, laboratory which deals with bacteriology, virology and environmental microbiology and hygiene.", [["four microbiology laboratories", "TEST", 20, 50]]], ["The medical staff comprises of 17, the ingenior staff of 11, technical staff of 88 and support staff of 13 persons for a total of 129 persons.", [["persons", "ORGANISM", 107, 114], ["persons", "ORGANISM", 134, 141], ["persons", "SPECIES", 107, 114], ["persons", "SPECIES", 134, 141]]], ["This organisation allowed reducing labour time for routine microbiology, to develop prospective and sophisticated time-consuming diagnostic methods and to develop advanced diagnostic methods such as molecular methods (real-time PCR-based tests, sequencing, and mass spectrometry identification) and new generation serology.", [["routine microbiology", "TEST", 51, 71], ["diagnostic methods", "TEST", 129, 147], ["advanced diagnostic methods", "PROBLEM", 163, 190], ["molecular methods", "TEST", 199, 216], ["PCR", "TEST", 228, 231], ["based tests", "TEST", 232, 243], ["sequencing", "TEST", 245, 255], ["mass spectrometry identification", "TEST", 261, 293], ["new generation serology", "TEST", 299, 322]]], ["New, sophisticated technologies such as automated serology and mass spectrometry were corner-stones on which to base the constant diminution of routine labour time and the development of time-consuming tasks such as fastidious organisms' isolation.", [["automated serology", "TEST", 40, 58], ["mass spectrometry", "PROBLEM", 63, 80], ["stones", "PROBLEM", 93, 99], ["fastidious organisms' isolation", "TREATMENT", 216, 247], ["stones", "OBSERVATION", 93, 99], ["constant", "OBSERVATION_MODIFIER", 121, 129], ["diminution", "OBSERVATION_MODIFIER", 130, 140]]], ["These evolutions paralleled the exponential increase in the ratio of ingeniors in the laboratory.", [["exponential", "OBSERVATION_MODIFIER", 32, 43], ["increase", "OBSERVATION_MODIFIER", 44, 52]]], ["This paradigm allowed for the constitution of large collections of biological specimens for retrospective analyses, the specialisation of every medical senior in one particular field of internationally recognized expertise and the increase in knowledge output in terms of peer-reviewed papers, patents and grants.", [["retrospective analyses", "TEST", 92, 114], ["large", "OBSERVATION_MODIFIER", 46, 51], ["collections", "OBSERVATION", 52, 63], ["increase", "OBSERVATION_MODIFIER", 231, 239]]], ["Implantation of point-of-care in the emergency department, in permanent internetbased connection with the central laboratory, was the last, but not least, evolution of this system.S. Hoffner\u00b0(Stockholm, SE)When tuberculosis epidemiology is seen in a global perspective, and the Millennium Development Goals are considered, it is clear that two regions of the world, Africa and Europe, are severely behind in the control of the disease.", [["tuberculosis", "DISEASE", 211, 223], ["Implantation", "TREATMENT", 0, 12], ["the disease", "PROBLEM", 423, 434], ["central", "ANATOMY_MODIFIER", 106, 113], ["tuberculosis", "OBSERVATION", 211, 223], ["disease", "OBSERVATION", 427, 434]]], ["In Africa, especially sub-Saharan Africa, the TB problem is closely related to the endemic HIV/AIDS situation.", [["TB", "DISEASE", 46, 48], ["HIV/AIDS", "DISEASE", 91, 99], ["HIV", "ORGANISM", 91, 94], ["HIV", "SPECIES", 91, 94], ["the TB problem", "PROBLEM", 42, 56], ["the endemic HIV/AIDS situation", "PROBLEM", 79, 109]]], ["In Europe, especially the eastern part and in parts of the former Soviet Union, the main obstacle to an effective TB control is related to drug resistant forms of M. tuberculosis.", [["TB", "DISEASE", 114, 116], ["M. tuberculosis", "DISEASE", 163, 178], ["M. tuberculosis", "ORGANISM", 163, 178], ["M. tuberculosis", "SPECIES", 163, 178], ["M. tuberculosis", "SPECIES", 163, 178], ["an effective TB control", "TREATMENT", 101, 124], ["M. tuberculosis", "PROBLEM", 163, 178], ["M. tuberculosis", "OBSERVATION", 163, 178]]], ["The prevalence of the most severe forms of resistance, MDR-and XDR-TB, is so high that it makes control efforts both extremely complicated and very expensive.", [["MDR-and XDR-TB", "DISEASE", 55, 69], ["MDR", "PROBLEM", 55, 58], ["XDR", "PROBLEM", 63, 66], ["TB", "PROBLEM", 67, 69], ["most severe", "OBSERVATION_MODIFIER", 22, 33]]], ["Unfortunately, increasing levels of drug resistant TB are today also seen in many African countries, and HIV infection is spreading in Eastern Europe.", [["TB", "DISEASE", 51, 53], ["HIV infection", "DISEASE", 105, 118], ["HIV", "ORGANISM", 105, 108], ["HIV", "SPECIES", 105, 108], ["HIV", "SPECIES", 105, 108], ["drug resistant TB", "PROBLEM", 36, 53], ["HIV infection", "PROBLEM", 105, 118], ["drug resistant TB", "OBSERVATION", 36, 53], ["HIV", "OBSERVATION_MODIFIER", 105, 108], ["infection", "OBSERVATION", 109, 118]]], ["During the last ten-year period new tools, based on molecular fingerprinting of M. tuberculosis strains, have been increasingly adapted to study TB transmission.", [["TB", "DISEASE", 145, 147], ["M. tuberculosis", "ORGANISM", 80, 95], ["M. tuberculosis", "SPECIES", 80, 95], ["M. tuberculosis", "SPECIES", 80, 95], ["M. tuberculosis strains", "PROBLEM", 80, 103], ["tuberculosis strains", "OBSERVATION", 83, 103]]], ["With such molecular methods to characterise clinical isolates of M. tuberculosis it is now possible to study the spread of individual strains of the bacteria in detail.", [["M. tuberculosis", "DISEASE", 65, 80], ["M. tuberculosis", "ORGANISM", 65, 80], ["M. tuberculosis", "SPECIES", 65, 80], ["M. tuberculosis", "SPECIES", 65, 80], ["M. tuberculosis", "PROBLEM", 65, 80], ["the bacteria", "PROBLEM", 145, 157], ["tuberculosis", "OBSERVATION", 68, 80], ["bacteria", "OBSERVATION", 149, 157]]], ["The laboratory tools used, RFLP, MIRU/VNTR, spoligotyping and others, will be presented and their use exemplified.", [["RFLP", "DNA", 27, 31], ["MIRU", "DNA", 33, 37], ["VNTR", "DNA", 38, 42], ["The laboratory tools", "TEST", 0, 20], ["RFLP", "TEST", 27, 31]]], ["How molecular epidemiology contributed to the detection and characterisation of a major outbreak of drug resistant TB in the Stockholm area will be discussed.", [["TB", "DISEASE", 115, 117], ["the detection", "TEST", 42, 55], ["drug resistant TB", "PROBLEM", 100, 117], ["major", "OBSERVATION_MODIFIER", 82, 87], ["drug resistant", "OBSERVATION", 100, 114]]], ["Molecular characterisation of clinical isolates from different parts of the world has led to an increased recognition of the differences between different families of M. tuberculosis strains.", [["tuberculosis", "DISEASE", 170, 182], ["M. tuberculosis strains", "ORGANISM", 167, 190], ["M. tuberculosis", "SPECIES", 167, 182], ["M. tuberculosis", "SPECIES", 167, 182], ["clinical isolates", "PROBLEM", 30, 47], ["M. tuberculosis strains", "PROBLEM", 167, 190], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["tuberculosis strains", "OBSERVATION", 170, 190]]], ["To further describe and understand the role of these differences in the clinical field as well as for TB epidemiology is an ongoing and interesting field of research.", [["TB", "DISEASE", 102, 104]]], ["An increased understanding of how TB is transmitted will hopefully help in the efforts to control this global health threat both on the local level and in a global perspective.J.S. Friedland\u00b0(London, UK)Living in the era of increasing tuberculosis drug resistance, the importance of making an early and accurate diagnosis with drug sensitivities has never been greater.", [["TB", "DISEASE", 34, 36], ["tuberculosis", "DISEASE", 235, 247], ["increasing tuberculosis drug resistance", "PROBLEM", 224, 263], ["drug sensitivities", "TEST", 327, 345], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["increasing", "OBSERVATION_MODIFIER", 224, 234], ["tuberculosis", "OBSERVATION", 235, 247], ["drug resistance", "OBSERVATION", 248, 263], ["greater", "OBSERVATION_MODIFIER", 361, 368]]], ["The epidemiology of tuberculosis defines the extent of latent disease and the proportion which becomes active.", [["tuberculosis", "DISEASE", 20, 32], ["tuberculosis", "PROBLEM", 20, 32], ["latent disease", "PROBLEM", 55, 69], ["tuberculosis", "OBSERVATION", 20, 32], ["extent", "OBSERVATION_MODIFIER", 45, 51], ["latent", "OBSERVATION_MODIFIER", 55, 61], ["disease", "OBSERVATION", 62, 69], ["active", "OBSERVATION_MODIFIER", 103, 109]]], ["Accurate diagnosis is vital if patients are to be treated in a timely manner and to reduce the amount of time infectious individuals go untreated in the community disseminating disease.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["disease", "OBSERVATION", 177, 184]]], ["In many areas of the world, DOTS programmes are at the forefront of tuberculosis control.", [["tuberculosis", "DISEASE", 68, 80], ["DOTS programmes", "TREATMENT", 28, 43], ["tuberculosis control", "TREATMENT", 68, 88], ["many", "OBSERVATION_MODIFIER", 3, 7], ["areas", "OBSERVATION_MODIFIER", 8, 13], ["tuberculosis", "OBSERVATION", 68, 80]]], ["However, as a diagnostic this currently relies on sputum smear microscopy which is known to miss 50% of cases of tuberculosis and provides no data on drug sensitivity.", [["tuberculosis", "DISEASE", 113, 125], ["sputum smear microscopy", "TEST", 50, 73], ["tuberculosis", "PROBLEM", 113, 125], ["drug sensitivity", "TEST", 150, 166], ["tuberculosis", "OBSERVATION", 113, 125]]], ["The second major issue around TB is the lack of worldwide diagnostic facilities.", [["TB", "DISEASE", 30, 32]]], ["There is a need for a simple, low cost, easily implemented diagnostic test.", [["diagnostic test", "TEST", 59, 74]]], ["This talk will briefly consider the issues around the diagnosis of latent and active disease which are quite distinct.", [["latent and active disease", "PROBLEM", 67, 92], ["latent", "OBSERVATION", 67, 73], ["active", "OBSERVATION_MODIFIER", 78, 84], ["disease", "OBSERVATION", 85, 92], ["distinct", "OBSERVATION_MODIFIER", 109, 117]]], ["The focus will be on the diagnosis of active infection.", [["infection", "DISEASE", 45, 54], ["active infection", "PROBLEM", 38, 54], ["active", "OBSERVATION_MODIFIER", 38, 44], ["infection", "OBSERVATION", 45, 54]]], ["In particular, the use of MODS (microscopic observation drug-susceptibility) assay in diagnosis of tuberculosis will be discussed.", [["MODS", "DISEASE", 26, 30], ["tuberculosis", "DISEASE", 99, 111], ["MODS", "PROBLEM", 26, 30], ["microscopic observation drug", "TEST", 32, 60], ["tuberculosis", "PROBLEM", 99, 111], ["tuberculosis", "OBSERVATION", 99, 111]]], ["The important issue of how to distinguish patients with latent and active disease will also be considered.", [["latent and active disease", "DISEASE", 56, 81], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["latent and active disease", "PROBLEM", 56, 81], ["active", "OBSERVATION_MODIFIER", 67, 73], ["disease", "OBSERVATION", 74, 81]]], ["Key issues and principles in diagnosis both now and in the future will be reviewed.J.S. Friedland\u00b0(London, UK)In terms of treatment, there are 2 main issues.", [["treatment", "TREATMENT", 122, 131], ["treatment", "OBSERVATION", 122, 131], ["main", "OBSERVATION_MODIFIER", 145, 149]]], ["This may result in drug resistance.", [["drug resistance", "PROBLEM", 19, 34], ["drug resistance", "OBSERVATION", 19, 34]]], ["The massive rise of multi-drug resistant tuberculosis to approximately 500,000 cases world-wide with around 50 countries reporting extensively drug-resistant disease means that the need for new approaches to therapy are urgent.", [["tuberculosis", "DISEASE", 41, 53], ["drug-resistant disease", "DISEASE", 143, 165], ["multi-drug resistant tuberculosis", "PROBLEM", 20, 53], ["extensively drug-resistant disease means", "PROBLEM", 131, 171], ["new approaches", "TREATMENT", 190, 204], ["therapy", "TREATMENT", 208, 215], ["massive", "OBSERVATION_MODIFIER", 4, 11], ["rise", "OBSERVATION_MODIFIER", 12, 16], ["multi", "OBSERVATION_MODIFIER", 20, 25], ["drug resistant", "OBSERVATION_MODIFIER", 26, 40], ["tuberculosis", "OBSERVATION", 41, 53]]], ["The second part of this talk will review different approaches to using current anti-mycobacterial drugs, the emergence of a small number of new drugs such as the diarylquinolones and entirely novel approaches to control and treat tuberculosis.V. Valtonen\u00b0(Helsinki, FI)There has been great success and also many threats in the field of infectious diseases during the previous year.", [["diarylquinolones", "CHEMICAL", 162, 178], ["tuberculosis", "DISEASE", 230, 242], ["infectious diseases", "DISEASE", 336, 355], ["diarylquinolones", "CHEMICAL", 162, 178], ["diarylquinolones", "SIMPLE_CHEMICAL", 162, 178], ["current anti-mycobacterial drugs", "TREATMENT", 71, 103], ["new drugs", "TREATMENT", 140, 149], ["the diarylquinolones", "TREATMENT", 158, 178], ["tuberculosis", "PROBLEM", 230, 242], ["infectious diseases", "PROBLEM", 336, 355], ["tuberculosis", "OBSERVATION", 230, 242], ["great", "OBSERVATION_MODIFIER", 284, 289], ["success", "OBSERVATION", 290, 297], ["infectious", "OBSERVATION", 336, 346]]], ["The antimicrobial resistance, especially increasing carbapenem resistance among aerobic Gram-negative rods and XDR Mycobacterial tuberculosis strains are already big threats in some countries and they will probably spread to many other areas all over the world in the future and we will need new drugs for these indications but unfortunately very few new promising drugs seem to be in the pipeline at the moment for these purposes.", [["carbapenem", "CHEMICAL", 52, 62], ["Mycobacterial tuberculosis", "DISEASE", 115, 141], ["carbapenem", "CHEMICAL", 52, 62], ["XDR Mycobacterial tuberculosis", "ORGANISM", 111, 141], ["Mycobacterial tuberculosis", "SPECIES", 115, 141], ["Mycobacterial tuberculosis", "SPECIES", 115, 141], ["The antimicrobial resistance", "TEST", 0, 28], ["increasing carbapenem resistance", "PROBLEM", 41, 73], ["aerobic Gram", "TEST", 80, 92], ["XDR Mycobacterial tuberculosis strains", "PROBLEM", 111, 149], ["new drugs", "TREATMENT", 292, 301], ["these indications", "TREATMENT", 306, 323], ["antimicrobial resistance", "OBSERVATION", 4, 28], ["increasing", "OBSERVATION_MODIFIER", 41, 51], ["carbapenem resistance", "OBSERVATION", 52, 73], ["negative rods", "OBSERVATION", 93, 106], ["XDR", "OBSERVATION_MODIFIER", 111, 114], ["Mycobacterial tuberculosis", "OBSERVATION", 115, 141]]], ["The virulent Clostridium difficile 027 strain spreads rapidly to many new countries and e.g. in Finland it killed many times more people compared with MRSA and ESBL strains in 2008.", [["Clostridium difficile", "DISEASE", 13, 34], ["Clostridium difficile 027", "ORGANISM", 13, 38], ["people", "ORGANISM", 130, 136], ["Clostridium difficile", "SPECIES", 13, 34], ["people", "SPECIES", 130, 136], ["MRSA", "SPECIES", 151, 155], ["Clostridium difficile 027", "SPECIES", 13, 38], ["MRSA", "SPECIES", 151, 155], ["The virulent Clostridium difficile 027 strain", "PROBLEM", 0, 45], ["MRSA", "PROBLEM", 151, 155], ["ESBL strains", "PROBLEM", 160, 172], ["virulent", "OBSERVATION_MODIFIER", 4, 12], ["Clostridium", "OBSERVATION_MODIFIER", 13, 24], ["difficile", "OBSERVATION_MODIFIER", 25, 34], ["new", "OBSERVATION_MODIFIER", 70, 73]]], ["However, it is possible to stop its spreading but it needs new thinking in antibiotic use policy and infection control policy in hospitals.", [["infection", "DISEASE", 101, 110], ["antibiotic use policy", "TREATMENT", 75, 96]]], ["Clostridium difficile 027 infection has a high relapse rate after metronidazole or vancomycin therapy, but an experimental \"stool exchange treatment\" is a promising therapy although controlled studies are needed to prove this assumption.", [["stool", "ANATOMY", 124, 129], ["Clostridium difficile 027 infection", "DISEASE", 0, 35], ["metronidazole", "CHEMICAL", 66, 79], ["vancomycin", "CHEMICAL", 83, 93], ["metronidazole", "CHEMICAL", 66, 79], ["vancomycin", "CHEMICAL", 83, 93], ["Clostridium difficile 027", "ORGANISM", 0, 25], ["metronidazole", "SIMPLE_CHEMICAL", 66, 79], ["vancomycin", "SIMPLE_CHEMICAL", 83, 93], ["stool", "ORGANISM_SUBSTANCE", 124, 129], ["Clostridium difficile", "SPECIES", 0, 21], ["Clostridium difficile 027", "SPECIES", 0, 25], ["Clostridium difficile 027 infection", "PROBLEM", 0, 35], ["metronidazole", "TREATMENT", 66, 79], ["vancomycin therapy", "TREATMENT", 83, 101], ["an experimental \"stool exchange treatment", "TREATMENT", 107, 148], ["a promising therapy", "TREATMENT", 153, 172]]], ["An interesting research area during the last years has been the role of infections in the etiopathogenesis of chronic diseases like cancer, atherosclerosis, cardiovascular diseases and many autoimmune diseases.", [["cancer", "ANATOMY", 132, 138], ["cardiovascular", "ANATOMY", 157, 171], ["infections", "DISEASE", 72, 82], ["chronic diseases", "DISEASE", 110, 126], ["cancer", "DISEASE", 132, 138], ["atherosclerosis", "DISEASE", 140, 155], ["cardiovascular diseases", "DISEASE", 157, 180], ["autoimmune diseases", "DISEASE", 190, 209], ["cancer", "CANCER", 132, 138], ["cardiovascular", "ANATOMICAL_SYSTEM", 157, 171], ["infections", "PROBLEM", 72, 82], ["chronic diseases like cancer", "PROBLEM", 110, 138], ["atherosclerosis", "PROBLEM", 140, 155], ["cardiovascular diseases", "PROBLEM", 157, 180], ["many autoimmune diseases", "PROBLEM", 185, 209], ["interesting", "OBSERVATION_MODIFIER", 3, 14], ["research", "OBSERVATION_MODIFIER", 15, 23], ["area", "OBSERVATION_MODIFIER", 24, 28], ["infections", "OBSERVATION", 72, 82], ["chronic", "OBSERVATION_MODIFIER", 110, 117], ["diseases", "OBSERVATION", 118, 126], ["cancer", "OBSERVATION", 132, 138], ["atherosclerosis", "OBSERVATION", 140, 155], ["cardiovascular", "ANATOMY", 157, 171], ["diseases", "OBSERVATION", 172, 180], ["many", "OBSERVATION_MODIFIER", 185, 189], ["autoimmune", "OBSERVATION", 190, 200]]], ["We can fight against many cancers like liver cancer and cervix cancer with virus vaccines and gastric cancer with antimicrobial drugs.", [["cancers", "ANATOMY", 26, 33], ["liver cancer", "ANATOMY", 39, 51], ["cervix cancer", "ANATOMY", 56, 69], ["gastric cancer", "ANATOMY", 94, 108], ["cancers", "DISEASE", 26, 33], ["liver cancer", "DISEASE", 39, 51], ["cervix cancer", "DISEASE", 56, 69], ["gastric cancer", "DISEASE", 94, 108], ["cancers", "CANCER", 26, 33], ["liver cancer", "CANCER", 39, 51], ["cervix cancer", "CANCER", 56, 69], ["gastric cancer", "CANCER", 94, 108], ["many cancers", "PROBLEM", 21, 33], ["liver cancer", "PROBLEM", 39, 51], ["cervix cancer", "PROBLEM", 56, 69], ["virus vaccines", "TREATMENT", 75, 89], ["gastric cancer", "PROBLEM", 94, 108], ["antimicrobial drugs", "TREATMENT", 114, 133], ["cancers", "OBSERVATION", 26, 33], ["liver", "ANATOMY", 39, 44], ["cancer", "OBSERVATION", 45, 51], ["cervix", "ANATOMY", 56, 62], ["cancer", "OBSERVATION", 63, 69], ["gastric", "ANATOMY", 94, 101], ["cancer", "OBSERVATION", 102, 108], ["antimicrobial drugs", "OBSERVATION", 114, 133]]], ["Also the high incidence of malignant tumours seems to decrease during Haart treatment in HIV patients.", [["malignant tumours", "ANATOMY", 27, 44], ["malignant tumours", "DISEASE", 27, 44], ["malignant tumours", "CANCER", 27, 44], ["HIV", "ORGANISM", 89, 92], ["patients", "ORGANISM", 93, 101], ["HIV", "SPECIES", 89, 92], ["patients", "SPECIES", 93, 101], ["HIV", "SPECIES", 89, 92], ["malignant tumours", "PROBLEM", 27, 44], ["Haart treatment", "TREATMENT", 70, 85], ["HIV patients", "TREATMENT", 89, 101], ["high", "OBSERVATION_MODIFIER", 9, 13], ["malignant", "OBSERVATION_MODIFIER", 27, 36], ["tumours", "OBSERVATION", 37, 44], ["decrease", "OBSERVATION_MODIFIER", 54, 62]]], ["The role of infections in the etiopathogenesis of cardiovascular diseases and atherosclerosis is complex.", [["cardiovascular", "ANATOMY", 50, 64], ["infections", "DISEASE", 12, 22], ["cardiovascular diseases", "DISEASE", 50, 73], ["atherosclerosis", "DISEASE", 78, 93], ["cardiovascular", "ANATOMICAL_SYSTEM", 50, 64], ["infections", "PROBLEM", 12, 22], ["cardiovascular diseases", "PROBLEM", 50, 73], ["atherosclerosis", "PROBLEM", 78, 93], ["infections", "OBSERVATION", 12, 22], ["cardiovascular", "ANATOMY", 50, 64], ["diseases", "OBSERVATION", 65, 73], ["atherosclerosis", "OBSERVATION", 78, 93], ["complex", "OBSERVATION_MODIFIER", 97, 104]]], ["It is obvious that infections play a role in the etiopathogenesis of atherosclerosis, stroke and myocardial infarction but the undirected routine antimicrobial treatment is not recommended for these patients but there seems to be subgroups in patients with various cardiovascular diseases which may benefit from antimicrobial treatment.", [["myocardial", "ANATOMY", 97, 107], ["cardiovascular", "ANATOMY", 265, 279], ["infections", "DISEASE", 19, 29], ["atherosclerosis", "DISEASE", 69, 84], ["stroke", "DISEASE", 86, 92], ["myocardial infarction", "DISEASE", 97, 118], ["cardiovascular diseases", "DISEASE", 265, 288], ["myocardial", "MULTI-TISSUE_STRUCTURE", 97, 107], ["patients", "ORGANISM", 199, 207], ["patients", "ORGANISM", 243, 251], ["patients", "SPECIES", 199, 207], ["patients", "SPECIES", 243, 251], ["infections", "PROBLEM", 19, 29], ["atherosclerosis", "PROBLEM", 69, 84], ["stroke", "PROBLEM", 86, 92], ["myocardial infarction", "PROBLEM", 97, 118], ["the undirected routine antimicrobial treatment", "TREATMENT", 123, 169], ["various cardiovascular diseases", "PROBLEM", 257, 288], ["antimicrobial treatment", "TREATMENT", 312, 335], ["infections", "OBSERVATION", 19, 29], ["atherosclerosis", "OBSERVATION", 69, 84], ["myocardial", "ANATOMY", 97, 107], ["infarction", "OBSERVATION", 108, 118], ["cardiovascular diseases", "OBSERVATION", 265, 288]]], ["Recent studies seem to suggest that there are HLA types which protect or make people susceptible for coronary heart disease.", [["coronary", "ANATOMY", 101, 109], ["heart", "ANATOMY", 110, 115], ["coronary heart disease", "DISEASE", 101, 123], ["people", "ORGANISM", 78, 84], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 101, 115], ["people", "SPECIES", 78, 84], ["Recent studies", "TEST", 0, 14], ["HLA types", "PROBLEM", 46, 55], ["coronary heart disease", "PROBLEM", 101, 123], ["heart", "ANATOMY", 110, 115], ["disease", "OBSERVATION", 116, 123]]], ["The HLA type HLA-B*35 seems to be a risk factor for coronary heart disease but it is also a risk factor for chronic Chlamydia pneumoniae infection.", [["coronary", "ANATOMY", 52, 60], ["heart", "ANATOMY", 61, 66], ["coronary heart disease", "DISEASE", 52, 74], ["Chlamydia pneumoniae infection", "DISEASE", 116, 146], ["HLA-B*35", "GENE_OR_GENE_PRODUCT", 13, 21], ["heart", "ORGAN", 61, 66], ["Chlamydia pneumoniae", "ORGANISM", 116, 136], ["Chlamydia pneumoniae", "SPECIES", 116, 136], ["Chlamydia pneumoniae", "SPECIES", 116, 136], ["The HLA type HLA", "TEST", 0, 16], ["coronary heart disease", "PROBLEM", 52, 74], ["a risk factor", "PROBLEM", 90, 103], ["chronic Chlamydia pneumoniae infection", "PROBLEM", 108, 146], ["heart", "ANATOMY", 61, 66], ["disease", "OBSERVATION", 67, 74], ["chronic", "OBSERVATION_MODIFIER", 108, 115], ["Chlamydia", "OBSERVATION", 116, 125], ["pneumoniae", "OBSERVATION_MODIFIER", 126, 136], ["infection", "OBSERVATION", 137, 146]]], ["The feared pandemia due to H5N1 influenza A did not appear during the recent year and the world is now much more prepared to meet the next pandemia which, however, hopefully does not come during the next year.Further spread of KPC-type carbapenemases O348 Emergence of KPC-producing Klebsiella pneumoniae in Norway is associated with hospitalisation abroad, nosocomial transmission and sporadic urinary tract infections in outpatients without recent hospitalisation\u00d8.", [["urinary tract", "ANATOMY", 395, 408], ["pandemia", "DISEASE", 11, 19], ["influenza", "DISEASE", 32, 41], ["KPC", "CHEMICAL", 269, 272], ["Klebsiella pneumoniae", "DISEASE", 283, 304], ["urinary tract infections", "DISEASE", 395, 419], ["KPC-type carbapenemases O348", "ORGANISM", 227, 255], ["KPC-producing Klebsiella pneumoniae", "ORGANISM", 269, 304], ["urinary tract", "ORGANISM_SUBDIVISION", 395, 408], ["H5N1 influenza", "SPECIES", 27, 41], ["Klebsiella pneumoniae", "SPECIES", 283, 304], ["outpatients", "SPECIES", 423, 434], ["Klebsiella pneumoniae", "SPECIES", 283, 304], ["The feared pandemia", "PROBLEM", 0, 19], ["H5N1 influenza A", "PROBLEM", 27, 43], ["KPC-type carbapenemases", "TREATMENT", 227, 250], ["KPC", "PROBLEM", 269, 272], ["Klebsiella pneumoniae", "PROBLEM", 283, 304], ["nosocomial transmission", "PROBLEM", 358, 381], ["sporadic urinary tract infections", "PROBLEM", 386, 419], ["recent hospitalisation\u00d8", "PROBLEM", 443, 466], ["H5N1", "OBSERVATION", 27, 31], ["Klebsiella pneumoniae", "OBSERVATION", 283, 304], ["urinary tract", "ANATOMY", 395, 408]]], ["Samuelsen\u00b0, C. Giske, U. Naseer, S. Tofteland, D.H. Skutlaberg, A. Onken, R. Hjetland, A. Sundsfjord (Troms\u00f8, NO; Stockholm, SE; Kristiansand, Bergen, Oslo, F\u00f8rde, NO) Objectives: The worldwide dissemination of KPC-producing multidrugresistant Enterobacteriaceae is worrisome.", [["NO", "CHEMICAL", 110, 112], ["NO", "CHEMICAL", 164, 166], ["KPC", "CHEMICAL", 211, 214], ["NO", "CHEMICAL", 164, 166], ["KPC", "GENE_OR_GENE_PRODUCT", 211, 214], ["KPC", "TEST", 211, 214], ["multidrugresistant Enterobacteriaceae", "PROBLEM", 225, 262], ["Enterobacteriaceae", "OBSERVATION", 244, 262]]], ["The first KPC-producing Klebsiella pneumoniae in Norway was isolated late 2007 from a patient after hospitalisation in Greece.", [["KPC", "CHEMICAL", 10, 13], ["Klebsiella pneumoniae", "DISEASE", 24, 45], ["KPC", "GENE_OR_GENE_PRODUCT", 10, 13], ["Klebsiella pneumoniae", "ORGANISM", 24, 45], ["patient", "ORGANISM", 86, 93], ["Klebsiella pneumoniae", "SPECIES", 24, 45], ["patient", "SPECIES", 86, 93], ["Klebsiella pneumoniae", "SPECIES", 24, 45], ["The first KPC", "TEST", 0, 13], ["Klebsiella pneumoniae", "PROBLEM", 24, 45], ["Klebsiella", "OBSERVATION_MODIFIER", 24, 34], ["pneumoniae", "OBSERVATION", 35, 45]]], ["Throughout the following year seven additional KPC-producing K. pneumoniae isolates have been detected in clinical samples from six new patients.", [["samples", "ANATOMY", 115, 122], ["KPC", "CHEMICAL", 47, 50], ["KPC", "GENE_OR_GENE_PRODUCT", 47, 50], ["K. pneumoniae", "ORGANISM", 61, 74], ["patients", "ORGANISM", 136, 144], ["K. pneumoniae", "SPECIES", 61, 74], ["patients", "SPECIES", 136, 144], ["K. pneumoniae", "SPECIES", 61, 74], ["additional KPC", "TEST", 36, 50], ["K. pneumoniae isolates", "PROBLEM", 61, 83]]], ["The aim of this study was to perform molecular characterisation of the strains and examine their epidemiological relatedness.", [["this study", "TEST", 11, 21], ["the strains", "PROBLEM", 67, 78]]], ["Materials and Methods: Antimicrobial susceptibility was examined by Etest.", [["Antimicrobial susceptibility", "TEST", 23, 51]]], ["Molecular characterisation was performed by MLST, PFGE and sequencing of the blaKPC genetic structure.", [["blaKPC", "GENE_OR_GENE_PRODUCT", 77, 83], ["Molecular characterisation", "TEST", 0, 26], ["MLST", "TEST", 44, 48], ["PFGE", "TEST", 50, 54]]], ["Plasmid analysis was carried out by PFGE of S1 nuclease-digested total DNA and Southern blot hybridisation using a blaKPC probe.", [["DNA", "CELLULAR_COMPONENT", 71, 74], ["S1 nuclease-digested total DNA", "DNA", 44, 74], ["blaKPC probe", "DNA", 115, 127], ["Plasmid analysis", "TEST", 0, 16], ["total DNA", "PROBLEM", 65, 74], ["Southern blot hybridisation", "PROBLEM", 79, 106], ["a blaKPC probe", "TREATMENT", 113, 127]]], ["Results: Eight KPC-producing clinical isolates of K. pneumoniae have been identified from seven patients in two different regions of Norway from the following specimens: blood culture (n = 3), urine (n = 2), expectorate (n = 1), perineal swab (n = 1) and wound secretion (n = 1).", [["specimens", "ANATOMY", 159, 168], ["blood", "ANATOMY", 170, 175], ["urine", "ANATOMY", 193, 198], ["perineal swab", "ANATOMY", 229, 242], ["wound", "ANATOMY", 255, 260], ["KPC", "CHEMICAL", 15, 18], ["K. pneumoniae", "ORGANISM", 50, 63], ["patients", "ORGANISM", 96, 104], ["blood", "ORGANISM_SUBSTANCE", 170, 175], ["urine", "ORGANISM_SUBSTANCE", 193, 198], ["wound", "PATHOLOGICAL_FORMATION", 255, 260], ["K. pneumoniae", "SPECIES", 50, 63], ["patients", "SPECIES", 96, 104], ["K. pneumoniae", "SPECIES", 50, 63], ["Eight KPC", "TEST", 9, 18], ["K. pneumoniae", "PROBLEM", 50, 63], ["blood culture", "TEST", 170, 183], ["urine", "TEST", 193, 198], ["expectorate (n = 1)", "PROBLEM", 208, 227], ["perineal swab", "TEST", 229, 242], ["wound secretion", "PROBLEM", 255, 270], ["perineal", "ANATOMY", 229, 237], ["wound", "ANATOMY", 255, 260], ["secretion", "OBSERVATION", 261, 270]]], ["Two blood culture isolates with clonally related but different PFGEprofiles were observed in one patient.", [["blood culture", "ANATOMY", 4, 17], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["PFGEprofiles", "CANCER", 63, 75], ["patient", "ORGANISM", 97, 104], ["patient", "SPECIES", 97, 104], ["Two blood culture isolates", "TEST", 0, 26], ["different PFGEprofiles", "PROBLEM", 53, 75]]], ["The detection of KPC-producing K. pneumoniae isolates in Norwegian patients was associated with import in four cases after hospitalisation in Greece.", [["KPC", "GENE_OR_GENE_PRODUCT", 17, 20], ["K. pneumoniae", "ORGANISM", 31, 44], ["patients", "ORGANISM", 67, 75], ["K. pneumoniae", "SPECIES", 31, 44], ["patients", "SPECIES", 67, 75], ["K. pneumoniae", "SPECIES", 31, 44], ["KPC", "PROBLEM", 17, 20], ["K. pneumoniae isolates", "PROBLEM", 31, 53]]], ["Two patients had been hospitalised at the same hospital in Greece.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Isolation of a KPC-producing isolate in a fifth patient was epidemiologically linked to one of these imported cases and was a case of nosocomial transmission in Norway.", [["KPC", "CHEMICAL", 15, 18], ["KPC", "GENE_OR_GENE_PRODUCT", 15, 18], ["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["a KPC", "TEST", 13, 18]]], ["For the latter two cases no risk factors were identified with respect to recent hospitalisation or travel abroad.", [["risk factors", "PROBLEM", 28, 40]]], ["Molecular analysis of six isolates has shown genetically related PFGE-patterns and a common sequence type (ST258).", [["Molecular analysis", "TEST", 0, 18], ["six isolates", "TEST", 22, 34]]], ["ST258 has been associated with dissemination of CTX-M-15 in Hungary.", [["ST258", "CHEMICAL", 0, 5], ["CTX-M-15", "CHEMICAL", 48, 56], ["ST258", "GENE_OR_GENE_PRODUCT", 0, 5], ["ST258", "DNA", 0, 5], ["CTX", "TEST", 48, 51], ["dissemination", "OBSERVATION_MODIFIER", 31, 44]]], ["The blaKPC gene was localised in Tn4401 on a~97 kb plasmid.", [["Tn4401", "ANATOMY", 33, 39], ["plasmid", "ANATOMY", 51, 58], ["blaKPC", "GENE_OR_GENE_PRODUCT", 4, 10], ["Tn4401", "GENE_OR_GENE_PRODUCT", 33, 39], ["blaKPC gene", "DNA", 4, 15], ["Tn4401", "DNA", 33, 39], ["~97 kb plasmid", "DNA", 44, 58], ["a~97 kb plasmid", "TREATMENT", 43, 58]]], ["The two most recent isolates are currently undergoing similar analysis.", [["similar analysis", "TEST", 54, 70]]], ["Conclusion: The first seven cases of KPC-producing K. pneumoniae in Norway are associated with hospitalisation abroad, nosocomial transmission in Norway, or urinary tract infections in outpatients without obvious risk factors.", [["urinary tract", "ANATOMY", 157, 170], ["KPC", "CHEMICAL", 37, 40], ["K. pneumoniae", "DISEASE", 51, 64], ["urinary tract infections", "DISEASE", 157, 181], ["KPC", "GENE_OR_GENE_PRODUCT", 37, 40], ["K. pneumoniae", "ORGANISM", 51, 64], ["urinary tract", "ORGANISM_SUBDIVISION", 157, 170], ["K. pneumoniae", "SPECIES", 51, 64], ["outpatients", "SPECIES", 185, 196], ["K. pneumoniae", "SPECIES", 51, 64], ["KPC", "PROBLEM", 37, 40], ["K. pneumoniae", "PROBLEM", 51, 64], ["urinary tract infections", "PROBLEM", 157, 181], ["obvious risk factors", "PROBLEM", 205, 225], ["pneumoniae", "OBSERVATION", 54, 64], ["urinary tract", "ANATOMY", 157, 170]]], ["The clonal relationship between isolates underlines the existence a biological fit genetic lineage of KPCproducing K. pneumoniae with an epidemic potential.P. Giakkoupi, H. Maltezou, M. Polemis, O. Pappa, G. Saroglou, A. Vatopoulos\u00b0on behalf of the National Surveillance System for Antimicrobial ResistanceObjectives: Two recent publications have reported the isolation of KPC producing K. pneumoniae from infections in two patients, one in France and one in Sweden, who originally had been hospitalised in Greece.", [["KPC", "CHEMICAL", 373, 376], ["K. pneumoniae", "DISEASE", 387, 400], ["infections", "DISEASE", 406, 416], ["KPCproducing", "ORGANISM", 102, 114], ["K. pneumoniae", "ORGANISM", 115, 128], ["K. pneumoniae", "ORGANISM", 387, 400], ["patients", "ORGANISM", 424, 432], ["K. pneumoniae", "SPECIES", 115, 128], ["K. pneumoniae", "SPECIES", 387, 400], ["patients", "SPECIES", 424, 432], ["K. pneumoniae", "SPECIES", 115, 128], ["K. pneumoniae", "SPECIES", 387, 400], ["KPCproducing K. pneumoniae", "PROBLEM", 102, 128], ["KPC", "PROBLEM", 373, 376], ["K. pneumoniae", "PROBLEM", 387, 400], ["pneumoniae", "OBSERVATION", 118, 128], ["epidemic", "OBSERVATION_MODIFIER", 137, 145]]], ["Since this resistant mechanism had not been identified before in this country, the purpose of this report was to confirm the presence of blaKPC producing K. pneumoniae in Greece, to assess the extent of its spread and to study the genetic relatedness of the respective bacterial strains and the transferability of the blaKPC harbouring plasmids.", [["plasmids", "ANATOMY", 336, 344], ["blaKPC", "GENE_OR_GENE_PRODUCT", 137, 143], ["K. pneumoniae", "ORGANISM", 154, 167], ["blaKPC", "GENE_OR_GENE_PRODUCT", 318, 324], ["blaKPC harbouring plasmids", "DNA", 318, 344], ["K. pneumoniae", "SPECIES", 154, 167], ["K. pneumoniae", "SPECIES", 154, 167], ["blaKPC producing K. pneumoniae", "PROBLEM", 137, 167], ["the respective bacterial strains", "PROBLEM", 254, 286], ["the blaKPC harbouring plasmids", "TREATMENT", 314, 344], ["bacterial strains", "OBSERVATION", 269, 286]]], ["Methods: For a three month period (February to April 2008) 40 hospitals participating in the Greek System for Surveillance of Antibiotic Resistance (www.mednet.gr/whonet) were asked to seek for possible KPC producers among K pneumoniae isolates displaying reduced susceptibility to imipenem (equal or higher than 1 mg/L), a positive Hodge test for the presence of carbapenemase and a negative EDTA synergy test for the presence of metalloenzymes.", [["K", "CHEMICAL", 223, 224], ["imipenem", "CHEMICAL", 282, 290], ["imipenem", "CHEMICAL", 282, 290], ["EDTA", "CHEMICAL", 393, 397], ["KPC", "GENE_OR_GENE_PRODUCT", 203, 206], ["K pneumoniae", "ORGANISM", 223, 235], ["imipenem", "SIMPLE_CHEMICAL", 282, 290], ["EDTA", "SIMPLE_CHEMICAL", 393, 397], ["carbapenemase", "PROTEIN", 364, 377], ["metalloenzymes", "PROTEIN", 431, 445], ["K pneumoniae", "SPECIES", 223, 235], ["K pneumoniae", "SPECIES", 223, 235], ["Antibiotic Resistance (www.mednet.gr/whonet)", "TREATMENT", 126, 170], ["KPC producers", "TREATMENT", 203, 216], ["K pneumoniae isolates", "PROBLEM", 223, 244], ["imipenem", "TEST", 282, 290], ["a positive Hodge test", "PROBLEM", 322, 343], ["carbapenemase", "PROBLEM", 364, 377], ["a negative EDTA synergy test", "TEST", 382, 410]]], ["The presence of blaKPC gene in these strains was confirmed by PCR and sequencing.", [["blaKPC", "GENE_OR_GENE_PRODUCT", 16, 22], ["blaKPC gene", "DNA", 16, 27], ["blaKPC gene in these strains", "PROBLEM", 16, 44], ["PCR", "TEST", 62, 65], ["sequencing", "TEST", 70, 80]]], ["MICs to carbapenems were determined by etest.", [["MICs", "CHEMICAL", 0, 4], ["carbapenems", "CHEMICAL", 8, 19], ["carbapenems", "CHEMICAL", 8, 19], ["carbapenems", "SIMPLE_CHEMICAL", 8, 19], ["carbapenems", "TREATMENT", 8, 19]]], ["Conjugation experiments were carried out both in broth and on agar.", [["Conjugation experiments", "TREATMENT", 0, 23]]], ["The possible absence of OmpK36 porin was detected by PCR.", [["OmpK36 porin", "GENE_OR_GENE_PRODUCT", 24, 36], ["OmpK36 porin", "PROTEIN", 24, 36], ["OmpK36 porin", "PROBLEM", 24, 36], ["PCR", "TEST", 53, 56], ["possible", "UNCERTAINTY", 4, 12]]], ["Molecular typing was performed by pulse-field gel electrophoresis of XbaI-restricted genomic DNA.", [["XbaI", "GENE_OR_GENE_PRODUCT", 69, 73], ["DNA", "CELLULAR_COMPONENT", 93, 96], ["XbaI-restricted genomic DNA", "DNA", 69, 96], ["Molecular typing", "TEST", 0, 16], ["XbaI", "PROBLEM", 69, 73], ["restricted genomic DNA", "PROBLEM", 74, 96], ["genomic DNA", "OBSERVATION", 85, 96]]], ["Results: Ninety two K. pneumoniae clinical isolates (one per patient) from 13 Hospitals all over Greece were found to harbour blaKPC-2 gene.", [["K. pneumoniae", "ORGANISM", 20, 33], ["patient", "ORGANISM", 61, 68], ["blaKPC-2", "GENE_OR_GENE_PRODUCT", 126, 134], ["blaKPC-2 gene", "DNA", 126, 139], ["K. pneumoniae", "SPECIES", 20, 33], ["patient", "SPECIES", 61, 68], ["K. pneumoniae", "SPECIES", 20, 33]]], ["Although colonies present in the inhibition zone made the exact determination of imipenem MIC difficult, the absence of OmpK36 porin was always associated with MIC of imipenem higher than 32 mg/L. All isolates exhibited resistance to all other drug classes except colistin, tetracycline and tigecycline.", [["colonies", "ANATOMY", 9, 17], ["imipenem", "CHEMICAL", 81, 89], ["MIC", "CHEMICAL", 160, 163], ["imipenem", "CHEMICAL", 167, 175], ["colistin", "CHEMICAL", 264, 272], ["tetracycline", "CHEMICAL", 274, 286], ["tigecycline", "CHEMICAL", 291, 302], ["imipenem", "CHEMICAL", 81, 89], ["imipenem", "CHEMICAL", 167, 175], ["colistin", "CHEMICAL", 264, 272], ["tetracycline", "CHEMICAL", 274, 286], ["tigecycline", "CHEMICAL", 291, 302], ["imipenem", "SIMPLE_CHEMICAL", 81, 89], ["OmpK36 porin", "GENE_OR_GENE_PRODUCT", 120, 132], ["imipenem", "SIMPLE_CHEMICAL", 167, 175], ["colistin", "SIMPLE_CHEMICAL", 264, 272], ["tetracycline", "SIMPLE_CHEMICAL", 274, 286], ["tigecycline", "SIMPLE_CHEMICAL", 291, 302], ["OmpK36 porin", "PROTEIN", 120, 132], ["colonies", "PROBLEM", 9, 17], ["imipenem MIC", "TREATMENT", 81, 93], ["OmpK36 porin", "TREATMENT", 120, 132], ["imipenem", "TREATMENT", 167, 175], ["all other drug classes", "TREATMENT", 234, 256], ["colistin", "TREATMENT", 264, 272], ["tetracycline", "TREATMENT", 274, 286], ["tigecycline", "TREATMENT", 291, 302], ["colonies", "OBSERVATION", 9, 17]]], ["PFGE analysis revealed that 85 isolates from 12 Hospitals displayed more than 95% similarity and were classified into one pulsotype, whereas the remaining seven isolates belonged into four different pulsotypes. blaKPC-2 gene could not be transferred by conjugation from strains belonging to the main pulsotype.", [["blaKPC-2", "GENE_OR_GENE_PRODUCT", 211, 219], ["blaKPC-2 gene", "DNA", 211, 224], ["PFGE analysis", "TEST", 0, 13], ["blaKPC", "TEST", 211, 217]]], ["Conclusion: Production of KPC-2 betalactamase seems to be a new emerging resistance mechanism in Klebsiella pneumoniae in Greece. blaKPC-2 gene's possible clonal spread imposes the urgent need of implication of infection control practices in the affected hospitals.O350 An outbreak of Klebsiella pneumoniae producing KPC-2 carbapenemase in a Greek universtity hospitalI.", [["KPC-2 betalactamase", "CHEMICAL", 26, 45], ["Klebsiella pneumoniae", "DISEASE", 97, 118], ["infection", "DISEASE", 211, 220], ["Klebsiella pneumoniae", "DISEASE", 285, 306], ["KPC-2 carbapenemase", "CHEMICAL", 317, 336], ["KPC-2", "GENE_OR_GENE_PRODUCT", 26, 31], ["Klebsiella pneumoniae", "ORGANISM", 97, 118], ["blaKPC-2", "GENE_OR_GENE_PRODUCT", 130, 138], ["Klebsiella pneumoniae", "ORGANISM", 285, 306], ["KPC-2 carbapenemase", "GENE_OR_GENE_PRODUCT", 317, 336], ["KPC-2 betalactamase", "PROTEIN", 26, 45], ["blaKPC-2 gene", "DNA", 130, 143], ["Klebsiella pneumoniae", "SPECIES", 97, 118], ["Klebsiella pneumoniae", "SPECIES", 285, 306], ["Klebsiella pneumoniae", "SPECIES", 97, 118], ["Klebsiella pneumoniae", "SPECIES", 285, 306], ["KPC", "TEST", 26, 29], ["Klebsiella pneumoniae", "PROBLEM", 97, 118], ["blaKPC", "TEST", 130, 136], ["clonal spread", "PROBLEM", 155, 168], ["infection control practices", "TREATMENT", 211, 238], ["Klebsiella pneumoniae", "PROBLEM", 285, 306], ["KPC", "PROBLEM", 317, 320], ["Klebsiella pneumoniae", "OBSERVATION", 97, 118], ["possible", "UNCERTAINTY", 146, 154], ["clonal spread", "OBSERVATION", 155, 168], ["infection", "OBSERVATION", 211, 220], ["Klebsiella pneumoniae", "OBSERVATION", 285, 306]]], ["Galani, M. Souli, E. Papadomichelakis, F. Panayea, N. Mitchell, A. Antoniadou, G. Poulakou, F. Kontopidou, H. Giamarellou\u00b0(Athens, GR) Background: Until now, carbapenem resistance among Klebsiella pneumoniae (Kp) clinical isolates in Greek hospitals has been attributed to the dissemination of VIM-1 metallo-beta-lactamase.", [["carbapenem", "CHEMICAL", 158, 168], ["Klebsiella pneumoniae", "DISEASE", 186, 207], ["VIM-1 metallo-beta-lactamase", "CHEMICAL", 294, 322], ["carbapenem", "CHEMICAL", 158, 168], ["carbapenem", "SIMPLE_CHEMICAL", 158, 168], ["Klebsiella pneumoniae", "ORGANISM", 186, 207], ["Kp)", "ORGANISM", 209, 212], ["VIM-1", "GENE_OR_GENE_PRODUCT", 294, 299], ["metallo-beta-lactamase", "GENE_OR_GENE_PRODUCT", 300, 322], ["VIM-1 metallo-beta-lactamase", "PROTEIN", 294, 322], ["Klebsiella pneumoniae", "SPECIES", 186, 207], ["Klebsiella pneumoniae", "SPECIES", 186, 207], ["carbapenem resistance", "PROBLEM", 158, 179], ["Klebsiella pneumoniae", "PROBLEM", 186, 207], ["VIM", "TEST", 294, 297], ["M. Souli", "OBSERVATION", 8, 16]]], ["We describe the first outbreak of KPC-producing Kp in Greece; the first to occur outside the USA or Israel.", [["KPC", "CHEMICAL", 34, 37], ["KPC", "PROBLEM", 34, 37]]], ["Methods: Kp isolates with an imipenem MIC > 1 mg/L and a negative EDTA-imipenem disk synergy test were submitted to boronic acid disk test, to PCR for a KPC gene with specific primers and sequencing.", [["imipenem", "CHEMICAL", 29, 37], ["EDTA", "CHEMICAL", 66, 70], ["imipenem", "CHEMICAL", 71, 79], ["boronic acid", "CHEMICAL", 116, 128], ["imipenem", "CHEMICAL", 29, 37], ["EDTA", "CHEMICAL", 66, 70], ["imipenem", "CHEMICAL", 71, 79], ["boronic acid", "CHEMICAL", 116, 128], ["imipenem", "SIMPLE_CHEMICAL", 29, 37], ["EDTA", "SIMPLE_CHEMICAL", 66, 70], ["boronic acid", "SIMPLE_CHEMICAL", 116, 128], ["KPC", "GENE_OR_GENE_PRODUCT", 153, 156], ["KPC gene", "DNA", 153, 161], ["Kp isolates", "TREATMENT", 9, 20], ["an imipenem MIC", "TREATMENT", 26, 41], ["imipenem disk synergy test", "TEST", 71, 97], ["boronic acid disk test", "TEST", 116, 138], ["PCR", "TEST", 143, 146], ["a KPC gene", "TREATMENT", 151, 161], ["specific primers", "TREATMENT", 167, 183]]], ["Records from patients colonised or infected with a KPC-producing Kp were retrospectively reviewed for clinical and epidemiological data.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["a KPC", "TEST", 49, 54]]], ["Environmental cultures for KPC-producers were performed.", [["KPC", "GENE_OR_GENE_PRODUCT", 27, 30], ["KPC", "PROTEIN", 27, 30], ["Environmental cultures", "TEST", 0, 22], ["KPC", "TEST", 27, 30]]], ["Clinical isolates were submitted to molecular typing using PFGE.", [["Clinical isolates", "PROBLEM", 0, 17]]], ["Results: From February to November 2008, 552 Kp were isolated from 95 patients, 132 (23.9%) of which were boronic acid positive and produced KPC-2.", [["boronic acid", "CHEMICAL", 106, 118], ["boronic acid", "CHEMICAL", 106, 118], ["patients", "ORGANISM", 70, 78], ["boronic acid", "SIMPLE_CHEMICAL", 106, 118], ["KPC-2", "GENE_OR_GENE_PRODUCT", 141, 146], ["patients", "SPECIES", 70, 78], ["boronic acid", "TEST", 106, 118], ["KPC", "TEST", 141, 144]]], ["A total of 24 patients were identified as colonised or infected by a KPC producer which in 22 of them belonged to the same genetic clone.", [["patients", "ORGANISM", 14, 22], ["clone", "CELL", 131, 136], ["patients", "SPECIES", 14, 22], ["a KPC producer", "TREATMENT", 67, 81], ["infected", "OBSERVATION", 55, 63]]], ["The source was faeces (73), bronchial secretions (26), blood (7), CVC tip (5), urine (15), pus (4) and throat (2).", [["faeces", "ANATOMY", 15, 21], ["bronchial secretions", "ANATOMY", 28, 48], ["blood", "ANATOMY", 55, 60], ["CVC tip", "ANATOMY", 66, 73], ["urine", "ANATOMY", 79, 84], ["pus", "ANATOMY", 91, 94], ["faeces", "ORGANISM_SUBSTANCE", 15, 21], ["bronchial secretions", "MULTI-TISSUE_STRUCTURE", 28, 48], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["CVC tip", "MULTI-TISSUE_STRUCTURE", 66, 73], ["urine", "ORGANISM_SUBSTANCE", 79, 84], ["pus", "ORGANISM_SUBSTANCE", 91, 94], ["bronchial secretions", "TEST", 28, 48], ["blood", "TEST", 55, 60], ["CVC tip", "TEST", 66, 73], ["urine", "TEST", 79, 84], ["pus", "PROBLEM", 91, 94], ["bronchial", "ANATOMY", 28, 37], ["secretions", "OBSERVATION", 38, 48], ["CVC", "ANATOMY", 66, 69], ["tip", "OBSERVATION_MODIFIER", 70, 73], ["pus", "OBSERVATION", 91, 94], ["throat", "ANATOMY", 103, 109]]], ["Among patients whose medical records were available, median age was 74, APACHE II score; 21, length of preceding hospital stay; 28 days, total length of stay; 50 days, immunosuppresion was identified in one and crude mortality was 71%.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["APACHE II score", "TEST", 72, 87], ["immunosuppresion", "TREATMENT", 168, 184]]], ["The KPC-producing Kp was more frequently ICU acquired whereas in a minority of patients it was already present on ICU admission.", [["KPC", "GENE_OR_GENE_PRODUCT", 4, 7], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["The KPC", "TEST", 0, 7]]], ["Seventy percent of the patients had previously received a carbapenem for a median of 15 days.", [["carbapenem", "CHEMICAL", 58, 68], ["carbapenem", "CHEMICAL", 58, 68], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["a carbapenem", "TREATMENT", 56, 68]]], ["Environmental colonisation was not identified.", [["Environmental colonisation", "PROBLEM", 0, 26], ["colonisation", "OBSERVATION", 14, 26]]], ["Ten (7.6%) of the KPCproducers from 8 (33.3%) patients were identified as the cause of an infection: bacteraemia (7), ventilator-associated pneumonia (2) and surgical site infection (1) and exhibited MIC90 (mg/L) for imipenem, >8; meropenem, >8; gentamicin, 4; ciprofloxacin, >2; fosfomycin, >128; colistin, 0.5 and tigecycline, 4.", [["KPCproducers", "ANATOMY", 18, 30], ["site", "ANATOMY", 167, 171], ["infection", "DISEASE", 90, 99], ["bacteraemia", "DISEASE", 101, 112], ["ventilator-associated pneumonia", "DISEASE", 118, 149], ["surgical site infection", "DISEASE", 158, 181], ["MIC90", "CHEMICAL", 200, 205], ["imipenem", "CHEMICAL", 217, 225], ["meropenem", "CHEMICAL", 231, 240], ["gentamicin", "CHEMICAL", 246, 256], ["ciprofloxacin", "CHEMICAL", 261, 274], ["fosfomycin", "CHEMICAL", 280, 290], ["colistin", "CHEMICAL", 298, 306], ["tigecycline", "CHEMICAL", 316, 327], ["imipenem", "CHEMICAL", 217, 225], ["meropenem", "CHEMICAL", 231, 240], ["gentamicin", "CHEMICAL", 246, 256], ["ciprofloxacin", "CHEMICAL", 261, 274], ["fosfomycin", "CHEMICAL", 280, 290], ["colistin", "CHEMICAL", 298, 306], ["tigecycline", "CHEMICAL", 316, 327], ["KPCproducers", "CANCER", 18, 30], ["patients", "ORGANISM", 46, 54], ["imipenem", "SIMPLE_CHEMICAL", 217, 225], ["meropenem", "SIMPLE_CHEMICAL", 231, 240], ["gentamicin", "SIMPLE_CHEMICAL", 246, 256], ["ciprofloxacin", "SIMPLE_CHEMICAL", 261, 274], ["fosfomycin", "SIMPLE_CHEMICAL", 280, 290], ["colistin", "SIMPLE_CHEMICAL", 298, 306], ["tigecycline", "SIMPLE_CHEMICAL", 316, 327], ["patients", "SPECIES", 46, 54], ["the KPCproducers", "TEST", 14, 30], ["an infection", "PROBLEM", 87, 99], ["bacteraemia", "PROBLEM", 101, 112], ["ventilator-associated pneumonia", "PROBLEM", 118, 149], ["surgical site infection", "PROBLEM", 158, 181], ["MIC90", "TEST", 200, 205], ["imipenem", "TREATMENT", 217, 225], ["meropenem", "TREATMENT", 231, 240], ["gentamicin", "TREATMENT", 246, 256], ["ciprofloxacin", "TREATMENT", 261, 274], ["fosfomycin", "TREATMENT", 280, 290], ["colistin", "TREATMENT", 298, 306], ["tigecycline", "TREATMENT", 316, 327], ["infection", "OBSERVATION", 90, 99], ["bacteraemia", "OBSERVATION", 101, 112], ["pneumonia", "OBSERVATION", 140, 149], ["infection", "OBSERVATION", 172, 181]]], ["Most patients were successfully treated with a colistin-containing combination mostly with a beta-lactam.", [["colistin", "CHEMICAL", 47, 55], ["colistin", "CHEMICAL", 47, 55], ["patients", "ORGANISM", 5, 13], ["colistin", "SIMPLE_CHEMICAL", 47, 55], ["beta-lactam", "SIMPLE_CHEMICAL", 93, 104], ["patients", "SPECIES", 5, 13], ["a colistin", "TREATMENT", 45, 55], ["a beta-lactam", "TREATMENT", 91, 104]]], ["There was no attributed mortality.", [["attributed mortality", "PROBLEM", 13, 33], ["no attributed", "UNCERTAINTY", 10, 23], ["mortality", "OBSERVATION", 24, 33]]], ["Isolates from the same bacterial species were typed by PFGE or automated ribotyping.", [["Isolates", "TREATMENT", 0, 8], ["the same bacterial species", "PROBLEM", 14, 40], ["automated ribotyping", "TEST", 63, 83], ["bacterial species", "OBSERVATION", 23, 40]]], ["KPC-encoding gene was fully sequenced.", [["KPC", "GENE_OR_GENE_PRODUCT", 0, 3], ["KPC-encoding gene", "DNA", 0, 17], ["KPC", "TEST", 0, 3]]], ["Plasmid preparations and I-Ceu digestion of total DNA were resolved in agarose gels, blotted and hybridised with a blaKPC probe.", [["Plasmid", "ANATOMY", 0, 7], ["I-Ceu", "GENE_OR_GENE_PRODUCT", 25, 30], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["agarose", "SIMPLE_CHEMICAL", 71, 78], ["blaKPC probe", "DNA", 115, 127], ["Plasmid preparations", "TREATMENT", 0, 20], ["total DNA", "PROBLEM", 44, 53], ["agarose gels", "PROBLEM", 71, 83], ["a blaKPC probe", "TREATMENT", 113, 127]]], ["The blaKPC-carrying element (Tn4401) was amplified with various primer pairs, digested with Eag I and sequenced.", [["blaKPC", "GENE_OR_GENE_PRODUCT", 4, 10], ["Tn4401", "GENE_OR_GENE_PRODUCT", 29, 35], ["Eag I", "GENE_OR_GENE_PRODUCT", 92, 97], ["blaKPC-carrying element", "DNA", 4, 27], ["Tn4401", "DNA", 29, 35], ["primer pairs", "DNA", 64, 76], ["Eag I", "DNA", 92, 97]]], ["Results: 30 strains each carried KPC-2 and KPC-3.", [["KPC-2", "GENE_OR_GENE_PRODUCT", 33, 38], ["KPC-3", "GENE_OR_GENE_PRODUCT", 43, 48], ["KPC-2 and KPC-3", "DNA", 33, 48], ["KPC", "TEST", 33, 36], ["KPC", "TEST", 43, 46]]], ["One E. cloacae carried KPC-4.", [["E. cloacae", "ORGANISM", 4, 14], ["KPC-4", "CELL", 23, 28], ["E. cloacae", "SPECIES", 4, 14], ["E. cloacae", "SPECIES", 4, 14], ["KPC", "TEST", 23, 26], ["cloacae", "OBSERVATION", 7, 14]]], ["13 K. oxytoca were KPC-2-producers and 2 S. marcescens harboured blaKPC-3, all from USA.", [["K. oxytoca", "ORGANISM", 3, 13], ["KPC-2", "CELL", 19, 24], ["S. marcescens", "ORGANISM", 41, 54], ["blaKPC-3", "GENE_OR_GENE_PRODUCT", 65, 73], ["K. oxytoca", "SPECIES", 3, 13], ["S. marcescens", "SPECIES", 41, 54], ["K. oxytoca", "SPECIES", 3, 13], ["S. marcescens", "SPECIES", 41, 54], ["K. oxytoca", "TEST", 3, 13], ["KPC", "TEST", 19, 22]]], ["Great genetic diversity was observed among the isolates (41 different types).", [["Great genetic diversity", "PROBLEM", 0, 23], ["the isolates", "TEST", 43, 55], ["genetic diversity", "OBSERVATION", 6, 23]]], ["One clone of 10 E. cloacae was detected in New York state (2006) (2007) .", [["clone", "CELL", 4, 9], ["E. cloacae", "ORGANISM", 16, 26], ["E. cloacae", "SPECIES", 16, 26], ["E. cloacae", "SPECIES", 16, 26]]], ["Small clusters of 2 and 3 strains were detected among E. coli, E. cloacae, K. oxytoca.", [["E. coli", "ORGANISM", 54, 61], ["E. cloacae", "ORGANISM", 63, 73], ["K. oxytoca", "ORGANISM", 75, 85], ["E. coli", "SPECIES", 54, 61], ["E. cloacae", "SPECIES", 63, 73], ["K. oxytoca", "SPECIES", 75, 85], ["E. coli", "SPECIES", 54, 61], ["E. cloacae", "SPECIES", 63, 73], ["K. oxytoca", "SPECIES", 75, 85], ["Small clusters of 2 and 3 strains", "PROBLEM", 0, 33], ["E. coli", "PROBLEM", 54, 61], ["E. cloacae", "PROBLEM", 63, 73], ["oxytoca", "PROBLEM", 78, 85], ["clusters", "OBSERVATION_MODIFIER", 6, 14], ["coli", "ANATOMY", 57, 61], ["cloacae", "OBSERVATION_MODIFIER", 66, 73]]], ["Plasmids were present in all but 3 isolates.", [["Plasmids", "TREATMENT", 0, 8]]], ["Persistence of clones throughout the years was not observed.", [["clones", "CELL", 15, 21], ["clones", "PROBLEM", 15, 21], ["clones", "OBSERVATION", 15, 21]]], ["In 35 isolates the KPC-encoding gene was located in high molecular weight plasmids (>54 Kb). blaKPC was located in the chromosome of 11 strains (E. cloacae, E. coli and K. oxytoca) and the location of this gene could not be determined in 15 strains.", [["chromosome", "ANATOMY", 119, 129], ["strains", "ANATOMY", 136, 143], ["KPC", "GENE_OR_GENE_PRODUCT", 19, 22], ["blaKPC", "GENE_OR_GENE_PRODUCT", 93, 99], ["chromosome", "CELLULAR_COMPONENT", 119, 129], ["E. cloacae", "ORGANISM", 145, 155], ["E. coli", "ORGANISM", 157, 164], ["K. oxytoca", "ORGANISM", 169, 179], ["KPC-encoding gene", "DNA", 19, 36], ["high molecular weight plasmids", "DNA", 52, 82], ["blaKPC", "DNA", 93, 99], ["E. cloacae", "SPECIES", 145, 155], ["E. coli", "SPECIES", 157, 164], ["K. oxytoca", "SPECIES", 169, 179], ["E. cloacae", "SPECIES", 145, 155], ["E. coli", "SPECIES", 157, 164], ["K. oxytoca", "SPECIES", 169, 179], ["the KPC", "TEST", 15, 22], ["blaKPC", "PROBLEM", 93, 99], ["E. cloacae", "PROBLEM", 145, 155], ["E. coli", "PROBLEM", 157, 164], ["K. oxytoca", "PROBLEM", 169, 179]]], ["Small plasmids were present in several strains, but did not harbour blaKPC.", [["plasmids", "ANATOMY", 6, 14], ["blaKPC", "GENE_OR_GENE_PRODUCT", 68, 74], ["blaKPC", "PROTEIN", 68, 74], ["Small plasmids", "PROBLEM", 0, 14], ["several strains", "PROBLEM", 31, 46], ["plasmids", "OBSERVATION", 6, 14], ["several strains", "OBSERVATION_MODIFIER", 31, 46]]], ["Tn4401 carried blaKPC in 46 isolates, and the transposon element was conserved.", [["Tn4401", "CHEMICAL", 0, 6], ["Tn4401", "GENE_OR_GENE_PRODUCT", 0, 6], ["blaKPC", "GENE_OR_GENE_PRODUCT", 15, 21], ["Tn4401", "DNA", 0, 6], ["blaKPC", "DNA", 15, 21], ["transposon element", "DNA", 46, 64], ["Tn", "TEST", 0, 2], ["the transposon element", "TREATMENT", 42, 64]]], ["This structure was not detected in 12 strains.", [["not detected", "UNCERTAINTY", 19, 31]]], ["Conclusions: KPC-encoding genes were most often located in Tn4401 among several Enterobacteriaceae species collected in USA and Israel.", [["KPC", "GENE_OR_GENE_PRODUCT", 13, 16], ["Tn4401", "GENE_OR_GENE_PRODUCT", 59, 65], ["KPC-encoding genes", "DNA", 13, 31], ["Tn4401", "DNA", 59, 65], ["Tn4401", "SPECIES", 59, 65], ["KPC", "TEST", 13, 16], ["encoding genes", "PROBLEM", 17, 31], ["several Enterobacteriaceae species", "PROBLEM", 72, 106], ["Enterobacteriaceae species", "OBSERVATION", 80, 106]]], ["This blaKPC-carrying element was located in plasmids and on the chromosome.", [["plasmids", "ANATOMY", 44, 52], ["chromosome", "ANATOMY", 64, 74], ["blaKPC", "GENE_OR_GENE_PRODUCT", 5, 11], ["chromosome", "CELLULAR_COMPONENT", 64, 74], ["blaKPC-carrying element", "DNA", 5, 28], ["plasmids", "DNA", 44, 52], ["This blaKPC-carrying element", "PROBLEM", 0, 28]]], ["This study highlights the importance of Tn4401 in the dissemination of blaKPC genes in several genetically diverse bacterial species. blaKPC was not associated with Tn4401 in only 12 of 61 strains.", [["Tn4401", "CHEMICAL", 40, 46], ["Tn4401", "CHEMICAL", 165, 171], ["Tn4401", "GENE_OR_GENE_PRODUCT", 40, 46], ["blaKPC", "GENE_OR_GENE_PRODUCT", 71, 77], ["blaKPC", "GENE_OR_GENE_PRODUCT", 134, 140], ["Tn4401", "GENE_OR_GENE_PRODUCT", 165, 171], ["Tn4401", "DNA", 40, 46], ["blaKPC genes", "DNA", 71, 83], ["blaKPC", "PROTEIN", 134, 140], ["Tn4401", "PROTEIN", 165, 171], ["This study", "TEST", 0, 10], ["blaKPC genes", "PROBLEM", 71, 83], ["several genetically diverse bacterial species", "PROBLEM", 87, 132], ["blaKPC", "TEST", 134, 140], ["Tn", "TEST", 165, 167], ["diverse", "OBSERVATION_MODIFIER", 107, 114], ["bacterial species", "OBSERVATION", 115, 132], ["not associated", "UNCERTAINTY", 145, 159]]], ["These strains are under further investigation.", [["further investigation", "TEST", 24, 45]]], ["Objective: To evaluate the carbapenem resistance mechanism in a Raoultella planticola bacteraemia isolate recovered from a patient hospitalised in Ohio, USA.", [["carbapenem", "CHEMICAL", 27, 37], ["Raoultella planticola bacteraemia", "DISEASE", 64, 97], ["carbapenem", "CHEMICAL", 27, 37], ["Raoultella planticola", "ORGANISM", 64, 85], ["patient", "ORGANISM", 123, 130], ["Raoultella planticola", "SPECIES", 64, 85], ["patient", "SPECIES", 123, 130], ["Raoultella planticola", "SPECIES", 64, 85], ["the carbapenem resistance mechanism", "PROBLEM", 23, 58], ["a Raoultella planticola bacteraemia isolate", "TREATMENT", 62, 105]]], ["Methods: Species identification was performed by VITEK 2 and confirmed by 16S rRNA sequencing.", [["VITEK 2", "DNA", 49, 56]]], ["Susceptibility testing used CLSI broth microdilution method. blaKPC was amplified and sequenced.", [["blaKPC", "GENE_OR_GENE_PRODUCT", 61, 67], ["blaKPC", "DNA", 61, 67], ["Susceptibility testing", "TEST", 0, 22], ["blaKPC", "TEST", 61, 67]]], ["The blaKPC genetic element (Tn4401) was amplified and sequenced.", [["blaKPC", "GENE_OR_GENE_PRODUCT", 4, 10], ["blaKPC genetic element", "DNA", 4, 26], ["Tn4401", "DNA", 28, 34]]], ["Plasmid extractions and conjugation experiments were carried out and the isolate was screened for ESBL-encoding genes, qnr and qepA.Results:A 83 year old female patient was admitted to a hospital located in Akron with a diagnosis of CAP in May/2008.", [["Plasmid", "ANATOMY", 0, 7], ["CAP", "DISEASE", 233, 236], ["ESBL", "GENE_OR_GENE_PRODUCT", 98, 102], ["qnr", "GENE_OR_GENE_PRODUCT", 119, 122], ["qepA", "GENE_OR_GENE_PRODUCT", 127, 131], ["female", "ORGANISM", 154, 160], ["patient", "ORGANISM", 161, 168], ["ESBL-encoding genes", "DNA", 98, 117], ["qnr", "DNA", 119, 122], ["qepA", "DNA", 127, 131], ["patient", "SPECIES", 161, 168], ["Plasmid extractions", "TREATMENT", 0, 19], ["conjugation experiments", "TEST", 24, 47], ["the isolate", "TEST", 69, 80], ["ESBL", "PROBLEM", 98, 102], ["qepA", "TREATMENT", 127, 131], ["CAP", "PROBLEM", 233, 236]]], ["Sputum, paracentesis and blood cultures were negative.", [["Sputum", "ANATOMY", 0, 6], ["blood cultures", "ANATOMY", 25, 39], ["Sputum", "ORGANISM_SUBSTANCE", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["Sputum", "TEST", 0, 6], ["paracentesis", "TREATMENT", 8, 20], ["blood cultures", "TEST", 25, 39], ["paracentesis", "OBSERVATION", 8, 20]]], ["Urine culture grew E. coli and patient received courses of moxifloxacin, ceftriaxone, azithromycin and meropenem.", [["Urine culture", "ANATOMY", 0, 13], ["moxifloxacin", "CHEMICAL", 59, 71], ["ceftriaxone", "CHEMICAL", 73, 84], ["azithromycin", "CHEMICAL", 86, 98], ["meropenem", "CHEMICAL", 103, 112], ["moxifloxacin", "CHEMICAL", 59, 71], ["ceftriaxone", "CHEMICAL", 73, 84], ["azithromycin", "CHEMICAL", 86, 98], ["meropenem", "CHEMICAL", 103, 112], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["E. coli", "ORGANISM", 19, 26], ["patient", "ORGANISM", 31, 38], ["moxifloxacin", "SIMPLE_CHEMICAL", 59, 71], ["ceftriaxone", "SIMPLE_CHEMICAL", 73, 84], ["azithromycin", "SIMPLE_CHEMICAL", 86, 98], ["meropenem", "SIMPLE_CHEMICAL", 103, 112], ["E. coli", "SPECIES", 19, 26], ["patient", "SPECIES", 31, 38], ["E. coli", "SPECIES", 19, 26], ["Urine culture", "TEST", 0, 13], ["E. coli", "PROBLEM", 19, 26], ["moxifloxacin", "TREATMENT", 59, 71], ["ceftriaxone", "TREATMENT", 73, 84], ["azithromycin", "TREATMENT", 86, 98], ["meropenem", "TREATMENT", 103, 112], ["E. coli", "OBSERVATION", 19, 26]]], ["The patient was discharged and returned after three weeks with respiratory problems.", [["respiratory", "ANATOMY", 63, 74], ["respiratory problems", "DISEASE", 63, 83], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["respiratory problems", "PROBLEM", 63, 83], ["respiratory", "ANATOMY", 63, 74], ["problems", "OBSERVATION", 75, 83]]], ["Tracheal aspirate grew a multidrug resistant A. baumannii and the blood culture grew the enteric-like Gramnegative bacillus.", [["Tracheal aspirate", "ANATOMY", 0, 17], ["blood culture", "ANATOMY", 66, 79], ["Tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 0, 17], ["A. baumannii", "ORGANISM", 45, 57], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["A. baumannii", "SPECIES", 45, 57], ["A. baumannii", "SPECIES", 45, 57], ["Tracheal aspirate", "TEST", 0, 17], ["a multidrug resistant A. baumannii", "PROBLEM", 23, 57], ["the blood culture", "TEST", 62, 79], ["the enteric-like Gramnegative bacillus", "PROBLEM", 85, 123], ["aspirate", "OBSERVATION", 9, 17], ["multidrug resistant", "OBSERVATION_MODIFIER", 25, 44], ["baumannii", "OBSERVATION", 48, 57], ["enteric", "ANATOMY", 89, 96], ["Gramnegative bacillus", "OBSERVATION", 102, 123]]], ["The isolate was identified as R. planticola by the VITEK 2, which was confirmed by 16S sequencing.", [["R. planticola", "ORGANISM", 30, 43], ["VITEK 2", "DNA", 51, 58], ["R. planticola", "SPECIES", 30, 43], ["R. planticola", "SPECIES", 30, 43], ["the VITEK", "TEST", 47, 56]]], ["R. planticola strain demonstrated resistance against most b-lactams, including carbapenems.", [["b-lactams", "CHEMICAL", 58, 67], ["carbapenems", "CHEMICAL", 79, 90], ["carbapenems", "CHEMICAL", 79, 90], ["R. planticola strain", "ORGANISM", 0, 20], ["b-lactams", "SIMPLE_CHEMICAL", 58, 67], ["carbapenems", "SIMPLE_CHEMICAL", 79, 90], ["R. planticola", "SPECIES", 0, 13], ["R. planticola", "SPECIES", 0, 13], ["R. planticola strain", "PROBLEM", 0, 20], ["resistance against most b-lactams", "PROBLEM", 34, 67], ["carbapenems", "TREATMENT", 79, 90], ["resistance", "OBSERVATION", 34, 44]]], ["Screening for KPC-encoding genes was positive and this strain carried blaKPC-2.", [["KPC", "GENE_OR_GENE_PRODUCT", 14, 17], ["blaKPC-2", "GENE_OR_GENE_PRODUCT", 70, 78], ["KPC-encoding genes", "DNA", 14, 32], ["blaKPC-2", "DNA", 70, 78], ["Screening", "TEST", 0, 9], ["KPC", "TEST", 14, 17], ["encoding genes", "PROBLEM", 18, 32], ["positive", "PROBLEM", 37, 45]]], ["Fluoroquinolone and aminoglycoside MIC values were elevated.", [["Fluoroquinolone", "CHEMICAL", 0, 15], ["aminoglycoside", "CHEMICAL", 20, 34], ["Fluoroquinolone", "CHEMICAL", 0, 15], ["aminoglycoside", "CHEMICAL", 20, 34], ["Fluoroquinolone", "SIMPLE_CHEMICAL", 0, 15], ["aminoglycoside MIC", "SIMPLE_CHEMICAL", 20, 38], ["Fluoroquinolone", "TREATMENT", 0, 15], ["aminoglycoside MIC values", "TEST", 20, 45]]], ["KPC-2-encoding gene was located in Tn4401, but conjugation experiments failed.", [["KPC-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Tn4401", "GENE_OR_GENE_PRODUCT", 35, 41], ["KPC-2-encoding gene", "DNA", 0, 19], ["Tn4401", "DNA", 35, 41], ["KPC", "TEST", 0, 3], ["conjugation experiments", "TREATMENT", 47, 70]]], ["ESBL and qnr/qepA genes were not detected.", [["ESBL", "GENE_OR_GENE_PRODUCT", 0, 4], ["qnr", "GENE_OR_GENE_PRODUCT", 9, 12], ["qepA", "GENE_OR_GENE_PRODUCT", 13, 17], ["ESBL and qnr/qepA genes", "DNA", 0, 23], ["ESBL", "TEST", 0, 4], ["qnr/qepA genes", "TEST", 9, 23]]], ["Conclusions: KPC serine-carbapenemases have been detected in several Gram-negative species commonly isolated from clinical specimens.", [["specimens", "ANATOMY", 123, 132], ["serine", "CHEMICAL", 17, 23], ["KPC serine", "GENE_OR_GENE_PRODUCT", 13, 23], ["Gram", "GENE_OR_GENE_PRODUCT", 69, 73], ["KPC serine", "TEST", 13, 23], ["carbapenemases", "PROBLEM", 24, 38], ["several Gram", "TEST", 61, 73], ["clinical specimens", "TEST", 114, 132]]], ["KPC genes are embedded in transposon-like structure usually harboured in conjugative plasmids carrying multiple antimicrobial resistance mechanisms.", [["conjugative plasmids", "ANATOMY", 73, 93], ["KPC", "GENE_OR_GENE_PRODUCT", 0, 3], ["KPC genes", "DNA", 0, 9], ["transposon", "DNA", 26, 36], ["conjugative plasmids", "DNA", 73, 93], ["KPC genes", "PROBLEM", 0, 9], ["conjugative plasmids", "TREATMENT", 73, 93], ["multiple antimicrobial resistance mechanisms", "TREATMENT", 103, 147], ["conjugative plasmids", "OBSERVATION", 73, 93], ["antimicrobial resistance", "OBSERVATION", 112, 136]]], ["This is the first report of KPC-producing R. planticola that is an environmental organism related to Klebsiella spp.", [["KPC", "CHEMICAL", 28, 31], ["KPC", "GENE_OR_GENE_PRODUCT", 28, 31], ["R. planticola", "ORGANISM", 42, 55], ["Klebsiella spp", "ORGANISM", 101, 115], ["R. planticola", "SPECIES", 42, 55], ["R. planticola", "SPECIES", 42, 55], ["KPC", "PROBLEM", 28, 31], ["R. planticola", "PROBLEM", 42, 55], ["an environmental organism", "PROBLEM", 64, 89], ["Klebsiella spp", "PROBLEM", 101, 115], ["environmental organism", "OBSERVATION", 67, 89], ["Klebsiella spp", "OBSERVATION", 101, 115]]], ["The similarity between these organisms could facilitate the transfer of genetic material.", [["these organisms", "PROBLEM", 23, 38]]], ["KPC-producing isolates appear to be prevalent among different Enterobacteriaceae species in USA hospitals and was detected in an isolates of apparent environmental origin.P. Wolffs\u00b0, E. Beuken, S. Ouburg, S. Morr\u00e9, F. Stassen (Maastricht, NL)Objectives: It is long known that not all individuals with a specific disease present with the same clinical manifestations, nor do they have identical prognoses or responses to treatments.", [["KPC", "CHEMICAL", 0, 3], ["KPC", "GENE_OR_GENE_PRODUCT", 0, 3], ["KPC", "TEST", 0, 3], ["different Enterobacteriaceae species", "PROBLEM", 52, 88], ["a specific disease", "PROBLEM", 301, 319], ["treatments", "TREATMENT", 420, 430], ["Enterobacteriaceae species", "OBSERVATION", 62, 88], ["environmental origin", "OBSERVATION", 150, 170]]], ["It has become clear that variations in the human genome are likely to have an impact on these aspects.", [["human", "ORGANISM", 43, 48], ["human genome", "DNA", 43, 55], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["clear", "OBSERVATION", 14, 19], ["variations", "OBSERVATION_MODIFIER", 25, 35], ["human genome", "OBSERVATION", 43, 55], ["impact", "OBSERVATION", 78, 84]]], ["TANK-binding kinase 1 (TBK1) is a central molecule in the induction of a.o. the type I interferon response to pathogens.", [["TANK-binding kinase 1", "GENE_OR_GENE_PRODUCT", 0, 21], ["TBK1", "GENE_OR_GENE_PRODUCT", 23, 27], ["type I interferon", "GENE_OR_GENE_PRODUCT", 80, 97], ["TANK-binding kinase 1", "PROTEIN", 0, 21], ["TBK1", "PROTEIN", 23, 27], ["TANK-binding kinase", "TEST", 0, 19], ["a central molecule", "PROBLEM", 32, 50], ["pathogens", "PROBLEM", 110, 119]]], ["Our goals for this study were 1) to investigate the frequency of single nucleotide polymorphisms (SNPs) in the promoter and coding region of TBK1 in a Dutch Caucasian population and 2) to search for potential associations between these SNPs and bloodstream infections.", [["bloodstream", "ANATOMY", 245, 256], ["bloodstream infections", "DISEASE", 245, 267], ["TBK1", "GENE_OR_GENE_PRODUCT", 141, 145], ["promoter", "DNA", 111, 119], ["TBK1", "PROTEIN", 141, 145], ["this study", "TEST", 14, 24], ["single nucleotide polymorphisms (SNPs)", "TREATMENT", 65, 103], ["TBK1", "PROBLEM", 141, 145], ["these SNPs", "PROBLEM", 230, 240], ["bloodstream infections", "PROBLEM", 245, 267], ["bloodstream", "ANATOMY", 245, 256], ["infections", "OBSERVATION", 257, 267]]], ["Methods: Whole blood samples or samples of positive blood cultures were collected and after genomic DNA was isolated, PCR and sequencing were performed for SNP identification.", [["Whole blood samples", "ANATOMY", 9, 28], ["samples", "ANATOMY", 32, 39], ["blood cultures", "ANATOMY", 52, 66], ["SNP", "CHEMICAL", 156, 159], ["blood samples", "ORGANISM_SUBSTANCE", 15, 28], ["blood cultures", "ORGANISM_SUBSTANCE", 52, 66], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["genomic DNA", "DNA", 92, 103], ["Whole blood samples", "TEST", 9, 28], ["positive blood cultures", "TEST", 43, 66], ["genomic DNA", "TEST", 92, 103], ["PCR", "TEST", 118, 121], ["sequencing", "TEST", 126, 136], ["SNP identification", "TEST", 156, 174]]], ["Functional studies included promoter activity measurements using a luciferase assay as well as electrophoretic mobility shift assays (EMSA) to study binding of the transcription factor USF1 to the wt and mutant promoter.", [["luciferase", "GENE_OR_GENE_PRODUCT", 67, 77], ["USF1", "GENE_OR_GENE_PRODUCT", 185, 189], ["luciferase", "PROTEIN", 67, 77], ["transcription factor", "PROTEIN", 164, 184], ["USF1", "PROTEIN", 185, 189], ["wt and mutant promoter", "DNA", 197, 219], ["Functional studies", "TEST", 0, 18], ["a luciferase assay", "TEST", 65, 83]]], ["SNP incidences were studied in a case control study.", [["SNP", "CHEMICAL", 0, 3], ["SNP incidences", "TREATMENT", 0, 14], ["a case control study", "TEST", 31, 51]]], ["Results: In samples from Dutch Caucasian healthy volunteers, 4 SNPs were found with allele frequencies higher than 5% whereas 6 other known SNPs had frequencies lower than 5% in our cohort.", [["samples", "ANATOMY", 12, 19], ["volunteers", "ORGANISM", 49, 59], ["4 SNPs", "TREATMENT", 61, 67], ["allele frequencies", "PROBLEM", 84, 102]]], ["Two SNPs (rs89208169 and rs89208163) located in the promoter region were studied in a larger cohort of 350 anonymised patients from the Maastricht University Medical Center with either Gram-positive or Gram-negative blood cultures.", [["blood cultures", "ANATOMY", 216, 230], ["patients", "ORGANISM", 118, 126], ["Gram-", "GENE_OR_GENE_PRODUCT", 185, 190], ["Gram", "GENE_OR_GENE_PRODUCT", 202, 206], ["promoter region", "DNA", 52, 67], ["Gram-positive or Gram-negative blood cultures", "CELL_LINE", 185, 230], ["patients", "SPECIES", 118, 126], ["Two SNPs", "TEST", 0, 8], ["Gram", "TEST", 202, 206], ["blood cultures", "TEST", 216, 230]]], ["We found that the prevalence of rs89208169 was significantly increased in patients with positive blood cultures in comparison with those with negative blood cultures or healthy volunteers.", [["blood cultures", "ANATOMY", 97, 111], ["blood cultures", "ANATOMY", 151, 165], ["rs89208169", "GENE_OR_GENE_PRODUCT", 32, 42], ["patients", "ORGANISM", 74, 82], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["volunteers", "ORGANISM", 177, 187], ["patients", "SPECIES", 74, 82], ["positive blood cultures", "PROBLEM", 88, 111], ["blood cultures", "TEST", 151, 165], ["significantly", "OBSERVATION_MODIFIER", 47, 60], ["increased", "OBSERVATION_MODIFIER", 61, 70]]], ["Further investigation of this SNP showed that it is located just outside a USF1-binding site.", [["SNP", "CHEMICAL", 30, 33], ["USF1", "GENE_OR_GENE_PRODUCT", 75, 79], ["USF1-binding site", "DNA", 75, 92], ["Further investigation", "TEST", 0, 21], ["this SNP", "TEST", 25, 33]]], ["Measuring the promoter activity using luciferase assays, the mutant promoter exhibited a decreased activity of <35%.", [["luciferase", "GENE_OR_GENE_PRODUCT", 38, 48], ["luciferase", "PROTEIN", 38, 48], ["mutant promoter", "DNA", 61, 76], ["luciferase assays", "TEST", 38, 55], ["activity", "OBSERVATION_MODIFIER", 23, 31], ["decreased", "OBSERVATION_MODIFIER", 89, 98], ["activity", "OBSERVATION_MODIFIER", 99, 107]]], ["This observation was confirmed by EMSA which showed that recombinant USF1 protein had a reduced binding affinity to the mutant promoter.P. Wolffs\u00b0, E. Beuken, S. Ouburg, S. Morr\u00e9, F. Stassen (Maastricht, NL)Conclusions: SNP rs89208169 in the promoter region of TBK1 has a significant association with Gram-positive infections.", [["SNP", "CHEMICAL", 220, 223], ["Gram-positive infections", "DISEASE", 301, 325], ["USF1", "GENE_OR_GENE_PRODUCT", 69, 73], ["TBK1", "GENE_OR_GENE_PRODUCT", 261, 265], ["Gram-", "GENE_OR_GENE_PRODUCT", 301, 306], ["USF1 protein", "PROTEIN", 69, 81], ["mutant promoter", "DNA", 120, 135], ["promoter region", "DNA", 242, 257], ["TBK1", "PROTEIN", 261, 265], ["This observation", "TEST", 0, 16], ["EMSA", "TEST", 34, 38], ["recombinant USF1 protein", "PROBLEM", 57, 81], ["a reduced binding affinity", "PROBLEM", 86, 112], ["SNP", "TEST", 220, 223], ["TBK1", "PROBLEM", 261, 265], ["Gram-positive infections", "PROBLEM", 301, 325], ["TBK1", "OBSERVATION", 261, 265], ["significant", "OBSERVATION_MODIFIER", 272, 283], ["positive", "OBSERVATION_MODIFIER", 306, 314], ["infections", "OBSERVATION", 315, 325]]], ["Our results demonstrate that this is likely due to a decreased expression of TBK1 due to reduced binding of the transcription factor USF1 to the mutant promoter.", [["TBK1", "GENE_OR_GENE_PRODUCT", 77, 81], ["USF1", "GENE_OR_GENE_PRODUCT", 133, 137], ["TBK1", "PROTEIN", 77, 81], ["transcription factor", "PROTEIN", 112, 132], ["USF1", "PROTEIN", 133, 137], ["mutant promoter", "DNA", 145, 160], ["a decreased expression of TBK1", "PROBLEM", 51, 81], ["reduced binding", "PROBLEM", 89, 104], ["likely due to", "UNCERTAINTY", 37, 50], ["decreased", "OBSERVATION", 53, 62], ["TBK1", "OBSERVATION", 77, 81]]], ["Our results support recent findings that TBK1 plays also an important role in the host response to Gram-positive infections.", [["infections", "DISEASE", 113, 123], ["TBK1", "GENE_OR_GENE_PRODUCT", 41, 45], ["Gram-", "GENE_OR_GENE_PRODUCT", 99, 104], ["TBK1", "PROTEIN", 41, 45], ["Gram-positive infections", "PROBLEM", 99, 123], ["infections", "OBSERVATION", 113, 123]]], ["Objective: Lymphocyte apoptosis has been recognized as an important factor contributing to both the onset of sepsis post infection and to the progression into septic shock.", [["Lymphocyte", "ANATOMY", 11, 21], ["sepsis", "DISEASE", 109, 115], ["infection", "DISEASE", 121, 130], ["septic shock", "DISEASE", 159, 171], ["Lymphocyte", "CELL", 11, 21], ["Lymphocyte apoptosis", "PROBLEM", 11, 31], ["sepsis", "PROBLEM", 109, 115], ["infection", "PROBLEM", 121, 130], ["septic shock", "PROBLEM", 159, 171], ["Lymphocyte apoptosis", "OBSERVATION", 11, 31], ["sepsis", "OBSERVATION", 109, 115], ["infection", "OBSERVATION", 121, 130], ["septic shock", "OBSERVATION", 159, 171]]], ["Animal data suggest that prevention of lymphocyte apoptosis by caspase inhibition stabilises the immune system, improves bacterial clearance and decreases mortality in experimental sepsis.", [["lymphocyte", "ANATOMY", 39, 49], ["immune system", "ANATOMY", 97, 110], ["sepsis", "DISEASE", 181, 187], ["lymphocyte", "CELL", 39, 49], ["caspase", "GENE_OR_GENE_PRODUCT", 63, 70], ["caspase", "PROTEIN", 63, 70], ["Animal data", "TEST", 0, 11], ["lymphocyte apoptosis", "PROBLEM", 39, 59], ["caspase inhibition", "TREATMENT", 63, 81], ["the immune system", "PROBLEM", 93, 110], ["bacterial clearance", "PROBLEM", 121, 140], ["experimental sepsis", "PROBLEM", 168, 187], ["lymphocyte apoptosis", "OBSERVATION", 39, 59], ["bacterial clearance", "OBSERVATION", 121, 140], ["experimental", "OBSERVATION_MODIFIER", 168, 180], ["sepsis", "OBSERVATION", 181, 187]]], ["The present study evaluated the potential of VX-166, a novel broad caspase inhibitor, as a therapy for sepsis.", [["VX-166", "CHEMICAL", 45, 51], ["sepsis", "DISEASE", 103, 109], ["VX-166", "CHEMICAL", 45, 51], ["VX-166", "SIMPLE_CHEMICAL", 45, 51], ["caspase", "GENE_OR_GENE_PRODUCT", 67, 74], ["VX-166", "SPECIES", 45, 51], ["The present study", "TEST", 0, 17], ["VX", "TEST", 45, 47], ["a novel broad caspase inhibitor", "TREATMENT", 53, 84], ["a therapy", "TREATMENT", 89, 98], ["sepsis", "PROBLEM", 103, 109], ["sepsis", "OBSERVATION", 103, 109]]], ["Methods and Results: Initial characterisation of VX-166 in a number of enzymatic and cellular assays clearly demonstrated that the compound is a broad caspase inhibitor with potent anti-apoptotic activity in vitro.", [["cellular", "ANATOMY", 85, 93], ["VX-166", "CHEMICAL", 49, 55], ["VX-166", "CHEMICAL", 49, 55], ["VX-166", "SIMPLE_CHEMICAL", 49, 55], ["cellular", "CELL", 85, 93], ["caspase", "GENE_OR_GENE_PRODUCT", 151, 158], ["VX", "TEST", 49, 51], ["cellular assays", "TEST", 85, 100], ["a broad caspase inhibitor", "TREATMENT", 143, 168], ["potent anti-apoptotic activity", "TREATMENT", 174, 204], ["anti-apoptotic activity", "OBSERVATION", 181, 204]]], ["In vivo, VX-166 was tested in a murine model of endotoxic shock and a clinically relevant model of peritonitis.O354 Evaluation of a novel small molecule caspase inhibitorIn the endotoxic shock model, male CD-1 mice (n = 28 per group) were administered LPS (20 mg/kg IV) and survival was monitored for 96 h.", [["VX-166", "CHEMICAL", 9, 15], ["endotoxic shock", "DISEASE", 48, 63], ["peritonitis", "DISEASE", 99, 110], ["endotoxic shock", "DISEASE", 177, 192], ["LPS", "CHEMICAL", 252, 255], ["VX-166", "CHEMICAL", 9, 15], ["VX-166", "SIMPLE_CHEMICAL", 9, 15], ["murine", "ORGANISM", 32, 38], ["caspase", "GENE_OR_GENE_PRODUCT", 153, 160], ["CD-1 mice", "ORGANISM", 205, 214], ["LPS", "SIMPLE_CHEMICAL", 252, 255], ["murine", "SPECIES", 32, 38], ["mice", "SPECIES", 210, 214], ["mice", "SPECIES", 210, 214], ["VX", "TEST", 9, 11], ["endotoxic shock", "PROBLEM", 48, 63], ["peritonitis", "PROBLEM", 99, 110], ["Evaluation", "TEST", 116, 126], ["a novel small molecule caspase inhibitor", "TREATMENT", 130, 170], ["LPS", "TREATMENT", 252, 255], ["survival", "TREATMENT", 274, 282], ["endotoxic shock", "OBSERVATION", 48, 63], ["peritonitis", "OBSERVATION", 99, 110], ["endotoxic shock", "OBSERVATION", 177, 192]]], ["VX-166 administered by repeat IV bolus (0, 4, 8 and 12 h post-LPS) significantly improved survival in a dose-dependent fashion (p < 0.0001).", [["VX-166", "CHEMICAL", 0, 6], ["LPS", "CHEMICAL", 62, 65], ["VX-166", "CHEMICAL", 0, 6], ["VX-166", "SIMPLE_CHEMICAL", 0, 6], ["VX", "TEST", 0, 2], ["repeat IV bolus", "TREATMENT", 23, 38]]], ["In the rat peritonitis model, adult male Sprague-Dawley rats (n = 12 per group) underwent caecal ligation and puncture (CLP) and survival was monitored over 10d.", [["caecal", "ANATOMY", 90, 96], ["peritonitis", "DISEASE", 11, 22], ["rat", "ORGANISM", 7, 10], ["Sprague-Dawley rats", "ORGANISM", 41, 60], ["caecal", "MULTI-TISSUE_STRUCTURE", 90, 96], ["rat", "SPECIES", 7, 10], ["Sprague-Dawley rats", "SPECIES", 41, 60], ["rat", "SPECIES", 7, 10], ["Sprague-Dawley rats", "SPECIES", 41, 60], ["caecal ligation", "TREATMENT", 90, 105], ["puncture (CLP", "TREATMENT", 110, 123], ["survival", "TREATMENT", 129, 137], ["peritonitis", "OBSERVATION", 11, 22], ["caecal", "ANATOMY", 90, 96], ["ligation", "OBSERVATION", 97, 105], ["puncture", "OBSERVATION", 110, 118]]], ["Continuous administration of VX-166 by mini-osmotic pump (0.9 mg/kg/h) immediately following surgery significantly improved survival (p < 0.01) from 38% in the control group to 88% in the compound-treated group.", [["VX-166", "CHEMICAL", 29, 35], ["VX-166", "CHEMICAL", 29, 35], ["VX-166", "SIMPLE_CHEMICAL", 29, 35], ["VX", "TEST", 29, 31], ["mini-osmotic pump", "TREATMENT", 39, 56], ["surgery", "TREATMENT", 93, 100]]], ["Mode of action studies in the rat CLP model confirmed that VX-166 reduced thymic atrophy and lymphocyte apoptosis (p < 0.01), supporting the anti-apoptotic activity of the compound in vivo.", [["thymic", "ANATOMY", 74, 80], ["lymphocyte", "ANATOMY", 93, 103], ["VX-166", "CHEMICAL", 59, 65], ["thymic atrophy", "DISEASE", 74, 88], ["VX-166", "CHEMICAL", 59, 65], ["rat", "ORGANISM", 30, 33], ["VX-166", "SIMPLE_CHEMICAL", 59, 65], ["thymic", "ORGAN", 74, 80], ["lymphocyte", "CELL", 93, 103], ["rat", "SPECIES", 30, 33], ["rat", "SPECIES", 30, 33], ["action studies", "TEST", 8, 22], ["the rat CLP model", "TEST", 26, 43], ["VX", "TEST", 59, 61], ["reduced thymic atrophy", "PROBLEM", 66, 88], ["lymphocyte apoptosis", "PROBLEM", 93, 113], ["thymic", "ANATOMY", 74, 80], ["atrophy", "OBSERVATION", 81, 88], ["lymphocyte apoptosis", "OBSERVATION", 93, 113]]], ["In addition, VX-166 reduced plasma endotoxin levels (p < 0.05), strongly suggesting an improved clearance of bacteria from the bloodstream.", [["plasma", "ANATOMY", 28, 34], ["bloodstream", "ANATOMY", 127, 138], ["VX-166", "CHEMICAL", 13, 19], ["endotoxin", "CHEMICAL", 35, 44], ["VX-166", "CHEMICAL", 13, 19], ["VX-166", "SIMPLE_CHEMICAL", 13, 19], ["plasma", "ORGANISM_SUBSTANCE", 28, 34], ["endotoxin", "SIMPLE_CHEMICAL", 35, 44], ["VX", "TEST", 13, 15], ["plasma endotoxin levels", "TEST", 28, 51], ["bacteria from the bloodstream", "PROBLEM", 109, 138], ["improved", "OBSERVATION_MODIFIER", 87, 95], ["clearance", "OBSERVATION", 96, 105], ["bacteria", "OBSERVATION", 109, 117], ["bloodstream", "ANATOMY", 127, 138]]], ["Most importantly, we demonstrated that VX-166 fully retained its efficacy when dosed 3 hours after insult (p < 0.01) by improving survival to 92% versus 42% in control animals, further highlighting the potential of anti-apoptotic therapy in sepsis.Conclusion:Overall these data demonstrate that VX-166 inhibits lymphocyte apoptosis, improves the clearance of bacterial endotoxin and improves survival in experimental sepsis.", [["lymphocyte", "ANATOMY", 311, 321], ["VX-166", "CHEMICAL", 39, 45], ["sepsis", "DISEASE", 241, 247], ["VX-166", "CHEMICAL", 295, 301], ["endotoxin", "CHEMICAL", 369, 378], ["sepsis", "DISEASE", 417, 423], ["VX-166", "CHEMICAL", 39, 45], ["VX-166", "CHEMICAL", 295, 301], ["VX-166", "SIMPLE_CHEMICAL", 39, 45], ["VX-166", "SIMPLE_CHEMICAL", 295, 301], ["lymphocyte", "CELL", 311, 321], ["bacterial endotoxin", "PROTEIN", 359, 378], ["VX", "TEST", 39, 41], ["insult", "PROBLEM", 99, 105], ["anti-apoptotic therapy", "TREATMENT", 215, 237], ["sepsis", "PROBLEM", 241, 247], ["VX", "TEST", 295, 297], ["lymphocyte apoptosis", "PROBLEM", 311, 331], ["bacterial endotoxin", "PROBLEM", 359, 378], ["experimental sepsis", "PROBLEM", 404, 423], ["anti-apoptotic therapy", "OBSERVATION", 215, 237], ["sepsis", "OBSERVATION", 241, 247], ["lymphocyte apoptosis", "OBSERVATION", 311, 331], ["bacterial endotoxin", "OBSERVATION", 359, 378], ["experimental", "OBSERVATION_MODIFIER", 404, 416], ["sepsis", "OBSERVATION", 417, 423]]], ["Importantly VX-166 improves survival in the CLP model when dosed post insult, and therefore represents significant progress in the development of therapeutically viable broad caspase inhibitors for the treatment of this disease.O355 Activation of Toll-like receptor 2 and Toll-like receptor 2/6 by lactobacilliV.", [["VX-166", "CHEMICAL", 12, 18], ["VX-166", "CHEMICAL", 12, 18], ["VX-166", "SIMPLE_CHEMICAL", 12, 18], ["caspase", "GENE_OR_GENE_PRODUCT", 175, 182], ["Toll-like receptor 2", "GENE_OR_GENE_PRODUCT", 247, 267], ["Toll-like receptor 2/6", "GENE_OR_GENE_PRODUCT", 272, 294], ["lactobacilliV", "GENE_OR_GENE_PRODUCT", 298, 311], ["Toll-like receptor 2", "PROTEIN", 247, 267], ["Toll-like receptor 2/6", "PROTEIN", 272, 294], ["lactobacilliV", "PROTEIN", 298, 311], ["the CLP model", "TREATMENT", 40, 53], ["insult", "PROBLEM", 70, 76], ["therapeutically viable broad caspase inhibitors", "TREATMENT", 146, 193], ["this disease", "PROBLEM", 215, 227], ["Toll-like receptor", "TREATMENT", 247, 265], ["receptor", "TREATMENT", 282, 290], ["significant", "OBSERVATION_MODIFIER", 103, 114], ["disease", "OBSERVATION", 220, 227]]], ["Vankerckhoven\u00b0, S. Van Voorden, N. Hens, H. Goossens, G. Molenberghs, E. Wiertz (Wilrijk, BE; Leiden, NL; Hasselt, BE) Objectives: Toll-like receptors function as key regulators of both innate and adaptive immunity.", [["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 131, 150], ["Toll-like receptors", "PROTEIN", 131, 150]]], ["Lactobacilli modulate the immune system in different ways.", [["immune system", "ANATOMY", 26, 39], ["Lactobacilli", "CHEMICAL", 0, 12], ["Lactobacilli", "SIMPLE_CHEMICAL", 0, 12], ["immune system", "ANATOMICAL_SYSTEM", 26, 39], ["Lactobacilli", "TREATMENT", 0, 12], ["immune system", "OBSERVATION", 26, 39]]], ["The aim of this study was to examine Toll-like receptor (TLR2, TLR2/6 and TLR4) signalling induced by clinical and probiotic Lactobacillus strains.", [["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 37, 55], ["TLR2", "GENE_OR_GENE_PRODUCT", 57, 61], ["TLR2", "GENE_OR_GENE_PRODUCT", 63, 67], ["6", "GENE_OR_GENE_PRODUCT", 68, 69], ["TLR4", "GENE_OR_GENE_PRODUCT", 74, 78], ["Toll-like receptor", "PROTEIN", 37, 55], ["TLR2", "PROTEIN", 57, 61], ["TLR2", "PROTEIN", 63, 67], ["TLR4", "PROTEIN", 74, 78], ["this study", "TEST", 11, 21], ["receptor (TLR2, TLR2/6 and TLR4)", "TREATMENT", 47, 79], ["probiotic Lactobacillus strains", "TREATMENT", 115, 146]]], ["Methods: A total of 45 Lactobacillus strains (19 L. paracasei and 26 L. rhamnosus) of different origin (22 probiotic, 2 faecal, and 21 clinical) were tested for TLR2, TLR2 in combination with TLR6, and TLR4.", [["faecal", "ANATOMY", 120, 126], ["Lactobacillus strains", "ORGANISM", 23, 44], ["L. paracasei", "ORGANISM", 49, 61], ["L. rhamnosus", "ORGANISM", 69, 81], ["TLR2", "GENE_OR_GENE_PRODUCT", 161, 165], ["TLR2", "GENE_OR_GENE_PRODUCT", 167, 171], ["TLR6", "GENE_OR_GENE_PRODUCT", 192, 196], ["TLR4", "GENE_OR_GENE_PRODUCT", 202, 206], ["TLR2", "PROTEIN", 161, 165], ["TLR2", "PROTEIN", 167, 171], ["TLR6", "PROTEIN", 192, 196], ["TLR4", "PROTEIN", 202, 206], ["L. paracasei", "SPECIES", 49, 61], ["L. rhamnosus", "SPECIES", 69, 81], ["L. paracasei", "SPECIES", 49, 61], ["L. rhamnosus", "SPECIES", 69, 81], ["Lactobacillus strains", "PROBLEM", 23, 44], ["L. paracasei", "TEST", 49, 61], ["L. rhamnosus", "TEST", 69, 81], ["probiotic", "TEST", 107, 116], ["TLR2", "TEST", 161, 165], ["TLR2", "TEST", 167, 171], ["TLR6", "TREATMENT", 192, 196], ["TLR4", "TREATMENT", 202, 206]]], ["TLR signalling was measured as relative IL-8 promotor activation in transfected human embryonic kidney (HEK) 293 cells.", [["embryonic kidney (HEK) 293 cells", "ANATOMY", 86, 118], ["TLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["IL-8", "GENE_OR_GENE_PRODUCT", 40, 44], ["human", "ORGANISM", 80, 85], ["embryonic kidney (HEK) 293 cells", "CELL", 86, 118], ["TLR", "PROTEIN", 0, 3], ["transfected human embryonic kidney (HEK) 293 cells", "CELL_LINE", 68, 118], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["relative IL", "TEST", 31, 42], ["kidney", "ANATOMY", 96, 102]]], ["IL-8 concentrations were measured using an enzyme-linked immunosorbent assay.", [["IL-8", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-8", "PROTEIN", 0, 4], ["an enzyme", "TEST", 40, 49], ["immunosorbent assay", "TEST", 57, 76]]], ["Heat-killed Listeria monocytogenes (HKLM) was used as positive control in all assays, whereas PAM3, PAM2, and LPS were used as positive controls for, respectively, TLR2, TLR2/6, and TLR4.", [["LPS", "CHEMICAL", 110, 113], ["Listeria monocytogenes", "ORGANISM", 12, 34], ["HKLM", "CELL", 36, 40], ["PAM3", "GENE_OR_GENE_PRODUCT", 94, 98], ["PAM2", "GENE_OR_GENE_PRODUCT", 100, 104], ["LPS", "SIMPLE_CHEMICAL", 110, 113], ["TLR2", "GENE_OR_GENE_PRODUCT", 164, 168], ["TLR2", "GENE_OR_GENE_PRODUCT", 170, 174], ["6", "GENE_OR_GENE_PRODUCT", 175, 176], ["TLR4", "GENE_OR_GENE_PRODUCT", 182, 186], ["TLR2", "PROTEIN", 164, 168], ["TLR2", "PROTEIN", 170, 174], ["TLR4", "PROTEIN", 182, 186], ["Listeria monocytogenes", "SPECIES", 12, 34], ["Listeria monocytogenes", "SPECIES", 12, 34], ["Listeria monocytogenes", "PROBLEM", 12, 34], ["all assays", "TEST", 74, 84], ["PAM3", "TEST", 94, 98], ["PAM2", "TEST", 100, 104], ["LPS", "TEST", 110, 113], ["TLR2", "TEST", 164, 168], ["Listeria monocytogenes", "OBSERVATION", 12, 34]]], ["All assays were performed at least in duplicate.", [["All assays", "TEST", 0, 10]]], ["Linear mixed model analyses and stepwise model selection were used to identify the statistically significant effects.", [["stepwise model selection", "TREATMENT", 32, 56], ["mixed", "OBSERVATION_MODIFIER", 7, 12]]], ["Random effects were used to account for heterogeneity across and homogeneity within isolates.", [["heterogeneity across and homogeneity within isolates", "PROBLEM", 40, 92]]], ["Results: HEK-TLR2 and HEK-TLR2/6, but not HEK-TLR4, cells released IL-8 upon stimulation with UV-inactivated lactobacilli, which was enhanced by co-transfection with CD-14.", [["HEK", "ANATOMY", 9, 12], ["HEK", "ANATOMY", 22, 25], ["HEK", "ANATOMY", 42, 45], ["cells", "ANATOMY", 52, 57], ["HEK-TLR2", "GENE_OR_GENE_PRODUCT", 9, 17], ["HEK-TLR2", "GENE_OR_GENE_PRODUCT", 22, 30], ["6", "GENE_OR_GENE_PRODUCT", 31, 32], ["HEK-TLR4", "GENE_OR_GENE_PRODUCT", 42, 50], ["cells", "CELL", 52, 57], ["IL-8", "GENE_OR_GENE_PRODUCT", 67, 71], ["lactobacilli", "SIMPLE_CHEMICAL", 109, 121], ["CD-14", "GENE_OR_GENE_PRODUCT", 166, 171], ["TLR2", "PROTEIN", 13, 17], ["TLR2", "PROTEIN", 26, 30], ["HEK", "PROTEIN", 42, 45], ["TLR4", "PROTEIN", 46, 50], ["IL-8", "PROTEIN", 67, 71], ["HEK", "TEST", 9, 12], ["TLR2", "TEST", 13, 17], ["HEK", "TEST", 22, 25], ["TLR2", "TEST", 26, 30], ["HEK", "TEST", 42, 45], ["IL", "TEST", 67, 69], ["UV", "TEST", 94, 96], ["inactivated lactobacilli", "PROBLEM", 97, 121], ["CD", "TEST", 166, 168], ["lactobacilli", "ANATOMY", 109, 121]]], ["Interestingly, the production of IL-8 was shown to be variable for the different Lactobacillus isolates.", [["IL-8", "GENE_OR_GENE_PRODUCT", 33, 37], ["IL", "PROTEIN", 33, 35], ["the different Lactobacillus isolates", "PROBLEM", 67, 103]]], ["Although similar results were seen for all isolates for TLR2 and TLR2/6, IL-8 production was significantly higher for TLR2 (8.4 log pg/ml) compared to TLR2/6 (6.05 log pg/ml) (P < 0.0001).", [["TLR2", "GENE_OR_GENE_PRODUCT", 56, 60], ["TLR2/6", "GENE_OR_GENE_PRODUCT", 65, 71], ["IL-8", "GENE_OR_GENE_PRODUCT", 73, 77], ["TLR2", "GENE_OR_GENE_PRODUCT", 118, 122], ["TLR2", "PROTEIN", 56, 60], ["TLR2", "PROTEIN", 65, 69], ["IL-8", "PROTEIN", 73, 77], ["TLR2", "PROTEIN", 118, 122], ["all isolates", "TEST", 39, 51], ["TLR2", "TEST", 56, 60], ["TLR2", "TEST", 65, 69], ["IL", "TEST", 73, 75], ["TLR2", "TEST", 118, 122], ["TLR2/6", "TEST", 151, 157]]], ["No significant differences in IL-8 production were seen between clinical and probiotic isolates.", [["IL-8", "GENE_OR_GENE_PRODUCT", 30, 34], ["IL-8", "PROTEIN", 30, 34], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION_MODIFIER", 15, 26]]], ["However, L. rhamnosus isolates induced a significantly higher IL-8 production compared to L. paracasei isolates in both cell lines, 7.88 and 6.84 log pg/ml, respectively (P = 0.0004).", [["cell lines", "ANATOMY", 120, 130], ["L. rhamnosus isolates", "ORGANISM", 9, 30], ["IL-8", "GENE_OR_GENE_PRODUCT", 62, 66], ["L. paracasei isolates", "ORGANISM", 90, 111], ["cell lines", "CELL", 120, 130], ["IL-8", "PROTEIN", 62, 66], ["L. rhamnosus", "SPECIES", 9, 21], ["L. paracasei", "SPECIES", 90, 102], ["L. rhamnosus", "SPECIES", 9, 21], ["L. paracasei", "SPECIES", 90, 102], ["L. rhamnosus isolates", "TEST", 9, 30], ["a significantly higher IL-8 production", "PROBLEM", 39, 77], ["L. paracasei isolates", "TEST", 90, 111], ["rhamnosus isolates", "OBSERVATION", 12, 30], ["significantly", "OBSERVATION_MODIFIER", 41, 54], ["higher", "OBSERVATION_MODIFIER", 55, 61], ["cell lines", "OBSERVATION", 120, 130]]], ["Intra-isolate correlation was found significant (P < 0.0022).", [["significant", "OBSERVATION_MODIFIER", 36, 47]]], ["Conclusions: Our study shows that lactobacilli activate both TLR2 and TLR2 in combination with TLR6.", [["lactobacilli", "SIMPLE_CHEMICAL", 34, 46], ["TLR2", "GENE_OR_GENE_PRODUCT", 61, 65], ["TLR2", "GENE_OR_GENE_PRODUCT", 70, 74], ["TLR6", "GENE_OR_GENE_PRODUCT", 95, 99], ["TLR2", "PROTEIN", 61, 65], ["TLR2", "PROTEIN", 70, 74], ["TLR6", "PROTEIN", 95, 99], ["Our study", "TEST", 13, 22], ["lactobacilli", "TREATMENT", 34, 46], ["TLR2", "TEST", 70, 74], ["TLR6", "TREATMENT", 95, 99]]], ["Our results also indicate that heterodimerisation of TLR2 with TLR6 does not lead to an improved recognition of lactobacilli.", [["TLR2", "GENE_OR_GENE_PRODUCT", 53, 57], ["TLR6", "GENE_OR_GENE_PRODUCT", 63, 67], ["lactobacilli", "SIMPLE_CHEMICAL", 112, 124], ["TLR2", "PROTEIN", 53, 57], ["TLR6", "PROTEIN", 63, 67], ["heterodimerisation of TLR2 with TLR6", "PROBLEM", 31, 67], ["lactobacilli", "PROBLEM", 112, 124], ["lactobacilli", "OBSERVATION", 112, 124]]], ["Finally, our results suggest that differences in immunomodulation by lactobacilli may be related to differential signalling through TLRs, including TLR2 and TLR2/6.O356 Mycobacteria affect group I CD1 expression and lipid-antigen presentation via p38 signalling in human DC precursorM.C. Gagliardi, V. Sargentini, R. Teloni, M.E. Remoli, G. Federico, M. Videtta, G. De Libero, E. Coccia, R. Nisini\u00b0(Rome, IT; Basel, CH) Objective: To gain insights into the mechanisms used by Mycobacterium tuberculosis and Bacillus Calmette Gu\u00e9rin to cause human monocytes differentiation into CD1 negative dendritic cells (My-MoDC), unable to present lipid antigens to specific T cells.", [["DC", "ANATOMY", 271, 273], ["monocytes", "ANATOMY", 547, 556], ["CD1 negative dendritic cells", "ANATOMY", 578, 606], ["My-MoDC", "ANATOMY", 608, 615], ["T cells", "ANATOMY", 663, 670], ["lactobacilli", "CHEMICAL", 69, 81], ["Mycobacterium tuberculosis", "DISEASE", 476, 502], ["lactobacilli", "SIMPLE_CHEMICAL", 69, 81], ["TLRs", "GENE_OR_GENE_PRODUCT", 132, 136], ["TLR2", "GENE_OR_GENE_PRODUCT", 148, 152], ["TLR2", "GENE_OR_GENE_PRODUCT", 157, 161], ["6.O356", "GENE_OR_GENE_PRODUCT", 162, 168], ["group I CD1", "GENE_OR_GENE_PRODUCT", 189, 200], ["lipid-antigen", "GENE_OR_GENE_PRODUCT", 216, 229], ["p38", "GENE_OR_GENE_PRODUCT", 247, 250], ["human", "ORGANISM", 265, 270], ["Mycobacterium tuberculosis", "ORGANISM", 476, 502], ["Bacillus Calmette Gu\u00e9rin", "ORGANISM", 507, 531], ["human", "ORGANISM", 541, 546], ["monocytes", "CELL", 547, 556], ["CD1", "GENE_OR_GENE_PRODUCT", 578, 581], ["dendritic cells", "CELL", 591, 606], ["My-MoDC", "CELL", 608, 615], ["lipid antigens", "GENE_OR_GENE_PRODUCT", 636, 650], ["T cells", "CELL", 663, 670], ["TLRs", "PROTEIN", 132, 136], ["TLR2", "PROTEIN", 148, 152], ["TLR2", "PROTEIN", 157, 161], ["group I CD1", "PROTEIN", 189, 200], ["p38", "PROTEIN", 247, 250], ["human monocytes", "CELL_TYPE", 541, 556], ["CD1 negative dendritic cells", "CELL_TYPE", 578, 606], ["MoDC", "CELL_TYPE", 611, 615], ["lipid antigens", "PROTEIN", 636, 650], ["T cells", "CELL_TYPE", 663, 670], ["human", "SPECIES", 265, 270], ["Mycobacterium tuberculosis", "SPECIES", 476, 502], ["Bacillus Calmette", "SPECIES", 507, 524], ["human", "SPECIES", 541, 546], ["human", "SPECIES", 265, 270], ["Mycobacterium tuberculosis", "SPECIES", 476, 502], ["Bacillus Calmette Gu\u00e9rin", "SPECIES", 507, 531], ["human", "SPECIES", 541, 546], ["lactobacilli", "TEST", 69, 81], ["TLRs", "TEST", 132, 136], ["TLR2", "TEST", 148, 152], ["TLR2", "TEST", 157, 161], ["lipid", "TEST", 216, 221], ["Gagliardi", "TEST", 288, 297], ["Mycobacterium tuberculosis", "PROBLEM", 476, 502], ["Bacillus Calmette Gu\u00e9rin", "TREATMENT", 507, 531], ["human monocytes differentiation", "TEST", 541, 572], ["dendritic cells", "PROBLEM", 591, 606], ["dendritic cells", "OBSERVATION", 591, 606]]], ["Methods: Human monocytes infected or not with mycobacteria were induced to differentiate into DC with GM-CSF and IL-4 in the presence or absence of p38 or ERK specific inhibitors.", [["monocytes", "ANATOMY", 15, 24], ["DC", "ANATOMY", 94, 96], ["GM", "CHEMICAL", 102, 104], ["Human", "ORGANISM", 9, 14], ["monocytes", "CELL", 15, 24], ["DC", "CELL", 94, 96], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 102, 108], ["IL-4", "GENE_OR_GENE_PRODUCT", 113, 117], ["p38", "GENE_OR_GENE_PRODUCT", 148, 151], ["ERK", "GENE_OR_GENE_PRODUCT", 155, 158], ["Human monocytes", "CELL_TYPE", 9, 24], ["DC", "CELL_TYPE", 94, 96], ["GM-CSF and IL-4", "PROTEIN", 102, 117], ["p38", "PROTEIN", 148, 151], ["ERK", "PROTEIN", 155, 158], ["Human", "SPECIES", 9, 14], ["Human", "SPECIES", 9, 14], ["Human monocytes infected", "PROBLEM", 9, 33], ["mycobacteria", "PROBLEM", 46, 58], ["IL", "TEST", 113, 115], ["p38", "PROBLEM", 148, 151], ["ERK specific inhibitors", "TREATMENT", 155, 178]]], ["Kinases activation was detected by western blot using antibodies specific for phosphorylated and non phosphorylated isoforms.", [["antibodies", "PROTEIN", 54, 64], ["phosphorylated isoforms", "PROTEIN", 101, 124], ["Kinases activation", "PROBLEM", 0, 18], ["phosphorylated and non phosphorylated isoforms", "TREATMENT", 78, 124]]], ["Differentiation of monocytes into DC and the CD1a, CD1b and CD1c expression was evaluated by flow cytometry and by real time PCR at different time points from infection.", [["monocytes", "ANATOMY", 19, 28], ["DC", "ANATOMY", 34, 36], ["infection", "DISEASE", 159, 168], ["monocytes", "CELL", 19, 28], ["DC", "CELL", 34, 36], ["CD1a", "GENE_OR_GENE_PRODUCT", 45, 49], ["CD1b", "GENE_OR_GENE_PRODUCT", 51, 55], ["CD1c", "GENE_OR_GENE_PRODUCT", 60, 64], ["monocytes", "CELL_TYPE", 19, 28], ["DC", "CELL_TYPE", 34, 36], ["CD1b", "PROTEIN", 51, 55], ["CD1c", "PROTEIN", 60, 64], ["the CD1a", "TEST", 41, 49], ["flow cytometry", "TEST", 93, 107], ["real time PCR", "TEST", 115, 128], ["infection", "PROBLEM", 159, 168], ["monocytes", "OBSERVATION", 19, 28], ["CD1c expression", "OBSERVATION", 60, 75], ["infection", "OBSERVATION", 159, 168]]], ["Functional expression of CD1 molecules was assessed by recognition of lipid antigens by CD1 restricted T cell clones.", [["T cell clones", "ANATOMY", 103, 116], ["CD1", "GENE_OR_GENE_PRODUCT", 25, 28], ["lipid antigens", "GENE_OR_GENE_PRODUCT", 70, 84], ["CD1", "GENE_OR_GENE_PRODUCT", 88, 91], ["T cell clones", "CELL", 103, 116], ["CD1 molecules", "PROTEIN", 25, 38], ["lipid antigens", "PROTEIN", 70, 84], ["CD1 restricted T cell clones", "CELL_LINE", 88, 116], ["CD1 molecules", "PROBLEM", 25, 38], ["cell clones", "OBSERVATION", 105, 116]]], ["Results: We show that mycobacteria trigger phosphorylation of ERK and p38 mitogen-activated protein kinase in human monocytes as well as of activating transcription factor (ATF)-2.", [["monocytes", "ANATOMY", 116, 125], ["ERK", "GENE_OR_GENE_PRODUCT", 62, 65], ["p38 mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 70, 106], ["human", "ORGANISM", 110, 115], ["monocytes", "CELL", 116, 125], ["activating transcription factor (ATF)-2", "GENE_OR_GENE_PRODUCT", 140, 179], ["ERK", "PROTEIN", 62, 65], ["p38 mitogen-activated protein kinase", "PROTEIN", 70, 106], ["human monocytes", "CELL_TYPE", 110, 125], ["activating transcription factor (ATF)-2", "PROTEIN", 140, 179], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["mycobacteria", "PROBLEM", 22, 34], ["ERK", "TEST", 62, 65], ["p38 mitogen", "TEST", 70, 81], ["activated protein kinase in human monocytes", "PROBLEM", 82, 125], ["mycobacteria", "OBSERVATION", 22, 34]]], ["Mycobacteria-infected monocytes treated with a specific p38 inhibitor, but not with a specific ERK inhibitor become insensitive to mycobacterial subversion and differentiate into CD1 positive My-MoDC, which are fully capable of presenting lipid antigens.", [["monocytes", "ANATOMY", 22, 31], ["monocytes", "CELL", 22, 31], ["p38", "GENE_OR_GENE_PRODUCT", 56, 59], ["ERK", "GENE_OR_GENE_PRODUCT", 95, 98], ["CD1", "GENE_OR_GENE_PRODUCT", 179, 182], ["My", "GENE_OR_GENE_PRODUCT", 192, 194], ["MoDC", "GENE_OR_GENE_PRODUCT", 195, 199], ["lipid antigens", "GENE_OR_GENE_PRODUCT", 239, 253], ["infected monocytes", "CELL_TYPE", 13, 31], ["ERK", "PROTEIN", 95, 98], ["CD1", "PROTEIN", 179, 182], ["MoDC", "PROTEIN", 195, 199], ["lipid antigens", "PROTEIN", 239, 253], ["Mycobacteria", "PROBLEM", 0, 12], ["infected monocytes", "PROBLEM", 13, 31], ["a specific p38 inhibitor", "TREATMENT", 45, 69], ["a specific ERK inhibitor", "PROBLEM", 84, 108], ["mycobacterial subversion", "PROBLEM", 131, 155], ["presenting lipid antigens", "PROBLEM", 228, 253], ["infected monocytes", "OBSERVATION", 13, 31]]], ["Data indicate that phosphorylation of p38 is directly involved in CD1 inhibition.", [["p38", "GENE_OR_GENE_PRODUCT", 38, 41], ["CD1", "GENE_OR_GENE_PRODUCT", 66, 69], ["p38", "PROTEIN", 38, 41], ["CD1", "PROTEIN", 66, 69], ["phosphorylation of p38", "PROBLEM", 19, 41]]], ["Conclusions: We propose p38 signaling as a pathway exploited by mycobacteria to affect CD1 expression, thus representing a novel target of possible pharmacological intervention in the treatment of mycobacterial infections.O357 Pro-inflammatory effect of activin A on microglial cellsS.", [["microglial cellsS", "ANATOMY", 267, 284], ["mycobacterial infections", "DISEASE", 197, 221], ["p38", "GENE_OR_GENE_PRODUCT", 24, 27], ["CD1", "GENE_OR_GENE_PRODUCT", 87, 90], ["activin A", "GENE_OR_GENE_PRODUCT", 254, 263], ["microglial cellsS", "CELL", 267, 284], ["p38", "PROTEIN", 24, 27], ["CD1", "PROTEIN", 87, 90], ["activin A", "PROTEIN", 254, 263], ["microglial cellsS", "CELL_TYPE", 267, 284], ["mycobacteria", "PROBLEM", 64, 76], ["pharmacological intervention", "TREATMENT", 148, 176], ["mycobacterial infections", "PROBLEM", 197, 221], ["mycobacteria", "OBSERVATION", 64, 76], ["mycobacterial infections", "OBSERVATION", 197, 221]]], ["Ebert\u00b0, S. Ribes, R. Nau, U. Michel (Gottingen, DE) Objective: Activin A (Act A) is a multifunctional cytokine with roles in the immune system and the inflammatory response.", [["immune system", "ANATOMY", 129, 142], ["Activin A", "GENE_OR_GENE_PRODUCT", 63, 72], ["Act A", "GENE_OR_GENE_PRODUCT", 74, 79], ["multifunctional cytokine", "PROTEIN", 86, 110], ["the inflammatory response", "PROBLEM", 147, 172], ["Ribes", "OBSERVATION_MODIFIER", 11, 16], ["inflammatory response", "OBSERVATION", 151, 172]]], ["Act A levels are elevated in the cerebrospinal fluid of patients with meningitis.", [["cerebrospinal fluid", "ANATOMY", 33, 52], ["meningitis", "DISEASE", 70, 80], ["Act A", "GENE_OR_GENE_PRODUCT", 0, 5], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 33, 52], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["A levels", "TEST", 4, 12], ["elevated", "PROBLEM", 17, 25], ["the cerebrospinal fluid", "TEST", 29, 52], ["meningitis", "PROBLEM", 70, 80], ["elevated", "OBSERVATION_MODIFIER", 17, 25], ["cerebrospinal", "ANATOMY", 33, 46], ["fluid", "OBSERVATION", 47, 52], ["meningitis", "OBSERVATION", 70, 80]]], ["Microglial cells, the major constituents of innate immunity within the brain, express Toll-like receptors (TLRs) recognising exogenous and endogenous ligands.", [["Microglial cells", "ANATOMY", 0, 16], ["brain", "ANATOMY", 71, 76], ["Microglial cells", "CELL", 0, 16], ["brain", "ORGAN", 71, 76], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 86, 105], ["TLRs", "GENE_OR_GENE_PRODUCT", 107, 111], ["Microglial cells", "CELL_TYPE", 0, 16], ["Toll-like receptors", "PROTEIN", 86, 105], ["TLRs", "PROTEIN", 107, 111], ["Microglial cells", "TEST", 0, 16], ["innate immunity within the brain", "PROBLEM", 44, 76], ["innate immunity", "OBSERVATION", 44, 59], ["brain", "ANATOMY", 71, 76], ["endogenous ligands", "OBSERVATION", 139, 157]]], ["Upon stimulation with TLR agonists, primary mouse microglial cells become activated and release nitric oxide (NO), cytokines, and also Act A, suggesting that they are a source of elevated Conclusions: Pre-treatment with Act A enhances NO release from microglial cells activated by agonists of the principal TLRs involved in the recognition of bacteria.", [["microglial cells", "ANATOMY", 50, 66], ["microglial cells", "ANATOMY", 251, 267], ["nitric oxide", "CHEMICAL", 96, 108], ["NO", "CHEMICAL", 110, 112], ["NO", "CHEMICAL", 235, 237], ["nitric oxide", "CHEMICAL", 96, 108], ["NO", "CHEMICAL", 110, 112], ["NO", "CHEMICAL", 235, 237], ["TLR", "GENE_OR_GENE_PRODUCT", 22, 25], ["mouse", "ORGANISM", 44, 49], ["microglial cells", "CELL", 50, 66], ["nitric oxide", "SIMPLE_CHEMICAL", 96, 108], ["NO", "SIMPLE_CHEMICAL", 110, 112], ["Act A", "GENE_OR_GENE_PRODUCT", 135, 140], ["Act A", "SIMPLE_CHEMICAL", 220, 225], ["NO", "SIMPLE_CHEMICAL", 235, 237], ["microglial cells", "CELL", 251, 267], ["TLRs", "GENE_OR_GENE_PRODUCT", 307, 311], ["TLR", "PROTEIN", 22, 25], ["primary mouse microglial cells", "CELL_TYPE", 36, 66], ["cytokines", "PROTEIN", 115, 124], ["microglial cells", "CELL_TYPE", 251, 267], ["TLRs", "PROTEIN", 307, 311], ["mouse", "SPECIES", 44, 49], ["mouse", "SPECIES", 44, 49], ["TLR agonists", "TREATMENT", 22, 34], ["primary mouse microglial cells", "TREATMENT", 36, 66], ["nitric oxide", "TREATMENT", 96, 108], ["cytokines", "PROBLEM", 115, 124], ["microglial cells", "TEST", 251, 267], ["bacteria", "PROBLEM", 343, 351], ["microglial cells", "OBSERVATION", 50, 66], ["microglial cells", "OBSERVATION", 251, 267], ["bacteria", "OBSERVATION", 343, 351]]], ["These findings provide further evidence for a role of Act A in the innate immune response and suggest that Act A acts as an pro-inflammatory modulator during infection and inflammatory processes in the CNS.L. Poirel\u00b0(Kremlin Bicetre, FR)Insertion sequences (IS) are genetic tools that can mediate expression of previously silent genes or be responsible for the overexpression of certain genes (in each case by providing promoter sequences).", [["infection", "DISEASE", 158, 167], ["Act A", "GENE_OR_GENE_PRODUCT", 54, 59], ["Act A", "GENE_OR_GENE_PRODUCT", 107, 112], ["Act A", "PROTEIN", 54, 59], ["Poirel\u00b0(Kremlin Bicetre, FR)Insertion sequences", "DNA", 209, 256], ["silent genes", "DNA", 322, 334], ["promoter sequences", "DNA", 420, 438], ["an pro-inflammatory modulator", "TREATMENT", 121, 150], ["infection", "PROBLEM", 158, 167], ["inflammatory processes", "PROBLEM", 172, 194], ["Poirel\u00b0(Kremlin Bicetre, FR)", "TREATMENT", 209, 237], ["Insertion sequences", "TEST", 237, 256], ["genetic tools", "PROBLEM", 266, 279], ["infection", "OBSERVATION", 158, 167], ["inflammatory", "OBSERVATION_MODIFIER", 172, 184]]], ["In addition to be involved in gene transcription levels, IS elements also play a very important role for gene acquisition/mobilisation.", [["IS elements", "DNA", 57, 68], ["gene acquisition/mobilisation", "TREATMENT", 105, 134]]], ["An IS is usually made of of two inverted-repeat sequences (IRs) bracketing a gene encoding the transposase which activity enables this entity to replicate and target another sequence.", [["inverted-repeat sequences", "DNA", 32, 57], ["IRs", "DNA", 59, 62], ["transposase", "DNA", 95, 106]]], ["The IS-related mechanisms at the origin of antibiotic resistance gene acquisition are diverse, including composite-transposition, rolling-circle transposition, one-ended transposition.", [["antibiotic resistance gene acquisition", "TREATMENT", 43, 81], ["composite-transposition", "TREATMENT", 105, 128], ["rolling-circle transposition", "TREATMENT", 130, 158], ["antibiotic resistance", "OBSERVATION", 43, 64]]], ["IS elements may be also involved in gene acquisition by mediating co-integration processes, or recombination events as hypothetized for IS26 in relation with blaSHV extendedspectrum b-lactamase (ESBL) genes originating from the chromosome of Klebsiella pneumoniae.", [["chromosome", "ANATOMY", 228, 238], ["IS26", "GENE_OR_GENE_PRODUCT", 136, 140], ["blaSHV extendedspectrum b-lactamase (ESBL)", "GENE_OR_GENE_PRODUCT", 158, 200], ["chromosome", "CELLULAR_COMPONENT", 228, 238], ["Klebsiella pneumoniae", "ORGANISM", 242, 263], ["IS elements", "DNA", 0, 11], ["IS26", "DNA", 136, 140], ["blaSHV extendedspectrum b-lactamase (ESBL) genes", "DNA", 158, 206], ["Klebsiella pneumoniae", "SPECIES", 242, 263], ["blaSHV", "SPECIES", 158, 164], ["Klebsiella pneumoniae", "SPECIES", 242, 263], ["recombination events", "PROBLEM", 95, 115], ["IS26", "TREATMENT", 136, 140], ["blaSHV extendedspectrum b-lactamase", "PROBLEM", 158, 193], ["ESBL) genes", "PROBLEM", 195, 206], ["Klebsiella pneumoniae", "PROBLEM", 242, 263], ["Klebsiella pneumoniae", "OBSERVATION", 242, 263]]], ["The blaCTX-M ESBL genes known to be extremely widespread worldwide are encoded on plasmids, and have been found in association with ISEcp1 (acting by one-ended transposition) or ISCR1 (acting by rolling-circle transposition).", [["plasmids", "ANATOMY", 82, 90], ["blaCTX-M ESBL", "GENE_OR_GENE_PRODUCT", 4, 17], ["ISEcp1", "GENE_OR_GENE_PRODUCT", 132, 138], ["ISCR1", "GENE_OR_GENE_PRODUCT", 178, 183], ["blaCTX-M ESBL genes", "DNA", 4, 23], ["plasmids", "DNA", 82, 90], ["ISEcp1", "PROTEIN", 132, 138], ["ISCR1", "DNA", 178, 183], ["The blaCTX", "TEST", 0, 10], ["ESBL genes", "PROBLEM", 13, 23], ["ISCR1", "PROBLEM", 178, 183]]], ["In that case, ISs have played a role in the mobilisation from the chromosome of Kluyvera spp. being the blaCTX-M progenitors and then in their expression.", [["chromosome", "ANATOMY", 66, 76], ["blaCTX-M progenitors", "ANATOMY", 104, 124], ["chromosome", "CELLULAR_COMPONENT", 66, 76], ["Kluyvera spp", "ORGANISM", 80, 92], ["blaCTX-M progenitors", "CELL", 104, 124], ["ISs", "DNA", 14, 17], ["blaCTX-M progenitors", "CELL_LINE", 104, 124], ["the mobilisation", "TREATMENT", 40, 56]]], ["Also, genes encoding acquired AmpC b-lactamases, being of the blaACC, blaDHA, and blaCMY-types, are mostly found in association with ISCR1 or ISEcp1.", [["AmpC b-lactamases", "GENE_OR_GENE_PRODUCT", 30, 47], ["blaACC", "GENE_OR_GENE_PRODUCT", 62, 68], ["blaDHA", "GENE_OR_GENE_PRODUCT", 70, 76], ["blaCMY", "GENE_OR_GENE_PRODUCT", 82, 88], ["ISCR1", "GENE_OR_GENE_PRODUCT", 133, 138], ["ISEcp1", "GENE_OR_GENE_PRODUCT", 142, 148], ["AmpC b-lactamases", "PROTEIN", 30, 47], ["blaACC", "PROTEIN", 62, 68], ["blaDHA", "PROTEIN", 70, 76], ["blaCMY", "PROTEIN", 82, 88], ["ISCR1", "PROTEIN", 133, 138], ["ISEcp1", "PROTEIN", 142, 148], ["genes encoding acquired AmpC b-lactamases", "PROBLEM", 6, 47], ["the blaACC", "PROBLEM", 58, 68], ["blaDHA", "PROBLEM", 70, 76], ["blaCMY-types", "PROBLEM", 82, 94], ["ISCR1", "PROBLEM", 133, 138], ["ISEcp1", "PROBLEM", 142, 148]]], ["Sometimes antibiotic resistance genes are mobilised by composite transposons which are made of two copies of a given IS bracketing the mobilised fragment.", [["fragment", "CELLULAR_COMPONENT", 145, 153], ["antibiotic resistance genes", "DNA", 10, 37], ["composite transposons", "DNA", 55, 76], ["IS bracketing the mobilised fragment", "DNA", 117, 153], ["antibiotic resistance genes", "TREATMENT", 10, 37], ["the mobilised fragment", "PROBLEM", 131, 153], ["antibiotic resistance", "OBSERVATION", 10, 31], ["mobilised fragment", "OBSERVATION", 135, 153]]], ["In Acinetobacter baumannii, the worldwide disseminated blaOXA-23 carbapenemase gene is part of a composite transposon structure made of two copies of ISAba1, forming transposon Tn2006 which had mobilised a chromosomal fragment from Acinetobacter radioresistens that actually corresponds to the progenitor of blaOXA-23.", [["chromosomal fragment", "ANATOMY", 206, 226], ["progenitor", "ANATOMY", 294, 304], ["Acinetobacter baumannii", "ORGANISM", 3, 26], ["blaOXA-23 carbapenemase", "GENE_OR_GENE_PRODUCT", 55, 78], ["ISAba1", "GENE_OR_GENE_PRODUCT", 150, 156], ["Tn2006", "GENE_OR_GENE_PRODUCT", 177, 183], ["chromosomal", "CELLULAR_COMPONENT", 206, 217], ["Acinetobacter radioresistens", "ORGANISM", 232, 260], ["progenitor", "CELL", 294, 304], ["blaOXA-23", "GENE_OR_GENE_PRODUCT", 308, 317], ["worldwide disseminated blaOXA-23 carbapenemase gene", "DNA", 32, 83], ["composite transposon structure", "DNA", 97, 127], ["ISAba1", "DNA", 150, 156], ["transposon Tn2006", "DNA", 166, 183], ["blaOXA-23", "DNA", 308, 317], ["Acinetobacter baumannii", "SPECIES", 3, 26], ["Acinetobacter radioresistens", "SPECIES", 232, 260], ["Acinetobacter baumannii", "SPECIES", 3, 26], ["Acinetobacter radioresistens", "SPECIES", 232, 260], ["Acinetobacter baumannii", "PROBLEM", 3, 26], ["carbapenemase gene", "TREATMENT", 65, 83], ["a composite transposon structure", "TREATMENT", 95, 127], ["a chromosomal fragment", "PROBLEM", 204, 226], ["Acinetobacter radioresistens", "PROBLEM", 232, 260], ["blaOXA", "TEST", 308, 314], ["Acinetobacter baumannii", "OBSERVATION", 3, 26], ["worldwide", "OBSERVATION_MODIFIER", 32, 41], ["disseminated", "OBSERVATION_MODIFIER", 42, 54], ["chromosomal fragment", "OBSERVATION", 206, 226]]], ["Another possibility can be the forming of composite transposon structure bracketed by two different IS (sharing similar IRs) as observed with the blaPER-1 ESBL gene in Pseudomonas aeruginosa.", [["blaPER-1 ESBL", "GENE_OR_GENE_PRODUCT", 146, 159], ["Pseudomonas aeruginosa", "ORGANISM", 168, 190], ["composite transposon structure", "DNA", 42, 72], ["blaPER-1 ESBL gene", "DNA", 146, 164], ["Pseudomonas aeruginosa", "SPECIES", 168, 190], ["Pseudomonas aeruginosa", "SPECIES", 168, 190], ["composite transposon structure", "PROBLEM", 42, 72], ["the blaPER", "TEST", 142, 152], ["ESBL gene in Pseudomonas aeruginosa", "PROBLEM", 155, 190], ["transposon structure", "OBSERVATION", 52, 72]]], ["This diversity of ISs elements at the origin of mobilisation/acquisition of antibiotic resistance genes is therefore responsible for the very efficient dissemination of many of them.L. Poirel\u00b0(Kremlin Bicetre, FR)S362 Resistance islands \u2212 their role in the accumulation and spread of antimicrobial resistance genesK.", [["ISs elements", "DNA", 18, 30], ["antibiotic resistance genes", "DNA", 76, 103], ["ISs elements", "PROBLEM", 18, 30], ["antibiotic resistance genes", "TREATMENT", 76, 103], ["the accumulation", "PROBLEM", 253, 269], ["antimicrobial resistance genesK", "TREATMENT", 284, 315], ["mobilisation", "OBSERVATION", 48, 60], ["spread", "OBSERVATION_MODIFIER", 274, 280], ["antimicrobial resistance", "OBSERVATION", 284, 308]]], ["Rajakumar\u00b0(Leicester, UK)Historically, multi-antibiotic resistance in many bacterial species was largely attributed to the acquisition of resistance (R)-plasmids encoding one or more resistance determinants.", [["multi-antibiotic", "CHEMICAL", 39, 55], ["resistance (R)-plasmids", "DNA", 138, 161], ["multi-antibiotic resistance", "PROBLEM", 39, 66], ["many bacterial species", "PROBLEM", 70, 92], ["resistance (R)-plasmids", "TREATMENT", 138, 161], ["bacterial species", "OBSERVATION", 75, 92]]], ["However, over the last decade the R-plasmid paradigm has begun to be challenged.", [["the R-plasmid paradigm", "TREATMENT", 30, 52]]], ["'Resistance islands' comprising large, chromosomally-integrated spans of alien DNA harbouring multiple antibiotic resistance genes have been identified in the major hospital pathogens methicillin-resistant Staphylococcus aureus (MRSA) and multi-resistant Acinetobacter baumannii, and the foodand water-borne diarrhoeal pathogens Shigella, Salmonella and Vibrio cholerae.", [["methicillin", "CHEMICAL", 184, 195], ["Staphylococcus aureus", "DISEASE", 206, 227], ["diarrhoeal pathogens", "DISEASE", 308, 328], ["methicillin", "CHEMICAL", 184, 195], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 184, 227], ["MRSA", "ORGANISM", 229, 233], ["Acinetobacter baumannii", "ORGANISM", 255, 278], ["Vibrio cholerae", "ORGANISM", 354, 369], ["alien DNA", "DNA", 73, 82], ["antibiotic resistance genes", "DNA", 103, 130], ["Staphylococcus aureus", "SPECIES", 206, 227], ["MRSA", "SPECIES", 229, 233], ["Acinetobacter baumannii", "SPECIES", 255, 278], ["Vibrio cholerae", "SPECIES", 354, 369], ["Staphylococcus aureus", "SPECIES", 206, 227], ["MRSA", "SPECIES", 229, 233], ["Acinetobacter baumannii", "SPECIES", 255, 278], ["Vibrio cholerae", "SPECIES", 354, 369], ["Resistance islands'", "PROBLEM", 1, 20], ["large, chromosomally", "PROBLEM", 32, 52], ["alien DNA", "TREATMENT", 73, 82], ["multiple antibiotic resistance genes", "TREATMENT", 94, 130], ["methicillin", "TEST", 184, 195], ["resistant Staphylococcus aureus", "PROBLEM", 196, 227], ["MRSA", "PROBLEM", 229, 233], ["multi-resistant Acinetobacter baumannii", "PROBLEM", 239, 278], ["the foodand water-borne diarrhoeal pathogens Shigella", "PROBLEM", 284, 337], ["Salmonella", "PROBLEM", 339, 349], ["Vibrio cholerae", "PROBLEM", 354, 369], ["Resistance", "OBSERVATION_MODIFIER", 1, 11], ["islands", "OBSERVATION_MODIFIER", 12, 19], ["large", "OBSERVATION_MODIFIER", 32, 37], ["antibiotic resistance", "OBSERVATION", 103, 124], ["Staphylococcus aureus", "OBSERVATION", 206, 227], ["multi-resistant", "OBSERVATION_MODIFIER", 239, 254], ["Acinetobacter baumannii", "OBSERVATION", 255, 278]]], ["In addition, comparative genomics analysis of the archetypal Haemophilus influenzae conjugative resistance element that had spread worldwide revealed that it belonged to a large syntenic family of integrative islands, members of which could be found in at least 15 other b-and g-Proteobacteria.", [["Haemophilus influenzae", "ORGANISM", 61, 83], ["archetypal Haemophilus influenzae conjugative resistance element", "DNA", 50, 114], ["Haemophilus influenzae", "SPECIES", 61, 83], ["Haemophilus influenzae", "SPECIES", 61, 83], ["comparative genomics analysis", "TEST", 13, 42], ["the archetypal Haemophilus influenzae conjugative resistance element", "PROBLEM", 46, 114], ["conjugative resistance", "OBSERVATION", 84, 106]]], ["With the exception of the A. baumannii island, these elements can be described as classic self-excising, -circularising and -integrative elements.", [["A. baumannii", "ORGANISM", 26, 38], ["classic self-excising, -circularising and -integrative elements", "DNA", 82, 145], ["A. baumannii", "SPECIES", 26, 38], ["A. baumannii", "SPECIES", 26, 38], ["the A. baumannii island", "TREATMENT", 22, 45], ["circularising", "PROBLEM", 106, 119], ["baumannii", "OBSERVATION", 29, 38]]], ["All three functions are mediated by short island-flanking direct repeats and cognate integrase proteins encoded by the islands.", [["short island-flanking direct repeats", "DNA", 36, 72], ["integrase proteins", "PROTEIN", 85, 103], ["short island-flanking direct repeats and cognate integrase proteins", "PROBLEM", 36, 103]]], ["In 2006 Fournier et al. described an 86 kb A. baumannii island (AbaR1) which harboured 45 resistance genes packaged within a highly mosaic, integron-rich element that had almost certainly evolved via recombination, transposition and integron-mediated cassette capture from an 'empty' ancestral prototype.", [["A. baumannii", "ORGANISM", 43, 55], ["AbaR1", "GENE_OR_GENE_PRODUCT", 64, 69], ["AbaR1", "DNA", 64, 69], ["45 resistance genes", "DNA", 87, 106], ["highly mosaic, integron-rich element", "DNA", 125, 161], ["A. baumannii", "SPECIES", 43, 55], ["A. baumannii", "SPECIES", 43, 55], ["baumannii island (AbaR1)", "TREATMENT", 46, 70], ["transposition and integron-mediated cassette capture", "TREATMENT", 215, 267], ["an 'empty' ancestral prototype", "TREATMENT", 273, 303], ["baumannii", "OBSERVATION", 46, 55]]], ["AbaR1 probably represents a new class of resistance island as it exhibits several features reminiscent of complex nested transposons, suggesting a distinct functional natute.", [["AbaR1", "CHEMICAL", 0, 5], ["AbaR1", "GENE_OR_GENE_PRODUCT", 0, 5], ["AbaR1", "DNA", 0, 5], ["complex nested transposons", "DNA", 106, 132], ["resistance island", "PROBLEM", 41, 58], ["complex nested transposons", "PROBLEM", 106, 132], ["a distinct functional natute", "PROBLEM", 145, 173], ["probably represents", "UNCERTAINTY", 6, 25], ["new", "OBSERVATION_MODIFIER", 28, 31], ["resistance island", "OBSERVATION", 41, 58], ["complex", "OBSERVATION_MODIFIER", 106, 113], ["nested transposons", "OBSERVATION", 114, 132], ["distinct", "OBSERVATION_MODIFIER", 147, 155], ["functional natute", "OBSERVATION", 156, 173]]], ["However, despite the widespread distribution of resistance and genomic islands only a minority are known to code for part or all of the conjugative machinery necessary for their dissemination; others have been mobilised by helper plasmids or bacteriophages.", [["plasmids", "ANATOMY", 230, 238], ["helper plasmids", "DNA", 223, 238], ["resistance and genomic islands", "PROBLEM", 48, 78], ["bacteriophages", "PROBLEM", 242, 256], ["widespread", "OBSERVATION_MODIFIER", 21, 31], ["distribution", "OBSERVATION_MODIFIER", 32, 44], ["resistance", "OBSERVATION_MODIFIER", 48, 58], ["genomic islands", "OBSERVATION", 63, 78]]], ["Regardless, data on the mechanisms of mobilisation of the vast majority of similar nonresistance islands remain sparse.", [["mobilisation", "TREATMENT", 38, 50], ["similar nonresistance islands", "PROBLEM", 75, 104], ["mobilisation", "OBSERVATION", 38, 50], ["similar", "OBSERVATION_MODIFIER", 75, 82], ["nonresistance", "OBSERVATION", 83, 96]]], ["Importantly, resistance islands may not consists merely of packages of resistance genes.", [["resistance genes", "DNA", 71, 87], ["resistance genes", "PROBLEM", 71, 87], ["resistance", "OBSERVATION_MODIFIER", 13, 23], ["islands", "OBSERVATION", 24, 31], ["resistance genes", "OBSERVATION", 71, 87]]], ["On the contrary, these diverse and frequently hybrid entities could potentially confer upon their hosts other advantageous traits relating to host-pathogen interaction, virulence, survival in the environment and/or transmissibility, truly justifying the label 'selfish islands' and further explaining their evolutionary success.L. Guy\u00b0(Uppsala, SE)Due to the availability of new techniques, genome sequencing of bacteria has become fast and inexpensive.", [["SE", "DISEASE", 345, 347], ["new techniques", "TREATMENT", 375, 389], ["bacteria", "PROBLEM", 412, 420], ["diverse", "OBSERVATION_MODIFIER", 23, 30]]], ["Furthermore, recent methods using paired-end reads located several kb apart in the genome eases the assembling process, even though no reference sequence is available.L. Guy\u00b0(Uppsala, SE)In a reasonably close future, it should be possible to obtain the fully assembled sequence of a bacterial isolate overnight.L. Guy\u00b0(Uppsala, SE)The new sequencing techniques generate enormous amounts of genomic data and, thereby, a need for new tools.", [["paired-end reads", "DNA", 34, 50], ["paired-end reads", "TREATMENT", 34, 50], ["reference sequence", "TEST", 135, 153], ["a bacterial isolate", "TREATMENT", 281, 300], ["genomic data", "TEST", 390, 402]]], ["These should able to quickly analyze genomes and point to zones of interest, prompting further analysis on a reduced number of regions or genes, such as genomic islands.L. Guy\u00b0(Uppsala, SE)Pathogenicity islands, a subset of genomic islands, carry genes such as toxins or resistance genes and have the particularity to be mobile, i.e. they may transfer to other species or strains.", [["genomic islands", "DNA", 153, 168], ["toxins or resistance genes", "DNA", 261, 287], ["further analysis", "TEST", 87, 103], ["Pathogenicity islands", "PROBLEM", 189, 210], ["genomic islands", "PROBLEM", 224, 239], ["resistance genes", "PROBLEM", 271, 287], ["strains", "PROBLEM", 372, 379], ["genomic islands", "OBSERVATION", 153, 168], ["Pathogenicity", "OBSERVATION_MODIFIER", 189, 202], ["islands", "OBSERVATION", 203, 210], ["subset", "OBSERVATION_MODIFIER", 214, 220], ["genomic islands", "OBSERVATION", 224, 239]]], ["Thereby, they confer their new hosts a more resistant or infectious phenotype, making this phenomenon particularly important to study.", [["a more resistant or infectious phenotype", "PROBLEM", 37, 77], ["this phenomenon", "PROBLEM", 86, 101], ["infectious", "OBSERVATION", 57, 67]]], ["Nucleotide composition of genomes is fairly homogeneous inside bacterial genomes.", [["bacterial genomes", "DNA", 63, 80], ["Nucleotide composition of genomes", "PROBLEM", 0, 33], ["genomes", "OBSERVATION", 26, 33], ["fairly", "OBSERVATION_MODIFIER", 37, 43], ["homogeneous", "OBSERVATION_MODIFIER", 44, 55], ["bacterial genomes", "OBSERVATION", 63, 80]]], ["In general, horizontally transferred regions can be spotted due to their particular nucleotide content, because they tend to retain the composition of their original host and don't share the one of their new hosts.", [["nucleotide", "CHEMICAL", 84, 94], ["nucleotide", "CHEMICAL", 84, 94]]], ["Several techniques relying on various compositional aspects and on different algorithmic methods have been recently developed to detect pathogenicity islands in bacterial genomes.", [["pathogenicity islands", "DNA", 136, 157], ["bacterial genomes", "DNA", 161, 178], ["Several techniques", "TREATMENT", 0, 18], ["pathogenicity islands in bacterial genomes", "PROBLEM", 136, 178], ["bacterial genomes", "OBSERVATION", 161, 178]]], ["Even very simple measures of the genome composition, such as the variation in T vs. A bias (TA skew) can lead to the identification of all known prophages in Streptococcus pyogenes.", [["Streptococcus pyogenes", "DISEASE", 158, 180], ["Streptococcus pyogenes", "ORGANISM", 158, 180], ["Streptococcus pyogenes", "SPECIES", 158, 180], ["Streptococcus pyogenes", "SPECIES", 158, 180], ["all known prophages", "PROBLEM", 135, 154], ["Streptococcus pyogenes", "PROBLEM", 158, 180], ["very", "OBSERVATION_MODIFIER", 5, 9], ["simple", "OBSERVATION_MODIFIER", 10, 16], ["Streptococcus pyogenes", "OBSERVATION", 158, 180]]], ["It can even trigger the discovery of a putative ancient genomic island carrying a large number of genes related to pathogenicity in all strains of that species.L. Guy\u00b0(Uppsala, SE)In conclusion, with the rise of fast and inexpensive genome sequencing, new quick and simple methods are being developed.", [["a putative ancient genomic island", "PROBLEM", 37, 70], ["pathogenicity", "PROBLEM", 115, 128], ["all strains of that species", "PROBLEM", 132, 159], ["fast and inexpensive genome sequencing", "PROBLEM", 212, 250], ["new quick and simple methods", "PROBLEM", 252, 280], ["large", "OBSERVATION_MODIFIER", 82, 87], ["number", "OBSERVATION_MODIFIER", 88, 94]]], ["They take the advantage of the homogeneous nucleotide composition of bacterial genomes to uncover mobile genetic elements carrying genes involved in pathogenicity.F. Zoulim\u00b0(Lyon, FR)In the past 10 years, significant progress has been achieved in the management of chronic hepatitis B with the successive development of six potent antiviral medications (lamivudine, adefovir dipivoxil, pegylated interferon alpha, entecavir, telbivudine and tenofovir).", [["nucleotide", "CHEMICAL", 43, 53], ["chronic hepatitis B", "DISEASE", 265, 284], ["lamivudine", "CHEMICAL", 354, 364], ["adefovir dipivoxil", "CHEMICAL", 366, 384], ["pegylated interferon alpha, entecavir", "CHEMICAL", 386, 423], ["telbivudine", "CHEMICAL", 425, 436], ["tenofovir", "CHEMICAL", 441, 450], ["nucleotide", "CHEMICAL", 43, 53], ["lamivudine", "CHEMICAL", 354, 364], ["adefovir dipivoxil", "CHEMICAL", 366, 384], ["entecavir", "CHEMICAL", 414, 423], ["telbivudine", "CHEMICAL", 425, 436], ["tenofovir", "CHEMICAL", 441, 450], ["lamivudine", "SIMPLE_CHEMICAL", 354, 364], ["adefovir dipivoxil", "SIMPLE_CHEMICAL", 366, 384], ["pegylated interferon alpha", "GENE_OR_GENE_PRODUCT", 386, 412], ["entecavir", "SIMPLE_CHEMICAL", 414, 423], ["telbivudine", "SIMPLE_CHEMICAL", 425, 436], ["tenofovir", "SIMPLE_CHEMICAL", 441, 450], ["bacterial genomes", "DNA", 69, 86], ["mobile genetic elements", "DNA", 98, 121], ["the homogeneous nucleotide composition of bacterial genomes", "TREATMENT", 27, 86], ["chronic hepatitis B", "PROBLEM", 265, 284], ["six potent antiviral medications", "TREATMENT", 320, 352], ["lamivudine", "TREATMENT", 354, 364], ["adefovir dipivoxil", "TREATMENT", 366, 384], ["pegylated interferon alpha", "TREATMENT", 386, 412], ["entecavir", "TREATMENT", 414, 423], ["telbivudine", "TREATMENT", 425, 436], ["tenofovir", "TREATMENT", 441, 450], ["bacterial genomes", "OBSERVATION", 69, 86], ["chronic", "OBSERVATION_MODIFIER", 265, 272], ["hepatitis", "OBSERVATION", 273, 282], ["six potent", "OBSERVATION_MODIFIER", 320, 330], ["antiviral medications", "OBSERVATION", 331, 352]]], ["However, the clinical results of antiviral therapy have been limited by the emergence of antiviral drug resistance especially with the first generation of nucleoside analogs (lamivudine, adefovir and telbivudine).", [["nucleoside", "CHEMICAL", 155, 165], ["lamivudine", "CHEMICAL", 175, 185], ["adefovir", "CHEMICAL", 187, 195], ["telbivudine", "CHEMICAL", 200, 211], ["nucleoside", "CHEMICAL", 155, 165], ["lamivudine", "CHEMICAL", 175, 185], ["adefovir", "CHEMICAL", 187, 195], ["telbivudine", "CHEMICAL", 200, 211], ["nucleoside analogs", "SIMPLE_CHEMICAL", 155, 173], ["lamivudine", "SIMPLE_CHEMICAL", 175, 185], ["adefovir", "SIMPLE_CHEMICAL", 187, 195], ["telbivudine", "SIMPLE_CHEMICAL", 200, 211], ["antiviral therapy", "TREATMENT", 33, 50], ["antiviral drug resistance", "TREATMENT", 89, 114], ["nucleoside analogs", "TREATMENT", 155, 173], ["lamivudine", "TREATMENT", 175, 185], ["adefovir", "TREATMENT", 187, 195], ["telbivudine", "TREATMENT", 200, 211], ["antiviral drug resistance", "OBSERVATION", 89, 114]]], ["Furthermore, the unique mechanism of viral genome replication and persistence within infected cells is responsible for viral persistence even after prolonged therapy with the newer antivirals (entecavir and tenofovir).", [["cells", "ANATOMY", 94, 99], ["entecavir", "CHEMICAL", 193, 202], ["tenofovir", "CHEMICAL", 207, 216], ["entecavir", "CHEMICAL", 193, 202], ["tenofovir", "CHEMICAL", 207, 216], ["cells", "CELL", 94, 99], ["entecavir", "SIMPLE_CHEMICAL", 193, 202], ["tenofovir", "SIMPLE_CHEMICAL", 207, 216], ["infected cells", "CELL_TYPE", 85, 99], ["viral genome replication", "PROBLEM", 37, 61], ["persistence within infected cells", "PROBLEM", 66, 99], ["viral persistence", "PROBLEM", 119, 136], ["prolonged therapy", "TREATMENT", 148, 165], ["the newer antivirals", "TREATMENT", 171, 191], ["entecavir", "TREATMENT", 193, 202], ["tenofovir", "TREATMENT", 207, 216], ["viral genome replication", "OBSERVATION", 37, 61], ["infected cells", "OBSERVATION", 85, 99], ["responsible for", "UNCERTAINTY", 103, 118]]], ["This is the major reason why life-long treatment is envisaged in the majority of patients, which may expose them to long-term risk of developing resistance.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["long treatment", "TREATMENT", 34, 48], ["developing resistance", "PROBLEM", 134, 155], ["long-term", "OBSERVATION_MODIFIER", 116, 125], ["resistance", "OBSERVATION", 145, 155]]], ["The use of in vitro phenotypic assays has been crucial for the characterisation of newly identified resistant mutants and determine their cross-resistance profile.", [["vitro phenotypic assays", "TEST", 14, 37], ["newly identified resistant mutants", "PROBLEM", 83, 117]]], ["Results allowed to understand the different mechanism of viral resistance to lamivudine and adefovir, the mechanism of primary failure to adefovir therapy, the unique mechanism of entecavir resistance, and to characterise the emergence of multi-drug-resistant strains in patients receiving sequential antiviral therapy.", [["lamivudine", "CHEMICAL", 77, 87], ["adefovir", "CHEMICAL", 92, 100], ["primary failure", "DISEASE", 119, 134], ["adefovir", "CHEMICAL", 138, 146], ["entecavir", "CHEMICAL", 180, 189], ["lamivudine", "CHEMICAL", 77, 87], ["adefovir", "CHEMICAL", 92, 100], ["adefovir", "CHEMICAL", 138, 146], ["entecavir", "CHEMICAL", 180, 189], ["lamivudine", "SIMPLE_CHEMICAL", 77, 87], ["adefovir", "SIMPLE_CHEMICAL", 92, 100], ["adefovir", "SIMPLE_CHEMICAL", 138, 146], ["entecavir", "SIMPLE_CHEMICAL", 180, 189], ["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 271, 279], ["viral resistance", "PROBLEM", 57, 73], ["lamivudine", "TREATMENT", 77, 87], ["adefovir", "TREATMENT", 92, 100], ["primary failure", "PROBLEM", 119, 134], ["adefovir therapy", "TREATMENT", 138, 154], ["entecavir resistance", "TREATMENT", 180, 200], ["multi-drug-resistant strains", "PROBLEM", 239, 267], ["sequential antiviral therapy", "TREATMENT", 290, 318], ["viral resistance", "OBSERVATION", 57, 73], ["entecavir resistance", "OBSERVATION", 180, 200], ["antiviral therapy", "OBSERVATION", 301, 318]]], ["The crossresistance profile for the main resistant mutants was determined which allowed to provide recommendation to clinicians for treatment adaptation based on molecular virology data.", [["The crossresistance profile", "TEST", 0, 27], ["the main resistant mutants", "PROBLEM", 32, 58], ["treatment adaptation", "TREATMENT", 132, 152], ["molecular virology data", "TEST", 162, 185]]], ["The understanding of the development of HBV drug resistance has allowed to significantly improve the management of antiviral resistance and to design better treatment strategies to prevent resistance.", [["HBV", "ORGANISM", 40, 43], ["HBV", "SPECIES", 40, 43], ["HBV drug resistance", "TREATMENT", 40, 59], ["antiviral resistance", "TREATMENT", 115, 135], ["better treatment strategies", "TREATMENT", 150, 177], ["resistance", "PROBLEM", 189, 199], ["HBV", "OBSERVATION", 40, 43], ["antiviral resistance", "OBSERVATION", 115, 135]]], ["The current standard of care relies on treatment initiation with antivirals combining a strong antiviral potency and a high barrier to resistance.", [["treatment initiation", "TREATMENT", 39, 59], ["antivirals", "TREATMENT", 65, 75], ["a strong antiviral potency", "TREATMENT", 86, 112], ["a high barrier to resistance", "TREATMENT", 117, 145], ["high barrier to resistance", "OBSERVATION_MODIFIER", 119, 145]]], ["A precise virologic monitoring is required to measure antiviral efficacy, and to diagnose partial response or viral breathrough at an early stage.", [["A precise virologic monitoring", "TEST", 0, 30], ["viral breathrough", "PROBLEM", 110, 127], ["viral breathrough", "OBSERVATION", 110, 127]]], ["This allows to adapt antiviral treatment preferrably using an add-on strategy with a drug having a complementary cross-resistance profile.", [["antiviral treatment", "TREATMENT", 21, 40], ["a drug", "TREATMENT", 83, 89]]], ["This strategy has been shown to be efficient in controling viral replication and preventing liver disease progression in the majority of patients.A. Dofferhoff\u00b0(Nijmegen, NL)Treatment of chronic hepatitis B virus (HBV) infection is aimed at suppressing viral replication to the lowest possible level.", [["liver", "ANATOMY", 92, 97], ["liver disease", "DISEASE", 92, 105], ["chronic hepatitis B virus (HBV) infection", "DISEASE", 187, 228], ["liver", "ORGAN", 92, 97], ["patients", "ORGANISM", 137, 145], ["chronic hepatitis B virus", "ORGANISM", 187, 212], ["HBV", "ORGANISM", 214, 217], ["patients", "SPECIES", 137, 145], ["hepatitis B virus", "SPECIES", 195, 212], ["hepatitis B virus", "SPECIES", 195, 212], ["HBV", "SPECIES", 214, 217], ["controling viral replication", "TREATMENT", 48, 76], ["liver disease progression", "PROBLEM", 92, 117], ["chronic hepatitis B virus", "PROBLEM", 187, 212], ["HBV) infection", "PROBLEM", 214, 228], ["viral replication", "TREATMENT", 253, 270], ["viral replication", "OBSERVATION", 59, 76], ["liver", "ANATOMY", 92, 97], ["disease", "OBSERVATION", 98, 105], ["chronic", "OBSERVATION_MODIFIER", 187, 194], ["hepatitis", "OBSERVATION", 195, 204]]], ["In many prospective clinical trials it has been shown that a sustained HBV DNA response was correlated with serologic, histologic, or biochemical responses.", [["HBV", "ORGANISM", 71, 74], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["HBV", "SPECIES", 71, 74], ["a sustained HBV DNA response", "PROBLEM", 59, 87], ["serologic", "TEST", 108, 117]]], ["Despite the recent progress in hepatitis B antiviral treatment, it is shown that antiviral drug resistance is inevitable against many of the nucleoside analogs.", [["hepatitis B", "CHEMICAL", 31, 42], ["nucleoside", "CHEMICAL", 141, 151], ["nucleoside", "CHEMICAL", 141, 151], ["hepatitis B antiviral", "ORGANISM", 31, 52], ["nucleoside analogs", "SIMPLE_CHEMICAL", 141, 159], ["hepatitis B", "SPECIES", 31, 42], ["hepatitis B antiviral treatment", "TREATMENT", 31, 62], ["antiviral drug resistance", "TREATMENT", 81, 106], ["the nucleoside analogs", "TREATMENT", 137, 159], ["hepatitis", "OBSERVATION", 31, 40]]], ["The emergence of antiviral-resistant strains of HBV leads to viral and subsequently biochemical breakthrough and may lead to disease progression and increased death.", [["death", "DISEASE", 159, 164], ["HBV", "ORGANISM", 48, 51], ["HBV", "SPECIES", 48, 51], ["antiviral", "TREATMENT", 17, 26], ["HBV", "PROBLEM", 48, 51], ["viral and subsequently biochemical breakthrough", "PROBLEM", 61, 108], ["disease progression", "PROBLEM", 125, 144], ["increased death", "PROBLEM", 149, 164], ["increased", "OBSERVATION_MODIFIER", 149, 158], ["death", "OBSERVATION", 159, 164]]], ["Most of the data on the clinical impact of antiviral resistant HBV came from the data derived from studies of lamivudine therapy.", [["lamivudine", "CHEMICAL", 110, 120], ["lamivudine", "CHEMICAL", 110, 120], ["HBV", "ORGANISM", 63, 66], ["lamivudine", "SIMPLE_CHEMICAL", 110, 120], ["HBV", "SPECIES", 63, 66], ["antiviral resistant HBV", "PROBLEM", 43, 66], ["lamivudine therapy", "TREATMENT", 110, 128]]], ["There is limited data on other HBV antiviral drugs like adefovir.", [["adefovir", "CHEMICAL", 56, 64], ["adefovir", "CHEMICAL", 56, 64], ["HBV", "ORGANISM", 31, 34], ["adefovir", "SIMPLE_CHEMICAL", 56, 64], ["HBV", "SPECIES", 31, 34], ["other HBV antiviral drugs", "TREATMENT", 25, 50], ["adefovir", "TREATMENT", 56, 64]]], ["It is shown in several studies that treatment of HBeAg-negative chronic hepatitis B with lamivudine effectively suppresses HBV replication and results in biochemical remission and histologic improvement in more than two thirds of patients.", [["HBeAg", "CHEMICAL", 49, 54], ["chronic hepatitis B", "DISEASE", 64, 83], ["lamivudine", "CHEMICAL", 89, 99], ["lamivudine", "CHEMICAL", 89, 99], ["HBeAg", "GENE_OR_GENE_PRODUCT", 49, 54], ["lamivudine", "SIMPLE_CHEMICAL", 89, 99], ["HBV", "ORGANISM", 123, 126], ["patients", "ORGANISM", 230, 238], ["patients", "SPECIES", 230, 238], ["hepatitis B", "SPECIES", 72, 83], ["HBV", "SPECIES", 123, 126], ["HBeAg", "TEST", 49, 54], ["chronic hepatitis B", "PROBLEM", 64, 83], ["lamivudine", "TREATMENT", 89, 99], ["HBV replication", "TREATMENT", 123, 138], ["biochemical remission", "TEST", 154, 175], ["chronic", "OBSERVATION_MODIFIER", 64, 71], ["hepatitis", "OBSERVATION", 72, 81]]], ["However, relapse has occurred in the majority of HBeAg-negative patients after the cessation of therapy.", [["HBeAg", "CHEMICAL", 49, 54], ["HBeAg", "GENE_OR_GENE_PRODUCT", 49, 54], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["relapse", "PROBLEM", 9, 16], ["HBeAg", "TEST", 49, 54], ["therapy", "TREATMENT", 96, 103], ["relapse", "OBSERVATION", 9, 16]]], ["There are several studies to support the occurrence of severe hepatic flares, and liver failure after the emergence of lamivudine resistance.", [["hepatic", "ANATOMY", 62, 69], ["liver", "ANATOMY", 82, 87], ["hepatic flares", "DISEASE", 62, 76], ["liver failure", "DISEASE", 82, 95], ["lamivudine", "CHEMICAL", 119, 129], ["lamivudine", "CHEMICAL", 119, 129], ["hepatic", "ORGAN", 62, 69], ["liver", "ORGAN", 82, 87], ["lamivudine", "SIMPLE_CHEMICAL", 119, 129], ["several studies", "TEST", 10, 25], ["severe hepatic flares", "PROBLEM", 55, 76], ["liver failure", "PROBLEM", 82, 95], ["lamivudine resistance", "TREATMENT", 119, 140], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["hepatic", "ANATOMY", 62, 69], ["flares", "OBSERVATION", 70, 76], ["liver", "ANATOMY", 82, 87], ["failure", "OBSERVATION", 88, 95], ["lamivudine resistance", "OBSERVATION", 119, 140]]], ["Several studies, where liver biopsies were taken, demonstrated that histological improvement was reduced in those patients experiencing lamivudine resistance.", [["liver biopsies", "ANATOMY", 23, 37], ["lamivudine", "CHEMICAL", 136, 146], ["lamivudine", "CHEMICAL", 136, 146], ["liver biopsies", "MULTI-TISSUE_STRUCTURE", 23, 37], ["patients", "ORGANISM", 114, 122], ["lamivudine", "SIMPLE_CHEMICAL", 136, 146], ["patients", "SPECIES", 114, 122], ["Several studies", "TEST", 0, 15], ["liver biopsies", "TEST", 23, 37], ["lamivudine resistance", "TREATMENT", 136, 157], ["liver", "ANATOMY", 23, 28], ["biopsies", "OBSERVATION", 29, 37], ["reduced", "OBSERVATION_MODIFIER", 97, 104], ["lamivudine resistance", "OBSERVATION", 136, 157]]], ["The clinical outcome for patients with antiviral resistance is related to their age, the severity of the underlying liver disease and the severity of the hepatic flares.", [["liver", "ANATOMY", 116, 121], ["hepatic", "ANATOMY", 154, 161], ["liver disease", "DISEASE", 116, 129], ["hepatic flares", "DISEASE", 154, 168], ["patients", "ORGANISM", 25, 33], ["liver", "ORGAN", 116, 121], ["hepatic", "ORGAN", 154, 161], ["patients", "SPECIES", 25, 33], ["antiviral resistance", "TREATMENT", 39, 59], ["the underlying liver disease", "PROBLEM", 101, 129], ["the hepatic flares", "PROBLEM", 150, 168], ["liver", "ANATOMY", 116, 121], ["disease", "OBSERVATION", 122, 129], ["hepatic", "ANATOMY", 154, 161], ["flares", "OBSERVATION", 162, 168]]], ["On the other hand in a different study it was found that long-term lamuvidine treatment was associated with a reduced chance of developing cirrhosis and HCC in patients without advanced disease but, although resistant mutants reduced the benefits from lamivudine therapy, the outcome of these patients was still better than untreated patients.", [["HCC", "ANATOMY", 153, 156], ["lamuvidine", "CHEMICAL", 67, 77], ["cirrhosis", "DISEASE", 139, 148], ["HCC", "DISEASE", 153, 156], ["lamivudine", "CHEMICAL", 252, 262], ["lamuvidine", "CHEMICAL", 67, 77], ["lamivudine", "CHEMICAL", 252, 262], ["lamuvidine", "SIMPLE_CHEMICAL", 67, 77], ["HCC", "CANCER", 153, 156], ["patients", "ORGANISM", 160, 168], ["lamivudine", "SIMPLE_CHEMICAL", 252, 262], ["patients", "ORGANISM", 293, 301], ["patients", "ORGANISM", 334, 342], ["patients", "SPECIES", 160, 168], ["patients", "SPECIES", 293, 301], ["patients", "SPECIES", 334, 342], ["a different study", "TEST", 21, 38], ["long-term lamuvidine treatment", "TREATMENT", 57, 87], ["developing cirrhosis", "PROBLEM", 128, 148], ["HCC", "PROBLEM", 153, 156], ["advanced disease", "PROBLEM", 177, 193], ["resistant mutants", "PROBLEM", 208, 225], ["lamivudine therapy", "TREATMENT", 252, 270], ["cirrhosis", "OBSERVATION", 139, 148], ["HCC", "OBSERVATION", 153, 156], ["without", "UNCERTAINTY", 169, 176], ["advanced", "OBSERVATION_MODIFIER", 177, 185], ["disease", "OBSERVATION", 186, 193]]], ["Results of several clinical trials have shown that the addition or substitution of newer antiviral agents can restore suppression of viral replication, normalisation of liver function and reverse histological progression in patients with antiviral resistance.", [["liver", "ANATOMY", 169, 174], ["liver", "ORGAN", 169, 174], ["patients", "ORGANISM", 224, 232], ["patients", "SPECIES", 224, 232], ["substitution", "TREATMENT", 67, 79], ["newer antiviral agents", "TREATMENT", 83, 105], ["viral replication", "TREATMENT", 133, 150], ["liver function", "TEST", 169, 183], ["reverse histological progression", "PROBLEM", 188, 220], ["antiviral resistance", "TREATMENT", 238, 258], ["viral replication", "OBSERVATION", 133, 150], ["liver", "ANATOMY", 169, 174], ["progression", "OBSERVATION_MODIFIER", 209, 220], ["antiviral resistance", "OBSERVATION", 238, 258]]], ["Consequently, well-tolerated, potent therapies that offer a strong genetic barrier against the development of resistance are desirable, since antiviral resistance and poor adherence are key risk factors for treatment failure and subsequent reversal of clinical improvement.T. P\u00e1l\u00b0(Al Ain, AE)Resistance of enteric fever-causing and non-typhoid salmonella serovars to agents traditionally used to treat these infections in the past shows extensive geographical variation.", [["enteric fever", "DISEASE", 306, 319], ["salmonella", "DISEASE", 344, 354], ["infections", "DISEASE", 408, 418], ["non-typhoid salmonella serovars", "SPECIES", 332, 363], ["potent therapies", "TREATMENT", 30, 46], ["a strong genetic barrier", "TREATMENT", 58, 82], ["resistance", "PROBLEM", 110, 120], ["antiviral resistance", "PROBLEM", 142, 162], ["treatment failure", "PROBLEM", 207, 224], ["enteric fever", "PROBLEM", 306, 319], ["non-typhoid salmonella serovars", "TREATMENT", 332, 363], ["agents", "TREATMENT", 367, 373], ["these infections", "PROBLEM", 402, 418], ["enteric", "ANATOMY", 306, 313], ["fever", "OBSERVATION", 314, 319], ["infections", "OBSERVATION", 408, 418], ["extensive", "OBSERVATION_MODIFIER", 437, 446], ["geographical variation", "OBSERVATION", 447, 469]]], ["Decreased susceptibility to ciprofloxacin is rapidly increasing all over the world with target alteration and increased efflux being the most important mechanisms behind.", [["ciprofloxacin", "CHEMICAL", 28, 41], ["ciprofloxacin", "CHEMICAL", 28, 41], ["ciprofloxacin", "SIMPLE_CHEMICAL", 28, 41], ["Decreased susceptibility", "PROBLEM", 0, 24], ["ciprofloxacin", "TREATMENT", 28, 41], ["target alteration", "PROBLEM", 88, 105], ["increased efflux", "PROBLEM", 110, 126], ["ciprofloxacin", "OBSERVATION", 28, 41], ["rapidly", "OBSERVATION_MODIFIER", 45, 52], ["increasing", "OBSERVATION_MODIFIER", 53, 63], ["increased efflux", "OBSERVATION", 110, 126]]], ["Infections with such strains often result in extended hospitalisation or even in therapeutic failures.", [["Infections", "DISEASE", 0, 10], ["Infections", "PROBLEM", 0, 10], ["such strains", "PROBLEM", 16, 28], ["therapeutic failures", "PROBLEM", 81, 101], ["therapeutic", "OBSERVATION_MODIFIER", 81, 92], ["failures", "OBSERVATION", 93, 101]]], ["Furthermore, it is likely that moderately increased MIC values facilitate the development of strains with higher level of resistance, i.e. a pattern described at various locations.", [["moderately increased MIC values", "PROBLEM", 31, 62], ["strains", "PROBLEM", 93, 100], ["is likely", "UNCERTAINTY", 16, 25], ["moderately", "OBSERVATION_MODIFIER", 31, 41], ["increased", "OBSERVATION_MODIFIER", 42, 51], ["MIC values", "OBSERVATION", 52, 62]]], ["Screening methods based on quinolone sensitivity testing may fail to indentify decreased fluoroquinolone susceptibility both in typhoid, as well as in non-typhoid salmonella.", [["quinolone", "CHEMICAL", 27, 36], ["fluoroquinolone", "CHEMICAL", 89, 104], ["typhoid", "DISEASE", 128, 135], ["salmonella", "DISEASE", 163, 173], ["quinolone", "CHEMICAL", 27, 36], ["fluoroquinolone", "CHEMICAL", 89, 104], ["quinolone", "SIMPLE_CHEMICAL", 27, 36], ["fluoroquinolone", "SIMPLE_CHEMICAL", 89, 104], ["non-typhoid salmonella", "ORGANISM", 151, 173], ["Screening methods", "TEST", 0, 17], ["quinolone sensitivity testing", "TEST", 27, 56], ["decreased fluoroquinolone susceptibility", "PROBLEM", 79, 119], ["typhoid", "PROBLEM", 128, 135], ["typhoid", "OBSERVATION", 128, 135]]], ["Plasmid mediated quinolone resistance genes are detected increasingly all around the world although neither the frequency nor the variety of genes identified has approached that seen in some other members of Enterobacteriaceae.", [["quinolone", "CHEMICAL", 17, 26], ["quinolone", "CHEMICAL", 17, 26], ["quinolone", "SIMPLE_CHEMICAL", 17, 26], ["Enterobacteriaceae", "CANCER", 208, 226], ["Plasmid mediated quinolone resistance genes", "DNA", 0, 43], ["Plasmid mediated quinolone resistance genes", "TREATMENT", 0, 43], ["Enterobacteriaceae", "PROBLEM", 208, 226], ["quinolone resistance", "OBSERVATION", 17, 37], ["Enterobacteriaceae", "OBSERVATION", 208, 226]]], ["Treatment with gatifloxacin or azithromycin are alternative options for invasive and systemic infections caused by strains with decreased susceptibility to ciprofloxacin.", [["gatifloxacin", "CHEMICAL", 15, 27], ["azithromycin", "CHEMICAL", 31, 43], ["infections", "DISEASE", 94, 104], ["ciprofloxacin", "CHEMICAL", 156, 169], ["gatifloxacin", "CHEMICAL", 15, 27], ["azithromycin", "CHEMICAL", 31, 43], ["ciprofloxacin", "CHEMICAL", 156, 169], ["gatifloxacin", "SIMPLE_CHEMICAL", 15, 27], ["azithromycin", "SIMPLE_CHEMICAL", 31, 43], ["ciprofloxacin", "SIMPLE_CHEMICAL", 156, 169], ["gatifloxacin", "TREATMENT", 15, 27], ["azithromycin", "TREATMENT", 31, 43], ["alternative options", "TREATMENT", 48, 67], ["invasive and systemic infections", "PROBLEM", 72, 104], ["strains", "PROBLEM", 115, 122], ["decreased susceptibility", "PROBLEM", 128, 152], ["ciprofloxacin", "TREATMENT", 156, 169], ["infections", "OBSERVATION", 94, 104]]], ["At some parts of the World resistance to extended spectrum cephalosporins reached such incidence that may have therapeutic implications particularly when initial, empiric treatment of invasive infections is concerned.", [["cephalosporins", "CHEMICAL", 59, 73], ["infections", "DISEASE", 193, 203], ["cephalosporins", "CHEMICAL", 59, 73], ["extended spectrum cephalosporins", "TREATMENT", 41, 73], ["empiric treatment", "TREATMENT", 163, 180], ["invasive infections", "PROBLEM", 184, 203], ["invasive", "OBSERVATION_MODIFIER", 184, 192], ["infections", "OBSERVATION", 193, 203]]], ["Resistance is due to plasmid coded AmpC type beta lactamases (particularly to CMY-2), and most often to ESBLs of which usually some of CTX-M types are the frequently encountered ones.", [["CTX", "CHEMICAL", 135, 138], ["AmpC type beta lactamases", "GENE_OR_GENE_PRODUCT", 35, 60], ["CMY-2", "GENE_OR_GENE_PRODUCT", 78, 83], ["ESBLs", "GENE_OR_GENE_PRODUCT", 104, 109], ["plasmid", "DNA", 21, 28], ["AmpC type beta lactamases", "PROTEIN", 35, 60], ["plasmid coded AmpC type beta lactamases", "PROBLEM", 21, 60], ["CMY", "TEST", 78, 81], ["ESBLs", "TEST", 104, 109], ["CTX", "TEST", 135, 138], ["ESBLs", "OBSERVATION", 104, 109]]], ["Carbapenem resistance is still rare, albeit does occur, among salmonella isolates.", [["Carbapenem", "CHEMICAL", 0, 10], ["salmonella", "DISEASE", 62, 72], ["Carbapenem resistance", "PROBLEM", 0, 21]]], ["The recent description of a non-typhoid salmonella strain with the blaIMP-4 gene co-located on a class-1 integron with several other resistance determinants on a conjugative plasmid is of particular concern.", [["plasmid", "ANATOMY", 174, 181], ["salmonella", "DISEASE", 40, 50], ["non-typhoid salmonella", "ORGANISM", 28, 50], ["blaIMP-4", "GENE_OR_GENE_PRODUCT", 67, 75], ["blaIMP-4 gene", "DNA", 67, 80], ["class-1 integron", "DNA", 97, 113], ["conjugative plasmid", "DNA", 162, 181], ["a non-typhoid salmonella strain", "PROBLEM", 26, 57], ["a class-1 integron", "TREATMENT", 95, 113], ["a conjugative plasmid", "TREATMENT", 160, 181], ["resistance", "OBSERVATION", 133, 143]]], ["Campylobacters exhibit natural resistance to a variety of antimicrobials.", [["Campylobacters", "CHEMICAL", 0, 14], ["Campylobacters", "SIMPLE_CHEMICAL", 0, 14], ["Campylobacters", "PROBLEM", 0, 14], ["natural resistance", "PROBLEM", 23, 41], ["a variety of antimicrobials", "TREATMENT", 45, 72], ["natural resistance", "OBSERVATION", 23, 41]]], ["The drugs of choice used to be fluoroqunolones or macrolides.", [["fluoroqunolones", "CHEMICAL", 31, 46], ["macrolides", "CHEMICAL", 50, 60], ["fluoroqunolones", "CHEMICAL", 31, 46], ["macrolides", "CHEMICAL", 50, 60], ["fluoroqunolones", "SIMPLE_CHEMICAL", 31, 46], ["macrolides", "SIMPLE_CHEMICAL", 50, 60], ["fluoroqunolones", "TREATMENT", 31, 46], ["macrolides", "TREATMENT", 50, 60]]], ["However, the current incidence of ciprofloxacin resistance made the former drugs already obsolete or seriously limited their use at several parts of the World.", [["ciprofloxacin", "CHEMICAL", 34, 47], ["ciprofloxacin", "CHEMICAL", 34, 47], ["ciprofloxacin", "SIMPLE_CHEMICAL", 34, 47], ["ciprofloxacin resistance", "TREATMENT", 34, 58], ["the former drugs", "TREATMENT", 64, 80], ["ciprofloxacin resistance", "OBSERVATION", 34, 58]]], ["With the exception of few locations the incidence of macrolide resistance is still relatively low and is seen more frequently in C. coli than in C. jejuni.", [["macrolide", "CHEMICAL", 53, 62], ["macrolide", "CHEMICAL", 53, 62], ["macrolide", "SIMPLE_CHEMICAL", 53, 62], ["C. coli", "ORGANISM", 129, 136], ["C. jejuni", "ORGANISM", 145, 154], ["C. coli", "SPECIES", 129, 136], ["C. jejuni", "SPECIES", 145, 154], ["C. coli", "SPECIES", 129, 136], ["C. jejuni", "SPECIES", 145, 154], ["macrolide resistance", "PROBLEM", 53, 73], ["C. coli", "PROBLEM", 129, 136], ["few", "OBSERVATION_MODIFIER", 22, 25], ["macrolide resistance", "OBSERVATION", 53, 73], ["relatively", "OBSERVATION_MODIFIER", 83, 93], ["low", "OBSERVATION_MODIFIER", 94, 97], ["more frequently", "OBSERVATION_MODIFIER", 110, 125], ["C. coli", "OBSERVATION_MODIFIER", 129, 136], ["jejuni", "ANATOMY", 148, 154]]], ["However, strains exhibiting resistance against both groups of drugs have been emerging, particularly in South-East Asia.P. Mastrantonio\u00b0, P. Stefanelli (Rome, IT)Neisseria meningitidis, the meningococcus, is a major cause of meningitis and septicaemia worldwide while Neisseria gonorrhoeae, the gonococcus, is responsible for one of the most widespread sexually trasmitted disease.", [["Neisseria meningitidis", "DISEASE", 162, 184], ["meningitis", "DISEASE", 225, 235], ["septicaemia", "DISEASE", 240, 251], ["Neisseria gonorrhoeae", "DISEASE", 268, 289], ["sexually trasmitted disease", "DISEASE", 353, 380], ["P. Stefanelli (Rome, IT)Neisseria meningitidis", "ORGANISM", 138, 184], ["Neisseria gonorrhoeae", "ORGANISM", 268, 289], ["Neisseria meningitidis", "SPECIES", 162, 184], ["Neisseria gonorrhoeae", "SPECIES", 268, 289], ["Neisseria meningitidis", "SPECIES", 162, 184], ["Neisseria gonorrhoeae", "SPECIES", 268, 289], ["strains", "PROBLEM", 9, 16], ["drugs", "TREATMENT", 62, 67], ["Neisseria meningitidis", "PROBLEM", 162, 184], ["the meningococcus", "PROBLEM", 186, 203], ["meningitis", "PROBLEM", 225, 235], ["septicaemia", "PROBLEM", 240, 251], ["Neisseria gonorrhoeae", "PROBLEM", 268, 289], ["the gonococcus", "PROBLEM", 291, 305], ["resistance", "OBSERVATION_MODIFIER", 28, 38], ["meningococcus", "OBSERVATION", 190, 203], ["meningitis", "OBSERVATION", 225, 235], ["septicaemia", "OBSERVATION", 240, 251], ["gonococcus", "OBSERVATION", 295, 305], ["trasmitted disease", "OBSERVATION", 362, 380]]], ["The behaviour of these two species towards antibiotics is very different: resistance in N. gonorrhoeae is now widespread occuring as both chromosomally and plasmid mediated to a variety of drugs, whereas, besides resistance to sulphonamides, N. meningitidis remains largely susceptible to antibiotics used both for therapy and prophylaxis.", [["plasmid", "ANATOMY", 156, 163], ["N. gonorrhoeae", "DISEASE", 88, 102], ["sulphonamides", "CHEMICAL", 227, 240], ["sulphonamides", "CHEMICAL", 227, 240], ["N. gonorrhoeae", "ORGANISM", 88, 102], ["sulphonamides", "SIMPLE_CHEMICAL", 227, 240], ["N. meningitidis", "ORGANISM", 242, 257], ["N. gonorrhoeae", "SPECIES", 88, 102], ["N. meningitidis", "SPECIES", 242, 257], ["N. gonorrhoeae", "SPECIES", 88, 102], ["N. meningitidis", "SPECIES", 242, 257], ["antibiotics", "TREATMENT", 43, 54], ["resistance in N. gonorrhoeae", "PROBLEM", 74, 102], ["drugs", "TREATMENT", 189, 194], ["sulphonamides", "TREATMENT", 227, 240], ["N. meningitidis", "PROBLEM", 242, 257], ["antibiotics", "TREATMENT", 289, 300], ["therapy", "TREATMENT", 315, 322], ["prophylaxis", "TREATMENT", 327, 338], ["N. gonorrhoeae", "OBSERVATION", 88, 102]]], ["However, as in the gonococcus, the resistance to antibiotics of N. meningitidis is also evolving, as documented by the ever higher frequency of strains with intermediate resistance to penicillin in many countries.", [["N. meningitidis", "DISEASE", 64, 79], ["penicillin", "CHEMICAL", 184, 194], ["penicillin", "CHEMICAL", 184, 194], ["N. meningitidis", "ORGANISM", 64, 79], ["penicillin", "SIMPLE_CHEMICAL", 184, 194], ["N. meningitidis", "SPECIES", 64, 79], ["N. meningitidis", "SPECIES", 64, 79], ["the gonococcus", "PROBLEM", 15, 29], ["antibiotics", "TREATMENT", 49, 60], ["N. meningitidis", "PROBLEM", 64, 79], ["penicillin", "TREATMENT", 184, 194], ["meningitidis", "OBSERVATION", 67, 79], ["intermediate resistance", "OBSERVATION", 157, 180]]], ["Transformation has apparently provided both species with a mechanism by which they can increase resistance to penicillin by replacing part of their penA gene, which encodes PBP2, with part of the penA gene of related species that fortuitously produces forms of PBP2 less susceptible to the antibiotic.", [["penicillin", "CHEMICAL", 110, 120], ["penicillin", "CHEMICAL", 110, 120], ["penicillin", "SIMPLE_CHEMICAL", 110, 120], ["penA", "GENE_OR_GENE_PRODUCT", 148, 152], ["PBP2", "GENE_OR_GENE_PRODUCT", 173, 177], ["penA", "GENE_OR_GENE_PRODUCT", 196, 200], ["PBP2", "GENE_OR_GENE_PRODUCT", 261, 265], ["penA gene", "DNA", 148, 157], ["PBP2", "PROTEIN", 173, 177], ["penA gene", "DNA", 196, 205], ["PBP2", "PROTEIN", 261, 265], ["penicillin", "TREATMENT", 110, 120], ["PBP2", "PROBLEM", 173, 177], ["related species", "PROBLEM", 209, 224], ["PBP2", "PROBLEM", 261, 265], ["the antibiotic", "TREATMENT", 286, 300]]], ["N. meningitidis is still at this step, whereas N. gonorrhoeae has acquired also mutation in the ponA gene that encodes PBP1, mutation in porin IB, increased expression of efflux pump and the TEM-1 b-lactamase plasmid.", [["N. meningitidis", "ORGANISM", 0, 15], ["N. gonorrhoeae", "ORGANISM", 47, 61], ["ponA", "GENE_OR_GENE_PRODUCT", 96, 100], ["PBP1", "GENE_OR_GENE_PRODUCT", 119, 123], ["porin IB", "GENE_OR_GENE_PRODUCT", 137, 145], ["TEM-1 b-lactamase", "GENE_OR_GENE_PRODUCT", 191, 208], ["ponA gene", "DNA", 96, 105], ["PBP1", "PROTEIN", 119, 123], ["porin IB", "PROTEIN", 137, 145], ["TEM-1 b-lactamase plasmid", "DNA", 191, 216], ["N. meningitidis", "SPECIES", 0, 15], ["N. gonorrhoeae", "SPECIES", 47, 61], ["N. meningitidis", "SPECIES", 0, 15], ["N. gonorrhoeae", "SPECIES", 47, 61], ["meningitidis", "PROBLEM", 3, 15], ["PBP1", "PROBLEM", 119, 123], ["mutation in porin IB", "PROBLEM", 125, 145], ["efflux pump", "TREATMENT", 171, 182], ["the TEM", "TEST", 187, 194], ["b-lactamase plasmid", "TREATMENT", 197, 216], ["meningitidis", "OBSERVATION", 3, 15], ["efflux pump", "OBSERVATION", 171, 182]]], ["The emergence and the spread of gonococci fully resistant to penicillin since the second half of the 1980 s years led to the recommended use of fluoroquinolones as primary therapy.", [["penicillin", "CHEMICAL", 61, 71], ["fluoroquinolones", "CHEMICAL", 144, 160], ["penicillin", "CHEMICAL", 61, 71], ["fluoroquinolones", "CHEMICAL", 144, 160], ["gonococci", "CELL", 32, 41], ["penicillin", "SIMPLE_CHEMICAL", 61, 71], ["fluoroquinolones", "SIMPLE_CHEMICAL", 144, 160], ["gonococci", "PROBLEM", 32, 41], ["penicillin", "TREATMENT", 61, 71], ["fluoroquinolones", "TREATMENT", 144, 160], ["primary therapy", "TREATMENT", 164, 179]]], ["However, this class of antibiotics became rapidly unefficacious, mainly in Asia, due to the emergence of mutations in gyrA and parC which are able to block the activity of the quinolones on gyrase and topoisomerase IV.", [["quinolones", "CHEMICAL", 176, 186], ["quinolones", "CHEMICAL", 176, 186], ["gyrA", "GENE_OR_GENE_PRODUCT", 118, 122], ["parC", "GENE_OR_GENE_PRODUCT", 127, 131], ["quinolones", "SIMPLE_CHEMICAL", 176, 186], ["gyrase", "GENE_OR_GENE_PRODUCT", 190, 196], ["topoisomerase IV", "GENE_OR_GENE_PRODUCT", 201, 217], ["gyrA", "DNA", 118, 122], ["parC", "DNA", 127, 131], ["gyrase", "PROTEIN", 190, 196], ["topoisomerase IV", "PROTEIN", 201, 217], ["antibiotics", "TREATMENT", 23, 34], ["rapidly unefficacious", "PROBLEM", 42, 63], ["mutations in gyrA", "PROBLEM", 105, 122], ["parC", "PROBLEM", 127, 131], ["the quinolones", "TREATMENT", 172, 186], ["gyrase", "TREATMENT", 190, 196], ["topoisomerase IV", "TREATMENT", 201, 217]]], ["Since 2006, CDC no longer recommends their use for treatment of gonococcal diseases.", [["gonococcal", "ANATOMY", 64, 74], ["gonococcal diseases", "DISEASE", 64, 83], ["treatment", "TREATMENT", 51, 60], ["gonococcal diseases", "PROBLEM", 64, 83], ["gonococcal", "OBSERVATION", 64, 74]]], ["Fortunately, the occurrence of quinolone resistant meningococci, due to mutations in gyrA, is still rare but even if cases are still few they are of great concern for the epidemic potential of this pathogen and the required prophylaxis of contacts.", [["quinolone", "CHEMICAL", 31, 40], ["meningococci", "DISEASE", 51, 63], ["quinolone", "CHEMICAL", 31, 40], ["quinolone resistant meningococci", "ORGANISM", 31, 63], ["gyrA", "GENE_OR_GENE_PRODUCT", 85, 89], ["gyrA", "DNA", 85, 89], ["quinolone resistant meningococci", "PROBLEM", 31, 63], ["mutations in gyrA", "PROBLEM", 72, 89], ["this pathogen", "PROBLEM", 193, 206], ["quinolone resistant meningococci", "OBSERVATION", 31, 63]]], ["Also for the other antibiotic, frequently used to this aim, rifampicin, some meningococci have showed to be resistant, again for the presence of mutations, in this case in the rpoB gene coding for the b-subunit of the meningococcal RNA polymerase.", [["rifampicin", "CHEMICAL", 60, 70], ["rifampicin", "CHEMICAL", 60, 70], ["rifampicin", "SIMPLE_CHEMICAL", 60, 70], ["rpoB", "GENE_OR_GENE_PRODUCT", 176, 180], ["rpoB gene", "DNA", 176, 185], ["meningococcal RNA polymerase", "PROTEIN", 218, 246], ["the other antibiotic", "TREATMENT", 9, 29], ["rifampicin", "TREATMENT", 60, 70], ["some meningococci", "PROBLEM", 72, 89], ["mutations", "PROBLEM", 145, 154], ["the meningococcal RNA polymerase", "TREATMENT", 214, 246], ["meningococcal RNA polymerase", "OBSERVATION", 218, 246]]], ["The molecular epidemiological identification of clonal clusters for both Neisseria species with distinct resistance profiles is required to monitor ongoing trends that may pose problems both in therapy and prophylaxis.Antibiotic use in primary care: new insights, better results?", [["Neisseria species", "ORGANISM", 73, 90], ["clonal clusters", "PROBLEM", 48, 63], ["both Neisseria species", "PROBLEM", 68, 90], ["distinct resistance profiles", "PROBLEM", 96, 124], ["therapy", "TREATMENT", 194, 201], ["prophylaxis", "TREATMENT", 206, 217], ["clonal clusters", "OBSERVATION", 48, 63], ["Neisseria species", "OBSERVATION", 73, 90], ["distinct resistance", "OBSERVATION", 96, 115]]], ["(Symposium arranged with ESPRIT) S374 Attitudes and perceptions of doctors and patients to antibiotic use for LRTI in EuropeL.", [["LRTI", "DISEASE", 110, 114], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["LRTI in EuropeL", "TREATMENT", 110, 125]]], ["Brookes-Howell\u00b0, C. Butler, K. Hood, L. Cooper, H. Goossens (Cardiff, UK; Antwerp, BE) Introduction: GRACE is a European Network of Excellence established to focus on antibiotic use for community-acquired lower respiratory tract infection (LRTI) and antimicrobial resistance across Europe.", [["lower respiratory tract", "ANATOMY", 205, 228], ["lower respiratory tract infection", "DISEASE", 205, 238], ["LRTI", "DISEASE", 240, 244], ["lower", "ORGANISM_SUBDIVISION", 205, 210], ["respiratory tract", "ORGANISM_SUBDIVISION", 211, 228], ["antibiotic use", "TREATMENT", 167, 181], ["community-acquired lower respiratory tract infection", "PROBLEM", 186, 238], ["antimicrobial resistance", "TREATMENT", 250, 274], ["lower", "ANATOMY_MODIFIER", 205, 210], ["respiratory tract", "ANATOMY", 211, 228], ["infection", "OBSERVATION", 229, 238], ["antimicrobial resistance", "OBSERVATION", 250, 274]]], ["GRACE-02, the second study to begin within GRACE, is a large qualitative study that explores the attitudes of clinicians and patients to antibiotic use for LRTI and antibiotic resistance.", [["LRTI", "DISEASE", 156, 160], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["GRACE", "TEST", 0, 5], ["the second study", "TEST", 10, 26], ["a large qualitative study", "TEST", 53, 78], ["antibiotic use", "TREATMENT", 137, 151], ["LRTI", "PROBLEM", 156, 160], ["antibiotic resistance", "TREATMENT", 165, 186], ["large", "OBSERVATION_MODIFIER", 55, 60]]], ["Aims: This presentation will focus on clinicians' accounts of the factors that contribute to variation in management of LRTI and patient views on when antibiotics are necessary.", [["LRTI", "DISEASE", 120, 124], ["patient", "ORGANISM", 129, 136], ["patient", "SPECIES", 129, 136], ["the factors", "PROBLEM", 62, 73], ["LRTI", "PROBLEM", 120, 124], ["patient views", "TEST", 129, 142], ["antibiotics", "TREATMENT", 151, 162]]], ["Methods: Semi-structured interviews with 81 clinicians and 121 patients were conducted in primary care networks in nine European countries.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71]]], ["Themes were identified, organised and compared using a Framework Approach.", [["a Framework Approach", "TREATMENT", 53, 73]]], ["Results: Analysis of clinician interviews shows that, beside clinical findings, factors which influence the management decision for patients can be divided into two main areas.", [["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["clinician interviews", "TEST", 21, 41]]], ["These factors include: near patient test usage, self-medication, patients' finances and lack of consistent, local prescribing guidelines.", [["patient", "ORGANISM", 28, 35], ["patients", "ORGANISM", 65, 73], ["patient", "SPECIES", 28, 35], ["patients", "SPECIES", 65, 73], ["self-medication", "TREATMENT", 48, 63]]], ["Analysis of patient interviews shows that beliefs about antibiotic use tend to draw on clinical factors, namely the severity of specific symptoms (fever and/or coughing).", [["fever", "DISEASE", 147, 152], ["coughing", "DISEASE", 160, 168], ["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19], ["Analysis of patient interviews", "TEST", 0, 30], ["antibiotic use", "TREATMENT", 56, 70], ["specific symptoms", "PROBLEM", 128, 145], ["fever", "PROBLEM", 147, 152], ["coughing", "PROBLEM", 160, 168]]], ["Many patients also implied a period of waiting or alternative action required before antibiotics are used \u2212 to identify whether the immune system would fight the infection or whether nonantibiotic management was effective before turning to antibiotics.", [["infection", "DISEASE", 162, 171], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["antibiotics", "TREATMENT", 85, 96], ["the immune system", "PROBLEM", 128, 145], ["the infection", "PROBLEM", 158, 171], ["nonantibiotic management", "TREATMENT", 183, 207], ["antibiotics", "TREATMENT", 240, 251], ["infection", "OBSERVATION", 162, 171]]], ["This analysis highlights the need for interventions to be sensitive to factors relating to the systems in which different European networks operate, to target the individual characteristics of specific groups of clinicians and to build on the clinical beliefs already held by patients.Infectious diseases in animal modelsO377 Pre-treatment with low-dose endotoxin prolongs survival from experimental lethal endotoxic shock K. Kopanakis, I. Tzepi, E.J. Giamarellos-Bourboulis\u00b0, A. Macheras (Athens, GR) Objective: Clinical trials of immunointervention with anti-endotoxin antibodies in patients with severe sepsis have failed to disclose survival benefit.", [["Infectious diseases", "DISEASE", 285, 304], ["endotoxin", "CHEMICAL", 354, 363], ["shock", "DISEASE", 417, 422], ["sepsis", "DISEASE", 606, 612], ["patients", "ORGANISM", 276, 284], ["endotoxin", "SIMPLE_CHEMICAL", 354, 363], ["anti-endotoxin antibodies", "GENE_OR_GENE_PRODUCT", 556, 581], ["patients", "ORGANISM", 585, 593], ["anti-endotoxin antibodies", "PROTEIN", 556, 581], ["patients", "SPECIES", 276, 284], ["patients", "SPECIES", 585, 593], ["This analysis", "TEST", 0, 13], ["interventions", "TREATMENT", 38, 51], ["low-dose endotoxin prolongs survival", "TREATMENT", 345, 381], ["experimental lethal endotoxic shock", "TREATMENT", 387, 422], ["immunointervention", "TREATMENT", 532, 550], ["anti-endotoxin antibodies", "TREATMENT", 556, 581], ["severe sepsis", "PROBLEM", 599, 612], ["severe", "OBSERVATION_MODIFIER", 599, 605], ["sepsis", "OBSERVATION", 606, 612]]], ["These failures led us to the assumption that the opposite approach with a low endotoxin stimulus may result to low level immunoaralysis and subsequent survival benefit.", [["These failures", "PROBLEM", 0, 14], ["a low endotoxin stimulus", "TREATMENT", 72, 96], ["low level immunoaralysis", "PROBLEM", 111, 135], ["failures", "OBSERVATION", 6, 14]]], ["This approach was tested in an experimental setting.", [["This approach", "TREATMENT", 0, 13]]], ["Methods: A total of 36 male C57B6 mice were studied divided into two groups: group A stimulated with the ip injection of sodium saline followed after one day by the ip injection of 30 mg/kg of lipopolysaccharide (LPS) of Escherichia coli O155:H5; and group B stimulated with the ip injection of 3 mg/kg of LPS of the same isolate followed after one day by the ip injection of 30 mg/kg LPS.", [["sodium", "CHEMICAL", 121, 127], ["lipopolysaccharide", "CHEMICAL", 193, 211], ["LPS", "CHEMICAL", 213, 216], ["LPS", "CHEMICAL", 306, 309], ["LPS", "CHEMICAL", 385, 388], ["sodium", "CHEMICAL", 121, 127], ["C57B6", "ORGANISM", 28, 33], ["mice", "ORGANISM", 34, 38], ["ip", "SIMPLE_CHEMICAL", 105, 107], ["sodium saline", "SIMPLE_CHEMICAL", 121, 134], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 193, 211], ["LPS", "SIMPLE_CHEMICAL", 213, 216], ["Escherichia coli", "ORGANISM", 221, 237], ["O155:H5", "ORGANISM", 238, 245], ["B", "CELL", 257, 258], ["ip", "SIMPLE_CHEMICAL", 279, 281], ["LPS", "SIMPLE_CHEMICAL", 306, 309], ["ip", "SIMPLE_CHEMICAL", 360, 362], ["LPS", "SIMPLE_CHEMICAL", 385, 388], ["mice", "SPECIES", 34, 38], ["Escherichia coli", "SPECIES", 221, 237], ["mice", "SPECIES", 34, 38], ["Escherichia coli O155:H5", "SPECIES", 221, 245], ["A total of 36 male C57B6 mice", "TREATMENT", 9, 38], ["the ip injection of sodium saline", "TREATMENT", 101, 134], ["lipopolysaccharide (LPS", "TREATMENT", 193, 216], ["Escherichia coli", "TREATMENT", 221, 237], ["the ip injection", "TREATMENT", 275, 291], ["LPS", "TREATMENT", 306, 309], ["the same isolate", "TREATMENT", 313, 329], ["Escherichia coli", "OBSERVATION", 221, 237]]], ["LPS was diluted in sodium saline and the volume of each injection was 0.2 ml.", [["LPS", "CHEMICAL", 0, 3], ["sodium", "CHEMICAL", 19, 25], ["sodium", "CHEMICAL", 19, 25], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["sodium saline", "SIMPLE_CHEMICAL", 19, 32], ["LPS", "TEST", 0, 3], ["sodium saline", "TREATMENT", 19, 32], ["the volume of each injection", "TREATMENT", 37, 65]]], ["Survival was recorded at six hour time intervals.", [["Survival", "TREATMENT", 0, 8]]], ["Thirteen mice of group A died (72.2%) compared with seven mice of group B (38.9%, p: 0.044 between group).", [["mice", "ORGANISM", 9, 13], ["mice", "ORGANISM", 58, 62], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 58, 62]]], ["Conclusions: Administration of low doses of LPS prolongs survival after lethal endotoxic shock.", [["LPS", "CHEMICAL", 44, 47], ["endotoxic shock", "DISEASE", 79, 94], ["LPS", "SIMPLE_CHEMICAL", 44, 47], ["LPS prolongs survival", "TREATMENT", 44, 65], ["lethal endotoxic shock", "PROBLEM", 72, 94], ["endotoxic shock", "OBSERVATION", 79, 94]]], ["This approach opens a promising novel pathway for immunointervention in sepsis. fragilis isolates with an MXF MIC of 2 mg/mL (n = 5), 4 mg/mL (n = 20) and 8 mg/mL (n = 8), which were virulent in the MGP model, were used to determine the efficacy of MXF.", [["sepsis", "DISEASE", 72, 78], ["MXF", "CHEMICAL", 106, 109], ["MXF", "CHEMICAL", 249, 252], ["fragilis isolates", "ORGANISM", 80, 97], ["MGP", "GENE_OR_GENE_PRODUCT", 199, 202], ["MXF", "SIMPLE_CHEMICAL", 249, 252], ["MGP", "PROTEIN", 199, 202], ["MXF", "PROTEIN", 249, 252], ["fragilis", "SPECIES", 80, 88], ["fragilis", "SPECIES", 80, 88], ["immunointervention", "TREATMENT", 50, 68], ["sepsis", "PROBLEM", 72, 78], ["fragilis isolates", "PROBLEM", 80, 97], ["an MXF MIC", "TREATMENT", 103, 113], ["sepsis", "OBSERVATION", 72, 78]]], ["For the MGP model, pouches were created by injecting 5 mL of air and 0.5 mL of 0.1% croton oil in olive oil under the skin of the back.", [["pouches", "ANATOMY", 19, 26], ["olive oil", "ANATOMY", 98, 107], ["skin", "ANATOMY", 118, 122], ["croton", "CHEMICAL", 84, 90], ["MGP", "GENE_OR_GENE_PRODUCT", 8, 11], ["pouches", "ORGAN", 19, 26], ["croton oil", "SIMPLE_CHEMICAL", 84, 94], ["olive oil", "ORGANISM_SUBSTANCE", 98, 107], ["skin", "ORGAN", 118, 122], ["back", "ORGANISM_SUBDIVISION", 130, 134], ["MGP", "PROTEIN", 8, 11], ["the MGP model, pouches", "TREATMENT", 4, 26], ["0.1% croton oil", "TREATMENT", 79, 94], ["pouches", "OBSERVATION", 19, 26], ["skin", "ANATOMY", 118, 122], ["back", "ANATOMY", 130, 134]]], ["On day 3, the air was withdrawn and replaced by 1 mL soft agar.", [["air", "ANATOMY", 14, 17]]], ["On day 5, a bacterial suspension was injected into the pouch.", [["pouch", "ANATOMY", 55, 60], ["pouch", "TISSUE", 55, 60], ["a bacterial suspension", "TREATMENT", 10, 32], ["pouch", "ANATOMY", 55, 60]]], ["Infected mice (n = 6 mice/group) were treated with MXF 100 mg/kg IV, b.i.d. for 2 days.", [["MXF", "CHEMICAL", 51, 54], ["MXF", "CHEMICAL", 51, 54], ["mice", "ORGANISM", 9, 13], ["mice", "ORGANISM", 21, 25], ["MXF", "SIMPLE_CHEMICAL", 51, 54], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 9, 13], ["Infected mice (n = 6 mice/group)", "TREATMENT", 0, 32], ["MXF", "TREATMENT", 51, 54]]], ["This dose simulates the AUC of the human 400 mg once-daily MXF IV dosage.", [["MXF", "CHEMICAL", 59, 62], ["human", "ORGANISM", 35, 40], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["the human", "TREATMENT", 31, 40], ["MXF IV dosage", "TREATMENT", 59, 72]]], ["Efficacy was assessed by the reduction in colony forming units (CFUs) in pouch exudates 48 hours post-infection compared with the untreated infection control.", [["colony", "ANATOMY", 42, 48], ["pouch exudates", "ANATOMY", 73, 87], ["infection", "DISEASE", 140, 149], ["the reduction in colony", "TREATMENT", 25, 48], ["pouch exudates", "PROBLEM", 73, 87], ["the untreated infection control", "TREATMENT", 126, 157], ["reduction", "OBSERVATION_MODIFIER", 29, 38], ["pouch", "ANATOMY", 73, 78], ["infection", "OBSERVATION", 140, 149]]], ["Results: In the MGP model, MXF, 100 mg/kg b.i.d., displayed good efficacy in term of CFU reduction against all used strains in this study.", [["MXF", "CHEMICAL", 27, 30], ["MXF", "CHEMICAL", 27, 30], ["MGP", "GENE_OR_GENE_PRODUCT", 16, 19], ["MXF", "SIMPLE_CHEMICAL", 27, 30], ["MXF", "TREATMENT", 27, 30], ["CFU reduction", "TREATMENT", 85, 98], ["all used strains", "PROBLEM", 107, 123], ["this study", "TEST", 127, 137]]], ["There were no non-responders in terms of CFU reductions.", [["non-responders", "PROBLEM", 14, 28], ["no", "UNCERTAINTY", 11, 13]]], ["Conclusion: The loss of atlE had no impact on the MICs of cloxacillin and vancomycin.", [["cloxacillin", "CHEMICAL", 58, 69], ["vancomycin", "CHEMICAL", 74, 84], ["cloxacillin", "CHEMICAL", 58, 69], ["vancomycin", "CHEMICAL", 74, 84], ["atlE", "GENE_OR_GENE_PRODUCT", 24, 28], ["cloxacillin", "SIMPLE_CHEMICAL", 58, 69], ["vancomycin", "SIMPLE_CHEMICAL", 74, 84], ["atlE", "PROTEIN", 24, 28], ["The loss of atlE", "PROBLEM", 12, 28], ["cloxacillin", "TREATMENT", 58, 69], ["vancomycin", "TREATMENT", 74, 84]]], ["Conversely, the mutant atlE(\u2212) strain was less susceptible to bactericidal activity of both antibiotics, supporting the implication of AtlE in the tolerance of S. epidermidis to cell wall active antibiotics.", [["cell wall", "ANATOMY", 178, 187], ["AtlE", "CHEMICAL", 135, 139], ["atlE", "GENE_OR_GENE_PRODUCT", 23, 27], ["AtlE", "GENE_OR_GENE_PRODUCT", 135, 139], ["S. epidermidis", "ORGANISM", 160, 174], ["cell", "CELL", 178, 182], ["AtlE", "PROTEIN", 135, 139], ["S. epidermidis", "SPECIES", 160, 174], ["S. epidermidis", "SPECIES", 160, 174], ["the mutant atlE(\u2212) strain", "PROBLEM", 12, 37], ["both antibiotics", "TREATMENT", 87, 103], ["S. epidermidis", "TREATMENT", 160, 174], ["cell wall active antibiotics", "TREATMENT", 178, 206], ["epidermidis", "OBSERVATION", 163, 174], ["active", "OBSERVATION_MODIFIER", 188, 194], ["antibiotics", "OBSERVATION", 195, 206]]], ["The loss of AtlE did not alter the virulence of S. epidermidis in the mouse peritonitis model, whereas it decreased virulence in previously published experiments using an intravenous catheter infection model.", [["intravenous", "ANATOMY", 171, 182], ["peritonitis", "DISEASE", 76, 87], ["infection", "DISEASE", 192, 201], ["AtlE", "GENE_OR_GENE_PRODUCT", 12, 16], ["S. epidermidis", "ORGANISM", 48, 62], ["mouse", "ORGANISM", 70, 75], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 171, 182], ["AtlE", "PROTEIN", 12, 16], ["S. epidermidis", "SPECIES", 48, 62], ["mouse", "SPECIES", 70, 75], ["S. epidermidis", "SPECIES", 48, 62], ["mouse", "SPECIES", 70, 75], ["S. epidermidis", "PROBLEM", 48, 62], ["the mouse peritonitis model", "PROBLEM", 66, 93], ["an intravenous catheter infection model", "TREATMENT", 168, 207], ["epidermidis", "OBSERVATION", 51, 62], ["mouse", "OBSERVATION_MODIFIER", 70, 75], ["peritonitis", "OBSERVATION", 76, 87], ["decreased", "OBSERVATION_MODIFIER", 106, 115], ["virulence", "OBSERVATION_MODIFIER", 116, 125], ["catheter", "OBSERVATION", 183, 191]]], ["Therefore, the mouse peritonitis model was suited to compare antibiotics efficacy against atlE(+) and atlE(\u2212) strains.", [["peritonitis", "DISEASE", 21, 32], ["mouse", "ORGANISM", 15, 20], ["atlE", "GENE_OR_GENE_PRODUCT", 90, 94], ["atlE", "GENE_OR_GENE_PRODUCT", 102, 106], ["mouse", "SPECIES", 15, 20], ["mouse", "SPECIES", 15, 20], ["the mouse peritonitis model", "PROBLEM", 11, 38], ["antibiotics efficacy", "TEST", 61, 81], ["atlE(+) and atlE(\u2212) strains", "PROBLEM", 90, 117], ["peritonitis", "OBSERVATION", 21, 32]]], ["Our results showed that the loss of atlE did not alter significantly the activity of cloxacillin and vancomycin in the mouse peritonitis model.", [["cloxacillin", "CHEMICAL", 85, 96], ["vancomycin", "CHEMICAL", 101, 111], ["peritonitis", "DISEASE", 125, 136], ["cloxacillin", "CHEMICAL", 85, 96], ["vancomycin", "CHEMICAL", 101, 111], ["atlE", "GENE_OR_GENE_PRODUCT", 36, 40], ["cloxacillin", "SIMPLE_CHEMICAL", 85, 96], ["vancomycin", "SIMPLE_CHEMICAL", 101, 111], ["mouse", "ORGANISM", 119, 124], ["mouse", "SPECIES", 119, 124], ["mouse", "SPECIES", 119, 124], ["the loss of atlE", "PROBLEM", 24, 40], ["cloxacillin", "TREATMENT", 85, 96], ["vancomycin", "TREATMENT", 101, 111], ["the mouse peritonitis model", "TREATMENT", 115, 142], ["peritonitis", "OBSERVATION", 125, 136]]], ["This study shows that the loss of atlE results in decreased susceptibility to bactericidal activity of cell wall active antibiotics, with no apparent impact on the activity of these antibiotics in the mouse peritonitis model.O381In infant rat pneumococcal meningitis, ceftriaxone plus daptomycin versus ceftriaxone attenuates brain damage and hearing loss while ceftriaxone plus rifampicin versus ceftriaxone does not D. Grandgirard, M. Burri, K. Oberson, A. B\u00fchlmann, F. Simon, S.L. Leib\u00b0(Berne, CH) Objectives: Lytic antibiotics for therapy of bacterial meningitis (BM) increase the release of pro-inflammatory bacterial compounds which, in turns, induce inflammation.", [["cell wall", "ANATOMY", 103, 112], ["brain", "ANATOMY", 326, 331], ["BM", "ANATOMY", 568, 570], ["atlE", "CHEMICAL", 34, 38], ["peritonitis", "DISEASE", 207, 218], ["pneumococcal meningitis", "DISEASE", 243, 266], ["ceftriaxone", "CHEMICAL", 268, 279], ["daptomycin", "CHEMICAL", 285, 295], ["ceftriaxone", "CHEMICAL", 303, 314], ["brain damage", "DISEASE", 326, 338], ["hearing loss", "DISEASE", 343, 355], ["ceftriaxone", "CHEMICAL", 362, 373], ["rifampicin", "CHEMICAL", 379, 389], ["ceftriaxone", "CHEMICAL", 397, 408], ["bacterial meningitis", "DISEASE", 546, 566], ["inflammation", "DISEASE", 657, 669], ["ceftriaxone", "CHEMICAL", 268, 279], ["daptomycin", "CHEMICAL", 285, 295], ["ceftriaxone", "CHEMICAL", 303, 314], ["ceftriaxone", "CHEMICAL", 362, 373], ["rifampicin", "CHEMICAL", 379, 389], ["ceftriaxone", "CHEMICAL", 397, 408], ["atlE", "GENE_OR_GENE_PRODUCT", 34, 38], ["cell", "CELL", 103, 107], ["mouse", "ORGANISM", 201, 206], ["rat", "ORGANISM", 239, 242], ["ceftriaxone", "SIMPLE_CHEMICAL", 268, 279], ["daptomycin", "SIMPLE_CHEMICAL", 285, 295], ["ceftriaxone", "SIMPLE_CHEMICAL", 303, 314], ["brain", "ORGAN", 326, 331], ["ceftriaxone", "SIMPLE_CHEMICAL", 362, 373], ["rifampicin", "SIMPLE_CHEMICAL", 379, 389], ["ceftriaxone", "SIMPLE_CHEMICAL", 397, 408], ["BM", "MULTI-TISSUE_STRUCTURE", 568, 570], ["atlE", "PROTEIN", 34, 38], ["mouse", "SPECIES", 201, 206], ["infant", "SPECIES", 232, 238], ["rat", "SPECIES", 239, 242], ["mouse", "SPECIES", 201, 206], ["pneumococcal", "SPECIES", 243, 255], ["This study", "TEST", 0, 10], ["the loss of atlE", "PROBLEM", 22, 38], ["decreased susceptibility", "PROBLEM", 50, 74], ["cell wall active antibiotics", "TREATMENT", 103, 131], ["these antibiotics", "TREATMENT", 176, 193], ["the mouse peritonitis model", "PROBLEM", 197, 224], ["infant rat pneumococcal meningitis", "TREATMENT", 232, 266], ["ceftriaxone", "TREATMENT", 268, 279], ["daptomycin", "TREATMENT", 285, 295], ["ceftriaxone", "TREATMENT", 303, 314], ["brain damage", "PROBLEM", 326, 338], ["hearing loss", "PROBLEM", 343, 355], ["ceftriaxone", "TREATMENT", 362, 373], ["rifampicin", "TREATMENT", 379, 389], ["ceftriaxone", "TREATMENT", 397, 408], ["Lytic antibiotics", "TREATMENT", 513, 530], ["therapy", "TREATMENT", 535, 542], ["bacterial meningitis", "PROBLEM", 546, 566], ["pro-inflammatory bacterial compounds", "PROBLEM", 596, 632], ["inflammation", "PROBLEM", 657, 669], ["decreased", "OBSERVATION_MODIFIER", 50, 59], ["wall", "OBSERVATION_MODIFIER", 108, 112], ["active", "OBSERVATION_MODIFIER", 113, 119], ["antibiotics", "OBSERVATION", 120, 131], ["mouse", "ANATOMY", 201, 206], ["peritonitis", "OBSERVATION", 207, 218], ["pneumococcal", "OBSERVATION_MODIFIER", 243, 255], ["meningitis", "OBSERVATION", 256, 266], ["bacterial", "OBSERVATION_MODIFIER", 546, 555], ["meningitis", "OBSERVATION", 556, 566], ["pro-inflammatory bacterial compounds", "OBSERVATION", 596, 632], ["inflammation", "OBSERVATION", 657, 669]]], ["Exacerbation of the inflammatory response in cerebrospinal fluid (CSF) contributes to the development of neurological sequelae in survivors of BM.", [["cerebrospinal fluid", "ANATOMY", 45, 64], ["neurological", "ANATOMY", 105, 117], ["BM", "ANATOMY", 143, 145], ["neurological sequelae", "DISEASE", 105, 126], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 45, 64], ["CSF", "ORGANISM_SUBSTANCE", 66, 69], ["BM", "CELL", 143, 145], ["Exacerbation", "PROBLEM", 0, 12], ["the inflammatory response in cerebrospinal fluid", "PROBLEM", 16, 64], ["neurological sequelae in survivors of BM", "PROBLEM", 105, 145], ["inflammatory", "OBSERVATION_MODIFIER", 20, 32], ["cerebrospinal fluid", "OBSERVATION", 45, 64], ["neurological", "OBSERVATION_MODIFIER", 105, 117], ["sequelae", "OBSERVATION", 118, 126], ["BM", "OBSERVATION", 143, 145]]], ["Daptomycin, a nonlytic antibiotic acting on Gram-positive bacteria has been shown to decrease inflammation and brain injury vs. ceftriaxone in experimental pneumococcal meningitis.", [["brain", "ANATOMY", 111, 116], ["Daptomycin", "CHEMICAL", 0, 10], ["inflammation", "DISEASE", 94, 106], ["brain injury", "DISEASE", 111, 123], ["ceftriaxone", "CHEMICAL", 128, 139], ["pneumococcal meningitis", "DISEASE", 156, 179], ["Daptomycin", "CHEMICAL", 0, 10], ["ceftriaxone", "CHEMICAL", 128, 139], ["Daptomycin", "SIMPLE_CHEMICAL", 0, 10], ["Gram", "GENE_OR_GENE_PRODUCT", 44, 48], ["brain", "ORGAN", 111, 116], ["ceftriaxone", "SIMPLE_CHEMICAL", 128, 139], ["pneumococcal", "SPECIES", 156, 168], ["Daptomycin", "TREATMENT", 0, 10], ["a nonlytic antibiotic", "TREATMENT", 12, 33], ["Gram", "TEST", 44, 48], ["positive bacteria", "PROBLEM", 49, 66], ["inflammation", "PROBLEM", 94, 106], ["brain injury", "PROBLEM", 111, 123], ["ceftriaxone", "TREATMENT", 128, 139], ["experimental pneumococcal meningitis", "PROBLEM", 143, 179], ["decrease", "OBSERVATION_MODIFIER", 85, 93], ["inflammation", "OBSERVATION", 94, 106], ["brain", "ANATOMY", 111, 116], ["injury", "OBSERVATION", 117, 123], ["pneumococcal", "OBSERVATION_MODIFIER", 156, 168], ["meningitis", "OBSERVATION", 169, 179]]], ["With a view on the clinical application for empiric therapy of paediatric bacterial meningitis we investigated, whether therapies combining daptomycin or rifampicin with ceftriaxone are beneficial when compared to ceftriaxone monotherapy in infant rat pneumococcal meningitis.O381Methods: Eleven day old Wistar rats were infected by intracisternal injection of S. pneumoniae and animals were treated with daptomycin (10 mg/kg, s.c., daily) plus ceftriaxone (100 mg/kg, s.c., bid), rifampicin (20 mg/kg, i.p., bid) plus ceftriaxone or ceftriaxone alone.", [["bacterial meningitis", "DISEASE", 74, 94], ["daptomycin", "CHEMICAL", 140, 150], ["rifampicin", "CHEMICAL", 154, 164], ["ceftriaxone", "CHEMICAL", 170, 181], ["ceftriaxone", "CHEMICAL", 214, 225], ["pneumococcal meningitis", "DISEASE", 252, 275], ["daptomycin", "CHEMICAL", 405, 415], ["ceftriaxone", "CHEMICAL", 445, 456], ["rifampicin", "CHEMICAL", 481, 491], ["ceftriaxone", "CHEMICAL", 519, 530], ["ceftriaxone", "CHEMICAL", 534, 545], ["daptomycin", "CHEMICAL", 140, 150], ["rifampicin", "CHEMICAL", 154, 164], ["ceftriaxone", "CHEMICAL", 170, 181], ["ceftriaxone", "CHEMICAL", 214, 225], ["daptomycin", "CHEMICAL", 405, 415], ["ceftriaxone", "CHEMICAL", 445, 456], ["rifampicin", "CHEMICAL", 481, 491], ["ceftriaxone", "CHEMICAL", 519, 530], ["ceftriaxone", "CHEMICAL", 534, 545], ["daptomycin", "SIMPLE_CHEMICAL", 140, 150], ["rifampicin", "SIMPLE_CHEMICAL", 154, 164], ["ceftriaxone", "SIMPLE_CHEMICAL", 170, 181], ["ceftriaxone", "SIMPLE_CHEMICAL", 214, 225], ["rat", "ORGANISM", 248, 251], ["Wistar rats", "ORGANISM", 304, 315], ["intracisternal", "IMMATERIAL_ANATOMICAL_ENTITY", 333, 347], ["S. pneumoniae", "ORGANISM", 361, 374], ["animals", "ORGANISM", 379, 386], ["daptomycin", "SIMPLE_CHEMICAL", 405, 415], ["ceftriaxone", "SIMPLE_CHEMICAL", 445, 456], ["rifampicin", "SIMPLE_CHEMICAL", 481, 491], ["bid", "SIMPLE_CHEMICAL", 509, 512], ["ceftriaxone", "SIMPLE_CHEMICAL", 519, 530], ["ceftriaxone", "SIMPLE_CHEMICAL", 534, 545], ["infant", "SPECIES", 241, 247], ["rat", "SPECIES", 248, 251], ["rats", "SPECIES", 311, 315], ["S. pneumoniae", "SPECIES", 361, 374], ["rat", "SPECIES", 248, 251], ["pneumococcal", "SPECIES", 252, 264], ["S. pneumoniae", "SPECIES", 361, 374], ["empiric therapy", "TREATMENT", 44, 59], ["paediatric bacterial meningitis", "PROBLEM", 63, 94], ["therapies", "TREATMENT", 120, 129], ["daptomycin", "TREATMENT", 140, 150], ["rifampicin", "TREATMENT", 154, 164], ["ceftriaxone", "TREATMENT", 170, 181], ["ceftriaxone monotherapy", "TREATMENT", 214, 237], ["infant rat pneumococcal meningitis", "PROBLEM", 241, 275], ["S. pneumoniae", "PROBLEM", 361, 374], ["daptomycin", "TREATMENT", 405, 415], ["ceftriaxone", "TREATMENT", 445, 456], ["rifampicin", "TREATMENT", 481, 491], ["ceftriaxone", "TREATMENT", 519, 530], ["ceftriaxone", "TREATMENT", 534, 545], ["pneumococcal", "OBSERVATION_MODIFIER", 252, 264], ["meningitis", "OBSERVATION", 265, 275], ["pneumoniae", "OBSERVATION", 364, 374]]], ["CSF was sampled at 6 h and 22 h after the initiation of therapy and assessed for concentrations of chemo-and cytokines (MCP-1, MIP-1a, IL-1b, IL-6, IL-10; IL-18 and TNF-a).", [["CSF", "ORGANISM_SUBSTANCE", 0, 3], ["MCP-1", "GENE_OR_GENE_PRODUCT", 120, 125], ["MIP-1a", "GENE_OR_GENE_PRODUCT", 127, 133], ["IL-1b", "GENE_OR_GENE_PRODUCT", 135, 140], ["IL-6", "GENE_OR_GENE_PRODUCT", 142, 146], ["IL-10", "GENE_OR_GENE_PRODUCT", 148, 153], ["IL-18", "GENE_OR_GENE_PRODUCT", 155, 160], ["TNF", "GENE_OR_GENE_PRODUCT", 165, 168], ["CSF", "PROTEIN", 0, 3], ["cytokines", "PROTEIN", 109, 118], ["MCP", "PROTEIN", 120, 123], ["MIP", "PROTEIN", 127, 130], ["IL-18", "PROTEIN", 155, 160], ["TNF", "PROTEIN", 165, 168], ["CSF", "TEST", 0, 3], ["therapy", "TREATMENT", 56, 63], ["chemo", "TREATMENT", 99, 104], ["cytokines", "TEST", 109, 118], ["MCP", "TEST", 120, 123], ["MIP", "TEST", 127, 130], ["IL", "TEST", 135, 137], ["IL", "TEST", 142, 144], ["IL", "TEST", 148, 150], ["IL", "TEST", 155, 157], ["TNF", "TEST", 165, 168]]], ["A subset of animals was sacrificed 40 h post infection (h pi) and brain damage quantified by histomorphometry.", [["brain", "ANATOMY", 66, 71], ["infection", "DISEASE", 45, 54], ["brain damage", "DISEASE", 66, 78], ["animals", "ORGANISM", 12, 19], ["brain", "ORGAN", 66, 71], ["infection", "PROBLEM", 45, 54], ["brain damage", "PROBLEM", 66, 78], ["brain", "ANATOMY", 66, 71], ["damage", "OBSERVATION", 72, 78]]], ["The remaining animals were treated for 3 d and were tested for hearing loss, by assessing the auditory brainstem response (ABR) at 3 weeks after infection.", [["brainstem", "ANATOMY", 103, 112], ["hearing loss", "DISEASE", 63, 75], ["infection", "DISEASE", 145, 154], ["animals", "ORGANISM", 14, 21], ["hearing loss", "PROBLEM", 63, 75], ["infection", "PROBLEM", 145, 154], ["infection", "OBSERVATION", 145, 154]]], ["Results: Compared to ceftriaxone alone, daptomycin plus ceftriaxone significantly (p < 0.04) lowered CSF concentrations of MCP-1, MIP-1alpha and IL-6 at 6 h and MIP-1a and IL-1b at 22 h after initiation of therapy, led to significantly (p < 0.01) less apoptosis assessed at 40 h pi, and significantly (p < 0.01) improved hearing capacity.", [["ceftriaxone", "CHEMICAL", 21, 32], ["daptomycin", "CHEMICAL", 40, 50], ["ceftriaxone", "CHEMICAL", 56, 67], ["ceftriaxone", "CHEMICAL", 21, 32], ["daptomycin", "CHEMICAL", 40, 50], ["ceftriaxone", "CHEMICAL", 56, 67], ["ceftriaxone", "SIMPLE_CHEMICAL", 21, 32], ["daptomycin", "SIMPLE_CHEMICAL", 40, 50], ["ceftriaxone", "SIMPLE_CHEMICAL", 56, 67], ["CSF", "ORGANISM_SUBSTANCE", 101, 104], ["MCP-1", "GENE_OR_GENE_PRODUCT", 123, 128], ["MIP-1alpha", "GENE_OR_GENE_PRODUCT", 130, 140], ["IL-6", "GENE_OR_GENE_PRODUCT", 145, 149], ["MIP-1a", "GENE_OR_GENE_PRODUCT", 161, 167], ["IL-1b", "GENE_OR_GENE_PRODUCT", 172, 177], ["CSF", "PROTEIN", 101, 104], ["MCP", "PROTEIN", 123, 126], ["MIP-1alpha and IL-6", "PROTEIN", 130, 149], ["MIP", "PROTEIN", 161, 164], ["IL", "PROTEIN", 172, 174], ["ceftriaxone", "TREATMENT", 21, 32], ["daptomycin", "TREATMENT", 40, 50], ["ceftriaxone", "TREATMENT", 56, 67], ["CSF concentrations", "TEST", 101, 119], ["MCP", "TEST", 123, 126], ["MIP", "TEST", 130, 133], ["IL", "TEST", 145, 147], ["MIP", "TEST", 161, 164], ["IL", "TEST", 172, 174], ["therapy", "TREATMENT", 206, 213], ["improved hearing capacity", "PROBLEM", 312, 337]]], ["While rifampicin plus ceftriaxone also led to lower CSF inflammation (p < 0.02 for IL-6 at 6 h), apoptosis and hearing loss were not significantly different from the ceftriaxone group.", [["rifampicin", "CHEMICAL", 6, 16], ["ceftriaxone", "CHEMICAL", 22, 33], ["inflammation", "DISEASE", 56, 68], ["hearing loss", "DISEASE", 111, 123], ["ceftriaxone", "CHEMICAL", 166, 177], ["rifampicin", "CHEMICAL", 6, 16], ["ceftriaxone", "CHEMICAL", 22, 33], ["ceftriaxone", "CHEMICAL", 166, 177], ["rifampicin", "SIMPLE_CHEMICAL", 6, 16], ["ceftriaxone", "SIMPLE_CHEMICAL", 22, 33], ["CSF", "GENE_OR_GENE_PRODUCT", 52, 55], ["IL-6", "GENE_OR_GENE_PRODUCT", 83, 87], ["ceftriaxone", "SIMPLE_CHEMICAL", 166, 177], ["IL", "PROTEIN", 83, 85], ["rifampicin", "TREATMENT", 6, 16], ["ceftriaxone", "TREATMENT", 22, 33], ["lower CSF inflammation", "PROBLEM", 46, 68], ["IL", "TEST", 83, 85], ["apoptosis", "PROBLEM", 97, 106], ["hearing loss", "PROBLEM", 111, 123], ["the ceftriaxone group", "TREATMENT", 162, 183], ["lower CSF", "ANATOMY", 46, 55], ["inflammation", "OBSERVATION", 56, 68], ["hearing loss", "OBSERVATION", 111, 123]]], ["Conclusion: Compared to ceftriaxone monotherapy, daptomycin plus ceftriaxone lowers the level of pro-inflammatory mediators in the CSF and reduces hippocampal apoptosis and hearing loss in infant rat pneumococcal meningitis.O382 Ceftaroline vs. ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia modelD.", [["CSF", "ANATOMY", 131, 134], ["hippocampal", "ANATOMY", 147, 158], ["ceftriaxone", "CHEMICAL", 24, 35], ["daptomycin", "CHEMICAL", 49, 59], ["ceftriaxone", "CHEMICAL", 65, 76], ["hearing loss", "DISEASE", 173, 185], ["pneumococcal meningitis", "DISEASE", 200, 223], ["O382", "CHEMICAL", 224, 228], ["Ceftaroline", "CHEMICAL", 229, 240], ["ceftriaxone", "CHEMICAL", 245, 256], ["penicillin", "CHEMICAL", 269, 279], ["pneumonia", "DISEASE", 303, 312], ["ceftriaxone", "CHEMICAL", 24, 35], ["daptomycin", "CHEMICAL", 49, 59], ["ceftriaxone", "CHEMICAL", 65, 76], ["Ceftaroline", "CHEMICAL", 229, 240], ["ceftriaxone", "CHEMICAL", 245, 256], ["penicillin", "CHEMICAL", 269, 279], ["ceftriaxone", "SIMPLE_CHEMICAL", 24, 35], ["daptomycin", "SIMPLE_CHEMICAL", 49, 59], ["ceftriaxone", "SIMPLE_CHEMICAL", 65, 76], ["CSF", "GENE_OR_GENE_PRODUCT", 131, 134], ["hippocampal", "MULTI-TISSUE_STRUCTURE", 147, 158], ["rat", "ORGANISM", 196, 199], ["O382", "SIMPLE_CHEMICAL", 224, 228], ["Ceftaroline", "SIMPLE_CHEMICAL", 229, 240], ["ceftriaxone", "SIMPLE_CHEMICAL", 245, 256], ["penicillin", "SIMPLE_CHEMICAL", 269, 279], ["pro-inflammatory mediators", "PROTEIN", 97, 123], ["infant", "SPECIES", 189, 195], ["rat", "SPECIES", 196, 199], ["pneumococcal", "SPECIES", 200, 212], ["pneumococcal", "SPECIES", 290, 302], ["ceftriaxone monotherapy", "TREATMENT", 24, 47], ["daptomycin", "TREATMENT", 49, 59], ["ceftriaxone", "TREATMENT", 65, 76], ["pro-inflammatory mediators", "TREATMENT", 97, 123], ["the CSF", "TEST", 127, 134], ["hippocampal apoptosis", "PROBLEM", 147, 168], ["hearing loss", "PROBLEM", 173, 185], ["infant rat pneumococcal meningitis", "PROBLEM", 189, 223], ["Ceftaroline", "TREATMENT", 229, 240], ["ceftriaxone", "TREATMENT", 245, 256], ["a highly penicillin", "TREATMENT", 260, 279], ["resistant pneumococcal pneumonia modelD", "PROBLEM", 280, 319], ["CSF", "ANATOMY", 131, 134], ["hippocampal apoptosis", "OBSERVATION", 147, 168], ["hearing loss", "OBSERVATION", 173, 185], ["pneumococcal", "OBSERVATION_MODIFIER", 200, 212], ["meningitis", "OBSERVATION", 213, 223], ["resistant", "OBSERVATION_MODIFIER", 280, 289], ["pneumococcal", "OBSERVATION_MODIFIER", 290, 302], ["pneumonia", "OBSERVATION", 303, 312]]], ["Croisier-Bertin\u00b0, L. Piroth, P.E. Charles, D. Biek, Y. Ge, P. Chavanet (Dijon, FR; Alameda, US) Objectives: Ceftaroline (CPT) is a novel, parenteral, broad-spectrum cephalosporin exhibiting bactericidal activity against Gram-positive organisms, including methicillin-resistant S. aureus (MRSA) and multidrug-resistant S. pneumoniae, as well as common Gram-negative pathogens.", [["Ceftaroline", "CHEMICAL", 108, 119], ["CPT", "CHEMICAL", 121, 124], ["cephalosporin", "CHEMICAL", 165, 178], ["methicillin", "CHEMICAL", 255, 266], ["MRSA", "CHEMICAL", 288, 292], ["Ceftaroline", "CHEMICAL", 108, 119], ["CPT", "CHEMICAL", 121, 124], ["cephalosporin", "CHEMICAL", 165, 178], ["methicillin", "CHEMICAL", 255, 266], ["Ceftaroline", "SIMPLE_CHEMICAL", 108, 119], ["CPT", "SIMPLE_CHEMICAL", 121, 124], ["cephalosporin", "SIMPLE_CHEMICAL", 165, 178], ["methicillin-resistant S. aureus", "ORGANISM", 255, 286], ["MRSA", "ORGANISM", 288, 292], ["multidrug-resistant", "ORGANISM", 298, 317], ["S. pneumoniae", "ORGANISM", 318, 331], ["Gram", "GENE_OR_GENE_PRODUCT", 351, 355], ["S. aureus", "SPECIES", 277, 286], ["MRSA", "SPECIES", 288, 292], ["S. pneumoniae", "SPECIES", 318, 331], ["S. aureus", "SPECIES", 277, 286], ["MRSA", "SPECIES", 288, 292], ["S. pneumoniae", "SPECIES", 318, 331], ["Ceftaroline (CPT)", "TREATMENT", 108, 125], ["parenteral", "TREATMENT", 138, 148], ["broad-spectrum cephalosporin", "TREATMENT", 150, 178], ["bactericidal activity", "TREATMENT", 190, 211], ["Gram-positive organisms", "PROBLEM", 220, 243], ["methicillin-resistant S. aureus", "PROBLEM", 255, 286], ["MRSA", "PROBLEM", 288, 292], ["multidrug-resistant S. pneumoniae", "PROBLEM", 298, 331], ["common Gram-negative pathogens", "PROBLEM", 344, 374], ["L. Piroth", "ANATOMY", 18, 27], ["aureus", "OBSERVATION", 280, 286], ["pneumoniae", "OBSERVATION", 321, 331], ["negative pathogens", "OBSERVATION", 356, 374]]], ["The efficacy of simulated human dosing with CPT or ceftriaxone (CRO) was evaluated in a rabbit model of penicillin-resistant pneumococcal pneumonia.", [["CPT", "CHEMICAL", 44, 47], ["ceftriaxone", "CHEMICAL", 51, 62], ["CRO", "CHEMICAL", 64, 67], ["penicillin", "CHEMICAL", 104, 114], ["pneumococcal pneumonia", "DISEASE", 125, 147], ["CPT", "CHEMICAL", 44, 47], ["ceftriaxone", "CHEMICAL", 51, 62], ["CRO", "CHEMICAL", 64, 67], ["penicillin", "CHEMICAL", 104, 114], ["human", "ORGANISM", 26, 31], ["CPT", "SIMPLE_CHEMICAL", 44, 47], ["ceftriaxone", "SIMPLE_CHEMICAL", 51, 62], ["CRO", "SIMPLE_CHEMICAL", 64, 67], ["rabbit", "ORGANISM", 88, 94], ["penicillin", "SIMPLE_CHEMICAL", 104, 114], ["pneumococcal", "ORGANISM", 125, 137], ["human", "SPECIES", 26, 31], ["rabbit", "SPECIES", 88, 94], ["human", "SPECIES", 26, 31], ["rabbit", "SPECIES", 88, 94], ["pneumococcal", "SPECIES", 125, 137], ["simulated human dosing", "TREATMENT", 16, 38], ["CPT", "TREATMENT", 44, 47], ["ceftriaxone (CRO", "TREATMENT", 51, 67], ["penicillin", "TREATMENT", 104, 114], ["resistant pneumococcal pneumonia", "PROBLEM", 115, 147], ["resistant", "OBSERVATION_MODIFIER", 115, 124], ["pneumococcal", "OBSERVATION_MODIFIER", 125, 137], ["pneumonia", "OBSERVATION", 138, 147]]], ["Methods: 3 S. pneumoniae strains were used to induce pneumonia in rabbits: PSSP, PISP, and PRSP.", [["strains", "ANATOMY", 25, 32], ["pneumonia", "DISEASE", 53, 62], ["S. pneumoniae", "ORGANISM", 11, 24], ["rabbits", "ORGANISM", 66, 73], ["PSSP", "GENE_OR_GENE_PRODUCT", 75, 79], ["PISP", "GENE_OR_GENE_PRODUCT", 81, 85], ["S. pneumoniae", "SPECIES", 11, 24], ["rabbits", "SPECIES", 66, 73], ["S. pneumoniae", "SPECIES", 11, 24], ["rabbits", "SPECIES", 66, 73], ["S. pneumoniae strains", "PROBLEM", 11, 32], ["pneumonia", "PROBLEM", 53, 62], ["PSSP", "PROBLEM", 75, 79], ["PISP", "PROBLEM", 81, 85], ["PRSP", "PROBLEM", 91, 95], ["pneumonia", "OBSERVATION", 53, 62]]], ["MICs (mg/L) were 0.06/0.015, 1/0.125, and 4/0.25 for CRO and CPT, respectively.", [["CRO", "CHEMICAL", 53, 56], ["CPT", "CHEMICAL", 61, 64], ["CPT", "SIMPLE_CHEMICAL", 61, 64], ["MICs (mg/L)", "TREATMENT", 0, 11], ["CPT", "TEST", 61, 64]]], ["The animals were randomised to no treatment (controls), intravenous (IV) CPT human equivalent (HE) dosage (600 mg/12 h), IV CRO HE dosage (1 g/24 h), or intramuscular (IM) CPT (5 or 20 mg/kg) for PRSP-infected rabbits.", [["intravenous", "ANATOMY", 56, 67], ["intramuscular", "ANATOMY", 153, 166], ["CPT", "CHEMICAL", 73, 76], ["CPT", "CHEMICAL", 172, 175], ["PRSP", "CHEMICAL", 196, 200], ["CPT", "CHEMICAL", 172, 175], ["animals", "ORGANISM", 4, 11], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 67], ["human", "ORGANISM", 77, 82], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 153, 166], ["CPT", "SIMPLE_CHEMICAL", 172, 175], ["PRSP", "SIMPLE_CHEMICAL", 196, 200], ["rabbits", "ORGANISM", 210, 217], ["human", "SPECIES", 77, 82], ["rabbits", "SPECIES", 210, 217], ["human", "SPECIES", 77, 82], ["treatment (controls)", "TREATMENT", 34, 54], ["intravenous (IV) CPT human equivalent (HE) dosage", "TREATMENT", 56, 105], ["IV CRO HE dosage", "TREATMENT", 121, 137], ["intramuscular (IM) CPT", "TREATMENT", 153, 175], ["PRSP", "PROBLEM", 196, 200], ["infected rabbits", "PROBLEM", 201, 217], ["infected", "OBSERVATION", 201, 209]]], ["Serum levels were measured by microbiological assay and PK data were obtained.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["PK", "GENE_OR_GENE_PRODUCT", 56, 58], ["Serum levels", "TEST", 0, 12], ["microbiological assay", "TEST", 30, 51], ["PK data", "TEST", 56, 63]]], ["Evaluation of efficacy was based on bacterial counts in lungs and spleen (per gram tissue).", [["lungs", "ANATOMY", 56, 61], ["spleen", "ANATOMY", 66, 72], ["gram tissue", "ANATOMY", 78, 89], ["lungs", "ORGAN", 56, 61], ["spleen", "ORGAN", 66, 72], ["tissue", "TISSUE", 83, 89], ["Evaluation", "TEST", 0, 10], ["bacterial counts in lungs and spleen", "PROBLEM", 36, 72], ["bacterial counts", "OBSERVATION", 36, 52], ["lungs", "ANATOMY", 56, 61], ["spleen", "ANATOMY", 66, 72], ["gram tissue", "OBSERVATION_MODIFIER", 78, 89]]], ["Results: 5\u22127 animals/group were tested.", [["animals", "ORGANISM", 13, 20]]], ["For IV CPT/IV CRO, mean AUC0\u221224 was 155/938 mg.h/L, Cmax was 20/158 mg/L and Cmin was 1.3/6 mg/L, respectively.", [["Cmax", "CHEMICAL", 52, 56], ["Cmax", "SIMPLE_CHEMICAL", 52, 56], ["IV CPT/IV CRO", "TREATMENT", 4, 17], ["mean AUC0", "TEST", 19, 28], ["Cmax", "TEST", 52, 56], ["Cmin", "TEST", 77, 81], ["L", "ANATOMY_MODIFIER", 49, 50]]], ["Bacterial counts in target tissues are listed in the IV CPT and IV CRO were highly efficacious against PSSP and PISP.", [["Bacterial", "ANATOMY", 0, 9], ["tissues", "ANATOMY", 27, 34], ["CRO", "CHEMICAL", 67, 70], ["tissues", "TISSUE", 27, 34], ["CRO", "SIMPLE_CHEMICAL", 67, 70], ["PSSP", "SIMPLE_CHEMICAL", 103, 107], ["PSSP", "SPECIES", 103, 107], ["Bacterial counts in target tissues", "PROBLEM", 0, 34], ["the IV CPT", "TEST", 49, 59], ["IV CRO", "TREATMENT", 64, 70], ["PSSP", "PROBLEM", 103, 107], ["PISP", "PROBLEM", 112, 116], ["counts", "OBSERVATION", 10, 16], ["target tissues", "OBSERVATION", 20, 34]]], ["IV and IM CPT were superior to IV CRO against PRSP with a quasi sterilisation of lungs and spleen.", [["lungs", "ANATOMY", 81, 86], ["spleen", "ANATOMY", 91, 97], ["CPT", "CHEMICAL", 10, 13], ["CRO", "CHEMICAL", 34, 37], ["PRSP", "DISEASE", 46, 50], ["CPT", "CHEMICAL", 10, 13], ["CPT", "SIMPLE_CHEMICAL", 10, 13], ["lungs", "ORGAN", 81, 86], ["spleen", "ORGAN", 91, 97], ["IV and IM CPT", "TREATMENT", 0, 13], ["IV CRO", "TREATMENT", 31, 37], ["PRSP", "PROBLEM", 46, 50], ["a quasi sterilisation of lungs", "TREATMENT", 56, 86], ["lungs", "ANATOMY", 81, 86], ["spleen", "ANATOMY", 91, 97]]], ["Combined results from the IV and IM studies indicated that %T > MIC for CPT of 30% and 45% were associated with 50% and 100% bacterial count reductions, respectively.Conclusion:In this rabbit model of penicillin-resistant pneumococcal pneumonia, CPT administered IV (with HE dosing) or by IM administration was more effective against PRSP than IV CRO.", [["CPT", "CHEMICAL", 72, 75], ["penicillin", "CHEMICAL", 201, 211], ["pneumococcal pneumonia", "DISEASE", 222, 244], ["CPT", "CHEMICAL", 246, 249], ["IM", "CHEMICAL", 289, 291], ["CRO", "CHEMICAL", 347, 350], ["penicillin", "CHEMICAL", 201, 211], ["CPT", "CHEMICAL", 246, 249], ["rabbit", "ORGANISM", 185, 191], ["penicillin", "SIMPLE_CHEMICAL", 201, 211], ["pneumococcal", "ORGANISM", 222, 234], ["CPT", "SIMPLE_CHEMICAL", 246, 249], ["IM", "SIMPLE_CHEMICAL", 289, 291], ["PRSP", "SIMPLE_CHEMICAL", 334, 338], ["rabbit", "SPECIES", 185, 191], ["rabbit", "SPECIES", 185, 191], ["pneumococcal", "SPECIES", 222, 234], ["the IV and IM studies", "TEST", 22, 43], ["CPT", "TEST", 72, 75], ["bacterial count reductions", "TEST", 125, 151], ["penicillin", "TREATMENT", 201, 211], ["resistant pneumococcal pneumonia", "PROBLEM", 212, 244], ["CPT administered IV", "TREATMENT", 246, 265], ["IV CRO", "TREATMENT", 344, 350], ["pneumococcal", "OBSERVATION_MODIFIER", 222, 234], ["pneumonia", "OBSERVATION", 235, 244]]], ["R. Endermann\u00b0, D. Hoepker, K. Merfort, M. Glenschek-Sieberth (Wuppertal, DE) Objective: Moxifloxacin (MXF) is approved in the USA and other countries for the treatment of complicated intra-abdominal infections (cIAIs).", [["intra-abdominal", "ANATOMY", 183, 198], ["Moxifloxacin", "CHEMICAL", 88, 100], ["MXF", "CHEMICAL", 102, 105], ["intra-abdominal infections", "DISEASE", 183, 209], ["IAIs", "DISEASE", 212, 216], ["Moxifloxacin", "CHEMICAL", 88, 100], ["MXF", "CHEMICAL", 102, 105], ["Moxifloxacin", "SIMPLE_CHEMICAL", 88, 100], ["MXF", "SIMPLE_CHEMICAL", 102, 105], ["intra-abdominal", "IMMATERIAL_ANATOMICAL_ENTITY", 183, 198], ["Moxifloxacin (MXF)", "TREATMENT", 88, 106], ["the treatment", "TREATMENT", 154, 167], ["complicated intra-abdominal infections", "PROBLEM", 171, 209], ["intra-abdominal", "ANATOMY", 183, 198], ["infections", "OBSERVATION", 199, 209]]], ["We compared the efficacy of MXF with piperacillin/tazobactam (PIP/TAZ), a commonly used treatment for cIAIs, in three different models: ( . c.", [["MXF", "CHEMICAL", 28, 31], ["piperacillin/tazobactam", "CHEMICAL", 37, 60], ["PIP", "CHEMICAL", 62, 65], ["cIAIs", "DISEASE", 102, 107], ["MXF", "CHEMICAL", 28, 31], ["piperacillin", "CHEMICAL", 37, 49], ["tazobactam", "CHEMICAL", 50, 60], ["PIP", "CHEMICAL", 62, 65], ["TAZ", "CHEMICAL", 66, 69], ["MXF", "SIMPLE_CHEMICAL", 28, 31], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 37, 60], ["PIP", "SIMPLE_CHEMICAL", 62, 65], ["TAZ", "SIMPLE_CHEMICAL", 66, 69], ["MXF", "TREATMENT", 28, 31], ["piperacillin", "TREATMENT", 37, 49], ["tazobactam", "TREATMENT", 50, 60], ["PIP/TAZ", "TREATMENT", 62, 69], ["treatment", "TREATMENT", 88, 97], ["cIAIs", "TREATMENT", 102, 107]]], ["CLP model: survival over 10 days was significantly higher in the MXF group than in the PIP/TAZ group (P < 0.0001).", [["MXF", "CANCER", 65, 68], ["TAZ", "GENE_OR_GENE_PRODUCT", 91, 94], ["TAZ", "PROTEIN", 91, 94], ["survival", "OBSERVATION_MODIFIER", 11, 19], ["higher", "OBSERVATION_MODIFIER", 51, 57]]], ["Conclusions: Using humanised dosages, MXF had greater antimicrobial activity and provided higher survival rates that PIP/TAZ in three different models for cIAI.O384 The haemochromatosis-associated Hfe mutation protects mice from Salmonella typhimurium infection via induction of lipocalin 2M.", [["MXF", "CHEMICAL", 38, 41], ["O384", "CHEMICAL", 160, 164], ["haemochromatosis", "DISEASE", 169, 185], ["Salmonella typhimurium infection", "DISEASE", 229, 261], ["MXF", "CHEMICAL", 38, 41], ["O384", "CHEMICAL", 160, 164], ["MXF", "SIMPLE_CHEMICAL", 38, 41], ["PIP", "GENE_OR_GENE_PRODUCT", 117, 120], ["TAZ", "GENE_OR_GENE_PRODUCT", 121, 124], ["Hfe", "GENE_OR_GENE_PRODUCT", 197, 200], ["mice", "ORGANISM", 219, 223], ["Salmonella typhimurium", "ORGANISM", 229, 251], ["lipocalin 2M", "GENE_OR_GENE_PRODUCT", 279, 291], ["PIP", "PROTEIN", 117, 120], ["TAZ", "PROTEIN", 121, 124], ["O384", "CELL_LINE", 160, 164], ["Hfe", "PROTEIN", 197, 200], ["lipocalin 2M", "PROTEIN", 279, 291], ["mice", "SPECIES", 219, 223], ["Salmonella typhimurium", "SPECIES", 229, 251], ["mice", "SPECIES", 219, 223], ["Salmonella typhimurium", "SPECIES", 229, 251], ["humanised dosages", "TREATMENT", 19, 36], ["greater antimicrobial activity", "TREATMENT", 46, 76], ["higher survival rates", "TREATMENT", 90, 111], ["PIP/TAZ", "TREATMENT", 117, 124], ["The haemochromatosis", "PROBLEM", 165, 185], ["Hfe mutation", "PROBLEM", 197, 209], ["Salmonella typhimurium infection", "PROBLEM", 229, 261], ["induction of lipocalin 2M", "TREATMENT", 266, 291], ["haemochromatosis", "OBSERVATION", 169, 185]]], ["Nairz, I. Theurl, A. Schroll, M. Theurl, S. Mair, T. Sonnweber, G. Fritsche, R. Bellmann-Weiler, G. Weiss\u00b0(Innsbruck, AT) Mutations in HFE predispose to hereditary haemochromatosis type I, a frequent genetic disorder characterised by progressive parenchymal iron deposition and eventual organ failure.", [["parenchymal", "ANATOMY", 246, 257], ["organ", "ANATOMY", 287, 292], ["HFE", "DISEASE", 135, 138], ["hereditary haemochromatosis type I", "DISEASE", 153, 187], ["genetic disorder", "DISEASE", 200, 216], ["organ failure", "DISEASE", 287, 300], ["iron", "CHEMICAL", 258, 262], ["parenchymal iron", "PATHOLOGICAL_FORMATION", 246, 262], ["organ", "ORGAN", 287, 292], ["hereditary haemochromatosis type I", "PROBLEM", 153, 187], ["a frequent genetic disorder", "PROBLEM", 189, 216], ["progressive parenchymal iron deposition", "PROBLEM", 234, 273], ["eventual organ failure", "PROBLEM", 278, 300], ["progressive", "OBSERVATION_MODIFIER", 234, 245], ["parenchymal", "ANATOMY_MODIFIER", 246, 257], ["iron deposition", "OBSERVATION", 258, 273], ["organ", "ANATOMY", 287, 292], ["failure", "OBSERVATION", 293, 300]]], ["Since HFE mutations are associated with reduced iron levels within mononuclear phagocytes, we hypothesized that Hfe deficiency may be beneficial in infections with intramacrophage pathogens.O384 The haemochromatosis-associated Hfe mutation protects mice from Salmonella typhimurium infection via induction of lipocalin 2Using Hfe+/+, Hfe+/\u2212 and Hfe\u2212/\u2212 mice in a model of typhoid fever, we found that animals lacking one or both Hfe alleles are protected from systemic infection with Salmonella typhimurium, displaying prolonged survival and improved bacterial control.", [["mononuclear phagocytes", "ANATOMY", 67, 89], ["iron", "CHEMICAL", 48, 52], ["Hfe", "CHEMICAL", 112, 115], ["infections", "DISEASE", 148, 158], ["O384", "CHEMICAL", 190, 194], ["haemochromatosis", "DISEASE", 199, 215], ["Salmonella typhimurium infection", "DISEASE", 259, 291], ["typhoid fever", "DISEASE", 371, 384], ["infection", "DISEASE", 468, 477], ["iron", "CHEMICAL", 48, 52], ["HFE", "GENE_OR_GENE_PRODUCT", 6, 9], ["iron", "SIMPLE_CHEMICAL", 48, 52], ["mononuclear phagocytes", "CELL", 67, 89], ["Hfe", "GENE_OR_GENE_PRODUCT", 112, 115], ["Hfe", "GENE_OR_GENE_PRODUCT", 227, 230], ["mice", "ORGANISM", 249, 253], ["Salmonella typhimurium", "ORGANISM", 259, 281], ["lipocalin", "GENE_OR_GENE_PRODUCT", 309, 318], ["Hfe", "GENE_OR_GENE_PRODUCT", 326, 329], ["Hfe", "GENE_OR_GENE_PRODUCT", 334, 337], ["\u2212", "GENE_OR_GENE_PRODUCT", 339, 340], ["Hfe\u2212", "GENE_OR_GENE_PRODUCT", 345, 349], ["Hfe", "GENE_OR_GENE_PRODUCT", 428, 431], ["Salmonella typhimurium", "ORGANISM", 483, 505], ["HFE", "PROTEIN", 6, 9], ["mononuclear phagocytes", "CELL_TYPE", 67, 89], ["Hfe", "PROTEIN", 227, 230], ["lipocalin", "PROTEIN", 309, 318], ["Hfe", "PROTEIN", 326, 329], ["Hfe", "PROTEIN", 334, 337], ["Hfe\u2212", "PROTEIN", 345, 349], ["Hfe alleles", "DNA", 428, 439], ["mice", "SPECIES", 249, 253], ["Salmonella typhimurium", "SPECIES", 259, 281], ["mice", "SPECIES", 352, 356], ["Salmonella typhimurium", "SPECIES", 483, 505], ["mice", "SPECIES", 249, 253], ["Salmonella typhimurium", "SPECIES", 259, 281], ["mice", "SPECIES", 352, 356], ["Salmonella typhimurium", "SPECIES", 483, 505], ["HFE mutations", "PROBLEM", 6, 19], ["reduced iron levels", "PROBLEM", 40, 59], ["Hfe deficiency", "PROBLEM", 112, 126], ["intramacrophage pathogens", "PROBLEM", 164, 189], ["The haemochromatosis", "PROBLEM", 195, 215], ["Hfe mutation", "PROBLEM", 227, 239], ["Salmonella typhimurium infection", "PROBLEM", 259, 291], ["lipocalin", "TEST", 309, 318], ["Hfe", "TEST", 326, 329], ["Hfe", "TEST", 334, 337], ["typhoid fever", "PROBLEM", 371, 384], ["Hfe alleles", "PROBLEM", 428, 439], ["systemic infection", "PROBLEM", 459, 477], ["Salmonella typhimurium", "PROBLEM", 483, 505], ["prolonged survival", "TREATMENT", 518, 536], ["improved bacterial control", "TREATMENT", 541, 567], ["mononuclear phagocytes", "OBSERVATION", 67, 89], ["may be", "UNCERTAINTY", 127, 133], ["infections", "OBSERVATION", 148, 158], ["haemochromatosis", "OBSERVATION", 199, 215], ["systemic", "OBSERVATION_MODIFIER", 459, 467], ["infection", "OBSERVATION", 468, 477], ["bacterial control", "OBSERVATION", 550, 567]]], ["This increased resistance can be referred to an enhanced production of the siderophore-binding peptide lipocalin 2 and the reduced availability of iron for Salmonella engulfed by Hfe deficient macrophages.", [["macrophages", "ANATOMY", 193, 204], ["iron", "CHEMICAL", 147, 151], ["iron", "CHEMICAL", 147, 151], ["siderophore-binding peptide lipocalin 2", "GENE_OR_GENE_PRODUCT", 75, 114], ["iron", "SIMPLE_CHEMICAL", 147, 151], ["Hfe", "GENE_OR_GENE_PRODUCT", 179, 182], ["macrophages", "CELL", 193, 204], ["lipocalin 2", "PROTEIN", 103, 114], ["Hfe deficient macrophages", "CELL_TYPE", 179, 204], ["Salmonella", "SPECIES", 156, 166], ["This increased resistance", "PROBLEM", 0, 25], ["the siderophore-binding peptide lipocalin", "TREATMENT", 71, 112], ["iron", "TREATMENT", 147, 151], ["Salmonella", "PROBLEM", 156, 166], ["increased", "OBSERVATION_MODIFIER", 5, 14], ["resistance", "OBSERVATION", 15, 25], ["deficient macrophages", "OBSERVATION", 183, 204]]], ["This effect is mediated via stimulation of lipocalin 2-dependent iron export from infected cells since Hfe\u2212/\u2212 macrophages concurrently knocked out for lipocalin 2 are unable to efficiently control the infection or to withhold iron from intracellular Salmonella.", [["cells", "ANATOMY", 91, 96], ["Hfe\u2212/\u2212 macrophages", "ANATOMY", 103, 121], ["intracellular", "ANATOMY", 236, 249], ["iron", "CHEMICAL", 65, 69], ["infection", "DISEASE", 201, 210], ["iron", "CHEMICAL", 226, 230], ["iron", "CHEMICAL", 65, 69], ["iron", "CHEMICAL", 226, 230], ["lipocalin 2", "GENE_OR_GENE_PRODUCT", 43, 54], ["iron", "SIMPLE_CHEMICAL", 65, 69], ["cells", "CELL", 91, 96], ["Hfe\u2212/\u2212 macrophages", "CELL", 103, 121], ["lipocalin 2", "GENE_OR_GENE_PRODUCT", 151, 162], ["iron", "SIMPLE_CHEMICAL", 226, 230], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 236, 249], ["lipocalin 2", "PROTEIN", 43, 54], ["infected cells", "CELL_TYPE", 82, 96], ["Hfe\u2212/\u2212 macrophages", "CELL_TYPE", 103, 121], ["lipocalin 2", "PROTEIN", 151, 162], ["lipocalin 2-dependent iron export", "TREATMENT", 43, 76], ["infected cells", "PROBLEM", 82, 96], ["Hfe\u2212/\u2212 macrophages", "TREATMENT", 103, 121], ["lipocalin 2", "PROBLEM", 151, 162], ["the infection", "PROBLEM", 197, 210], ["iron", "TREATMENT", 226, 230], ["intracellular Salmonella", "PROBLEM", 236, 260], ["infected cells", "OBSERVATION", 82, 96], ["infection", "OBSERVATION", 201, 210], ["intracellular Salmonella", "OBSERVATION", 236, 260]]], ["Correspondingly, infection of Hfe+/+ and Hfe\u2212/\u2212 mice with siderophore deficient Salmonella abolishes the protection conferred by the Hfe defect.", [["infection", "DISEASE", 17, 26], ["Hfe", "GENE_OR_GENE_PRODUCT", 30, 33], ["Hfe\u2212", "GENE_OR_GENE_PRODUCT", 41, 45], ["Hfe", "GENE_OR_GENE_PRODUCT", 133, 136], ["Hfe", "PROTEIN", 30, 33], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["Salmonella", "SPECIES", 80, 90], ["Hfe", "TEST", 30, 33], ["Hfe\u2212/\u2212 mice", "TREATMENT", 41, 52], ["siderophore deficient Salmonella", "TREATMENT", 58, 90], ["the protection", "TREATMENT", 101, 115], ["the Hfe defect", "PROBLEM", 129, 143], ["infection", "OBSERVATION", 17, 26], ["defect", "OBSERVATION", 137, 143]]], ["Thus, by inducing the formation of the iron-capturing peptide lipocalin 2, the Hfe mutation harbours a genetically determined immunological advantage towards infections with intracellular pathogens such as Salmonella.O385 Allogeneic transplantation of mononuclear cells as successful immunotherapy in experimental sepsis by multidrug-resistant Pseudomonas aeruginosaI.", [["intracellular", "ANATOMY", 174, 187], ["mononuclear cells", "ANATOMY", 252, 269], ["infections", "DISEASE", 158, 168], ["sepsis", "DISEASE", 314, 320], ["lipocalin 2", "GENE_OR_GENE_PRODUCT", 62, 73], ["Hfe", "GENE_OR_GENE_PRODUCT", 79, 82], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 174, 187], ["mononuclear cells", "CELL", 252, 269], ["Pseudomonas aeruginosaI", "ORGANISM", 344, 367], ["iron-capturing peptide lipocalin 2", "PROTEIN", 39, 73], ["Hfe", "PROTEIN", 79, 82], ["mononuclear cells", "CELL_TYPE", 252, 269], ["Pseudomonas aeruginosaI", "SPECIES", 344, 367], ["Pseudomonas aeruginosaI", "SPECIES", 344, 367], ["the iron-capturing peptide lipocalin", "TREATMENT", 35, 71], ["intracellular pathogens", "PROBLEM", 174, 197], ["Salmonella", "PROBLEM", 206, 216], ["Allogeneic transplantation of mononuclear cells", "TREATMENT", 222, 269], ["successful immunotherapy", "TREATMENT", 273, 297], ["experimental sepsis", "PROBLEM", 301, 320], ["multidrug-resistant Pseudomonas aeruginosaI", "PROBLEM", 324, 367], ["mononuclear cells", "OBSERVATION", 252, 269], ["sepsis", "OBSERVATION", 314, 320], ["resistant", "OBSERVATION_MODIFIER", 334, 343], ["Pseudomonas aeruginosaI", "OBSERVATION", 344, 367]]], ["Koutelidakis, A. Kotsaki, P.D. Carrer, K. Louis, A. Savva, E.J. Giamarellos-Bourboulis\u00b0(Thessaloniki, Athens, GR) Objective: The majority of clinical trials of immunointervention in severe sepsis have failed to disclose survival benefit.", [["sepsis", "DISEASE", 189, 195], ["immunointervention", "TREATMENT", 160, 178], ["severe sepsis", "PROBLEM", 182, 195], ["severe", "OBSERVATION_MODIFIER", 182, 188], ["sepsis", "OBSERVATION", 189, 195]]], ["A likely explanation may be administration of therapy when immunoparalysis of the septic host supervenes.", [["septic", "DISEASE", 82, 88], ["therapy", "TREATMENT", 46, 53], ["immunoparalysis", "TREATMENT", 59, 74], ["the septic host supervenes", "PROBLEM", 78, 104], ["likely explanation may be", "UNCERTAINTY", 2, 27], ["septic host", "OBSERVATION", 82, 93]]], ["In an attempt to reverse immunoparalysis, injection of mononuclear cells was attempted in experimental sepsis by multidrugresistant Pseudomonas aeruginosa (MDRPA).", [["mononuclear cells", "ANATOMY", 55, 72], ["sepsis", "DISEASE", 103, 109], ["mononuclear cells", "CELL", 55, 72], ["Pseudomonas aeruginosa", "ORGANISM", 132, 154], ["MDRPA", "SIMPLE_CHEMICAL", 156, 161], ["mononuclear cells", "CELL_TYPE", 55, 72], ["Pseudomonas aeruginosa", "SPECIES", 132, 154], ["Pseudomonas aeruginosa", "SPECIES", 132, 154], ["reverse immunoparalysis", "TREATMENT", 17, 40], ["injection of mononuclear cells", "TREATMENT", 42, 72], ["experimental sepsis", "PROBLEM", 90, 109], ["multidrugresistant Pseudomonas aeruginosa", "PROBLEM", 113, 154], ["sepsis", "OBSERVATION", 103, 109]]], ["Methods: Peripheral blood mononuclear cells (PBMCs) diluted in RPMI were isolated from five healthy human volunteers after gradient centrifugation over Ficoll.", [["Peripheral blood mononuclear cells", "ANATOMY", 9, 43], ["PBMCs", "ANATOMY", 45, 50], ["Peripheral blood mononuclear cells", "CELL", 9, 43], ["PBMCs", "CELL", 45, 50], ["RPMI", "CELL", 63, 67], ["human", "ORGANISM", 100, 105], ["volunteers", "ORGANISM", 106, 116], ["Peripheral blood mononuclear cells", "CELL_TYPE", 9, 43], ["PBMCs", "CELL_TYPE", 45, 50], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["Peripheral blood mononuclear cells", "TREATMENT", 9, 43], ["PBMCs", "TEST", 45, 50], ["RPMI", "TEST", 63, 67], ["gradient centrifugation over Ficoll", "TREATMENT", 123, 158], ["Peripheral", "ANATOMY_MODIFIER", 9, 19], ["blood", "ANATOMY", 20, 25], ["mononuclear cells", "OBSERVATION", 26, 43]]], ["1\u00d710 7 /kg of one MDRPA live or heat-killed isolate from one patient with severe sepsis was injected intraperitoneally for bacterial challenge.", [["MDRPA", "CHEMICAL", 18, 23], ["sepsis", "DISEASE", 81, 87], ["MDRPA", "ORGANISM", 18, 23], ["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["heat-killed isolate", "TREATMENT", 32, 51], ["severe sepsis", "PROBLEM", 74, 87], ["bacterial challenge", "PROBLEM", 123, 142], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["sepsis", "OBSERVATION", 81, 87]]], ["A total of 72 male C57B6 mice were studied divided into four groups: group A (n = 26) pre-treated with RPMI and challenged after one hour with live isolate; group B (n = 26) pretreated with 5\u00d710 7 PBMCs/kg and challenged after one hour with live isolate; group C (n = 10) pre-treated with RPMI and challenged after one hour with heat-killed isolate; group D (n = 10) pre-treated with 5\u00d710 7 PBMCs/kg and challenged after one hour with heat-killed isolate.", [["PBMCs", "ANATOMY", 197, 202], ["PBMCs", "ANATOMY", 391, 396], ["C57B6", "ORGANISM", 19, 24], ["mice", "ORGANISM", 25, 29], ["PBMCs", "CELL_TYPE", 197, 202], ["PBMCs", "CELL_TYPE", 391, 396], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["RPMI", "TREATMENT", 103, 107], ["live isolate", "TREATMENT", 143, 155], ["RPMI", "TREATMENT", 289, 293], ["heat-killed isolate", "TREATMENT", 329, 348], ["group D (n", "TEST", 350, 360], ["heat-killed isolate", "TREATMENT", 435, 454]]], ["Survival was recorded for 20 mice of groups A and B and for all mice of groups C and D. Six mice of groups A and B were sacrificed six hours after challenge.", [["mice", "ORGANISM", 29, 33], ["B", "CELL", 50, 51], ["mice", "ORGANISM", 64, 68], ["mice", "ORGANISM", 92, 96], ["B", "CELL", 113, 114], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 92, 96]]], ["Blood was collected from the lower vena cava and TNFalpha and IL-6 were estimated in serum by an enzyme immunoassay.", [["Blood", "ANATOMY", 0, 5], ["lower vena cava", "ANATOMY", 29, 44], ["serum", "ANATOMY", 85, 90], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["lower vena cava", "MULTI-TISSUE_STRUCTURE", 29, 44], ["TNFalpha", "GENE_OR_GENE_PRODUCT", 49, 57], ["IL-6", "GENE_OR_GENE_PRODUCT", 62, 66], ["serum", "ORGANISM_SUBSTANCE", 85, 90], ["TNFalpha", "PROTEIN", 49, 57], ["IL-6", "PROTEIN", 62, 66], ["Blood", "TEST", 0, 5], ["TNFalpha and IL", "TEST", 49, 64], ["an enzyme immunoassay", "TEST", 94, 115], ["lower vena cava", "ANATOMY", 29, 44], ["TNFalpha", "ANATOMY", 49, 57]]], ["Bacterial growth of liver and lung at the same time was assessed.", [["liver", "ANATOMY", 20, 25], ["lung", "ANATOMY", 30, 34], ["liver", "ORGAN", 20, 25], ["lung", "ORGAN", 30, 34], ["Bacterial growth of liver and lung", "PROBLEM", 0, 34], ["growth", "OBSERVATION_MODIFIER", 10, 16], ["liver", "ANATOMY", 20, 25], ["lung", "ANATOMY", 30, 34]]], ["Median serum TNF-a of groups A and B at sacrifice was 31 and 184 pg/ml respectively (p: 0.048).", [["serum", "ANATOMY", 7, 12], ["serum", "ORGANISM_SUBSTANCE", 7, 12], ["TNF", "GENE_OR_GENE_PRODUCT", 13, 16], ["B", "CELL", 35, 36], ["TNF", "PROTEIN", 13, 16], ["Median serum TNF", "TEST", 0, 16]]], ["Respective values for IL-6 were 2084 and 2231 pg/ml (pNS); for liver bacterial cells 3.63 and 4.99 log10 cfu/g (pNS); and for lung bacterial cells 2.56 and 4.22 log10 cfu/g (pNS).", [["liver bacterial cells", "ANATOMY", 63, 84], ["lung bacterial cells", "ANATOMY", 126, 146], ["IL-6", "GENE_OR_GENE_PRODUCT", 22, 26], ["liver bacterial cells", "CELL", 63, 84], ["lung bacterial cells", "CELL", 126, 146], ["IL", "PROTEIN", 22, 24], ["liver bacterial cells", "CELL_TYPE", 63, 84], ["lung bacterial cells", "CELL_TYPE", 126, 146], ["Respective values", "TEST", 0, 17], ["IL", "TEST", 22, 24], ["pNS", "TEST", 53, 56], ["liver bacterial cells", "TEST", 63, 84], ["cfu/g", "TEST", 105, 110], ["pNS", "TEST", 112, 115], ["lung bacterial cells", "TEST", 126, 146], ["NS", "TEST", 175, 177], ["liver", "ANATOMY", 63, 68], ["lung", "ANATOMY", 126, 130], ["bacterial cells", "OBSERVATION", 131, 146]]], ["Conclusions: Allogeneic transplantation with PBMCs prolonged survival in experimental sepsis by MDRPA.", [["PBMCs", "ANATOMY", 45, 50], ["sepsis", "DISEASE", 86, 92], ["MDRPA", "CHEMICAL", 96, 101], ["PBMCs", "CELL", 45, 50], ["MDRPA", "SIMPLE_CHEMICAL", 96, 101], ["PBMCs", "CELL_TYPE", 45, 50], ["Allogeneic transplantation", "TREATMENT", 13, 39], ["PBMCs prolonged survival", "TREATMENT", 45, 69], ["experimental sepsis", "PROBLEM", 73, 92], ["MDRPA", "TREATMENT", 96, 101], ["Allogeneic transplantation", "OBSERVATION", 13, 39], ["sepsis", "OBSERVATION", 86, 92]]], ["Its mechanism of action was related with a) blockade of cell wall structures as shown by survival experiments with heat killed isolate; and b) reversal of immunoparalysis as evidenced by increase of serum TNF-a.", [["cell wall structures", "ANATOMY", 56, 76], ["serum", "ANATOMY", 199, 204], ["immunoparalysis", "DISEASE", 155, 170], ["cell wall", "TISSUE", 56, 65], ["serum", "ORGANISM_SUBSTANCE", 199, 204], ["TNF-a.", "GENE_OR_GENE_PRODUCT", 205, 211], ["TNF", "PROTEIN", 205, 208], ["a) blockade of cell wall structures", "TREATMENT", 41, 76], ["heat killed isolate", "TREATMENT", 115, 134], ["immunoparalysis", "PROBLEM", 155, 170], ["serum TNF", "TEST", 199, 208], ["increase", "OBSERVATION_MODIFIER", 187, 195]]], ["This approach creates a promising novel perspective for immunointervention in sepsis.O386 Small-animal positron emission tomography in the mouse model of genital Chlamydia infectionA.", [["sepsis", "DISEASE", 78, 84], ["Chlamydia infectionA", "DISEASE", 162, 182], ["mouse", "ORGANISM", 139, 144], ["genital Chlamydia", "ORGANISM", 154, 171], ["mouse", "SPECIES", 139, 144], ["mouse", "SPECIES", 139, 144], ["immunointervention", "TREATMENT", 56, 74], ["sepsis", "PROBLEM", 78, 84], ["animal positron emission tomography", "TEST", 96, 131], ["genital Chlamydia infectionA", "PROBLEM", 154, 182], ["sepsis", "OBSERVATION", 78, 84], ["genital", "ANATOMY", 154, 161], ["Chlamydia", "OBSERVATION", 162, 171]]], ["Marangoni\u00b0, C. Nanni, M. Donati, R. Aldini, D. di Pierro, S. Trespidi, S. Accardo, S. Fanti, R. Cevenini (Bologna, IT) Objectives: Chlamydia trachomatis is one of the world's major causes of sexually transmitted diseases of the cervix and urethra and it is a major agent of pelvic inflammatory disease.", [["cervix", "ANATOMY", 228, 234], ["urethra", "ANATOMY", 239, 246], ["pelvic", "ANATOMY", 274, 280], ["Chlamydia trachomatis", "DISEASE", 131, 152], ["sexually transmitted diseases of the cervix and urethra", "DISEASE", 191, 246], ["pelvic inflammatory disease", "DISEASE", 274, 301], ["Chlamydia trachomatis", "ORGANISM", 131, 152], ["cervix", "ORGAN", 228, 234], ["urethra", "ORGAN", 239, 246], ["pelvic", "ORGAN", 274, 280], ["Chlamydia trachomatis", "SPECIES", 131, 152], ["Chlamydia trachomatis", "SPECIES", 131, 152], ["Marangoni\u00b0", "TREATMENT", 0, 10], ["Chlamydia trachomatis", "PROBLEM", 131, 152], ["sexually transmitted diseases of the cervix and urethra", "PROBLEM", 191, 246], ["pelvic inflammatory disease", "PROBLEM", 274, 301], ["C. Nanni", "OBSERVATION", 12, 20], ["Chlamydia", "OBSERVATION", 131, 140], ["cervix", "ANATOMY", 228, 234], ["urethra", "ANATOMY", 239, 246], ["pelvic", "ANATOMY", 274, 280], ["inflammatory", "OBSERVATION", 281, 293]]], ["Genital tract infection of female mice with Chlamydia muridarum closely mimics acute genital tract infection in women.", [["Genital tract", "ANATOMY", 0, 13], ["genital tract", "ANATOMY", 85, 98], ["Genital tract infection", "DISEASE", 0, 23], ["Chlamydia muridarum", "DISEASE", 44, 63], ["acute genital tract infection", "DISEASE", 79, 108], ["Genital tract", "ORGAN", 0, 13], ["mice", "ORGANISM", 34, 38], ["Chlamydia muridarum", "ORGANISM", 44, 63], ["genital tract", "ORGANISM_SUBDIVISION", 85, 98], ["women", "ORGANISM", 112, 117], ["mice", "SPECIES", 34, 38], ["Chlamydia muridarum", "SPECIES", 44, 63], ["women", "SPECIES", 112, 117], ["mice", "SPECIES", 34, 38], ["Chlamydia muridarum", "SPECIES", 44, 63], ["Genital tract infection", "PROBLEM", 0, 23], ["Chlamydia muridarum", "PROBLEM", 44, 63], ["acute genital tract infection", "PROBLEM", 79, 108], ["tract", "OBSERVATION_MODIFIER", 8, 13], ["infection", "OBSERVATION", 14, 23], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["genital tract", "ANATOMY", 85, 98], ["infection", "OBSERVATION", 99, 108]]], ["Aim of this study was to assess the predictivity of 68Ga-chloride Small Animal Positron Emission Tomography (Nosocomial infections: a major clinical problemO387 Inadequate statistical power of published comparative cohort studies on ventilator-associated pneumonia to detect mortality differences between the compared groups M. Falagas\u00b0, V. Kouranos, A. Michalopoulos, S. Rodopoulou, A. Athanasoulia, D. Karageorgopoulos (Athens, GR) Objective: Comparative cohort studies are often conducted to identify novel therapeutic strategies or prognostic factors for ventilator-associated pneumonia (VAP).", [["68Ga-chloride", "CHEMICAL", 52, 65], ["Nosocomial infections", "DISEASE", 109, 130], ["pneumonia", "DISEASE", 255, 264], ["ventilator-associated pneumonia", "DISEASE", 559, 590], ["VAP", "DISEASE", 592, 595], ["68Ga-chloride", "CHEMICAL", 52, 65], ["68Ga-chloride", "SIMPLE_CHEMICAL", 52, 65], ["this study", "TEST", 7, 17], ["the predictivity", "TEST", 32, 48], ["68Ga", "TEST", 52, 56], ["Nosocomial infections", "PROBLEM", 109, 130], ["a major clinical problem", "PROBLEM", 132, 156], ["cohort studies", "TEST", 215, 229], ["ventilator", "TREATMENT", 233, 243], ["pneumonia", "PROBLEM", 255, 264], ["mortality differences", "PROBLEM", 275, 296], ["Comparative cohort studies", "TEST", 445, 471], ["prognostic factors", "PROBLEM", 536, 554], ["ventilator-associated pneumonia", "PROBLEM", 559, 590], ["VAP", "PROBLEM", 592, 595], ["pneumonia", "OBSERVATION", 255, 264], ["pneumonia", "OBSERVATION", 581, 590]]], ["We aimed to evaluate the statistical power of such studies to provide statistically and clinically significant conclusions.", [["such studies", "TEST", 46, 58]]], ["Methods: We searched in PubMed and Scopus for comparative cohort studies evaluating the mortality of patients with VAP.", [["VAP", "DISEASE", 115, 118], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["comparative cohort studies", "TEST", 46, 72], ["VAP", "PROBLEM", 115, 118]]], ["We calculated for each of the included studies the statistical power to detect the observed difference in mortality between the compared groups (observed power), as well as 3 expected, clinically relevant, effect sizes (expected power).Results:We identified 39 (20 prospective) comparative cohort studies on VAP as eligible for inclusion in this analysis.", [["VAP", "DISEASE", 308, 311], ["comparative cohort studies", "TEST", 278, 304], ["VAP", "TREATMENT", 308, 311], ["this analysis", "TEST", 341, 354], ["sizes", "OBSERVATION_MODIFIER", 213, 218]]], ["The median observed power of these studies was 17.9% [interquartile range (IQR), 9.8\u221252.4%].", [["these studies", "TEST", 29, 42], ["IQR", "TEST", 75, 78]]], ["The median expected power was 10.0% (IQR, 7.2\u221213.6%) for a risk ratio for mortality of 0.85 between the compared groups; 14.7% (IQR, 10.6\u221221.8%) for a risk ratio of 0.80; and 7.9% (IQR, 6.3\u221210.2%) for a reduction in mortality from 30% to 25%.", [["IQR", "TEST", 37, 40], ["a risk ratio", "TEST", 57, 69], ["mortality", "TEST", 74, 83], ["IQR", "TEST", 128, 131], ["a risk ratio", "TEST", 149, 161], ["IQR", "TEST", 181, 184], ["a reduction in mortality", "PROBLEM", 201, 225], ["reduction", "OBSERVATION_MODIFIER", 203, 212]]], ["All expected power measures were significantly lower than the observed power.Conclusion:The statistical power of most cohort studies to detect the observed difference in mortality between compared groups of patients with VAP is low.", [["VAP", "DISEASE", 221, 224], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 207, 215], ["most cohort studies", "TEST", 113, 132], ["VAP", "PROBLEM", 221, 224], ["power", "OBSERVATION_MODIFIER", 13, 18], ["VAP", "OBSERVATION", 221, 224], ["low", "OBSERVATION_MODIFIER", 228, 231]]], ["The power is even lower when expected, clinically relevant, differences in mortality are considered.", [["power", "OBSERVATION_MODIFIER", 4, 9], ["even lower", "OBSERVATION_MODIFIER", 13, 23]]], ["For a wiser utilisation of resources allocated to research, we favour the conduction of cohort studies with larger sample size so that potential differences between the compared groups are more likely to be shown.", [["cohort studies", "TEST", 88, 102], ["size", "OBSERVATION_MODIFIER", 122, 126]]], ["Objective: To clarify issues regarding the frequency, prevention, outcome, and treatment of patients with ventilator-associated tracheobronchitis (VAT), which is a lower respiratory tract infection involving the tracheobronchial tree, while sparing the lung parenchyma.", [["VAT", "ANATOMY", 147, 150], ["lower respiratory tract", "ANATOMY", 164, 187], ["tracheobronchial tree", "ANATOMY", 212, 233], ["lung parenchyma", "ANATOMY", 253, 268], ["ventilator-associated tracheobronchitis", "DISEASE", 106, 145], ["VAT", "DISEASE", 147, 150], ["respiratory tract infection", "DISEASE", 170, 197], ["patients", "ORGANISM", 92, 100], ["VAT", "TISSUE", 147, 150], ["respiratory tract", "ORGANISM_SUBDIVISION", 170, 187], ["tracheobronchial tree", "MULTI-TISSUE_STRUCTURE", 212, 233], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 253, 268], ["patients", "SPECIES", 92, 100], ["treatment", "TREATMENT", 79, 88], ["ventilator-associated tracheobronchitis", "PROBLEM", 106, 145], ["a lower respiratory tract infection involving the tracheobronchial tree", "PROBLEM", 162, 233], ["tracheobronchitis", "OBSERVATION", 128, 145], ["lower", "ANATOMY_MODIFIER", 164, 169], ["respiratory tract", "ANATOMY", 170, 187], ["infection", "OBSERVATION", 188, 197], ["tracheobronchial", "ANATOMY", 212, 228], ["tree", "ANATOMY_MODIFIER", 229, 233], ["lung", "ANATOMY", 253, 257], ["parenchyma", "ANATOMY_MODIFIER", 258, 268]]], ["A conservative random effects model was used to calculate pooled odds ratios (OR) and 95% confidence intervals (CI).", [["CI", "TEST", 112, 114]]], ["Frequency of VAT was 10.2%.", [["VAT", "ANATOMY", 13, 16], ["VAT", "TISSUE", 13, 16], ["VAT", "TEST", 13, 16]]], ["Selective digestive decontamination was proved an effective preventive strategy against VAT.", [["digestive", "ANATOMY", 10, 19], ["VAT", "ANATOMY", 88, 91], ["digestive", "ORGAN", 10, 19], ["VAT", "TISSUE", 88, 91], ["Selective digestive decontamination", "TREATMENT", 0, 35], ["VAT", "PROBLEM", 88, 91]]], ["Presence, as opposed to the absence, of VAT was not associated with higher mortality (OR: 1.18, 95% CI 0.90\u22121.53).", [["VAT", "TISSUE", 40, 43], ["CI", "TEST", 100, 102]]], ["Administration of systemic antimicrobials (with or without inhaled ones), as opposed to placebo or no treatment, in patients with VAT was not associated with lower mortality (OR: 0.56, 95% CI 0.27\u22121.14).", [["patients", "ORGANISM", 116, 124], ["VAT", "TISSUE", 130, 133], ["patients", "SPECIES", 116, 124], ["systemic antimicrobials", "TREATMENT", 18, 41], ["placebo", "TREATMENT", 88, 95], ["treatment", "TREATMENT", 102, 111], ["CI", "TEST", 189, 191]]], ["Most of the studies providing relevant data noted that administration of antimicrobial agents, as opposed to placebo or no treatment, in patients with VAT was associated with more ventilator-free days and lower frequency of subsequent pneumonia, but without shorter length of intensive care unit stay or shorter duration of mechanical ventilation.Conclusion:Conclusions: Approximately one tenth of mechanically ventilated patients suffer from VAT; an infection potentially prevented by the implementation of selective digestive decontamination.", [["digestive", "ANATOMY", 518, 527], ["pneumonia", "DISEASE", 235, 244], ["VAT", "DISEASE", 443, 446], ["infection", "DISEASE", 451, 460], ["patients", "ORGANISM", 137, 145], ["VAT", "TISSUE", 151, 154], ["patients", "ORGANISM", 422, 430], ["VAT", "TISSUE", 443, 446], ["digestive", "ORGANISM_SUBDIVISION", 518, 527], ["patients", "SPECIES", 137, 145], ["patients", "SPECIES", 422, 430], ["the studies", "TEST", 8, 19], ["antimicrobial agents", "TREATMENT", 73, 93], ["placebo", "TREATMENT", 109, 116], ["treatment", "TREATMENT", 123, 132], ["VAT", "PROBLEM", 151, 154], ["subsequent pneumonia", "PROBLEM", 224, 244], ["mechanical ventilation", "TREATMENT", 324, 346], ["mechanically ventilated", "TREATMENT", 398, 421], ["VAT", "PROBLEM", 443, 446], ["an infection", "PROBLEM", 448, 460], ["selective digestive decontamination", "TREATMENT", 508, 543], ["pneumonia", "OBSERVATION", 235, 244], ["mechanical ventilation", "OBSERVATION", 324, 346], ["infection", "OBSERVATION", 451, 460]]], ["Antimicrobial treatment of patients with VAT may protect against the development of subsequent ventilator-associated pneumonia.Conclusion:degranulation.", [["VAT", "ANATOMY", 41, 44], ["pneumonia", "DISEASE", 117, 126], ["patients", "ORGANISM", 27, 35], ["VAT", "TISSUE", 41, 44], ["patients", "SPECIES", 27, 35], ["Antimicrobial treatment", "TREATMENT", 0, 23], ["VAT", "TREATMENT", 41, 44], ["subsequent ventilator-associated pneumonia", "PROBLEM", 84, 126], ["ventilator", "OBSERVATION", 95, 105], ["pneumonia", "OBSERVATION", 117, 126], ["degranulation", "OBSERVATION", 138, 151]]], ["Subsequently, allergen specific IgE to chlorhexidine was demonstrated and skin prick/intradermal testing was positive to chlorhexidine, confirming the diagnosis of chlorhexidine-precipitated anaphylaxis in each patient.", [["skin", "ANATOMY", 74, 78], ["chlorhexidine", "CHEMICAL", 39, 52], ["chlorhexidine", "CHEMICAL", 121, 134], ["chlorhexidine", "CHEMICAL", 164, 177], ["anaphylaxis", "DISEASE", 191, 202], ["chlorhexidine", "CHEMICAL", 39, 52], ["chlorhexidine", "CHEMICAL", 121, 134], ["chlorhexidine", "CHEMICAL", 164, 177], ["IgE", "GENE_OR_GENE_PRODUCT", 32, 35], ["chlorhexidine", "SIMPLE_CHEMICAL", 39, 52], ["skin", "ORGAN", 74, 78], ["chlorhexidine", "SIMPLE_CHEMICAL", 121, 134], ["chlorhexidine", "SIMPLE_CHEMICAL", 164, 177], ["patient", "ORGANISM", 211, 218], ["IgE", "PROTEIN", 32, 35], ["patient", "SPECIES", 211, 218], ["allergen specific IgE to chlorhexidine", "TREATMENT", 14, 52], ["skin prick/intradermal testing", "TEST", 74, 104], ["chlorhexidine", "TREATMENT", 121, 134], ["chlorhexidine", "TREATMENT", 164, 177], ["anaphylaxis", "PROBLEM", 191, 202], ["skin", "ANATOMY", 74, 78], ["anaphylaxis", "OBSERVATION", 191, 202]]], ["A detailed review of the case-notes revealed that each patient had manifest evidence of minor cutaneous reactions to pre-operative chlorhexidine use that had not been ascribed to chlorhexidine at the time.Conclusion:Discussion: FDA issued a public health notice [1998] following 1st description of anaphylaxis to chlorhexidine coated central venous catheter.", [["cutaneous", "ANATOMY", 94, 103], ["venous", "ANATOMY", 342, 348], ["chlorhexidine", "CHEMICAL", 131, 144], ["chlorhexidine", "CHEMICAL", 179, 192], ["anaphylaxis", "DISEASE", 298, 309], ["chlorhexidine", "CHEMICAL", 313, 326], ["chlorhexidine", "CHEMICAL", 131, 144], ["chlorhexidine", "CHEMICAL", 179, 192], ["chlorhexidine", "CHEMICAL", 313, 326], ["patient", "ORGANISM", 55, 62], ["chlorhexidine", "SIMPLE_CHEMICAL", 131, 144], ["chlorhexidine", "SIMPLE_CHEMICAL", 179, 192], ["chlorhexidine", "SIMPLE_CHEMICAL", 313, 326], ["central venous", "MULTI-TISSUE_STRUCTURE", 334, 348], ["patient", "SPECIES", 55, 62], ["minor cutaneous reactions", "PROBLEM", 88, 113], ["pre-operative chlorhexidine use", "TREATMENT", 117, 148], ["chlorhexidine", "TREATMENT", 179, 192], ["anaphylaxis", "PROBLEM", 298, 309], ["chlorhexidine coated central venous catheter", "TREATMENT", 313, 357], ["venous", "ANATOMY", 342, 348], ["catheter", "OBSERVATION", 349, 357]]], ["A recent case cluster has also been reported from another cardiac centre in the UK [3-cases over a 9-month period].", [["cardiac", "ANATOMY", 58, 65]]], ["It is interesting that these reports of chlorhexidine anaphylaxis have all occurred in patients undergoing cardiac surgery.", [["cardiac", "ANATOMY", 107, 114], ["chlorhexidine", "CHEMICAL", 40, 53], ["anaphylaxis", "DISEASE", 54, 65], ["chlorhexidine", "CHEMICAL", 40, 53], ["chlorhexidine", "SIMPLE_CHEMICAL", 40, 53], ["patients", "ORGANISM", 87, 95], ["cardiac", "ORGAN", 107, 114], ["patients", "SPECIES", 87, 95], ["chlorhexidine anaphylaxis", "PROBLEM", 40, 65], ["cardiac surgery", "TREATMENT", 107, 122], ["cardiac", "ANATOMY", 107, 114], ["surgery", "OBSERVATION", 115, 122]]], ["These patients receive multiple exposures to chlorhexidine during their pre-operative investigations and preparation.", [["chlorhexidine", "CHEMICAL", 45, 58], ["chlorhexidine", "CHEMICAL", 45, 58], ["patients", "ORGANISM", 6, 14], ["chlorhexidine", "SIMPLE_CHEMICAL", 45, 58], ["patients", "SPECIES", 6, 14], ["chlorhexidine", "TREATMENT", 45, 58], ["their pre-operative investigations", "TEST", 66, 100]]], ["This has increased recently as a result of the drive to reduce the incidence of hospital-acquired infections.", [["infections", "DISEASE", 98, 108], ["hospital-acquired infections", "PROBLEM", 80, 108], ["increased", "OBSERVATION_MODIFIER", 9, 18]]], ["We wish to postulate that these patients have been sensitised by repeated topical exposure to chlorhexidine and have exhibited anaphylaxis when this allergen was presented to the patient in the form of the chlorhexidine coated central venous catheter.", [["venous", "ANATOMY", 235, 241], ["chlorhexidine", "CHEMICAL", 94, 107], ["anaphylaxis", "DISEASE", 127, 138], ["chlorhexidine", "CHEMICAL", 206, 219], ["chlorhexidine", "CHEMICAL", 94, 107], ["chlorhexidine", "CHEMICAL", 206, 219], ["patients", "ORGANISM", 32, 40], ["chlorhexidine", "SIMPLE_CHEMICAL", 94, 107], ["patient", "ORGANISM", 179, 186], ["chlorhexidine", "SIMPLE_CHEMICAL", 206, 219], ["venous", "MULTI-TISSUE_STRUCTURE", 235, 241], ["patients", "SPECIES", 32, 40], ["patient", "SPECIES", 179, 186], ["chlorhexidine", "TREATMENT", 94, 107], ["anaphylaxis", "PROBLEM", 127, 138], ["this allergen", "TREATMENT", 144, 157], ["the chlorhexidine coated central venous catheter", "TREATMENT", 202, 250], ["venous", "ANATOMY", 235, 241], ["catheter", "OBSERVATION", 242, 250]]], ["Type I strains of Helicobacter pylori possess the cag pathogenicity island to deliver virulence factors. cag is a specialised Type IV secretion machinery that is activated during infection and comprises 31 genes originated from a distant event of horizontal transfer.", [["infection", "DISEASE", 179, 188], ["Helicobacter pylori", "ORGANISM", 18, 37], ["cag", "GENE_OR_GENE_PRODUCT", 50, 53], ["cag", "GENE_OR_GENE_PRODUCT", 105, 108], ["Type IV", "GENE_OR_GENE_PRODUCT", 126, 133], ["cag pathogenicity island", "DNA", 50, 74], ["virulence factors", "PROTEIN", 86, 103], ["cag", "DNA", 105, 108], ["Helicobacter pylori", "SPECIES", 18, 37], ["Type I", "SPECIES", 0, 6], ["Helicobacter pylori", "SPECIES", 18, 37], ["Type I strains", "PROBLEM", 0, 14], ["Helicobacter pylori", "PROBLEM", 18, 37], ["the cag pathogenicity island", "PROBLEM", 46, 74], ["virulence factors", "PROBLEM", 86, 103], ["Type IV secretion machinery", "TREATMENT", 126, 153], ["infection", "PROBLEM", 179, 188], ["Helicobacter pylori", "OBSERVATION", 18, 37], ["infection", "OBSERVATION", 179, 188]]], ["After translocation the effector protein CagA is phosphorylated on tyrosine residues restricted to a previously identified repeated sequence called D1.", [["tyrosine", "CHEMICAL", 67, 75], ["tyrosine", "CHEMICAL", 67, 75], ["CagA", "GENE_OR_GENE_PRODUCT", 41, 45], ["tyrosine", "AMINO_ACID", 67, 75], ["D1", "GENE_OR_GENE_PRODUCT", 148, 150], ["effector protein", "PROTEIN", 24, 40], ["CagA", "PROTEIN", 41, 45], ["D1", "PROTEIN", 148, 150], ["translocation the effector protein CagA", "TREATMENT", 6, 45], ["tyrosine residues", "TREATMENT", 67, 84]]], ["This sequence is located in the C-terminal half of the protein and contains the five amino acid motif EPIYA, which is amplified by duplications in a large fraction of clinical isolates.", [["amino acid", "CHEMICAL", 85, 95], ["C", "CHEMICAL", 32, 33], ["amino acid", "CHEMICAL", 85, 95], ["amino acid", "AMINO_ACID", 85, 95], ["EPIYA", "GENE_OR_GENE_PRODUCT", 102, 107], ["C-terminal half", "PROTEIN", 32, 47], ["amino acid motif", "PROTEIN", 85, 101], ["EPIYA", "PROTEIN", 102, 107], ["This sequence", "TEST", 0, 13], ["the five amino acid motif EPIYA", "TREATMENT", 76, 107], ["terminal", "ANATOMY_MODIFIER", 34, 42], ["large", "OBSERVATION_MODIFIER", 149, 154]]], ["Tyrosine-phosphorylation of CagA is essential for the activation process that leads to dramatic changes in the morphology of cells growing in culture.", [["cells", "ANATOMY", 125, 130], ["Tyrosine", "CHEMICAL", 0, 8], ["Tyrosine", "AMINO_ACID", 0, 8], ["CagA", "GENE_OR_GENE_PRODUCT", 28, 32], ["cells", "CELL", 125, 130], ["CagA", "PROTEIN", 28, 32], ["Tyrosine-phosphorylation of CagA", "TREATMENT", 0, 32], ["the activation process", "PROBLEM", 50, 72], ["dramatic changes in the morphology of cells", "PROBLEM", 87, 130], ["culture", "TEST", 142, 149], ["dramatic", "OBSERVATION_MODIFIER", 87, 95]]], ["In addition, we observed that two members of the Src kinases family, c-Src and Lyn, account for most of the CagA-specific kinase activity in AGS cell lysates.", [["AGS cell lysates", "ANATOMY", 141, 157], ["Src", "GENE_OR_GENE_PRODUCT", 49, 52], ["c-Src", "GENE_OR_GENE_PRODUCT", 69, 74], ["Lyn", "GENE_OR_GENE_PRODUCT", 79, 82], ["CagA", "GENE_OR_GENE_PRODUCT", 108, 112], ["AGS cell lysates", "CELL", 141, 157], ["Src kinases family", "PROTEIN", 49, 67], ["c-Src", "PROTEIN", 69, 74], ["Lyn", "PROTEIN", 79, 82], ["CagA", "PROTEIN", 108, 112], ["the CagA", "TEST", 104, 112], ["AGS cell lysates", "PROBLEM", 141, 157], ["Lyn", "ANATOMY", 79, 82], ["AGS cell lysates", "OBSERVATION", 141, 157]]], ["Translocated CagA interacts with the ZO-1 and Jam host-cell proteins causing disruption of the apical junctional complex.", [["cell", "ANATOMY", 55, 59], ["apical junctional", "ANATOMY", 95, 112], ["CagA", "GENE_OR_GENE_PRODUCT", 13, 17], ["ZO-1", "GENE_OR_GENE_PRODUCT", 37, 41], ["apical junctional complex", "CELLULAR_COMPONENT", 95, 120], ["CagA", "PROTEIN", 13, 17], ["ZO-1 and Jam host-cell proteins", "PROTEIN", 37, 68], ["apical junctional complex", "PROTEIN", 95, 120], ["disruption of the apical junctional complex", "PROBLEM", 77, 120], ["CagA", "OBSERVATION", 13, 17], ["apical", "ANATOMY_MODIFIER", 95, 101], ["junctional complex", "OBSERVATION", 102, 120]]], ["Transfection of the cagA gene into polarised epithelial cells induces disruption of cell-to-cell contacts and altered morphology.", [["epithelial cells", "ANATOMY", 45, 61], ["cell", "ANATOMY", 84, 88], ["cell", "ANATOMY", 92, 96], ["cagA", "GENE_OR_GENE_PRODUCT", 20, 24], ["epithelial cells", "CELL", 45, 61], ["cell", "CELL", 84, 88], ["cell", "CELL", 92, 96], ["cagA gene", "DNA", 20, 29], ["polarised epithelial cells", "CELL_TYPE", 35, 61], ["altered morphology", "PROBLEM", 110, 128], ["epithelial cells", "OBSERVATION", 45, 61], ["cell", "OBSERVATION", 84, 88], ["cell contacts", "OBSERVATION", 92, 105], ["altered", "OBSERVATION_MODIFIER", 110, 117], ["morphology", "OBSERVATION_MODIFIER", 118, 128]]], ["Strikingly CagA-expressing cells become migratory and invasive penetrating into collagen gel.", [["cells", "ANATOMY", 27, 32], ["CagA", "GENE_OR_GENE_PRODUCT", 11, 15], ["cells", "CELL", 27, 32], ["collagen", "GENE_OR_GENE_PRODUCT", 80, 88], ["CagA", "PROTEIN", 11, 15], ["expressing cells", "CELL_TYPE", 16, 32], ["invasive penetrating into collagen gel", "TREATMENT", 54, 92], ["CagA", "OBSERVATION", 11, 15], ["migratory", "OBSERVATION_MODIFIER", 40, 49]]], ["The study of different portions of the molecule revealed the presence of two distinct functional domains and both are necessary to induce abnormal cell differentiation through interactions with host cell morphogens.", [["cell", "ANATOMY", 147, 151], ["cell", "ANATOMY", 199, 203], ["cell", "CELL", 147, 151], ["cell", "CELL", 199, 203], ["host cell morphogens", "PROTEIN", 194, 214], ["The study", "TEST", 0, 9], ["two distinct functional domains", "PROBLEM", 73, 104], ["abnormal cell differentiation", "PROBLEM", 138, 167], ["host cell morphogens", "TREATMENT", 194, 214], ["distinct", "OBSERVATION_MODIFIER", 77, 85], ["functional domains", "OBSERVATION", 86, 104], ["abnormal cell differentiation", "OBSERVATION", 138, 167], ["host cell morphogens", "OBSERVATION", 194, 214]]], ["Cell polarity and invasion have been suggested to contribute to both early and late stages of cancer formation.", [["Cell", "ANATOMY", 0, 4], ["cancer", "ANATOMY", 94, 100], ["cancer", "DISEASE", 94, 100], ["Cell", "CELL", 0, 4], ["cancer", "CANCER", 94, 100], ["Cell polarity", "TEST", 0, 13], ["invasion", "PROBLEM", 18, 26], ["cancer formation", "PROBLEM", 94, 110], ["invasion", "OBSERVATION", 18, 26], ["late stages", "OBSERVATION_MODIFIER", 79, 90], ["cancer", "OBSERVATION", 94, 100]]], ["These results suggest a mechanism by which CagA may acts at the early stage of tumorigenic progression causing loss of cell polarity, increased cell motility and invasiveness of epithelial cells.P. Parola\u00b0(Marseille, FR)After a period of 50 years of silence, a disease with an unpronouncable name, \"chikungunya\" (CHIK), has recently become a medical reality and reached the public throughout the world.", [["cell", "ANATOMY", 119, 123], ["cell", "ANATOMY", 144, 148], ["epithelial cells", "ANATOMY", 178, 194], ["chikungunya", "DISEASE", 299, 310], ["CagA", "GENE_OR_GENE_PRODUCT", 43, 47], ["cell", "CELL", 119, 123], ["cell", "CELL", 144, 148], ["epithelial cells", "CELL", 178, 194], ["CagA", "PROTEIN", 43, 47], ["epithelial cells", "CELL_TYPE", 178, 194], ["tumorigenic progression", "PROBLEM", 79, 102], ["loss of cell polarity", "PROBLEM", 111, 132], ["increased cell motility", "PROBLEM", 134, 157], ["epithelial cells", "PROBLEM", 178, 194], ["a disease", "PROBLEM", 259, 268], ["chikungunya", "PROBLEM", 299, 310], ["tumorigenic", "OBSERVATION", 79, 90], ["cell polarity", "OBSERVATION", 119, 132], ["increased", "OBSERVATION_MODIFIER", 134, 143], ["cell motility", "OBSERVATION", 144, 157], ["invasiveness", "OBSERVATION_MODIFIER", 162, 174], ["epithelial cells", "OBSERVATION", 178, 194], ["disease", "OBSERVATION", 261, 268]]], ["Conclusion: Low mHLA-DR expression after septic shock independently predicts NI.", [["septic shock", "DISEASE", 41, 53], ["mHLA-DR", "GENE_OR_GENE_PRODUCT", 16, 23], ["mHLA", "PROTEIN", 16, 20], ["DR", "PROTEIN", 21, 23], ["septic shock", "PROBLEM", 41, 53], ["Low mHLA", "OBSERVATION_MODIFIER", 12, 20], ["septic shock", "OBSERVATION", 41, 53]]], ["This promising biomarker may be of major interest in identifying patients at increased NI risk who could benefit from targeted and tailored therapy aimed at restoring immune functions.T. van der Poll\u00b0(Amsterdam, NL)Pneumonia, the leading infectious cause of death in the US, kills more people annually than AIDS, tuberculosis, meningitis and endocarditis combined.", [["Pneumonia", "DISEASE", 215, 224], ["death", "DISEASE", 258, 263], ["AIDS", "DISEASE", 307, 311], ["tuberculosis", "DISEASE", 313, 325], ["meningitis", "DISEASE", 327, 337], ["endocarditis", "DISEASE", 342, 354], ["patients", "ORGANISM", 65, 73], ["people", "ORGANISM", 286, 292], ["patients", "SPECIES", 65, 73], ["people", "SPECIES", 286, 292], ["T. van der Poll\u00b0", "SPECIES", 184, 200], ["tailored therapy", "TREATMENT", 131, 147], ["Pneumonia", "PROBLEM", 215, 224], ["death", "PROBLEM", 258, 263], ["AIDS", "PROBLEM", 307, 311], ["tuberculosis", "PROBLEM", 313, 325], ["meningitis", "PROBLEM", 327, 337], ["endocarditis", "PROBLEM", 342, 354], ["Pneumonia", "OBSERVATION", 215, 224], ["infectious", "OBSERVATION_MODIFIER", 238, 248], ["tuberculosis", "OBSERVATION", 313, 325], ["meningitis", "OBSERVATION", 327, 337], ["endocarditis", "OBSERVATION", 342, 354]]], ["From a wide range of observational studies of communityacquired pneumonia (CAP), only half of the cases had an aetiologic agent identified.", [["pneumonia", "DISEASE", 64, 73], ["CAP", "DISEASE", 75, 78], ["observational studies", "TEST", 21, 42], ["communityacquired pneumonia", "PROBLEM", 46, 73], ["an aetiologic agent", "PROBLEM", 108, 127], ["wide", "OBSERVATION_MODIFIER", 7, 11], ["pneumonia", "OBSERVATION", 64, 73]]], ["Streptococcus pneumoniae was consistently the predominant bacterial aetiology.", [["Streptococcus pneumoniae", "ORGANISM", 0, 24], ["Streptococcus pneumoniae", "SPECIES", 0, 24], ["Streptococcus pneumoniae", "SPECIES", 0, 24], ["Streptococcus pneumoniae", "PROBLEM", 0, 24], ["pneumoniae", "OBSERVATION", 14, 24], ["predominant", "OBSERVATION_MODIFIER", 46, 57], ["bacterial aetiology", "OBSERVATION", 58, 77]]], ["This lecture will primarily focus on the innate immune response to pneumococcal pneumonia.", [["pneumonia", "DISEASE", 80, 89], ["pneumococcal", "SPECIES", 67, 79], ["pneumococcal pneumonia", "PROBLEM", 67, 89], ["pneumococcal", "OBSERVATION_MODIFIER", 67, 79], ["pneumonia", "OBSERVATION", 80, 89]]], ["Toll-like receptors (TLRs) are key molecules that recognize pathogen associated molecular patterns (PAMPs) and induce an inflammatory response.", [["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 0, 19], ["TLRs", "GENE_OR_GENE_PRODUCT", 21, 25], ["pathogen associated molecular patterns", "GENE_OR_GENE_PRODUCT", 60, 98], ["Toll-like receptors", "PROTEIN", 0, 19], ["TLRs", "PROTEIN", 21, 25], ["pathogen associated molecular patterns", "PROTEIN", 60, 98], ["PAMPs", "PROTEIN", 100, 105], ["key molecules", "PROBLEM", 31, 44], ["an inflammatory response", "PROBLEM", 118, 142], ["inflammatory", "OBSERVATION", 121, 133]]], ["Pneumolysin, an intracellular toxin found in all S. pneumoniae clinical isolates, is an important virulence factor of the pneumococcus that is recognized by TLR4.", [["intracellular", "ANATOMY", 16, 29], ["Pneumolysin", "CHEMICAL", 0, 11], ["Pneumolysin", "CHEMICAL", 0, 11], ["Pneumolysin", "GENE_OR_GENE_PRODUCT", 0, 11], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 16, 29], ["S. pneumoniae", "ORGANISM", 49, 62], ["pneumococcus", "ORGANISM", 122, 134], ["TLR4", "GENE_OR_GENE_PRODUCT", 157, 161], ["virulence factor", "PROTEIN", 98, 114], ["TLR4", "PROTEIN", 157, 161], ["S. pneumoniae", "SPECIES", 49, 62], ["S. pneumoniae", "SPECIES", 49, 62], ["Pneumolysin", "PROBLEM", 0, 11], ["an intracellular toxin", "TEST", 13, 35], ["all S. pneumoniae clinical isolates", "PROBLEM", 45, 80], ["the pneumococcus", "PROBLEM", 118, 134], ["pneumoniae", "OBSERVATION", 52, 62], ["pneumococcus", "OBSERVATION", 122, 134]]], ["Although TLR2 is considered the most important receptor for Gram-positive bacteria, TLR2 does not play a decisive role in host defence against S. pneumoniae pneumonia;T. van der Poll\u00b0(Amsterdam, NL)likely, pneumolysin-induced TLR4 signalling can compensate for TLR2 deficiency during respiratory tract infection with S. pneumoniae.", [["respiratory tract", "ANATOMY", 284, 301], ["pneumonia", "DISEASE", 157, 166], ["pneumolysin", "CHEMICAL", 206, 217], ["respiratory tract infection", "DISEASE", 284, 311], ["TLR2", "GENE_OR_GENE_PRODUCT", 9, 13], ["Gram", "GENE_OR_GENE_PRODUCT", 60, 64], ["TLR2", "GENE_OR_GENE_PRODUCT", 84, 88], ["S. pneumoniae", "ORGANISM", 143, 156], ["T. van der Poll\u00b0", "ORGANISM", 167, 183], ["pneumolysin", "GENE_OR_GENE_PRODUCT", 206, 217], ["TLR4", "GENE_OR_GENE_PRODUCT", 226, 230], ["TLR2", "GENE_OR_GENE_PRODUCT", 261, 265], ["tract", "ORGANISM_SUBDIVISION", 296, 301], ["S. pneumoniae", "ORGANISM", 317, 330], ["TLR2", "PROTEIN", 9, 13], ["TLR2", "PROTEIN", 84, 88], ["pneumolysin", "PROTEIN", 206, 217], ["TLR4", "PROTEIN", 226, 230], ["TLR2", "PROTEIN", 261, 265], ["S. pneumoniae", "SPECIES", 143, 156], ["S. pneumoniae", "SPECIES", 317, 330], ["S. pneumoniae", "SPECIES", 143, 156], ["T. van der Poll\u00b0", "SPECIES", 167, 183], ["S. pneumoniae", "SPECIES", 317, 330], ["Gram-positive bacteria", "PROBLEM", 60, 82], ["S. pneumoniae pneumonia", "PROBLEM", 143, 166], ["pneumolysin", "PROBLEM", 206, 217], ["TLR4 signalling", "PROBLEM", 226, 241], ["TLR2 deficiency", "PROBLEM", 261, 276], ["respiratory tract infection", "PROBLEM", 284, 311], ["S. pneumoniae", "PROBLEM", 317, 330], ["pneumoniae", "OBSERVATION", 146, 156], ["respiratory tract", "ANATOMY", 284, 301], ["pneumoniae", "OBSERVATION", 320, 330]]], ["Besides TLR2 and TLR4, TLR9 contributes to an effective host defence against S. pneumoniae in the airways.", [["airways", "ANATOMY", 98, 105], ["TLR2", "GENE_OR_GENE_PRODUCT", 8, 12], ["TLR4", "GENE_OR_GENE_PRODUCT", 17, 21], ["TLR9", "GENE_OR_GENE_PRODUCT", 23, 27], ["S. pneumoniae", "ORGANISM", 77, 90], ["airways", "MULTI-TISSUE_STRUCTURE", 98, 105], ["TLR2", "PROTEIN", 8, 12], ["TLR4", "PROTEIN", 17, 21], ["TLR9", "PROTEIN", 23, 27], ["S. pneumoniae", "SPECIES", 77, 90], ["S. pneumoniae", "SPECIES", 77, 90], ["TLR2 and TLR4", "TREATMENT", 8, 21], ["TLR9", "TREATMENT", 23, 27], ["S. pneumoniae in the airways", "PROBLEM", 77, 105], ["pneumoniae", "OBSERVATION", 80, 90], ["airways", "ANATOMY", 98, 105]]], ["The importance of TLR signaling for host defence against pneumococcal pneumonia is illustrated by the fact that mice lacking the common TLR adaptor protein MyD88 are highly susceptible to this infection.", [["pneumococcal pneumonia", "DISEASE", 57, 79], ["infection", "DISEASE", 193, 202], ["TLR", "GENE_OR_GENE_PRODUCT", 18, 21], ["mice", "ORGANISM", 112, 116], ["TLR", "GENE_OR_GENE_PRODUCT", 136, 139], ["MyD88", "GENE_OR_GENE_PRODUCT", 156, 161], ["TLR", "PROTEIN", 18, 21], ["TLR adaptor protein", "PROTEIN", 136, 155], ["MyD88", "PROTEIN", 156, 161], ["mice", "SPECIES", 112, 116], ["pneumococcal", "SPECIES", 57, 69], ["mice", "SPECIES", 112, 116], ["TLR signaling", "TREATMENT", 18, 31], ["host defence", "TREATMENT", 36, 48], ["pneumococcal pneumonia", "PROBLEM", 57, 79], ["the common TLR adaptor protein MyD88", "TREATMENT", 125, 161], ["this infection", "PROBLEM", 188, 202], ["pneumonia", "OBSERVATION", 70, 79], ["infection", "OBSERVATION", 193, 202]]], ["Activation of TLRs results in the production of proinflammatory cytokines.", [["TLRs", "GENE_OR_GENE_PRODUCT", 14, 18], ["TLRs", "PROTEIN", 14, 18], ["proinflammatory cytokines", "PROTEIN", 48, 73], ["proinflammatory cytokines", "TREATMENT", 48, 73], ["proinflammatory cytokines", "OBSERVATION", 48, 73]]], ["There is ample evidence that underlines the importance of tumour necrosis factor (TNF) and interleukin (IL)-1 in host defence in bacterial pneumonia: In a murine S. pneumoniae pneumonia model, treatment with a neutralising anti-TNF mAb strongly impaired antibacterial defence.", [["tumour", "DISEASE", 58, 64], ["necrosis", "DISEASE", 65, 73], ["pneumonia", "DISEASE", 139, 148], ["S. pneumoniae pneumonia", "DISEASE", 162, 185], ["tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 58, 80], ["TNF", "GENE_OR_GENE_PRODUCT", 82, 85], ["interleukin (IL)-1", "GENE_OR_GENE_PRODUCT", 91, 109], ["murine", "ORGANISM", 155, 161], ["S. pneumoniae", "ORGANISM", 162, 175], ["anti-TNF mAb", "GENE_OR_GENE_PRODUCT", 223, 235], ["tumour necrosis factor", "PROTEIN", 58, 80], ["TNF", "PROTEIN", 82, 85], ["interleukin (IL)-1", "PROTEIN", 91, 109], ["anti-TNF mAb", "PROTEIN", 223, 235], ["murine", "SPECIES", 155, 161], ["S. pneumoniae", "SPECIES", 162, 175], ["S. pneumoniae", "SPECIES", 162, 175], ["tumour necrosis factor", "PROBLEM", 58, 80], ["interleukin (IL)", "TREATMENT", 91, 107], ["bacterial pneumonia", "PROBLEM", 129, 148], ["a murine S. pneumoniae pneumonia model", "TREATMENT", 153, 191], ["treatment", "TREATMENT", 193, 202], ["a neutralising anti-TNF mAb", "TREATMENT", 208, 235], ["impaired antibacterial defence", "PROBLEM", 245, 275], ["tumour", "OBSERVATION_MODIFIER", 58, 64], ["necrosis", "OBSERVATION", 65, 73], ["bacterial", "OBSERVATION_MODIFIER", 129, 138], ["pneumonia", "OBSERVATION", 139, 148], ["pneumoniae", "OBSERVATION_MODIFIER", 165, 175], ["pneumonia", "OBSERVATION", 176, 185], ["antibacterial defence", "OBSERVATION", 254, 275]]], ["In addition, IL-1a receptor type I deficient mice infected with S. pneumoniae displayed an increased bacterial outgrowth.T. van der Poll\u00b0(Amsterdam, NL)Of considerable interest, treating IL-1 receptor deficient mice with a neutralising anti-TNF antibody made them extremely susceptible to pneumococcal pneumonia.", [["pneumonia", "DISEASE", 302, 311], ["IL-1a receptor type I", "GENE_OR_GENE_PRODUCT", 13, 34], ["mice", "ORGANISM", 45, 49], ["S. pneumoniae", "ORGANISM", 64, 77], ["IL-1 receptor", "GENE_OR_GENE_PRODUCT", 187, 200], ["mice", "ORGANISM", 211, 215], ["IL", "PROTEIN", 13, 15], ["IL-1 receptor", "PROTEIN", 187, 200], ["anti-TNF antibody", "PROTEIN", 236, 253], ["mice", "SPECIES", 45, 49], ["S. pneumoniae", "SPECIES", 64, 77], ["mice", "SPECIES", 211, 215], ["mice", "SPECIES", 45, 49], ["S. pneumoniae", "SPECIES", 64, 77], ["T. van der Poll\u00b0", "SPECIES", 121, 137], ["mice", "SPECIES", 211, 215], ["pneumococcal", "SPECIES", 289, 301], ["IL-1a receptor type I deficient", "TREATMENT", 13, 44], ["S. pneumoniae", "PROBLEM", 64, 77], ["an increased bacterial outgrowth", "PROBLEM", 88, 120], ["IL-1 receptor deficient mice", "TREATMENT", 187, 215], ["a neutralising anti-TNF antibody", "TREATMENT", 221, 253], ["pneumococcal pneumonia", "PROBLEM", 289, 311], ["pneumoniae", "OBSERVATION", 67, 77], ["increased", "OBSERVATION_MODIFIER", 91, 100], ["bacterial outgrowth", "OBSERVATION", 101, 120], ["pneumococcal", "OBSERVATION_MODIFIER", 289, 301], ["pneumonia", "OBSERVATION", 302, 311]]], ["Infection of the lower airways by S. pneumoniae is associated with complex interaction between the pathogen (e.g. cell wall components, pneumolysin) and the host (e.g. TLRs, cytokines).", [["lower airways", "ANATOMY", 17, 30], ["cell wall", "ANATOMY", 114, 123], ["Infection of the lower airways", "DISEASE", 0, 30], ["lower airways", "ORGAN", 17, 30], ["S. pneumoniae", "ORGANISM", 34, 47], ["pneumolysin", "GENE_OR_GENE_PRODUCT", 136, 147], ["TLRs", "GENE_OR_GENE_PRODUCT", 168, 172], ["pneumolysin", "PROTEIN", 136, 147], ["TLRs", "PROTEIN", 168, 172], ["cytokines", "PROTEIN", 174, 183], ["S. pneumoniae", "SPECIES", 34, 47], ["S. pneumoniae", "SPECIES", 34, 47], ["Infection of the lower airways", "PROBLEM", 0, 30], ["S. pneumoniae", "PROBLEM", 34, 47], ["the pathogen (e.g. cell wall components", "PROBLEM", 95, 134], ["pneumolysin", "PROBLEM", 136, 147], ["lower", "ANATOMY_MODIFIER", 17, 22], ["airways", "ANATOMY", 23, 30], ["pneumoniae", "OBSERVATION", 37, 47]]], ["These interactions play a crucial role in the outcome of this clinically important infection.S. Opal\u00b0(Pawtucket, US)Severe bacterial pneumonia remains uncommon unless specific conditions exist that tip the balance between the host and pathogen in favour of the microorganism.", [["infection", "DISEASE", 83, 92], ["bacterial pneumonia", "DISEASE", 123, 142], ["this clinically important infection", "PROBLEM", 57, 92], ["Severe bacterial pneumonia", "PROBLEM", 116, 142], ["specific conditions", "PROBLEM", 167, 186], ["pathogen", "PROBLEM", 235, 243], ["the microorganism", "PROBLEM", 257, 274], ["infection", "OBSERVATION", 83, 92], ["Severe", "OBSERVATION_MODIFIER", 116, 122], ["bacterial", "OBSERVATION_MODIFIER", 123, 132], ["pneumonia", "OBSERVATION", 133, 142]]], ["Such conditions include: persons at the extremes of age; exposure to especially virulent organisms; patients with concomitant illness impairing pulmonary clearance mechanisms; and immunocompromised hosts.", [["pulmonary", "ANATOMY", 144, 153], ["persons", "ORGANISM", 25, 32], ["patients", "ORGANISM", 100, 108], ["pulmonary", "ORGAN", 144, 153], ["persons", "SPECIES", 25, 32], ["patients", "SPECIES", 100, 108], ["virulent organisms", "PROBLEM", 80, 98], ["concomitant illness impairing pulmonary clearance mechanisms", "PROBLEM", 114, 174], ["immunocompromised hosts", "PROBLEM", 180, 203], ["pulmonary", "ANATOMY", 144, 153], ["clearance", "OBSERVATION", 154, 163], ["immunocompromised hosts", "OBSERVATION", 180, 203]]], ["The known virulence traits of three common respiratory pathogens (Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa) will be briefly reviewed.", [["respiratory pathogens", "DISEASE", 43, 64], ["Streptococcus pneumoniae", "DISEASE", 66, 90], ["Staphylococcus aureus", "DISEASE", 92, 113], ["Streptococcus pneumoniae", "ORGANISM", 66, 90], ["Staphylococcus aureus", "ORGANISM", 92, 113], ["Pseudomonas aeruginosa", "ORGANISM", 119, 141], ["Streptococcus pneumoniae", "SPECIES", 66, 90], ["Staphylococcus aureus", "SPECIES", 92, 113], ["Pseudomonas aeruginosa", "SPECIES", 119, 141], ["Streptococcus pneumoniae", "SPECIES", 66, 90], ["Staphylococcus aureus", "SPECIES", 92, 113], ["Pseudomonas aeruginosa", "SPECIES", 119, 141], ["three common respiratory pathogens", "PROBLEM", 30, 64], ["Streptococcus pneumoniae", "PROBLEM", 66, 90], ["Staphylococcus aureus", "PROBLEM", 92, 113], ["Pseudomonas aeruginosa", "PROBLEM", 119, 141], ["virulence", "OBSERVATION_MODIFIER", 10, 19], ["three", "OBSERVATION_MODIFIER", 30, 35], ["common", "OBSERVATION_MODIFIER", 36, 42], ["respiratory pathogens", "OBSERVATION", 43, 64], ["Streptococcus pneumoniae", "OBSERVATION", 66, 90]]], ["The capsular polysaccharide of pneumococci is the major anti-phagocytic virulence trait but many other factors contribute to disease pathogenesis including the critically important exotoxin known as pneumolysin, bacteriocins, adherence factors, choline binding proteins, lipoteichoic acid, iron, manganese and magnesium transporters, pili, competence and biofilm capacity, and virulence genes that promote invasion and impair clearance once the organism has entered the blood stream.", [["biofilm", "ANATOMY", 355, 362], ["blood stream", "ANATOMY", 470, 482], ["choline", "CHEMICAL", 245, 252], ["lipoteichoic acid", "CHEMICAL", 271, 288], ["iron", "CHEMICAL", 290, 294], ["manganese", "CHEMICAL", 296, 305], ["magnesium", "CHEMICAL", 310, 319], ["choline", "CHEMICAL", 245, 252], ["lipoteichoic acid", "CHEMICAL", 271, 288], ["iron", "CHEMICAL", 290, 294], ["manganese", "CHEMICAL", 296, 305], ["magnesium", "CHEMICAL", 310, 319], ["exotoxin", "GENE_OR_GENE_PRODUCT", 181, 189], ["pneumolysin", "GENE_OR_GENE_PRODUCT", 199, 210], ["choline binding proteins", "GENE_OR_GENE_PRODUCT", 245, 269], ["lipoteichoic acid", "SIMPLE_CHEMICAL", 271, 288], ["iron", "SIMPLE_CHEMICAL", 290, 294], ["manganese", "SIMPLE_CHEMICAL", 296, 305], ["magnesium transporters", "SIMPLE_CHEMICAL", 310, 332], ["pili", "GENE_OR_GENE_PRODUCT", 334, 338], ["blood", "ORGANISM_SUBSTANCE", 470, 475], ["pneumolysin", "PROTEIN", 199, 210], ["adherence factors", "PROTEIN", 226, 243], ["choline binding proteins", "PROTEIN", 245, 269], ["virulence genes", "DNA", 377, 392], ["pneumococci", "PROBLEM", 31, 42], ["the major anti-phagocytic virulence trait", "PROBLEM", 46, 87], ["disease pathogenesis", "PROBLEM", 125, 145], ["pneumolysin", "PROBLEM", 199, 210], ["bacteriocins", "TREATMENT", 212, 224], ["adherence factors", "PROBLEM", 226, 243], ["choline binding proteins", "TREATMENT", 245, 269], ["lipoteichoic acid", "TREATMENT", 271, 288], ["iron", "TREATMENT", 290, 294], ["manganese", "TREATMENT", 296, 305], ["magnesium transporters", "TREATMENT", 310, 332], ["biofilm capacity", "PROBLEM", 355, 371], ["virulence genes", "PROBLEM", 377, 392], ["the blood stream", "TEST", 466, 482], ["capsular", "OBSERVATION_MODIFIER", 4, 12], ["polysaccharide", "OBSERVATION_MODIFIER", 13, 27], ["pneumococci", "OBSERVATION", 31, 42], ["invasion", "OBSERVATION", 406, 414]]], ["S. aureus is notorious for the numerous A/B type toxins, cytotoxins, and superantigens it generates during the course of invasion.", [["S. aureus", "ORGANISM", 0, 9], ["A/B type toxins", "ORGANISM", 40, 55], ["cytotoxins", "PROTEIN", 57, 67], ["superantigens", "PROTEIN", 73, 86], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "PROBLEM", 0, 9], ["the numerous A/B type toxins", "PROBLEM", 27, 55], ["cytotoxins", "PROBLEM", 57, 67], ["superantigens", "PROBLEM", 73, 86], ["invasion", "PROBLEM", 121, 129], ["aureus", "OBSERVATION", 3, 9], ["notorious", "OBSERVATION_MODIFIER", 13, 22], ["invasion", "OBSERVATION", 121, 129]]], ["Staphylococci deploy a complex series of quorum sensing signals that coordinate adhesin and invasion genes within biofilms or between planktonic organisms and likely contribute to the success of this pathogen.", [["biofilms", "ANATOMY", 114, 122], ["adhesin", "GENE_OR_GENE_PRODUCT", 80, 87], ["adhesin and invasion genes", "DNA", 80, 106], ["Staphylococci", "PROBLEM", 0, 13], ["quorum sensing signals", "PROBLEM", 41, 63], ["invasion genes within biofilms", "PROBLEM", 92, 122], ["planktonic organisms", "PROBLEM", 134, 154], ["this pathogen", "PROBLEM", 195, 208], ["complex", "OBSERVATION_MODIFIER", 23, 30], ["invasion genes", "OBSERVATION", 92, 106]]], ["P. aeruginosa produces an array of extracellular exotoxins and cytotoxins delivered by type III secretion systems.", [["extracellular", "ANATOMY", 35, 48], ["P. aeruginosa", "ORGANISM", 0, 13], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 48], ["type III secretion systems", "GENE_OR_GENE_PRODUCT", 87, 113], ["extracellular exotoxins", "PROTEIN", 35, 58], ["cytotoxins", "PROTEIN", 63, 73], ["P. aeruginosa", "SPECIES", 0, 13], ["P. aeruginosa", "SPECIES", 0, 13], ["P. aeruginosa", "PROBLEM", 0, 13], ["extracellular exotoxins", "TREATMENT", 35, 58], ["cytotoxins", "TREATMENT", 63, 73]]], ["These include elastase, phospholipases C, a series of apoptotic and anti-phagocytic exotoxins, along with an alginate capsule and an unusual and variable LPS structure that participate in microbial invasion.", [["elastase", "GENE_OR_GENE_PRODUCT", 14, 22], ["phospholipases C", "GENE_OR_GENE_PRODUCT", 24, 40], ["capsule", "CANCER", 118, 125], ["LPS", "SIMPLE_CHEMICAL", 154, 157], ["elastase", "PROTEIN", 14, 22], ["phospholipases C", "PROTEIN", 24, 40], ["apoptotic and anti-phagocytic exotoxins", "PROTEIN", 54, 93], ["elastase, phospholipases C", "TEST", 14, 40], ["apoptotic", "TREATMENT", 54, 63], ["anti-phagocytic exotoxins", "PROBLEM", 68, 93], ["an alginate capsule", "TREATMENT", 106, 125], ["an unusual and variable LPS structure", "PROBLEM", 130, 167], ["microbial invasion", "PROBLEM", 188, 206], ["elastase", "OBSERVATION", 14, 22], ["variable LPS", "OBSERVATION_MODIFIER", 145, 157], ["microbial invasion", "OBSERVATION", 188, 206]]], ["The pathogen expresses at least three interacting, quorum sensing systems to coordinate virulence and biofilm formation.", [["biofilm", "ANATOMY", 102, 109]]], ["A detailed understanding of these virulence factors is now providing therapeutic options to control these respiratory pathogens.", [["respiratory", "ANATOMY", 106, 117], ["respiratory pathogens", "DISEASE", 106, 127], ["virulence factors", "PROTEIN", 34, 51], ["these virulence factors", "PROBLEM", 28, 51], ["therapeutic options", "TREATMENT", 69, 88], ["these respiratory pathogens", "PROBLEM", 100, 127], ["respiratory", "ANATOMY", 106, 117], ["pathogens", "OBSERVATION", 118, 127]]], ["Surface expressed and extracellular toxins of pneumococci have been selected as new vaccine targets.", [["extracellular", "ANATOMY", 22, 35], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 35], ["pneumococci", "CANCER", 46, 57], ["extracellular toxins", "TEST", 22, 42], ["pneumococci", "PROBLEM", 46, 57], ["new vaccine targets", "TREATMENT", 80, 99], ["pneumococci", "OBSERVATION", 46, 57]]], ["Inhibitory peptides and small molecule inhibitors of quorum sensing and biofilm formation are under investigation for staphylococcal and P. aeruginosa infections.", [["biofilm", "ANATOMY", 72, 79], ["staphylococcal and P. aeruginosa infections", "DISEASE", 118, 161], ["P. aeruginosa", "ORGANISM", 137, 150], ["P. aeruginosa", "SPECIES", 137, 150], ["P. aeruginosa", "SPECIES", 137, 150], ["Inhibitory peptides", "TREATMENT", 0, 19], ["small molecule inhibitors", "TREATMENT", 24, 49], ["quorum sensing", "TREATMENT", 53, 67], ["biofilm formation", "TREATMENT", 72, 89], ["staphylococcal", "PROBLEM", 118, 132], ["P. aeruginosa infections", "PROBLEM", 137, 161], ["small", "OBSERVATION_MODIFIER", 24, 29], ["molecule inhibitors", "OBSERVATION", 30, 49]]], ["These innovative and non-antibiotic treatment strategies are gaining greater importance as progressive antibiotic resistance threatens the management of these severe bacterial infections in the future.G. Pappas\u00b0(Ioannina, GR)Brucellosis, possibly the commonest zoonotic infection worldwide, has troubled humans since antiquity.", [["bacterial infections", "DISEASE", 166, 186], ["Brucellosis", "DISEASE", 225, 236], ["zoonotic infection", "DISEASE", 261, 279], ["humans", "ORGANISM", 304, 310], ["humans", "SPECIES", 304, 310], ["humans", "SPECIES", 304, 310], ["These innovative", "TREATMENT", 0, 16], ["non-antibiotic treatment strategies", "TREATMENT", 21, 56], ["progressive antibiotic resistance", "TREATMENT", 91, 124], ["the management", "TREATMENT", 135, 149], ["these severe bacterial infections", "PROBLEM", 153, 186], ["Brucellosis", "PROBLEM", 225, 236], ["the commonest zoonotic infection", "PROBLEM", 247, 279], ["antibiotic resistance", "OBSERVATION", 103, 124], ["severe", "OBSERVATION_MODIFIER", 159, 165], ["bacterial", "OBSERVATION_MODIFIER", 166, 175], ["infections", "OBSERVATION", 176, 186], ["Brucellosis", "OBSERVATION", 225, 236], ["infection", "OBSERVATION", 270, 279]]], ["Recent years have seen the expansion of the animal reservoir of the disease to a wide spectrum of wildlife species, extending to marine mammals, and the recognition of novel Brucella species.", [["Brucella species", "ORGANISM", 174, 190], ["the disease", "PROBLEM", 64, 75], ["wildlife species", "PROBLEM", 98, 114], ["novel Brucella species", "PROBLEM", 168, 190], ["expansion", "OBSERVATION_MODIFIER", 27, 36], ["animal", "OBSERVATION_MODIFIER", 44, 50], ["reservoir", "OBSERVATION_MODIFIER", 51, 60], ["disease", "OBSERVATION", 68, 75], ["wide", "OBSERVATION_MODIFIER", 81, 85], ["wildlife species", "OBSERVATION", 98, 114], ["Brucella species", "OBSERVATION", 174, 190]]], ["Furthermore, animal and human disease has re-emerged in numerous countries which were brucellosis-free, and currently the most important endemic foci include Near East and Central Asia.", [["animal and human disease", "DISEASE", 13, 37], ["brucellosis", "DISEASE", 86, 97], ["human", "ORGANISM", 24, 29], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29], ["animal and human disease", "PROBLEM", 13, 37], ["brucellosis", "PROBLEM", 86, 97], ["human disease", "OBSERVATION", 24, 37], ["endemic", "OBSERVATION_MODIFIER", 137, 144], ["foci", "OBSERVATION", 145, 149]]], ["Complex socioeconomic and political factors may be incriminated for these alterations in endemicity.", [["Complex socioeconomic and political factors", "PROBLEM", 0, 43], ["these alterations in endemicity", "PROBLEM", 68, 99]]], ["The complex mechanisms by which Brucella evades immune response and survives intracellularly are progressively clarified.", [["The complex mechanisms", "PROBLEM", 0, 22], ["Brucella", "PROBLEM", 32, 40]]], ["Novel diagnostic techniques as real time PCR may shed light in the life cycle of Brucella inside the human host; preliminary studies have indicated that the pathogen may persist in latent form for years after apparent clinical cure, in asymptomatic individuals.", [["Brucella", "ORGANISM", 81, 89], ["human", "ORGANISM", 101, 106], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["Novel diagnostic techniques", "TEST", 0, 27], ["real time PCR", "TEST", 31, 44], ["preliminary studies", "TEST", 113, 132], ["the pathogen", "PROBLEM", 153, 165]]], ["Treatment principles have not evolved significantly.", [["Treatment principles", "TREATMENT", 0, 20]]], ["The expert guidelines issued recently under the name of \"Ioannina Recommendations\" support the need for a six-week combined treatment that includes traditional antibacterials and is modified accordingly in serious complications as spondylitis and central nervous system involvement.", [["central nervous system", "ANATOMY", 247, 269], ["spondylitis", "DISEASE", 231, 242], ["central nervous system", "ANATOMICAL_SYSTEM", 247, 269], ["a six-week combined treatment", "TREATMENT", 104, 133], ["traditional antibacterials", "TREATMENT", 148, 174], ["serious complications", "PROBLEM", 206, 227], ["spondylitis", "PROBLEM", 231, 242], ["central nervous system involvement", "PROBLEM", 247, 281], ["spondylitis", "OBSERVATION", 231, 242], ["central", "ANATOMY_MODIFIER", 247, 254], ["nervous system", "ANATOMY", 255, 269]]], ["The road to the development of a vaccine for humans seems long though.M. Doganay\u00b0(Kayseri, TR)Anthrax is ancient diseases and relatively a forgotten disease in western world until 2001 when spores were mailed in USA causing five deaths.", [["Anthrax", "DISEASE", 94, 101], ["deaths", "DISEASE", 229, 235], ["humans", "ORGANISM", 45, 51], ["humans", "SPECIES", 45, 51], ["humans", "SPECIES", 45, 51], ["a vaccine", "TREATMENT", 31, 40], ["ancient diseases", "PROBLEM", 105, 121], ["diseases", "OBSERVATION", 113, 121]]], ["Currently, human anthrax is seen most commonly in agricultural regions of the world where anthrax in animals is prevalent, in which countries of Middle East, in Africa, Central Asia and South America.", [["anthrax", "DISEASE", 17, 24], ["anthrax", "DISEASE", 90, 97], ["human", "ORGANISM", 11, 16], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["Middle", "ANATOMY_MODIFIER", 145, 151]]], ["It is also an endemic disease in Turkey.", [["an endemic disease", "PROBLEM", 11, 29], ["endemic", "OBSERVATION_MODIFIER", 14, 21], ["disease", "OBSERVATION", 22, 29]]], ["Human cases may occur in an agricultural or an industrial environment.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5]]], ["The infection is an occupational hazard of workers who process hides, hair, bone and bone products, and wool and of veterinarians and agricultural workers who handle infected animals.", [["hair", "ANATOMY", 70, 74], ["bone", "ANATOMY", 76, 80], ["bone", "ANATOMY", 85, 89], ["infection", "DISEASE", 4, 13], ["hair", "TISSUE", 70, 74], ["bone", "TISSUE", 76, 80], ["bone", "TISSUE", 85, 89], ["The infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13], ["bone", "ANATOMY", 76, 80], ["bone", "ANATOMY", 85, 89]]], ["The main route of transmission is contact with or ingestion of contaminated meal with or inhalation of Bacillus anthracis spores.P.A. Tambyah\u00b0(Singapore, SG)Leptospirosis is a very old disease that has been known for more than a hundred years and possibly even longer since the time of Hippocrates.", [["Leptospirosis", "DISEASE", 157, 170], ["Bacillus anthracis spores", "ORGANISM", 103, 128], ["Bacillus anthracis", "SPECIES", 103, 121], ["Bacillus anthracis", "SPECIES", 103, 121], ["Bacillus anthracis spores", "PROBLEM", 103, 128], ["Leptospirosis", "PROBLEM", 157, 170], ["a very old disease", "PROBLEM", 174, 192], ["main", "OBSERVATION_MODIFIER", 4, 8], ["Bacillus anthracis", "OBSERVATION", 103, 121], ["disease", "OBSERVATION", 185, 192]]], ["It remains a major cause of illness in many tropical and subtropical countries and thus in travellers.", [["illness", "PROBLEM", 28, 35], ["illness", "OBSERVATION", 28, 35]]], ["It has also been identified as a zoonosis in Europe and North America.", [["zoonosis", "DISEASE", 33, 41], ["zoonosis", "OBSERVATION", 33, 41]]], ["It is a disease that can surprise us because the clinical presentations are not always typical.", [["a disease", "PROBLEM", 6, 15], ["disease", "OBSERVATION", 8, 15]]], ["In recent years, pulmonary and other atypical presentations have been more widely recognised.", [["pulmonary", "ANATOMY", 17, 26], ["pulmonary", "ORGAN", 17, 26], ["pulmonary and other atypical presentations", "PROBLEM", 17, 59], ["pulmonary", "ANATOMY", 17, 26], ["atypical", "OBSERVATION_MODIFIER", 37, 45], ["more widely", "OBSERVATION_MODIFIER", 70, 81]]], ["There is no effective vaccine but chemoprophylaxis is effective in selected populations.", [["effective vaccine", "TREATMENT", 12, 29], ["chemoprophylaxis", "TREATMENT", 34, 50], ["no", "UNCERTAINTY", 9, 11], ["effective", "OBSERVATION_MODIFIER", 12, 21], ["vaccine", "OBSERVATION", 22, 29]]], ["Prompt recognition and early institution of appropriate treatment as with most other infectious diseases appear to be critical in ensuring a good outcome for our patients.", [["infectious diseases", "DISEASE", 85, 104], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["appropriate treatment", "TREATMENT", 44, 65]]], ["There are interesting new developments in diagnostics and molecular epidemiology but clearly there are many challenges remaining in this field.", [["new", "OBSERVATION_MODIFIER", 22, 25], ["many", "OBSERVATION_MODIFIER", 103, 107], ["challenges", "OBSERVATION", 108, 118]]], ["Objectives: The spread of carbapenemase genes within Gram negative bacteria is of great cause for concern.", [["carbapenemase", "GENE_OR_GENE_PRODUCT", 26, 39], ["Gram", "GENE_OR_GENE_PRODUCT", 53, 57], ["carbapenemase genes", "DNA", 26, 45], ["carbapenemase genes", "PROBLEM", 26, 45], ["Gram negative bacteria", "PROBLEM", 53, 75]]], ["In 2008, the first report of a blaOXA-58 gene outwith Acinetobacter baumannii was reported in Acinetobacter genospecies 3.", [["blaOXA-58", "GENE_OR_GENE_PRODUCT", 31, 40], ["Acinetobacter baumannii", "ORGANISM", 54, 77], ["blaOXA-58 gene", "DNA", 31, 45], ["Acinetobacter baumannii", "SPECIES", 54, 77], ["Acinetobacter baumannii", "SPECIES", 54, 77], ["a blaOXA", "TEST", 29, 37], ["Acinetobacter baumannii", "PROBLEM", 54, 77], ["Acinetobacter genospecies", "PROBLEM", 94, 119]]], ["We had also identified a genospecies 3 isolate encoding a blaOXA-58-like gene, and the aim of this study was to examine the genetic environment of the gene to investigate the mobilisation between species.", [["blaOXA-58", "GENE_OR_GENE_PRODUCT", 58, 67], ["blaOXA-58-like gene", "DNA", 58, 77], ["a genospecies", "PROBLEM", 23, 36], ["this study", "TEST", 94, 104]]], ["Methods: Restriction analysis of rRNA was used to confirm identity to the species level.", [["rRNA", "CELLULAR_COMPONENT", 33, 37]]], ["Susceptibility to imipenem and meropenem was determined through the plate doubling dilution method.", [["imipenem", "CHEMICAL", 18, 26], ["meropenem", "CHEMICAL", 31, 40], ["imipenem", "CHEMICAL", 18, 26], ["meropenem", "CHEMICAL", 31, 40], ["imipenem", "SIMPLE_CHEMICAL", 18, 26], ["meropenem", "SIMPLE_CHEMICAL", 31, 40], ["imipenem", "TREATMENT", 18, 26], ["meropenem", "TREATMENT", 31, 40], ["the plate doubling dilution method", "TREATMENT", 64, 98]]], ["Screening by PCR for blaOXA-51-like, blaOXA-23-like, blaOXA-40-like and blaOXA-58-like genes was carried out.", [["blaOXA-51", "GENE_OR_GENE_PRODUCT", 21, 30], ["blaOXA-23", "GENE_OR_GENE_PRODUCT", 37, 46], ["blaOXA-40", "GENE_OR_GENE_PRODUCT", 53, 62], ["blaOXA-58", "GENE_OR_GENE_PRODUCT", 72, 81], ["blaOXA-51-like, blaOXA-23-like, blaOXA-40-like and blaOXA-58-like genes", "DNA", 21, 92], ["Screening", "TEST", 0, 9], ["PCR", "TEST", 13, 16], ["blaOXA", "TEST", 21, 27], ["blaOXA", "TEST", 37, 43], ["blaOXA", "TEST", 53, 59], ["blaOXA", "TEST", 72, 78]]], ["Analysis of the genetic environment surrounding the blaOXA-58-like gene was conducted by sequencing inverse PCR products and gene-walking fragments.", [["blaOXA-58", "GENE_OR_GENE_PRODUCT", 52, 61], ["blaOXA-58-like gene", "DNA", 52, 71], ["gene-walking fragments", "DNA", 125, 147], ["the blaOXA", "TEST", 48, 58], ["sequencing inverse PCR products", "TREATMENT", 89, 120], ["gene-walking fragments", "PROBLEM", 125, 147], ["walking fragments", "OBSERVATION", 130, 147]]], ["The structure of the surrounding sequence was confirmed using internal primers, which were also used to screen other blaOXA-58-like positive isolates in our collection.", [["blaOXA-58", "GENE_OR_GENE_PRODUCT", 117, 126], ["internal primers", "TREATMENT", 62, 78], ["blaOXA", "TEST", 117, 123], ["positive isolates in our collection", "PROBLEM", 132, 167]]], ["Results: Restriction analysis confirmed the isolate belonged to Acinetobacter genospecies 3.", [["Restriction analysis", "TEST", 9, 29], ["Acinetobacter genospecies", "PROBLEM", 64, 89]]], ["The isolate showed reduced susceptibility to imipenem and meropenem with MICs of 2 mg/L for both antibiotics.", [["imipenem", "CHEMICAL", 45, 53], ["meropenem", "CHEMICAL", 58, 67], ["MICs", "CHEMICAL", 73, 77], ["imipenem", "CHEMICAL", 45, 53], ["meropenem", "CHEMICAL", 58, 67], ["imipenem", "SIMPLE_CHEMICAL", 45, 53], ["meropenem", "SIMPLE_CHEMICAL", 58, 67], ["reduced susceptibility", "PROBLEM", 19, 41], ["imipenem", "TREATMENT", 45, 53], ["meropenem", "TREATMENT", 58, 67], ["MICs", "TREATMENT", 73, 77], ["both antibiotics", "TREATMENT", 92, 108], ["reduced susceptibility", "OBSERVATION", 19, 41]]], ["The isolate was negative for a blaOXA-51-like, blaOXA-23-like or blaOXA-40-like gene, but positive for a blaOXA-58-like gene.", [["blaOXA-51", "GENE_OR_GENE_PRODUCT", 31, 40], ["blaOXA-23", "GENE_OR_GENE_PRODUCT", 47, 56], ["blaOXA-40", "GENE_OR_GENE_PRODUCT", 65, 74], ["blaOXA-58", "GENE_OR_GENE_PRODUCT", 105, 114], ["blaOXA-51-like, blaOXA-23-like or blaOXA-40-like gene", "DNA", 31, 84], ["blaOXA-58-like gene", "DNA", 105, 124], ["The isolate", "TEST", 0, 11], ["a blaOXA", "TEST", 29, 37], ["blaOXA", "TEST", 47, 53], ["blaOXA", "TEST", 65, 71], ["a blaOXA", "TEST", 103, 111]]], ["Analysis of the genetic environment of the blaOXA-58-like gene revealed the gene was within a novel genetic structure.", [["blaOXA-58", "GENE_OR_GENE_PRODUCT", 43, 52], ["blaOXA-58-like gene", "DNA", 43, 62], ["the blaOXA", "TEST", 39, 49]]], ["Upstream of the blaOXA-58-like gene was the left-hand end of an ISAba3 element, interrupted by an ISAba125 element.", [["left-hand", "ANATOMY", 44, 53], ["blaOXA-58", "GENE_OR_GENE_PRODUCT", 16, 25], ["ISAba3", "GENE_OR_GENE_PRODUCT", 64, 70], ["blaOXA-58-like gene", "DNA", 16, 35], ["left-hand end", "DNA", 44, 57], ["ISAba3 element", "DNA", 64, 78], ["ISAba125 element", "DNA", 98, 114], ["the blaOXA", "TEST", 12, 22], ["an ISAba3 element", "PROBLEM", 61, 78], ["left", "ANATOMY_MODIFIER", 44, 48], ["hand", "ANATOMY", 49, 53], ["ISAba3 element", "OBSERVATION", 64, 78]]], ["The elements contained putative promoter sequences.", [["putative promoter sequences", "DNA", 23, 50]]], ["Downstream was an araC1 and a lysE gene, followed by a sequence similar to the Re27 element described previously.", [["araC1", "GENE_OR_GENE_PRODUCT", 18, 23], ["lysE", "GENE_OR_GENE_PRODUCT", 30, 34], ["araC1", "DNA", 18, 23], ["lysE gene", "DNA", 30, 39], ["Re27 element", "DNA", 79, 91], ["a sequence", "TEST", 53, 63]]], ["Following this was a complex region containing the right-hand end of an ISAba3 tnpA gene, interrupted by an incomplete tnpA gene with 99% similarity to ISAba3, itself interrupted by an ISAba125 sequence.", [["right-hand", "ANATOMY", 51, 61], ["ISAba3", "GENE_OR_GENE_PRODUCT", 72, 78], ["tnpA", "GENE_OR_GENE_PRODUCT", 79, 83], ["tnpA", "GENE_OR_GENE_PRODUCT", 119, 123], ["ISAba3", "GENE_OR_GENE_PRODUCT", 152, 158], ["right-hand end", "DNA", 51, 65], ["ISAba3 tnpA gene", "DNA", 72, 88], ["tnpA gene", "DNA", 119, 128], ["ISAba3", "DNA", 152, 158], ["ISAba125 sequence", "DNA", 185, 202], ["a complex region", "PROBLEM", 19, 35], ["an ISAba3 tnpA gene", "TREATMENT", 69, 88], ["an ISAba125 sequence", "TEST", 182, 202], ["right", "ANATOMY_MODIFIER", 51, 56], ["hand end", "ANATOMY_MODIFIER", 57, 65]]], ["This region was followed by a second blaOXA-58-like gene.", [["blaOXA-58", "GENE_OR_GENE_PRODUCT", 37, 46], ["blaOXA-58-like gene", "DNA", 37, 56], ["a second blaOXA", "TEST", 28, 43]]], ["All other blaOXA-58-like positive isolates in our collection were negative for ISAba125 upstream of blaOXA-58.Conclusion:This study is the first to report multiple copies of a blaOXA-58-like gene in an Acinetobacter genospecies 3 isolate, and has identified a novel structure containing two blaOXA-58-like genes and two ISAba125 sequences.", [["blaOXA-58", "GENE_OR_GENE_PRODUCT", 10, 19], ["blaOXA-58", "GENE_OR_GENE_PRODUCT", 100, 109], ["blaOXA-58", "GENE_OR_GENE_PRODUCT", 176, 185], ["blaOXA-58", "GENE_OR_GENE_PRODUCT", 291, 300], ["ISAba125 upstream", "DNA", 79, 96], ["blaOXA-58", "DNA", 100, 109], ["blaOXA-58-like gene", "DNA", 176, 195], ["blaOXA-58-like genes", "DNA", 291, 311], ["ISAba125 sequences", "DNA", 320, 338], ["All other blaOXA", "TEST", 0, 16], ["positive isolates", "PROBLEM", 25, 42], ["our collection", "TEST", 46, 60], ["ISAba", "TEST", 79, 84], ["blaOXA", "TEST", 100, 106], ["This study", "TEST", 121, 131], ["a blaOXA", "TEST", 174, 182], ["an Acinetobacter genospecies", "PROBLEM", 199, 227], ["blaOXA", "TEST", 291, 297]]], ["The ISAba125 elements may be responsible for the duplication of the blaOXA-58-like gene.", [["ISAba125", "GENE_OR_GENE_PRODUCT", 4, 12], ["blaOXA-58", "GENE_OR_GENE_PRODUCT", 68, 77], ["ISAba125 elements", "DNA", 4, 21], ["blaOXA-58-like gene", "DNA", 68, 87], ["the blaOXA", "TEST", 64, 74], ["may be responsible for", "UNCERTAINTY", 22, 44]]], ["Objective: Acinetobacter baumannii is an important nosocomial pathogen with wide intrinsic resistance.", [["Acinetobacter baumannii", "ORGANISM", 11, 34], ["Acinetobacter baumannii", "SPECIES", 11, 34], ["Acinetobacter baumannii", "SPECIES", 11, 34], ["Acinetobacter baumannii", "PROBLEM", 11, 34], ["an important nosocomial pathogen", "PROBLEM", 38, 70], ["Acinetobacter baumannii", "OBSERVATION", 11, 34], ["nosocomial pathogen", "OBSERVATION", 51, 70], ["intrinsic resistance", "OBSERVATION", 81, 101]]], ["However, due to the dissemination of the acquired resistance mechanisms; such as extended-spectrum beta-lactamase (ESBL) and metallo betalactamase (MBL) production, multidrug resistant strains have been isolated more often.", [["metallo betalactamase", "CHEMICAL", 125, 146], ["extended-spectrum beta-lactamase", "GENE_OR_GENE_PRODUCT", 81, 113], ["ESBL", "GENE_OR_GENE_PRODUCT", 115, 119], ["metallo betalactamase", "SIMPLE_CHEMICAL", 125, 146], ["MBL", "GENE_OR_GENE_PRODUCT", 148, 151], ["extended-spectrum beta-lactamase", "PROTEIN", 81, 113], ["ESBL", "PROTEIN", 115, 119], ["metallo betalactamase", "PROTEIN", 125, 146], ["MBL", "PROTEIN", 148, 151], ["the acquired resistance mechanisms", "PROBLEM", 37, 71], ["extended-spectrum beta-lactamase", "TEST", 81, 113], ["ESBL", "PROBLEM", 115, 119], ["metallo betalactamase (MBL) production", "PROBLEM", 125, 163], ["multidrug resistant strains", "PROBLEM", 165, 192]]], ["PER-1 was first detected in Turkey and was found to be widespread among Acinetobacter spp. and P. aeruginosa.", [["PER-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["Acinetobacter spp.", "ORGANISM", 72, 90], ["P. aeruginosa", "ORGANISM", 95, 108], ["Acinetobacter spp.", "SPECIES", 72, 90], ["P. aeruginosa", "SPECIES", 95, 108], ["Acinetobacter spp.", "SPECIES", 72, 90], ["P. aeruginosa", "SPECIES", 95, 108], ["Acinetobacter spp.", "PROBLEM", 72, 90], ["P. aeruginosa", "PROBLEM", 95, 108], ["Acinetobacter", "OBSERVATION", 72, 85], ["aeruginosa", "OBSERVATION", 98, 108]]], ["Since then, PER-1 has been discovered in other countries, and most recently found in northern Italy and in Korea.", [["PER-1", "GENE_OR_GENE_PRODUCT", 12, 17], ["PER", "PROTEIN", 12, 15]]], ["In this study, the presence of PER-1 type ESBL was investigated in caftazidime resistant A. baumannii strains isolated from bloodstream infections by PCR and also the clonal relatedness of the isolates were investigated by Random Amplified Polymorphic DNA (RAPD) and Pulsed Field Gel Electrophoresis (PFGE) in all PER-1 producing A. baumannii strains.", [["bloodstream", "ANATOMY", 124, 135], ["strains", "ANATOMY", 343, 350], ["caftazidime", "CHEMICAL", 67, 78], ["bloodstream infections", "DISEASE", 124, 146], ["caftazidime", "CHEMICAL", 67, 78], ["PER-1", "GENE_OR_GENE_PRODUCT", 31, 36], ["ESBL", "GENE_OR_GENE_PRODUCT", 42, 46], ["caftazidime resistant", "ORGANISM", 67, 88], ["A. baumannii strains", "ORGANISM", 89, 109], ["DNA", "CELLULAR_COMPONENT", 252, 255], ["PER-1", "GENE_OR_GENE_PRODUCT", 314, 319], ["A. baumannii strains", "ORGANISM", 330, 350], ["PER", "PROTEIN", 31, 34], ["A. baumannii", "SPECIES", 89, 101], ["A. baumannii", "SPECIES", 330, 342], ["A. baumannii", "SPECIES", 89, 101], ["A. baumannii", "SPECIES", 330, 342], ["this study", "TEST", 3, 13], ["PER-1 type ESBL", "PROBLEM", 31, 46], ["caftazidime resistant A. baumannii strains", "PROBLEM", 67, 109], ["bloodstream infections", "PROBLEM", 124, 146], ["PCR", "TEST", 150, 153], ["the isolates", "PROBLEM", 189, 201], ["Random Amplified Polymorphic DNA (RAPD)", "PROBLEM", 223, 262], ["Pulsed Field Gel Electrophoresis", "TEST", 267, 299], ["A. baumannii strains", "PROBLEM", 330, 350], ["baumannii", "OBSERVATION", 92, 101], ["bloodstream infections", "OBSERVATION", 124, 146]]], ["Methods: A. baumannii strains isolated from bloodstream infections was included in this study.", [["bloodstream", "ANATOMY", 44, 55], ["bloodstream infections", "DISEASE", 44, 66], ["A. baumannii strains", "ORGANISM", 9, 29], ["A. baumannii", "SPECIES", 9, 21], ["A. baumannii", "SPECIES", 9, 21], ["baumannii strains", "PROBLEM", 12, 29], ["bloodstream infections", "PROBLEM", 44, 66], ["this study", "TEST", 83, 93], ["bloodstream infections", "OBSERVATION", 44, 66]]], ["The isolates were identified as A. baumannii by conventional methods and Phoenix 100 BD automated System system (Becton Dickinson Diagnostic Systems, Sparks).", [["A. baumannii", "ORGANISM", 32, 44], ["A. baumannii", "SPECIES", 32, 44], ["A. baumannii", "SPECIES", 32, 44], ["baumannii", "OBSERVATION", 35, 44]]], ["Ceftazidime resistance was determined by E-test.", [["Ceftazidime", "CHEMICAL", 0, 11], ["Ceftazidime", "CHEMICAL", 0, 11], ["Ceftazidime", "SIMPLE_CHEMICAL", 0, 11], ["Ceftazidime resistance", "TREATMENT", 0, 22], ["E-test", "TEST", 41, 47]]], ["PER-1 genes were screened by These clusters encode: (i) resistance genes and transporters plausibly involved in drug efflux (30 transporters of the MFS, DMT, ABC, RND, MOP and ACR3 families were unique of drug resistant strains and absent in the susceptible SDF strain); (ii) pili and fimbriae systems related to biofilm formation and motility; (iii) haemolysin-and haemagglutininrelated proteins differently distributed among the four genomes, (iv) iron uptake and other metabolic genes.", [["biofilm", "ANATOMY", 313, 320], ["DMT", "CHEMICAL", 153, 156], ["iron", "CHEMICAL", 450, 454], ["iron", "CHEMICAL", 450, 454], ["PER-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["ABC", "GENE_OR_GENE_PRODUCT", 158, 161], ["MOP", "GENE_OR_GENE_PRODUCT", 168, 171], ["ACR3", "GENE_OR_GENE_PRODUCT", 176, 180], ["pili", "GENE_OR_GENE_PRODUCT", 276, 280], ["fimbriae", "GENE_OR_GENE_PRODUCT", 285, 293], ["haemolysin", "GENE_OR_GENE_PRODUCT", 351, 361], ["iron", "SIMPLE_CHEMICAL", 450, 454], ["PER-1 genes", "DNA", 0, 11], ["resistance genes", "DNA", 56, 72], ["MFS", "PROTEIN", 148, 151], ["DMT", "PROTEIN", 153, 156], ["ABC", "PROTEIN", 158, 161], ["RND", "PROTEIN", 163, 166], ["MOP", "PROTEIN", 168, 171], ["ACR3 families", "PROTEIN", 176, 189], ["pili", "PROTEIN", 276, 280], ["fimbriae", "PROTEIN", 285, 293], ["haemolysin", "PROTEIN", 351, 361], ["haemagglutininrelated proteins", "PROTEIN", 366, 396], ["metabolic genes", "DNA", 472, 487], ["drug resistant strains", "PROBLEM", 205, 227], ["the susceptible SDF strain", "PROBLEM", 242, 268], ["pili and fimbriae systems", "PROBLEM", 276, 301], ["biofilm formation", "PROBLEM", 313, 330], ["haemolysin", "TEST", 351, 361], ["haemagglutininrelated proteins", "PROBLEM", 366, 396], ["iron uptake", "TEST", 450, 461], ["metabolic genes", "OBSERVATION", 472, 487]]], ["Conclusion: Genome comparison identified unique features of A. baumannii epidemic clones and provided novel insights into the genetic basis of multidrug resistance and pathogenesis in this species.", [["A. baumannii", "ORGANISM", 60, 72], ["clones", "CELL", 82, 88], ["A. baumannii", "SPECIES", 60, 72], ["A. baumannii", "SPECIES", 60, 72], ["A. baumannii epidemic clones", "PROBLEM", 60, 88], ["multidrug resistance", "PROBLEM", 143, 163], ["pathogenesis in this species", "PROBLEM", 168, 196], ["multidrug resistance", "OBSERVATION", 143, 163]]], ["This study may contribute to understand the concept of infection, invasiveness and colonisation in the emergent pathogen A. baumannii.Conclusion:Hard to swallow \u2212 emerging and re-emerging issues in food-borne infection (Symposium arranged with EFWISG) S460 MRSA in food products: cause for concern or case for complacency?J. Kluytmans\u00b0(Breda, NL)In 2003 First, a switch from intravenous-to oral medication (01-2006); second, education programs for interns/residents and physicians and the release of a new antimicrobial formulary (05-2006); third, a restriction note was printed on all laboratory rapports (10-2006) and fourth, active monitoring and giving feedback on prescriptions (01-2007).", [["intravenous", "ANATOMY", 375, 386], ["oral", "ANATOMY", 390, 394], ["infection", "DISEASE", 55, 64], ["food-borne infection", "DISEASE", 198, 218], ["MRSA", "CHEMICAL", 257, 261], ["A. baumannii", "ORGANISM", 121, 133], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 375, 386], ["oral", "ORGANISM_SUBDIVISION", 390, 394], ["A. baumannii", "SPECIES", 121, 133], ["MRSA", "SPECIES", 257, 261], ["A. baumannii", "SPECIES", 121, 133], ["This study", "TEST", 0, 10], ["infection", "PROBLEM", 55, 64], ["invasiveness", "PROBLEM", 66, 78], ["colonisation", "PROBLEM", 83, 95], ["baumannii", "PROBLEM", 124, 133], ["borne infection", "PROBLEM", 203, 218], ["MRSA", "PROBLEM", 257, 261], ["complacency", "PROBLEM", 310, 321], ["intravenous", "TREATMENT", 375, 386], ["oral medication", "TREATMENT", 390, 405], ["a new antimicrobial formulary", "TREATMENT", 500, 529], ["active monitoring", "TEST", 628, 645], ["infection", "OBSERVATION", 55, 64], ["baumannii", "OBSERVATION", 124, 133], ["infection", "OBSERVATION", 209, 218]]], ["Susceptibility patterns for E. coli including ciprofloxacin, cefuroxim, ceftazidim, co-trimoxazole and tobramycin from hospitalised patients were analyzed starting in 2004.", [["ciprofloxacin", "CHEMICAL", 46, 59], ["cefuroxim", "CHEMICAL", 61, 70], ["ceftazidim", "CHEMICAL", 72, 82], ["co-trimoxazole", "CHEMICAL", 84, 98], ["tobramycin", "CHEMICAL", 103, 113], ["ciprofloxacin", "CHEMICAL", 46, 59], ["cefuroxim", "CHEMICAL", 61, 70], ["ceftazidim", "CHEMICAL", 72, 82], ["co-trimoxazole", "CHEMICAL", 84, 98], ["tobramycin", "CHEMICAL", 103, 113], ["E. coli", "ORGANISM", 28, 35], ["ciprofloxacin", "SIMPLE_CHEMICAL", 46, 59], ["cefuroxim", "SIMPLE_CHEMICAL", 61, 70], ["ceftazidim", "SIMPLE_CHEMICAL", 72, 82], ["co-trimoxazole", "SIMPLE_CHEMICAL", 84, 98], ["tobramycin", "SIMPLE_CHEMICAL", 103, 113], ["patients", "ORGANISM", 132, 140], ["E. coli", "SPECIES", 28, 35], ["patients", "SPECIES", 132, 140], ["E. coli", "SPECIES", 28, 35], ["Susceptibility patterns", "TEST", 0, 23], ["E. coli", "PROBLEM", 28, 35], ["ciprofloxacin", "TREATMENT", 46, 59], ["cefuroxim", "TREATMENT", 61, 70], ["ceftazidim", "TREATMENT", 72, 82], ["co-trimoxazole", "TREATMENT", 84, 98], ["tobramycin", "TREATMENT", 103, 113], ["E. coli", "OBSERVATION", 28, 35]]], ["Statistical analyses were performed using segmented Poisson regression models to look at effect of interventions on resistance (both sudden stepwise changes and changes in trends).", [["Statistical analyses", "TEST", 0, 20], ["segmented Poisson regression models", "TREATMENT", 42, 77], ["interventions on resistance", "TREATMENT", 99, 126], ["sudden stepwise changes", "PROBLEM", 133, 156]]], ["Bayesian model averaging was used to account for model uncertainty.J. Kluytmans\u00b0(Breda, NL)Results: Before the start of the interventions the resistance rate was increasing by an average of 2.6% per year.", [["the interventions", "TREATMENT", 120, 137], ["the resistance rate", "TEST", 138, 157]]], ["The interventions resulted in a significant reduction of QUIN use from on average 550 Prescribed Daily Doses to 350 PDD per month.", [["QUIN", "CHEMICAL", 57, 61], ["PDD", "DISEASE", 116, 119], ["QUIN", "CHEMICAL", 57, 61], ["QUIN", "SIMPLE_CHEMICAL", 57, 61], ["The interventions", "TREATMENT", 0, 17], ["a significant reduction of QUIN use", "TREATMENT", 30, 65], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["reduction", "OBSERVATION_MODIFIER", 44, 53]]], ["In the best fitting Poisson model for the resistance data, a significant stepwise decrease was found to be associated with interventions 2 and 4.", [["the resistance data", "TEST", 38, 57], ["a significant stepwise decrease", "PROBLEM", 59, 90]]], ["However, there was substantial uncertainty in the model choice, and after accounting for this there was no conclusive evidence in support of any particular intervention, although there was evidence that at least one of the interventions was associated with the observed reduction in resistance.", [["the observed reduction in resistance", "PROBLEM", 257, 293], ["substantial", "OBSERVATION_MODIFIER", 19, 30], ["uncertainty", "OBSERVATION_MODIFIER", 31, 42], ["no conclusive evidence", "UNCERTAINTY", 104, 126], ["reduction", "OBSERVATION_MODIFIER", 270, 279], ["resistance", "OBSERVATION", 283, 293]]], ["There were no stepwise decreases or decreasing trends in resistance rates to other antimicrobials during the study period.J. Kluytmans\u00b0(Breda, NL)Conclusion: Many MDs prescribe antibiotics often and believe their practice may have an effect on antibiotic resistance.", [["stepwise decreases", "PROBLEM", 14, 32], ["other antimicrobials", "TREATMENT", 77, 97], ["the study", "TEST", 105, 114], ["antibiotics", "TREATMENT", 177, 188], ["antibiotic resistance", "TREATMENT", 244, 265], ["no", "UNCERTAINTY", 11, 13], ["stepwise", "OBSERVATION_MODIFIER", 14, 22], ["decreases", "OBSERVATION_MODIFIER", 23, 32], ["decreasing", "OBSERVATION_MODIFIER", 36, 46], ["antibiotic resistance", "OBSERVATION", 244, 265]]], ["Results indicate that MDs value information, interventions and surveillance in order to support responsible use of antibiotics.", [["interventions", "TREATMENT", 45, 58], ["surveillance", "TEST", 63, 75], ["antibiotics", "TREATMENT", 115, 126]]], ["There is an ongoing effort in Germany to address these findings at the national level e.g. by establishing a surveillance system for antibiotic resistance and antibiotic usage.", [["a surveillance system", "TEST", 107, 128], ["antibiotic resistance", "TREATMENT", 133, 154], ["antibiotic usage", "TREATMENT", 159, 175]]], ["IR for PN, ER and TT were always higher in children (CH) than in adults (AD).", [["AD", "DISEASE", 73, 75], ["ER", "GENE_OR_GENE_PRODUCT", 11, 13], ["children", "ORGANISM", 43, 51], ["ER", "PROTEIN", 11, 13], ["children", "SPECIES", 43, 51], ["PN", "TREATMENT", 7, 9], ["TT", "TREATMENT", 18, 20]]], ["Significant differences were found for PN (1995), ER (1997 ER ( , 2004 ER ( , 2006 ER ( , 2007 ER ( , 2008 , TT (2004 TT ( , 2006 .", [["ER", "GENE_OR_GENE_PRODUCT", 50, 52], ["ER", "PROTEIN", 50, 52], ["ER", "PROTEIN", 59, 61], ["TT", "TEST", 109, 111], ["TT", "TEST", 118, 120]]], ["Generally, CP-IR was higher in AD than in CH.", [["CP-IR", "CHEMICAL", 11, 16], ["AD", "DISEASE", 31, 33], ["CP", "PROBLEM", 11, 13]]], ["IR was lower in the North (N) than in the South (S).", [["lower", "OBSERVATION_MODIFIER", 7, 12]]], ["Both N and S knew a deceasing IR tendency: PN= N (12.1\u22128.1), S (18.8\u221213.2); CP= N (11.6\u22125.9), S (18.9\u22125.9); TT= N (27.4\u221221.5), S (35.9\u221223.5).", [["PN", "TEST", 43, 45], ["S", "TEST", 61, 62], ["CP", "TEST", 76, 78], ["N", "TEST", 80, 81], ["\u2212", "TEST", 87, 88], ["S", "TEST", 94, 95], ["TT", "TEST", 108, 110], ["N", "TEST", 112, 113], ["S", "TEST", 127, 128]]], ["ER increased in the N (20.9\u221229.7).", [["ER", "GENE_OR_GENE_PRODUCT", 0, 2], ["ER", "PROTEIN", 0, 2], ["increased", "OBSERVATION_MODIFIER", 3, 12]]], ["Total outpatient antibiotic use (DID) decreased from 26.2 (1999) to 22.7 (2004) and increased to 24.2 (2006) .", [["Total outpatient antibiotic use", "TREATMENT", 0, 31]]], ["DID for PN and FQ increased, MLS stabilised and TT decreased.", [["FQ", "CHEMICAL", 15, 17], ["FQ", "SIMPLE_CHEMICAL", 15, 17], ["PN", "TREATMENT", 8, 10], ["FQ", "PROBLEM", 15, 17], ["MLS", "TEST", 29, 32], ["TT", "PROBLEM", 48, 50], ["decreased", "OBSERVATION_MODIFIER", 51, 60]]], ["Conclusions: Since 2001-2003 an IR decrease was noted for PN, CP and TT.", [["PN", "PROBLEM", 58, 60], ["CP", "PROBLEM", 62, 64], ["TT", "PROBLEM", 69, 71]]], ["ER-IR increased further over the years.", [["ER", "GENE_OR_GENE_PRODUCT", 0, 2], ["ER", "PROTEIN", 0, 2], ["increased", "OBSERVATION_MODIFIER", 6, 15]]], ["The decrease paralleled the start of public campaigns on antibiotic use.", [["public campaigns", "TREATMENT", 37, 53], ["antibiotic use", "TREATMENT", 57, 71], ["decrease", "OBSERVATION_MODIFIER", 4, 12]]], ["IR rates remain higher in CH than in AD.", [["AD", "DISEASE", 37, 39], ["IR rates", "TEST", 0, 8], ["higher", "OBSERVATION", 16, 22]]], ["The N/S difference became less marked.", [["The N/S difference", "PROBLEM", 0, 18], ["less marked", "OBSERVATION_MODIFIER", 26, 37]]], ["Objectives: Parachlamydia acanthamoebae is a new recognized member of the order Chlamydiales.", [["Parachlamydia acanthamoebae", "DISEASE", 12, 39], ["Parachlamydia acanthamoebae", "ORGANISM", 12, 39], ["Parachlamydia acanthamoebae", "SPECIES", 12, 39], ["Parachlamydia acanthamoebae", "SPECIES", 12, 39]]], ["Growing evidences suggest that this bacteria may have a pathogenic role in humans causing respiratory diseases.", [["respiratory", "ANATOMY", 90, 101], ["respiratory diseases", "DISEASE", 90, 110], ["humans", "ORGANISM", 75, 81], ["humans", "SPECIES", 75, 81], ["humans", "SPECIES", 75, 81], ["this bacteria", "PROBLEM", 31, 44], ["respiratory diseases", "PROBLEM", 90, 110], ["respiratory diseases", "OBSERVATION", 90, 110]]], ["It has also been recently identified as an agent of bovine abortion and may be a cause of miscarriage in women.", [["bovine abortion", "DISEASE", 52, 67], ["miscarriage", "DISEASE", 90, 101], ["bovine", "ORGANISM", 52, 58], ["women", "ORGANISM", 105, 110], ["bovine", "SPECIES", 52, 58], ["women", "SPECIES", 105, 110], ["bovine", "SPECIES", 52, 58], ["bovine abortion", "TREATMENT", 52, 67], ["miscarriage", "PROBLEM", 90, 101], ["bovine abortion", "OBSERVATION", 52, 67], ["may be a cause", "UNCERTAINTY", 72, 86], ["miscarriage", "OBSERVATION", 90, 101]]], ["In contrast, little is known about the pathogenic role of Rhabdochlamydia crassificans, another related Chlamydiales.", [["Rhabdochlamydia crassificans", "ORGANISM", 58, 86], ["Chlamydiales", "CANCER", 104, 116], ["Rhabdochlamydia crassificans", "SPECIES", 58, 86], ["Rhabdochlamydia crassificans", "SPECIES", 58, 86], ["Rhabdochlamydia crassificans", "PROBLEM", 58, 86], ["another related Chlamydiales", "PROBLEM", 88, 116], ["Rhabdochlamydia", "OBSERVATION", 58, 73]]], ["Molecular diagnostic tools are useful to detect these obligate intracellular bacteria because of their inability to grow on conventional culture media.", [["intracellular", "ANATOMY", 63, 76], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 63, 76], ["Molecular diagnostic tools", "TEST", 0, 26], ["these obligate intracellular bacteria", "PROBLEM", 48, 85], ["conventional culture media", "TREATMENT", 124, 150]]], ["The aim of this work was (i) to develop a real-time PCR for the diagnosis of Rhabdochlamydia infection and (ii) to study respiratory secretions of newborns for the presence of Parachlamydia and Rhabdochlamydia DNA.", [["respiratory secretions", "ANATOMY", 121, 143], ["Rhabdochlamydia infection", "DISEASE", 77, 102], ["Rhabdochlamydia", "ORGANISM", 77, 92], ["newborns", "ORGANISM", 147, 155], ["DNA", "CELLULAR_COMPONENT", 210, 213], ["Rhabdochlamydia infection", "PROBLEM", 77, 102], ["study respiratory secretions", "TEST", 115, 143], ["Parachlamydia", "PROBLEM", 176, 189], ["Rhabdochlamydia DNA", "PROBLEM", 194, 213], ["infection", "OBSERVATION", 93, 102], ["Parachlamydia", "OBSERVATION", 176, 189], ["Rhabdochlamydia DNA", "OBSERVATION", 194, 213]]], ["Methods: A new quantitative real-time TaqMan PCR (q-PCR) to be used on ABI Prism 7900 was developed.", [["TaqMan PCR", "TEST", 38, 48], ["ABI Prism", "TEST", 71, 80]]], ["The q-PCR was then blindly applied to 41 consecutive respiratory samples (endotracheal or nasopharyngeal secretions) taken from 29 critically-ill newborns admitted in the neonatology ward of our university hospital.", [["respiratory samples", "ANATOMY", 53, 72], ["endotracheal", "ANATOMY", 74, 86], ["nasopharyngeal secretions", "ANATOMY", 90, 115], ["critically-ill", "DISEASE", 131, 145], ["endotracheal", "MULTI-TISSUE_STRUCTURE", 74, 86], ["nasopharyngeal secretions", "MULTI-TISSUE_STRUCTURE", 90, 115], ["newborns", "ORGANISM", 146, 154], ["The q-PCR", "TEST", 0, 9], ["consecutive respiratory samples", "TEST", 41, 72], ["endotracheal or nasopharyngeal secretions", "PROBLEM", 74, 115], ["endotracheal", "ANATOMY", 74, 86], ["nasopharyngeal", "ANATOMY", 90, 104]]], ["These samples were also tested using a previously developed Parachlamydiaspecific PCR.", [["samples", "ANATOMY", 6, 13], ["These samples", "TEST", 0, 13], ["a previously developed Parachlamydiaspecific PCR", "PROBLEM", 37, 85]]], ["Results: Most newborns (28/29) were premature (median gestational age: 28.6 weeks; range: 24.6\u221241.2).", [["newborns", "ORGANISM", 14, 22]]], ["Initial respiratory distress syndrome was present in 86% of them.", [["respiratory", "ANATOMY", 8, 19], ["respiratory distress syndrome", "DISEASE", 8, 37], ["Initial respiratory distress syndrome", "PROBLEM", 0, 37], ["respiratory", "OBSERVATION", 8, 19], ["distress syndrome", "OBSERVATION", 20, 37]]], ["Positive PCR results were obtained in 12/29 (41%) patients (8 Parachlamydia, 3 Rhabdochlamydia, 1 both species) at a median of 17.5 days (range: 2-230) after birth.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["Positive PCR", "TEST", 0, 12], ["Parachlamydia", "TEST", 62, 75], ["Rhabdochlamydia", "TEST", 79, 94]]], ["When compared to the control group (17 patients with negative PCR), these 12 newborns had a significantly worse primary adaptation and a higher incidence of resuscitation maneuvers at birth (Table) .", [["patients", "ORGANISM", 39, 47], ["newborns", "ORGANISM", 77, 85], ["patients", "SPECIES", 39, 47], ["PCR", "TEST", 62, 65], ["resuscitation maneuvers", "TREATMENT", 157, 180]]], ["Duration of noninvasive mechanical ventilation and stay in neonatology ward were also significantly longer.", [["noninvasive mechanical ventilation", "TREATMENT", 12, 46], ["mechanical ventilation", "OBSERVATION", 24, 46]]], ["A fatal issue was observed in 3 infected cases, as compared to no death in controls (p = 0.06).", [["death", "DISEASE", 66, 71], ["A fatal issue", "PROBLEM", 0, 13], ["death", "PROBLEM", 66, 71], ["fatal", "OBSERVATION_MODIFIER", 2, 7]]], ["Gestational age at birth as well as the incidence of pulmonary or systemic infections did not differ between cases and controls.", [["pulmonary", "ANATOMY", 53, 62], ["pulmonary or systemic infections", "DISEASE", 53, 85], ["pulmonary", "ORGAN", 53, 62], ["Gestational age", "PROBLEM", 0, 15], ["pulmonary or systemic infections", "PROBLEM", 53, 85], ["pulmonary", "ANATOMY", 53, 62], ["systemic", "OBSERVATION_MODIFIER", 66, 74], ["infections", "OBSERVATION", 75, 85]]], ["Conclusion: A high prevalence of Parachlamydia and Rhabdochlamydia DNA was observed in respiratory secretions of premature critically-ill newborns.", [["respiratory secretions", "ANATOMY", 87, 109], ["premature critically-ill", "DISEASE", 113, 137], ["Parachlamydia", "CANCER", 33, 46], ["Rhabdochlamydia", "ORGANISM", 51, 66], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["newborns", "ORGANISM", 138, 146], ["Parachlamydia", "PROBLEM", 33, 46], ["Rhabdochlamydia DNA", "PROBLEM", 51, 70], ["respiratory secretions", "PROBLEM", 87, 109], ["premature critically-ill newborns", "PROBLEM", 113, 146], ["respiratory secretions", "OBSERVATION", 87, 109]]], ["The presence of DNA of these microorganisms was associated with a worse primary adaptation, a more severe respiratory distress syndrome and a trend towards a higher mortality.", [["respiratory", "ANATOMY", 106, 117], ["respiratory distress syndrome", "DISEASE", 106, 135], ["DNA", "CELLULAR_COMPONENT", 16, 19], ["these microorganisms", "PROBLEM", 23, 43], ["a more severe respiratory distress syndrome", "PROBLEM", 92, 135], ["a higher mortality", "PROBLEM", 156, 174], ["microorganisms", "OBSERVATION", 29, 43], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["respiratory distress syndrome", "OBSERVATION", 106, 135]]], ["The genus Kingella consists of 3 species, K. kingae, K. oralis and K. denitrificans.", [["K. kingae", "ORGANISM", 42, 51], ["K. oralis", "ORGANISM", 53, 62], ["K. denitrificans", "ORGANISM", 67, 83], ["K. kingae", "SPECIES", 42, 51], ["K. oralis", "SPECIES", 53, 62], ["K. denitrificans", "SPECIES", 67, 83], ["K. kingae", "SPECIES", 42, 51], ["K. oralis", "SPECIES", 53, 62], ["K. denitrificans", "SPECIES", 67, 83], ["genus", "ANATOMY", 4, 9], ["Kingella", "OBSERVATION", 10, 18]]], ["All are Gram negative, sometimes difficult to stain, rod shaped bacteria that are normal respiratory and genitourinary flora.", [["respiratory", "ANATOMY", 89, 100], ["genitourinary flora", "ANATOMY", 105, 124], ["genitourinary flora", "PATHOLOGICAL_FORMATION", 105, 124], ["Gram", "TEST", 8, 12], ["rod shaped bacteria", "PROBLEM", 53, 72], ["rod shaped", "OBSERVATION_MODIFIER", 53, 63], ["bacteria", "OBSERVATION", 64, 72], ["normal", "OBSERVATION", 82, 88], ["respiratory", "ANATOMY", 89, 100], ["genitourinary flora", "OBSERVATION", 105, 124]]], ["They are slow-growing and fastidious.", [["slow", "OBSERVATION_MODIFIER", 9, 13], ["growing", "OBSERVATION_MODIFIER", 14, 21], ["fastidious", "OBSERVATION_MODIFIER", 26, 36]]], ["Although improved recovery was shown when using Fan or PEDs-F blood culture bottles, the majority of these infections remain undetected, especially in pre-treated patients.", [["infections", "DISEASE", 107, 117], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["blood culture bottles", "TEST", 62, 83], ["these infections", "PROBLEM", 101, 117], ["infections", "OBSERVATION", 107, 117]]], ["We report the use of real time polymerase chain reaction (rt-PCR) assays for detection of K. kingae and S. aureus in paediatric osteoarticular infections.", [["osteoarticular", "ANATOMY", 128, 142], ["osteoarticular infections", "DISEASE", 128, 153], ["K. kingae", "ORGANISM", 90, 99], ["S. aureus", "ORGANISM", 104, 113], ["osteoarticular", "ORGAN", 128, 142], ["K. kingae", "SPECIES", 90, 99], ["S. aureus", "SPECIES", 104, 113], ["K. kingae", "SPECIES", 90, 99], ["S. aureus", "SPECIES", 104, 113], ["real time polymerase chain reaction", "PROBLEM", 21, 56], ["rt-PCR) assays", "TEST", 58, 72], ["K. kingae", "PROBLEM", 90, 99], ["S. aureus", "PROBLEM", 104, 113], ["paediatric osteoarticular infections", "PROBLEM", 117, 153], ["aureus", "OBSERVATION", 107, 113], ["osteoarticular infections", "OBSERVATION", 128, 153]]], ["Methods: 116 synovial fluid samples from 97 patients, 1 month and 17 years of age, were collected over 19 months (03/2006 to 10/2007).", [["synovial fluid samples", "ANATOMY", 13, 35], ["synovial fluid samples", "CANCER", 13, 35], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["synovial fluid samples", "TEST", 13, 35]]], ["The samples were from 54 knees, 39 hips, 9 ankles, 6 elbows, 4 shoulders, 2 wrists and 2 femur abscesses.", [["samples", "ANATOMY", 4, 11], ["knees", "ANATOMY", 25, 30], ["hips", "ANATOMY", 35, 39], ["ankles", "ANATOMY", 43, 49], ["elbows", "ANATOMY", 53, 59], ["shoulders", "ANATOMY", 63, 72], ["wrists", "ANATOMY", 76, 82], ["femur abscesses", "ANATOMY", 89, 104], ["abscesses", "DISEASE", 95, 104], ["ankles", "ORGANISM_SUBDIVISION", 43, 49], ["femur abscesses", "CANCER", 89, 104], ["The samples", "TEST", 0, 11], ["knees", "TEST", 25, 30], ["hips", "TEST", 35, 39], ["ankles", "TEST", 43, 49], ["elbows", "TEST", 53, 59], ["2 wrists and 2 femur abscesses", "PROBLEM", 74, 104], ["knees", "ANATOMY", 25, 30], ["hips", "ANATOMY", 35, 39], ["ankles", "ANATOMY", 43, 49], ["elbows", "ANATOMY", 53, 59], ["shoulders", "ANATOMY", 63, 72], ["wrists", "ANATOMY", 76, 82], ["femur", "ANATOMY", 89, 94], ["abscesses", "OBSERVATION", 95, 104]]], ["After automated DNA/RNA extraction, specimens were subjected to 4 hour pathogen-specific rt-PCR.", [["specimens", "ANATOMY", 36, 45], ["DNA", "CELLULAR_COMPONENT", 16, 19], ["automated DNA/RNA extraction", "TREATMENT", 6, 34], ["specimens", "TEST", 36, 45], ["specific rt-PCR", "TEST", 80, 95]]], ["Samples were inoculated onto sheep blood and chocolate agar as well as a Peds-F bottle.", [["Samples", "ANATOMY", 0, 7], ["blood", "ANATOMY", 35, 40], ["sheep", "ORGANISM", 29, 34], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["sheep", "SPECIES", 29, 34], ["sheep", "SPECIES", 29, 34], ["Samples", "TEST", 0, 7], ["chocolate agar", "TREATMENT", 45, 59], ["a Peds-F bottle", "TREATMENT", 71, 86]]], ["Final species identification and antimicrobial susceptibilities were determined by Phoenix (TM).", [["Final species identification", "TEST", 0, 28], ["antimicrobial susceptibilities", "TEST", 33, 63]]], ["Results: 45 patients (56 specimens) had positive culture and/or rt-PCR, resulting in an overall positivity rate of 46%.", [["specimens", "ANATOMY", 25, 34], ["patients", "ORGANISM", 12, 20], ["specimens", "CANCER", 25, 34], ["patients", "SPECIES", 12, 20], ["specimens", "TEST", 25, 34], ["positive culture", "PROBLEM", 40, 56], ["rt-PCR", "TEST", 64, 70]]], ["S. aureus was the predominant pathogen accounting for 31 specimens of 23 patients (12 MRSA, 11 MSSA) and.", [["specimens", "ANATOMY", 57, 66], ["S. aureus", "ORGANISM", 0, 9], ["patients", "ORGANISM", 73, 81], ["S. aureus", "SPECIES", 0, 9], ["patients", "SPECIES", 73, 81], ["MRSA", "SPECIES", 86, 90], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "PROBLEM", 0, 9], ["the predominant pathogen", "PROBLEM", 14, 38], ["31 specimens", "TEST", 54, 66], ["MRSA", "TEST", 86, 90], ["MSSA", "TEST", 95, 99], ["aureus", "OBSERVATION", 3, 9], ["predominant", "OBSERVATION_MODIFIER", 18, 29], ["pathogen", "OBSERVATION_MODIFIER", 30, 38]]], ["37% of positive specimens (18 patients) were due to K. kingae (n = 21).", [["specimens", "ANATOMY", 16, 25], ["specimens", "CANCER", 16, 25], ["patients", "ORGANISM", 30, 38], ["K. kingae", "ORGANISM", 52, 61], ["patients", "SPECIES", 30, 38], ["K. kingae", "SPECIES", 52, 61], ["K. kingae", "SPECIES", 52, 61], ["positive specimens", "TEST", 7, 25], ["K. kingae", "TEST", 52, 61]]], ["Among children 0\u22122 years (n = 35), K. kingae was the predominant pathogen accounting for 16 positive patients (46%), followed by MSSA in 4 patients (11%).", [["children", "ORGANISM", 6, 14], ["K. kingae", "ORGANISM", 35, 44], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 139, 147], ["children", "SPECIES", 6, 14], ["K. kingae", "SPECIES", 35, 44], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 139, 147], ["K. kingae", "SPECIES", 35, 44], ["MSSA", "PROBLEM", 129, 133], ["MSSA", "OBSERVATION", 129, 133]]], ["The positivity rate for this age group was 57%.", [["The positivity rate", "TEST", 0, 19]]], ["Only 2 children >2 years (5 and 9 years) were positive for K. kingae.", [["children", "ORGANISM", 7, 15], ["K. kingae", "ORGANISM", 59, 68], ["children", "SPECIES", 7, 15], ["K. kingae", "SPECIES", 59, 68], ["K. kingae", "SPECIES", 59, 68]]], ["MRSA was the predominant pathogen in 6\u221212 year olds, and MSSA was evenly distributed among children 3\u221217 years old.", [["MRSA", "CHEMICAL", 0, 4], ["children", "ORGANISM", 91, 99], ["MRSA", "SPECIES", 0, 4], ["children", "SPECIES", 91, 99], ["MRSA", "SPECIES", 0, 4], ["MSSA", "SPECIES", 57, 61], ["MRSA", "PROBLEM", 0, 4], ["MSSA", "PROBLEM", 57, 61], ["predominant", "OBSERVATION_MODIFIER", 13, 24], ["pathogen", "OBSERVATION_MODIFIER", 25, 33], ["MSSA", "OBSERVATION", 57, 61]]], ["Culture detected only 5 of 21 specimens positive for K. kingae and 25 of 31 S. aureus.", [["specimens", "ANATOMY", 30, 39], ["K. kingae", "ORGANISM", 53, 62], ["S. aureus", "ORGANISM", 76, 85], ["K. kingae", "SPECIES", 53, 62], ["S. aureus", "SPECIES", 76, 85], ["K. kingae", "SPECIES", 53, 62], ["S. aureus", "SPECIES", 76, 85], ["Culture", "TEST", 0, 7], ["21 specimens", "TEST", 27, 39], ["K. kingae", "TEST", 53, 62], ["S. aureus", "PROBLEM", 76, 85], ["aureus", "OBSERVATION", 79, 85]]], ["4 other pathogens were detected by culture only.Conclusion:The use of these molecular assays enhances detection of organisms, especially for K. kingae (19% vs. 5% for culture).", [["K. kingae", "ORGANISM", 141, 150], ["K. kingae", "SPECIES", 141, 150], ["K. kingae", "SPECIES", 141, 150], ["4 other pathogens", "PROBLEM", 0, 17], ["culture", "TEST", 35, 42], ["these molecular assays", "TEST", 70, 92], ["organisms", "PROBLEM", 115, 124], ["K. kingae", "TEST", 141, 150], ["culture", "TEST", 167, 174], ["pathogens", "OBSERVATION", 8, 17]]], ["Additionally, faster identification (TAT 4 hrs) allows for rapid targeted therapy.", [["rapid targeted therapy", "TREATMENT", 59, 81]]], ["This improvement in TAT could lead to shorter hospital stays in about 54% of cases.", [["TAT", "GENE_OR_GENE_PRODUCT", 20, 23], ["TAT", "PROTEIN", 20, 23], ["TAT", "PROBLEM", 20, 23]]], ["Results: Genotyping revealed a high degree of diversity, indicative of a panmictic bacterial population.", [["Genotyping", "TEST", 9, 19], ["a high degree of diversity", "PROBLEM", 29, 55], ["a panmictic bacterial population", "PROBLEM", 71, 103], ["high degree", "OBSERVATION_MODIFIER", 31, 42], ["diversity", "OBSERVATION", 46, 55], ["indicative of", "UNCERTAINTY", 57, 70], ["panmictic", "OBSERVATION_MODIFIER", 73, 82], ["bacterial population", "OBSERVATION", 83, 103]]], ["Further, there was no association between genotype and colonisation frequency, or year of isolation.", [["genotype and colonisation frequency", "PROBLEM", 42, 77], ["no association between", "UNCERTAINTY", 19, 41], ["colonisation", "OBSERVATION", 55, 67]]], ["PCR screening for virulence genes revealed an incidence of 98% for uspA1, 81% for hag, 82% for uspA2 and 18% for uspA2H.", [["uspA2H", "GENE_OR_GENE_PRODUCT", 113, 119], ["virulence genes", "DNA", 18, 33], ["A2H", "PROTEIN", 116, 119], ["PCR screening", "TEST", 0, 13], ["virulence genes", "TEST", 18, 33], ["uspA1", "TEST", 67, 72], ["hag", "TEST", 82, 85], ["uspA2", "TEST", 95, 100]]], ["No significant difference was observed in the prevalence of virulence-associated genes between isolates originating from children who were colonised only once or children colonised on all 3 occasions (P = 1).", [["children", "ORGANISM", 121, 129], ["children", "ORGANISM", 162, 170], ["virulence-associated genes", "DNA", 60, 86], ["children", "SPECIES", 121, 129], ["children", "SPECIES", 162, 170], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["PCR-RFLP analysis of uspA1, hag and uspA2 showed many gene variants, with no association between PCR-RFLP patterns and colonisation frequency, or year of isolation.", [["uspA1", "GENE_OR_GENE_PRODUCT", 21, 26], ["hag", "GENE_OR_GENE_PRODUCT", 28, 31], ["uspA2", "GENE_OR_GENE_PRODUCT", 36, 41], ["uspA1", "DNA", 21, 26], ["hag", "DNA", 28, 31], ["uspA2", "DNA", 36, 41], ["PCR", "TEST", 0, 3], ["RFLP analysis", "TEST", 4, 17], ["uspA1", "TEST", 21, 26], ["hag", "TEST", 28, 31], ["uspA2", "TEST", 36, 41], ["many gene variants", "PROBLEM", 49, 67], ["PCR", "TEST", 97, 100], ["RFLP patterns", "TEST", 101, 114], ["colonisation frequency", "PROBLEM", 119, 141], ["gene variants", "OBSERVATION", 54, 67]]], ["Conclusion: Even in relatively localised geographical settings, the genotypic diversity of M. catarrhalis isolates colonising children is large, with no yearly pattern of genotype predominance.", [["M. catarrhalis", "ORGANISM", 91, 105], ["children", "ORGANISM", 126, 134], ["M. catarrhalis", "SPECIES", 91, 105], ["children", "SPECIES", 126, 134], ["M. catarrhalis", "SPECIES", 91, 105], ["M. catarrhalis isolates colonising children", "PROBLEM", 91, 134], ["genotype predominance", "PROBLEM", 171, 192], ["M. catarrhalis", "OBSERVATION", 91, 105], ["large", "OBSERVATION_MODIFIER", 138, 143], ["genotype predominance", "OBSERVATION", 171, 192]]], ["Children serially colonised with M. catarrhalis isolates appear to clear a particular genotype only to become subsequently colonised with a different genotype.", [["Children", "ORGANISM", 0, 8], ["M. catarrhalis", "ORGANISM", 33, 47], ["Children", "SPECIES", 0, 8], ["M. catarrhalis", "SPECIES", 33, 47], ["M. catarrhalis", "SPECIES", 33, 47], ["M. catarrhalis isolates", "PROBLEM", 33, 56]]], ["The incidence of virulence genes in this relatively localised study group is remarkably similar to that reported in global M. catarrhalis isolates, possibly indicating that similar selection pressure exists for M. catarrhalis at both the local and global level.", [["M. catarrhalis", "ORGANISM", 123, 137], ["isolates", "ORGANISM", 138, 146], ["M. catarrhalis", "ORGANISM", 211, 225], ["virulence genes", "DNA", 17, 32], ["M. catarrhalis", "SPECIES", 123, 137], ["M. catarrhalis", "SPECIES", 211, 225], ["M. catarrhalis", "SPECIES", 123, 137], ["M. catarrhalis", "SPECIES", 211, 225], ["virulence genes", "PROBLEM", 17, 32], ["global M. catarrhalis isolates", "PROBLEM", 116, 146], ["M. catarrhalis", "PROBLEM", 211, 225], ["virulence genes", "OBSERVATION", 17, 32], ["catarrhalis isolates", "OBSERVATION", 126, 146], ["possibly indicating", "UNCERTAINTY", 148, 167], ["catarrhalis", "OBSERVATION", 214, 225]]], ["Virulence gene variation appears to be high, even in this relatively restricted geographical group.", [["Virulence gene variation", "PROBLEM", 0, 24], ["high", "OBSERVATION_MODIFIER", 39, 43]]], ["These results could have consequences for vaccines designed against virulence genes.O471 Epidemiology of cytomegalovirus in pregnancy and risk evaluation for delivering a child with congenital CMV infectionA.", [["cytomegalovirus", "DISEASE", 105, 120], ["congenital CMV infectionA", "DISEASE", 182, 207], ["cytomegalovirus", "ORGANISM", 105, 120], ["child", "ORGANISM", 171, 176], ["CMV", "ORGANISM", 193, 196], ["virulence genes", "DNA", 68, 83], ["child", "SPECIES", 171, 176], ["CMV", "SPECIES", 193, 196], ["vaccines", "TREATMENT", 42, 50], ["virulence genes", "PROBLEM", 68, 83], ["cytomegalovirus in pregnancy", "PROBLEM", 105, 133], ["risk evaluation", "TEST", 138, 153], ["congenital CMV infectionA", "PROBLEM", 182, 207], ["cytomegalovirus", "OBSERVATION", 105, 120], ["congenital", "OBSERVATION_MODIFIER", 182, 192], ["CMV infectionA", "OBSERVATION", 193, 207]]], ["Naessens\u00b0, I. Foulon, A. Casteels, W. Foulon (Brussels, BE) Objectives: To evaluate the epidemiology of cytomegalovirus in pregnancy and to evaluate the risk for delivering a child with congenital CMV (cCMV).", [["cytomegalovirus", "DISEASE", 104, 119], ["congenital CMV (cCMV", "DISEASE", 186, 206], ["cytomegalovirus", "ORGANISM", 104, 119], ["CMV", "ORGANISM", 197, 200], ["CMV", "SPECIES", 197, 200], ["cCMV", "SPECIES", 202, 206], ["cytomegalovirus in pregnancy", "PROBLEM", 104, 132], ["congenital CMV (cCMV)", "PROBLEM", 186, 207], ["cytomegalovirus", "OBSERVATION", 104, 119], ["CMV", "OBSERVATION", 197, 200]]], ["Methods: Between 1996-2006, 11825 unselected mother-infant pairs were included.", [["infant", "ORGANISM", 52, 58], ["infant", "SPECIES", 52, 58]]], ["In the mother a serological screening was performed consisting in the detection of CMV IgG and IgM antibodies at the first prenatal visit and at birth.", [["CMV", "ORGANISM", 83, 86], ["IgG", "GENE_OR_GENE_PRODUCT", 87, 90], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 95, 109], ["CMV IgG", "PROTEIN", 83, 90], ["IgM antibodies", "PROTEIN", 95, 109], ["CMV", "SPECIES", 83, 86], ["a serological screening", "TEST", 14, 37], ["the detection", "TEST", 66, 79], ["CMV IgG", "TEST", 83, 90], ["IgM antibodies", "TEST", 95, 109]]], ["In the neonate CMV urine culture was performed to diagnose congenital infection.", [["urine", "ANATOMY", 19, 24], ["congenital infection", "DISEASE", 59, 79], ["neonate", "ORGANISM", 7, 14], ["CMV", "ORGANISM", 15, 18], ["urine", "ORGANISM_SUBSTANCE", 19, 24], ["CMV", "SPECIES", 15, 18], ["the neonate CMV urine culture", "TEST", 3, 32], ["congenital infection", "PROBLEM", 59, 79], ["congenital", "OBSERVATION_MODIFIER", 59, 69], ["infection", "OBSERVATION", 70, 79]]], ["When a pregnant woman was found to have a second trimester spontaneous abortion or a death in utero, an investigation for possible congenital CMV infection was carried out.", [["spontaneous abortion", "DISEASE", 59, 79], ["death", "DISEASE", 85, 90], ["congenital CMV infection", "DISEASE", 131, 155], ["woman", "ORGANISM", 16, 21], ["CMV", "ORGANISM", 142, 145], ["woman", "SPECIES", 16, 21], ["CMV", "SPECIES", 142, 145], ["a second trimester spontaneous abortion", "PROBLEM", 40, 79], ["a death in utero", "PROBLEM", 83, 99], ["an investigation", "TEST", 101, 117], ["congenital CMV infection", "PROBLEM", 131, 155], ["CMV infection", "OBSERVATION", 142, 155]]], ["Results: Serological screening at the first prenatal visit showed no immunity in 4701 women, evidence of past infection (IgG positive IgM negative) in 6877 women (58.2%) and in 250 women (2.0%) both IgG and IgM antibodies were detected.", [["infection", "DISEASE", 110, 119], ["women", "ORGANISM", 86, 91], ["women", "ORGANISM", 156, 161], ["women", "ORGANISM", 181, 186], ["IgG", "GENE_OR_GENE_PRODUCT", 199, 202], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 207, 221], ["IgG", "PROTEIN", 121, 124], ["IgM", "PROTEIN", 134, 137], ["IgG", "PROTEIN", 199, 202], ["IgM antibodies", "PROTEIN", 207, 221], ["women", "SPECIES", 86, 91], ["women", "SPECIES", 156, 161], ["women", "SPECIES", 181, 186], ["Serological screening", "TEST", 9, 30], ["past infection", "PROBLEM", 105, 119], ["IgG", "TEST", 121, 124], ["IgM", "TEST", 134, 137], ["both IgG", "TEST", 194, 202], ["IgM antibodies", "TEST", 207, 221], ["infection", "OBSERVATION", 110, 119]]], ["After investigation of stored and follow up samples from these 250 patients, 14 could be classified as having a primary CMV infection during pregnancy, 99 patients had previous immunity before the current pregnancy and from 137 patients the type of the maternal CMV infection could not be determined.", [["samples", "ANATOMY", 44, 51], ["CMV infection", "DISEASE", 120, 133], ["CMV infection", "DISEASE", 262, 275], ["patients", "ORGANISM", 67, 75], ["CMV", "ORGANISM", 120, 123], ["patients", "ORGANISM", 155, 163], ["patients", "ORGANISM", 228, 236], ["CMV", "ORGANISM", 262, 265], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 155, 163], ["patients", "SPECIES", 228, 236], ["CMV", "SPECIES", 120, 123], ["CMV", "SPECIES", 262, 265], ["follow up samples", "TEST", 34, 51], ["a primary CMV infection", "PROBLEM", 110, 133], ["the maternal CMV infection", "PROBLEM", 249, 275], ["CMV infection", "OBSERVATION", 120, 133], ["CMV", "OBSERVATION", 262, 265]]], ["Follow-up serology of the 4701 women without immunity revealed a seroconversion in 58 of them (1.2%).", [["women", "ORGANISM", 31, 36], ["women", "SPECIES", 31, 36], ["Follow-up serology", "TEST", 0, 18], ["a seroconversion", "PROBLEM", 63, 79]]], ["A total of 61 (0.52%) congenital infections (cCMV) were diagnosed.", [["congenital infections", "DISEASE", 22, 43], ["cCMV", "SPECIES", 45, 49], ["congenital infections (cCMV)", "PROBLEM", 22, 50], ["total", "OBSERVATION_MODIFIER", 2, 7], ["congenital", "OBSERVATION_MODIFIER", 22, 32], ["infections", "OBSERVATION", 33, 43]]], ["The incidence of the cCMV among the different groups of women are summarised in the table.O471 Epidemiology of cytomegalovirus in pregnancy and risk evaluation for delivering a child with congenital CMV infectionConclusion: cCMV infection occurs in 0.52% of our population of pregnant women. cCMV was considered to be due to a primary maternal CMV infection in 54% of the infants; 33% due to a recurrent maternal CMV infection and in 13% the type of maternal infection could not be determined.O471 Epidemiology of cytomegalovirus in pregnancy and risk evaluation for delivering a child with congenital CMV infectionThe risk for a seronegative pregnant woman of acquiring CMV during pregnancy is 1.2%.", [["cytomegalovirus", "DISEASE", 111, 126], ["congenital CMV infection", "DISEASE", 188, 212], ["cCMV infection", "DISEASE", 224, 238], ["CMV infection", "DISEASE", 344, 357], ["CMV infection", "DISEASE", 413, 426], ["maternal infection", "DISEASE", 450, 468], ["cytomegalovirus", "DISEASE", 514, 529], ["congenital CMV infection", "DISEASE", 591, 615], ["cCMV", "CANCER", 21, 25], ["women", "ORGANISM", 56, 61], ["cytomegalovirus", "ORGANISM", 111, 126], ["CMV", "ORGANISM", 199, 202], ["cCMV", "ORGANISM", 224, 228], ["women", "ORGANISM", 285, 290], ["CMV", "ORGANISM", 344, 347], ["infants", "ORGANISM", 372, 379], ["CMV", "ORGANISM", 413, 416], ["cytomegalovirus", "ORGANISM", 514, 529], ["child", "ORGANISM", 580, 585], ["CMV", "ORGANISM", 602, 605], ["woman", "ORGANISM", 652, 657], ["CMV", "ORGANISM", 671, 674], ["women", "SPECIES", 56, 61], ["child", "SPECIES", 177, 182], ["women", "SPECIES", 285, 290], ["infants", "SPECIES", 372, 379], ["child", "SPECIES", 580, 585], ["woman", "SPECIES", 652, 657], ["cCMV", "SPECIES", 21, 25], ["CMV", "SPECIES", 199, 202], ["cCMV", "SPECIES", 224, 228], ["cCMV", "SPECIES", 292, 296], ["CMV", "SPECIES", 344, 347], ["CMV", "SPECIES", 413, 416], ["CMV", "SPECIES", 602, 605], ["CMV", "SPECIES", 671, 674], ["the cCMV", "TREATMENT", 17, 25], ["cytomegalovirus in pregnancy", "PROBLEM", 111, 139], ["risk evaluation", "TEST", 144, 159], ["congenital CMV infection", "PROBLEM", 188, 212], ["cCMV infection", "PROBLEM", 224, 238], ["cCMV", "PROBLEM", 292, 296], ["a primary maternal CMV infection", "PROBLEM", 325, 357], ["a recurrent maternal CMV infection", "PROBLEM", 392, 426], ["maternal infection", "PROBLEM", 450, 468], ["cytomegalovirus in pregnancy", "PROBLEM", 514, 542], ["risk evaluation", "TEST", 547, 562], ["congenital CMV infection", "PROBLEM", 591, 615], ["a seronegative pregnant", "PROBLEM", 628, 651], ["acquiring CMV during pregnancy", "PROBLEM", 661, 691], ["cCMV", "OBSERVATION", 21, 25], ["cytomegalovirus", "OBSERVATION", 111, 126], ["CMV infection", "OBSERVATION", 199, 212], ["cCMV", "OBSERVATION_MODIFIER", 224, 228], ["infection", "OBSERVATION", 229, 238], ["considered to be due to", "UNCERTAINTY", 301, 324], ["CMV infection", "OBSERVATION", 344, 357], ["CMV infection", "OBSERVATION", 413, 426], ["infection", "OBSERVATION", 459, 468], ["cytomegalovirus", "OBSERVATION", 514, 529], ["CMV infection", "OBSERVATION", 602, 615]]], ["The transmission risk after a maternal primary infection is 45%.", [["primary infection", "DISEASE", 39, 56], ["a maternal primary infection", "PROBLEM", 28, 56], ["infection", "OBSERVATION", 47, 56]]], ["Women with prior immunity have a very low risk (0.20%) for cCMV, this risk increases to 3% when IgM are find in women with know prior immunity.", [["Women", "ORGANISM", 0, 5], ["IgM", "GENE_OR_GENE_PRODUCT", 96, 99], ["women", "ORGANISM", 112, 117], ["IgM", "PROTEIN", 96, 99], ["Women", "SPECIES", 0, 5], ["women", "SPECIES", 112, 117], ["cCMV", "SPECIES", 59, 63], ["cCMV", "PROBLEM", 59, 63]]], ["The risk for women with undetermined infectious status in early pregnancy to give birth to a congenitally infected neonate is 5.8%.", [["congenitally infected", "DISEASE", 93, 114], ["women", "ORGANISM", 13, 18], ["women", "SPECIES", 13, 18], ["undetermined infectious status", "PROBLEM", 24, 54], ["a congenitally infected neonate", "PROBLEM", 91, 122], ["infectious", "OBSERVATION", 37, 47]]], ["This report provides the first data on rotavirus epidemiology and disease burden in Norway.", [["rotavirus", "ORGANISM", 39, 48], ["rotavirus", "SPECIES", 39, 48], ["rotavirus epidemiology", "PROBLEM", 39, 61], ["disease burden", "PROBLEM", 66, 80]]], ["Further studies are needed to assess the economic impact of rotavirus disease and the cost-effectiveness of vaccination to inform decisions on introduction of rotavirus vaccines into the national program of childhood immunisation.T. K\u00f6hler\u00b0(Geneva, CH)Pseudomonas aeruginosa may colonise the lungs of cystic fibrosis patients over years but may also cause acute infections in mechanically ventilated patients and immuno-compromised hosts within a matter of days.", [["lungs", "ANATOMY", 292, 297], ["rotavirus disease", "DISEASE", 60, 77], ["cystic fibrosis", "DISEASE", 301, 316], ["infections", "DISEASE", 362, 372], ["rotavirus", "ORGANISM", 60, 69], ["rotavirus", "ORGANISM", 159, 168], ["T. K\u00f6hler\u00b0", "ORGANISM", 230, 240], ["Geneva, CH)Pseudomonas aeruginosa", "ORGANISM", 241, 274], ["lungs", "ORGAN", 292, 297], ["patients", "ORGANISM", 317, 325], ["patients", "ORGANISM", 400, 408], ["Pseudomonas aeruginosa", "SPECIES", 252, 274], ["patients", "SPECIES", 317, 325], ["patients", "SPECIES", 400, 408], ["rotavirus", "SPECIES", 60, 69], ["rotavirus", "SPECIES", 159, 168], ["Pseudomonas aeruginosa", "SPECIES", 252, 274], ["Further studies", "TEST", 0, 15], ["rotavirus disease", "PROBLEM", 60, 77], ["vaccination", "TREATMENT", 108, 119], ["rotavirus vaccines", "TREATMENT", 159, 177], ["childhood immunisation", "TREATMENT", 207, 229], ["Pseudomonas aeruginosa", "PROBLEM", 252, 274], ["cystic fibrosis", "PROBLEM", 301, 316], ["acute infections in mechanically ventilated patients", "PROBLEM", 356, 408], ["immuno-compromised hosts", "PROBLEM", 413, 437], ["rotavirus", "OBSERVATION", 60, 69], ["lungs", "ANATOMY", 292, 297], ["cystic", "OBSERVATION_MODIFIER", 301, 307], ["fibrosis", "OBSERVATION", 308, 316], ["may also cause", "UNCERTAINTY", 341, 355], ["acute", "OBSERVATION_MODIFIER", 356, 361], ["infections", "OBSERVATION", 362, 372]]], ["Despite aggressive antibiotic treatments the organism is rarely eradicated.", [["aggressive antibiotic treatments", "TREATMENT", 8, 40], ["the organism", "PROBLEM", 41, 53]]], ["Instead P. aeruginosa adapts to its host environment by developing resistance mechanisms and changing its lifestyle and virulence properties.", [["P. aeruginosa", "ORGANISM", 8, 21], ["P. aeruginosa", "SPECIES", 8, 21], ["P. aeruginosa", "SPECIES", 8, 21], ["aeruginosa", "OBSERVATION", 11, 21], ["resistance", "OBSERVATION", 67, 77]]], ["Focusing on mechanically ventilated patients, we will detail the dynamics of resistance emergence and persistence of P. aeruginosa lung populations during antibiotic therapy.", [["lung", "ANATOMY", 131, 135], ["patients", "ORGANISM", 36, 44], ["P. aeruginosa", "ORGANISM", 117, 130], ["lung", "ORGAN", 131, 135], ["patients", "SPECIES", 36, 44], ["P. aeruginosa", "SPECIES", 117, 130], ["P. aeruginosa", "SPECIES", 117, 130], ["resistance emergence", "PROBLEM", 77, 97], ["P. aeruginosa lung populations", "PROBLEM", 117, 147], ["antibiotic therapy", "TREATMENT", 155, 173], ["lung", "ANATOMY", 131, 135]]], ["We further discuss how P. aeruginosa populations evolve naturally in the absence of any antimicrobial treatment within the lungs of intubated patients by changing their virulence properties.", [["lungs", "ANATOMY", 123, 128], ["P. aeruginosa populations", "ORGANISM", 23, 48], ["lungs", "ORGAN", 123, 128], ["patients", "ORGANISM", 142, 150], ["P. aeruginosa", "SPECIES", 23, 36], ["patients", "SPECIES", 142, 150], ["P. aeruginosa", "SPECIES", 23, 36], ["P. aeruginosa populations", "PROBLEM", 23, 48], ["any antimicrobial treatment", "TREATMENT", 84, 111], ["lungs", "ANATOMY", 123, 128]]], ["The relevance of these findings both with respect to concepts of social evolution and the development of novel anti-infective strategies will be highlighted.", [["novel anti-infective strategies", "TREATMENT", 105, 136]]], ["The genome of P. aeruginosa encodes many potential efflux systems.", [["P. aeruginosa", "ORGANISM", 14, 27], ["P. aeruginosa", "SPECIES", 14, 27], ["P. aeruginosa", "SPECIES", 14, 27], ["P. aeruginosa", "PROBLEM", 14, 27], ["potential efflux systems", "PROBLEM", 41, 65], ["P. aeruginosa", "OBSERVATION", 14, 27], ["efflux systems", "OBSERVATION", 51, 65]]], ["However, only a few of them appear to play a significant role in antibiotic resistance.", [["antibiotic resistance", "TREATMENT", 65, 86], ["antibiotic resistance", "OBSERVATION", 65, 86]]], ["In this respect, the Mex (for Multiple efflux) systems are of particular interest because of their ability to extrude a wide range of antimicrobials.", [["Mex", "GENE_OR_GENE_PRODUCT", 21, 24], ["the Mex", "TREATMENT", 17, 24], ["Multiple efflux) systems", "TREATMENT", 30, 54], ["a wide range of antimicrobials", "TREATMENT", 118, 148]]], ["These polyspecific machineries result from the assembly of (i) a drug/proton antiporter, (ii) a periplasmic adaptor protein, and (iii) an outer membrane gated channel.", [["outer membrane", "ANATOMY", 138, 152], ["outer membrane", "CELLULAR_COMPONENT", 138, 152], ["proton antiporter", "PROTEIN", 70, 87], ["periplasmic adaptor protein", "PROTEIN", 96, 123], ["outer membrane gated channel", "PROTEIN", 138, 166], ["a drug/proton antiporter", "TREATMENT", 63, 87], ["a periplasmic adaptor protein", "TEST", 94, 123], ["an outer membrane gated channel", "TREATMENT", 135, 166]]], ["It is now well established that the constitutive expression of the tripartite pump MexAB-OprM provides P. aeruginosa with a relatively high intrinsic resistance to quinolones, blactams (except imipenem), tetracyclines, macrolides, chloramphenicol, trimethoprim, and novobiocin.", [["quinolones", "CHEMICAL", 164, 174], ["blactams", "CHEMICAL", 176, 184], ["imipenem", "CHEMICAL", 193, 201], ["tetracyclines", "CHEMICAL", 204, 217], ["macrolides", "CHEMICAL", 219, 229], ["chloramphenicol", "CHEMICAL", 231, 246], ["trimethoprim", "CHEMICAL", 248, 260], ["novobiocin", "CHEMICAL", 266, 276], ["quinolones", "CHEMICAL", 164, 174], ["blactams", "CHEMICAL", 176, 184], ["imipenem", "CHEMICAL", 193, 201], ["tetracyclines", "CHEMICAL", 204, 217], ["macrolides", "CHEMICAL", 219, 229], ["chloramphenicol", "CHEMICAL", 231, 246], ["trimethoprim", "CHEMICAL", 248, 260], ["novobiocin", "CHEMICAL", 266, 276], ["MexAB", "GENE_OR_GENE_PRODUCT", 83, 88], ["OprM", "GENE_OR_GENE_PRODUCT", 89, 93], ["P. aeruginosa", "ORGANISM", 103, 116], ["quinolones", "SIMPLE_CHEMICAL", 164, 174], ["blactams", "SIMPLE_CHEMICAL", 176, 184], ["imipenem", "SIMPLE_CHEMICAL", 193, 201], ["tetracyclines", "SIMPLE_CHEMICAL", 204, 217], ["macrolides", "SIMPLE_CHEMICAL", 219, 229], ["chloramphenicol", "SIMPLE_CHEMICAL", 231, 246], ["trimethoprim", "SIMPLE_CHEMICAL", 248, 260], ["novobiocin", "SIMPLE_CHEMICAL", 266, 276], ["MexAB", "PROTEIN", 83, 88], ["OprM", "PROTEIN", 89, 93], ["P. aeruginosa", "SPECIES", 103, 116], ["P. aeruginosa", "SPECIES", 103, 116], ["the tripartite pump MexAB", "TREATMENT", 63, 88], ["P. aeruginosa", "PROBLEM", 103, 116], ["quinolones", "TREATMENT", 164, 174], ["blactams", "TREATMENT", 176, 184], ["imipenem", "TREATMENT", 193, 201], ["tetracyclines", "TREATMENT", 204, 217], ["macrolides", "TREATMENT", 219, 229], ["chloramphenicol", "TREATMENT", 231, 246], ["trimethoprim", "TREATMENT", 248, 260], ["novobiocin", "TREATMENT", 266, 276]]], ["This protective mechanism is potentiated by the poor permeability of the outer membrane and activity of another pump, MexXY/OprM, whose expression is induced by substrates targeting the ribosome (e.g., tetracyclines, macrolides, aminoglycosides).S474 Drug efflux in intrinsic and acquired resistance inAccumulating reports indicate that multidrug resistant mutants upregulating one or both of these systems are quite common in the clinical setting.", [["outer membrane", "ANATOMY", 73, 87], ["tetracyclines", "CHEMICAL", 202, 215], ["macrolides", "CHEMICAL", 217, 227], ["aminoglycosides", "CHEMICAL", 229, 244], ["S474", "CHEMICAL", 246, 250], ["tetracyclines", "CHEMICAL", 202, 215], ["macrolides", "CHEMICAL", 217, 227], ["aminoglycosides", "CHEMICAL", 229, 244], ["S474", "CHEMICAL", 246, 250], ["outer membrane", "CELLULAR_COMPONENT", 73, 87], ["MexXY", "GENE_OR_GENE_PRODUCT", 118, 123], ["OprM", "GENE_OR_GENE_PRODUCT", 124, 128], ["ribosome", "CELLULAR_COMPONENT", 186, 194], ["tetracyclines", "SIMPLE_CHEMICAL", 202, 215], ["macrolides", "SIMPLE_CHEMICAL", 217, 227], ["aminoglycosides", "SIMPLE_CHEMICAL", 229, 244], ["S474", "GENE_OR_GENE_PRODUCT", 246, 250], ["MexXY", "PROTEIN", 118, 123], ["OprM", "PROTEIN", 124, 128], ["another pump", "TREATMENT", 104, 116], ["OprM", "TREATMENT", 124, 128], ["the ribosome", "TREATMENT", 182, 194], ["tetracyclines", "TREATMENT", 202, 215], ["macrolides", "TREATMENT", 217, 227], ["aminoglycosides", "TREATMENT", 229, 244], ["Drug efflux", "TEST", 251, 262], ["multidrug resistant mutants upregulating", "PROBLEM", 337, 377], ["outer membrane", "ANATOMY_MODIFIER", 73, 87], ["Drug efflux", "OBSERVATION", 251, 262], ["multidrug resistant", "OBSERVATION", 337, 356]]], ["Such mutants, which are readily selected by sub-optimal treatments with fluoroquinolones, b-lactams or aminoglycosides, tend to accumulate various resistance mechanisms without loosing the wildtype pathogenicity of P. aeruginosa.", [["fluoroquinolones", "CHEMICAL", 72, 88], ["b-lactams", "CHEMICAL", 90, 99], ["aminoglycosides", "CHEMICAL", 103, 118], ["fluoroquinolones", "CHEMICAL", 72, 88], ["b-lactams", "CHEMICAL", 90, 99], ["aminoglycosides", "CHEMICAL", 103, 118], ["fluoroquinolones", "SIMPLE_CHEMICAL", 72, 88], ["b-lactams", "SIMPLE_CHEMICAL", 90, 99], ["aminoglycosides", "SIMPLE_CHEMICAL", 103, 118], ["P. aeruginosa", "ORGANISM", 215, 228], ["P. aeruginosa", "SPECIES", 215, 228], ["P. aeruginosa", "SPECIES", 215, 228], ["Such mutants", "PROBLEM", 0, 12], ["fluoroquinolones", "TREATMENT", 72, 88], ["b-lactams", "TREATMENT", 90, 99], ["aminoglycosides", "TREATMENT", 103, 118], ["various resistance mechanisms", "PROBLEM", 139, 168], ["the wildtype pathogenicity of P. aeruginosa", "PROBLEM", 185, 228]]], ["Whether the low resistance levels (MIC x 2-to 8-fold) conferred by efflux may promote second-step mutants with altered drug targets (GyrA, GyrB, ParC) or derepressed AmpC b-lactamase has not been confirmed in vitro.", [["GyrA", "GENE_OR_GENE_PRODUCT", 133, 137], ["GyrB", "GENE_OR_GENE_PRODUCT", 139, 143], ["ParC", "GENE_OR_GENE_PRODUCT", 145, 149], ["AmpC b-lactamase", "GENE_OR_GENE_PRODUCT", 166, 182], ["GyrA", "PROTEIN", 133, 137], ["GyrB", "PROTEIN", 139, 143], ["ParC", "PROTEIN", 145, 149], ["AmpC b-lactamase", "PROTEIN", 166, 182], ["the low resistance levels", "PROBLEM", 8, 33], ["MIC", "TEST", 35, 38], ["altered drug targets", "PROBLEM", 111, 131], ["GyrA", "TEST", 133, 137], ["derepressed AmpC b-lactamase", "PROBLEM", 154, 182], ["low resistance", "OBSERVATION_MODIFIER", 12, 26]]], ["In the specific context of cystic fibrosis (CF), a recent study from our laboratory showed that the MexXY/OprM pump can be responsible for much higher resistance levels to aminoglycosides (64-to 128-fold).", [["cystic", "ANATOMY", 27, 33], ["cystic fibrosis", "DISEASE", 27, 42], ["CF", "DISEASE", 44, 46], ["aminoglycosides", "CHEMICAL", 172, 187], ["aminoglycosides", "CHEMICAL", 172, 187], ["cystic fibrosis", "PATHOLOGICAL_FORMATION", 27, 42], ["MexXY", "GENE_OR_GENE_PRODUCT", 100, 105], ["OprM pump", "GENE_OR_GENE_PRODUCT", 106, 115], ["aminoglycosides", "SIMPLE_CHEMICAL", 172, 187], ["MexXY", "PROTEIN", 100, 105], ["OprM", "PROTEIN", 106, 110], ["cystic fibrosis", "PROBLEM", 27, 42], ["a recent study", "TEST", 49, 63], ["our laboratory", "TEST", 69, 83], ["the MexXY/OprM pump", "TREATMENT", 96, 115], ["much higher resistance levels", "PROBLEM", 139, 168], ["aminoglycosides", "TEST", 172, 187], ["cystic", "OBSERVATION_MODIFIER", 27, 33], ["fibrosis", "OBSERVATION", 34, 42]]], ["This increased efficacy of the system partially results from adaptive mutations in the mexY gene.", [["mexY", "GENE_OR_GENE_PRODUCT", 87, 91], ["mexY gene", "DNA", 87, 96], ["adaptive mutations", "PROBLEM", 61, 79]]], ["In contrast, subpopulations deficient in MexAB-OprM tend to emerge during long-term colonisation of CF airways.", [["CF airways", "ANATOMY", 100, 110], ["MexAB-OprM", "GENE_OR_GENE_PRODUCT", 41, 51], ["CF airways", "MULTI-TISSUE_STRUCTURE", 100, 110], ["MexAB", "PROTEIN", 41, 46], ["OprM", "PROTEIN", 47, 51], ["subpopulations deficient", "PROBLEM", 13, 37], ["MexAB", "TEST", 41, 46], ["subpopulations deficient", "OBSERVATION", 13, 37], ["airways", "ANATOMY", 103, 110]]], ["While easily selected in vitro on selective media, mutants overexpressing other Mex systems (MexCD-OprJ, MexEF-OprN, MexGHI-OpmD, MexJK/OprM, MexVW/OprM) have been rarely described in CF and non-CF patients.", [["Mex", "GENE_OR_GENE_PRODUCT", 80, 83], ["MexCD-OprJ", "GENE_OR_GENE_PRODUCT", 93, 103], ["MexEF-OprN", "GENE_OR_GENE_PRODUCT", 105, 115], ["MexGHI-OpmD", "GENE_OR_GENE_PRODUCT", 117, 128], ["MexJK", "GENE_OR_GENE_PRODUCT", 130, 135], ["OprM", "GENE_OR_GENE_PRODUCT", 136, 140], ["MexVW", "GENE_OR_GENE_PRODUCT", 142, 147], ["OprM", "GENE_OR_GENE_PRODUCT", 148, 152], ["CF", "CANCER", 184, 186], ["patients", "ORGANISM", 198, 206], ["Mex systems", "PROTEIN", 80, 91], ["MexCD", "PROTEIN", 93, 98], ["OprJ", "PROTEIN", 99, 103], ["MexEF", "PROTEIN", 105, 110], ["OprN", "PROTEIN", 111, 115], ["MexGHI", "PROTEIN", 117, 123], ["OpmD", "PROTEIN", 124, 128], ["MexJK", "PROTEIN", 130, 135], ["OprM", "PROTEIN", 136, 140], ["MexVW", "PROTEIN", 142, 147], ["OprM", "DNA", 148, 152], ["patients", "SPECIES", 198, 206], ["selective media", "TREATMENT", 34, 49], ["Mex systems", "TREATMENT", 80, 91], ["MexCD", "TEST", 93, 98], ["OprJ", "TREATMENT", 99, 103], ["MexEF", "TREATMENT", 105, 110], ["OprN", "TREATMENT", 111, 115], ["MexGHI", "TREATMENT", 117, 123], ["MexJK/OprM", "TREATMENT", 130, 140], ["MexVW/OprM", "TREATMENT", 142, 152]]], ["Some data support the notion that up-regulation of MexCD-OprJ or MexEF-OprN might be detrimental to the virulence of P. aeruginosa.", [["MexCD", "GENE_OR_GENE_PRODUCT", 51, 56], ["OprJ", "GENE_OR_GENE_PRODUCT", 57, 61], ["MexEF-OprN", "GENE_OR_GENE_PRODUCT", 65, 75], ["P. aeruginosa", "ORGANISM", 117, 130], ["MexCD", "PROTEIN", 51, 56], ["OprJ", "PROTEIN", 57, 61], ["MexEF", "PROTEIN", 65, 70], ["OprN", "PROTEIN", 71, 75], ["P. aeruginosa", "SPECIES", 117, 130], ["P. aeruginosa", "SPECIES", 117, 130], ["MexCD", "TREATMENT", 51, 56], ["OprJ", "TREATMENT", 57, 61], ["MexEF", "TREATMENT", 65, 70], ["OprN", "TREATMENT", 71, 75], ["P. aeruginosa", "PROBLEM", 117, 130]]], ["In conclusion, therapeutic strategies based on efflux inhibitors should target the MexAB-OprM and the MexXY/OprM systems in priority.S474 Drug efflux in intrinsic and acquired resistance inEuropean aspects of malaria S478 Rapid diagnostic tests for malaria: twenty years to convince . . .B. Genton\u00b0(Lausanne, CH)Prompt diagnosis and treatment of malaria are critical factors in reducing morbidity and mortality.", [["S474", "CHEMICAL", 133, 137], ["malaria", "DISEASE", 209, 216], ["malaria", "DISEASE", 249, 256], ["malaria", "DISEASE", 346, 353], ["S474", "CHEMICAL", 133, 137], ["MexAB-OprM", "GENE_OR_GENE_PRODUCT", 83, 93], ["MexXY", "GENE_OR_GENE_PRODUCT", 102, 107], ["MexAB", "PROTEIN", 83, 88], ["OprM", "PROTEIN", 89, 93], ["MexXY", "PROTEIN", 102, 107], ["therapeutic strategies", "TREATMENT", 15, 37], ["efflux inhibitors", "TREATMENT", 47, 64], ["the MexAB", "TREATMENT", 79, 88], ["OprM", "TREATMENT", 89, 93], ["the MexXY/OprM systems", "TREATMENT", 98, 120], ["Drug efflux", "TEST", 138, 149], ["malaria", "PROBLEM", 209, 216], ["Rapid diagnostic tests", "TEST", 222, 244], ["malaria", "PROBLEM", 249, 256], ["malaria", "PROBLEM", 346, 353], ["critical factors", "PROBLEM", 358, 374], ["reducing morbidity", "PROBLEM", 378, 396], ["Drug efflux", "OBSERVATION", 138, 149], ["malaria", "OBSERVATION", 209, 216], ["malaria", "OBSERVATION", 346, 353]]], ["Microscopy has long been the gold standard for malaria diagnosis, but the newer rapid diagnostic tests (RDTs) now offer considerable advantages, especially so in endemic countries.", [["malaria", "DISEASE", 47, 54], ["Microscopy", "TEST", 0, 10], ["malaria diagnosis", "PROBLEM", 47, 64], ["the newer rapid diagnostic tests", "TEST", 70, 102], ["RDTs", "TEST", 104, 108]]], ["After close to twenty years of development and operational research, the diagnostic performance of RDTs is now established in all settings.B. Genton\u00b0(Lausanne, CH)Meta-analyses have clearly demonstrated equivalence of RDTs over expert microscopy to detect parasites, and clear superiority over routine microscopy.", [["RDTs", "TEST", 99, 103], ["RDTs", "TEST", 218, 222], ["expert microscopy", "TEST", 228, 245], ["parasites", "PROBLEM", 256, 265], ["routine microscopy", "TEST", 294, 312]]], ["Actually, one of the major reasons that have delayed successful implementation of RDT in endemic areas was the use of poor quality microscopy that has impeded reliable measurement of sensitivity and specificity and undermined confidence of health workers in RDTs.B. Genton\u00b0(Lausanne, CH)Other factors were poor product performance, inadequate methods to determine the quality of products and a lack of emphasis and capacity to deal with these issues.", [["RDT in endemic areas", "PROBLEM", 82, 102], ["poor quality microscopy", "PROBLEM", 118, 141]]], ["For the potential of RDTs to be realised, it is crucial that high-quality products that perform reliably and accurately under field conditions are made available and that quality insurance is performed on all steps of the procedure.", [["RDTs", "PROBLEM", 21, 25], ["the procedure", "TREATMENT", 218, 231]]], ["In achieving this goal, the shift from symptom-based diagnosis to parasite-based management of malaria can bring significant improvement for the management of fever in endemic areas.", [["malaria", "DISEASE", 95, 102], ["fever", "DISEASE", 159, 164], ["symptom", "PROBLEM", 39, 46], ["parasite", "PROBLEM", 66, 74], ["malaria", "PROBLEM", 95, 102], ["the management", "TREATMENT", 141, 155], ["fever in endemic areas", "PROBLEM", 159, 181], ["malaria", "OBSERVATION", 95, 102], ["fever", "OBSERVATION", 159, 164]]], ["For travelers returning in temperate climates with fever, RDTs have also the potential to improve diagnostic procedures, especially so in hospitals where reliable microscopy is not available out of hours.", [["fever", "DISEASE", 51, 56], ["fever", "PROBLEM", 51, 56], ["RDTs", "PROBLEM", 58, 62], ["diagnostic procedures", "TEST", 98, 119], ["reliable microscopy", "TEST", 154, 173]]], ["In patients with no danger sign or significant thrombopenia, a negative RDT is sufficient to exclude malaria and allows waiting 12\u221224 hours for performing or reading the microscopy slide.", [["thrombopenia", "DISEASE", 47, 59], ["malaria", "DISEASE", 101, 108], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["danger sign", "PROBLEM", 20, 31], ["significant thrombopenia", "PROBLEM", 35, 59], ["malaria", "PROBLEM", 101, 108], ["the microscopy slide", "TEST", 166, 186], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["thrombopenia", "OBSERVATION", 47, 59]]], ["RDTs should be repeated every 12\u221224 hours for three consecutive days if fever persists and in the absence of alternative diagnosis.", [["fever", "DISEASE", 72, 77], ["RDTs", "TEST", 0, 4], ["fever", "PROBLEM", 72, 77]]], ["RDTs represent a revolution in the fight against malaria and will tremendously help to manage appropriately patients with fever, especially so when malaria is declining and hence other causes of fever increasing.", [["malaria", "DISEASE", 49, 56], ["fever", "DISEASE", 122, 127], ["malaria", "DISEASE", 148, 155], ["fever", "DISEASE", 195, 200], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["RDTs", "TEST", 0, 4], ["malaria", "PROBLEM", 49, 56], ["fever", "PROBLEM", 122, 127], ["malaria", "PROBLEM", 148, 155], ["fever", "PROBLEM", 195, 200], ["fever", "OBSERVATION", 195, 200]]], ["The ambitious deployment that is foreseen in the coming years in Africa through large grants from the Global Fund should contribute to achieving the millennium goals.C. Hatz\u00b0(Basel, CH)Fever is the key symptom of malaria among returning travellers (97%).", [["Fever", "DISEASE", 185, 190], ["malaria", "DISEASE", 213, 220], ["The ambitious deployment", "TREATMENT", 0, 24], ["Fever", "PROBLEM", 185, 190], ["malaria", "PROBLEM", 213, 220], ["large", "OBSERVATION_MODIFIER", 80, 85], ["grants", "OBSERVATION", 86, 92], ["malaria", "OBSERVATION", 213, 220]]], ["Headache, chills, myalgia, sweating and lack of a focus are frequently recorded, but non-specific.", [["Headache", "DISEASE", 0, 8], ["chills", "DISEASE", 10, 16], ["myalgia", "DISEASE", 18, 25], ["sweating", "DISEASE", 27, 35], ["Headache", "PROBLEM", 0, 8], ["chills", "PROBLEM", 10, 16], ["myalgia", "PROBLEM", 18, 25], ["sweating", "PROBLEM", 27, 35], ["chills", "OBSERVATION", 10, 16], ["myalgia", "OBSERVATION", 18, 25], ["non-specific", "OBSERVATION_MODIFIER", 85, 97]]], ["Nausea and vomiting are often seen in children.", [["Nausea", "DISEASE", 0, 6], ["vomiting", "DISEASE", 11, 19], ["children", "ORGANISM", 38, 46], ["children", "SPECIES", 38, 46], ["Nausea", "PROBLEM", 0, 6], ["vomiting", "PROBLEM", 11, 19]]], ["The differential diagnosis of other infections, mainly of viral origin, is further difficult because (dry) cough and (mild) diarrhoea are often present.", [["infections", "DISEASE", 36, 46], ["cough", "DISEASE", 107, 112], ["diarrhoea", "DISEASE", 124, 133], ["other infections", "PROBLEM", 30, 46], ["viral origin", "PROBLEM", 58, 70], ["dry) cough and (mild) diarrhoea", "PROBLEM", 102, 133], ["infections", "OBSERVATION", 36, 46], ["viral origin", "OBSERVATION", 58, 70], ["cough", "OBSERVATION", 107, 112], ["mild", "OBSERVATION_MODIFIER", 118, 122], ["diarrhoea", "OBSERVATION", 124, 133]]], ["Laboratory findings (thrombocytopenia, low or normal leucocyte count) can be helpful in the assessment of mild to moderate malaria.", [["leucocyte", "ANATOMY", 53, 62], ["thrombocytopenia", "DISEASE", 21, 37], ["malaria", "DISEASE", 123, 130], ["leucocyte", "CELL", 53, 62], ["Laboratory findings", "TEST", 0, 19], ["thrombocytopenia", "PROBLEM", 21, 37], ["the assessment", "TEST", 88, 102], ["mild to moderate malaria", "PROBLEM", 106, 130], ["thrombocytopenia", "OBSERVATION", 21, 37], ["mild", "OBSERVATION_MODIFIER", 106, 110], ["moderate", "OBSERVATION_MODIFIER", 114, 122], ["malaria", "OBSERVATION", 123, 130]]], ["Clinical signs and symptoms, e.g. fever, may be mitigated in semiimmune patients (visiting friends and relatives, foreign visitors) seen in non-endemic countries who represent the majority of cases diagnosed in industrialised countries.", [["fever", "DISEASE", 34, 39], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["Clinical signs and symptoms", "PROBLEM", 0, 27], ["fever", "PROBLEM", 34, 39]]], ["Caution is warranted in assessing such patients as many of them may no longer be exposed to malaria in their countries of origin, thus no longer partially protected and also at risk of suffering from severe complications.", [["malaria", "DISEASE", 92, 99], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["malaria", "PROBLEM", 92, 99], ["severe complications", "PROBLEM", 200, 220], ["malaria", "OBSERVATION", 92, 99], ["no longer", "UNCERTAINTY", 135, 144], ["severe", "OBSERVATION_MODIFIER", 200, 206], ["complications", "OBSERVATION", 207, 220]]], ["Up to 10% of all imported malaria cases may be severe, presenting with jaundice, impaired consciousness to coma, acute renal failure, and, in the course of events, acute respiratory failure.", [["renal", "ANATOMY", 119, 124], ["respiratory", "ANATOMY", 170, 181], ["malaria", "DISEASE", 26, 33], ["jaundice", "DISEASE", 71, 79], ["impaired consciousness", "DISEASE", 81, 103], ["coma", "DISEASE", 107, 111], ["acute renal failure", "DISEASE", 113, 132], ["respiratory failure", "DISEASE", 170, 189], ["renal", "ORGAN", 119, 124], ["all imported malaria cases", "PROBLEM", 13, 39], ["jaundice", "PROBLEM", 71, 79], ["impaired consciousness to coma", "PROBLEM", 81, 111], ["acute renal failure", "PROBLEM", 113, 132], ["acute respiratory failure", "PROBLEM", 164, 189], ["malaria", "OBSERVATION", 26, 33], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["jaundice", "OBSERVATION", 71, 79], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["renal", "ANATOMY", 119, 124], ["failure", "OBSERVATION", 125, 132], ["acute", "OBSERVATION_MODIFIER", 164, 169], ["respiratory failure", "OBSERVATION", 170, 189]]], ["Delay in diagnosis and start of treatment is partly responsible for fatality rates of 1% and more in some countries.C. Hatz\u00b0(Basel, CH)If you don't look for them, you won't find them: anaerobes revisited S481 Anaerobic microbiota of the mouth \u2212 friend or foe?E. K\u00f6n\u00f6nen\u00b0(Turku, FI)Anaerobes form a major part of the commensal microbiota in the digestive tract where they constitute an integral component of the function on mucosal surfaces.", [["mouth", "ANATOMY", 237, 242], ["digestive tract", "ANATOMY", 344, 359], ["mucosal surfaces", "ANATOMY", 423, 439], ["mouth", "ORGANISM_SUBDIVISION", 237, 242], ["commensal microbiota", "PATHOLOGICAL_FORMATION", 316, 336], ["digestive tract", "ORGAN", 344, 359], ["mucosal surfaces", "TISSUE", 423, 439], ["treatment", "TREATMENT", 32, 41], ["fatality rates", "TEST", 68, 82], ["anaerobes", "PROBLEM", 184, 193], ["Anaerobes", "TREATMENT", 281, 290], ["commensal microbiota", "OBSERVATION", 316, 336], ["digestive tract", "ANATOMY", 344, 359], ["integral", "OBSERVATION_MODIFIER", 385, 393], ["component", "OBSERVATION_MODIFIER", 394, 403], ["function", "OBSERVATION_MODIFIER", 411, 419], ["mucosal surfaces", "OBSERVATION", 423, 439]]], ["In the mouth, teeth create a unique, non-shedding environment for bacteria to attach and to form biofilms.", [["mouth", "ANATOMY", 7, 12], ["teeth", "ANATOMY", 14, 19], ["mouth", "ORGANISM_SUBDIVISION", 7, 12], ["teeth", "ORGAN", 14, 19], ["bacteria", "PROBLEM", 66, 74], ["mouth", "ANATOMY", 7, 12], ["teeth", "ANATOMY", 14, 19]]], ["There is an age-related succession order of species in bacterial colonisation of the mouth, and once established, individual anaerobic species tend to remain as members of the oral microbiota.", [["mouth", "ANATOMY", 85, 90], ["oral", "ANATOMY", 176, 180], ["mouth", "ORGANISM_SUBDIVISION", 85, 90], ["oral", "ORGANISM_SUBDIVISION", 176, 180], ["microbiota", "PATHOLOGICAL_FORMATION", 181, 191], ["bacterial colonisation of the mouth", "PROBLEM", 55, 90], ["individual anaerobic species", "PROBLEM", 114, 142], ["bacterial colonisation", "OBSERVATION", 55, 77], ["mouth", "ANATOMY", 85, 90]]], ["The agerelated pattern of the colonisation of anaerobic bacteria is partly connected with the development (or loss) of the dentition.", [["dentition", "ORGAN", 123, 132], ["the colonisation of anaerobic bacteria", "PROBLEM", 26, 64], ["loss) of the dentition", "PROBLEM", 110, 132], ["colonisation", "OBSERVATION_MODIFIER", 30, 42], ["anaerobic bacteria", "OBSERVATION", 46, 64], ["loss", "OBSERVATION_MODIFIER", 110, 114], ["dentition", "ANATOMY", 123, 132]]], ["Interactions between different bacteria residing in the same microenvironment influence the composition of the microbiota \u2212 or the development of pathologic conditions.", [["different bacteria", "PROBLEM", 21, 39], ["pathologic conditions", "PROBLEM", 146, 167], ["bacteria", "OBSERVATION_MODIFIER", 31, 39]]], ["Although commensal bacteria are regarded beneficial to the host, some anaerobic members of the oral microbiota contain characteristics potentially detrimental for the health status of an individual.", [["oral microbiota", "ANATOMY", 95, 110], ["oral microbiota", "PATHOLOGICAL_FORMATION", 95, 110], ["commensal bacteria", "PROBLEM", 9, 27], ["commensal", "OBSERVATION_MODIFIER", 9, 18], ["bacteria", "OBSERVATION", 19, 27]]], ["Molecular means of characterisation have resulted in increased knowledge about the \"normal\" microbiota of the mouth and in detection of new species and genera as well as phylotypes, which can be associated with infectious situations in the mouth.", [["mouth", "ANATOMY", 110, 115], ["mouth", "ANATOMY", 240, 245], ["mouth", "ORGANISM_SUBDIVISION", 110, 115], ["mouth", "ORGANISM_SUBDIVISION", 240, 245], ["new species and genera", "PROBLEM", 136, 158], ["phylotypes", "PROBLEM", 170, 180], ["infectious situations in the mouth", "PROBLEM", 211, 245], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["mouth", "ANATOMY", 110, 115], ["new", "OBSERVATION_MODIFIER", 136, 139], ["species", "OBSERVATION", 140, 147], ["can be associated with", "UNCERTAINTY", 188, 210], ["infectious", "OBSERVATION", 211, 221], ["mouth", "ANATOMY", 240, 245]]], ["Oral infections are multifactorial and polymicrobial in nature, and their aetiologic organisms originate mainly from the oral resident microbiota.", [["Oral", "ANATOMY", 0, 4], ["oral", "ANATOMY", 121, 125], ["Oral infections", "DISEASE", 0, 15], ["oral", "ORGANISM_SUBDIVISION", 121, 125], ["Oral infections", "PROBLEM", 0, 15], ["multifactorial", "PROBLEM", 20, 34], ["polymicrobial in nature", "PROBLEM", 39, 62], ["their aetiologic organisms", "PROBLEM", 68, 94], ["infections", "OBSERVATION", 5, 15], ["polymicrobial", "OBSERVATION_MODIFIER", 39, 52]]], ["The involvement of anaerobes is most obvious in infections of root canals, periodontal tissues, and tissues surrounding erupting wisdom teeth where typical anaerobic findings are Gram-negative rods.", [["root canals", "ANATOMY", 62, 73], ["periodontal tissues", "ANATOMY", 75, 94], ["tissues", "ANATOMY", 100, 107], ["teeth", "ANATOMY", 136, 141], ["infections", "DISEASE", 48, 58], ["root canals", "MULTI-TISSUE_STRUCTURE", 62, 73], ["periodontal tissues", "TISSUE", 75, 94], ["tissues", "TISSUE", 100, 107], ["teeth", "ORGAN", 136, 141], ["Gram", "GENE_OR_GENE_PRODUCT", 179, 183], ["anaerobes", "PROBLEM", 19, 28], ["infections of root canals, periodontal tissues, and tissues", "PROBLEM", 48, 107], ["erupting wisdom teeth", "PROBLEM", 120, 141], ["typical anaerobic findings", "PROBLEM", 148, 174], ["Gram-negative rods", "PROBLEM", 179, 197], ["anaerobes", "OBSERVATION", 19, 28], ["most obvious", "UNCERTAINTY", 32, 44], ["infections", "OBSERVATION", 48, 58], ["root canals", "ANATOMY", 62, 73], ["periodontal tissues", "ANATOMY", 75, 94], ["tissues", "ANATOMY", 100, 107], ["negative rods", "OBSERVATION", 184, 197]]], ["In addition, Gram-positive anaerobic cocci and non-spore-forming Gram-positive anaerobic rods are common in odontogenic infections.", [["odontogenic infections", "DISEASE", 108, 130], ["Gram-positive anaerobic cocci", "PROBLEM", 13, 42], ["non-spore-forming Gram-positive anaerobic rods", "PROBLEM", 47, 93], ["odontogenic infections", "PROBLEM", 108, 130], ["anaerobic cocci", "OBSERVATION", 27, 42], ["positive", "OBSERVATION_MODIFIER", 70, 78], ["anaerobic rods", "OBSERVATION", 79, 93], ["odontogenic", "OBSERVATION_MODIFIER", 108, 119], ["infections", "OBSERVATION", 120, 130]]], ["On some occasions, anaerobes of localised dentoalveolar infections can spread to adjacent tissues and even to the bloodstream, resulting in severe complications in extraoral sites.", [["dentoalveolar", "ANATOMY", 42, 55], ["tissues", "ANATOMY", 90, 97], ["bloodstream", "ANATOMY", 114, 125], ["dentoalveolar infections", "DISEASE", 42, 66], ["dentoalveolar", "ORGAN", 42, 55], ["tissues", "TISSUE", 90, 97], ["extraoral sites", "MULTI-TISSUE_STRUCTURE", 164, 179], ["anaerobes of localised dentoalveolar infections", "PROBLEM", 19, 66], ["the bloodstream", "PROBLEM", 110, 125], ["severe complications in extraoral sites", "PROBLEM", 140, 179], ["localised", "OBSERVATION_MODIFIER", 32, 41], ["dentoalveolar", "ANATOMY", 42, 55], ["infections", "OBSERVATION", 56, 66], ["bloodstream", "ANATOMY", 114, 125], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["complications", "OBSERVATION", 147, 160], ["extraoral sites", "OBSERVATION", 164, 179]]], ["Interestingly, a relatively limited number of anaerobic species are involved in clinically severe infections, however, microbial findings seem to vary depending on geography.", [["infections", "DISEASE", 98, 108], ["anaerobic species", "PROBLEM", 46, 63], ["clinically severe infections", "PROBLEM", 80, 108], ["anaerobic species", "OBSERVATION", 46, 63], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["infections", "OBSERVATION", 98, 108]]], ["Concomitant with the increase in the number of immunosuppressed patients, the number of opportunistic infections caused by commensal anaerobes may increase.", [["immunosuppressed", "DISEASE", 47, 63], ["infections", "DISEASE", 102, 112], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["opportunistic infections", "PROBLEM", 88, 112], ["commensal anaerobes", "PROBLEM", 123, 142], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["immunosuppressed", "OBSERVATION", 47, 63], ["opportunistic", "OBSERVATION_MODIFIER", 88, 101], ["infections", "OBSERVATION", 102, 112], ["commensal", "OBSERVATION_MODIFIER", 123, 132], ["anaerobes", "OBSERVATION", 133, 142]]], ["Identification to the species level will help to establish associations between individual anaerobic species and specific disease states.D.M. Citron\u00b0(Culver City, US)Studies on the bacteriology of diabetic foot infections (DFI) have yielded varied and often contradictory results.", [["foot", "ANATOMY", 206, 210], ["diabetic foot infections", "DISEASE", 197, 221], ["DFI", "DISEASE", 223, 226], ["foot", "ORGANISM_SUBDIVISION", 206, 210], ["the species level", "PROBLEM", 18, 35], ["individual anaerobic species", "PROBLEM", 80, 108], ["specific disease states", "PROBLEM", 113, 136], ["diabetic foot infections", "PROBLEM", 197, 221], ["diabetic", "OBSERVATION_MODIFIER", 197, 205], ["foot", "ANATOMY", 206, 210], ["infections", "OBSERVATION", 211, 221]]], ["The role of anaerobes is particularly unclear, often because the type and severity of the infection is poorly defined, recent antibiotic therapy is unknown, and specimen collection and culture techniques are inadequate.", [["specimen", "ANATOMY", 161, 169], ["infection", "DISEASE", 90, 99], ["anaerobes", "PROBLEM", 12, 21], ["the infection", "PROBLEM", 86, 99], ["recent antibiotic therapy", "TREATMENT", 119, 144], ["specimen collection", "TEST", 161, 180], ["culture techniques", "TEST", 185, 203], ["anaerobes", "OBSERVATION", 12, 21], ["infection", "OBSERVATION", 90, 99], ["poorly defined", "OBSERVATION_MODIFIER", 103, 117]]], ["When optimal collection, transport, and culture techniques are used, multiple organisms including aerobes and anaerobes are usually recovered from severe DFI.", [["culture techniques", "TEST", 40, 58], ["multiple organisms", "PROBLEM", 69, 87], ["aerobes", "PROBLEM", 98, 105], ["anaerobes", "PROBLEM", 110, 119], ["severe DFI", "PROBLEM", 147, 157], ["collection", "OBSERVATION", 13, 23], ["severe", "OBSERVATION_MODIFIER", 147, 153], ["DFI", "OBSERVATION", 154, 157]]], ["Interactions within these polymicrobial soups lead to production of virulence factors, such as haemolysins, proteases, collagenases, and short chain fatty acids, which promote inflammation, impede healing and contribute to the chronicity of the infection.", [["fatty acids", "CHEMICAL", 149, 160], ["inflammation", "DISEASE", 176, 188], ["infection", "DISEASE", 245, 254], ["fatty acids", "CHEMICAL", 149, 160], ["haemolysins", "GENE_OR_GENE_PRODUCT", 95, 106], ["collagenases", "GENE_OR_GENE_PRODUCT", 119, 131], ["virulence factors", "PROTEIN", 68, 85], ["haemolysins", "PROTEIN", 95, 106], ["proteases", "PROTEIN", 108, 117], ["collagenases", "PROTEIN", 119, 131], ["these polymicrobial soups", "TREATMENT", 20, 45], ["virulence factors", "PROBLEM", 68, 85], ["haemolysins", "TREATMENT", 95, 106], ["proteases", "TREATMENT", 108, 117], ["collagenases", "TREATMENT", 119, 131], ["short chain fatty acids", "PROBLEM", 137, 160], ["inflammation", "PROBLEM", 176, 188], ["impede healing", "PROBLEM", 190, 204], ["the infection", "PROBLEM", 241, 254], ["inflammation", "OBSERVATION", 176, 188], ["infection", "OBSERVATION", 245, 254]]], ["To better define the bacteriology of diabetic foot infections, we analyzed our data from a large prospective U.S. multicentre trial of patients with moderate to severe infection that required initial parenteral antibiotic therapy and used optimal post-debridement sample collection, transport and culture procedures.", [["foot", "ANATOMY", 46, 50], ["sample", "ANATOMY", 264, 270], ["diabetic foot infections", "DISEASE", 37, 61], ["infection", "DISEASE", 168, 177], ["foot", "ORGANISM_SUBDIVISION", 46, 50], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["diabetic foot infections", "PROBLEM", 37, 61], ["moderate to severe infection", "PROBLEM", 149, 177], ["initial parenteral antibiotic therapy", "TREATMENT", 192, 229], ["optimal post-debridement sample collection", "TREATMENT", 239, 281], ["transport and culture procedures", "TEST", 283, 315], ["diabetic", "OBSERVATION_MODIFIER", 37, 45], ["foot", "ANATOMY", 46, 50], ["infections", "OBSERVATION", 51, 61], ["moderate", "OBSERVATION_MODIFIER", 149, 157], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["infection", "OBSERVATION", 168, 177]]], ["Of the 427 culture-positive specimens (of 454 total), only 16.2% were pure cultures while 30.4% yielded 5 or more organisms.", [["specimens", "ANATOMY", 28, 37], ["the 427 culture", "TEST", 3, 18], ["pure cultures", "TEST", 70, 83]]], ["A total of 462 anaerobes (range 0\u22129, average 2.3, per specimen) were recovered from 49% of patients, with Gram-positive cocci (GPC) accounting for 45.5% of all anaerobic strains.Shifting from cultures to direct detection of bacterial componentsS485 Is culture still the gold standard, really?M. Struelens\u00b0(Brussels, BE)Tremendous technological advances are made in culture-independent methods of detection and identification of human bacterial pathogens, such as PCR or hybridisation of their genomic DNA.", [["specimen", "ANATOMY", 54, 62], ["patients", "ORGANISM", 91, 99], ["Gram-positive cocci", "GENE_OR_GENE_PRODUCT", 106, 125], ["human", "ORGANISM", 428, 433], ["DNA", "CELLULAR_COMPONENT", 501, 504], ["genomic DNA", "DNA", 493, 504], ["patients", "SPECIES", 91, 99], ["human", "SPECIES", 428, 433], ["human", "SPECIES", 428, 433], ["anaerobes", "TEST", 15, 24], ["average", "TEST", 37, 44], ["Gram-positive cocci", "PROBLEM", 106, 125], ["GPC", "TEST", 127, 130], ["all anaerobic strains", "PROBLEM", 156, 177], ["Shifting from cultures", "TEST", 178, 200], ["bacterial components", "PROBLEM", 224, 244], ["culture", "TEST", 252, 259], ["culture", "TEST", 365, 372], ["human bacterial pathogens", "PROBLEM", 428, 453], ["PCR", "TEST", 463, 466], ["hybridisation of their genomic DNA", "PROBLEM", 470, 504], ["total", "OBSERVATION_MODIFIER", 2, 7], ["positive cocci", "OBSERVATION", 111, 125]]], ["Yet, time honoured Pastorian bacterial culture in liquid and solid nutritive media still remains the gold standard for the laboratory diagnosis of a majority of bacterial infections.", [["bacterial infections", "DISEASE", 161, 181], ["Pastorian bacterial culture", "TEST", 19, 46], ["liquid and solid nutritive media", "TREATMENT", 50, 82], ["bacterial infections", "PROBLEM", 161, 181], ["bacterial", "OBSERVATION_MODIFIER", 161, 170], ["infections", "OBSERVATION", 171, 181]]], ["This unusual robustness of a 19th century technology stems from its unmatched operational characteristics: 1. broad range of detected agents, depending on adequate combination of media/incubation conditions; 2. unlimited source of clonal population for individual isolate, allowing versatile characterisation of antibiotic susceptibility and/or pathogenic factor production and/or epidemiological subtyping; 3. possibility of storage/bio-banking of cells for complementary clinical testing, research and diseases surveillance collections; 4. proof of pathogenic role of agent at the time of viable cell isolation from the site of infection, in contrast to false-positive results with molecular tests (tissue translocation or persistence of bacterial DNA, soluble antigen,. . . ).", [["cells", "ANATOMY", 449, 454], ["cell", "ANATOMY", 598, 602], ["tissue", "ANATOMY", 701, 707], ["infection", "DISEASE", 630, 639], ["clonal population", "CELL", 231, 248], ["cells", "CELL", 449, 454], ["cell", "CELL", 598, 602], ["tissue", "TISSUE", 701, 707], ["DNA", "CELLULAR_COMPONENT", 750, 753], ["soluble antigen", "GENE_OR_GENE_PRODUCT", 755, 770], ["soluble antigen", "PROTEIN", 755, 770], ["media/incubation conditions", "TREATMENT", 179, 206], ["clonal population", "PROBLEM", 231, 248], ["individual isolate", "PROBLEM", 253, 271], ["antibiotic susceptibility", "PROBLEM", 312, 337], ["pathogenic factor production", "PROBLEM", 345, 373], ["storage/bio-banking of cells", "TREATMENT", 426, 454], ["complementary clinical testing", "TEST", 459, 489], ["surveillance collections", "TEST", 513, 537], ["agent", "TREATMENT", 570, 575], ["viable cell isolation", "TREATMENT", 591, 612], ["infection", "PROBLEM", 630, 639], ["molecular tests", "TEST", 684, 699], ["tissue translocation", "PROBLEM", 701, 721], ["bacterial DNA", "PROBLEM", 740, 753], ["soluble antigen", "TEST", 755, 770], ["clonal population", "OBSERVATION", 231, 248], ["antibiotic susceptibility", "OBSERVATION", 312, 337], ["viable cell isolation", "OBSERVATION", 591, 612], ["infection", "OBSERVATION", 630, 639], ["bacterial DNA", "OBSERVATION", 740, 753]]], ["Major drawbacks of bacteriological culture include long turn-around time, cost and labour/skill intensity.", [["bacteriological culture", "TEST", 19, 42]]], ["These are partly alleviated by new technologies, including automated processing, physical/chemical growth detection and rapid molecular fingerprinting (MALDI-TOF, Raman spectrometry, 16S rDNA SNP detection).", [["SNP", "CHEMICAL", 192, 195], ["physical/chemical growth detection", "TEST", 81, 115], ["rapid molecular fingerprinting", "TEST", 120, 150], ["MALDI", "TEST", 152, 157], ["Raman spectrometry", "TEST", 163, 181], ["new", "OBSERVATION_MODIFIER", 31, 34]]], ["It is likely that the next decade will see a complete redefinition of the place of direct detection methods and culture-based confirmation methods in clinical bacteriology, enabling a rejuvenation rather than elimination of culture as a daily diagnostic tool.J. Schrenzel\u00b0(Geneva, CH)The advent of real-time PCR revealed instrumental to the successful implementation of molecular methods in routine clinical microbiology laboratories.", [["direct detection methods", "TEST", 83, 107], ["culture", "TEST", 112, 119], ["clinical bacteriology", "TEST", 150, 171], ["a rejuvenation", "TREATMENT", 182, 196], ["culture", "TEST", 224, 231], ["is likely", "UNCERTAINTY", 3, 12]]], ["Automated nucleic extraction platforms can now be coupled to robotic handling for large-scale detection and quantification purposes, mostly in virology.", [["Automated nucleic extraction platforms", "PROBLEM", 0, 38], ["large-scale detection", "TEST", 82, 103], ["quantification purposes", "TEST", 108, 131]]], ["I will review here the attempts of implementing home-brew and commercial nucleic-acid based detection methods directly from blood samples and highlight hopes and pitfalls.", [["blood samples", "ANATOMY", 124, 137], ["nucleic-acid", "CHEMICAL", 73, 85], ["nucleic-acid", "SIMPLE_CHEMICAL", 73, 85], ["blood samples", "ORGANISM_SUBSTANCE", 124, 137], ["blood samples", "TEST", 124, 137]]], ["I will then expand on two promising nucleic acid amplification methods: LAMP (loop mediated isothermal amplification) and a protein-free method called DNAzyme.", [["nucleic acid", "CHEMICAL", 36, 48], ["LAMP (loop mediated isothermal amplification", "TREATMENT", 72, 116], ["a protein-free method called DNAzyme", "TREATMENT", 122, 158]]], ["These isothermal amplification methods share several strengths: robustness across highly diversified physico-chemical conditions, versatility in assay development and minimal requirements (if any) for sample preparation.", [["sample", "ANATOMY", 201, 207], ["These isothermal amplification methods", "TREATMENT", 0, 38], ["sample preparation", "TREATMENT", 201, 219], ["minimal", "OBSERVATION_MODIFIER", 167, 174]]], ["They will definitely compete against current real-time PCR assays and might become a novel standard, due to lower costs and improved performances.R.I. Amann\u00b0, B.M. Fuchs (Bremen, DE)The ribosomal RNA (rRNA) approach to microbial evolution and ecology has become an integral part of microbiology.", [["ribosomal RNA", "RNA", 186, 199], ["PCR assays", "TEST", 55, 65], ["lower costs", "PROBLEM", 108, 119], ["The ribosomal RNA (rRNA)", "PROBLEM", 182, 206], ["Fuchs", "OBSERVATION", 164, 169], ["ribosomal RNA", "ANATOMY", 186, 199]]], ["Rapidly growing databases exist that encompass besides the 16S rRNA sequences of almost all validly described Bacteria and Archaea also numerous 16S rRNA sequences of so far uncultivated microbes, directly retrieved from the environment by PCR or metagenomics.", [["Bacteria", "CELL", 110, 118], ["16S rRNA sequences", "DNA", 59, 77], ["16S rRNA sequences", "DNA", 145, 163], ["Rapidly growing databases", "PROBLEM", 0, 25], ["the 16S rRNA sequences", "TEST", 55, 77], ["Bacteria", "PROBLEM", 110, 118], ["Archaea", "PROBLEM", 123, 130], ["numerous 16S rRNA sequences", "TEST", 136, 163], ["uncultivated microbes", "PROBLEM", 174, 195], ["PCR", "TEST", 240, 243], ["metagenomics", "PROBLEM", 247, 259]]], ["Based on the patchy evolutionary conservation of rRNA genes oligonucleotide probes can be designed in a directed way with specificities ranging from species up to large evolutionary entities like phyla or even domains.", [["rRNA genes", "DNA", 49, 59], ["rRNA genes oligonucleotide probes", "TREATMENT", 49, 82], ["patchy", "OBSERVATION_MODIFIER", 13, 19], ["rRNA genes", "OBSERVATION", 49, 59]]], ["When such probes are labeled with fluorescent dyes or the enzyme horseradish peroxidase they can be used to identify single microbial cells by fluorescence in situ hybridisation (FISH) directly in complex environmental samples.", [["cells", "ANATOMY", 134, 139], ["samples", "ANATOMY", 219, 226], ["horseradish peroxidase", "GENE_OR_GENE_PRODUCT", 65, 87], ["microbial cells", "CELL", 124, 139], ["enzyme horseradish peroxidase", "PROTEIN", 58, 87], ["microbial cells", "CELL_TYPE", 124, 139], ["horseradish", "SPECIES", 65, 76], ["fluorescent dyes", "TREATMENT", 34, 50], ["the enzyme horseradish peroxidase", "TREATMENT", 54, 87], ["single microbial cells", "PROBLEM", 117, 139]]], ["An update on recent applications and methodological improvements will be given which includes the identification of small bacterial cells by catalyzed reporter deposition (CARD)-FISH.", [["cells", "ANATOMY", 132, 137], ["small bacterial cells", "CELL", 116, 137], ["small bacterial cells", "CELL_TYPE", 116, 137], ["CARD", "PROTEIN", 172, 176], ["recent applications", "TREATMENT", 13, 32], ["small bacterial cells", "PROBLEM", 116, 137], ["small bacterial cells", "OBSERVATION", 116, 137]]], ["With optimised methods and proper controls FISH yields exact cell numbers and spatial distributions for defined bacterial populations also in highly complex mixed microbial communities.Reference(s)R. Amann & B.M. Fuchs (2008) Nature Reviews Microbiology 6:339-348.A. Mellmann\u00b0(M\u00fcnster, DE)Quick and reliable species identification of microorganisms is of great importance in medical microbiology.", [["cell", "ANATOMY", 61, 65], ["communities", "ANATOMY", 173, 184], ["cell", "CELL", 61, 65], ["optimised methods", "TREATMENT", 5, 22], ["exact cell numbers", "TEST", 55, 73], ["defined bacterial populations", "PROBLEM", 104, 133], ["microorganisms", "PROBLEM", 334, 348], ["bacterial populations", "OBSERVATION", 112, 133], ["highly complex", "OBSERVATION_MODIFIER", 142, 156], ["mixed", "OBSERVATION_MODIFIER", 157, 162], ["microbial communities", "OBSERVATION", 163, 184]]], ["Several bacterial and fungal species can be identified only using laborious and time-consuming methods.", [["Several bacterial and fungal species", "PROBLEM", 0, 36], ["bacterial", "OBSERVATION_MODIFIER", 8, 17], ["fungal species", "OBSERVATION", 22, 36]]], ["Furthermore, in many cases misidentification occurs due to e.g. limited biochemical reactivity, different morphotypes or limited information in reference panels.", [["limited biochemical reactivity", "PROBLEM", 64, 94]]], ["In this talk, matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry will be presented as a method for species identification.", [["matrix-assisted laser desorption/ionisation time", "TREATMENT", 14, 62], ["mass spectrometry", "PROBLEM", 85, 102], ["species identification", "TEST", 137, 159]]], ["This technology applies protein pattern matching based on mass spectrometry.", [["This technology applies protein pattern", "TREATMENT", 0, 39], ["mass spectrometry", "PROBLEM", 58, 75]]], ["During the identification process, a mass pattern is generated for each organism.", [["a mass pattern", "PROBLEM", 35, 49], ["each organism", "PROBLEM", 67, 80], ["mass", "OBSERVATION", 37, 41]]], ["As examples, the identification of various nonfermenting bacterial strains isolated from clinical specimens in comparison to partial 16S rDNA sequencing will be shown.", [["specimens", "ANATOMY", 98, 107], ["rDNA", "CELLULAR_COMPONENT", 137, 141], ["16S rDNA", "DNA", 133, 141], ["various nonfermenting bacterial strains", "PROBLEM", 35, 74], ["clinical specimens", "TEST", 89, 107], ["partial 16S rDNA sequencing", "PROBLEM", 125, 152], ["bacterial strains", "OBSERVATION", 57, 74]]], ["Moreover, speed, accuracy in comparison to other methods, and inter-and intra-laboratory reproducibility of MALDI-TOF MS-based species identification will be discussed.Streptococci: mechanisms of resistance and epidemiologyO489 Trends in invasive Streptococcus pneumoniae serogroup 1 sequence types in Belgium T. Goegebuer, K. Van Pelt, J. Verhaegen, J. Van Eldere\u00b0(Leuven, BE) Objectives: S. pneumoniae serogroup 1 (SG1) isolates frequently cause invasive pneumococcal disease, particularly in children.", [["O489", "CHEMICAL", 223, 227], ["pneumococcal disease", "DISEASE", 457, 477], ["O489", "CHEMICAL", 223, 227], ["Streptococcus pneumoniae", "ORGANISM", 247, 271], ["S. pneumoniae serogroup 1", "ORGANISM", 390, 415], ["SG1", "ORGANISM", 417, 420], ["children", "ORGANISM", 495, 503], ["Streptococcus pneumoniae serogroup", "SPECIES", 247, 281], ["S. pneumoniae serogroup 1", "SPECIES", 390, 415], ["children", "SPECIES", 495, 503], ["O489", "SPECIES", 223, 227], ["Streptococcus pneumoniae", "SPECIES", 247, 271], ["S. pneumoniae serogroup 1", "SPECIES", 390, 415], ["pneumococcal", "SPECIES", 457, 469], ["other methods", "TEST", 43, 56], ["MALDI", "TEST", 108, 113], ["Streptococci", "PROBLEM", 168, 180], ["invasive Streptococcus pneumoniae serogroup", "PROBLEM", 238, 281], ["S. pneumoniae serogroup", "PROBLEM", 390, 413], ["invasive pneumococcal disease", "PROBLEM", 448, 477], ["invasive", "OBSERVATION_MODIFIER", 238, 246], ["invasive", "OBSERVATION_MODIFIER", 448, 456], ["pneumococcal disease", "OBSERVATION", 457, 477]]], ["From 2003 onwards a marked increase in SG1 isolates was observed; overall prevalence increased from 8.", [["SG1", "GENE_OR_GENE_PRODUCT", 39, 42], ["a marked increase in SG1 isolates", "PROBLEM", 18, 51], ["marked", "OBSERVATION_MODIFIER", 20, 26], ["increase", "OBSERVATION_MODIFIER", 27, 35]]], ["We determined the sequence types (ST) in SG1 isolates in order to better understand trends in SG1 resistance and spread.", [["SG1", "SIMPLE_CHEMICAL", 94, 97], ["the sequence types (ST) in SG1 isolates", "PROBLEM", 14, 53]]], ["Methods: As national reference centre, we receive all invasive isolates from more than 100 of 182 laboratories in Belgium.", [["all invasive isolates", "TEST", 50, 71]]], ["124 randomly chosen SG1 isolates from all ages from 1998 to 2006 were analysed via multi-locus sequence typing (MLST) as described by Enright & Spratt (Microbiol.", [["Microbiol", "SIMPLE_CHEMICAL", 152, 161], ["SG1 isolates", "TEST", 20, 32], ["multi-locus sequence typing", "TEST", 83, 110]]], ["We also included data on strain characteristics and patient characteristics.", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59]]], ["Results: 10 different sequence types (ST) were identified: ST350 (n = 66), ST306 (n = 24), ST304 (n = 13), ST227 (n = 10), ST228 (n = 5), ST2915 (n = 2), ST305 (n = 2), ST612 (n = 1), and ST217 (n = 1 mutations usually increase the MIC slightly, but enhance the probability of further mutations.", [["further mutations", "PROBLEM", 277, 294]]], ["Efflux pumps like PmrA reduce antibiotic concentrations in the bacterial cell, enabling longer survival.", [["cell", "ANATOMY", 73, 77], ["PmrA", "CHEMICAL", 18, 22], ["PmrA", "SIMPLE_CHEMICAL", 18, 22], ["bacterial cell", "CELL", 63, 77], ["PmrA", "PROTEIN", 18, 22], ["bacterial cell", "CELL_TYPE", 63, 77], ["Efflux pumps", "TREATMENT", 0, 12], ["PmrA", "TREATMENT", 18, 22], ["antibiotic concentrations", "TREATMENT", 30, 55], ["the bacterial cell", "PROBLEM", 59, 77], ["bacterial cell", "OBSERVATION", 63, 77]]], ["We hypothesised that efflux positive bacteria are more likely to develop resistance than efflux negative bacteria.Streptococci: mechanisms of resistance and epidemiologyThe following questions were addressed: 1.", [["efflux positive bacteria", "PROBLEM", 21, 45], ["resistance than efflux negative bacteria", "PROBLEM", 73, 113], ["Streptococci", "PROBLEM", 114, 126], ["resistance", "PROBLEM", 142, 152], ["more likely", "UNCERTAINTY", 50, 61], ["bacteria", "OBSERVATION_MODIFIER", 105, 113]]], ["Do the efflux pump inhibitors reserpine and verapamil reduce the mutation frequency? 2.", [["reserpine", "CHEMICAL", 30, 39], ["verapamil", "CHEMICAL", 44, 53], ["reserpine", "CHEMICAL", 30, 39], ["verapamil", "CHEMICAL", 44, 53], ["reserpine", "SIMPLE_CHEMICAL", 30, 39], ["verapamil", "SIMPLE_CHEMICAL", 44, 53], ["the efflux pump inhibitors", "TREATMENT", 3, 29], ["reserpine", "TREATMENT", 30, 39], ["verapamil", "TREATMENT", 44, 53], ["the mutation frequency", "PROBLEM", 61, 83]]], ["Do fluoroquinolone-susceptible efflux positive pneumococci exhibit higher parC or gyrA QRDR mutation frequencies than efflux negative isolates? 3.", [["fluoroquinolone", "CHEMICAL", 3, 18], ["gyrA", "CHEMICAL", 82, 86], ["fluoroquinolone", "CHEMICAL", 3, 18], ["fluoroquinolone", "SIMPLE_CHEMICAL", 3, 18], ["parC", "DNA", 74, 78], ["fluoroquinolone", "TREATMENT", 3, 18], ["susceptible efflux", "TEST", 19, 37], ["pneumococci", "PROBLEM", 47, 58], ["higher parC or gyrA QRDR mutation frequencies", "PROBLEM", 67, 112], ["efflux", "TEST", 118, 124]]], ["Does efflux phenotype impose a fitness cost?", [["efflux phenotype", "OBSERVATION", 5, 21]]], ["Methods: Matched efflux positive and negative pneumococcal isolates with identical or similar genotype according to multi-locus sequence typing collected by the German community acquired pneumonia network CAPNETZ were analysed (n = 17).", [["pneumonia", "DISEASE", 187, 196], ["pneumococcal", "ORGANISM", 46, 58], ["pneumococcal", "SPECIES", 46, 58], ["Matched efflux positive", "PROBLEM", 9, 32], ["pneumococcal isolates", "PROBLEM", 46, 67], ["multi-locus sequence typing", "TEST", 116, 143], ["the German community acquired pneumonia network CAPNETZ", "PROBLEM", 157, 212], ["pneumonia", "OBSERVATION", 187, 196]]], ["Strains TIGR4 and R6 were included as efflux negative controls.", [["R6", "CELL", 18, 20], ["Strains TIGR4 and R6", "TREATMENT", 0, 20]]], ["Ciprofloxacin (CIP) MICs and efflux phenotype were measured by agar dilution method, for efflux detection reserpine (10 mg/l) was added and a fourfold decrease in MIC was considered as efflux positive.", [["Ciprofloxacin", "CHEMICAL", 0, 13], ["CIP", "CHEMICAL", 15, 18], ["MICs", "CHEMICAL", 20, 24], ["reserpine", "CHEMICAL", 106, 115], ["MIC", "CHEMICAL", 163, 166], ["Ciprofloxacin", "CHEMICAL", 0, 13], ["CIP", "CHEMICAL", 15, 18], ["reserpine", "CHEMICAL", 106, 115], ["Ciprofloxacin", "SIMPLE_CHEMICAL", 0, 13], ["CIP", "SIMPLE_CHEMICAL", 15, 18], ["reserpine", "SIMPLE_CHEMICAL", 106, 115], ["MIC", "SIMPLE_CHEMICAL", 163, 166], ["Ciprofloxacin (CIP) MICs", "TREATMENT", 0, 24], ["efflux phenotype", "TEST", 29, 45], ["efflux detection reserpine", "TREATMENT", 89, 115], ["a fourfold decrease in MIC", "TREATMENT", 140, 166], ["efflux positive", "PROBLEM", 185, 200]]], ["Mutation frequencies were determined by plating bacterial suspensions onto agar with and without CIP.", [["Mutation frequencies", "PROBLEM", 0, 20], ["CIP", "TREATMENT", 97, 100]]], ["After incubation colonies were counted and the ratio of CFU/ml yielded the mutation frequency.", [["colonies", "ANATOMY", 17, 25], ["incubation colonies", "TEST", 6, 25], ["the mutation frequency", "PROBLEM", 71, 93]]], ["Equally, the mutation frequency was determined adding different concentrations of verapamil (10, 25, 50, 100, 500 mg/l) or reserpine (0.01, 0.1, 1, 5, 10 mg/l).", [["verapamil", "CHEMICAL", 82, 91], ["reserpine", "CHEMICAL", 123, 132], ["verapamil", "CHEMICAL", 82, 91], ["reserpine", "CHEMICAL", 123, 132], ["verapamil", "SIMPLE_CHEMICAL", 82, 91], ["reserpine", "SIMPLE_CHEMICAL", 123, 132], ["verapamil", "TREATMENT", 82, 91], ["reserpine", "TREATMENT", 123, 132]]], ["Biological fitness was calculated as the maximum slope of growth curves recorded in a microtitre plate reader.", [["growth curves", "TEST", 58, 71], ["a microtitre plate", "TREATMENT", 84, 102]]], ["Results: 1) Even at low concentrations, reserpine clearly reduced the mutation frequency of efflux positive and, to a lesser extent, efflux negative pneumococci when exposed to CIP (figure 1); verapamil exhibited this effect merely at high concentrations.", [["reserpine", "CHEMICAL", 40, 49], ["CIP", "CHEMICAL", 177, 180], ["verapamil", "CHEMICAL", 193, 202], ["reserpine", "CHEMICAL", 40, 49], ["CIP", "CHEMICAL", 177, 180], ["verapamil", "CHEMICAL", 193, 202], ["reserpine", "SIMPLE_CHEMICAL", 40, 49], ["verapamil", "SIMPLE_CHEMICAL", 193, 202], ["reserpine", "TREATMENT", 40, 49], ["efflux positive", "PROBLEM", 92, 107], ["pneumococci", "PROBLEM", 149, 160], ["verapamil", "TREATMENT", 193, 202], ["low concentrations", "OBSERVATION_MODIFIER", 20, 38], ["negative pneumococci", "OBSERVATION", 140, 160]]], ["2) Efflux positive isolates produced more frequently mutants (8/9) than efflux negative isolates (2/10) (p = 0.005, Fisher's exact test).", [["Efflux positive isolates", "PROBLEM", 3, 27], ["Fisher's exact test", "TEST", 116, 135], ["Efflux", "OBSERVATION", 3, 9], ["positive isolates", "OBSERVATION", 10, 27]]], ["3) Efflux phenotype had no measurable impact on the biological fitness.", [["Efflux phenotype", "PROBLEM", 3, 19], ["Efflux phenotype", "OBSERVATION", 3, 19], ["no", "UNCERTAINTY", 24, 26], ["measurable", "OBSERVATION_MODIFIER", 27, 37], ["impact", "OBSERVATION_MODIFIER", 38, 44]]], ["Conclusion: A positive efflux phenotype increases the QRDR mutation frequencies in the presence of fluoroquinolones and this effect can be inhibited by very low concentrations of reserpine.", [["fluoroquinolones", "CHEMICAL", 99, 115], ["reserpine", "CHEMICAL", 179, 188], ["fluoroquinolones", "CHEMICAL", 99, 115], ["reserpine", "CHEMICAL", 179, 188], ["QRDR", "GENE_OR_GENE_PRODUCT", 54, 58], ["fluoroquinolones", "SIMPLE_CHEMICAL", 99, 115], ["reserpine", "SIMPLE_CHEMICAL", 179, 188], ["QRDR", "PROTEIN", 54, 58], ["A positive efflux phenotype", "PROBLEM", 12, 39], ["the QRDR mutation frequencies", "PROBLEM", 50, 79], ["fluoroquinolones", "TREATMENT", 99, 115], ["reserpine", "TREATMENT", 179, 188], ["efflux phenotype", "OBSERVATION", 23, 39]]], ["As a matter of concern, efflux is not associated with decreased biological fitness.", [["efflux", "PROBLEM", 24, 30], ["decreased biological fitness", "PROBLEM", 54, 82], ["efflux", "OBSERVATION", 24, 30], ["not associated with", "UNCERTAINTY", 34, 53], ["decreased", "OBSERVATION_MODIFIER", 54, 63], ["biological fitness", "OBSERVATION", 64, 82]]], ["Background: Use of fluoroquinolone (FQ) has been associated with increasing FQ resistance in S. pneumoniae.", [["fluoroquinolone", "CHEMICAL", 19, 34], ["FQ", "CHEMICAL", 36, 38], ["FQ", "CHEMICAL", 76, 78], ["fluoroquinolone", "CHEMICAL", 19, 34], ["fluoroquinolone", "SIMPLE_CHEMICAL", 19, 34], ["FQ", "SIMPLE_CHEMICAL", 36, 38], ["FQ", "SIMPLE_CHEMICAL", 76, 78], ["S. pneumoniae", "ORGANISM", 93, 106], ["S. pneumoniae", "SPECIES", 93, 106], ["S. pneumoniae", "SPECIES", 93, 106], ["fluoroquinolone (FQ", "TREATMENT", 19, 38], ["increasing FQ resistance in S. pneumoniae", "PROBLEM", 65, 106], ["increasing", "OBSERVATION_MODIFIER", 65, 75], ["FQ resistance", "OBSERVATION", 76, 89], ["pneumoniae", "OBSERVATION", 96, 106]]], ["Because respiratory FQs (levofloxacin (Levo) and moxifloxacin (Moxi)) are first line therapy for serious respiratory infections, increasing FQ resistance (FQR) in SP is a concern.", [["respiratory", "ANATOMY", 8, 19], ["respiratory", "ANATOMY", 105, 116], ["FQs", "CHEMICAL", 20, 23], ["levofloxacin", "CHEMICAL", 25, 37], ["Levo", "CHEMICAL", 39, 43], ["moxifloxacin", "CHEMICAL", 49, 61], ["Moxi", "CHEMICAL", 63, 67], ["respiratory infections", "DISEASE", 105, 127], ["FQ", "CHEMICAL", 140, 142], ["FQs", "CHEMICAL", 20, 23], ["levofloxacin", "CHEMICAL", 25, 37], ["Levo", "CHEMICAL", 39, 43], ["moxifloxacin", "CHEMICAL", 49, 61], ["Moxi", "CHEMICAL", 63, 67], ["FQs", "SIMPLE_CHEMICAL", 20, 23], ["levofloxacin", "SIMPLE_CHEMICAL", 25, 37], ["Levo", "SIMPLE_CHEMICAL", 39, 43], ["moxifloxacin", "SIMPLE_CHEMICAL", 49, 61], ["Moxi", "SIMPLE_CHEMICAL", 63, 67], ["FQ", "SIMPLE_CHEMICAL", 140, 142], ["respiratory FQs", "TREATMENT", 8, 23], ["levofloxacin (Levo)", "TREATMENT", 25, 44], ["moxifloxacin (Moxi)", "TREATMENT", 49, 68], ["first line therapy", "TREATMENT", 74, 92], ["serious respiratory infections", "PROBLEM", 97, 127], ["increasing FQ resistance (FQR)", "PROBLEM", 129, 159], ["SP", "PROBLEM", 163, 165], ["serious", "OBSERVATION_MODIFIER", 97, 104], ["respiratory", "ANATOMY", 105, 116], ["infections", "OBSERVATION", 117, 127], ["FQ resistance", "OBSERVATION", 140, 153]]], ["Levo targets parC, and Moxi targets gyrA, which may permit differentiation of degree of selective pressure.", [["parC", "GENE_OR_GENE_PRODUCT", 13, 17], ["Moxi", "GENE_OR_GENE_PRODUCT", 23, 27], ["gyrA", "GENE_OR_GENE_PRODUCT", 36, 40], ["parC", "DNA", 13, 17], ["Moxi", "DNA", 23, 27], ["gyrA", "DNA", 36, 40], ["Levo", "TREATMENT", 0, 4], ["selective", "OBSERVATION_MODIFIER", 88, 97], ["pressure", "OBSERVATION_MODIFIER", 98, 106]]], ["We examined FQ use, and changes in the prevalence of FQR and QRDR mutations in Canadian isolates of SP.", [["FQ", "CHEMICAL", 12, 14], ["FQ", "SIMPLE_CHEMICAL", 12, 14], ["FQR", "GENE_OR_GENE_PRODUCT", 53, 56], ["QRDR", "GENE_OR_GENE_PRODUCT", 61, 65], ["SP", "PROTEIN", 100, 102], ["FQR", "PROBLEM", 53, 56], ["QRDR mutations", "PROBLEM", 61, 75], ["SP", "PROBLEM", 100, 102]]], ["Methods: CBSN is a Canadian collaborative network of microbiology laboratories that has performed surveillance for antibiotic resistance in SP since 1988.", [["microbiology laboratories", "TEST", 53, 78], ["surveillance", "TEST", 98, 110], ["antibiotic resistance", "TREATMENT", 115, 136]]], ["Antimicrobial resistance is performed in a central lab to CLSI standards.", [["Antimicrobial resistance", "TEST", 0, 24], ["resistance", "OBSERVATION", 14, 24]]], ["We sequenced QRDR regions of all FQR isolates and a stratified sample of FQ susceptible isolates.", [["FQ", "CHEMICAL", 73, 75], ["QRDR regions", "DNA", 13, 25], ["all FQR isolates", "TEST", 29, 45], ["FQ susceptible isolates", "PROBLEM", 73, 96]]], ["Population FQ use was obtained from IMS Canada.", [["FQ", "CHEMICAL", 11, 13]]], ["Results: From 1995 to 2007, FQ use increased from 53 to 97 Rx/ 1000pop/yr; Levo use from 0 to 10 Rx/1000pop/yr, and Moxi use from 0 to 17 Rx/1000pop/yr.", [["FQ", "CHEMICAL", 28, 30], ["Levo", "TREATMENT", 75, 79]]], ["31081 isolates were available for testing.", [["testing", "TEST", 34, 41]]], ["Levo R rates increased from 0 in 1993 to 1.8% in 2002 then remained stable until 2008 (1.6% in 2008).", [["Levo R rates", "TEST", 0, 12], ["stable", "OBSERVATION_MODIFIER", 68, 74]]], ["Moxi R rates increased to 0.6% in 2004, then stabilised (0.7% in 2008).", [["Moxi R", "GENE_OR_GENE_PRODUCT", 0, 6], ["Moxi R rates", "TREATMENT", 0, 12]]], ["The prevalence of parC only mutations has not increased significantly in the last decade (see Table) .", [["parC", "GENE_OR_GENE_PRODUCT", 18, 22], ["parC", "DNA", 18, 22], ["parC only mutations", "PROBLEM", 18, 37], ["parC", "OBSERVATION", 18, 22], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["significantly", "OBSERVATION_MODIFIER", 56, 69]]], ["The prevalence of isolates with both parC and gyrA mutations increased until 2002, but has decreased in 2008.", [["parC", "GENE_OR_GENE_PRODUCT", 37, 41], ["gyrA", "GENE_OR_GENE_PRODUCT", 46, 50], ["parC", "DNA", 37, 41], ["isolates", "PROBLEM", 18, 26], ["both parC and gyrA mutations", "PROBLEM", 32, 60], ["decreased", "OBSERVATION_MODIFIER", 91, 100]]], ["The first gyrA only mutant was detected in 2000; the prevalence of gyrA only mutants since then has increased, but remains very low (7/2044, 0.34% in 2007) .", [["gyrA", "GENE_OR_GENE_PRODUCT", 10, 14], ["gyrA", "GENE_OR_GENE_PRODUCT", 67, 71], ["gyrA", "DNA", 10, 14], ["gyrA", "PROBLEM", 67, 71], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["very", "OBSERVATION_MODIFIER", 123, 127], ["low", "OBSERVATION_MODIFIER", 128, 131]]], ["Conclusion: Despite increasing use of respiratory FQs, FQR in pneumococci is very low and not increasing in Canada.", [["FQR", "CHEMICAL", 55, 58], ["FQR", "SIMPLE_CHEMICAL", 55, 58], ["respiratory FQs", "TREATMENT", 38, 53], ["FQR", "PROBLEM", 55, 58], ["pneumococci", "PROBLEM", 62, 73], ["respiratory FQs", "OBSERVATION", 38, 53], ["pneumococci", "OBSERVATION", 62, 73], ["very", "OBSERVATION_MODIFIER", 77, 81], ["low", "OBSERVATION_MODIFIER", 82, 85], ["increasing", "OBSERVATION_MODIFIER", 94, 104]]], ["The prevalence of isolates with parC mutations is decreasing.", [["parC", "GENE_OR_GENE_PRODUCT", 32, 36], ["parC mutations", "PROBLEM", 32, 46], ["parC mutations", "OBSERVATION", 32, 46], ["decreasing", "OBSERVATION_MODIFIER", 50, 60]]], ["Isolates with mutations in gyrA alone remain extremely rare, suggesting that Moxi exerts minimal selective pressure for resistance.", [["gyrA", "CHEMICAL", 27, 31], ["Moxi", "CHEMICAL", 77, 81], ["gyrA", "GENE_OR_GENE_PRODUCT", 27, 31], ["Moxi", "SIMPLE_CHEMICAL", 77, 81], ["gyrA", "DNA", 27, 31], ["mutations in gyrA", "PROBLEM", 14, 31]]], ["In Streptococci, two well characterised macrolide resistance have been described: target modification and active drug efflux.", [["macrolide", "CHEMICAL", 40, 49], ["macrolide", "CHEMICAL", 40, 49], ["macrolide", "SIMPLE_CHEMICAL", 40, 49], ["Streptococci", "PROBLEM", 3, 15], ["macrolide resistance", "TREATMENT", 40, 60], ["active drug efflux", "PROBLEM", 106, 124], ["Streptococci", "OBSERVATION", 3, 15], ["well characterised", "OBSERVATION_MODIFIER", 21, 39], ["macrolide resistance", "OBSERVATION", 40, 60], ["active", "OBSERVATION_MODIFIER", 106, 112], ["drug efflux", "OBSERVATION", 113, 124]]], ["Target site modification is mediated by the erm genes -erm(B), erm(A), erm(C)which confers the MLSB phenotype.", [["erm", "GENE_OR_GENE_PRODUCT", 44, 47], ["erm(B)", "GENE_OR_GENE_PRODUCT", 55, 61], ["erm(A)", "GENE_OR_GENE_PRODUCT", 63, 69], ["erm(C)", "GENE_OR_GENE_PRODUCT", 71, 77], ["MLSB", "GENE_OR_GENE_PRODUCT", 95, 99], ["erm genes", "DNA", 44, 53], ["erm", "DNA", 55, 58], ["B", "DNA", 59, 60], ["erm(C)", "DNA", 71, 77], ["Target site modification", "PROBLEM", 0, 24], ["the MLSB phenotype", "PROBLEM", 91, 109], ["MLSB phenotype", "OBSERVATION", 95, 109]]], ["Target modification by mutations in 23S rRNA as well as mutation in L4 and L22 ribosomal proteins have also been reported.", [["23S rRNA", "GENE_OR_GENE_PRODUCT", 36, 44], ["L22", "GENE_OR_GENE_PRODUCT", 75, 78], ["23S rRNA", "DNA", 36, 44], ["L4 and L22 ribosomal proteins", "PROTEIN", 68, 97], ["Target modification by mutations in 23S rRNA", "PROBLEM", 0, 44], ["mutation in L4 and L22 ribosomal proteins", "PROBLEM", 56, 97], ["L4", "ANATOMY", 68, 70]]], ["Expression of mef(A) genes activate an efflux mechanism responsible for M-type resistance We characterised a clinical isolate of S. agalactiae MB56GBS022 exhibiting the MLSB phenotype and tetracycline resistance.", [["tetracycline", "CHEMICAL", 188, 200], ["tetracycline", "CHEMICAL", 188, 200], ["mef(A)", "GENE_OR_GENE_PRODUCT", 14, 20], ["S. agalactiae", "ORGANISM", 129, 142], ["MB56GBS022", "ORGANISM", 143, 153], ["tetracycline", "SIMPLE_CHEMICAL", 188, 200], ["mef(A) genes", "DNA", 14, 26], ["S. agalactiae", "SPECIES", 129, 142], ["S. agalactiae", "SPECIES", 129, 142], ["an efflux mechanism", "PROBLEM", 36, 55], ["M-type resistance", "PROBLEM", 72, 89], ["S. agalactiae", "PROBLEM", 129, 142], ["the MLSB phenotype", "PROBLEM", 165, 183], ["tetracycline resistance", "TREATMENT", 188, 211], ["tetracycline resistance", "OBSERVATION", 188, 211]]], ["In this study, we determined the resistance genes, their association, and their localisation and mobility by conjugation.", [["resistance genes", "DNA", 33, 49], ["this study", "TEST", 3, 13]]], ["Methods: The macrolide and tetracycline resistance genes were confirmed by PCR.", [["macrolide", "CHEMICAL", 13, 22], ["tetracycline", "CHEMICAL", 27, 39], ["macrolide", "CHEMICAL", 13, 22], ["tetracycline", "CHEMICAL", 27, 39], ["macrolide", "SIMPLE_CHEMICAL", 13, 22], ["tetracycline", "SIMPLE_CHEMICAL", 27, 39], ["macrolide and tetracycline resistance genes", "DNA", 13, 56], ["The macrolide", "TREATMENT", 9, 22], ["tetracycline resistance genes", "TREATMENT", 27, 56], ["PCR", "TEST", 75, 78]]], ["The association between macrolide and tetracycline genes was investigated by Long-PCR and sequencing.", [["macrolide", "CHEMICAL", 24, 33], ["tetracycline", "CHEMICAL", 38, 50], ["macrolide", "CHEMICAL", 24, 33], ["tetracycline", "CHEMICAL", 38, 50], ["macrolide", "SIMPLE_CHEMICAL", 24, 33], ["tetracycline", "SIMPLE_CHEMICAL", 38, 50], ["macrolide and tetracycline genes", "DNA", 24, 56], ["macrolide and tetracycline genes", "TREATMENT", 24, 56]]], ["Conjugation experiments were performed by filter matings.", [["Conjugation experiments", "TREATMENT", 0, 23]]], ["The genetic localisation of resistance genes was determined by endonuclease I CeuI -followed by PFGE and Southern blot.", [["endonuclease I CeuI", "GENE_OR_GENE_PRODUCT", 63, 82], ["resistance genes", "DNA", 28, 44], ["endonuclease I CeuI", "PROTEIN", 63, 82], ["resistance genes", "OBSERVATION", 28, 44]]], ["The hybridisation study was performed using three specific probes for the 16S and 23S rRNA genes, for erm(B) and tet(O) genes.", [["erm(B)", "GENE_OR_GENE_PRODUCT", 102, 108], ["tet(O)", "GENE_OR_GENE_PRODUCT", 113, 119], ["16S and 23S rRNA genes", "DNA", 74, 96], ["erm(B) and tet(O) genes", "DNA", 102, 125], ["The hybridisation study", "TEST", 0, 23], ["the 16S", "TEST", 70, 77]]], ["Results: S. agalactiae MB56GBS022 carried erm(B) and tet(O) genes on the same amplicon of 7 kb in size.", [["S. agalactiae", "ORGANISM", 9, 22], ["MB56GBS022", "ORGANISM", 23, 33], ["erm(B)", "GENE_OR_GENE_PRODUCT", 42, 48], ["tet(O)", "GENE_OR_GENE_PRODUCT", 53, 59], ["erm(B) and tet(O) genes", "DNA", 42, 65], ["S. agalactiae", "SPECIES", 9, 22], ["S. agalactiae", "SPECIES", 9, 22], ["size", "OBSERVATION_MODIFIER", 98, 102]]], ["The nucleotide sequence analysis of the entire product was identical to the pEOC01 of 11 kb from Pediococcus acidilactici that contains four orfs, of which orf2 and orf3 encode a putative resolvase and topoisomerase type I, respectively.", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["Pediococcus acidilactici", "ORGANISM", 97, 121], ["orfs", "GENE_OR_GENE_PRODUCT", 141, 145], ["orf2", "GENE_OR_GENE_PRODUCT", 156, 160], ["orf3", "GENE_OR_GENE_PRODUCT", 165, 169], ["topoisomerase type I", "GENE_OR_GENE_PRODUCT", 202, 222], ["pEOC01", "DNA", 76, 82], ["orfs", "PROTEIN", 141, 145], ["orf2", "PROTEIN", 156, 160], ["orf3", "PROTEIN", 165, 169], ["putative resolvase", "PROTEIN", 179, 197], ["topoisomerase type I", "PROTEIN", 202, 222], ["Pediococcus acidilactici", "SPECIES", 97, 121], ["Pediococcus acidilactici", "SPECIES", 97, 121], ["The nucleotide sequence analysis", "TEST", 0, 32], ["Pediococcus acidilactici", "PROBLEM", 97, 121]]], ["The endonuclease I CeuI method, that easily distinguishes between plasmid and chromosomal localisations as I-CeuI only cuts chromosomal DNA, revealed the localisation of resistance genes on the plasmid.", [["plasmid", "ANATOMY", 66, 73], ["chromosomal", "ANATOMY", 78, 89], ["chromosomal", "ANATOMY", 124, 135], ["plasmid", "ANATOMY", 194, 201], ["endonuclease I", "GENE_OR_GENE_PRODUCT", 4, 18], ["chromosomal", "CELLULAR_COMPONENT", 78, 89], ["chromosomal", "CELLULAR_COMPONENT", 124, 135], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["endonuclease I CeuI method", "DNA", 4, 30], ["resistance genes", "DNA", 170, 186], ["plasmid", "DNA", 194, 201], ["The endonuclease I CeuI method", "TREATMENT", 0, 30], ["chromosomal DNA", "PROBLEM", 124, 139], ["the plasmid", "TREATMENT", 190, 201], ["chromosomal localisations", "OBSERVATION", 78, 103], ["resistance genes", "OBSERVATION", 170, 186]]], ["All attempts to transfer erm(B)-tet(O) structure by conjugation from S. agalactiae MB56GBS022 to OG1SS E. faecalis as recipient failed.", [["OG1SS", "CHEMICAL", 97, 102], ["erm(B)-tet(O)", "CHEMICAL", 25, 38], ["S. agalactiae", "ORGANISM", 69, 82], ["MB56GBS022", "ORGANISM", 83, 93], ["OG1SS E. faecalis", "ORGANISM", 97, 114], ["tet(O) structure", "PROTEIN", 32, 48], ["S. agalactiae", "SPECIES", 69, 82], ["E. faecalis", "SPECIES", 103, 114], ["S. agalactiae", "SPECIES", 69, 82], ["E. faecalis", "SPECIES", 103, 114]]], ["Conclusion: Our results show the first case of the association between erm(B) and tet(O) genes on the unique mosaic structure in S. agalactiae, probably on the plasmid, as demonstrated by the I CeuI-assay.", [["plasmid", "ANATOMY", 160, 167], ["erm(B)", "GENE_OR_GENE_PRODUCT", 71, 77], ["tet(O)", "GENE_OR_GENE_PRODUCT", 82, 88], ["S. agalactiae", "ORGANISM", 129, 142], ["CeuI", "GENE_OR_GENE_PRODUCT", 194, 198], ["erm(B) and tet(O) genes", "DNA", 71, 94], ["plasmid", "DNA", 160, 167], ["CeuI", "PROTEIN", 194, 198], ["S. agalactiae", "SPECIES", 129, 142], ["S. agalactiae", "SPECIES", 129, 142], ["S. agalactiae", "PROBLEM", 129, 142], ["mosaic structure", "OBSERVATION", 109, 125], ["agalactiae", "OBSERVATION", 132, 142]]], ["Further studies are on going to characterise the entire genetic element carrying resistance genes.Clinical virologyO499 Improving influenza pre-analytic collection systems: alternative collection systems to inactivate, preserve, or extract influenza for rapid testing S. Castriciano\u00b0, K. Luinstra, M. Ackerman, A. Petrich, M. Smieja (Brescia, IT; Hamilton, CA) Objectives: In this study, 3 alternative influenza sample collection systems were evaluated for potential use in a pandemic situation.", [["influenza", "DISEASE", 240, 249], ["resistance genes", "DNA", 81, 97], ["S. Castriciano\u00b0", "SPECIES", 268, 283], ["Further studies", "TEST", 0, 15], ["Improving influenza pre-analytic collection systems", "PROBLEM", 120, 171], ["alternative collection systems", "TREATMENT", 173, 203], ["extract influenza", "PROBLEM", 232, 249], ["rapid testing", "TEST", 254, 267], ["this study", "TEST", 376, 386], ["3 alternative influenza sample collection systems", "PROBLEM", 388, 437], ["resistance genes", "OBSERVATION", 81, 97]]], ["The objectives were to develop: 1) a non-temperature dependent swab collection and transport system, that inactivates influenza virus infectivity but preserves cell morphology and nucleic acid (NA) for the detection of suspected influenza infections and/or 2) a system compatible with direct NA testing without the need for purification prior to detection by a rapid real-time RT-PCR.", [["swab", "ANATOMY", 63, 67], ["cell", "ANATOMY", 160, 164], ["nucleic acid", "CHEMICAL", 180, 192], ["NA", "CHEMICAL", 194, 196], ["influenza infections", "DISEASE", 229, 249], ["influenza virus", "ORGANISM", 118, 133], ["cell", "CELL", 160, 164], ["nucleic acid", "SIMPLE_CHEMICAL", 180, 192], ["influenza virus", "SPECIES", 118, 133], ["influenza virus", "SPECIES", 118, 133], ["a non-temperature dependent swab collection", "PROBLEM", 35, 78], ["transport system", "TEST", 83, 99], ["influenza virus infectivity", "PROBLEM", 118, 145], ["nucleic acid", "TEST", 180, 192], ["suspected influenza infections", "PROBLEM", 219, 249], ["direct NA testing", "TEST", 285, 302], ["purification", "TREATMENT", 324, 336]]], ["Methods: Flocked nasopharyngeal swabs (NPS) collected in UTM (U) were compared to NPS collected in a CyMol (C), M-swab (M) or Dry (D) Flocked Swab collection system (Copan, Italia).", [["nasopharyngeal swabs", "ANATOMY", 17, 37], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 17, 37], ["NPS", "TEST", 82, 85], ["Swab collection system", "TEST", 142, 164], ["nasopharyngeal", "ANATOMY", 17, 31]]], ["CyMol is an alcoholbased medium that preserves cells for DFA testing.", [["cells", "ANATOMY", 47, 52], ["CyMol", "CHEMICAL", 0, 5], ["DFA", "CHEMICAL", 57, 60], ["CyMol", "SIMPLE_CHEMICAL", 0, 5], ["cells", "CELL", 47, 52], ["DFA testing", "TEST", 57, 68]]], ["The M-swab contains 600 uL of medium and 150 uL of glass beads, and requires no NA purification step.", [["glass beads", "TREATMENT", 51, 62], ["glass beads", "OBSERVATION", 51, 62], ["no", "UNCERTAINTY", 77, 79]]], ["Shell vial culture was used to assess influenza virus inactivation after 30 minutes exposure to the collection media.", [["influenza virus", "SPECIES", 38, 53], ["Shell vial culture", "TEST", 0, 18], ["influenza virus inactivation", "PROBLEM", 38, 66], ["the collection media", "TREATMENT", 96, 116]]], ["A mockinfected Influenza A virus sample was absorbed to duplicate swabs then placed into the 4 collection systems.", [["sample", "ANATOMY", 33, 39], ["Influenza A virus", "ORGANISM", 15, 32], ["Influenza A virus", "SPECIES", 15, 32], ["Influenza A virus", "SPECIES", 15, 32], ["A mockinfected Influenza A virus sample", "PROBLEM", 0, 39], ["Influenza", "OBSERVATION", 15, 24]]], ["The infected collection media were held at RT for 30 minutes and then inoculated in duplicate into shell vial culture and stained after 48 hours.", [["The infected collection media", "TREATMENT", 0, 29], ["shell vial culture", "TEST", 99, 117], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["collection", "OBSERVATION_MODIFIER", 13, 23], ["media", "OBSERVATION_MODIFIER", 24, 29]]], ["Influenza A stability and NA recovery after mock infection of each collection system was assessed after 1, 7, 14 and 21 days (d) at 4\u00baC, \u221220\u00baC, room temperature (RT) and 37\u00baC.", [["NA", "CHEMICAL", 26, 28], ["infection", "DISEASE", 49, 58], ["Influenza", "PROBLEM", 0, 9], ["mock infection of each collection system", "PROBLEM", 44, 84], ["stability", "OBSERVATION_MODIFIER", 12, 21]]], ["Aliquots of infected collection media were extracted by easyMag and 5 uL of purified NA tested by a quantitative influenza A RT-PCR on the Roche LightCycler.", [["Aliquots", "ANATOMY", 0, 8], ["infected collection media", "TREATMENT", 12, 37], ["easyMag", "TREATMENT", 56, 63], ["the Roche LightCycler", "TREATMENT", 135, 156], ["infected", "OBSERVATION_MODIFIER", 12, 20], ["collection media", "OBSERVATION", 21, 37]]], ["M-Swab collected samples were also tested directly or after boiling, without NA purification.", [["samples", "ANATOMY", 17, 24], ["Swab collected samples", "TEST", 2, 24], ["NA purification", "TREATMENT", 77, 92]]], ["Results: Shell vial culture found that Influenza A virus was inactivated after 30 minutes exposure to the C medium but not when exposed to the U and M media.", [["Influenza A virus", "ORGANISM", 39, 56], ["Influenza A virus", "SPECIES", 39, 56], ["Influenza A virus", "SPECIES", 39, 56], ["Shell vial culture", "TEST", 9, 27], ["Influenza A virus", "PROBLEM", 39, 56], ["the C medium", "TREATMENT", 102, 114]]], ["Influenza A was detected by DFA from the U and C cell smears.", [["C cell", "ANATOMY", 47, 53], ["Influenza A", "CANCER", 0, 11], ["C cell", "CELL", 47, 53], ["Influenza A", "SPECIES", 0, 11], ["Influenza A", "PROBLEM", 0, 11], ["the U and C cell smears", "TEST", 37, 60]]], ["Quantitation of Influenza A RNA was constant after 1, 7 and 14 d in U, C, M and D collection systems at \u221220, 4\u00baC and RT.", [["Influenza A", "ORGANISM", 16, 27], ["Influenza A RNA", "RNA", 16, 31], ["Influenza A", "SPECIES", 16, 27], ["Influenza A RNA", "PROBLEM", 16, 31], ["D collection systems", "TEST", 80, 100], ["Influenza", "OBSERVATION", 16, 25]]], ["The quantity of RNA recovered declined significantly after 14 d at 37\u00baC in all 4 collection systems.", [["quantity", "OBSERVATION_MODIFIER", 4, 12], ["RNA", "OBSERVATION_MODIFIER", 16, 19], ["recovered", "OBSERVATION_MODIFIER", 20, 29], ["declined", "OBSERVATION_MODIFIER", 30, 38]]], ["M with boiling yielded data comparable to the easyMag extraction.Conclusions:The Copan CyMol medium inactivates influenza infectivity, preserves cells and stabilises RNA up to 14 days at \u221220, 4\u00baC and RT.", [["cells", "ANATOMY", 145, 150], ["influenza", "ORGANISM", 112, 121], ["cells", "CELL", 145, 150], ["the easyMag extraction", "TREATMENT", 42, 64], ["The Copan CyMol medium", "TREATMENT", 77, 99], ["influenza infectivity", "PROBLEM", 112, 133], ["stabilises RNA", "PROBLEM", 155, 169]]], ["CyMol medium is a potential alternative for safe sample collection during a pandemic influenza situation.", [["sample", "ANATOMY", 49, 55], ["CyMol", "CHEMICAL", 0, 5], ["influenza", "DISEASE", 85, 94], ["safe sample collection", "PROBLEM", 44, 66], ["a pandemic influenza situation", "PROBLEM", 74, 104]]], ["The M-swab presents a rapid testing alternative.O500 Molecular detection of 12 viruses and subtypes byLuminex respiratory viral panel in respiratory specimens from children R. Selvarangan\u00b0, S. Selvaraju, D. Baker, K. Estes, L. Hays, D. Abel, S. Hiraki (Kansas City, US) Objective: Luminex respiratory viral panel (RVP) is a multiplex PCR capable of detecting and differentiating twelve different respiratory viruses and their subtypes; influenza A (Flu A) (subtypes H1 and H3), influenza B (Flu B), Respiratory syncytial virus (RSV) (subtypes A and B), Adenovirus (AdV), Parainfluenza 1 (PIV 1), Parainfluenza 2 (PIV 2), Parainfluenza 3 (PIV 3), human metapneumovirus (hMPV) and Rhinovirus (RhV).", [["respiratory specimens", "ANATOMY", 137, 158], ["respiratory viruses", "DISEASE", 396, 415], ["influenza A", "DISEASE", 436, 447], ["influenza B", "DISEASE", 478, 489], ["Respiratory syncytial virus (RSV)", "DISEASE", 499, 532], ["human metapneumovirus (hMPV)", "DISEASE", 646, 674], ["children", "ORGANISM", 164, 172], ["influenza A (Flu A) (subtypes H1", "ORGANISM", 436, 468], ["H3", "GENE_OR_GENE_PRODUCT", 473, 475], ["influenza B (Flu B),", "ORGANISM", 478, 498], ["Respiratory syncytial virus", "ORGANISM", 499, 526], ["RSV", "ORGANISM", 528, 531], ["subtypes A and B", "ORGANISM", 534, 550], ["Adenovirus (AdV", "ORGANISM", 553, 568], ["Parainfluenza 1", "ORGANISM", 571, 586], ["PIV 1", "ORGANISM", 588, 593], ["Parainfluenza 2", "ORGANISM", 596, 611], ["PIV 2", "ORGANISM", 613, 618], ["Parainfluenza 3", "ORGANISM", 621, 636], ["PIV 3", "ORGANISM", 638, 643], ["human metapneumovirus", "ORGANISM", 646, 667], ["hMPV", "ORGANISM", 669, 673], ["children", "SPECIES", 164, 172], ["Respiratory syncytial virus", "SPECIES", 499, 526], ["human", "SPECIES", 646, 651], ["metapneumovirus", "SPECIES", 652, 667], ["hMPV", "SPECIES", 669, 673], ["influenza A (Flu A", "SPECIES", 436, 454], ["H1", "SPECIES", 466, 468], ["Respiratory syncytial virus", "SPECIES", 499, 526], ["RSV", "SPECIES", 528, 531], ["Adenovirus", "SPECIES", 553, 563], ["AdV", "SPECIES", 565, 568], ["Parainfluenza 1 (PIV 1", "SPECIES", 571, 593], ["PIV", "SPECIES", 638, 641], ["human metapneumovirus", "SPECIES", 646, 667], ["hMPV", "SPECIES", 669, 673], ["RhV", "SPECIES", 691, 694], ["a rapid testing", "TEST", 20, 35], ["Molecular detection", "TEST", 53, 72], ["12 viruses", "PROBLEM", 76, 86], ["respiratory viral panel", "TEST", 110, 133], ["respiratory specimens", "TEST", 137, 158], ["Luminex respiratory viral panel", "TEST", 281, 312], ["RVP", "TEST", 314, 317], ["a multiplex PCR", "TEST", 322, 337], ["twelve different respiratory viruses", "PROBLEM", 379, 415], ["influenza", "PROBLEM", 436, 445], ["H1", "TEST", 466, 468], ["H3", "TEST", 473, 475], ["influenza B (Flu B)", "TEST", 478, 497], ["Respiratory syncytial virus", "PROBLEM", 499, 526], ["RSV", "TEST", 528, 531], ["Adenovirus", "PROBLEM", 553, 563], ["Parainfluenza", "PROBLEM", 571, 584], ["PIV", "TEST", 588, 591], ["Parainfluenza", "PROBLEM", 596, 609], ["PIV", "TEST", 613, 616], ["Parainfluenza", "PROBLEM", 621, 634], ["PIV", "TEST", 638, 641], ["human metapneumovirus (hMPV", "PROBLEM", 646, 673], ["Rhinovirus", "PROBLEM", 679, 689], ["viral panel", "OBSERVATION", 122, 133], ["respiratory viruses", "OBSERVATION", 396, 415], ["Respiratory syncytial", "ANATOMY", 499, 520]]], ["The aim of this study was to evaluate the analytical performance characteristics of RVP assay and to evaluate its ability to detect respiratory viruses from nasopharyngeal aspirates obtained from children.", [["nasopharyngeal aspirates", "ANATOMY", 157, 181], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 157, 181], ["children", "ORGANISM", 196, 204], ["children", "SPECIES", 196, 204], ["this study", "TEST", 11, 21], ["RVP assay", "TEST", 84, 93], ["respiratory viruses", "PROBLEM", 132, 151], ["nasopharyngeal aspirates", "TEST", 157, 181], ["respiratory", "ANATOMY", 132, 143], ["viruses", "OBSERVATION", 144, 151], ["nasopharyngeal", "ANATOMY", 157, 171], ["aspirates", "OBSERVATION", 172, 181]]], ["Method: Analytical sensitivity, specificity, accuracy and precision of the Luminex RVP assay were determined using control viral stocks and respiratory specimens previously tested by Rmix shell vial culture.", [["respiratory specimens", "ANATOMY", 140, 161], ["accuracy", "TEST", 45, 53], ["the Luminex RVP assay", "TEST", 71, 92], ["control viral stocks", "TREATMENT", 115, 135], ["respiratory specimens", "TEST", 140, 161], ["shell vial culture", "TEST", 188, 206]]], ["Result: Luminex RVP assay reliably detected ATCC viral stocks of Flu A, Flu B, RSVB, RhV and PIV3 in the range of 10e-2 to 10e-4 TCID50/ml.", [["Flu A", "CHEMICAL", 65, 70], ["Flu B", "CHEMICAL", 72, 77], ["Flu A", "CHEMICAL", 65, 70], ["Flu B", "CHEMICAL", 72, 77], ["Flu A", "SIMPLE_CHEMICAL", 65, 70], ["Flu B", "ORGANISM", 72, 77], ["RSVB", "GENE_OR_GENE_PRODUCT", 79, 83], ["RhV", "GENE_OR_GENE_PRODUCT", 85, 88], ["PIV3", "SIMPLE_CHEMICAL", 93, 97], ["ATCC", "SPECIES", 44, 48], ["Flu A", "SPECIES", 65, 70], ["Luminex RVP assay", "TEST", 8, 25], ["RSVB", "TEST", 79, 83], ["RhV", "TEST", 85, 88], ["PIV3", "TEST", 93, 97]]], ["No cross reactivity was noted with CMV, HSV, HHV6, EBV, VZV, PIV4, cornoavirus 229E and OC43.", [["CMV", "ORGANISM", 35, 38], ["HSV", "ORGANISM", 40, 43], ["HHV6", "GENE_OR_GENE_PRODUCT", 45, 49], ["EBV", "ORGANISM", 51, 54], ["VZV", "ORGANISM", 56, 59], ["PIV4", "GENE_OR_GENE_PRODUCT", 61, 65], ["cornoavirus 229E", "ORGANISM", 67, 83], ["OC43", "GENE_OR_GENE_PRODUCT", 88, 92], ["CMV", "SPECIES", 35, 38], ["HSV", "SPECIES", 40, 43], ["HHV6", "SPECIES", 45, 49], ["EBV", "SPECIES", 51, 54], ["VZV", "SPECIES", 56, 59], ["PIV4", "SPECIES", 61, 65], ["cross reactivity", "PROBLEM", 3, 19], ["CMV", "TEST", 35, 38], ["HSV", "TEST", 40, 43], ["HHV6", "TEST", 45, 49], ["EBV", "TEST", 51, 54], ["VZV", "TEST", 56, 59], ["PIV4", "TEST", 61, 65], ["cornoavirus", "TEST", 67, 78], ["OC43", "PROBLEM", 88, 92], ["cross reactivity", "OBSERVATION", 3, 19]]], ["Among 146 respiratory specimens previously characterised by culture 138 specimens were accurately detected with overall accuracy of 95%.", [["respiratory specimens", "ANATOMY", 10, 31], ["specimens", "ANATOMY", 72, 81], ["respiratory specimens", "TEST", 10, 31], ["culture 138 specimens", "TEST", 60, 81], ["overall accuracy", "TEST", 112, 128]]], ["The median coefficient of variation in mean fluorescent index values of signals from replicate analyses of influenza A, B and RSV was 9% (7% to 25%).", [["influenza", "DISEASE", 107, 116], ["B", "CANCER", 120, 121], ["RSV", "ORGANISM", 126, 129], ["RSV", "SPECIES", 126, 129], ["mean fluorescent index values", "TEST", 39, 68], ["influenza A", "TEST", 107, 118], ["RSV", "TEST", 126, 129], ["median coefficient", "OBSERVATION_MODIFIER", 4, 22], ["variation", "OBSERVATION_MODIFIER", 26, 35]]], ["The 146 clinical specimens tested by RVP assay included 109 culture positive and 37 culture negative specimens.", [["specimens", "ANATOMY", 17, 26], ["specimens", "ANATOMY", 101, 110], ["specimens", "CANCER", 17, 26], ["clinical specimens", "TEST", 8, 26], ["RVP assay", "TEST", 37, 46], ["109 culture", "TEST", 56, 67], ["37 culture", "TEST", 81, 91]]], ["Respiratory viruses isolated from the culture positive specimens include the following; 19 AdV, 11 Flu A, 10 Flu B, 19 RSV, 9 PIV1, 6 PIV2, 5 PIV3, 19 hMPV and 14 RhV.", [["specimens", "ANATOMY", 55, 64], ["AdV", "ORGANISM", 91, 94], ["Flu A", "ORGANISM", 99, 104], ["Flu B", "ORGANISM", 109, 114], ["RSV", "ORGANISM", 119, 122], ["PIV3", "GENE_OR_GENE_PRODUCT", 142, 146], ["hMPV", "ORGANISM", 151, 155], ["AdV", "SPECIES", 91, 94], ["Flu A", "SPECIES", 99, 104], ["RSV", "SPECIES", 119, 122], ["hMPV", "SPECIES", 151, 155], ["Respiratory viruses", "PROBLEM", 0, 19], ["the culture", "TEST", 34, 45], ["AdV", "TEST", 91, 94], ["RSV", "TEST", 119, 122], ["PIV1", "TEST", 126, 130], ["PIV2", "TEST", 134, 138], ["PIV3", "TEST", 142, 146], ["hMPV", "TEST", 151, 155], ["viruses", "OBSERVATION", 12, 19]]], ["RVP assay detected all of the respiratory viruses except one each of RSV, PIV1 and PIV2 virus with overall sensitivity ranging from 88% to 100% for the different respiratory viral groups.", [["RSV", "ORGANISM", 69, 72], ["PIV1", "GENE_OR_GENE_PRODUCT", 74, 78], ["PIV2 virus", "ORGANISM", 83, 93], ["RSV", "SPECIES", 69, 72], ["PIV1", "SPECIES", 74, 78], ["PIV2 virus", "SPECIES", 83, 93], ["RVP assay", "TEST", 0, 9], ["the respiratory viruses", "PROBLEM", 26, 49], ["RSV", "PROBLEM", 69, 72], ["PIV1", "TREATMENT", 74, 78], ["PIV2 virus", "PROBLEM", 83, 93], ["overall sensitivity", "TEST", 99, 118], ["the different respiratory viral groups", "PROBLEM", 148, 186], ["respiratory", "ANATOMY", 30, 41], ["viruses", "OBSERVATION", 42, 49], ["RSV", "OBSERVATION", 69, 72], ["respiratory", "OBSERVATION", 162, 173], ["viral groups", "OBSERVATION", 174, 186]]], ["Among the 37 culture negative specimens 20 respiratory viruses were detected by RVP of which 15 were subsequently confirmed by repeat analyses.", [["specimens", "ANATOMY", 30, 39], ["respiratory viruses", "DISEASE", 43, 62], ["the 37 culture", "TEST", 6, 20], ["specimens", "TEST", 30, 39], ["respiratory viruses", "TEST", 43, 62], ["RVP", "TEST", 80, 83], ["repeat analyses", "TEST", 127, 142], ["respiratory viruses", "OBSERVATION", 43, 62]]], ["Conclusion: Luminex RVP assay is a highly sensitive and specific test useful in the detection of commonly encountered respiratory viruses in respiratory specimens.", [["respiratory", "ANATOMY", 118, 129], ["respiratory specimens", "ANATOMY", 141, 162], ["respiratory viruses", "DISEASE", 118, 137], ["Luminex RVP assay", "TEST", 12, 29], ["specific test", "TEST", 56, 69], ["commonly encountered respiratory viruses in respiratory specimens", "PROBLEM", 97, 162], ["respiratory viruses", "OBSERVATION", 118, 137], ["respiratory specimens", "OBSERVATION", 141, 162]]], ["The addition of RVP assay to the viral testing algorithm of respiratory infections in children provides rapid results, improves diagnostic yield and may result in decreased antibiotic usage, reduced diagnostic testing and reduced hospital stay.O501 Aetiological role of viruses in hospitalised patients with acute gastroenteritis in GreeceM.", [["respiratory", "ANATOMY", 60, 71], ["respiratory infections", "DISEASE", 60, 82], ["gastroenteritis", "DISEASE", 314, 329], ["children", "ORGANISM", 86, 94], ["patients", "ORGANISM", 294, 302], ["children", "SPECIES", 86, 94], ["patients", "SPECIES", 294, 302], ["RVP assay", "TEST", 16, 25], ["the viral testing", "TEST", 29, 46], ["respiratory infections", "PROBLEM", 60, 82], ["decreased antibiotic usage", "PROBLEM", 163, 189], ["diagnostic testing", "TEST", 199, 217], ["acute gastroenteritis in GreeceM", "PROBLEM", 308, 340], ["respiratory", "ANATOMY", 60, 71], ["infections", "OBSERVATION", 72, 82], ["viruses", "OBSERVATION", 270, 277], ["acute", "OBSERVATION_MODIFIER", 308, 313], ["gastroenteritis", "OBSERVATION", 314, 329]]], ["Savvala, I. Daniil, I. Berberidou, A. Koutsibiri, A. Stambolidi, M. Papachristodoulou, N. Spanakis, D. Petropoulou\u00b0, A. Tsakris (Athens, GR) Objective: In developed countries, viruses, particularly noroviruses, are recognized as the leading cause of acute gastroenteritis.", [["noroviruses", "DISEASE", 198, 209], ["gastroenteritis", "DISEASE", 256, 271], ["viruses", "PROBLEM", 176, 183], ["noroviruses", "PROBLEM", 198, 209], ["acute gastroenteritis", "PROBLEM", 250, 271], ["acute", "OBSERVATION_MODIFIER", 250, 255], ["gastroenteritis", "OBSERVATION", 256, 271]]], ["We determined the aetiology, prevalence and seasonal distribution of viral gastrointestinal infections in hospitalised patients with acute diarrhoea.", [["gastrointestinal", "ANATOMY", 75, 91], ["viral gastrointestinal infections", "DISEASE", 69, 102], ["diarrhoea", "DISEASE", 139, 148], ["gastrointestinal", "ORGANISM_SUBDIVISION", 75, 91], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["viral gastrointestinal infections", "PROBLEM", 69, 102], ["acute diarrhoea", "PROBLEM", 133, 148], ["viral", "OBSERVATION_MODIFIER", 69, 74], ["gastrointestinal", "ANATOMY", 75, 91], ["infections", "OBSERVATION", 92, 102], ["acute", "OBSERVATION_MODIFIER", 133, 138], ["diarrhoea", "OBSERVATION", 139, 148]]], ["Methods: During one-year period (November 2007-November 2008), a total of 201 faecal specimens were collected from 165 children, 21 premature neonates and 15 adults who were hospitalised with symptoms and signs of acute gastroenteritis.", [["faecal specimens", "ANATOMY", 78, 94], ["gastroenteritis", "DISEASE", 220, 235], ["faecal specimens", "CANCER", 78, 94], ["children", "ORGANISM", 119, 127], ["neonates", "ORGANISM", 142, 150], ["children", "SPECIES", 119, 127], ["faecal specimens", "TEST", 78, 94], ["symptoms", "PROBLEM", 192, 200], ["acute gastroenteritis", "PROBLEM", 214, 235], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["gastroenteritis", "OBSERVATION", 220, 235]]], ["Stool samples were tested for the presence of rotavirus, adenovirus, astrovirus and norovirus.", [["Stool samples", "ANATOMY", 0, 13], ["rotavirus, adenovirus, astrovirus and norovirus", "DISEASE", 46, 93], ["Stool samples", "ORGANISM_SUBSTANCE", 0, 13], ["rotavirus", "ORGANISM", 46, 55], ["adenovirus", "ORGANISM", 57, 67], ["astrovirus", "ORGANISM", 69, 79], ["rotavirus", "SPECIES", 46, 55], ["adenovirus", "SPECIES", 57, 67], ["Stool samples", "TEST", 0, 13], ["rotavirus", "PROBLEM", 46, 55], ["adenovirus", "PROBLEM", 57, 67], ["astrovirus", "PROBLEM", 69, 79], ["norovirus", "PROBLEM", 84, 93]]], ["Rotavirus, adenovirus and astrovirus antigen detection was performed by chromatographic immunoassays (Rotavirus and Adenovirus, VIKIA \u00ae -bioMerieux, France; H&R Astrovirus-Vegal Farmaceutica, Spain).", [["Rotavirus", "DISEASE", 0, 9], ["Rotavirus", "ORGANISM", 0, 9], ["adenovirus", "ORGANISM", 11, 21], ["astrovirus", "ORGANISM", 26, 36], ["Adenovirus", "ORGANISM", 116, 126], ["adenovirus", "SPECIES", 11, 21], ["astrovirus", "SPECIES", 26, 36], ["Adenovirus", "SPECIES", 116, 126], ["Rotavirus", "PROBLEM", 0, 9], ["adenovirus", "PROBLEM", 11, 21], ["astrovirus antigen detection", "TEST", 26, 54], ["chromatographic immunoassays", "TEST", 72, 100], ["Rotavirus", "TEST", 102, 111], ["Adenovirus", "TEST", 116, 126], ["VIKIA", "TEST", 128, 133], ["Astrovirus", "PROBLEM", 161, 171]]], ["Noroviruses were detected by an enzyme immunoassay (Ridascreen \u00ae rbiopharm, Germany) and confirmed by reverse transcription-PCR.", [["Noroviruses", "GENE_OR_GENE_PRODUCT", 0, 11], ["Noroviruses", "PROBLEM", 0, 11], ["an enzyme immunoassay", "TEST", 29, 50]]], ["Data were analyzed for seasonality of infection and possible transmission mode.Results:The overall incidence of viral identification in acute diarrhoeal stool was 24% (48 of 201 patients).", [["infection", "DISEASE", 38, 47], ["diarrhoeal stool", "DISEASE", 142, 158], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["infection", "PROBLEM", 38, 47], ["viral identification", "TEST", 112, 132], ["acute diarrhoeal stool", "PROBLEM", 136, 158], ["infection", "OBSERVATION", 38, 47], ["viral", "OBSERVATION", 112, 117], ["acute", "OBSERVATION_MODIFIER", 136, 141]]], ["Fifty one viral antigens were detected One patient with positive antigen detection is suffering from a disease of unclear aetiology.", [["patient", "ORGANISM", 43, 50], ["viral antigens", "PROTEIN", 10, 24], ["patient", "SPECIES", 43, 50], ["one viral antigens", "TEST", 6, 24], ["positive antigen detection", "PROBLEM", 56, 82], ["a disease", "PROBLEM", 101, 110], ["disease", "OBSERVATION", 103, 110]]], ["So, an association of replication of CIHHV-6 with the disease might be considered.", [["CIHHV-6", "ORGANISM", 37, 44], ["CIHHV", "TREATMENT", 37, 42], ["the disease", "PROBLEM", 50, 61], ["disease", "OBSERVATION", 54, 61], ["might be considered", "UNCERTAINTY", 62, 81]]], ["In contrast, the other patient did not show any symptoms at the time of antigen detection.", [["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["any symptoms", "PROBLEM", 44, 56], ["antigen detection", "TEST", 72, 89]]], ["This patient shows a special mode of acquisition of CIHHV-6 (by BMT) possibly resulting in differences in the immunological priming and response.", [["patient", "ORGANISM", 5, 12], ["CIHHV-6", "GENE_OR_GENE_PRODUCT", 52, 59], ["BMT", "CANCER", 64, 67], ["CIHHV-6", "PROTEIN", 52, 59], ["patient", "SPECIES", 5, 12], ["CIHHV", "TEST", 52, 57]]], ["In addition, in the latter patient CIHHV-6 is restricted to blood cells.", [["blood cells", "ANATOMY", 60, 71], ["patient", "ORGANISM", 27, 34], ["CIHHV-6", "CELL", 35, 42], ["blood cells", "CELL", 60, 71], ["blood cells", "CELL_TYPE", 60, 71], ["patient", "SPECIES", 27, 34]]], ["Two other patients did not show antigen expression.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["So, it is unclear how the transcription and translation of viral genes is influenced?", [["viral genes", "DNA", 59, 70], ["viral genes", "PROBLEM", 59, 70]]], ["Furthermore, is there a pathophysiological impact of viral replication in individuals with CIHHV-6?", [["CIHHV", "TEST", 91, 96], ["viral replication", "OBSERVATION", 53, 70]]], ["Objectives: Several case studies have reported on meningo-encephalitis caused by a primary Epstein-Barr virus (EBV) infection.", [["meningo-encephalitis", "DISEASE", 50, 70], ["primary Epstein-Barr virus (EBV) infection", "DISEASE", 83, 125], ["meningo-encephalitis", "ORGANISM", 50, 70], ["Epstein-Barr virus", "ORGANISM", 91, 109], ["EBV", "ORGANISM", 111, 114], ["Barr virus", "SPECIES", 99, 109], ["Epstein-Barr virus", "SPECIES", 91, 109], ["EBV", "SPECIES", 111, 114], ["Several case studies", "TEST", 12, 32], ["meningo-encephalitis", "PROBLEM", 50, 70], ["a primary Epstein-Barr virus (EBV) infection", "PROBLEM", 81, 125], ["encephalitis", "OBSERVATION", 58, 70], ["Barr virus", "OBSERVATION", 99, 109], ["infection", "OBSERVATION", 116, 125]]], ["We aimed to investigate the viral loads, and the inflammatory characteristics of this thus far poorly defined disease entity.Methods:We evaluated all cases from 2003-2008, in which an EBV polymerase chain reaction test (PCR) was requested on a cerebro spinal fluid (CSF) sample.", [["cerebro spinal fluid", "ANATOMY", 244, 264], ["EBV", "ORGANISM", 184, 187], ["CSF", "ORGANISM_SUBSTANCE", 266, 269], ["EBV", "SPECIES", 184, 187], ["the viral loads", "PROBLEM", 24, 39], ["the inflammatory characteristics", "PROBLEM", 45, 77], ["poorly defined disease entity", "PROBLEM", 95, 124], ["an EBV polymerase chain reaction test", "TEST", 181, 218], ["PCR", "TEST", 220, 223], ["a cerebro spinal fluid (CSF) sample", "TEST", 242, 277], ["viral loads", "OBSERVATION", 28, 39], ["inflammatory", "OBSERVATION_MODIFIER", 49, 61], ["poorly defined", "OBSERVATION_MODIFIER", 95, 109], ["disease", "OBSERVATION", 110, 117], ["spinal", "ANATOMY", 252, 258]]], ["Primary infection was defined as a clinical presentation with sore throat/pharyngitis/malaise in combination with lymphocytosis, and detectable heterophile antibodies or positive EBV IgM antibodies.", [["Primary infection", "DISEASE", 0, 17], ["sore throat", "DISEASE", 62, 73], ["pharyngitis", "DISEASE", 74, 85], ["lymphocytosis", "DISEASE", 114, 127], ["throat", "ORGANISM_SUBDIVISION", 67, 73], ["EBV", "ORGANISM", 179, 182], ["heterophile antibodies", "PROTEIN", 144, 166], ["positive EBV IgM antibodies", "PROTEIN", 170, 197], ["EBV", "SPECIES", 179, 182], ["Primary infection", "PROBLEM", 0, 17], ["sore throat", "PROBLEM", 62, 73], ["pharyngitis", "PROBLEM", 74, 85], ["malaise", "PROBLEM", 86, 93], ["lymphocytosis", "PROBLEM", 114, 127], ["detectable heterophile antibodies", "PROBLEM", 133, 166], ["positive EBV IgM antibodies", "PROBLEM", 170, 197], ["infection", "OBSERVATION", 8, 17], ["pharyngitis", "OBSERVATION", 74, 85], ["malaise", "OBSERVATION", 86, 93], ["heterophile antibodies", "OBSERVATION", 144, 166], ["EBV IgM antibodies", "OBSERVATION", 179, 197]]], ["Patients with proven neuroborreliosis served as control group.", [["neuroborreliosis", "DISEASE", 21, 37], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["neuroborreliosis", "PROBLEM", 21, 37], ["neuroborreliosis", "OBSERVATION", 21, 37]]], ["Leukocyte response and EBV viral loads in CSF, and serum were compared between primary EBV and neuroborreliosis cases.", [["Leukocyte", "ANATOMY", 0, 9], ["CSF", "ANATOMY", 42, 45], ["serum", "ANATOMY", 51, 56], ["primary EBV and neuroborreliosis", "DISEASE", 79, 111], ["Leukocyte", "CELL", 0, 9], ["EBV", "ORGANISM", 23, 26], ["CSF", "ORGANISM_SUBSTANCE", 42, 45], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["EBV", "ORGANISM", 87, 90], ["CSF", "PROTEIN", 42, 45], ["EBV", "SPECIES", 23, 26], ["EBV", "SPECIES", 87, 90], ["Leukocyte response", "TEST", 0, 18], ["EBV viral loads in CSF", "TEST", 23, 45], ["serum", "TEST", 51, 56], ["primary EBV and neuroborreliosis cases", "PROBLEM", 79, 117], ["EBV viral loads", "OBSERVATION", 23, 38]]], ["Results: We identified six cases with a primary EBV infection (median age: 22, male: 4) with neurological symptoms ranging from meningeal signs to encephalitis.", [["neurological", "ANATOMY", 93, 105], ["meningeal", "ANATOMY", 128, 137], ["primary EBV infection", "DISEASE", 40, 61], ["neurological symptoms", "DISEASE", 93, 114], ["encephalitis", "DISEASE", 147, 159], ["EBV", "ORGANISM", 48, 51], ["a primary EBV infection", "PROBLEM", 38, 61], ["neurological symptoms", "PROBLEM", 93, 114], ["meningeal signs", "PROBLEM", 128, 143], ["encephalitis", "PROBLEM", 147, 159], ["EBV infection", "OBSERVATION", 48, 61], ["meningeal", "ANATOMY", 128, 137], ["encephalitis", "OBSERVATION", 147, 159]]], ["These were compared to 14 patients with neuroborreliosis (median age: 27, male: 6).", [["neuroborreliosis", "DISEASE", 40, 56], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["neuroborreliosis", "PROBLEM", 40, 56]]], ["In four out of six patients with a primary EBV infection with neurological symptoms EBV DNA was detected in CSF and in serum, whereas all neuroborreliosis cases were EBV PCR negative in both compartments.", [["neurological", "ANATOMY", 62, 74], ["serum", "ANATOMY", 119, 124], ["EBV infection", "DISEASE", 43, 56], ["neuroborreliosis", "DISEASE", 138, 154], ["patients", "ORGANISM", 19, 27], ["EBV", "ORGANISM", 43, 46], ["EBV", "ORGANISM", 84, 87], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["CSF", "ORGANISM_SUBSTANCE", 108, 111], ["serum", "ORGANISM_SUBSTANCE", 119, 124], ["EBV", "ORGANISM", 166, 169], ["EBV DNA", "DNA", 84, 91], ["patients", "SPECIES", 19, 27], ["EBV", "SPECIES", 43, 46], ["EBV", "SPECIES", 84, 87], ["EBV", "SPECIES", 166, 169], ["a primary EBV infection", "PROBLEM", 33, 56], ["neurological symptoms", "PROBLEM", 62, 83], ["EBV DNA", "PROBLEM", 84, 91], ["CSF and in serum", "TEST", 108, 124], ["all neuroborreliosis cases", "TEST", 134, 160], ["EBV PCR", "TEST", 166, 173], ["EBV", "OBSERVATION_MODIFIER", 43, 46], ["infection", "OBSERVATION", 47, 56]]], ["Viral loads were lower in CSF as compared to serum.", [["serum", "ANATOMY", 45, 50], ["Viral", "ORGANISM", 0, 5], ["CSF", "ORGANISM_SUBSTANCE", 26, 29], ["serum", "ORGANISM_SUBSTANCE", 45, 50], ["Viral loads", "TEST", 0, 11], ["serum", "TEST", 45, 50], ["lower", "OBSERVATION_MODIFIER", 17, 22]]], ["In blood, leukocytes, lymphocyte, and monocyte counts were significantly increased as compared to the neuroborreliosis cases (see table 1 ). specific for VP7 and VP4 genes, using pools of G and P type specific primers.", [["blood", "ANATOMY", 3, 8], ["leukocytes", "ANATOMY", 10, 20], ["lymphocyte", "ANATOMY", 22, 32], ["monocyte", "ANATOMY", 38, 46], ["neuroborreliosis", "DISEASE", 102, 118], ["blood", "ORGANISM_SUBSTANCE", 3, 8], ["leukocytes", "CELL", 10, 20], ["lymphocyte", "CELL", 22, 32], ["monocyte", "CELL", 38, 46], ["VP7", "GENE_OR_GENE_PRODUCT", 154, 157], ["VP4", "GENE_OR_GENE_PRODUCT", 162, 165], ["leukocytes", "CELL_TYPE", 10, 20], ["lymphocyte", "CELL_TYPE", 22, 32], ["VP7 and VP4 genes", "DNA", 154, 171], ["G and P type specific primers", "DNA", 188, 217], ["blood", "TEST", 3, 8], ["leukocytes", "TEST", 10, 20], ["lymphocyte", "TEST", 22, 32], ["monocyte counts", "TEST", 38, 53], ["the neuroborreliosis cases", "TEST", 98, 124], ["VP7", "PROBLEM", 154, 157], ["G and P type specific primers", "TREATMENT", 188, 217], ["blood", "ANATOMY", 3, 8], ["leukocytes", "ANATOMY", 10, 20], ["lymphocyte", "ANATOMY", 22, 32], ["monocyte counts", "OBSERVATION", 38, 53], ["significantly", "OBSERVATION_MODIFIER", 59, 72], ["increased", "OBSERVATION_MODIFIER", 73, 82]]], ["All strains (NIV/BRV/68, NIV/BRV/79, and NIV/BRV/86) were not typeable for the VP4 and VP7 genes.", [["BRV/68", "ORGANISM", 17, 23], ["NIV/BRV/79", "ORGANISM", 25, 35], ["NIV/BRV/86", "ORGANISM", 41, 51], ["VP4", "GENE_OR_GENE_PRODUCT", 79, 82], ["VP7", "GENE_OR_GENE_PRODUCT", 87, 90], ["VP4 and VP7 genes", "DNA", 79, 96], ["NIV/BRV/68, NIV/BRV/79", "SPECIES", 13, 35], ["NIV/BRV/86", "SPECIES", 41, 51], ["All strains", "PROBLEM", 0, 11], ["NIV/BRV", "TREATMENT", 13, 20], ["NIV", "TREATMENT", 25, 28], ["NIV", "TREATMENT", 41, 44], ["the VP4 and VP7 genes", "PROBLEM", 75, 96]]], ["After purification by \"Qiaquick Gel Extraction Kit\" (QIAGEN, Germany), the VP4, VP6, VP7, and NSP4 first amplicons of the BoRV-A strains were subjected to sequence analysis with automated sequencer ABI 3130 XL DNA Analyzer (Applied Biosystems, USA).", [["VP4", "GENE_OR_GENE_PRODUCT", 75, 78], ["VP6", "GENE_OR_GENE_PRODUCT", 80, 83], ["VP7", "GENE_OR_GENE_PRODUCT", 85, 88], ["NSP4", "GENE_OR_GENE_PRODUCT", 94, 98], ["DNA", "CELLULAR_COMPONENT", 210, 213], ["VP4, VP6, VP7, and NSP4 first amplicons", "DNA", 75, 114], ["BoRV-A", "SPECIES", 122, 128], ["Qiaquick Gel Extraction", "TREATMENT", 23, 46], ["the VP4", "TEST", 71, 78], ["VP6", "TEST", 80, 83], ["VP7", "TEST", 85, 88], ["NSP4", "PROBLEM", 94, 98], ["A strains", "PROBLEM", 127, 136], ["sequence analysis", "TEST", 155, 172], ["automated sequencer ABI", "TEST", 178, 201], ["DNA Analyzer", "TEST", 210, 222]]], ["Phylogenetic analysis was performed using MEGA version 4.0.", [["Phylogenetic analysis", "TEST", 0, 21], ["MEGA version", "TEST", 42, 54]]], ["Objectives: Dengue is a flavivirus and is among the most widely-spread viral diseases.", [["Dengue", "DISEASE", 12, 18], ["flavivirus", "DISEASE", 24, 34], ["viral diseases", "DISEASE", 71, 85], ["Dengue", "ORGANISM", 12, 18], ["Dengue", "PROBLEM", 12, 18], ["a flavivirus", "PROBLEM", 22, 34], ["spread viral diseases", "PROBLEM", 64, 85], ["Dengue", "OBSERVATION", 12, 18], ["flavivirus", "OBSERVATION", 24, 34], ["spread", "OBSERVATION_MODIFIER", 64, 70], ["viral diseases", "OBSERVATION", 71, 85]]], ["Our previous report demonstrates existence of live dengue virus in blood and urine even in the convalescent postfebrile period.", [["blood", "ANATOMY", 67, 72], ["urine", "ANATOMY", 77, 82], ["dengue virus in blood and urine", "DISEASE", 51, 82], ["dengue virus", "ORGANISM", 51, 63], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["urine", "ORGANISM_SUBSTANCE", 77, 82], ["dengue virus", "SPECIES", 51, 63], ["live dengue virus in blood and urine", "PROBLEM", 46, 82]]], ["In some cases, excretion in the patient's urine can be detected as late as 28 days after the onset of illness.", [["urine", "ANATOMY", 42, 47], ["illness", "DISEASE", 102, 109], ["patient", "ORGANISM", 32, 39], ["urine", "ORGANISM_SUBSTANCE", 42, 47], ["patient", "SPECIES", 32, 39], ["excretion in the patient's urine", "TEST", 15, 47], ["illness", "PROBLEM", 102, 109]]], ["This goes along with the model of West Nile virus, another type of flavivirus, which can be excreted in the urine for months after acute infection in both animal studies and human case report.", [["urine", "ANATOMY", 108, 113], ["flavivirus", "DISEASE", 67, 77], ["acute infection", "DISEASE", 131, 146], ["West Nile virus", "ORGANISM", 34, 49], ["flavivirus", "ORGANISM", 67, 77], ["urine", "ORGANISM_SUBSTANCE", 108, 113], ["human", "ORGANISM", 174, 179], ["Nile virus", "SPECIES", 39, 49], ["human", "SPECIES", 174, 179], ["West Nile virus", "SPECIES", 34, 49], ["human", "SPECIES", 174, 179], ["West Nile virus", "PROBLEM", 34, 49], ["flavivirus", "PROBLEM", 67, 77], ["acute infection", "PROBLEM", 131, 146], ["flavivirus", "OBSERVATION", 67, 77], ["acute", "OBSERVATION_MODIFIER", 131, 136], ["infection", "OBSERVATION", 137, 146]]], ["Here we report a pilot study to address a magnitude of such findings.", [["a pilot study", "TEST", 15, 28]]], ["Methods: Between April 2007 and October 2008, paediatric and adult febrile patients suspected of dengue infection were enrolled.", [["febrile", "DISEASE", 67, 74], ["dengue infection", "DISEASE", 97, 113], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["dengue", "SPECIES", 97, 103], ["dengue infection", "PROBLEM", 97, 113], ["dengue", "OBSERVATION_MODIFIER", 97, 103], ["infection", "OBSERVATION", 104, 113]]], ["Diagnosis of dengue was based on standard specific serology on paired sera.", [["sera", "ANATOMY", 70, 74], ["dengue", "DISEASE", 13, 19], ["sera", "ORGANISM_SUBSTANCE", 70, 74], ["dengue", "SPECIES", 13, 19], ["dengue", "PROBLEM", 13, 19], ["standard specific serology", "TEST", 33, 59], ["dengue", "OBSERVATION", 13, 19]]], ["Patients with negative serology served as controls.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["serology", "TEST", 23, 31]]], ["Blood and urine specimens were collected at several time points.", [["Blood", "ANATOMY", 0, 5], ["urine specimens", "ANATOMY", 10, 25], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["urine specimens", "ORGANISM_SUBSTANCE", 10, 25], ["Blood and urine specimens", "TEST", 0, 25], ["urine", "ANATOMY", 10, 15]]], ["Whole blood was separated into plasma and peripheral blood mononuclear cells (PBMC).", [["Whole blood", "ANATOMY", 0, 11], ["plasma", "ANATOMY", 31, 37], ["peripheral blood mononuclear cells", "ANATOMY", 42, 76], ["PBMC", "ANATOMY", 78, 82], ["Whole", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["plasma", "ORGANISM_SUBSTANCE", 31, 37], ["peripheral blood mononuclear cells", "CELL", 42, 76], ["PBMC", "CELL", 78, 82], ["plasma", "CELL_TYPE", 31, 37], ["peripheral blood mononuclear cells", "CELL_TYPE", 42, 76], ["PBMC", "CELL_TYPE", 78, 82], ["Whole blood", "TEST", 0, 11], ["peripheral", "ANATOMY_MODIFIER", 42, 52], ["blood", "ANATOMY", 53, 58], ["mononuclear cells", "OBSERVATION", 59, 76]]], ["These have been aliquoted and used for earlier studies and some stored in freezers.", [["earlier studies", "TEST", 39, 54]]], ["Available plasma, PBMC, and urine were processed and inoculated into Aedes aegypti.", [["plasma", "ANATOMY", 10, 16], ["PBMC", "ANATOMY", 18, 22], ["urine", "ANATOMY", 28, 33], ["plasma", "ORGANISM_SUBSTANCE", 10, 16], ["PBMC", "CELL", 18, 22], ["urine", "ORGANISM_SUBSTANCE", 28, 33], ["Aedes aegypti", "ORGANISM", 69, 82], ["PBMC", "CELL_TYPE", 18, 22], ["Aedes aegypti", "SPECIES", 69, 82], ["Aedes aegypti", "SPECIES", 69, 82], ["Available plasma, PBMC, and urine", "TEST", 0, 33]]], ["Surviving mosquitoes at 14 days after inoculation were employed for viral detection by dengue-specific RT-PCR.", [["inoculation", "TREATMENT", 38, 49], ["viral detection", "TEST", 68, 83]]], ["Indirect fluorescence antibody (IFA) staining of mosquito heads was performed on all positive RT-PCR specimens, except for the one from PBMC (awaiting IFA result).", [["specimens", "ANATOMY", 101, 110], ["PBMC", "ANATOMY", 136, 140], ["Indirect fluorescence antibody", "GENE_OR_GENE_PRODUCT", 0, 30], ["PBMC", "CELL", 136, 140], ["PBMC", "CELL_TYPE", 136, 140], ["Indirect fluorescence antibody", "TEST", 0, 30], ["IFA", "TEST", 32, 35], ["mosquito heads", "TEST", 49, 63], ["PCR specimens", "TEST", 97, 110], ["PBMC", "TEST", 136, 140]]], ["Results: 5 and 45 cases of primary and secondary infections, respectively, and 4 negative controls were included.", [["primary and secondary infections", "DISEASE", 27, 59], ["primary and secondary infections", "PROBLEM", 27, 59], ["secondary", "OBSERVATION_MODIFIER", 39, 48], ["infections", "OBSERVATION", 49, 59]]], ["These translated into 55 and 59 early and late dengue specimens, and 6 and 4 early and late negative-control counterparts, respectively.", [["specimens", "ANATOMY", 54, 63], ["dengue", "DISEASE", 47, 53], ["dengue specimens", "TEST", 47, 63]]], ["Dengue virus were isolated in some blood and urine specimens as late as 46 days after the onset of illness.", [["blood", "ANATOMY", 35, 40], ["urine specimens", "ANATOMY", 45, 60], ["Dengue", "DISEASE", 0, 6], ["illness", "DISEASE", 99, 106], ["Dengue virus", "ORGANISM", 0, 12], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["urine specimens", "ORGANISM_SUBSTANCE", 45, 60], ["Dengue virus", "SPECIES", 0, 12], ["Dengue virus", "SPECIES", 0, 12], ["Dengue virus", "PROBLEM", 0, 12], ["urine specimens", "TEST", 45, 60], ["illness", "PROBLEM", 99, 106], ["virus", "OBSERVATION", 7, 12], ["illness", "OBSERVATION", 99, 106]]], ["No virus was isolated from control specimens.", [["specimens", "ANATOMY", 35, 44], ["virus", "PROBLEM", 3, 8], ["virus", "OBSERVATION", 3, 8]]], ["All but 5 positive RT-PCR specimens also demonstrated positive IFA.", [["specimens", "ANATOMY", 26, 35], ["PCR specimens", "TEST", 22, 35], ["positive IFA", "PROBLEM", 54, 66], ["positive", "OBSERVATION_MODIFIER", 54, 62]]], ["4 out of 5 negatives were from early-phase specimens.", [["specimens", "ANATOMY", 43, 52]]], ["Conclusion: Our study demonstrates prolonged survival of dengue virus after clinical recovery.", [["dengue", "DISEASE", 57, 63], ["dengue virus", "ORGANISM", 57, 69], ["dengue virus", "SPECIES", 57, 69], ["Our study", "TEST", 12, 21], ["dengue virus", "PROBLEM", 57, 69]]], ["This finding has pathologic and epidemiologic significance, adding a potential role of urine in the transmission of the disease.", [["urine", "ANATOMY", 87, 92], ["urine", "ORGANISM_SUBSTANCE", 87, 92], ["the disease", "PROBLEM", 116, 127], ["pathologic", "OBSERVATION", 17, 27], ["urine", "OBSERVATION", 87, 92], ["disease", "OBSERVATION", 120, 127]]], ["Spread of the virus to humans might occur through infectious urine with help from arthropod vectors.", [["urine", "ANATOMY", 61, 66], ["humans", "ORGANISM", 23, 29], ["urine", "ORGANISM_SUBSTANCE", 61, 66], ["humans", "SPECIES", 23, 29], ["humans", "SPECIES", 23, 29], ["the virus", "PROBLEM", 10, 19], ["infectious urine", "PROBLEM", 50, 66], ["arthropod vectors", "TREATMENT", 82, 99], ["virus", "OBSERVATION", 14, 19], ["infectious", "OBSERVATION", 50, 60]]], ["This research could provide new insights into our understanding of the pathogenesis of DENV infection.ResultsIsolation of dengue virus from blood and urine specimens during early (days 1\u22127 after onset of illness) and late (days 8\u221246) phases of infection (specimens with dengue isolated/total specimens for mosquito inoculation)ResultsEarly phase Late phase Plasma 16/25 (64%) 0/13 (0%) PBMC not performed 1/2 (50%) Urine 8/29 (28%) 12/44 (27%) All specimens 24/54 (44%) 13/59 (22%)", [["blood", "ANATOMY", 140, 145], ["urine specimens", "ANATOMY", 150, 165], ["specimens", "ANATOMY", 255, 264], ["specimens", "ANATOMY", 292, 301], ["PBMC", "ANATOMY", 386, 390], ["specimens", "ANATOMY", 448, 457], ["DENV infection", "DISEASE", 87, 101], ["dengue virus from blood and urine", "DISEASE", 122, 155], ["illness", "DISEASE", 204, 211], ["infection", "DISEASE", 244, 253], ["dengue", "DISEASE", 270, 276], ["DENV", "ORGANISM", 87, 91], ["dengue virus", "ORGANISM", 122, 134], ["blood", "ORGANISM_SUBSTANCE", 140, 145], ["urine specimens", "ORGANISM_SUBSTANCE", 150, 165], ["Plasma", "ORGANISM_SUBSTANCE", 357, 363], ["PBMC", "CELL", 386, 390], ["PBMC", "CELL_TYPE", 386, 390], ["DENV", "SPECIES", 87, 91], ["dengue virus", "SPECIES", 122, 134], ["dengue", "SPECIES", 270, 276], ["DENV infection", "PROBLEM", 87, 101], ["dengue virus", "PROBLEM", 122, 134], ["blood and urine specimens", "TEST", 140, 165], ["illness", "PROBLEM", 204, 211], ["infection", "PROBLEM", 244, 253], ["specimens", "TEST", 255, 264], ["dengue isolated/total specimens", "TEST", 270, 301], ["mosquito inoculation", "TEST", 306, 326], ["Plasma", "TEST", 357, 363], ["PBMC", "TEST", 386, 390], ["Urine", "TEST", 415, 420], ["All specimens", "TEST", 444, 457], ["DENV", "OBSERVATION_MODIFIER", 87, 91], ["infection", "OBSERVATION", 92, 101], ["dengue virus", "OBSERVATION", 122, 134], ["infection", "OBSERVATION", 244, 253]]]], "PMC7166375": [["Materials and MethodsTo ascertain the utility of an ANM\u2010PCR respiratory pathogen panel in aiding cause of death determination, such tests were performed by six forensic pathologists on 35 of 145 coronial pediatric decedents from December 1, 2011, to June 30, 2015, in the Medical and Forensic Autopsy Section of the Department of Pathology and Laboratory Medicine at the Medical University of South Carolina.", [["death", "DISEASE", 106, 111], ["an ANM\u2010PCR respiratory pathogen panel", "TEST", 49, 86], ["such tests", "TEST", 127, 137]]], ["Cases were selected for PCR on the basis of the attending pathologists\u2019 suspicion that a respiratory illness may have contributed to death.", [["respiratory", "ANATOMY", 89, 100], ["respiratory illness", "DISEASE", 89, 108], ["death", "DISEASE", 133, 138], ["PCR", "TEST", 24, 27], ["a respiratory illness", "PROBLEM", 87, 108], ["death", "PROBLEM", 133, 138]]], ["Samples were acquired via postmortem mucosal swabs from nasal, nasopharyngeal, tracheal, and/or bronchial regions.", [["Samples", "ANATOMY", 0, 7], ["mucosal swabs", "ANATOMY", 37, 50], ["nasal", "ANATOMY", 56, 61], ["nasopharyngeal", "ANATOMY", 63, 77], ["tracheal", "ANATOMY", 79, 87], ["bronchial regions", "ANATOMY", 96, 113], ["postmortem mucosal swabs", "ORGANISM_SUBSTANCE", 26, 50], ["nasal", "ORGANISM_SUBDIVISION", 56, 61], ["nasopharyngeal", "CANCER", 63, 77], ["tracheal", "MULTI-TISSUE_STRUCTURE", 79, 87], ["bronchial regions", "MULTI-TISSUE_STRUCTURE", 96, 113], ["Samples", "TEST", 0, 7], ["postmortem mucosal swabs", "TEST", 26, 50], ["nasal, nasopharyngeal, tracheal, and/or bronchial regions", "PROBLEM", 56, 113], ["nasal", "ANATOMY", 56, 61], ["nasopharyngeal", "ANATOMY", 63, 77], ["tracheal", "ANATOMY", 79, 87], ["bronchial", "ANATOMY", 96, 105], ["regions", "ANATOMY_MODIFIER", 106, 113]]], ["Samples were then analyzed using an ANM\u2010PCR panel of respiratory pathogens, specifically the BioFire FilmArray\u00ae20 (BioFire Diagnostics, Inc., Salt Lake City, UT).", [["Samples", "ANATOMY", 0, 7], ["respiratory pathogens", "DISEASE", 53, 74], ["Samples", "TEST", 0, 7], ["an ANM\u2010PCR panel", "TEST", 33, 49], ["respiratory pathogens", "PROBLEM", 53, 74], ["respiratory pathogens", "OBSERVATION", 53, 74]]], ["Briefly, each sample was acquired from a patient in the form of a mucosal swab, which was placed into BD Universal Viral Transport for Viruses, Chlamydiae, Mycoplasmas and Ureaplasmas (Becton, Dickinson and Company, Franklin Lakes, NJ).", [["sample", "ANATOMY", 14, 20], ["mucosal swab", "ANATOMY", 66, 78], ["patient", "ORGANISM", 41, 48], ["mucosal swab", "ORGANISM_SUBSTANCE", 66, 78], ["patient", "SPECIES", 41, 48], ["a mucosal swab", "TREATMENT", 64, 78], ["Viruses", "PROBLEM", 135, 142], ["Chlamydiae", "PROBLEM", 144, 154], ["Mycoplasmas", "PROBLEM", 156, 167], ["Ureaplasmas", "PROBLEM", 172, 183]]], ["Specimens were transported in person to the microbiology laboratory within 2 h from the time of procurement.", [["Specimens", "ANATOMY", 0, 9], ["person", "SPECIES", 30, 36]]], ["Upon receipt in the microbiology laboratory, hydration solution was injected into a compartmentalized pouch where the ANM\u2010PCRs occur, the patient sample was mixed with denaturing buffer and added to the pouch, the pouch was then inserted into the analyzer, and the remaining reactions and analyses were performed by the bench top instrument.", [["pouch", "ANATOMY", 102, 107], ["pouch", "ANATOMY", 203, 208], ["pouch", "ANATOMY", 214, 219], ["pouch", "ORGAN", 102, 107], ["patient", "ORGANISM", 138, 145], ["pouch", "PATHOLOGICAL_FORMATION", 203, 208], ["pouch", "ORGAN", 214, 219], ["patient", "SPECIES", 138, 145], ["hydration solution", "TREATMENT", 45, 63], ["a compartmentalized pouch", "TREATMENT", 82, 107], ["the ANM\u2010PCRs", "TEST", 114, 126], ["denaturing buffer", "TREATMENT", 168, 185], ["the pouch", "TREATMENT", 210, 219], ["the analyzer", "TEST", 243, 255], ["analyses", "TEST", 289, 297], ["pouch", "ANATOMY", 102, 107], ["pouch", "ANATOMY", 203, 208], ["pouch", "ANATOMY", 214, 219]]], ["Two process controls were included in each pouch, an RNA process control and a PCR2 control.", [["pouch", "PATHOLOGICAL_FORMATION", 43, 48], ["an RNA process control", "TREATMENT", 50, 72], ["a PCR2 control", "TREATMENT", 77, 91], ["pouch", "ANATOMY", 43, 48]]], ["The RNA Process Control assay targets an RNA transcript from the yeast Schizosaccharomyces pombe.", [["yeast Schizosaccharomyces pombe", "ORGANISM", 65, 96], ["RNA transcript", "RNA", 41, 55], ["yeast", "SPECIES", 65, 70], ["Schizosaccharomyces pombe", "SPECIES", 71, 96], ["yeast", "SPECIES", 65, 70], ["Schizosaccharomyces pombe", "SPECIES", 71, 96], ["The RNA Process", "TREATMENT", 0, 15], ["an RNA transcript", "PROBLEM", 38, 55], ["yeast Schizosaccharomyces pombe", "OBSERVATION", 65, 96]]], ["The yeast is present in the pouch in a freeze\u2010dried form and becomes rehydrated when sample is loaded.", [["pouch", "ANATOMY", 28, 33], ["sample", "ANATOMY", 85, 91], ["pouch", "ORGAN", 28, 33], ["yeast", "SPECIES", 4, 9], ["yeast", "SPECIES", 4, 9], ["The yeast", "PROBLEM", 0, 9], ["yeast", "OBSERVATION", 4, 9], ["pouch", "ANATOMY", 28, 33]]], ["The control material is carried through all stages of the test process, including lysis, nucleic acid purification, reverse transcription, first\u2010stage PCR, dilution, second\u2010stage PCR, and DNA melting.", [["nucleic acid", "CHEMICAL", 89, 101], ["DNA", "CELLULAR_COMPONENT", 188, 191], ["the test process", "TEST", 54, 70], ["lysis", "TREATMENT", 82, 87], ["nucleic acid purification", "TREATMENT", 89, 114], ["reverse transcription", "TREATMENT", 116, 137], ["first\u2010stage PCR", "TEST", 139, 154], ["second\u2010stage PCR", "TEST", 166, 182], ["DNA melting", "PROBLEM", 188, 199]]], ["A positive control result indicates that all steps carried out in the FilmArray RP pouch were successful.", [["all steps", "PROBLEM", 41, 50], ["pouch", "ANATOMY", 83, 88]]], ["The PCR2 Control assay detects a DNA target that is dried into wells of the array along with the corresponding primers.", [["DNA", "CELLULAR_COMPONENT", 33, 36], ["PCR2", "DNA", 4, 8], ["DNA target", "DNA", 33, 43], ["The PCR2 Control assay", "TEST", 0, 22], ["a DNA target", "PROBLEM", 31, 43], ["the corresponding primers", "PROBLEM", 93, 118]]], ["A positive result indicates that the second\u2010stage PCR was successful.", [["the second\u2010stage PCR", "TEST", 33, 53]]], ["Both control assays must be positive for the test run to pass.", [["Both control assays", "TEST", 0, 19], ["the test", "TEST", 41, 49]]], ["External positive and negative controls were run with each new lot of reagents.Materials and MethodsOver the course of the study, the respiratory pathogen panel detected from 15 (version 1) to 20 (version 2) potentially pathogenic agents.", [["the study", "TEST", 119, 128], ["the respiratory pathogen panel", "TEST", 130, 160], ["pathogenic agents", "TREATMENT", 220, 237], ["positive", "OBSERVATION", 9, 17], ["negative", "OBSERVATION", 22, 30]]], ["The initial panel screened for adenovirus, coronavirus (229E and HKU1), human metapneumovirus, human rhinovirus/enterovirus, influenza (A, A/H1, A/H1 2009, A/H3, and B), parainfluenza 1, 2, 3, 4, and RSV.", [["human metapneumovirus", "DISEASE", 72, 93], ["rhinovirus/enterovirus", "DISEASE", 101, 123], ["influenza", "DISEASE", 125, 134], ["parainfluenza", "DISEASE", 170, 183], ["adenovirus", "ORGANISM", 31, 41], ["coronavirus", "ORGANISM", 43, 54], ["HKU1", "GENE_OR_GENE_PRODUCT", 65, 69], ["human", "ORGANISM", 72, 77], ["metapneumovirus", "ORGANISM", 78, 93], ["human", "ORGANISM", 95, 100], ["rhinovirus", "ORGANISM", 101, 111], ["enterovirus", "ORGANISM", 112, 123], ["A, A/H1, A/H1 2009, A/H3", "ORGANISM", 136, 160], ["B", "GENE_OR_GENE_PRODUCT", 166, 167], ["parainfluenza 1", "ORGANISM", 170, 185], ["3", "GENE_OR_GENE_PRODUCT", 190, 191], ["4", "GENE_OR_GENE_PRODUCT", 193, 194], ["RSV", "ORGANISM", 200, 203], ["human", "SPECIES", 72, 77], ["metapneumovirus", "SPECIES", 78, 93], ["human", "SPECIES", 95, 100], ["rhinovirus", "SPECIES", 101, 111], ["parainfluenza", "SPECIES", 170, 183], ["adenovirus", "SPECIES", 31, 41], ["human metapneumovirus", "SPECIES", 72, 93], ["human rhinovirus/enterovirus", "SPECIES", 95, 123], ["A", "SPECIES", 136, 137], ["A/H1, A/H1 2009, A/H3", "SPECIES", 139, 160], ["RSV", "SPECIES", 200, 203], ["The initial panel", "TEST", 0, 17], ["adenovirus", "PROBLEM", 31, 41], ["coronavirus", "PROBLEM", 43, 54], ["HKU1", "TEST", 65, 69], ["human metapneumovirus", "PROBLEM", 72, 93], ["human rhinovirus", "PROBLEM", 95, 111], ["enterovirus", "PROBLEM", 112, 123], ["influenza", "PROBLEM", 125, 134], ["A/H1", "TEST", 139, 143], ["A/H1", "TEST", 145, 149], ["A/H3", "TEST", 156, 160], ["parainfluenza", "TEST", 170, 183], ["RSV", "PROBLEM", 200, 203], ["metapneumovirus", "OBSERVATION", 78, 93], ["parainfluenza", "OBSERVATION", 170, 183]]], ["The most recent panel also included coronavirus (OC43 and NL63), Bordetella pertussis, Chlamydia pneumoniae, and Mycoplasma pneumoniae.", [["Bordetella pertussis", "DISEASE", 65, 85], ["Chlamydia pneumoniae", "DISEASE", 87, 107], ["Mycoplasma pneumoniae", "DISEASE", 113, 134], ["coronavirus", "ORGANISM", 36, 47], ["OC43", "GENE_OR_GENE_PRODUCT", 49, 53], ["NL63", "GENE_OR_GENE_PRODUCT", 58, 62], ["Bordetella pertussis", "ORGANISM", 65, 85], ["Chlamydia pneumoniae", "ORGANISM", 87, 107], ["Mycoplasma pneumoniae", "ORGANISM", 113, 134], ["Bordetella pertussis", "SPECIES", 65, 85], ["Chlamydia pneumoniae", "SPECIES", 87, 107], ["Mycoplasma pneumoniae", "SPECIES", 113, 134], ["OC43", "SPECIES", 49, 53], ["Bordetella pertussis", "SPECIES", 65, 85], ["Chlamydia pneumoniae", "SPECIES", 87, 107], ["Mycoplasma pneumoniae", "SPECIES", 113, 134], ["The most recent panel", "TEST", 0, 21], ["coronavirus", "PROBLEM", 36, 47], ["OC43", "TEST", 49, 53], ["NL63", "TEST", 58, 62], ["Bordetella pertussis", "PROBLEM", 65, 85], ["Chlamydia pneumoniae", "PROBLEM", 87, 107], ["Mycoplasma pneumoniae", "PROBLEM", 113, 134], ["Chlamydia pneumoniae", "OBSERVATION", 87, 107], ["Mycoplasma pneumoniae", "OBSERVATION", 113, 134]]], ["Rhino\u2010 and enteroviruses are grouped together because multiplex PCR tests cannot reliably distinguish between them due to their high degree of genetic similarity 3.", [["enteroviruses", "ORGANISM", 11, 24], ["Rhino\u2010 and enteroviruses", "PROBLEM", 0, 24], ["multiplex PCR tests", "TEST", 54, 73], ["enteroviruses", "OBSERVATION", 11, 24]]], ["Complete autopsies, including histology and toxicology, were conducted on each case.", [["histology", "TEST", 30, 39]]], ["Due to the retrospective nature of this study, investigational techniques were not standardized.", [["this study", "TEST", 35, 45], ["investigational techniques", "TREATMENT", 47, 73]]], ["At minimum, each autopsy investigation included examination of each body cavity and organ, including the cranial cavity and brain.", [["body cavity", "ANATOMY", 68, 79], ["organ", "ANATOMY", 84, 89], ["cranial cavity", "ANATOMY", 105, 119], ["brain", "ANATOMY", 124, 129], ["body cavity", "MULTI-TISSUE_STRUCTURE", 68, 79], ["organ", "ORGAN", 84, 89], ["cranial cavity", "MULTI-TISSUE_STRUCTURE", 105, 119], ["brain", "ORGAN", 124, 129], ["each autopsy investigation", "TEST", 12, 38], ["examination of each body cavity", "TEST", 48, 79], ["organ, including the cranial cavity and brain", "PROBLEM", 84, 129], ["organ", "ANATOMY", 84, 89], ["cranial cavity", "ANATOMY", 105, 119], ["brain", "ANATOMY", 124, 129]]], ["Histologic sections were submitted on all of the study cases and typically included heart, lung, liver, and kidney tissue.", [["sections", "ANATOMY", 11, 19], ["heart", "ANATOMY", 84, 89], ["lung", "ANATOMY", 91, 95], ["liver", "ANATOMY", 97, 102], ["kidney tissue", "ANATOMY", 108, 121], ["Histologic sections", "CANCER", 0, 19], ["heart", "ORGAN", 84, 89], ["lung", "ORGAN", 91, 95], ["liver", "ORGAN", 97, 102], ["kidney tissue", "TISSUE", 108, 121], ["Histologic sections", "TEST", 0, 19], ["the study cases", "TEST", 45, 60], ["typically included heart, lung, liver, and kidney tissue", "PROBLEM", 65, 121], ["heart", "ANATOMY", 84, 89], ["lung", "ANATOMY", 91, 95], ["liver", "ANATOMY", 97, 102], ["kidney", "ANATOMY", 108, 114]]], ["Bacterial cultures were performed in some cases at the discretion of the pathologist.", [["Bacterial cultures", "CELL", 0, 18], ["Bacterial cultures", "TEST", 0, 18]]], ["Vitreous electrolytes were regularly performed on nontraumatic cases without antemortem documentation of electrolyte levels.", [["Vitreous", "ANATOMY", 0, 8], ["electrolyte", "SIMPLE_CHEMICAL", 105, 116], ["Vitreous electrolytes", "TEST", 0, 21], ["nontraumatic cases", "TEST", 50, 68], ["antemortem documentation", "TEST", 77, 101], ["electrolyte levels", "TEST", 105, 123]]], ["The contribution of each positive PCR result to the cause of death was critically examined and interpreted based on the autopsy findings and known circumstances surrounding death by the certifying pathologist.Materials and MethodsFor data analysis, forensic reports were reviewed for the tested cases.", [["death", "DISEASE", 61, 66], ["death", "DISEASE", 173, 178], ["each positive PCR", "PROBLEM", 20, 37], ["death", "PROBLEM", 61, 66], ["the autopsy findings", "TEST", 116, 136], ["data analysis", "TEST", 234, 247]]], ["The swab location was categorized as nasal, nasopharyngeal, tracheal, bronchial, or respiratory site, not otherwise specified, based on information provided in the forensic reports and laboratory information system.", [["swab", "ANATOMY", 4, 8], ["nasal", "ANATOMY", 37, 42], ["nasopharyngeal", "ANATOMY", 44, 58], ["tracheal", "ANATOMY", 60, 68], ["bronchial", "ANATOMY", 70, 79], ["respiratory site", "ANATOMY", 84, 100], ["nasal", "ORGANISM_SUBDIVISION", 37, 42], ["nasopharyngeal", "ORGAN", 44, 58], ["tracheal", "MULTI-TISSUE_STRUCTURE", 60, 68], ["bronchial", "MULTI-TISSUE_STRUCTURE", 70, 79], ["The swab location", "TEST", 0, 17], ["nasal, nasopharyngeal, tracheal, bronchial, or respiratory site", "PROBLEM", 37, 100], ["nasal", "ANATOMY", 37, 42], ["nasopharyngeal", "ANATOMY", 44, 58], ["tracheal", "ANATOMY", 60, 68], ["bronchial", "ANATOMY", 70, 79], ["respiratory site", "OBSERVATION", 84, 100]]], ["The positive ANM\u2010PCR results were divided into three categories based on the determined contribution to the cause of death: (i) significant, (ii) not significant, or (iii) undetermined.", [["death", "DISEASE", 117, 122], ["The positive ANM\u2010PCR", "TEST", 0, 20], ["death", "PROBLEM", 117, 122]]], ["The contribution of ANM\u2010PCR results to cause of death was determined solely on statements within the final reports directly related to the cause of death or ANM\u2010PCR results.", [["death", "DISEASE", 48, 53], ["death", "DISEASE", 148, 153], ["ANM\u2010PCR", "TEST", 20, 27], ["death", "PROBLEM", 48, 53], ["death", "PROBLEM", 148, 153], ["ANM\u2010PCR", "TEST", 157, 164]]], ["\u201cSignificant\u201d results were clearly reflected in the report as causing or contributing to death, \u201cnot significant\u201d results were those in which the test result was clearly not contributory to the death based on documented statements of the certifying pathologist, and results of \u201cundetermined significance\u201d were those in which the role of the pathogen remained indeterminate relative to cause of death based on the final report.", [["death", "DISEASE", 89, 94], ["death", "DISEASE", 194, 199], ["death", "DISEASE", 394, 399], ["death", "PROBLEM", 89, 94], ["the test", "TEST", 142, 150], ["the death", "PROBLEM", 190, 199], ["the pathogen", "PROBLEM", 337, 349], ["death", "PROBLEM", 394, 399]]], ["Chi\u2010square analyses were performed using GraphPad Prism version 6.0h, \u00a91994\u20132015 (GraphPad Software, Inc., La Jolla, CA).ResultsRespiratory pathogen PCR panels were completed in 24.1% (35/145) of 0\u2010 to 12\u2010year\u2010old decedents examined (Fig. 1).", [["Chi\u2010square analyses", "TEST", 0, 19], ["Software", "TEST", 91, 99], ["ResultsRespiratory pathogen PCR panels", "TEST", 121, 159]]], ["Of those, 18 (51.4%) yielded positive PCR results.", [["positive PCR results", "PROBLEM", 29, 49]]], ["Potentially pathogenic agents detected included rhinovirus/enterovirus (13 cases), RSV (five cases), adenovirus (two cases), coronavirus NL63 (two cases), and influenza B (one case) (Fig. 2).ResultsIn 38.9% (7/18) of cases with a positive respiratory pathogen ANM\u2010PCR result (or 20% of total tested cases), a detected pathogen was considered significant to the cause of death (Fig. 3).", [["rhinovirus/enterovirus", "DISEASE", 48, 70], ["coronavirus NL63", "DISEASE", 125, 141], ["influenza B", "DISEASE", 159, 170], ["death", "DISEASE", 370, 375], ["rhinovirus", "ORGANISM", 48, 58], ["enterovirus", "ORGANISM", 59, 70], ["RSV", "ORGANISM", 83, 86], ["adenovirus", "ORGANISM", 101, 111], ["coronavirus NL63", "ORGANISM", 125, 141], ["influenza B", "ORGANISM", 159, 170], ["RSV", "SPECIES", 83, 86], ["coronavirus", "SPECIES", 125, 136], ["RSV", "SPECIES", 83, 86], ["adenovirus", "SPECIES", 101, 111], ["pathogenic agents", "PROBLEM", 12, 29], ["rhinovirus", "PROBLEM", 48, 58], ["enterovirus", "PROBLEM", 59, 70], ["RSV", "PROBLEM", 83, 86], ["adenovirus", "PROBLEM", 101, 111], ["coronavirus", "PROBLEM", 125, 136], ["influenza B", "PROBLEM", 159, 170], ["ResultsIn", "TEST", 191, 200], ["a positive respiratory pathogen", "PROBLEM", 228, 259], ["PCR result", "TEST", 264, 274], ["total tested cases", "TEST", 286, 304], ["a detected pathogen", "PROBLEM", 307, 326], ["death", "PROBLEM", 370, 375]]], ["Three (16.7%) of the cases with a positive ANM\u2010PCR result were determined not significant in the cause of death.", [["death", "DISEASE", 106, 111], ["a positive ANM\u2010PCR", "TEST", 32, 50], ["death", "PROBLEM", 106, 111]]], ["The role of the detected pathogen in the eight remaining ANM\u2010PCR\u2010positive cases remained undetermined.", [["PCR", "TEST", 61, 64]]], ["Of the 23 cases in which the decedent was under 1 year of age, 10 (43.5%) had a positive ANM\u2010PCR result.", [["a positive ANM\u2010PCR result", "PROBLEM", 78, 103]]], ["Of these, 40% (4/10) were significant, 50% (5/10) were of undetermined significance, and 10% (1/10) were not significant to cause of death.", [["death", "DISEASE", 133, 138], ["death", "PROBLEM", 133, 138], ["significant", "OBSERVATION_MODIFIER", 26, 37]]], ["The significance of each detected potential pathogen to cause of death is depicted in Fig. 4.ResultsRhinovirus/enterovirus was the most commonly detected potential pathogen (12/18, 66.7%).", [["death", "DISEASE", 65, 70], ["Rhinovirus", "GENE_OR_GENE_PRODUCT", 100, 110], ["enterovirus", "ORGANISM", 111, 122], ["death", "PROBLEM", 65, 70], ["Rhinovirus", "PROBLEM", 100, 110], ["enterovirus", "PROBLEM", 111, 122]]], ["Results in 33.3% (4/12) of cases that tested positive for rhinovirus/enterovirus were significant to the cause of death, 58.3% (7/12) were of undetermined significance, and 16.7% (2/12) had no significance.", [["rhinovirus/enterovirus", "DISEASE", 58, 80], ["death", "DISEASE", 114, 119], ["rhinovirus", "ORGANISM", 58, 68], ["enterovirus", "ORGANISM", 69, 80], ["cases", "TEST", 27, 32], ["rhinovirus", "PROBLEM", 58, 68], ["enterovirus", "PROBLEM", 69, 80], ["death", "PROBLEM", 114, 119]]], ["RSV was the second most commonly detected pathogen (5/18, 27.8%).", [["RSV", "ORGANISM", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3]]], ["Sixty percent (3/5) of RSV positive results were significant to the cause of death, and 40% (2/5) were of undetermined significance.", [["death", "DISEASE", 77, 82], ["RSV", "ORGANISM", 23, 26], ["RSV", "SPECIES", 23, 26], ["RSV positive results", "PROBLEM", 23, 43], ["death", "PROBLEM", 77, 82]]], ["The three remaining detected potential pathogens (adenovirus, coronavirus NL63, and influenza B) were determined not to be significant to the cause of death.ResultsCoinfections/exposures were documented by ANM\u2010PCR in four cases, all of which were in decedents \u22641 year of age (Table 1).", [["influenza B", "DISEASE", 84, 95], ["death", "DISEASE", 151, 156], ["adenovirus", "ORGANISM", 50, 60], ["coronavirus NL63", "ORGANISM", 62, 78], ["influenza B", "ORGANISM", 84, 95], ["coronavirus", "SPECIES", 62, 73], ["potential pathogens (adenovirus, coronavirus NL63", "PROBLEM", 29, 78], ["influenza B", "PROBLEM", 84, 95], ["death", "PROBLEM", 151, 156], ["potential", "OBSERVATION_MODIFIER", 29, 38], ["pathogens", "OBSERVATION", 39, 48]]], ["One case was positive for rhinovirus/enterovirus and coronavirus NL63.", [["rhinovirus/enterovirus and coronavirus NL63", "DISEASE", 26, 69], ["rhinovirus", "ORGANISM", 26, 36], ["enterovirus", "ORGANISM", 37, 48], ["coronavirus", "ORGANISM", 53, 64], ["coronavirus", "SPECIES", 53, 64], ["rhinovirus", "PROBLEM", 26, 36], ["enterovirus", "PROBLEM", 37, 48], ["coronavirus NL63", "PROBLEM", 53, 69]]], ["A second case was positive for rhinovirus/enterovirus, RSV, and coronavirus NL63.", [["rhinovirus/enterovirus, RSV", "DISEASE", 31, 58], ["rhinovirus", "ORGANISM", 31, 41], ["enterovirus", "ORGANISM", 42, 53], ["RSV", "ORGANISM", 55, 58], ["coronavirus NL63", "ORGANISM", 64, 80], ["coronavirus NL63", "PROTEIN", 64, 80], ["coronavirus", "SPECIES", 64, 75], ["RSV", "SPECIES", 55, 58], ["A second case", "TEST", 0, 13], ["rhinovirus", "PROBLEM", 31, 41], ["enterovirus", "PROBLEM", 42, 53], ["RSV", "PROBLEM", 55, 58], ["coronavirus NL63", "PROBLEM", 64, 80]]], ["A third case demonstrated coinfection with rhinovirus/enterovirus and RSV.", [["coinfection", "DISEASE", 26, 37], ["rhinovirus/enterovirus and RSV", "DISEASE", 43, 73], ["rhinovirus", "ORGANISM", 43, 53], ["enterovirus", "ORGANISM", 54, 65], ["RSV", "ORGANISM", 70, 73], ["RSV", "SPECIES", 70, 73], ["coinfection", "PROBLEM", 26, 37], ["rhinovirus", "PROBLEM", 43, 53], ["enterovirus", "PROBLEM", 54, 65], ["RSV", "PROBLEM", 70, 73], ["coinfection", "OBSERVATION", 26, 37], ["rhinovirus", "OBSERVATION", 43, 53]]], ["The contributions of the potential pathogens in these three cases to cause of death remained undetermined.", [["death", "DISEASE", 78, 83], ["the potential pathogens", "PROBLEM", 21, 44], ["death", "PROBLEM", 78, 83]]], ["A fourth case was positive for coinfection with rhinovirus/enterovirus and adenovirus.", [["coinfection", "DISEASE", 31, 42], ["rhinovirus/enterovirus and adenovirus", "DISEASE", 48, 85], ["rhinovirus", "ORGANISM", 48, 58], ["enterovirus", "ORGANISM", 59, 70], ["adenovirus", "ORGANISM", 75, 85], ["coinfection", "PROBLEM", 31, 42], ["rhinovirus", "PROBLEM", 48, 58], ["enterovirus", "PROBLEM", 59, 70], ["adenovirus", "PROBLEM", 75, 85], ["positive for", "UNCERTAINTY", 18, 30], ["coinfection", "OBSERVATION", 31, 42], ["rhinovirus", "OBSERVATION", 48, 58], ["enterovirus", "OBSERVATION", 59, 70]]], ["This sample was sent to an outside laboratory for further characterization, which revealed the presence of coxsackievirus A6.", [["sample", "ANATOMY", 5, 11], ["coxsackievirus A6", "ORGANISM", 107, 124], ["coxsackievirus A6", "SPECIES", 107, 124], ["This sample", "TEST", 0, 11], ["further characterization", "TEST", 50, 74], ["coxsackievirus A6", "PROBLEM", 107, 124], ["coxsackievirus", "OBSERVATION", 107, 121]]], ["Coxsackievirus A6 encephalitis was determined to be the cause of death.ResultsSamples from seven cases with positive PCR results for rhinovirus/enterovirus, including the case just mentioned, were ultimately sent to the Centers for Disease Control for further viral subtyping by reverse transcription, seminested PCR amplification of the genetic sequence encoding the viral capsid protein VP1 21.", [["Coxsackievirus A6 encephalitis", "DISEASE", 0, 30], ["death", "DISEASE", 65, 70], ["rhinovirus/enterovirus", "DISEASE", 133, 155], ["Coxsackievirus A6 encephalitis", "ORGANISM", 0, 30], ["rhinovirus", "ORGANISM", 133, 143], ["enterovirus", "ORGANISM", 144, 155], ["viral capsid protein VP1 21", "PROTEIN", 368, 395], ["Coxsackievirus A6 encephalitis", "SPECIES", 0, 30], ["rhinovirus/enterovirus", "SPECIES", 133, 155], ["Coxsackievirus A6 encephalitis", "PROBLEM", 0, 30], ["death", "PROBLEM", 65, 70], ["ResultsSamples", "TEST", 71, 85], ["positive PCR results", "PROBLEM", 108, 128], ["rhinovirus", "PROBLEM", 133, 143], ["enterovirus", "PROBLEM", 144, 155], ["Disease Control", "TREATMENT", 232, 247], ["further viral subtyping", "TEST", 252, 275], ["the genetic sequence", "TEST", 334, 354], ["the viral capsid protein VP1", "TEST", 364, 392], ["encephalitis", "OBSERVATION", 18, 30]]], ["These cases were submitted for further viral typing in large part due to the enterovirus D68 outbreak in 2014 in which more than 1000 positive cases were reported, many of which involved children with significant respiratory disease 22.", [["respiratory", "ANATOMY", 213, 224], ["enterovirus D68", "DISEASE", 77, 92], ["respiratory disease", "DISEASE", 213, 232], ["children", "ORGANISM", 187, 195], ["children", "SPECIES", 187, 195], ["further viral typing", "TEST", 31, 51], ["the enterovirus", "PROBLEM", 73, 88], ["significant respiratory disease", "PROBLEM", 201, 232], ["significant", "OBSERVATION_MODIFIER", 201, 212], ["respiratory disease", "OBSERVATION", 213, 232]]], ["The pathogens identified on further workup of these seven cases were enterovirus D68, coxsackievirus A4, coxsackievirus A6, human rhinovirus 49, human rhinovirus B6, human rhinovirus 77, human rhinovirus A63, and parechovirus.", [["enterovirus D68", "DISEASE", 69, 84], ["rhinovirus A63", "DISEASE", 193, 207], ["enterovirus D68", "ORGANISM", 69, 84], ["coxsackievirus A4", "ORGANISM", 86, 103], ["coxsackievirus A6", "ORGANISM", 105, 122], ["human", "ORGANISM", 124, 129], ["rhinovirus 49", "ORGANISM", 130, 143], ["human", "ORGANISM", 145, 150], ["rhinovirus B6", "ORGANISM", 151, 164], ["human", "ORGANISM", 166, 171], ["rhinovirus 77", "ORGANISM", 172, 185], ["human", "ORGANISM", 187, 192], ["rhinovirus A63", "ORGANISM", 193, 207], ["human", "SPECIES", 124, 129], ["rhinovirus", "SPECIES", 130, 140], ["human", "SPECIES", 145, 150], ["rhinovirus", "SPECIES", 151, 161], ["human", "SPECIES", 166, 171], ["rhinovirus", "SPECIES", 172, 182], ["human", "SPECIES", 187, 192], ["rhinovirus", "SPECIES", 193, 203], ["enterovirus D68", "SPECIES", 69, 84], ["coxsackievirus A4", "SPECIES", 86, 103], ["coxsackievirus A6", "SPECIES", 105, 122], ["human rhinovirus 49", "SPECIES", 124, 143], ["human rhinovirus", "SPECIES", 145, 161], ["human rhinovirus 77", "SPECIES", 166, 185], ["human rhinovirus A63", "SPECIES", 187, 207], ["The pathogens", "PROBLEM", 0, 13], ["further workup", "TEST", 28, 42], ["enterovirus", "TEST", 69, 80], ["coxsackievirus", "PROBLEM", 86, 100], ["coxsackievirus", "PROBLEM", 105, 119], ["human rhinovirus", "TEST", 124, 140], ["human rhinovirus B6", "TEST", 145, 164], ["human rhinovirus", "TEST", 166, 182], ["human rhinovirus A63", "TEST", 187, 207], ["parechovirus", "PROBLEM", 213, 225]]], ["Three of these pathogens (coxsackievirus A6, human rhinovirus 49, and human rhinovirus 77) were significant to the cause of death.ResultsFor sixteen of the 35 cases tested, the cause of death remained unexplained (Table 1).", [["death", "DISEASE", 124, 129], ["death", "DISEASE", 186, 191], ["coxsackievirus A6", "ORGANISM", 26, 43], ["human rhinovirus 49", "ORGANISM", 45, 64], ["human", "ORGANISM", 70, 75], ["rhinovirus", "ORGANISM", 76, 86], ["human", "SPECIES", 45, 50], ["rhinovirus", "SPECIES", 51, 61], ["human", "SPECIES", 70, 75], ["rhinovirus", "SPECIES", 76, 86], ["coxsackievirus A6", "SPECIES", 26, 43], ["human rhinovirus 49", "SPECIES", 45, 64], ["human rhinovirus", "SPECIES", 70, 86], ["these pathogens", "PROBLEM", 9, 24], ["coxsackievirus", "TEST", 26, 40], ["human rhinovirus", "TEST", 45, 61], ["human rhinovirus", "TEST", 70, 86], ["death", "PROBLEM", 124, 129], ["death", "PROBLEM", 186, 191], ["pathogens", "OBSERVATION", 15, 24]]], ["Eight of these 16 (50%) cases yielded a positive ANM\u2010PCR result, all of which detected rhinovirus/enterovirus.", [["rhinovirus/enterovirus", "DISEASE", 87, 109], ["rhinovirus", "ORGANISM", 87, 97], ["enterovirus", "ORGANISM", 98, 109], ["a positive ANM\u2010PCR result", "PROBLEM", 38, 63], ["rhinovirus", "PROBLEM", 87, 97], ["enterovirus", "PROBLEM", 98, 109], ["rhinovirus", "OBSERVATION", 87, 97], ["enterovirus", "OBSERVATION", 98, 109]]], ["One case had known antemortem respiratory viral PCR testing, and the results were congruent with postmortem ANM\u2010PCR panel results.ResultsSampling of the airways occurred along multiple sites along the respiratory tract, including nasal, nasopharyngeal, tracheal, bronchial, and unspecified sites (Fig. 5).", [["airways", "ANATOMY", 153, 160], ["sites", "ANATOMY", 185, 190], ["respiratory tract", "ANATOMY", 201, 218], ["nasal", "ANATOMY", 230, 235], ["nasopharyngeal", "ANATOMY", 237, 251], ["tracheal", "ANATOMY", 253, 261], ["bronchial", "ANATOMY", 263, 272], ["airways", "MULTI-TISSUE_STRUCTURE", 153, 160], ["respiratory tract", "ORGANISM_SUBDIVISION", 201, 218], ["nasal", "ORGANISM_SUBDIVISION", 230, 235], ["nasopharyngeal", "ORGAN", 237, 251], ["tracheal", "MULTI-TISSUE_STRUCTURE", 253, 261], ["bronchial", "MULTI-TISSUE_STRUCTURE", 263, 272], ["antemortem respiratory viral PCR testing", "TEST", 19, 59], ["postmortem ANM", "TEST", 97, 111], ["PCR panel", "TEST", 112, 121], ["the airways", "PROBLEM", 149, 160], ["nasal, nasopharyngeal, tracheal, bronchial, and unspecified sites", "PROBLEM", 230, 295], ["airways", "ANATOMY", 153, 160], ["multiple", "OBSERVATION_MODIFIER", 176, 184], ["sites", "OBSERVATION_MODIFIER", 185, 190], ["respiratory tract", "ANATOMY", 201, 218], ["nasal", "ANATOMY", 230, 235], ["nasopharyngeal", "ANATOMY", 237, 251], ["tracheal", "ANATOMY", 253, 261], ["bronchial", "ANATOMY", 263, 272]]], ["Only a single site was sampled in each case, and the site was determined at the discretion of the pathologist as no definitive gold standard existed.", [["a single site", "PROBLEM", 5, 18]]], ["Each of these sample sites yielded at least one positive ANM\u2010PCR result.", [["sample sites", "ANATOMY", 14, 26], ["PCR result", "TEST", 61, 71]]], ["Chi\u2010square analysis revealed no significant difference in the number of positive and negative ANM\u2010PCR results from the different sites (\u03c72(1, n = 35) = 0.5362, p = 0.4640).ResultsPositive PCR results were acquired in postmortem intervals ranging from 3 to 40 h, and 40 h was the longest postmortem interval in the dataset.", [["Chi\u2010square analysis", "TEST", 0, 19], ["significant difference", "PROBLEM", 32, 54], ["PCR", "TEST", 98, 101], ["p", "TEST", 160, 161], ["ResultsPositive PCR", "TEST", 172, 191], ["postmortem intervals", "TEST", 217, 237], ["no", "UNCERTAINTY", 29, 31], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["difference", "OBSERVATION", 44, 54]]], ["Chi\u2010square analysis was performed using four postmortem interval categories: <12, 12\u201324, 24\u201336, and >36 h, and there was no significant difference in the number of positive and negative ANM\u2010PCR results from the postmortem interval ranges tested (\u03c72(1, n = 34) = 0.02738, p = 0.8686; Fig. 6).ResultsManners of death in cases not tested using ANM\u2010PCR were as follows: one suicide, 20 natural deaths, 42 accidents, 10 homicides, and 37 undetermined.", [["death", "DISEASE", 309, 314], ["deaths", "DISEASE", 390, 396], ["accidents", "DISEASE", 401, 410], ["homicides", "DISEASE", 415, 424], ["Chi\u2010square analysis", "TEST", 0, 19], ["four postmortem interval categories", "TEST", 40, 75], ["significant difference", "PROBLEM", 124, 146], ["PCR", "TEST", 190, 193], ["the postmortem interval", "TEST", 207, 230], ["p", "TEST", 271, 272], ["death", "PROBLEM", 309, 314], ["ANM\u2010PCR", "TEST", 341, 348], ["no", "UNCERTAINTY", 121, 123], ["significant", "OBSERVATION_MODIFIER", 124, 135], ["difference", "OBSERVATION", 136, 146]]], ["Causes of death in these cases were as follows: 35 asphyxiations, 20 traumatic deaths, 22 with natural disease, and 33 that remained undetermined.DiscussionThese results indicate that an ANM\u2010PCR respiratory pathogen panel currently used for diagnostic purposes in living patients can be applied at the time of autopsy to aid in determining the cause of death.", [["death", "DISEASE", 10, 15], ["asphyxiations", "DISEASE", 51, 64], ["deaths", "DISEASE", 79, 85], ["natural disease", "DISEASE", 95, 110], ["death", "DISEASE", 353, 358], ["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 271, 279], ["death", "PROBLEM", 10, 15], ["20 traumatic deaths", "PROBLEM", 66, 85], ["natural disease", "PROBLEM", 95, 110], ["an ANM\u2010PCR respiratory pathogen panel", "TEST", 184, 221], ["diagnostic purposes", "TEST", 241, 260], ["autopsy", "TEST", 310, 317], ["death", "PROBLEM", 353, 358], ["natural disease", "OBSERVATION", 95, 110]]], ["In the current study, at least 24.1% (35/145) of pediatric forensic cases warranted the use of a respiratory pathogen ANM\u2010PCR panel based on pathologist suspicion.", [["the current study", "TEST", 3, 20], ["a respiratory pathogen", "TEST", 95, 117], ["PCR panel", "TEST", 122, 131], ["pathologist suspicion", "TEST", 141, 162]]], ["51.4% of these cases yielded a positive ANM\u2010PCR result, and of the positive cases 38.9% (20% of tested cases) yielded a result that was significant to the cause of death.", [["death", "DISEASE", 164, 169], ["these cases", "TEST", 9, 20], ["the positive cases", "TEST", 63, 81], ["tested cases", "TEST", 96, 108], ["death", "PROBLEM", 164, 169]]], ["In decedents under 1 year of age, 40% of cases that tested positive for a respiratory pathogen were significant to the cause of death.DiscussionOf the 20 potential pathogens included in the panel, only five were detected in pediatric decedents during this study period.", [["respiratory pathogen", "DISEASE", 74, 94], ["death", "DISEASE", 128, 133], ["a respiratory pathogen", "PROBLEM", 72, 94], ["death", "PROBLEM", 128, 133], ["this study", "TEST", 251, 261]]], ["The ratio of detected to tested pathogens is low, but the use of molecular techniques, such as PCR and IHC, to diagnose respiratory pathogens has historically been limited by the need to identify specific potential infections prior to testing to choose appropriate primers or antibodies, thus leaving many potential infectious agents untested and potentially overlooked.", [["respiratory pathogens", "DISEASE", 120, 141], ["infections", "DISEASE", 215, 225], ["antibodies", "PROTEIN", 276, 286], ["The ratio", "TEST", 0, 9], ["pathogens", "PROBLEM", 32, 41], ["molecular techniques", "TEST", 65, 85], ["PCR", "TEST", 95, 98], ["IHC", "TEST", 103, 106], ["respiratory pathogens", "PROBLEM", 120, 141], ["specific potential infections", "PROBLEM", 196, 225], ["testing", "TEST", 235, 242], ["appropriate primers", "TREATMENT", 253, 272], ["antibodies", "PROBLEM", 276, 286], ["low", "OBSERVATION_MODIFIER", 45, 48], ["infectious", "OBSERVATION", 316, 326]]], ["A benefit of the ANM\u2010PCR panel is the ability to cast a wide net with a sensitive technique without significantly increasing turn\u2010around time or cost if an unexpected pathogen is involved.", [["the ANM\u2010PCR panel", "TEST", 13, 30], ["a sensitive technique", "TREATMENT", 70, 91], ["an unexpected pathogen", "PROBLEM", 153, 175]]], ["The available panel expanded during the course of the present study from 15 to 20 potential pathogens, and panels will likely continue to include more candidate pathogens in the future for the same or decreasing cost.DiscussionRhinovirus/enterovirus infections are common; thus, it was not surprising that 72.2% (13/18) of positive cases documented exposure to these potential pathogens.", [["enterovirus infections", "DISEASE", 238, 260], ["enterovirus", "ORGANISM", 238, 249], ["the present study", "TEST", 50, 67], ["DiscussionRhinovirus/enterovirus infections", "PROBLEM", 217, 260], ["these potential pathogens", "PROBLEM", 361, 386], ["enterovirus infections", "OBSERVATION", 238, 260], ["pathogens", "OBSERVATION", 377, 386]]], ["In approximately half of these cases, the role of these viruses in the cause of death was unclear.", [["death", "DISEASE", 80, 85], ["these viruses", "PROBLEM", 50, 63], ["death", "PROBLEM", 80, 85], ["viruses", "OBSERVATION", 56, 63]]], ["Explanations exist regarding these trends: (i) these viruses are extremely common with typically mild presentations, and (ii) shedding of these viruses can occur for weeks following acute illness 23.", [["these viruses", "PROBLEM", 47, 60], ["typically mild presentations", "PROBLEM", 87, 115], ["these viruses", "PROBLEM", 138, 151], ["acute illness", "PROBLEM", 182, 195], ["mild", "OBSERVATION_MODIFIER", 97, 101], ["viruses", "OBSERVATION", 144, 151]]], ["Despite the low level of significance of these potential pathogens to cause of death, it remains important to include such pathogens in respiratory pathogen panels.", [["death", "DISEASE", 79, 84], ["death", "PROBLEM", 79, 84], ["respiratory pathogen panels", "TEST", 136, 163]]], ["Previous studies have indicated that these viruses can contribute to death, although the incidence is low 3.DiscussionRespiratory syncytial virus was the second most commonly detected potential pathogen and exhibited the highest percentage of cases that were significant to cause of death (60%).", [["death", "DISEASE", 69, 74], ["death", "DISEASE", 283, 288], ["DiscussionRespiratory syncytial virus", "ORGANISM", 108, 145], ["DiscussionRespiratory syncytial virus", "SPECIES", 108, 145], ["Previous studies", "TEST", 0, 16], ["these viruses", "PROBLEM", 37, 50], ["death", "PROBLEM", 69, 74], ["DiscussionRespiratory syncytial virus", "PROBLEM", 108, 145], ["pathogen", "PROBLEM", 194, 202], ["death", "PROBLEM", 283, 288], ["viruses", "OBSERVATION", 43, 50], ["syncytial virus", "OBSERVATION", 130, 145]]], ["Forensic pathologists are positioned to enhance public knowledge of the epidemiology of respiratory pathogens, such as RSV, among decedents from the community that have not been hospitalized 7.", [["respiratory", "ANATOMY", 88, 99], ["respiratory pathogens", "DISEASE", 88, 109], ["RSV", "DISEASE", 119, 122], ["RSV", "ORGANISM", 119, 122], ["RSV", "SPECIES", 119, 122], ["respiratory pathogens", "PROBLEM", 88, 109], ["RSV", "PROBLEM", 119, 122], ["respiratory pathogens", "OBSERVATION", 88, 109]]], ["Continued use of ANM\u2010PCR respiratory pathogen panels in the forensic setting will broaden understanding of significant respiratory pathogens, such as RSV, in the community.DiscussionDuring the course of this study, sample sites from the nasal cavity to the lower airways were utilized, all of which yielded at least one positive ANM\u2010PCR result.", [["respiratory", "ANATOMY", 119, 130], ["sample sites", "ANATOMY", 215, 227], ["nasal cavity", "ANATOMY", 237, 249], ["lower airways", "ANATOMY", 257, 270], ["RSV", "ORGANISM", 150, 153], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 237, 249], ["lower airways", "MULTI-TISSUE_STRUCTURE", 257, 270], ["RSV", "SPECIES", 150, 153], ["ANM\u2010PCR", "TREATMENT", 17, 24], ["respiratory pathogen panels", "TEST", 25, 52], ["significant respiratory pathogens", "PROBLEM", 107, 140], ["RSV", "PROBLEM", 150, 153], ["this study", "TEST", 203, 213], ["sample sites", "TEST", 215, 227], ["significant", "OBSERVATION_MODIFIER", 107, 118], ["respiratory pathogens", "OBSERVATION", 119, 140], ["nasal cavity", "ANATOMY", 237, 249], ["lower airways", "ANATOMY", 257, 270]]], ["Furthermore, there was no significant difference in potential pathogen detection among the sites tested.", [["potential pathogen detection", "PROBLEM", 52, 80], ["no", "UNCERTAINTY", 23, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["difference", "OBSERVATION_MODIFIER", 38, 48], ["potential", "OBSERVATION_MODIFIER", 52, 61], ["pathogen", "OBSERVATION", 62, 70]]], ["In living patients, the nasopharyngeal swab is ideal as it is relatively less invasive than the more inferior samples sites, such as tracheal and bronchial mucosae.", [["nasopharyngeal swab", "ANATOMY", 24, 43], ["inferior samples sites", "ANATOMY", 101, 123], ["tracheal", "ANATOMY", 133, 141], ["bronchial mucosae", "ANATOMY", 146, 163], ["patients", "ORGANISM", 10, 18], ["nasopharyngeal swab", "ORGAN", 24, 43], ["samples sites", "MULTI-TISSUE_STRUCTURE", 110, 123], ["tracheal", "MULTI-TISSUE_STRUCTURE", 133, 141], ["bronchial mucosae", "MULTI-TISSUE_STRUCTURE", 146, 163], ["patients", "SPECIES", 10, 18], ["the nasopharyngeal swab", "TEST", 20, 43], ["tracheal and bronchial mucosae", "PROBLEM", 133, 163], ["nasopharyngeal", "ANATOMY", 24, 38], ["swab", "OBSERVATION", 39, 43], ["relatively", "OBSERVATION_MODIFIER", 62, 72], ["less", "OBSERVATION_MODIFIER", 73, 77], ["invasive", "OBSERVATION_MODIFIER", 78, 86], ["tracheal", "ANATOMY", 133, 141], ["bronchial mucosae", "ANATOMY", 146, 163]]], ["At the time of autopsy, the entire respiratory tract is available for sample acquisition.", [["respiratory tract", "ANATOMY", 35, 52], ["sample", "ANATOMY", 70, 76], ["respiratory tract", "ORGANISM_SUBDIVISION", 35, 52], ["autopsy", "TEST", 15, 22], ["sample acquisition", "TEST", 70, 88], ["respiratory tract", "ANATOMY", 35, 52]]], ["Therefore, the existence of a site or sites more amenable to potential pathogen detection using ANM\u2010PCR is possible.", [["a site", "PROBLEM", 28, 34], ["potential pathogen detection", "TEST", 61, 89], ["ANM\u2010PCR", "TEST", 96, 103]]], ["Furthermore, different pathogens may demonstrate different optimal sample sites.", [["sample sites", "ANATOMY", 67, 79], ["different pathogens", "PROBLEM", 13, 32]]], ["At this time, data are not available regarding the optimum sample site(s) for detection of potential respiratory pathogens by ANM\u2010PCR in the forensic setting.", [["potential respiratory pathogens", "PROBLEM", 91, 122], ["ANM\u2010PCR", "TEST", 126, 133], ["respiratory pathogens", "OBSERVATION", 101, 122]]], ["Further testing, possibly including testing multiple sites from a single decedent, could clarify the presence or absence of the optimal sample site for postmortem respiratory pathogen detection using automated PCR techniques.DiscussionDetection of potential respiratory pathogens by ANM\u2010PCR from swabs of the respiratory tract was possible at the highest postmortem interval tested in the current study, 40 h.", [["sample site", "ANATOMY", 136, 147], ["respiratory tract", "ANATOMY", 309, 326], ["respiratory tract", "ORGANISM_SUBDIVISION", 309, 326], ["Further testing", "TEST", 0, 15], ["postmortem respiratory pathogen detection", "TEST", 152, 193], ["automated PCR techniques", "TEST", 200, 224], ["potential respiratory pathogens", "PROBLEM", 248, 279], ["ANM\u2010PCR", "TEST", 283, 290], ["swabs", "TEST", 296, 301], ["the respiratory tract", "PROBLEM", 305, 326], ["the current study", "TEST", 385, 402], ["respiratory pathogens", "OBSERVATION", 258, 279], ["respiratory tract", "ANATOMY", 309, 326]]], ["In addition, there was no significant difference in detection of potential respiratory pathogens among the postmortem interval ranges tested.", [["respiratory", "ANATOMY", 75, 86], ["potential respiratory pathogens", "PROBLEM", 65, 96], ["no", "UNCERTAINTY", 23, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["difference", "OBSERVATION_MODIFIER", 38, 48], ["respiratory pathogens", "OBSERVATION", 75, 96]]], ["Postmortem interval has not routinely been reported in other studies, but future investigation into the reliability and outer limits of detection of potential respiratory pathogens by molecular methods is necessary for further validation of such techniques.DiscussionThe cost and time investments for implementing these tests are relatively low.", [["other studies", "TEST", 55, 68], ["potential respiratory pathogens", "PROBLEM", 149, 180], ["such techniques", "TREATMENT", 241, 256], ["these tests", "TEST", 314, 325], ["respiratory pathogens", "OBSERVATION", 159, 180]]], ["The instrument costs c. $35,000, and each pouch, in which the ANM\u2010PCR reactions take place, is about $140.", [["pouch", "PATHOLOGICAL_FORMATION", 42, 47], ["pouch", "ANATOMY", 42, 47]]], ["The time required for inoculating the sample into the pouch and placing the pouch on the machine is 3 min, and the results are reportable in about an hour.", [["sample", "ANATOMY", 38, 44], ["pouch", "ANATOMY", 54, 59], ["pouch", "ANATOMY", 76, 81], ["pouch", "ORGAN", 54, 59], ["pouch", "ORGAN", 76, 81], ["inoculating the sample into the pouch", "TREATMENT", 22, 59], ["pouch", "ANATOMY", 54, 59], ["pouch", "ANATOMY", 76, 81]]], ["Furthermore, one can successfully learn to prepare the samples and operate the machine with little training.DiscussionOf the 110 cases that were not tested using ANM\u2010PCR, half (55/110) were due to either asphyxia or trauma with significant autopsy or scene findings sufficient to explain the cause of death.", [["asphyxia", "DISEASE", 204, 212], ["trauma", "DISEASE", 216, 222], ["death", "DISEASE", 301, 306], ["little training", "TREATMENT", 92, 107], ["ANM\u2010PCR", "TEST", 162, 169], ["asphyxia", "PROBLEM", 204, 212], ["trauma", "PROBLEM", 216, 222], ["significant autopsy", "PROBLEM", 228, 247], ["scene findings", "TEST", 251, 265], ["death", "PROBLEM", 301, 306]]], ["In addition, many of the untested cases in which a natural disease process contributed to the cause of death exhibited florid disease that would preclude ANM\u2010PCR testing.", [["death", "DISEASE", 103, 108], ["a natural disease process", "PROBLEM", 49, 74], ["death", "PROBLEM", 103, 108], ["florid disease", "PROBLEM", 119, 133], ["ANM\u2010PCR testing", "TEST", 154, 169], ["disease", "OBSERVATION", 59, 66], ["florid disease", "OBSERVATION", 119, 133]]], ["However, cause of death in 33 of the untested cases remained undetermined.", [["death", "DISEASE", 18, 23], ["death", "PROBLEM", 18, 23]]], ["It is impossible to determine whether ANM\u2010PCR testing would have proved beneficial in these cases.", [["ANM\u2010PCR testing", "TEST", 38, 53]]], ["Future, carefully standardized, prospective studies of ANM\u2010PCR in the forensic setting should be performed to develop solid guidelines for its future implementation.DiscussionThe current study had several limitations that might be improved upon in future investigations.", [["prospective studies", "TEST", 32, 51], ["ANM\u2010PCR", "TEST", 55, 62], ["The current study", "TEST", 175, 192], ["future investigations", "TEST", 248, 269]]], ["Epidemiologically, the study was limited by the small sample size, so generalizations regarding these potential pathogens in the community cannot yet be extrapolated.", [["the study", "TEST", 19, 28], ["the small sample size", "PROBLEM", 44, 65], ["these potential pathogens", "PROBLEM", 96, 121], ["small", "OBSERVATION_MODIFIER", 48, 53], ["size", "OBSERVATION_MODIFIER", 61, 65]]], ["The respiratory pathogen panel tested did not include all existing potential pathogens, so pathogens may have been present that were not included in the panel.", [["The respiratory pathogen panel", "TEST", 0, 30], ["potential pathogens", "PROBLEM", 67, 86], ["pathogens", "PROBLEM", 91, 100], ["pathogens", "OBSERVATION", 77, 86]]], ["Furthermore, potential pathogens that were added to the panel later in the study may have been undetectable in earlier cases.", [["potential pathogens", "PROBLEM", 13, 32], ["the panel", "TEST", 52, 61], ["the study", "TEST", 71, 80]]], ["The respiratory pathogen status of cases that were not tested remains unknown.", [["The respiratory pathogen status of cases", "PROBLEM", 0, 40], ["respiratory", "ANATOMY", 4, 15]]], ["The sample sites tested were left to the pathologists\u2019 discretion.", [["sample sites", "ANATOMY", 4, 16], ["The sample sites", "TEST", 0, 16]]], ["The contribution of the potential pathogens detected to the cause of death was up to the interpretation of the pathologist based on all of the elements of each individual case.", [["death", "DISEASE", 69, 74], ["the potential pathogens", "PROBLEM", 20, 43], ["death", "PROBLEM", 69, 74]]], ["Thus, it is possible that two pathologists could disagree regarding the significance of potential pathogens to cause of death.", [["death", "DISEASE", 120, 125], ["death", "PROBLEM", 120, 125]]], ["The sample sites were not standardized.", [["sample sites", "ANATOMY", 4, 16], ["The sample sites", "TREATMENT", 0, 16]]], ["The postmortem intervals did not exceed 40 h, so the utility of the ANM\u2010PCR respiratory pathogen panel beyond 40 h is unclear.", [["the ANM\u2010PCR respiratory pathogen panel", "TEST", 64, 102]]], ["Also, low sample size and lack of experimental controls disallowed any measurement of sensitivity of the test at any time point.DiscussionIn summary, regular use of ANM\u2010PCR panels postmortem could have a significant impact on our knowledge of public health and epidemiology.", [["sample", "ANATOMY", 10, 16], ["low sample size", "PROBLEM", 6, 21], ["experimental controls", "PROBLEM", 34, 55], ["the test", "TEST", 101, 109], ["ANM\u2010PCR panels", "TEST", 165, 179], ["low sample", "OBSERVATION_MODIFIER", 6, 16], ["size", "OBSERVATION_MODIFIER", 17, 21], ["experimental controls", "OBSERVATION", 34, 55]]], ["Results of the current study demonstrate that this affordable, easy\u2010to\u2010use technology is useful in the evaluation of the cause of death in the pediatric forensic population.", [["death", "DISEASE", 130, 135], ["the current study", "TEST", 11, 28], ["the evaluation", "TEST", 99, 113], ["death", "PROBLEM", 130, 135]]], ["Further study to identify ideal sample sites and postmortem time intervals for the optimum use of such technology is warranted in both pediatric and adult populations.", [["sample sites", "ANATOMY", 32, 44], ["Further study", "TEST", 0, 13], ["such technology", "TREATMENT", 98, 113]]]], "PMC4280815": [["IntroductionLate-season influenza B activity occurred in Canada during the 2013\u20132014 season, with circulating viruses predominantly belonging to the B/Yamagata-lineage included in the 2013\u20132014 trivalent influenza vaccine (TIV).", [["influenza B", "DISEASE", 24, 35], ["influenza", "DISEASE", 204, 213], ["influenza B", "ORGANISM", 24, 35], ["trivalent influenza vaccine", "SPECIES", 194, 221], ["TIV", "SPECIES", 223, 226], ["circulating viruses", "PROBLEM", 98, 117], ["trivalent influenza vaccine", "TREATMENT", 194, 221]]], ["In March 2014, an outbreak of influenza-like illness (ILI) involving the elementary and high school (\u223c200 students combined) of a rural community (population < 1500) of British Columbia (BC), Canada, was reported, with 15% and 8% of the student populations affected, respectively.", [["influenza-like illness", "DISEASE", 30, 52], ["ILI", "DISEASE", 54, 57], ["influenza-", "SPECIES", 30, 40], ["influenza", "PROBLEM", 30, 39], ["influenza", "OBSERVATION", 30, 39]]], ["Rash associated with ILI was noted in four students, including generalized maculopapular rash in an elementary-school child.", [["maculopapular", "ANATOMY", 75, 88], ["Rash", "DISEASE", 0, 4], ["ILI", "DISEASE", 21, 24], ["maculopapular rash", "DISEASE", 75, 93], ["Rash", "PROBLEM", 0, 4], ["ILI", "PROBLEM", 21, 24], ["generalized maculopapular rash", "PROBLEM", 63, 93], ["generalized", "OBSERVATION_MODIFIER", 63, 74], ["maculopapular", "OBSERVATION_MODIFIER", 75, 88], ["rash", "OBSERVATION", 89, 93]]], ["Interest in fever associated with rash illness was heightened because of a large measles outbreak occurring simultaneously elsewhere in the province.", [["fever", "DISEASE", 12, 17], ["rash illness", "DISEASE", 34, 46], ["fever", "PROBLEM", 12, 17], ["rash illness", "PROBLEM", 34, 46], ["a large measles outbreak", "PROBLEM", 73, 97], ["fever", "OBSERVATION", 12, 17], ["large", "OBSERVATION_MODIFIER", 75, 80], ["measles", "OBSERVATION", 81, 88]]], ["This case series describes an outbreak of ILI and rash associated with laboratory-confirmed influenza B in schoolchildren.MethodsOutbreak investigation was conducted under the authority of the Medical Health Officer, and research ethics board approval was not required.", [["ILI", "DISEASE", 42, 45], ["rash", "DISEASE", 50, 54], ["influenza B", "DISEASE", 92, 103], ["schoolchildren", "ORGANISM", 107, 121], ["schoolchildren", "SPECIES", 107, 121], ["ILI", "PROBLEM", 42, 45], ["rash", "PROBLEM", 50, 54], ["influenza", "PROBLEM", 92, 101], ["MethodsOutbreak investigation", "TEST", 122, 151]]], ["Laboratory testing was conducted according to standard protocols at the BC Public Health Microbiology and Reference Laboratory1 that encourage submission of specimens from up to six patients to arrive at ILI outbreak diagnosis.", [["specimens", "ANATOMY", 157, 166], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["Laboratory testing", "TEST", 0, 18], ["specimens", "TEST", 157, 166]]], ["Further specimens were collected to ensure that ILI cases with rash known to the local health unit were included in diagnostic testing.", [["specimens", "ANATOMY", 8, 17], ["rash", "DISEASE", 63, 67], ["Further specimens", "TEST", 0, 17], ["ILI cases", "PROBLEM", 48, 57], ["rash", "PROBLEM", 63, 67], ["diagnostic testing", "TEST", 116, 134]]], ["Nasopharyngeal swabs were tested for influenza by reverse-transcription polymerase chain reaction (RT-PCR) and for respiratory viruses by the Respiratory Virus Panel Luminex\u00ae assay, which includes targets for influenza A/H3, A/H1 and B; RSV; coronaviruses 229E, OC43, NL63, and HKU1; parainfluenza 1\u20134; human metapneumovirus A/B; entero/rhinovirus; adenovirus; and bocavirus.", [["Nasopharyngeal swabs", "ANATOMY", 0, 20], ["influenza", "DISEASE", 37, 46], ["respiratory viruses", "DISEASE", 115, 134], ["parainfluenza 1\u20134", "DISEASE", 284, 301], ["Nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 0, 20], ["influenza A/H3", "ORGANISM", 209, 223], ["A/H1", "ORGANISM", 225, 229], ["B", "GENE_OR_GENE_PRODUCT", 234, 235], ["RSV", "ORGANISM", 237, 240], ["coronaviruses 229E", "ORGANISM", 242, 260], ["OC43", "GENE_OR_GENE_PRODUCT", 262, 266], ["NL63", "GENE_OR_GENE_PRODUCT", 268, 272], ["HKU1", "GENE_OR_GENE_PRODUCT", 278, 282], ["parainfluenza 1\u20134", "ORGANISM", 284, 301], ["human metapneumovirus A/B", "ORGANISM", 303, 328], ["entero/rhinovirus", "ORGANISM", 330, 347], ["adenovirus", "ORGANISM", 349, 359], ["parainfluenza", "SPECIES", 284, 297], ["human", "SPECIES", 303, 308], ["metapneumovirus", "SPECIES", 309, 324], ["rhinovirus", "SPECIES", 337, 347], ["influenza A/H3", "SPECIES", 209, 223], ["A/H1", "SPECIES", 225, 229], ["RSV", "SPECIES", 237, 240], ["human metapneumovirus A", "SPECIES", 303, 326], ["Nasopharyngeal swabs", "TEST", 0, 20], ["influenza", "PROBLEM", 37, 46], ["RT-PCR", "TEST", 99, 105], ["respiratory viruses", "PROBLEM", 115, 134], ["the Respiratory Virus Panel", "TEST", 138, 165], ["Luminex\u00ae assay", "TEST", 166, 180], ["influenza", "PROBLEM", 209, 218], ["H3", "PROBLEM", 221, 223], ["A/H1", "TEST", 225, 229], ["RSV", "PROBLEM", 237, 240], ["coronaviruses", "TEST", 242, 255], ["OC43", "TEST", 262, 266], ["NL63", "TEST", 268, 272], ["HKU1", "TEST", 278, 282], ["parainfluenza", "TEST", 284, 297], ["human metapneumovirus A/B", "PROBLEM", 303, 328], ["entero", "PROBLEM", 330, 336], ["rhinovirus", "PROBLEM", 337, 347], ["adenovirus", "PROBLEM", 349, 359], ["bocavirus", "PROBLEM", 365, 374]]], ["Further nucleic acid testing for measles, enterovirus and mumps was conducted.", [["nucleic acid", "CHEMICAL", 8, 20], ["measles, enterovirus and mumps", "DISEASE", 33, 63], ["enterovirus", "ORGANISM", 42, 53], ["measles", "SPECIES", 33, 40], ["Further nucleic acid testing", "TEST", 0, 28], ["measles", "PROBLEM", 33, 40], ["enterovirus", "PROBLEM", 42, 53], ["mumps", "PROBLEM", 58, 63]]], ["Influenza-positive specimens were sequenced to determine lineage and where possible, virus was isolated in cell culture to determine strain by haemagglutination inhibition (HI) assay.", [["specimens", "ANATOMY", 19, 28], ["cell", "ANATOMY", 107, 111], ["Influenza", "ORGANISM", 0, 9], ["cell culture", "CELL", 107, 119], ["Influenza", "PROBLEM", 0, 9], ["positive specimens", "PROBLEM", 10, 28], ["virus", "PROBLEM", 85, 90], ["cell culture", "TEST", 107, 119]]], ["Paired sera were collected, and antibody titres were assessed by HI using live and ether-extracted B/Massachusetts/02/2012-like (Yamagata-lineage) and B/Brisbane/60/2008-like (Victoria-lineage) viruses.", [["sera", "ANATOMY", 7, 11], ["ether", "CHEMICAL", 83, 88], ["sera", "ORGANISM_SUBSTANCE", 7, 11], ["ether", "SIMPLE_CHEMICAL", 83, 88], ["02/2012", "ORGANISM", 115, 122], ["B/Brisbane/60/2008-like", "ORGANISM", 151, 174], ["Victoria-lineage", "ORGANISM", 176, 192], ["B/Brisbane/60/2008", "SPECIES", 151, 169], ["Paired sera", "TEST", 0, 11], ["antibody titres", "TEST", 32, 47]]], ["Sera were also tested for IgM/IgG to measles, human parvovirus-B19 and rubella.", [["parvovirus-B19 and rubella", "DISEASE", 52, 78], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["IgM", "GENE_OR_GENE_PRODUCT", 26, 29], ["IgG", "GENE_OR_GENE_PRODUCT", 30, 33], ["measles", "ORGANISM", 37, 44], ["human", "ORGANISM", 46, 51], ["parvovirus-B19", "ORGANISM", 52, 66], ["rubella", "ORGANISM", 71, 78], ["IgM", "PROTEIN", 26, 29], ["IgG", "PROTEIN", 30, 33], ["human", "SPECIES", 46, 51], ["parvovirus-B19", "SPECIES", 52, 66], ["human parvovirus-B19", "SPECIES", 46, 66], ["Sera", "TEST", 0, 4], ["IgM", "TEST", 26, 29], ["IgG", "TEST", 30, 33], ["measles", "TEST", 37, 44], ["human parvovirus", "TEST", 46, 62], ["rubella", "PROBLEM", 71, 78]]], ["Clinical and epidemiological information was obtained by local public health staff using a standard questionnaire.Case seriesSix tested students (C1\u2013C6) had laboratory-confirmed influenza B infection, including three (C4\u2013C6) with localized rash (Tables 1 and 2).", [["influenza B infection", "DISEASE", 178, 199], ["rash", "DISEASE", 240, 244], ["influenza B", "ORGANISM", 178, 189], ["Case seriesSix", "TEST", 114, 128], ["laboratory", "TEST", 157, 167], ["influenza B infection", "PROBLEM", 178, 199], ["three (C4\u2013C6", "PROBLEM", 211, 223], ["localized rash", "PROBLEM", 230, 244], ["influenza", "OBSERVATION", 178, 187], ["infection", "OBSERVATION", 190, 199], ["localized", "OBSERVATION_MODIFIER", 230, 239], ["rash", "OBSERVATION", 240, 244]]], ["One additional student (E1) developed generalized rash and was epidemiologically linked through shared classroom exposure to C1 and C5 but was RT-PCR negative for influenza.", [["rash", "DISEASE", 50, 54], ["influenza", "DISEASE", 163, 172], ["C1", "DNA", 125, 127], ["C5", "DNA", 132, 134], ["generalized rash", "PROBLEM", 38, 54], ["RT-PCR", "TEST", 143, 149], ["influenza", "PROBLEM", 163, 172], ["generalized", "OBSERVATION_MODIFIER", 38, 49], ["rash", "OBSERVATION", 50, 54], ["C1", "ANATOMY", 125, 127], ["C5", "ANATOMY", 132, 134], ["negative for", "UNCERTAINTY", 150, 162], ["influenza", "OBSERVATION", 163, 172]]], ["ILI symptoms did not substantially differ across cases.Case seriesAmong the three students with localized rash, two were high-school students in the same grade with erythematous, non-pruritic rash of the back of the hands, sparing the palms, one macular (C4) and one papular (C6; Figure 1A).", [["back", "ANATOMY", 204, 208], ["hands", "ANATOMY", 216, 221], ["palms", "ANATOMY", 235, 240], ["macular", "ANATOMY", 246, 253], ["papular", "ANATOMY", 267, 274], ["rash", "DISEASE", 106, 110], ["rash", "DISEASE", 192, 196], ["papular", "DISEASE", 267, 274], ["hands", "ORGANISM_SUBDIVISION", 216, 221], ["palms", "ORGANISM_SUBDIVISION", 235, 240], ["macular", "TISSUE", 246, 253], ["ILI symptoms", "PROBLEM", 0, 12], ["localized rash", "PROBLEM", 96, 110], ["erythematous, non-pruritic rash of the back of the hands", "PROBLEM", 165, 221], ["localized", "OBSERVATION_MODIFIER", 96, 105], ["rash", "OBSERVATION", 106, 110], ["erythematous", "OBSERVATION_MODIFIER", 165, 177], ["non-pruritic", "OBSERVATION_MODIFIER", 179, 191], ["rash", "OBSERVATION", 192, 196], ["back", "ANATOMY", 204, 208], ["hands", "ANATOMY", 216, 221], ["palms", "ANATOMY", 235, 240], ["one macular", "ANATOMY", 242, 253], ["C4", "ANATOMY_MODIFIER", 255, 257], ["one", "OBSERVATION_MODIFIER", 263, 266], ["papular", "OBSERVATION_MODIFIER", 267, 274], ["C6", "ANATOMY", 276, 278]]], ["The third student with localized rash (C5) attended the elementary school and reported facial rash that was erythematous, pruritic, macular and continuous over the cheeks, nose and around the eyes, with conjunctivitis and photophobia.Case seriesE1's rash was erythematous, pruritic and maculopapular, beginning on the arms and face 2 days after ILI onset with spread to the rest of the body, sparing the palms and soles (Figure 1B\u2013D).", [["facial", "ANATOMY", 87, 93], ["macular", "ANATOMY", 132, 139], ["cheeks", "ANATOMY", 164, 170], ["nose", "ANATOMY", 172, 176], ["eyes", "ANATOMY", 192, 196], ["maculopapular", "ANATOMY", 286, 299], ["body", "ANATOMY", 386, 390], ["palms", "ANATOMY", 404, 409], ["soles", "ANATOMY", 414, 419], ["rash", "DISEASE", 33, 37], ["rash", "DISEASE", 94, 98], ["pruritic", "DISEASE", 122, 130], ["conjunctivitis", "DISEASE", 203, 217], ["photophobia", "DISEASE", 222, 233], ["rash", "DISEASE", 250, 254], ["pruritic", "DISEASE", 273, 281], ["maculopapular", "DISEASE", 286, 299], ["macular", "TISSUE", 132, 139], ["cheeks", "ORGANISM_SUBDIVISION", 164, 170], ["nose", "ORGAN", 172, 176], ["eyes", "ORGAN", 192, 196], ["body", "ORGANISM_SUBDIVISION", 386, 390], ["palms", "ORGANISM_SUBDIVISION", 404, 409], ["soles", "ORGANISM_SUBDIVISION", 414, 419], ["localized rash (C5)", "PROBLEM", 23, 42], ["facial rash", "PROBLEM", 87, 98], ["erythematous", "PROBLEM", 108, 120], ["pruritic", "PROBLEM", 122, 130], ["macular", "PROBLEM", 132, 139], ["conjunctivitis", "PROBLEM", 203, 217], ["photophobia", "PROBLEM", 222, 233], ["Case seriesE1's rash", "PROBLEM", 234, 254], ["erythematous", "PROBLEM", 259, 271], ["pruritic", "PROBLEM", 273, 281], ["maculopapular", "PROBLEM", 286, 299], ["ILI onset", "PROBLEM", 345, 354], ["localized", "OBSERVATION_MODIFIER", 23, 32], ["rash", "OBSERVATION", 33, 37], ["facial", "ANATOMY", 87, 93], ["rash", "OBSERVATION", 94, 98], ["erythematous", "OBSERVATION_MODIFIER", 108, 120], ["pruritic", "OBSERVATION_MODIFIER", 122, 130], ["macular", "OBSERVATION", 132, 139], ["cheeks", "ANATOMY", 164, 170], ["nose", "ANATOMY", 172, 176], ["eyes", "ANATOMY", 192, 196], ["conjunctivitis", "OBSERVATION", 203, 217], ["photophobia", "OBSERVATION", 222, 233], ["erythematous", "OBSERVATION_MODIFIER", 259, 271], ["pruritic", "OBSERVATION_MODIFIER", 273, 281], ["maculopapular", "OBSERVATION", 286, 299], ["arms", "ANATOMY", 318, 322], ["face", "ANATOMY", 327, 331], ["body", "ANATOMY", 386, 390], ["palms", "ANATOMY", 404, 409], ["soles", "ANATOMY", 414, 419]]], ["There was no oral enanthem.", [["oral", "ANATOMY", 13, 17], ["oral", "ORGANISM_SUBDIVISION", 13, 17], ["oral enanthem", "PROBLEM", 13, 26], ["no", "UNCERTAINTY", 10, 12], ["oral", "OBSERVATION_MODIFIER", 13, 17], ["enanthem", "OBSERVATION", 18, 26]]], ["Rash persisted 9 days, worsening with exposure to cold air/water.", [["Rash", "DISEASE", 0, 4], ["Rash", "PROBLEM", 0, 4], ["9 days", "OBSERVATION_MODIFIER", 15, 21], ["worsening", "OBSERVATION_MODIFIER", 23, 32]]], ["Tearing and photophobia, without conjunctivitis, and nausea, vomiting, abdominal pain and loss of appetite were accompanying symptoms.Case seriesNone of the students with rash reported change in diet, detergent, or other products in contact with skin, had an allergic history or comorbidity, or took medications in the week before/after symptom onset to explain rash illness.", [["abdominal", "ANATOMY", 71, 80], ["skin", "ANATOMY", 246, 250], ["photophobia", "DISEASE", 12, 23], ["conjunctivitis", "DISEASE", 33, 47], ["nausea", "DISEASE", 53, 59], ["vomiting", "DISEASE", 61, 69], ["abdominal pain", "DISEASE", 71, 85], ["loss of appetite", "DISEASE", 90, 106], ["rash", "DISEASE", 171, 175], ["allergic", "DISEASE", 259, 267], ["rash", "DISEASE", 362, 366], ["abdominal", "ORGANISM_SUBDIVISION", 71, 80], ["skin", "ORGAN", 246, 250], ["Tearing", "PROBLEM", 0, 7], ["photophobia", "PROBLEM", 12, 23], ["conjunctivitis", "PROBLEM", 33, 47], ["nausea", "PROBLEM", 53, 59], ["vomiting", "PROBLEM", 61, 69], ["abdominal pain", "PROBLEM", 71, 85], ["loss of appetite", "PROBLEM", 90, 106], ["accompanying symptoms", "PROBLEM", 112, 133], ["rash", "PROBLEM", 171, 175], ["detergent", "TREATMENT", 201, 210], ["an allergic history", "PROBLEM", 256, 275], ["comorbidity", "PROBLEM", 279, 290], ["medications", "TREATMENT", 300, 311], ["symptom", "PROBLEM", 337, 344], ["rash illness", "PROBLEM", 362, 374], ["photophobia", "OBSERVATION", 12, 23], ["without", "UNCERTAINTY", 25, 32], ["conjunctivitis", "OBSERVATION", 33, 47], ["abdominal", "ANATOMY", 71, 80], ["pain", "OBSERVATION", 81, 85], ["skin", "ANATOMY", 246, 250]]], ["The one exception may be C5 who receives daily aspirin prophylaxis for an unrelated medical condition and completed a 5-day course of amoxicillin for the current ILI episode beginning 2 days prior to rash onset; however, rash did not recur with subsequent use of amoxicillin for another indication.", [["aspirin", "CHEMICAL", 47, 54], ["amoxicillin", "CHEMICAL", 134, 145], ["rash", "DISEASE", 200, 204], ["rash", "DISEASE", 221, 225], ["amoxicillin", "CHEMICAL", 263, 274], ["aspirin", "CHEMICAL", 47, 54], ["amoxicillin", "CHEMICAL", 134, 145], ["amoxicillin", "CHEMICAL", 263, 274], ["aspirin", "SIMPLE_CHEMICAL", 47, 54], ["amoxicillin", "SIMPLE_CHEMICAL", 134, 145], ["amoxicillin", "SIMPLE_CHEMICAL", 263, 274], ["daily aspirin prophylaxis", "TREATMENT", 41, 66], ["an unrelated medical condition", "PROBLEM", 71, 101], ["amoxicillin", "TREATMENT", 134, 145], ["the current ILI episode", "PROBLEM", 150, 173], ["rash onset", "PROBLEM", 200, 210], ["rash", "PROBLEM", 221, 225], ["amoxicillin", "TREATMENT", 263, 274], ["may be", "UNCERTAINTY", 18, 24], ["C5", "OBSERVATION_MODIFIER", 25, 27]]], ["All but one received two measles/mumps/rubella (MMR) vaccine doses, with one single-dose recipient.", [["mumps/rubella", "DISEASE", 33, 46], ["mumps", "ORGANISM", 33, 38], ["rubella", "ORGANISM", 39, 46], ["measles/mumps/rubella", "SPECIES", 25, 46], ["two measles", "TREATMENT", 21, 32], ["mumps", "PROBLEM", 33, 38], ["rubella (MMR) vaccine doses", "TREATMENT", 39, 66], ["one single-dose recipient", "TREATMENT", 73, 98]]], ["Only E1 had received the 2013\u20132014 TIV (inactivated) administered as a single dose 11\u00b75 weeks prior to ILI onset.", [["ILI onset", "PROBLEM", 103, 112]]], ["E1 had also previously received TIV in 2006, 2007 and 2008.Case seriesAll six influenza-positive specimens were characterized by RT-PCR as B/Yamagata-lineage; of the four viruses that could be isolated in cell culture, all were characterized as B/Massachusetts/02/2012-like (Table 2).", [["specimens", "ANATOMY", 97, 106], ["cell culture", "ANATOMY", 205, 217], ["specimens", "CANCER", 97, 106], ["cell culture", "CELL", 205, 217], ["B/Massachusetts/02/2012", "SPECIES", 245, 268], ["TIV", "TREATMENT", 32, 35], ["All six influenza-positive specimens", "TEST", 70, 106], ["RT", "TEST", 129, 131], ["PCR", "TEST", 132, 135], ["the four viruses", "PROBLEM", 162, 178], ["cell culture", "TEST", 205, 217]]], ["Although a nasopharyngeal specimen collected from E1 at 6 days post-ILI onset was influenza negative by RT-PCR, HI antibody titres to B/Massachusetts/02/2012-like virus in sera collected from E1 were comparable to or higher than titres in C1\u2013C6.", [["nasopharyngeal specimen", "ANATOMY", 11, 34], ["sera", "ANATOMY", 172, 176], ["nasopharyngeal specimen", "CANCER", 11, 34], ["HI antibody", "GENE_OR_GENE_PRODUCT", 112, 123], ["B/Massachusetts/02/2012-like virus", "ORGANISM", 134, 168], ["sera", "ORGANISM_SUBSTANCE", 172, 176], ["C1\u2013C6", "CELL", 239, 244], ["C1", "PROTEIN", 239, 241], ["B/Massachusetts/02/2012-like virus", "SPECIES", 134, 168], ["a nasopharyngeal specimen", "TEST", 9, 34], ["influenza", "PROBLEM", 82, 91], ["RT", "TEST", 104, 106], ["PCR", "TEST", 107, 110], ["HI antibody titres", "TEST", 112, 130], ["B/Massachusetts", "TEST", 134, 149], ["like virus in sera", "PROBLEM", 158, 176], ["nasopharyngeal", "ANATOMY", 11, 25], ["C6", "ANATOMY", 242, 244]]], ["In all cases, titres were lower in paired sera collected 21\u201333 days after the first serum.", [["sera", "ANATOMY", 42, 46], ["serum", "ANATOMY", 84, 89], ["sera", "ORGANISM_SUBSTANCE", 42, 46], ["serum", "ORGANISM_SUBSTANCE", 84, 89], ["titres", "TEST", 14, 20], ["the first serum", "TEST", 74, 89]]], ["This likely reflects the 8- to 14-day delay from ILI onset to first serum collection, at which point infection-induced titres may have already been peaking and fourfold rise (i.e. sero-conversion) could not subsequently be shown.", [["serum", "ANATOMY", 68, 73], ["ILI", "DISEASE", 49, 52], ["infection", "DISEASE", 101, 110], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["ILI", "PROBLEM", 49, 52], ["first serum collection", "PROBLEM", 62, 84], ["infection", "PROBLEM", 101, 110], ["induced titres", "PROBLEM", 111, 125], ["infection", "OBSERVATION", 101, 110]]], ["On balance, serologic findings in E1 are more consistent with recent influenza B infection than prior immunization.", [["influenza B infection", "DISEASE", 69, 90], ["E1", "GENE_OR_GENE_PRODUCT", 34, 36], ["influenza B", "ORGANISM", 69, 80], ["serologic findings", "TEST", 12, 30], ["recent influenza B infection", "PROBLEM", 62, 90], ["prior immunization", "TREATMENT", 96, 114], ["balance", "OBSERVATION", 3, 10], ["more consistent with", "UNCERTAINTY", 41, 61], ["influenza", "OBSERVATION", 69, 78], ["infection", "OBSERVATION", 81, 90]]], ["In all children, HI titres were higher when using ether-extracted versus live influenza B virus, as expected, but trends were similar.", [["ether", "CHEMICAL", 50, 55], ["children", "ORGANISM", 7, 15], ["ether", "SIMPLE_CHEMICAL", 50, 55], ["live influenza B virus", "ORGANISM", 73, 95], ["children", "SPECIES", 7, 15], ["influenza B virus", "SPECIES", 78, 95], ["influenza B virus", "SPECIES", 78, 95], ["live influenza B virus", "PROBLEM", 73, 95]]], ["In two children with localized rash (C4, C5), titres were similar or higher to the alternate B/Victoria-lineage compared to the B/Yamagata-lineage strain confirmed by PCR and/or culture to be the cause of their current ILI.Case seriesNo other viral aetiology was identified based on multiplex nucleic acid testing or serology (Table 2).DiscussionHere, we describe rash associated with influenza B in schoolchildren during a late-season ILI outbreak.", [["rash", "DISEASE", 31, 35], ["ILI", "DISEASE", 219, 222], ["nucleic acid", "CHEMICAL", 293, 305], ["rash", "DISEASE", 364, 368], ["influenza B", "DISEASE", 385, 396], ["ILI", "DISEASE", 436, 439], ["children", "ORGANISM", 7, 15], ["rash", "PATHOLOGICAL_FORMATION", 31, 35], ["B", "GENE_OR_GENE_PRODUCT", 93, 94], ["influenza B", "ORGANISM", 385, 396], ["schoolchildren", "ORGANISM", 400, 414], ["children", "SPECIES", 7, 15], ["schoolchildren", "SPECIES", 400, 414], ["localized rash (C4, C5)", "PROBLEM", 21, 44], ["titres", "PROBLEM", 46, 52], ["lineage strain", "PROBLEM", 139, 153], ["PCR", "TEST", 167, 170], ["culture", "TEST", 178, 185], ["other viral aetiology", "PROBLEM", 237, 258], ["multiplex nucleic acid testing", "TEST", 283, 313], ["serology", "TEST", 317, 325], ["rash", "PROBLEM", 364, 368], ["influenza B", "PROBLEM", 385, 396], ["localized", "OBSERVATION_MODIFIER", 21, 30], ["rash", "OBSERVATION", 31, 35], ["viral", "OBSERVATION", 243, 248], ["rash", "OBSERVATION", 364, 368]]], ["In addition to typical ILI symptoms, three students developed localized rash and one developed generalized morbilliform rash.", [["rash", "DISEASE", 72, 76], ["rash", "DISEASE", 120, 124], ["typical ILI symptoms", "PROBLEM", 15, 35], ["localized rash", "PROBLEM", 62, 76], ["generalized morbilliform rash", "PROBLEM", 95, 124], ["rash", "OBSERVATION", 72, 76], ["generalized", "OBSERVATION_MODIFIER", 95, 106], ["morbilliform rash", "OBSERVATION", 107, 124]]], ["Six of seven students investigated (including three with localized rash) had laboratory-confirmed influenza B, while the seventh with generalized rash had serologic evidence of infection and was confirmed through epidemiological links to two laboratory-confirmed cases of influenza B in the same classroom (one also with rash).", [["rash", "DISEASE", 67, 71], ["influenza B", "DISEASE", 98, 109], ["rash", "DISEASE", 146, 150], ["infection", "DISEASE", 177, 186], ["influenza B", "DISEASE", 272, 283], ["rash", "DISEASE", 321, 325], ["localized rash", "PROBLEM", 57, 71], ["influenza B", "PROBLEM", 98, 109], ["generalized rash", "PROBLEM", 134, 150], ["infection", "PROBLEM", 177, 186], ["influenza B", "PROBLEM", 272, 283], ["rash", "PROBLEM", 321, 325], ["generalized", "OBSERVATION_MODIFIER", 134, 145], ["rash", "OBSERVATION", 146, 150], ["infection", "OBSERVATION", 177, 186], ["influenza", "OBSERVATION", 272, 281]]], ["Although amoxicillin may have been a contributing factor in the laboratory-confirmed classmate with localized rash, lack of recurrence with subsequent re-exposure to the same antibiotic argues against allergic aetiology.", [["amoxicillin", "CHEMICAL", 9, 20], ["rash", "DISEASE", 110, 114], ["allergic aetiology", "DISEASE", 201, 219], ["amoxicillin", "CHEMICAL", 9, 20], ["amoxicillin", "SIMPLE_CHEMICAL", 9, 20], ["amoxicillin", "TREATMENT", 9, 20], ["classmate", "PROBLEM", 85, 94], ["localized rash", "PROBLEM", 100, 114], ["recurrence", "PROBLEM", 124, 134], ["the same antibiotic", "TREATMENT", 166, 185], ["allergic aetiology", "PROBLEM", 201, 219], ["localized", "OBSERVATION_MODIFIER", 100, 109], ["rash", "OBSERVATION", 110, 114]]], ["No co-infection or other viral aetiology was identified in any of the seven ILI cases investigated.DiscussionRash is an uncommon manifestation of influenza.", [["co-infection", "DISEASE", 3, 15], ["ILI", "DISEASE", 76, 79], ["DiscussionRash", "DISEASE", 99, 113], ["influenza", "DISEASE", 146, 155], ["co-infection", "PROBLEM", 3, 15], ["other viral aetiology", "PROBLEM", 19, 40], ["influenza", "PROBLEM", 146, 155], ["co-infection", "OBSERVATION", 3, 15], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["influenza", "OBSERVATION", 146, 155]]], ["Two prior published reports describe rash with laboratory-confirmed influenza B, both noting morbilliform features: a case report from India in an 11-year-old2 and a case series including six children in Germany aged 4\u201313 years old with ILI and generalized exanthem and enanthem.3 Hope\u2013Simpson reported \u223c2% and 8%, respectively, of medically attended influenza A and B infections in a British community between 1962 and 1966 had rash, but rash features were not described.4 Among 151 patients hospitalized with influenza in Australia in 1982, 4 of 56 (7%) <15 years old (and none \u226515 years old) presented with rash; 3/4 were initially diagnosed as measles, and of these three, two were influenza B.5 Among adult Singaporean military recruits, rash (undescribed) was more often associated with influenza A/H3N2 than A(H1N1) pdm09 or influenza B.6 Rash associated with influenza A has been variously characterized as petechial,7,8 macular,7 papular,9 maculopapular,10 reticular9 or purpuric11,12 and has been localized,9 multifocal7,8,12 or generalized,10 pruritic9 and non-pruritic.7 Generalized maculopapular rash associated with influenza A(H1N1) pdm09 spared the palms and soles, as was also noted here for influenza B.10DiscussionWhile no conclusions can be drawn from a single case, it is interesting that the child with generalized rash was the only one in the current series to have received influenza vaccine.", [["petechial", "ANATOMY", 915, 924], ["macular", "ANATOMY", 929, 936], ["papular", "ANATOMY", 939, 946], ["maculopapular", "ANATOMY", 1095, 1108], ["palms", "ANATOMY", 1165, 1170], ["soles", "ANATOMY", 1175, 1180], ["rash", "DISEASE", 37, 41], ["influenza B", "DISEASE", 68, 79], ["ILI", "DISEASE", 237, 240], ["exanthem", "DISEASE", 257, 265], ["enanthem", "DISEASE", 270, 278], ["influenza A and B infections", "DISEASE", 351, 379], ["rash", "DISEASE", 429, 433], ["rash", "DISEASE", 439, 443], ["influenza", "DISEASE", 511, 520], ["rash", "DISEASE", 610, 614], ["measles", "DISEASE", 648, 655], ["influenza B.5", "DISEASE", 686, 699], ["rash", "DISEASE", 743, 747], ["influenza A/H3N2", "DISEASE", 793, 809], ["Rash", "DISEASE", 846, 850], ["influenza A", "DISEASE", 867, 878], ["maculopapular", "DISEASE", 949, 962], ["rash", "DISEASE", 1109, 1113], ["influenza A", "DISEASE", 1130, 1141], ["influenza B.10Discussion", "DISEASE", 1209, 1233], ["rash", "DISEASE", 1337, 1341], ["children", "ORGANISM", 192, 200], ["patients", "ORGANISM", 484, 492], ["influenza A/H3N2", "ORGANISM", 793, 809], ["A(H1N1) pdm09", "ORGANISM", 815, 828], ["influenza B.6 Rash", "ORGANISM", 832, 850], ["macular", "TISSUE", 929, 936], ["influenza A(H1N1) pdm09", "ORGANISM", 1130, 1153], ["palms", "ORGANISM_SUBDIVISION", 1165, 1170], ["soles", "PATHOLOGICAL_FORMATION", 1175, 1180], ["child", "ORGANISM", 1314, 1319], ["children", "SPECIES", 192, 200], ["patients", "SPECIES", 484, 492], ["H3N2", "SPECIES", 805, 809], ["influenza A(H1N1", "SPECIES", 1130, 1146], ["child", "SPECIES", 1314, 1319], ["rash", "PROBLEM", 37, 41], ["influenza B", "PROBLEM", 68, 79], ["ILI", "PROBLEM", 237, 240], ["generalized exanthem and enanthem", "PROBLEM", 245, 278], ["influenza", "PROBLEM", 351, 360], ["B infections", "PROBLEM", 367, 379], ["rash", "PROBLEM", 429, 433], ["rash features", "PROBLEM", 439, 452], ["influenza", "PROBLEM", 511, 520], ["rash", "PROBLEM", 610, 614], ["measles", "PROBLEM", 648, 655], ["influenza", "PROBLEM", 686, 695], ["rash", "PROBLEM", 743, 747], ["influenza", "PROBLEM", 793, 802], ["H3N2", "PROBLEM", 805, 809], ["A(H1N1) pdm09", "PROBLEM", 815, 828], ["influenza", "PROBLEM", 832, 841], ["Rash", "PROBLEM", 846, 850], ["influenza A", "PROBLEM", 867, 878], ["petechial", "TEST", 915, 924], ["macular", "TEST", 929, 936], ["purpuric", "PROBLEM", 980, 988], ["non-pruritic", "PROBLEM", 1068, 1080], ["Generalized maculopapular rash", "PROBLEM", 1083, 1113], ["influenza A(H1N1)", "PROBLEM", 1130, 1147], ["pdm09", "PROBLEM", 1148, 1153], ["the palms and soles", "PROBLEM", 1161, 1180], ["influenza", "PROBLEM", 1209, 1218], ["generalized rash", "PROBLEM", 1325, 1341], ["influenza vaccine", "TREATMENT", 1398, 1415], ["generalized", "OBSERVATION_MODIFIER", 245, 256], ["exanthem", "OBSERVATION", 257, 265], ["infections", "OBSERVATION", 369, 379], ["influenza", "OBSERVATION", 511, 520], ["rash", "OBSERVATION", 610, 614], ["petechial", "OBSERVATION_MODIFIER", 915, 924], ["7,8 macular", "OBSERVATION_MODIFIER", 925, 936], ["papular", "ANATOMY", 939, 946], ["9 maculopapular", "OBSERVATION_MODIFIER", 947, 962], ["purpuric", "OBSERVATION_MODIFIER", 980, 988], ["9 multifocal7", "OBSERVATION_MODIFIER", 1017, 1030], ["generalized", "OBSERVATION_MODIFIER", 1039, 1050], ["10 pruritic9", "OBSERVATION_MODIFIER", 1051, 1063], ["Generalized", "OBSERVATION_MODIFIER", 1083, 1094], ["maculopapular", "OBSERVATION_MODIFIER", 1095, 1108], ["rash", "OBSERVATION", 1109, 1113], ["soles", "ANATOMY", 1175, 1180], ["generalized", "OBSERVATION_MODIFIER", 1325, 1336], ["rash", "OBSERVATION", 1337, 1341]]], ["Immunization would not have been a direct cause of rash 3 months later but prior sensitization may nevertheless be relevant.", [["rash", "DISEASE", 51, 55], ["Immunization", "TREATMENT", 0, 12], ["rash", "PROBLEM", 51, 55], ["prior sensitization", "PROBLEM", 75, 94]]], ["Pre-existing vaccine- or infection-induced antibody might be hypothesized to play a role in rash pathogenesis through the rapid formation of antigen\u2013antibody complexes upon re-exposure.", [["infection", "DISEASE", 25, 34], ["rash", "DISEASE", 92, 96], ["rash", "PATHOLOGICAL_FORMATION", 92, 96], ["antigen\u2013antibody complexes", "PROTEIN", 141, 167], ["Pre-existing vaccine", "PROBLEM", 0, 20], ["infection", "PROBLEM", 25, 34], ["induced antibody", "PROBLEM", 35, 51], ["rash pathogenesis", "PROBLEM", 92, 109], ["antigen\u2013antibody complexes", "PROBLEM", 141, 167], ["infection", "OBSERVATION", 25, 34]]], ["In that regard, it is also interesting that 2 of 3 children with localized rash (and no history of prior influenza immunization) raised substantial antibody titres to previously circulating B/Victoria-lineage virus, suggesting prior infection-induced priming to epitopes shared with the currently infecting B/Yamagata-lineage strain.", [["rash", "DISEASE", 75, 79], ["infection", "DISEASE", 233, 242], ["children", "ORGANISM", 51, 59], ["B/Victoria-lineage virus", "ORGANISM", 190, 214], ["B/Yamagata-lineage strain", "ORGANISM", 307, 332], ["epitopes", "PROTEIN", 262, 270], ["children", "SPECIES", 51, 59], ["B/Victoria-lineage virus", "SPECIES", 190, 214], ["localized rash", "PROBLEM", 65, 79], ["prior influenza immunization", "TREATMENT", 99, 127], ["substantial antibody titres", "PROBLEM", 136, 163], ["lineage virus", "PROBLEM", 201, 214], ["prior infection", "PROBLEM", 227, 242], ["lineage strain", "PROBLEM", 318, 332], ["rash", "OBSERVATION", 75, 79], ["lineage virus", "OBSERVATION", 201, 214], ["infection", "OBSERVATION", 233, 242], ["lineage strain", "OBSERVATION", 318, 332]]], ["Antigen and antibody levels at a precise balance may be required for complex formation and in explaining the unusual occurrence and varying nature of influenza-associated rash, particularly late in the season.", [["influenza", "DISEASE", 150, 159], ["rash", "DISEASE", 171, 175], ["rash", "PATHOLOGICAL_FORMATION", 171, 175], ["Antigen and antibody levels", "TEST", 0, 27], ["complex formation", "PROBLEM", 69, 86], ["influenza", "PROBLEM", 150, 159], ["associated rash", "PROBLEM", 160, 175], ["influenza", "OBSERVATION", 150, 159], ["rash", "OBSERVATION", 171, 175]]], ["Ultimately, proposed mechanisms for influenza-associated rash remain speculative.", [["influenza", "DISEASE", 36, 45], ["rash", "DISEASE", 57, 61], ["influenza", "PROBLEM", 36, 45], ["associated rash", "PROBLEM", 46, 61], ["rash", "OBSERVATION", 57, 61]]], ["However, prior receipt of the current season's TIV is nevertheless important because it may have attenuated the amount and duration of virus shedding, relevant given the negative RT-PCR result in the child with generalized rash and 6-day delay to nasopharyngeal specimen collection.", [["nasopharyngeal specimen", "ANATOMY", 247, 270], ["rash", "DISEASE", 223, 227], ["nasopharyngeal specimen", "MULTI-TISSUE_STRUCTURE", 247, 270], ["child", "SPECIES", 200, 205], ["the current season's TIV", "TREATMENT", 26, 50], ["virus shedding", "PROBLEM", 135, 149], ["generalized rash", "PROBLEM", 211, 227], ["nasopharyngeal specimen collection", "PROBLEM", 247, 281], ["amount", "OBSERVATION_MODIFIER", 112, 118], ["generalized", "OBSERVATION_MODIFIER", 211, 222], ["rash", "OBSERVATION", 223, 227], ["nasopharyngeal", "ANATOMY", 247, 261], ["specimen", "OBSERVATION", 262, 270]]], ["High titres to B/Massachusetts/02/2012-like virus in that child's sera reinforce the influenza B diagnosis otherwise confirmed through epidemiologic links.", [["sera", "ANATOMY", 66, 70], ["influenza B", "DISEASE", 85, 96], ["B/Massachusetts/02/2012-like virus", "ORGANISM", 15, 49], ["child", "ORGANISM", 58, 63], ["sera", "ORGANISM_SUBSTANCE", 66, 70], ["influenza B", "ORGANISM", 85, 96], ["child", "SPECIES", 58, 63], ["B/Massachusetts/02/2012-like virus", "SPECIES", 15, 49], ["virus", "PROBLEM", 44, 49]]], ["Ultimately, however, we cannot rule out other unrecognized aetiologies or contributing factors.", [["other unrecognized aetiologies", "PROBLEM", 40, 70]]], ["Multiplex testing did not identify another viral infection, but the association between influenza and rash does not prove causality; it remains possible that patients in this series were simultaneously infected with an unidentified pathogen or that some other environmental factor contributed.DiscussionIn conclusion, this is the first report from North America of rash associated with influenza B. Influenza B should be included in the differential diagnosis of febrile exanthem recognizing that, as for influenza A, rash may include varied clinical presentations.", [["viral infection", "DISEASE", 43, 58], ["influenza", "DISEASE", 88, 97], ["rash", "DISEASE", 102, 106], ["rash", "DISEASE", 365, 369], ["influenza", "DISEASE", 386, 395], ["Influenza B", "DISEASE", 399, 410], ["febrile exanthem", "DISEASE", 463, 479], ["influenza A", "DISEASE", 505, 516], ["rash", "DISEASE", 518, 522], ["patients", "ORGANISM", 158, 166], ["influenza B.", "ORGANISM", 386, 398], ["Influenza B", "ORGANISM", 399, 410], ["patients", "SPECIES", 158, 166], ["influenza B. Influenza", "SPECIES", 386, 408], ["Multiplex testing", "TEST", 0, 17], ["another viral infection", "PROBLEM", 35, 58], ["influenza", "PROBLEM", 88, 97], ["rash", "PROBLEM", 102, 106], ["an unidentified pathogen", "PROBLEM", 216, 240], ["rash", "PROBLEM", 365, 369], ["influenza B. Influenza B", "PROBLEM", 386, 410], ["febrile exanthem", "PROBLEM", 463, 479], ["influenza A", "PROBLEM", 505, 516], ["rash", "PROBLEM", 518, 522], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["infection", "OBSERVATION", 49, 58], ["pathogen", "OBSERVATION", 232, 240]]], ["Further evaluation of the nature, incidence and contributing agent\u2013host\u2013environment interactions, and immunologic mechanisms to possibly explain influenza-associated rash is warranted.", [["influenza", "DISEASE", 145, 154], ["rash", "DISEASE", 166, 170], ["Further evaluation", "TEST", 0, 18], ["agent\u2013host\u2013environment interactions", "PROBLEM", 61, 96], ["immunologic mechanisms", "PROBLEM", 102, 124], ["influenza", "PROBLEM", 145, 154], ["associated rash", "PROBLEM", 155, 170]]]], "PMC7336909": [["In various countries, physiotherapists have reported improvements in the academic research culture of the profession,1 innovations in support for researchers,2,3 greater success at securing research funding4 and expanding scientific output.5 It is therefore unsurprising that clinical physiotherapy research is accumulating rapidly.6,7 For example, over 35 000 randomised trials of physiotherapy interventions have been indexed on the PEDro website (Figure 1) and over 1500 diagnostic test accuracy studies relevant to physiotherapy clinical practice have been indexed on the DiTA website (Figure 2).", [["physiotherapy interventions", "TREATMENT", 382, 409], ["diagnostic test accuracy studies", "TEST", 474, 506], ["physiotherapy clinical practice", "TREATMENT", 519, 550], ["scientific output", "OBSERVATION", 222, 239], ["rapidly", "OBSERVATION_MODIFIER", 324, 331]]], ["Presumably, there is similarly marked growth in other forms of clinical physiotherapy research such as prospective cohort studies and qualitative research.", [["prospective cohort studies", "TEST", 103, 129], ["marked", "OBSERVATION_MODIFIER", 31, 37], ["growth", "OBSERVATION_MODIFIER", 38, 44]]], ["Clinical research studies like these require approval by an ethics review committee, so physiotherapists must realise that their profession also ought to be making an increasing contribution to reviewing the ethical aspects of research proposals.", [["Clinical research studies", "TEST", 0, 25]]]], "c03f8a8070ec37a716e4ae44b07ad9dcfc35782a": [["8.1Inleiding: onderzoek naar uitbraken van ziekte is lastig maar reuzespannend8.1Er is sprake van een plotselinge uitbraak van ziekte als het aantal nieuwe ziektegevallen dat men in een bepaalde situatie en in een relatief korte tijd waarneemt aanzienlijk groter is dan men zou verwachten.", [["men", "SPECIES", 175, 178], ["men", "SPECIES", 270, 273]]], ["Doel van het onderzoek naar plotselinge uitbraken is de omvang van de uitbraak in kaart te brengen en zo snel mogelijk zowel het agens (de determinant) als de bron op te sporen, omdat in beide het aangrijpingspunt voor interventie gelegen kan zijn.", [["Doel van het onderzoek naar plotselinge uitbraken is de omvang van de uitbraak in kaart te brengen en zo snel mogelijk zowel het agens (de determinant) als de bron op te sporen, omdat in beide het aangrijpingspunt voor interventie gelegen kan zijn", "SPECIES", 0, 247]]], ["Hierbij moet men denken aan het behandelen van de ziektegevallen zelf, het nemen van maatregelen die de uitbraak tot staan brengen, en het doen van aanbevelingen om te voorkomen dat zich in de toekomst hier of elders vergelijkbare plotselinge uitbraken voordoen.8.1In hoofdstuk 4 is onderscheid gemaakt tussen particularistische vraagstellingen, gebonden aan een specifiek moment en/of specifieke plaats, en abstracte, wetenschappelijke vraagstellingen die kennis genereren over de abstracte werkelijkheid.8.1Onderzoek naar plotselinge uitbraken zal bijna altijd particularistisch van aard zijn.", [["men", "SPECIES", 13, 16], ["Hierbij moet men denken aan het behandelen van de ziektegevallen zelf, het nemen van maatregelen die de uitbraak tot staan brengen, en het doen van aanbevelingen om te voorkomen dat zich", "SPECIES", 0, 186]]], ["Met deze kennis kan men lokaal maatregelen nemen om de uitbraak te stoppen en vergelijkbare uitbraken te voorkomen.", [["men", "SPECIES", 20, 23]]], ["Als men het heeft over determinanten van plotselinge uitbraken, dan denkt men doorgaans aan uitbraken van infectieziekten (voedselinfecties, open tuberculose, drinkwaterverontreinigingen) .", [["men", "SPECIES", 4, 7], ["men", "SPECIES", 74, 77], ["open tuberculose", "TREATMENT", 141, 157]]], ["Toch blijken diverse plotselinge uitbraken het gevolg te zijn van een milieu-incident (spelen van kinderen op gifgronden, onbedoelde uitstoot van giftige stoffen, rampen), of van fouten bij de behandeling en verzorging van pati\u00ebnten (iatrogene uitbraken, bijvoorbeeld aangeboren afwijkingen ten gevolge van het gebruik van thalidomide tijdens de zwangerschap, oogafwijkingen ten gevolge van te hoge zuurstofconcentraties in couveuses van prematuur geboren kinderen enzovoort).", [["van fouten bij de behandeling en verzorging van pati\u00ebnten (iatrogene uitbraken, bijvoorbeeld aangeboren afwijkingen ten gevolge van het gebruik van thalidomide tijdens de zwangerschap, oogafwijkingen ten gevolge van te hoge zuurstofconcentraties in couveuses van prematuur geboren kinderen enzovoort", "SPECIES", 175, 474]]], ["Specifiek voor de infectieziektenepidemiologie is, dat men te maken heeft met een micro-organisme (virus, bacterie, parasiet) .", [["men", "ORGANISM", 55, 58], ["men", "SPECIES", 55, 58]]], ["Deze overdracht kan direct van mens tot mens plaatsvinden, of door tussenkomst van een 'tussengastheer' (bijvoorbeeld een insect, zoals bij malaria).", [["malaria", "DISEASE", 140, 147], ["mens", "SPECIES", 40, 44]]], ["Alleen bij directe mens-totmensoverdracht spreekt men van besmettelijke ziekten.8.1Tegenover de neiging van het infectieuze agens om te reproduceren staat de neiging van de gastheer zich te verdedigen.", [["men", "SPECIES", 50, 53]]], ["Een micro-organisme zoals het poliovirus kan immers alleen een epidemie veroorzaken als het micro-organisme kan circuleren in een gemeenschap van mensen die nog niet immuun zijn voor het virus.", [["Een micro-organisme zoals het poliovirus kan immers alleen een epidemie veroorzaken als het micro-organisme kan circuleren in een gemeenschap van mensen die nog niet immuun zijn voor het virus", "SPECIES", 0, 192], ["Een", "TEST", 0, 3], ["micro-organisme", "TEST", 4, 19], ["zoals", "TEST", 20, 25]]], ["Interventie bij infectieziekten (zoals het geven van een poliovaccin) heeft dan ook niet alleen gevolgen voor de persoon die de interventie ondergaat, maar ook voor de andere individuen in de populatie.8.1Er zijn dus twee elementen waarin de infectieziekte-epidemiologie verschilt van de epidemiologie van chronische ziekten: -Een pati\u00ebnt kan ook een determinant zijn voor een andere persoon.", [["Er zijn dus twee elementen waarin de infectieziekte-epidemiologie verschilt van de epidemiologie van chronische ziekten: -Een pati\u00ebnt kan ook een determinant zijn voor een andere persoon", "SPECIES", 205, 391], ["Interventie bij infectieziekten", "TREATMENT", 0, 31], ["Er zijn dus", "TREATMENT", 205, 216]]], ["Bovendien verlopen de gebeurtenissen die tot een infectieziekte leiden (en haar gevolgen) vaak veel sneller dan bij niet-infectieuze ziekten, een fenomeen dat zich bij uitstek voordoet bij plotselinge uitbraken.", [["Bovendien verlopen", "TREATMENT", 0, 18]]], ["Daardoor gaan allerlei gebruikelijke assumpties, zoals die van onafhankelijke ziektekansen, niet op en moeten aangepaste analysemethoden worden gebruikt.8.1Wanneer een persoon ge\u00efnfecteerd wordt, kunnen na een zekere tijd (de incubatieperiode) symptomen optreden en wordt de ziekte manifest.", [["Daardoor", "TREATMENT", 0, 8]]], ["Na enige tijd (de latentieperiode) is het besmette individu zelf besmettelijk en kan het de ziekte doorgeven aan anderen.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2]]], ["Zo kan een individu al besmettelijk zijn voordat het symptomen heeft (bijvoorbeeld bij waterpokken onder kinderen en bij besmetting met het hiv-virus), en in andere gevallen kan de besmettelijkheid voortduren als de symptomen al verdwenen zijn (bijvoorbeeld bij hepatitis B, waar zelfs jarenlang asymptomatisch infectieus dragerschap mogelijk is).8.1De kans dat een persoon ge\u00efnfecteerd wordt bij contact met een ander, besmet individu noemt men de transmissiekans (p).", [["hepatitis B", "DISEASE", 262, 273], ["men", "SPECIES", 442, 445], ["al verdwenen zijn", "TREATMENT", 226, 243], ["bij hepatitis B", "TREATMENT", 258, 273]]], ["Het gaat echter vaak om particularistisch onderzoek, dat doorgaans niet tot nieuwe wetenschappelijke bevindingen leidt, maar wel tot snel ingrijpen.", [["Het", "TEST", 0, 3]]], ["Epidemiologen betrokken bij onderzoek naar plotselinge uitbraken dienen, behalve over methodologische vaardigheden, ook te beschikken over sociale, politieke en praktische vaardigheden.", [["Epidemiologen", "TREATMENT", 0, 13]]], ["Ten slotte geldt dat de tijdsdruk vaak noodzaakt tot compromissen voor wat betreft de zorgvuldigheid waarmee het onderzoek wordt opgezet en de kwaliteit waarmee de gegevens verkregen kunnen worden.8.2Surveillance om tijdig alarm te kunnen slaan8.2Vrijwel elke plotselinge uitbraak begint met de ontdekking van een ongebruikelijke ziektebevinding in de bevolking.", [["tijdsdruk vaak noodzaakt tot compromissen voor wat betreft de zorgvuldigheid waarmee het onderzoek wordt opgezet en de kwaliteit waarmee de gegevens verkregen kunnen worden", "SPECIES", 24, 196], ["Surveillance om tijdig alarm te kunnen slaan", "TEST", 200, 244]]], ["Vaker echter is de aanleiding voor het vermoeden van een uitbraak dat twee of meer ziektegevallen dicht bij elkaar of spoedig na elkaar worden waargenomen.", [["na", "CHEMICAL", 126, 128], ["spoedig na elkaar worden waargenomen", "PROBLEM", 118, 154]]], ["Men spreekt dan van een ziektecluster (zie paragraaf 8.6).", [["Men", "SPECIES", 0, 3]]], ["Dit heeft geleid tot allerlei vormen van surveillance, de continue verzameling, bewerking, analyse en rapportage van gegevens over ziekten.", [["verzameling", "TREATMENT", 67, 78]]], ["Met surveillance detecteert en signaleert men opvallende verschuivingen, in tijd en plaats, van de ziektefrequentie.8.2Surveillance is als activiteit al eeuwen oud en van grote waarde gebleken om autoriteiten te informeren over de ontwikkeling van de staat van gezondheid van de bevolking.", [["Met", "CHEMICAL", 0, 3], ["men", "SPECIES", 42, 45]]], ["Na de Tweede Wereldoorlog zijn speciale instanties, zoals het Center for Disease Control and Prevention (CDC) in de Verenigde Staten aangewezen om de surveillancetaken uit te voeren.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2], ["Na de Tweede Wereldoorlog zijn speciale instanties", "TREATMENT", 0, 50], ["Disease Control", "TREATMENT", 73, 88]]], ["Sinds 2005 is er ook een Europese pendant, het European Center for Disease Prevention and Control (ECDC) in Stockholm met een netwerk van centra in elk aangesloten land.", [["Disease", "DISEASE", 67, 74], ["Disease Prevention", "TREATMENT", 67, 85]]], ["Voor Nederland is het Centrum voor Infectieziekten Bestrijding (CIB) van het Rijksinstituut voor Volksgezondheid en Milieuhygi\u00ebne (RIVM) aangewezen om de surveillance voor infectieziekten te verzorgen.8.2Dankzij actieve surveillance is men er wereldwijd in geslaagd om pokken definitief uit te bannen.", [["men", "ORGANISM", 236, 239], ["men", "SPECIES", 236, 239], ["Centrum voor Infectieziekten Bestrijding (CIB) van het Rijksinstituut voor Volksgezondheid en Milieuhygi\u00ebne (RIVM) aangewezen om de surveillance voor infectieziekten te verzorgen", "SPECIES", 22, 200], ["Volksgezondheid en Milieuhygi\u00ebne (RIVM)", "TREATMENT", 97, 136]]], ["Ook kanker, aangeboren afwijkingen, ongevaltraumata en andere ziekten zijn onderwerp van surveillance en met hetzelfde idee opgezet: tijdig signalen krijgen over veranderingen in het ziektepatroon die aanleiding geven voor nader onderzoek en/of maatregelen.8.2Surveillance is niet in de eerste plaats bedoeld als een vorm van epidemiologisch onderzoek, maar als een instrument om snel ingrijpen mogelijk te maken en daarmee een uitbraak in de kiem te smoren.", [["maar als een instrument", "TREATMENT", 353, 376], ["mogelijk te", "TREATMENT", 395, 406]]], ["Snelheid gaat daarom voor nauwkeurigheid.8.2Het belangrijkste surveillancesysteem is gebaseerd op meldingen van ziektegevallen.", [["Snelheid gaat daarom voor nauwkeurigheid", "SPECIES", 0, 40], ["Het belangrijkste surveillancesysteem", "TREATMENT", 44, 81]]], ["Alle artsen, microbiologische laboratoria en hoofden van instellingen die ziektegevallen op het spoor komen die onder deze meldingsplicht vallen, dienen deze te melden bij de arts infectieziektebestrijding van de Gemeenschappelijke Gezondheidsdienst (GGD) in diens werkgebied.", [["microbiologische laboratoria en hoofden van instellingen die ziektegevallen op het spoor komen die onder deze meldingsplicht vallen, dienen deze te melden bij de arts infectieziektebestrijding van de Gemeenschappelijke Gezondheidsdienst (GGD)", "SPECIES", 13, 255]]], ["Deze wijze van surveillance, waarbij in specifieke geografische locaties, zorginstellingen, of populaties in omschreven tijdsperioden gegevens worden verzameld, worden ook wel sentinel systemen genoemd.8.2Omdat het doel is om zo snel mogelijk veranderingen te signaleren in ziektefrequentie en clusters van ziekte in tijd en plaats, moet een surveillancesysteem veel van de ziektegevallen oppikken en dus een hoge sensitiviteit hebben.", [["tijdsperioden gegevens", "SPECIES", 120, 142]]], ["Dit mag, mede gelet op de consequenties, desnoods ten koste gaan van de specificiteit.8.2Surveillancesystemen kunnen ook nuttig worden ingezet om de effectiviteit van volksgezondheidsmaatregelen te monitoren.", [["Dit mag", "TEST", 0, 7]]], ["Inventarisatie van het aantal meldingen van bijna-ongevallen geeft in ziekenhuizen en bedrijven informatie over de mate waarin men zich aan allerlei voorschriften voor kwaliteit en veiligheid houdt.", [["men", "SPECIES", 127, 130]]], ["Zo is de toename van het aantal gevallen van kinkhoest bij kinderen in 1996-1997 aanleiding geweest om een extra vaccinatie op de leeftijd van 4 jaar te introduceren (zie casus 8.1).", [["Zo", "SIMPLE_CHEMICAL", 0, 2], ["van het aantal gevallen van kinkhoest bij kinderen in 1996-1997 aanleiding geweest om een extra vaccinatie op de leeftijd van 4 jaar te introduceren (zie casus", "SPECIES", 17, 176], ["een extra vaccinatie op", "TREATMENT", 103, 126], ["van 4 jaar te introduceren (zie casus", "TREATMENT", 139, 176]]], ["Jaarlijks worden er nu 4000 tot 8000 gevallen van kinkhoest gemeld.", [["Jaarlijks worden er nu 4000 tot 8000 gevallen van kinkhoest gemeld", "SPECIES", 0, 66]]], ["Sterfte ten gevolge van kinkhoest komt slechts bij hoge uitzondering voor.8.2Voor de preventie van kinkhoest zijn zowel cellulaire als acellulaire vaccins beschikbaar.", [["van kinkhoest zijn zowel cellulaire als acellulaire vaccins beschikbaar", "TREATMENT", 95, 166]]], ["Cellulaire vaccins zijn gemaakt van dode bacteri\u00ebn.", [["Cellulaire vaccins", "TREATMENT", 0, 18]]], ["Zij bevatten veel antigenen en veroorzaken soms milde tot heftige bijwerkingen.", [["Zij bevatten", "TREATMENT", 0, 12]]], ["Acellulaire vaccins bevatten combinaties van eiwitcomponenten afkomstig van de bacterie.", [["Acellulaire vaccins", "TREATMENT", 0, 19]]], ["Ook hiervan kunnen lichte bijwerkingen optreden, zoals roodheid, pijn en zwelling op de plaats van injectie alsmede huilen en hangerigheid.8.2Vanaf de start van het Rijksvaccinatieprogramma in 1953 werd op de leeftijd van 2, 3, 4 en 11 maanden een DKTP-injectie gegeven met een cellulaire K-component.", [["cellulaire K-component", "OBSERVATION", 278, 300]]], ["Omdat in de jaren rond de eeuwwisseling de effectiviteit van de K-component van de DKTP-inenting achteruit bleek te gaan en bij herhaling omvangrijke epidemische golven van kinkhoest over Nederland trokken (zie figuur 8.1), mogelijk door verandering in de circulerende B. pertussis-bacteri\u00ebn, heeft de minister van Volksgezondheid in 2000 besloten een extra vaccinatie tegen kinkhoest voor 4-jarigen in te voeren als onderdeel van het Rijksvaccinatieprogramma.", [["een extra vaccinatie", "TREATMENT", 348, 368]]], ["Er is voor een acellulair vaccin gekozen omdat het cellulair vaccin op vierjarige leeftijd te veel bijwerkingen geeft.", [["een acellulair vaccin", "TREATMENT", 11, 32]]], ["Vanaf 2005 wordt ook in het eerste levensjaar een acellulair kinkhoestvaccin gebruikt.8.2Er wordt een gecombineerd DTP-acellulair kinkhoestvaccin ontwikkeld dat in de toekomst de huidige DKTP kinkhoestvaccinaties kan vervangen.", [["Vanaf", "TREATMENT", 0, 5]]], ["1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 jaren Naar aanleiding van epidemie\u00ebn van severe acute respiratory syndrome (SARS), vogelgriepvirus type H5N1 en bioterrorisme rond de recente eeuwwisseling is ook de behoefte gegroeid om ongebruikelijke ziekteverheffingen te signaleren van (combinaties van) aspecifieke klachten en symptomen.", [["acute respiratory syndrome", "DISEASE", 138, 164], ["SARS", "DISEASE", 166, 170], ["H5N1", "SPECIES", 194, 198], ["1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 jaren", "SPECIES", 0, 95], ["Naar aanleiding van epidemie\u00ebn van severe acute respiratory syndrome (SARS)", "SPECIES", 96, 171], ["acute respiratory syndrome", "PROBLEM", 138, 164], ["SARS", "PROBLEM", 166, 170], ["acute", "OBSERVATION_MODIFIER", 138, 143], ["respiratory syndrome", "OBSERVATION", 144, 164]]], ["Bij deze zogenaamde syndroomsurveillance bestudeert men de frequentie van vroege, aspecifieke klachten of verschijnselen die bij bijvoorbeeld huisarts, ziekenhuis, apotheker (verkoop van geneesmiddelen) of arbodienst (ziekteverzuim) worden gerapporteerd.", [["men", "SPECIES", 52, 55], ["Bij deze zogenaamde syndroomsurveillance", "TREATMENT", 0, 40], ["arbodienst (ziekteverzuim)", "TREATMENT", 206, 232]]], ["Een verhoogd voorkomen van een dergelijk syndroom vormt dan aanleiding voor nader onderzoek of zelfs maatregelen.8.2Een toename van het aantal ziektegevallen behoeft niet altijd te betekenen dat er sprake is van een plotselinge uitbraak.", [["Een toename van het aantal ziektegevallen", "TREATMENT", 116, 157]]], ["Men dient ook bedacht te zijn op de mogelijkheid dat de populatie naar omvang of samenstelling is veranderd, of dat er sprake is van een verandering in de wijze waarop ziektegevallen worden opgespoord of geregistreerd.", [["Men", "SPECIES", 0, 3]]], ["Op zo'n moment heeft men bij elk ziektegeval behoefte aan een hele range van gegevens, zoals: -naam, leeftijd, geslacht, etniciteit; -woonplaats; -datum en tijdstip waarop de ziekte zich voor het eerst manifesteerde; -symptomen en duur van de ziekteverschijnselen; eventueel datum van overlijden; -mogelijke manieren van transmissie, risicogedrag; -andere relevante informatie (vaccinatiestatus, beroep enz.).8.2Naarmate een surveillancesysteem per ziektegeval reeds (een deel van) deze kenmerken heeft vastgelegd, zullen deze systemen ook beter ingezet kunnen worden voor het onderzoek dat volgt op het moment dat met zo'n systeem een uitbraak is gesignaleerd.", [["men", "SPECIES", 21, 24], ["elk ziektegeval behoefte aan een hele range van gegevens, zoals: -naam, leeftijd, geslacht, etniciteit; -woonplaats; -datum en tijdstip waarop de ziekte zich voor het eerst manifesteerde; -symptomen en duur van de ziekteverschijnselen; eventueel datum van overlijden; -mogelijke manieren van transmissie, risicogedrag; -andere relevante informatie", "SPECIES", 29, 376], ["Naarmate een surveillancesysteem per ziektegeval reeds (een deel van) deze kenmerken heeft vastgelegd, zullen deze systemen ook beter ingezet kunnen worden voor het onderzoek dat volgt op het moment dat met zo'n systeem een uitbraak", "SPECIES", 412, 644], ["Naarmate een", "TREATMENT", 412, 424]]], ["Casus 8.2 beschrijft een uitbraak van toxischeshocksyndroom (TSS) bij jonge vrouwen.", [["Casus", "TEST", 0, 5]]], ["Wettelijke verplichting tot melden, zoals bij een aantal infectieziekten en kindermishandeling het geval is, is daarbij echter onvoldoende.", [["zoals", "TREATMENT", 36, 41]]], ["Melders zullen vooral gemotiveerd worden doordat ze terugkoppeling krijgen en kunnen waarnemen dat het systeem daadwerkelijk leidt tot vroege signalering en effectieve actie.", [["Melders", "TEST", 0, 7]]], ["Het meldingspercentage zal verder toenemen wanneer de administratieve last die het melden met zich meebrengt tot een minimum beperkt blijft.snelle alarmering zonder valse meldingOm (dreigende) uitbraken tijdig te signaleren, maakt men voortdurend vergelijkingen van het aantal waargenomen ziektegevallen met de aantallen die men zou verwachten bij een vergelijking in de tijd of bij een vergelijking met andere regio's.", [["men", "SPECIES", 231, 234], ["men", "SPECIES", 325, 328]]], ["Hierbij wil men vals alarm natuurlijk zo veel mogelijk voorkomen.", [["men", "ORGANISM", 12, 15], ["men", "SPECIES", 12, 15]]], ["Dat betekent dat men, alvorens te concluderen dat er sprake is van een uitbraak, andere verklaringen zal willen uitsluiten: toeval, een verkeerd geschat uitgangsniveau, veranderingen in demografische kenmerken (bijvoorbeeld een geboortegolf) of veranderingen in registratieprocedures.", [["men", "SPECIES", 17, 20]]], ["Er zijn enkele statistische technieken beschikbaar om het aantal waarschuwingen dat slechts een gevolg is van toevallige variatie terug te dringen tot een acceptabel niveau.", [["Er zijn enkele statistische", "TREATMENT", 0, 27], ["een gevolg", "TREATMENT", 92, 102]]], ["Dat wil overigens niet zeggen dat vals alarm helemaal uitgesloten is.", [["Dat", "TEST", 0, 3]]], ["Voordat men overgaat tot toepassing van allerlei statistische technieken dient men eerst een grafische voorstelling te maken van de ziektefrequentiecijfers, bijvoorbeeld door in een grafiek het (cumulatief) aantal gevallen dat men waarneemt en de aantallen die men zou verwachten op basis van een stabiele ziekte-incidentie, uit te zetten tegen de tijd.", [["men", "SPECIES", 8, 11], ["men", "SPECIES", 79, 82], ["men", "SPECIES", 227, 230], ["men", "SPECIES", 261, 264], ["een grafiek het (cumulatief) aantal gevallen dat men waarneemt en de aantallen die men zou verwachten op basis van een stabiele ziekte-incidentie", "SPECIES", 178, 323]]], ["Hiervoor gebruikt men bij voorkeur niet de datum van de melding, maar de datum waarop de diagnose is gesteld.snelle alarmering zonder valse meldingLokale variaties kunnen bestudeerd worden door de ziektefrequenties (incidentiedichtheden, zie paragraaf 2.5.2) op een kaart uit te zetten, waarbij men bijvoorbeeld vijf klassen van ziektefrequentie onderscheidt die men op de kaart met opklimmende kleursterktes weergeeft.", [["men", "SPECIES", 18, 21], ["men", "SPECIES", 295, 298], ["op een kaart uit te zetten", "TREATMENT", 259, 285]]], ["Met behulp van zogeheten autocorrelatieco\u00ebffici\u00ebnten, die de correlatie weergeven tussen ziektefrequenties in aangrenzende gebieden, kan men patronen in het totale gebied tot uitdrukking brengen.", [["men", "SPECIES", 137, 140]]], ["Bovendien zijn verschillen in de wijze waarop geregistreerd wordt kleiner tussen aangrenzende gebieden.", [["Bovendien", "TREATMENT", 0, 9]]], ["Om te voorkomen dat men zich te veel laat leiden door toevallige variatie tussen gebieden, kunnen de ziektefrequenties 'gesmoothd' worden, dat wil zeggen dat men gecorrigeerde frequenties berekent aan de hand van de informatie in de aangrenzende gebieden.", [["men", "SPECIES", 20, 23], ["men", "SPECIES", 158, 161]]], ["Men noemt deze techniek ook wel 'empirisch bayesiaanse schattingen'.", [["Men", "SPECIES", 0, 3]]], ["Door het toepassen van deze methoden (waarvan de technische beschrijving het karakter van dit boek overstijgt), neemt men onderliggende patronen in ziektefrequenties beter waar dan met de niet-gesmoothde cijfers.", [["men", "SPECIES", 118, 121]]], ["Een nadere uitleg is te vinden in de referenties aan het eind van dit hoofdstuk.snelle alarmering zonder valse meldingOok wordt vaak gebruikgemaakt van Geografische Informatie Systemen (GIS) om pati\u00ebnten op een kaart te plotten en de gegevens te analyseren.", [["om pati\u00ebnten op een kaart te plotten en", "TREATMENT", 191, 230]]], ["Een belangrijk probleem van geografische methoden is dat men zich vaak moet baseren op de informatie uit surveillancesystemen die alleen de locatie vermelden waar de diagnose heeft plaatsgevonden.", [["heeft plaatsgevonden", "DISEASE", 175, 195], ["men", "SPECIES", 57, 60]]], ["Zo gaven de eerste internationale kaarten van de verspreiding van gevallen van het aquired immunodeficiency syndrome (aids) een beter beeld van de belangrijkste vliegroutes, dan van enig epidemiologisch patroon.", [["immunodeficiency syndrome", "DISEASE", 91, 116], ["immunodeficiency syndrome", "PROBLEM", 91, 116]]], ["Voor een lokale uitbraak die veroorzaakt wordt door een gemeenschappelijke watervoorziening zijn deze geografische methoden juist wel heel geschikt.snelle alarmering zonder valse meldingMet behulp van specifieke software (onder de naam 'SaTScan' te vinden op het internet) wordt de analyse van gegevens naar tijd en plaats gecombineerd en kan men gelijktijdig tijd-en plaatsgerelateerde uitbraken detecteren.", [["men", "SPECIES", 343, 346], ["een gemeenschappelijke", "TREATMENT", 52, 74]]], ["In feite registreert de software elk ziektegeval in tijd en plaats en bepaalt deze voor iedere locatie op ieder moment het aantal geobserveerde en het aantal verwachte ziektegevallen.snelle alarmering zonder valse meldingMet behulp van statistische procedures die rekening houden met het feit dat veel toetsen worden uitgevoerd, worden clusters gedetecteerd die zich van toevalsfluctuatie onderscheiden.snelle alarmering zonder valse meldingMeestal is de ziekte waar men bij uitbraakonderzoek mee geconfronteerd wordt als zodanig bekend en richt het onderzoek zich op het vinden (en elimineren) van de bron, het micro-organisme en/of de verspreidingswijze van deze ziekte.", [["men", "SPECIES", 467, 470], ["wordt als zodanig bekend en richt het onderzoek zich op het vinden (en elimineren) van de bron, het micro-organisme en/of de verspreidingswijze van deze ziekte", "SPECIES", 512, 671]]], ["Toch komen er op gezette tijden en plaatsen ook nieuwe ziekten voor die men nog niet eerder kende (hiv/aids was bijvoorbeeld v\u00f3 \u00f3r 1983 nog een onbekend fenomeen), of waarvan men het optreden in het specifieke gebied niet (meer) kende.", [["men", "SPECIES", 72, 75], ["men", "SPECIES", 175, 178], ["Toch komen er op gezette tijden en plaatsen ook nieuwe ziekten voor die men nog niet eerder kende (hiv/aids was bijvoorbeeld v\u00f3 \u00f3r 1983 nog een onbekend fenomeen", "SPECIES", 0, 161]]], ["De opkomst van het West Nile Virus in de VS aan het eind van de vorige eeuw is daarvan een bekend voorbeeld, maar men kan ook denken aan de opmars van malaria in Nederland in de huidige tijd.", [["opmars van malaria", "DISEASE", 140, 158], ["West Nile Virus", "ORGANISM", 19, 34], ["men", "SPECIES", 114, 117]]], ["Aan zo'n opkomende ziekte kunnen verschillende oorzaken ten grondslag liggen: -veranderingen in gedrag van mensen (bijv. het delen van naalden onder intraveneuzedruggebruikers; toename van het internationaal toerisme); -oorlogen en natuurrampen (bijv. het grote aantal verkrachtingen met hiv-besmetting onder de daaruit voortkomende kinderen tijdens de burgeroorlog in Rwanda); -veranderingen in de omgeving (vervuiling, klimaat); -veranderingen in het agens zelf (bijv. resistentieontwikkeling door excessief gebruik van antimicrobi\u00eble middelen; spontane mutaties in het genetisch materiaal van het micro-organisme, zoals bij vogelgriep); -veranderingen in de gezondheidszorg (bijv. de introductie van behandelingen die als bijwerking hebben dat de afweer sterk vermindert; verslappen van preventieve maatregelen); -veranderingen in voedselbereiding of voedselketen (bijv. de variante vorm van ziekte van Creutzfeldt-Jakob in 1996 door introductie van met boviene spongiforme encefalopathie (BSE of gekkekoeienziekte) besmet dierlijk afval in de voedselketen in de jaren daarvoor).snelle alarmering zonder valse meldingNaast surveillance en de ontwikkeling van rampenplannen, worden diverse preventieve maatregelen genomen om het risico op nieuwe ziekten te verminderen.", [["-oorlogen en natuurrampen (bijv", "TREATMENT", 219, 250]]], ["Deze maatregelen zijn vooral gericht op het aanpakken van de hierboven ge-noemde oorzaken, zoals de verbetering van de hygi\u00ebne van bloed, voedsel en water; terughoudendheid in het gebruik van antibiotica; ontwikkeling van nieuwe vaccins; vermindering van de humane blootstelling aan dierlijke infecties; bescherming van gevoelige groepen (kinderen, bejaarden, zwangeren) en de bestrijding van bioterrorisme.", [["Deze maatregelen zijn vooral gericht op het aanpakken van de hierboven ge-noemde oorzaken, zoals de verbetering van de hygi\u00ebne van bloed, voedsel en water; terughoudendheid in het gebruik van antibiotica; ontwikkeling van nieuwe vaccins; vermindering van de humane blootstelling aan dierlijke infecties; bescherming van gevoelige groepen (kinderen, bejaarden, zwangeren) en de bestrijding van bioterrorisme", "SPECIES", 0, 406], ["Deze", "TREATMENT", 0, 4]]], ["Vaak gaat het om door hoteldouches of airconditioners veroorzaakte gevallen, pati\u00ebnten die pas na terugkomst in eigen land ziek worden en zich als ge\u00efsoleerd geval presenteren.", [["na", "CHEMICAL", 95, 97]]], ["Door internationaal deze gegevens te combineren, worden uitbraken van legionellose gesignaleerd en kan de bron worden opgespoord en aangepakt.snelle alarmering zonder valse meldingVoor een meer uitgebreide bespreking van opzet, uitvoering en gebruik van surveillancesystemen wordt verwezen naar de literatuur achterin dit hoofdstuk.8.3Designs voor epidemiologisch onderzoek naar plotselinge uitbraken; detectivewerk en systematisch onderzoek8.3Uitbraken zijn ongeplande gebeurtenissen en kunnen dus alleen bestudeerd worden als de uitbraak al gestart of zelfs al voorbij is.", [["epidemiologisch", "TEST", 348, 363]]], ["Bovendien is er meestal sprake van tijdsdruk en zijn de meeste uitbraken van beperkte omvang, waardoor het lastig wordt om het effect van specifieke determinanten te onderscheiden van toevallige variatie in het voorkomen van ziekte bij subgroepen.Casus 8.2 ToxischeshocksyndroomIn 1978 beschreven Todd en collega's al de eerste gevallen van toxischeshocksyndroom (TSS) bij zeven adolescenten.", [["Casus", "TEST", 247, 252]]], ["TSS gaat gepaard met plotseling hoge koorts, lage bloeddruk of shock, en een vuurrode huiduitslag die \u00e9\u00e9n tot twee weken aanhoudt.", [["shock", "DISEASE", 63, 68], ["shock", "PROBLEM", 63, 68], ["shock", "OBSERVATION", 63, 68]]], ["TSS-pati\u00ebnten voelen zich verder lamlendig en hebben vaak maag-darm-en spierproblemen.", [["TSS", "DNA", 0, 3], ["TSS", "TEST", 0, 3]]], ["De oorzaak van TSS is een gelokaliseerde infectie met groep 1-Staphylokokken aureus.Casus 8.2 ToxischeshocksyndroomIn 1980 werden bij de eerstehulppost van ziekenhuizen in Wisconsin en Minnesota diverse jonge, overigens gezonde vrouwen binnengebracht met de hierboven beschreven klachten en verschijnselen.", [["Staphylokokken aureus", "ORGANISM", 62, 83], ["Staphylokokken aureus", "SPECIES", 62, 83], ["Staphylokokken aureus", "SPECIES", 62, 83], ["De oorzaak van TSS", "TREATMENT", 0, 18], ["Staphylokokken aureus", "PROBLEM", 62, 83], ["aureus", "OBSERVATION", 77, 83]]], ["Bijzonder was dat bij hen steeds de ziekte was begonnen bij de start van een, verder normaal verlopen menstruatie.", [["hen", "SPECIES", 22, 25]]], ["Omdat het aantal ziektegevallen onder menstruerende vrouwen niet afnam, werd besloten vrouwen met deze verschijnselen gekoppeld aan de menstruatie, te melden bij het Center for Disease Control (CDC), zodat pati\u00ebntcontroleonderzoek kon starten.", [["zodat pati\u00ebntcontroleonderzoek", "TREATMENT", 200, 230]]], ["Via telefonische interviews verzamelde men gegevens over burgerlijke staat, seksuele gewoonten, aanwijzingen voor een seksueel overdraagbare aandoening, menstruatieduur en intensiteit, gebruik van anticonceptie en gebruik van tampons.", [["men", "SPECIES", 39, 42]]], ["Pati\u00ebnten bleken vaker (97%) tampons te gebruiken dan controlepersonen (76%).", [["tampons", "TREATMENT", 29, 36]]], ["Er bleek geen verschil in het type en merk van de gebruikte tampons.", [["verschil", "PROBLEM", 14, 22]]], ["Zowel pati\u00ebnten als controlepersonen rapporteerden vaak het gebruik van 'sterk absorberende' tampons van het merk Rely.", [["Zowel pati\u00ebnten als controlepersonen rapporteerden vaak het gebruik van 'sterk absorberende' tampons van het merk Rely", "SPECIES", 0, 118], ["Zowel pati\u00ebnten als controlepersonen", "TREATMENT", 0, 36]]], ["In dit onderzoek vroeg men alle vrouwen het doosje op te zoeken waaruit de recent gebruikte tampons waren gehaald en het daarop vermelde merk en serienummer op te geven.", [["men", "SPECIES", 23, 26], ["recent gebruikte tampons", "TREATMENT", 75, 99]]], ["Omdat 100% van de pati\u00ebnten tampons gebruikte, waarvan 83% van het merk Rely, tegen 75% gebruik van tampons onder de controlepersonen met 26% gebruik van Rely, werd de conclusie getrokken dat de oorzaak van TSS bij deze jonge vrouwen moest worden gezocht in het gebruik van dit merk tampons.", [["Omdat", "TREATMENT", 0, 5], ["waarvan", "TREATMENT", 47, 54]]], ["Hoewel de tampons inderdaad meer bloed absorbeerden, bleken ze ook aanleiding te 1979 1981 1983 1985 1987 1989 jaar ginguitbraak), dan kan uit de figuur het meest waarschijnlijke tijdstip van blootstelling worden afgeleid.Casus 8.2 ToxischeshocksyndroomDe epidemische curve dient al in een vroeg stadium van de uitbraak gemaakt te worden, om van nut te kunnen zijn bij de evaluatie van genomen maatregelen.", [["bleken ze ook aanleiding te 1979 1981 1983 1985 1987 1989 jaar ginguitbraak", "SPECIES", 53, 128], ["een vroeg stadium van de uitbraak gemaakt te worden, om van nut te kunnen zijn bij de evaluatie van genomen maatregelen", "SPECIES", 286, 405], ["Casus", "TEST", 222, 227], ["ToxischeshocksyndroomDe epidemische curve", "TREATMENT", 232, 273]]], ["Het is in feite een van de eerste analysen die men onderneemt wanneer de definitie van een ziektegeval is vastgesteld en de cases geteld zijn.Casus 8.2 ToxischeshocksyndroomDe vorm van de epidemische curve geeft vaak informatie over de meest waarschijnlijke vorm van overdracht.", [["men", "SPECIES", 47, 50], ["Casus", "TEST", 142, 147]]], ["Een puntbronuitbraak, waarbij alle ziektegevallen op een bepaald moment door dezelfde bron zijn besmet, leidt meestal tot een snel stijgende curve met een enkele vroege piek, gevolgd door een gestage afname van het aantal nieuwe gevallen (zie figuur 8.3).", [["Een puntbronuitbraak", "TREATMENT", 0, 20], ["zijn besmet", "TREATMENT", 91, 102], ["leidt meestal tot een", "TREATMENT", 104, 125]]], ["Een uitbraak die veroorzaakt wordt door besmetting van persoon tot persoon (zoals het geval kan zijn bij influenza of mazelen), leidt tot een epidemische curve met meerdere kleinere pieken, waarvan de onderlinge afstand overeenkomt met de gemiddelde incubatieperiode.", [["kan zijn bij influenza of mazelen", "TREATMENT", 92, 125]]], ["In de praktijk blijkt zo'n kenmerkend patroon echter toch vaak moeilijk zichtbaar te maken door variatie in de latente periode na infectie.", [["na", "CHEMICAL", 127, 129]]], ["Hierdoor zal het piekenpatroon vervagen.Casus 8.2 ToxischeshocksyndroomDe epidemische curve biedt ook informatie over het verloop van de uitbraak.", [["Hierdoor zal het piekenpatroon vervagen", "SPECIES", 0, 39], ["Casus", "TEST", 40, 45]]], ["Zolang men nog in het stijgende deel van de curve zit, is de uitbraak kennelijk nog aan de gang, terwijl een dalende lijn aangeeft dat de uitbraak kennelijk al tot staan is gebracht.", [["men", "SPECIES", 7, 10]]], ["Het spreekt vanzelf dat deze informatie van het grootste belang is voor de vraag of, en zo ja welke, maatregelen genomen moeten worden, alsmede voor de inhoud van een eventuele boodschap aan het publiek.cohortonderzoek: vergelijking van attack-rates leidt tot de bronOmdat plotselinge uitbraken meestal in korte tijd plaatsvinden en dus de invloed van veranderingen in de samenstelling van de populatie 'at risk' verwaarloosbaar zullen zijn, wordt de ziektefrequentie veelal uitgedrukt in de vorm van attackrates.", [["van attack", "PROBLEM", 233, 243]]], ["Een attack-rate is eigenlijk een cumulatieve incidentie, dus een proportie, en strikt genomen geen 'rate', zoals de incidentiedichtheid een 'rate' is (zie paragraaf 2.5.2).", [["Een attack", "PROBLEM", 0, 10], ["dus een proportie", "TREATMENT", 57, 74]]], ["Tabel 8.1 geeft een voorbeeld van een salmonellose-uitbraak bij 226 deelnemers aan een groot buffet, Uit deze tabel wordt aannemelijk dat besmetting van de huzarensalade de meest waarschijnlijke oorzaak was van de epidemie onder deze buffetgebruikers.", [["Tabel", "TEST", 0, 5]]], ["Wanneer er slechts weinig ziektegevallen blootgesteld zijn aan de veronderstelde factor, dan zal ook slechts een kleine proportie van de ziektegevallen door de betreffende factor veroorzaakt kunnen zijn, zelfs bij een sterk verhoogd relatief risico.", [["Wanneer er slechts weinig ziektegevallen blootgesteld zijn aan de veronderstelde factor, dan zal ook slechts een kleine proportie van de ziektegevallen door de betreffende factor veroorzaakt kunnen zijn, zelfs bij een sterk verhoogd relatief risico", "SPECIES", 0, 248], ["kunnen zijn", "TREATMENT", 191, 202]]], ["Zo is in het voorbeeld van tabel 8.1 het relatieve risico voor het eten van kiwi 1,8 maar gaf slechts 9% van de pati\u00ebnten aan kiwi gegeten te hebben.", [["Zo", "CHEMICAL", 0, 2], ["Zo", "SIMPLE_CHEMICAL", 0, 2]]], ["Dat betekent dat het eten van kiwi slechts voor 0,09 x (1,8 -1) / (0,09 x (1,8 -1) + 1) = 0,07, ofwel 7% verantwoordelijk zou kunnen zijn.", [["1,8 -1) + 1", "SIMPLE_CHEMICAL", 75, 86]]], ["Voor de huzarensalade daarentegen, die door 90% van de pati\u00ebnten werd gerapporteerd, zou deze attributieve proportie uitkomen op 60% van de ziektegevallen in de populatie.pati\u00ebntcontroleonderzoek als je niet meer weet wie is blootgesteldIn het voorbeeld van tabel 8.1 was het kennelijk mogelijk een lijst samen te stellen van alle deelnemers aan een groot buffet, waarmee men een cohort kon defini\u00ebren van potenti\u00eble ziektegevallen.", [["men", "SPECIES", 372, 375]]], ["Dit is echter een uitzondering.", [["een uitzondering", "OBSERVATION", 14, 30]]], ["Meestal is men niet in staat een cohort van potenti\u00eble ziektegevallen samen te stellen.", [["men", "ORGANISM", 11, 14], ["men", "SPECIES", 11, 14]]], ["In dat geval neemt men zijn toevlucht tot een pati\u00ebntcontroleonderzoek.", [["men", "ORGANISM", 19, 22], ["men", "SPECIES", 19, 22], ["dat geval neemt men zijn", "TREATMENT", 3, 27], ["tot een pati\u00ebntcontroleonderzoek", "TREATMENT", 38, 70]]], ["Idealiter haalt men de controlepersonen uit de populatie die, wanneer ze de ziekte ontwikkeld zouden hebben, in de pati\u00ebntengroep terecht zouden zijn gekomen (zie paragraaf 4.3.2).", [["men", "SPECIES", 16, 19]]], ["Dus bij een uitbraak onder de bezoekers van een popfestival zoekt men ook de controlepersonen onder de bezoekers van dit festival.", [["men", "SPECIES", 66, 69]]], ["Als men bijvoorbeeld wil nagaan of het spelen op verontreinigde grond oorzaak kan zijn van een uitbraak van vergiftigingsgevallen bij kinderen, dan mag wel of niet spelen op verontreinigde grond de kans om in de controlegroep te komen niet be\u00efnvloeden.pati\u00ebntcontroleonderzoek als je niet meer weet wie is blootgesteldHoe langer men wacht met de interviews na de initi\u00eble blootstelling, hoe lastiger het wordt om accurate gegevens te verkrijgen over de relevante determinanten.", [["na", "CHEMICAL", 357, 359], ["men", "SPECIES", 4, 7], ["men", "SPECIES", 329, 332]]], ["Anders dan bij epidemiologisch onderzoek naar chronische aan-doeningen heeft men bij pati\u00ebntcontroleonderzoek naar een plotselinge uitbraak dus haast om de gegevens te verzamelen, wat op zichzelf al een bedreiging is voor de kwaliteit van het onderzoek.", [["men", "SPECIES", 77, 80], ["dan bij epidemiologisch onderzoek naar chronische aan-doeningen heeft men bij pati\u00ebntcontroleonderzoek naar een plotselinge uitbraak dus haast om de gegevens te verzamelen, wat op zichzelf al een bedreiging is voor de kwaliteit van het onderzoek", "SPECIES", 7, 252]]], ["Door gebruik te maken van standaardmeetinstrumenten en getraind personeel voor de gegevensverzameling kan men toch ook in dit soort onderzoeken voldoende kwaliteit realiseren.Casus 8.3 Legionella in BovenkarspelVeteranenziekte is voor het eerst beschreven na een grote uitbraak van longontsteking bij deelnemers aan een re\u00fcnie van Amerikaanse veteranen in Philadelphia in 1976.", [["men", "SPECIES", 106, 109], ["Casus", "TEST", 175, 180]]], ["Het onderzoek leidde tot de ontdekking van een tot dan toe onbekend organisme in het sputum van de ziektegevallen: Legionella pneumophila.", [["Legionella pneumophila", "DISEASE", 115, 137], ["Legionella pneumophila", "ORGANISM", 115, 137], ["Legionella pneumophila", "SPECIES", 115, 137], ["Legionella pneumophila", "SPECIES", 115, 137], ["Legionella pneumophila", "PROBLEM", 115, 137], ["toe", "ANATOMY", 55, 58], ["Legionella pneumophila", "OBSERVATION", 115, 137]]], ["De bacterie bleek zich te verspreiden via de luchtbehandelinginstallatie van het conferentiehotel.", [["conferentiehotel", "CHEMICAL", 81, 97]]], ["Na die eerste uitbraak zijn nog vele plotselinge uitbraken van legionellose beschreven.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2], ["Na", "TEST", 0, 2]]], ["Inmiddels zijn meer dan veertig verschillende soorten Legionella ge\u00efdentificeerd, maar serotype I van L. pneumophila blijkt de belangrijkste ziekteverwekker te zijn.", [["L. pneumophila", "SPECIES", 102, 116], ["I van L. pneumophila blijkt de belangrijkste ziekteverwekker te zijn", "SPECIES", 96, 164]]], ["Nederland werd in maart 1999 getroffen door een zeer massale uitbraak in het Noord-Hollandse Bovenkarspel.Casus 8.3 Legionella in BovenkarspelOp 6 maart 1999 werd in het West-Fries Gasthuis (WFG) in Hoorn de eerste pati\u00ebnt met een ernstige longontsteking opgenomen en een week later was het aantal gevallen opgelopen tot twaalf.", [["Casus", "TEST", 106, 111]]], ["Acht van hen verkeerden in een dermate slechte conditie dat beademing op de intensivecareafdeling noodzakelijk was.", [["hen", "SPECIES", 9, 12]]], ["Aanvankelijk dachten de behandelend artsen aan een virusinfectie.", [["een virusinfectie", "OBSERVATION", 47, 64]]], ["De directie van het WFG alarmeerde de gemeenschappelijke gezondheidsdienst (GGD) van West-Friesland, en gezien de ernst van de situatie organiseerde de secretaris van het Landelijk Co\u00f6rdinatiecentrum Infectieziektebestrijding (LCI) direct een spoedberaad met verschillende medisch specialisten en vertegenwoordigers van de openbare gezondheidszorg.", [["De directie van het WFG alarmeerde de gemeenschappelijke gezondheidsdienst (GGD) van West-Friesland, en gezien de ernst van de situatie organiseerde de secretaris van het Landelijk Co\u00f6rdinatiecentrum Infectieziektebestrijding (LCI) direct een spoedberaad met verschillende medisch specialisten en vertegenwoordigers van de openbare gezondheidszorg", "SPECIES", 0, 347]]], ["Op basis van de symptomen werd onder andere een snelle urinetest op Legionella pneumophila uitgevoerd.", [["Legionella pneumophila", "SPECIES", 68, 90], ["Legionella pneumophila uitgevoerd", "PROBLEM", 68, 101], ["pneumophila uitgevoerd", "OBSERVATION", 79, 101]]], ["Deze test gaf bij zeven pati\u00ebnten een positieve uitslag.", [["Deze test gaf", "TEST", 0, 13]]], ["Gezien het grote aantal bezoekers (80.000) werd groot alarm geslagen.Casus 8.3 Legionella in BovenkarspelEind april waren er 233 pati\u00ebnten gemeld die ziek waren geworden na een bezoek aan de West-Friese Flora.", [["Gezien het grote aantal bezoekers", "SPECIES", 0, 33], ["BovenkarspelEind april waren er 233 pati\u00ebnten gemeld die ziek waren geworden na een bezoek aan de West-Friese", "SPECIES", 93, 202], ["Casus", "TEST", 69, 74]]], ["Van de pati\u00ebnten zijn er 23 overleden.", [["Van de pati\u00ebnten zijn er", "TREATMENT", 0, 24]]], ["Uitgebreider onderzoek naar de locaties in de Flora waar de pati\u00ebnten waren geweest, leidde tot ernstige verdenking van met Legionella besmette whirlpools die op de West-Friese Flora werden gedemonstreerd.", [["tot ernstige verdenking van met Legionella besmette whirlpools die op de West-Friese Flora werden gedemonstreerd", "SPECIES", 92, 204]]], ["Het is echter ondenkbaar dat de bacterie zelf uit de samenleving ge\u00eblimineerd zou kunnen worden.Casus 8.3 Legionella in Bovenkarspel(Bron: Hoepelman IM.", [["Casus", "TEST", 96, 101]]], ["Legionella-epidemie in Nederland.", [["Legionella", "TEST", 0, 10], ["epidemie", "PROBLEM", 11, 19]]], ["Ned Tijdschr Geneeskd 1999; 143:1192-6.)risico's voor individu en risico's voor populatiesInfectieziekten worden veroorzaakt door microorganismen die worden overgedragen en die zich in de gastheer kunnen vermenigvuldigen.", [["Infectieziekten", "PROBLEM", 90, 105]]], ["Deze tijdsafhankelijke gebeurtenissen, uniek voor infectieziekten, maken dat men verschillende niveaus van ziekterisico moet onderscheiden.", [["men", "SPECIES", 77, 80]]], ["Vervolgens heeft dat ge\u00efnfecteerde individu een zekere kans om daar ziek van te worden, en ten slotte een zekere kans om aan de ziekte te overlijden.", [["Vervolgens", "TREATMENT", 0, 10], ["een zekere", "TREATMENT", 44, 54]]], ["Afhankelijk van de vraag of men zich richt op de klinische epidemiologische context van de kans op ziekte bij een individu met een zeker risicoprofiel, dan wel op de public-healthcontext van de kans op een uitbraak van deze infectieziekte in de bevolking, worden de gegevens anders gebruikt en ge\u00efnterpreteerd.risico's voor individu en risico's voor populatiesZo is de overdracht door besmettelijke personen afhankelijk van de duur van de besmettelijkheid en het aantal contacten dat men heeft met personen die de ziekte nog kunnen ontwikkelen.", [["men", "ORGANISM", 28, 31], ["men", "SPECIES", 28, 31], ["men", "SPECIES", 484, 487]]], ["Men heeft immers geen tijd en gelegenheid zich die kennis eigen te maken nadat de uitbraak is opgetreden.", [["Men", "SPECIES", 0, 3]]], ["Van het begin af aan moet ook duidelijk zijn wie welke verantwoordelijkheden heeft, inclusief de vraag wie de uiteindelijke leiding heeft over het uitbraakonderzoek en van de uitbraakbestrijding.", [["Van het begin af aan moet ook duidelijk zijn wie welke verantwoordelijkheden heeft, inclusief de vraag wie de uiteindelijke leiding heeft over het uitbraakonderzoek en van de uitbraakbestrijding", "SPECIES", 0, 194]]], ["Wanneer het waargenomen aantal ziektegevallen het verwachte aantal overschrijdt, wil dit nog niet zeggen dat er ook daadwerkelijk een uitbraak is.", [["Wanneer het waargenomen aantal ziektegevallen het verwachte aantal overschrijdt, wil dit nog niet zeggen dat er ook daadwerkelijk een uitbraak", "SPECIES", 0, 142]]], ["Eerst dient men bijvoorbeeld na te gaan of er geen ander systeem van ziekteregistratie is gekomen, of ziektegevallen anders gedefinieerd worden, enzovoort.", [["bijvoorbeeld na te gaan of er geen", "CHEMICAL", 16, 50], ["men", "SPECIES", 12, 15]]], ["Men bestudeert hiertoe de medische dossiers en de laboratoriumuitslagen van de gerapporteerde gevallen en vat deze samen in een overzichtelijke tabel.", [["Men", "SPECIES", 0, 3]]], ["Hoe eerder de uitbraak is gedetecteerd en in een microbiologische diagnose bevestigd, hoe eerder men de mogelijkheid heeft om maatregelen te nemen die de uitbraak beteugelen.Stap 3: verifieer de diagnoseHet kan in dit stadium ook heel verstandig zijn een aantal pati\u00ebnten met de betreffende ziekte op te zoeken en zelf een beeld te vormen van de aard van de uitbraak.", [["betreffende ziekte op te zoeken en zelf een beeld te vormen van de aard van de uitbraak", "SPECIES", 279, 366], ["heel verstandig zijn", "TREATMENT", 230, 250], ["heel", "ANATOMY", 230, 234]]], ["Uiteraard neemt men hierbij de nodige hygi\u00ebnemaatregelen in acht.Stap 4: stel een definitie voor ziektegevallen vast, spoor deze gevallen van ziekte op en tel zeHet doel van een goede casusdefinitie is te zorgen dat zo veel mogelijk echte pati\u00ebnten van de plotselinge uitbraak worden ge\u00efncludeerd en zo weinig mogelijk ziektegevallen die er niets mee te maken hebben.", [["men", "SPECIES", 16, 19], ["spoor deze gevallen van ziekte op en tel zeHet doel van een goede casusdefinitie is te zorgen dat zo veel mogelijk echte pati\u00ebnten van de plotselinge uitbraak worden ge\u00efncludeerd en zo weinig mogelijk ziektegevallen die er niets mee te maken hebben", "SPECIES", 118, 366]]], ["In het begin zal men een brede definitie willen hanteren om geen ziektegevallen te missen, en over deze pati\u00ebnten zo veel mogelijk informatie willen verzamelen om een goed beeld te krijgen van wat er aan de hand is.", [["men", "SPECIES", 17, 20]]], ["Spoedig daarna wordt de omschrijving van welke pati\u00ebnten men wel en welke niet tot de uitbraak rekent verder ingeperkt tot een operationele definitie van de te onderzoeken ziekte.", [["men", "SPECIES", 57, 60]]], ["In deze definitie zijn klachten, symptomen en laboratoriumbevindingen, maar ook specifieke persoonlijke kenmerken (bijvoorbeeld leeftijd) en plaats-of tijdsaanduidingen opgenomen.", [["tijdsaanduidingen opgenomen", "TREATMENT", 151, 178]]], ["Hanteer zo nodig een indeling van ziektegevallen in 'waarschijnlijke' gevallen en 'bevestigde' gevallen, waarbij men voor de laatste categorie een ondersteunende laboratoriumuitslag heeft.Stap 4: stel een definitie voor ziektegevallen vast, spoor deze gevallen van ziekte op en tel zeActieve opsporing van alle ziektegevallen vormt de basis om de omvang van de plotse uitbraak te kunnen vaststellen.", [["men", "SPECIES", 113, 116], ["spoor deze gevallen van ziekte op en tel zeActieve opsporing van alle ziektegevallen vormt de basis om de omvang van de plotse uitbraak te kunnen vaststellen", "SPECIES", 241, 398]]], ["Men doet dit door bijvoorbeeld de lokale huisartsen, specialisten en klinische laboratoria actief te vragen naar bij hen bekende gevallen en hen alert te maken op nieu-we gevallen.", [["Men", "SPECIES", 0, 3], ["hen", "SPECIES", 117, 120]]], ["Ook kan het publiek ingeschakeld worden om nieuwe gevallen te melden.", [["Ook kan het publiek ingeschakeld worden om nieuwe gevallen te melden", "SPECIES", 0, 68]]], ["Deze beschrijving begint met een systematische lijst van alle opgespoorde gevallen met tabellarische informatie over leeftijd, geslacht, diagnosedatum, datum waarop de verschijnselen begonnen, de aanwezigheid van specifieke symptomen, eventuele laboratoriumuitslagen en eventuele andere factoren die in dit vroege stadium van het onderzoek al van belang zijn gebleken.Stap 5: beschrijf het voorkomen van deze ziektegevallen naar tijd, plaats en persoonlijke karakteristiekenMet de in stap 4 verkregen tabel van de ziektegevallen kunnen al eenvoudige beschrijvende analysen gedaan worden.", [["dit vroege stadium van het onderzoek al van belang zijn gebleken", "SPECIES", 303, 367]]], ["Casus 8.3 laat zien hoe op deze wijze hypothesen over de mogelijke oorzaak gevormd kunnen worden.", [["Casus", "TEST", 0, 5]]], ["Ook Snow (zie hoofdstuk 1, casus 1.5) ontdekte op die manier de bron van besmetting tijdens de Londense cholera-epidemie.Stap 5: beschrijf het voorkomen van deze ziektegevallen naar tijd, plaats en persoonlijke karakteristiekenDezelfde informatie wordt ook gebruikt om een epidemische curve te tekenen en te interpreteren, inzake de aard, het mogelijke tijdstip van blootstelling en het verloop van de uitbraak (zie paragraaf 8.3.1).Stap 5: beschrijf het voorkomen van deze ziektegevallen naar tijd, plaats en persoonlijke karakteristiekenStap 6: ontwikkel hypothesen over de aard van de ziekteverwekker Door interviews met de pati\u00ebnten te houden, kan men op idee\u00ebn komen over de mogelijke aard en bron van de besmetting.", [["cholera-epidemie", "DISEASE", 104, 120], ["beschrijf het voorkomen van deze ziektegevallen naar tijd, plaats en persoonlijke karakteristiekenDezelfde informatie wordt ook gebruikt om een epidemische curve te tekenen en te interpreteren, inzake de aard, het mogelijke tijdstip van blootstelling en het verloop van de uitbraak", "SPECIES", 129, 410]]], ["Is er sprake van een onbekende ziekteverwekker, dan zal men in deze interviews meer explorerend te werk moeten gaan.", [["men", "SPECIES", 56, 59]]], ["Met de aldus verkregen hypothesen over mogelijke oorzaken voor de uitbraak kan men verder onderzoek gaan plannen.Stap 7: evalueer de hypothesenEvaluatie van de hypothesen kan geschieden door vergelijking met bestaande feiten of door middel van aanvullende epidemiologische studies.", [["men", "SPECIES", 79, 82]]], ["Het programma EpiInfo is speciaal gemaakt voor het invoeren en analyseren van gegevens uit onderzoek naar plotselinge uitbraken, maar ook andere software kan uiteraard gebruikt worden.Stap 7: evalueer de hypothesenOmdat plotselinge uitbraken meestal in korte tijd plaatsvinden en dus de veranderingen in de populatie 'at risk' verwaarloosbaar zullen zijn, wordt de ziektefrequentie veelal uitgedrukt in de vorm van attack-rates (zie paragraaf 8.3.2).Stap 7: evalueer de hypothesenStap 9: neem maatregelen om de uitbraak tot staan te brengen en nieuwe uitbraken te voorkomen Doorgaans leiden de resultaten van de onderzoeken naar plotse uitbraken tot een bepaalde oorzaak en/of een bepaalde bron.", [["neem maatregelen om de uitbraak tot staan te brengen en nieuwe uitbraken te voorkomen Doorgaans leiden de resultaten van de onderzoeken naar plotse uitbraken tot een bepaalde oorzaak en/of een bepaalde bron", "SPECIES", 488, 694]]], ["Er zijn twee soorten interventies: -verwijderen van de bron of het agens (product uit de markt halen, verwijderen van een besmettelijk dier, aanpassen van hygi\u00ebnemaatregelen, enz.); -beschermen van niet-zieken of niet-geinfecteerden door bijvoorbeeld vaccinatie, vroegbehandeling (postexpositieprofylaxe), door screenen van contacten, door immunisatie, door persoonlijke hygi\u00ebneadviezen en/of door het isoleren van ziektegevallen.Stap 7: evalueer de hypothesenHoe eerder maatregelen genomen worden hoe groter de kans om de uitbraak te controleren en nieuwe uitbraken te voorkomen.", [["verwijderen van een besmettelijk dier, aanpassen van hygi\u00ebnemaatregelen, enz.); -beschermen van niet-zieken of niet-geinfecteerden door bijvoorbeeld vaccinatie, vroegbehandeling (postexpositieprofylaxe), door screenen van contacten, door immunisatie, door persoonlijke hygi\u00ebneadviezen en/of door het isoleren van ziektegevallen", "SPECIES", 102, 429], ["Hoe eerder maatregelen genomen worden hoe groter de kans om de uitbraak te controleren en nieuwe uitbraken te voorkomen", "SPECIES", 460, 579]]], ["Met surveillancesystemen kan men vervolgens evalueren of de genomen maatregelen, ook op de lange termijn, effect hebben gesorteerd.Stap 7: evalueer de hypothesenStap 10: maak de bevindingen bekend bij verantwoordelijke personen en bij het publiek Effectieve, duidelijke en tijdige informatievoorziening is een cruciaal element in elk onderzoek van een plotselinge uitbraak.", [["men", "SPECIES", 29, 32], ["elk onderzoek van een plotselinge uitbraak", "SPECIES", 330, 372], ["duidelijke en tijdige informatievoorziening", "TREATMENT", 259, 302]]], ["Men kan daarbij denken aan de volgende aspecten: -Informeren van het publiek over de aard van de ziekte en de wijze waarop deze herkend, behandeld en voorkomen kan worden.", [["Men", "SPECIES", 0, 3]]], ["Voor het verspreiden van deze informatie kan men gebruikmaken van persberichten en andere media.", [["men", "SPECIES", 45, 48]]], ["Alle betrokken medewerkers dienen dagelijks op de hoogte te worden gehouden van het verloop van de uitbraak en van het onderzoek naar de oorzaken. -Informeren van de verantwoordelijke bestuurders.", [["Alle betrokken medewerkers dienen dagelijks op de hoogte te worden gehouden van het verloop van de uitbraak en van het onderzoek naar", "SPECIES", 0, 133]]], ["Om hun verantwoordelijkheid te kunnen dragen, dienen de personen die verantwoordelijk zijn voor de volksgezondheid en het algemene bestuur van de betreffende populatie dagelijks te worden ge\u00efnformeerd over de voortgang van het onderzoek. -Informeren van de lokale huisartsen, specialisten (voor zover relevant voor de betreffende ziekte) en andere gezondheidszorgwerkers die met pati\u00ebnten of van ziekte verdachte personen te maken kunnen krijgen. -Informeren van andere instanties die mogelijk bij de uitbraak betrokken kunnen raken: instellingen of gebieden elders met vergelijkbare blootstellingen, maar ook instanties die indirect betrokken kunnen zijn (Ministerie van Volkshuisvesting, Ruimtelijke Ordening en Milieubeheer, waterleidingbedrijven, de Voedsel en Waren Autoriteit, milieudiensten). -Informeren van collega-onderzoekers.", [["Om hun verantwoordelijkheid te kunnen dragen, dienen de personen die verantwoordelijk zijn voor de volksgezondheid en het algemene bestuur van de betreffende populatie dagelijks te worden ge\u00efnformeerd over de voortgang van het onderzoek", "SPECIES", 0, 236]]], ["Generaliseerbare bevindingen daaruit kunnen van nut zijn om door te geven (bijv. in de vorm van een publicatie) aan de collega's elders.Stap 7: evalueer de hypothesenHet spreekt vanzelf dat men in concrete situaties niet altijd strikt de volgorde van deze tien stappen zal kunnen aanhouden.", [["men", "SPECIES", 190, 193], ["Generaliseerbare bevindingen daaruit kunnen van nut zijn om door te geven", "SPECIES", 0, 73]]], ["Ook dit versterkt het chaotische karakter van het onderzoek, maar men wacht natuurlijk niet met handenwasinstructies op een basisschool totdat duidelijk is welk toilet de bron is van een uitbraak van diarree.Interpretatie van gegevens over vermeende plotselinge uitbraken blijft moeilijkOver de vraag of er sprake is van een uitbraak of niet is in de praktijk veel discussie, mede omdat er ook veel vormen van bias zijn die een goede interpretatie bemoeilijken: -De keuze van de populatie of het gebied waarin men de uitbraak vermoedt, is van belang.", [["men", "SPECIES", 66, 69], ["men", "SPECIES", 510, 513]]], ["Hoe strikter de populatie wordt gedefinieerd, hoe kleiner het aantal te verwachten gevallen, hoe groter het overschot aan gevallen en hoe sneller significantie bereikt wordt, ook in situaties waarin sprake is van een normale variatie in ziekteincidentie. -Kleine populaties en kleine aantallen ziektegevallen zijn inherent aan uitbraakonderzoek, maar zorgen voor onnauwkeurige schattingen. -Een slecht geformuleerde hypothese, of zelfs het ontbreken van een hypothese, leidt tot het missen van werkelijke determinanten of het vinden van determinanten die er niet toe doen. -Onnauwkeurige gegevens over de ziektegevallen en gemiste gevallen kunnen het zoeken van de oorzaken van uitbraken ernstig hinderen.", [["Kleine populaties", "TREATMENT", 256, 273], ["toe", "ANATOMY", 563, 566]]], ["Uit een snel uitgevoerde clusteranalyse over de periode 1989-1992 bleek dat in Weurt 56 gevallen van kanker waren waargenomen, terwijl er 40 verwacht mochten worden.", [["een snel uitgevoerde clusteranalyse over de periode 1989-1992 bleek dat in Weurt 56 gevallen van kanker waren waargenomen, terwijl er 40 verwacht mochten worden", "SPECIES", 4, 164]]], ["De inwoners van Weurt vreesden dat deze extra gevallen van kanker waren veroorzaakt door de uitstoot van dioxinen door een naburige afvalverbrandingsinstallatie.", [["een naburige afvalverbrandingsinstallatie", "TREATMENT", 119, 160]]], ["Omdat in zo'n relatief klein gebied de incidentie van kanker onderhevig is aan grote toevalsfluctuaties, werd een verfijnde statistische methode (met gebruikmaking van de ruimtelijke correlatie tussen aangrenzende gebieden) toegepast op de gegevens van de kankerregistratie in de jaren 1989-2001 in een gebied van circa een miljoen inwoners, verdeeld over 263 postcodegebieden.", [["werd een verfijnde statistische methode (met gebruikmaking van de ruimtelijke correlatie tussen aangrenzende gebieden) toegepast op de gegevens van de kankerregistratie in de jaren 1989-2001 in een gebied van circa een miljoen inwoners, verdeeld over 263 postcodegebieden", "SPECIES", 105, 376]]], ["Dit betekent een gecorrigeerde 'standardi-zed mortality ratio' (SMR) van 1,18 (95%-BI 0,95-1,44) voor de mannen en van 1,10 (95%-BI 0,29-2,13) voor de vrouwen.", [["BI", "TEST", 83, 85]]], ["Voor longkanker was de gecorrigeerde SMR bij mannen 1,35 (95%-BI 0,88-1,94) en bij de vrouwen 1,00 (95%-BI 0,29-2,13).", [["BI", "TEST", 62, 64]]], ["Ook andere vormen van kanker werden niet statistisch significant vaker gediagnosticeerd in Weurt.Casus 8.4 Kankercluster in WeurtDeze resultaten laten derhalve geen duidelijk kankercluster zien.", [["Casus", "TEST", 97, 102]]], ["Ned Tijdschr Geneeskd 2004, 148: 828-35.) 8.6Casus 8.4 Kankercluster in WeurtSoms zijn er voor het bestuderen van uitbraken en clusters bijzondere benaderingen nodigCasus 8.4 Kankercluster in WeurtGing het in het voorgaande uitdrukkelijk om plotselinge uitbraken, ook in situaties van (ogenschijnlijk) evenwicht kunnen infecties een belangrijke invloed hebben op de volksgezondheid en er kunnen sluipenderwijs ook epidemie\u00ebn ontstaan.", [["Casus", "TEST", 45, 50], ["het bestuderen van uitbraken en clusters bijzondere benaderingen nodigCasus", "TREATMENT", 95, 170]]], ["Doorgaans kan men bij het analyseren van gegevens uit onderzoek naar uitbraken uit de voeten met de klassieke methoden van statistische analyse van de gegevens: men vertaalt de epidemiologische functie in een (logistisch) regressiemodel, en schat de regressieco\u00ebffici\u00ebnten als maat voor het effect van de determinant op het ontstaan van de aandoening, waarbij men in het model corrigeert voor eventuele confounders en met behulp van betrouwbaarheidsintervallen de precisie van de schatting weergeeft.Casus 8.4 Kankercluster in WeurtDe specifieke eigenschappen van infectieziekten en van clusters in het algemeen dwingen de onderzoeker echter soms tot het gebruik van spe-ciale methoden en technieken.", [["men", "SPECIES", 14, 17], ["men", "SPECIES", 161, 164], ["regressiemodel", "TREATMENT", 222, 236], ["Casus", "TEST", 500, 505]]], ["Het grote voordeel van modellen is dat men geen last heeft van het effect van allerlei toevallige variaties.", [["men", "ORGANISM", 39, 42], ["men", "SPECIES", 39, 42]]], ["Maar een aantal ziekten (zoals bof, mazelen, rodehond) zijn ernstiger wanneer ze optreden op latere leeftijd.", [["Maar een aantal ziekten (zoals bof, mazelen, rodehond) zijn ernstiger wanneer ze optreden op latere leeftijd", "SPECIES", 0, 108], ["Maar een aantal ziekten", "TREATMENT", 0, 23], ["zijn", "TREATMENT", 55, 59]]], ["Door een vaccinatiecampagne kan dus het totaal aantal ziektegevallen afnemen, terwijl het aantal ernstig zieken toeneemt.", [["een vaccinatiecampagne kan dus het totaal aantal ziektegevallen afnemen, terwijl het aantal ernstig zieken toeneemt", "SPECIES", 5, 120]]], ["Simpele modellen veronderstellen dat de gevoelige individuen in een populatie willekeurig zijn verdeeld en daarmee een even grote kans lopen als elk ander individu om contact te maken met een besmettelijk individu en besmet te raken.", [["een populatie", "TREATMENT", 64, 77]]], ["Bij uitbraken van influenza echter zijn het juist de kleuterscholen die een groot aandeel in de ziekteverspreiding hebben, omdat kinderen uit verschillende wijken daar samenkomen en intensief contact met elkaar hebben.", [["influenza echter", "SPECIES", 18, 34], ["Bij uitbraken van influenza echter zijn", "TREATMENT", 0, 39]]], ["In deze benadering wordt in een hypothetische populatie een epidemie gesimuleerd, waarbij men realistische parameters invoert voor het gedrag van micro-organismen, mensen, enzovoort.", [["men", "SPECIES", 90, 93]]], ["Op deze wijze kan men -gegeven deze aannamesheel precies (infectie)ziektekansen schatten.", [["men", "SPECIES", 18, 21]]], ["Uitwerking van deze wijzen van modelvorming en het gebruik ervan in de infectieziekte-epidemiologie valt buiten het bestek van dit boek.Casus 8.5 Een meningitisuitbraak in SudanIn januari 1999 brak er een meningitisepidemie uit in het noordwesten van Sudan.", [["Casus", "TEST", 136, 141]]], ["In Sudan zijn de klimatologische omstandigheden een groot gedeelte van het jaar ideaal voor de verspreiding van meningokokkenmeningitis.", [["meningokokkenmeningitis", "DISEASE", 112, 135], ["Sudan zijn de klimatologische omstandigheden een groot gedeelte van het jaar ideaal voor de verspreiding van meningokokkenmeningitis", "SPECIES", 3, 135]]], ["Begin februari werden in dit gebied de eerste ziektegevallen gezien en in week 8 was het aantal ziektegevallen opgelopen tot 15 per 10.000 per week, waarna men in dit gebied kon spreken van een epidemie.", [["men", "ORGANISM", 156, 159], ["men", "SPECIES", 156, 159], ["het aantal ziektegevallen opgelopen tot", "TREATMENT", 85, 124]]], ["Uit deze monsters isoleerde men Neisseria meningitidis groep A. In week 10 werd begonnen met de voorbereiding van een vaccinatiecampagne.", [["men", "SPECIES", 28, 31]]], ["Meningitispati\u00ebnten werden effectief behandeld met intramusculair toegediende chlooramfenicol in olie.", [["chlooramfenicol", "CHEMICAL", 78, 93], ["chlooramfenicol", "CHEMICAL", 78, 93], ["chlooramfenicol", "SIMPLE_CHEMICAL", 78, 93]]], ["In de stad werden per dag tot maximaal twaalfduizend mensen gevaccineerd.Casus 8.5 Een meningitisuitbraak in SudanGezondheidswerkers buiten de stad werden getraind in het gebruik van de casusdefinitie, in de medicatie en in het geven van voorlichting aan de bevolking.", [["Casus", "TEST", 73, 78]]], ["Zo kon de epidemie in kaart worden gebracht en konden verdere vaccinatieactiviteiten doeltreffend worden geregeld.Casus 8.5 Een meningitisuitbraak in SudanDe casusdefinitie luidde als volgt: -verdacht als vanaf februari 1999 in de provincie West-Darfur snel optredende koorts, een stijve nek of een uitslag met kleine rode vlekjes (petechie\u00ebn) optreedt (voor zuigelingen geldt als symptoom een bolle fontanel); -waarschijnlijk als een verdachte casus een troebele lumbaalpunctie heeft; -bevestigd als een verdachte casus een positieve kweek of antigeendetectie heeft in de lumbaalpunctie.Casus 8.5 Een meningitisuitbraak in SudanDoordat R 0 van zoveel factoren afhangt, is het basaal reproductiegetal als zodanig niet goed te interpreteren.", [["een uitslag met kleine rode vlekjes (petechie\u00ebn) optreedt (voor zuigelingen geldt als symptoom een bolle fontanel); -waarschijnlijk als een verdachte casus een troebele lumbaalpunctie heeft; -bevestigd als een verdachte casus een positieve kweek", "SPECIES", 295, 540], ["Casus", "TEST", 114, 119], ["een uitslag", "TREATMENT", 295, 306], ["waarschijnlijk als", "PROBLEM", 412, 430], ["Casus", "TEST", 588, 593]]], ["Als x de proportie personen is die gevoelig is voor de ziekte in een goed gemixte populatie, dan geldt:Casus 8.5 Een meningitisuitbraak in SudanAls het basaal reproductiegetal voor mazelen 16 is en de helft van de populatie kinderen is immuun, dan zal een kind met mazelen slechts 8 nieuwe (besmettelijke) gevallen van mazelen kunnen veroorzaken.", [["Casus", "TEST", 103, 108], ["Een meningitisuitbraak", "TREATMENT", 113, 135]]], ["Zo zal in een stabiele situatie waarin de incidentie en prevalentie van een infectieziekte niet veranderen, elke zieke gemiddeld \u00e9\u00e9n nieuwe zieke produceren.", [["Zo zal", "CHEMICAL", 0, 6]]], ["Ook kan men gebruikmaken van het feit dat in een stabiele situatie de gemiddelde leeftijd waarop de infectie optreedt afhankelijk is van het basaal reproduc-tiecijfer: hoe lager de R 0 , hoe hoger de gemiddelde leeftijd.", [["men", "SPECIES", 8, 11]]], ["Langs deze indirecte wegen kan men een grove indicatie van de R 0 verkrijgen.Casus 8.5 Een meningitisuitbraak in SudanHet basaal reproductiegetal is een complex begrip, waarin verschillende belangrijke kenmerken van het gedrag van een infectieus agens in een bevolking zijn opgenomen en waarmee veel belangrijke aspecten van preventie en controle van epidemie\u00ebn kunnen worden begrepen.", [["men", "SPECIES", 31, 34], ["Casus", "TEST", 77, 82], ["waarin verschillende belangrijke", "TREATMENT", 169, 201]]], ["Stel dat voor hiv-infectie in een bevolking geldt dat R 0 = 5 en dat condoomgebruik de transmissiekans p met 90% terugbrengt, dan zou het basaal reproductiegetal tot 0,5 kunnen worden verlaagd als iedereen condooms zou gebruiken.", [["dan zou het basaal reproductiegetal tot 0,5 kunnen worden verlaagd als iedereen condooms zou gebruiken", "SPECIES", 126, 228], ["hiv", "PROBLEM", 14, 17], ["infectie", "PROBLEM", 18, 26]]], ["Op deze manier kan men berekenen hoe groot de fractie ge\u00efmmuniseerden (f) moet zijn om een epidemie te voorkomen.", [["men", "SPECIES", 19, 22]]], ["Omdat f = 1 -x, geldt:Casus 8.5 Een meningitisuitbraak in SudanOm een uitbraak te voorkomen moet gelden: R < 1.", [["Casus", "TEST", 22, 27]]], ["Dit betekent dat:Casus 8.5 Een meningitisuitbraak in SudanBij het voorbeeld van de mazelen met een R 0 van ongeveer 16 betekent dit dat 1 -1/16 = 0,94, dat wil zeggen: 94% van de kinderen die kans lopen op een eerste infectie, moet zijn ge\u00efmmuniseerd (op natuurlijke wijze of via vaccinatie) om een uitbraak van mazelen te voorkomen.", [["Casus", "TEST", 17, 22], ["moet zijn ge\u00efmmuniseerd", "TREATMENT", 227, 250]]], ["Met deze term karakteriseert men de immunologische status van de populatie (in tegenstelling tot die van het individu) voor een bepaald infectieus agens.", [["Met deze", "CHEMICAL", 0, 8], ["bepaald infectieus agens", "CELL", 128, 152], ["men", "SPECIES", 29, 32], ["bepaald infectieus", "SPECIES", 128, 146]]], ["Een populatie is immuun als het reproductiegetal R kleiner is dan 1.", [["dan 1", "DNA", 62, 67], ["Een populatie", "TREATMENT", 0, 13]]], ["Hiervoor hoeven niet noodzakelijkerwijs alle individuen in die populatie immuun te zijn De groepsimmuniteit neemt toe naarmate meer mensen zijn gevaccineerd tegen het betreffende agens of naarmate meer mensen door een eerste besmetting immuun zijn geworden.Casus 8.5 Een meningitisuitbraak in SudanOok zal het meestal niet zo zijn dat een vaccin voor volledige afweer zorgt bij alle gevaccineerden.", [["SudanOok zal het meestal niet zo zijn dat een vaccin voor volledige afweer zorgt bij alle gevaccineerden", "SPECIES", 293, 397], ["De groepsimmuniteit neemt toe naarmate", "TREATMENT", 88, 126], ["Casus", "TEST", 257, 262]]], ["Steeds meer komt men dan in de sfeer van de modellen en simulaties waarop in paragraaf 8.6.1 kort is ingegaan. -Soms zijn er voor de analyse van epidemieen bijzondere benaderingen nodig. -Pas op voor vals alarm bij het zoeken naar clusters in tijd en plaats. -Modellen en simulaties heb je nodig als de werkelijkheid te ingewikkeld is. -Met het basaal reproductiegetal karakteriseer je de infectiedruk in de bevolking. -Er is sprake van groepsimmuniteit, omdat de populatie meer is dan de som van de samenstellende individuen.OpdrachtenTabel 8.2Opdrachtenf De bovenstaande bevindingen waren aanleiding om \u00e9\u00e9n maaltijd in het bijzonder als verdacht aan te merken.", [["Opdrachtenf", "CHEMICAL", 545, 556], ["bij het zoeken naar clusters", "DNA", 211, 239], ["men", "SPECIES", 17, 20], ["Opdrachtenf", "SPECIES", 545, 556], ["Pas op voor", "TEST", 188, 199], ["vals", "TEST", 200, 204], ["Modellen en simulaties", "TREATMENT", 260, 282], ["OpdrachtenTabel", "TEST", 526, 541]]], ["Door de informatie over het begintijdstip van de klachten te koppelen aan het tijdstip waarop deze maaltijd geserveerd werd, kreeg men een indruk van de verdeling van de individuele incubatietijden van de ziekte (tabel 8.5).", [["men", "SPECIES", 131, 134]]], ["Allerlei selectiefilters spelen een rol.", [["een rol", "OBSERVATION", 32, 39]]], ["Tot de notoire boosdoeners behoren onder andere Salmonella enteritidis, Clostridium perfringens, Staphylococcus aureus, Escherichia coli (serotype O157:H7), Campylobacter jejuni, Salmo-", [["Salmonella enteritidis", "DISEASE", 48, 70], ["Clostridium perfringens", "DISEASE", 72, 95], ["Staphylococcus aureus", "DISEASE", 97, 118], ["Campylobacter jejuni", "DISEASE", 157, 177], ["Tot de notoire boosdoeners", "ORGANISM", 0, 26], ["onder andere Salmonella enteritidis", "ORGANISM", 35, 70], ["Clostridium perfringens", "ORGANISM", 72, 95], ["Staphylococcus aureus", "ORGANISM", 97, 118], ["Escherichia coli", "ORGANISM", 120, 136], ["serotype O157:H7", "ORGANISM", 138, 154], ["Campylobacter jejuni", "ORGANISM", 157, 177], ["Salmonella enteritidis", "SPECIES", 48, 70], ["Clostridium perfringens", "SPECIES", 72, 95], ["Staphylococcus aureus", "SPECIES", 97, 118], ["Escherichia coli", "SPECIES", 120, 136], ["Campylobacter jejuni", "SPECIES", 157, 177], ["Salmo", "SPECIES", 179, 184], ["Salmonella enteritidis", "SPECIES", 48, 70], ["Clostridium perfringens", "SPECIES", 72, 95], ["Staphylococcus aureus", "SPECIES", 97, 118], ["Escherichia coli", "SPECIES", 120, 136], ["serotype O157:H7", "SPECIES", 138, 154], ["Campylobacter jejuni", "SPECIES", 157, 177], ["Salmo-", "SPECIES", 179, 185], ["Tot de notoire boosdoeners", "TREATMENT", 0, 26], ["Salmonella enteritidis", "PROBLEM", 48, 70], ["Clostridium perfringens", "PROBLEM", 72, 95], ["Staphylococcus aureus", "PROBLEM", 97, 118], ["Escherichia coli", "PROBLEM", 120, 136], ["Campylobacter jejuni", "PROBLEM", 157, 177], ["Staphylococcus aureus", "OBSERVATION", 97, 118], ["Escherichia coli", "OBSERVATION", 120, 136], ["Campylobacter jejuni", "ANATOMY", 157, 177]]]]}